<SEC-DOCUMENT>0000885590-23-000009.txt : 20230223
<SEC-HEADER>0000885590-23-000009.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230223163729
ACCESSION NUMBER:		0000885590-23-000009
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		156
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		23660316

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bhc-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d,d:57fbe32677504c888f142dd82b99b37f--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:bhc="http://www.bauschhealth.com/20221231" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y18zLTEtMS0xLTE2OTYwOA_2e824ff0-355a-48c8-8b38-cd7407c8fbe6">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y180LTEtMS0xLTE2OTYwOA_ff632a02-30c2-430a-b042-a88c4bf40be1">2022</ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y181LTEtMS0xLTE2OTYwOA_88fd21e5-4b70-4022-829a-604ad8f6f5e1">FY</ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y182LTEtMS0xLTE2OTYwOA_48af0d3d-9227-4ee1-be9f-7ef405368584">false</ix:nonNumeric><ix:nonNumeric contextRef="i0b5355a46f96463087fd4837bdefc2b9_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMC0xLTEtMTc5NzE2_2939de66-932c-4e6b-ad04-11490b474fee">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i20afac804c4041ed899b450f18e9dc96_D20220101-20221231" name="bhc:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTI3_ff4eb31c-416c-4e09-84fe-f967761f1790">P30D</ix:nonNumeric><ix:nonNumeric contextRef="iac38adbc92884946ae5f917cf58ca323_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDc5_7ac9b54d-f1f9-4a3c-9aa7-dc857eb1ddf1">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="iac38adbc92884946ae5f917cf58ca323_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTcz_3643a3d1-f7d7-4998-afc9-5317fb44ffa9">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i28625644c7474c10beae0b5bf10ac394_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDMvZnJhZzowNWQzNWRkN2Y4YTQ0ZWRiYjI2MmI2ZmZiYjBlZDQ3NC90YWJsZTo5Nzk4ODUwZTc2YjY0NDY0YTZhODUzZTlkNDA3NzU3ZS90YWJsZXJhbmdlOjk3OTg4NTBlNzZiNjQ0NjRhNmE4NTNlOWQ0MDc3NTdlXzAtMS0xLTEtMTY5NjA4_d8394bad-084c-46d9-9338-e40cd6061742">0.5</ix:nonFraction><ix:nonNumeric contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4ff6893c5f5d415f9e29b9f99c2ebded_D20220905-20220905" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NDM_93af1e70-6189-47b5-bbc3-e0e2bb7a586f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc1MDMxNjk_b501e15b-da5b-47c2-acd7-f8740cbbba2e">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNDI_bd3faf2e-8d53-4f0a-9ea0-1f5a151830e1">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NTY_abbdaf34-1a0a-4131-b1a8-ee77e636b7d4">P10Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="iba32dedd928944da83299aa3d3ed3346_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjA0_55974b33-e4c2-4c2e-9a34-2e9068d74704">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1a4ddffae3344372a182a6c72cc2f5fc_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjEy_a0978419-85e2-41cb-9484-209b4ac8d8d0">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ied619ca0067f4cbabf0c52c7b99335ca_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjIw_f462411f-aaf1-409b-86d4-2144fd669537">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibd0b6c724836415c81fb64b147921edd_D20220701-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjI4_e6349cae-54be-48eb-acbc-821e8fc19139">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iaab69c0d93144f0a90dcb5aceff25294_D20220701-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjM2_d9f519c3-a4ae-4f72-8c05-f94176e2f277">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i22321ba60ab64391a853e3a1ffd653d5_D20220701-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjQ0_22051d0a-83ca-4eed-856b-f295062bbaaa">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc68bd369cd4500b13aaae303a6c383_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i76ecf876aad94246b25154ba566eebd1_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ica54d07af4a0484896e86ce0129c4df1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1a172f25a841aeaa5ee92611763bda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic504eef7811a496cb440f3d265414631_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i352ec3a38f244bdbafd755de208aa067_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia31a4f763ded4502b9e4fa2d840d63f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28edfd63f7b14bc8bcd18527c6781606_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e70e662458f40bb8c987a1572e53027_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42242da77914d51bc567ec579238930_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc69aab44eb84be4ac14baf7ef6a6ac2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5355a46f96463087fd4837bdefc2b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad43210cdbd45f0b0a9a371bd0993dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5b0ddd5ab97433abadd6e743429df67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f603a5a47f6490291f143a008712675_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b88f1ca9e1a48ad9446d9187ae673ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1162a0c4e547519003679dc043973a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7beef9cf290b4312a60d7c32efde693f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744ebc157dbb4a0b86ccfabc060e848f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d9756007b6d4f3d84623153c2dddeff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9599e56128940a0955ca4ff88d8639a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687d9364584e4a7ca7034a3483a95a7d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9effac2c66724eed803dffd7950879ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2c612fd89643298310e38a8883f365_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4869d1047a0141b19a3fbf5790033030_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcee2b5169a8459c8cbccfe68bebb595_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9dde3b1c18435faec13820801e4e34_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4522c45ac1c44145a7ecea556295fe2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if48c23e1700a4f49ba421b5d2cbc0242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03c547eba26f449dbd67bd40c78e03b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85093372ad449739b9c5caf68d08cbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89640c6de2df463b91359c26584e4b54_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i666af66f47b4407393455522d3f67aab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d90679865d741fea3690267adba920e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286802cacb2b47a7aac5819b6b1ae881_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcfc9710ac6749858b8d7495fde87d13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414d863f79fc4e20a1c5842fb6a72ba3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ad12432cad49608f2807386679107d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="i9854d974005d4f129d1f349b2e8e9e0e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571caf526a3f498d9102359d54985610_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664418729e77455ea311715c8025ba3c_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4af7206f3dc4cb7ae55779f23145348_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb85da3e8b8943f38dca2d158d722362_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4538c7b5b4ca4fdeab03c2bf4233e8d9_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285925d86568407da8a3757803694323_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b9870676f542a6aac864bbace50b24_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>bhc:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="ie91578972bdb40a3af61e355b78d5073_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9466cb58824868850dfff1f0fc66e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15bd253c0ab41118c4045afdf0da935_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1524d212be2e451fb87eaa66b46428f1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f0642352c64cc196cfc2d1d9b89a93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32df11a6c7b427ea3edf23629b832da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica86b1d3841f48b0a4940ae2217f149d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829741d1c6804070b7cafb83060ea664_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073d5fbb37a74b6896df8b862273a349_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fddaa647d224e77a75b08d87ff4b3b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7338914353884cdba4212e42f3f0a816_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce6f99808e4460581a8ecf630ae0e44_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba264d87eb1844f383743044281eca57_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b60e4e1ba344759f420bb9dbb9e07f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33f7392918d41c58f5a2c8261fd0cfd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idafb37adc38a40a1bddab0dddf725726_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42fbedcd6cef45eda7bf77d1487a41c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95efbf91ff384469ba31cc31eabf84f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43679a56867547b585e61a8bebd30a9b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f5735466294af0bf44c228f9e7909e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e3ff0b63c54e8195b04d98b1f2ea94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35c9ecdf3caa44afb7674f4ff6cfa6bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab447034f3cb4a3f80c5615de06f525e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1298ccb8014e2e952b7df5ed8488c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec7611adc424942b82f55c3fddc6e0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f3ba9f79754b2ea2362524743f75b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa6fc4c28dfc4f42aa151ae93e67746a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd7e5042c154abd8c3fb0ba3a5333b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719c1c8681de42628cd8a33f7cf93c13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffab7018d0f4f64a53a07c03c589447_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9afa3f38b75645c38047038819ab8039_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af36779781240ea8b5a9fc2a8a18c0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b3071dbd0b4c22a7410dae4bf7b27e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f6251d34e449328ee02711fb471754_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b3dad0951e4afdafdd9832d60755e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a778a0ae49a449791a3ba321887c7e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1634ddcaf934a68ad0cbcba62dae846_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12975a1db9344dbda6b24ceb8ae4993b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc88addf22a44ee8b85946edc015b2db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879910dcddad4e1ba3539787593b400e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20afac804c4041ed899b450f18e9dc96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3066bc5404d6492ba2a9b0f3e2e60f4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac38adbc92884946ae5f917cf58ca323_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9a436ca4734f6f94506b064f541daf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:AssetAcquisitionAndBusinessCombinationAxis">bhc:ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f28cdba1c984df9bb56e87ea0c43627_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d21286a1db84d29b25753aac5f56c63_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idefdc69a4d2748c3a652f4a956103762_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524d6ebfb9f44cdab7f8e33886bbb169_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf28d9434964d1dba31bb27dbb684d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide1f360554f7411582424cb25e12139f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955e95f8176a41949983431111fba814_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic539170d6fff4d05972a7397e5960010_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3360f8949ed24c0b940f86ac34748add_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ca3e5e97be45d19824357bc3ee379e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccec48614f5d4821a0e8b30e1252d2b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17110427cd8e4e619785b7b0d32f0f70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbc775b178554f5cbfa0bd80dfded44e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85324249cb304f399a6dfe976b7fe743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a3da17c145a49f8b5870436902391af_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2117911a26c0491389f1d3defbed0a7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71f74f577b3494b8e2ac929500c8376_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019d338e616445d7a5081ae3d42d3429_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2af8e02fe54c78b7f35ee1a9e11c90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id050355187a44ec58d9dae39638c996e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0359fde753a243faa8a6b23ba6f302f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic910749763294350870635de86bbe6aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46e9550a1a424a89b1dee40213b0de3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b90092334445a8849506fc89a086ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a4eaca0ff74acda11e62ff530e7678_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="appeal"><xbrli:measure>bhc:appeal</xbrli:measure></xbrli:unit><xbrli:context id="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f44a4aff374a1ca74b044ad084bef4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000ff44669fd472ba78d6de1cb550d21_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686c1137885f4b3fa7d3a9b34364ed73_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73819dbe86f345268ddb7db8c71128b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6823e843294bcd88d2a409c815988c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1694f371b3534c56984cb0cfe3ef6fdb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9a242b4bc754037b318a7c4cdf5b1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681759bbcf4146c19403440ab8bc7434_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd1a2af87dd427db7a4b552da531b07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id964973a928249758deda08b15dea7a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2804a8dc9ae48539fdb9519f6b3726f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4a269030174bbb968a2388290df2a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496ec6bb7c5c49b189881126f8ba44cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2232f920079d4878afb7b64f68af1b49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a2a0cc3ed3047c0ad4ecaa58c71ceab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2851d6501645e39f0bde92ff897991_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4532439f68449aa15050571c32b49c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie158e865d7084cd7820657aac3a943d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f6b23e952b4a29adb188680f77e15f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib48f720a184c4ef7a34f2bd1ad005549_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8dd91ce28d94179ac8fb005c89c2151_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib340705dabb047c38f3e490247c25c10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6298df68baef4a31a4dfad39a62b592c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i21918f466bf24354a1c6d6444bc04589_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90a06531e4448a48622699307e4ff02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d01deeac67f4ce7862d6b348bdaf675_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2d9d196bf448729e83961b2b2b79ef_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a29668b30ec453bbf648449343ac881_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536a23a0ae454cadbc22242f347ae91a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301added27ee4e56a32e9279750f97a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a10a38645a4e64ba544a15e76a1aac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046977fe683b41e79f01810b4a036c3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd74bed9d620431aa82e098aceab060b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5251c4b7112b46c6b9fc7a4f6cb910a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f238094cdda40f1b2d7750a45917f53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic47f900acdec465e98ce7071671bb8e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbea40e3c0740518b9890e6748531fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9e292759354aeda24365245bac9d90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6b4338793a4025bda029ab360f1d32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da1f0ee4e9641a2a9e84287bf32dc6e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24b70b9839e4a32ae3eb6fcc78cbb99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic51c16e7f763491085dd8ffc5944f6eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabdd5d523d9a4a00884669c513d28162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93aa5bfa4146474da5d319dd6afdca60_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72736a422df241408c61594fa909e273_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9fae444f1343bc9673dcae7bca4e9d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f982f471504a4d886d0828ec908c63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d556e8c69b5410fac594e6bc3f63165_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a2da26e9934eb883d8c56c01e510d0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13d7cff51ec4364a60ff99c788582e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideec9371c4594543a2df71f87382e5d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1289ce27c69445a4b28904e412ddc6b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83781ceb47d40ad91cb275c07538fe6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7187691ddb4f3baf53a15b1e780054_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03171de550654b9094b2686785213340_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654780d358bc47d9b9208fc7318b418b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied86354202574859ba53d8251730ef25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076eb2797d7b4496a5587e804a530855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8779797f0c542ae8f67e21fea46bf5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81dc99f8258b4049aee820556d44657d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d4fc2538f545c38a76406207865da4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9971091867b4c49bc0d165d080d95a5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2847dfc8dcef4913b6cf4a248d8cb28d_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec174dd9a974db9a84eee065064aebc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia131f8f45b8e4955bded72abc02da48e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd14aff977d4b488fc11c018551212d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5894755ae0f14e1abd383f2cc912473b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd356ccb740d484fac8d36718bbab19d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0672a8f98ecd4dec9b3ca1e0bb2cd304_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf428232eff4699b8da41866a4f1306_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc58ca927074377a059e6afb1cdbc07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida153af5024646c5860c4d0e1d881318_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd69ca9b861e4a609f1e5f5da66792b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d069e331e9d4278a420482bdaf3f937_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd4d61250f445c8a4800bb452ccef13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0924cb562dd24071ba12d72afe82bbec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ddf60ecd98b4f768f11e6a38f661960_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0deab0ec61405097152c610065909b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff63ef6faace45498e346825d00e01a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1576ddc62d446f3a6d5e4978c7937d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6defc1abe0499b87b8d9ba0729620e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie978af0fcc4247feacd32583a9786a9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db8916c81ee460fac6b5d6d2d6a779f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052132743b504af0bdf4f85716745c47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5770479e5eef445e811659815d6ded32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94689023eb444f91a13a7e4d47e5db0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd0757d629c4245891c0a910034923c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id815a410db39410abd908f92b68de9ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d74453ca604456b90988495dfb2c935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82bb7cbf3457475e9a924170769182c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9856ff949f043bc9821f51eec5c0ca9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0699fe85526c4352aebcd5347c7b8ffb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibde1691268ac403c8e6b3decd6654cb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda7752d38634982add22e8fe5ee38e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibceccba7710c415bad87fdec58072ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf06d2028b254481bcde95fc6c3cc519_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e057f632e184647ae17542d539bd24a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i619f20c616f04a608422a936c94246b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1732052987b04886a0b885788267de2e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c413cdb1b164432877c83f54ab2b752_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad4945bf5b946aeac343ddf77e3ca2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc6df613d904efa9a6c5d3e9e8453e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd76bc2237554c19bf5f7b2da6fedd79_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ddd8e4ef73432abf45d8222d362bc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91663006f1f64ef9b72e553828a29c56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8822a2ac32419c8920e934ce9eb11e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e14db2c7cd143aa8caf8a8b3aee8506_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b234d01c94442fe91530027b0f6530b_D20200331-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8020b17bcc3445ea7163d7ebd53a470_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a0c24b9ab774864babd19a173d572a2_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34640daea4d7462a9d9640c91a9681d6_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89e8badccef47d0a7d7bc1e901ceebf_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e6ce0d73164ddf964bb0ea4fa23010_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib099140ae6db41829838038f01c73b6b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ab98d4a236452a8fb70057836d164c_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c967a98aaf490f85d7f7da1b415ab3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac26985514b44cee99c565494437c9bf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dab83ba8be74e6ea0cc6457f87cc786_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdf52fd4b1141df99e98d44fc5f54cc_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae8581e17154d79af15b43340cf71ed_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723051ff458540289de98a13ff5b824e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4c382c97644eb7a14b499b2e665d51_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b53b103dc24a0eb09366a47de8f0f4_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ecaaa094ed49849e4e48a5f2f59700_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab863accad34439cad8d1a61aba863c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i71a29147694c4aa784a0508f3b8b0b83_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1860ad2ed2945a9a9f05e0807ab6a99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c3ea7a8793435088d6fb6d8ae58077_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b89ed8a12b41e9b73c9ba2e0663772_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7598aed7ec34bddb36dd9a1f40c947e_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide546e7ecff04d7b8671f8b40f6612e1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42871f56c57941c385528783c1e999c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263addd715b04b329673b5c1f5ccba82_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dad95c441654101809dec4ce04cb340_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7647535adfe442f6b2bad4ec71e6c424_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48916ae978b944169cbdc730b06bc6fb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a7459d4547245ad9a36ea070c5f5ec3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f86b5f573824c0b99316ea9e59d1842_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf2cce057f44b058a16380acebfee7b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e03f7f94044004815a278acfe122e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4915118e4c47e39d266ed6aa6df20d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3237e29dcce54fe4a18404bf646a22a3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if150371b70684386a5836a8b20ae71bf_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72666ab0833443e986330313e8a4c321_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3567189e676429991222cd3e3e1213b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84c3447e94e4cf08b00cd1500e214d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba65689930cd459f9a5372d1a52fcc18_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40adc4228d5649c8b5ea39c9bb7e19b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SurgicalReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e26e58975e443e0b51918f03cee7d5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2961e7ea8ce40b29f24b00453ac5571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780fe08a52e14ab1bac7e028c782c9c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c8e00c14544d52a42942914e81c273_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2604b11090a343939a4cfcab0196957a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aaac0c0174b4c27bd54436507088ceb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59050beb6a5f4285ae430ef5a8f35377_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc26a76728a46aab695daedd417d9fc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8163e10398b746e7a5edad1b5513c5c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e127eb541b94518be190909675ed289_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6f95a9036b477e8cb580382038f606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb29815fc9674a7c99be25fdb001b3a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07aa5fc5a9e841de925a2df849619500_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3f8766f9504fd1bf68133e1f140db2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaccccd91c84bd69bb27eb24388fe86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409f129e0bfc49478eb8d9d221ae81ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ac2987c7a84f5eb6926a647891d84f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d7411313624b009890802c2b02341a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e1627198084241927fb3193e16c19e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9aaa9954e64952b709312f105f0242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d26b379509d423eb7d0672c56517477_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf79ff56bc204a2c9936be929b812f08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd671799f9f141918a55117de2700d25_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d3d40cb3df41cb9891422a15f11c46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07fe67aba19647d8a1e332514379f9d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1fad0f4ca745f2846087891acdaa52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3871b29377e94ec5b038d5daba56ff08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie524823ade0a444c94da1bd1ed833f9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378ff1b395ad4dbdafa627b96247ff1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i881d1e751ebe415e99bf6d231a16fcfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76d935f691748a49d6a2c6eca7e979e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic646016282634f4faf802c21a106b8cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3678917bb79c4121986b9218d5ffed64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59d52dbecab4068a233f40b5bbb55aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01229077aac498c8cda3d570f0e07b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e40adf4f7647f89d1e9fa9364e241d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1486c4b57084e97aee9abcf914db494_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0745c7074bc48f0ade1f704c884d877_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca0d50d36f246238babe463a6168a0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af86776c3d44c6e88302711b8c5846e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd85d5e6a46425692fc6df9be6d1548_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e536bc640ae47de8bac8ed86aa24e83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721f7910e79b40e1aebc37232add279e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8438d9428d694b1b806321debd8fbf57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1261229BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470227bdb89e493fb8816f0ffa6ac326_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336001093a5145dc9bdc0d6e370b605d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd991f205a44e65bd6187fabb7e37c4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcdaaed0902414c803acc0f1fab8685_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i875efb41d7fe43c6bb3f59c8192b9d6a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb07bff0ebd439fb019a10f099085be_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1517f47c4054556b04ca7e9f7836241_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9afad4d704c441b8aca72f314828730_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9830466dc5e4c1b9a52f500da56a52d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed6355aa8404cc9862ff4ff062d0399_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5769552bffcc48e19f81962c26dee7ad_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice52a066605a4e9897aa4694669ec4cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e844fc59da8465586a93905777c04be_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf91aadd30904af7ab5ff5c49b173483_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f74ab6a22d445758697179f2d0c1807_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb3d1e5412446dc811ba962259a01d4_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i523d17064ca94b16900c15d5f8c804de_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0475cb4c7ac43abbf4df21604027a97_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfb98dcef094732bcafe6f62012d336_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9ce2c21b474762a7da6161958145b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic42bbc3c6bf3452bb704930c76f7dde5_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i377918284ec1474f8fdb964743a3854e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b85ff842a240e69cd341f8a97baf08_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02adb91ce4244dcfb8903780127e4950_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2371a67c1d5d4ce6bb8affa16d99a8ee_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc22bae41d747e1bf892fd0aff2bac1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b21613190a42c48428381118250a85_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08144428b8f74cbfa6a5eb11eec200bc_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b61046449c4453948b31ac17dcf49f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib987a52fcaed4951afb151a82a0665fe_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i279595da75be49f6a0842b392c5e04e2_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba9e35b10d64b8f8d73e9204b9ccbf3_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e403587348b4dbd9a36b1f6aa5ca65a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4085e18b60c748e48cf892810f08a0c3_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ca66a8836a40cb85dd578b9e98529f_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7b201553ea840b8882b868dc71cc5f0_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e771793b9549488be559466ddda99e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic889bd7bbe3b4f05a299372748c68b3d_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3e0b748c154802a58a1beafbe2cff5_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c6d66c35ee4080bdc94c23a19b52a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie320b639a3cd47dc961878584dd8c3af_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abed56d79f84c52a16d613195c7f1dc_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5222261a43e242bd96ba62a6d53496dc_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b348dc7be84fe6845f94845ff52de8_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b9fcb7582349bdaf4dcf63e1033674_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d957402ceb40b8a787c5e4f4236ebf_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1cf2c8c91a4a85aba037eee43e16a0_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a3c2097c9343febaf0889f97fafd58_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3678fe7d442d4e65a3e4b646e9a46587_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8fc1d36257456c85af865931829d7d_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf08cd8ce2848bfb0ffd1ba61fd6396_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1587227fe18483fbd9cf40bd7d77115_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce57f96608f474f8f53043e82f4429e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b6aa60fd3b4cb8a9c35ca0b87ae3bd_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4684fb9c9da34175aa3d87f334fea43d_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie357a3d3d5a5421cbd36adeb99212916_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfcad9639644d1aa8dd1ea244c8e451_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cab5412f0764a9597e25ac424d2566b_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71bde11f22654ef58395cb62e46066e8_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieedc4eac3b8d4a698d8cb9a05c341498_I20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic538128a88704c54a42c782f1c49cea7_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e218676fac849289a6c340912b014b8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aacff91d3fd4e97930a57ce23252d07_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157619cd6dcb473cb47ad7bdd54e90f3_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044da1c8e8644f5d923942355e34d8ff_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb6552099344d328f3d1d048ca4608d_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b481eb38c945c59569b06b12fbff6f_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfc736c31a94604bb0c70ced892d8b7_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae7bb4dd25840828cd9d3be1c5cf334_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd58703f4d64effbac9da3441381c5d_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88775d2b6196454d8a77ee9d6235695d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0698b60423314874943ed0139e7bdff1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a449c4bfa5041418ee1aa7972a1256e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7729b9b40f4da1b234f69afa941cbe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9e2bcfdfc8462abc99097872f4c5a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff3554474d984129a7b72717cf870c74_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd69ab9daab24aac824807091b8a5671_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c469d793b6f4ee882b2681b6838c579_I20150130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8228270dba34df8adb389c08897a92f_D20200101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3b96fbff084df6af99651fb95d52b6_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a80fb088e54c2f87adcda10dca8eba_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8bda88c9492434b8ad71e6d24f403d9_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f42826c47ed4f49b649fda634dc4a0a_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i2c4e650a31d242bbb5c5d585c03cb333_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5cda3faa264c738c116577d2729461_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e615859d6bb4a4e90467e2add18e800_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadc1532b7b04afba0801fa41303f107_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia297817a7541403aa01709acbd44a471_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb93a16e162462585252110ee36a962_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa832e82c1d49a2a3ff00d4b061892e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669d24178a614762a12dfff0155fe19e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfed71661ee944d49ddb49203d8a286a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50380855fc2e44f5b6be1ffc1d533681_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9882b34fe6474ac8b75496ebe2306941_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df3f1e3d2554c78ad4cbb459875b7bf_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18218eacfbb142faaa9a5d87297b9a13_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696a075a54064b0997717cd8d8a32b6c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc611b24a90474d83f2f66f38a20f88_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib223f403a7154cc18ac343122c9c3e06_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe5dc0384494154a1e6d8f92d81bdcd_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10012d6ae2a4a9a8da2d30e73d8fbe6_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc3ea4063504440ada3d5c75d466bff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e135d7f019a49849b913e4b90edfb2d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81f73f3e85d440bab9c87b07c094950_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274a447de4c946398cf00b10748b1942_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if254b82a71434782ad56911693096e5f_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecbd9075b4a94899961c7585f2aed5b7_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d9a11ba7b5b4f3ba097f6f466955097_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ebc47cf5eb41e4b68a050da347702f_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0457826532364f8e9c2bd5bce176537a_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c9aae9869547b990b47d9f024d2b7e_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f524e92b57548fcb59a5560034d56ea_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40215fdad1084cdd819206c295150373_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a746c21c7a14bc3bc2a6e2b9323019a_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdadcd473052481b9f108756b569bcf5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700f313b8feb4a02af4dbbaaf4864a43_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4a098d6f0545d9a3df6e94e3949b54_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28625644c7474c10beae0b5bf10ac394_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e7ab6a195b4f8a8f49a061d91b6087_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f6923561a7e494dbd4b2c015eaf76da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="defined_benefit_plan"><xbrli:measure>bhc:defined_benefit_plan</xbrli:measure></xbrli:unit><xbrli:context id="i16516120cd164448a3c89f1ebb6cd381_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96b54eac8a34eb6b8925e566ef51275_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6738f26e1aaf424082202a7be5272d77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce272f013fa44ac973752d5610d84eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea04213dece64c3497dd259bdea83001_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0e93f49dae408e8c386793727d9086_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfa7c677eed24732a11e7ab6f1654f25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901b9016f0344620b9f6802621dd347c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbb4a6b3049041e6a53d4e6874579447_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c981d7a36cd45b285c23ca5fdc44f66_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia086606e46a34f71bfb9e605f2e6266e_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7def2285ac5140d38d1f9ffcf8a7126e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i890e5bee618d469cab458bb423035b53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd01159712142d2a14941af601cba4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c9b32cd0a64bd9a48e14dc09730b3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib186ad161aa040e7a1a0cfe3d0b2add9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7b19941aba4839893beff2b2339518_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if909172682784a94b3a8faea6d1af750_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6097557c0fd439483e7592516150539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if82393cee0c6403aad0994b42e1b3e03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21af5dc5f9dd4f15985aaa4c4bfd5822_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ecb8307bf5d4aff94f54ff6b76837d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb616bbdc2974979a68ab30bf4d7f508_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d55bf5477448368b255cbbc9f9ac2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id842fbc0d8ad486aaae75003e4167df9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba3108451ff34c44bdccaa78adf4e451_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0fdbd98ed940e8bb4f138e20fe4aad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b66f09a9c794304941a8e256c67d221_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id46544209ecf4725a093aaefe444ca63_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7cd997e52074902b6b0f11a459c1455_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddfe10a628844d85a9f16739ece8b000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e72c38588c34bcebd41f5dee9e6e442_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80c26c19111d4d8f9acc24b805792584_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebcb27b8c53e41a4a7f03c7a9ce24b16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4aff83b9c634a5894b070163727d3ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bfb9a5fc6b5416cabb3992fd6d9866a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c83ee90555c4d4388fe2aad369a07ca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94c6b830d4d4e83b5455bc50c831168_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596d5259e41b4516a9b8bd8bff994b04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d65fd0099884d129c8955aeded2ab3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59f1bfdacbdc49e58897e6ed02cc3ba3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eff69c67fc94f7ea63429c1b535269f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06cde57fea89421ca93bc357400547db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcca6398a69456491cd915adc6cf018_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1025885b5b041c495101b7c543c11f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4749a66112794a748f77060b21d3a4ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d3fed8097a4daeab0e728d1fa59dec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4325c973be4bb49485892fb209d262_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbdd4eaf78224b6ba6820bf1639d0b9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib57fb1d627d84572b6935e5a91bc1ddb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce670f0334749faaec2717ea665b0a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1b1a26770b4939981b10056497e10c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ffcdeee6044901ab85b83bfab8de15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia469039e78794b72b821fd03d9c90ec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943e5fbfcbe84d65b033540f48279c89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940816bafd874e0ebc01474cfb7a3a65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b2464e33b44bf28fa58498386246b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0537dc089def43d3936e05d8a4ff751b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i166bc7feb587436bbb13eac98a8a0cbd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba4611dcd504efcb55fd69027047b6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4161b216dc5142939aa46e36e819cc8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cd435007f84ea6a463f1c697369c5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6ff1609d90414882841cc6046a9951_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0966710236bc43c2af312375aaf2ff7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if627813ab5da419892b99795959e6aa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20160fde44604a6aaa038ff97269bd4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838299195fbf4b9a822896bdc73e1fa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia604d8b17aee4a76b705119871e72bb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a13cdeaf0a4538ae66a0cb4eaac793_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cd29133231149b7b1b8a8ee26abb9c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9487a86efc54fb68c486f5b06c683f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeac84c7747644e18df3b02f9009bcf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d0aeff6b0247bbb772f435284fb4ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022e7bc0a5b44851ae8856c5d2c73a9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25e42f7f8fb44b94a825edd38ce13b8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b44a8ef5108400eb1f8766f7e0fcec7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec9432798a24a7081587f93c9df9218_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c542d4e97f492fb79c2d7ea87bc43c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c92c43460b4f029f30adcfddd56c4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87b5c5cd3884bc6a0c85db52ded0201_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba16f047558a4012b26c69b39abe5903_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85986033cb94474b99f01b19273837dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5849250174794a5294b9599a5268d9ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e897629c0e405197197192231ed87e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i586cba0ddcd34f2182b8f7a26689b550_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a90c8afe5049298baf47464adba23f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3b750ecf0264c51acd1b84640243687_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1ee6e5579e4fbbac27d5f4d6d6c071_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7beb776c2d084696af8546fb16fbfb0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e418ec04bde4a42807126013e7f6e28_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id064c3e553534ddf8d58196348abc463_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc34f3620a04953983302095d065919_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e718d2c489345649ae9f4b875a944c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b786c529ecc420a98bfcc8623fd3887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192fabe7c1564743b0a4bfd0ec76367f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2583535030e04ec19d33ff6aa980c232_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbace4328d64e68ae9985b0db92a939_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54976a88d71c4f29a87ce8b7fbb1f390_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if368c75fe2714137b5b2bec4f478ed08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874f6ee73d0b4d708cde5f122a628b5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ab17d153f94ce28b4f3c1f077f073e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78598f7e1204321a742adcc1939f548_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84605640b59c4cdfaca45e277d8f930e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0da8fd5fa784526af1d7dcba6682ea3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a9b377100548608bea1fb0de4c4b8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d15c8b03fa84bebadf0ca964ff394c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a9caf7ad8a43c2a1cf9ec9bf2be638_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f47aed6238c4f0d8374cffa9d1ccc3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943967018a284fddb2383dd48804e6ce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica42099d7cb54b18ab0758ac46934fdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b4988948464da080807bfacdb2fd60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0e958e564b34a8ea6e5d23a9dd1d9bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15ca0c069774a069fc140fe27c34672_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e7bb314271400dadeec64d6689bab1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a1b6f04f9843a3a430cc23faab2335_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460709745cf1459d8d83a3ef3c4c4028_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i807af49d13d7419ca0ef798eab13affb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a95e634eae482ba0ca850423b7cbd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ada76f87a244e6ba2a626f4f5d2f68c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4bb0efe5f2746f4ab125458e68b1cbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643e656337e04c8482c55cf8750c1308_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34397ecd5a048799f2dbb74323fe7fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0933dfd2b3014b3982966e76c30667ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id83bd552fb8241e68b041b00d4deb904_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5317bcb7e0b4df8aa18bb103e434600_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2c0591c4a3a4e679502344b5b1c1371_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e710e9f1a5d4373996e9b7fcded1add_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229dc35bd984450fa43d45f7faba215d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i951ceb7ff1d646c9b3fef0581a1b618f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id767817a5a2e453c9618655dde1bbe6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90326ac3a5c64cfaa3de8f4582846b0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a56c8726ff045a281148a00e040766e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc9006276854ef785d74a884a2fbd50_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6026f5c4ae10476cb57fa85da364cc1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aa0fc165cad4c259a0114c60066cc26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd34b48ca86f4bb9a48ea67c0a464fdf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f30f4d8fd4e467cb57e4293e32ca3d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d49fa28b18849f4835a0e22941c0d50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07679a14e86417f8712f8cbb82b60ff_D20200428-20200428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-28</xbrli:startDate><xbrli:endDate>2020-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4afe550a6c481c97793e197c5bce51_D20220621-20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-21</xbrli:startDate><xbrli:endDate>2022-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b69fb3977c4adc9d0e3708349c1838_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff6893c5f5d415f9e29b9f99c2ebded_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090655bf437c47a08f93010b3050db91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b78b13259aa479f924ecd7471c6be3d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62e3c2748eaf4aafa359630b13935a24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00b7cd8fe45432a9a85664c569eeb15_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d64492eb2e4908a69e9f58b7558e25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0946c8396b744fe99205ccf1dee3017f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede2de5499f441559e821dbcad622021_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f0f7903cd849f3b7151828b60fac8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a380354c968473db359c0f5368d07a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia45df334731c4a1288356ac1f33c7415_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia355745004ed4515ab1169c8dee886ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6f01dc7e7849e1afb697e1681e7989_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic888605118c2447e80ad019de50268f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f438587dede4b58b5187b50c6366f8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2492e7b35404d8e87840515f9d9a6c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae249c92a22044b9807b386e185de759_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee78b80f312454f958d6185baba0299_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d52467dd2c048db873fab55177a674a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8820b0a3beb24bed91da8f3c82e42606_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c7a9138ff04e618e86f8caa65ef150_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371264615c75420297fa60d12cdd7590_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i976c4ead5b5e43388410dab98e1380f6_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c08f6b4a1bb4b97b88bd4703a8f0c70_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eae6ead96a941d1b21a4d5924929d5c_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798f17f8800a4c818af00babd1be3910_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c83dd26ed54f1789ce908d1c7409fc_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e72a61294341d795cb93013ab5a0ea_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee915a0af56457092546e18d9f5b2b1_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba9807196544553bf6afedfc7ef764f_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba13317aa60c47fdbe720638efeb8a32_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4972cc1494f64143a33a8f5939165fb1_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9246f8b8e1204a3b9c57cd2cd7d1f32b_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia300b8d00c054934a733fe79c976c8df_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff6d6c9c84647b1b1dce247dcafc619_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad5cc2f654041548ac38459ec8e3737_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158545ece5364e96bdae2027c13c3e8d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57057d66fc88405090a8ce98ca6c8e2c_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60f66139de8490cb251cef704102616_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f724b3f1785466b94b544893b47c1bb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e52757684147129eded077c6efccfd_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic466f5201e554473806f5d23207321c7_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0ac44894434f3c838f08217170a230_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496a8139703848748c2af0e1c60eba9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5ab484db4f47cea101682d1dc38960_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e87d37abd4499ea01e8038522b296c_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if701cbfe1c6a4dcd881783198bdf3bf1_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3174916bf904c96b87d8033569c321d_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7365ac3a4d640af8c0c8f6f469cd387_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d68de5df36c4a3eaab2e8b8f62dbb07_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694231e10d404b83a250ebe6cbae790f_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6757e09e35d643fa9be873511bd89c4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337510976d6d4c44a85e9ccfb0130e9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b929374818a40479322ab79af8f337f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d4815a98c184418bbffa029558875ff_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba32dedd928944da83299aa3d3ed3346_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4ddffae3344372a182a6c72cc2f5fc_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied619ca0067f4cbabf0c52c7b99335ca_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0b6c724836415c81fb64b147921edd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab69c0d93144f0a90dcb5aceff25294_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22321ba60ab64391a853e3a1ffd653d5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2ee13540d244e58ee59a9ca76630cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9476d0eb2004c5589302c03748dd6c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01756a362e44beb92a479cf33c85af9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f95881b6ece465992d0a8b5672f70a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc8cd56812542429247ba8cba9a093a_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c97c4ec64941ccb13c8842880f03f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id14bc647bd66490ea555f0a1a8e9d50f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a3cb34cfce4c28be127d8715fd26f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8dabfb23996479799c6a595815ba441_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb60c46f2cd493491ad50061773a9d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea89cae1b5a49169da66c58b3a977ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8f4b7199a04a1bb0f06da2481be68c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a003bd56204fbfb30cc08651a430f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3502a33c4974412bb446b4520804d72c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23665fcb8d984723906982059409b87d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cac628e4a8a43a0a0981c64688ec2f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c140b9741d2496b919924cb9b494679_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9bffc500cd4f18857b951c1603f412_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76d6ec50d164eb3bcb9478a77019aa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>bhc:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="id57f6448d77d4f498fcb2c7411041826_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id573807c0c8f4975a352cd6f593b3ab3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8aa63b12662497fb48a3704825ff944_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9c4983bcb5449091d89286c6560f44_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb5e7e6a6a4b4b2fbad5eb1887c77136_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a938ef7652a479b9208cc583c1cbeaf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4cab1a9a354692a1713dfef6925e58_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01997882e0124cea82496489c90aa07b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb51eb021dc4b9b8b4658c2bc2a3b97_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e5f1133b38c4d24b01b931471fd8da0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d1dfe888bd45a8883f343b6c477481_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd1521a412949fbbc1e51c170d1e007_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16aed0f16ef84c42b74c7c39bd8a6462_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96036ac44ae4695a0fb252d5f81f219_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia889587b544748498683a9f94901e27e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ie4f2bc454f0c4e1ca352bcd59e982748_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9234e9d2a34cee8234f5493a02f5a8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35b381adaa44c21ae46f412455f4ded_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb1927f7b53477f9d023db6485f371a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b848aa660941a6becd4eec0de3f15d_D20221108-20221108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2018And2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab5fbd88668641d49bf8a11320bf0006_D20170808-20170808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-08</xbrli:startDate><xbrli:endDate>2017-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie20353a11f9f453cbff47b23ba9b5303_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c1ed23b8494ad19285b0fa18785f85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee43a25eaadf4d2d863f02a387856a5a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a3b000967c54376bcaa8d1227ab2fc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89e7a814f74a4ae5ac92920a38079cc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd34d570f3b45a0a89bc7b370627a8f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb1e399c6334b55a693b8c539d5389b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c9837df7684cbbb933fd9a731877c7_D20230201-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="icae732543b524862bc31fb3dbb9b61d5_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="iea1d9d4e5a1f4370a7144323d17979c8_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a775a1f0484870a58370f98e7e7bd6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="i7097559c54d642c9938d351b2479cbdd_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbd4359a33044d39494365672dd2a82_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i134d05f75047419881c27f05c3e5188c_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number_business"><xbrli:measure>bhc:number_business</xbrli:measure></xbrli:unit><xbrli:context id="i6a47c7281a5a4ca797223076080e2992_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24e6b01a46e406cbeeb1ee5f895c977_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="id939f2c8095a466db826592c2f72f9f7_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="ib4df41256cea4da189ae84ef1efc2dde_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb9217417cee498197ad26aaa5c98390_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34b9f8ec08464feea2782555631f70ea_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0963b261572a4ed8bec2d26c9a930742_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c21c165a2814f47b755c7aa53f9e73f_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8128027f2f4ab58c24767a783dd7af_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id79311217c224c53ba11bdccb33324d8_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea8d20caee843099f9d0591402372e4_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278dafa9c31e41f38e93fbc21fe0ffb0_D20220721-20220721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf27d74757bd461caae17e74579bbe7f_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65a96a0fece84234b0dc8fea3877eca8_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ebb4f96f1c4839a1c7d994f5ba8dce_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:AurobindoPharmaLimitedLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>bhc:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>bhc:proceeding</xbrli:measure></xbrli:unit><xbrli:context id="i125a5a3114cb4f8f806bb33e49ba3344_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4a7cbf453c49c3960027b1664103fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f029dc1a644b39abdd1b72ba3c573f_D20230223-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-23</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4097e666fef649debbac3e331a2e144b_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie319856acc814519a20ff1bbd24232a7_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70dad8274b624fa288d5880f291cefaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>bhc:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="id902c97014ef4d54ad1d3eccc0cc5fa5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24bd15be9a6b4930b6fa4d6deae79314_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacdad21d98743ffac6109a55707e12d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ed2bf0eb0249fdbb1fea6f1bf3256d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec102f85ef9435f9389768c72affe6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1a585708ab453a905d7caaf12d2868_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6fd7f81bf2c4837ae0cd2c5aeed8804_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bb3b3e1cbc48a8a7d48f7ba06845e6_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CaliforniaProposition65RelatedMatterLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808a1d4b464940449c1d6cc1d68d3e33_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib662b0cd90234eab9ce6b4ef74639960_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa7f0c978d24ea089c5cb9062c953d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib717bd3b56334329b39872e4c89c7193_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45faea11a7064b63813ba6b35593aff5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b39b3e635847789adf70ed040317c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1daf50b967543b5947399752d3b8bb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579071a879594866a10f896450838c2b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="id9d231d4c2ab49b88a385d4e4c1d3968_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da3bcf08f654fea916793d2c53d072a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fdaef4346ea429ab8f2ee8fecb44632_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb853490a8ee49a2aef8cfbf3f5a4de1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d95ea31c71446ff881e3c3c83eb2a25_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca6b9323bd346c6b92ed1a1b30acf7f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6deac1f013064d42938f9021d70b9b61_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413ad399c5bb4928a8f7ac2c6f964ef9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie76b4f5598c542e8977f57517d459b26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f4fddaf6544a54a803b97715d8b8b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47333b2e0a19447cbe86b126460626aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be54156c43349909ea3602fe0d42877_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb70824cb234539868d27d67b554357_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia502c9842e5f4891ada76a5da18cdc8a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eaa6892d2db49f1aacde5bc7fa45a10_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8e8b2dc20c42a1a2e9a6dadeb73a2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e2a9d241f34eeba2efe5bd5d76a0a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63d862bb8366425a880c22f5380b0024_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7420a01c31714c0fa1134b1dabf8a3ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3abb30c5b704481e9f90a6b9c448bf3a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6294656f6f1a45a794681c73c8296f8c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b09aa9c7b94449b67cecd0b45214cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id206b5af67f845f58c6cd1d88e1b3a4e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d5a2c5a359458caf52d23f7b41228b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if159fdd5fead48bc90289f41c8322f11_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ee52ba866140689495745ea109e4fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i863f2f8de85147fda44457a636fe5c45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3715256e943148cdb22ee0f5bdb45137_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27712a14a4da4b038f73217c93180d68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia596d06d5cf7420d91cbacaa63a7e5b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9b8d6292204ceb88174f589a719bc8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4219dd6acfb54efb9311c9475b6e23e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4aa6ffca7904bdeb3915ca156eb077d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9483d11a5c444a2da894062077c18c91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia595e166454e4a1ba18f073f7077f6f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079da80c54a848e2aa47e7dbcab9ffb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c31bfc35c5482fadce56e0fa82199d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a404c0e4ddc483fa3b4bfdba829dc37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f17d0100c9f4f9aa8dbe75ac00e0ff4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2776913bc0da414c927cea557f03e444_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7fcc4d25bd4e2a964cb2338ff036d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90da407f7f24ea2a426ee198bfd832e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacba9807dca4896944c3cb14d2c9965_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce14bf04cd843c59432531a3a383d1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0a21d5a4a145ef887145fc4fc218ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf694cf9ac304e0d96169b4f91bcd66b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be0fb17d5df42c29867d7fecd2c7ca2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db8a506550548a299d51ad491787e26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e9fb9964a742fcb99f6da99aa5fe35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic263815e2d40493288266b33e37dac17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5940ce49e304337951488a51673e969_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54a0cc879b847ffbe785ec9a5afa987_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6a43da1e3e4fffa44339a4a14cb01a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89989032253542c28bdb051d0db5aa09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7610e8eccb34bc18c4be768f086e8dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica8a2661bf384208942b587c9911db16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9e5472be5c451db5b0eff1fef54cfb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e3baf2a6764650b923ffaa42fce977_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8931f56328824e31b191e53741aba6ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4a3aeeec784319bdc81ce480a56718_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5885f21d2149079bae27f669de3070_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1702ecacf6b4d2d8df8794ce2cd972a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae851ca48674d748baf9c5b2236ce7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d622f630994275af93f8255a42e4e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebef6967183a4000beed50717736f608_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f9df991d2e45d79da2861c921c97f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f6371e887c4f53b390250e5b574807_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414790932066409fa853afdc5c75d6ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210933c886d5414891a7858fd7293231_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd0782133c89472a992a06cebb386638_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d7ab2322e5421986e53954e29c023e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a29bd754c024342b29079e34fda7eea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22303d42e3dc44f9bc0a9b6f8d915e17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52852499987d44ba88be1554788eb30e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0fdf48aa584499db19f9a47cf66ee0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i165688f9a68b45b9816d827111639efe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f22081fec247ddad4a592c3c9311fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f6805b61b17427ba6040ceb5f878cbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied66a5e8bad6417fa24276e949d9d54e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18258b56d6c404f9c117e6a1895e87b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c1edf6e9fd47c09ba561d2d4f5fb45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aed53df917a48138c9cdb27cea9d59a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3c0300743443bebb82772ee9a1de17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d30a1f1928e4154abdcb87a862c2799_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410f367d50a54973b5eb040cfd166964_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifabc22558a014281b9c2cb444e967f08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6753cdad5c40adb3809316bce79647_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d99817ee7714f4d8639154cc1b22ccb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2f801792d54e30b73e332c26636016_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc14b7106ace4ecfaf704ff0c5ede253_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a2f472ad0740f09224cd8980cd10c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c691843b3b442e859dea2281143b48_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f907111c71342ffb50f8e77dabca249_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5509eedbfcd4499ab1122c8107d4239_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a97db7f7054e388365a90a087bb5a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96fd34fed22f422381e2ab562615f33e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54e5dc2b3f045dea402afba64c50a72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c150c6fffe6495186bf61df0c286556_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40881288dfcd4d5f8699bf1f6a8b2dda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ca09d20c2147509bcbb33af6032e74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23a06260b684c668693d6e121b4629a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie840834914ec48429fa235a8dc4f3d2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8ae97db4704ce7ade6a7925a3558e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884b037761c04998921745217361f61e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98514049314c405da4e7a37f55ab7cbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693f697c02b7481cb3047f296b40c30b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6767d56cea04e58a135696afeaefc93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6f8147a44e4a9992f6184af1c058f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49a7c59a5a1434eadff4dbbe1111a8e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b7ce85a70745f3b0574cc6d9621b9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6026773180f1437d92209ced4c2d11a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9827e7af8fa146468a1dd0ec9ff82b94_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c021e3945bd49d8a09d3bcdecca9997_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia095099872674785b26d32c3d7479727_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c9a8e8837a4dd4bbd6b5d7dbdbade1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ed3916283a42a2919dd657f1cf7467_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b13de71c9b467fbaed74e0a22f2208_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7910566e68784de489fe82fff799babb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3040f78c5bbe4353a9ac62b021035148_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01e7baf1c6eb4c6fbd09d3daa5ddbf4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db976941a0d4666bd6e1f2ba49f58ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61760936cfa34d0f9b4aa7868541b7a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd26ef4e5ea4afc84ba00e232ce717f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73181f4bbbaf41faa1cdd2014a22c967_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0786250ca0c04b9db12a0fedb2ff1574_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121eb01d5e11421ca0cc55f4358e2054_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee77d5bca934fc3a6b0ca93dcb21db4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1273cfab17884bd791ec54e9980c98c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18297ec700d4c0d9f6bab6013cd53e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bf70598ac04fe18dc183a56f3b216d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79145fcaf1184069bcfc23b15cc6a8eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5a4355f0974bdca065bb27be79f476_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie06d30f1eb264b3fac209b850960d0be_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie73da62401a74fc195467ebcc7934a92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f7e3e748d041d1acbb6216d4655c28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i369d1b4494f84c38a91722618c2cf34f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1987f37ff1840ed95338c32804401c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf48590013554b98a5e052a00383ec48_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760a6d7fc1f9409fb0004ef8b8b7dce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1303985937d7476c974821a08256950b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64031ed4889a463f9456655e410c4b3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4e3bbdcdd9403c9ada12b8321e0c39_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcefb49efbb64a5d85dc32f0d8d4c60d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df23a7c7aee42d4ae92346947a9d5d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678b31ef25e240feb62147dc14a7ff6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf1d0feae3e4b1bacd61edd48477cd0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54abc6f54a194617920ce31c6643901c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd0a8a5a2cb41e4a36e68bcd7a52224_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c46b45670f44dc39f81dd4b7a35274f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859c12825f9e40189f911741e94ae963_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id690161da57c4e36a166af99a7b6395f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6727e28116b84a2b96efd2e5c433536b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18f01abf983a4e2a888777c7d9856df7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ec6a0287cf469d8a40521df7bd0d92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c57f85e61143298ba638df79853385_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76b30129b7749b2bedad7175c4b9154_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4de5305b33748bab90c89fa03a2293a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6353361e06042eabedeb74c21af8174_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa738464b0a547659602f730d5711e8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cdc5afe35b143799f38340807d6c40e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa065d85099a481aa7a155608fa5076e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0b47abb6d8430b807a5fb4299b8bc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7665331a2b9c46119262f653ad0439d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfbab45127e4011bd04bc7151f71978_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1cd06e58564300a92b6fa77154d967_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7c5e9fab0f4527a04532a1453031a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i57fbe32677504c888f142dd82b99b37f_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 40.50pt 31.50pt 40.50pt"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjI5_360555b5-2bbb-4a36-90b2-2cabca0ceaf8">10-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:530.25pt"><tr><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8wLTAtMS0xLTE2OTYwOA_efa04582-9abb-414d-bb6d-17d9487b3216">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Fiscal Year Ended</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8xLTItMS0xLTE2OTYwOA_fe351237-b680-48e1-9a71-8b8278279fbf"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8xLTItMS0xLTE2OTYwOA_403a7df3-ba14-46c3-bde7-e2bb9db1f857">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8zLTAtMS0xLTE2OTYwOA_ba7eeb7a-4777-496b-b313-6e0f5692aad8">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the transition period from&#160;____________&#160;to ____________</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMw_726e3b82-d90b-41cd-ae45-161dd5f7400d">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM3_446b0b61-3dbb-450d-99bc-afe4ee7c9b23">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:484.50pt"><tr><td style="width:1.0pt"></td><td style="width:112.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTAtMS0xLTE2OTYwOA_99582be6-e221-4b80-891a-db2e75753f94">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTQtMS0xLTE2OTYwOA_025b3556-3ba8-4182-912d-4460335e4099">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTctMS0xLTE2OTYwOA_d1c7068e-ccf3-4e2b-a983-0fbbd6bdca69">98-0448205</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMx_3637086d-2681-4865-9355-7c34e2f5173e">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM4_08aca0f3-0b34-4c62-85ff-fdd7e24a4d58">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM5_03dfe834-b386-4a93-bcb9-a9fda38fda1d">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMy_2837d5c8-3b21-4e94-8bfd-8be223dddf1f">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQw_449e3088-d747-4906-afe9-7b3c0ca784bb">H7L 4A8</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQx_f8c55d4a-0bdd-4235-a035-b07b33a8d5c3">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQ0_833e30aa-a914-40cc-86c1-8551e43689f7">744-6792</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:465.75pt"><tr><td style="width:1.0pt"></td><td style="width:136.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:117.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTAtMS0xLTE2OTYwOA_182efb26-506e-42e1-a7af-c4b8b5c58654">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTEtMS0xLTE2OTYwOA_4d07ce5c-a4c3-491a-90ce-4878dad7c9b2">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTItMS0xLTE2OTYwOA_f1242615-c111-4115-91a7-580dc0a746bc">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of class)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMz_de23f8ce-f0b1-4d36-bed9-e241fc54d4ed">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM0_0a453464-fd60-4057-8d32-6d687de71370">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjI4_db937546-85f1-4d5b-a1bb-fe7646a71b55">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQy_bcef411a-a0a5-4852-8a23-abb6fcf8cbe5">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.740%"><tr><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTAtMS0xLTE2OTYwOA_6d63f3e4-296f-4d95-a606-8c5ceb52aa03">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer<br/>(Do&#160;not check if a smaller <br/>reporting company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTctMS0xLTE2OTYwOA_2f938ea7-5484-4a28-a05b-e1749614b23b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTktMS0xLTE2OTYwOA_b2602c93-f63f-4e16-a3c2-81eba0649eb5">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM1_2863bcaa-f60e-44c0-bc03-af65a7df44ef">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Securities Act Section 12(b), indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to Exchange Act Section 10D-1(b). Yes &#9744; No  &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No  <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18xNjQ5MjY3NDQ3MjI3_069d7c41-832d-4ccb-9622-a20e724d58c9">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the common shares held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="i6fc68bd369cd4500b13aaae303a6c383_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18yNzU0_443ec42a-85cc-44bd-a526-76d9896e69a3">2,507,122,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">based on the last reported sale price on the New&#160;York Stock Exchange on June&#160;30,&#160;2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock as of February&#160;17, 2023 was <ix:nonFraction unitRef="shares" contextRef="i76ecf876aad94246b25154ba566eebd1_I20230217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18yOTM2_c576461b-f909-4cae-bfd6-433cfde2a13f">362,037,191</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM2_239e0549-2be0-4683-b37a-79523f157c8b" escape="true">Part&#160;III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</ix:nonNumeric></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL INFORMATION</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_82">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_85">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_88">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_91">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_94">54</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_100">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserved</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_133">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_136">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and&#160;Qualitative Disclosures About Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_235">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_238">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_241">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_244">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_247">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_250">108</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_256">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_259">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_262">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_265">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accounting Fees and Services</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_268">109</a></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits and&#160;Financial Statement Schedules</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_274">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K Summary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_274">110</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIGNATURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_280">117</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Annual Report on Form&#160;10-K (&#8220;Form&#160;10-K&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-K, references to&#160;&#8220;$&#8221; or &#8220;USD&#8221; are to United&#160;States dollars, references to &#8220;&#8364;&#8221; are to Euros, and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-K are presented as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trademarks</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Form 10-K contains trademarks, trade names and service marks that are the property of the Company, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, &#8482; and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;), as described in more detail under the heading &#8220;Forward-Looking Statements&#8221; in Item 7 of Part II of this Form 10-K.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional information about these statements and about the material factors or assumptions underlying such forward-looking statements may be found under Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K and in the Company&#8217;s other filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the aforementioned factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the factors referred to in this Form 10-K are not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i57fbe32677504c888f142dd82b99b37f_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Business</span></div><div id="i57fbe32677504c888f142dd82b99b37f_22"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introduction</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its majority ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately 100 countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. These segments are discussed in detail in Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical (&#8220;Solta&#8221;) aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the discussion in Item 1. &#8220;Business &#8212; Segment Information&#8221; and Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for further details on these reportable segments.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_2815"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb Global Vision Care (formerly Vision Care/Consumer Health), Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb, separate from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). During May 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold shares of Bausch + Lomb pursuant to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;). The underwriters partially exercised the over-allotment option granted by the Selling Shareholder. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of Bausch + Lomb&#8217;s outstanding common shares. We continue to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. We continue to evaluate all factors and considerations related to the B+L Separation, including the effect of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements) on the B+L Separation.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, if consummated, will result in two separate, independent companies:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Health excluding Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals, and aesthetic medical devices. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics, and aesthetic medical devices businesses; and</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, &#8220;pure play&#8221; eye health company built on the iconic Bausch + Lomb brand and long history of innovation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L IPO was a large step in creating two attractive but dissimilar businesses. As independent entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs. Further, the B+L Separation will allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes the B+L Separation will unlock value, there can be no assurance that it will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, as such, it is a primary objective of our plan of separation. For additional details on the B+L Separation, see &#8220;Separation of the Bausch + Lomb Eye Health Business&#8221; in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_28"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus our business on core therapeutic classes and geographies that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We have found and continue to believe there is significant opportunity in each of our businesses and we believe our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have a well-established diversified product portfolio across all our businesses that provides a sustainable revenue stream to fund our operations. Our continued success is dependent upon our ability to refresh our pipeline on an ongoing basis and bring new product solutions to the market that meet changing demands and replace other products that have lost momentum. We have a robust pipeline that we believe not only provides for the next generation of our existing products but is also poised to bring new and innovative solutions to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have focused our research and development (&#8220;R&amp;D&#8221;) to advance development programs that we believe will drive growth in our core businesses, while creating efficiencies in our R&amp;D efforts and expenses. Although we primarily rely on our R&amp;D organization to build-out and refresh our product portfolio, to supplement those efforts, we continually seek out opportunities, such as co-promotions, licensing agreements and strategic acquisitions, to leverage our commercial footprint, particularly our sales force, by strategically aligning ourselves with other innovative product solutions that, when coupled with our existing product portfolio, address specific needs in the market. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_31"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues for 2022, 2021 and 2020 were $8,124 million, $8,434 million and $8,027 million, respectively. We have approximately 1,100&#160;products in our portfolio of products, which fall into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. Segment revenues for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comparative segment information for 2022, 2021 and 2020 is further presented in Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment consists of sales in the U.S. of GI products and includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We have been making investments in our Salix business since 2017, including: (i) hiring 200 trained and experienced sales representatives to expand the commercial field force for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) increasing the focus on the development of next generation formulations of our Salix products to address new indications, (iii) completing the strategic acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), which included the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, and (iv) increasing the number of sales force representatives for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we have entered into licensing agreements for investigational products, which, once developed and if approved by the FDA, will be new treatments for certain GI and liver diseases and we anticipate will contribute to our future growth. Each of these opportunities potentially provides us with the ability to expand our GI portfolio and allows us to leverage our existing GI sales force, supply channel and distribution channel. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued, that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed this decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the Salix segment (including products of our third-party co-promotion partners) include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which includes: (i) tablets indicated for the treatment of irritable bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) in adults and for the reduction in risk of overt hepatic encephalopathy recurrence in adults and (ii) tablets indicated for the treatment of travelers&#8217; diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age and older. Our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product accounted for revenues of $1,692&#160;million, $1,644 million and $1,482 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(metformin hydrochloride) extended release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(methylnaltrexone) is given to adults who use narcotic medicine to treat severe chronic pain that is not caused by cancer to prevent constipation without reducing the pain-relieving effects of the narcotic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) is a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our International business includes, with the exception of our Bausch + Lomb and Solta products, sales in Canada, Europe, Asia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which in aggregate accounted for approximately 12%, 14% and 15% of our Company&#8217;s revenues for 2022, 2021 and 2020, respectively. Our principal products in this segment include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bisocard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bisoprolol fumarate) is an orally administered tablet dosed once daily for patients with hypertension, angina pectoris or heart failure and is a leading brand in Poland.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Thrombo ASS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (gastroprotective coated form of acetylsalicylic acid 50mg and 100mg) is an antithrombotic agent dosed once daily for secondary prophylaxis of thrombotic complications after such events as a stroke or heart attack. Thrombo ASS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a leading brand in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contrave</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/Mysimba</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a fixed-dose combination prolonged-release tablet for the treatment of obesity. Used alongside diet and exercise, it is designed to help manage weight in adults who are obese or overweight. The formulation is designed to initiate weight loss and sustain it over a longer period of time by switching off natural compensatory mechanisms involved in the typical weight loss plateau stage. Contrave</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> / Mysimba</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized in Canada, Poland and other Central Eastern European countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus). Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized in Canada (the only market outside the U.S.).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Espaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Dimethicone tablets, drops, suspension) is a complete line of gastrointestinal treatments for diverse digestive indications such as: antiflatulence, dyspepsia, absolute or relative enzyme deficiency, steatorrhea, irritable colon syndrome, pancreatic insufficiency and poor fat digestion. Espaven</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is commercialized primarily in Mexico and South America.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bedoyecta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a multivitamin that is used to obtain sufficient energy and have optimal performance during the day, by avoiding deficiencies of the nutrients that the body requires to function properly.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tazarotene) Lotion, 0.045% is an acne treatment available in a lotion formulated with PRISMATREX technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness of skin) and has shown to provide a good tolerability profile. It is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older and in January 2023, became available to patients throughout Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solta Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Solta business is dedicated to the development of innovative treatment technologies that provide proven and effective aesthetic medical and therapeutic benefits to consumers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global Solta revenues were $300 million, $308&#160;million and $253&#160;million for 2022, 2021 and 2020, respectively. Solta&#8217;s revenue is primarily attributable to Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics of Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and improve patient outcomes. Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been launched in the U.S., Hong Kong, Japan, Korea, Chinese Taipei, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe. We plan to continue to expand into other regions, paced by country-specific regulatory registrations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the Solta business include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a non-invasive radiofrequency treatment that can smooth, tighten and contour skin for an overall younger-looking appearance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fraxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a treatment that improves tone, texture and radiance for aging, sun damaged or scarred skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a&#160;laser treatment that can help prevent the visible signs of aging and address the overall effects time and the environment can have on skin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VASERlipo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for minimally invasive aesthetic body contouring that yields dramatic results with less pain and downtime than traditional liposuction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversified Products </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. The Company utilizes the Diversified Products segment to extend the long-term cash flows from a number of assets that are expected to decline over time due to the loss of exclusivity, by launching and selling authorized generic versions of certain branded assets. Our principal products in this segment include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology and Other Pharmaceuticals </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an extended release formulation of bupropion indicated for the treatment of major depressive disorder in adults.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(bupropion hydrobromide extended release tablets) is indicated for the treatment of major depressive disorder, and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a treatment for Wilson&#8217;s disease (a condition in which high levels of copper in the body cause damage to the liver, brain, and other organs), cystinuria (a condition which leads to&#160;cystine stones in the kidneys) and for patients with severe rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Primidone) is an anticonvulsant drug used to control seizures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lorazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated for the treatment of chorea associated with Huntington&#8217;s disease. In the U.S., Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is distributed for us by Lundbeck&#160;LLC under an exclusive marketing, distribution and supply agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a treatment for Wilson&#8217;s disease in patients who cannot take the medication known as penicillamine.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Librax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(chlordiazepoxide and clidinium) is indicated to control emotional and somatic factors in gastrointestinal disorders. Librax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generics </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorized generic (&#8220;AG&#8221;)&#160;(diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration for certain patients with epilepsy who are already taking antiepileptic medications, and who require occasional use of diazepam to control bouts of increased seizure activity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(budesonide) extended release tablets are a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control (induce remission).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG (pimecrolimus) is a second-line therapy for short term and intermittent long-term therapy of mild to moderate atopic dermatitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy and was launched in the U.S. in June 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in June 2019 and is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in 2017 and is an IL-17 receptor blocker monoclonal antibody for patients with moderate-to-severe plaque psoriasis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bexarotene) capsules and gel are prescription medicines used to treat the skin problems arising from the disease cutaneous T-cell lymphoma, or CTCL, in patients who have not responded well to other treatments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S. in November 2018 and is a novel product that contains a unique, lower concentration of halobetasol propionate for the treatment of moderate-to-severe psoriasis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An acne franchise, which includes Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tretinoin 0.05%), launched in the U.S. in October 2018 and is a lotion approved for the topical treatment of acne vulgaris in patients 9 years of age and older, and Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Onexton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, a fixed combination 1.2% clindamycin phosphate and 3.75% benzoyl peroxide medication for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 years of age and older.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dentistry </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(minocycline hydrochloride) is a subgingival sustained-release antibiotic. Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated as an adjunct to scaling and root planing (&#8220;SRP&#8221;) procedures for reduction of pocket depth in patients with adult periodontitis. Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NeutraSal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is indicated for dryness of the mouth (hyposalivation, xerostomia) and dryness of the oral mucosa due to drugs that suppress salivary secretion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">OSSIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a line of cross-linked collagen regenerative products that provide biocompatibility and bio-durability to perform a diverse range of guided bone and tissue regeneration procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bausch + Lomb segment includes our global Bausch + Lomb eye health business. Our global Bausch + Lomb eye health business includes our Vision Care, Surgical and Ophthalmic Pharmaceuticals products, which in aggregate accounted for approximately 46%, 45% and 42% of our Company&#8217;s revenues for 2022, 2021 and 2020, respectively.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bausch + Lomb business is a fully integrated eye health business with a portfolio of established lines of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products. Bausch + Lomb takes a holistic approach to solving eye health problems, including by investing in physician training, patient and customer education, disease prevention and other initiatives through both traditional and digital platforms to continue to advance eye health. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently our principal products in the eye health business include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PreserVision</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 is a patented eye vitamin formula that contains the exact nutrient formula recommended by the National Eye Institute for people with moderate to advanced age-related macular degeneration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) following the landmark AREDS 2 clinical study. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ocuvite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a family of nutritional supplements that contain antioxidant vitamins and minerals and other nutrients beneficial for eye health, including lutein and zeaxanthin (antioxidant carotenoids), nutrients that support macular health by helping filter harmful blue light. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multi-purpose solution helps prevent certain tear proteins from denaturing and fights germs for healthy contact lens wear. Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multi-purpose solution contains hyaluronic acid (sodium hyaluronate) a lubricant naturally found in eyes and is pH balanc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed to match healthy tears.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb Renu</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Formula multi-purpose solution was launched in 2017 and is a novel soft and silicone hydrogel contact lens solution that makes use of three disinfectants and two moisture agents. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LUMIFY</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) is an OTC eye drop developed as an ocular redness reliever. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Bausch + Lomb INFUSE</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (known as BAUSCH + LOMB ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ONE DAY in Canada, Australia and Hong Kong), a silicone hydrogel daily disposable contact lens designed with a next generation material infused with ProBalance Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to help maintain ocular surface homeostasis and help reduce symptoms of contact lens dryness. Bausch + Lomb INFUSE</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was launched in the United States in August 2020 and BAUSCH + LOMB ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ONE DAY was launched in Canada, Australia, and Hong Kong in November 2020 and in Europe during 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb ULTRA</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a silicone hydrogel frequent replacement contact lens for patients with myopia or hyperopia that uses our proprietary MoistureSeal</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, which allows the contact lens to retain 95% of moisture after 16 hours of wear, limiting lens dryness and resulting symptoms. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotrue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses for patients with myopia or hyperopia, which are made of a unique material inspired by the natural biology of the eye and feature Surface Active Technology</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a patented dehydration barrier. The lens contains 78% water, more moisture than any other soft contact lens and the same water content as the cornea and maintains nearly 100% of its moisture for up to 16 hours. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vitreoretinal Surgery</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vision enhancement system, is a combined system with cataract and vitreoretinal capability featuring the Bi-Blade vitrectomy handpiece.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-indent:-13.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Synergetics</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> instruments include reusable and single use devices and are marketed for use in vitreoret</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inal surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cataract Surgery and Laser Systems</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">The Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vision enhancement system configured for cataract procedures is our latest generation phacoemulsification cataract platform, Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first phacoemulsification platform on the market to offer Adaptive Fluidics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which combines aspiration control with predictive infusion management to create a responsive and controlled surgical environment for efficient cataract lens removal. Our Stellaris Elite</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vision enhancement system was launched in the United States in 2017 and internationally in 2018. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">VICTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fe</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mtosecond laser for cataract and corneal refractive surgery, which delivers multi- mode versatility for cataract and corneal procedures on a single platform. This single laser platform enables surgeons to perform capsulotomies, fragmentation, arcuate incisions, corneal incisions, and LASIK flaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lotemax</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SM (loteprednol etabonate ophthalmic gel 0.38%), a new gel drop formulation of loteprednol etabonate, which was designed with novel SubMicron (SM) technology for efficient penetration to key ocular tissues at a low </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preservative (BAK) level (3.5-10) and a pH close to human tears, indicated for the treatment of postoperative inflammation and pain following ocular surgery. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_34"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D organization focuses on the development of products through clinical trials. Currently, we have approximately 140 R&amp;D projects in our pipeline. As of December 31, 2022, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D expenses for 2022, 2021 and 2020, were $529 million, $465 million and $452 million, respectively. R&amp;D expenses as a percentage of revenue were approximately 7% in 2022 as compared to approximately 6% in 2021 and 2020. We have rebalanced our portfolio to better align with our long-term plans and focus on core businesses. Our investment in R&amp;D reflects our commitment to drive organic growth through internal development of new products, a pillar of our strategy. We further supplement these efforts by continually seeking out other opportunities, such as co-promotions, licensing agreements and strategic acquisitions. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_37"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks, Patents, Exclusivity and Proprietary Know-How</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business. Our policy is to vigorously protect, enforce and defend our rights to our intellectual property and proprietary rights, as appropriate. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on the risks associated with our intellectual property and proprietary rights.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that trademark protection is an important part of establishing product and brand recognition. We own or license a number of registered trademarks and trademark applications in the U.S., Canada and in various other countries throughout the world. U.S. federal registrations for trademarks remain in force for 10 years and may be renewed every 10 years after issuance, provided the mark is still being used in commerce. Trademark registrations in Canada issued on or before June 17, 2019 remain in force for 15 years and may be renewed for 10-year terms, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Trademark registrations in Canada issued after June 17, 2019 remain in force for 10 years and may be renewed every 10 years after issuance, provided that, as in the case of U.S. federal trademark registrations, the mark is still being used in commerce. Other countries generally have similar but varying terms and renewal policies with respect to trademarks registered in those countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data and Patent Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products, we rely on a combination of regulatory and patent rights to protect the value of our investment in the development of these&#160;products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent is the grant of a property right which allows its holder to exclude others from, among other things, selling the subject invention in, or importing such invention into, the jurisdiction that granted the patent. In the U.S., Canada and the European Union (&#8220;EU&#8221;), generally patents expire 20&#160;years from the date of&#160;application. We have obtained, acquired or in-licensed a number of patents and patent applications covering key aspects of certain of our principal products. In the aggregate, our patents are of material importance to our business taken as a whole. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S., at the federal, state and local level, in Canada, in the EU and in all other countries extensively regulate, among other things, the research, development, testing, approval, manufacturing, labeling, post-approval monitoring and reporting, packaging, advertising and promotion, storage, distribution, marketing and export and import of pharmaceutical products and medical devices. As such, our products and product candidates are subject to extensive regulation both before and after approval. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with these regulations could result in, among other things, warning letters, civil penalties, delays in approving or refusal to approve a product candidate, product recall, product seizure, interruption of production, operating restrictions, suspension or withdrawal of product approval, injunctions or criminal prosecution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to human use, FDA approval or marketing clearance must be obtained in the U.S., approval by Health Canada must be obtained in Canada, EMA approval (drugs) or a CE Marking (devices) and/or registration under the European Commission&#8217;s Medical Device Regulation (&#8220;MDR&#8221;), must be obtained for countries that are part of the EU and approval must be obtained </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from comparable agencies in other countries prior to manufacturing or marketing new pharmaceutical products or medical devices. Generally, preclinical studies and clinical trials of the products must first be conducted and the results submitted to the applicable regulatory agency (such as the FDA) for approval. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation by other federal agencies, such as the Drug Enforcement Administration, and state and local authorities in the U.S., and by comparable agencies in certain foreign countries, is also required. In the U.S., the Federal Trade Commission (the &#8220;FTC&#8221;), the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and state and local authorities regulate the advertising of medical devices, prescription drugs, OTC drugs and cosmetics. The Federal Food, Drug and Cosmetic Act, as amended and the regulations promulgated thereunder, and other federal and state statutes and regulations, govern, among other things, the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, sale, distribution, advertising and promotion of our products. The FDA requires a Boxed Warning (sometimes referred to as a &#8220;Black Box&#8221; Warning) for products that have shown a significant risk of severe or life-threatening adverse events and similar warnings are also required to be displayed on the product in certain other jurisdictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with respect to medical devices, in April 2017, the European Commission adopted the MDR, which replaced the Medical Device Directive. Pursuant to the terms of the new regulations, in order to continue to market medical device products in the EU, such products must achieve compliance with these new regulations and be re-registered in the EU within a specified transition period, which, for a portion of products, ended as early as May 26, 2021. While EU law is applicable in Northern Ireland, the UK Medical Devices Regulations 2002/68 also needs to be complied with in Great Britain. Medical device manufacturers who have CE marked devices will be able to continue to place them on the market in the whole of the United Kingdom (the &#8220;UK&#8221;) until July 1, 2023 without a change in labeling. After that, devices destined for Great Britain will be required to follow the UK regulatory regime and to be labeled with the UKCA mark. Northern Ireland will, however, continue to accept CE marked devices. There are some additional requirements for manufacturers who are based outside the UK, such as the requirement to appoint a UK Responsible Person (&#8220;UKRP&#8221;) to take on certain regulatory responsibilities with respect to the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) and users or customers in the UK. To enable devices to be placed on the market in the UK after January 1, 2021 (even for CE marked devices), a UK manufacturer must register with the MHRA, as must a UKRP for an overseas manufacturer. Such registering entity will then register each of the devices for which they are responsible for placing on the market in the UK, whether in Great Britain or Northern Ireland. Until May 25, 2021, our products bearing a CE mark could be exported from the EEA to Switzerland. However, as of May 26, 2021, the EU no longer applies the Mutual Recognition Agreement between the EEA and Switzerland. Accordingly, legal manufacturers in Switzerland will be required to appoint a European Union authorized representative, and manufacturers outside of Switzerland will be required to appoint a Swiss authorized representative in compliance with the Medical Device Ordinance. As a consequence, beginning in January 2022 through August 2022 (depending on the class of the device or system in question), we have been required to appoint an authorized representative in Switzerland in order to export our CE-marked medical devices to Switzerland. Additionally, the name and address of the Swiss authorized representative must be placed on the packaging.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of pharmaceutical products and medical devices are required to comply with manufacturing regulations, including current good manufacturing practices and quality system management requirements, enforced by the FDA and Health Canada, in the U.S. and Canada, respectively, and similar regulations enforced by regulatory agencies in other countries and we face periodic audits of our facilities and plants and those of our contract manufacturers by the FDA and such other regulatory agencies. In addition, we are subject to price control restrictions on our pharmaceutical products in many countries in which we&#160;operate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to extensive U.S.&#160;federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulations in Canada and similar regulations in foreign countries in which we may conduct our business. The federal False Claims Act imposes civil and criminal liability on individuals or entities who submit (or&#160;cause the submission of) false or fraudulent claims for payment to the government. The U.S. federal Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal or state health care program such as the Medicare and Medicaid programs. Some state anti-kickback laws also prohibit such conduct where commercial insurance, rather than federal or state, programs are involved. Due to recent legislative changes, violations of the U.S. federal Anti-Kickback Statute also carry potential federal False Claims Act liability. In addition, in the U.S., Canada and various other countries, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses - that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved or cleared by the FDA, Health Canada or applicable regulatory agency in such other countries - - and &#8220;off-label promotion&#8221; in the U.S. has also formed the predicate for False Claims Act liability resulting in significant financial settlements. These and other laws and regulations, rules and policies may significantly impact the manner in which we are permitted to market our products. If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, the curtailment or restructuring of our&#160;operations or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Department of Health and Human Services Office of Inspector General recommends, and increasingly states require pharmaceutical companies to have comprehensive compliance programs. Moreover, the Physician Payment Sunshine Act enacted in 2010 imposes reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed to prescribers and other health care providers. Failure to submit this required information may result in significant civil monetary penalties. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the Canadian Corruption of Foreign Public Officials Act and similar worldwide anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. Violations of these laws could result in criminal or civil penalties or remedial measures.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (collectively, &#8220;HIPAA&#8221;). HIPAA mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions (e.g., health care claims information and plan eligibility, referral certification and authorization, claims status, plan enrollment, coordination of benefits and related information), as well as standards relating to the privacy and security of individually identifiable health information. These standards require the adoption of administrative, physical and technical safeguards to protect such information. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which went into effect on January 1, 2020, imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents, including, among other things, new disclosures to California consumers and providing such consumers new data protection and privacy rights, including the ability to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. The CCPA has been amended from time to time, and, further a new privacy law, the California Privacy Rights Act (&#8220;CPRA&#8221;), which took effect on January 1, 2023, significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. It remains unclear how various provisions of the CCPA and CPRA will be interpreted and enforced, and multiple states have enacted or are expected to enact similar laws. The effects on our business of the CCPA, CPRA and other similar state laws are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some statutory requirements, both in the U.S. and abroad, include obligations for companies to notify individuals of security breaches involving particular personal information, which could result from breaches experienced by us or our service providers. For example, laws in all 50 U.S. states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states have been frequently amending existing laws, requiring attention to changing regulatory requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, in the European Economic Area (the &#8220;EEA&#8221;), the collection and use of personal data, including clinical trial data, is governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR became effective on May 25, 2018, repealing its predecessor directive and increasing responsibility and liability of companies in relation to the processing of personal data of EU data subjects. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. In particular, the GDPR includes obligations and restrictions concerning the consent and rights of the individuals to whom the personal data relates, the transfer of personal data out of the EEA, security breach notifications and the security and confidentiality of personal data. In July 2020, the Court of Justice of the European Union issued a decision that struck down the EU-U.S. Privacy Shield framework, which provided companies with a </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mechanism to comply with data protection requirements when transferring personal data from the EU to the United States and additionally called into question the validity of the European Commission&#8217;s Standard Contractual Clauses, on which U.S. companies rely to transfer personal data from EU member states to the United States and elsewhere. In September 2020, the Swiss Federal Data Protection and Information Commissioner issued an opinion that stated it no longer considers the Swiss-U.S. Privacy Shield adequate for the purposes of personal data transfers from Switzerland to the United States. These developments may result in European data protection regulators applying differing standards for, and requiring ad hoc verification of, transfers of personal data from EU member states to the United States. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, following the United Kingdom&#8217;s withdrawal from the EU and the EEA, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into the United Kingdom national law, the Data Protection Act of 2018, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk. Beginning in 2021, the United Kingdom is a &#8220;third country&#8221; under the GDPR. We may incur liabilities, expenses, costs and other operational losses under the GDPR and privacy laws of the applicable EU and EEA Member States and the United Kingdom in connection with any measures we take to comply with them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Canada&#8217;s federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronic Documents Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD 10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in China, the Personal Information Protection Law (the &#8220;PIPL&#8221;) came into force in November 2021. The PIPL is the first national-level law comprehensively regulating issues in relation to personal information protection. The PIPL provides for very specific administrative requirements and security controls when transferring personal data outside the Peoples Republic of China. These transfer requirements come into effect on March 1, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products may depend, in part, on the availability of governmental and third-party payor reimbursement for the cost of our products. Third-party payors may include government health administration authorities, private health insurers and other organizations. In the U.S., the E.U. and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, which has resulted in lower average realized prices. In the U.S., these pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement policies and pricing in general. In particular, sales of our products may be subject to discounts from list price and rebate obligations, as well as formulary coverage decisions impacting or limiting the types of patients for whom coverage will be provided. Various U.S. health care and other laws regulate our interactions with government agencies, private insurance companies and other third-party payors regarding coverage and reimbursement for our products. Failure to comply with these laws could subject us to civil, criminal and administrative sanctions. In countries outside the U.S., the success of our products may depend, at least in part, on obtaining and maintaining government reimbursement because, in many countries, patients are unlikely to use prescription drugs that are not reimbursed by their governments. In addition, negotiating prices with certain governmental authorities for newly developed products can delay commercialization. In Canada and many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes, tenders and profit control, and they expect prices of prescription pharmaceuticals to decline over the life of the product or as volumes increase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordable Care Act (the &#8220;PPACA&#8221;), as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid drug rebates for pharmaceutical companies, expanded the 340B drug discount program, and made changes to affect the Medicare Part D coverage gap, or &#8220;donut hole.&#8221; The law also revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which may affect the amount of our Medicaid drug rebates to states. Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &amp; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act (&#8220;IRA&#8221;) was signed into law, which includes implementation of a new corporate alternative minimum tax (&#8220;CAMT&#8221;), among other provisions. The CAMT imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also made significant changes to how drugs are covered and paid for under the Medicare program, including imposing financial penalties if drug prices are increased at a rate faster than inflation, redesigning Medicare Part D benefits to shift a greater portion of the costs to manufacturers and allowing the U.S. government to set prices for certain drugs in Medicare. We continue to evaluate the impact of the IRA legislation on our results of operations and it is possible that these changes may result in a material impact on our business and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although efforts at replacing the Health Care Reform Act have stalled in Congress, there could still be changes to this legislation in the near term. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Legislative efforts relating to drug pricing, the cost of prescription drugs under Medicare, the relationship between pricing and manufacturer patient programs, and government program reimbursement methodologies for drugs have been proposed and considered at the U.S. federal and state level. Congress and the Biden Administration have each indicated an intent to continue to seek new legislative or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on the risks associated with these regulations and related matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Other Regulation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities and operations are subject to a broad range of federal, state and local environmental and occupational health and safety laws and regulations in both the U.S. and countries outside the U.S. (including Canada), including those governing the discharge of substances into the air, water and land, the handling, treatment, storage and disposal of hazardous substances and wastes, wastewater and solid waste, the cleanup of contaminated properties and other environmental matters. Certain of our development and manufacturing activities involve the use of hazardous substances. If we fail to comply with these environmental, health and safety laws and regulations, including failing to obtain any necessary permits, we could incur substantial civil or criminal fines or penalties or enforcement actions, including regulatory or judicial orders enjoining or curtailing our operations or requiring us to conduct or fund remedial or corrective measures, install pollution control equipment, reformulate or cease the marketing of our products or perform other actions. Under certain laws, we may be subject to joint and several liability for environmental investigations and cleanups, including at properties that we currently or previously owned or operated, or at sites at which waste we generated was disposed, even if the contamination was not caused by us or was legal at the time it occurred. We are also subject to extensive and evolving regulations regarding the manufacturing, processing, distribution, importing, exporting and labeling of our products and their raw materials. In the EU, the REACH regulations came into effect in 2007, with implementation rolling out over time. Registered chemicals then can be subject to further evaluation and potential restrictions. Since the promulgation of REACH, other countries have enacted or are in the process of </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementing similar comprehensive chemical regulations. These laws and regulations may materially affect our operations by subjecting our products or raw materials to testing or reporting requirements or restrictions, moratoria, phase outs or other limitations on their sale or use. In particular, some of our products might be characterized as nanomaterials and then be subject to evolving, new nanomaterial regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are in compliance in all material respects with applicable environmental and occupational health and safety laws and regulations. We are not aware of any pending environmental or occupational health and safety litigation or significant liabilities that are likely to have a material adverse effect on our financial position. We cannot assure, however, that environmental liabilities relating to us or facilities owned, leased or operated by us will not develop in the future, and we cannot predict whether any such liabilities, if they were to develop, would require significant expenditures on our part. In addition, we are unable to predict what environmental or and occupational health and safety legislation or regulations may be adopted or enacted in the future. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers and Marketing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the U.S. and Puerto Rico accounted for approximately 60% and China accounted for approximately 5% of our total revenue, respectively. No other country accounted for more than 5%. See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for revenues by geographic area.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of our total revenue for 2022, 2021 and 2020 are as follows: </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:67.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently promote our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff. As part of our marketing program for pharmaceuticals, we use direct to customer advertising, direct mailings, advertise in trade, social media and medical periodicals, exhibit products at medical conventions and sponsor medical education symposia.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive Landscape for Products and Products in Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and medical device industries are highly competitive. Our competitors include specialty and other large pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, Europe, Asia, Latin America, Middle East, Africa and in other countries in which we market our products. The dermatology competitive landscape is highly fragmented, with a large number of mid-size and smaller companies competing in both the prescription sector and the OTC and cosmeceutical sectors. With respect to the GI market, generic entrants continue to capture significant share for treatment of many GI conditions. In the area of irritable bowel syndrome (&#8220;IBS&#8221;) and opioid induced constipation (&#8220;OIC&#8221;), competitors have recently launched new competing products, which should increase the size of these markets and intensify competition.&#160;The market for Bausch + Lomb products is very competitive, both across product categories and geographies. In addition to larger diversified pharmaceutical and medical device companies, we face competition in the eye health market from mid-size and smaller, regional and entrepreneurial companies with fewer products in niche areas or regions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors are pursuing the development and/or acquisition of pharmaceuticals, medical devices and OTC products that target the same diseases and conditions that we are targeting in dermatology, GI, eye health and other therapeutic areas. Academic and other research and development institutions may also develop products or technologies that compete with our products, which technologies and products may be acquired or licensed by our competitors. These competitors may have greater financial, R&amp;D or marketing resources than we do. If competitors introduce new products, delivery systems or processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both. Most new products that we introduce must compete with other products already on the market or products that are later developed by competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell a broad range of products, and competitive factors vary by product line and geographic area in which the products are&#160;sold. The principal methods of competition for our products include quality, efficacy, market acceptance, price and marketing and promotional efforts.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increased competition from manufacturers of generic pharmaceutical products when patents covering certain of our currently marketed products expire or are successfully challenged or when the regulatory exclusivity for our products expires or is otherwise lost. Generic versions are generally significantly less expensive than branded versions, and, where available, may be required to be utilized before or in preference to the branded version under third-party reimbursement programs, or substituted by pharmacies. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. To successfully compete for business with managed care and pharmacy benefits management organizations, we must often demonstrate that our products offer not only medical benefits, but also cost advantages as compared with other forms of&#160;care.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details regarding products that are facing generic competition, products that could potentially face generic competition, the corresponding potential revenue impact and infringement proceedings we initiated against potential generic competition, see Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Business Trends &#8212;&#160;Generic Competition and Loss of Exclusivity&#8221; of this Form&#160;10-K. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on our competition risks.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate approximately 35 manufacturing sites worldwide, of which 24 are Bausch + Lomb facilities. We continue to make capital investments in these facilities as discussed in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Businesses&#8221; of this Form&#160;10-K.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. In August 2022, we received a non-compliant rating from Health Canada related to our pharmaceutical manufacturing facility in Laval, Quebec. This rating was received without any restrictive conditions on plant operations so the production of important treatments for Canadians and for export continues without interruption as we work on remediating the non-compliant rating.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates, and all Company products and all other operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have observed any condition that in their judgment may constitute violations of current good manufacturing practices</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also subcontract the manufacturing of certain of our products, including products manufactured under the rights acquired from other pharmaceutical companies. Products representing approximately 22% of our product sales for 2022 are produced in total, or in part, by third-party manufacturers under manufacturing arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the principal raw materials, including active pharmaceutical ingredients, used by us (or our third-party manufacturers) for our various products are purchased in the open market or are otherwise available from several sources. However, some of the active pharmaceutical ingredients and other raw materials used in our products and some of the finished products themselves are currently only available from a single source; or others may in the future become available from only one source. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral and PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral products are also only available from a single source. Any disruption in the supply of any such single-sourced active pharmaceutical ingredient, other raw material or finished product or an increase in the cost of such materials or products could adversely impact our ability to manufacture or sell such products, the ability of our third-party manufacturers to supply us with such products, or our profitability. We attempt to manage the risks associated with reliance on single sources of active pharmaceutical ingredient, other raw materials or finished products by carrying additional inventories or, where possible, developing second sources of supply. See Item 1A. &#8220;Risk Factors&#8221; for additional information on the risks associated with our manufacturing arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global supply team worked diligently to stay ahead of the challenges presented by the COVID-19 pandemic. See Item 7. &#8220;Management&#8217;s Discussion and Analysis &#8212; Impacts of COVID-19 Pandemic&#8221; for further information.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to achieve our vision of being a trusted health care partner, we strive to ensure our employees around the world feel proud to be a part of Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had approximately 19,900 employees, of which approximately 12,900 were Bausch + Lomb employees. We had approximately 10,300&#160;employees in production, 6,600 in sales and marketing, 1,700&#160;in general and administrative positions and 1,300&#160;in R&amp;D. These employees are located around the world, with 7,600 in the United States and Canada, 6,920 in Europe, 2,440 in Asia-Pacific countries, 2,110 in Latin America, 630 in Russia and Commonwealth of Independent State countries and 200 in the Middle East and Africa. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collective bargaining exists for some employees in several countries in which Bausch + Lomb does business. We consider our relations with our employees to be good and have not experienced any work stoppages, slowdowns or other serious labor problems that have materially impeded our business operations.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 our turnover trended higher than our target turnover rate, but we have not experienced any significant disruption to date as a result of turnover.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety and Wellness</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees&#8217; health, safety, and wellness are important to us. On an ongoing basis, Bausch Health excluding Bausch + Lomb and Bausch + Lomb measure how well we are fostering the health and safety of our employees through our Days Away Rate (&#8220;DAR&#8221;), which is a standard used in our industry to capture the number of days that our employees are away from work as a result of a work-related injury or illness. For the year 2022, Bausch Health excluding Bausch + Lomb&#8217;s DAR was 17 days per 100 employees. This was higher than the goal we established for DAR of less than 7 days per 100 employees but was favorable to our industry&#8217;s average DAR of 24 days per 100 employees. The higher than target DAR was primarily attributable to two extended absences and DAR stabilized and trended downward in the 2nd half of 2022. In 2022, Bausch + Lomb&#8217;s DAR was 5.6, which met its goal not to exceed 7.17 and is far below similar industry standard DAR of 21.7.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that physical, emotional and financial wellbeing are significant contributors to our employees&#8217; success at work and home. We aim to support our employees in their everyday life by centering programs and activities around these three pillars of wellbeing. Across each of these pillars, we offer a range of resources to help our employees be healthy and feel successful in both their professional and personal lives, including through employee assistance programs.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to fostering an inclusive work environment where everyone feels welcomed, supported and valued for their talents and contributions. Our Bausch Health Diversity, Equity &amp; Inclusion (&#8220;DE&amp;I&#8221;) strategy centers on connecting our employees to our Company, each other, and our communities to cultivate a sense of trust, respect and belonging for all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to advance candid conversations among employees regarding such key topics as inclusion, racism and gender equality. Through our diversity and inclusion training and education efforts, all employees have been provided with educational tools and resources to understand how to talk about these topics at work and how to become more aware of unconscious biases they may have. During 2022, all employees were invited to participate in interactive workshops on various topics including equitable leadership, understanding and managing conflict styles, building awareness, skills and confidence to support LGBTQ+ colleagues, and creating and fostering inclusive environments.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are committed to the development of our employees and believe that our success coincides with our employees&#8217; achievements of personal and professional goals. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our Employee Development Framework, we endeavor to support our employees&#8217; interests to grow to&#8239;their full potential, achieve career goals, and contribute to&#8239;the success&#8239;of our Company. We empower employees to explore roles that are of interest and gain insights into their strengths and development needs. We provide a variety of development programs to support our employees at every stage of their career and incorporate individual development plans that aim to help our employees reach their career goals. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a robust, global succession planning process that allows us to define talent needs based on business strategy, identify talent and drive their development and growth, strengthen the pipeline for critical leadership positions, and optimize talent deployment across the business. As detailed in its charter, the Talent and Compensation Committee of the Board of Directors assists the Board with oversight of our Company&#8217;s talent management and succession planning process. The Board of Directors reviews succession planning progress and specifically the plans for Executive Committee roles. To support this </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process, the Board interacts with leaders and managers throughout the organization during the year to get to know these employees and their work.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total rewards philosophy is designed to attract, retain, motivate and engage our employees. We provide comprehensive and market competitive compensation and benefit programs across our geographies, aligning these programs with the interests of our shareholders and balancing appropriate risk taking. Collectively, these programs comprise our Total Rewards package.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation program includes base pay, short-term incentives and long-term incentives. We provide the opportunity for our employees to earn more when we deliver against objectives &#8211; both as a total company and individually. We also provide competitive benefit programs based on local practice in the countries where our employees work. Our programs include medical coverage, retirement benefits, paid time off, and life and other insurances.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_67"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are proud to support the communities in which we live and work with their charitable initiatives. Bausch Health provides monetary and product donations to not for profit organizations for use in indigent care, public education, advocacy efforts, disaster relief or other charitable efforts. Bausch Health also provides grants to organizations that deliver independent, professional education initiatives for healthcare providers, including continuing medical education, as well as requests to provide funding or free product for investigator initiated studies.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand that some patients may face financial obstacles that can keep them from obtaining the prescription products they need. Bausch Health is committed to improving access to medications through our patient assistance programs. The purpose of the Bausch Health Patient Assistance Program is to provide eligible patients in the U.S. with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 7. &#8220;Management&#8217;s Discussion and Analysis &#8212; Overview &#8212; Focus on Core Businesses &#8212; Improve Patient Access&#8221; for additional discussion regarding Company programs to address the affordability and availability of our products.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_70"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Insurance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. In the future, we will continue to re-evaluate our decision to self-insure and may purchase additional product liability insurance to cover product liability risk. See Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K for additional information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality of Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, revenues from our business tend to be weighted toward the second half of the year. Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.&#160;Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs. However, there are no assurances that these historical trends will continue in the future. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Areas</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues is generated from operations or otherwise earned outside the U.S. and Canada. All of our foreign operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls, fluctuations in the relative values of currencies, political and economic instability and restrictive governmental actions including possible nationalization or expropriation. Changes in the relative values of currencies may materially affect our results of operations. For a discussion of these risks, see Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for revenues and long-lived assets by geographic area.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue and income was earned in Canada and Ireland, which have low effective tax rates. See Item&#160;1A. &#8220;Risk Factors&#8221; of this Form&#160;10-K relating to tax&#160;rates for more information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet address is </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.bauschhealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We post links on our website to the following filings as soon as reasonably practicable after they are electronically filed or furnished to the SEC: annual reports on Form&#160;10-K, quarterly reports </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on Form&#160;10-Q, current reports on Form&#160;8-K and&#160;any amendment to those reports filed or furnished pursuant to Section&#160;13(a) or&#160;15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. The information on our Internet website is not incorporated by reference into this Form&#160;10-K or&#160;our other securities filings and is not a part of such&#160;filings. The SEC also maintains an Internet website at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the&#160;SEC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also required to file reports and other information with the securities commissions in all provinces in Canada. You are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval (&#8220;SEDAR&#8221;) at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Canadian equivalent of the SEC&#8217;s electronic document gathering and retrieval system.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business, financial condition, cash flows and results of operations are subject to various risks and uncertainties. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Form 10-K, including those risks set forth under the heading entitled &#8220;Forward-Looking Statements&#8221; and in other documents that we file with the SEC and the CSA, before making any investment decision with respect to our common shares or debt securities. If any of the risks or uncertainties actually occur or develop, our business, financial condition, cash flows, results of operations and/or future growth prospects could change, and such change could be materially adverse. Under these circumstances, the market value of our common shares and/or debt securities could decline, and you could lose all or part of your investment in our common shares and/or debt securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this &#8220;Risk Factors&#8221; section in full. Some of the risks we face include: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental entities in Russia, Belarus and parts of Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of the COVID-19 pandemic on our business, financial condition, cash flows, and results of operations;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the B+L Separation and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business from the closing of the B+L IPO, the uncertainties with respect to the expected timing of completion of the B+L Separation, including the impact of a failure to maintain the tax-free treatment of such transaction, the continued reliance on Bausch + Lomb employees for certain transitional services, a failure to obtain replacement contracts, any actual or perceived conflict of interest of our directors and officers who also serve roles in Bausch + Lomb and the cross-indemnification obligations on us and Bausch + Lomb;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts on our business related to the suspension of the Solta IPO;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing legal proceedings, investigations, and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes to our pricing practices, whether imposed, legislated or voluntary;</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse impact of legal and governmental proceedings that are uncertain, costly and time-consuming;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third parties to meet their contractual, legal, regulatory, and other obligations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of product recalls and related product liability claims; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with extensive regulation concerning marketing, promotional and business practices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with restrictive covenants in our debt agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate cash in order to service our debt;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business of restrictions imposed by our significant indebtedness;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of interest rate changes, including the discontinuation of the London Interbank Offered Rate (&#8220;LIBOR&#8221;);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the transition of our key management positions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit and retain executives and key personnel;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential increase of our effective tax rates, including as a result of proposed changes to applicable tax laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with generic competitors in products that represent a significant amount of our revenue;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, enforce or defend the intellectual property rights required to conduct our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of current and potential intellectual property litigation; </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices than our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of our commitment to the cessation of or limitation on pricing increases for certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of divestitures of certain of our assets and business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effect of acquisitions of assets, products and businesses; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and provide appropriate training in our products to our health care providers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize our pipeline products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with ongoing regulatory review of our marketed drugs, including our dietary products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our revenues and profits from generic products as a result of changes to regulatory policy;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business of interruptions in our manufacturing processes;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on a limited number of sources for certain of our finished products and raw materials;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve or maintain expected levels of market acceptance for our new products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on reimbursements from governmental and other third-party payors; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of a failure to be included in formularies developed by managed care organizations and third-party payors;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of pricing controls, social or governmental pressure to lower the cost of drugs, and consolidation across the supply chain;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of catastrophic events that may disrupt our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the illegal distribution and sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction of profits due to imports from countries where our products are available at lower prices;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction of revenues in future fiscal periods due to our policies regarding returns, allowances, and chargebacks;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the decline in sales volumes or prices of our products as the result of the concentration of sales to wholesalers;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the decline in pricing and/or volume of our products in our distribution agreements with other companies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the international scope of our operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exposure on the translation into U.S. dollars of the financial results of our international operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breakdown, interruption, breach or other compromise of our information technology systems;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with applicable laws and regulations and prevail in any litigation related to noncompliance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact that reforms of the health care system may have on our ability to sell our products profitably;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with environmental laws and regulations and environmental remediation obligations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with climate change;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain adequate internal controls and to provide an assertion as to the effectiveness of such controls on an annual basis;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effect of shareholder activism;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our profitability from the potential impairment of goodwill and other intangible assets;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively monitor and respond to expectations regarding environmental, social and governance matters;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential obligations under our indemnity agreements and arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fluctuation of our operating results and financial condition from quarter to quarter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the Russia and Ukraine conflict</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, Russia launched a military invasion of Ukraine. The ongoing military conflict between Ukraine and Russia has provoked strong reactions from the United States, the UK, the EU, Canada and various other countries around the world, including the imposition of export controls and broad financial and economic sanctions against Russia, Belarus and specific areas of Ukraine. Additional sanctions or other measures may be imposed by the global community, and counteractive measures may be taken by the Russian government, other entities in Russia or governments or other entities outside of Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2022 and 2021, we derived approximately 2% of our revenues from sales of our products in Russia, less than 1% of our revenues from sales of our products in both Ukraine and Belarus. The conflict between Ukraine and Russia has begun to impact our business in the region, and we are continuously monitoring developments to assess any potential future impact that may arise. Given the nature of our products, we do not believe that the current sanctions and other measures imposed by the United States and other countries preclude us from conducting business in the region. However, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response may continue to hinder our ability to conduct business with customers and vendors in this region. For example, we have experienced and may in the future experience disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We have experienced and may in the future also experience decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we may experience difficulties in collecting receivables from such customers. If we are hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to, or suspension of, our business and operations in Russia, Belarus and Ukraine would adversely impact our business, financial condition, cash flows and results of operations in this region which may, in turn, materially adversely impact our overall business, financial condition, cash flows and results of operations, which impact could be material, and could cause the market value of our common shares to decline. Finally, we are also subject to risks if exchange controls were to be imposed that would limit the repatriation of profits from our operations in Russia. While we do not rely on profits or dividends from our Russian operations to fund our debt repayment or other business activities generally, as our operations from Russia primarily involve the sale of products purchased from our affiliates located outside of Russia, any exchange controls that would limit the purchase of or payment for products or goods from outside of Russia may have an adverse impact on our operations in Russia or the way we conduct business in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the precise effects of the ongoing military conflict and sanctions on the Russian and global economies remain uncertain, they have already resulted in significant volatility in financial markets and depreciation of the Russian ruble and the Ukrainian hryvnia against the U.S. dollar, as well as in an increase in energy and commodity prices globally. Should the conflict continue or escalate, there may be various economic and security consequences including, but not limited to, supply shortages of different kinds, further increases in prices of commodities, including piped gas, oil and agricultural goods, reduced consumer purchasing power, significant disruptions in logistics infrastructure, telecommunications services and risks relating to the unavailability of information technology systems and infrastructure. The resulting impacts to the global economy, financial markets, inflation, interest rates and unemployment, among others, could adversely impact economic and financial conditions, and may disrupt the global economy&#8217;s ongoing recovery following the COVID-19 pandemic. Other potential consequences include, but are not limited to, growth in the number of popular uprisings in the region, increased political discontent, especially in the regions most affected by the conflict or economic sanctions, increase in cyberterrorism activities and attacks, displacement of persons to regions close to the areas of conflict and an increase in the number of refugees fleeing across Europe, among other unforeseen social and humanitarian effects.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the ongoing conflict between Russia and Ukraine, we may experience other risks, difficulties and challenges in the way we conduct our business and operations generally. For example, there may be an increased risk of cybersecurity attacks due to the current conflict between Russia and Ukraine, including cyber security attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of its invasion of Ukraine. Any increase in such attacks on us or our third-party providers or other systems could adversely affect our network systems or other operations. In order to address the risks associated with cybersecurity attacks from the region (including state-sponsored cybersecurity attacks), we have taken action to consolidate network traffic from Russia and Belarus through a single point, which is designed to allow us to more closely inspect that traffic. In addition, if required, this consolidation provides a single point to quickly and efficiently disconnect the region from our corporate network. At this time, to the best of our knowledge, we do not believe we have experienced any cyberattacks that are related to the conflict between Russia and Ukraine. Although we have taken steps to enhance our protections against such attacks, we may not be able to address these cybersecurity threats proactively or implement adequate preventative measures and there can be no assurance that we will promptly detect and address any such disruption or security breach, if at all. In addition, as a result of the risk of collectability of receivables from our customers in Russia, Belarus and Ukraine, we may be required to adjust our accounting practices relating to revenue recognition in this region, with the result that we may not be able to recognize revenue from these customers until collected. We may also suffer reputational harm as a result of our continued operations in Russia, which may adversely impact our sales and other businesses in other countries. Finally, we have one global clinical trial involving Russia, Ukraine and Belarus with patients enrolled. We continue to support the existing patients, but have no plans to enroll new patients at this time. Plans for any additional trials involving Russia, Ukraine and Belarus have been postponed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protracted conflict between Ukraine and Russia, any escalation of that conflict, and the financial and economic sanctions and import and/or export controls imposed on Russia by the U.S., the UK, the EU, Canada and others, and the above-mentioned adverse effect on our operations (both in this region and generally) and on the wider global economy and market conditions could, in turn, have a material adverse impact on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing impact of the COVID-19 pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and/or the associated economic impact of the pandemic and the reactions to it, could adversely and materially impact our business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing impact of the COVID-19 pandemic, and the rapidly evolving reaction of governments, private sector participants and the public in an effort to contain the spread of COVID-19 (and variants thereof) and/or address its impacts have had significant direct and indirect effects on businesses and commerce generally, including disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions, and significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, travel and elective surgery.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impact of COVID-19, we have experienced and may continue to experience delays in and postponement of our clinical trial programs, reduced demand for certain of our products due to the deferral of elective medical procedures and of doctor and dentist visits and restrictions on outpatient surgery and other medical procedures, and if such issues recur in the future, our results of operations may be adversely impacted as a result. In addition, certain of our facilities were temporarily closed in connection with the COVID-19 pandemic, and we have also experienced some disruptions to our supply chain as a result of challenges associated with the COVID-19 pandemic. Although we are not currently experiencing these effects, depending on future developments with respect to COVID-19, we may continue to experience those effects as a result of the pandemic, the emergence of new variants, the reactions of governments, private sector participants and the public to the pandemic and the associated disruption to business and commerce generally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and duration of the pandemic, the reactions of governments, private sector participants and the public to that pandemic and the associated disruption to business and commerce generally, and the extent to which these may impact our business, financial condition, cash flows and results of operations in particular, will depend on future developments which are highly uncertain and many of which are outside our control and cannot be predicted with confidence. Such developments include the ultimate geographic spread and duration of the pandemic, the availability and effectiveness of vaccines for COVID-19, vaccine hesitancy, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, new information which may emerge concerning the severity of COVID-19, the effectiveness and intensity of measures to contain COVID-19 and/or address its impacts, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline and may exacerbate other risk factors disclosed in this Item 1A. &#8220;Risk Factors.&#8221;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments such as those described above, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the B+L Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The B+L Separation is subject to challenge and could be subject to further challenges in the future, any of which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, including a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders, is subject to challenge, which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect. For example, in March 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain of its current or former officers and directors. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. In addition, the Company could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements elsewhere in this Form 10-K. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the outcome of any such proceedings, investigations and inquiries, but we may incur significant costs and diversion of management attention as a result of these matters, regardless of the outcome. Some or all of these proceedings, investigations and inquiries may lead to damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against us. Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The B+L Separation is subject to uncertainties</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unanticipated developments, including disruptions to business and commerce induced by the COVID-19 pandemic, changes in market conditions, possible delays in obtaining any necessary shareholder, stock exchange, regulatory or other approval or the failure to obtain any such approvals, possible delays in obtaining any required tax opinions or rulings or the failure to obtain any such tax opinions or rulings, that a portion of Bausch Health&#8217;s ownership of Bausch + Lomb is pledged as collateral securing the 9.00% Intermediate Holdco Secured Notes, negotiating challenges, the uncertainty of the financial markets, changes in the law, and other challenges could delay or prevent the completion of the B+L Separation (including the Distribution, as defined below), result in changes to the anticipated structure of the B+L Separation, or cause the B+L Separation to occur on terms or conditions that are different or less favorable than expected. Any changes to the B+L Separation or delay in completing the B+L Separation could cause us not to realize some or all of the expected benefits or realize them on a different timeline than expected. Further, our Board of Directors could decide, either because of a failure to satisfy conditions or because of market or other factors, to delay, abandon or alter the structure or terms of the B+L Separation. No assurance can be given as to whether and when the full B+L Separation will occur, on what terms the B+L Separation will occur or whether the B+L Separation will achieve the benefits we expect. As a result, there can be no assurance as to the timing of the completion of the B+L Separation or its structure or terms.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the B+L Separation is completed, we may not be able to achieve the full strategic and financial benefits expected to result from the B+L Separation. The B+L Separation is expected to unlock value by creating an independent business and distinct investment identity with enhanced strategic and management focus that allows more efficient allocation of resources and capital. In addition, though the proceeds from the B+L IPO facilitated further reductions in the aggregate amount of our outstanding indebtedness, we may not achieve these and other anticipated benefits for a variety of reasons, including, among others: (i) Bausch + Lomb may prove to be less valuable on an independent basis than we anticipate, including because it is more susceptible to economic downturns and other adverse events than if it were still a part of the Company and because its business will be less diversified than the Company&#8217;s business prior to the B+L Separation and (ii) other actions required to separate the respective businesses could disrupt our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the B+L Separation has and will continue to require significant resources, time and attention from our senior management and employees, which could cause distractions and divert attention and resources away from other projects and the day-to-day operation of our business. We may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the B+L Separation and following its completion. For more information on these and other related risks, see Item 1A. &#8220;Risk Factors&#8212;Employment-related Risks&#8221; of this Form 10-K. The </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B+L Separation, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties. The price of our common shares could also fluctuate significantly in response to developments or market speculation related to the B+L Separation. The B+L Separation, if completed, may also have the effect of exacerbating other risk factors disclosed in this Item 1A. &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already incurred expenses in connection with the B+L Separation, and expect that the process of completing the B+L Separation will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the B+L Separation is not completed on the timeline and terms currently anticipated or at all. In addition, if the B+L Separation is not completed or if it is delayed or restructured, we will still be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the B+L Separation, if completed, is expected to result in dyssynergy costs, which may be greater than we anticipate and/or may be significant. In addition, we could be subject to legal proceedings or other claims challenging the B+L Separation, which could result in substantial costs and liability and also divert management&#8217;s attention and resources, any of which could harm our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors could cause the B+L Separation (or the failure to consummate the B+L Separation) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the distribution of the shares in Bausch + Lomb (the &#8220;Distribution&#8221;) proceeds pursuant to the Arrangement, to preserve the tax-free treatment of certain transactions related to the Distribution, we may not be able to engage in certain transactions. In such case, we could incur significant tax liabilities, or be liable to Bausch + Lomb, if certain transactions occur which result in these transactions or the Distribution being subject to tax. The application of certain requirements of the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Canadian Tax Act depend on events that may not be within our control.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that the Distribution will be effected pursuant to the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Income Tax Act (Canada) (the &#8220;Canadian Tax Act&#8221;). If the Distribution is effected pursuant to the public company &#8220;butterfly reorganization&#8221; rules in Section 55 of the Tax Act as currently anticipated, we and Bausch + Lomb will recognize a taxable gain on the Distribution if (a) within three years of the Distribution, Bausch + Lomb engages in a subsequent spin-off or split-up transaction under Section 55 of the Canadian Tax Act or the Company engages in a split-up (but not spin-off) transaction under Section 55 of the Canadian Tax Act; (b) a &#8220;specified shareholder&#8221; as defined for purposes of the &#8220;butterfly reorganization&#8221; rules in Section 55 of the Canadian Tax Act disposes of our shares or shares of Bausch + Lomb, or property that derives 10% or more of its value from such shares and an unrelated person or partnership acquires such property or property substituted therefore as part of the &#8220;series of transactions&#8221; which includes the Distribution; (c) there is an acquisition of control of the Company or Bausch + Lomb that is part of the &#8220;series of transactions&#8221; that includes the Distribution; or (d) certain persons acquire shares in the capital of Bausch + Lomb (other than in specified permitted transactions) in contemplation of and as part of the &#8220;series of transactions&#8221; that includes, the Distribution. If any of the above events, certain of which are outside the control of the Company and Bausch + Lomb, were to occur and to cause the Distribution to be taxable to us and/or to Bausch + Lomb, then we or Bausch + Lomb, as applicable, and, in some cases, both us and Bausch + Lomb, would be liable for a substantial amount of tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these potentially significant tax consequences, if the Arrangement is pursued, it is anticipated that we will agree with Bausch + Lomb to certain tax-related covenants, which may restrict us from taking certain actions that we might otherwise choose to take, some of which could be material, and the nature, extent and effect of these restrictions will depend on the manner in which the Distribution is effected. Furthermore, if we breach any of these tax-related covenants, we may be required to indemnify Bausch + Lomb against any taxes or other losses suffered or incurred from or in connection with such breach, which loss may include the taxable gain recognized by Bausch + Lomb if the Separation were to be taxable, as further described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with the B+L Separation, we will continue to rely on Bausch + Lomb for certain services, which services may not be sufficient to meet our needs, which may result in increased costs and otherwise adversely affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we anticipate that we and Bausch + Lomb will provide to each other certain services for a transitional period in exchange for certain agreed-upon fees. If we no longer receive these services from Bausch + Lomb due to the termination or expiration of these transitional services, we may not be able to perform these services ourselves and/or find appropriate third-party arrangements at a reasonable cost (and any such costs may be higher than those charged by Bausch + Lomb). In addition, in connection with the B+L Separation, we expect that a number of the employees that support our business (which number of employees may be significant) will be employed by legal entities that are owned by Bausch + Lomb and not by us. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain contracts used in our business may need to be replaced in connection with the B+L Separation and failure to obtain such replacement contracts could increase our expenses or otherwise adversely affect our results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we may be required to replace certain shared contracts. It is possible that, in connection with the replacement process, some parties may seek more favorable contractual terms from us. If we are unable to obtain such replacement contracts, the loss of these contracts could increase our expenses or otherwise materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with the B+L Separation, some of our directors and officers may have actual or potential conflicts of interest because of their equity ownership in Bausch + Lomb, and/or because they also serve as officers or directors of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of their positions with Bausch + Lomb, in connection with the B+L Separation, some of our directors and executive officers may own common shares of Bausch + Lomb or have options to acquire shares of Bausch + Lomb, and the individual holdings may be significant for some of these individuals compared to their total assets. In addition, in connection with the B+L Separation, certain of our current or former officers and directors will also serve as officers or directors of Bausch + Lomb. A director who has a material interest in a matter before our Board of Directors or any committee on which he or she serves is required to disclose such interest as soon as the director becomes aware of it in accordance with applicable law. In situations where a director has a material interest in a matter to be considered by our Board of Directors or any committee on which he or she serves, such director may be required to excuse himself or herself from the meeting while discussions and voting with respect to the matter are taking place. Although all transactions with related parties will be approved by independent members of our Board of Directors that may meet in the absence of senior executive officers or non-independent directors, the ownership of Bausch + Lomb equity or service to Bausch + Lomb may create the appearance of conflicts of interest when the Bausch + Lomb-affiliated directors and officers are faced with decisions that could have different implications for Bausch + Lomb or us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Bausch + Lomb and us regarding the terms of the B+L Separation. Potential conflicts of interest could also arise if we enter into commercial arrangements with Bausch + Lomb in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives. While the Board of Directors believes that, given its size and structure, such actual or potential conflicts of interest can be managed adequately, including that the independent members of our Board of Directors may meet in the absence of senior executive officers or non-independent directors in respect of the relevant matter, the actual or perceived conflicts of interest that may arise could cause reputational or other harm.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In connection with the B+L Separation and the various separation-related agreements entered into by us and Bausch + Lomb in connection with the proposed transaction, we have agreed to indemnify Bausch + Lomb, for certain liabilities, and Bausch + Lomb has agreed to indemnify us for certain liabilities. However, there can be no assurance that Bausch + Lomb&#8217;s indemnity will be sufficient to insure us against the full amount of such liabilities, or that Bausch + Lomb&#8217;s ability to satisfy its indemnification obligation will not be impaired in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the various separation-related agreements entered into between Bausch + Lomb and us in connection with the B+L Separation, Bausch + Lomb, agreed to indemnify us for certain liabilities. However, there can be no assurance that the indemnity from Bausch + Lomb will be sufficient to protect us against the full amount of such liabilities, or that Bausch + Lomb will be able to fully satisfy its indemnification obligations in the future. Even if we ultimately succeed in recovering from Bausch + Lomb any amounts for which we are held liable, we may be temporarily required to bear these losses. Each of these risks could negatively affect our business, financial condition, results of operations and cash flows. Furthermore, any indemnification claim against us by Bausch + Lomb, including for a breach of the tax-related covenants described above, could be substantial, may not be able to be satisfied and may have a material adverse effect on us. Each of these risks could also negatively affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We suspended our plan to pursue an IPO of our Solta Medical device aesthetics business.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we announced that we intended to pursue an IPO of Solta Medical. The proposed Solta IPO would establish Solta Medical as a separate publicly traded company that consists of our medical aesthetics business. On June 16, 2022, we announced the suspension of the Solta IPO. Accordingly, the Solta IPO will not be completed in accordance with the previously-anticipated timeline and if resumed</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will involve significant time, expense, and distraction, any of which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Reputational Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are the subject of a number of ongoing legal proceedings, investigations and inquiries respecting certain of our historical distribution, marketing, pricing, disclosure and accounting practices, including our former relationship with Philidor, which have had and could continue to have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations, could result in additional claims and material liabilities, and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have successfully settled or otherwise resolved a number of legacy legal proceedings, investigations and inquiries relating to, among other things, our disclosure and accounting practices and our former relationship with Philidor, including the securities class action litigation matters in both the U.S. and Canada, the investigation by the SEC, the investigation order from the Autorit&#233; des marches financiers (the &#8220;AMF&#8221;) (our principal securities regulator in Canada) and certain derivative lawsuits, we are currently still the subject of a number of other ongoing legal proceedings and investigations and inquiries by governmental agencies, including, but not limited to, the following: (i) a number of pending securities litigations, including certain opt-out actions in the U.S. (related to the U.S. Securities Litigation which has been settled), and in Canada (related to the securities class action litigation in Canada which has been settled), the allegations of which relate to, among other things, allegedly false and misleading statements by the Company and/or failures to disclose information about our business and prospects, including relating to drug pricing, our policies and accounting practices, our use of specialty pharmacies, and our former relationship with Philidor and (ii) a lawsuit brought against the Company in the Superior Court of New Jersey asserting claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. In addition, we could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict how long such proceedings, investigations and inquiries will continue, but we anticipate that we will continue to incur significant costs in connection with some or all of these matters and that some or all of these proceedings, investigations and inquiries will result in a substantial distraction of management&#8217;s time, regardless of the outcome. Some or all of these proceedings, investigations and inquiries will likely result in damages, settlement payments (such as the $1,210 million payment made by the Company in connection with the previously settled U.S. Securities Litigation), fines, penalties, consent orders or other administrative sanctions (including exclusion from federal programs) against the Company and/or certain of our directors and officers, any of which could be material, or in changes to our business practices, which, in turn, may result in or may contribute to an inability by us to meet the financial covenant contained in our 2022 Amended Credit Agreement (as defined below). Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our historical business practices, including with respect to past pricing practices, are under scrutiny. Any changes to our practices relating to pricing or the current prices of products, whether imposed, legislated or voluntary, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are under scrutiny with respect to our historical business practices (including with respect to past pricing practices), including various securities litigations, including certain opt-out actions in the U.S. (related to the previously settled securities class action) and in Canada (related to the settled securities class action), and certain other lawsuits. We are unable to predict how such proceedings, investigations and inquiries will impact our current business practices, including with respect to pricing, or the prices of our products, including whether we will be required to impose pricing freezes or controls, pricing reductions (including on a retroactive basis) or other price regulation for some or all of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in recent years, in the U.S., state and federal governments have considered implementing legislation that would control or regulate the prices of drugs. Other countries have announced or implemented measures on pricing, including suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments. These measures and proposed measures vary by country. These measures and these proposed measures and legislation, if implemented, could lead to impairment of certain of our intangible assets which could be significant, and/or could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in various other legal and governmental proceedings that are uncertain, costly and time-consuming and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of other legal and governmental proceedings and may be involved in additional litigation in the future. These proceedings are complex and extended and occupy the resources of our management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor. We may also be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. Defending against or settling such claims and any unfavorable legal decisions, settlements or orders could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the pharmaceutical industry, including our Company, has been the focus of both private payor and governmental concern regarding pricing of pharmaceutical products. Related actions, including Congressional and other governmental investigations and litigation, are costly and time-consuming, and adverse resolution of such actions or changes in our business practices, such as our approach to the pricing of our pharmaceutical products, could adversely affect our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we expect this litigation activity to continue. As a result, we expect that patents related to our products will be routinely challenged, and the validity or enforceability of our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. Our patents may also be challenged in administrative proceedings in the United States Patent and Trademark Office and patent offices outside of the United States. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. Even in cases where we prevail in an infringement claim, legal remedies available for harm caused to us may not be sufficient to make us whole. We may also become subject to, or threatened with, legal proceedings and infringement claims by third parties and may have to defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial and include treble damages and attorneys&#8217; fees, if we are found to willfully infringe any intellectual property rights of others. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Any of the foregoing events could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent. Such claims by direct and indirect purchasers and other payers are typically filed as class actions. The relief sought may include treble damages and restitution claims. Similarly, antitrust claims may be brought by government entities or private parties following settlement of patent litigation, alleging that such settlements are anti-competitive and in violation of antitrust laws. In the U.S. and Europe, regulatory authorities have continued to challenge as anti-competitive so-called &#8220;reverse payment&#8221; settlements between branded and generic drug manufacturers. We may also be subject to other antitrust litigation involving competition claims unrelated to patent infringement and prosecution. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements. A successful antitrust claim by a private party or government entity against us could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third parties to meet their contractual, legal, regulatory, and other obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on distributors, suppliers, contract research organizations, vendors, service providers, business partners and other third parties to research, develop, manufacture, distribute, market and sell many of our products, as well as perform other services relating to our business. We rely on these third parties to meet their contractual, legal, regulatory and other obligations. A failure to maintain these relationships or poor performance by these third parties could negatively impact our business. In addition, we cannot guarantee that the contractual terms and protections and compliance controls, policies and procedures we have put in place will be sufficient to ensure that such third parties will meet their legal, contractual and regulatory obligations or that these terms, controls, policies, procedures and other protections will protect us from acts committed by our agents, contractors, distributors, suppliers, service providers or business partners that violate contractual obligations or the laws or regulations of the jurisdictions in which we operate, including matters respecting anti-corruption, fraud, bribery and kickbacks </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and false claims, pricing, sales and marketing practices, privacy laws and other legal obligations. Any failure of such third parties to meet these legal, contractual and regulatory obligations or any improper actions by such third parties or even allegations of such non-compliance or actions could damage our reputation, adversely impact our ability to conduct business in certain markets and subject us to civil or criminal legal proceedings and regulatory investigations, monetary and non-monetary damages and penalties and could cause us to incur significant legal and investigatory fees and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For example, the allegations about the activities of Philidor and our former relationship with Philidor have resulted in a number of investigations, inquiries and legal proceedings against us, which have damaged and may further damage our reputation and result in damages, fines, penalties or administrative sanctions against the Company and/or certain of our officers. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products cause, or are alleged to cause, serious or widespread personal injury, we may have to withdraw those products from the market and/or incur significant costs, including payment of substantial sums in damages, and we may be subject to exposure relating to product liability claims. In addition, our product liability self-insurance program may not be adequate to cover future losses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent business risk of exposure to significant product liability and other claims in the event that the use of our products caused, or is alleged to have caused, adverse effects. These product liability proceedings may be costly to prosecute and defend and may involve substantial awards or damages payable by us if not found in our favor.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may cause, or may appear to have caused, adverse side effects (including death) or potentially dangerous drug interactions that we may not learn about or understand fully until the drug has been administered to patients for some time. The withdrawal of a product following complaints and/or incurring significant costs, including the requirement to pay substantial damages in personal injury cases or product liability cases, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, since March 31, 2014, we have self-insured substantially all of our product liability risk for claims arising after that date. We periodically evaluate and adjust our claims reserves to reflect trends in our own experience, as well as industry trends. However, historical loss trends may not be adequate to cover future losses, as historical trends may not be indicative of future losses. If ultimate results exceed our estimates, this would result in losses in excess of our reserved amounts. If we were required to pay a significant amount on account of these liabilities for which we self-insure, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketing, promotional and business practices, as well as the manner in which sales forces interact with purchasers, prescribers and patients, are subject to extensive regulation and any material failure to comply could result in significant sanctions against us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketing, promotional and business practices of pharmaceutical and medical device companies, as well as the manner in which companies&#8217; in-house or third-party sales forces interact with purchasers, prescribers, and patients, are subject to extensive regulation, enforcement of which may result in the imposition of civil, regulatory and/or criminal penalties, injunctions, and/or limitations on marketing practice for some of our products and/or pricing restrictions or mandated price reductions for some of our products. Many companies, including us, have been the subject of claims related to these practices asserted by federal authorities. These claims have resulted in fines and other consequences, such as entering into corporate integrity agreements with the U.S. government. Companies may not promote drugs or devices for &#8220;off-label&#8221; uses-that is, uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA, Health Canada, EMA or other applicable regulatory agencies. A company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the U.S. government), as well as criminal sanctions. In addition, management&#8217;s attention could be diverted from our business operations and our reputation could be damaged. For more information regarding legal proceedings, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our 2022 Amended Credit Agreement and the indentures governing our senior notes impose restrictive covenants on us. Our failure to comply with these covenants could trigger events, which could result in the acceleration of the related debt, a cross-default or cross-acceleration to other debt, foreclosure upon any collateral securing the debt and termination of any commitments to lend, each of which would have a material adverse effect on our business, financial condition, cash flows </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and results of operations and would cause the market value of our common shares and/or debt securities to decline and could lead to bankruptcy or liquidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Amended Credit Agreement (as defined below) and the various indentures governing our senior notes contain covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. For example, the 2022 Amended Credit Agreement contains a financial covenant that requires us to maintain a certain financial ratio at fiscal quarter end. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2022 Amended Credit Agreement contains a specified quarterly financial maintenance covenant (consisting of a first lien leverage ratio). As of December 31, 2022, we were in compliance with this financial maintenance covenant. However, we can make no assurance that we will be able to comply with the restrictive covenants contained in the 2022 Amended Credit Agreement and indentures in the future. Based on our current forecast for the next twelve months from the date of issuance of this Form 10-K, we expect to remain in compliance with this financial maintenance covenant and meet our debt obligations over that same period. In the event that we perform below our forecasted levels, we may also implement certain additional cost-efficiency initiatives, such as rationalization of selling, general and administrative expenses (&#8220;SG&amp;A&#8221;) and R&amp;D spend, which would allow us to continue to comply with the financial maintenance covenant. The Company may consider taking other actions, including divesting other businesses, refinancing debt, issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations, or may negotiate with the applicable lenders for an amendment or modification to such covenant, as deemed appropriate. However, we cannot guarantee that any of the above-noted actions would be achieved. If we perform below our forecasted levels and the actions referenced above are not effective, we would fail to comply with our financial maintenance covenant. In that instance, we would be in default, and our lenders would be permitted to accelerate our debt unless we could obtain an amendment. If our debt was accelerated, we would not have sufficient funds to repay our debt absent a refinancing, and we cannot provide assurance that we would be able to obtain a refinancing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Amended Credit Agreement and holders of our senior notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, a majority of lenders in principal amount under our 2022 Amended Credit Agreement or the trustee or holders of at least 25% in principal amount of a series of our senior notes may accelerate the maturity of the related debt under these agreements, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our common shares and/or debt securities to decline. Furthermore, under these circumstances, we may not have sufficient funds or other resources to satisfy all of our obligations and we may be unable to obtain alternative financing on terms acceptable to us or at all. In such circumstances, we could be forced into bankruptcy or liquidation and, as a result, investors could lose all or a portion of their investment in our securities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500 million (&#8220;the 2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new $975 million revolving credit facility (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of December 31, 2022, the Company had drawn $470 million on the 2027 Revolving Credit Facility. The Credit Agreement Refinancing, among other things, permitted us to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary of the 2022 Amended Credit Agreement covenants upon achievement of a 7.60:1.00 pro forma &#8220;Remainco Total Leverage Ratio.&#8221; On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To service our debt, we will be required to generate a significant amount of cash. Our ability to generate cash depends on a number of factors, some of which are beyond our control, and any failure to meet our debt obligations would have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant amount of indebtedness. For details regarding our debt and the maturity dates thereof, see Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements. Our ability to satisfy our debt obligations, will depend principally upon our future operating performance. As a result, prevailing economic conditions and financial, business and other factors, many of which are beyond our control, may affect our ability to make payments on our debt. If we do not generate sufficient cash flow to satisfy our debt obligations, we may have to undertake alternative financing plans, such as refinancing or restructuring our debt, selling assets, reducing or delaying capital investments or seeking to raise additional capital. Alternatively, as we have done in the past, we may also elect to refinance certain of our debt, for example, to extend maturities. Our ability to restructure or refinance our debt will depend on the capital markets and our financial condition at such time. If we are unable to access the capital markets, whether because of the condition of those capital markets or our own financial condition or reputation within such capital markets, we may be unable to refinance our debt. In addition, any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. Further, given our capital structure, any refinancing of our senior unsecured debt may be with secured debt, thereby increasing our first lien and/or secured leverage ratios. Our inability to generate sufficient cash flow to satisfy our debt obligations or to refinance our obligations on commercially reasonable terms, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of our indebtedness is dependent on the generation of cash flow by our subsidiaries and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Our subsidiaries may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries. Certain subsidiaries include non-U.S. subsidiaries that may be prohibited by law or other regulations from distributing funds to us and/or we may be subject to payment of taxes and withholdings on such distributions. In the event that we do not receive distributions from our subsidiaries or receive cash via services rendered, loans and intellectual property licensed, we may be unable to make required principal and interest payments on our indebtedness.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to reduce our indebtedness will depend upon factors including our future operating performance, our ability to access the capital markets to refinance existing debt and prevailing economic conditions and financial, business and other factors, many of which are beyond our control. We can provide no assurance of the amount by which we will reduce our debt, if at all. In addition, servicing our debt will result in a reduction in the amount of our cash flow available for other purposes, including operating costs and capital expenditures that could improve our competitive position and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant indebtedness, which restricts the manner in which we conduct business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant indebtedness, including in connection with our prior acquisitions. We may incur additional long-term debt and working capital lines of credit to meet future financing needs, subject to certain restrictions and prohibitions under the agreements governing our indebtedness, which would increase our total debt. This additional debt may be substantial and some of this indebtedness may be secured.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements governing our indebtedness contain restrictive covenants which impose certain limitations on the way we conduct our business, including limitations on the amount of additional debt we are able to incur, prohibitions on incurring additional debt if certain financial covenants are not met and restrictions on our ability to make certain investments and other restricted payments. Any additional debt, to the extent we are able to incur it, may further restrict the manner in which we conduct business. Such restrictions, prohibitions and limitations could impact our ability to implement elements of our strategy, including in the following ways:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our flexibility to plan for, or react to, competitive challenges in our business and the pharmaceutical and medical device industries may be compromised;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we may be put at a competitive disadvantage relative to competitors that do not have as much debt as we have, and competitors that may be in a more favorable position to access additional capital resources; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to make acquisitions and execute business development activities through acquisitions will be limited and may, in future years, continue to be limited; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to resolve regulatory and litigation matters may be limited.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, our credit ratings have been downgraded. Any further downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks related to interest rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior secured credit facilities bear interest based on a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) or U.S. Prime Rate, or Federal Funds effective rate (for U.S. dollar loans) and Canadian Prime Rate or Canada Bankers&#8217; Acceptance Rate (for Canadian dollar loans). Thus, a change in the short-term interest rate environment (especially a material change) could have an adverse effect on our business, financial condition, cash flows and results of operations (which adverse effect could be material) and could cause the market value of our common shares and/or debt securities to decline. As of December 31, 2022, we did not have any outstanding interest rate swap contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The transition of our key management positions in connection with the B+L IPO will be critical to our success, and the failure to successfully manage this transition could adversely impact our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L IPO, we appointed a new chief executive officer, chief financial officer, general counsel and other executives and key employees. In addition, the current CEO of Bausch + Lomb is expected to depart pursuant to the previously announced separation agreement. Bausch + Lomb recently announced that they have appointed a new Chairman of the Board of Directors and CEO, effective March 6, 2023. The transition may be difficult to manage and Bausch + Lomb cannot guarantee that the new CEO and Chairman of the Board will efficiently transition into these new roles or ultimately be successful in such roles. The departure of key leadership personnel often results in the loss of significant knowledge and experience, and the ability of our new management to quickly expand their knowledge of our business will be critical to their ability to make informed decisions about our strategy and operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant leadership change or senior management transition involves inherent risks, and any future changes to our management that may occur during the transition could cause significant disruption to the Company and its operations. The failure to adequately manage succession of senior management and other key personnel or the failure of key employees to successfully transition into new roles could cause further disruption to our business. In addition, changes in senior management may create uncertainty among investors, employees, business partners and others concerning the Company&#8217;s future direction and performance. Any disruption in our operations or adverse impacts from such uncertainty could have a material adverse effect on our business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of the services of, or our inability to recruit, retain or motivate, our executives and other key employees could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must continue to retain and motivate our executives and other key employees, and to recruit other executives and employees, in order to strengthen our management team and workforce. Our ability to retain or recruit executive and other key employees may be hindered or delayed by, among other things, competition from other employers who may be able to offer more attractive compensation packages, the reputational challenges the Company has faced as a result of historical issues and may in the future continue to face and the perceived or actual uncertainty created by the B+L Separation, the changes to our executive team in connection with the B+L IPO. A failure by us to retain, motivate and recruit executives and other key employees or the unanticipated loss of the services of any of these executives or key employees for any reason, whether temporary or permanent, could create disruptions in our business, could cause concerns and instability for management and employees, current and potential customers, credit rating agencies and other third parties with whom we do business and our shareholders and debt holders and could cause concern regarding our ability to execute our business strategy or to manage operations in the manner previously conducted and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Furthermore, as a result of any failure to retain, or loss of, any executives or key employees, we may experience increased costs in order to identify and recruit a suitable replacement in a timely manner (and, even if we are able to hire a qualified successor, the search process and transition period may be difficult to manage and result in additional periods of uncertainty), which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, once identified and recruited, the transition of new executives and key employees may be difficult to manage, and we cannot guarantee that new executives and employees will efficiently transition into their roles or ultimately be successful in their roles. Finally, as a result of changes in our executives and key employees, there may be changes in the way we conduct our business, as well as changes to our business strategy. We cannot predict what these changes may involve or the timing of any such changes and how they will impact our product sales, revenue, business, financial condition, cash flows or results of operations, but any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could cause the market value of our common shares and/or debt securities to&#160;decline. Any of these factors could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax-related Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rates may increase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in various countries that have differing tax laws and rates. Our tax reporting is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned among the different jurisdictions in which we operate; changes in tax laws in these jurisdictions; changes in the tax treaties between various countries in which we operate; changes in our eligibility for benefits under those tax treaties; and changes in the estimated values of deferred tax assets and liabilities. Tax laws, regulations, and administrative practices in various jurisdictions may be subject to significant change, with or without notice, due to economic, political, and other conditions, and significant judgment is required in evaluating and estimating our provision and accruals for these taxes. Such changes could result in a substantial increase in the effective tax rate on all or a portion of our income. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to tax law in the U.S. and outside of the U.S. could affect our corporate tax rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed the Inflation Reduction Act into law, which includes implementation of a new alternative minimum tax, an excise tax on stock buybacks and significant tax incentives for energy and climate initiatives, among other provisions. The corporate alternative minimum tax (&#8220;CAMT&#8221;) imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. We currently do not believe this will have a significant impact on our tax results but will continue to evaluate the law and its provisions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreement reached by the Inclusive Framework in October 2021. On December 13 2022, the European Union member states reached an agreement to implement pillar two rules. The rules are expected to be transposed into domestic laws in 2023 with certain elements becoming effective for fiscal years beginning on or after December 31, 2023. On February 1, 2023, the Inclusive Framework released a package of technical and administrative guidance on the implementation of pillar two, including the scope of companies that will be subject to the Global Anti-Base Erosion Rules, transition rules, and guidance on domestic minimum taxes that countries may choose to adopt, among other topics. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate, could have a material effect on our liability for corporate taxes and our consolidated effective tax rate. On February 1, 2023, the US Financial Accounting Standards Board indicated that they believe the minimum tax imposed under pillar two is an alternative minimum tax, and, accordingly, deferred tax assets and liabilities associated with the minimum tax would not be recognized or adjusted for the estimated future effects of the minimum tax but would be recognized in the period incurred. On April 19, 2021, the Canadian federal government delivered its 2021 budget which contained proposed measures related to limitations on interest deductibility and changes in relation to international taxation. Draft legislative proposals pertaining to interest deductibility were initially released for public comment on February 4, 2022, with revised legislative proposals subsequently released on November 3, 2022. The proposed rules on interest deductibility are expected to be effective no earlier than January 1, 2024. The proposed rules and their application are complex and could have a material adverse impact on our consolidated effective tax rate and financial results in future years if enacted as drafted. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate and such implementation of the Inclusive Framework agreement, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is based on certain estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of pre-tax income earned in our various operating jurisdictions, the availability of benefits under tax treaties, and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in respect of which the tax treatment is not entirely certain. We therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than we will allocate to our business in such countries. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals. This could result in a material adverse effect on our consolidated income tax provision, financial condition and the net income for the period in which such determinations are made. See Note 17, &#8220;INCOME TAXES&#8221; to our audited Consolidated Financial Statements for a discussion of the tax audits, examinations, and other proceedings currently being conducted with respect to the Company and its subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax liabilities, deferred tax assets and any related valuation allowances are affected by events and transactions arising in the ordinary course of business, acquisitions of assets and businesses, and non-recurring items. The assessment of the appropriate amount of a valuation allowance against the deferred tax assets is dependent upon several factors, including estimates of the realization of deferred income tax assets, which realization will be primarily based on future taxable income, including the reversal of existing taxable temporary differences. Significant judgment is applied to determine the appropriate amount of valuation allowance to record. Changes in the amount of any valuation allowance required could materially increase or decrease our provision for income taxes in a given period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, &#8220;INCOME TAXES&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Intellectual Property and Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The expiration or loss of patent protection or regulatory exclusivity rights for our key products could adversely impact our business. In addition, we have faced generic competition in the past and expect to face additional generic competition in the future. Competitors (including generic and biosimilar competitors) of our products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new and innovative products, as well as protecting the underlying intellectual property of our product portfolio, is important to our success in all areas of our business. A significant number of the products we sell either: (i) have no meaningful exclusivity protection via patent or marketing or data exclusivity rights or (ii) are protected by patents or regulatory exclusivity periods that will be expiring in the near future. These products represent a significant amount of our revenues (See Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Business Trends &#8212; Generic Competition and Loss of Exclusivity&#8221; in this Form 10-K for a list of some of these products). The expiration or loss of patent protection or regulatory exclusivity rights for our key products could adversely impact our business. In addition, even for our products that have patent protection or exclusivity rights, we face competition from similar products in the markets in which we participate. As a result, we face significant competition with respect to a substantial majority of our products</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without exclusivity protection, competitors and other third parties (including generics and biosimilars) face fewer barriers in introducing competing products. Upon the expiration or loss of patent exclusivity or regulatory exclusivity for our products or otherwise upon the introduction of generic, biosimilar or other competitors (which may be sold at significantly lower prices than our products), we could lose a significant portion of sales and market share of the applicable products in a very short period and, as a result, our revenues could be lower. In addition, the introduction of generic and biosimilar competitors may have a significant downward pressure on the pricing of our branded products which compete with such generics and biosimilars. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third party) prior to, upon or following generic entry, which may mitigate a portion of the anticipated decrease in product sales; however, even with the launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material. The introduction of competing products (including generic products and biosimilars) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain, maintain, license, enforce or defend the intellectual property and proprietary rights required to conduct our business, or third parties may allege that we are infringing, misappropriating or otherwise violating their intellectual property rights, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to acquire, maintain, enforce and defend patent, trademark and other intellectual property and proprietary protections over our products and the processes used to manufacture these products. However, we may not be successful in obtaining such protections, or the patent, trademark and other intellectual property and proprietary rights we do obtain may not be sufficient in breadth and scope to fully protect our products or prevent competing products, or such rights may be susceptible to third-party challenges, which could result in the loss of such intellectual property rights or the narrowing of scope of protection afforded by such rights. Our intellectual property and proprietary rights may also be circumvented by third parties. The failure to obtain, maintain, enforce or defend such intellectual property and proprietary rights, for any reason, could allow third parties to manufacture and sell products that compete with our products or may impact our ability to develop, manufacture and market our own products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the pharmaceutical and medical device industries historically have generated substantial litigation concerning the manufacture, use and sale of products and we expect this litigation activity to continue. As a result, we expect that patents related to our products will be routinely challenged, and the validity or enforceability of our patents may not be upheld. In order to protect or enforce patent rights, we may initiate litigation against third parties. Our patents may also be challenged in administrative proceedings in the United States Patent and Trademark Office and patent offices outside of the United States. If we are not successful in defending an attack on our patents and maintaining exclusive rights to market one or more of our products still under patent protection, we could lose a significant portion of sales in a very short period. Even in cases where we prevail in an infringement claim, legal remedies available for harm caused to us may not be sufficient to make us whole. We may also become subject to, or threatened with, legal proceedings and infringement claims by third parties and may have to defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of others, we could lose our right to develop, manufacture or sell products, including our generic products, or could be required to pay monetary damages or royalties to license proprietary rights from third parties, which could be substantial and include treble damages and attorneys&#8217; fees, if we are found to willfully infringe any intellectual property rights of others. However, we may not be able to obtain any required license from any third party on commercially reasonable terms or at all. Any of the foregoing events could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information, see Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products and manufacturing processes, we rely on trade secrets and other proprietary information, which we seek to protect, in part, through information technology systems discussed in more detail in the following section, and, in part, by confidentiality and nondisclosure agreements with our employees, consultants, advisors and partners. Trade secrets and proprietary information are difficult to protect. We also attempt to enter into agreements whereby such employees, consultants, advisors and partners assign to us the rights in any intellectual property they develop in the course of their engagement with us. These agreements may be breached, and we may not have adequate remedies for any breach. There can be no assurance that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information. These agreements may not effectively prevent disclosure or misappropriation of such information and disputes may still arise with respect to the ownership of intellectual property. In addition, third parties may independently develop the same or similar proprietary information or otherwise gain access to our trade secrets or disclose our technology. Further, we have employed and expect to employ individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, advisors and partners do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or such persons have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. The unauthorized access to or disclosure of our proprietary information or the loss of such intellectual property rights may impact our ability to develop, manufacture and market our own products or may assist competitors in the development, manufacture and sale of competing products, which could have a material adverse effect on our revenues, financial condition, cash flows or results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a number of our commercialized products and pipeline products, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the pipeline products that are the subject of our recently announced licenses with Eyenovia, Inc., Novaliq GmbH, BHVI and Clearside Biomedical, Inc., we rely on licenses to patents and other technologies, know-how and intellectual property and proprietary rights held by third parties. Any loss, expiration, termination or suspension of our rights to such licensed intellectual property would result in our inability to continue to develop, manufacture and market the applicable products or product candidates and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. If these licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, third parties, including our competitors, could have the freedom to seek regulatory approval of, and to market, products identical or similar to ours, and we may be required to cease our development and commercialization of certain of our products. Under some license agreements, we may not control the preparation, filing, prosecution or maintenance of the licensed intellectual property, or may not have the first right to enforce the intellectual property. In those cases, we may not be able to adequately influence patent prosecution or enforcement, or prevent inadvertent lapses of coverage due to failure to pay maintenance fees and we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business and that does not compromise the patent rights. In the future, we may also need to obtain such licenses from third parties to develop, manufacture, market or continue to develop, manufacture or market our products. If we are unable to timely obtain these licenses on commercially reasonable terms or at all, our ability to develop, manufacture and market our products may be inhibited or prevented, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources, distract our personnel from their normal responsibilities and cause the value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the value of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development collaborations that would help us commercialize our product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competitive Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in extremely competitive industries. If competitors develop or acquire more effective or less costly pharmaceutical or OTC products or medical devices for our target indications, it could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The pharmaceutical, OTC and medical device industries are extremely competitive. Our success and future growth depend, in part, on our ability to develop, license or acquire products that are more effective than those of our competitors or that incorporate the latest technologies and our ability to effectively manufacture and market those products. New market entrants and existing competitors are also challenging distribution models with innovation in non-traditional, disruptive models such as direct-to-consumer, Internet and other e-commerce sales opportunities. Many of our competitors, particularly larger pharmaceutical, OTC and medical device companies, have substantially greater financial, technical and human resources than we do. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors spend significantly more on research and development related activities than we do. Others may succeed in developing or acquiring products and technologies that are more effective, more advanced or less costly than those currently marketed or proposed for development by us. In addition, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products and may also establish exclusive collaborative or licensing relationships with our competitors. These competitors and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the introduction of competing products (that may be more effective or less costly than our products) could make our products less competitive or obsolete, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the timing or impact of the introduction of competitive products, including new market entries, &#8220;generic&#8221; versions of our approved products, or private label products that treat the same conditions as those of our products. In addition, the introduction of alternatives in medical devices and medical prescriptions could also alter the market and impede our sales growth. Our ability to respond to these competitive pressures will depend on our ability to decrease our costs and maintain gross margins and operating results and to introduce new products successfully and on a timely basis, and to achieve manufacturing efficiencies and sufficient manufacturing capacity and capabilities for such products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business Strategy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have previously made commitments and public statements with respect to limitations on pricing increases for certain of our products. These pricing decisions, or decisions to increase prices, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formed a Patient Access and Pricing Team which is committed to maintaining patients ability to access our branded prescription pharmaceutical products. All future pricing actions will be subject to review by the Patient Access and Pricing Team.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot predict what specific pricing changes the Pricing Team will make for the remainder of 2023 or beyond nor can we predict what other changes in our business practices we may implement with respect to pricing (such as imposing limits or prohibitions on the amount of pricing increases we may take on certain of our products or taking retroactive or future price reductions). We also cannot predict the impact such pricing decisions or changes will or would have on our business. However, any such changes could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, any pricing changes and programs could affect the average realized prices for our products and may have a significant impact on our revenue trends. In addition, limiting or eliminating price increases on certain of our products will result in fewer or lower price appreciation credits from certain of our wholesalers. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. In wholesaler contracts, such credits, which can be significant, are offset against the total distribution service fees we pay on all of our products to each wholesaler. As a result, to the extent we decide to cease or limit price increases, we will have fewer or lower price appreciation credits to use to offset against our distribution fees owing to these wholesalers. In addition, under certain of our agreements with our wholesaler customers, we have price protection or price depreciation provisions, pursuant to which we have agreed to adjust the value of any on-hand or in-transit inventory with such customers in the event we reduce the price of any of our products. As a result, to the extent we reduce the WAC price for any of our products, we may owe a payment to such customers (or such customers may earn a credit to be offset against any amounts owing to us) equal to the amount of such inventory multiplied by the difference between the price at which they acquired the product inventory and the new reduced price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In prior years, we have undertaken a number of divestitures of certain of our assets and business. We may, in the future, seek to divest additional assets and/or businesses, some of which may be material and/or transformative, which could adversely affect our business, prospects and opportunities for growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have completed a number of divestitures of our assets, products or businesses that were not considered core to our ongoing operations or the needs of our primary-customer base, including the divestitures of our Obagi Medical Products business, our iNova Pharmaceuticals business, our Dendreon Pharmaceuticals subsidiary, our Sprout Pharmaceuticals subsidiary, the CeraVe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AcneFree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AMBI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skincare brands and our Amoun Pharmaceutical subsidiary.&#160;We may, in the future, seek to complete additional divestitures. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these divestitures has been time-consuming and has diverted management&#8217;s attention. As a result of these divestitures (and others we may complete in the future), we may experience lower revenue and lower cash flows from operations. In addition, as was the case with our sale of our Sprout Pharmaceuticals subsidiary, we may recognize a loss on sale in connection with such divestitures. We may also suffer adverse tax consequences as a result of such divestitures, including capital gains tax or the accelerated use of NOLs or other attributes. Furthermore, divesting certain of our businesses or assets may require us to incur restructuring charges, and we may not be able to achieve the cost savings that we expect from any such restructuring efforts or divestitures. Any such divestiture could reduce the size or scope of our business, our market share in particular markets, our opportunities with respect to certain markets, products or therapeutic categories or our ability to compete </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain markets and therapeutic categories. Furthermore, we will be required to use the net proceeds (or substantial portions thereof) from certain asset sales to repay the term loans under the 2022 Amended Credit Agreement, subject to certain reinvestment rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should we seek to divest other of our assets and business, we may be unable to dispose of such businesses and assets on satisfactory or commercially reasonable terms within our anticipated timeline. In addition, our ability to identify, enter into and/or consummate divestitures may be limited by competition we face from other companies in pursuing similar transactions in the pharmaceutical industry. Any divestiture or other disposition we pursue, whether we are able to complete it or not, may be complex, time consuming and expensive, may divert the management&#8217;s attention, have a negative impact on our customer relationships, cause us to incur costs associated with maintaining the business of the targeted divestiture during the disposition process and also to incur costs of closing and disposing the affected business or transferring the operations of the business to other facilities. The divestiture process may also further expose us to operational inefficiencies. In addition, if such transactions are not completed for any reason, the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, any divestiture (whether or not completed) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As part of our business strategy, we seek to identify and acquire certain assets, products and businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, part of our business strategy included acquiring and integrating complementary businesses, products, technologies or other assets. As part of our current business strategy, we again are seeking to complete certain acquisitions of assets, products and businesses, including by way of in-license arrangements, although not at the volume and pace that we did historically. Acquisitions or similar arrangements may be complex, time consuming and expensive. We may not consummate some negotiations for acquisitions or other arrangements, which could result in significant diversion of management and other employee time, as well as substantial out-of-pocket costs. In addition, there are a number of risks and uncertainties relating to our closing transactions. If such transactions are not completed for any reason, we will be subject to several risks, including the following: (i)&#160;the market price of our common shares may reflect a market assumption that such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares and (ii)&#160;many costs relating to such transactions may be payable by us whether or not such transactions are&#160;completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an acquisition is consummated, the integration of the acquired business, product or other assets into our Company may also be complex and time-consuming and, if such businesses, products and assets are not successfully integrated, we may not achieve the anticipated benefits, cost-savings or growth opportunities. Potential difficulties that may be encountered in the integration process include the&#160;following: integrating personnel, operations and systems, while maintaining focus on selling and promoting existing and newly-acquired products; coordinating geographically dispersed organizations; distracting management and employees from operations; retaining existing customers and attracting new customers; maintaining the business relationships the acquired company has established, including with health care providers; and managing inefficiencies associated with integrating the operations of the&#160;Company and the acquired business, product or other assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we may incur restructuring and integration costs and a number of non-recurring transaction costs associated with these acquisitions, combining the operations of the Company and the acquired company and achieving desired synergies. These fees and costs may be substantial. Non-recurring transaction costs include, but are not limited to, fees paid to legal, financial and accounting advisors, filing fees and printing costs. Additional unanticipated costs may be incurred in the integration of the businesses of the Company and the acquired company. There can be no assurance that the elimination of certain duplicative costs, as well as the realization of other efficiencies related to the integration of the acquired business, will offset the incremental transaction-related costs over time. Therefore, any net benefit may not be achieved in the near term, the long term or at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, these acquisitions and other arrangements, even if successfully integrated, may fail to further our business strategy as anticipated or to achieve anticipated benefits and success, expose us to increased competition or challenges with respect to our products or geographic markets, and expose us to additional liabilities associated with an acquired business, product, technology or other asset or arrangement. Any one of these challenges or risks could impair our ability to realize any benefit from our acquisition or arrangement after we have expended resources on&#160;them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain our relationships with, and provide appropriate training in our products to, health care providers, including physicians, eyecare professionals, hospitals, large drug store chains, wholesale distributors, pharmacies, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">government entities and group purchasing organizations, customers may not buy certain of our products and our sales and profitability may decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our pharmaceutical products to physicians, hospitals, pharmacies and wholesalers through our own sales force and sell through wholesalers. In some markets, we additionally sell directly to physicians, hospitals and large drug store chains and we sell through distributors in countries where we do not have our own sales staff. We have developed and strive to maintain strong relationships with members of each of these groups who assist in product research and development and advise us on how to satisfy the full range of consumer needs. We rely on these groups to educate their patients and other members of their organizations regarding our products. Consumers in the pharmaceutical industry, particularly the contact lens and lens care customers in the eye health industry, have a tendency not to switch products regularly and are repeat consumers. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically benefitted from our strong relationships with these physicians, hospitals, pharmacies and wholesalers. Our ability to maintain strong relationships is essential to our future performance; however, we may not be able to maintain these relationships in the future. The success of certain of our products, particularly our vision care products, is impacted by a physician&#8217;s initial recommendation of such products and a consumer&#8217;s initial choice to use such products. As a result, the failure of certain of our products, particularly in our vision care business, to retain the support of pharmaceutical professionals, hospitals or group purchasing organizations and to retain the support of the end-users and the distributors and retailers to whom we sell such products, could have a material adverse effect on our sales and profitability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development and Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful development of our pipeline products is highly uncertain and requires significant expenditures and time. In addition, obtaining necessary government approvals is time-consuming and not assured. The failure to commercialize certain of our pipeline products could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a number of pipeline products in development. We and our development partners, as applicable, conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our pipeline products in order to obtain regulatory approval for the sale of our pipeline products. Preclinical studies and clinical trials are expensive, complex, can take many years and have uncertain outcomes. None of, or only a small number of, our research and development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. Furthermore, success in preclinical studies or early-stage clinical trials does not ensure that later stage clinical trials will be successful nor does it ensure that regulatory approval for the product candidate will be obtained. In addition, the process for the completion of pre-clinical and clinical trials is lengthy and may be subject to a number of delays for various reasons, which would delay the commercialization of any successful product. If our development projects are not successful or are significantly delayed, we may not recover our substantial investments in the pipeline product and our failure to bring these pipeline products to market on a timely basis, or at all, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA and Health Canada approval must be obtained in the U.S. and Canada, respectively, EMA approval (drugs) and CE Marking (devices) and/or registration under the European Commission&#8217;s Medical Device Regulation (&#8220;MDR&#8221;) 2017/745 must be obtained in countries in the EU and similar approvals must be obtained from comparable agencies in other countries, prior to marketing or manufacturing new pharmaceutical and medical device products for use by humans. Obtaining such regulatory approvals for new products and devices and manufacturing processes can take a number of years and involves the expenditure of substantial resources. We may face additional challenges with respect to EMA approval and CE Marking in the EU as a result of additional requirements for approval in the EU that may be more burdensome than those required by the FDA and Health Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if such products appear promising in development stages, regulatory approval may not be achieved and no assurance can be given that we will obtain approval in those countries where we wish to commercialize such products. Nor can any assurance be given that if such approval is secured, the approved labeling will not have significant labeling limitations, including limitations on the indications for which we can market a product, or require onerous risk management programs. Furthermore, from time to time, changes to the applicable legislation, regulations or policies may be introduced that change these review and approval processes for our products, which changes may make it more difficult and costly to obtain or maintain regulatory approvals. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketed products will be subject to ongoing regulatory review.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following initial regulatory approval of any products, we or our partners may develop or acquire, we will be subject to continuing regulatory review by various government authorities in those countries where our products are marketed or intended </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be marketed, including the review of adverse drug events and clinical results that are reported after product candidates become commercially available. In addition, we are subject to ongoing audits and investigations of our facilities and products by the FDA, as well as other regulatory agencies in and outside the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the regulatory requirements in those countries where our products are sold, we could lose our marketing approvals or be subject to fines or other sanctions. Also, as a condition to granting marketing approval of a product, the applicable regulatory agencies may require a company to conduct additional clinical trials or remediate Current Good Manufacturing Practice (&#8220;CGMP&#8221;) issues, the results of which could result in the subsequent loss of marketing approval, changes in product labeling or new or increased concerns about side effects or efficacy of a product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, the European Union adopted MDR, which repeals and replaces the Medical Device Directive (&#8220;MDD&#8221;) and Active Implantable Medical Devices Directive (&#8220;AIMDD&#8221;) 90/385/EEC. The MDR, for most parts, became applicable on May 26, 2021. Under the MDR, several transitional measures apply to medical devices that are certified under the MDD or AIMDD prior to May 26, 2021 or, for class I devices, for which a declaration of conformity was drawn up prior to May 26, 2021, allowing these devices to be placed on the market after May 26, 2021 under certain conditions for a transitional period. However, if we make any significant changes in the design or intended purpose of our devices, they will no longer benefit from such transitional periods. Generally, the MDR imposes stricter requirements on manufacturers, importers and distributors of medical devices. Moreover, the requirements to provide clinical data for medical devices has become stricter and as a result we may need to conduct new time consuming and costly clinical investigations with our existing medical devices to meet the new requirements, including to obtain CE certificates under the MDR. We may, or may not, be able to provide this data in time to obtain MDR certifications in a timely fashion when our existing certificates expire. These new regulations impact all of our existing and pipeline medical device products being sold in the EEA for which we are legal manufacturer, importer and/or distributor, including contact lens, lens care, eye health, aesthetic and surgical areas, as well as certain of our products outside the EEA, which rely on the EEA registration to support registration in those other countries. These products, in the aggregate, account for a meaningful portion of our net revenue in this region. While we are working to ensure compliance with these new regulations for all impacted products, we may not be able to achieve compliance for all products within the applicable transition period. If we fail to achieve compliance, we will not be able to market and sell the non-compliant products in the EEA, nor will we be able to rely on the non-compliant registration for such products in regions outside of the EEA, which could have a material adverse effect on our business, financial condition, cash flows and results of operations in the EEA and, possibly, on a consolidated basis, and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While EU law is applicable in Northern Ireland, the UK Medical Devices Regulations 2002/68 also need to be complied with in Great Britain. Medical device manufacturers who have CE marked devices will be able to continue to place them on the market in the whole of the United Kingdom (the &#8220;UK&#8221;) until July 1, 2023 without a change in labeling. After that, devices destined for Great Britain will be required to follow the UK regulatory regime and to be labeled with the UKCA mark. Northern Ireland will, however, continue to accept CE marked devices. There are some additional requirements for manufacturers who are based outside the UK such as the requirement to appoint a UK Responsible Person (&#8220;UKRP&#8221;) to take on certain regulatory responsibilities with respect to the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) and users or customers in the UK. To enable devices to be placed on the market in the UK after January 1, 2022 (even for CE marked devices), a UK manufacturer must register with the MHRA, as must a UKRP for an overseas manufacturer. Such registering entity will then register each of the devices for which they are responsible for placing on the market in the UK, whether in Great Britain or Northern Ireland. This may create added expense and challenges as explained below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until May 25, 2021, our products bearing a CE mark could be exported from the EEA to Switzerland. However, as of May 26, 2021, the EU no longer applies the Mutual Recognition Agreement between the EEA and Switzerland. Accordingly, legal manufacturers in Switzerland are required to appoint a European Union authorized representative, and manufacturers outside of Switzerland are required to appoint a Swiss authorized representative in compliance with the Medical Device Ordinance. As a consequence, we have been required to appoint an authorized representative in Switzerland in order to export our CE-marked medical devices to Switzerland. Additionally, the name and address of the Swiss authorized representative must be placed on the packaging. This has created added expenses and challenges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, incidents of adverse drug reactions, unintended side effects or misuse relating to our products could result in additional regulatory controls or restrictions, or even lead to the regulatory authority requiring us to recall or withdraw the product from the market. Further, if faced with these incidents of adverse drug reactions, unintended side effects or misuse relating to our products, we may elect to voluntarily implement a recall or market withdrawal of our product. A recall or market withdrawal, whether voluntary or required by a regulatory authority, may involve significant costs to us, potential disruptions in the supply of our products to our customers and reputational harm to our products and business, all of which could harm our ability to market our products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complying with existing government regulation of dietary supplements, including our eye vitamins and mineral supplements, in the U.S., Canada and elsewhere could increase our costs significantly and adversely affect our financial results. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing, formulation, packaging, labeling and advertising of the Company&#8217;s dietary supplement products are also subject to regulation by certain federal, state and foreign agencies, including the FDA, the Federal Trade Commission (the &#8220;FTC&#8221;), and the Consumer Product Safety Commission, in the U.S., and by Health Canada in Canada. The FDA has authority in the U.S. over the adulteration or misbranding of dietary supplements. There are requirements relating to ingredient safety, new dietary ingredient notifications, labeling, claims notifications, and adverse event reporting among other requirements. While we believe our products comply with those requirements, the FDA may challenge positions we have taken with respect to the formulation or labeling of a dietary supplement product. We are also subject to risks relating to evolving regulations of dietary supplement products, including our eye vitamins and mineral supplements, as the FDA and other applicable agencies have in the past and may in the future consider additional or more stringent regulations of dietary supplements and other products. Such developments could require reformulation of certain of our products to meet new standards, additional record-keeping obligations, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, adverse event reporting or similar obligations, or could result in recalls or the discontinuance of certain of our products that are not able to be reformulated. Any such developments could increase our costs significantly. In addition, the FDA also has comprehensive regulations for CGMP for those who manufacture, package or hold dietary supplement products. These regulations focus on practices that ensure the identity, purity, quality, strength and composition of dietary supplements that are manufactured. We or our contract manufacturers may not be able to comply with such regulations without incurring additional expenses, which could be significant.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues and profits from generic products may decline as a result of changes in regulatory policy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Congress and various state legislatures in the U.S. have passed, or have proposed passing, legislation that could have an adverse impact on pharmaceutical manufacturers&#8217; ability to: (i) settle litigation initiated pursuant to the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), (ii) secure the full benefit of first-to-file regulatory approval status secured under the Hatch-Waxman Act and (iii) change the value of the brand products prior to the launch of generic versions. The Hatch-Waxman Act and BPCIA create various pathways for generic drug manufacturers to secure accelerated approvals of their abbreviated new drug applications and abbreviated biologics license applications. The new laws and proposals from the federal and state governments could serve to change, directly and indirectly, the Hatch-Waxman Act and BPCIA, including the incentives to develop generic and biosimilar products, as well as the ability of generic manufacturers to accelerate the launch of their new generic and biosimilar products. They also could impact the ability of brand manufacturers to protect their investments in the intellectual property associated with their branded specialty and innovative biologic products. We continue to monitor these legislative developments and advocate for policies that support both innovation and access to high quality medicines for patients.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Risks</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party manufacturers are unable to manufacture our products or the manufacturing process is interrupted due to failure to comply with regulations or for other reasons, the interruption of the manufacture of our products could adversely affect our business. Other manufacturing and supply difficulties or delays may also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facilities and those of our contract manufacturers must be inspected and found to be in full compliance with CGMP, quality system management requirements or similar standards before approval for marketing. Compliance with CGMP regulations requires the dedication of substantial resources and requires significant expenditures. In addition, while we attempt to build in certain contractual obligations on our third-party manufacturers, we may not be able to ensure that such third-parties comply with these obligations. Our failure or that of our contract manufacturers to comply with CGMP regulations, quality system management requirements or similar regulations outside of the U.S. could result in enforcement action by the FDA or its foreign counterparts, including, but not limited to, warning letters, fines, injunctions, civil or criminal penalties, recall or seizure of products, total or partial suspension of production or importation, suspension or withdrawal of regulatory approval for approved or in-market products, refusal of the government to renew marketing applications or approve pending applications or supplements, refusal of certificates for export to foreign jurisdictions, suspension of ongoing clinical trials, imposition of new manufacturing requirements, closure of facilities and criminal prosecution. These enforcement actions could lead to a delay or suspension in production, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows and could cause the market value of our common shares and/or debt securities to decline. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing and other processes use complicated and sophisticated equipment, which sometimes requires a significant amount of time to obtain and install. Manufacturing complexity, testing requirements and safety and security processes combine to increase the overall difficulty of manufacturing these products and resolving manufacturing problems that we may encounter. Although we endeavor to properly maintain our equipment (and require our contract manufacturers to properly maintain their equipment), including through on-site quality control and experienced manufacturing supervision, and have key spare parts on hand, our business could suffer if certain manufacturing or other equipment, or all or a portion of our or their facilities, were to become inoperable for a period of time. We could experience substantial production delays or inventory shortages in the event of any such occurrence until we or they repair such equipment or facility or we or they build or locate replacement equipment or a replacement facility, as applicable, and seek to obtain necessary regulatory approvals for such replacement. For example, in 2021, a third-party supplier of sterilization services for our lens care solution bottles and caps at our Milan, Italy facility notified us of inconsistencies in the sterilization data versus certificates of conformance previously submitted to us by that supplier. Although we determined that this issue did not affect the safety or performance of any of our products and was limited to a specific number of lots for certain of our products, out of an abundance of caution, in conjunction with the appropriate notified body and responsible health authorities, we contained and/or recalled down to the consumer level the limited number of affected lots of products, which resulted in $8 million of manufacturing variances and $6 million of returns. Further, due to the limited availability of qualified materials caused by this issue, production at the Milan facility could not keep up with demand (even with leveraging increased production at another of our manufacturing facilities to support some of the demand), which negatively impacted our sales for the affected products in this region during 2021. Any interruption in our manufacture of products could adversely affect the sales of our current products or introduction of new products and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supply of our products to our customers (or, in some cases, supply from our contract manufacturers to us) is subject to and dependent upon the use of transportation services. Disruption of transportation services (including as a result of weather conditions) could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, any prolonged disruption in the operations of our existing distribution facilities, whether due to technical, labor or other difficulties, weather conditions, equipment malfunction, contamination, failure to follow specific protocols and procedures, destruction of or damage to any facility or other reasons, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For some of our finished products and raw materials, we obtain supply from one or a limited number of sources. If we are unable to obtain components or raw materials, or products supplied by third parties, our ability to manufacture and deliver our products to the market would be impeded, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some components and raw materials used in our manufactured products, and some finished products sold by us, are currently available only from one or a limited number of domestic or foreign suppliers. For example, with respect to some of our largest or most significant products, the supply of the finished product for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral and PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products are only available from a single source and the supply of active pharmaceutical ingredient for each of our Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Oral products are also only available from a single source. In the event an existing supplier fails to supply product on a timely basis and/or in the requested amount, supplies product that fails to meet regulatory requirements, becomes unavailable through business interruption or financial insolvency or loses its regulatory status as an approved source or we are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we may be unable to obtain the required components, raw materials or products on a timely basis or at commercially reasonable prices. We attempt to mitigate these risks by maintaining safety stock of these products, but such safety stock may not be sufficient. In addition, in some cases, only a single source of active pharmaceutical ingredient is identified in filings with regulatory agencies, including the FDA, and cannot be changed without prior regulatory approval, which would involve time and expense to us. A prolonged interruption in the supply of a single-sourced raw material, including the active pharmaceutical ingredient, or single-sourced finished product could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. In addition, these third-party manufacturers may have the ability to increase the supply price payable by us for the manufacture and supply of our products, in some cases without our consent.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our dependence upon others to manufacture and supply our products may adversely affect our profit margins and our ability to obtain approval for and produce our products on a timely and competitive basis, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers may adversely affect our sales and earnings and add to sales variability from quarter to quarter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We balance the need to maintain inventory levels that are sufficient to ensure competitive lead times against the risk of inventory obsolescence because of changing customer requirements, fluctuating commodity prices, changes to our products, product transfers or the life-cycle of our products. In order to successfully manage our inventories, we must estimate demand from our customers and produce products that substantially correspond to that demand. If we fail to adequately forecast demand for any new or existing product or fail to determine the appropriate product mix for production purposes, we may face production capacity issues in manufacturing sufficient quantities of a given product. In addition, failures in our information technology systems or human error could also lead to inadequate forecasting of our overall demand or product mix.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of unique products, and we anticipate that number will continue to grow over time. As a result, the demand forecasting precision required for us to avoid production capacity issues will also increase, which could increase the risk of product unavailability and lost sales. Additionally, an increasing number of unique products could increase global inventory requirements, negatively impacting our working capital performance and leading to write-offs due to obsolescence and expired products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lead times necessary to obtain and install new equipment and ramp up production of product lines, if we fail to adequately forecast the need for additional manufacturing capacity, whether for new or existing products, we may be unable to scale production in a timely manner to meet demand for our products. In addition, the technically complex manufacturing processes required to manufacture many of our products increase the risk of production failures and can increase the cost of producing our goods. As a result, because the production process for many of our products is complex and sensitive, the cost of production and the chance of production failures and lengthy supply interruptions is increased, which can have a substantial impact on our inventory levels.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, a significant portion of our products are sold to major health care distributors and major retail chains in Canada, the United States and abroad. Consequently, our sales and quarterly growth comparisons, as well as our estimates for required inventory levels, may be affected by fluctuations in the buying patterns of major distributors, retail chains and other trade buyers. These fluctuations may result from seasonality, pricing, large retailers&#8217; and distributors&#8217; buying decisions or other factors. If we overestimate demand and produce too much of a particular product, we face a risk of inventory obsolescence, leaving us with inventory that we cannot sell profitably or at all. In addition, we may have to write down such inventory if we are unable to sell it for its recorded value. Conversely, if we underestimate demand and produce insufficient quantities of a product, we could be forced to produce that product at a higher price and forego profitability in order to meet customer demand. For example, if a competitor initiates a recall and there is an unexpected increase in the demand for our products, we may not be able to meet such increased demand. Insufficient inventory levels may lead to shortages that result in loss of sales opportunities altogether as potential end-customers turn to competitors' products that are readily available. If any of these situations occur frequently or in large volumes or if we are unable to effectively manage our inventory and that of our distribution partners, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization Risks</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approved products may not achieve or maintain expected levels of market acceptance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to obtain and maintain regulatory approvals for our pharmaceutical and medical device products, generic or branded, the success of these products is dependent upon achieving and maintaining market acceptance. Launching and commercializing products is time consuming, expensive and unpredictable. The commercial launch of a product takes significant time, resources, personnel and expertise, which we may not have in sufficient levels to achieve success, and is subject to various market conditions, some of which may be beyond our control. There can be no assurance that we will be able to, either by ourselves or in collaboration with our partners or through our licensees or distributors, successfully launch and commercialize new products or gain market acceptance for such products. New product candidates that appear promising in development may fail to reach the market or may have only limited or no commercial success. While we have been successful in launching some of our products, we may not achieve the same level of success with respect to all of our new products. Our inability to successfully launch our new products may negatively impact the commercial success of such product, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. Our inability to successfully launch our new products could also lead to material impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Levels of market acceptance for our new products could be impacted by several factors, some of which are not within our control, including but not limited to the following:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">safety, efficacy, convenience and cost-effectiveness of our products compared to products of our competitors;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">scope of approved uses and marketing approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">availability of patent or regulatory exclusivity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">timing of market approvals and market entry;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing regulatory obligations following approval, such as the requirement to conduct Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) programs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">any restrictions or &#8220;black box&#8221; warnings required on the labeling of such products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">availability of alternative products from our competitors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">acceptance of the price of our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">effectiveness of our sales forces and promotional efforts;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the level of reimbursement of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">acceptance of our products on government and private formularies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ability to market our products effectively at the retail level or in the appropriate setting of care; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the reputation of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the market perception and reputation of our products and their safety and efficacy are important to our business and the continued acceptance of our products. Any negative publicity about our products, such as the discovery of safety issues with our products, adverse events involving our products, or even public rumors about such events, could have a material adverse effect on our business, financial condition, cash flows or results of operation or could cause the market value of our common shares and/or debt securities to decline. In addition, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products or the withdrawal or recall of such similar products could have a material adverse effect on sales of our products. Accordingly, new data about our products, or products similar to our products, could cause us reputational harm and could negatively impact demand for our products due to real or perceived side effects or uncertainty regarding safety or efficacy and, in some cases, could result in product withdrawal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products fail to gain, or lose, market acceptance, our revenues would be adversely impacted and we may be required to take material impairment charges, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For certain of our products, we depend on reimbursement from governmental and other third-party payors and a reduction in reimbursement could reduce our product sales and/or revenue. In addition, failure to be included in formularies developed by managed care organizations and coverage by other organizations may negatively impact the utilization of our products, which could harm our market share and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of certain of our products are dependent, in part, on the availability and extent of reimbursement from government health administration authorities, private health insurers, pharmacy benefit managers and other organizations of the costs of our products and the continued reimbursement and coverage of our products in such programs. Changes in government regulations or private third-party payors&#8217; reimbursement policies may reduce reimbursement for our products. In addition, such third-party payors may otherwise make the decision to reduce reimbursement of some or all our products or fail to cover some or all our products in such programs or assert that reimbursements were not in accordance with applicable requirements. For example, these decisions may be based on the price of our products or our current or former pricing practices and decisions. Any reduction or elimination of such reimbursement or coverage could result in a negative impact on the utilization of our products and, as a result, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their cost for medications. Formularies can be based on the prices and therapeutic benefits of the available products. Due to their lower costs, generic products are often favored. The breadth of the products covered by formularies varies considerably from one managed care organization to another, and many formularies include alternative and competitive products for treatment of particular medical conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the utilization and market share of our products. If our products are not included within an adequate number of formularies or adequate reimbursement levels are not provided, or if those policies increasingly favor generic products, this could have a material adverse effect on our business, financial condition, cash flows and results of operations or result in additional pricing pressure on our products and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and may continue to experience pressure on the pricing of certain of our products due to pricing controls, social or government pressure to lower the cost of drugs, and consolidation across the supply chain.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face numerous cost-containment measures by governments and other payors, including certain government-imposed industry-wide price reductions, mandatory rebates or pricing, international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries), volume-based procurement, tender systems, shifting of the payment burden to patients through higher co-payments and requirements for increased transparency on pricing, all of which may have an adverse impact on the pricing of our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many markets in which we operate have implemented or may implement tender systems for generic and biosimilar pharmaceuticals in an effort to lower prices. Under such tender systems, manufacturers submit bids which establish prices for generic pharmaceutical products. Upon winning the tender, the winning company will receive a preferential reimbursement for a period of time. If our bids do not win, we may not be able to participate in the given market or may lose out on market share. While criteria other than price can be included in tenders, tender systems often select the lowest bid, which often results in companies underbidding one another by proposing low pricing in order to win the tender. Other markets may also consider the implementation of a tender system and even if a tender system or other price controls are ultimately not implemented, the anticipation of such could result in price reductions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, U.K. and some other international markets, the government provides healthcare at low cost to consumers and regulates pharmaceutical prices, patient eligibility and/or reimbursement levels to control costs for the government-sponsored healthcare system. These systems of price regulations may lead to inconsistent and lower prices. Within the EU and in other countries, the availability of our products in some markets at lower prices undermines our sales in other markets with higher prices. Additionally, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may also impair our ability to obtain acceptable prices in existing and potential new markets and may create the opportunity for third party cross-border trade. In addition to the impacts of these government-sponsored healthcare systems, in the EU, U.K. and other international markets, certain governmental agencies have or are considering enacting further measures to decrease the costs of providing healthcare, including government mandated price reductions and/or other forms of price controls, including retrospective &#8220;clawback&#8221; price reductions. as a result of the COVID-19 pandemic and the changing healthcare landscape in those markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been increasing U.S. federal and state legislative and enforcement interest with respect to drug pricing, as well as from international organizations like the United Nations, World Health Organization and Organization for Economic Cooperation and Development, in addition to intense publicity and scrutiny regarding such matters, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that some have deemed excessive.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been executive orders, legislation, and legislative and regulatory proposals, including in connection with government programs such as Medicare, concerning drug prices and related issues, including the perceived need to bring more transparency to drug pricing, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. These include legislation promulgated by the Inflation Reduction Act of 2022 (IRA) that enables the U.S. government to impose penalties if drug prices are increased at a rate faster than inflation, redesigns Medicare Part D benefits to shift a greater portion of the costs to manufacturers and allows for the U.S. government to set prices for certain drugs in Medicare. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect to see continued focus in regulating pricing, we cannot predict what, if any, additional legislative or regulatory developments may transpire at the state or country level, or what the ultimate impact may be.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Our fulfillment arrangements with Walgreens and our dermatology cash-pay prescription program may not be successful.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the beginning of 2016, we launched a brand fulfillment arrangement with Walgreens, pursuant to which we have made certain of our dermatology and ophthalmology products available to eligible patients through a patient access and co-pay program available at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. We have, in the past, experienced certain operational and other issues respecting this arrangement, including lower than anticipated average realized prices associated with these products through this arrangement. In July 2019, we entered into an amendment to the existing fulfillment agreement to address some of these issues. We cannot guarantee this arrangement will continue to be successful in the future, nor can we guarantee that additional operational issues will not be encountered, nor can we guarantee that we will be able to successfully negotiate with Walgreens any improvements or amendments to this arrangement we identify as necessary or desired. In addition, we cannot predict how the market, including customers, doctors, patients, pharmacy benefit managers and third-party payors, or governmental agencies, will continue to react to these arrangements and programs. If this arrangement or program fails, if they do not achieve sufficient success and market acceptance, if we face retaliation from third parties as a result of this arrangement and program (for example, in the form of limitations on or exclusions from the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement of our products) or if any part of this arrangement is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. This program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings. We cannot guarantee that this program will be successful or that we will continue to add new products to the program. In addition, we cannot predict how the market, including customers, doctors and patients will react to this program. If this program fails, if it does not achieve sufficient success and market acceptance or if any part of this program is found to be non-compliant with applicable law or regulations, this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Catastrophic events may disrupt our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations and facilities which sell and distribute our products in many parts of the world. Natural events (such as a hurricane or major earthquake), terrorist attacks, pandemics or other catastrophic events, including adverse weather events, could cause delays in developing, manufacturing or selling our products. Such events that occur in major markets where we sell our products could reduce the demand for our products in those areas and, as a result, impact our sales into those markets. In either case, any such disruption could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale of counterfeit versions of our products may reduce demand for our products or have a negative impact on the reputation of our products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet or adhere to the rigorous quality, safety, manufacturing, storage and handling standards and regulations that apply to our products. The prevalence of counterfeit products is a growing industry-wide issue due to the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit products can be advertised, purchased and delivered. The discovery of safety or efficacy issues, adverse events or even death or personal injury associated with or caused by counterfeit products may be attributed to our products and may cause reputational harm to our products or the Company. We may not be able to detect or, if detected, prevent or prohibit the sale of such counterfeit products. As a result, the illegal sale or distribution of counterfeit products may negatively impact the demand for and sales of our products, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues and profits could be reduced by imports from countries where our products are available at lower prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported into those or other countries from lower price markets. If this happens with our products, our revenues and profits may be adversely affected, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers, may reduce our revenues in future fiscal periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain rebates, allowances, chargebacks and other credits to our customers with respect to certain of our products. For example, we make payments or give credits to certain wholesalers for the difference between the invoice price paid to us by our wholesaler customer for a particular product and the negotiated price that such wholesaler sells such products to its hospitals, group purchasing organizations, pharmacies or other retail customers. We also give certain of our customers credits on our products that such customers hold in inventory after we have decreased the WAC prices of such products, such credit being for the difference between the old and new price. In addition, we also implement and maintain returns policies, pursuant to which our customers may return product to us in certain circumstances in return for a credit. Although we establish reserves based on our prior experience, wholesaler data, then-current on-hand inventory, our best estimates of the impact that these policies may have in subsequent periods and certain other considerations, we cannot ensure that our reserves are adequate </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or that actual product returns, rebates, allowances and chargebacks will not exceed our estimates, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience declines in sales volumes or prices of certain of our products as the result of the concentration of sales to wholesalers and the continuing trend towards consolidation of such wholesalers and other customer groups and this could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain of our products, a significant portion of our sales are to a relatively small number of customers. If our relationship with one or more of such customers is disrupted or changes adversely or if one or more of such customers experience financial difficulty or other material adverse changes in their businesses, it could materially and adversely affect our sales and financial results, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business. The result of these developments could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into distribution agreements with other companies to distribute certain of our products at supply prices based on net sales. Declines in the pricing and/or volume, over which we have no or limited control, of such products, and therefore the amounts paid to us, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are the subject of third-party distribution or sublicense agreements, pursuant to which we may manufacture and sell products to other companies, which distribute such products in return for a royalty or a supply price, in both cases which are often based on net sales. Our ability to control pricing and volume of these products may be limited and, in some cases, these companies make all distribution and pricing decisions independently of us. If the pricing or volume of such products declines, our revenues would be adversely impacted which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the International Scope of our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, financial condition, cash flows and results of operations are subject to risks arising from the international scope of our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a significant portion of our business outside the U.S. and Canada and may, in the future, expand our operations into new countries, including emerging markets. We sell our pharmaceutical and medical device products in many countries around the world. All of our foreign operations are subject to risks inherent in conducting business abroad, including, among other things:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">difficulties in coordinating and managing foreign operations, including ensuring that foreign operations comply with foreign laws as well as Canadian and U.S. laws applicable to Canadian companies with U.S. and foreign operations, such as export and sanctions laws and the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the Canadian Corruption of Foreign Public Officials Act, and other applicable worldwide anti-bribery laws; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">price and currency exchange controls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on the repatriation of funds;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">scarcity of hard currency, including the U.S. dollar, which may require a transfer or loan of funds to the operations in such countries, which they may not be able to repay on a timely basis;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">political and economic instability;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with multiple regulatory regimes;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">compliance with economic sanctions laws and other laws that apply to our activities in the countries where we operate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">less established legal and regulatory regimes in certain jurisdictions, including as relates to enforcement of anti-bribery and anti-corruption laws and the reliability of the judicial systems;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing degrees of protection for intellectual property;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">unexpected changes in foreign regulatory requirements, including quality standards and other certification requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">new export license requirements;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">adverse changes in tariff and trade protection measures;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing labor regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">potentially negative consequences from changes in or interpretations of tax laws;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictive governmental actions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">possible nationalization or expropriation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">credit market uncertainty;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on business activities and other challenges associated with pandemics, including the ongoing COVID-19 pandemic;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing local practices, customs and cultures, some of which may not align or comply with our Company practices and policies or U.S. or Canadian laws and regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">difficulties with licensees, contract counterparties, or other commercial partners; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">differing local product preferences and product requirements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of changes to U.S. trade policy, there may be changes to existing trade agreements and greater restrictions on trade generally. On November 30, 2018, the United States, Canada and Mexico signed the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) as an overhaul and update to the North American Free Trade Agreement. The USMCA was subsequently revised on December 10, 2019 and fully ratified on March 13, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the USMCA, support for protectionism and rising anti-globalization sentiment in the United States and other countries may slow global growth. In particular, a protracted and wide-ranging trade conflict between the United States and China could adversely affect global economic growth. Concerns also remain around the social, political and economic impacts of the changing political landscape in Europe. In addition, there are growing concerns over an economic slowdown in emerging markets in light of capital outflows in favor of developed markets and expected interest rate increases. Broader geopolitical tensions remained high amongst the U.S., Russia, Ukraine, China, and across the Middle East. For example, in response to potential conflict between Russia and Ukraine, the U.S. and/or other countries in which we operate may impose sanctions or other restrictive actions against governmental or other entities in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the international scope of our operations, any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, adverse economic conditions impacting our customers in these countries or uncertainty about global economic conditions could cause purchases of our products to decline, which would adversely affect our revenues and operating results. In addition, accelerating rates of inflation may continue in the near future and have resulted, and may continue to result, in increased costs of labor, raw materials, other supplies and freight and distribution costs, among others. For the pharmaceutical industry and the healthcare systems in the markets in which we participate, the pricing dynamics of our products generally does not provide the opportunity to pass on such costs to customers. Inflation may also result in higher interest rates and increased costs of capital. Moreover, our projected revenues and operating results are based on assumptions concerning certain levels of customer spending. Any failure to attain our projected revenues and operating results as a result of adverse economic or market conditions could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the large portion of our business conducted in currency other than U.S. dollars, we have significant foreign currency risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign currency exposure on the translation into U.S. dollars of the financial results of our operations in Europe, Canada, Latin America, Asia, Africa and the Middle East and other regions. Where possible, we manage foreign currency risk by managing same currency revenue in relation to same currency expenses. We may also use derivative financial instruments from time to time to mitigate our foreign currency risk and not for trading or speculative purposes. We face foreign currency exposure in those countries where we have revenue denominated in the local foreign currency and expenses denominated in other currencies. Both favorable and unfavorable foreign currency impacts to our foreign currency-denominated operating expenses are mitigated to a certain extent by the natural, opposite impact on our foreign currency-denominated revenue. In addition, the repurchase of our U.S. dollar denominated debt may result in foreign exchange gains or losses for Canadian income tax purposes. One half of any foreign exchange gains or losses will be included in our Canadian taxable income. Any foreign exchange gain will result in a corresponding reduction in our available Canadian tax attributes. Further strengthening of the U.S. dollar and/or the devaluation of other countries&#8217; currencies could have a negative impact on our reported international revenue.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Information Technology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have become increasingly dependent on information technology systems and infrastructure and any breakdown, interruption, breach or other compromise of our or our third-party service providers&#8217; information technology systems could compromise sensitive information related to our business or prevent us from accessing critical information and subject us to liability or interrupt the operation of our business, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon our information technology systems and infrastructure, as well as those of third parties with whom we interact, and internal and public internet sites, data hosting and processing facilities, cloud-based services and hardware, social media sites and mobile technology, in connection with the conduct of our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must constantly update our information technology systems and infrastructure and undertake investments in new information technology systems and infrastructure. However, we cannot provide assurance that the information technology systems and infrastructure on which we depend, including those of third parties, will continue to meet our current and future business needs or adequately safeguard our operations. Furthermore, modification, upgrade or replacement of such systems and infrastructure may be costly or out of our control.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to so modify, upgrade or replace such systems and infrastructure, any disruptions that occur during the process of such modification, upgrade or replacement and/or any breakdown, interruption or corruption of the information technology systems and infrastructure on which we rely could create system disruptions, shutdowns, delays in generating or the corruption of data and information or other disruptions that could result in negative financial, operational, business or reputational consequences for us.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The size and complexity of the information technology systems and infrastructure on which we rely makes such systems and infrastructure potentially vulnerable to internal or external inadvertent or intentional security breaches, including as a result of private or state-sponsored cybercrimes, terrorism, war, malware, ransomware, human error, system malfunction, telecommunication and electrical failures, natural disaster, fire, misplaced or lost data, socially engineered breaches or other similar events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the normal course of our business operations, including through the use of information technology systems and infrastructure, we are involved in the collection, transmission, use, retention and other processing of sensitive, confidential, non-public or personal data and information in Canada, the United States and abroad.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in frequency, sophistication and intensity and are made by groups and individuals with a wide range of motives and expertise. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, worms, social engineering, improper modification of information, fraudulent &#8220;phishing&#8221; e-mails and other means to affect service reliability or threaten data confidentiality, integrity or availability. Techniques used in these attacks are often highly sophisticated, change frequently and may be difficult to detect for long periods of time. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established (i) physical, electronic and organizational measures intended to safeguard and secure our systems to prevent a compromise and (ii) policies and procedures designed to provide for the timely investigation of cybersecurity incidents and the timely disclosure of cybersecurity incidents consistent with our legal and contractual obligations. We also rely on commercially available systems, software, tools and monitoring to provide security for the processing, transmission and storage of digital information. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we attempt to take appropriate security and cybersecurity measures to protect our information technology systems and infrastructure (including any trade secrets, confidential or other sensitive information) and to prevent and detect breakdowns, unauthorized breaches and cyber-attacks, we cannot guarantee that such measures will be successful and that breakdowns and breaches of, or attacks on, our systems and data, or those of third parties upon which we rely, will be prevented. Such breakdowns and breaches of, or attacks on, our systems and infrastructure, or the public perception that we or any third party upon which we rely have suffered a cybersecurity incident or breakdown, may cause business interruption and could have a material adverse effect on our business, financial condition, cash flows and results of operations, damage our reputation with customers, employees and third parties with whom we do business and cause the market value of our common shares and/or debt securities to decline, and we may suffer financial damage or other loss, including fines or criminal penalties or may be subject to litigation, including potentially class action lawsuits because of lost or misappropriated information. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain insurance against some of these risks, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from a breakdown, breach, cyber-attack or other compromise of or interruption to our information technology systems and infrastructure or confidential and other sensitive information.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we provide confidential and other sensitive information to third parties when necessary to pursue our business objectives. While we obtain assurances that these third parties will protect this information and, where appropriate, monitor the protections employed by these third parties, there is a risk that the confidentiality of information held by third parties, including trade secrets and sensitive personal information, may be compromised, including as a result of cybersecurity breaches, breakdowns or other incidents. If personal information of our customers or employees is misappropriated, our reputation with our customers and employees may be injured, resulting in loss of business and/or morale. Any such incidents could require us to incur costs to remediate possible injury to our customers and employees, to further improve our protective measures or to pay fines or take other action with respect to litigation, judicial or regulatory actions arising out of such incidents, which may be significant. We also cannot ensure that any limitation of liability or indemnity provisions in our contracts, including with vendors and service providers, for a security lapse or breach or other security incident would be enforceable or adequate or would otherwise protect us from any liabilities or damages with respect to any particular claim. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Specific Legislation and Regulations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various laws and regulations, including &#8220;fraud and abuse&#8221; laws, anti-bribery laws, environmental laws and privacy and security laws, and a failure to comply with such laws and related regulations or prevail in any litigation related to noncompliance could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and medical device companies have faced lawsuits and investigations pertaining to violations of health care &#8220;fraud and abuse&#8221; laws, such as the federal False Claims Act, the federal Anti-Kickback Statute (&#8220;AKS&#8221;) and other state and federal laws and regulations. The AKS prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical or medical device manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other health care related professionals, on the other hand. More generally, the federal False Claims Act, among other things, prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Pharmaceutical and medical device companies have been prosecuted or faced civil liability under these laws for a variety of alleged promotional and marketing activities, including engaging in off-label promotion that caused claims to be submitted for non-covered off-label uses. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, this could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Department of Health and Human Services Office of Inspector General recommends, and increasingly states require pharmaceutical companies to have comprehensive compliance programs. Moreover, the Physician Payment Sunshine Act enacted in 2010 imposes reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed to prescribers and other health care providers. Failure to submit this required information may result in significant civil monetary penalties. While we have developed corporate compliance programs based on what we believe to be current best practices, we cannot provide assurance that we or our employees or agents are or will be in compliance with all applicable federal, state or foreign regulations and laws. If we are in violation of any of these requirements or any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant criminal and civil fines and penalties, exclusion from federal health care programs or other sanctions, including consent orders or corporate integrity agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. FCPA, the Canadian Corruption of Foreign Public Officials Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to officials for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in many parts of the world that have experienced governmental corruption and in certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than in the U.S. and Canada. We cannot provide assurance that our internal control policies and procedures will protect us from reckless or criminal acts committed by our employees, consultants, distributors, third party contractors or agents. Violations of these laws, or allegations of such violations, could disrupt our business and result in criminal or civil penalties or remedial measures, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various state, federal and international laws and regulations governing the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information, including HIPAA. Many states in which we operate have laws that protect the privacy and security of sensitive and personal information, including health-related information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) imposes stringent data privacy and security requirements and obligations with respect to the personal information of California residents and provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal data that may increase the likelihood of, and risks associated with, data breach litigation. The effects on our business of the CCPA and other similar state laws are potentially significant. State laws are changing rapidly and there is discussion in Congress of a new federal data protection and privacy law to which we may be subject. For instance, the California Privacy Rights Act (&#8220;CPRA&#8221;) was passed in November 2020. When it takes effect in January 2023, it will maintain the core framework of the CCPA, while also making a number of substantive changes. Since these data security regimes are evolving, uncertain and complex, especially for a global business such as ours, we will need to update or enhance our compliance measures from time to time and these updates or enhancements will require further implementation costs. Any failure, or perceived failure, by us to comply with current and future regulatory or customer-driven privacy, data protection, and information security requirements, or to prevent or mitigate security breaches, cyberattacks, or improper access to, use of, or disclosure of data, or any security issues or cyber-attacks affecting our business, could result in significant liability, costs (including the costs of mitigation and recovery), a material loss of revenue resulting from the adverse impact on its reputation and brand, loss of proprietary information and data, disruption to its business and relationships, and diminished ability to retain or attract customers and business partners. Such events may result in governmental enforcement actions and prosecutions, private litigation, fines and penalties or adverse publicity, and could cause customers and business partners to lose trust in us, which could have an adverse effect on our reputation and business.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, the EU&#8217;s General Data Protection Regulation (&#8220;GDPR,&#8221;), and the UK&#8217;s General Data Protection Regulation (&#8220;UK GDPR&#8221;) together with national legislation, regulations and guidelines of the EU member states and the UK governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, (or GBP 17.5 million under the UK GDPR), whichever is greater. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA or the UK. Guidance on implementation and compliance practices is often updated or otherwise revised. These laws require data controllers to implement stringent operational requirements, including, for example, transparent and expanded disclosure to data subjects about how their personal data is collected and processed, grant rights for data subjects to access, delete or object to the processing of their data, mandatory data breach notification requirements (and in certain cases, affected individuals), set limitations on retention of information and outline significant documentary requirements to demonstrate compliance through policies, procedures, training and audits. The GDPR also provides that EU member states may introduce further conditions, including limitations, and make their own laws and regulations, further limiting the processing of &#8216;special categories of personal data,&#8217; including personal data related to health, biometric data used for unique identification purposes and genetic information, which could limit our ability to collect, use and share EU data, and could cause our compliance costs to increase, ultimately having an adverse impact on our business, and harm our business and financial condition. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The withdrawal of the UK from the European Union (&#8220;Brexit&#8221;) also has created uncertainty with regard to the regulation of data protection in the UK. Since January 1, 2021, when the transitional period following Brexit expired, we have been required to comply with the GDPR as well as the UK GDPR (combining the GDPR and the UK&#8217;s Data Protection Act of 2018), which exposes us to two parallel regimes, each of which authorizes similar fines and may subject us to increased compliance risk based on differing, and potentially inconsistent or conflicting, interpretation and enforcement by regulators and authorities (particularly, if the laws are amended in the future in divergent ways). With respect to transfers of personal data from the EEA, on June 28, 2021, the European Commission issued an adequacy decision in respect of the UK&#8217;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs, it could lead to additional costs and increase our overall risk exposure.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in China, the Personal Information Protection Law (the &#8220;PIPL&#8221;) came into force in November 2021. The PIPL is the first national-level law comprehensively regulating issues in relation to personal information protection. The PIPL provides for very specific administrative requirements and security controls when transferring personal data outside the Peoples Republic of China. These transfer requirements come into effect on March 1, 2023.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Canada&#8217;s federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronic Documents Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and substantially similar equivalents at the provincial level with respect to the collection, use and disclosure of personal information in Canada. Such federal and provincial legislation impose data privacy and security obligations on our processing of personal information of Canadian residents. The federal and Alberta legislation include mandatory data breach notification requirements. Canada&#8217;s Anti-Spam Legislation (&#8220;CASL&#8221;) also applies to the extent that we send commercial electronic messages from Canada or to electronic addresses in Canada. CASL contains prescriptive consent, form, content and unsubscribe mechanism requirements. Penalties for non-compliance with CASL are up to CAD $10 million per violation. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible they will be interpreted and applied in ways that will materially and adversely affect our business. The regulatory framework for data privacy, data security and data transfers worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Complying with all of these laws and regulations involves costs to our business, and failure to comply with these laws and regulations can result in the imposition of significant civil and criminal penalties, as well as litigation, all of which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. For more information regarding applicable data privacy and security laws and regulations, see Item 1. &#8220;Business &#8212;&#160;Government Regulations&#8221; of this Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to U.S. federal laws regarding reporting and payment obligations with respect to our participation in federal health care programs, including Medicare and Medicaid. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in changes that could have material adverse legal, regulatory, or economic consequences.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory reform of the health care system may affect our ability to sell our products profitably and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act, as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid drug rebates for pharmaceutical companies, expanded the 340B drug discount program, and made changes to affect the Medicare Part D coverage gap, or &#8220;donut hole.&#8221; The law also revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which may affect the amount of our Medicaid drug rebates to states. Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &amp; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although efforts at replacing the Health Care Reform Act have stalled in Congress, there could still be changes to this legislation. We cannot predict what those changes will be or when they will take effect, and we could face additional risks arising from such changes. Because of this continued uncertainty, including the potential for further legal challenges or repeal of that legislation, we cannot quantify or predict with any certainty the likely impact of this legislation or its repeal on our business model, prospects, financial condition or results of operations, in particular on the pricing, coverage or reimbursement of any of our product candidates that may receive marketing approval. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Legislative efforts relating to drug pricing, the cost of prescription drugs under Medicare, the relationship between pricing and manufacturer patient programs, and government program reimbursement methodologies for drugs have been proposed and considered at the U.S. federal and state level. Congress and the administration have each indicated an intent to continue to seek new legislative or administrative measures to control drug costs such as the Inflation Reduction Act, which, among other things, enables the U.S. government to impose penalties if drug prices are increased at a rate faster than inflation. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policy changes or implementations effecting additional fundamental changes in the health care delivery system. We cannot provide assurance as to the ultimate content, timing, or effect of changes, nor is it possible at this time to estimate the impact of any such potential legislation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Health and Human Services Administration announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the current administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. We cannot provide assurance as to the ultimate content, timing, effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations became effective on July 1, 2022. The new regulations, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Care Reform Act and further changes to health care laws or regulatory framework that reduce our revenues or increase our costs could also have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to a broad range of environmental laws and regulations and may be subject to environmental remediation obligations under such safety and related laws and regulations. The impact of these obligations and the Company&#8217;s ability to respond effectively to them may have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a broad range of federal, state, provincial and local environmental laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where we manufacture and sell our products or otherwise operate our business. These requirements include, among other matters, regulation of the handling, manufacture, transportation, storage, use and disposal of materials, including the discharge of pollutants, hazardous substances and waste into the environment. Compliance with environmental, health and safety laws and regulations could require us to incur significant operating or capital expenditures or result in significant restrictions on our operations. If we fail to comply with these environmental, health and safety laws and regulations, including failing to obtain or comply with any necessary permits, we could incur substantial civil or criminal fines or penalties or enforcement actions, including regulatory or judicial orders enjoining or curtailing our operations or requiring us to conduct or fund remedial or corrective measures, install pollution control equipment, reformulate or cease the marketing of our products or perform other actions. In the normal course of our business, regulated substances and waste may be released into the environment, which could cause environmental or property damage or personal injuries, and which could subject us to remediation obligations regarding contaminated soil and groundwater, potential liability for damage claims or to social or reputational harm and other similar adverse impacts. Under certain laws, we may be subject to joint and several liability for environmental investigations and cleanups, including at properties that we currently or previously owned or operated, or at sites at which waste we generated was disposed, even if the contamination was not caused by us or was legal at the time it occurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive and evolving regulations regarding the manufacturing, processing, distribution, importing, exporting and labeling of our products and their raw materials. In the EU, the REACH regulations came into effect in 2007, with implementation rolling out over time. Registered chemicals then can be subject to further evaluation and potential restrictions. Since the promulgation of REACH, other countries have enacted or are in the process of implementing similar comprehensive chemical regulations. These laws and regulations may materially affect our operations by subjecting our products or raw materials to testing or reporting requirements or restrictions, moratoria, phase outs or other limitations on their sale or use. In particular, some of our products might be characterized as nanomaterials and then be subject to evolving, new nanomaterial regulations.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, legislation and regulation related to environmental protection have become increasingly stringent. Such legislation and regulations are complex and constantly changing. On July 14, 2021, the European Commission adopted a set of proposals to ensure polices are aligned with the goal of reducing net greenhouse gas emissions by at least 55% by 2030 (the &#8220;EU Green Deal&#8221;). There is a growing focus on environmental impact of self-care products, their ingredients, components, packaging, manufacturing and disposal. This focus could lead to new requirements and restrictions in the coming years across all product categories. In particular, legislation and regulation relating to climate change, sustainability and product stewardship including greenhouse gas emissions, are at various stages of consideration and implementation. Future events, such as changes </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in existing laws or regulations or the enforcement thereof or the discovery of contamination at our facilities may, among other things, require us to install additional controls for certain of our emission sources, undertake changes in our manufacturing processes, remediate soil or groundwater contamination at facilities where such cleanup is not currently required, take action to address social expectations or concerns arising from or relating to such changes and our response to such changes or adversely impact our suppliers. These impacts may be significant and could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The consequences of climate change, such as extreme weather and water scarcity, could pose risks to our facilities and disruption of our activities.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters and extreme weather events resulting from climate change, such as floods, heatwaves, blizzards, hurricanes, wildfires, the rise of sea level and water stress, could impact our business activities and our ability to deliver our products to customers. We evaluate these risks in our supply planning, loss prevention and business continuity planning. The implementation of an Environmental, Health and Safety Management System across our facilities has resulted in the development of processes to prepare and respond to a range of natural emergencies that may occur, including extreme weather events. We have been placing increased attention on water management, implementing a scarcity-focused approach to water conservation to align with community needs and advance toward sustainable operations. If our planning and risk management regarding natural disasters and extreme weather events fail, our facilities could be impacted and our activities could be significantly disrupted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Risks</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports. We spend a substantial amount of management and other employee time and resources to comply with laws, regulations and standards relating to corporate governance and public disclosure. In the U.S., such regulations include the Sarbanes-Oxley Act of 2002, SEC regulations and the NYSE listing standards, and in Canada, applicable securities laws. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires management&#8217;s annual review and evaluation of our internal control over financial reporting and attestation as to the effectiveness of these controls by our independent registered public accounting firm. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting. Additionally, internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, this could have a material adverse effect on our business, financial condition, results of operations, cash flows and/or stock price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could be negatively affected by shareholder activism, which could cause us to incur significant expenses, hinder execution of our business strategy and impact our share price.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, shareholder activism involving corporate governance, fiduciary duties of directors and officers, strategic direction and operations has become increasingly prevalent. One of our investors, which currently owns approximately 9.59% of our outstanding common shares, filed a Schedule 13D with the SEC in February 2021, in which it was indicated that the investor intended to engage in discussions with our management and board regarding ways to enhance shareholder value, including our ongoing strategic review and that it may also seek board representation. We subsequently entered into a Director Appointment and Nomination Agreement with such investor, pursuant to which they have appointed two members to our Board of Directors. Another of our investors, which currently owns approximately 4.75% of our outstanding common shares, filed a Schedule 13D with the SEC in July 2020, in which it indicated that it intended to consider, explore and/or develop plans and/or make proposals respecting, among other things, our businesses, assets, operations, and strategy, and to explore ways to strengthen the Company and enhance shareholder value. In February 2021, this investor also sent the Company a public letter, in which it stated its views on the timing of the completion of the B+L Separation and recommended, among other things, the divestiture of certain of our businesses and assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event such investors continue to pursue such proposals or we become the subject of additional shareholder activism, this may create a significant distraction for our management and employees. This could negatively impact our ability </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to execute our business plans (including the B+L Separation) and may require our management to expend significant time, resources and costs, including legal fees and other expenses incurred in connection with any proxy contest that may result from any such shareholder activism. Furthermore, when individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our shareholders and could lead us to adopt other plans that we cannot predict and which could focus on short-term benefits with longer-term costs or that may not be in the best interests of the Company. Such shareholder activism may also create uncertainties with respect to our financial position and operations, may adversely affect our ability to attract and retain key employees and may result in loss of potential business opportunities with our current and potential customers and business partners, any of which could have a material adverse effect on our business, financial condition, cash flows and results of operations. In addition, such shareholder activism may cause significant fluctuations in our share price based on temporary or speculative market perceptions, uncertainties or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, and could cause the market value of our common shares to decline. While we will remain responsive to shareholder demands, there is no assurance that we will achieve their objectives, or that doing so will decrease the likelihood of activist shareholder engagement in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have significant goodwill and other intangible assets and potential impairment of goodwill and other intangibles may have a significant adverse impact on our profitability. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets represent a significant portion of our total assets. Finite-lived intangible assets are subject to an impairment analysis whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset may be impaired. If impairment exists, we would be required to take an impairment charge with respect to the impaired asset. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, for 2022, 2021 and 2020, we recognized impairments to finite-lived and indefinite-lived intangible assets of $15 million, $146 million and $18 million, respectively. These asset impairments were primarily attributable to revisions in sales forecasts associated with discontinuances, generic competition and other market forces. In addition to impairments to finite-lived and indefinite-lived intangible assets, for 2022 and 2021, we recognized $824 million in impairments to the goodwill of our Neurology and Other and Ortho Dermatologics reporting units and $469 million in impairments to the goodwill of our Ortho Dermatologics reporting unit. These impairments to goodwill were primarily the result of revisions to our long-term forecasts as well as increases in market interest rates which resulted in higher discount rates used in the impairment analysis for the reporting units due to changing business dynamics and market conditions. There were no goodwill impairments for the year 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2022, which included performing separate quantitative fair value tests for the Neurology and Other reporting unit in the Diversified Products segment and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, no impairment to the goodwill of was identified. If market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further information on these impairment charges.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events giving rise to impairment are difficult to predict, including the uncertainties associated with the launch of new products, and are an inherent risk in the pharmaceutical and medical device industries. As a result of the significance of goodwill and intangible assets, our financial condition and results of operations in a future period could be negatively impacted should such an impairment of goodwill or intangible assets occur, which could cause the market value of our common shares and/or debt securities to decline. We may be required to take additional impairment charges in the future and such impairment charges may be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance (&#8220;ESG&#8221;) matters, including related social expectations and concerns, may impose unexpected costs on the Company or result in reputational or other harm to the Company that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are rapid and ongoing developments and changing expectations relating to ESG matters and factors such as the impact of our operations on climate change, water and waste management, our practices relating to sustainability and product stewardship, product safety, access to health care and affordable drugs, management of business ethics and human capital development, which may result in increased regulatory, social, investor or other scrutiny on us. If we are not able to adequately recognize and respond to such developments and governmental, investor and social expectations, including expectations of </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lenders, investors and other stakeholders relating to ESG matters, we may miss corporate opportunities for the Company, become subject to additional regulatory, social, investor or other scrutiny, incur unexpected costs or experience damage to the reputation of the Company or its various brands with governments, customers, employees, investors, third parties and the communities in which we operate, in each case that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have various indemnity agreements and indemnity arrangements in place, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All directors and/or officers of the Company, and each of its various subsidiary entities, are indemnified by the Company in respect of their service as directors and/or officers, subject to certain restrictions. We have also purchased directors&#8217; and officers&#8217; liability insurance to mitigate the cost of any potential future lawsuits or actions. The maximum amount of any potential future payment cannot be reasonably estimated but could have a material adverse effect on the Company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we have entered or may enter into agreements that include indemnities in favor of third parties, such as purchase and sale agreements, license agreements, engagement letters with advisors and consultants and various product and service agreements. These indemnification arrangements may require us to compensate counterparties for losses incurred by the counterparties as a result of breaches in representations, covenants and warranties provided by us or as a result of litigation or other third-party claims or statutory sanctions that may be suffered by the counterparties as a consequence of the relevant transaction. In some instances, the terms of these indemnities are not explicitly defined. We, whenever possible, try to limit this potential liability within the particular agreement or contract, but due to the unpredictability of future events the maximum amount of any potential reimbursement cannot be reasonably estimated, but could have a material adverse effect on the Company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results and financial condition may fluctuate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and financial condition may fluctuate from quarter to quarter for a number of reasons. In addition, our stock price can be volatile. The following events or occurrences, among others, could cause fluctuations in our financial performance and/or stock price from period to period:</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of COVID-19;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development and launch of new competitive products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and receipt of FDA and other regulatory approvals or lack of approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to business development transactions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the amount we spend to promote our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays between our expenditures to acquire new products, technologies or businesses and the generation of revenues from those acquired products, technologies or businesses;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in treatment practices of physicians that currently prescribe certain of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the cost of raw materials used to manufacture our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory agencies relating to our manufacturers or suppliers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and supply interruptions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our responses to price competition;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new legislation that would control or regulate the prices of drugs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a protracted and wide-ranging trade conflict between the United States and China;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures as a result of legal actions (and settlements thereof), including the defense of our patents and other intellectual property;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of wholesaler and distributor purchases and success of our wholesaler and distributor arrangements; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and industry conditions, including potential fluctuations in interest rates; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in seasonality of demand for certain of our products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency exchange rate fluctuations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, structure and terms of the B+L Separation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to, or the confidence in, our business strategy;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to, or the confidence in, our management; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expectations for future growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, quarter-to-quarter comparisons of results from operations, or any other similar period-to-period comparisons, may not be reliable indicators of our future performance. In any quarterly period, our results may be below the expectations of market analysts and investors, which could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties </span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and lease a number of important properties. Our headquarters and one of our manufacturing facilities are located in Laval, Quebec. We own several manufacturing facilities throughout the U.S. We also own or have an interest in manufacturing plants or other properties outside the U.S., including in Canada, Mexico, and certain countries in Europe, Asia and South America.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our facilities to be in satisfactory condition and suitable for their intended use. Our administrative, marketing, research/laboratory, distribution and warehousing facilities are located in various parts of the world. We co-locate our R&amp;D activities with our manufacturing at the plant level in a number of facilities. Our scientists, engineers, quality assurance/quality control professionals and manufacturing technicians work side-by-side in designing and manufacturing products that fit the needs and requirements of our customers, regulators and business units.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have sufficient facilities to conduct our operations. Our facilities in aggregate are approximately 10&#160;million square feet and include, among others, the following principal properties:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned<br/>or<br/>Leased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate<br/>Square<br/>Footage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laval, Quebec, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate headquarters, R&amp;D, manufacturing and warehouse facility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bridgewater, New&#160;Jersey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Administration shared with Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Juan del Rio, Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices and manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jelenia Gora, Poland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rzeszow, Poland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Steinbach, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb Location</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purpose</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Owned<br/>or<br/>Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate<br/>Square<br/>Footage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaughan, Ontario, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate headquarters and distribution facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rochester, New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D and manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Waterford, Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D and manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Woodruff, South Carolina</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jinan, China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices and manufacturing facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berlin, Germany</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing, distribution and office facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greenville, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing and distribution facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lynchburg, Virginia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices and distribution facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aubenas, France</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Louis, Missouri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D and manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macherio, Italy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Offices, R&amp;D, manufacturing and warehouse facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beijing, China</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacturing facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#8212; A lease for a second building in Bridgewater, New Jersey was signed in 2015 and was not included in the square footage shown in the table above as the Company has never occupied the second building. In 2016, the Company concluded that it would not occupy the second building and recognized the appropriate charge for all future rents due, net of the anticipated sub-let income associated with the second building.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for details on legal proceedings.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i57fbe32677504c888f142dd82b99b37f_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div id="i57fbe32677504c888f142dd82b99b37f_103"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are traded on the New&#160;York Stock Exchange (&#8220;NYSE&#8221;) and on the Toronto Stock Exchange (&#8220;TSX&#8221;) under the symbol &#8220;BHC&#8221;.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_106"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Price Volatility of Common Shares </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market prices for the securities of pharmaceutical, medical devices and biotechnology companies, including our securities, have historically been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in our operating results, the aftermath of public announcements by us or by others about us, changes in our executive management, changes in our business strategy, concern as to the safety of drugs and medical devices, the commencement or outcome of legal or governmental proceedings, changes in our ability to access credit markets, changes in the cost of capital, investigations or inquiries, and general market conditions can have an adverse effect on the market price of our common shares and other securities. For example, during 2015 and 2016, we experienced significant fluctuations and decreases in the market price of our common shares as a result of, among other things, legal and governmental proceedings and investigations with respect to certain of our distribution, marketing, pricing, disclosure and accounting practices, rising interest rates and certain public allegations made by short sellers and other third parties relating to certain of these matters. See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_109"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approximate number of holders of record of our common shares as of February&#160;17, 2023 was 1,800.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the cumulative total return on a $100 investment on December 31, 2017, assuming reinvestment of all dividends, in: (i) our common shares, (ii) the S&amp;P 500 Index, (iii) the S&amp;P/TSX Composite Index, (iv) the NASDAQ Biotechnology Index and (v) a composite peer group of 14 major pharmaceutical companies for the five years ended December&#160;31, 2022. The composite peer group of 14 major pharmaceutical companies, which consists of Alcon Ag., Amgen Inc., Baxter International Inc., Biogen Inc, Cooper Companies Inc., Eli Lilly and Company, Endo International plc, Jazz Pharmaceuticals Plc, Perrigo Company Plc, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Viatris Inc., Zimmer Biomet Holdings, Inc. and Zoetis Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Five Year Performance - Cumulative total return on a $100 investment on December 31, 2017</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><img src="bhc-20221231_g1.jpg" alt="bhc-20221231_g1.jpg" style="height:438px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$133</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$126</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$149</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$192</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$157</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S&amp;P/TSX Composite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$112</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$118</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$148</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$139</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NASDAQ Biotechnology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$114</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$144</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$130</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peer Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$108</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$129</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$177</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$189</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i57fbe32677504c888f142dd82b99b37f_115"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No dividends were declared or paid in 2022, 2021 or 2020. While our Board of Directors will review our dividend policy periodically, we currently do not intend to pay any cash dividends in the foreseeable future. In addition, our 2022 Amended Credit Agreement and indentures include restrictions on the payment of&#160;dividends.&#160;See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details regarding these restrictions.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizational documents on the right of foreigners to hold or vote securities of our Company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act (Canada)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the&#160;&#8220;Investment Canada Act&#8221;) may require review and approval by the Minister of Innovation, Science and Industry (Canada) (the &#8220;Minister&#8221;) of an acquisition of &#8220;control&#8221; of our Company by a &#8220;non-Canadian&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Canada Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An acquisition of control of a Canadian business by a non-Canadian is either reviewable (a&#160;&#8220;Reviewable Transaction&#8221;), in which case it is subject to both a reporting obligation and an approval process, or notifiable, in which case it is subject to only a reporting obligation. In the case of a Reviewable Transaction, the non-Canadian acquirer must submit an application for review with the prescribed information. The Minister is then required to determine whether the Reviewable Transaction is likely to be of net benefit to Canada, taking into account the assessment factors specified in the Investment Canada Act and any written undertakings that may have been given by the non-Canadian acquirer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investment Canada Act provides that any investment by a non-Canadian in a Canadian business, even where control has not been acquired, can be reviewed on grounds of whether it may be injurious to national security. Where an investment is determined to be injurious to national security, Cabinet can prohibit closing or, if closed, can order the investor to divest control. Short of a prohibition or divestment order, Cabinet can impose terms or conditions on the investment or can require the investor to provide binding undertakings to remove the national security concern.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;IX of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) (the&#160;&#8220;Competition Act&#8221;) requires that a pre-merger notification filing be submitted to the Commissioner of Competition (the&#160;&#8220;Commissioner&#8221;) in respect of certain classes of merger transactions that exceed certain prescribed thresholds. If a proposed transaction exceeds such thresholds, subject to certain exceptions, the notification filing must be submitted to the Commissioner and the statutory waiting period must expire or be terminated early or waived by the Commissioner before the transaction can be&#160;completed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All mergers, regardless of whether they are subject to Part&#160;IX of the Competition Act, are subject to the substantive mergers provisions under Section&#160;92 of the Competition Act. In particular, the Commissioner may challenge a transaction before the Competition Tribunal where the transaction prevents or lessens, or is likely to prevent or lessen, competition substantially in a market. The Commissioner may not make an application to the Competition Tribunal under Section&#160;92 of the Competition Act more than one year after the merger has been substantially completed. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_121"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Controls</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada has no system of exchange controls. There are no Canadian exchange restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no Canadian exchange restrictions affecting the remittance of dividends, profits, interest, royalties and other payments to non-resident holders of our securities.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Canadian Federal Income Taxation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion is a summary of the principal Canadian federal income tax considerations generally applicable to a holder of our common shares who, at all relevant times, for purposes of the Income Tax&#160;Act (Canada) and the Income Tax Regulations (collectively, the &#8220;Canadian Tax&#160;Act&#8221;) deals at arm&#8217;s-length with, and is not affiliated with, our Company, beneficially owns its common shares as capital property, does not use or hold and is not deemed to use or hold such common shares in carrying on a business in Canada, does not with respect to common shares enter into a &#8220;derivative forward agreement&#8221; as defined in the Canadian Tax Act, and who, at all relevant times, for purposes of the application of the Canadian Tax&#160;Act and the Canada-U.S.&#160;Income Tax Convention (1980, as amended) (the&#160;&#8220;U.S.&#160;Treaty&#8221;), is resident in the U.S., is not, and is not deemed to be, resident in Canada and is eligible for benefits under the U.S.&#160;Treaty (a&#160;&#8220;U.S.&#160;Holder&#8221;). Special rules, which are not discussed in the summary, may apply to a non-resident holder that is an insurer that carries on an insurance business in Canada and elsewhere or that is an &#8220;authorized foreign bank&#8221; as defined in the Canadian Tax&#160;Act.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S.&#160;Treaty includes limitation on benefits rules that restrict the ability of certain persons who are resident in the U.S.&#160;to claim any or all benefits under the U.S.&#160;Treaty. Furthermore, limited liability companies (&#8220;LLCs&#8221;) that are not taxed as corporations pursuant to the provisions of the U.S.&#160;Internal Revenue Code of 1986, as amended do not generally qualify as resident in the U.S.&#160;for purposes of the U.S.&#160;Treaty. Under the U.S.&#160;Treaty, a resident of the U.S.&#160;who is a member of such an&#160;LLC and is otherwise eligible for benefits under the U.S.&#160;Treaty may generally be entitled to claim benefits under the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.&#160;Treaty in respect of income, profits or gains derived through the&#160;LLC. Residents of the U.S.&#160;should consult their own tax advisors with respect to their eligibility for benefits under the U.S.&#160;Treaty, having regard to these&#160;rules.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the U.S.&#160;Treaty and the Canadian Tax&#160;Act and our understanding of the current administrative policies and assessing practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the U.S.&#160;Treaty and the Canadian Tax&#160;Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof. This summary does not otherwise take into account or anticipate changes in law or administrative policies and assessing practices, whether by judicial, regulatory, administrative or legislative decision or action, nor does it take into account provincial, territorial or foreign tax legislation or considerations, which may differ from those discussed herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice generally or to any particular holder. Holders should consult their own tax advisors with respect to their own particular circumstances.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gains on Disposition of Common Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, a U.S.&#160;Holder will not be subject to tax under the Canadian Tax&#160;Act on capital gains arising on the disposition of such holder&#8217;s common shares unless the common shares are &#8220;taxable Canadian property&#8221; to the U.S.&#160;Holder and are not &#8220;treaty-protected property&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As long as the common shares are then listed on a &#8220;designated stock exchange&#8221;, which currently includes the NYSE and TSX, the common shares generally will not constitute taxable Canadian property of a U.S.&#160;Holder, unless: (a)&#160;at any time during the 60-month period preceding the disposition, the U.S.&#160;Holder, persons not dealing at arm&#8217;s length with such U.S.&#160;Holder or the U.S.&#160;Holder together with all such persons, owned 25% or more of the issued shares of any class or series of the capital stock of the Company and (b) more than 50% of the fair market value of the common shares was derived, directly or indirectly, from any combination of: (i)&#160;real or immovable property situated in Canada, (ii)&#160;&#8220;Canadian resource property&#8221; (as&#160;such term is defined in the Canadian Tax&#160;Act), (iii)&#160;&#8220;timber resource property&#8221; (as&#160;such term is defined in the Canadian Tax&#160;Act) or (iv)&#160;options in respect of, or interests in, or for civil law rights in, any such properties whether or not the property exists or the common shares are otherwise deemed to be taxable Canadian property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares will be treaty-protected property where the U.S.&#160;Holder is exempt from income tax under the Canadian Tax&#160;Act on the disposition of common shares because of the U.S.&#160;Treaty. Common shares owned by a U.S.&#160;Holder will generally be treaty-protected property where the value of the common shares is not derived principally from real property situated in Canada, as defined in the U.S.&#160;Treaty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends on Common Shares</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited on the common shares or deemed to be paid or credited on the common shares to a U.S.&#160;Holder that is the beneficial owner of such dividends will generally be subject to non-resident withholding tax under the Canadian Tax&#160;Act and the U.S.&#160;Treaty at the rate of: (a)&#160;5% of the amounts paid or credited if the U.S.&#160;Holder is a company that owns (or&#160;is deemed to own) at least 10% of our voting stock or (b)&#160;15% of the amounts paid or credited in all other cases. The rate of withholding under the Canadian Tax&#160;Act in respect of dividends paid to non-residents of Canada is 25% where no tax treaty&#160;applies.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item will be included in our definitive proxy statement for the 2023 Annual Meeting of Shareholders expected to be filed with the SEC no later than 120&#160;days after the end of the fiscal year covered by this Form&#160;10-K (the&#160;&#8220;2023 Proxy Statement&#8221;), and such required information is incorporated herein by&#160;reference.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_130"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Company and Affiliated Purchases </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no purchases of equity securities by the Company during the fourth quarter of the year ended December&#160;31, 2022.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_133"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Reserved</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i57fbe32677504c888f142dd82b99b37f_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through February&#160;23, 2023 and should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this discussion. Additional company information, including this Form&#160;10-K, is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the U.S.&#160;Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_142"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its majority ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately 100 countries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated revenues for 2022, 2021 and 2020, of $8,124 million, $8,434 million and $8,027 million, respectively. Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical (&#8220;Solta&#8221;) aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the discussion in Item 1. &#8220;Business &#8212; Segment Information&#8221; and Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for further details on these reportable segments.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb Global Vision Care (formerly Vision Care/Consumer Health), Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). During May 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold shares of Bausch + Lomb pursuant to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;). The underwriters partially exercised the over-allotment option granted by the Selling Shareholder. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of Bausch + Lomb&#8217;s outstanding common shares. We continue to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. We continue to evaluate all factors and considerations related to the B+L Separation, including the effect of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements) on the B+L Separation.&#160;&#160;&#160;&#160;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, if consummated, will result in two separate, independent companies:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Health excluding Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals, and aesthetic medical devices. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics, and aesthetic medical devices businesses; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, &#8220;pure play&#8221; eye health company built on the iconic Bausch + Lomb brand and long history of innovation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L IPO was a large step in creating two attractive but dissimilar businesses. As independent entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs. Further, the B+L Separation will allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes the B+L Separation will unlock value, there can be no assurance that it will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. &#8220;Risk Factors &#8212;&#160;Risks Relating to the B+L Separation&#8221; of this Form 10-K for additional risks relating to the B+L Separation.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_145"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, we have been executing a multi-year plan designed to transform and bring out value in our Company, which includes focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management. As discussed below, we have taken actions that among other things include: (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure. These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other actions we have taken have helped to focus our operations and improve our capital structure. These actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical and eye health businesses. Although management believes the B+L Separation will bring out additional value, there can be no assurance that it will be successful in doing so.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focus on Core Businesses</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. In line with this focus on our core businesses, we have: (i) made measurable progress in effectively managing our capital structure, including taking actions to reduce the principal balances of our long-term debt, (ii) directed capital allocation to drive growth within these core businesses, (iii) divested assets to improve our capital structure and simplify our business, (iv) resolved certain of the Company&#8217;s legacy litigation matters originating back to 2015 and prior, (v) increased our efforts to improve patient access and (vi) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other actions we have taken to transform our Company, have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters. We believe that these measures, along with our continued commitment to improving people&#8217;s lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our eye health and pharmaceutical businesses. Although management believes the B+L Separation will unlock additional value, there can be no assurance that it will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, as such, it is a primary objective of our plan of separation. For additional details on the B+L Separation, see &#8220;Separation of the Bausch + Lomb Eye Health Business&#8221; in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Managing Our Capital Structure 2016 through 2021</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, we have been executing and continue to execute on our plan to improve our Company&#8217;s capital structure. As a result of a series of debt repayments and transactions from 2016 through 2021, the Company had positioned itself to add value through the B+L Separation while at the same time providing for the appropriate capitalization and leverage of these businesses post-separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the $1,210&#160;million financing of the U.S. Securities Litigation settlement (discussed in the subsequent section titled &#8220;LIQUIDITY AND CAPITAL RESOURCES&#8221;), we repaid (net of additional borrowings) approximately $10,000&#160;million of long-term debt during the period January 1, 2016 through December 31, 2021 using the net cash proceeds from divestitures of non-core assets and cash generated from operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Managing Our Capital Structure in 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further below, during 2022, we reduced the aggregate principal amount of our debt obligations by approximately $3,800&#160;million, as we: (i) utilized the net proceeds from the B+L IPO which closed on May 10, 2022, to make repayments of debt, (ii) reduced our debt through open market repurchases of debt with a principal value of approximately $927 million for approximately $550 million, (iii) extended the maturities of our debt through refinancing and (iv) completed an exchange offer which reduced the outstanding principal balance of our debt by $2,469&#160;million by exchanging $5,594&#160;million of aggregate principal value of existing unsecured senior notes (the &#8220;Existing Unsecured Senior Notes&#8221;) for newly issued secured notes with an aggregate principal balance of $3,125&#160;million (the &#8220;Exchange Offer&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The B+L IPO, 2022 Notes Issuance and Credit Agreement Refinancing - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L IPO, we completed a series of transactions in support of our commitment to improve our liquidity, reduce our leverage and better capitalize the two business entities post-separation. These transactions included:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2022, the Company issued (the &#8220;2022 Notes Issuance&#8221;) $1,000 million aggregate principal amount of 6.125% Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due February 2027 (the &#8220;February 2027 Secured Notes&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 10, 2022: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The B+L IPO closed, with aggregate net proceeds (including from the partial exercise of the over-allotment option by the underwriters), after deducting underwriting commissions, of approximately $675&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company entered into the 2022 Amended Credit Agreement as defined and discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The 2022 Amended Credit Agreement consists of new term loans of $2,500 million and a revolving credit facility of $975 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb entered into the B+L Credit Agreement, as defined and discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The B+L Credit Agreement provides for a five-year term loan facility in an initial principal amount of $2,500 million and also provides for a five-year revolving credit facility of $500 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from these transactions, along with cash on hand, allowed us to: (i) repay certain amounts outstanding under our then existing June 2025 Term Loan B Facility and November 2025 Term Loan B Facility (each as defined and discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;), (ii) replace our existing revolving credit facility which was due to mature in 2023, with revolving credit facilities that mature in 2027, (iii) redeem in full all of our then outstanding 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221;) and (iv) replace our then remaining amounts outstanding under our June 2025 Term Loan B Facility and November 2025 Term Loan B Facility with term loan facilities that expire in 2027. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishment of Debt - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022 and December 2022, through a series of transactions we repurchased and retired, outstanding senior notes with an aggregate par value of $927&#160;million in the open market, for approximately $550&#160;million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $369 million, net of write-offs of debt premiums, discounts and deferred issuance costs, representing the differences between the amounts paid to retire the senior unsecured notes and their carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;, we made the strategic decision based on the fair value of our Senior Unsecured Notes to undertake the Exchange Offer in September 2022. We exchanged certain validly tendered existing senior unsecured notes, with an aggregate outstanding principal balance of approximately $5,594&#160;million with maturities of 2025 through 2031 for newly issued senior secured notes, with an aggregate principal balance of approximately $3,125 million with maturities of 2028 and 2030. After fees and expenses, the Exchange Offer reduced the principal balances of our outstanding debt obligations by $2,469 million and extended the maturities of approximately $2,400 million of principal balances coming due during the years 2025 through 2027 to the years 2028 and 2030. We also recorded a net gain of $570&#160;million as the future undiscounted cash flows of certain New Secured Notes (as defined in &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;) were less than the net carrying value of the Existing Unsecured Senior Notes which were exchanged.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of: (i) the 2022 Notes Issuance and Credit Agreement Refinancing (as defined below under &#8220;&#8212;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&#8221;), (ii) the early extinguishment of debt, (iii) the Exchange Offer and (iv) other debt repayments (net of additional borrowings under our Revolving Credit Facility) we reduced the principal balances of our contractual debt obligations in 2022 by approximately $3,800&#160;million. The contractual principal amount of our debt obligations as of December 31, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Term Loan Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other, net of premiums, discounts and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual principal and interest payments of the New Secured Notes. Contractual interest payments will be allocated to the reduction of the recorded premium and interest expense as presented below. Additionally, the amount of interest which reduces the premium will be reported as a Financing activity in the Consolidated Statement of Cash Flows when paid.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments recorded as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium reduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These transactions also had the effect of reducing our cash debt service requirements over the next five years thereby providing us with additional flexibility as it relates to liquidity to operate. Prior to these transactions, our aggregate principal contractual debt repayment requirements through the year 2026 were approximately $11,500 million. As a result of these transactions, as of December 31, 2022, we have reduced our aggregate principal contractual debt repayment requirements through the year 2026 to approximately $4,000 million. Maturities of our principal balances of debt obligations as of December 31, 2022 and 2021, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions improve our overall capitalization and leverage. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. The Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements and Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; for further details and additional discussion regarding these matters. Cash requirements for future debt repayments including interest can be found in this Item &#8220;&#8212; Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is also driven by our long-term growth strategies. We allocate resources to promote our core businesses globally through: (i) strategic acquisitions, (ii) R&amp;D investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We search for new product opportunities through internal development and strategic licensing agreements, that, if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December&#160;31, 2022, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately 140 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gastrointestinal </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study and other clinical data of SSD in cirrhotic patients will help inform further research on potential new indications for rifaximin. A Phase 3 study has commenced (RED-C) with patients actively enrolling for the prevention of the first episode of Overt Hepatic Encephalopathy.</span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell disease. A phase 2 study with novel dosage formulation is currently enrolling patients for the treatment of sickle cell disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Envive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances. In April 2021, we expanded the launch to additional territories in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Amiselimod (S1P modulator) - A Phase 2 study to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis is actively enrolling.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Internal Development Project (&#8220;IDP&#8221;) 120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study has completed enrollment in July 2022. The New Drug Application (&#8220;NDA&#8221;) was filed on December 21, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lens. In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. During 2021 and 2022, Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY was launched in Korea, Singapore, New Zealand, India, Taiwan, Europe, Malaysia and Indonesia. Additional rollout is planned for 2023 and 2024. In the second quarter of 2022, a second SiHy Daily was launched in Japan under the brand name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY UV SHIN.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">LUMIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018, in South Korea and UAE in December 2021 and in Canada in June 2022. In 2022, we gained regulatory approvals in Jordan, Lebanon and the European Union and plan launches in these markets starting in 2023. We have also acquired the right to launch into new geographies. Currently, we have several innovative new line extension formulations under development. The first Phase 3 study in support of these line extensions was completed. Additional studies are currently on-going.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">New Ophthalmic Viscosurgical Device (&#8220;OVD&#8221;) product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during IOL delivery. A clinical study report was completed for the cohesive OVD product (StableVisc&#8482;) during the second quarter of 2022. FDA approval is expected in early 2023 and launch is expected during the second quarter of 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb is expanding its portfolio of premium IOLs built on the enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with Monofocal Plus, EDOF and Trifocal optical designs for presbyopia correction. Bausch + Lomb expects that they will be commercialized together with a new preloaded inserter with two options: non-Toric, as well as Toric for astigmatism patients. Bausch + Lomb anticipates launching Monofocal Plus, Trifocal and EDOF optical designs for presbyopia in the U.S. in 2023, 2024 and 2025/2026, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs tested and has a dual surfactant system that provides up to 20 hours of moisture. Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogel lenses. Prior to 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in the U.S., India, Brazil, Mexico, Korea, Europe, Turkey, Greece and other Latin American markets, and gained regulatory approvals in Indonesia, Malaysia, Singapore, Belarus, Taiwan and China. In 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Taiwan, Czech Republic, Israel, Poland, Slovakia, China and Argentina. We anticipate future launches in Slovenia, other parts of Europe, the Nordic regions and the Andean states.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_172"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_166"></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as &#8220;bolt on&#8221; acquisitions. In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2022, Bausch + Lomb acquired Paragon BioTeck, Inc., an eye-care focused drug development company, having a primary emphasis on the early detection of ocular diseases. This acquisition allows Bausch + Lomb to maximize the revenues and margins associated with Paragon&#8217;s products, for which it had previously had commercialization rights.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2022, Bausch + Lomb acquired Total Titanium Inc., an ophthalmic microsurgical instrument and machined parts manufacturing company. Bausch + Lomb believes that this acquisition is an important step in continuing to expand the surgical portfolio as it provides the opportunity to increase its manufacturing capacity and more specifically bolster its position in the ophthalmic microsurgical instrumentation market.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, Bausch + Lomb acquired AcuFocus, Inc. (&#8220;AcuFocus&#8221;), an ophthalmic medical device company that has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care. The IC-8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Apthera&#8482; IOL, which was approved by the FDA in July 2022 as the first and only small aperture non-toric EDOF IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time. Bausch + Lomb believes the IC-8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Apthera&#8482; EDOF IOL will bolster its surgical portfolio by enhancing the IOL offerings, which is a strategic area of focus for the Company.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_154"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including divesting non-core assets in order to narrow the Company&#8217;s activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date, we received approximately $4,100&#160;million in net proceeds from these divestitures, which includes the sale of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments (the &#8220;Amoun Sale&#8221;). Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment). Revenues associated with Amoun were $157&#160;million for the period of January 1, 2021 through July 26, 2021 and were $247&#160;million for the year 2020. Following the completion of the Amoun Sale, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility, using the net proceeds from the Amoun Sale and cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our audited Consolidated Financial Statements for additional information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_2831"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resolved Legacy Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, we resolved certain of the Company&#8217;s legacy legal matters originating back to 2015 and prior, including settling the U.S. Securities Litigation (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 20, &#8220;LEGAL PROCEEDINGS&#8221;). The Securities Class Action Settlement resolves the most significant of the Company&#8217;s remaining legacy legal matters and eliminates a material uncertainty regarding the Company. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We formed the Patient Access and Pricing Team which is committed to maintaining patients ability to access our branded prescription pharmaceutical products. All future pricing actions will be subject to review by the Patient Access and Pricing Team. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients through our Patient Assistance Program which offers free medication for patients who meet income and other eligibility criteria. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The cash-pay program was concepted to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings. This program is currently limited to a select group of our brands and offered through our unique telemedicine platform which allows for patients to choose direct delivery to their home or to use a pharmacy of their choice. This program is designed to connect patients with dermatologists and provide patients both a predictable customer experience and a predictable cost for their dermatology health care needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum. We believe we have a robust pipeline that not only provides for the next generation of our existing products but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we have built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is well positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales force has been successful in delivering consistent growth in demand for our GI products, demonstrated by our growth in Salix revenues of 33% when comparing 2022 to 2017. We continue to seek ways to bring out further value through leveraging our existing sales force.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Solta Aesthetic Medical Device Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radio frequency platform designed to optimize key functional characteristics and improve patient outcomes, has been on sale since 2017 in the U.S., Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, in the U.S., our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics business is our medical dermatology business dedicated to the treatment of a range of therapeutic areas, including aesthetics, psoriasis, actinic keratosis, acne, atopic dermatitis, onychomycosis and other dermatoses. As part of our business strategy for the Ortho Dermatologics segment, we continue to look for investments to build out our product portfolios, where we see the greatest opportunities, with a focus on topical gel and lotion products over injectable biologics. We continue to support the use of injectable biologics; however, we believe some patients prefer topical products as an alternative to injectable biologics. Further, as topical products can, in many cases, defer the use of injectable biologics that often come with associated risk/benefit profiles, a topical product is usually readily adopted by payors, is less expensive and can be more cost-effective than injectable biologics. Therefore, we believe topical products represent alternative treatments for physicians, payors and patients, and as the preferred choice of treatment, have the potential to drive greater volumes, generate better margins and potentially be a key contributing factor of our Ortho Dermatologics business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) building on our brands including Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Micro 0.06% to improve and meet today&#8217;s physician relevance and customer service, (ii) making key investments in our core dermatological products portfolios, (iii) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business&#8217; profitability, (iv) refocusing our operational and promotional resources and (v) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. In addition, in support of our established acne product portfolio we also have a unique project in our pipeline, IDP-126, which is an acne product with a fixed combination of benzoyl </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">peroxide, clindamycin phosphate and adapalene. We filed an NDA for IDP-126 in December 2022, and if approved by the FDA, we believe this product will further innovate and advance the treatment of acne.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain Forward-Looking Statements. Please see &#8220;Forward-Looking Statements&#8221; for additional information.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_2766"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity and sanctions against Russia, Belarus and specific areas of Ukraine have continued, the war has increasingly affected economic and global financial markets and exacerbated ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues attributable to Russia, Ukraine and Belarus for 2022, 2021 and 2020, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:42.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the geopolitical situation in Eastern Europe continues to intensify, political events and sanctions are continually changing, and we continue to assess the impact that the Russia-Ukraine war has had and will have on our businesses. These impacts may include but are not limited to: (i) interruptions or stoppage of production, (ii) damage or loss of inventories, (iii) supply-chain and product distribution disruptions in Eastern Europe, (iv) volatility in commodity prices and currencies, (v) disruption in banking systems and capital markets, (vi) reductions in sales and earnings of business in affected areas, (vii) increased costs and (viii) cyberattacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, these challenges have not yet had a material impact on our operations; however, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response will continue to affect our ability to conduct business with customers and vendors in this region. For example, we expect to experience further disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We may also experience further decreased demand for our products in these countries as a result of the conflict. In addition, we expect to experience difficulties in collecting receivables from such customers. If we continue to be hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to or suspension of our business and operations in Russia, Belarus and Ukraine may have a material adverse impact on our business, financial condition, cash flows and results of operations. We will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on our businesses.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. We believe we responded quickly to these and other human and commercial challenges brought on by the COVID-19 pandemic and that our actions allowed us to: (i) maintain a reliable supply of our products, (ii) protect the health, safety and well-being of our employees, (iii) reduce operating expenses and preserve cash through profit protection measures initiated in response to the COVID-19 pandemic, (iv) limit the disruptions to our product development pipeline and (v) ensure affordability of and access to our products. We will continue to monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the omicron variant in China in 2022 resulted in government enforced lockdowns and other social restrictions, which impacted our ability to conduct business as usual in certain regions in China, particularly Shanghai. The </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lockdowns in China have impacted the demand for certain products, particularly our consumer, vision care and Solta products, as shelter in place orders limit the demand and need for the use of contact lenses and related products as well as for aesthetic medical treatments. Our revenues in China for 2022 and 2021 were $413&#160;million and $490&#160;million, respectively, a decrease of $77&#160;million&#160;and, in part, reflects the impact of the surge of the omicron variant in China. During the third quarter of 2022, the impact on our revenues from the headwinds from China&#8217;s COVID-19 policies and lockdowns that we saw during the first half of 2022 began to normalize and we began to see growth in volumes in this region. Additionally, government enforced lockdowns have caused certain businesses to suspend operations, creating distribution and other logistic issues for the distribution of our products and the sourcing for a limited number of raw materials. Through the date of this filing, we have dealt with these issues in China with only a minimal impact on our manufacturing and distribution processes. However, as the impacts of global reaction to the COVID-19 pandemic remains a fluid situation, we continue to monitor the impacts on our businesses of the COVID-19 virus and variant and subvariant strains thereof in order to timely address new issues if and when they arise.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors&#8212; Risks Relating to COVID-19&#8221; of this Form 10-K.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_2757"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Inflation Reduction Act (the (&#8220;IRA&#8221;) was signed into law, which includes implementation of a new corporate alternative minimum tax (&#8220;CAMT&#8221;), among other provisions. The CAMT imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also made significant changes to how drugs are covered and paid for under the Medicare program, including imposing financial penalties if drug prices are increased at a rate faster than inflation, redesigning Medicare Part D benefits to shift a greater portion of the costs to manufacturers and allowing the U.S. government to set prices for certain drugs in Medicare. We continue to evaluate the impact of the IRA legislation on our results of operations and it is possible that these changes may result in a material impact on our business and results of operations.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2024. On December 13, 2022, the European Union member states unanimously adopted the directive to implement pillar two rules. According to the directive, the member states are expected to enact pillar two rules into domestic law in 2023, with certain elements becoming effective for fiscal years beginning on or after December 31, 2023. The OECD has published model rules and other guidance with respect to pillar two, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021. On February 1, 2023, the Inclusive Framework released a package of technical and administrative guidance on the implementation of pillar two, including the scope of companies that will be subject to the Global Anti-Base Erosion Rules, transition rules, and guidance on domestic minimum taxes that countries may choose to adopt, among other topics. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate, could have a material effect on our liability for corporate taxes and our consolidated effective tax rate. On February 1, 2023, the US. Financial Accounting Standards Board indicated that they believe the minimum tax imposed under pillar two is an alternative minimum tax, and, accordingly, deferred tax assets and liabilities associated with the minimum tax would not be recognized or adjusted for the estimated future effects of the minimum tax but would be recognized in the period incurred. On April 19, 2021, the Canadian federal government delivered its 2021 budget which contained proposed measures related to limitations on interest deductibility and changes in relation to international taxation. Draft legislative proposals pertaining to interest deductibility were initially released for public comment on February 4, 2022, with revised legislative proposals subsequently released on November 3, 2022. The proposed rules on interest deductibility are expected to be effective no earlier than January 1, 2024. The proposed rules and their application are complex and could have a material adverse impact on our consolidated effective tax rate and financial results in future years if enacted as drafted. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. Although we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate, could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2023, the U.S. Financial Accounting Standards Board indicated that they believe the minimum tax imposed under pillar two is an alternative minimum tax, and, accordingly, deferred tax assets and liabilities associated with the minimum tax would not be recognized or adjusted for the estimated future effects of the minimum tax but would be recognized in the period incurred.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_196"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. Many of these changes focus on health care cost containment, which result in pricing pressures relating to the sales and reimbursements of healthcare products. The Biden Administration and Congress continue to focus on health care cost containment which could result in legislative and regulatory changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to face various proposed health care pricing changes and regulations from governments throughout the world in locations in which we operate our business. These proposed changes may also continue to result in pricing pressures relating to sales, promotions and reimbursement of our product portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rule making and guidance published by the U.S. Department of Health and Human Services, the FDA, and applicable foreign governments in locations in which we operate; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2023 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2023 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic (&#8220;AG&#8221;) of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition. Prior to and during 2021, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream. In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Branded products that began facing generic competition in the U.S. during 2022 included Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel and Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 through 2027 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2023 through 2027. These products and year of expected LOE include, but are not limited to, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2026), Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2026), Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2023), Onexton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023), Prolensa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023) and Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023). These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Colazal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company&#8217;s patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company&#8217;s pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on our competition risks.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS </span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides financial performance highlights for each of the last three&#160;years: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 to 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2022 Compared with 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2022 and 2021 were $8,124 million and $8,434 million, respectively, a decrease of $310 million, or 4%. The decrease was primarily driven by: (i) the unfavorable impact of foreign currencies, (ii) the impact of our divestiture of Amoun on July 26, 2021 and (iii) a decrease in volumes primarily attributable to our Diversified Products and Salix segments partially offset by the increase in volumes in our Bausch + Lomb and International segments. These decreases were partially offset by an increase in net realized pricing, primarily in our Salix, Bausch + Lomb and International segments. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $454 million and $450 million for 2022 and 2021, respectively, an increase in our operating results of $4 million which reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $271 million. The decrease was primarily driven by: (i) the</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unfavorable impact of foreign currencies, (ii) the impact of our divestiture of Amoun on July 26, 2021 and (iii) the decrease</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in volumes, as previously discussed, partially offset by the increase in net realized pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Selling, general, and administrative (&#8220;SG&amp;A&#8221;) expenses of $1 million;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $64 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic and did not normalize until later in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $160 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Goodwill impairments of $355 million as we recognized impairments of $824 million and $469 million for 2022 and 2021, respectively, associated with our Neurology and Other and Ortho Dermatologics reporting units;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $219 million, primarily attributable to adjustments to the loss on assets held for sale in connection with the Amoun Sale during 2021; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a favorable change in Other expense, net of $338 million, primarily attributable: (i) to higher adjustments related to the settlements of certain litigation matters during 2021 and (ii) the loss on the completion of the Amoun Sale 2021, partially offset by insurance recoveries related to certain litigation matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $454 million and $450 million for 2022 and 2021, respectively, and includes non-cash charges for Depreciation and amortization of intangible assets of $1,394 million and $1,552 million, Asset impairments, including loss on assets held for sale of $15 million and $234 million, Goodwill impairments of $824 million and $469 million and Share-based compensation of $126 million and $128&#160;million for 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before income taxes for 2022 and 2021 was $129 million and $1,024 million, respectively, a decrease in our loss of $895 million. This was primarily attributable to: (i) the favorable change in Gain (loss) on extinguishment of debt of $937 million primarily driven by the Exchange Offer and open market repurchases of senior notes and (ii) the increase in our </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating results of $4 million, partially offset by: (i) an increase in Interest expense of $38 million and (ii) an unfavorable net change in Foreign exchange and other of $15 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health for 2022 and 2021 was $225 million and $948 million, respectively, a decrease in our loss of $723 million. This was primarily due to the decrease in our Loss before income taxes of $895 million, as previously discussed, partially offset by the unfavorable change in our provision for income taxes of $170 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2021 Compared with 2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by: (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by: (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, a decrease in our operating results of $226 million which reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $259 million. The increase was primarily driven by: (i) the increase in volumes, as previously discussed, and (ii) the favorable impact of foreign currencies, partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the decrease in net realized pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in SG&amp;A expenses of $257 million, primarily attributable to: (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, (ii) Separation-related and IPO-related costs incurred in 2021 and (iii) the impact of foreign currencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $13 million primarily attributable to the non-recurrence of the temporary suspension in certain R&amp;D activities and clinical trials in 2020, partially offset by a rebalancing of our portfolio within the Ortho Dermatologics business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $270 million primarily attributable to fully amortized intangible assets no longer being amortized in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Goodwill impairments of $469 million related to the impairment to the goodwill of the Ortho Dermatologics reporting unit during the three months ended March 31, 2021 as a result of revised forecasts due to: (i) certain products that continued to experience longer launch cycles than originally anticipated, in part due to COVID-19 pandemic factors, and (ii) other changes to its product pipeline;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments, including loss on assets held for sale of $120 million, primarily attributable to: (i) higher impairments to certain products and (ii) additional losses during 2021 related to assets classified as held for sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Other expense, net of $129 million, primarily attributable: (i) higher insurance recoveries related to certain litigation matters in 2021 as compared to 2020 and (ii) decreases in charges for Acquisition-related contingent consideration and Acquired in-process research and development costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, and includes non-cash charges for Depreciation and amortization of intangible assets of $1,552 million and $1,825 million, Asset impairments, including loss on assets held for sale of $234 million and $114 million, Goodwill impairments of $469 million and $0 and Share-based compensation of $128 million and $105 million for 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before income taxes for 2021 and 2020 was $1,024 million and $934 million, respectively, an increase in our Loss before income taxes of $90 million. The increase in our Loss before income taxes is primarily attributable to the decrease in our operating results of $226 million, as previously discussed, partially offset by: (i) a decrease in Interest expense of $108 million and (ii) the favorable net change in Foreign exchange and other of $37 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for 2021 and 2020 was $948 million and $560 million, respectively, an increase in our loss of $388 million. This was primarily due to: (i) a decrease in the Benefit from income taxes </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $288 million, primarily attributable to the release of a portion of our valuation allowance against deferred tax assets in 2020 and (ii) the increase in Loss before income taxes of $90 million, as previously discussed.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results for the years 2022, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2021 results compared with that of 2020 can be found under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K&#8221; in Exhibit 99.1 of our Form 8-K filed on May 10, 2022.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Compared with 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,124 million and $8,434 million for 2022 and 2021, respectively, a decrease of $310 million, or 4%. The decrease was due to: (i) the unfavorable impact of foreign currencies of $264 million primarily in Europe and Asia, (ii) the impact of divestitures and discontinuations of $178 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (iii) a decrease in volumes of $88 million primarily in our Diversified, Salix and Solta segments partially offset by an increase in volumes in our Bausch + Lomb and International segments. These decreases were partially offset by an increase in net realized pricing of $220 million, primarily in our Salix, Bausch + Lomb and International segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for 2022 and 2021 were as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution service fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances, returns, rebates, chargebacks and distribution service fees as a percentage of gross product sales were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 40.9% and 39.4% in 2022 and 2021, respectively, an increase of 1.5% percentage points and includes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily due to lower gross product sales for certain generic products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG and Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and lower discount rates for certain other generic products, such as Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales was unchanged as: (i) the result of the Company&#8217;s improving return experience and (ii) the favorable year over year impact due to the recall of certain Bausch + Lomb consumer products as a result of a quality issue at a third-party supplier during the three months ended June 30, 2021, as discussed below, were offset by increases in our International segment of approximately $11&#160;million during the three months ended June 30, 2022, to reflect a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions and a change of distributors. Included in the product returns provision for 2022 and 2021 are reductions in variable consideration for sales returns related to past sales of approximately $21 million and $28 million, respectively. Further, we estimate that a 1% change in our return experience would have impacted our pre-tax earnings by approximately $97&#160;million for the year 2022. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements regarding further details related to product sales provisions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of an increase in gross product sales of certain branded products with higher rebate rates, such as Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .06% and Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .08%. We estimate that a 1% change in our estimated rates used in determining the Medicaid rebate reserve would have impacted our pre-tax earnings by approximately $83&#160;million for 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due the impact of an increase in gross product sales of certain branded products with higher chargeback rates for certain branded products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales for certain generic products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and by lower chargeback rates and gross product sales for certain branded products such as Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were higher primarily due to higher gross product sales of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Price appreciation credits were $10 million and $17&#160;million for 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or net realizable value adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $2,336 million and $2,361 million for 2022 and 2021, respectively, a decrease of $25 million, or 1%. The decrease was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies, partially offset by increase in volumes and higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Bausch + Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) was notified by a third-party supplier of sterilization services for its lens care solution bottles and caps at its Milan, Italy facility, of inconsistencies in the sterilization data versus certificates of conformance previously submitted to B&amp;L Inc. by that supplier. Based on B&amp;L Inc.&#8217;s internal Health and Safety Analysis, it was determined that this issue did not affect the safety or performance of any of its products and was limited to a specific number of lots for certain Consumer products within our Bausch + Lomb segment. However, out of an abundance of caution and working with the appropriate notified body and responsible health authorities, B&amp;L Inc. has contained and/or recalled down to the consumer level the limited number of affected lots of products resulting in $8&#160;million of manufacturing variances and $6&#160;million of returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of Product sales revenue was 29.0% and 28.3% for 2022 and 2021, respectively, an increase of 0.7 percentage points primarily attributable to: (i) higher manufacturing variances and (ii) year-over-year changes in product mix.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; separation-related and IPO-related costs; and other general and administrative costs. The Company has incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and, for 2022 and 2021, has incurred costs associated with the suspended Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs, (iii) costs associated with facility relocation and/or modification and (iv) costs to operating two public companies as a result of the B+L IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $2,625 million and $2,624 million for 2022 and 2021, respectively, an increase of $1 million. The increase was primarily attributable to: (i) higher selling expenses, primarily related to freight and (ii) higher compensation expenses partially offset by: (i) the favorable impact of foreign currencies, (ii) the impact of our divestiture of Amoun on July 26, 2021 and (iii) lower Separation-related and IPO-related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $529 million and $465 million for 2022 and 2021, respectively, an increase of $64 million, or 14%. The increase was primarily attributable to: (i) the result of lower R&amp;D spend in early 2021 as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic and did not normalize until later in 2021, as previously discussed, and (ii) higher spend on certain Solta and Bausch + Lomb projects. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 1 to 20 years. Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $1,215 million and $1,375 million for 2022 and 2021, respectively, a decrease of $160 million, or 12%. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. A reporting unit is the same as, or one level below, an operating segment. We test reporting units for impairment by comparing the estimated fair value of each reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment based on the difference between fair value and carrying amount of the reporting unit as a reduction to goodwill. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit in an orderly transaction between market participants. We estimate the fair values of our reporting units using a discounted cash flow model, which utilizes Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $824 million and $469 million for 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). As a result of these market conditions and given the reporting unit&#8217;s limited headroom, goodwill for our Ortho Dermatologics reporting unit was impaired </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three month period ended June 30, 2022 reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed as of June 30, 2022, an $83&#160;million impairment to the goodwill of the Ortho Dermatologics reporting unit was recognized. As a result, there was zero headroom in the Ortho Dermatologics reporting unit as of June 30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022. As a result of these market conditions and given there was no headroom as a result of the impairment to goodwill in the previous quarter, goodwill for our Ortho Dermatologics reporting unit was impaired during the three month period ended September 30, 2022, reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed as of September 30, 2022, a $119&#160;million impairment to the goodwill of the Ortho Dermatologics reporting unit was recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology and Other</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands (such as pharmaceutical market access and contractual pricing), health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. This includes recent changes related to pharmaceutical pricing by the Federal government, including the passage of the IRA in August 2022 and, effective in 2024, changes to Medicaid rebate caps (passed as part of the American Rescue Plan Act of 2021). The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature more directly impacted by these changing market dynamics, creating increased pressure on the reporting unit&#8217;s long-term financial performance. In response to these pressures, as well as to consider anticipated increased competition from new market entrants in 2023, during the fourth quarter of 2022, we began taking steps to: (i) reassess our pricing strategies, (ii) re-evaluate our marketing and promotional efforts and (iii) reduce our cost structure and revised our long-term forecasts for the Neurology and Other reporting unit to reflect these developments. As a result of the revisions to our long-term expectations for these changes and other factors, goodwill for our Neurology and Other reporting unit was impaired during our most recent annual impairment test reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed as October 1, 2022, a $622&#160;million impairment to the goodwill of the Neurology and Other reporting unit was recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, increased insurance coverage pressures within the U.S. were limiting patient access to topical acne and psoriasis products. In response to these developments, during the first quarter of 2021, we began taking steps to: (i) redirect our R&amp;D spend to eliminate projects we had identified as high cost and high risk, (ii) redirect a portion of our marketing and product development outside the U.S. to geographies where there was better patient access and (iii) reduce our cost structure to be more competitive. As a result of these and other factors, goodwill for our Ortho Dermatologics reporting unit was impaired during the three month period ended March 31, 2021 reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed as of March 31, 2021, a $469 million impairment to the goodwill of the Ortho Dermatologics reporting unit was recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements and &#8220;CRITICAL ACCOUNTING POLICIES AND ESTIMATES &#8212; Goodwill&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details related to our goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset impairments, including loss on assets held for sale </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statements of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $15 million and $234 million for 2022 and 2021, respectively, a decrease of $219 million. Asset impairments, including loss on assets held for sale for 2022 includes: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines. Asset impairments, including loss on assets held for sale for 2021 includes: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $63 million and $50 million for 2022 and 2021, respectively, an increase of $13 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $30&#160;million and $18&#160;million for 2022 and 2021, respectively, an increase of $12&#160;million. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. The Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were $33&#160;million and $32&#160;million for 2022 and 2021, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 4, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our audited Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for 2022 and 2021 consists of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for 2021, includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries of $213 million related to certain litigation matters. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding these matters</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development costs primarily consists of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization and write-off of debt discounts, premiums and debt issuance costs under our credit facilities and notes as well as, the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company&#8217;s cross-currency swaps. In November 2021, we entered into a transaction to unwind our cross-currency swaps. In July 2022, Bausch + Lomb entered into new cross-currency swaps with aggregate notional amounts of $1,000&#160;million. Following the completion of the debt exchange in September 2022, interest payments on certain of our debt will not be classified as interest expense but rather will be a reduction in premium recorded at the time of the debt exchange.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1,464 million and $1,426 million and included non-cash amortization and write-offs of debt discounts, premiums and debt issuance costs of $99 million and $55 million for 2022 and 2021, respectively. Interest expense increased $38 million, or 3%, in 2022 as compared to 2021, primarily attributable to higher write-offs of debt issuance costs in 2022 as well as higher interest rates partially offset by the impact of lower outstanding debt balances and the impact of the accounting treatment for the New Secured Notes, which resulted in lower interest expense of $74 million in the fourth quarter of 2022 as compared to the stated rate of interest on the New Secured Notes. The weighted average stated rate of interest as of December 31, 2022 and 2021 was 7.74% and 5.88%, respectively. The increase in the weighted average stated rate of interest of 186 bps is primarily attributable to the New Secured Notes and term loan facilities. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. The gain on extinguishment of debt was $875 million for 2022, as compared to loss on extinguishment of debt of $62 million for 2021, primarily associated with certain refinancing transactions that occurred each year and represents the differences between the amounts paid to settle the extinguished debt and its carrying value. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Business&#8221; for additional information regarding our gain on extinguishment of debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt for 2022 includes: (i) the gain associated with the Exchange Offer of $570 million and (ii) the gains associated with the early retirement of certain senior unsecured notes of $369 million discussed below, partially offset by $64&#160;million of losses associated with the refinancing and modification to certain debt obligations completed in connection with the B+L IPO, each as discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022 and December 2022, through a series of transactions we repurchased and retired, outstanding senior notes with an aggregate par value of $927&#160;million in the open market, for approximately $550&#160;million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. The senior notes retired had maturities of November 2025 through February 2031 and had a weighted average interest rate of approximately 5.60%. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $369 million. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Focus on Core Businesses &#8212; Exchange Offer" for details of maturities and principal balances debt obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a loss of $8&#160;million and a gain of $7 million for 2022 and 2021, respectively, an unfavorable net change of $15 million primarily due to: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future. Provision for income taxes was $83 million in 2022 and benefit from income taxes was $87 million in 2021, an unfavorable net change of $170 million, primarily attributable to changes in our jurisdictional mix of earnings. In 2022, the Company&#8217;s valuation allowance decreased $199 million primarily attributable to the impact of book taxable income in Canada and the expiration of tax losses in the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated foreign rate differential reflects the net total tax cost or benefit on income earned or losses incurred in jurisdictions outside of Canada as compared to the net total tax cost or benefit of such income (on a jurisdictional basis) at the Canadian statutory rate of 26.9%. Tax costs below the Canadian statutory rate generate a beneficial foreign rate differential as do tax benefits generated in jurisdictions where the statutory tax rate exceeds the Canadian statutory tax rate. The net total foreign rate differentials generated in each jurisdiction in which we operate is not expected to bear a direct relationship to the net total amount of foreign income (or loss) earned outside of Canada. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2021, our effective tax rate differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is recorded, (ii) changes in uncertain tax positions, (iii) changes in tax attributes, (iv) the tax provision generated from our mix of earnings by jurisdiction, (v) impairment to goodwill which is non-deductible under tax laws and (vi) changes in the valuation allowance related to foreign tax credits and net operating losses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a valuation allowance against our deferred tax assets to reduce their net carrying value to an amount that we believe is more likely than not to be realized. In determining our deferred tax asset valuation allowance, we estimate our ability to utilize future sources of income to realize the benefits of our temporary income tax differences including: (i) net operating loss carryforwards in each jurisdiction, primarily in Canada, the U.S. and Ireland, (ii) research and development tax credit carryforwards, (iii) scientific research and experimental development pool carryforwards and (iv) investment tax credit carryforwards. When we establish/increase or reduce/decrease the valuation allowance, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. Our valuation allowance against deferred tax assets as of December 31, 2022 and 2021 was $2,023 million and $2,222 million, respectively, a decrease of $199 million, as discussed above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, &#8220;INCOME TAXES&#8221; to our audited Consolidated Financial Statements for further details.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_211"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of our segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented 80% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical (&#8220;Solta&#8221;) aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for a reconciliation of segment profit to Loss before income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues and the year over year changes in segment revenues for 2022 and 2021. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for 2022 and 2021. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 to 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue (non-GAAP) and change in organic revenue (non-GAAP), are defined as GAAP Revenue and change in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments, and the Company in total. The Company believes that providing these measures is useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustments to GAAP Revenue and changes in GAAP revenue to determine organic revenue (non-GAAP) and changes in organic revenue (non-GAAP) are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and organic growth/change exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Revenues attributable to acquisitions completed in 2022 were less than $1 million during 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and presents organic revenue (Non-GAAP) and the year over year changes in organic revenue (Non-GAAP) for 2022 and 2021 by segment.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.907%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 81% and 79% of the Salix segment revenues and approximately 21% and 19% of the Company&#8217;s revenues for 2022 and 2021, respectively. No other single product group represents 10% or more of the Salix segment revenues. The Salix segment revenue was $2,090 million and $2,074 million for 2022 and 2021, respectively, an increase of $16 million, or 1%. The increase was primarily attributable to increases in net realized pricing of $95 million, primarily attributable to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line partially offset by a decrease in volumes of $79 million, primarily attributable to: (i) unfavorable inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by certain wholesalers and (ii) the impact of generic competition for certain other products as they have lost exclusivity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit was $1,489 million and $1,493 million for 2022 and 2021, respectively, a decrease of $4 million. The decrease was primarily driven by higher selling, advertising and promotion expenses primarily associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower litigation costs and the increase in revenue, as previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $988 million and $1,166 million for 2022 and 2021, respectively, a decrease of $178 million, or 15%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $167 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $65 million, primarily in Europe and Canada. The decreases were partially offset by: (i) an increase in net realized pricing of $30 million and (ii) an increase in volumes of $24 million. The increase in volumes is primarily attributable to Europe and was partially offset by charges for approximately $15 million of returns in connection with a change in certain distribution agreements representing a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions as well as a change of distributors, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for 2022 and 2021 was $324 million and $403 million, respectively, a decrease of $79 million, or 20%. The decrease was primarily driven by the decrease in contribution primarily attributable to: (i) our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies, partially offset by an increase in net realized pricing and higher volumes. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines, which accounted for approximately 77% of the Solta segment revenues for 2022, respectively. No other single product group represents 10% or more of the Solta segment revenues. The Solta segment revenue was $300 million and $308 million for 2022 and 2021, respectively, a decrease of $8 million, or 3%. The decrease was primarily attributable to: (i) a net decrease in volume of $16 million primarily driven by the impact of the government enforced COVID-19 pandemic related shutdowns in China, as previously discussed, partially offset by increases in volumes in other Asia Pacific countries and (ii) the unfavorable impact of foreign currencies of $15&#160;million, partially offset by an increase in net realized pricing of $23&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit was $135 million and $167 million for 2022 and 2021, respectively, a decrease of $32 million, or 19%. The decrease is primarily attributable to an increase in R&amp;D and the unfavorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue was $978 million and $1,121 million for 2022 and 2021, respectively, a decrease of $143 million, or 13%. The decrease was primarily driven by: (i) a decrease in volume of $131 million and (ii) a decrease in net realized pricing of $11 million. The decrease in volumes was primarily attributable to our Neurology and Other and Generics businesses due to: (i) decreases in several products attributable to the non-recurring pandemic related government mail order programs in 2021 and (ii) the impacts of more generic competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit was $612 million and $722 million for 2022 and 2021, respectively, a decrease of $110 million, or 15% and was primarily driven by the decrease in revenues, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its segment revenues. The Bausch + Lomb segment revenue was $3,768 million and $3,765 million for 2022 and 2021, respectively, an increase of $3 million. The increase was primarily attributable to: (i) increase in volumes of $114 million and net realized pricing of $83 million, partially offset by: (i) the unfavorable impact of foreign currencies across all of Bausch + Lomb international businesses of $184 million, primarily in Europe and Asia and (ii) the impact of divestitures and discontinuations of $10 million, related to the discontinuation of certain products. The increase in volumes was primarily driven by: (i) the consumer eye care business, driven by: (a) increased demand for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) the non-recurrence of a third-party supplier quality issue on the prior year revenues of certain consumer eye care products, as discussed below, (ii) increased demand of consumables and intraocular lenses within the Surgical business and (iii) increased demand and new launches within the Ophthalmic Pharmaceuticals business. These increases in volumes and pricing were partially offset by: (i) the impact of the COVID-19 pandemic on the consumer and contact lens businesses in China and (ii) a claw-back related to the Ministerial Decree (&#8220;DM&#8221;) certifying a spending ceiling for the Italian National Health Fund for the years 2015-2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit was $874 million and $958 million for 2022 and 2021, respectively, a decrease of $84 million, or 9%. The decrease was primarily driven by: (i) higher selling expenses, primarily due to freight and (ii) higher manufacturing variances, driven by inflationary pressures and higher manufacturing efficiency ramp-up costs of Daily SiHy lenses and, partially offset by the non-recurrence of prior year charges related to a quality issue at a third-party supplier. These decreases were partially offset by the increase in revenues, as previously discussed. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized cash flow information for the years 2022, 2021 and 2020 is as follows: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 to 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile Net loss to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,154)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,528)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2021 results compared with that of 2020 can be found under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K&#8221; in Exhibit 99.1 of our Form 8-K filed on May 11, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $728 million in 2022 as compared to Net cash provided by operating activities of $1,426 million in 2021, a decrease of $2,154 million. The decrease was attributable to: (i) the decrease in Cash provided by operating activities before changes in operating assets and liabilities and (ii) Changes in operating assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities before changes in operating assets and liabilities in 2022 was $332 million as compared to Cash provided by operating activities before changes in operating assets and liabilities in 2021 of $1,554 million, a decrease of $1,886 million. The decrease is primarily attributable to: (i) payments of $1,572&#160;million of accrued legal settlements related to the Securities Class Action Settlement, the Glumetza Antitrust Litigation and a RICO class action matter paid during 2022, (ii) changes in business performance, (iii) the impact of our divestiture of Amoun on July 26, 2021 and (iv) an increase in payments for separation costs, separation-related costs, IPO costs and IPO-related costs in 2022 as compared to 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $1,210&#160;million of payments into an escrow fund under the terms of Securities Class Action Settlement which was subject to one objector&#8217;s appeal of the final court approval of the agreement. The period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the Securities Class Action Settlement has become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company&#8217;s rights in the funds previously paid into the escrow account were extinguished in accordance with the terms of the Securities Class Action Settlement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits also included $300 million of payments into escrow funds under the terms of settlement in the Glumetza Antitrust Litigation. On February 3, 2022 the court granted final approval of the class settlement and ordered dismissal of the class plaintiff&#8217;s claims. The deadline to appeal the final approval of the class settlement has now passed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $396 million and $128 million in 2022 and 2021, respectively, an unfavorable change of $268 million. During 2022, Changes in operating assets and liabilities was negatively impacted by: (i) an increase in inventories of $198&#160;million, (ii) increase in Accounts payable, accrued and other liabilities of $75&#160;million, (iii) the timing of other payments in the ordinary course of business of $66&#160;million, driven in part by the impact of the interest payments made on September 30, 2022 associated with the notes tendered in the Exchange Offer and (iv) increase in trade receivables of $57&#160;million. During 2021, Changes in operating assets and liabilities was negatively impacted by: (i) the increase in trade receivables of $229&#160;million, (ii) an increase in inventories of $16&#160;million and (iii) lower interest payable due to the timing of payments of $13 million, partially offset by the positive impact of the timing of other payments in the ordinary course of business of $130&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $303 million in 2022 and was primarily driven by Purchases of property, plant and equipment of $218 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $409 million in 2021 and was primarily driven by: (i) Proceeds from sale of assets and businesses, net of costs to sell of $669 million, which is primarily attributable to the Amoun Sale and (ii) Settlements from cross-currency swaps of $27 million, partially offset by Purchases of property, plant and equipment of $269 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2022 was $474 million and was primarily driven by: (i) the issuance of long-term debt (net of discounts) of $6,836 million related to the February 2027 Secured Notes, 2027 Term Loan B Facility, draws on the 2027 Revolving Credit Facility and the B+L Term Loan Facility and (ii) net proceeds from the B+L IPO of $675 million, partially offset by the repayment of long-term debt of $7,846 million related to: (i) the repayment of the outstanding balance under our 2023 Revolving Credit Facility, (ii) the repayment of the outstanding balance of our 6.125% Senior Unsecured Notes, (iii) the repayment of the outstanding balances under our 2025 Term Loan B Facilities and (iv) the repurchase and retirement of certain outstanding senior notes in the open market with an aggregate par value of $927 million for approximately $550 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2021 was $1,513 million and was primarily driven by the repayments of debt of $3,440 million which consisted of: (i) $1,600 million of 7.000% Senior Secured Notes due 2024 as part of the 2021 Refinancing Transactions (as defined below), (ii) the aggregate prepayments of $1,600 million using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale and (iii) the repayment of $240 million previously drawn under our 2023 Revolving Credit Facility. Issuance of long-term debt (net of discounts) of $2,100 million primarily includes: (i) the proceeds of $1,575 million from the issuance of $1,600 million in principal amount of 4.875% Senior Secured Notes due June 2028 and (ii) draw downs of $525 million under our 2023 Revolving Credit Facility which we used primarily to make deposits of approximately $300 million, in the aggregate, into escrow funds under the terms of settlement agreements regarding the Glumetza Antitrust Litigation and to pay interest and other business expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details regarding the financing activities previously described.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for the next twelve months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of December 31, 2022 includes $380&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $20,766 million and $22,654 million as of December 31, 2022 and 2021, respectively. Aggregate contractual principal amounts due under our debt obligations were $19,110 million and $22,870 million as of December 31, 2022 and 2021, respectively, a decrease of $3,760 million.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we closed the Exchange Offer, pursuant to which existing unsecured senior notes as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) with an aggregate outstanding principal balance of $5,594&#160;million were exchanged for $3,125&#160;million in aggregate principal balance of New Secured Notes (as defined below). The Exchange Offer reduced our then aggregate outstanding principal debt balance by $2,469 million. In accordance with U.S. GAAP, we recognized a portion of this reduction as a gain of $570 million, net of third-party fees and the write-off of the unamortized debt discounts and issuance costs related to the Existing Unsecured Senior Notes, and were required to record the balance of the reduction in our debt balance of $1,835 million, as a premium on the New Secured Notes. This premium will be reduced as we make interest payments on the New Secured Notes in the amounts as presented in the previously provided table under the caption &#8220;Exchange Offer&#8221;. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the contractual interest due at the New Secured Notes&#8217; stated rates of interest. Additionally, the portion of interest payments that reduce the premium recorded will be classified within Financing Activities in the Company&#8217;s Consolidated Statement of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details on the accounting for the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221;, and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% Intermediate Holdco Secured Notes&#8221;, and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Aggregate Principal Amount Validly Tendered</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Outstanding Existing Notes Validly Tendered</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer reduced the principal balances of our outstanding debt obligations by $2,469 million. The Exchange Offer also had the effect of extending the maturities of approximately $2,400 million of aggregate principal balances of senior notes coming due during the years 2025 through 2027 out to the years 2028 and 2030. Additionally, we have reduced our estimated interest requirements for the year 2023 by approximately $65 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Exchange Offer, we made debt repayments and completed refinancing transactions during 2022 that reduced our outstanding debt obligations and extended certain maturities of our remaining debt obligations as previously discussed under &#8220;&#8212; Liquidity and Capital Resources &#8212; Cash Flows &#8212; Financing Activities&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below) and available cash on hand. As of December 31, 2022, the Company had drawn $470&#160;million on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%. The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and 3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $500&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of December 31, 2022, the principal amount outstanding under the B+L Term Facility was $2,488&#160;million and $2,439&#160;million net of issuance costs. The B+L Revolving Credit Facility remained undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to term SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate plus an applicable margin of 3.25% or (ii) a US dollar base rate plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum and the first installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the Term Facility were $106 million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.00% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of 11.00% per year that is payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 11.00% First Lien Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 14.00% Second Lien Secured Notes mature on October 15, 2030, and have a stated interest of 14.00% per year that is payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">9.00% Intermediate Holdco Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of 9.00% per year that is payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of December 31, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes and 9.00% Intermediate Holdco Secured Notes as of December 31, 2022 and 2021 was $7,905&#160;million and $3,850&#160;million, respectively, an increase of $4,055&#160;million. The increase is attributable to: (i) the issuance of the New BHC Secured Notes and the issuance of the 9.00% Intermediate Holdco Secured Notes in connection with the Exchange Offer as previously discussed and (ii) the issuance of the February 2027 Secured Notes as previously discussed, partially offset by the repurchase of $70 million of secured notes in the open market.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release under the 2022 Amended Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of December 31, 2022 and 2021 was $5,798 million and $14,900 million, respectively, a decrease of $9,102 million, attributable to: (i) Existing Unsecured Notes of $5,594&#160;million validly tendered and accepted in connection with the Exchange Offer, (ii) the redemption in full of $2,650 million of April 2025 Unsecured Notes and (iii) the repurchase and retirement of certain outstanding Senior Unsecured Notes in the open market with an aggregate par value of approximately $857&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Availability Under Revolving Credit Facilities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, February&#160;23, 2023, there were $420&#160;million of outstanding borrowings, $25&#160;million of issued and outstanding letters of credit and approximately $530&#160;million of remaining availability under the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, February&#160;23, 2023, there were no outstanding borrowings, $24 million of issued and outstanding letters of credit and $476 million remaining availability under the B+L Revolving Credit Facility. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our 2022 Amended Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Amended Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017 through the date of this filing, the Company completed several actions which included repaying debt with proceeds from divestitures and cash flows from operations, as well as refinancing debt with near term maturities. These actions have reduced the Company&#8217;s debt balance and positively affected the Company&#8217;s ability to comply with its financial maintenance covenant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s indentures. In connection therewith, Bausch + Lomb and its subsidiaries, are now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the relevant Bausch Health indentures, and the earnings and debt of Bausch + Lomb, as defined in the relevant indentures, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company was in compliance with the financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast for the next twelve months from the date of issuance of this Form 10-K, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations over that same period. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to seek to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes and Secured Notes are guaranteed by a portion of the Company&#8217;s subsidiaries. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $12,800&#160;million and $2,161&#160;million and total liabilities of $5,401&#160;million and $942&#160;million as of December&#160;31, 2022 and 2021, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had revenues of $4,164 million and $1,755&#160;million for 2022 and 2021, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had operating income of $114&#160;million and $116&#160;million for 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for the Exchange Offer results in the New Secured Notes being carried at a premium relative to their principal amount and will result in no interest expense being recorded in our financial statements for a significant portion of the New Secured Notes. Therefore, interest expense recorded in our consolidated financial statements will differ significantly from the contractual interest rates of the New Secured Notes and term loan facilities. The weighted average interest rate of our debt as reported in our financial statements and the weighted average stated rate of interest was 6.13% and 7.74%, respectively, as of December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company&#8217;s outstanding debt as of December 31, 2021 was 5.88%. The increase in the weighted average stated rate of interest of 186 bps is due to the issuance of the New Secured Notes in connection with the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and it continues to be a primary objective of our plan of separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;23, 2023, the credit ratings and outlook from Moody&#8217;s, Standard &amp; Poor&#8217;s and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:15.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Positive</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No Outlook</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rating Watch Evolving</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Companies Inc. -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2022, Moody&#8217;s downgraded all ratings to: a corporate rating of Caa2, a senior secured rating of Caa1 and a senior unsecured rating of Ca. On October 4, 2022, S&amp;P lowered its senior secured rating to B-. On October 6, 2022, Fitch downgraded all ratings to: a corporate rating of CCC, a senior secured rating of B and a senior unsecured rating of CC. These downgrades were a result of the Exchange Offer (see Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Corporation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- During December 2022, S&amp;P upgraded these ratings one notch from CCC+ to B-, as a result of BHC designating Bausch + Lomb as an unrestricted subsidiary under the BHC Credit Agreement and the BHC Indentures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration, separation and IPO costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We are considering further acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of December&#160;31, 2022, we expect our primary cash requirements for 2023 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:line-through">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments and interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on our debt portfolio, we expect to make mandatory amortization and interest payments of $1,649&#160;million during 2023. We have and, in the future, may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $275&#160;million for property, plant and equipment during 2023;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As previously discussed, we filed an NDA for NOV03 with the FDA in June 2022. If approved, we anticipate launching NOV03 in the U.S. in the second half of 2023, upon which we expect to make a payment of $45 million in 2023, under the terms of a December 2019 agreement with Novaliq GmbH, related to the future sales associated with NOV03.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development/approval/sales-based milestone payments of approximately $112&#160;million during 2023;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $8&#160;million during 2023. See Note 11, &#8220;PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&#8221; to our audited Consolidated Financial Statements for further details of our benefit obligations; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred costs associated with activities to complete the B+L Separation and the suspended Solta IPO and will continue to incur costs associated with the B+L Separation. These activities include the costs of: (i) separating Bausch + Lomb businesses from the remainder of the Company and (ii) registering Bausch + Lomb as an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for Bausch + Lomb. The Company has also incurred, and will incur, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation. These costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. During 2022, we made $1,572&#160;million in payments of accrued legal settlements including payments related to the Securities Class Action Settlement, the Glumetza Antitrust Litigation and a RICO class action matter. As of December 31, 2022, the Company&#8217;s Consolidated Balance Sheet includes accrued loss contingencies of $326&#160;million related to matters which are both probable and reasonably estimable, however, a reliable estimate of the period in which the remaining loss contingencies will be payable, if&#160;ever, cannot be made. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had unrecognized tax benefits totaling $4 million which are expected to be realized within the next twelve months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Repurchases of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, we may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_220"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on the TSX and the NYSE under the ticker symbol&#160;&#8220;BHC&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At February&#160;17, 2023, we had 362,037,191 issued and outstanding common shares. In addition, as of February&#160;17, 2023, we had 10,688,071 stock options and 8,868,404 time-based restricted share units (&#8220;RSUs&#8221;) that each represent the right of a holder to receive one of the Company&#8217;s common shares and 1,467,680 performance-based RSUs that represent the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. A maximum of 1,100,234 common shares could be issued upon vesting of the performance-based RSUs outstanding.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_223"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and financial results are affected by fluctuations in world financial markets, including the impacts of foreign currency exchange rate and interest rate movements. We evaluate our exposure to such risks on an ongoing basis and seek ways to manage these risks to an acceptable level, based on management&#8217;s judgment of the appropriate trade-off between risk, opportunity and cost. We may use derivative financial instruments from time to time as a risk management tool and not for trading or speculative purposes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation; Seasonality </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we now operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some&#160;markets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, revenues from our business tend to be weighted toward the second half of the year. Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.&#160;Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs. However, there are no assurances that these historical trends will continue in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, a majority of our revenue and expense activities and capital expenditures were denominated in U.S.&#160;dollars.&#160;We have exposure to multiple foreign currencies, including, among others, the Euro, Chinese yuan, Polish zloty, Canadian dollar and Mexican peso. Our operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls and fluctuations in the relative values of currencies. In addition, to the extent that we require, as a source of debt repayment, earnings and cash flows from some of our operations located in foreign countries, we are subject to risk of changes in the value of the U.S.&#160;dollar, relative to all other currencies in which we operate, which may materially affect our results of operations. Where possible, we manage foreign currency risk by managing same currency revenues in relation to same currency expenses. Further strengthening of the U.S. dollar and/or further devaluation of foreign currencies will have a negative impact on our reported revenue and reported results. As of December 31, 2022, a 1% change in foreign currency exchange rates would have impacted our shareholders&#8217; deficit by approximately $39&#160;million.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the unrealized foreign exchange loss on the translation of the remaining principal amount of U.S. denominated credit facility, senior secured and unsecured notes was $585&#160;million, for Canadian income tax purposes. Additionally, as of December&#160;31, 2022, the unrealized foreign exchange gain on certain intercompany balances was equal to $207&#160;million. One-half of any realized foreign exchange gain or loss will be included in our Canadian taxable income. Any resulting gain will result in a corresponding reduction in our available Canadian Losses, Scientific Research and Experimental Development Pool, and/or Investment Tax Credit carryforward balances. However, the repayment of the credit facility, senior notes and the intercompany loans denominated in U.S. dollars does not result in a foreign exchange gain or loss being recognized in our Consolidated Financial Statements, as these statements are prepared in U.S. dollars.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not hold financial instruments for speculative purposes. Our financial assets are not subject to significant interest rate risk due to their short duration. The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and accordingly, we generally invest in high quality, money market investments and time deposits with varying maturities, but typically less than three months. As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate&#160;risk. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $13,715 million and $5,395&#160;million principal amount of issued fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of December&#160;31, 2022 was $9,317&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $323&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $332&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates, would have an annualized pre-tax effect of approximately $54&#160;million in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_226"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgments due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. We base our estimates on historical experience and other factors that we believe to be reasonable under the circumstances. On an ongoing basis, we review our estimates to ensure that these estimates appropriately reflect changes in our business and new information as it becomes available. If historical experience and other factors we use to make these estimates do not reasonably reflect future activity, our results of operations and financial condition could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, GI and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and application of the critical accounting policies associated with the revenue recognition guidance, including the policies associated with each of our product sales provisions and the table showing the activity and ending balances for our product sales provisions, are discussed in more detail in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the business combinations that we have consummated include contingent consideration to be potentially paid based upon the occurrence of future events, such as sales performance and the achievement of certain future development, regulatory and sales milestones. Acquisition-related contingent consideration associated with a business combination is initially recognized at fair value and remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The estimates of fair value involve the use of acceptable valuation methods, such as probability-weighted discounted cash flow analysis and Monte Carlo Simulation (when appropriate), and contain uncertainties as they require assumptions about the likelihood of achieving specified milestone criteria, projections of future financial performance and assumed discount rates. Changes in the fair value of the acquisition-related contingent consideration result from several factors including changes in the timing and amount of revenue estimates, changes in probability assumptions with respect to the likelihood of achieving specified milestone criteria and changes in discount rates. A change in any of these assumptions could produce a different fair value, which could have a material impact on our results of&#160;operations. At December&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate potential impairments of amortizable intangible assets acquired through asset acquisitions or business combinations if events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable. Our evaluation is based on an assessment of potential indicators of impairment, such&#160;as:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in legal factors or in the business climate that could affect the value of an asset. For example, a successful challenge of our patent rights resulting in earlier than expected generic competition;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in the extent or manner in which an asset is used or is expected to be used. For example, a decision not to pursue a product line-extension strategy to enhance an existing product due to changes in market conditions and/or technological advances;&#160;or</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">current or forecasted reductions in revenue, operating income, or cash flows associated with the use of an asset. For example, the introduction of a competing product that results in a significant loss of market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment exists when the carrying value of the asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If impairment exists, the carrying value of the asset is adjusted to its fair value. A discounted cash flow analysis is typically used to determine an asset&#8217;s fair value, using estimates and assumptions that market participants would apply. Some of the estimates and assumptions inherent in a discounted cash flow model include the amount and timing of the projected future cash flows, and the discount rate used to reflect the risks inherent in the future cash flows. A change in any of these estimates and assumptions could produce a different fair value, which could have a material impact on our results of operations. In addition, an intangible asset&#8217;s expected useful life can increase estimation risk, as longer-lived assets necessarily require longer-term cash flow forecasts, which for some of our intangible assets can be up to 20&#160;years. In connection with an impairment evaluation, we also reassess the remaining useful life of the intangible asset and modify it, as&#160;appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives of the Company&#8217;s long-lived assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, including Acquired in-process research and development and the B&amp;L corporate trademark, are tested for impairment annually, or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. In particular, we will continue to monitor closely the progression of our R&amp;D programs as their likelihood of success is contingent upon the achievement of future milestones. See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Business&#8221; for additional information regarding our R&amp;D&#160;programs.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years 2022, 2021 and 2020, we recorded goodwill impairment charges of $824 million, $469 million and $0, respectively. As of December 31, 2022, we maintain 10 reporting units, eight of which comprise our goodwill balance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test our reporting units for impairment annually as of October 1, or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Such events and circumstances could include increased competition and unexpected loss of market share, increased input costs relative to our projections (for example due to regulatory or industry changes), disposals of significant products or components of our business, unexpected business disruptions (for example due to a natural disaster, pandemic, unexpected changes in the regulatory environment, unexpected loss of exclusivity to a significant product, loss of a supplier, or other significant business relationship), unexpected significant declines in operating results, significant adverse changes in the markets in which we operate, or changes in management strategy. During our assessment, we consider each of the above potential events and circumstances, as well as the existence of any positive and/or mitigating events and circumstances, including the difference between a reporting unit&#8217;s fair value and carrying amount if determined in a recent fair value calculation (&#8220;headroom&#8221;), giving more weight to those events and circumstances that impact most significantly a reporting unit&#8217;s fair value or carrying amount. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test reporting units for impairment by comparing the estimated fair value of each reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its estimated fair value, we record an impairment based on the difference between the fair value and carrying amount the reporting units as a reduction to goodwill. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions, estimates, and market factors. Estimating the fair value of individual reporting units requires us to make assumptions and estimates regarding our business strategies, as well as industry, economic, and regulatory conditions. These assumptions and estimates include estimated future annual net cash flows, income tax considerations, discount rates, growth rates and other market factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we performed interim impairment assessments of our Ortho Dermatologics reporting unit within the Diversified Products segment, our Salix reporting unit, and our Vision Care, Surgical and Ophthalmic reporting units within the Bausch + Lomb segment. Our annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit within the Diversified Products segment, as well as the Vision Care, Surgical and Ophthalmic reporting units within the Bausch + Lomb segment. For our remaining reporting units, we conducted our annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on our qualitative assessment as of October 1, 2022, management believed that it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our 2021 annual testing, we determined that the Ortho Dermatologics reporting unit had approximately 10% headroom as of October 1, 2021. Given its limited headroom, we continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit during each quarterly reporting period and performed quantitative fair value testing as of March 31, 2022, June 30, 2022 and September 30, 2022. The quantitative fair value tests utilized our most recent cash flow projections for the Ortho Dermatologics reporting unit as revised at each testing date to reflect current market conditions and current trends in business performance. Our discounted cash flow models for the reporting unit also considered among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. As a result of these market conditions, trends in business performance, the revisions to our long-term expectations and other factors, our Ortho Dermatologics reporting unit was impaired during our interim testing reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed no impairment was identified during the three months ended March 31, 2022, however goodwill impairments of $83 million and $119 million were recorded during the three months ended June 30, 2022 and September 30, 2022, respectively. As a result, there was zero headroom in the Ortho Dermatologics reporting unit as of September 30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, we evaluated the reporting unit&#8217;s performance as well as our revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, we concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. As a result, no facts or circumstances were identified which indicate that additional fair value quantitative testing during the period October 1, 2022 through December 31, 2022 was necessary. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paragraph IV Proceedings&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details of this litigation matter and our response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately 80% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues we performed a quantitative fair value test as of September 30, 2022. Our quantitative fair value test used a probability-weighted discounted cash flow analysis, with a base case representing the our most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. We assigned a probability weighting to each scenario reflecting our best estimate of likelihood of the outcome and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. Under our probability-weighted valuation model the carrying value of the Salix reporting unit was less than its fair value and therefore no impairment was recorded as of September 30, 2022. However, as our probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, the headroom for the Salix reporting was less than 5%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given its limited headroom, we continued to monitor market conditions affecting the Salix reporting unit, as well as any developments in the Norwich Legal Decision. Through December 31, 2022, there were no material developments in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to January 2028, if they are able to launch one at all. During the fourth quarter of 2022, we evaluated the reporting unit&#8217;s performance as well as our revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported our previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. As a result, no facts or circumstances were identified which would indicate that additional fair value quantitative testing during the period October 1, 2022 through December 31, 2022 was necessary. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurology and Other</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands (such as pharmaceutical market access and contractual pricing), health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. This includes recent changes related to pharmaceutical pricing by the Federal government, including the passage of the Inflation Reduction Act (IRA) in August 2022 and, effective in 2024, changes to Medicaid rebate caps (passed as part of the American Rescue Plan Act of 2021). The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature more directly impacted by these changing market dynamics, creating increased pressure on the reporting unit&#8217;s long-term financial performance. In response to these pressures, as well as to consider current market conditions and anticipated increased competition from new market entrants in 2023, we have begun taking steps to: (i) reassess our pricing strategies, (ii) re-evaluate our marketing and promotional efforts and (iii) reduce our cost structure, and we have revised our long-term forecasts for the Neurology and Other reporting unit to reflect these developments. As a result of the revisions to our long-term expectations for these and other factors, goodwill for our Neurology and Other reporting unit was impaired during our most recent annual impairment test reflecting our best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value testing performed as October 1, 2022, a $622 million impairment to the goodwill of the Neurology and Other reporting unit was recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment as of October 1, 2022 utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. After completing </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the testing, the fair value of each of these reporting units had headroom in excess of 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period October 1, 2022 through December 31, 2022, we continued to monitor the market conditions and trends in business performance for all our reporting units, including the Salix, Neurology and Other and Ortho Dermatologics reporting units, as discussed above. We determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value as of December 31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units that were impaired were written down to their respective fair values resulting in zero headroom as of the applicable impairment test dates. Accordingly, these reporting units and others that have 10% or less excess fair value over carrying amount have a heightened risk of future impairments if any assumptions, estimates, or market factors change in the future. Any such impairment could be material to our results of operations in the period in which it was to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market factors outside of our control, which could result in future impairment to our reporting units, include but are not limited to: additional government-mandated pricing actions, higher than expected inflation, continued interest rate pressures, changes in medical reimbursements by third-party payors, additional unforeseen market entrants, unforeseen loss or exclusivity to significant products, changes in foreign currency exchange rates, the resurgence of COVID-19 or additional variants, unforeseen challenges to our patents including the ultimate outcome to the Norwich Legal Decision, geopolitical factors, changes in tax legislation and other significant adverse changes in the markets in which we operate. Additionally, factors such as our inability to successfully execute our business strategies, failure to attain our assumed growth rates and margins or should we decide to divest certain non-strategic assets could lead to the impairment of one or more of our reporting units in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined above, our quantitative fair value testing procedures performed during the three months ended September 30, 2022 and as of October 1, 2022 represented in the aggregate, approximately $10,325 million, or 89% of our $11,547 million goodwill balance as of December 31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details on the goodwill impairments recognized in 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Other than loss contingencies that are assumed in business combinations for which we can reliably estimate the fair value, we are required to accrue for such loss contingencies if it is probable that the outcome will be unfavorable and if the amount of the loss can be reasonably estimated. We evaluate our exposure to loss based on the progress of each contingency, experience in similar contingencies and consultation with our legal counsel. We re-evaluate all contingencies as additional information becomes available. Given the uncertainties inherent in complex litigation and other contingencies, these evaluations can involve significant judgment about future events. The ultimate outcome of any litigation or other contingency may be material to our results of operations, financial condition and cash flows. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding our current legal proceedings. If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in various countries that have differing tax laws and rates. Our tax structure is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign tax authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned under our intercompany arrangements among the different jurisdictions in which we operate, changes in tax laws in these jurisdictions, changes in tax treaties between various countries in which we operate, changes in our eligibility for benefits under those tax treaties and changes in the estimated values of deferred tax assets and liabilities. Such changes could result in an increase in the effective tax rate on all or a portion of our income and/or any of our subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is based on a number of estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of income earned in our various operating jurisdictions, the availability of benefits under tax treaties and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in which the tax treatment is not entirely certain. We must therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than has been provided for by us. The final outcome of any audits by taxation </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities may differ from the estimates and assumptions we have used in determining our consolidated income tax provisions and accruals. This could result in a material effect on our consolidated income tax provision, results of operations, and financial condition for the period in which such determinations are&#160;made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit in various jurisdictions. Existing and future audits by, or other disputes with, tax authorities may not be resolved favorably for us and could have a material adverse effect on our reported effective tax rate and after-tax cash flows. We record liabilities for uncertain tax positions, which involve significant management judgment. New laws and new interpretations of laws and rulings by tax authorities may affect the liability for uncertain tax positions. Due to the subjectivity and complex nature of the underlying issues, actual payments or assessments may differ from our estimates. To the extent that our estimates differ from amounts eventually assessed and paid our income and cash flows may be materially and adversely affected.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether it is more likely than not that we will realize the tax benefits associated with our deferred tax assets and establish a valuation allowance for assets that are not expected to result in a realized tax benefit. A significant amount of judgment is used in this process, including preparation of forecasts of future taxable income and evaluation of tax planning initiatives. If we revise these forecasts or determine that certain planning events will not occur, an adjustment to the valuation allowance will be made to tax expense in the period such determination is&#160;made.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_229"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the recently issued new accounting guidance (adopted and not adopted as of December 31, 2022) is contained in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_232"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for 2023 and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in the 2022 Amended Credit Agreement, and senior notes indentures; the ability of our subsidiary, Bausch + Lomb, to comply with the financial and other covenants contained in the B+L Credit Agreement; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the anticipated impact from the ongoing conflict between Russia and Ukraine; and the Company&#8217;s plan to separate its eye- health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. All of the, statements in this Form&#160;10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse impact on our business and operations resulting from the current conflict between Russia and Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition, costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the B+L IPO, including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the Company&#8217;s B+L Separation, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the B+L Separation, the expected timing of completion of the B+L Separation and its terms, the Company&#8217;s ability to complete the B+L Separation considering the various conditions to the completion of the B+L Separation (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and applicable shareholder and stock exchange approvals), that market or other conditions are no longer favorable to completing the B+L Separation, that the previously announced planned Solta IPO has been suspended, that the Norwich Legal Decision (see &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paragraph IV Proceedings&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements) may affect the timing of, or our ability to complete the B+L Separation, that applicable shareholder, stock exchange, regulatory or other approvals are not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the B+L Separation, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the B+L Separation (some of which are beyond their control), limitations on the Company&#8217;s ability to sell a portion of the Company&#8217;s interest in Bausch + Lomb in order to maintain the tax-free status of the B+L Separation (including due to dilution from B+L&#8217;s issuance of share-based compensation awards), other potential tax or other liabilities that may arise as a result of the B+L Separation, the potential dissynergy costs resulting from the B+L Separation, the impact of the B+L Separation on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any B+L Separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the B+L Separation and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action and certain opt-out actions in Canada relating to the previously settled class action in </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2023 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, the 2027 Revolving Credit Facility, the 2022 Amended Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements, including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Amended Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2023 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in the 2022 Amended Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2022 Amended Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our eligibility for benefits under tax treaties and the availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions, including rates of inflation, and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith) and the impact of the Norwich Legal Decision on, among other things, our business results, financial results, and the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in the Company&#8217;s lawsuit against Norwich in connection with Norwich&#8217;s ANDA and challenge Norwich&#8217;s ability to achieve a modified ANDA that avoids the August 10, 2022 final judgement by the District Court and omits the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hepatic encephalopathy (&#8220;HE&#8221;) indication and HE safety data;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that a substantial amount of our revenues are derived from the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, and that we may be materially impacted by the entry of a generic rifaximin product earlier than January 2028, including the risk of a competitor launching a generic rifaximin at risk prior to a final unappealable decision;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the current administration;</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any plans for the Company&#8217;s aesthetic medical business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. &#8220;Risk Factors&#8221; and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-K or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to quantitative and qualitative disclosures about market risk is detailed in Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;&#8212;&#160;Quantitative and Qualitative Disclosures About Market Risk&#8221; and is incorporated herein by&#160;reference.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_238"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is contained in the financial statements set forth in Item&#160;15. &#8220;Exhibits and Financial Statement Schedules&#8221; as part of this Form&#160;10-K and&#160;is incorporated herein by&#160;reference.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_241"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_244"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;Controls and&#160;Procedures </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of December&#160;31, 2022. Based on that evaluation, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer have concluded that as of December&#160;31, 2022, the Company&#8217;s disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f) and&#160;15d-15(f) under the Exchange Act. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of management, including the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer, the Company conducted an evaluation of the effectiveness of its internal control over financial reporting as of December&#160;31, 2022 based on the framework described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, management has concluded that the Company maintained effective internal control over financial reporting as of December&#160;31, 2022.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in the Company&#8217;s internal control over financial reporting (as&#160;such term is defined in Rules&#160;13a-15(f) and&#160;15d-15(f) under the Exchange Act) during the last fiscal quarter of 2022 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_247"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2023, the Talent and Compensation Committee of the Board of Directors of the Company (the &#8220;Committee&#8221;) approved changes to the compensation of Thomas J. Appio, the Company&#8217;s Chief Executive Officer, based on a review of market data and Mr. Appio&#8217;s performance. The Committee increased Mr. Appio&#8217;s annual base salary to $1,200,000 effective February 25, 2023 and his target annual cash bonus opportunity to 125% of his base salary commencing with his 2023 bonus.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Committee also determined that Mr. Appio&#8217;s annual aggregate target equity incentive compensation opportunity will be set at $11,000,000 commencing with annual equity awards to be made in 2023. For 2023, Mr. Appio&#8217;s annual equity award will be granted in the form of performance share units (subject to achievement of performance-based vesting conditions) and service-based restricted stock units. This amount reflects only the target value of Mr. Appio&#8217;s annual equity incentive awards; the actual value that may be realized by Mr. Appio in connection with these equity incentive awards will depend on the level of achievement of the applicable performance goals and satisfaction of the applicable service-vesting conditions. </span></div><div id="i57fbe32677504c888f142dd82b99b37f_250"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i57fbe32677504c888f142dd82b99b37f_256"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item is incorporated herein by reference from information included in the 2023 Proxy Statement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a code of ethics (the &#8220;Code of Conduct&#8221;) that applies to our employees, including the Chief Executive Officer, Chief Financial Officer, the principal accounting officer, controller, and all vice presidents and above in the finance department of the Company worldwide. A copy of the Code of Conduct can be found on our website at: </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.bauschhealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to satisfy the SEC disclosure requirements regarding amendments to, or waivers from, any provisions of our Code of Conduct on our&#160;website.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_259"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to executive compensation is incorporated herein by reference from information included in the 2023 Proxy Statement.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_262"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to securities authorized for issuance under equity compensation plans and to security ownership of certain beneficial owners and management is incorporated herein by reference from information included in the 2023 Proxy Statement.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_265"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to certain relationships and transactions with related parties and about director independence is incorporated herein by reference from information included in the 2023 Proxy Statement.</span></div><div id="i57fbe32677504c888f142dd82b99b37f_268"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required under this Item relating to the fees for professional services rendered by our independent auditors in 2022 and 2021 is incorporated herein by reference from information included in the 2023 Proxy Statement.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i57fbe32677504c888f142dd82b99b37f_274"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Documents filed as a part of the report:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The consolidated financial statements required to be filed in the Annual Report on Form&#160;10-K are listed on page F-1 hereof.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable, or the required information is included in the financial statements or notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex31.htm">Certificate of Continuation, dated August&#160;9, 2013, originally filed as Exhibit 3.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex31.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex31.htm">s Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex32.htm">Notice of Articles of Valeant Pharmaceuticals International, Inc., dated August 9, 2013, originally filed as Exhibit 3.2 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex32.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex32.htm">s Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex33.htm">Articles of Valeant Pharmaceuticals International, Inc., dated August 8, 2013, originally filed as Exhibit 3.3 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex33.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312513331879/d583672dex33.htm">s Current Report on Form 8-K filed on August 13, 2013, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0301.htm">Notice of Articles of Bausch Health Companies Inc., as of July 16, 2018, originally filed as Exhibit 3.1 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0301.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0301.htm">s Current Report on Form 8-K filed on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0302.htm">Articles of Bausch Health Companies Inc., as of July 13, 2018, originally filed as Exhibit 3.2 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0302.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0302.htm">s Current Report on Form 8-K filed on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010317002656/dp74230_ex401.htm">Indenture, dated as of March 21, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto, governing the 6.500% Senior Secured Notes due 2022 and the 7.000% Senior Secured Notes due 2024, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on March 21, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517311840/d213139dex41.htm">Indenture, dated as of October&#160;17, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee and the notes collateral agents party thereto, governing the 5.500% Senior Secured Notes due 2025, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on October 17, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312517372069/d513316dex41.htm">Indenture, dated as of December 18, 2017, by and among Valeant Pharmaceuticals International, Inc., the guarantors party thereto and The Bank of New York Mellon, as trustee, governing the 9.000% Senior Notes due 2025, originally filed as Exhibit&#160;4.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on December 18, 2017, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000020/a90716981v2-valeantxindent.htm">Indenture, dated as of March 26, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., the other guarantors party thereto and The Bank of New York Mellon, as trustee, governing the 9.250% Senior Secured Notes due 2026, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 27, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex41.htm">Indenture, dated as of June 1, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals international, Inc., the other guarantors party thereto and The Bank of New York Mellon, as trustee, governing the 8.500% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 1, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519069218/d717351dex41.htm">Indenture, dated as of March 8, 2019, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon Trust Company, N.A., as trustee, and the notes collateral agents party thereto, governing the 5.750% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 8, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519155605/d746123dex41.htm">Indenture, dated as of May 23, 2019, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 7.000% Senior Notes due 2028 and the 7.250% Senior Notes due 2029, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on May 24, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312519326023/d851034dex41.htm">Indenture, dated as of December 30, 2019, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 5.000% Senior Notes due 2028 and the 5.250% Senior Notes due 2030, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312520151620/d892097dex41.htm">Indenture, dated as of May 26, 2020, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon Trust Company, N.A., as trustee, governing the 6.250% Senior Notes due 2029, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on May 26, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312520309615/d73841dex41.htm">Indenture, dated as of December 3, 2020, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon, N.A., as trustee, governing the 5.000% Senior Notes due 2029 and the 5.250% Senior Notes due 2031, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on December 3, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312521185432/d186085dex41.htm">Indenture, dated as of June 8, 2021, by and among Bausch Health Companies Inc., the guarantors named therein and The Bank of New York Mellon, N.A., as trustee, governing the 4.875% Senior Notes due 2028, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 8, 2021, which is incorporated by reference herein.</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522034549/d293207dex41.htm">Indenture, dated as of February 10, 2022, by and among Bausch Health Companies Inc., the guarantors named therein, The Bank of New York Mellon, N.A., as trustee and the notes collateral agents party thereto, governing the 6.125% Senior Secured Notes due 2027, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on February 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex41.htm">Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, governing the 11.00% Senior Secured Notes due 2028, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex42.htm">Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, governing the 14.00% Senior Secured Notes due 2030, originally filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex43.htm">Indenture, dated as of September 30, 2022, by and among 1375209 B.C. Ltd., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, as notes collateral agent, governing the 9.00% Senior Secured Notes due 2028, originally filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0401.htm">Form of Common Share Certificate of Bausch Health Companies Inc., originally filed as Exhibit 4.1 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0401.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000095010318008539/dp93294_ex0401.htm">s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 16, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit4122019ye.htm">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended, originally filed as Exhibit 4.12 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed on February 19, 2020, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit104supplementalinde.htm">Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of March 26, 2018 relating to the BHA</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit104supplementalinde.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit104supplementalinde.htm">s 9.250% Senior Notes due 2026, originally filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit108supplementalinde.htm">Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. (&#8220;BHA&#8221;) and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of June 1, 2018 relating to the BHA&#8217;s 8.500% Senior Notes due 2027, originally filed as 10.5 to the Company&#8217;s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit106supplementalinde.htm">Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company&#8217;s 7.000% Senior Notes due 2028, originally filed as 10.6 to the Company&#8217;s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit107supplementalinde.htm">Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of December 30, 2019 relating to the Company&#8217;s 5.000% Senior Notes due 2028, originally filed as 10.7 to the Company&#8217;s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000061/exhibit105supplementalinde.htm">Fifteenth Supplemental Indenture, dated as of September 28, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company&#8217;s 7.250% Senior Notes due 2029, originally filed as 10.8 to the Company&#8217;s Current Report on Form 10-Q filed on November 3, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of April 28, 2020 (the "Amended and Restated 2014 Omnibus Incentive Plan"), originally filed as Exhibit 10.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit1012020ye.htm">s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on February 24, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000047/exhibit104msuagreement.htm">Form of Matching Restricted Stock Unit Agreement (Matching Units) under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed on August 7, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit103.htm">Form of 2016 Stock Option Grant Agreement under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 6, 2019, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit103xstocko.htm">Form of Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit106xdirect.htm">Form of Director Restricted Share Units Award Agreement (Annual Grants), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.6 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein. &#8224;</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1017.htm">Form of Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2016 filed on March 1, 2017, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1011xformo.htm">Form of 2018 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000025/exhibit1013formofrsugranta.htm">Form of RSU Grant Agreement, originally filed as Exhibit 10.13 to the Company&#8217;s Current Report on Form 10-Q filed on May 10, 2022, which is incorporated by reference herein. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000025/exhibit1013formofrsugranta.htm">&#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1012xformo.htm">Form of 2018 Restricted Stock Unit Agreement, under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.12 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000025/exhibit1014formofoptiongra.htm">Form of Option Grant Agreement, originally filed as Exhibit 10.14 to the Company&#8217;s Current Report on Form 10-Q filed on May 10, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559018000017/a10k2017-exhibit1013xformo.htm">Form of 2018 Stock Option Grant Agreement (Nonstatutory Stock Options), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed on February 28, 2018, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000030/exhibit102q12021.htm">Form of 2021 Share Unit Grant Agreement (Performance Vesting) (Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 filed on May 4, 2021, which is incorporated by reference herein.&#8224; </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000055/exhibit101-formof2021share.htm">Form of 2021 Share Unit Grant Agreement (TSR Performance Restricted Share Units), under the Amended and Restated 2014 Omnibus Incentive Plan, originally filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed on November 2, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">Valeant Pharmaceuticals International,&#160;Inc.&#160;2011 Omnibus Incentive Plan (the &#8220;2011&#160;Omnibus Incentive Plan&#8221;), effective as of April&#160;6, 2011, as amended on and approved by the shareholders on May&#160;16, 2011, originally filed as Annex&#160;A to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">s Management Proxy Circular and Proxy Statement on Schedule&#160;14A filed on April&#160;14, 2011, as amended by the Supplement dated May&#160;10, 2011 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100411001049/defa14a.htm">s Management Proxy Circular and Proxy Statement filed on May&#160;10, 2011, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522136867/d296110ddef14a.htm#tx296110_38">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of June 21, 2022, originally filed as Exhibit B to the Company&#8217;s definitive proxy statement (File No. 001-14956) filed on May 2, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746912001906/a2207517zex-10_2.htm">Form of Stock Option Grant Agreement under the 2011 Omnibus Incentive Plan, originally filed as Exhibit&#160;10.2 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746912001906/a2207517zex-10_2.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746912001906/a2207517zex-10_2.htm">s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2011 filed on February 28, 2012, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">Form of Spinoff Bonus Program Letter Agreement dated November 2, 2020, originally filed as Exhibit 10.14 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000011/exhibit10142020ye.htm">s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed on February 24, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746911007046/a2205082zex-10_6.htm">Valeant Pharmaceuticals International,&#160;Inc. Directors Share Unit Plan, effective May&#160;16, 2011, originally filed as Exhibit&#160;10.6 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746911007046/a2205082zex-10_6.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000104746911007046/a2205082zex-10_6.htm">s Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June&#160;30, 2011 filed on August 8, 2011, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">Employment Agreement, dated as of April 25, 2016, between Valeant Pharmaceuticals International, Inc. and Joseph C. Papa, originally filed as Exhibit&#160;10.1 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000134100416001356/ex-agmt.htm">s Current Report on Form&#160;8-K filed on April 27, 2016, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559017000015/d343902dex1023.htm">Employment Agreement, dated July 8, 2016, between Valeant Pharmaceuticals International, Inc. and Christina Ackermann, originally filed as Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2016 filed on March 1, 2017, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000010/exhibit10202021ye.htm">Amended and Restated Employment Agreement, dated February 18, 2022, between Bausch Health Companies Inc. and Thomas Appio, originally filed as Exhibit 10.20 on the Company&#8217;s Annual Report on Form 10-K filed on February 23, 2022, which is incorporated by reference herein. &#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000017/a10qq12019-exhibit102.htm">Employment Agreement, dated August 2, 2018, between Bausch Health Companies Inc. and Joseph F. Gordon, originally filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 6, 2019, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000039/exhibit107bauschpharmacfoe.htm">Employment Agreement, dated as of October 20, 2021, by and between Bausch Health Companies Inc. and Tom Vadaketh, originally filed as 10.7 to the Company&#8217;s Current Report on Form 10-Q filed on August 9, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559022000039/exhibit108bauschpharmagcem.htm">Employment Agreement, dated as of December 3, 2021, by and between Bausch Health Companies Inc. and Seana Carson, originally filed as 10.8 to the Company&#8217;s Current Report on Form 10-Q filed on August 9, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000041/exhibit101q22021.htm">Employment Agreement, dated as of June 1, 2021, between Bausch Health Companies Inc. and Sam Eldessouky, originally filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 filed on August 3, 2021, which is incorporated by reference herein.&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518335247/d595829dex101.htm">First Incremental Amendment, dated as of November 27, 2018, to the Fourth Amended and Restated Credit and Guaranty Agreement, by and among Bausch Health Companies Inc., Valeant Pharmaceuticals International, certain subsidiaries of Bausch Health Companies Inc. as guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit&#160;10.1 to&#160;the Company&#8217;s Current Report on Form&#160;8-K filed on November 27, 2018, which is incorporated by reference herein and which First Incremental Amendment appends, as an exhibit thereto, a copy of such Fourth Amended and Restated Credit and Guaranty Agreement, as amended to date.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522146413/d298928dex101.htm">Second Amendment to the Fourth Amended &amp; Restated Credit and Guaranty Agreement, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522146413/d298928dex102.htm">Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522146413/d298928dex102.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10252018ye.htm">Amended and Restated Supply Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant Pharmaceuticals Luxembourg s.&#224; r.l. and Alfasigma S.p.A., originally filed as Exhibit 10.25 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1095.htm">Amended and Restated License Agreement dated August 6, 2012 by and between Alfa Wassermann S.p.A. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.95 to Salix Pharmaceutical Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex10100.htm">Letter Amendment dated September 5, 2012 by and between Alfa Wassermann S.p.A. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.100 to Salix Pharmaceutical Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10282018ye.htm">Amendment No. 2 to the Amended and Restated License Agreement dated October 25, 2018 among Salix Pharmaceuticals, Inc., Valeant Pharmaceuticals Ireland Limited, Valeant Pharmaceuticals Luxembourg s.&#224; r.l. and Alfasigma S.p.A., originally filed as Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1009356/000119312512459233/d402656dex1098.htm">Trademark License Agreement (Alfa to Salix) dated August 6, 2012 by and between Alfa Wassermann Hungary Kft. and Salix Pharmaceuticals, Inc., originally filed as Exhibit 10.98 to Salix Pharmaceutical Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed on November 8, 2012, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex101.htm">Restatement Agreement, dated as of June&#160;1, 2018, among Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, certain subsidiaries of Valeant Pharmaceuticals International, Inc. as guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to&#160;the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex101.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312518181925/d506785dex101.htm">s Current Report on Form 8-K filed on June 1, 2018, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10322018ye.htm">Amended and Restated Asset Purchase Agreement dated January 4, 2019 among Bausch Health Companies Inc., Bausch Health Ireland Limited, Synergy Pharmaceuticals Inc. and Synergy Advanced Pharmaceuticals, Inc., originally filed as Exhibit 10.32 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10322018ye.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559019000006/exhibit10322018ye.htm">s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed on February 20, 2019, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559020000006/exhibit10302019ye.htm">Stipulation of Settlement dated December 15, 2019 in the U.S. Securities Litigation, originally filed as Exhibit 10.30 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on February 19, 2020, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000088559021000008/ex101-q4x2020.htm">Director Nomination and Appointment Agreement, dated February 23, 2021, by and among Bausch Health Companies Inc., Carl C. Icahn and the persons and entities listed therein, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 24, 2021, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522125782/d283951dex991.htm">Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein. &#8224;#</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex991.htm">Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522125782/d283951dex992.htm">Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex992.htm">Transition Services Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex993.htm">Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522125782/d283951dex993.htm">Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex994.htm">Employee Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.4 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex995.htm">Intellectual Property Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.5 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex996.htm">Real Estate Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein &#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522090302/d338836dex997.htm">Registration Rights Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of March 30, 2022, originally filed as Exhibit 99.7 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2022, which is incorporated by reference herein #</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1860742/000119312522090313/d178785dex1010.htm">Loan Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of January 1, 2022, originally filed as Exhibit 10.10 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1860742/000119312522090313/d178785dex1018.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph Papa dated as of January 3, 2022, originally filed as Exhibit 10.18 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1860742/000119312522090313/d178785dex1019.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Sam A. Eldessouky dated as of January 3, 2022, originally filed as Exhibit 10.19 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1860742/000119312522090313/d178785dex1020.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Christina M. Ackermann dated as of January 3, 2022, originally filed as Exhibit 10.20 to Bausch + Lomb Corporation&#8217;s Registration on Statement Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1860742/000119312522090313/d178785dex1021.htm">Assignment, Assumption and Amendment Agreement between Bausch Health Companies Inc., Bausch + Lomb Corporation and Joseph F. Gordon dated as of January 3, 2022, originally filed as Exhibit 10.21 to Bausch + Lomb Corporation&#8217;s Registration Statement on Form S-1 filed on April 28, 2022, which is incorporated by reference herein. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2112022ye.htm">Subsidiaries of Bausch Health Companies Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2312022ye.htm">Consent of PricewaterhouseCoopers&#160;LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112022ye.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122022ye.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212022ye.htm">Certificate of the Chief Executive Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222022ye.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#    Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to Bausch Health Companies Inc. if publicly disclosed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;One or more exhibits or schedules to this exhibit have been omitted pursuant to Item&#160;601(a)(5) or Item&#160;601(b)(2) of Regulation&#160;S-K. We undertake to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon&#160;request.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_280"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES&#160;INC.<br/>(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;THOMAS J. APPIO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ THOMAS J. APPIO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ TOM G. VADAKETH</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom G. Vadaketh</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;JOHN S. BARRESI</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John S. Barresi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Controller and<br/>Chief Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;JOHN A. PAULSON</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Paulson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairperson of the Board, Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;RICHARD U. DE SCHUTTER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard U. De Schutter</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;BRETT ICAHN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett Icahn</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;ARGERIS N. KARABELAS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argeris N. Karabelas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;SARAH B. KAVANAGH</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarah B. Kavanagh</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;STEVEN D. MILLER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven D. Miller</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;RICHARD C. MULLIGAN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard C. Mulligan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;ROBERT N. POWER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert N. Power</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;RUSSEL C. ROBERTSON</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russel C. Robertson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;THOMAS W. ROSS, SR.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas W. Ross, Sr.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;AMY B. WECHSLER</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy B. Wechsler</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:92.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODMvZnJhZzpjMmVjZWVjNmZkOTk0MjM2YTNiMGY0ZDMzNGY3ZWY3Mi90YWJsZTo1Nzc0MzhkZjIxNTA0OGQ4OTNhMTU4MWE3MzAyYjUxMS90YWJsZXJhbmdlOjU3NzQzOGRmMjE1MDQ4ZDg5M2ExNTgxYTczMDJiNTExXzItMC0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTllNWZkOWQ3MjAxNDM1YmE5Yzg2YWY0NjkzYzg2YmFfNzE_1da03a03-9a32-4dde-b3cc-74e15211ef5a">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_289">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_289">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_295">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_295">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for the years ended December&#160;31, 2022, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_298">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_298">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_301">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_301">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2022, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_304">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_304">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_307">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_307">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_310">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i57fbe32677504c888f142dd82b99b37f_310">11</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Bausch Health Companies Inc.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Bausch Health Companies Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of operations, of comprehensive loss, of shareholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Rebates and Sales Returns Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. The provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue as a reduction in revenue. The variable consideration provisions, either recognized within accrued and other current liabilities or as a reduction of trade receivables, included $427 million related to returns allowances and $1,023 million related to rebates, including Medicaid rebates as of December 31, 2022. For certain rebate programs, such as Medicaid, provisions recognized by management are based on the terms of state government-managed programs, estimates of outstanding and future claims for end-customer sales and the sales mix. For sales returns, management estimates provisions utilizing existing return policies with customers, historical return and exchange levels, external data with respect to inventory levels in the distribution channel, external data with respect to prescription demand for products, remaining shelf lives of products at the date of sale, and estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to Medicaid rebates and sales returns allowances is a critical audit matter are (i) the significant judgment by management when developing the estimate of Medicaid rebates and sales returns allowances which is based on the terms of state government-managed Medicaid programs and existing return policies with customers; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating the terms of state government-managed Medicaid programs and existing return policies with customers and in evaluating management&#8217;s significant assumptions related to estimates of outstanding and future claims for end-customer sales; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s estimation of provisions for Medicaid rebates and sales returns allowances, including controls over the assumptions used to estimate these rebates and sales returns allowances. These procedures also included, among others (i) developing an independent estimate of Medicaid rebates by utilizing third-party information on inventory levels in the distribution channel, the terms of the specific Medicaid rebate programs, and the historical trends of actual Medicaid rebate claims paid, adjusted for price and projected market conditions; (ii) comparing the independent estimate for these Medicaid rebates to management&#8217;s estimates to evaluate the reasonableness of management&#8217;s estimate; (iii) testing management&#8217;s process for developing the estimate of sales returns allowances; (iv) evaluating the appropriateness of the method for estimating the sales returns allowances; (v) testing the completeness and accuracy of underlying data used in the estimate of sales returns allowances; (vi) evaluating the reasonableness of the sales returns allowances by considering current and historical return trends and whether assumptions related to estimates of outstanding and future claims for end-user sales were consistent with evidence obtained in other areas of the audit; and (vii) testing, on a sample basis, Medicaid rebates and sales returns claims processed by the Company, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s arrangements and policies. Professionals with specialized skill and knowledge were used to assist in evaluating whether the Company&#8217;s Medicaid rebate program policies and methodology for estimating Medicaid rebates are compliant with the Center for Medicare and Medicaid Services (CMS) and federal regulations.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Assessments &#8211; Ortho Dermatologics, Vision Care, Ophthalmic Pharmaceuticals, Surgical and Neurology and Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 8 to the consolidated financial statements, the Company&#8217;s goodwill balance was $11,547 million as of December 31, 2022, and the goodwill associated with the Ortho Dermatologics reporting unit, the Bausch + Lomb segment, and the Neurology and Other reporting unit was $480 million, $5,246 million, and $1,439 million, respectively. The Bausch + Lomb segment consists of the Vision Care, Ophthalmic Pharmaceuticals, and Surgical reporting units. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. Goodwill impairment is measured by the amount the carrying value exceeds the fair value. Fair value of each reporting unit is estimated by management using a discounted cash flow model. During the first, second and third quarters of 2022, increased interest rates and other macroeconomic factors suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying value, and therefore, quantitative fair value tests were performed, resulting in no impairment to goodwill as of March 31, 2022, and the recognition of goodwill impairments of $83 million and $119 million as of June 30, 2022 and September 30, 2022, respectively. In addition, during the second quarter of 2022, the equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors, and therefore, separate quantitative fair value tests were performed for the Vision Care, Ophthalmic Pharmaceuticals, and Surgical reporting units of the Bausch + Lomb segment, resulting in no impairment to goodwill as of June 30, 2022. During the annual goodwill impairment test as of October 1, 2022, management performed separate quantitative fair value tests for the Neurology and Other, Vision Care, Ophthalmic Pharmaceuticals, and Surgical reporting units. As a result of revisions to long-term expectations to reflect changes in payer demands, health care legislation, and other regulations for the Neurology and Other reporting unit, management determined goodwill was impaired and the Company recognized a goodwill impairment of $622 million for the Neurology and Other reporting unit. Utilizing the most recent cash flow projections to reflect current market conditions and current trends in business performance for the Vision Care, Ophthalmic Pharmaceuticals, and Surgical reporting units, management determined there was no impairment to goodwill. Management&#8217;s discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments of the Ortho Dermatologics, Vision Care, Ophthalmic Pharmaceuticals, Surgical, and Neurology and Other reporting units is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the reporting units; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to revenue growth rates, discount rates, and terminal growth rates; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s goodwill impairment assessments, including controls over the valuation of the Ortho Dermatologics, Vision Care, Ophthalmic Pharmaceuticals, Surgical, and Neurology and Other reporting units. These procedures also included, among others (i) testing management&#8217;s process for developing the fair value estimate of the Ortho Dermatologics, Vision Care, Ophthalmic Pharmaceuticals, Surgical, and Neurology and Other reporting units; (ii) evaluating the appropriateness of the discounted cash flow model; (iii) testing the completeness and accuracy of underlying data used in the discounted cash flow model; and (iv) evaluating the reasonableness of the significant assumptions used by management related to revenue growth rates, discount rates, and terminal growth rates. Evaluating management&#8217;s significant assumptions related to revenue growth rates involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting units; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company&#8217;s discounted cash flow model and (ii) the reasonableness of the discount rates and terminal growth rates significant assumptions. </span></div><div style="text-indent:-0.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Finite-Lived Intangible Assets and Goodwill Impairment Assessments - Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Finite-Lived Intangible Assets and Salix Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 8 to the consolidated financial statements, the Company&#8217;s finite-lived intangible assets associated with Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and goodwill associated with the Salix reporting unit was $2,693 million and $3,159 million, respectively, as of December 31, 2022. Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents approximately 80% of the Salix reporting unit&#8217;s revenue. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Both goodwill and finite-lived intangible assets are tested for impairment if events occur that indicate an impairment might be present. If indicators of impairment are present, impairment is measured by the amount the carrying value exceeds the fair value. During the third quarter of 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were invalid (the &#8220;Norwich Legal Decision&#8221;). The ultimate outcome of this decision and other potential future related developments could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, management performed an assessment of the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and the Salix reporting unit&#8217;s goodwill for potential impairment, resulting in no impairment as of September 30, 2022. Management performed the assessments of the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and Salix reporting unit using a probability-weighted undiscounted and discounted cash flow analyses, respectively. Management&#8217;s probability-weighted undiscounted and discounted cash flow analyses have a base case and different scenarios representing a range of different outcomes which address the timing of loss of exclusivity for Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Management assigned a probability weighting to each scenario and calculated a weighted average of the valuations </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derived from the undiscounted and discounted cash flows under each scenario. Management&#8217;s probability-weighted undiscounted cash flow analysis for valuing the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets also relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses, and research and development expenses. Management&#8217;s probability-weighted discounted cash flow analysis for valuing the Salix reporting unit also relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rate, discount rate and terminal growth rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the interim finite-lived intangible assets and goodwill impairment assessments of the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and Salix reporting unit is a critical audit matter are (i) the significant judgment by management when developing the undiscounted cash flows associated with the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and when developing the fair value of the Salix reporting unit; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating the probability weighting assigned to each scenario to address the estimated timing of the potential loss of exclusivity for the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product and in evaluating management&#8217;s significant assumptions related to revenue growth rates used in developing the undiscounted cash flows for the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and fair value of the Salix reporting unit and the discount rate and terminal growth rate used in developing the fair value of the Salix reporting unit; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s finite-lived intangible assets and goodwill impairment assessments, including controls over the valuation of the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and Salix reporting unit. These procedures also included, among others (i) testing management&#8217;s process for developing the undiscounted cash flows associated with the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and developing the fair value of the Salix reporting unit; (ii) evaluating the appropriateness of the probability-weighted undiscounted and discounted cash flow analyses; (iii) testing the completeness and accuracy of underlying data used in the undiscounted and discounted cash flow analyses; and (iv) evaluating the reasonableness of the probability weighting assigned to each scenario to address the estimated timing of the potential loss of exclusivity for the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product and management&#8217;s significant assumptions related to revenue growth rates used in developing the undiscounted cash flows for the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and fair value of the Salix reporting unit and the discount rate and terminal growth rate used in developing the fair value the Salix reporting unit. Evaluating the reasonableness of the probability weighting assigned to each scenario to address the estimated timing of the potential loss of exclusivity involved considering (i) the consistency with reports issued by investment analysts related to the timing of when a generic version of Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could potentially launch; (ii) the consistency with internal and external briefings; and (iii) whether the estimated timing of the potential loss of exclusivity was consistent with evidence obtained in other areas of the audit. Evaluating management&#8217;s significant assumptions related to revenue growth rates for the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets and Salix reporting unit involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line and Salix reporting unit; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company&#8217;s probability-weighted discounted cash flow analyses and (ii) the reasonableness of the discount rate and terminal growth rate significant assumptions for the Salix reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODkvZnJhZzowOTcwNTYyM2M4MWU0ZGZjOTI0MjlmNDQ1OTMyNGY2NC90ZXh0cmVnaW9uOjA5NzA1NjIzYzgxZTRkZmM5MjQyOWY0NDU5MzI0ZjY0XzE3MDg4_5fc16266-650a-45dd-bbf0-256a43a1a9c5">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODkvZnJhZzowOTcwNTYyM2M4MWU0ZGZjOTI0MjlmNDQ1OTMyNGY2NC90ZXh0cmVnaW9uOjA5NzA1NjIzYzgxZTRkZmM5MjQyOWY0NDU5MzI0ZjY0XzE3MDkw_df34e038-65ce-44fa-b703-c3d8b6f61e60">Florham Park, New Jersey</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023 </span></div><div style="margin-top:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2012. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_292"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span><br/></span></div><div id="i57fbe32677504c888f142dd82b99b37f_295"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzQtMi0xLTEtMTY5NjA4_ac6d0ddf-3c80-459c-99e6-ff7129269eb8">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzQtNC0xLTEtMTY5NjA4_9354e81f-d7c5-435b-ba5e-2c611bd58fe7">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzUtMi0xLTEtMTY5NjA4_5cb3f4ad-f865-44be-9f25-b0ab98678884">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzUtNC0xLTEtMTY5NjA4_3d38d40c-db8e-44ad-9c16-91050690bcf0">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzYtMi0xLTEtMTY5NjA4_e568a811-1e75-48ec-a6f9-6dc8d5c75968">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzYtNC0xLTEtMTY5NjA4_50e0e12f-be92-4d8f-9784-7aee415b1385">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzctMi0xLTEtMTY5NjA4_35c61c2e-c851-45d1-9165-9a764e7de026">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzctNC0xLTEtMTY5NjA4_3525fc8a-02b0-45a4-90e1-757735993f83">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzgtMi0xLTEtMTY5NjA4_af8fc1f8-8a38-4f8f-81d2-f44e712fb860">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzgtNC0xLTEtMTY5NjA4_62dbb50f-4508-453e-85ae-f3fca8c1b05e">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzktMi0xLTEtMTY5NjA4_c0a9c83e-ba0c-4266-9b1b-0c377f168405">4,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzktNC0xLTEtMTY5NjA4_18f86aa3-ef4e-45e1-bfa5-3b026f859e0e">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEwLTItMS0xLTE2OTYwOA_6f27af42-3044-4125-86a6-adf60e52deb4">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEwLTQtMS0xLTE2OTYwOA_8fd40ab7-a812-466a-8c27-04bf8900ac2f">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzExLTItMS0xLTE2OTYwOA_ef1e9611-bb9d-4edb-8977-a502956c0d58">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzExLTQtMS0xLTE2OTYwOA_8b7cb339-c919-4b80-a06c-fea08d60325b">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEyLTItMS0xLTE2OTYwOA_4f39d349-65ba-4ca5-817a-975decdf79b0">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEyLTQtMS0xLTE2OTYwOA_f7d7b8ac-74be-4c68-b15a-7c56f5cec87e">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEzLTItMS0xLTE2OTYwOA_a64a1852-aa7b-467a-a159-ff27cabe043b">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEzLTQtMS0xLTE2OTYwOA_c3075745-8e8a-47a2-8c21-cb48e6f0517f">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE0LTItMS0xLTE2OTYwOA_f0b0b181-2723-4970-9471-9060ed07d6ed">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE0LTQtMS0xLTE2OTYwOA_ade9f53e-e0d2-437b-8239-e62edeb5b400">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE1LTItMS0xLTE2OTYwOA_c640148d-6343-4673-84d3-41f8e9a2f57a">25,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE1LTQtMS0xLTE2OTYwOA_16658233-696e-4b84-b16d-3f8846f2dee3">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE4LTItMS0xLTE2OTYwOA_f9720cb5-e90b-462e-beb8-c916efa99035">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE4LTQtMS0xLTE2OTYwOA_3593523d-274d-461d-bbd2-8460bd4c772a">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE5LTItMS0xLTE2OTYwOA_2370dbae-5ffe-4bcb-bd3f-38e9fc1bb814">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE5LTQtMS0xLTE2OTYwOA_088260f1-40cc-44df-a4ad-3b64cd28320d">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTItMS0xLTE3MTI4OQ_8a5d20d7-fad5-4528-9a20-18752ed38857">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTQtMS0xLTE3OTQ0NQ_c4feb5a6-83c9-4ee9-880a-e8aed99eeb03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTItMS0xLTE2OTYwOA_f1b2211d-a600-46cf-8805-9464753668b0">3,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTQtMS0xLTE2OTYwOA_9a9a1cc3-6559-4e4a-bf95-e0214e8cb0a7">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIxLTItMS0xLTE2OTYwOA_bf1f150d-4c84-4356-b59b-882710bb10cc">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIxLTQtMS0xLTE2OTYwOA_562aa1ef-5190-4edc-946b-9af14d2d22e7">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIyLTItMS0xLTE2OTYwOA_bd13a912-d41e-41a9-91f5-504f606178fc">20,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIyLTQtMS0xLTE2OTYwOA_c3acbe7b-afba-415f-b4ad-fa870a0fe88c">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIzLTItMS0xLTE2OTYwOA_61044d76-4101-438d-8970-2e39ce776694">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIzLTQtMS0xLTE2OTYwOA_47a038db-dcff-4e58-b9f0-b82568a3b32c">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI0LTItMS0xLTE2OTYwOA_18e896af-1857-40d8-b87c-ef9557f243bc">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI0LTQtMS0xLTE2OTYwOA_d23f8ea9-bfd5-48c2-8747-f0b44d56210b">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI1LTItMS0xLTE2OTYwOA_3c061888-345f-46b4-8d8c-e56b93331053">25,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI1LTQtMS0xLTE2OTYwOA_45766ed9-6674-44db-a84e-8a0981dcdab2">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Notes&#160;20 and 21)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI2LTItMS0xLTE2OTYwOA_35f88275-ccb7-4f79-8030-c9b8a059382b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI2LTQtMS0xLTE2OTYwOA_566b8c01-2cea-4c94-8c1a-be566b8d3cd6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzYy_bbb042f9-6576-4faa-b429-c94a0a242183"><ix:nonFraction unitRef="shares" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzYy_f0734da7-b3b7-4297-88f3-38fd355d2718">361,898,846</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzY5_59355c67-cc00-472b-af4e-6bc870402bab"><ix:nonFraction unitRef="shares" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzY5_6f13473f-a992-4474-ab82-c85d3f7d167b">359,405,748</ix:nonFraction></ix:nonFraction>&#160;issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTItMS0xLTE2OTYwOA_6f53aa88-6c18-46b0-aeda-5dbb8c9a2a05">10,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTQtMS0xLTE2OTYwOA_54d367ee-01fe-45e5-aeda-57a5c51dde44">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI5LTItMS0xLTE2OTYwOA_5df41696-35dd-4c98-b55d-6453ee10ff2c">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI5LTQtMS0xLTE2OTYwOA_a67d6c63-1fc1-4552-a47d-58e912724705">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMwLTItMS0xLTE2OTYwOA_9d9d6242-d4b8-4871-8a65-00ad97f0cdd4">9,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMwLTQtMS0xLTE2OTYwOA_2cc39520-f8db-4964-b1de-73f84dcafeac">8,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMxLTItMS0xLTE2OTYwOA_6cb92171-9bd7-4319-bbbf-f9a7e8da51f5">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMxLTQtMS0xLTE2OTYwOA_307fe095-5d5b-4623-b6fd-a60df178f1c6">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMyLTItMS0xLTE2OTYwOA_b5383492-fbd7-4439-b3fc-f353824e30bd">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMyLTQtMS0xLTE2OTYwOA_646099c6-01aa-4358-bf48-0c339435c113">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMzLTItMS0xLTE2OTYwOA_31c8a3c6-51f7-4ed7-a76d-e7e91ecc4f32">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMzLTQtMS0xLTE2OTYwOA_3f24a50f-5803-4a77-b565-88f3653266f3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity (deficit) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM0LTItMS0xLTE2OTYwOA_2f63f134-7c30-4c27-a89c-52bcb6e91581">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM0LTQtMS0xLTE2OTYwOA_037625c4-0158-45c5-8975-18929bd07fdf">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM1LTItMS0xLTE2OTYwOA_aae82288-dacf-4cfa-850d-09c1185e5f0f">25,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM1LTQtMS0xLTE2OTYwOA_07f4836a-cbc6-4de0-b1d9-77b411bc4777">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 36.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share&#160;amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:67.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtMS0xLTEtMTY5NjA4_93ef4266-6114-4fb7-aefb-854a9ccb694e">8,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtMy0xLTEtMTY5NjA4_d02c4bac-5966-44c2-9ace-108df2be9cd2">8,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtNS0xLTEtMTY5NjA4_52e44209-8902-44e1-8d14-e74a84b544ac">7,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtMS0xLTEtMTY5NjA4_72af3a5f-cd84-4cd7-bfb5-8969dca9f024">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtMy0xLTEtMTY5NjA4_59cb5417-dd27-4d1d-ab50-69ec8177700a">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtNS0xLTEtMTY5NjA4_5ceef2f8-eefb-4070-99b1-cc1bca44427d">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtMS0xLTEtMTY5NjA4_03a7c9ae-98f3-42d0-9821-cf36c0956bb7">8,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtMy0xLTEtMTY5NjA4_3e412892-c466-4b6d-ba78-a2b96f6b5bb9">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtNS0xLTEtMTY5NjA4_07fa5f4a-188b-4fe7-90e8-8ea92422ea7c">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctMS0xLTEtMTY5NjA4_c325d17c-14d5-4947-8c6b-e6711868564a">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctMy0xLTEtMTY5NjA4_f1793d4d-9d3e-4ffd-800e-91d5308e4a80">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctNS0xLTEtMTY5NjA4_030a6ea6-449c-4ebd-9809-1c547979d0cd">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtMS0xLTEtMTY5NjA4_cf8cbd62-d079-432b-912c-8cb835a6f091">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtMy0xLTEtMTY5NjA4_31b88fdf-48fe-4d94-983f-0e4883a6bed5">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtNS0xLTEtMTY5NjA4_4e0de6ac-07e6-4ac9-adbf-eddf2437bfab">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktMS0xLTEtMTY5NjA4_24dac994-1676-402e-be43-e8e8f06b6bd6">2,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktMy0xLTEtMTY5NjA4_71b9c52f-47ec-47ca-8a72-f98b38928ed4">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktNS0xLTEtMTY5NjA4_91d9f56a-9c03-4059-8c42-56da561c6379">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTEtMS0xLTE2OTYwOA_b9e7a7a2-292c-4223-8c05-edb045e65cea">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTMtMS0xLTE2OTYwOA_faff6b98-13af-4f27-9eed-6c1a6269422a">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTUtMS0xLTE2OTYwOA_40d893fc-a075-45d7-b7ee-616f4f6760da">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTEtMS0xLTE2OTYwOA_68e1622b-4a7e-4762-96bd-09b315f3710a">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTMtMS0xLTE2OTYwOA_a9f46f74-f77e-4f6a-a780-99a4f7742af5">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTUtMS0xLTE2OTYwOA_f8a20886-a370-4d0d-a534-457a8e0ee9b5">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTEtMS0xLTE2OTYwOA_17eef924-3fc7-45d5-a7fe-f45661f65a57">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTMtMS0xLTE2OTYwOA_3d7566b8-48da-46f1-8265-384318a5b011">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTUtMS0xLTE2OTYwOA_a51929ef-828e-44e7-8d3b-d0a5cdfa81a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTEtMS0xLTE2OTYwOA_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTMtMS0xLTE2OTYwOA_bb166372-19b5-4873-8286-13042a66b5f6">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTUtMS0xLTE2OTYwOA_4cc0dfd6-f8f3-46d6-8461-cac87df7ad73">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTEtMS0xLTE2OTYwOA_9e7f5d05-9384-4a3d-9662-4e6c96f62636">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTMtMS0xLTE2OTYwOA_c6ad5c2b-09db-4c54-bf5c-aaf62601a899">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTUtMS0xLTE2OTYwOA_79e771b6-5e16-4dfa-bc2a-4ba3dc240198">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTEtMS0xLTE2OTYwOA_a5b68590-e864-456a-bd3b-63b7b51d8bfb">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTMtMS0xLTE2OTYwOA_85f75121-7c62-4d7e-b8f6-ac884e144328">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTUtMS0xLTE2OTYwOA_5fd0177b-6f61-4033-b283-43448e63f5c5">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTEtMS0xLTE2OTYwOA_9610c08d-7bec-44bb-bb86-0a28071cc988">7,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTMtMS0xLTE2OTYwOA_627eda17-5415-4cb5-bd70-5db35cf60a77">7,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTUtMS0xLTE2OTYwOA_05be6cb9-361b-4d4e-9cde-65eae0938711">7,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTEtMS0xLTE2OTYwOA_ef948fff-a12f-4611-9634-cfccd35d0767">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTMtMS0xLTE2OTYwOA_f22c3fa6-219a-460b-8846-b38e01600852">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTUtMS0xLTE2OTYwOA_68afa60d-4844-484e-9dc9-5c4bd333ecc7">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTEtMS0xLTE2OTYwOA_0030c4cb-95e8-4aee-9687-0d01e02c2fca">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTMtMS0xLTE2OTYwOA_dab70423-56a0-453d-8970-d6d55f8df5f4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTUtMS0xLTE2OTYwOA_54e642f0-bdd3-4f45-9359-e2ba3d08870d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTEtMS0xLTE2OTYwOA_7352e363-b6c2-4c90-ac29-d3a29ae84c7c">1,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTMtMS0xLTE2OTYwOA_198034be-ce63-4b38-ba4b-09d091b10ae0">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTUtMS0xLTE2OTYwOA_47bc1925-93db-40ca-9038-5ab0987288f4">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTEtMS0xLTE2OTYwOA_4a02e589-f95f-4990-ae98-c69e615f921e">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTMtMS0xLTE2OTYwOA_4478786f-c25e-4143-9d0b-b59822795c3c">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTUtMS0xLTE2OTYwOA_e4d74243-d6d1-4e9a-8733-8b7fccbabadb">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTEtMS0xLTE2OTYwOA_cf821268-4f8c-4751-b56e-3d91e133bbb5">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTMtMS0xLTE2OTYwOA_a7e1b2fb-1db4-49ca-9c52-c8f0323ebeae">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTUtMS0xLTE2OTYwOA_ef72c913-2f3d-4389-bbe0-783c830438c3">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTEtMS0xLTE2OTYwOA_ea7e4d89-1c9a-4c18-b086-0253213b42d8">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTMtMS0xLTE2OTYwOA_7d12da12-b08c-48ee-82f8-70077f74decc">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTUtMS0xLTE2OTYwOA_13a558d1-5502-4957-9b9c-6e35d3e6e58c">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTEtMS0xLTE2OTYwOA_bbe26775-ded9-495f-83f2-7fa8ad43378d">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTMtMS0xLTE2OTYwOA_cfe01621-7ec9-4f4b-8c03-9c4d113b4d6c">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTUtMS0xLTE2OTYwOA_872ec6c8-8cb9-4152-ab4c-639eca258877">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTEtMS0xLTE2OTYwOA_e854f6a8-eb53-4c0d-a8b9-1184816d3d1c">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTMtMS0xLTE2OTYwOA_055abd8a-745b-41eb-8db1-247689c47164">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTUtMS0xLTE2OTYwOA_8b230bbb-3254-47f0-b65e-52507093b17a">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTEtMS0xLTE2OTYwOA_780be002-7593-43e2-8efb-7e8acb7d2c7c">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTMtMS0xLTE2OTYwOA_05698ebe-5f81-423c-93b3-22219872745a">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTUtMS0xLTE2OTYwOA_8e0728ab-67f2-4ebd-94f8-7deff9595f15">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTEtMS0xLTE2OTYwOA_189c56a4-655f-4e4d-933b-c80d2020a833">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTMtMS0xLTE2OTYwOA_ba8802d3-4081-4d13-8516-a18df5b209c9">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTUtMS0xLTE2OTYwOA_d675aa28-8da8-4945-81c8-73d7a24754c6">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTEtMS0xLTE4OTE0OQ_074dedc6-4b93-4795-a2d1-9158444fa194"><ix:nonFraction unitRef="usdPerShare" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTEtMS0xLTE4OTE0OQ_f1d23e70-0535-4a34-8a83-8e16d3366c7d">0.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTMtMS0xLTE4OTE0OQ_020ba721-cbbd-416b-8342-77e1a07b9c0a"><ix:nonFraction unitRef="usdPerShare" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTMtMS0xLTE4OTE0OQ_6157e492-a4d2-43da-a9c6-4fc459813e4d">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTUtMS0xLTE4OTE0OQ_2454d3cd-d555-49aa-97ff-1692159134fa"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTUtMS0xLTE4OTE0OQ_a9e8d7fd-813e-4f30-9172-1e9f74ede8df">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTEtMS0xLTE2OTYwOA_467e5c95-13cf-4fb9-ad59-a24399b0be88"><ix:nonFraction unitRef="shares" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTEtMS0xLTE2OTYwOA_a1254015-0ee6-4f31-9e77-10fc39961c87">362.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTMtMS0xLTE2OTYwOA_882dbe33-8b46-4adc-8d2f-bf25fec84a27"><ix:nonFraction unitRef="shares" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTMtMS0xLTE2OTYwOA_f8709c2d-accd-48a5-a9b1-d51fc14ac6ef">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTUtMS0xLTE2OTYwOA_30c06caf-655e-4111-a354-86ea2e527f4c"><ix:nonFraction unitRef="shares" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTUtMS0xLTE2OTYwOA_65a891fa-0feb-4019-8627-3e2058670499">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_301"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-bottom:16pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItMS0xLTEtMTY5NjA4_ba981429-5910-4460-8a9a-2573ccf435b1">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItMy0xLTEtMTY5NjA4_5bd94db1-fefa-4395-945d-cbbbc51cbf31">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItNS0xLTEtMTY5NjA4_c27a2e55-315b-487a-850b-45544a127173">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial gain (loss) arising during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtMS0xLTEtMTY5NjA4_de822d4c-1a95-453a-a04a-bc6f4e655556">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtMy0xLTEtMTY5NjA4_f44d0c5b-2c80-470d-87f5-b1a8c1d185ab">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtNS0xLTEtMTY5NjA4_db052499-2de7-4ec4-bfd6-f2a0c6c2a9b6">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtMS0xLTEtMTY5NjA4_7c431916-7531-4019-9d8d-732fd12ba1ae">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtMy0xLTEtMTY5NjA4_21c558ad-8c2a-4348-96c9-a69a7f16fef3">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtNS0xLTEtMTY5NjA4_24b35a1b-f7be-440c-b9b2-a984fc888f40">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization or settlement recognition of net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctMS0xLTEtMTY5NjA4_69da70f7-40dd-4086-bdc1-45f9917ee321">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctMy0xLTEtMTY5NjA4_6ed2fc71-ecae-4f76-a495-a007751e2426">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctNS0xLTEtMTY5NjA4_95bfe2aa-890a-41ec-acc3-623e5c22f221">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtMS0xLTEtMTY5NjA4_1c4ae4d3-cec7-457f-8df7-26843308983a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtMy0xLTEtMTY5NjA4_9508f7cb-b043-4276-b59b-3801f50afcc6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtNS0xLTEtMTY5NjA4_79d2b183-b9a1-4cca-bfd9-26e88103d76d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktMS0xLTEtMTY5NjA4_ec31e053-1011-4bfd-a081-edae93949a59">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktMy0xLTEtMTY5NjA4_0fde5529-f63a-42c4-803a-c042b420c3e9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktNS0xLTEtMTY5NjA4_d162d7dd-8cdd-4e0d-bad4-a486fabd13ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension and postretirement benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTEtMS0xLTE2OTYwOA_8958ff33-8b7d-4732-91f5-471e549538b6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTMtMS0xLTE2OTYwOA_3fa3c831-60e7-4394-8ce1-103634ee808d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTUtMS0xLTE2OTYwOA_52a5114b-d644-427e-8cb8-a3509e048d89">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTEtMS0xLTE2OTYwOA_978eb50a-7e0f-4626-aedd-ad6dce496fbd">257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTMtMS0xLTE2OTYwOA_79b6f164-9419-428b-84dc-3a3305333df6">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTUtMS0xLTE2OTYwOA_b4e8f2dd-4a12-4836-a15d-3840fe9097d1">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTEtMS0xLTE2OTYwOA_65453037-da36-4544-bb78-01d01afd9b89">256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTMtMS0xLTE2OTYwOA_a0812da2-7afc-42a7-9ca9-b16a32e45ef9">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTUtMS0xLTE2OTYwOA_39a9d4e3-4580-4211-9030-b1e24edc02fb">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTEtMS0xLTE2OTYwOA_c5bc8679-69aa-499d-ba3f-6410109b6b8b">468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTMtMS0xLTE2OTYwOA_cd44fddf-d956-43a1-a039-75826743447b">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTUtMS0xLTE2OTYwOA_b779c2b1-43f3-470b-b728-f934d0aed89c">604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTEtMS0xLTE2OTYwOA_31b6ac9f-6f86-453b-bc44-dcf3f3b15c50">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTMtMS0xLTE2OTYwOA_7b2dc1f0-43c9-4c99-ba33-94e483b583c8">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTUtMS0xLTE2OTYwOA_2d56bab2-412c-4fbf-9edf-6d1220feae9e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTEtMS0xLTE2OTYwOA_e6ec0c16-dee5-44a4-9275-48f9f319fc58">494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTMtMS0xLTE2OTYwOA_09d5f84c-d366-4963-97c2-bca738714642">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTUtMS0xLTE2OTYwOA_b149f415-01a5-4821-b3cb-c7b1fe159384">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_304"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:28.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders&#8217;<br/>Equity (Deficit)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, January&#160;1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i352ec3a38f244bdbafd755de208aa067_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMi0xLTEtMTY5NjA4_1a3ae807-8f30-4529-9455-3f28935568e7">352.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352ec3a38f244bdbafd755de208aa067_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtNC0xLTEtMTY5NjA4_ffeba8c2-458a-4929-8c8f-7e62346d0898">10,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31a4f763ded4502b9e4fa2d840d63f8_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtNi0xLTEtMTY5NjA4_bbef3009-fd78-492c-98c0-4d9cb288c5de">429</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28edfd63f7b14bc8bcd18527c6781606_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtOC0xLTEtMTY5NjA4_e5ab3a7e-d3b9-4263-b0c7-764c7a82cb37">7,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e70e662458f40bb8c987a1572e53027_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTAtMS0xLTE2OTYwOA_1675c33a-33b0-40e4-bd3b-41b72f0c8c2b">2,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42242da77914d51bc567ec579238930_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTItMS0xLTE2OTYwOA_265ce0e2-fd4e-42bd-8187-304db7aee6a1">1,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc69aab44eb84be4ac14baf7ef6a6ac2_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTQtMS0xLTE2OTYwOA_c6b328cd-94ca-4f8e-a94a-3592aaf4a3b4">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTYtMS0xLTE2OTYwOA_e6f13aa6-c491-42e3-ab8e-97d5b49500e9">1,136</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMC0xLTEtMTc5NzE2_2939de66-932c-4e6b-ad04-11490b474fee">Effect of application of new accounting standard: financial instruments - credit losses</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtOC0xLTEtMTc5NzA0_a77686f7-3ce0-4318-a322-61e3e17d158a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaad43210cdbd45f0b0a9a371bd0993dc_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTItMS0xLTE3OTcwNA_36e44774-3871-4d63-9356-d183db9d7647">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5b0ddd5ab97433abadd6e743429df67_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTYtMS0xLTE3OTcwNA_780f42a4-d968-4aca-ab5d-2058a7cc4007">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMi0xLTEtMTY5NjA4_b6ba0af1-d56a-48e3-8aa6-8d061af7ba69">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtNC0xLTEtMTY5NjA4_1361ba85-9166-4289-8e9b-a1b0a32519cf">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtNi0xLTEtMTY5NjA4_e3d14607-3619-4b31-a8ef-83689488e4ee">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTItMS0xLTE2OTYwOA_ea907e3d-1cbc-4bb0-8b26-8e98ebde8632">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTYtMS0xLTE2OTYwOA_0518a02a-01a2-44b2-a8d3-d711a7d4c576">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtNi0xLTEtMTY5NjA4_2a92cddf-1212-4827-99b8-bc5fffdb1fbe">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtMTItMS0xLTE2OTYwOA_92767e22-bd0a-477d-977b-dd33a16a36aa">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtMTYtMS0xLTE2OTYwOA_4201b51b-bc85-47cf-b6be-acd35667b472">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtNi0xLTEtMTY5NjA4_58eeff58-1d9b-48f2-838c-181f980e923d">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtMTItMS0xLTE2OTYwOA_f5ff7337-8c2d-485d-9980-ce6903acf643">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtMTYtMS0xLTE2OTYwOA_1b98f45c-bf89-46a2-9bf2-49cf3e475321">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzctMTQtMS0xLTE2OTYwOA_cd2e0568-7563-4f38-a776-0ef9afc0a4a8">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzctMTYtMS0xLTE2OTYwOA_ad6efa0f-e5a4-4888-ad03-c49d6876b206">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b88f1ca9e1a48ad9446d9187ae673ab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtOC0xLTEtMTY5NjA4_483c87e3-1d30-485e-a356-b86afcc58295">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTItMS0xLTE2OTYwOA_ccca44c6-68cb-4fb6-9d5c-3cc45cfb43a9">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTQtMS0xLTE2OTYwOA_351a529c-3301-4493-9a00-0328fa74eded">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTYtMS0xLTE2OTYwOA_9bf7d6e1-b903-4ca4-b001-db9fbe6d34cc">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1162a0c4e547519003679dc043973a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTAtMS0xLTE2OTYwOA_316f905b-102e-42bb-bcc9-0129b34acffd">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTItMS0xLTE2OTYwOA_a9c12e62-d091-4231-b454-03e218b5dfec">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTQtMS0xLTE2OTYwOA_0c256a0a-9d3f-4ad1-825c-deca1a9779a2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTYtMS0xLTE2OTYwOA_be9a4f01-435e-4e49-8558-df26a7e92cd2">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7beef9cf290b4312a60d7c32efde693f_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTItMS0xLTE2OTYwOA_cbfa90d1-be7c-4b2f-b1dc-f9696e48986d">355.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beef9cf290b4312a60d7c32efde693f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTQtMS0xLTE2OTYwOA_557ed271-7b0d-475f-be6b-abf45ef5c172">10,227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744ebc157dbb4a0b86ccfabc060e848f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTYtMS0xLTE2OTYwOA_7f82667d-80ff-4677-9362-07a02d007254">454</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d9756007b6d4f3d84623153c2dddeff_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTgtMS0xLTE2OTYwOA_18a6fcb5-3085-4dd0-b51d-4ea63ebb8ea0">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9599e56128940a0955ca4ff88d8639a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTEwLTEtMS0xNjk2MDg_4152e921-b559-42c5-a822-5bc801986130">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687d9364584e4a7ca7034a3483a95a7d_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTEyLTEtMS0xNjk2MDg_8e499a74-096b-436a-a9d1-7f4d9b755490">535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9effac2c66724eed803dffd7950879ea_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTE0LTEtMS0xNjk2MDg_95768e73-96c8-47d0-afb2-ee225b1a97a4">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTE2LTEtMS0xNjk2MDg_ad0969cb-ab0f-4c6f-ac62-d171bf832e25">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTItMS0xLTE2OTYwOA_43c8fd1a-547f-4698-8e23-eb238d8bc0e8">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTQtMS0xLTE2OTYwOA_56138d7c-6ca6-4210-8f05-bad10024bc83">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTYtMS0xLTE2OTYwOA_3a256ad1-704f-456e-9e0b-ad9d9e51a168">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTEyLTEtMS0xNjk2MDg_9a51dfa1-3db8-447e-9f1e-10bb0b75afc2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTE2LTEtMS0xNjk2MDg_68339b4a-b7c0-4a49-a9f1-d5075020a907">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTYtMS0xLTE2OTYwOA_1b73b051-34c0-4477-ba55-d751ed12cc7d">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTEyLTEtMS0xNjk2MDg_98de21a9-ac55-40fc-a394-1602e92016c0">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTE2LTEtMS0xNjk2MDg_03e03fef-2c93-45ff-8157-60980d243fd9">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTYtMS0xLTE2OTYwOA_e63fefc7-5e3c-4f04-ad5b-f45bc4ffa3e1">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTEyLTEtMS0xNjk2MDg_6e108b13-466c-4e97-b42b-e8eb292a024b">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTE2LTEtMS0xNjk2MDg_9b9e8844-2020-4a12-aa77-7df4e071941d">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Release of foreign currency translation losses upon disposal of assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTEwLTEtMS0xNzk3MDY_862b1ff5-706d-4ab2-8514-0d1aad4c30c0">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTEyLTEtMS0xNzk3MDY_de586aac-a265-463f-ae2c-64c6a7ddb8d3">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE2LTEtMS0xNzk3MDY_2248998b-6ecc-4328-a857-199f52f56860">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE0LTEtMS0xNjk2MDg_9d426ef4-339a-4a0f-92f9-a443381ff88e">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE2LTEtMS0xNjk2MDg_6a595392-11f4-43ff-9ba7-cf72c8e099bf">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b2c612fd89643298310e38a8883f365_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTgtMS0xLTE2OTYwOA_80a5dd62-b18e-404c-8b60-5fb38c87a013">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTEyLTEtMS0xNjk2MDg_2b4c5b8a-b052-4cfd-986a-1c5441a38ae8">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTE0LTEtMS0xNjk2MDg_ebe432eb-0dc6-4aa6-b27d-5f70c4e846ea">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTE2LTEtMS0xNjk2MDg_d1a7b296-9e22-407b-8e3b-72c9ef0fbcac">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTEwLTEtMS0xNjk2MDg_79767c6a-682c-48a9-a012-10fff5f15585">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTEyLTEtMS0xNjk2MDg_d7013c90-6c5e-4480-ae4c-f8fbbc21ba80">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTE0LTEtMS0xNjk2MDg_528a2c72-86ce-4607-a845-53f8f940ade7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTE2LTEtMS0xNjk2MDg_ca75da20-781e-4254-adbf-1499dcc631eb">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4869d1047a0141b19a3fbf5790033030_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTItMS0xLTE2OTYwOA_845c1c62-3d02-446f-949a-e4f6213521b0">359.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4869d1047a0141b19a3fbf5790033030_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTQtMS0xLTE2OTYwOA_082b9972-f504-4ea0-9fbd-1929c87320a6">10,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcee2b5169a8459c8cbccfe68bebb595_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTYtMS0xLTE2OTYwOA_943251f3-451c-4235-80e2-4e5d7bca4a31">462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea9dde3b1c18435faec13820801e4e34_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTgtMS0xLTE2OTYwOA_394b6360-d9a2-4bc3-a6fb-3dc88c952a8e">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4522c45ac1c44145a7ecea556295fe2a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTEwLTEtMS0xNjk2MDg_444cbc7a-69b3-4cc5-beec-5ce7bbf74e47">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if48c23e1700a4f49ba421b5d2cbc0242_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTEyLTEtMS0xNjk2MDg_05631cf1-290e-4db1-bb96-7f3554920e8d">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c547eba26f449dbd67bd40c78e03b4_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTE0LTEtMS0xNjk2MDg_bcce9663-ef4b-4dce-9af9-cf270b20211c">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTE2LTEtMS0xNjk2MDg_792032ed-fa88-417f-b3f4-5560e548f1c3">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTYtMS0xLTE3OTcxMA_fb483163-7285-4772-a26c-aa519efd6ec9">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEwLTEtMS0xNzk3MTA_d94066d6-589e-4546-9ef0-f8c6bc26df65">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEyLTEtMS0xNzk3MTA_0c24b066-af53-4e8f-a1ef-3359cbe4ed3a">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE0LTEtMS0xNzk3MTA_fd45ff5e-481f-4223-b6a9-1b16a1bbf53b">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE2LTEtMS0xNzk3MTA_c1a45580-b858-4c67-a73c-75caf146b414">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTItMS0xLTE2OTYwOA_664b6bcd-3f3d-41e9-a249-cdf32da43e56">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTQtMS0xLTE2OTYwOA_0501e575-4083-4806-b79d-77e61024789c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTYtMS0xLTE2OTYwOA_92840c40-a4fb-4cf9-98a9-8fb9fde28dc1">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTEyLTEtMS0xNjk2MDg_31696484-39ab-4b8c-9adf-7d98f4ca805c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTE2LTEtMS0xNjk2MDg_91568d00-cb9d-42c8-9849-4d2d18aeb259">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTYtMS0xLTE2OTYwOA_89146f2c-443a-4ada-9b35-19cedbd93673">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEyLTEtMS0xNjk2MDg_da294cd6-ca60-44b4-84e2-a18fe252c414">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE2LTEtMS0xNjk2MDg_3df5aae5-89c3-4fd0-b0fc-f80d82a6d744">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTYtMS0xLTE2OTYwOA_942c0c8d-443e-4a00-b89c-fdc048608b74">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTEyLTEtMS0xNjk2MDg_be284137-f455-4fa9-8a08-b752bdc9a9e6">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTE2LTEtMS0xNjk2MDg_405d5014-af2e-4c52-8add-4ca7e0082f40">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIzLTE0LTEtMS0xNjk2MDg_344a7c6e-bf07-4017-b8bc-62fa6eb70ff6">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIzLTE2LTEtMS0xNjk2MDg_e838fc2f-7671-45a2-841f-012a53f1a293">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85093372ad449739b9c5caf68d08cbe_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTgtMS0xLTE2OTYwOA_1d8c2f43-2946-44af-8404-d8aaea1a404c">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTEyLTEtMS0xNjk2MDg_f7da9a79-98d8-4189-8e86-847e0198115a">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTE0LTEtMS0xNjk2MDg_df4e59d7-ac68-4c99-a33d-97a032c6647a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTE2LTEtMS0xNjk2MDg_e00e7b55-9a99-4be8-9d3c-dca740e00596">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTEwLTEtMS0xNjk2MDg_f379a791-e610-43a6-ae51-edee26f75561">269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTEyLTEtMS0xNjk2MDg_bc653cf7-55c0-4900-bf95-bd63330b76c3">269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTE0LTEtMS0xNjk2MDg_202516b1-fffe-4850-ae89-9fbe06747fc9">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTE2LTEtMS0xNjk2MDg_3cbe7e39-cabf-4fbc-a4cc-8f2253cf17bb">256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89640c6de2df463b91359c26584e4b54_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTItMS0xLTE2OTYwOA_05f8fc9f-6c4e-4cce-9a8a-f4f4cf7ca141">361.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89640c6de2df463b91359c26584e4b54_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTQtMS0xLTE2OTYwOA_0d4496d6-9e14-4764-b458-00e465f304ec">10,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666af66f47b4407393455522d3f67aab_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTYtMS0xLTE2OTYwOA_838831e2-0dd3-4247-876a-b30b05e5cfc5">159</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d90679865d741fea3690267adba920e_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTgtMS0xLTE2OTYwOA_f5cbac72-9391-4d6f-a104-7b85865d9327">9,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i286802cacb2b47a7aac5819b6b1ae881_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTEwLTEtMS0xNjk2MDg_83a8aad3-38a8-4993-9658-9359122595dc">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcfc9710ac6749858b8d7495fde87d13_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTEyLTEtMS0xNjk2MDg_7d025dfa-c425-4105-91b8-36b5998f34b8">692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414d863f79fc4e20a1c5842fb6a72ba3_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTE0LTEtMS0xNjk2MDg_ad040ee5-db5c-445a-85a1-b9f7f946e987">952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTE2LTEtMS0xNjk2MDg_048615b5-f6eb-49ac-af1d-746a4e13507f">260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_307"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtMi0xLTEtMTY5NjA4_ba981429-5910-4460-8a9a-2573ccf435b1">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtNC0xLTEtMTY5NjA4_5bd94db1-fefa-4395-945d-cbbbc51cbf31">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtNi0xLTEtMTY5NjA4_c27a2e55-315b-487a-850b-45544a127173">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtMi0xLTEtMTY5NjA4_cea72393-38be-4336-a6cc-ae1c1a4e1043">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtNC0xLTEtMTY5NjA4_b39ef577-00ca-4c6d-b7c8-11114fc3f566">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtNi0xLTEtMTY5NjA4_43b65728-dfbe-4528-9638-08d35afa2191">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and write-off of debt discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtMi0xLTEtMTY5NjA4_838be25c-a503-4518-8371-04c16aa76af5">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtNC0xLTEtMTY5NjA4_cb90e45c-8a32-49ae-a428-b9e8d10688d2">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtNi0xLTEtMTY5NjA4_532d64f7-aed8-417b-9dd7-8c39154070fe">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctMi0xLTEtMTY5NjA4_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctNC0xLTEtMTY5NjA4_bb166372-19b5-4873-8286-13042a66b5f6">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctNi0xLTEtMTY5NjA4_4cc0dfd6-f8f3-46d6-8461-cac87df7ad73">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtMi0xLTEtMTY5NjA4_17eef924-3fc7-45d5-a7fe-f45661f65a57">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtNC0xLTEtMTY5NjA4_cc8ae32c-2906-4cb0-9413-0dae29542196">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtNi0xLTEtMTY5NjA4_b924cc6a-8708-4c3b-8ed5-e89c37d4f0dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktMi0xLTEtMTY5NjA4_1dde2730-9b87-4082-b494-65c7b70fefd4">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktNC0xLTEtMTY5NjA4_5b72fb9f-a9f6-46ec-8451-7afaac2975aa">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktNi0xLTEtMTY5NjA4_af72793d-69b3-4be3-b08d-27687d784e36">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowances for losses on trade receivables and inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTItMS0xLTE2OTYwOA_a030d8e8-dfa3-4459-a0e5-ea2402367adf">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTQtMS0xLTE2OTYwOA_9099abd8-e45d-48c8-bab1-a2fc51c8325d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTYtMS0xLTE2OTYwOA_b6b3c8ea-31e4-4a1e-acbe-8d87d2c91438">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTItMS0xLTE2OTYwOA_8ea3e725-8b63-4b51-a7f2-97daa4b9f137">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTQtMS0xLTE2OTYwOA_4d8274dc-bf6e-49fd-90c3-9d6dbca5d8d7">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTYtMS0xLTE2OTYwOA_f77384d8-9748-4a81-a49e-f5273c15e434">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTItMS0xLTE2OTYwOA_919a99f1-a739-4d9c-a380-9f1cd84ff9fc">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTQtMS0xLTE2OTYwOA_2e8cb237-d3db-4a5f-b09f-a6e30e4d204e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTYtMS0xLTE2OTYwOA_ffcfd1e7-525d-4d34-bf8b-eee9c66ab086">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to accrued legal settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTItMS0xLTE2OTYwOA_ac17c885-8e1c-4447-bc3b-59e8cded3900">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTQtMS0xLTE2OTYwOA_0189c598-d572-4d04-a7e1-b405e1b4f378">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTYtMS0xLTE2OTYwOA_4ca99d68-ee14-4981-8f8a-1668f0d6c655">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTItMS0xLTE2OTYwOA_6f49ec95-5cab-4e69-bfc7-22df1a958310">1,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTQtMS0xLTE2OTYwOA_7ede46ed-0f75-499c-a536-5ffe6eeac428">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTYtMS0xLTE2OTYwOA_a0267a8c-3273-4cd5-93db-ae7e644ccb28">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTItMS0xLTE2OTYwOA_c422a9c7-f2f7-494d-825f-46bb43306d3c">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTQtMS0xLTE2OTYwOA_895faae0-089a-443f-8d7d-053467060c16">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTYtMS0xLTE2OTYwOA_e7e4017c-c1ac-4a9e-8fec-83b9a0d79b0c">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTItMS0xLTE2OTYwOA_ae55b261-03b6-4d32-872a-541a61bd546a">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTQtMS0xLTE2OTYwOA_3eb7cbc2-bff6-4cad-b7e6-6ffef1d30226">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTYtMS0xLTE2OTYwOA_db983d07-e638-4b04-bcb6-76dcec7e7c60">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTItMS0xLTE2OTYwOA_9f93dd14-11ea-497f-b169-a77d5e39817b">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTQtMS0xLTE2OTYwOA_eb991c00-c18e-4eb0-b1bd-48a977a28a00">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTYtMS0xLTE2OTYwOA_ad598499-8b03-4f17-b3e6-ece8c587ec9e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Third party fees paid in connection with the Exchange Offer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTItMS0xLTE3MTMwNw_d40febbb-d8d9-4adc-ad27-ded869270d93">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTQtMS0xLTE3OTczNw_c2f08c34-9665-486b-9e39-11400255b250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTYtMS0xLTE3OTczNw_e3030244-f4d1-42e9-b2d9-d975675ad652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTItMS0xLTE2OTYwOA_3ead9d46-cf9c-487f-88da-2ac6abe974a3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTQtMS0xLTE2OTYwOA_dd49a9a8-ff1f-482d-90a8-16e16948095d">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTYtMS0xLTE2OTYwOA_dba7a963-7728-4fa1-ba2e-9ae44779e7d0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTItMS0xLTE2OTYwOA_101f2d20-c076-493e-a37f-2dd07d4eb1a9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTQtMS0xLTE2OTYwOA_63c50634-d570-4d1f-8210-fd9078ce56d9">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTYtMS0xLTE2OTYwOA_7f8e1eb5-b0b2-4a88-a9b5-4f6f7973f8ae">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTItMS0xLTE2OTYwOA_92d34cb1-8145-4d93-a344-cb814c95e1a4">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTQtMS0xLTE2OTYwOA_dbf5e460-0ef8-4009-b33f-4e9478fd3d9f">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTYtMS0xLTE2OTYwOA_818ceddf-6af5-4966-a36f-8234535b1e52">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTItMS0xLTE2OTYwOA_8ec133c4-357b-4d9d-a1fa-a3ec8a041da7">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTQtMS0xLTE2OTYwOA_c033b66e-00ed-4162-85ce-0bed23474926">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTYtMS0xLTE2OTYwOA_a3e181f2-c75b-4f7f-a456-2d4fff48a327">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTItMS0xLTE2OTYwOA_3b3e61e8-b9fa-4949-ac73-da985f93926f">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTQtMS0xLTE2OTYwOA_5b5573cf-6e9d-49ad-a300-88771a0e2625">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTYtMS0xLTE2OTYwOA_1629e58d-1d6f-40f7-a151-a4334c804c2a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTItMS0xLTE2OTYwOA_0b282640-7f29-4951-9eb5-87dc01868595">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTQtMS0xLTE2OTYwOA_23ef705f-7cad-4eb0-953c-60908d4ebc21">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTYtMS0xLTE2OTYwOA_4d305449-ff38-4261-8a6c-d21508fd727d">471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTItMS0xLTE2OTYwOA_984735dd-e20a-4c46-b145-096fa118435e">728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTQtMS0xLTE2OTYwOA_4de96915-10de-4c42-88fa-84f156dd7370">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTYtMS0xLTE2OTYwOA_d6c7fd57-da70-4e47-872a-3f1078d1e43c">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTItMS0xLTE2OTYwOA_2b30b8a3-b64a-49f8-b31d-bb3f28752135">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTQtMS0xLTE2OTYwOA_40340aea-3a74-428f-8ed9-e8cd540d2495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTYtMS0xLTE2OTYwOA_fc8cecc5-fd7e-4823-be37-4ffacb30714d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of intangible assets and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTItMS0xLTE2OTYwOA_dfce5807-8574-4dc5-8806-404b0259f221">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTQtMS0xLTE2OTYwOA_d2689134-ff94-439e-a179-1923e43ab30d">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTYtMS0xLTE2OTYwOA_9e41db87-3b08-49b8-80dc-fd99b6d93426">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTItMS0xLTE2OTYwOA_38e8ee9a-ac25-4b21-ad9b-cd41c37259ff">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTQtMS0xLTE2OTYwOA_42604880-d577-4247-81e7-e71e9e8308d1">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTYtMS0xLTE2OTYwOA_1765ca82-e36d-41bb-98ba-2d5580541019">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTItMS0xLTE2OTYwOA_3739eb4a-b9c7-467c-88e3-8a73773b3f7f">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTQtMS0xLTE2OTYwOA_24534ec9-7c1c-4995-b873-7ed1975a1365">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTYtMS0xLTE2OTYwOA_b2eb56a0-5ace-4728-9f9c-8ed20b1b1f9e">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTItMS0xLTE2OTYwOA_e40b4112-fad9-4416-8da2-210c8eeb1d28">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTQtMS0xLTE2OTYwOA_5e4008ca-efd2-4b73-9d05-1f74781fcda9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTYtMS0xLTE2OTYwOA_a031e3a4-a7dc-4bc9-9993-25cf7f62dead">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTItMS0xLTE2OTYwOA_2e16f5df-d713-45fb-8e49-7dbf69785a4d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTQtMS0xLTE2OTYwOA_ce4a5808-8e9a-4f00-a8eb-51a2226d54f3">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTYtMS0xLTE2OTYwOA_7e75b674-07bc-4704-8729-403bc5f736f2">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTItMS0xLTE2OTYwOA_329322f9-b5e2-40b8-8326-255343f95000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTQtMS0xLTE2OTYwOA_1faa674c-d7cb-4766-b60a-af44b2651bf1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTYtMS0xLTE2OTYwOA_f7c26f63-74b1-4ce3-ac46-5f07b1b2d76b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTItMS0xLTE2OTYwOA_09deb267-d507-4f17-86e0-550289518dc4">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTQtMS0xLTE2OTYwOA_8b13b771-3a3a-49c6-99fb-d72954a35e6c">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTYtMS0xLTE2OTYwOA_a6cce20a-05b8-4142-88bf-2d3d80c09acd">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTItMS0xLTE2OTYwOA_adda07c7-b7a4-4201-83e3-ec97b93f774d">6,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTQtMS0xLTE2OTYwOA_ee078d60-f997-419e-865a-6e19581791b5">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTYtMS0xLTE2OTYwOA_337793a5-3b7d-492b-be26-4c44e4040372">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTItMS0xLTE2OTYwOA_6d12d6bd-db8e-4cd8-a79c-7afd4a088e23">7,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTQtMS0xLTE2OTYwOA_8ac7e08c-a68f-4cd4-9c54-a79812950562">3,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTYtMS0xLTE2OTYwOA_544befcd-2bc7-4a5a-ad2b-aed9d57298b4">5,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTItMS0xLTE3MTM0NQ_84b34851-0932-410a-a084-26690951e270">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTQtMS0xLTE3OTc0Mw_91f1df3e-f38e-4875-960c-3165d7075dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTYtMS0xLTE3OTc0Mw_146eedc8-05f4-4b2f-8228-efbaf58b65ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTItMS0xLTE2OTYwOA_c76666eb-c6c1-49a4-88a9-d51dc4552a92">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTQtMS0xLTE2OTYwOA_5038ea7c-1ec8-4ef7-80e7-7196578a12a1">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTYtMS0xLTE2OTYwOA_b9138e08-e452-4c27-ac39-7a4f76ffc8e7">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTItMS0xLTE2OTYwOA_e90bf8ba-a9a2-4b3f-8d96-6d0235b1837e">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTQtMS0xLTE2OTYwOA_9721b989-8b00-47c9-b838-138c66f23244">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTYtMS0xLTE2OTYwOA_07df6af1-476b-4471-b1db-792d0e2c3907">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTItMS0xLTE2OTYwOA_f9f12fbf-a17e-43ce-9db3-8a85b4821d59">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTQtMS0xLTE2OTYwOA_2b8e45a3-c527-4264-b663-24d7495e2167">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTYtMS0xLTE2OTYwOA_9d9ea72d-af0d-4bb6-8015-65a38f976bc3">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTItMS0xLTE2OTYwOA_c34b63c5-ae1e-4cab-86f8-ce836162fa14">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTQtMS0xLTE2OTYwOA_c77fb692-a76b-43e5-a7a5-e7673e342550">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTYtMS0xLTE2OTYwOA_cd224ac0-2f21-41f7-8b0b-18d4c2f48f41">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTItMS0xLTE2OTYwOA_cb621696-f1af-4f86-9d95-fa3f91d18bc6">474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTQtMS0xLTE2OTYwOA_419df6ef-4eba-4ab9-be86-74756d1111b9">1,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTYtMS0xLTE2OTYwOA_59c922e5-f4f0-448f-a59b-dc099248f0b4">2,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTItMS0xLTE2OTYwOA_460910e1-1dcd-4d73-94a5-6b57c5dac03c">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTQtMS0xLTE2OTYwOA_a5c7e7e9-eb0d-446f-a488-443faf47d004">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTYtMS0xLTE2OTYwOA_b6eed6d0-5720-4788-b781-6b710e4d6463">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTItMS0xLTE2OTYwOA_89687c7d-e33a-40e2-b73a-d14ff83d183a">1,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTQtMS0xLTE2OTYwOA_1ea97607-7e82-4db4-a10b-681b08c1734f">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTYtMS0xLTE2OTYwOA_ab31cdac-4697-49a4-9185-9d76b727234e">1,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTItMS0xLTE2OTYwOA_9ce12bc3-31c6-4f3f-9e2c-e0d4bf2e1c37">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTQtMS0xLTE2OTYwOA_ea7d7842-b82d-4a71-a0bc-1cbb7fc505d4">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTYtMS0xLTE2OTYwOA_7d575ce0-18a0-42da-8517-cc785d0adcfb">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTItMS0xLTE2OTYwOA_27f799cf-e2a2-452b-a568-613b35e49423">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTQtMS0xLTE2OTYwOA_9ad6badb-995e-4262-a759-b5fcf07fb0bf">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTYtMS0xLTE2OTYwOA_386ad3c3-ebf0-4a52-bba7-68b2d32f0bab">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTItMS0xLTE2OTYwOA_ac6d0ddf-3c80-459c-99e6-ff7129269eb8">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTQtMS0xLTE2OTYwOA_9354e81f-d7c5-435b-ba5e-2c611bd58fe7">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTYtMS0xLTE2OTYwOA_5d2e77b9-dad0-41a8-86fd-206cf9457380">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTItMS0xLTE2OTYwOA_5cb3f4ad-f865-44be-9f25-b0ab98678884">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTQtMS0xLTE2OTYwOA_3d38d40c-db8e-44ad-9c16-91050690bcf0">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTYtMS0xLTE2OTYwOA_d6ed8d13-4fec-49b6-9ab1-c414044dd32c">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTItMS0xLTE2OTYwOA_5b46ef98-1540-4c83-a054-1bf7dd3cba5e">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTQtMS0xLTE2OTYwOA_6649e5d2-5fe2-4f03-94e8-abf30122ff90">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTYtMS0xLTE2OTYwOA_6e68a0a6-bc9d-4d0e-a458-226145b35d8a">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_310"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i57fbe32677504c888f142dd82b99b37f_313"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzEwOTY_c1d4af01-9330-413c-b6a3-cef914ebabdf" continuedAt="ib8a743b4d15d4295be20fa09a2c9584b" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib8a743b4d15d4295be20fa09a2c9584b">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately <ix:nonFraction unitRef="number" contextRef="i35ad12432cad49608f2807386679107d_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzE2NDkyNjc0NDQwNTI_38778cec-8ef6-4e0c-b174-2753a6309002">89</ix:nonFraction>% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzE2NDkyNjc0NDQwNDc_cf0b75ef-e3b7-410d-a6d7-5e45304e86f0">100</ix:nonFraction> countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</ix:continuation></span></div><div id="i57fbe32677504c888f142dd82b99b37f_316"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTYy_bbe16f0c-4512-45e2-a629-2abe0824dafb" continuedAt="i4d5ec2482b6542a49b682e0a599f1e78" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4d5ec2482b6542a49b682e0a599f1e78" continuedAt="i25be48f9d04a475dbe03d42ab2af74b9"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjEw_ab7694cc-e717-401b-a235-40ed879d637a" continuedAt="i55a38a63ff8a4a10b05a6288f7e47036" escape="true">Basis of Presentation and Use of Estimates </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55a38a63ff8a4a10b05a6288f7e47036">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold <ix:nonFraction unitRef="shares" contextRef="i9854d974005d4f129d1f349b2e8e9e0e_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5NzM_3d01fe22-b992-486b-aeb3-fa00c67fa892">35,000,000</ix:nonFraction> common shares of Bausch + Lomb, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i571caf526a3f498d9102359d54985610_I20220510" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5ODU_72b100e5-0d44-4d54-9e5e-44329e376422">18.00</ix:nonFraction> per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of <ix:nonNumeric contextRef="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510" name="bhc:SaleOfStockOverAllotmentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyMjk_cffea732-b06a-4e81-82a6-26c34d851234">30</ix:nonNumeric> days from the date of the B+L IPO to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510" decimals="INF" name="bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyMTk_6486c715-10ce-47bd-bce9-c677f7090657">5,250,000</ix:nonFraction> common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional <ix:nonFraction unitRef="shares" contextRef="i664418729e77455ea311715c8025ba3c_D20220601-20220601" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNDM_9a540386-7401-4df6-811a-1dae435a7ea2">4,550,357</ix:nonFraction> common shares of Bausch + Lomb at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie4af7206f3dc4cb7ae55779f23145348_I20220601" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5OTM_ed631fb7-578a-475d-984d-ecada0416dbe">18.00</ix:nonFraction> per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds <ix:nonFraction unitRef="shares" contextRef="ibb85da3e8b8943f38dca2d158d722362_I20220601" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTIwMDE_3f35289a-35c9-4931-8eb9-3ead2630dfd5">310,449,643</ix:nonFraction> Bausch + Lomb common shares, which represent approximately <ix:nonFraction unitRef="number" contextRef="i4538c7b5b4ca4fdeab03c2bf4233e8d9_D20220601-20220601" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNjk_fc16d1c3-8eba-457d-8515-9c5c766bec8f">89</ix:nonFraction>% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $<ix:nonFraction unitRef="usd" contextRef="i285925d86568407da8a3757803694323_D20220601-20220601" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNTU_03b6ce4e-4d17-46a3-8162-900a310437ed">675</ix:nonFraction>&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International, Diversified (dentistry, neurology, medical dermatology and generic pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these audited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i25be48f9d04a475dbe03d42ab2af74b9" continuedAt="i2d7d246cc2ac41bd98e7ad904aada6ea"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Suspended Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221; or &#8220;Solta Medical&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDE4_eeee03fe-24cc-4ce1-a020-b05a87e05452" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company&#8217;s Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjA0_47c3e150-1ffd-4930-a0dc-58a3545138e4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i2d7d246cc2ac41bd98e7ad904aada6ea" continuedAt="ic324bbd4fa494e51a932ceec0b97d757"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTgz_7ea750c8-73c5-45e8-9082-e356dbc0e9e4" continuedAt="ia306b83c92e943519f42ed097c326a43" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjUw_0a269a98-5fdd-4ed1-b526-8144e772f870" continuedAt="ib6d3be5d384444058ad0d08335401e13" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib6d3be5d384444058ad0d08335401e13">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</ix:continuation> </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjA4_47291656-c9e4-4ad0-afb4-1bb4908f8b6f" continuedAt="i4390ad853d434bf093e832ceea1248e0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualified for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4390ad853d434bf093e832ceea1248e0">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows.</ix:continuation> </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTg3_eae3fa0f-bcac-4fc6-8729-3a7457ac3226" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwNjAy_5c3f5865-3042-443b-b426-bd12cb964763">three months</ix:nonNumeric> or less when&#160;purchased.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTky_69b1234e-9151-4f80-baa6-bd18e246d488" continuedAt="i2bf823af4f3241d5958d350554e894ab" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzExMDYy_a5d26158-a9c3-4120-aac3-20a7efd8c834">three months</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic324bbd4fa494e51a932ceec0b97d757" continuedAt="ied2ebe41f9dc4ebba54e7500d3bf3792"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bf823af4f3241d5958d350554e894ab" continuedAt="iaa53d208a8a245fda5f68a4e78bb722e">reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa53d208a8a245fda5f68a4e78bb722e">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela have been weak in recent years.</ix:continuation> These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company&#8217;s <ix:nonFraction unitRef="wholesaler" contextRef="i83b9870676f542a6aac864bbace50b24_D20220101-20221231" decimals="INF" name="bhc:NumberOfLargestWholesaleCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyNjAx_24ad25a1-02d3-424c-b873-6c720a790990">three</ix:nonFraction> largest U.S. wholesaler customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="2" name="bhc:ConcentrationRiskPercentageofNetTradeReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyNjY2_81950fd8-f860-4e3a-bc75-a9a51119c659">46</ix:nonFraction>% of net trade receivables. In addition, as of December 31, 2022 and 2021, the Company&#8217;s net trade receivable balance from Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela amounted to $<ix:nonFraction unitRef="usd" contextRef="ie91578972bdb40a3af61e355b78d5073_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyODY3_2c0f0906-e856-457b-9e10-bd709522be64">136</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3f9466cb58824868850dfff1f0fc66e1_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyODc0_3db44387-9bbf-4a16-8a75-15ee5ae6c6af">78</ix:nonFraction>&#160;million, respectively, the majority of which is current or less than <ix:nonNumeric contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231" name="bhc:PastDuePeriodForAccountsReceivableToBeNegligible" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyOTM4_38906f33-2ada-48d0-87c4-9f0820a5ad19">90</ix:nonNumeric> days past due. The portion of the net trade receivable from these countries that is past due more than <ix:nonNumeric contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMDQ0_a2da58f4-24a1-43c4-9399-181be279c881">90</ix:nonNumeric>&#160;days amounted to $<ix:nonFraction unitRef="usd" contextRef="ie91578972bdb40a3af61e355b78d5073_I20221231" decimals="-6" name="bhc:TradeReceivableNetPortionPastDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMDY0_71e99516-eed5-4ad8-9023-c5bf869f57b3">2</ix:nonFraction> million, as of December 31, 2022, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than <ix:nonNumeric contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMzcw_bf3aadfe-6a82-4113-b84e-b7ff65790596">90</ix:nonNumeric> days for such countries. Over the three-year period ended December&#160;31, 2022, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company&#8217;s cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for additional details regarding the Company&#8217;s cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTA5_2452b79e-4001-4744-8c5b-0c680cff7689" continuedAt="i73e7c9def4604fdb997287428370ccb4" escape="true">Allowance for Credit Losses</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73e7c9def4604fdb997287428370ccb4">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</ix:continuation> Allowance for credit losses were $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MTk1_6b8a01c4-b6a4-4f9f-b2a4-cbc0e590b68d">33</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MTk5_595b0f6e-447d-4a78-835f-1e367c229467">35</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MjA2_a0be026d-ef0d-4736-a039-0ae00da6316e">39</ix:nonFraction>&#160;million as of December 31, 2022, 2021 and 2020, respectively. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDcw_9be1ae17-c450-43a9-a150-4f40c787b4af" continuedAt="i2811325fc39d4af1aa875492a0f8bb87" escape="true">The activity in the allowance for credit losses for trade receivables was as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:continuation id="i2811325fc39d4af1aa875492a0f8bb87"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtMS0xLTEtMTY5NjA4_f669fe1f-8eb4-43d9-ab38-a344209fd399">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtMy0xLTEtMTY5NjA4_e1b74fc3-7600-4f80-8bd2-b75f18bd4df0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtNS0xLTEtMTY5NjA4_d25f6fae-b9c2-4204-b9c7-8d239a07953d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItMS0xLTEtMTY5NjA4_c90abe9a-6777-4568-a467-5f80ff0a0ae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItMy0xLTEtMTY5NjA4_45af9eb6-fddf-46ad-a869-a8253cf9d9a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItNS0xLTEtMTY5NjA4_21adff16-837f-46aa-b288-80bd9b31eaea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtMS0xLTEtMTY5NjA4_c4bc7417-039f-4ea8-bc85-03d68005b41b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtMy0xLTEtMTY5NjA4_bdb1e41f-fb5f-4ac7-9f6c-15c9d6e51711">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtNS0xLTEtMTY5NjA4_bd85ac87-13c1-4a32-bb69-19983315c86b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtMS0xLTEtMTY5NjA4_73d4096b-8427-411f-aa6e-ed3bf4830ac5">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtMy0xLTEtMTY5NjA4_d52488a5-a24f-4616-8714-c365a970791a">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtNS0xLTEtMTY5NjA4_45be36f4-d6a7-4729-98a3-59ec4b7b0cb7">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtMS0xLTEtMTY5NjA4_ab55f6a1-a8c9-48a8-b3e9-98e4b124826a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtMy0xLTEtMTY5NjA4_67308d4c-339a-4ecf-9bf0-d854fde2f142">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtNS0xLTEtMTY5NjA4_0b0e1446-f726-4a98-8fbd-760183e33b41">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtMS0xLTEtMTY5NjA4_893fcb12-89cd-4ee7-9fe7-4083edb3aa7e">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtMy0xLTEtMTY5NjA4_ec4063dc-ae32-49db-bafe-e9282611aa9d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtNS0xLTEtMTY5NjA4_f3842161-dbeb-483a-8b01-9678e92a8766">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctMS0xLTEtMTY5NjA4_6b8a01c4-b6a4-4f9f-b2a4-cbc0e590b68d">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctMy0xLTEtMTY5NjA4_7e681143-84f6-4e0a-9463-5ae6e783f32c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctNS0xLTEtMTY5NjA4_bcccc805-ab91-47bc-9b6b-10c6d25f590c">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQz_b5dd6121-6acc-496e-8dd5-69d0c65091c7" continuedAt="i6ba58bba24094f2fb0510c9146b8829a" escape="true">Inventories</ix:nonNumeric></span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ied2ebe41f9dc4ebba54e7500d3bf3792" continuedAt="i1143b990f02c48ef93a0b1005abcac37"><ix:continuation id="i6ba58bba24094f2fb0510c9146b8829a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div></ix:continuation><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTE2_86b43457-ee65-4876-8598-7a09f28f5847" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTIz_51a6e9e6-578e-4f7a-ac79-c4b95028aafb" continuedAt="i0ab758e6a0df407f94b6bebd7edeb272" escape="true">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i0ab758e6a0df407f94b6bebd7edeb272"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmQ2ZTg1ZWMwMDUzNDVmOTlmMzhhMTQxYzcwNDIxNDlfNA_b28b5193-8480-43ca-8b0a-8db09df9f8ac">15</ix:nonNumeric> - <ix:nonNumeric contextRef="ic15bd253c0ab41118c4045afdf0da935_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmQ2ZTg1ZWMwMDUzNDVmOTlmMzhhMTQxYzcwNDIxNDlfOQ_c4b414c1-45ca-4c12-83e1-cd9905ff1e68">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="i1524d212be2e451fb87eaa66b46428f1_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246N2I0YzJkYWYzZDVhNDgxZDkxNjYwMDljYTE5N2IyMDdfMTA_a225e206-ed7a-4687-8875-1c75f5f0b7ef">40</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9f0642352c64cc196cfc2d1d9b89a93_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NDFkYzI1YTM0NjQ2NDM3YThkNWNlMzM4YjIyNTg2NjFfNA_e7ddc8a5-e1e6-4cc7-a36b-99283203a669">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="if32df11a6c7b427ea3edf23629b832da_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NDFkYzI1YTM0NjQ2NDM3YThkNWNlMzM4YjIyNTg2NjFfOQ_7c54a46a-c164-4f6b-852f-405c2660afa9">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica86b1d3841f48b0a4940ae2217f149d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGQ4MGQwZTAyYTVlNGFmYTkyMjU5MGY4Y2YzMTdlNjZfNA_40946f9e-80d6-4cad-bc97-c078370aac11">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="i829741d1c6804070b7cafb83060ea664_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGQ4MGQwZTAyYTVlNGFmYTkyMjU5MGY4Y2YzMTdlNjZfOQ_89d4e7da-5673-44ea-aad8-d66b3527f0ed">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="i073d5fbb37a74b6896df8b862273a349_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246Zjk5ZGE2OWZjZWQyNDk3ZmI5ZWViNWFiYWYzZGNhYmZfMTA_38b7044c-e414-4c37-b230-5a1c6061ef83">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or <ix:nonNumeric contextRef="i6fddaa647d224e77a75b08d87ff4b3b3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzUtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZjUzZjJiNWY0NmNkNGRiN2I0NWM5MjFjMDRhZjJiNDNfMzE_c53acef2-4cf3-4623-bf6b-c9dbe11a76ab">10</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTUx_3e5b4b16-c4a3-4ad5-ad02-856f623619bc" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDI4_dd713bab-4a84-4b10-a627-f1651cc8d760" continuedAt="i5e73a4f33dc545328fc7728932aa2e46" escape="true">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt"><ix:continuation id="i5e73a4f33dc545328fc7728932aa2e46"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7338914353884cdba4212e42f3f0a816_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZmQwM2Y4ZGM5OWNlNDU2NGEyNWUyZWE3YjRkYzMyNDlfNA_895fb916-8b6f-4da1-9b43-d03f13d5e006">1</ix:nonNumeric> - <ix:nonNumeric contextRef="i0ce6f99808e4460581a8ecf630ae0e44_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZmQwM2Y4ZGM5OWNlNDU2NGEyNWUyZWE3YjRkYzMyNDlfOQ_0f5fe397-73ec-44fa-8795-f1f9959fa56f">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iba264d87eb1844f383743044281eca57_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NWRhY2QxNWNhNmNhNDMyOWE0Nzg3NTgwNDAxZTk1YzBfNA_5cbad66d-ca05-402c-b753-cdba09f980d4">9</ix:nonNumeric> - <ix:nonNumeric contextRef="i58b60e4e1ba344759f420bb9dbb9e07f_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NWRhY2QxNWNhNmNhNDMyOWE0Nzg3NTgwNDAxZTk1YzBfOQ_183f46b3-1687-43a2-94df-a555010199ac">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id33f7392918d41c58f5a2c8261fd0cfd_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTdkMTYzNWUwMzlmNGZlNmFlOTc3ZTNlMTExZDJkYTdfNA_18011c84-b006-42d0-a06b-26dac02827af">4</ix:nonNumeric> - <ix:nonNumeric contextRef="idafb37adc38a40a1bddab0dddf725726_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTdkMTYzNWUwMzlmNGZlNmFlOTc3ZTNlMTExZDJkYTdfOQ_461bc9b3-b598-495e-9423-32ef92dff8da">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42fbedcd6cef45eda7bf77d1487a41c0_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDgyNGU4NDRlY2NlNDc0OWEzZDI1MzNhZDhmMWRhZGNfNA_ed8d0130-74c6-4929-9d8c-78f738320e79">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i95efbf91ff384469ba31cc31eabf84f4_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDgyNGU4NDRlY2NlNDc0OWEzZDI1MzNhZDhmMWRhZGNfOQ_17bcddf8-1a40-4adc-b4ac-a4f0ff9cc608">9</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43679a56867547b585e61a8bebd30a9b_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246YmY2YmFhMGJjNjAzNGFkYTlhYzJhYmY0NmY5MjRkZjRfNA_c6fc69ad-6551-498f-aeaf-c6908b000186">8</ix:nonNumeric> - <ix:nonNumeric contextRef="if0f5735466294af0bf44c228f9e7909e_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246YmY2YmFhMGJjNjAzNGFkYTlhYzJhYmY0NmY5MjRkZjRfOQ_45704082-b148-46a8-930e-9cc40855a6ee">9</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:DivestituresOfNoncoreProductsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTI0_c5e9874d-7980-477a-a256-240dd18fbd4f" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTI5_eb39246b-0c3b-4457-bb37-ac0235a3b1e2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjU1_f365aed3-bedf-488a-be74-33c270123fbf" continuedAt="i24ceb71e243c4388bd3545c149aa0851" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i1143b990f02c48ef93a0b1005abcac37" continuedAt="icea83b4cbd69448495fd8e2373903f54"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24ceb71e243c4388bd3545c149aa0851">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8220;B&amp;L Trademark&#8221;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</ix:continuation></span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTMw_766b0e95-1d45-4053-be59-982c5f33cd56" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors, including rising interest rates and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDU3_9a41fa7f-85a4-4d96-b5ad-95606e43cc18" continuedAt="idb0a6d4a72944a068775649ec0c02821" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. </span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idb0a6d4a72944a068775649ec0c02821">The carrying value of modified debt accounted for as a troubled debt restructuring consists of all future undiscounted cash flows, both principal and contractual future interest, associated with such debt. The excess of the carrying value over the principal amount of such debt is recorded as a premium and is reduced as stated interest payments are made on such debt.</ix:continuation> </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDk3_128669b7-a3a8-481d-8aea-52d2ec8539cb" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="icea83b4cbd69448495fd8e2373903f54" continuedAt="i3a80d870d1244031bf5a75e704239185"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTc5_ff90b253-5c2f-456e-baa7-c363f450636e" continuedAt="i1a8936a0e4c140959e58db5a96bcfbd2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQ1_e6bfe8a8-971c-4ac1-ac72-49d8d07f1bc9" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2022 and 2021.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e3ff0b63c54e8195b04d98b1f2ea94_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMi0xLTEtMTY5NjA4_494b98e3-e6c9-452e-a20f-f0dcebc42bb3">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c9ecdf3caa44afb7674f4ff6cfa6bf_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtNC0xLTEtMTY5NjA4_99d01828-a556-447b-8377-a55288cbab6b">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab447034f3cb4a3f80c5615de06f525e_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtNi0xLTEtMTY5NjA4_4d57d1da-66ec-4b71-9020-ae2cdb033104">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1298ccb8014e2e952b7df5ed8488c0_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtOC0xLTEtMTY5NjA4_f126cdcf-2ae8-4986-8352-603f6a355c91">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ec7611adc424942b82f55c3fddc6e0c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMTAtMS0xLTE2OTYwOA_02dde61e-2710-4765-8ba0-c4bafbff775a">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMTItMS0xLTE2OTYwOA_77f59811-53ac-4cc2-9d75-8faf85b3774b">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMi0xLTEtMTY5NjA4_d6d867cc-e463-4301-9297-e1f4e5595562">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItNC0xLTEtMTY5NjA4_07c72923-7006-4837-98e8-a0dc1cb21b74">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItNi0xLTEtMTY5NjA4_65aa9de1-029f-46de-b010-747b5726f31d">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItOC0xLTEtMTY5NjA4_b1d3780e-9295-4adf-b2c5-4c106e22dc9d">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMTAtMS0xLTE2OTYwOA_a05d3e84-3d72-457a-b093-6040c959ec55">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMTItMS0xLTE2OTYwOA_00f23e63-6dd6-4d76-a4c6-12cd1f6f971d">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMi0xLTEtMTY5NjA4_bdf27bbc-8348-45b6-aa67-7a85a5abede6">593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtNC0xLTEtMTY5NjA4_2e26c13d-b68b-4700-913b-4d8b08b4582a">224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtNi0xLTEtMTY5NjA4_09f4d17a-a920-425a-9216-0395c21cbcca">2,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtOC0xLTEtMTY5NjA4_04dc3312-f501-4b84-8d73-469290dd2f44">2,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMTAtMS0xLTE2OTYwOA_cf4c0013-6ae9-497b-9304-11ae8a246d5d">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMTItMS0xLTE2OTYwOA_e96f145f-e12f-4860-8fe2-215bb434b1b3">5,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f3ba9f79754b2ea2362524743f75b0_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMi0xLTEtMTY5NjA4_096b5c49-4df1-4b89-b303-2335ebeaa023">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa6fc4c28dfc4f42aa151ae93e67746a_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtNC0xLTEtMTY5NjA4_c000d0a0-94b3-4dd1-a63f-85188e6e7eca">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd7e5042c154abd8c3fb0ba3a5333b1_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtNi0xLTEtMTY5NjA4_af769179-01a4-4d25-a947-ab957425418e">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719c1c8681de42628cd8a33f7cf93c13_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtOC0xLTEtMTY5NjA4_51fe56fa-ceb2-44d7-8741-2d500255531c">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ffab7018d0f4f64a53a07c03c589447_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMTAtMS0xLTE2OTYwOA_a5bb3364-50e8-414b-8448-56cd2f27ac38">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMTItMS0xLTE2OTYwOA_34126a7c-9582-47e3-a0d0-e20471d557c0">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMi0xLTEtMTY5NjA4_d8f26d02-1372-428c-adc1-53031235e703">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtNC0xLTEtMTY5NjA4_d608d20a-97a5-4193-86f5-796291abca4c">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtNi0xLTEtMTY5NjA4_d800e88f-01b6-4d76-9ce6-17d2b44b6504">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtOC0xLTEtMTY5NjA4_68120421-1219-4da6-961b-e0e76f99ce0d">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afa3f38b75645c38047038819ab8039_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMTAtMS0xLTE2OTYwOA_91c5eb1e-2152-4af8-888b-e8605d89727f">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMTItMS0xLTE2OTYwOA_cde888f6-19b2-4afa-abcd-480df174234d">5,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMi0xLTEtMTY5NjA4_4e3e7a25-db8a-4808-a5b1-c9c7ca9c4c86">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtNC0xLTEtMTY5NjA4_1639a179-6416-4ab5-bbc9-d14c17d7c5ef">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtNi0xLTEtMTY5NjA4_a3af2318-a27d-4566-9e42-ee7e606626f5">2,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtOC0xLTEtMTY5NjA4_e7bbec91-57e2-46f7-ade6-4688f9bb9e1b">2,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9afa3f38b75645c38047038819ab8039_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMTAtMS0xLTE2OTYwOA_f3ae2dff-de21-48eb-b2b0-fa9376d9356a">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMTItMS0xLTE2OTYwOA_a67f5dce-70e4-47b4-a3c9-2c689afdbf42">5,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af36779781240ea8b5a9fc2a8a18c0e_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMi0xLTEtMTY5NjA4_b45571e6-5a31-4d17-913a-b815cab12c38">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b3071dbd0b4c22a7410dae4bf7b27e_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctNC0xLTEtMTY5NjA4_f18a0edb-9cb6-498b-a755-89a0c6c8db2a">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f6251d34e449328ee02711fb471754_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctNi0xLTEtMTY5NjA4_3c8335dd-36c0-4b78-8ccb-981f4e98611f">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b3dad0951e4afdafdd9832d60755e6_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctOC0xLTEtMTY5NjA4_367b73ad-094c-41f2-8a9c-7836cbe501e6">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a778a0ae49a449791a3ba321887c7e1_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMTAtMS0xLTE2OTYwOA_ccf2d8db-7753-4baf-b8da-03e3e73b35fb">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMTItMS0xLTE2OTYwOA_9003aed2-ec87-4b1c-b9a5-15e8f8c995c3">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="ic1634ddcaf934a68ad0cbcba62dae846_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI2OTQ3_3c89bfef-ec52-4fed-8efe-9f3f4a0eece1">40</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i12975a1db9344dbda6b24ceb8ae4993b_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI2OTU0_497f8447-4682-4959-8d4f-af28abf2f7dd">36</ix:nonFraction> million as of December 31, 2022 and 2021, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3a80d870d1244031bf5a75e704239185" continuedAt="ib26a5c311e884285a3746e0a69bf70be"><ix:continuation id="i1a8936a0e4c140959e58db5a96bcfbd2" continuedAt="ie1e0c95acc8044409527aeca39e0d46e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:CashDiscountsAndAllowancesSettlementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI5NDUz_ddf974de-ff1f-48a9-bcc8-bb1465a7b871">one month</ix:nonNumeric> of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib26a5c311e884285a3746e0a69bf70be" continuedAt="i4296f13bf958439087185668454d5fb6"><ix:continuation id="ie1e0c95acc8044409527aeca39e0d46e" continuedAt="ib0025a3242de4f2fb35f6a8f0ac8e050"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMTc3_859e9cf4-acde-423a-98d9-20010aef4e19"><ix:nonFraction unitRef="usd" contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMTc3_b745aa0f-e1a8-4b3f-9364-3f00f6d01d79">131</ix:nonFraction></ix:nonFraction>&#160;million in each period, and include reductions in variable consideration for sales return provisions related to past sales of approximately $<ix:nonFraction unitRef="usd" contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMzE5_62ddc654-c407-4d59-9456-2bcbc7614241">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMzI2_9d9e111c-05c2-4b7c-98f9-c6a2f2d25719">28</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160;The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product mix and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2022 and 2021 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a </span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4296f13bf958439087185668454d5fb6" continuedAt="i762813ff21924998aa2ba3f2cbf32bfc"><ix:continuation id="ib0025a3242de4f2fb35f6a8f0ac8e050" continuedAt="ic155b8677c314bf9b3efca534a25e867"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $<ix:nonFraction unitRef="usd" contextRef="ifc88addf22a44ee8b85946edc015b2db_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5MTA5_da81a542-be2c-4a9c-b9ca-3c64c2262c32">10</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i879910dcddad4e1ba3539787593b400e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5MTE2_2be397bf-8b0c-4dd8-a6fe-662b5b6d6b68">17</ix:nonFraction> million for the years 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic155b8677c314bf9b3efca534a25e867">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</ix:continuation> The Company&#8217;s global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTI3_ff4eb31c-416c-4e09-84fe-f967761f1790">thirty</span> to <ix:nonNumeric contextRef="i3066bc5404d6492ba2a9b0f3e2e60f4e_D20220101-20221231" name="bhc:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTMz_4eae5ac7-68da-460a-a657-fc758f423b02">ninety days</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDc5_7ac9b54d-f1f9-4a3c-9aa7-dc857eb1ddf1">one</span> to <ix:nonNumeric contextRef="i3d9a436ca4734f6f94506b064f541daf_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDg1_dff224df-09ee-49bc-a68a-d14bfccc10c8">twenty years</ix:nonNumeric>, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTcz_3643a3d1-f7d7-4998-afc9-5317fb44ffa9">one</span> to <ix:nonNumeric contextRef="i3d9a436ca4734f6f94506b064f541daf_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTc5_26d12a7e-2aed-4a34-ac69-bff62b68c6be">five years</ix:nonNumeric> or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company&#8217;s lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTgw_f284532f-db47-490a-bc73-82e5bf9202ba" continuedAt="ic0d94a7118074f1d800c94ccf6695979" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i762813ff21924998aa2ba3f2cbf32bfc" continuedAt="id0cf60aa3c4c4e81a8bf000ddb972699"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0d94a7118074f1d800c94ccf6695979">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</ix:continuation></span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTQz_95db29ab-e9f7-43e4-8cea-7afe5305b8a3" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sale of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQ2_c159cbee-d61a-4b31-862e-0a5c204fd83f" continuedAt="i42d503844d5a4dfba741fd08cdf457b2" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42d503844d5a4dfba741fd08cdf457b2">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</ix:continuation> Included in Selling, general and administrative expenses are advertising costs of $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjU3_d9763f59-761b-4214-a06d-46c914766d85">518</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjYx_c23b0bdf-e45b-4d67-9ace-5461ee20445f">515</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjY4_15915bb1-8f14-4652-96fb-03596ab420fb">451</ix:nonFraction> million, for 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDc1_c86803fc-85a9-46ce-a29c-d12cc81b3c1a" continuedAt="i8ecb8839c3b64566bc46ad59134c8eac" escape="true">Share-Based Compensation </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ecb8839c3b64566bc46ad59134c8eac">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</ix:continuation> </span></div><ix:continuation id="ia306b83c92e943519f42ed097c326a43"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:InterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDgz_5dc10af9-de21-4a97-a3cd-e56629ef1462" continuedAt="ia56248e25814409eaaeaa33a885bf022" escape="true">Interest Expense </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia56248e25814409eaaeaa33a885bf022">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company&#8217;s cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</ix:continuation> Capitalized interest related to construction in progress as of December 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ2NTky_cb5ca372-f5fa-47c1-b11f-acfd08ba9404">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ2NTk5_0e459049-2c10-44f9-abb7-8c14061d0956">60</ix:nonFraction>&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjIx_b7a06343-331a-4b3e-be3d-e95435fa0cd7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than <ix:nonFraction unitRef="number" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="bhc:TaxBenefitRecognitionMeasurementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ3Njgz_deae431a-df4f-4b0c-babf-aeb4069a7bcf">50</ix:nonFraction>% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ3ODQ2_788f707c-75f3-4cf4-8759-b8dd28849916">one year</ix:nonNumeric>. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTc3_94ca78bd-02b2-4adf-afe7-4b095b4f588b" continuedAt="i8358cdbbdcdc426bbc37568a7ea74c3e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id0cf60aa3c4c4e81a8bf000ddb972699" continuedAt="i3e29bb47260c4a48b56a9101c18a6ff8"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8358cdbbdcdc426bbc37568a7ea74c3e">Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</ix:continuation></span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTM4_84757d0f-3d75-4c14-a639-011e044099ec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive loss. Other comprehensive loss includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDE0_d7ba23eb-9208-4601-9576-1511c8944a9d" continuedAt="ifd4f5707235d4fa9b90a4cb9b5727f00" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd4f5707235d4fa9b90a4cb9b5727f00">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDk0_8a719ee8-7a9e-4442-b1aa-4c457c10abea" continuedAt="i6390f7f85900409d82cf14be0f37ccef" escape="true">Employee Benefit Plans </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6390f7f85900409d82cf14be0f37ccef">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed <ix:nonFraction unitRef="number" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzUwNTY0_b49b0194-2219-48ca-9e45-0e7b1137017e">10</ix:nonFraction> percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</ix:continuation> </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDI3_d5a74000-d324-4b77-993c-1db58ccd4e86" continuedAt="i200199f14de04afcbf5cd2fe761c54ae" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $<ix:nonFraction unitRef="usd" contextRef="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzUxNTU1_22b38246-9d5f-49a2-aa72-fa85aa09f052">1</ix:nonFraction>&#160;million. The application of this guidance did not have a material effect on the Company&#8217;s results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company&#8217;s disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance was effective for the Company beginning January 1, 2021.&#160;The application of this guidance did not have a material effect on the Company&#8217;s financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160;Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e29bb47260c4a48b56a9101c18a6ff8"><ix:continuation id="i200199f14de04afcbf5cd2fe761c54ae">as of March 12, 2020, through December 31, 2024. For the years presented, the Company has not entered into any contract modifications in which the optional expedients were applied.</ix:continuation></ix:continuation></span></div><div id="i57fbe32677504c888f142dd82b99b37f_319"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzY1Nzk_06270414-a497-428d-8784-57711486ac07" continuedAt="i546512b5a5ad4fb28be85d747992fc10" escape="true">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="i546512b5a5ad4fb28be85d747992fc10"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragon BioTeck, Inc.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2022, Bausch + Lomb acquired Paragon BioTeck, Inc., an eye-care focused drug development company, having a primary emphasis on the early detection of ocular diseases. The acquisition of Paragon Bioteck has been accounted for as an asset acquisition. The primary assets in the transaction, the trademarks, represented substantially all of the fair value of the gross assets acquired. There are no future sales milestones associated with this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Titanium</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2022, Bausch + Lomb acquired Total Titanium, Inc., a privately held ophthalmic microsurgical instrument and machined parts manufacturing company. The transaction was completed to assist in driving revenue growth as well as increasing manufacturing capacity. The fair value of the acquisition has been accounted for as a business combination. Additional contingent payments may be payable upon reaching key future milestone achievements related to sales and employee retention.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these transactions, recorded within the Consolidated Balance Sheet are Trade receivables, net of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3Njc_80d4d129-d323-4490-a905-778adc823455">1</ix:nonFraction>&#160;million, Inventories, net of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3Nzk_a39dafe2-f1be-40b2-b5ba-ea7cf5a97599">1</ix:nonFraction>&#160;million, Property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3OTE_81245ccf-616b-4170-b909-130541966aae">2</ix:nonFraction>&#160;million, Intangibles, net of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4MDM_09ed35c1-6cbc-4601-bc0a-26bbe682b8a6">43</ix:nonFraction>&#160;million, Goodwill of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4MTY_c5741357-b352-47a8-8b3e-60340268ae86">5</ix:nonFraction>&#160;million and Deferred tax liabilities, net of $<ix:nonFraction unitRef="usd" contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4Mjg_45459ca5-f052-4207-b77c-0dbfa4e13feb">11</ix:nonFraction>&#160;million. Supplemental pro forma information related to revenue and earnings for 2022 were not provided for the aforementioned transaction as they did not have a material impact on the Company&#8217;s operations. Refer to Note 21, &#8220;COMMITMENTS AND CONTINGENCIES&#8221; for further detail regarding potential future milestone payments related to previously entered transactions and agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i7f28cdba1c984df9bb56e87ea0c43627_D20210331-20210331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzQ3NzE_fbd42408-1721-4161-84bf-d2f838f662fa">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i6d21286a1db84d29b25753aac5f56c63_D20201001-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzU3MTY_ff26ddc7-6e65-4cc3-91f3-fcd001d3023d">96</ix:nonFraction>&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $<ix:nonFraction unitRef="usd" contextRef="idefdc69a4d2748c3a652f4a956103762_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzU4MDQ_95451280-57b6-48f3-8402-1379c6c6679b">88</ix:nonFraction>&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $<ix:nonFraction unitRef="usd" contextRef="i524d6ebfb9f44cdab7f8e33886bbb169_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYwMzE_c12d32a2-2127-4f77-a1fe-bab4f156d1da">26</ix:nonFraction>&#160;million during 2021, included within Other (income) expense, net in the Consolidated Statements of Operations. The total loss of $<ix:nonFraction unitRef="usd" contextRef="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYxNTE_8966fc2c-e234-44ad-9354-e8498cbb1106">210</ix:nonFraction>&#160;million includes the release of non-cash cumulative foreign currency translation losses of $<ix:nonFraction unitRef="usd" contextRef="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231" decimals="-6" name="bhc:NoncashCumulativeForeignCurrencyTranslationLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYyMzc_8caa6444-a9fb-40ca-a31e-b98dcc2679a5">340</ix:nonFraction>&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_322"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIzODI_6be903ca-8969-4b3b-99b0-2e3551d9a699" continuedAt="i090085392979427787d21baeefa6d822" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ix:nonNumeric></span></div><ix:continuation id="i090085392979427787d21baeefa6d822"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iebf28d9434964d1dba31bb27dbb684d3_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY1OA_02e83f20-4f18-4d3c-abdc-20503babc1d1">12</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY4Mw_07571652-7011-4d00-ae9c-23a35b8682b4">30</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY4Nw_64dfef02-477f-47cd-a824-b37352e6d049">18</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY5NA_21376adb-3577-4d4d-b1b2-5261de337fa4">11</ix:nonFraction>&#160;million of <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE2NDkyNjc0NDU3MDk_0606c3ba-99d4-4052-9fd9-143598f22791">restructuring and integration-related costs</ix:nonNumeric> and made payments of $<ix:nonFraction unitRef="usd" contextRef="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc2NQ_ee278414-4ef2-43f2-b96f-b9d7a47d3086">41</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc2OQ_48f005b1-2f0e-4e5e-a56a-06f12e575bb7">19</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc3Ng_36f45a0d-eb14-493d-bc8b-2b67cc34fefb">18</ix:nonFraction> million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022 and 2021, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2022 and 2021 are Separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE3MTU_1c7bfdac-1ae8-4028-bb75-c00e6c3d22b7">33</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE3MjI_daae52ff-abd6-40ab-9e8c-f0dcaa503897">32</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2022 and 2021 are Separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIyMzY_de3e47da-4ee6-4e1e-9858-a896837fae9e">94</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIyNDM_f2f16f67-00c9-458c-b67d-6b1683ea0625">132</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_325"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MzI_7c694c80-9e46-4dc6-ad57-8c227e29caee" continuedAt="i86e28f740f2e42eba81a7875e8d4a6f9" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i86e28f740f2e42eba81a7875e8d4a6f9" continuedAt="id93e62f7665943b7b3aa8cab5eeaf663"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id93e62f7665943b7b3aa8cab5eeaf663" continuedAt="ic56825e388b44bc4894cfb7d20f504a4"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjM_9a9568ff-7ca1-401a-998f-03fdb4ee9ea4" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:25.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1f360554f7411582424cb25e12139f_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMi0xLTEtMTY5NjA4_bd36812a-2284-4734-98cd-4fbb236a8f0f">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955e95f8176a41949983431111fba814_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtNC0xLTEtMTY5NjA4_7f1a0822-c482-4b33-bfd8-90930a412ecb">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic539170d6fff4d05972a7397e5960010_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtNi0xLTEtMTY5NjA4_3054d63f-f597-434a-a19e-47db73c05c09">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtOC0xLTEtMTY5NjA4_12ec3b7e-cb49-47d7-a347-87ac1883abec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTAtMS0xLTE2OTYwOA_846c5c95-2d23-41d3-8309-80e0e526c897">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTItMS0xLTE2OTYwOA_ddadc037-d1bc-4315-93f4-5962cf5227c3">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTQtMS0xLTE2OTYwOA_0a70424c-119c-4ffb-ad48-7053327c2e10">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTYtMS0xLTE2OTYwOA_4bbc36ab-5523-474b-bcaa-416205b62542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1f360554f7411582424cb25e12139f_I20221231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMi0xLTEtMTY5NjA4_d5702d0e-31c2-4116-ad58-220dcd6a64a2">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955e95f8176a41949983431111fba814_I20221231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtNC0xLTEtMTY5NjA4_60c15d26-236c-4914-9b9a-0bd0b33f9fe4">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic539170d6fff4d05972a7397e5960010_I20221231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtNi0xLTEtMTY5NjA4_fc45a433-a157-4d7d-84ae-047716a3b5c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtOC0xLTEtMTY5NjA4_e2c8eff1-2e5d-486f-a950-d4d94ae16f48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTAtMS0xLTE2OTYwOA_7d169576-f7cf-47be-9c69-c370b5a8d437">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTItMS0xLTE2OTYwOA_2583047c-4943-407f-9110-be013e838121">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTQtMS0xLTE2OTYwOA_7474be01-b6aa-457d-968a-af355073f430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTYtMS0xLTE2OTYwOA_ae2b3a78-2814-41ac-a64b-b4c68f5b4bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMi0xLTEtMTY5NjA4_97d505d7-d4c9-4d97-8047-f5d41efe6369">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtNC0xLTEtMTY5NjA4_0ddc5ac4-7ab5-44a7-9682-ff9d66e2f130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtNi0xLTEtMTY5NjA4_b0b7e9fb-e8c2-4991-87d5-bb6819c797d2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtOC0xLTEtMTY5NjA4_1fb6b30a-f95b-4327-b08f-09a2438f968b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTAtMS0xLTE2OTYwOA_a4433082-5283-487c-9dbd-ab90bf839ff3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTItMS0xLTE2OTYwOA_fad02fde-0027-4d8f-b428-c201c326e1a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTQtMS0xLTE2OTYwOA_f152eac9-1c6c-4c68-a4df-39049d85a293">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85324249cb304f399a6dfe976b7fe743_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTYtMS0xLTE2OTYwOA_729e275b-da08-42b7-b396-90ac9dedffa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide1f360554f7411582424cb25e12139f_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMi0xLTEtMTY5NjA4_3198768f-80d6-45d7-a58b-02311bed435e">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955e95f8176a41949983431111fba814_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctNC0xLTEtMTY5NjA4_1a1e4f2f-1350-4100-956f-12d6dfe03361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic539170d6fff4d05972a7397e5960010_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctNi0xLTEtMTY5NjA4_6a4c7f74-fecb-4ef5-a079-0fcc76799914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctOC0xLTEtMTY5NjA4_f7b719b0-bd3d-4bba-87fd-7618db3e2902">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTAtMS0xLTE2OTYwOA_d7379a36-0bef-4c0c-bd03-1ac0194e046b">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTItMS0xLTE2OTYwOA_b096fb1d-6c3c-4eec-89ec-d70670501ee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTQtMS0xLTE2OTYwOA_40815bdc-0f64-41ae-ac4d-05da897d436b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTYtMS0xLTE2OTYwOA_b88b97df-8217-4bd7-aff6-3302f7278643">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a3da17c145a49f8b5870436902391af_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMi0xLTEtMjAzMzA4_3071fc09-5bdb-42b4-ba21-731f4e3aedf7">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2117911a26c0491389f1d3defbed0a7d_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtNC0xLTEtMjAzMzA4_f42ea785-68d5-4d5c-be42-3ffd9034201f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id71f74f577b3494b8e2ac929500c8376_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtNi0xLTEtMjAzMzA4_4cb3c97c-f66e-4f1e-9c70-88a64d44aba5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019d338e616445d7a5081ae3d42d3429_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtOC0xLTEtMjAzMzA4_fa097157-f494-4b3d-8ec2-6d8289b8db22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2af8e02fe54c78b7f35ee1a9e11c90_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTAtMS0xLTIwMzMwOA_bc100d42-8d06-4045-aeee-2184a1495478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id050355187a44ec58d9dae39638c996e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTItMS0xLTIwMzMwOA_e8397c68-8d27-4893-913a-2c02c1933188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0359fde753a243faa8a6b23ba6f302f1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTQtMS0xLTIwMzMwOA_66be8146-97cb-4e59-a4a3-39195c4ec430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic910749763294350870635de86bbe6aa_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTYtMS0xLTIwMzMwOA_7b79f619-4118-42dd-b42f-fb3dc15cca06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMi0xLTEtMjAzMzA4_376eafc5-befd-46b7-86c6-c7a99289a27a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktNC0xLTEtMjAzMzA4_a5715b91-2e05-4203-890a-24a0f7d63529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktNi0xLTEtMjAzMzA4_55db2cd1-9c84-4a3d-aa95-4b5eaa6f0fc8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktOC0xLTEtMjAzMzA4_04d582bd-ccb4-4355-8dc8-d8e9b4f52585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTAtMS0xLTIwMzMwOA_0ab9cb15-cff5-434f-82e8-083bd1ed2745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTItMS0xLTIwMzMwOA_190d0a41-2a77-4af9-b17d-dc69b03aba4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTQtMS0xLTIwMzMwOA_f267b2ec-f147-4c55-9f3d-2d183d422204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85324249cb304f399a6dfe976b7fe743_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTYtMS0xLTIwMzMwOA_c64aa301-3dd9-4a75-a5e2-0c292377ce9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzEzODk_f73e2c97-3d6d-4a65-88d1-668f7e444b01">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of December 31, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i46e9550a1a424a89b1dee40213b0de3d_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2NDg_90306d6e-7e6e-4e60-978c-bf4bd122a63a">380</ix:nonFraction>&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $<ix:nonFraction unitRef="usd" contextRef="i32b90092334445a8849506fc89a086ea_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2NjI_1a4b39d4-a0d0-4a12-9f17-090db4450e79">1,510</ix:nonFraction>&#160;million of payments into escrow funds under the terms of settlement agreements regarding certain U.S. securities litigation, which was subject to <ix:nonFraction unitRef="appeal" contextRef="ic7a4eaca0ff74acda11e62ff530e7678_I20211231" decimals="INF" name="bhc:LitigationSettlementNumberOfObjectorsAppeals" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2Nzc_858a9a5c-8210-4759-8f82-95f5b0796ac3">one</ix:nonFraction> objector&#8217;s appeal of the final court approval and the Glumetza Antitrust Litigation. With respect to the U.S. Securities Litigation, the period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the securities litigation settlement and judgment have become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company&#8217;s rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company&#8217;s Consolidated Balance Sheets, by $<ix:nonFraction unitRef="usd" contextRef="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930" decimals="-6" sign="-" name="bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2ODY_121e0990-8d01-4617-b1cc-1473b3d1a364"><ix:nonFraction unitRef="usd" contextRef="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930" decimals="-6" sign="-" name="bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2ODY_9680efa4-7381-47fa-9eff-10228c190ebc">1,210</ix:nonFraction></ix:nonFraction>&#160;million during the third quarter of 2022. See &#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for additional details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ia5f44a4aff374a1ca74b044ad084bef4_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDI4Mg_9faa5b80-e5b2-46e6-b82c-c6f0a7d5e057">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDcwNA_1c49bfde-e8af-42e9-8c2d-c48ea36c5c31">4</ix:nonFraction>&#160;million, which included interest income of $<ix:nonFraction unitRef="usd" contextRef="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDc0Mw_ce9ef390-ae7d-4981-9b44-87471a6e5c57">6</ix:nonFraction>&#160;million, offset by the amount owed by the Company upon the unwinding of $<ix:nonFraction unitRef="usd" contextRef="i000ff44669fd472ba78d6de1cb550d21_D20211101-20211130" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDgxMQ_18d5484c-dd39-45ad-a512-ef0dd86b43cc">2</ix:nonFraction>&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss. As of December 31, 2021, there were no cross-currency swaps.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic56825e388b44bc4894cfb7d20f504a4" continuedAt="i249dc55a5cb249d5adadb5f68e5cfbcd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps (the &#8220;2022 Cross-Currency Swaps&#8221;), with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i686c1137885f4b3fa7d3a9b34364ed73_I20220930" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc3MDI_5d23e0e5-890b-4e43-8489-def85e1726b1">1,000</ix:nonFraction>&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjA_04c90120-d69b-4b3e-b8ed-7f539c2625cd" continuedAt="i30cd2b2cf0e644b8af868a9686cc5de6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73819dbe86f345268ddb7db8c71128b0_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzEtMS0xLTEtMTY5NjA4_3dc3e81b-1471-4a18-a4e5-0edcd1a87ccd">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6823e843294bcd88d2a409c815988c_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzEtMy0xLTEtMTY5NjA4_e7a58358-9470-4a30-b947-e16189fe0f10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1694f371b3534c56984cb0cfe3ef6fdb_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzItMS0xLTEtMTY5NjA4_13ebe43a-7068-4e7b-a4af-5f6e13e41bad">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a242b4bc754037b318a7c4cdf5b1fc_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzItMy0xLTEtMTY5NjA4_027b9312-1bc3-4079-b0cf-8045670a5bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681759bbcf4146c19403440ab8bc7434_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzMtMS0xLTEtMTY5NjA4_53a3cc97-0989-4494-a52f-416c216e21e6">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd1a2af87dd427db7a4b552da531b07_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzMtMy0xLTEtMTY5NjA4_63b37e45-f0cc-4445-b393-1d6bb5d19388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MTE_d7cabdab-5690-4207-8b3e-3ca2ca874d19" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2022 and 2021: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id964973a928249758deda08b15dea7a2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzEtMS0xLTEtMTY5NjA4_8f84aed7-3740-4f25-a191-307811ad907f">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2804a8dc9ae48539fdb9519f6b3726f_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzEtMy0xLTEtMTY5NjA4_58325246-b98a-4e9f-8f7e-981bcc566941">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b4a269030174bbb968a2388290df2a9_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzItMS0xLTEtMTY5NjA4_bcadff0c-2cae-4ff3-8648-9aace39b2be1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496ec6bb7c5c49b189881126f8ba44cf_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzItMy0xLTEtMTY5NjA4_ab358728-47b0-4934-9f22-85f6608c2ddd">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest settlement of the 2022 Cross-Currency Swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 Cross-Currency Swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022 and 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="i2232f920079d4878afb7b64f68af1b49_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzMyOTg1MzQ5MDQ1NDM_6e1c546b-e0fb-4865-8005-f39c5fe6fa73">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4a2a0cc3ed3047c0ad4ecaa58c71ceab_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzMyMjY_491fccaa-d8c4-4257-8a21-55b439b5f2a9">27</ix:nonFraction>&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company entered into foreign currency exchange contracts. As of December&#160;31, 2022, these contracts had an aggregate outstanding notional amount of $<ix:nonFraction unitRef="usd" contextRef="iab2851d6501645e39f0bde92ff897991_I20221231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzM1NzE_b28f864a-d7c6-4739-84f5-52d59e3cf52d">455</ix:nonFraction>&#160;million.</span></div><ix:continuation id="i30cd2b2cf0e644b8af868a9686cc5de6"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife4532439f68449aa15050571c32b49c_I20221231" decimals="-6" sign="-" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzEtMS0xLTEtMTY5NjA4_770bac45-06be-4515-b80c-668e39a025bf">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie158e865d7084cd7820657aac3a943d8_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzEtMy0xLTEtMTY5NjA4_13ff19d3-55ca-414e-bd18-dc9c13c52ec2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f6b23e952b4a29adb188680f77e15f_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzItMS0xLTEtMTY5NjA4_5018af59-8fe2-4449-bb91-5d7892f91a87">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48f720a184c4ef7a34f2bd1ad005549_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzItMy0xLTEtMTY5NjA4_c337fa7c-5fce-4440-b702-16f212285b8b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2851d6501645e39f0bde92ff897991_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzMtMS0xLTEtMTY5NjA4_28a38559-23e2-4e9f-b751-92e885de7d19">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8dd91ce28d94179ac8fb005c89c2151_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzMtMy0xLTEtMTY5NjA4_49eacb9d-f04f-4a8d-b89a-892136c0e372">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4Mjg_c2debf8c-dfea-4047-9525-74b34e272335" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzEtMS0xLTEtMTY5NjA4_0a6eb30b-ef83-4d1f-9373-8778e6762511">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib340705dabb047c38f3e490247c25c10_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzEtMy0xLTEtMTY5NjA4_3620151e-d963-415b-be01-74ccb52c1150">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzItMS0xLTEtMTY5NjA4_c0fd6a7f-7382-4183-aab7-72c5a984a470">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib340705dabb047c38f3e490247c25c10_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzItMy0xLTEtMTY5NjA4_0ae42b1d-6cce-4951-b021-7164a489a976">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="i6298df68baef4a31a4dfad39a62b592c_I20221231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ3NTY_22143c4d-db96-4462-8e7a-589ee95e68c6">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i21918f466bf24354a1c6d6444bc04589_I20221231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ3NjI_44201a20-f07c-4d88-b311-8f87a94972ba">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i249dc55a5cb249d5adadb5f68e5cfbcd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of <ix:nonFraction unitRef="rate" contextRef="ic90a06531e4448a48622699307e4ff02_I20221231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ4MjA_2e9659ab-db57-4818-aa6c-affb4a448dc3">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjI_3b5fd58a-39f3-4141-8f90-ca0c894dad80" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2022 and 2021:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:63.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEtNC0xLTEtMTY5NjA4_b026e669-887b-4280-8a07-c75720b558f4">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEtOC0xLTEtMTY5NjA4_02e9c034-8d7d-4583-9c72-c46ff0f98a74">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d01deeac67f4ce7862d6b348bdaf675_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzMtMi0xLTEtMTY5NjA4_0a801896-03cb-4c9c-8230-c72309f35719">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2d9d196bf448729e83961b2b2b79ef_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzMtNi0xLTEtMTY5NjA4_5e818052-cdbe-48a3-ac32-82198cbdd4d6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a29668b30ec453bbf648449343ac881_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzQtMi0xLTEtMTY5NjA4_2222f192-7d07-4846-bf42-f83da8173e6b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i536a23a0ae454cadbc22242f347ae91a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzQtNi0xLTEtMTY5NjA4_ceb474c5-f7c5-447e-ada5-a77ab3375fed">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtMC0xLTEtMTY5NjA4_2fc25c3a-fe81-45c4-b834-9c67fe5e649f"><ix:nonNumeric contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" name="bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtMC0xLTEtMTY5NjA4_f6b220cf-2591-4f65-821e-819255473f18">Acquisition-related contingent consideration adjustments</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtNC0xLTEtMTY5NjA4_a7428265-829f-4b69-9165-c198a560e7ac">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtOC0xLTEtMTY5NjA4_7bd7a770-50a0-472a-959c-4ee8914fc993">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzYtNC0xLTEtMTY5NjA4_de43908e-f6f9-4e68-9da9-0d4975a19257">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzYtOC0xLTEtMTY5NjA4_7d05787b-9aca-4fb1-a3f5-0748be1f796e">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzctNC0xLTEtMTY5NjA4_9e15dff9-ffb8-4324-bda1-5d44f93084db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzctOC0xLTEtMTY5NjA4_de45ca4c-fb1f-4095-a811-24a5fec64d8b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzgtNC0xLTEtMTY5NjA4_90929267-a141-457e-9a1c-db14967e62c0">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzgtOC0xLTEtMTY5NjA4_bf28397b-3853-4801-83d0-b754ad18a3a2">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzktNC0xLTEtMTY5NjA4_433b5870-1884-411b-9c9d-6aaedee9f878">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzktOC0xLTEtMTY5NjA4_7c9adcf2-3efc-4572-862b-6fb434bdc769">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEwLTQtMS0xLTE2OTYwOA_78479711-21fa-4312-bd90-ad9a3602b10d">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEwLTgtMS0xLTE2OTYwOA_fa7353e7-ca34-4be9-a982-644f6545758a">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i301added27ee4e56a32e9279750f97a2_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU2ODg_2f0a5410-c182-4ced-a355-019418be2c2d">14,011</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6a10a38645a4e64ba544a15e76a1aac_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU2OTU_e744dcfe-897b-4f00-8d32-0b8d58eca889">22,689</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_328"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90ZXh0cmVnaW9uOmUzMGYzMmEwNGU4NTQzNWViODlkZmI3MjE4MGZmMTJkXzUz_f87b22b0-f6fd-49fd-a722-495716c82e75" continuedAt="i96ef9bd1d2094b0190ea3d3938171bb3" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i96ef9bd1d2094b0190ea3d3938171bb3"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90ZXh0cmVnaW9uOmUzMGYzMmEwNGU4NTQzNWViODlkZmI3MjE4MGZmMTJkXzQ4_89d1c123-d0ed-4f80-aebe-479b1b24876d" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzEtMi0xLTEtMTY5NjA4_04253d12-62d2-477a-b659-161c5602228d">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzEtNC0xLTEtMTY5NjA4_db7ca277-7f03-4631-9ef4-6fe70ea7339f">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzItMi0xLTEtMTY5NjA4_ff5aba9b-9fad-48bf-88d5-644cf5a001e1">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzItNC0xLTEtMTY5NjA4_f80b78fd-4ac3-4abf-acf4-a04cf0a0b7de">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzMtMi0xLTEtMTY5NjA4_cb3d49ab-1bd4-4be7-9a24-4534c4b4eb97">666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzMtNC0xLTEtMTY5NjA4_cd50c462-0fae-4af8-87d5-760e1d3372d7">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzQtMi0xLTEtMTY5NjA4_a5670c8d-c2d8-414b-add6-f73981da568f">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzQtNC0xLTEtMTY5NjA4_a30ca7ba-8046-42bb-a790-3a4320fb77db">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_331"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzE2Mg_92ee0894-0a83-4d7d-afd6-38f739de4573" continuedAt="ifbb19fa2429542b38bf19f54867b1110" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="ifbb19fa2429542b38bf19f54867b1110"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzE1Nw_9e16f508-08ad-4dd9-a876-7a8a2a99abc3" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i046977fe683b41e79f01810b4a036c3a_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzEtMi0xLTEtMTY5NjA4_e353779f-dca9-4dab-9c97-c1ee402219bc">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd74bed9d620431aa82e098aceab060b_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzEtNC0xLTEtMTY5NjA4_e9273849-6322-4f32-b6e5-d0df04989415">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5251c4b7112b46c6b9fc7a4f6cb910a7_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzItMi0xLTEtMTY5NjA4_115e024a-0892-4238-9edd-99c7946f11ea">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f238094cdda40f1b2d7750a45917f53_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzItNC0xLTEtMTY5NjA4_e7e0a4bc-2916-4609-a6fd-f21aab4c0f99">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47f900acdec465e98ce7071671bb8e1_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzMtMi0xLTEtMTY5NjA4_0358efef-2bcb-471e-a787-648c6b1d8f9b">1,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbea40e3c0740518b9890e6748531fa_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzMtNC0xLTEtMTY5NjA4_e637b9a5-e67d-47e6-808b-914b28cc220e">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9e292759354aeda24365245bac9d90_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzQtMi0xLTEtMTY5NjA4_5b0377cc-d91d-45b1-9839-131dba4993bf">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6b4338793a4025bda029ab360f1d32_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzQtNC0xLTEtMTY5NjA4_63e3a00b-2d8a-4a24-94ae-f59450d20822">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da1f0ee4e9641a2a9e84287bf32dc6e_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzUtMi0xLTEtMTY5NjA4_52d142c3-0e7f-49e7-a356-2fdc45734546">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic24b70b9839e4a32ae3eb6fcc78cbb99_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzUtNC0xLTEtMTY5NjA4_e736eab6-0219-49d6-8222-e9e2943757dd">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51c16e7f763491085dd8ffc5944f6eb_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzYtMi0xLTEtMTY5NjA4_4a2097ce-609c-4322-ac7f-e84acb60fea1">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdd5d523d9a4a00884669c513d28162_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzYtNC0xLTEtMTY5NjA4_d82e4f5f-baa6-47c5-9c3b-4819bd8a93d7">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzctMi0xLTEtMTY5NjA4_1c8da833-650b-46fc-a371-04211f240c1c">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzctNC0xLTEtMTY5NjA4_6587e31c-c449-4ce3-8206-eefd434c2ef6">3,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzgtMi0xLTEtMTY5NjA4_25055da6-d8da-4ff5-94dc-b754f4652c2e">1,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzgtNC0xLTEtMTY5NjA4_2a4b1058-3034-4b64-9f7a-15a398c0ac61">1,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzktMi0xLTEtMTY5NjA4_e30f6057-11d4-4849-ab40-e8ab2fac63ad">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzktNC0xLTEtMTY5NjA4_0505a31a-f2e6-4edf-b020-e5e2f5ef0f12">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzEwNg_4519d49b-a124-44ef-b9fe-24dcceac2bd4">179</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzExMA_42489959-5d3f-4c8a-89b7-522bd30385bf">177</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzExNw_76730ad4-83ec-4c6c-b356-dfc9e5837fc0">180</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_334"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDEz_36ac6e42-12b9-42df-965b-c0796f78c4b4" continuedAt="i1f09472002d0445dadb2c000a969dee8" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="i1f09472002d0445dadb2c000a969dee8" continuedAt="ic9efeab0502f4268a81e522304e46d29"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDMz_fe0f8fe3-26c0-4381-b581-ac89b4ca1ef2" escape="true"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDM2_e9e75ba3-7eab-4ea8-98c3-bd2b7dab42f8" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:27.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.984%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMS0xLTEtMTY5NjA4_632dfe7c-458c-42ab-b3dc-ce388562a567">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMy0xLTEtMTY5NjA4_83ad21b3-8b85-4dcb-9ab5-274a1f125acf">20,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtNS0xLTEtMTY5NjA4_49ebd07e-d095-46a7-88d5-59a2f1a0939e">17,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtNy0xLTEtMTY5NjA4_b893c60c-6dab-45c9-922b-c6643bc616f1">3,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72736a422df241408c61594fa909e273_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtOS0xLTEtMTY5NjA4_578ad635-acbc-4dd1-961f-334cea00412d">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72736a422df241408c61594fa909e273_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMTEtMS0xLTE2OTYwOA_522894d3-9d32-48b3-b99f-b6c160a626f5">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72736a422df241408c61594fa909e273_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMTMtMS0xLTE2OTYwOA_8ab872ed-ac89-4aef-8dc7-26a7bb0e4554">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b9fae444f1343bc9673dcae7bca4e9d_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMS0xLTEtMTY5NjA4_b6d406c0-1aee-4ed6-8c00-feef8c045029">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMy0xLTEtMTY5NjA4_7bfdd079-9827-4e43-b909-c018e2862374">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtNS0xLTEtMTY5NjA4_ed3880f3-de29-4618-b90e-a819dc051378">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtNy0xLTEtMTY5NjA4_2d88e4fe-77bd-465a-808e-8fc72e1d27fb">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtOS0xLTEtMTY5NjA4_a7d03196-5b27-4f13-bee2-73c0eaae72af">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMTEtMS0xLTE2OTYwOA_b9599d95-67ac-41c2-9d68-365afa4683f8">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMTMtMS0xLTE2OTYwOA_4d630e8d-446f-4f69-9728-ea21320cc979">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i84a2da26e9934eb883d8c56c01e510d0_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMS0xLTEtMTY5NjA4_0c2d3d9a-d06c-41c4-a8d0-83f0d1e8d722">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMy0xLTEtMTY5NjA4_a8c8d88f-a538-424d-a67e-68d6d9fc4451">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtNS0xLTEtMTY5NjA4_674a61f1-eb1b-40de-9a99-ad214ee34e01">3,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtNy0xLTEtMTY5NjA4_6e794bb1-494f-45f7-91bb-b2f5837f3ddd">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtOS0xLTEtMTY5NjA4_5be3887a-ac67-423e-aa18-4db94654e659">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMTEtMS0xLTE2OTYwOA_05776d65-0abf-452b-b431-da51a02f84aa">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMTMtMS0xLTE2OTYwOA_b1e693e1-d84c-4e14-879b-3ef3989f96a9">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1289ce27c69445a4b28904e412ddc6b4_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMS0xLTEtMTY5NjA4_214075b2-2970-43b5-a47a-75d0e364e117">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMy0xLTEtMTY5NjA4_0cd27640-472d-4716-9c06-bbee7e9ff726">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtNS0xLTEtMTY5NjA4_db261d44-003a-483b-965d-8b39add35cef">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtNy0xLTEtMTY5NjA4_7df0aa41-07ef-4254-8714-bf79822dea2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtOS0xLTEtMTY5NjA4_615294c9-d261-4809-a059-0c3233f4203a">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMTEtMS0xLTE2OTYwOA_58b3a24e-3143-41c5-9145-5d9ebf73a47e">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMTMtMS0xLTE2OTYwOA_d82b3a6e-0659-4d98-9bfe-e902680218e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03171de550654b9094b2686785213340_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMS0xLTEtMTY5NjA4_71cdb605-6f83-4760-8616-888218e30b3d">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMy0xLTEtMTY5NjA4_69591950-86c5-4d3a-b721-853b78db9a65">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctNS0xLTEtMTY5NjA4_688415b5-c42b-479a-86cb-ec6d3b88c9f8">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctNy0xLTEtMTY5NjA4_e50e2cc8-10cb-4198-9c79-bdda953d5a1c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied86354202574859ba53d8251730ef25_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctOS0xLTEtMTY5NjA4_c53641f4-cf9a-4ca6-8aae-45e048ca0e45">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied86354202574859ba53d8251730ef25_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMTEtMS0xLTE2OTYwOA_b79ebf08-bd28-4f81-a640-53da7aadfa37">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied86354202574859ba53d8251730ef25_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMTMtMS0xLTE2OTYwOA_b63d7392-e45f-401c-a021-9c125eb3479b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMy0xLTEtMTY5NjA4_578d9697-bbfc-4245-a3f9-8b41db4d4b99">25,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtNS0xLTEtMTY5NjA4_bdc047a6-8e4c-43e4-9699-2a260b0d6eb1">21,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtNy0xLTEtMTY5NjA4_9951b5b9-5aa4-4994-b0ad-18ee2b47033c">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtOS0xLTEtMTY5NjA4_d25227a6-30a6-4d24-8700-f00406b0ef17">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMTEtMS0xLTE2OTYwOA_28d867d7-f4cc-4072-b376-7b466b3e575c">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMTMtMS0xLTE2OTYwOA_ed39d62a-c409-45ad-8f8e-5e73bed36b0f">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076eb2797d7b4496a5587e804a530855_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTMtMS0xLTE2OTYwOA_311aa6c5-689d-48bd-8806-a9d16c3c57d9">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076eb2797d7b4496a5587e804a530855_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTctMS0xLTE2OTYwOA_c1a2c8d3-e8c8-4adc-a107-9527924627af">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8779797f0c542ae8f67e21fea46bf5a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTktMS0xLTE2OTYwOA_bfb1d6a7-77e2-4d06-8e63-1ea1217c58b1">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8779797f0c542ae8f67e21fea46bf5a_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTEzLTEtMS0xNjk2MDg_a02535d9-f75a-4a2a-bb21-4aebf56e4b40">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTMtMS0xLTE2OTYwOA_7e18eec6-5125-43b6-97ac-93cadf363924">27,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTUtMS0xLTE2OTYwOA_2d3fb085-9878-4d6b-b932-b04f08ef0f7e">21,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTctMS0xLTE2OTYwOA_8a0a08a6-a02c-4205-accc-a79af41fd2d3">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTktMS0xLTE2OTYwOA_a2dd47d1-0f37-4092-bf04-14d68897cfa8">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTExLTEtMS0xNjk2MDg_cd1f4e3e-1987-4e31-95cf-563262730f8c">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTEzLTEtMS0xNjk2MDg_b696569d-4c3f-4efa-9a83-1acb5767b72d">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses, research and development expenses. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2022 were $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE2ODY3NTk_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0">15</ix:nonFraction>&#160;million and included: (i) <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2MzQ_15fa253c-9263-43de-8457-d80059a6d3d4">impairments</ix:nonNumeric> of $<ix:nonFraction unitRef="usd" contextRef="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2MzY_9e23bbdb-1648-4150-bed7-af5ea71e7ead">10</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i81dc99f8258b4049aee820556d44657d_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2NDk_9fcc4ee2-06c1-4344-a817-b515ef811455">5</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $<ix:nonFraction unitRef="usd" contextRef="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTk5NzQ_a4e0b411-2cb5-436f-8d2f-742c6d6acd6c">1,216</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i90d4fc2538f545c38a76406207865da4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1MDAwMDU_8cb5e1d2-3df6-48c0-8194-9eb34a666530">1,194</ix:nonFraction>&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in <ix:nonFraction unitRef="usd" contextRef="ic9971091867b4c49bc0d165d080d95a5_D20220701-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTg3NjM_28bf6c37-bfc5-41fb-a3e1-79c7cb4e954b">no</ix:nonFraction> impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets as of September 30, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on these factors, <ix:nonFraction unitRef="usd" contextRef="i2847dfc8dcef4913b6cf4a248d8cb28d_D20221001-20221231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1MDAwMjM_183a3c6e-cb2c-444b-b7a8-4f4b3cadf64f">no</ix:nonFraction> impairment to the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was identified as of December 31, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was required. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets included in the audited Consolidated Balance Sheets had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i6ec174dd9a974db9a84eee065064aebc_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTkyMTU2Mw_a72bc7d0-a8d2-4694-b9e2-85cf1da6fde9">2,693</ix:nonFraction>&#160;million and an estimated remaining useful life of <ix:nonNumeric contextRef="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTkyMTYwOQ_f13dab8b-2ee6-49f3-9d42-1aaeef1a7199">60</ix:nonNumeric> months as of December 31, 2022. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic9efeab0502f4268a81e522304e46d29" continuedAt="i3fdde0be13f74f0a9716e8092325664d"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) <ix:nonNumeric contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" name="bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1Mjk_854cbdb9-52ff-474b-a4df-36a71ada4875">impairments</ix:nonNumeric> of $<ix:nonFraction unitRef="usd" contextRef="ia131f8f45b8e4955bded72abc02da48e_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzYwNg_8e5021a4-95d5-4581-9af7-99f7acc1ee0b">105</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $<ix:nonFraction unitRef="usd" contextRef="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzY5NQ_c1fd5b8f-b31c-4c98-ae4a-6d12e7e1cbc5">88</ix:nonFraction>&#160;million loss on assets held for sale in connection with the Amoun Sale as discussed in Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;, (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i9fd14aff977d4b488fc11c018551212d_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1Xzc4Mw_735c1a08-be37-4e6e-8fa1-2283d62a0e11">23</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $<ix:nonFraction unitRef="usd" contextRef="i5894755ae0f14e1abd383f2cc912473b_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1Xzg2NQ_1e8497db-0e10-4d00-91f5-32398c6bfeb0">18</ix:nonFraction>&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="ibd356ccb740d484fac8d36718bbab19d_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMTA_30b7e1c0-7837-47bd-ad27-64ea76fd87c8">96</ix:nonFraction>&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $<ix:nonFraction unitRef="usd" contextRef="i0672a8f98ecd4dec9b3ca1e0bb2cd304_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMjM_8948107d-7a27-4af0-8e83-ab862f2bc77f">16</ix:nonFraction>&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $<ix:nonFraction unitRef="usd" contextRef="i6cf428232eff4699b8da41866a4f1306_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMzY_2984d71c-4c80-420d-b023-d1105a287b5a">1</ix:nonFraction>&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company&#8217;s core businesses and (iv) $<ix:nonFraction unitRef="usd" contextRef="i6fc58ca927074377a059e6afb1cdbc07_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNDg_74acf6ca-0c76-428e-92bc-eebb5e9b4ff2">1</ix:nonFraction>&#160;million related to Acquired IPR&amp;D not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity (&#8220;LOE&#8221;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDEy_67a8c962-1893-4ea6-ad0b-5c78961563b1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:16.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMi0xLTEtMTY5NjA4_6dae1cad-6937-41b9-8251-c5a9a2eef52d">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtNC0xLTEtMTY5NjA4_f405818b-9fee-4004-a1e8-36c9a246a3d7">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtNi0xLTEtMTY5NjA4_632adbea-6fcd-4246-8fab-e3e24fdef84e">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtOC0xLTEtMTY5NjA4_8bf86cfd-5767-4ba6-a94d-5f6a36cec11a">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTAtMS0xLTE2OTYwOA_3b177a16-21eb-4a1b-9c6f-caa5cb5729e5">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTItMS0xLTE2OTYwOA_8b41d5b1-c00d-4e93-8691-9b0351b0dbf9">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTQtMS0xLTE2OTYwOA_08d9cc4d-4afe-4dcb-9346-208b5aa19e04">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3fdde0be13f74f0a9716e8092325664d" continuedAt="i2b3fedeade1646969c823ae32aa061bc"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDQ3_a1bfc2b2-6f8e-412a-a3d1-f0d20513699e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:22.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida153af5024646c5860c4d0e1d881318_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMi0xLTEtMTY5NjA4_b9ec54ee-f0ea-41f7-92c6-99ffe0771f8f">5,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd69ca9b861e4a609f1e5f5da66792b9_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtNC0xLTEtMTc5ODI5_622f22ef-bd63-4f4a-bed9-4c177c3b874e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d069e331e9d4278a420482bdaf3f937_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtNi0xLTEtMTY5NjA4_c08990d7-690a-43aa-9f24-acc76e1cfbab">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd4d61250f445c8a4800bb452ccef13_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtOC0xLTEtMTc5ODQx_2d5623a9-ec28-42fd-9e32-a77a1ec6c320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0924cb562dd24071ba12d72afe82bbec_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTAtMS0xLTE2OTYwOA_09709b08-f27a-4197-8971-d5375f5555dd">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddf60ecd98b4f768f11e6a38f661960_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTItMS0xLTE3OTg1Nw_a0b7219d-c7a3-4665-97d8-e9c2f1f0dfda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0deab0ec61405097152c610065909b_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTItMS0xLTE2OTYwOA_c207599a-81a0-4f15-9c2d-c7fed9f30221">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTQtMS0xLTE2OTYwOA_e15923f3-b009-4967-b043-4aad3c30bfac">13,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMi0xLTEtMTc5ODMx_f960e0ef-725e-41e9-88fb-13dd78d1f2fe">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItNC0xLTEtMTc5ODI5_7ffefa99-6c0e-44a6-b9f8-a8dd4152f494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItNi0xLTEtMTY5NjA4_4a5124e4-8825-471b-995d-ebb79d11bb71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItOC0xLTEtMTc5ODQx_0f1e7e8f-6fee-4f25-9a4f-35ed5f3241f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTAtMS0xLTE3OTg0NQ_4a2742c8-d04d-4f47-9609-df9faee255d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTItMS0xLTE3OTg1Nw_d410fa9f-c61f-4aa4-b4a6-418741fef4ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTQtMS0xLTE3OTg1OQ_8f0bc7e8-326a-4124-b1ab-70565e1bac90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTQtMS0xLTE2OTYwOA_01a19da5-78c4-498c-a7c0-8ce6f0005f4e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMi0xLTEtMTY5NjA4_bae6cef6-85a0-485e-8ba0-4416cdfd31e1">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtNC0xLTEtMTc5ODI5_b0d6f73a-83d0-4404-a320-a8ebe26c4b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtNi0xLTEtMTc5ODM1_81bd02d8-5ed4-40ff-a7eb-82230c49fe41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtOC0xLTEtMTc5ODQx_c3736914-7711-4550-b8ca-3c724b5c6be3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTAtMS0xLTE3OTg0NQ_ec767026-0f88-4e0a-b65a-587f7f877ba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTItMS0xLTE3OTg1Nw_96ed4b2b-8eb0-40af-beaa-7c12618b627f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTQtMS0xLTE3OTg1OQ_014bbc2f-5fd3-486c-9362-0768901cfcbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTQtMS0xLTE2OTYwOA_92ccf373-ff67-4da0-a9dd-8b888bea498d">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMi0xLTEtMTY5NjA4_209a0380-33fd-459c-92d0-eab011d0798e">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtNC0xLTEtMTc5ODI5_1390fc9e-a53a-4818-9d51-84a23a42b242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtNi0xLTEtMTc5ODM1_dd16f4be-7531-4f67-981a-ee573db01792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtOC0xLTEtMTc5ODQx_829ee60c-3476-4a93-9dce-9c8995fa3db6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTAtMS0xLTE3OTg0NQ_03a85a91-a233-4bb4-b50a-aaec3c138c26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTItMS0xLTE3OTg1Nw_975805a3-45dd-4d47-9e3b-1e6c0cb7ab66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTQtMS0xLTE3OTg1OQ_4c80898c-cdeb-4ea4-b8ff-649fa34139b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTQtMS0xLTE2OTYwOA_e09fb6a3-8a20-4e67-ad56-4289d073d283">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1576ddc62d446f3a6d5e4978c7937d0_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMi0xLTEtMTY5NjA4_8606fe1a-d543-418c-b1bf-f65ad8c64be1">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6defc1abe0499b87b8d9ba0729620e_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtNC0xLTEtMTc5ODI5_92f47779-27cc-4b8f-bd5e-64a02c1cc98a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie978af0fcc4247feacd32583a9786a9f_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtNi0xLTEtMTY5NjA4_aa4b89e8-47a5-49cc-be5f-e1c27785101c">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db8916c81ee460fac6b5d6d2d6a779f_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtOC0xLTEtMTc5ODQx_47c71a09-a428-41ba-9219-ae50a4cfc4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052132743b504af0bdf4f85716745c47_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTAtMS0xLTE2OTYwOA_b2bf154a-c98c-49d7-aa61-d21a2ce1f326">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5770479e5eef445e811659815d6ded32_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTItMS0xLTE3OTg1Nw_4b248c14-ac1e-4142-bb9b-fedbbc60ae8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94689023eb444f91a13a7e4d47e5db0c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTItMS0xLTE2OTYwOA_1d221512-f320-4642-8d17-e42333059be7">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTQtMS0xLTE2OTYwOA_2c73d785-c389-4c55-af74-ae5b167994ce">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMi0xLTEtMTY5NjA4_4074f0e1-12a9-49a9-ac77-e329e47fcd43">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtNC0xLTEtMTc5ODI5_2c28bc79-b831-4a97-836c-bac09e3501b7">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtNi0xLTEtMTc5ODM3_0aaecf65-c6a8-4226-a2d1-bf32fc462b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtOC0xLTEtMTc5ODQx_c4e1eb7b-2363-4313-ac00-c102397ba27e">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTAtMS0xLTE3OTg0Nw_c6412202-fb1b-4dca-8552-0aec5be4d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTItMS0xLTE3OTg1Nw_4960ebdb-bc86-4504-a813-e406e7c1c91c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTQtMS0xLTE3OTg2MQ_68143581-d548-4a02-8b26-c4bbbc40dff1">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTQtMS0xLTE2OTYwOA_f4b07c44-ca59-4f46-a695-7ee4d194e769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMi0xLTEtMTY5NjA4_64a4bcf4-2d79-4b8e-8348-32e15eadc517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctNC0xLTEtMTc5ODI5_cd272321-6a16-46c6-9248-faaec1da398b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctNi0xLTEtMTc5ODM3_a2e78c18-1d36-4650-b4a3-4f98a2b4f9ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctOC0xLTEtMTc5ODQx_3189f624-70f9-447e-878b-018f0299329f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTAtMS0xLTE3OTg1NQ_70a8ef04-2080-47eb-8737-8b22808589cc">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTItMS0xLTE3OTg1Nw_9f669b8b-369e-4d74-959b-355eb8c0508e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTQtMS0xLTE3OTg2MQ_6f992392-914e-4c91-901e-a002909e47e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTQtMS0xLTE2OTYwOA_42af7b5d-b7d1-480e-9e39-51c0c405939f">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMi0xLTEtMTY5NjA4_2f0443df-bc2f-4f48-8f72-1de46b874e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtNC0xLTEtMTc5ODI5_1fffc726-338c-4154-a7a6-c64af3621577">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtNi0xLTEtMTc5ODM3_4d3d6fdc-ba90-41cc-8891-f13ba8781c94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtOC0xLTEtMTc5ODQx_768f1557-87d2-480d-ae3f-69dd8989a35e">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTAtMS0xLTE3OTg0OQ_4faafbf6-245e-450a-87ea-e427dcc2ced7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTItMS0xLTE3OTg1Nw_3ae4dfd7-9858-460f-b9c3-f1986577a60f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTQtMS0xLTE3OTg2MQ_e3f55f61-f3d4-4893-9fba-414650b58ba5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTQtMS0xLTE2OTYwOA_e7a3fa02-1c18-487a-890f-5d53e6f5e26c">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82bb7cbf3457475e9a924170769182c5_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMi0xLTEtMTY5NjA4_c98a0c9e-f302-4a3a-a185-6c59ae21123d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9856ff949f043bc9821f51eec5c0ca9_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktNC0xLTEtMTc5ODI5_19b0a99c-1ab2-4fbc-8d61-6b49cf2aa443">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0699fe85526c4352aebcd5347c7b8ffb_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktNi0xLTEtMTY5NjA4_15d17848-ad68-4285-8da8-335dea20b45c">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde1691268ac403c8e6b3decd6654cb1_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktOC0xLTEtMTc5ODQx_a0d82769-2229-4930-9a56-7d0fe42f592e">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda7752d38634982add22e8fe5ee38e8_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTAtMS0xLTE2OTYwOA_f52efa19-2a9b-41e2-a887-5e39cca37f37">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibceccba7710c415bad87fdec58072ed1_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTItMS0xLTE3OTg1Nw_ce7b1e16-ad7a-4128-9e05-08f652bed1be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf06d2028b254481bcde95fc6c3cc519_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTItMS0xLTE2OTYwOA_9ddecf99-84d2-4fe7-ab01-5a270e4bcd1f">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTQtMS0xLTE2OTYwOA_449745e5-a866-40d0-8a11-8ec99144af6e">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTItMS0xLTE2OTYwOA_0feb4cfa-6a18-4257-b12d-8837d28e4526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTQtMS0xLTE2OTYwOA_fccf5964-87f5-4b0b-a564-5b5058333014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTYtMS0xLTE3OTgzOQ_18ec76b9-a319-4987-afa4-d8de69818134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTgtMS0xLTE2OTYwOA_e2a2721b-90ce-4f73-a520-d962b5c77e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEwLTEtMS0xNzk4NTE_c4c4cd1e-b2d4-4579-aa1a-4c096272148c">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEyLTEtMS0xNzk4NTc_47019b2b-4ff8-494d-9893-e75775b061fb">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEyLTEtMS0xNjk2MDg_85dcb331-21ec-4ba9-a55b-7ac4b5d6b461">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTE0LTEtMS0xNjk2MDg_8767db35-026a-471a-b58b-4b8f7e15bcea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTItMS0xLTIwMzMxNQ_425bc67b-45f2-42bf-9d61-9de56b24e97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTQtMS0xLTIwMzMxNQ_9eca9ed6-f2b4-4793-9bab-73b9cd87ddfc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTYtMS0xLTIwMzMxNQ_9d2ad67e-3a06-4a30-b478-81ccfeb46653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTgtMS0xLTIwMzMxNQ_20ad4004-092c-486b-abf6-9814ac1a6ddd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEwLTEtMS0yMDMzMTU_6549dd8b-ce96-4d8e-bb04-fc868f4305cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEyLTEtMS0yMDMzMTU_735b817b-f960-4bba-a01a-44f18bedcc97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0yMDMzMTU_b6671f8b-5679-401c-ab9d-12ec7e72693b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE2LTEtMS0yMDMzMTU_e2dcb421-13dd-43e2-8c21-bca722f13fa7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTItMS0xLTE2OTYwOA_cae9e80f-c42e-4eef-b2c4-31b4c8c33897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTQtMS0xLTE3OTgzMw_1340698d-2a01-4903-9903-f49d4c0b00cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTYtMS0xLTE3OTgzOQ_442c59a9-872c-4b80-b87f-f17f0686f980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTgtMS0xLTE3OTg0Mw_173b0ce4-be3c-4e6c-bfc9-f60aa4fafc6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEwLTEtMS0xNjk2MDg_4942a68a-b990-4cbb-87e3-c1847749fbb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEyLTEtMS0xNzk4NTc_5e295253-4ab8-4707-b8d7-9807eda75399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0xNzk4NjM_fce26811-b73e-4b69-a382-01a9505c839c">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0xNjk2MDg_ed83d435-7d96-4977-aaf2-74030b914bf5">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTItMS0xLTE2OTYwOA_e37f91f7-a908-423e-912f-f3bc9930f26a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTQtMS0xLTE2OTYwOA_252b8127-fd5c-4846-ab71-20b87c4b34a1">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTYtMS0xLTE3OTgzOQ_6c82ffc3-5209-4044-a975-64ce4833caf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTgtMS0xLTE2OTYwOA_917e70c6-f500-4b74-b25f-144abc3e66a8">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEwLTEtMS0xNzk4NTM_d2ad9164-5af7-490f-ba99-b41efc79b813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEyLTEtMS0xNzk4NTc_d417eaaa-99ab-4f1b-8cb7-634a926ca85c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEyLTEtMS0xNjk2MDg_e85359c6-b654-4b5a-8d0f-460fe36b2ba7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTE0LTEtMS0xNjk2MDg_2272f13c-3ac3-4308-b159-e5715ca455ea">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c413cdb1b164432877c83f54ab2b752_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTItMS0xLTE2OTYwOA_da3fe3ac-6c7e-476f-80de-b8cf42726dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad4945bf5b946aeac343ddf77e3ca2b_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTQtMS0xLTE2OTYwOA_fe897d29-8401-4118-9b85-440d10c051d3">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc6df613d904efa9a6c5d3e9e8453e4_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTYtMS0xLTE2OTYwOA_66d83aa8-fac0-46e8-ac68-56042669efb2">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76bc2237554c19bf5f7b2da6fedd79_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTgtMS0xLTE2OTYwOA_d5c0ad89-3e50-4224-aac6-74d9db187865">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ddd8e4ef73432abf45d8222d362bc8_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEwLTEtMS0xNjk2MDg_55ce874e-172a-4b5d-a5a2-41073ee96558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91663006f1f64ef9b72e553828a29c56_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEyLTEtMS0xNzk4NTc_61516f7d-b6f2-4a2e-a0c9-91749522fc54">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8822a2ac32419c8920e934ce9eb11e_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEyLTEtMS0xNjk2MDg_a4679444-a251-44c6-93a6-02b3a09fcfd6">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTE0LTEtMS0xNjk2MDg_80549f87-8181-4fca-a8b8-544499289653">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i2b3fedeade1646969c823ae32aa061bc" continuedAt="i540716bb7b0040c3932a99d4a858de54"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 Interim Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy led to significant volatility in the global equity markets and the Company was able to continue its operations with limited disruptions. In performing its assessment during 2020, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and made adjustments to the long-term forecasts used in previous goodwill impairment assessments, for these and other matters. After completing this assessment, the Company believed that, with the exception of the Ortho Dermatologics reporting unit, its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, did not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company&#8217;s forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="i8e14db2c7cd143aa8caf8a8b3aee8506_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwNDgy_eea7ba67-1b3e-4351-9eb6-30ee19a33d2c">no</ix:nonFraction> impairments were recorded. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the then respective quarter of 2020 which reflected current market conditions and current trends in business performance. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i3b234d01c94442fe91530027b0f6530b_D20200331-20200331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzExNDk0_210f5f30-4d34-4936-87c9-848f0d536d14"><ix:nonFraction unitRef="usd" contextRef="ib8020b17bcc3445ea7163d7ebd53a470_D20200630-20200630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzExNDk0_928c9323-cb66-4684-a3e2-1641bed15407">no</ix:nonFraction></ix:nonFraction> impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2020 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i2a0c24b9ab774864babd19a173d572a2_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyODc5_3d406d89-580e-4936-ae10-453e88770d6f">2.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i34640daea4d7462a9d9640c91a9681d6_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyOTIw_8fab8333-aa93-4829-ae06-50c6982d0d0a">9.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if89e8badccef47d0a7d7bc1e901ceebf_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyOTI3_473a7a9d-480f-4b08-9451-f0dcc0e95dd8">9.75</ix:nonFraction>%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i2a0c24b9ab774864babd19a173d572a2_I20201001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEzMTA2_97198071-921b-4139-8aa6-1d8b495dffc0">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i90e6ce0d73164ddf964bb0ea4fa23010_D20201001-20201001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEzMTY3_de74003a-aee6-48c4-aebc-d92fbc470e9e">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i540716bb7b0040c3932a99d4a858de54" continuedAt="i0cf4313da6ee4121b46610e2162dd644"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International Rx segment consisted of the International Rx reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1Njg3_77ad0cef-f60d-4d11-a5ac-933f9df40275">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1Njkz_d864bbc2-0ad3-48c9-8a88-fcbd782d6164">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1NzM0_86e58f5e-76cd-4506-9ba8-d1cede69541b">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1NzQx_acbb5c0e-cafe-4eea-84d5-42bc6d6bce50">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="ib099140ae6db41829838038f01c73b6b_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1OTIw_608b2a98-69a0-4efe-b962-cec8f0345244">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i96ab98d4a236452a8fb70057836d164c_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1OTUw_29b23a05-dd14-4e13-b3c0-8060fa89999f">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i91c967a98aaf490f85d7f7da1b415ab3_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MTk4_1e1691d2-6634-4ba9-af63-fc45c583fb2e">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="iac26985514b44cee99c565494437c9bf_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MjM5_f7a6e7ec-c32b-4458-8409-f5dc34030516">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7dab83ba8be74e6ea0cc6457f87cc786_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MjQ2_56e91197-6c8e-473f-a67d-d40d24acbd73">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="idbdf52fd4b1141df99e98d44fc5f54cc_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4NDQ5_16d27b78-fa70-42f0-8ad4-4e5dd553cc88">469</ix:nonFraction>&#160;million.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i0cf4313da6ee4121b46610e2162dd644" continuedAt="ic951c230a4aa46d9886c91531e5f3b69"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ieae8581e17154d79af15b43340cf71ed_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTAw_ad868069-d6f1-46f7-99ab-06f40e69217b">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i723051ff458540289de98a13ff5b824e_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTA3_5c08a39b-2270-4573-b9bd-55800e217de2">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="ieae8581e17154d79af15b43340cf71ed_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTQ4_86493441-ac89-40a4-9ad6-fbb054846233">7.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i723051ff458540289de98a13ff5b824e_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTU1_2c7bd09a-d0b1-4f33-8c2b-d05c132f57f4">10.0</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i5d4c382c97644eb7a14b499b2e665d51_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNzM0_6313d08c-d41f-43be-af9b-62e4b6c6b129">45</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i25b53b103dc24a0eb09366a47de8f0f4_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNzY0_cca8d60c-4990-47af-9ce7-69199eec1b96">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The Company&#8217;s latest forecasts for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit&#8217;s results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit&#8217;s assets and were not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic951c230a4aa46d9886c91531e5f3b69" continuedAt="i73236e2f3c5040f7b64776dd771d5c86"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzNzEx_6f97acaa-d15e-4226-b86a-d3d7928e9f13">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzNzM3_0ace43f4-e9d5-402b-9ff8-871e8953a703">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzOTE2_e27dd9d7-e256-453a-a40d-0104e12a2c96">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="ic3ecaaa094ed49849e4e48a5f2f59700_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzOTc3_5201700c-60dc-47a5-bc3f-e7c5bfd9c0c9">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="iab863accad34439cad8d1a61aba863c1_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1NzA_48640298-495d-43a8-80c9-2d215303c96d">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjA_def0d5f4-8c87-419d-b2a4-289ea076f399">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjQ_9e9e1e70-9d28-4964-a9cf-52811c0767fe">9</ix:nonFraction>%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than <ix:nonFraction unitRef="number" contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjg_24ca871d-0bec-4ea4-abb3-5f67a24e9d9e">2</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="if1860ad2ed2945a9a9f05e0807ab6a99_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNzE_ac4ffef9-1d30-4003-b419-e7e96df6bd47">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit as of March 31, 2022. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODA_9f485bd9-9f0a-42de-8a57-3cbd60ae3446">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODQ_08482a14-c954-4437-8985-7d84d9adde4c">10</ix:nonFraction>%. The discount rate had increased <ix:nonFraction unitRef="number" contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODk_4625d481-c787-40ea-bed9-7a7dc789be37">1</ix:nonFraction>% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="ib1b89ed8a12b41e9b73c9ba2e0663772_D20220401-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzOTM_f8cfda5b-cdbf-41fe-a9c6-12a87a0111bf">83</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i73236e2f3c5040f7b64776dd771d5c86" continuedAt="iba37beb48c4c4fd0a74729be48c1b3cc"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the <ix:nonFraction unitRef="reporting_unit" contextRef="ie7598aed7ec34bddb36dd9a1f40c947e_D20220506-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MDU_4941557a-9997-4412-99b5-c84c650fda92">three</ix:nonFraction> reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value tests utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ide546e7ecff04d7b8671f8b40f6612e1_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MTY_2e3e6439-551f-4ed8-a1a2-6efdf1d84ae3">2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i42871f56c57941c385528783c1e999c2_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MjA_06e21138-26cb-48f2-ac02-3cd3cdd230a4">3</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="ide546e7ecff04d7b8671f8b40f6612e1_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MjQ_5494beca-8ca0-46da-8284-53247ef01d1e">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i42871f56c57941c385528783c1e999c2_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MzA_f0fe0e91-9538-4f14-890f-8d6c6b363838">11.5</ix:nonFraction>%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than <ix:nonFraction unitRef="number" contextRef="i263addd715b04b329673b5c1f5ccba82_I20220630" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0Mzc_5c78d324-73ab-4a46-896d-c125e5c0731a">25</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i0dad95c441654101809dec4ce04cb340_D20220506-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NDE_fca787b3-2828-452a-99a3-d0062b726865">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Ortho Dermatologics reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NTk_1efbd917-0c16-4383-bca6-5bf5eb933476">1</ix:nonFraction>% and the discount rate increased from <ix:nonFraction unitRef="number" contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NjM_74a07880-6f71-4ebd-ae5c-b6c85a6af3c0">10.0</ix:nonFraction>% at June 30, 2022 to <ix:nonFraction unitRef="number" contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NzI_e33116e9-f894-4c7c-b3c0-49a875cf42ce">10.5</ix:nonFraction>% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="i48916ae978b944169cbdc730b06bc6fb_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0Nzk_8b926f4a-58fa-4179-8881-a72f0c911441">119</ix:nonFraction>&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Ortho Dermatologics reporting unit had remaining goodwill of $<ix:nonFraction unitRef="usd" contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3NDI_9088eb82-df26-4a40-a870-0f5d81370b3e">480</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately <ix:nonFraction unitRef="number" contextRef="i0a7459d4547245ad9a36ea070c5f5ec3_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTM_74313222-a71f-4ada-a6db-ed4d59ab4660"><ix:nonFraction unitRef="number" contextRef="i6f86b5f573824c0b99316ea9e59d1842_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTM_7ed318dd-77e3-415a-9859-4c850c7ce951">80</ix:nonFraction></ix:nonFraction>% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i9cf2cce057f44b058a16380acebfee7b_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTg_7eaf20c3-20ce-4ee1-bfe0-c9c074a0632e">2.5</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i99e03f7f94044004815a278acfe122e8_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MDQ_db676392-241a-407a-8988-38d112f3b28b">9.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1c4915118e4c47e39d266ed6aa6df20d_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MTE_edb3fb2b-5b9c-4bed-b630-2989946d8343">10.0</ix:nonFraction>%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iba37beb48c4c4fd0a74729be48c1b3cc" continuedAt="i70553c48e1fb48a18fd44f864567d554"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore <ix:nonFraction unitRef="usd" contextRef="i3237e29dcce54fe4a18404bf646a22a3_D20220701-20220930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MTc_b0de0f52-3c1b-4d8e-9507-aecbf6742f84">no</ix:nonFraction> impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than <ix:nonFraction unitRef="number" contextRef="i9cf2cce057f44b058a16380acebfee7b_I20220930" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MjY_523cddd6-8931-4272-90db-ecfa778932d3">5</ix:nonFraction>%.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology and Other </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts, and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -<ix:nonFraction unitRef="number" contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231" decimals="INF" sign="-" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1NTg3MjY_e79cba4e-149d-4ed7-a001-500b7366237a">2.5</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1NTg3MzM_f2968623-4329-4d3c-b12f-b088457b6d51">10.25</ix:nonFraction>%, in the estimation of the reporting unit&#8217;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#8217;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="if150371b70684386a5836a8b20ae71bf_D20221001-20221001" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE3NDQ4MDc_d642f0ba-76a0-4dfe-8a03-64b144b3122a">622</ix:nonFraction>&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $<ix:nonFraction unitRef="usd" contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE3NDQ4MjE_66753578-c360-4399-9e86-01ff1f6da98b">1,439</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i72666ab0833443e986330313e8a4c321_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3ODc_43a589a3-3442-4cbd-a48c-33282a1056ed">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic3567189e676429991222cd3e3e1213b_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3OTM_3dc5d343-4b4a-43ab-9bad-e775a6195b84">3.0</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i72666ab0833443e986330313e8a4c321_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3OTk_cc7b014d-2249-4dc6-8782-26d4d349ce68">9.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic3567189e676429991222cd3e3e1213b_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MDY_f6373663-0d07-4b26-94a6-014f0d547de3">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than <ix:nonFraction unitRef="number" contextRef="ie84c3447e94e4cf08b00cd1500e214d6_I20221231" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MTQ_a7347b90-b59c-43bb-affb-31112197c8af">25</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="iba65689930cd459f9a5372d1a52fcc18_D20221001-20221231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MTg_e65549dd-50e7-49f9-a2b1-bf1faee3459d">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Ortho Dermatologics and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i70553c48e1fb48a18fd44f864567d554"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in the third quarter of 2022, the Ortho Dermatologics reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company evaluated the reporting unit&#8217;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Ortho Dermatologics reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, given the reporting unit&#8217;s limited headroom, any changes or other potential future developments may adversely impact the estimated fair value of the Ortho Dermatologics reporting unit in one or more future periods requiring an impairment to goodwill to be recognized. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it was to occur.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022, and as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#8217;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, it is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix reporting unit in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December&#160;31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i40adc4228d5649c8b5ea39c9bb7e19b3_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDA2_65837740-a9e4-47b9-8d9b-286adf59010d">5,004</ix:nonFraction> million.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_337"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90ZXh0cmVnaW9uOjNkOTQ1YTNjMWYxODQ1NWFiZmUxMTVkYjU5ODhkODJjXzY1_07e906bf-4167-46fe-a08f-90372e1774ca" continuedAt="ica888b04885942069dc5518e6a73cdfb" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="ica888b04885942069dc5518e6a73cdfb"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90ZXh0cmVnaW9uOjNkOTQ1YTNjMWYxODQ1NWFiZmUxMTVkYjU5ODhkODJjXzc1_46a6b7ad-ed27-44ae-bc3d-6c8f32b128fb" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:LegalSettlementsAndRelatedFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzEtMi0xLTEtMTY5NjA4_12124347-671e-420d-8b28-6b7bb1f2d8a9">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:LegalSettlementsAndRelatedFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzEtNC0xLTEtMTY5NjA4_b0417a47-f222-4ee5-936d-a0a84367ee5f">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzItMi0xLTEtMTY5NjA4_d56cfb8d-06bd-41ff-b4c7-7e34ae3c4013">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzItNC0xLTEtMTY5NjA4_d1efe7a2-2cd7-42bb-82d8-1ecdfb129723">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzMtMi0xLTEtMTY5NjA4_5ba6707c-bd16-45e3-85c6-30c5b8c048b2">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzMtNC0xLTEtMTY5NjA4_60466004-7b56-46a7-a848-e9a32413e3ea">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzQtMi0xLTEtMTY5NjA4_bccf929b-da82-42d0-b179-a67f7f0558ad">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzQtNC0xLTEtMTY5NjA4_64549322-fba4-4b9c-8656-c7bfea8cf41b">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzUtMi0xLTEtMTY5NjA4_2a4e70a9-d0a4-4a8b-b927-79979cc77dfd">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzUtNC0xLTEtMTY5NjA4_d45d4847-46f4-4691-9abe-8830b1c7836d">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzYtMi0xLTEtMTY5NjA4_e1690229-088e-4804-b6c1-43c2c568ceb0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzYtNC0xLTEtMTY5NjA4_b0541d1e-bfbb-48c3-9fc0-d15ec4ab4cd0">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzctMi0xLTEtMTY5NjA4_0a737564-0c2c-4d31-ac0c-d0610dac51c5">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzctNC0xLTEtMTY5NjA4_b3647e33-18e2-4aee-82c9-d3ddaf7bfddc">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzgtMi0xLTEtMTY5NjA4_23c5af79-91f2-4d90-a45c-ea21d294b6bb">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzgtNC0xLTEtMTY5NjA4_bad3e622-5da3-44a1-aae3-1eb2052875a1">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_340"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNzA_248f7863-e5b7-4cff-9d04-5b5706d7cca6" continuedAt="i781e9c07146b4bf68f7f1af0ffd53bef" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i781e9c07146b4bf68f7f1af0ffd53bef" continuedAt="i0a6186b93b6547728012e68f8a0ef3b9"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzM0Mjg0_697d06b0-dc7d-4441-b06a-c4b62d9eaa1b" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2022 and 2021 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:34.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e26e58975e443e0b51918f03cee7d5e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtNC0xLTEtMTY5NjA4_ebea29bb-ffe6-473b-8d88-2f0583937892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e26e58975e443e0b51918f03cee7d5e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtNi0xLTEtMTY5NjA4_d4282406-28c5-419f-8eb0-887cb8ededff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2961e7ea8ce40b29f24b00453ac5571_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtOC0xLTEtMTY5NjA4_ef96f4e9-ad79-4a11-95a8-a542dabe6d7a">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2961e7ea8ce40b29f24b00453ac5571_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtMTAtMS0xLTE2OTYwOA_1b2c74a6-9dab-443e-8641-054c7011ea74">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780fe08a52e14ab1bac7e028c782c9c0_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtNC0xLTEtMTY5NjA4_e1853570-8d07-466a-b8f2-6df6319300f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780fe08a52e14ab1bac7e028c782c9c0_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtNi0xLTEtMTY5NjA4_4e3b495f-3749-4015-bea5-dcc4f92c8ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c8e00c14544d52a42942914e81c273_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtOC0xLTEtMTY5NjA4_787d62fe-30c6-47b3-a586-3f5c1d5a8336">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c8e00c14544d52a42942914e81c273_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtMTAtMS0xLTE2OTYwOA_6bb12fce-0e72-410a-9bae-da874688ad0c">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2604b11090a343939a4cfcab0196957a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtNC0xLTEtMTY5NjA4_2f17fc4f-e36d-4618-a39a-84c860366e5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2604b11090a343939a4cfcab0196957a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtNi0xLTEtMTY5NjA4_efda17d4-c594-44a2-bcc8-b9dea6515b6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aaac0c0174b4c27bd54436507088ceb_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtOC0xLTEtMTY5NjA4_7db3ad99-b041-4d6a-998d-28a3a11b3644">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aaac0c0174b4c27bd54436507088ceb_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtMTAtMS0xLTE2OTYwOA_4f1c81b5-d4e0-4175-8540-0a1296022c29">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNC0xLTEtMTc4NDk1_fbc9702d-1fe2-41d8-89dd-40152e12c095">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNi0xLTEtMTc4NDk3_c644e1ad-049b-41d7-9a62-f5048aabbf7a">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtOC0xLTEtMTc4NDk5_cd4394c4-08e1-43d0-a8ac-d3a347a1498e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMTAtMS0xLTE3ODUwMQ_4c09053c-6d61-4e5a-951f-a5a7852ca0a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc26a76728a46aab695daedd417d9fc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNC0xLTEtMTc4NDk1_1b7501e9-f504-49be-bbc8-76f2f608f213">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc26a76728a46aab695daedd417d9fc_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNi0xLTEtMTc4NDk3_65b79b08-e390-4e90-aef1-06a167ba0b34">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktOC0xLTEtMTc4NDk5_70e02824-a2b5-4725-aeec-763607e902fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMTAtMS0xLTE3ODUwMQ_a55813bb-c39b-491c-9f83-bc55120fb372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTQtMS0xLTE3ODUwMw_d677d1f1-e8b8-4726-9c85-6f2633ca566a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTYtMS0xLTE3ODUwMw_9bc1b00d-7610-4747-8387-5bd53add73c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e127eb541b94518be190909675ed289_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTgtMS0xLTE3ODUwMw_729aae0c-a101-43fe-8712-3965cb1de6f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e127eb541b94518be190909675ed289_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTEwLTEtMS0xNzg1MDM_ace14d5e-23d3-4030-b295-94718c979ebd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTQtMS0xLTE3ODUwMw_4b133578-5364-4b36-97e7-ea09e2b544ba">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTYtMS0xLTE3ODUwMw_b28b4674-9524-4fe8-9d9c-5694ee006fbd">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6f95a9036b477e8cb580382038f606_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTgtMS0xLTE3ODUwMw_b64b1582-a8d0-4572-a199-9bd3eb1b2bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6f95a9036b477e8cb580382038f606_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTEwLTEtMS0xNzg1MDM_54a9d2ad-d105-4b8d-8ed8-cfa67267ea24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMC0xLTEtMTY5NjA4L3RleHRyZWdpb246MGMyNTFkMDVlZWUyNDBmMzhiYzk5YTQwNGQ1NmQwYWZfNA_8cc8436f-729d-49a7-a14f-faadd2e71134">5.500</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNC0xLTEtMTY5NjA4_984c8924-c5c6-4118-b8c3-412db0d94fd2">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNi0xLTEtMTY5NjA4_1e611f07-6d74-481a-9088-6e84990d0062">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa5fc5a9e841de925a2df849619500_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtOC0xLTEtMTY5NjA4_7dab57bb-4ad2-4a56-8b74-a0adc592fca4">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa5fc5a9e841de925a2df849619500_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMTAtMS0xLTE2OTYwOA_a48a90f2-702b-45b9-8b9f-0965e0dde967">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTAtMS0xLTE3MDc1Mi90ZXh0cmVnaW9uOmM1ZjRmOGQyODgyNTRhOWVhZjFmMDM1YzY1ZjdhMzAxXzQ_1d622a30-6072-4e69-b6fd-00fdbe966284">6.125</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTQtMS0xLTE3ODUwNg_caabb19e-bb9a-4812-aad9-d5ee6f77333f">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTYtMS0xLTE3ODUwNg_4f2d38cb-aa32-4992-b53e-30d05ba7e8e7">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaccccd91c84bd69bb27eb24388fe86_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTgtMS0xLTE3ODUwNg_a9e605e2-9daf-4d5e-81ee-891597b885c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaccccd91c84bd69bb27eb24388fe86_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTEwLTEtMS0xNzg1MDY_62cbf4d8-f1e2-47f3-af5d-0ef2366be161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMC0xLTEtMTY5NjA4L3RleHRyZWdpb246MDg5ZmJjMDg1YzY0NDAwNWI0MjA2MDBjMGM2MTZmNDdfNA_59814e61-b226-426f-8a9f-fbd665cfb5c6">5.750</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNC0xLTEtMTY5NjA4_18503b41-ceb6-474d-879c-3cbffb64b5be">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNi0xLTEtMTY5NjA4_66d6bd84-916c-43a3-95d8-712bc95c7f97">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ac2987c7a84f5eb6926a647891d84f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktOC0xLTEtMTY5NjA4_adc8e1dd-9710-43c2-990c-1cd1cb5d157b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ac2987c7a84f5eb6926a647891d84f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMTAtMS0xLTE2OTYwOA_5347b3fd-3c08-40cc-87a8-b2a26c45285a">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41d7411313624b009890802c2b02341a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjA2MDNmZjJkYjgyOTQ4NjY5Y2RkYTg0OWE3Yjg0MmYxXzQ_3e539cbe-46ae-4f01-ad45-131b047697bc">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d7411313624b009890802c2b02341a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTQtMS0xLTE2OTYwOA_32719070-72fa-45ee-807a-7c79b20226e2">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d7411313624b009890802c2b02341a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTYtMS0xLTE2OTYwOA_1a8aaf99-151c-40db-901b-d14ba5570a48">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTgtMS0xLTE2OTYwOA_e6a4d49c-aff9-4fe9-890a-65d6db0fafe2">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTEwLTEtMS0xNjk2MDg_1e49ebc4-e7aa-43a5-8f1d-03ea96b320ec">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTAtMS0xLTE3MDc2MS90ZXh0cmVnaW9uOjMyMjllZWVlNzFmYTRjYzA4OGRkMjQ3NGU2OGYwMWNiXzQ_c0549f31-0753-43a0-a857-6a5b09642778">11.00</ix:nonFraction>% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTQtMS0xLTE3ODUwOQ_4b49c953-fb89-4496-9f30-0bee3606adfa">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTYtMS0xLTE3ODUwOQ_cd965b24-3bd2-4602-9a96-a8f10e3878e4">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9aaa9954e64952b709312f105f0242_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTgtMS0xLTE3ODUwOQ_8d09c51b-ed97-4d41-8cf3-b46299a9e6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9aaa9954e64952b709312f105f0242_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTEwLTEtMS0xNzg1MDk_f340f72f-52d3-4ec8-866a-c5d57f1a5467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTAtMS0xLTE3MDc2MS90ZXh0cmVnaW9uOjg3NWY1NmUwOTU1MDQzMjhhMzljOThmM2E3MWUyZTZmXzQ_9072abfd-ee57-44d1-9686-87ff40a06beb">14.00</ix:nonFraction>% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTQtMS0xLTE3ODUxMw_89045c35-f359-447b-8482-3feb02172db5">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTYtMS0xLTE3ODUxMw_83642f1f-f124-4e92-a257-4f9b18ebba78">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79ff56bc204a2c9936be929b812f08_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTgtMS0xLTE3ODUxMw_1c3f28a6-b73d-4e3d-a225-ab7d00d54d14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf79ff56bc204a2c9936be929b812f08_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTEwLTEtMS0xNzg1MTM_ee405513-d831-4962-9baa-8800bfe7844b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTAtMS0xLTE3MDc2OC90ZXh0cmVnaW9uOjRhMDY1NDlmNmUwYTQyODU5YmE1ZmNmMDhmZDgwZTU5XzQ_fe7516b8-aabc-4d0a-8a5f-f928ce5adfbe">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTQtMS0xLTE3ODUxMw_3667a206-85c5-40c9-9289-209594652355">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTYtMS0xLTE3ODUxMw_f2ce8548-45ac-4145-b024-a13dc099ca15">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd671799f9f141918a55117de2700d25_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTgtMS0xLTE3ODUxMw_36147125-0506-478f-9aff-b5204a8cceee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd671799f9f141918a55117de2700d25_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTEwLTEtMS0xNzg1MTM_6c5d282e-05c7-4e64-87ff-a7b45f96afa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjlkYWNmOTIyNGNkYjQ5ODI4NzU0NWUwNTJjMTFjYzYxXzQ_f4d44a92-e693-4042-8de5-d943130fdf10">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTQtMS0xLTE2OTYwOA_976e32c6-7669-441e-b16d-4a4b2076ebeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTYtMS0xLTE2OTYwOA_ebeff1b4-8dc3-4bc8-b5ce-f55821e7b356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fe67aba19647d8a1e332514379f9d3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTgtMS0xLTE2OTYwOA_e1385576-a302-4638-b384-727877ead957">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fe67aba19647d8a1e332514379f9d3_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTEwLTEtMS0xNjk2MDg_d0d21fda-3be2-49d9-98f2-4e1c74f534d1">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmMxY2MxMWMwYzMwYjQ0ZDJiODE2YmQ5M2VkYjEwNTY4XzQ_2f75a0bf-aea2-468b-880a-80f2fd0bce62">9.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTQtMS0xLTE2OTYwOA_b64f7a8b-cc49-474c-9cfd-b36b806d3e10">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTYtMS0xLTE2OTYwOA_436932d6-6d9b-43bb-8104-887fb5ac7781">951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3871b29377e94ec5b038d5daba56ff08_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTgtMS0xLTE2OTYwOA_233363c9-1304-4873-9bc5-632a77a8a855">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3871b29377e94ec5b038d5daba56ff08_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTEwLTEtMS0xNjk2MDg_1076cfb6-5e4d-412b-83b8-7d24fb90c434">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjhhYWJiYzgxMzE3MzQ1YjliZjIzZjE4NGFiNTFjZDUyXzQ_0cc6e12c-320c-4bb1-9c60-2b1ef5dfd8f0">9.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTQtMS0xLTE2OTYwOA_ddc52934-ae7a-4da6-a1f6-6ac5c8d20097">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTYtMS0xLTE2OTYwOA_c0514e1b-6558-46a8-bb8c-9d004c9405b1">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie524823ade0a444c94da1bd1ed833f9b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTgtMS0xLTE2OTYwOA_9def6f5a-ece8-4507-bd04-afc8652da2a8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie524823ade0a444c94da1bd1ed833f9b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTEwLTEtMS0xNjk2MDg_a8626f89-15e9-4420-ae5d-4786358d0283">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmM1YTQwNmNmYTg1OTQxYzM5MTYzYTk4ZTUyMTk4MzYwXzQ_090411ed-08bb-4401-b15a-d19444eb5b6c">8.500</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTQtMS0xLTE2OTYwOA_ef086f43-a15b-4c3a-9f94-7254414f2c71">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTYtMS0xLTE2OTYwOA_f7879c9a-f3f2-425a-8ac7-568555bad59d">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTgtMS0xLTE2OTYwOA_6c1f74d1-88c5-4b59-aaf0-ed0e2f7666ce">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTEwLTEtMS0xNjk2MDg_1afa0636-824d-4af0-bf5c-bca21a97d173">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjlkNGRkOTdmMDc0ZDRmYmY4YzAyYjM0NDYzODA3NGEyXzQ_c2ff696f-821d-4f49-8f8c-994ab6506e57">7.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTQtMS0xLTE2OTYwOA_8b845ce4-45d8-4f00-be0a-0937225a8a33">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTYtMS0xLTE2OTYwOA_e35e1ddd-6eb2-44bc-87a4-11965c11dc5b">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76d935f691748a49d6a2c6eca7e979e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTgtMS0xLTE2OTYwOA_17ad6bf5-c36f-411e-b9bf-292efff3ae47">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76d935f691748a49d6a2c6eca7e979e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTEwLTEtMS0xNjk2MDg_36a1eedd-7fa8-4654-8ecc-7299ef0e51ab">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic646016282634f4faf802c21a106b8cc_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjFlMDBjZGM1ODk5MjQ0YzBiMGNmM2E3OTgxMDA0ZDQxXzQ_41083b44-16d5-4ddc-beae-6c8d6cec7e39">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic646016282634f4faf802c21a106b8cc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTQtMS0xLTE2OTYwOA_68c3954e-e6f5-4905-a922-cba16fed95f3">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic646016282634f4faf802c21a106b8cc_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTYtMS0xLTE2OTYwOA_a945c3a9-e512-4bae-aea6-0c11ee105fcc">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3678917bb79c4121986b9218d5ffed64_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTgtMS0xLTE2OTYwOA_5fa43f8f-ec20-4590-aa47-ea973aadda28">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3678917bb79c4121986b9218d5ffed64_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTEwLTEtMS0xNjk2MDg_62de0fcf-50a8-4fdf-bf87-f67bd223ee10">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmRiMTIwZThlMmIzNjQ2NzI4ZDdlMTQ4YzVmYzNiOGFiXzQ_90a0bfdc-378e-41e4-99ca-57b9054ff5a8">6.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTQtMS0xLTE2OTYwOA_c336f664-2fa9-4b91-9bb3-1ae3ec4363b9">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTYtMS0xLTE2OTYwOA_5c26cc6f-7a91-446e-9a1f-1ff528ab8d48">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01229077aac498c8cda3d570f0e07b2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTgtMS0xLTE2OTYwOA_94f2f489-8ec7-4d4e-8434-1a6d4af10f49">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01229077aac498c8cda3d570f0e07b2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTEwLTEtMS0xNjk2MDg_663b75b3-507f-41c0-b5af-48faba868498">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmExODM2ODhiOGYzMDRlZGFhYmNkNjJkY2Y0M2Y5NTQzXzQ_083527f6-777b-47d1-af85-36fcf5af5b28">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTQtMS0xLTE2OTYwOA_95401792-fe1d-4058-9101-6fe1fa0d84ae">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTYtMS0xLTE2OTYwOA_c73cd80f-d9de-4442-8b19-ed9af619304c">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1486c4b57084e97aee9abcf914db494_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTgtMS0xLTE2OTYwOA_60f48664-71b8-490d-9e4a-8aa494495976">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1486c4b57084e97aee9abcf914db494_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTEwLTEtMS0xNjk2MDg_090face3-d4aa-4437-97c4-dd5c991d54ff">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjQ3NDU4NWJlNjM4MTRmY2E4Zjg5ZmE4ZGQ0Y2RkODQyXzQ_988ca696-435a-43fe-95b0-97657bd31c09">7.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTQtMS0xLTE2OTYwOA_2e4cff11-6e9a-4fb1-bb7c-6f96c8a437a7">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTYtMS0xLTE2OTYwOA_97e4fbd3-d29c-4609-9898-ad6ebe402927">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTgtMS0xLTE2OTYwOA_b075e6ec-b97c-4b13-be03-a999b54fb38f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTEwLTEtMS0xNjk2MDg_da67cfe4-a4a0-4805-8a34-4912e4aea2cd">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmE2NTViYWE3YjQ2NTRhMjNhZDI3ZGQyYmUxNWU4ODNkXzQ_f098739f-f19f-475b-93ef-170186a29149">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTQtMS0xLTE2OTYwOA_0354fcdf-e3db-4301-99c1-ae928ea65021">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTYtMS0xLTE2OTYwOA_4e427621-be8d-41f3-a030-30307a048fe5">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af86776c3d44c6e88302711b8c5846e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTgtMS0xLTE2OTYwOA_a209b19f-fb73-4300-aba8-4fb78ced024e">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af86776c3d44c6e88302711b8c5846e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTEwLTEtMS0xNjk2MDg_17a15151-0f3d-4afd-8b50-69a60954b0bc">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjMxM2I3MWZmYzQwNTRjOTBhODQyZmE5MGFkNjRjN2E2XzQ_1b9b5217-0b0e-4213-a1be-ca704d7f2a98">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTQtMS0xLTE2OTYwOA_afd6da7a-a450-4df2-9a94-fdfacba5aaac">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTYtMS0xLTE2OTYwOA_bd53ef9d-bf36-49d7-89b7-e1298c3d3add">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e536bc640ae47de8bac8ed86aa24e83_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTgtMS0xLTE2OTYwOA_ae8111d2-dea2-4daf-afc9-8d3502cced00">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e536bc640ae47de8bac8ed86aa24e83_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTEwLTEtMS0xNjk2MDg_165fa76e-1f18-4381-acc9-ce0baaf24d16">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721f7910e79b40e1aebc37232add279e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTQtMS0xLTE2OTYwOA_cf6486f3-ae63-46d1-be48-1839d6577d1b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721f7910e79b40e1aebc37232add279e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTYtMS0xLTE2OTYwOA_26a1967c-8436-448f-90dc-17198e579b1a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTgtMS0xLTE2OTYwOA_1cd2adbc-09c5-4878-bdf4-9b62eda8c83b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTEwLTEtMS0xNjk2MDg_9c26b9c3-38d1-4bea-ab5f-751d403e5eec">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTQtMS0xLTE2OTYwOA_40920591-6c8c-46fe-93ea-0221fc69d49b">19,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTYtMS0xLTE2OTYwOA_e8e97b28-4a65-48d0-9307-8afd71685b24">20,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTgtMS0xLTE2OTYwOA_b84588c3-4778-49b3-9da5-4053dec3a5ad">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTEwLTEtMS0xNjk2MDg_f63b4419-5a4d-4911-bf06-6492326ec1ac">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI1LTYtMS0xLTE2OTYwOA_8a5d20d7-fad5-4528-9a20-18752ed38857">432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI1LTEwLTEtMS0xNjk2MDg_222a91ef-7c29-44da-82e6-6b15af4cb493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI2LTYtMS0xLTE2OTYwOA_6ce7e82d-83cc-4741-b311-7a0b93de1cb9">20,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI2LTEwLTEtMS0xNjk2MDg_c3acbe7b-afba-415f-b4ad-fa870a0fe88c">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1Mzg_3581e7c3-af60-46aa-aeb0-caf1e6ef4e47">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i0a6186b93b6547728012e68f8a0ef3b9" continuedAt="i472344e12c9a4062922e75bd6833708f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i8438d9428d694b1b806321debd8fbf57_I20221231" decimals="-6" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1NDU_8fa3a286-cc0c-4b6c-9be8-9777c52fa4a3">9,600</ix:nonFraction>&#160;million (although such availability is subject to the Company&#8217;s compliance with a <ix:nonFraction unitRef="number" contextRef="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1NjI_a3ff92fd-b7ef-42be-8fa2-67001d6f103c">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1Njg_27ef165d-fe64-4efa-9b3a-720ecfdf1313">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds <ix:nonFraction unitRef="number" contextRef="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMjA_4be2aa54-0036-4961-b563-8f02fbe2b704">89</ix:nonFraction>% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s indentures. In connection therewith, Bausch + Lomb and its subsidiaries, are now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the relevant Bausch Health indentures, and the earnings and debt of Bausch + Lomb, as defined in the relevant indentures, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="i470227bdb89e493fb8816f0ffa6ac326_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTI3Nzg_ee3e3775-cb0a-4b71-b051-e07b34d4aae2">5,594</ix:nonFraction>&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMTE_d9677b97-7ef9-4098-8732-d82d7cec06f9">3,125</ix:nonFraction>&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $<ix:nonFraction unitRef="usd" contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930" decimals="INF" name="bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMjc_ce393058-3113-46de-bf35-f43f4fa7dc90">2,469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $<ix:nonFraction unitRef="usd" contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNDM_d1acf2f8-bf44-4677-b33f-006ffad55539">1,774</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNTk_8fed4677-c025-4049-82ab-cbee440ceaf6">11.00</ix:nonFraction>% First Lien Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNjc_93b7e33d-d5ba-4560-94b2-ae176e553368">11.00</ix:nonFraction>% First Lien Secured Notes&#8221;) issued by the Company, (ii) $<ix:nonFraction unitRef="usd" contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNzU_deddb99e-0748-45a6-9450-ba6a1c3b33d0">352</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwODk_3c3b81a5-8363-4221-9dd9-59dbfb2cca3a">14.00</ix:nonFraction>% Second Lien Secured Notes due 2030 (the &#8220;<ix:nonFraction unitRef="number" contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwOTc_bc76758c-423c-4d00-8d75-3330a9ea12ec">14.00</ix:nonFraction>% Second Lien Secured Notes&#8221; and, together with the <ix:nonFraction unitRef="number" contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMDU_61adbe93-a60e-4677-b9a8-dae8473d2442">11.00</ix:nonFraction>% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $<ix:nonFraction unitRef="usd" contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMTM_cbaa3472-cd46-4d7c-b5c5-053e29cdf733">999</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMjc_14356b2b-934a-4776-b9af-1e52cfff2ea7">9.00</ix:nonFraction>% Senior Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMzQ_00aed306-221e-4153-902b-06ffb8594509">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds <ix:nonFraction unitRef="number" contextRef="i875efb41d7fe43c6bb3f59c8192b9d6a_I20220930" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNDE_3d97800b-bd8b-4c3b-abf0-d6ddf37a0bab">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i472344e12c9a4062922e75bd6833708f" continuedAt="i63ed060e370f46abbcbd15996b7d2a22"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMDk_b7fe6ffb-a247-4b09-83e6-760430c38a16" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bb07bff0ebd439fb019a10f099085be_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEtMC0xLTEtMTcwODc1L3RleHRyZWdpb246YTVmMmM1ZTljZWFhNDliMjg0ZDE4OTc4OGM0NGJlODZfNA_0b8e7e61-4c3a-43ce-9f25-9df024b42a96">9.00</ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb07bff0ebd439fb019a10f099085be_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEtMi0xLTEtMTc4NjQ3_1c583e90-4f28-475b-80fa-ce253e49b55a">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzItMC0xLTEtMTcwODc1L3RleHRyZWdpb246NjY0OWIzMTM1YmZiNDgwOGFhOGUzMzAzNmI2NDE4MTVfNA_2a426f2c-b461-4b20-834c-3e587306a68c">9.25</ix:nonFraction>% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzItMi0xLTEtMTc4NjQ3_2776cb21-2419-4f17-bb04-f33e9d6892fc">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzMtMC0xLTEtMTcwODc1L3RleHRyZWdpb246MDQ1N2E4YzAyYzQxNDhhYWE0ZWMyYmIzOThkMjhkOTFfNA_6ba528a9-1256-44a2-aea7-5541face57f8">8.50</ix:nonFraction>% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzMtMi0xLTEtMTc4NjQ3_99cdc9d1-964f-4e3e-984c-776979403f8a">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9afad4d704c441b8aca72f314828730_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzQtMC0xLTEtMTcwODc1L3RleHRyZWdpb246ZWE4YzJlNTVlYzcwNGJlMzg3NjA1NzdhMjc5YzcyMWZfNA_2d5b341f-6027-432b-b7c0-14095622bc61">7.00</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9afad4d704c441b8aca72f314828730_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzQtMi0xLTEtMTc4NjQ3_c40b817d-8ceb-4a43-8c89-7b3bbe753552">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzUtMC0xLTEtMTcwODc1L3RleHRyZWdpb246OTQ1YTg0OWY3ZmVkNGNiY2I5NzllZmJmOWY5Y2M4ODVfNA_c4dfced8-5678-499a-b37f-4d45cca52b1e">5.00</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzUtMi0xLTEtMTc4NjQ3_e1422766-32be-42ea-92d9-1c85bba376c3">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzYtMC0xLTEtMTcwODc1L3RleHRyZWdpb246Mjk5ZWIxNmNhNWIyNDNjMjkyNGYzZmNkNjNiNWQ5NGRfNA_b7f8a934-1338-43ab-8c11-291a3f6acd6d">7.25</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzYtMi0xLTEtMTc4NjQ3_376988a6-87e5-4c24-b691-353aeb9007be">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzctMC0xLTEtMTcwODc1L3RleHRyZWdpb246ZjA5OTE5Y2Q5NDBmNDQ5NGFlOTNkOTlmZTU5ODUwNjZfNA_7035d803-ceab-4f19-8501-718fe2cc4725">6.25</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzctMi0xLTEtMTc4NjQ3_417c4f7a-f506-4177-a49b-3d4498494ef8">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzgtMC0xLTEtMTcwODc1L3RleHRyZWdpb246Yjg3ZmZkYTEzOTIxNDQxM2JjYjRiMWRmMzAzZjQ3OTBfNA_988cfd79-8a6f-489c-b726-26f18fcead04">5.00</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzgtMi0xLTEtMTc4NjQ3_2c16277f-b296-4057-aafc-91ca34f3b944">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5769552bffcc48e19f81962c26dee7ad_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzktMC0xLTEtMTcwODc1L3RleHRyZWdpb246YmY4OTJiM2YyYjBmNGEyMmE1YzEzNWViNmYzZDdmNGNfNA_3f4a4a92-1b98-4d5b-8f1c-9d8baecdaff4">5.25</ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5769552bffcc48e19f81962c26dee7ad_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzktMi0xLTEtMTc4NjQ3_23bb142c-cae7-40f4-962c-453f7d1eaea4">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEwLTAtMS0xLTE3MDg3NS90ZXh0cmVnaW9uOmM4YTA2ZjYxNTFlNzQ3ZmI4MzI4MTE3MzQ4YWNjOTJhXzQ_40982d25-55e6-446c-b05b-8b1aa06fd9ab">5.25</ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEwLTItMS0xLTE3ODY0Nw_97625692-3a04-4fa5-8d64-2ebd323f0608">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470227bdb89e493fb8816f0ffa6ac326_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzExLTItMS0xLTE3ODY0Nw_8c48e9b9-e785-4da1-b2f9-3c78b2d6a913">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the <ix:nonFraction unitRef="number" contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNDg_7c92c90d-c532-4eaa-82ed-5f35b03fb1f4">9.25</ix:nonFraction>% Senior Notes due 2026, <ix:nonFraction unitRef="number" contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNTU_2831e523-7b5d-473e-9f10-b207043ddf7e">8.50</ix:nonFraction>% Senior Notes due 2027, <ix:nonFraction unitRef="number" contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNjI_3b6948f6-dd3b-4f1e-a43a-f1a1a00cc2e7">5.00</ix:nonFraction>% Senior Notes due 2028, <ix:nonFraction unitRef="number" contextRef="if9afad4d704c441b8aca72f314828730_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNjk_a24df9e0-bd37-48e2-a639-7df8636c6f8c">7.00</ix:nonFraction>% Senior Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNzY_cad46d1d-63fe-4dd0-8e59-6e21044d43d8">7.25</ix:nonFraction>% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#8217;s Consolidated Balance Sheet.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="i8e844fc59da8465586a93905777c04be_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxODM_3d629f48-0ff9-4110-9931-fbf772ba8a85">570</ix:nonFraction>&#160;million, net of third party fees of $<ix:nonFraction unitRef="usd" contextRef="i8e844fc59da8465586a93905777c04be_D20220701-20220930" decimals="-6" name="bhc:ExtinguishmentOfDebtThirdPartyFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxOTc_2d5971f2-f1bb-4411-88fc-1ca95f66723f">25</ix:nonFraction>&#160;million, in connection with the Exchange Offer. The premium recorded on the New Secured Notes was $<ix:nonFraction unitRef="usd" contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyMTA_4bf0c6a5-c999-4dcf-97ef-5de8f97fff27">1,835</ix:nonFraction>&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="iaf91aadd30904af7ab5ff5c49b173483_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyMjg_a6983c87-a45b-49e7-8f84-e88aa73fc760">1,225</ix:nonFraction>&#160;million, maturing on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i5f74ab6a22d445758697179f2d0c1807_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNDQ_e25a6df8-b41d-4fd9-ade5-120f79f0d226">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="iaf91aadd30904af7ab5ff5c49b173483_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNTM_c70c53f9-c28e-4705-9180-642dde2236c9">1,000</ix:nonFraction>&#160;million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i63ed060e370f46abbcbd15996b7d2a22" continuedAt="ic137c5c6a30243949d30ebde8a737d1e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts of $<ix:nonFraction unitRef="usd" contextRef="i3cb3d1e5412446dc811ba962259a01d4_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNjk_a0e2a643-b22b-4a44-ac6c-a3f5f4aeb61f">4,565</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i523d17064ca94b16900c15d5f8c804de_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyODU_d6ae81a9-7839-463c-a86b-29801feee11a">1,500</ix:nonFraction>&#160;million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="id0475cb4c7ac43abbf4df21604027a97_I20220510" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMDE_f5dff486-e95e-44fa-9e5c-a9a73244eb1a">2,500</ix:nonFraction>&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMTc_e6af45a4-571a-490f-9939-fbc5fd6b79f5">975</ix:nonFraction>&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is <ix:nonNumeric contextRef="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMzE_b7be15e7-264b-48a3-9369-391dd1e67d0b">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMzk_b7477e8c-5f2c-4e7a-94be-e61dd8494d9d">1,000</ix:nonFraction>&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of December 31, 2022, the Company had drawn $<ix:nonFraction unitRef="usd" contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzNTU_17bb6b7d-176a-43e2-8865-5474eb298475">470</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c9ce2c21b474762a7da6161958145b1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEwOTk1MTE3Mzc1MDE_620617e9-b78e-4e7a-9fad-e6e11729810e">25</ix:nonFraction>&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="ic42bbc3c6bf3452bb704930c76f7dde5_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNTM_723d7d1b-390a-47a7-b8a6-3add103241c3">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i377918284ec1474f8fdb964743a3854e_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNjA_724d9824-5dd9-4c63-a2f3-f4d3de094983">1.50</ix:nonFraction>%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i20b85ff842a240e69cd341f8a97baf08_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNjc_7b6ccbb5-a90b-4538-88a9-40adc68f8113">0.50</ix:nonFraction>% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of <ix:nonFraction unitRef="number" contextRef="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNzQ_b5563180-8447-434e-a118-f1eb2ef11b2f">0.00</ix:nonFraction>% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of <ix:nonFraction unitRef="number" contextRef="i02adb91ce4244dcfb8903780127e4950_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxODI_dfd43e0b-1108-4c45-9a97-b7950ef1e822">0.00</ix:nonFraction>% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from <ix:nonFraction unitRef="number" contextRef="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxOTA_21c95e59-60cb-4463-b1af-c89bb877d119">0.10</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i2371a67c1d5d4ce6bb8affa16d99a8ee_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxOTc_86445fe8-1eb3-4427-8580-b2c0921e7166">0.25</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i377918284ec1474f8fdb964743a3854e_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMDQ_db9aa685-6d44-4c4e-bfb8-43d826bc0f6a">5.25</ix:nonFraction>% for term SOFR rate loans and <ix:nonFraction unitRef="number" contextRef="icfc22bae41d747e1bf892fd0aff2bac1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMTE_90129778-29ee-45fa-b499-527a7b8b5b56">4.25</ix:nonFraction>% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from <ix:nonFraction unitRef="number" contextRef="i12b21613190a42c48428381118250a85_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMTg_6f63a14d-828f-4aee-b9bf-d46aca3b5cdd">4.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i08144428b8f74cbfa6a5eb11eec200bc_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMjU_267cf219-7794-44d5-908d-945bf49007b4">5.25</ix:nonFraction>% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic2b61046449c4453948b31ac17dcf49f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMzI_f1e16594-9116-470a-bd57-e094467c6035">3.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib987a52fcaed4951afb151a82a0665fe_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMzk_8427555a-ec8c-4a29-8cc5-bea1cbdad828">4.25</ix:nonFraction>% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i279595da75be49f6a0842b392c5e04e2_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNDY_dca58585-78c6-4e3d-bd0d-a8621f5bf35c">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5ba9e35b10d64b8f8d73e9204b9ccbf3_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNTM_a657876c-a26d-40e2-8e40-d72d076619ee">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNjA_68c4bf6d-5aa9-4a26-8845-cb779804204e">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) <ix:nonFraction unitRef="number" contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNjY_54e33537-e1b8-433d-afc9-87c2f94393c1">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNzI_a724ab55-5839-402c-9835-63b22bd1c422">50</ix:nonFraction>% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNzc_21bb2963-30e2-43c1-9fc7-ac0b1c20457f">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="id0475cb4c7ac43abbf4df21604027a97_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyODM_84a48adf-85aa-4db9-9b2a-07807fd05536">5.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i4e403587348b4dbd9a36b1f6aa5ca65a_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyOTA_603c21fe-9385-458b-a64c-1180c1dc7286">125</ix:nonFraction>&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $<ix:nonFraction unitRef="usd" contextRef="i4085e18b60c748e48cf892810f08a0c3_D20221231-20221231" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMDQ_4ff7c2c2-30c0-4c37-b4ea-02fed41de1bb">500</ix:nonFraction>&#160;million through December 2026.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic137c5c6a30243949d30ebde8a737d1e" continuedAt="i3d6d86c08b804d4489616e62160b5ae9"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMTg_e02c17c2-0486-4ef9-bd6d-d79c77e847f9">1,000</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMzQ_2a354a56-4ee7-461d-ac7e-0de5fb871bea">40</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i08ca66a8836a40cb85dd578b9e98529f_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMzk_60b511ff-569a-4b22-80f8-24eaa49d7932">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="id7b201553ea840b8882b868dc71cc5f0_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNDU_0de25925-fc50-4b2a-b6d2-e548d60f5c40">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNTE_bf354181-2671-4eaf-9315-b3e5a1b243aa">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than <ix:nonFraction unitRef="number" contextRef="i19e771793b9549488be559466ddda99e_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNTc_30d1fb5c-1949-4356-8937-17ecb002fe11">7.60</ix:nonFraction>:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately <ix:nonFraction unitRef="number" contextRef="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk5MTc_51daf64e-6534-45f2-b88b-a0b3f07de93d">89</ix:nonFraction>% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $<ix:nonFraction unitRef="usd" contextRef="ic889bd7bbe3b4f05a299372748c68b3d_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNjM_5a26ff1c-4cd7-4429-b792-06d91b5eeb03">2,500</ix:nonFraction>&#160;million with a <ix:nonNumeric contextRef="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzODg_d9119925-1942-402b-97ea-f788af4227f0">five-year</ix:nonNumeric> term to maturity (the &#8220;B+L Term Facility&#8221;) and a <ix:nonNumeric contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzOTk_65397b26-dbeb-4c46-a1d8-6330a8cf9b77">five-year</ix:nonNumeric> revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="idb3e0b748c154802a58a1beafbe2cff5_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MDE_1c021bc3-1f72-4b3f-a54d-ee5d29ba68d0">500</ix:nonFraction>&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility may be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of December 31, 2022, the principal amount outstanding under the B+L Term Facility was $<ix:nonFraction unitRef="usd" contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MTU_34d95d2f-eb08-4719-be49-62cb607e23fa">2,488</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MzE_36b9a4b0-60fa-4cb6-9e6d-c5d9ae3d42d9">2,439</ix:nonFraction>&#160;million net of issuance costs. As of December 31, 2022, Bausch + Lomb had <ix:nonFraction unitRef="usd" contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk4ODE_d6f079ef-874a-47b2-9ca3-f272e6c54240">no</ix:nonFraction> outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="i15c6d66c35ee4080bdc94c23a19b52a0_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk4OTA_47e49d3c-e8dd-4982-9fd5-c3c3f70ed4bb">24</ix:nonFraction>&#160;million of issued and outstanding letters of credit and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk5MDM_6d29601e-f9a1-4bcf-938f-e95da670417d">476</ix:nonFraction>&#160;million under its Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than <ix:nonFraction unitRef="number" contextRef="ie320b639a3cd47dc961878584dd8c3af_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NDc_dcc12549-ce01-464e-b8da-aaf7299c2592">0.00</ix:nonFraction>% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i8abed56d79f84c52a16d613195c7f1dc_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NTU_994e8efa-d192-4ca1-b625-ffab6e647ee6">1.00</ix:nonFraction>% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i5222261a43e242bd96ba62a6d53496dc_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NjI_c891623a-fd62-4d27-9111-639bc6821a6a">0.10</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between <ix:nonFraction unitRef="number" contextRef="ia4b348dc7be84fe6845f94845ff52de8_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0Njk_910372f4-2960-48c1-9b22-bbf294c79249">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i08b9fcb7582349bdaf4dcf63e1033674_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NzY_a374d381-8a48-4637-96db-d3b2f4d114e0">1.75</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="ia1d957402ceb40b8a787c5e4f4236ebf_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0ODM_6388da4e-88d9-4e20-9437-e9752d3792ec">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8c1cf2c8c91a4a85aba037eee43e16a0_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0OTA_c089f806-c7e5-4ea8-a2ce-046156135af4">2.75</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between <ix:nonFraction unitRef="number" contextRef="i12a3c2097c9343febaf0889f97fafd58_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0OTc_60da778f-f0bf-45b5-a552-a9a5cb3b8e09">0.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3678fe7d442d4e65a3e4b646e9a46587_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MDU_d19d990f-287d-40a3-8867-0cb92791bb49">0.475</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i1d8fc1d36257456c85af865931829d7d_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MTM_634e498c-de56-4645-b0a9-c5b23550e321">1.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7bf08cd8ce2848bfb0ffd1ba61fd6396_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MjE_02fa632b-9844-443e-b435-a822c4607157">1.475</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1Mjk_8f2a013e-ccb6-4e7c-9235-de8569171e0c">0.25</ix:nonFraction>% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between <ix:nonFraction unitRef="number" contextRef="ia1587227fe18483fbd9cf40bd7d77115_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MzY_ce90b262-b578-4990-be3f-b762f0edbe31">0.110</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6ce57f96608f474f8f53043e82f4429e_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NDQ_25842606-23f5-4d23-8970-f51badf58070">0.275</ix:nonFraction>% of the total revolving commitments, whether used or unused, based </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i3d6d86c08b804d4489616e62160b5ae9" continuedAt="ic2ff9ac489b0404b88d5065bfc8a1e60"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NTI_b14ddb79-0723-4a74-bf53-6b7c01c666c6">3.25</ix:nonFraction>% or (ii) a U.S. dollar base rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i34b6aa60fd3b4cb8a9c35ca0b87ae3bd_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NTk_e822dd17-949c-4bc4-b4f5-c55d9e0ffff3">2.25</ix:nonFraction>% (provided, however, that the term SOFR-based rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i4684fb9c9da34175aa3d87f334fea43d_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NjY_406abacd-e2b5-4a3b-a557-3c96137578cb">0.50</ix:nonFraction>% per annum at any time and the U.S. dollar base rate shall not be lower than <ix:nonFraction unitRef="number" contextRef="ie357a3d3d5a5421cbd36adeb99212916_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NzM_5925f64d-ad23-4db7-bd1e-253a77da44e3">1.50</ix:nonFraction>% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1ODA_42d06870-3d9b-43bf-a724-d21754032e18">0.10</ix:nonFraction>%. The stated rate of interest under the Term Facility at December&#160;31, 2022 was <ix:nonFraction unitRef="number" contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1ODc_a97c14a9-efb7-45ed-93bd-0fa746e51413">7.84</ix:nonFraction>% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1OTQ_096ed541-250f-48b5-bdbc-a8e95500ed0d">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MDA_107b5d8e-c5d4-4c7c-8aa8-8d7a8c528a57">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MDY_4775fbaf-bee7-49e6-ae03-0c83ffc583ef">50</ix:nonFraction>% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MTE_431a6db9-0dab-482c-9d54-df92f694f208">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is <ix:nonFraction unitRef="number" contextRef="ic889bd7bbe3b4f05a299372748c68b3d_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MTc_9acf272a-77f3-463a-94b5-398085465ecb">1.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MjQ_ac47aa00-c635-4a1a-b95f-27db7d09ef60">25</ix:nonFraction>&#160;million, and the first installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $<ix:nonFraction unitRef="usd" contextRef="iccfcad9639644d1aa8dd1ea244c8e451_D20220101-20221231" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2Mzc_8d7d2688-31ea-454e-8c97-c79b08e544e8">106</ix:nonFraction>&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1OTc_5179969b-2913-4700-b9fe-fa63336d10ab">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MDU_311f1f44-ad05-4a66-a879-20d4e3fc2b05">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNDI0_a568efd5-1df3-416f-8731-3902342c27d7">6.500</ix:nonFraction>% Senior Secured Notes due 2022 and <ix:nonFraction unitRef="number" contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNDYx_f1a4cd88-0eac-4ac2-b681-c94bb2fba4f4">7.00</ix:nonFraction>% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNTI5_d1bacd87-242e-45e5-8659-717f395aa45d">1,250</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNTYy_a568efd5-1df3-416f-8731-3902342c27d7">6.500</ix:nonFraction>% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNjQy_010b335d-7ada-4060-a41b-989eb1088972">2,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNjc1_f1a4cd88-0eac-4ac2-b681-c94bb2fba4f4">7.000</ix:nonFraction>% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic2ff9ac489b0404b88d5065bfc8a1e60" continuedAt="ibc3743cc9b7f4fd2b373952c75db66ac"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMTQy_198b6a3a-9286-47c0-adf8-bee6b96b13bd">5.500</ix:nonFraction>% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMjE1_96789e1f-03f0-4ff9-a7e4-be6168b69001">1,000</ix:nonFraction>&#160;million, and, on November 21, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ieedc4eac3b8d4a698d8cb9a05c341498_I20171121" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMjY1_aea3d4dc-9e12-4df6-a079-80fdc81b8180">750</ix:nonFraction>&#160;million, aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMzAw_198b6a3a-9286-47c0-adf8-bee6b96b13bd">5.500</ix:nonFraction>% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyNjc3_a4244f0d-363f-4720-8610-77a4ef3f4486">5.750</ix:nonFraction>% Senior Secured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i2e218676fac849289a6c340912b014b8_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyNzk4_7fc81555-efb7-4e69-a6ac-9784c3df82f1">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i8aacff91d3fd4e97930a57ce23252d07_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyODMx_6e273eb6-aedb-4d7d-bf2b-6d20400b32e4">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027 (the &#8220;January 2027 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyOTEy_d90b5a5c-c39e-426b-990c-abe804454f9e">500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyOTQ1_e3a3dfdd-e9db-4a3e-9a9e-061b5a504d10">5.750</ix:nonFraction>% Senior Secured Notes due August 2027 (the &#8220;August 2027 Secured Notes&#8221;), respectively, in a private placement. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at the redemption prices set forth in the indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0NzU0_3a55634f-9557-4b80-bb08-f78898f5046e">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0ODYw_83b08718-068d-4f2f-9b2a-23e46041739d">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0ODkz_3a55634f-9557-4b80-bb08-f78898f5046e">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="i157619cd6dcb473cb47ad7bdd54e90f3_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE1MDg0_372659b0-22c6-46e9-900a-441fe60d5476">1,600</ix:nonFraction>&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i044da1c8e8644f5d923942355e34d8ff_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE1NDg1_977d46c3-661e-4ad9-83e2-a9392563df58">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i1eb6552099344d328f3d1d048ca4608d_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2MDQw_b5eca4fa-a104-48f3-b99c-f2ab5e1ac8b0">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i90b481eb38c945c59569b06b12fbff6f_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2MjY1_b3f55f0b-d3e7-49d2-a486-82329c06b740">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MTE_381ab1fe-3bdc-451e-97f0-27b24c9e269b">6.125</ix:nonFraction>% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MTk_f78a92df-cd28-4a2e-99d1-ec614201c6af">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MzU_614de583-cf75-419e-aee7-7b28a0ba0a51">6.125</ix:nonFraction>% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NDM_7b29dbe5-26db-44ab-a58f-4b671173abf8">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i0ae7bb4dd25840828cd9d3be1c5cf334_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NTE_70b86d30-89e4-43fb-9876-42974927eb4e">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="iccd58703f4d64effbac9da3441381c5d_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NTc_0cd2d037-bda7-41c2-981d-4dc862253057">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NTE_c449a57e-e673-4363-9739-903c1099acff">11.00</ix:nonFraction>% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of <ix:nonFraction unitRef="number" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NTk_fd35e2ba-fb76-44c1-9e03-a81d9fd8c9d8">11.00</ix:nonFraction>% per year that is payable semi-annually in arrears on each March 30 and September 30. The <ix:nonFraction unitRef="number" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2Njc_1ad27d7b-5822-4d4c-8d65-0b60f193bb86">11.00</ix:nonFraction>% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to <ix:nonFraction unitRef="number" contextRef="i88775d2b6196454d8a77ee9d6235695d_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NzU_223f2f75-fbae-4db5-a9c8-a97e89fe457b">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="ia0e1627198084241927fb3193e16c19e_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2ODE_df1858db-47e9-4edf-99b3-6c8c248029bd">11.00</ix:nonFraction>% First Lien Secured Notes indenture.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibc3743cc9b7f4fd2b373952c75db66ac" continuedAt="i32c96bb4d7244521a30922248db542ab"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2ODk_b14318f5-74d5-40ff-a99e-745b166ce835">14.00</ix:nonFraction>% Second Lien Secured Notes mature on October 15, 2030, and have stated interest of <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2OTc_a256653e-547d-4834-bea4-a7db65dafd15">14.00</ix:nonFraction>% per year that is payable semi-annually in arrears on each April 15 and October 15. The <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MDU_c57401d7-f1bb-48d1-bbae-9d1f393e1c9b">14.00</ix:nonFraction>% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MTM_d3eb0acc-1d46-4d8b-98f3-e3cc703af5cd">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. In addition, some or all of the <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MjE_c4421d8e-67de-4b27-aad0-0d5d34d4bdba">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to <ix:nonFraction unitRef="number" contextRef="i0698b60423314874943ed0139e7bdff1_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3Mjk_55da5599-3cba-47ce-a237-836cbff87c8a">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MzU_a38575c1-ec9f-4330-a68b-776cca3ef886">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to <ix:nonFraction unitRef="number" contextRef="i7a449c4bfa5041418ee1aa7972a1256e_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NDM_6748978b-d7e3-43e7-885f-109d6458fcb6">40</ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NDg_977638df-b4a1-4e37-9724-bef53a092b47">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i0d26b379509d423eb7d0672c56517477_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NTY_888f4561-855d-4c93-ab9a-101a59972635">14.00</ix:nonFraction>% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NjQ_1c5f6853-0b5e-450e-9742-82c34b1438b8">9.00</ix:nonFraction>% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NzE_393a7aba-c53a-47d0-bcc4-628c0c9363d3">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3Nzg_d960d0f9-83eb-4b63-953b-e31dbfae913f">9.00</ix:nonFraction>% per year that is interest payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3ODU_c97140b4-4697-4da7-a734-e13393684e7a">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3OTI_4804980f-70fd-41f1-be33-b7e6c5d85196">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3OTk_4d7959bc-1f85-4e80-b8c4-303c19257761">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of December 31, 2022 were comprised of <ix:nonFraction unitRef="number" contextRef="i7d7729b9b40f4da1b234f69afa941cbe_I20221231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MTM_80f01a09-8bcb-45d4-bdbc-951317c87bfd">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb Corporation. The <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MDY_162f23ad-2432-4cbe-9bf4-c924f11ebd92">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MjA_87beabd2-acbb-4501-b671-fc30cba0ac14">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes under the <ix:nonFraction unitRef="number" contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4Mjc_6992bbbc-7cbd-4284-9f0e-6cc933fb1e57">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ibc9e2bcfdfc8462abc99097872f4c5a1_D20220101-20221231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3MzIw_0a7f4130-0c23-457e-a656-ddf7ce3dca29">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $<ix:nonFraction unitRef="usd" contextRef="iff3554474d984129a7b72717cf870c74_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMjU_abc063c6-43b0-4924-913d-7834545bb5de">370</ix:nonFraction>&#160;million in aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="number" contextRef="iff3554474d984129a7b72717cf870c74_I20220118" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMzk_24d7587d-93a8-41ac-9080-bfbf1835e629">9.00</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $<ix:nonFraction unitRef="usd" contextRef="iff3554474d984129a7b72717cf870c74_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyNDY_bb12d31b-a832-41de-9ad2-1ff624c45148">7,000</ix:nonFraction>&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="idd69ab9daab24aac824807091b8a5671_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyNjI_a55771d2-32db-46f0-8064-f4e35fc5cdb0">101.021</ix:nonFraction>% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i32c96bb4d7244521a30922248db542ab" continuedAt="i341e3d246b9b4b60a1c96a717317aac2"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NDM0_86e4421c-ad60-4c36-a7b8-979feb424ade">5.500</ix:nonFraction>% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NTA5_f91314f4-55df-4011-a892-cdf064cd0ed0">1,000</ix:nonFraction> million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NjU2_86e4421c-ad60-4c36-a7b8-979feb424ade">5.500</ix:nonFraction>% per year, payable semi-annually in arrears. Throughout 2020, the Company repurchased, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="ic8228270dba34df8adb389c08897a92f_D20200101-20201130" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3ODk3_f6bcd1ee-8b6c-41e2-bbdf-62961e227619">169</ix:nonFraction>&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="i1a3b96fbff084df6af99651fb95d52b6_D20201201-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MDEx_e7897059-04a1-4f68-966c-248c80716794">233</ix:nonFraction>&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTA1_ad5efd57-7063-427a-9afb-fdec4cb5d41b">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020, <ix:nonFraction unitRef="number" contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTQx_75550855-2b2c-4986-b2cf-fcd11a183d4c">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023, <ix:nonFraction unitRef="number" contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTc3_a2f08c7a-64d3-4e98-9513-a7049312cff1">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 and <ix:nonFraction unitRef="number" contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MjE2_36289daa-76e5-4e24-bf32-eed8851002ac">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp., a newly formed wholly owned subsidiary of the Company, issued $<ix:nonFraction unitRef="usd" contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MzY5_9041e3c5-f5b0-45ab-86d5-2da8dadbb33a">2,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NDAy_eaaa52c4-4272-4eb9-9111-9c7c689ae59d">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020 (the &#8220;March 2020 Unsecured Notes&#8221;), $<ix:nonFraction unitRef="usd" contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NDcz_db5a1a91-3ec6-4a30-b59f-ec1d3b1f2a03">3,250</ix:nonFraction> million aggregate principal amount of May 2023 Unsecured Notes, &#8364;<ix:nonFraction unitRef="eur" contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NTMy_5c1380df-f295-4d74-91d1-3a79ce51a356">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NTY1_320acecc-5677-4e83-b1d5-9d5f1c21edd9">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 (the &#8220;Euro Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NjIz_20ae2649-423f-4d13-a7f7-b760aa083955">3,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NjU2_cae417be-2496-4896-a49e-b74da7a69d03">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and, together with the March 2020 Unsecured Notes&#8221;, the May 2023 Unsecured Notes and the Euro Notes) in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4ODU5_63c0505e-7a54-404a-84da-c51a3d4c0dcd">5.375</ix:nonFraction>% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MDI1_8068ecb6-9e56-4c02-a402-fe8c260f00d7">5.875</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MDMy_6c1e8343-49e2-4bb8-99c8-f19c2a6c7e84">4.500</ix:nonFraction>% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MTk1_b073eb03-9ed7-4d5d-a2fc-fffcca4d6ddd">6.125</ix:nonFraction>% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2020, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="i2c4e650a31d242bbb5c5d585c03cb333_I20200116" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5NjQ2_88d43419-02ed-4a07-8e80-bd59259a1e35">1,240</ix:nonFraction> million aggregate principal amount of the May 2023 Unsecured Notes. Throughout 2020, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="idb5cda3faa264c738c116577d2729461_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5ODI1_1e95c224-08a9-4081-82b1-77afad5b5b54">208</ix:nonFraction>&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="i1e615859d6bb4a4e90467e2add18e800_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwMTYw_f18649ea-a29f-48f9-a589-97b36f479e11">600</ix:nonFraction>&#160;million of the April 2025 Unsecured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the April 2025 Unsecured Notes were redeemed and discharged in the second quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="idadc1532b7b04afba0801fa41303f107_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwMzk2_e5228871-1cc6-4432-ace2-cb30fa94730e">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="idadc1532b7b04afba0801fa41303f107_I20171218" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwNDcz_b11f0eb8-f48d-43aa-aa9a-d81894522c29">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="idadc1532b7b04afba0801fa41303f107_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwNTA2_210e12b6-cd3f-4898-8dbb-4a6f9a9051e0">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement. The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="idadc1532b7b04afba0801fa41303f107_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwODgx_f4419b1b-f42d-42d5-aa58-8cedd1351c0a">9.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes, at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ia297817a7541403aa01709acbd44a471_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5ODM_c8ce78e6-3508-4503-969e-59b5b164d530">541</ix:nonFraction>&#160;million in aggregate principal balance of the December 2025 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxNzk2_331930e8-2695-448b-b30d-beb55cd843ad">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $<ix:nonFraction unitRef="usd" contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxODYx_07c76e78-3393-49c1-bda3-36ea77bb808d">1,500</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxODk3_331930e8-2695-448b-b30d-beb55cd843ad">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $<ix:nonFraction unitRef="usd" contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIyMDYw_e3312b81-1d4f-4947-ba74-ba1fee92418c">1,500</ix:nonFraction> million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIyMzE5_331930e8-2695-448b-b30d-beb55cd843ad">9.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i6bb93a16e162462585252110ee36a962_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5NTM_0c51565c-e277-4bf9-b5db-4186ea33f187">752</ix:nonFraction>&#160;million in aggregate principal balance of the April 2026 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i341e3d246b9b4b60a1c96a717317aac2" continuedAt="i1145f928cdcf4665a72f5959ac29b845"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i2e218676fac849289a6c340912b014b8_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzMTgx_86a087d8-9e6d-44cd-b7a0-ad9a896ae083">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, BHA issued $<ix:nonFraction unitRef="usd" contextRef="i5fa832e82c1d49a2a3ff00d4b061892e_I20180630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzMjcw_61e46650-90d8-43ff-800b-e86294b15efd">750</ix:nonFraction> million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i2e218676fac849289a6c340912b014b8_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNDIz_86a087d8-9e6d-44cd-b7a0-ad9a896ae083">8.500</ix:nonFraction>% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, BHA issued $<ix:nonFraction unitRef="usd" contextRef="i2e218676fac849289a6c340912b014b8_I20190331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNTUx_7fc81555-efb7-4e69-a6ac-9784c3df82f1">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2e218676fac849289a6c340912b014b8_I20190331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNTg0_86a087d8-9e6d-44cd-b7a0-ad9a896ae083">8.500</ix:nonFraction>% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i669d24178a614762a12dfff0155fe19e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5Njc_55df0481-d674-4f93-abde-985272bec09f">1,099</ix:nonFraction>&#160;million in aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="ibfed71661ee944d49ddb49203d8a286a_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNjM_31191404-cc2e-4680-923d-797f94003df1">8.500</ix:nonFraction>% January 2027 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NTI4_2d2d9ad5-facc-41a1-9a30-e95384258716">7.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NTY3_3b899dd2-9a6b-4b95-a838-b5332e69ca60">7.250</ix:nonFraction>% Senior Unsecured Notes due 2029</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0Njc5_6910b970-ea00-4ba5-a973-2e6a7ff83f8e">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NzEy_2d2d9ad5-facc-41a1-9a30-e95384258716">7.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NzYx_cae1fdfd-13b4-46c7-a807-cdbd84374f78">7.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0ODA0_b4fe1f72-30d6-416d-9b8b-393877ae4928">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0ODM3_3b899dd2-9a6b-4b95-a838-b5332e69ca60">7.250</ix:nonFraction>% Senior Unsecured Notes due May 2029 (the &#8220;May 2029 Unsecured Notes&#8221;), respectively, in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI1Njkz_a6351379-e763-4040-ba49-5eaea5eaa5a8">7.000</ix:nonFraction>% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MDAz_3693ef92-85b2-4642-955c-f319c55030f2">7.000</ix:nonFraction>% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="i9df3f1e3d2554c78ad4cbb459875b7bf_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MTQ1_28314832-f509-4d6a-8b46-a92d86c50374"><ix:nonFraction unitRef="number" contextRef="i18218eacfbb142faaa9a5d87297b9a13_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MTQ1_8b4b1dc5-69a2-464e-9c40-7937744d62c2">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i696a075a54064b0997717cd8d8a32b6c_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MDk_f35201a2-c0b0-43df-bd20-7681aa49f522">540</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9cc611b24a90474d83f2f66f38a20f88_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MjM_b9eb1234-c0ad-49e7-992f-ea3a0cda377d">373</ix:nonFraction>&#160;million in aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5Mzc_a9b5bbf7-01c8-4cd1-be53-e3aa1876a771">7.000</ix:nonFraction>% January 2028 Unsecured Notes and <ix:nonFraction unitRef="number" contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5NDU_a7581650-be62-428c-8008-0b1251bb845c">7.250</ix:nonFraction>% May 2029 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NTE0_fb111677-8a1a-4156-b940-e4634fab8baf">5.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NTUz_ff4bd4b7-6997-44e2-9981-25c814706c1f">5.250</ix:nonFraction>% Senior Unsecured Notes due 2030</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2Njg5_2f2c748a-e916-452e-a8e6-ebf5241583fa">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NzIy_855f55e2-9aef-43d8-be34-890e154f391e">5.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2Nzcx_18cd6c21-5371-4ae7-a3f5-c6e612d3342a">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2ODE0_6803ed10-62e0-48d6-904e-9d93689340cc">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2ODQ3_5a83fa9d-9f8c-4f7c-b913-871c15b0a760">5.250</ix:nonFraction>% Senior Unsecured Notes due January 2030 (the &#8220;January 2030 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the <ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI3NTk3_18cd6c21-5371-4ae7-a3f5-c6e612d3342a">5.000</ix:nonFraction>% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI3NzYy_18cd6c21-5371-4ae7-a3f5-c6e612d3342a">5.000</ix:nonFraction>% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MDI4_18cd6c21-5371-4ae7-a3f5-c6e612d3342a">5.000</ix:nonFraction>% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="i3fe5dc0384494154a1e6d8f92d81bdcd_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MTI2_1f6c8083-aabf-495e-8970-4f43fe5975f1"><ix:nonFraction unitRef="number" contextRef="id10012d6ae2a4a9a8da2d30e73d8fbe6_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MTI2_3a620a45-eba3-404c-9edc-e3619f1b4236">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i3fc3ea4063504440ada3d5c75d466bff_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4NjU_3c91c027-fbae-4a0b-ba2c-786ea40c2795">710</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e135d7f019a49849b913e4b90edfb2d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4Nzk_43b73b74-9192-46e7-a49f-ff83f78bc164">332</ix:nonFraction>&#160;million in aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4OTM_75c36869-4be0-4f5f-9e20-1fff909a3a78">5.000</ix:nonFraction>% January 2028 Unsecured Notes and <ix:nonFraction unitRef="number" contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MDE_a798784a-b23f-477a-b393-d9494f7a0027">5.250</ix:nonFraction>% January 2030 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NDE3_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% Senior Unsecured Notes due 2029</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NTI0_22d00e50-8102-4720-8114-e2242e122688">1,500</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NTU3_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the &#8220;<ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NjA3_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="i274a447de4c946398cf00b10748b1942_I20200526" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NzI1_0aef5546-acd9-4123-b2dc-bbd5d3fff8da">1,250</ix:nonFraction>&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $<ix:nonFraction unitRef="usd" contextRef="if254b82a71434782ad56911693096e5f_D20200526-20200526" decimals="-6" name="bhc:PaymentForDebtAmortizationPrepaymentCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4ODEy_89e2fade-30c9-4b33-a7c9-ddf06da5f47a">303</ix:nonFraction>&#160;million of mandatory amortization scheduled for payment in 2022 under the Company&#8217;s June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2020 Refinancing Transactions&#8221;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="iecbd9075b4a94899961c7585f2aed5b7_D20200526-20200526" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5MjE3_d1b1e547-3677-492c-bd19-7aa465517431">27</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. The <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5MzUy_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NDE2_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i1145f928cdcf4665a72f5959ac29b845" continuedAt="icb8ab3f37334483b9ffc9bc0e64ce6dd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NTQ3_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="i0d9a11ba7b5b4f3ba097f6f466955097_D20200526-20200526" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NjQw_f0b9bb6e-9d90-4df3-ada5-29cadbe67864">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i35ebc47cf5eb41e4b68a050da347702f_D20200526-20200526" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5ODU0_a264ec91-fefc-49d1-99fb-a7d74b72d745">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5OTEw_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMDM0_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMTU2_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMjQy_6fe9169c-ad4f-4e33-a57d-25b832b91816">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5OTc_c5532106-5aa4-4e4c-b748-67b78aaaa810">540</ix:nonFraction>&#160;million in aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMTE_d46dba89-c3e5-4b6f-a66b-80071b9f8487">6.250</ix:nonFraction>% February 2029 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMzY2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% Senior Unsecured Notes due 2029 and <ix:nonFraction unitRef="number" contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNDA1_7a2ddfb8-846b-4889-9466-9ecb7304c3aa">5.250</ix:nonFraction>% Senior Unsecured Notes due 2031</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNTIx_b2d9b729-7e10-459d-b60f-e1cd3b9407a9">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNTU0_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjA0_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% February 2029 Unsecured Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjQz_79cb67cc-bb20-4032-b51d-a65260c39375">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjc2_7a2ddfb8-846b-4889-9466-9ecb7304c3aa">5.250</ix:nonFraction>% Senior Unsecured Notes due February 2031 (the &#8220;February 2031 Unsecured Notes&#8221;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="i6f524e92b57548fcb59a5560034d56ea_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwODk4_0a4cf65d-d48c-42a3-bb41-4d7d18118c52">1,500</ix:nonFraction>&#160;million of the Euro Notes, (ii) $<ix:nonFraction unitRef="usd" contextRef="i40215fdad1084cdd819206c295150373_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwOTI1_cadfc032-dad2-437c-86a3-80ff29e5205d">233</ix:nonFraction>&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2020 Refinancing Transactions&#8221;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i7a746c21c7a14bc3bc2a6e2b9323019a_D20201203-20201203" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxMjQ3_ff01b560-8420-4236-83f1-c894960dc74e">7</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. The <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxMzgy_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNDQ2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNTk1_7a2ddfb8-846b-4889-9466-9ecb7304c3aa">5.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNzI2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxODE5_419fb918-12cf-40ae-a1ac-fed21e629376">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMDM1_f1cd33ce-7b6b-4370-9189-3c56fc5dc6d8">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMDkx_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMjE1_c7bcec0e-3463-4bb2-8c5d-6f05bb4c5b30">5.000</ix:nonFraction>% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMzM3_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e">5.000</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyNDIz_32cda7bb-1747-4009-b24f-577fcb61c42a">5.000</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to <ix:nonFraction unitRef="number" contextRef="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyNjg0_8df2d438-317a-4c4c-a756-7b00a1c5180a">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTAw_900e5b44-aff4-4c97-b6d6-d3ed1eff5875">40</ix:nonFraction>% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMTk_b7ce7d13-37e5-4fcf-9a0b-5e5c8f7ec5aa">371</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMzM_8eadecf0-0c9a-4e76-9963-fc0d360cafe7">336</ix:nonFraction>&#160;million in aggregate principal balance of the <ix:nonFraction unitRef="number" contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNDc_a9c8d6c6-03c7-461e-897b-670b830b46d2">5.000</ix:nonFraction>% February 2029 Unsecured Notes and <ix:nonFraction unitRef="number" contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNTU_a5affc76-e4a2-4797-8b41-f980b9096885">5.250</ix:nonFraction>% February 2031 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of December 31, 2022 and 2021 was <ix:nonFraction unitRef="number" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMzNTQw_b58ed975-53ce-405d-a3ac-f359f57cc0bb">7.74</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMzNTQ3_5efdd0e7-b959-4d83-8a8b-821aec75d038">5.88</ix:nonFraction>%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements for 2022 and in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 and December 2022, the Company repurchased and retired certain outstanding Senior Notes with an aggregate par value of $<ix:nonFraction unitRef="usd" contextRef="ifdadcd473052481b9f108756b569bcf5_I20221231" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NjI_7d66a73d-41f4-4193-a3af-be13f50190c9">927</ix:nonFraction>&#160;million in the open market, for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NzY_63244f71-c9c2-49a4-81ca-62ec2131dce8">550</ix:nonFraction>&#160;million. In connection with these repurchases, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2OTA_dc3d8067-6970-4677-8e3c-95f9efc5da15">369</ix:nonFraction>&#160;million, net of write-offs of debt premiums, discounts and deferred </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="icb8ab3f37334483b9ffc9bc0e64ce6dd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance costs, on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company completed the Exchange Offer and recorded a net gain on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i700f313b8feb4a02af4dbbaaf4864a43_D20220901-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE3MDQ_2ed1834e-ba9e-42a2-be36-dd5b7e608871">570</ix:nonFraction>&#160;million as described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="icc4a098d6f0545d9a3df6e94e3949b54_D20220510-20220510" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE3MTg_fb275e4f-f955-4134-8bfe-d001e8bb9e0d">64</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzM0MjU2_50e9a270-ec29-4b6d-af0c-20c861f843bb" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:88.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzEtMS0xLTEtMTY5NjA4_a706fa4f-f1b5-4344-9e47-d976ee5c9a34">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzItMS0xLTEtMTY5NjA4_d519d961-8dd6-45b7-9fc0-de4c4b444558">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzMtMS0xLTEtMTY5NjA4_202e6856-7376-4dbe-ae5c-b33ed91ab14e">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzQtMS0xLTEtMTY5NjA4_a8b5c6ed-7394-41e2-b0a1-6917dcdce918">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzUtMS0xLTEtMTY5NjA4_f9c677b1-9883-496a-aedc-277a69491774">6,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzYtMS0xLTEtMTY5NjA4_1a0961c4-b290-4313-9bf1-563b6d69b7df">8,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzctMS0xLTEtMTY5NjA4_e4551eb2-1d80-4439-9a9d-9354ad9551ec">19,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzgtMS0xLTEtMTY5NjA4_8fef4f4c-1f34-4b7a-92b3-f09944e51491">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzktMS0xLTEtMTY5NjA4_e8e97b28-4a65-48d0-9307-8afd71685b24">20,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2022 Amended Credit Agreement, there is no Excess Cash Flow payment due for 2022.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_346"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzOTg_d708f385-a9d8-4127-891a-ccfcb4d54a43" continuedAt="i5c630e1715a54da08b6a7a9016163792" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i5c630e1715a54da08b6a7a9016163792" continuedAt="i91b7879fa66a43d1aafb6d56887e6b53"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8220;B&amp;L&#8221;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) <ix:nonFraction unitRef="number" contextRef="i24e7ab6a195b4f8a8f49a061d91b6087_I20221231" decimals="INF" name="bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzY3Mg_1ec1e233-fb3f-4209-af36-094e61399bb8">4.50</ix:nonFraction>%. The most significant non-U.S. plans are <ix:nonFraction unitRef="defined_benefit_plan" contextRef="i8f6923561a7e494dbd4b2c015eaf76da_I20221231" decimals="INF" name="bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzcxNg_55e26615-08e9-4839-a47f-6a6af9589028">two</ix:nonFraction> defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, <ix:nonFraction unitRef="defined_benefit_plan" contextRef="i16516120cd164448a3c89f1ebb6cd381_D20141201-20141231" decimals="INF" name="bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzOA_f69c43cb-746d-44a4-b845-59d5f9048502">one</ix:nonFraction> of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age <ix:nonNumeric contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" name="bhc:DefinedBenefitPlanEmployerContributionMaximumAge" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzE0MjM_3399b7fc-7602-4946-a66e-26125aa32a23">65</ix:nonNumeric> for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company&#8217;s employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i91b7879fa66a43d1aafb6d56887e6b53" continuedAt="if8c0f3b48d7843df97e52cd9eb160e91"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0Mjc_a6255919-ba08-4532-b147-481ccbcd6a20" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:38.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.963%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMi0xLTEtMTY5NjA4_eed5d28a-bf95-409a-837e-237ad47cf60f">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtNC0xLTEtMTY5NjA4_c9139263-75e7-41ca-bf49-88e5a069dcd3">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtNi0xLTEtMTY5NjA4_df1c8d59-377f-471f-a4a8-e9424f7bd2c3">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtOC0xLTEtMTY5NjA4_6a05e694-8807-4d84-8b15-6eaa841fb8b8">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMTAtMS0xLTE2OTYwOA_e47e6aef-dbe3-4cec-bb72-ead21b45a5cd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMTItMS0xLTE2OTYwOA_182b9d9b-66f0-46e0-910b-95fd4fa525b9">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMi0xLTEtMTY5NjA4_812b2870-9b76-4757-af35-cf8db92862a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtNC0xLTEtMTY5NjA4_3755b302-3270-4ab6-b720-53a9297352a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtNi0xLTEtMTY5NjA4_fb6308c0-da79-48d7-9bf4-84ddc3d09553">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtOC0xLTEtMTY5NjA4_743dac0a-952e-49f9-97e2-76baa2f16fc0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMTAtMS0xLTE2OTYwOA_632a7910-f087-410a-aa74-b3e9ea04c724">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMTItMS0xLTE2OTYwOA_9e53fff4-1d10-4dd5-8f80-0a94ed14950e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MDg_bf408f8c-6032-450a-96dc-c03c8141bdf7" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:25.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMi0xLTEtMTY5NjA4_f769a719-c709-46f1-8246-d85ede05ed1f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtNC0xLTEtMTY5NjA4_8da62794-da43-4a31-ae7c-978f9b44139a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtNi0xLTEtMTY5NjA4_6e42a9ad-841b-4c29-99ff-ea577a75ea83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtOC0xLTEtMTY5NjA4_b855e4c2-da59-4d08-b559-7b75f1584eb9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTAtMS0xLTE2OTYwOA_dad7027f-e43d-492d-b5c4-efc6f4a0e4ca">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTItMS0xLTE2OTYwOA_7e370462-ad23-48b3-9b40-c88a76ceba47">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTQtMS0xLTE2OTYwOA_879d91a5-6ebd-4fa3-ab2a-dcd20d061af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTYtMS0xLTE2OTYwOA_bf2df45b-3a02-412a-a776-b2c1b00fdabe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTgtMS0xLTE2OTYwOA_5fd34237-b8a9-4a5b-b558-1895b8b3e0b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMi0xLTEtMTY5NjA4_ac507fbf-446d-4c0a-89b5-a415f95b054e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtNC0xLTEtMTY5NjA4_c6cd4b24-6fce-4f48-90e6-0ee664b31123">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtNi0xLTEtMTY5NjA4_5c54a370-0c1d-436b-b610-a2d5f963cda2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtOC0xLTEtMTY5NjA4_5a7dfaf3-cdd0-494d-9a52-fa0a18309c8f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTAtMS0xLTE2OTYwOA_27489259-8350-49c4-9408-d1ec83bd9145">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTItMS0xLTE2OTYwOA_2518a640-df9c-4682-8b90-978993c3b22c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTQtMS0xLTE2OTYwOA_b7effb68-52ef-4dbd-81bb-a4001e2acc79">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTYtMS0xLTE2OTYwOA_7d918f92-566b-4f0b-becc-842451d84c13">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTgtMS0xLTE2OTYwOA_9e13dcb0-4307-45c8-b1bb-f8b23f2e374b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMi0xLTEtMTY5NjA4_2fc0433f-d46e-40fb-98ce-c72766e40450">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtNC0xLTEtMTY5NjA4_bd3729df-0d10-4919-9da1-70b80c2a93bc">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtNi0xLTEtMTY5NjA4_06a07d1d-0217-4c17-9334-afae6b48e56f">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtOC0xLTEtMTY5NjA4_be2cbf9a-6479-48db-a3c9-da0e4e169dbb">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTAtMS0xLTE2OTYwOA_1f30b0c9-28f0-4b05-a729-930ee56ee5d8">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTItMS0xLTE2OTYwOA_7f1e3f4d-5c5b-47cf-8604-f8d6bf91910c">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTQtMS0xLTE2OTYwOA_452c1069-4c49-47cb-9141-a12d0f34c251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTYtMS0xLTE2OTYwOA_0b8d7c94-8ba2-4bcd-8b29-47aff3491854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTgtMS0xLTE2OTYwOA_70844ce7-8ee6-4d34-ad98-9d5d6bc5346e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMi0xLTEtMTY5NjA4_ca0d533a-9eae-474c-9169-00f2d578f503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtNC0xLTEtMTY5NjA4_551daec4-4e49-498c-8590-47e85b4158d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtNi0xLTEtMTY5NjA4_ae9a90c8-7e27-443d-b893-5906d4d08383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtOC0xLTEtMTY5NjA4_8213f73d-5ed1-490c-8827-5e9f4c47a518">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTAtMS0xLTE2OTYwOA_fa2337f0-2120-424f-b5c3-bcffe043c075">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTItMS0xLTE2OTYwOA_01c21fb6-0dec-4c1e-9d64-51b830db075b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTQtMS0xLTE2OTYwOA_2f8339bf-78c3-42b4-bc56-39e343ef9586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTYtMS0xLTE2OTYwOA_bd5d3ecb-f41b-466b-9f66-35bbf9f55106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTgtMS0xLTE2OTYwOA_3695363c-7eed-47a2-98bb-16b198bd8ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMi0xLTEtMTY5NjA4_173e0070-985c-4967-8512-30aba9d97e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctNC0xLTEtMTY5NjA4_bf6983eb-4d91-4201-a2df-a3be7c6d2a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctNi0xLTEtMTY5NjA4_6bf293ea-97d4-4dcb-b34c-d7d6799140c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctOC0xLTEtMTY5NjA4_b600af3f-61ee-4af3-943f-608cd7976163">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTAtMS0xLTE2OTYwOA_482a9f49-dfe1-456c-be9b-e3d3f79ccedf">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTItMS0xLTE2OTYwOA_19404ffb-5e52-4918-acee-8474e78d36ea">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTQtMS0xLTE2OTYwOA_f8cf9017-02ff-4411-ac16-a44157f42c0f">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTYtMS0xLTE2OTYwOA_80fb8fe0-4c6d-4776-b85b-3f73cca678b5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTgtMS0xLTE2OTYwOA_433979c4-7edc-490c-b679-cae5d9cfe017">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMi0xLTEtMTY5NjA4_625018bc-8503-45aa-8b53-d9ecd310b14a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtNC0xLTEtMTY5NjA4_7bf00178-9eba-4263-88de-124abc1ba0b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtNi0xLTEtMTY5NjA4_07db7a2b-a931-46af-a7fc-7675fc3f928b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtOC0xLTEtMTY5NjA4_fdd65c4a-0bfa-4a58-85d0-35e21fed2964">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTAtMS0xLTE2OTYwOA_af5cef01-a37a-437a-a553-2eb11259b743">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTItMS0xLTE2OTYwOA_0e18b360-d624-4d99-bfae-b8bd2e9032b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTQtMS0xLTE2OTYwOA_49b6c700-ddfd-4cc5-80eb-032eb0c35d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTYtMS0xLTE2OTYwOA_9d5a8791-8224-4f61-b6d0-6135a1c5b356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTgtMS0xLTE2OTYwOA_634eb40e-9c18-49e6-a729-7beba2c6cb75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTItMS0xLTE2OTYwOA_b97a00db-34c3-44ea-9a4f-8fe64cb9e367">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTQtMS0xLTE2OTYwOA_4f26c397-d44c-4508-bce8-8bb165c50948">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTYtMS0xLTE2OTYwOA_922adb13-775e-4ffd-b471-908914935f0a">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTgtMS0xLTE2OTYwOA_22003849-596a-437b-9da9-f7c945955289">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTEwLTEtMS0xNjk2MDg_1a4bbad3-47af-4262-8f42-5543f2d3332e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTEyLTEtMS0xNjk2MDg_2adac560-334b-470a-9d88-f0bcc810494a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE0LTEtMS0xNjk2MDg_7e2ca78b-411b-4f60-b5c3-7b21cfc02901">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE2LTEtMS0xNjk2MDg_2e245f40-0a08-41f7-bad8-d88450a67d05">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE4LTEtMS0xNjk2MDg_ef590664-2f52-4a17-b1a9-07fbad1ae6d8">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if8c0f3b48d7843df97e52cd9eb160e91" continuedAt="ia27adf1579d84d0183a8ba7ad19a8fa2"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MzA_b2a83639-1466-4e49-979c-8ad2a157f274" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2022 and 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:40.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.025%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMi0xLTEtMTY5NjA4_8337be31-7e78-4fb8-92a7-147b5e51ef10">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0e93f49dae408e8c386793727d9086_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtNC0xLTEtMTY5NjA4_6a8818a0-5d25-4912-85b3-0f1d9697dae3">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtNi0xLTEtMTY5NjA4_6aa5af47-d239-4e59-b270-ddf826467fd6">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtOC0xLTEtMTY5NjA4_0f5ecd9b-e470-4e32-80f8-5eb7a3989753">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMTAtMS0xLTE2OTYwOA_d553710a-a4e5-4b81-b05a-f9cc17e2a031">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa7c677eed24732a11e7ab6f1654f25_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMTItMS0xLTE2OTYwOA_af2924d2-5c3b-4165-8528-d74e24ef0a0b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMi0xLTEtMTY5NjA4_a233f4f7-8830-4759-8349-8e251d9ad326">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtNC0xLTEtMTY5NjA4_25d73ac1-1542-442d-bd6d-8b8789d50348">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtNi0xLTEtMTY5NjA4_81d7cdd0-9c09-457f-9f28-eedb82ac1fa1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtOC0xLTEtMTY5NjA4_1c8d7e5e-9b10-45c4-878f-5557b45032d4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMTAtMS0xLTE2OTYwOA_b80a42ad-c4c2-49bd-aba0-2805fdfe8448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMTItMS0xLTE2OTYwOA_7e872f10-4995-498d-aad1-ca0c1c99b5da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMi0xLTEtMTY5NjA4_18eb01d5-ec54-4722-85d8-f75ddacf3fbd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtNC0xLTEtMTY5NjA4_b1d13ab9-17cf-4457-ba40-46aca652c271">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtNi0xLTEtMTY5NjA4_f9ebaa99-e885-413a-8eab-d56b87260819">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtOC0xLTEtMTY5NjA4_244e1a28-91ce-4909-85fb-57fe82e94d2b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMTAtMS0xLTE2OTYwOA_32e9665e-5b37-4901-a3de-59e953b4e91c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMTItMS0xLTE2OTYwOA_d51dada2-9c57-4186-876e-8860ef5fb3b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMi0xLTEtMTY5NjA4_84fd56e8-22e6-4c4d-92be-306860d90cd5">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtNC0xLTEtMTY5NjA4_87b65910-dc7e-4b4c-8b99-ec44fed4d7c7">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtNi0xLTEtMTY5NjA4_07df6c3d-2356-49b8-bfbf-d7e7e45a41e5">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtOC0xLTEtMTY5NjA4_381aeac7-cb63-40cd-b282-7dfd4f3b5136">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMTAtMS0xLTE2OTYwOA_dc068465-4090-4607-bbca-63172b375f5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMTItMS0xLTE2OTYwOA_be02fa0d-8492-4513-8b1f-a2202468be82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMi0xLTEtMTY5NjA4_9c36a412-b6ce-4353-9747-3f8b8d5ad419">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktNC0xLTEtMTY5NjA4_e7a53690-ad31-4a64-8e03-832af4bbd773">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktNi0xLTEtMTY5NjA4_47a3c3dd-0a4e-4b57-8160-2c8d7bb216e4">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktOC0xLTEtMTY5NjA4_911ade8a-1e51-4cc4-94fb-d4235436b95f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMTAtMS0xLTE2OTYwOA_e8da97a4-9e21-4345-ad00-048232a1adcf">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMTItMS0xLTE2OTYwOA_d85dbbb8-b3fc-4bd4-8d6f-31881cb55710">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTItMS0xLTE2OTYwOA_5d626a8f-bdf0-45d3-9fbc-5d7ad993a991">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTQtMS0xLTE2OTYwOA_a1f6d533-c560-4f04-b26b-6d740474d21a">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTYtMS0xLTE2OTYwOA_3943748a-cbd9-4364-9908-c59ebe2f14f9">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTgtMS0xLTE2OTYwOA_25a364d5-0cc2-4ae7-97e0-f2bf198740e5">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTEwLTEtMS0xNjk2MDg_4b13fc54-643a-4e29-aa17-31a71098949f">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTEyLTEtMS0xNjk2MDg_650c713c-f7f6-461f-83aa-992b42d8bbb2">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTItMS0xLTE2OTYwOA_1c3458d9-932e-4724-adf3-a7f2b8f59495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTQtMS0xLTE2OTYwOA_c656cbc2-ee36-4c24-b055-cd7e9ed92f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTYtMS0xLTE2OTYwOA_7b633a72-abca-47ab-9731-471fbc21a0b3">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTgtMS0xLTE2OTYwOA_3a256e34-6551-4463-861e-d927107be43d">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTEwLTEtMS0xNjk2MDg_af39e3de-4d98-4e6b-a6a7-28f6f40b0dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTEyLTEtMS0xNjk2MDg_316fd283-f286-4beb-a36c-44305ba9900c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTItMS0xLTE2OTYwOA_3fd52400-e4fe-43c3-a8ee-10dad00ec772">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTQtMS0xLTE2OTYwOA_61f017d9-e372-44a6-b44e-efc258fa48b4">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTYtMS0xLTE2OTYwOA_c0b43d79-bfc6-4f4f-9c40-438a92893364">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTgtMS0xLTE2OTYwOA_7d9adf64-789f-4b80-9fce-fb473db7456f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTEwLTEtMS0xNjk2MDg_dc72df34-5a18-4b0f-9cf8-c6992f507dd7">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTEyLTEtMS0xNjk2MDg_77d7535d-a6f0-4105-87a6-3d7eef775517">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTItMS0xLTE2OTYwOA_36b84ca0-4d17-415f-ba79-ad55729b025e">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0e93f49dae408e8c386793727d9086_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTQtMS0xLTE2OTYwOA_7de2b4e4-dd3f-43ad-9e62-57a9ecc5a9ba">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTYtMS0xLTE2OTYwOA_a2bdb351-bfef-4d0a-97e8-b420e88747a7">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTgtMS0xLTE2OTYwOA_7d216c01-7a3f-4eb2-a5c8-00a4b096d353">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTEwLTEtMS0xNjk2MDg_b33b8ba5-a0ab-4709-aeca-6a975f01d615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfa7c677eed24732a11e7ab6f1654f25_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTEyLTEtMS0xNjk2MDg_d7099b96-ab61-4b92-a57f-f30e4b3e01e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTItMS0xLTE2OTYwOA_cc2c2a55-2420-470d-8703-68363a069992">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTQtMS0xLTE2OTYwOA_3099697c-6399-4674-a1d9-d6cf2bc62138">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTYtMS0xLTE2OTYwOA_4e44dd61-c553-4bd3-a717-b7bb1dcf5903">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTgtMS0xLTE2OTYwOA_07939094-a5bb-43fe-8af7-f0aaf80bf158">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTEwLTEtMS0xNjk2MDg_426df5f4-12a2-4833-9278-fc56e0ed304e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTEyLTEtMS0xNjk2MDg_013eccb0-981a-437e-ad0a-bf9d280dadff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTItMS0xLTE2OTYwOA_48a8a385-ae20-4ffc-b994-296953c38faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTQtMS0xLTE2OTYwOA_43d01525-e849-4131-86dc-cf3afc07d6d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTYtMS0xLTE2OTYwOA_76cf3b1e-2339-4184-a797-3bb35da6efb7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTgtMS0xLTE2OTYwOA_6bf84ee6-96da-47a7-9250-bf9c13c27bc6">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTEwLTEtMS0xNjk2MDg_ad38e992-70ae-47ec-b025-2c70b16230b6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTEyLTEtMS0xNjk2MDg_842caf8a-e5a7-4f18-a711-bd61fc6facbe">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTItMS0xLTE2OTYwOA_235cbb2e-0528-4cae-a660-b2c89536b250">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTQtMS0xLTE2OTYwOA_457b28ba-9118-4f07-aedc-d909779ebbeb">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTYtMS0xLTE2OTYwOA_3246bf06-118b-49f0-acfd-5e230ba75551">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTgtMS0xLTE2OTYwOA_20b9273a-32dd-483c-83ee-c1e0cd856ad3">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTEwLTEtMS0xNjk2MDg_2113fde5-e7d0-4908-82be-2c2a68811b40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTEyLTEtMS0xNjk2MDg_33c5a1fd-1ead-44a8-ad27-9ebe794938cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTItMS0xLTE2OTYwOA_ceed5d0a-2d20-4f50-97ac-d029f7d62910">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTQtMS0xLTE2OTYwOA_103ff14a-f2ba-455d-985d-7555739a1781">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTYtMS0xLTE2OTYwOA_893c322c-d79e-4c61-b59b-65fff0ca015d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTgtMS0xLTE2OTYwOA_281b7e3e-77f8-4676-afe4-b098e1e12c9b">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTEwLTEtMS0xNjk2MDg_1ab635c2-9142-41f9-910b-aad27556652a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTEyLTEtMS0xNjk2MDg_5eed5b18-cc95-4ff0-93b4-a31cd9920716">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTItMS0xLTE2OTYwOA_39d1e428-d1c9-485f-9ce7-edf116c17564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTQtMS0xLTE2OTYwOA_f4f2beb6-fdcd-4e77-a93b-a04b6c706955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTYtMS0xLTE2OTYwOA_195cd979-0207-4609-a73b-1fd148fbe6e7">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTgtMS0xLTE2OTYwOA_32f6c479-5d7d-40c8-8fb4-6120877ddeba">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTEwLTEtMS0xNjk2MDg_82027250-12b8-47ca-880a-f1dc6fcbe0fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTEyLTEtMS0xNjk2MDg_15018c9e-3f2f-4a70-a261-498afa7f4338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTItMS0xLTE2OTYwOA_6c57df2f-f4f7-4349-8f1a-b3f9318a98d5">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTQtMS0xLTE2OTYwOA_145971d1-1385-4042-bdbd-4add97e1de8d">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTYtMS0xLTE2OTYwOA_b9c74d4e-45be-4d38-a0cd-87fa116eab20">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTgtMS0xLTE2OTYwOA_1faade55-13e6-4696-b16f-400667ad75ba">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTEwLTEtMS0xNjk2MDg_e774a0a0-8709-4ef7-a170-35f6bbfd84e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTEyLTEtMS0xNjk2MDg_9afeca02-c0bc-470d-92e6-2805e01e1ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTItMS0xLTE2OTYwOA_1eb90bb6-f0da-4030-a6b0-752ee0a8ef9b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTQtMS0xLTE2OTYwOA_56c8c0c7-4935-4c99-95f5-91232d5f946f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTYtMS0xLTE2OTYwOA_6681e55a-fdaf-485e-a741-aa4c71aab89a">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTgtMS0xLTE2OTYwOA_1a6e544d-4c71-49b9-bf39-0176b9f1b92e">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTEwLTEtMS0xNjk2MDg_632df2ce-2c5a-4877-8fcf-8ac0f229e33b">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTEyLTEtMS0xNjk2MDg_5d0bf5f6-93ab-4a43-afb0-1a6c32b51192">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTItMS0xLTE2OTYwOA_95c99294-8c61-42b9-9279-9ecc2c8ce8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTQtMS0xLTE2OTYwOA_b2f4f312-d46d-4462-b439-e9e0d84a21e0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTYtMS0xLTE2OTYwOA_ddc15bf7-e40d-4094-8060-6910ba562dab">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTgtMS0xLTE2OTYwOA_ecdcb815-d11b-479a-a4e8-d36e94fa786a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTEwLTEtMS0xNjk2MDg_fcd8be3a-7496-430c-b105-2cbf8364455d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTEyLTEtMS0xNjk2MDg_2e16fb3b-a039-4e7a-9259-1ea336847447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTItMS0xLTE2OTYwOA_e5b2b82c-4674-46fe-a87f-bbe7440c307b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTQtMS0xLTE2OTYwOA_728b0c77-d75e-4a2d-9df5-599c42950a85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTYtMS0xLTE2OTYwOA_07782651-84e5-4496-8538-7be15fa3d361">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTgtMS0xLTE2OTYwOA_ef4a66bf-3138-49b5-9a92-8ec54a8beb9a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTEwLTEtMS0xNjk2MDg_a895e95d-5530-4630-86e9-337f98f33ce7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTEyLTEtMS0xNjk2MDg_b4f7c608-809c-4df9-bcce-26ea1e888a48">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTItMS0xLTE2OTYwOA_da2a76fe-e3cf-4be1-b0ea-2983fc5c2108">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTQtMS0xLTE2OTYwOA_9e48a15a-6cc3-49af-8097-92123996dcd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTYtMS0xLTE2OTYwOA_cabf8771-a494-40a7-9e36-f70c3b17de73">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTgtMS0xLTE2OTYwOA_42a7e1e1-1202-4b12-886a-c3f4ec78538d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTEwLTEtMS0xNjk2MDg_f12293bd-2b14-46e1-837a-427557339e95">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTEyLTEtMS0xNjk2MDg_26fb8830-afbd-4ac7-a290-6c66ef4f8eee">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2022 and 2021, having accumulated benefit obligations exceeding the fair value of plan assets. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MzE_27f177d0-b154-407f-a290-c359b0a333ae" continuedAt="i86ef463b964246fd88c41f03b4db57b2" escape="true">Information for the underfunded pension benefit plans is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i86ef463b964246fd88c41f03b4db57b2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:56.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItMi0xLTEtMTY5NjA4_b0ba418e-37a1-4f6a-bcfe-b6e6b6724011">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901b9016f0344620b9f6802621dd347c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItNC0xLTEtMTY5NjA4_739027df-9040-4b68-9fab-1b454dd6f61e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItNi0xLTEtMTY5NjA4_24b07080-d558-4ffc-ade9-6826066bb475">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItOC0xLTEtMTY5NjA4_2fd75a39-0072-4f94-9d20-d64cf8d72e17">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtMi0xLTEtMTY5NjA4_4bdb3241-c90b-4315-9e2a-f0d2d8cfb780">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901b9016f0344620b9f6802621dd347c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtNC0xLTEtMTY5NjA4_0c8dc66f-1389-4833-9511-bbcb029c4776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtNi0xLTEtMTY5NjA4_7263b13d-6ea5-487c-98de-32774719ae0d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtOC0xLTEtMTY5NjA4_ca153e50-fa01-49e8-a033-2602c3bc15fa">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtMi0xLTEtMTY5NjA4_3c511fe8-4511-4f80-8fb5-bd646ac0b1ba">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901b9016f0344620b9f6802621dd347c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtNC0xLTEtMTY5NjA4_adff2e2b-5b2f-4980-809f-6a86a89233e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtNi0xLTEtMTY5NjA4_8da1564d-f3c7-43c5-9dd9-24dba90a6e0d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtOC0xLTEtMTY5NjA4_f5bf7fe8-79f1-4bea-9905-74d14faedbe7">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2023, the Company expects to contribute $<ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQwMzE_7706bbb7-cb45-48a1-88b9-126f96b41002">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzE2NDkyNjc0NTExODI_020abd4e-2297-4ade-ab45-6bb07cfd1c78">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQwNDI_725d1cf9-519a-4f5f-a01f-697f0116d27c">4</ix:nonFraction> million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2023.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ia27adf1579d84d0183a8ba7ad19a8fa2" continuedAt="id3bc56300d36418a9749b621eaea2363"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0Mjg_bb98549b-6443-4743-8299-89f7af160586" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQ0MDM_b522cbe2-0321-4e40-9867-ce3763c12dff">10</ix:nonNumeric> years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItMi0xLTEtMTY5NjA4_5597e84f-1751-4e1a-81bb-efedd7870e7c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItNC0xLTEtMTY5NjA4_691376e7-0ae9-4165-af96-97073e92e44f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItNi0xLTEtMTY5NjA4_772ec6a6-bcf9-4462-a7db-71de0a8c1b0f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtMi0xLTEtMTY5NjA4_2c6b77af-2d97-49e0-bf7d-9ec2b1b361e7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtNC0xLTEtMTY5NjA4_ba34a06d-03de-46cc-9446-4c303d6eacf1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtNi0xLTEtMTY5NjA4_23a874b6-cf80-44d7-843c-dc2b35f1bf0c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtMi0xLTEtMTY5NjA4_65169090-5c22-4344-a7c0-1883a473e97b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtNC0xLTEtMTY5NjA4_16194dba-96ed-4031-97a1-3ffe1e4a13a5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtNi0xLTEtMTY5NjA4_ae98de83-d723-41b0-bdb2-71e218eac917">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtMi0xLTEtMTY5NjA4_4460cef9-4654-4980-bc62-445d13919693">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtNC0xLTEtMTY5NjA4_2ee7942d-0d56-4876-9ab8-65b219943540">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtNi0xLTEtMTY5NjA4_5ef0ed1f-06fe-4781-9946-064ad55b1297">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtMi0xLTEtMTY5NjA4_b5910e17-2739-4a81-9086-5f9fb860da35">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtNC0xLTEtMTY5NjA4_aeb395bb-14c4-417b-8056-223ce549f237">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtNi0xLTEtMTY5NjA4_0767299b-d4d3-4e6a-8123-e0d1b32b9b8b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctMi0xLTEtMTY5NjA4_404a7a58-fa41-4bfb-997b-a600d6347d0f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctNC0xLTEtMTY5NjA4_9886fcb8-edeb-4da9-a654-81eaccbe15db">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctNi0xLTEtMTY5NjA4_4492a638-3336-4eac-b206-5de03a5d5680">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MDU_396b1186-1931-48c8-a663-b8cec0a3f707" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMi0xLTEtMTY5NjA4_72df5fda-fcd4-4b1b-9bf7-5c0608725ce8">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtNC0xLTEtMTY5NjA4_d8849762-c1a3-47ec-9bcd-03d1739b2d0a">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtNi0xLTEtMTY5NjA4_c1a4cd0e-1077-4079-bc11-ac331e6efa23">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtOC0xLTEtMTY5NjA4_54bfedab-608c-4ca3-9076-294cee44add9">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMTAtMS0xLTE2OTYwOA_ffc90187-36ba-4a30-a586-fb5df9c019ad">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMTItMS0xLTE2OTYwOA_3ce0c81f-307d-416c-be1a-f04bcad8d294">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMi0xLTEtMTY5NjA4_705e49bc-229e-4335-a549-454249fdcaf8">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtNC0xLTEtMTY5NjA4_111b6a52-a838-4c39-9f87-7e7a1edafc88">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtNi0xLTEtMTY5NjA4_09dd077f-15be-43a3-87ff-bbabf4e2ec39">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtOC0xLTEtMTY5NjA4_66d61c5b-9cab-46cb-9f61-b6cb1133c19a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMTAtMS0xLTE2OTYwOA_59f5330a-a790-4551-8686-7028545119c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMTItMS0xLTE2OTYwOA_26b2a8d4-89ff-406a-affc-8eda17a5478a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMi0xLTEtMTY5NjA4_0d42724f-9e6c-4d9b-a672-bf736ee6266f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtNC0xLTEtMTY5NjA4_9084bbd9-ecd1-4508-be92-94de95f50344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtNi0xLTEtMTY5NjA4_a6f73b43-d9f3-4ee2-bb2d-68c02566335c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtOC0xLTEtMTY5NjA4_04f8393e-e999-467b-b456-8bf38ed1b8a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMTAtMS0xLTE2OTYwOA_22b5a026-af2b-4437-83e8-df1b641618a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMTItMS0xLTE2OTYwOA_34dee60b-55b9-4e9f-8a87-923757efe95a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctMi0xLTEtMTY5NjA4_f89eaf74-cb13-42cc-ba9f-6c89f7e56d48">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctNC0xLTEtMTY5NjA4_2f81522a-4911-4a49-8b82-93d2faa6aa6a">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctNi0xLTEtMTY5NjA4_50598120-c133-4c10-aa96-4d1f03ab3053">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktMi0xLTEtMTY5NjA4_16610d4c-f8da-4bcc-bec5-2681a1aedb12">4.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktNC0xLTEtMTY5NjA4_6dd5b546-fccd-434e-9e2f-c1d8bcf8d080">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktNi0xLTEtMTY5NjA4_59da1a72-633a-4618-824b-0d89eda6ed8f">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTItMS0xLTE2OTYwOA_bf606d75-3db2-4d9e-8160-43f4396e967c">5.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTQtMS0xLTE2OTYwOA_1bdfdfeb-dd24-497e-b26c-d17ba3848b52">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTYtMS0xLTE2OTYwOA_45d987c0-8944-4ee8-94e8-5d04fd0deb6a">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTItMS0xLTE2OTYwOA_83a80952-53ff-4a2c-ba51-6636828aa475">3.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTQtMS0xLTE2OTYwOA_470784d0-e084-416c-a624-9c1455870697">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTYtMS0xLTE2OTYwOA_179d60c8-6ace-4848-b41a-c9c8c3305d93">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTItMS0xLTE2OTYwOA_ba8c546d-bec1-4b9b-9c0f-1c0688d32a64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTQtMS0xLTE2OTYwOA_cb1cbd7a-3ce3-4c24-901e-5d87f48f7bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTYtMS0xLTE2OTYwOA_8d1cbecf-5aae-4cfd-b95a-71cc333adb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:55.197%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.073%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtMi0xLTEtMTY5NjA4_6995655a-24da-4c48-908b-d73eeb90f26e">5.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtNC0xLTEtMTY5NjA4_ceae4c98-3688-4cda-9616-45786c104f26">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtNi0xLTEtMTY5NjA4_6be485cd-7348-4bff-ba2d-c1f0cfef4dc1">5.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtOC0xLTEtMTY5NjA4_2207ff1e-1055-431c-9320-99a973193c4d">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtMi0xLTEtMTY5NjA4_a9ef5780-fcb0-4405-82e8-561e9f9c5bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtNC0xLTEtMTY5NjA4_17aef501-cea0-491d-b583-b8387dcd6607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtNi0xLTEtMTY5NjA4_6734a791-fb1d-482e-b2a4-4dbc28028d62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtOC0xLTEtMTY5NjA4_b6f217e8-2c49-429c-9bd6-a46fcd98ffce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzctMi0xLTEtMTY5NjA4_4c4f9de3-780c-41f4-adcd-75f8dd21b697">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzctNC0xLTEtMTY5NjA4_46fb06dd-ecf2-4309-8dcc-ea3d75c12464">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzktMi0xLTEtMTY5NjA4_86d0f6ad-c450-47c9-b666-2ffd11ebb44d">6.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzktNC0xLTEtMTY5NjA4_d268b006-80d9-4b39-badf-fb41bc30ff6c">1.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzEwLTItMS0xLTE2OTYwOA_42644ba6-3bb1-4d4b-b668-2f2e27aaea83">3.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzEwLTQtMS0xLTE2OTYwOA_e5a08855-4191-4506-ace2-326ccab8c685">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzExLTItMS0xLTE2OTYwOA_b5b644c2-4018-4a08-86ba-dc22082e9a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzExLTQtMS0xLTE2OTYwOA_59e53e33-bd15-4677-a182-ea7f710c3371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2022 was <ix:nonFraction unitRef="number" contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU0OTI_705e49bc-229e-4335-a549-454249fdcaf8">4.50</ix:nonFraction>%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was <ix:nonFraction unitRef="number" contextRef="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU1NzU_8167e7f8-641c-4f3b-a04f-a3d90d498942">2.75</ix:nonFraction>% for 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id3bc56300d36418a9749b621eaea2363" continuedAt="ia0b3417a632b4355acedaf5cdf30b5e7"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 expected rate of return for the U.S. pension benefit plan will be <ix:nonFraction unitRef="number" contextRef="i6c981d7a36cd45b285c23ca5fdc44f66_D20230101-20231231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU4Nzg_815a5618-74b7-47d0-a093-3067a171e601">6.00</ix:nonFraction>%. The 2023 expected rate of return for the Ireland pension benefit plans will be <ix:nonFraction unitRef="number" contextRef="ia086606e46a34f71bfb9e605f2e6266e_D20230101-20231231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU5NTk_178ceb54-4b82-4cab-ae23-64fa4754b6f8">4.25</ix:nonFraction>%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plan Assets </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MTk_33f72322-a8a6-499a-bd09-aac21589860f" continuedAt="ibee4f2c155424eea964e3800618a6386" escape="true">The following presents the actual asset allocation as of December 31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="ibee4f2c155424eea964e3800618a6386"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:77.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7def2285ac5140d38d1f9ffcf8a7126e_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzItMi0xLTEtMTY5NjA4_8948aacd-8dc3-4b73-aef4-f0243934e64f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i890e5bee618d469cab458bb423035b53_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzItNC0xLTEtMTY5NjA4_f94219c5-223f-4e04-bdfc-43e6b6bf27d3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfd01159712142d2a14941af601cba4b_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzMtMi0xLTEtMTY5NjA4_76661634-6d08-4015-9298-3ceff5200e41">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10c9b32cd0a64bd9a48e14dc09730b3d_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzMtNC0xLTEtMTY5NjA4_51db6a2f-f5c7-4e54-8cac-303672608d7f">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib186ad161aa040e7a1a0cfe3d0b2add9_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzQtMi0xLTEtMTY5NjA4_9e8ab924-5a1a-45ee-9759-341b2cb761ef">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a7b19941aba4839893beff2b2339518_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzQtNC0xLTEtMTY5NjA4_c11247de-de22-4088-a3ed-f6f2ad34917f">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if909172682784a94b3a8faea6d1af750_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzYtMi0xLTEtMTY5NjA4_59563e50-de71-4654-9810-916eda4af55c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6097557c0fd439483e7592516150539_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzYtNC0xLTEtMTY5NjA4_65b4160c-5f4b-4db4-a666-a90885d5729c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if82393cee0c6403aad0994b42e1b3e03_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzctMi0xLTEtMTY5NjA4_1deac76c-ad2b-4d9a-ba63-4934d1bdc266">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21af5dc5f9dd4f15985aaa4c4bfd5822_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzctNC0xLTEtMTY5NjA4_6ab6909e-08bc-425f-9b66-6d08f93164bb">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ecb8307bf5d4aff94f54ff6b76837d3_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzgtMi0xLTEtMTY5NjA4_c45c81d0-5071-4a3b-bf45-16dd433bee35">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb616bbdc2974979a68ab30bf4d7f508_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzgtNC0xLTEtMTY5NjA4_606bf1fa-a04b-463d-8dde-09a250be37eb">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37d55bf5477448368b255cbbc9f9ac2d_I20221231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzktMi0xLTEtMTY5NjA4_a841eedf-26eb-4e7d-a8b1-0508c200d089">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id842fbc0d8ad486aaae75003e4167df9_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzktNC0xLTEtMTY5NjA4_b08714c2-e922-4619-999e-67f40cb520ed">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for details on the Company&#8217;s fair value measurements based on a three-tier hierarchy.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ia0b3417a632b4355acedaf5cdf30b5e7"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzODU_62776645-d163-43d5-9c9e-2a351ad6f25f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2022 and 2021.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3108451ff34c44bdccaa78adf4e451_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMi0xLTEtMTY5NjA4_a36aebf1-2e6d-45b8-990d-668670248f28">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a0fdbd98ed940e8bb4f138e20fe4aad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtNC0xLTEtMTY5NjA4_8be214a7-6af4-48e0-bde2-710f127d462f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b66f09a9c794304941a8e256c67d221_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtNi0xLTEtMTY5NjA4_bb68533c-ac2d-4087-baa8-4d9fb740bfd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46544209ecf4725a093aaefe444ca63_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtOC0xLTEtMTY5NjA4_b6c3c902-343d-45c6-9f9d-67682ea18261">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7cd997e52074902b6b0f11a459c1455_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTAtMS0xLTE2OTYwOA_aca6688b-579e-4d70-a89b-720b1263f7ee">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfe10a628844d85a9f16739ece8b000_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTItMS0xLTE2OTYwOA_b1981f42-637f-47af-ba81-214c950c4473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e72c38588c34bcebd41f5dee9e6e442_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTQtMS0xLTE2OTYwOA_592b7731-faf3-41b9-8fa8-eb0840f2afed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c26c19111d4d8f9acc24b805792584_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTYtMS0xLTE2OTYwOA_942e8901-168d-488b-bdf9-b221d364fc25">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebcb27b8c53e41a4a7f03c7a9ce24b16_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMi0xLTEtMTY5NjA4_170d775a-8514-488d-b1f8-0bc60e5e1629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4aff83b9c634a5894b070163727d3ad_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtNC0xLTEtMTY5NjA4_eb5556d9-2452-40a0-afa8-9b6317e03c3a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bfb9a5fc6b5416cabb3992fd6d9866a_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtNi0xLTEtMTY5NjA4_3c071664-ed0a-4fde-94c5-35679df3a90e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c83ee90555c4d4388fe2aad369a07ca_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtOC0xLTEtMTY5NjA4_aa4aa84b-64e3-4a8e-81a0-07364290b790">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94c6b830d4d4e83b5455bc50c831168_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTAtMS0xLTE2OTYwOA_a2c08ede-130c-4cd2-b2e2-776de7c0cf25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i596d5259e41b4516a9b8bd8bff994b04_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTItMS0xLTE2OTYwOA_74ea4084-eaad-459c-ba5e-0bafbb7ea1fa">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d65fd0099884d129c8955aeded2ab3e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTQtMS0xLTE2OTYwOA_f81b0813-760e-4fe4-9216-829ad2c80f8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f1bfdacbdc49e58897e6ed02cc3ba3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTYtMS0xLTE2OTYwOA_72730de7-5398-40d2-9d9b-a8bdcf1df742">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eff69c67fc94f7ea63429c1b535269f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMi0xLTEtMTY5NjA4_5b19eaa4-44ab-48fa-be70-957b6bd82428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06cde57fea89421ca93bc357400547db_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctNC0xLTEtMTY5NjA4_0fab27a9-145f-419c-a8a4-9839c5c78f26">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fcca6398a69456491cd915adc6cf018_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctNi0xLTEtMTY5NjA4_e8b402ca-d072-4c5d-8fe7-f9b3bb352a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1025885b5b041c495101b7c543c11f2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctOC0xLTEtMTY5NjA4_cd7e3d94-5703-450e-b18d-061b91f109fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4749a66112794a748f77060b21d3a4ca_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTAtMS0xLTE2OTYwOA_c3d6b631-7d13-4865-b97d-93961b4865be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d3fed8097a4daeab0e728d1fa59dec_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTItMS0xLTE2OTYwOA_051e03aa-495a-4419-b9f1-72c8aa2399bc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4325c973be4bb49485892fb209d262_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTQtMS0xLTE2OTYwOA_b42dffc8-1076-44dd-8147-653a9bafd906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbdd4eaf78224b6ba6820bf1639d0b9b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTYtMS0xLTE2OTYwOA_73655479-9763-4182-bd7b-d56f34de258d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57fb1d627d84572b6935e5a91bc1ddb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMi0xLTEtMTY5NjA4_7f211f5d-b0ad-4b40-adab-90b8620ed624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce670f0334749faaec2717ea665b0a2_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtNC0xLTEtMTY5NjA4_9ae3cf5c-e399-471c-9b0d-12b7bf5936f1">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1b1a26770b4939981b10056497e10c_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtNi0xLTEtMTY5NjA4_2afbb2af-445f-4853-9776-09fb04508ccb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2ffcdeee6044901ab85b83bfab8de15_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtOC0xLTEtMTY5NjA4_d5f6e201-8554-46b4-92a8-e1bd1731ba85">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia469039e78794b72b821fd03d9c90ec4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTAtMS0xLTE2OTYwOA_d1008dc0-9a51-4671-8720-79f14bcd2cb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943e5fbfcbe84d65b033540f48279c89_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTItMS0xLTE2OTYwOA_26f2ce49-e9da-423f-886e-266c2a088d1c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940816bafd874e0ebc01474cfb7a3a65_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTQtMS0xLTE2OTYwOA_55f6e0fa-c3e8-4dd9-8420-29ef7a51fa5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b2464e33b44bf28fa58498386246b9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTYtMS0xLTE2OTYwOA_aee2ce96-3c47-4ddd-aab6-70db9f1d6525">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0537dc089def43d3936e05d8a4ff751b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMi0xLTEtMTY5NjA4_5d11bf1a-9ab3-49da-bd72-61f9ddfadcd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166bc7feb587436bbb13eac98a8a0cbd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktNC0xLTEtMTY5NjA4_8a5095d0-75d8-482d-b552-2c3fc516f471">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba4611dcd504efcb55fd69027047b6f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktNi0xLTEtMTY5NjA4_f65e626f-ccd2-4281-9a46-a0463ff4b8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4161b216dc5142939aa46e36e819cc8d_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktOC0xLTEtMTY5NjA4_4525c800-460e-4678-bcad-28c45d1b4d68">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12cd435007f84ea6a463f1c697369c5c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTAtMS0xLTE2OTYwOA_17d69908-8239-410a-a618-80102e3086f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6ff1609d90414882841cc6046a9951_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTItMS0xLTE2OTYwOA_ffc58850-888e-4b3f-b7a9-c262635c51d4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0966710236bc43c2af312375aaf2ff7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTQtMS0xLTE2OTYwOA_7eb086d4-6cc6-478f-8037-4d3f0b3c762c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if627813ab5da419892b99795959e6aa9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTYtMS0xLTE2OTYwOA_9af9a1b0-a24f-4ae3-a0d0-8d77d52f4b79">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20160fde44604a6aaa038ff97269bd4b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTItMS0xLTE2OTYwOA_fc4a1d15-8609-4c64-8206-2f1b38d209f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838299195fbf4b9a822896bdc73e1fa9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTQtMS0xLTE2OTYwOA_9427305d-58a7-4a85-a0fe-c9a4206af27a">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia604d8b17aee4a76b705119871e72bb9_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTYtMS0xLTE2OTYwOA_09fa8335-c952-4e15-be1c-6ee9f8fa91e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a13cdeaf0a4538ae66a0cb4eaac793_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTgtMS0xLTE2OTYwOA_c51164c9-9d4b-4e72-9178-cfcef03bafd6">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd29133231149b7b1b8a8ee26abb9c2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTEwLTEtMS0xNjk2MDg_b4c5a567-1186-4df1-8e5c-d7668293fd2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9487a86efc54fb68c486f5b06c683f7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTEyLTEtMS0xNjk2MDg_937f491c-0db3-4adf-849c-a13127a4ea2a">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeac84c7747644e18df3b02f9009bcf8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTE0LTEtMS0xNjk2MDg_1fe604ab-470e-4c28-9a9e-9f3ca108c066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d0aeff6b0247bbb772f435284fb4ee_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTE2LTEtMS0xNjk2MDg_4f19b728-fc36-4d3d-b7ba-b2acbc12378d">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022e7bc0a5b44851ae8856c5d2c73a9b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTItMS0xLTE2OTYwOA_90804b57-f74f-45fe-b57c-27ec02d55009">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e42f7f8fb44b94a825edd38ce13b8e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTQtMS0xLTE2OTYwOA_b13f30ce-4578-4608-9c1f-33b44fa7f55a">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b44a8ef5108400eb1f8766f7e0fcec7_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTYtMS0xLTE2OTYwOA_81d308cf-5e9d-489d-8f9f-c478444712ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec9432798a24a7081587f93c9df9218_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTgtMS0xLTE2OTYwOA_1272a53b-bc75-4bf0-a1ae-1aa78e0e1289">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c542d4e97f492fb79c2d7ea87bc43c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTEwLTEtMS0xNjk2MDg_b6259dd5-ec1a-4499-b026-34188902582c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c92c43460b4f029f30adcfddd56c4f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTEyLTEtMS0xNjk2MDg_7430fb5e-dcbd-4589-9bbd-8ff914fb6f77">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87b5c5cd3884bc6a0c85db52ded0201_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTE0LTEtMS0xNjk2MDg_c33bcea4-9236-4060-9ef7-9db789ace242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba16f047558a4012b26c69b39abe5903_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTE2LTEtMS0xNjk2MDg_0881427b-6bdd-44b1-96bb-f712774c1939">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:31.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85986033cb94474b99f01b19273837dc_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMi0xLTEtMTY5NjA4_7af821be-f9c9-4c95-bfd5-48cb90298b45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5849250174794a5294b9599a5268d9ae_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtNC0xLTEtMTY5NjA4_771286fe-c06a-48f9-87d0-ef15ba7e7cd0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e897629c0e405197197192231ed87e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtNi0xLTEtMTY5NjA4_da254bf5-6104-44f4-88b1-18da4821ca08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586cba0ddcd34f2182b8f7a26689b550_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtOC0xLTEtMTY5NjA4_ef2c2c51-a298-4854-beaf-ff3b53dcf8bd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a90c8afe5049298baf47464adba23f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTAtMS0xLTE2OTYwOA_32addd28-4c65-4d13-87f6-298d4fe86595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b750ecf0264c51acd1b84640243687_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTItMS0xLTE2OTYwOA_881d9a9d-d461-4b3f-988b-9e2116892191">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d1ee6e5579e4fbbac27d5f4d6d6c071_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTQtMS0xLTE2OTYwOA_d7e2fc29-f37f-492e-8500-8e4fd4b2b65e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beb776c2d084696af8546fb16fbfb0c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTYtMS0xLTE2OTYwOA_c5c8a9bb-da6d-4791-99b8-3d3f604be130">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e418ec04bde4a42807126013e7f6e28_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMi0xLTEtMTY5NjA4_6cd6293b-e291-4863-b98f-62d4841228a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id064c3e553534ddf8d58196348abc463_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtNC0xLTEtMTY5NjA4_f9e8667d-31a9-4460-ace5-a7d1c3bacdfc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc34f3620a04953983302095d065919_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtNi0xLTEtMTY5NjA4_f1a830ff-207f-482e-b21b-df0de6b31a7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e718d2c489345649ae9f4b875a944c6_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtOC0xLTEtMTY5NjA4_475ed940-58ad-4824-874e-15d0d28badcc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b786c529ecc420a98bfcc8623fd3887_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTAtMS0xLTE2OTYwOA_8223e66b-4309-44c7-add1-2d7d7698f0af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i192fabe7c1564743b0a4bfd0ec76367f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTItMS0xLTE2OTYwOA_47694244-af6a-4c9d-8f58-5b0ae4414cd7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2583535030e04ec19d33ff6aa980c232_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTQtMS0xLTE2OTYwOA_c126948a-778e-49d6-a32c-a0d38dbb2c66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dbace4328d64e68ae9985b0db92a939_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTYtMS0xLTE2OTYwOA_e6da70a4-7b1f-40d9-b726-cb5b854e3b73">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54976a88d71c4f29a87ce8b7fbb1f390_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMi0xLTEtMTY5NjA4_8e3d0d64-2a5d-4f65-85a4-82e2d622a1ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if368c75fe2714137b5b2bec4f478ed08_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctNC0xLTEtMTY5NjA4_f9d3455d-7568-4d29-a9ea-e9875b658db8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f6ee73d0b4d708cde5f122a628b5b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctNi0xLTEtMTY5NjA4_71333336-d1ac-451f-8522-3d4bb279e526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ab17d153f94ce28b4f3c1f077f073e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctOC0xLTEtMTY5NjA4_59bafd51-d2f1-4f57-8cbd-0362c7c12a43">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78598f7e1204321a742adcc1939f548_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTAtMS0xLTE2OTYwOA_bb898a14-669a-44ad-a340-3b7a526982b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84605640b59c4cdfaca45e277d8f930e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTItMS0xLTE2OTYwOA_7b7b59d8-fd51-48e4-875c-cfc2540df4d9">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0da8fd5fa784526af1d7dcba6682ea3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTQtMS0xLTE2OTYwOA_6522f165-42f1-4162-bc52-221c5ef77c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a9b377100548608bea1fb0de4c4b8f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTYtMS0xLTE2OTYwOA_de61265e-1c8c-4cf3-aec6-1d908cf5e8c5">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d15c8b03fa84bebadf0ca964ff394c4_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMi0xLTEtMTY5NjA4_66d2d705-faad-4f54-a0d0-da60cca7e176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a9caf7ad8a43c2a1cf9ec9bf2be638_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktNC0xLTEtMTY5NjA4_c4e4e2d0-eab2-4ab6-932e-9889f69af988">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f47aed6238c4f0d8374cffa9d1ccc3b_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktNi0xLTEtMTY5NjA4_196263cb-ab9f-4088-bfea-4bca7206adf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943967018a284fddb2383dd48804e6ce_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktOC0xLTEtMTY5NjA4_61b29532-4820-4542-9b14-f897021f9745">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica42099d7cb54b18ab0758ac46934fdf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTAtMS0xLTE2OTYwOA_fd034ea4-5fd0-4342-8de4-41344ae758c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b4988948464da080807bfacdb2fd60_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTItMS0xLTE2OTYwOA_57c97137-415d-4800-b4bf-3f992dab5ec0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e958e564b34a8ea6e5d23a9dd1d9bc_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTQtMS0xLTE2OTYwOA_3dc4d25c-9b0e-4b7b-8cf0-ed5df8328e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15ca0c069774a069fc140fe27c34672_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTYtMS0xLTE2OTYwOA_4b9eeeca-0658-47e4-bbe2-cee9e74fcd3e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e7bb314271400dadeec64d6689bab1_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTItMS0xLTE2OTYwOA_dd190d16-c066-4bc6-b87b-02d41f8c2491">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a1b6f04f9843a3a430cc23faab2335_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTQtMS0xLTE2OTYwOA_35948f58-675a-4c5b-b029-a6ab626b6f17">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460709745cf1459d8d83a3ef3c4c4028_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTYtMS0xLTE2OTYwOA_0bba6266-fceb-4598-8d18-7bb3159d9f71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i807af49d13d7419ca0ef798eab13affb_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTgtMS0xLTE2OTYwOA_eefa413b-78da-4989-874b-0fb904de8a65">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a95e634eae482ba0ca850423b7cbd2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTEwLTEtMS0xNjk2MDg_9ba62bae-cd22-4fa5-a4ae-35faab0b886b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ada76f87a244e6ba2a626f4f5d2f68c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTEyLTEtMS0xNjk2MDg_7ade16ef-e162-4cd6-a6d1-d78485311baa">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4bb0efe5f2746f4ab125458e68b1cbd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTE0LTEtMS0xNjk2MDg_6a2165bf-1660-4f3c-bb06-793bddd8a2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643e656337e04c8482c55cf8750c1308_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTE2LTEtMS0xNjk2MDg_93b0d1ab-3d1d-4149-90c0-f9d426ceb3ae">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if34397ecd5a048799f2dbb74323fe7fd_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTItMS0xLTE2OTYwOA_91deeaba-67ec-4e5e-9624-28e3dd159e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0933dfd2b3014b3982966e76c30667ba_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTQtMS0xLTE2OTYwOA_45081570-6486-4637-a58d-12de93a62fb5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83bd552fb8241e68b041b00d4deb904_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTYtMS0xLTE2OTYwOA_6c0cac42-7965-4bb3-9b30-e46dc6982262">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5317bcb7e0b4df8aa18bb103e434600_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTgtMS0xLTE2OTYwOA_5b364ad6-d863-415b-a7d6-ce5d81f0cca6">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c0591c4a3a4e679502344b5b1c1371_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTEwLTEtMS0xNjk2MDg_5d27b7a1-d067-47d0-9bdd-13b423ab56da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e710e9f1a5d4373996e9b7fcded1add_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTEyLTEtMS0xNjk2MDg_2a657731-a05c-4630-b45e-11f9924a69ee">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i229dc35bd984450fa43d45f7faba215d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTE0LTEtMS0xNjk2MDg_6c1708e6-ba33-4f1e-806f-5294c8c891f8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951ceb7ff1d646c9b3fef0581a1b618f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTE2LTEtMS0xNjk2MDg_161daaa1-18b3-4328-93b0-b32ca11ddff9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id767817a5a2e453c9618655dde1bbe6f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTItMS0xLTE2OTYwOA_0c8aae34-bd78-4acc-930c-f3e585ee6e53">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90326ac3a5c64cfaa3de8f4582846b0f_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTQtMS0xLTE2OTYwOA_7acff833-e9f1-4bfc-a6d7-c38012371073">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a56c8726ff045a281148a00e040766e_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTYtMS0xLTE2OTYwOA_d50402af-9139-44d5-8262-1a6b7f0a1bf6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc9006276854ef785d74a884a2fbd50_I20221231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTgtMS0xLTE2OTYwOA_a7a87dc5-2757-4254-98c5-69bfbf7f10b9">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6026f5c4ae10476cb57fa85da364cc1a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTEwLTEtMS0xNjk2MDg_60870fe9-4046-47b8-9c93-af53af7db335">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa0fc165cad4c259a0114c60066cc26_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTEyLTEtMS0xNjk2MDg_e6a622ec-2597-482a-8c09-6640b382874b">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd34b48ca86f4bb9a48ea67c0a464fdf_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTE0LTEtMS0xNjk2MDg_48047d22-0c91-45bd-bf2a-d51b7474dade">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f30f4d8fd4e467cb57e4293e32ca3d3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTE2LTEtMS0xNjk2MDg_68acad19-0421-4754-bdc6-be25625b4c40">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately <ix:nonFraction unitRef="number" contextRef="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzg1OTE_2bf81483-81fb-4519-a7c5-e308c6c5d07e">92</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8d49fa28b18849f4835a0e22941c0d50_D20210101-20211231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzg1OTg_a6b3210c-ea46-4f6e-8ef1-894943971068">95</ix:nonFraction>% of the non-U.S. commingled funds in 2022 and 2021, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans and the Company matches a portion of the employee contributions. The Company contributed $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMjI_73626834-85ba-4b10-8b46-492a2c9728bf">47</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMjY_ff6ac971-aa0f-461b-a1aa-95faacda7f0a">44</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMzM_db7a59f4-3506-4c0f-b198-75e1a4d6c755">43</ix:nonFraction> million to these plans during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_349"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNA_d871689d-e86f-42c2-8581-7de7b78e5240" continuedAt="i948fd85ec0ba4c6f9611043ab7907bb3" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i948fd85ec0ba4c6f9611043ab7907bb3"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNQ_d6d433a4-a636-4478-8796-cb167921e6a4" escape="true"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company&#8217;s operating leases are included in the Consolidated Balance Sheet as of December 31, 2022 and 2021 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMS0xLTEtMTY5NjA4_09c5874c-8de5-42cd-b65c-27e3b46550ce">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMy0xLTEtMTY5NjA4_366ca798-31f9-4354-8e33-ce03e951a67b">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMS0xLTEtMTY5NjA4_873cd13b-1924-4a0f-9866-4c2531d43c57">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMy0xLTEtMTY5NjA4_17d7cfcb-8d1f-49fd-a943-f15d631f1b04">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMS0xLTEtMTY5NjA4_bf822d62-8a7d-4b2a-b2dd-f35e1fb8e59e">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMy0xLTEtMTY5NjA4_642f7af6-e046-4314-af8b-8b0dde4a07f9">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzYtMS0xLTEtMTY5NjA4_cf544acd-7a03-44a1-985a-56c95c7a6402">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzYtMy0xLTEtMTY5NjA4_7528ed17-d66a-4fa1-9bb1-c980d87fefb8">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020 the Company&#8217;s finance leases were <ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_102ca61d-037a-4e60-9af8-e7ede42dfc6d"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_7409e9f7-9d89-4b14-b6f9-8fd2ebff920d"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_e623c275-b3b2-411c-bc87-61b0ea4192f0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material and for the years 2022, 2021 and 2020 sub-lease income and short-term lease expense were <ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_34526e1a-789d-4a37-866f-5853c00d3dfa"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_4b2d68b4-522c-4df8-8308-df42c9dc86ea"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_5cce738a-0e20-4fff-8652-ca1e12e80b26"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_8d9f14e1-6ab7-4217-b446-fef286a01397"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_aee2adba-c6da-48f2-b988-f83634ce9dac"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_d5e9e8fe-e6e7-4807-8927-6389aed12936">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNg_1a3c3487-bb3a-4cee-b730-a8e678695a51" continuedAt="i784aeef041004c95ba8ffd97abd1c78e" escape="true">Lease expense for the years 2022, 2021 and 2020 include:</ix:nonNumeric></span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i784aeef041004c95ba8ffd97abd1c78e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtMS0xLTEtMTY5NjA4_60bb9b8c-fe30-425b-af05-af123b7e6aa9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtMy0xLTEtMTY5NjA4_c1653096-865c-4f7c-a173-714217e00473">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtNS0xLTEtMTY5NjA4_a6e6b351-68c2-4665-8f78-bf570c02818b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItMS0xLTEtMTY5NjA4_b5c6ea7e-1893-4d53-8051-be6262631039">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItMy0xLTEtMTY5NjA4_015d3c37-ff09-456e-b524-f91a584277d1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItNS0xLTEtMTY5NjA4_3f84f939-5fc2-4d4d-9f7e-c2bf3911e74e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNw_0ab181ca-c112-43c2-84e0-b0b02ee4c3f1" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtMS0xLTEtMTY5NjA4_8ec6584c-4d7d-458c-a885-9c530cb6999e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtMy0xLTEtMTY5NjA4_46afb3f7-135f-452a-869d-10872b9f800f">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtNS0xLTEtMTY5NjA4_c834c6be-fa6f-4c86-b204-9f2972f4167d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItMS0xLTEtMTY5NjA4_4a327afd-5e15-4785-9f3d-69379045df03">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItMy0xLTEtMTY5NjA4_15074fd3-a6bb-4a52-b8ed-59ae103ae1d5">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItNS0xLTEtMTY5NjA4_5a05033d-c7e6-4a6b-9b1c-fa018f9ab78d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtMS0xLTEtMTY5NjA4_9ee7f040-9fea-4334-84c1-ecaebdfecfc1">6.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtMy0xLTEtMTY5NjA4_1e36d52c-1b93-48a8-832f-16b7e969f5cf">7.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtNS0xLTEtMTY5NjA4_31f171fc-8c1c-4b5f-8b80-2d98c352bd9c">7.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtMS0xLTEtMTY5NjA4_eedc5161-86d1-4de9-8a4d-38fde0db6545">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtMy0xLTEtMTY5NjA4_c85db72d-f9f6-472c-a4f5-caec9de7c143">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtNS0xLTEtMTY5NjA4_d06ec30d-9e53-400d-808f-ab14de3c7724">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwOA_a578d11c-b4e9-48c8-89c2-8e0bf51b7771" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:91.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzEtMi0xLTEtMTY5NjA4_0005391e-48ea-4426-a7f3-5c2cdcea8e7b">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzItMi0xLTEtMTY5NjA4_95c7a45b-04c0-41dc-a540-5afc5e37312d">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzMtMi0xLTEtMTY5NjA4_ce842c25-b322-4be2-8139-974f2fd11ceb">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzQtMi0xLTEtMTY5NjA4_eec2d1e3-44cb-41d1-9109-8e462f5fa599">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzUtMi0xLTEtMTY5NjA4_323ae119-2732-4d72-bba5-fe5de26af794">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzYtMi0xLTEtMTY5NjA4_5717085c-6ba1-4264-890e-fcec7e5d29cf">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzctMi0xLTEtMTY5NjA4_b25c41b6-8745-4ef4-ada4-3ea98cb862bf">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzgtMi0xLTEtMTY5NjA4_da05665b-5402-4539-814f-bee53fd2ade6">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzktMi0xLTEtMTY5NjA4_f76d4a98-edfb-4ffc-9e11-868867a00fa5">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzEwLTItMS0xLTE2OTYwOA_d6a12664-9bcf-457e-9226-dec269f61c46">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzExLTItMS0xLTE2OTYwOA_8656016c-1fc2-4a94-af27-990d0ad00aee">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_352"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjEw_3633204c-ec52-4418-9b8d-6ed208e72725" continuedAt="i2016847d5c46430388d4e1e24082a2d6" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i2016847d5c46430388d4e1e24082a2d6" continuedAt="ibd41a9928fac4a01ab5a63e9ed049cc2"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQyMw_88e47ac9-5fd9-4d9c-b39c-7a54f417531c">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibd41a9928fac4a01ab5a63e9ed049cc2" continuedAt="i8d4330ca4e2c4c9e8264924fdc648f7b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzc4Mw_df7f6ee4-a195-4e8e-af4a-530bf0389a9a">20,000,000</ix:nonFraction> common shares of common stock for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, Bausch Health further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="ic07679a14e86417f8712f8cbb82b60ff_D20200428-20200428" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzIyMTQ_e02b4931-cecc-4d3c-88ab-058b7cafedf5">13,500,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional <ix:nonFraction unitRef="shares" contextRef="iad4afe550a6c481c97793e197c5bce51_D20220621-20220621" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5MzI_c13e0c3c-5f28-4334-832f-9dae25a9a2a7">11,500,000</ix:nonFraction> common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="ic7b69fb3977c4adc9d0e3708349c1838_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzMwMjE_4c0921dd-c726-4ef7-a078-c20ff5269354">18,226,000</ix:nonFraction> common shares were available for future grants as of December&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of Bausch Health&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NDM_93af1e70-6189-47b5-bbc3-e0e2bb7a586f">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjQ2_a17bdeaf-7f25-4a79-bc28-6a1dfa2eb156" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expense related to stock options and&#160;RSUs for the years 2022, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:67.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtMi0xLTEtMTY5NjA4_cf2bf457-ea6d-4413-a878-4a7f283725a6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtNC0xLTEtMTY5NjA4_2d9f90d4-01a6-4e40-913d-09cc03fd35d2">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtNi0xLTEtMTY5NjA4_029f5108-89ce-4f91-9da5-e35d02aa56ae">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItMi0xLTEtMTY5NjA4_af962139-2264-42ab-a546-48a18fa90222">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b78b13259aa479f924ecd7471c6be3d_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItNC0xLTEtMTY5NjA4_a4af2c15-99b6-4314-b7b5-4548b76a5d32">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e3c2748eaf4aafa359630b13935a24_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItNi0xLTEtMTY5NjA4_58b6c9b7-0533-4247-9735-f854c4f049c5">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtMi0xLTEtMTY5NjA4_fd78823b-0c9b-4ed9-85ae-3fcd232e81c0">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtNC0xLTEtMTY5NjA4_244850ad-c101-458e-9910-8039d1a47008">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtNi0xLTEtMTY5NjA4_2334ecd4-e699-452b-ba57-a124c8232a88">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if00b7cd8fe45432a9a85664c569eeb15_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtMi0xLTEtMTY5NjA4_09c92296-12e9-4c01-a6c1-9254449ec067">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d64492eb2e4908a69e9f58b7558e25_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtNC0xLTEtMTY5NjA4_2ee7e11f-9c70-48da-a891-711aaee009fd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0946c8396b744fe99205ccf1dee3017f_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtNi0xLTEtMTY5NjA4_729d775c-a2bb-4b9d-bdf3-d2f3e196134a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede2de5499f441559e821dbcad622021_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtMi0xLTEtMTY5NjA4_48949181-5c38-4ad2-a939-c081b662c617">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f0f7903cd849f3b7151828b60fac8b_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtNC0xLTEtMTY5NjA4_6352b1f0-39af-40b8-a40e-feeb09ad2ee8">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a380354c968473db359c0f5368d07a8_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtNi0xLTEtMTY5NjA4_d01a3bc9-e8cb-458c-8a22-1db1c98f2b90">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctMi0xLTEtMTY5NjA4_f7751b18-b9a4-4886-8d79-0ad3cb184d62">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctNC0xLTEtMTY5NjA4_0151946e-6c3d-4bfd-9c4b-158fe5b8006b">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctNi0xLTEtMTY5NjA4_3cdd15a2-3b54-47de-9a41-cb6fa35fef3c">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc1MDMxNjk_b501e15b-da5b-47c2-acd7-f8740cbbba2e">ten</span>th anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest <ix:nonFraction unitRef="number" contextRef="ia45df334731c4a1288356ac1f33c7415_D20220101-20221231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQ1OTg_8f847938-1b6e-4613-a6f3-d11182b6b1da">33</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia355745004ed4515ab1169c8dee886ef_D20220101-20221231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQ2MDU_73dccad0-929d-4f7b-bf21-a4d593858ced">25</ix:nonFraction>% each year over a <ix:nonNumeric contextRef="i2a6f01dc7e7849e1afb697e1681e7989_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjU1_c9be6ae3-42a9-45d5-853c-4248fa9d0570">three-year</ix:nonNumeric> and <ix:nonNumeric contextRef="ic888605118c2447e80ad019de50268f8_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjMy_3d1ed1f6-7437-43a8-8087-e7b86185d949">four-year</ix:nonNumeric> period, respectively, on the anniversary of the date of&#160;grant.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8d4330ca4e2c4c9e8264924fdc648f7b" continuedAt="ibad6fe4f1b4f4ec0afb9fc45dc753e53"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjE3_cae9223f-1e37-49d6-868d-3ec4f71bb541" continuedAt="i93bf927f2e4b44abb73906d2b11fe64f" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2022, 2021 and 2020 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtMi0xLTEtMTY5NjA4_4279d211-547a-4e83-9edf-7f95ed738c2d">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtNC0xLTEtMTY5NjA4_bd2868e4-7ddb-4828-8f9f-12d4975191c8">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtNi0xLTEtMTY5NjA4_eeab039e-5020-4b06-ac18-6cbd8541aa9b">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItMi0xLTEtMTY5NjA4_c1ada56a-89a4-476d-9471-8cbaa947849b">37.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItNC0xLTEtMTY5NjA4_2949657f-fd12-4b55-8c09-a10ec97b29db">50.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItNi0xLTEtMTY5NjA4_bf8c4d7e-be04-4e14-9ceb-523332a012d9">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtMi0xLTEtMTY5NjA4_4256283e-ed30-4350-a2e6-bbe9b0d34d95">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtNC0xLTEtMTY5NjA4_f3282774-8ddd-4e09-b7e7-bfe7594d5b2d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtNi0xLTEtMTY5NjA4_03a74bc8-73b3-48e5-99d8-9157c3b0def1">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtMi0xLTEtMTY5NjA4_058beb2f-17d9-4d96-98ed-f1cc168c00a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtNC0xLTEtMTY5NjA4_a27c5ecc-b5d3-443d-aa6c-8b2d7cbb3196">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtNi0xLTEtMTY5NjA4_6598eb43-092f-4d8e-8e62-9e42a092ba39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjM0_e7ce2fad-df4d-4475-87b8-7a759e80c613" continuedAt="ic5e44b82112d486b9d3218e573ce2b4a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzEtMi0xLTEtMTY5NjA4_128b4c5e-9b25-4de8-acbe-3994765295a3">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzEtNC0xLTEtMTY5NjA4_6792fa42-af95-411d-9d7c-69a7683d6649">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzItMi0xLTEtMTY5NjA4_b5d57eb1-66b6-4240-979c-6bbe52754f30">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzItNC0xLTEtMTY5NjA4_6c2f1f2d-a8fc-4d3f-800a-ab464731a90c">23.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzMtMi0xLTEtMTY5NjA4_52b40e02-9486-4893-983c-e2934e93443b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzMtNC0xLTEtMTY5NjA4_fad7266e-ead3-4fb0-85af-5531da3d6854">19.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzQtMi0xLTEtMTY5NjA4_50e79726-79ec-4672-bf83-890a9ab2030b">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzQtNC0xLTEtMTY5NjA4_eff084cf-5a2f-4110-9342-2df0804c95c5">28.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtMi0xLTEtMTY5NjA4_31154aaa-f0e4-4c8d-b630-4bf0daa86ec8">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtNC0xLTEtMTY5NjA4_c41913d8-cbed-47f0-9ef7-caffb2c4f257">26.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtNi0xLTEtMTY5NjA4_35bb6a75-dcb9-4ab7-918f-234da037466e">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtOC0xLTEtMTY5NjA4_83c1e84f-fe5c-4038-b83a-03d585942301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtMi0xLTEtMTY5NjA4_fd1b493f-600b-461b-9c02-ab6f18f2ac22">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtNC0xLTEtMTY5NjA4_129798b5-7bdb-46b3-b2f8-ea7952982f6f">26.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtNi0xLTEtMTY5NjA4_1a59f766-bcf1-48f0-b541-551d25f8db8e">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtOC0xLTEtMTY5NjA4_ff192376-1cf1-4bb4-a5a9-d5bf5a149bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctMi0xLTEtMTY5NjA4_e632a28f-c4f9-44fc-a647-16043c637cd0">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctNC0xLTEtMTY5NjA4_c8af5121-481e-47cc-bf20-5557071c8aef">27.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctNi0xLTEtMTY5NjA4_cc08fba2-a755-457a-9cce-61f32cbd9520">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctOC0xLTEtMTY5NjA4_c80bffc8-d788-49ad-9f13-db26df2cebe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwNzI_416d6438-e879-4125-8906-2bd4e6da9af6">6.60</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwNzY_bcd75772-3e5b-4a05-976c-82f1a5001d9e">10.92</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwODM_30167043-66c1-49fb-a050-2d2178063cbb">6.60</ix:nonFraction>, respectively. The total intrinsic values of stock options exercised in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNjY_e5c1f3b6-ee56-40de-a437-c21a96feccba">1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNzA_27a51d6a-cadf-405a-b72e-48acd5ff0124">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNzc_20a074b5-9cea-4a3b-9161-82dd0565951c">2</ix:nonFraction> million, respectively. Proceeds received on the exercise of stock options in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNTc_8ecbcafa-d9d5-4f4b-8aa5-65346e0dd1e9">3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNjE_feb70b48-fc09-4940-89b3-79aa37ef9e41">22</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNjg_b5d49170-6846-4b98-a02b-c355462ee2b4">5</ix:nonFraction> million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $<ix:nonFraction unitRef="usd" contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYzOTI_fc212a39-2198-4217-8b4d-870ea65f681e">14</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzY0OTg_e06e09a3-b782-403a-a99a-c9cfdc38d762">1.5</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM0Mg_253e43fe-d56c-4127-bad1-c14cf9bbf9a1">15</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM1NQ_7ff304c2-0676-49f1-9683-c541c3dbfd59">15</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM2OA_17d39930-d02a-45f7-8faf-ef94b971b68c">15</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or <ix:nonFraction unitRef="number" contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzY2ODM_26c03b42-0f0b-4456-a237-42f2a7058d4c">33</ix:nonFraction>% a year over a <ix:nonNumeric contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjM4_f27baae6-1f75-4a8b-b579-e771917dfacf">three-year</ix:nonNumeric> period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibad6fe4f1b4f4ec0afb9fc45dc753e53" continuedAt="i516e2e6d790d4a9ca2272f47bbb947af"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjQ5_fb481732-c7d8-4662-a39f-02386ba03acf" continuedAt="i7abbc2d3a94b472e94bfcde921aed9cd" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2022: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2492e7b35404d8e87840515f9d9a6c5_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzEtMi0xLTEtMTY5NjA4_b1695ca0-28e1-4629-98e1-1cdd5cb184fb">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2492e7b35404d8e87840515f9d9a6c5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzEtNC0xLTEtMTY5NjA4_175509c8-cb02-4572-a319-3bbf7aef4cdd">28.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzItMi0xLTEtMTY5NjA4_e3be2369-4a6a-4831-a4e8-de83ad79de95">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzItNC0xLTEtMTY5NjA4_3310fef1-d0af-4325-b782-1d13a9257631">11.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzMtMi0xLTEtMTY5NjA4_3cd2ed16-4d1c-4cb8-b3a5-9b586fdfeb70">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzMtNC0xLTEtMTY5NjA4_08100fe7-3193-40c5-9e0e-33a14da78d36">26.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzQtMi0xLTEtMTY5NjA4_e1e8b902-2fac-4983-90ad-c2b0acff35c0">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzQtNC0xLTEtMTY5NjA4_160ed7c5-cee5-421d-8486-2a429dd19832">24.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae249c92a22044b9807b386e185de759_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzUtMi0xLTEtMTY5NjA4_9fb5ab79-3877-45cd-9fb4-d4bc58d7d4aa">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae249c92a22044b9807b386e185de759_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzUtNC0xLTEtMTY5NjA4_68c24b85-bc3a-44fd-98c5-f53174cedb30">15.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="iae249c92a22044b9807b386e185de759_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg0OTU_bd350da4-f7c9-48e7-8b59-d69f9e98b7db">94</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2MDE_0ef293b8-4b90-4715-ab23-a2303690ae9d">1.7</ix:nonNumeric> years. The total fair value of time-based RSUs vested in 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2Njk_828b1786-5d23-49ee-9b11-574a9395ce9c">80</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iaee78b80f312454f958d6185baba0299_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2NzM_505c8f47-af62-4e07-b999-ebc5bfcf8338">69</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0d52467dd2c048db873fab55177a674a_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2ODA_e18f1cf7-e264-4591-a660-f78433ec536f">66</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2022, 2021 and 2020 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i8820b0a3beb24bed91da8f3c82e42606_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk2OTE_a6789100-5433-42cf-9318-0b08f178bf0b">no</ix:nonFraction> TSR performance-based RSUs granted in 2022. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjA5_8205e5db-5472-4c7f-a451-15b594ef5425" continuedAt="i90e7f8742b384b4483fee71a0dace7ba" escape="true">The fair values of TSR performance-based RSUs granted during 2021 and 2020 were estimated with the following assumptions:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i90e7f8742b384b4483fee71a0dace7ba"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:58.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzEtNC0xLTEtMTY5NjA4_6d6090be-b022-4de8-8c02-a0c05672a0da">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzEtNi0xLTEtMTY5NjA4_86d5443a-aa45-420d-899f-e773f89a233d">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzItNC0xLTEtMTY5NjA4_960bb68b-8717-4feb-8cf6-9ea16c9fc37f">52</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzItNi0xLTEtMTY5NjA4_d32e0220-c716-4054-b5ce-478d9119fe03">38.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzMtNC0xLTEtMTY5NjA4_e10974bc-fdee-4092-a385-e2c989fd0bf0">0.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzMtNi0xLTEtMTY5NjA4_7cfff11d-733e-47c5-a51e-4b2fa6dfbcc7">1.2</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i516e2e6d790d4a9ca2272f47bbb947af" continuedAt="i7c239edb67e84be285be83f3ede8bda1"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjIw_891db957-1c0d-4acb-a5cd-1809d5154598" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzEtMi0xLTEtMTY5NjA4_6cb43cd1-3f5a-4417-b8bd-2096ac2ba477">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzEtNC0xLTEtMTY5NjA4_3a75b919-939e-4c95-b2c1-07e37dc2439c">33.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzItMi0xLTEtMTY5NjA4_1ae359ba-f902-42ff-9f5d-d38eaf220424">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzItNC0xLTEtMTY5NjA4_32c5bb8e-5685-4051-b9df-0ebfec60639c">9.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzMtMi0xLTEtMTY5NjA4_bddc113d-2cb8-4a3d-82ac-19f2b6cd4137">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzMtNC0xLTEtMTY5NjA4_32d93a84-5dda-4dda-9d30-f354987006dd">30.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtMi0xLTEtMTkyNzU2_b213e4b2-601c-44e2-9701-15e8441a91db">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtNC0xLTEtMTkyNzU4_7fdef447-dd86-495e-ae63-5f5e356a7dde">34.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtMi0xLTEtMTY5NjA4_ca94502a-45bd-4e0d-bb61-bc8558bb6576">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtNC0xLTEtMTY5NjA4_84d5b542-56f7-448e-bac1-beca1c6d6254">29.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwNDg3_0396e60b-c048-4e31-a79d-8f0ca8abe06c">369,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of ROTC performance-based RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i371264615c75420297fa60d12cdd7590_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwNzM3_c7b6e8c3-060e-497d-bc5c-d421a11ee8a3">9.40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwOTcy_3c76fad7-59a6-416d-a182-3697a669763b">7</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMDc4_f00146b6-a313-47be-b2b8-64982a5ab308">0.4</ix:nonNumeric> years. A maximum of approximately <ix:nonFraction unitRef="shares" contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231" decimals="-3" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMTE2_e07e2097-2fba-49a1-9abc-bd78ce7d30e2">1,104,000</ix:nonFraction> common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2022. The total fair value of performance-based RSUs vested in 2022 was $<ix:nonFraction unitRef="usd" contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwOTk1MTE2ODkzODU_7654039a-188b-4d69-9ea0-00a93749a94e">31</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="i976c4ead5b5e43388410dab98e1380f6_I20220505" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NTU_79956789-12ed-41ca-aae6-941ff12f1b10">28,000,000</ix:nonFraction> common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of <ix:nonNumeric contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NjY_2fef6eb2-c6d5-4b68-bae6-ac5f66222d3f">ten years</ix:nonNumeric> and a <ix:nonNumeric contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5OTI_25fd3fea-3472-4c07-871f-3ae2c9c67f3e">three-year</ix:nonNumeric> vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, Bausch + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately <ix:nonFraction unitRef="shares" contextRef="i4c08f6b4a1bb4b97b88bd4703a8f0c70_D20220505-20220505" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5OTQ_a2581b57-caca-4c76-b0fa-35156bc9e2c5">3,900,000</ix:nonFraction> IPO Founder Grants were issued to Bausch + Lomb executive officers and were awarded <ix:nonFraction unitRef="number" contextRef="i8eae6ead96a941d1b21a4d5924929d5c_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMDU_5e16adc7-e855-4f04-9400-cd06ed45ac63">50</ix:nonFraction>% in the form of stock options and <ix:nonFraction unitRef="number" contextRef="i798f17f8800a4c818af00babd1be3910_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMTA_7b80252a-6bdf-4cef-8adb-8304f7808aa3">50</ix:nonFraction>% in the form of RSUs. Additionally, Bausch + Lomb granted approximately <ix:nonFraction unitRef="shares" contextRef="i92c83dd26ed54f1789ce908d1c7409fc_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMTU_b1a4cff2-16d1-46d6-8924-59a80ebc1aa2">5,700,000</ix:nonFraction> stock options and RSUs to non-executive eligible recipients, of which approximately <ix:nonFraction unitRef="shares" contextRef="i52e72a61294341d795cb93013ab5a0ea_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMjY_7e08704c-c8c8-45aa-b8d5-16aa0ddb2d27">4,300,000</ix:nonFraction> were B+L IPO Founder Grants. The IPO Founder grants in the form of stock options have a <ix:nonNumeric contextRef="ifee915a0af56457092546e18d9f5b2b1_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNDY_9c36c729-23cc-4200-9a26-f4d7e2bbe1c8">three-year</ix:nonNumeric> graded vesting period and the IPO Founder RSUs vest <ix:nonFraction unitRef="number" contextRef="ibba9807196544553bf6afedfc7ef764f_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNDg_580faf06-b250-4d61-9476-81e638706f89">50</ix:nonFraction>% in the second year and <ix:nonFraction unitRef="number" contextRef="iba13317aa60c47fdbe720638efeb8a32_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNTM_75301352-2908-4b9a-a77b-ef152d368249">50</ix:nonFraction>% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, Bausch + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#8220;CEO&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original <ix:nonNumeric contextRef="i4972cc1494f64143a33a8f5939165fb1_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNjc_617a9de8-214b-41db-a80d-f77839edd0f8">three-year</ix:nonNumeric> vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the <ix:nonNumeric contextRef="i9246f8b8e1204a3b9c57cd2cd7d1f32b_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNzc_9e42aa76-ad93-4400-9dd7-12c9fda7c1e8">two-year</ix:nonNumeric> anniversary of the CEO&#8217;s termination of service date (such applicable date, the &#8220;Unrestricted Date&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original <ix:nonNumeric contextRef="ia300b8d00c054934a733fe79c976c8df_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwODg_4946830c-3fa6-431d-96d6-19e90898018f">three-year</ix:nonNumeric> vesting period associated with such grants) upon the Unrestricted Date and will remain exercisable for <ix:nonNumeric contextRef="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwOTg_b03163e0-a1e0-41ff-94e1-19cc8e28812f">two years</ix:nonNumeric> following this date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, Bausch + Lomb entered into an Amended and Restated Separation Agreement (the &#8220;A&amp;R Separation Agreement&#8221;) in connection with the departure of Bausch + Lomb&#8217;s CEO. Under the A&amp;R Separation Agreement, Bausch + Lomb&#8217;s CEO agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board determines in its discretion or his successor is appointed, but no later than June 30, 2023. On the CEO&#8217;s termination date, in lieu of pro-rated vesting, partial vesting of a set number of the CEO&#8217;s IPO Founder Grants, in the amount of: (a) <ix:nonFraction unitRef="shares" contextRef="icff6d6c9c84647b1b1dce247dcafc619_I20221222" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MDA_3055ee27-4f77-47c7-9bdb-c10b1e651195">315,592</ix:nonFraction> of the CEO&#8217;s IPO Founder Grants in the form of restricted stock units will accelerate and vest, but the shares received upon settlement will still remain fully restricted and nontransferable until the Unrestricted Date and (b) </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i7c239edb67e84be285be83f3ede8bda1" continuedAt="i62b73d2633794e15b9622e71b8d72112"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icad5cc2f654041548ac38459ec8e3737_I20221222" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MDk_4ad09fb7-305d-4e4f-b451-e9a4585c965b">1,248,496</ix:nonFraction> of the CEO&#8217;s IPO Founder Grants in the form of stock options will remain eligible to vest upon the Unrestricted Date and remain exercisable for <ix:nonNumeric contextRef="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MTk_a21bba2f-67a9-4abe-b82e-6009b413e3c0">two years</ix:nonNumeric> following the Unrestricted Date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes Bausch + Lomb&#8217;s named executive officers (other than the CEO) and certain other employees. This program provides these Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by Bausch + Lomb without &#8220;cause&#8221; or the executive&#8217;s resignation for &#8220;good reason&#8221;, in each case within the <ix:nonNumeric contextRef="i158545ece5364e96bdae2027c13c3e8d_D20220701-20220930" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMjE_7a52c7ff-0b85-40cd-b47d-337e21423e6e">one-year</ix:nonNumeric> anniversary of Bausch + Lomb&#8217;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original <ix:nonNumeric contextRef="i57057d66fc88405090a8ce98ca6c8e2c_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMzI_6e3d9ce5-026b-466e-86b0-b06ae8df4811">three-year</ix:nonNumeric> vesting period associated with such grants). However, the IPO Founder Grants in the form of RSUs (while settled in connection with the termination of employment) will not be transferrable until, and the IPO Founder Grants in the form of stock options will not be exercisable until, the earliest to occur of: (i) the date the spinoff distribution is completed, (ii) a &#8220;change in control&#8221; (as defined in the applicable retention award letter), (iii) the date the Board of Directors of the Company determines that it will no longer pursue the spinoff distribution and (iv) the <ix:nonNumeric contextRef="ia60f66139de8490cb251cef704102616_D20220701-20220930" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NDE_b9f97913-b78b-4e92-b9f4-86d41605e4e2">two-year</ix:nonNumeric> anniversary of the executive&#8217;s termination of employment and the IPO Founder Grants in the form of stock options will be exercisable for <ix:nonNumeric contextRef="ia60f66139de8490cb251cef704102616_D20220701-20220930" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NDI_79129784-f171-428e-a063-f97b35a533ff">two years</ix:nonNumeric> following the later of this date and the termination date Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately <ix:nonFraction unitRef="shares" contextRef="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMzQ_cefc0585-931b-47fd-bd47-747dd65cb5b4">850,000</ix:nonFraction> RSUs under the retention program pursuant to Bausch + Lomb&#8217;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNDI_bd3faf2e-8d53-4f0a-9ea0-1f5a151830e1">three</span> anniversaries of the grant date based on continuous employment with Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i2f724b3f1785466b94b544893b47c1bb_I20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNTQ_71ecf785-67fc-41c9-a8f0-1f2e82488e98">17,500,000</ix:nonFraction> Bausch + Lomb common shares were available for future grants as of December&#160;31, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the B+L Plan generally expire on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NTY_abbdaf34-1a0a-4131-b1a8-ee77e636b7d4">ten</span>th anniversary of the grant date. The exercise price of any stock option granted under the B+L Plan will not be less than the closing price per common share preceding the date of grant. Stock options generally vest <ix:nonFraction unitRef="number" contextRef="i15e52757684147129eded077c6efccfd_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_3d8d190a-cc75-41ef-8504-298de74d7dde"><ix:nonFraction unitRef="number" contextRef="ic466f5201e554473806f5d23207321c7_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_b38bb77c-e16d-4db7-870f-971b7690e919"><ix:nonFraction unitRef="number" contextRef="i2d0ac44894434f3c838f08217170a230_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_b39a7177-a1a6-4a2e-98de-0f1e7c7a6ceb">33</ix:nonFraction></ix:nonFraction></ix:nonFraction>% each year over a <ix:nonNumeric contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExOTk_e50eeea9-abe7-4576-a69b-b1f222f8858f">three-year</ix:nonNumeric> period, on the anniversary of the date of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan for the year <ix:continuation id="i93bf927f2e4b44abb73906d2b11fe64f" continuedAt="iba53ae1456fb4e74bdf2afc5c79ab21a">2022 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:</ix:continuation></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="iba53ae1456fb4e74bdf2afc5c79ab21a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzEtNi0xLTEtMTgwNDk0_4d6a892e-3e0c-4131-8eb1-ebefa25dad3d">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzItNi0xLTEtMTgwNDk0_44023514-fca8-4ccb-98e7-9f597d99eae8">31.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzMtNi0xLTEtMTgwNDk0_d0d17830-6be6-4558-8a29-7f0b83495d48">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzQtNi0xLTEtMTgwNDk0_b4543137-35c8-4098-85cb-c13e99d477b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns associated with historical stock options granted to Bausch + Lomb employees under BHC&#8217;s long-term incentive plan. The expected volatility was determined based on implied and historical volatility of Bausch + Lomb&#8217;s selected peer companies. Bausch + Lomb will continue to leverage BHC&#8217;s historical stock option experience and peer company data until it has sufficient experience with its own equity awards and market data. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected Bausch + Lomb annual dividend rate at the time of grant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradable, fully transferable stock options without vesting restrictions, which significantly differ from Bausch + Lomb&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i62b73d2633794e15b9622e71b8d72112" continuedAt="i6fee5371dff4445eba41e426531e13d2"><ix:continuation id="ic5e44b82112d486b9d3218e573ce2b4a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under Bausch + Lomb&#8217;s Plan during 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i496a8139703848748c2af0e1c60eba9d_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzEtMi0xLTEtMTgwNTAw_c48bd599-5a3c-45db-89e2-2c9d60a8881f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i496a8139703848748c2af0e1c60eba9d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzEtNC0xLTEtMTgwNTAy_d8c22855-313f-4ef1-abd9-03c3ab4cc6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzItMi0xLTEtMTgwNTAw_529ea439-5332-4ad9-9134-c679288acf7f">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzItNC0xLTEtMTgwNTAy_0ac47cef-c3e7-43b8-8465-79582c00d969">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzMtMi0xLTEtMTgwNTAw_f57ec692-859e-42fd-9dd4-426a0957d8b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzMtNC0xLTEtMTgwNTAy_2d5b062c-a8e9-40e2-9aa1-cd0b0eb0525f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzQtMi0xLTEtMTgwNTAw_20d8602b-864f-43e3-ba2a-c54e42bb09ce">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzQtNC0xLTEtMTgwNTAy_5babaf03-cbd2-4928-927e-6c32f52bbc04">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtMi0xLTEtMTgwNTAw_a01f8506-e3f5-4894-9234-148251bb27a0">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtNC0xLTEtMTgwNTAy_9253626a-201b-431f-9256-6febc3e2faae">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtNi0xLTEtMTgwNTA0_70f904e9-9cc2-4c46-a8ae-d2bb80aa0169">9.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtOC0xLTEtMTgwNTA2_25ca5ed0-7d8d-4e11-b25e-dedf148843d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtMi0xLTEtMTgwNTAw_66a9b924-01e2-4d64-ac32-9422055d0104">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtNC0xLTEtMTgwNTAy_c71c25ed-c876-45b5-aba8-9f56ffc66f66">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtNi0xLTEtMTgwNTA0_e9f79e42-03ef-4828-9d71-e2ca7bad405f">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtOC0xLTEtMTgwNTA2_90c06989-0126-4c07-8de8-3ceccb0c0623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctMi0xLTEtMTgwNTAw_79e9fbd3-48ab-48b8-aa06-e8258bafdc0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctNC0xLTEtMTgwNTAy_1ff8a2d5-2d0d-4f3f-88d9-8a718fa03608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctNi0xLTEtMTgwNTA0_312b29a7-9780-423d-9d0c-f6f75c7fc12d">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctOC0xLTEtMTgwNTA2_a92928bb-3113-4984-9f6c-1852fe2dbd0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxNTU_3a917275-403e-4464-89d8-0b293d1c243b">3.84</ix:nonFraction>. There were <ix:nonFraction unitRef="shares" contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NjY_39b958ba-08e4-4304-b9ec-f58e118fba15">no</ix:nonFraction> stock options exercised in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $<ix:nonFraction unitRef="usd" contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxNjM_29266a51-6cd2-457c-8c34-73f2bf8e1c07">4</ix:nonFraction>&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEyMjQ_9e748450-62bb-4b4e-ad90-d7724936d8a9">0.7</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. There were no stock options that vested during 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan generally vest <ix:nonFraction unitRef="number" contextRef="i56e87d37abd4499ea01e8038522b296c_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_57506c91-bcfd-4e19-adc7-6757c1b7df84"><ix:nonFraction unitRef="number" contextRef="if701cbfe1c6a4dcd881783198bdf3bf1_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_c553065c-c1fc-4c48-84c7-a0ded6c3cc8a"><ix:nonFraction unitRef="number" contextRef="ic3174916bf904c96b87d8033569c321d_D20220505-20220505" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_e4b7f706-665d-4418-952a-9d81efee4c3d">33</ix:nonFraction></ix:nonFraction></ix:nonFraction>% a year over a <ix:nonNumeric contextRef="ib7365ac3a4d640af8c0c8f6f469cd387_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3Nzk_65292be1-6ed1-4b07-97da-c1e99950aa62">three-year</ix:nonNumeric> period with the exception of IPO Founder RSUs which vest <ix:nonFraction unitRef="number" contextRef="i6d68de5df36c4a3eaab2e8b8f62dbb07_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQzOTgwNDY1NTY1ODQ_e311c8c0-7e0f-43ac-b35a-f72e2a6f0804">50</ix:nonFraction>% in the second year and <ix:nonFraction unitRef="number" contextRef="i694231e10d404b83a250ebe6cbae790f_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3ODU_b27e6042-1b6c-4fdc-a92a-51e928852e2d">50</ix:nonFraction>% in the third year after the grant. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Bausch + Lomb&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, Bausch + Lomb may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i6fee5371dff4445eba41e426531e13d2"><ix:continuation id="i7abbc2d3a94b472e94bfcde921aed9cd"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity under Bausch + Lomb&#8217;s Plan during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6757e09e35d643fa9be873511bd89c4c_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzEtMi0xLTEtMTgwNTc0_7e70f2c2-36ba-4bcc-abfb-a5ca991f44b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6757e09e35d643fa9be873511bd89c4c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzEtNC0xLTEtMTgwNTc2_ffc973c8-e9a4-4bcc-b997-29c20ef6d75f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzItMi0xLTEtMTgwNTc0_8cb8cff8-5b99-4110-a959-8d4d41ae1785">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzItNC0xLTEtMTgwNTc2_723c966d-e3c5-4606-847e-eaed0c402ec4">16.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzMtMi0xLTEtMTgwNTc0_9f514bf7-7988-46c0-98d3-254cff35b919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzMtNC0xLTEtMTgwNTc2_2cadddb4-f7cd-4456-9df8-bee3d2cddc64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtMi0xLTEtMTg3MTkx_c95b1f70-84c4-459b-b234-41258b85b09e">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtNC0xLTEtMTg3MTk0_9de3f468-9375-4035-b4e1-653f4fe6d7a1">17.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtMi0xLTEtMTgwNTc0_3e64c7e6-afea-4983-9ce4-5122cc511bff">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtNC0xLTEtMTgwNTc2_b64ebf6f-2060-4bba-88d2-0881ce806fc6">16.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxOTU_6906dd69-80d1-41f8-8f03-d2aa438f7b36">41</ix:nonFraction>&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEyNzA_7d4efb6c-4172-4979-a387-18b46efc4123">1.5</ix:nonNumeric> years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. The total fair value of time-based RSUs vested in 2022 was not material.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while Bausch + Lomb did not grant performance-based RSUs during 2022, certain Bausch + Lomb employees continued to participate in BHC&#8217;s performance-based RSUs granted prior to May 5, 2022. As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i0b929374818a40479322ab79af8f337f_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3OTE_e5e757a4-67a1-4529-9b3a-f73d3a483bbc">4</ix:nonFraction>&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i8d4815a98c184418bbffa029558875ff_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk4MDI_e937dd3a-26ec-44dc-b062-0b6864f22c45">0.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_355"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzQxOA_aa539f3a-cdfb-44f2-a9d1-7fefc569b65c" continuedAt="i6ef5198eab3c489298841beb893b082c" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS </ix:nonNumeric></span></div><ix:continuation id="i6ef5198eab3c489298841beb893b082c"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzQyNg_fe22913a-550e-4eaa-aa97-0b56c353bd68" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2022 and 2021 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e2ee13540d244e58ee59a9ca76630cb_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzEtMi0xLTEtMTY5NjA4_a7351712-4cf6-4fb6-8d67-848309ac6d81">2,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9476d0eb2004c5589302c03748dd6c9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzEtNC0xLTEtMTY5NjA4_e080250c-3df6-4448-bb83-b135a44cdba8">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id01756a362e44beb92a479cf33c85af9_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzItMi0xLTEtMTY5NjA4_38c1e6b1-2b0b-4ee1-afbe-634d59df8dc8">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f95881b6ece465992d0a8b5672f70a8_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzItNC0xLTEtMTY5NjA4_68aa2821-6dcd-4a32-919d-8518fc1c536e">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i286802cacb2b47a7aac5819b6b1ae881_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzMtMi0xLTEtMTY5NjA4_b81a8eb8-2c1c-448c-a271-ace4ffc706cf">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4522c45ac1c44145a7ecea556295fe2a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzMtNC0xLTEtMTY5NjA4_80204a43-770f-4fd0-be30-5220e99e03c6">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $<ix:nonFraction unitRef="usd" contextRef="ibdc8cd56812542429247ba8cba9a093a_D20221001-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzE2NDkyNjc0NDI0MTU_7117b752-e3cb-40ac-a757-4778f5acbe87">137</ix:nonFraction>&#160;million to equity attributable to the Company.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_358"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90ZXh0cmVnaW9uOmUzMTUwNDRkYzY0YTQ4ZjVhOWYyYzhhNjM4NDRkODM4XzI4Nw_184ee076-4628-4165-af2a-3bb19b1bcb75" continuedAt="i925e9006362b4cc6b8857be129f6585e" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="i925e9006362b4cc6b8857be129f6585e"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90ZXh0cmVnaW9uOmUzMTUwNDRkYzY0YTQ4ZjVhOWYyYzhhNjM4NDRkODM4XzI4Ng_bca7aab7-1de1-4c3d-9ae1-b89a09dd2e04" continuedAt="i8d4df484ecaa42bca1c042239ee41790" escape="true">Research and development costs for the years 2022, 2021 and 2020 consists of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="i8d4df484ecaa42bca1c042239ee41790"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtMi0xLTEtMTY5NjA4_a1df3580-487f-4ff4-ac4b-956d3147aa2a">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtNC0xLTEtMTY5NjA4_f8546d36-68d8-4473-b5fe-b8e2864f74d8">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtNi0xLTEtMTY5NjA4_253a0e3b-0783-49b7-b069-06a579999382">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItMi0xLTEtMTY5NjA4_ecba8e62-c4e7-452e-9385-95f9a501bc53">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItNC0xLTEtMTY5NjA4_33618a04-f884-41ee-b3b6-df15ec37c1f1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItNi0xLTEtMTY5NjA4_c9ed7981-ea43-45f7-ac5a-2d6bcfaf966a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtMi0xLTEtMTY5NjA4_34bfe495-dfc6-4332-957e-e2bc39f1b702">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtNC0xLTEtMTY5NjA4_411083d4-c414-4725-bf97-b2d0bfe326cc">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtNi0xLTEtMTY5NjA4_09424f01-e048-4d23-a17d-b06849c65302">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-62</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_361"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzk4Nw_b46b2542-96b7-401b-9840-8bac5258b8a4" continuedAt="iae16ddef18694e8497842d84d8173591" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="iae16ddef18694e8497842d84d8173591" continuedAt="i99392284ecb542458aa5da647d992b79"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzk4NQ_6e2c58c9-1bc6-44f3-84a6-eb6f5fcac397" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2022, 2021 and 2020 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItMi0xLTEtMTY5NjA4_12c9e791-9c1e-4884-b7d0-bb172f1c9e4c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItNC0xLTEtMTY5NjA4_3dcdacaf-6ce6-4a71-afaf-faac288fc1f7">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItNi0xLTEtMTY5NjA4_841509f3-7c08-4836-8076-355f261adea1">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtMi0xLTEtMTY5NjA4_8b75fe51-55a3-482d-877e-2a0731cbde43">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtNC0xLTEtMTY5NjA4_202ee63d-6a73-4689-8865-c5dcb864ea4e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtNi0xLTEtMTY5NjA4_c52be17c-7a40-401b-8995-854a8c1e1b77">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtMi0xLTEtMTY5NjA4_607647c2-7000-409b-9989-0ef7fe85a861">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtNC0xLTEtMTY5NjA4_7b3665a4-9c0e-4f84-947f-9de9d585af83">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtNi0xLTEtMTY5NjA4_a8e0f038-5de7-4e6f-9614-4c4a01b0c71e">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtMi0xLTEtMTY5NjA4_a44105ce-cbf4-4dcb-8b90-8b5d48d78455">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtNC0xLTEtMTY5NjA4_909b7cf1-0674-4f0a-a80d-d5fb26f6fb09">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtNi0xLTEtMTY5NjA4_55f761d5-25c9-45d4-9216-82a3cfe47865">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtMi0xLTEtMTY5NjA4_05203c28-ce78-4d43-a0b7-ed5626ae41c8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtNC0xLTEtMTY5NjA4_f0b1cbf9-5720-412a-b15d-c40e06c4b794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtNi0xLTEtMTY5NjA4_5c448ad8-3b71-45af-ae7a-32a64aff4c5e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctMi0xLTEtMTY5NjA4_0dc3ad24-ce15-4d7e-8308-1a26eb2501a0">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctNC0xLTEtMTY5NjA4_418426c9-243a-4f1d-bc34-483e6111d7c7">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctNi0xLTEtMTY5NjA4_7f3169fc-d280-4376-b0d0-18e722bb5033">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2Mjg3NzE_3dcdacaf-6ce6-4a71-afaf-faac288fc1f7">356</ix:nonFraction> million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2Mjg3Nzc_841509f3-7c08-4836-8076-355f261adea1">422</ix:nonFraction> million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gain on sales of assets includes $<ix:nonFraction unitRef="usd" contextRef="ib3c97c4ec64941ccb13c8842880f03f3_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzE2NDkyNjc0NDMyODA_694fb24f-47e4-42e6-81c4-befc7694107f">25</ix:nonFraction>&#160;million related to the achievement of a milestone related to a certain product and a $<ix:nonFraction unitRef="usd" contextRef="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzE2NDkyNjc0NDMzMDU_9bfd3340-1f27-4897-b87c-192a7241b576">26</ix:nonFraction>&#160;million loss upon completion of the Amoun Sale during 2021.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99392284ecb542458aa5da647d992b79">In 2020, Acquired in-process research and development costs of $<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2MjkwMTA_c52be17c-7a40-401b-8995-854a8c1e1b77">32</ix:nonFraction> million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements.</ix:continuation> </span></div><div id="i57fbe32677504c888f142dd82b99b37f_364"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODE2_9594934c-eab6-40df-831c-98fec1c9701e" continuedAt="ie39ffed34c594e778b795076ed8b1498" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ie39ffed34c594e778b795076ed8b1498" continuedAt="i898b76bc931f4d489276bc53f78e087b"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzgy_1abe34c8-e494-4517-a690-b2eb5311e536" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before income taxes for 2022, 2021 and 2020 consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtMi0xLTEtMTY5NjA4_2f95ada8-dda8-45f5-98ab-c2a12264aeee">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtNC0xLTEtMTY5NjA4_18567352-7db9-4263-a389-59efc7e2784d">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtNi0xLTEtMTY5NjA4_086db271-bda5-49e5-9045-6371186e9b58">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItMi0xLTEtMTY5NjA4_d0ccabbf-93b6-4549-a55a-f7e09573979f">193</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItNC0xLTEtMTY5NjA4_36154b39-5f9c-46e0-8393-5706e9e33bca">701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItNi0xLTEtMTY5NjA4_dc7d86ff-247f-484b-a27b-c6b70015915d">524</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtMi0xLTEtMTY5NjA4_3c5009bd-33b2-4a5b-bc9d-f65abe183799">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtNC0xLTEtMTY5NjA4_e6463f25-5cb1-461f-a1ee-6de2d33374fb">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtNi0xLTEtMTY5NjA4_ade5324c-3b73-4bed-8486-9ed008c830ac">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzkx_3917b006-b668-40dd-9430-75c63ac6e496" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of (Provision for) benefit from income taxes for 2022, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItMi0xLTEtMTY5NjA4_467f5cf7-8f91-4a2e-b59a-a749e2d45bc6">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItNC0xLTEtMTY5NjA4_f2fb6c3a-de28-450d-81a1-ac0159a10953">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItNi0xLTEtMTY5NjA4_8cea1518-4ba1-4bcf-86dd-036a64d25ffe">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtMi0xLTEtMTY5NjA4_64b382ef-d94b-4a69-9143-10ff9d08ba3c">256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtNC0xLTEtMTY5NjA4_a7ae243d-a63e-4ac3-bf75-39886481b3d4">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtNi0xLTEtMTY5NjA4_d6c67398-9df6-4c31-9c46-acb30c556b73">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtMi0xLTEtMTY5NjA4_e058ea5b-a25b-4191-8886-053d9fba64f1">271</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtNC0xLTEtMTY5NjA4_5c4b0d74-9027-45b7-9cec-acd069271db1">51</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtNi0xLTEtMTY5NjA4_7293c8e1-c077-44bb-834f-768175bb8ad1">224</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtMi0xLTEtMTY5NjA4_03d1541b-a51b-4f7c-a7be-e4a08dc4d136">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtNC0xLTEtMTY5NjA4_2fbe9dee-e960-41e5-9b59-8cee4eab3bcc">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtNi0xLTEtMTY5NjA4_477d9e2e-ef99-4a34-ac1e-93a5c30e6326">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctMi0xLTEtMTY5NjA4_c45288c1-f58c-4add-9e17-64d943021d82">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctNC0xLTEtMTY5NjA4_c0c44cc5-8b9a-4ef1-a739-010059d803f3">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctNi0xLTEtMTY5NjA4_239fc324-79b2-4a90-91c9-6b403aefc905">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtMi0xLTEtMTY5NjA4_2651ff91-e309-4dbe-a9d1-0e2b10905714">188</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtNC0xLTEtMTY5NjA4_db8b04c4-eb61-4aeb-9b4c-4f5d6896c117">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtNi0xLTEtMTY5NjA4_16cec0c6-6aa7-4e91-aafa-f382784eeff6">599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktMi0xLTEtMTY5NjA4_eada04c8-b3ed-4bfd-b656-d938cbc32449">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktNC0xLTEtMTY5NjA4_93084cac-4428-4e49-8b70-5af0b15df4b7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktNi0xLTEtMTY5NjA4_1ec65331-0249-4832-9fbf-f4b2251b5d67">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i898b76bc931f4d489276bc53f78e087b" continuedAt="i8231688887384c5188b94db5cf6d57d9"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzg5_706e41af-9269-4288-ba7a-8479a31ce78b" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (Provision for) benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of <ix:nonFraction unitRef="number" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_3b344862-7aa0-422e-99c8-c899163ad178"><ix:nonFraction unitRef="number" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_89c40325-d24b-4f3d-b182-bf324e1634f9"><ix:nonFraction unitRef="number" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_f80c91cc-d583-4e99-88e2-13cb4d4d4814">26.9</ix:nonFraction></ix:nonFraction></ix:nonFraction>% to Loss before income taxes for 2022, 2021 and 2020 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtMi0xLTEtMTY5NjA4_59b8f0b7-19c5-4f9a-84c5-a83a03b184f8">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtNC0xLTEtMTY5NjA4_d54125f2-3e29-4f24-b95a-a99245cdf6f1">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtNi0xLTEtMTY5NjA4_df04d0ec-6add-4bb3-a7d6-b3c182e661b2">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtMi0xLTEtMTY5NjA4_52c0a5ca-6503-4d0b-a8da-b449c2c0dc98">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtNC0xLTEtMTY5NjA4_6fc2284f-a658-43e4-a025-d9ff6bce522d">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtNi0xLTEtMTY5NjA4_0f645a8e-8827-472c-860d-6f28edd78c89">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtMi0xLTEtMTY5NjA4_a37ad6d3-b698-4d5d-86f0-acfaaa0b6400">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtNC0xLTEtMTY5NjA4_7e97051b-0f8d-46c5-8e64-8e5375445731">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtNi0xLTEtMTY5NjA4_85a1b818-a280-4f00-b1ac-983ae6eaa2ad">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtMi0xLTEtMTY5NjA4_86397086-5ba2-4471-8374-7e934a7c5857">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtNC0xLTEtMTY5NjA4_b5572b3e-89fb-4664-946f-361cadd39597">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtNi0xLTEtMTY5NjA4_ef873b9e-1eb7-4ac2-a42b-0eff4d9d1a91">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtMi0xLTEtMTY5NjA4_59de652e-bc21-4e93-b463-595474a5cad0">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtNC0xLTEtMTY5NjA4_352d67fc-aea3-4027-b089-697345290b5a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtNi0xLTEtMTY5NjA4_0d87913d-ca58-4b13-812a-e43e201a310b">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctMi0xLTEtMTY5NjA4_7046b9ff-3050-4b8e-90b9-bde49d71be0e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctNC0xLTEtMTY5NjA4_93846d8f-4880-4485-b057-fbfe563bc282">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctNi0xLTEtMTY5NjA4_1426a477-c09d-4d15-973a-64b199c8e3e7">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtMi0xLTEtMTY5NjA4_e0e87131-5cef-41dd-8293-0e2b6dee9fac">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtNC0xLTEtMTY5NjA4_4d4ea763-7fb6-451c-97d7-1faae1f24203">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtNi0xLTEtMTY5NjA4_1f9b46cf-0b58-408c-a1fc-108d0b61052b">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktMi0xLTEtMTY5NjA4_0848e327-1c9c-4242-a50e-a8131018acb3">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktNC0xLTEtMTY5NjA4_fd4a9823-695a-4e9b-9b06-d3234219dc65">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktNi0xLTEtMTY5NjA4_d1585e23-7145-4d33-a991-55545111181c">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTItMS0xLTE2OTYwOA_ccf4c86b-dc40-4464-8fbe-4cb7fa138868">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTQtMS0xLTE2OTYwOA_4647eb2c-9d18-484b-b809-b1df4c8395b8">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTYtMS0xLTE2OTYwOA_ecf8c50e-ca1b-40bc-9c49-1dae678db63e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTItMS0xLTE2OTYwOA_ce14564b-f195-4887-bc79-5a228585519c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTQtMS0xLTE2OTYwOA_9fee0135-7b56-4e2b-afd3-68b64558e0b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTYtMS0xLTE2OTYwOA_ae57d995-1b78-42af-9b32-44bddb490bab">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTItMS0xLTE2OTYwOA_5c702a32-21d3-4f62-9b68-faf5179120f3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTQtMS0xLTE2OTYwOA_0ff3c74d-9f20-453c-a1e6-b38a5c2ed77b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTYtMS0xLTE2OTYwOA_d56b1512-823c-4bdb-b19d-052d9f3c9465">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTItMS0xLTE2OTYwOA_ec6b4c99-a466-44eb-9573-9523f138d383">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTQtMS0xLTE2OTYwOA_116d28f9-3687-4857-993c-d539254dd4f4">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTYtMS0xLTE2OTYwOA_9de06775-dc70-4b17-9cdc-d49e0e328ca1">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other consists of immaterial adjustments affecting the tax provision such as those related to the filing of tax returns.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODI5_337362f4-c675-4fee-a5de-dddbf0c8df96" continuedAt="i1a93db484f9e4fb0815885e6fe2f88c0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzItMi0xLTEtMTY5NjA4_b2329514-b88b-4b14-add5-d573c4c08fa4">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzItNC0xLTEtMTY5NjA4_9ed1a7e5-be7b-46da-be40-da9778957978">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzMtMi0xLTEtMTY5NjA4_b9e33c5c-9352-457f-a4d0-ea263a1cd8c3">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzMtNC0xLTEtMTY5NjA4_50e87ac9-7145-4db4-87b9-49575d10ae8a">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtMi0xLTEtMjAzNTkw_ff46398e-b57f-4a6e-a84a-c1d1dd261930">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtNC0xLTEtMjAzNTky_593a346a-7965-4af8-94aa-49ea702efd17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtMi0xLTEtMTY5NjA4_0fee1acb-5cc5-484f-ab86-851eb3be7af7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtNC0xLTEtMTY5NjA4_d9ab0934-573d-431b-9f83-f91b4009bf63">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzUtMi0xLTEtMTY5NjA4_5660acb6-228b-47a7-94ba-79bb8f9f6499">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzUtNC0xLTEtMTY5NjA4_74c4dcc0-cb4b-49f4-892e-4528bb9db64a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzYtMi0xLTEtMTY5NjA4_e1db80cc-6031-4bd4-a061-0d80dc57a910">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzYtNC0xLTEtMTY5NjA4_7bbc75f3-e5e2-4de4-8a1f-11ae55d8a5e8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzctMi0xLTEtMTY5NjA4_757e93fd-b44f-420a-af80-7ded14df1257">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzctNC0xLTEtMTY5NjA4_a0f0da94-1887-4d42-a718-8d15aea4e7c5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzgtMi0xLTEtMTY5NjA4_b6611304-e176-4aeb-9ad4-08a9d3883140">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzgtNC0xLTEtMTY5NjA4_719fff9f-9b89-4f1d-89f5-d45c931802af">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzktMi0xLTEtMTY5NjA4_265abe07-a065-44bb-85bb-af40a8962483">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzktNC0xLTEtMTY5NjA4_e746c78d-7d2b-4e43-9b4d-becf03b7e47e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEwLTItMS0xLTE2OTYwOA_a65b7850-3d60-414a-979a-f1cf5d8e3b37">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEwLTQtMS0xLTE2OTYwOA_6b14fc75-74bf-4941-afdf-006bc5648e7f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzExLTItMS0xLTE2OTYwOA_0f45ffaf-bbe2-4031-885b-887aa5bb75cd">4,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzExLTQtMS0xLTE2OTYwOA_e5bc28d3-37c8-4433-9360-33b7db59081c">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEyLTItMS0xLTE2OTYwOA_76574d90-e161-48c7-9d5e-0213b8cf3a47">2,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEyLTQtMS0xLTE2OTYwOA_bc577b26-234d-4719-a133-7fdff0a5d651">2,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEzLTItMS0xLTE2OTYwOA_4b744db8-96fe-4f96-b788-6dc9d11bd576">2,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEzLTQtMS0xLTE2OTYwOA_8d15f468-4810-4f88-acdc-8b5db315d90a">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE1LTItMS0xLTE2OTYwOA_bb574bf0-c6c9-4920-b11f-ba1ade0c3a00">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE1LTQtMS0xLTE2OTYwOA_5b872b72-26ae-4900-a250-f5c23120a118">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE2LTItMS0xLTE2OTYwOA_1dcfb0b7-2ecc-4bb2-8297-fe62efce48eb">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE2LTQtMS0xLTE2OTYwOA_1af2382b-be13-41aa-a11f-959547d0bc00">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE3LTItMS0xLTE2OTYwOA_8a9ba9df-425b-4ef9-9183-722ac75624eb">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE3LTQtMS0xLTE2OTYwOA_578612e9-df43-4492-bbf2-313a78ce3956">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE5LTItMS0xLTE2OTYwOA_604ff789-954f-4999-9282-bad02b19dbcc">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE5LTQtMS0xLTE2OTYwOA_6deefc69-5bc0-4fef-a6b8-6d185a199d48">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzIwLTItMS0xLTE2OTYwOA_23bb4368-f3dd-4b88-aa43-41cc4cfcecca">1,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzIwLTQtMS0xLTE2OTYwOA_a1ea3a6b-91fa-452f-9ab8-ef565f452da6">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8231688887384c5188b94db5cf6d57d9" continuedAt="if0963dc090794ba38c60cc0362637ad0"><ix:continuation id="i1a93db484f9e4fb0815885e6fe2f88c0"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2022, 2021 and 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14bc647bd66490ea555f0a1a8e9d50f_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtMi0xLTEtMTY5NjA4_8ddaa84e-f185-4340-a8fb-a25be889675b">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a3cb34cfce4c28be127d8715fd26f5_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtNC0xLTEtMTY5NjA4_c7947b2b-577d-4365-8f76-181dc43413de">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8dabfb23996479799c6a595815ba441_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtNi0xLTEtMTY5NjA4_5c375681-4e4e-4442-83e1-0940ddae39b5">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItMi0xLTEtMTY5NjA4_1e2f4cf1-0d43-4b24-b350-3d25bcca562e">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItNC0xLTEtMTY5NjA4_26d7e1b9-b694-41ed-b672-f61eda8bdf63">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItNi0xLTEtMTY5NjA4_6d7fd28b-f444-4303-b4f3-d9ef5af5fd6b">773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtMi0xLTEtMTY5NjA4_c27e8b41-dbf7-4232-9b45-469ce6e77318">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtNC0xLTEtMTY5NjA4_14b344e0-282a-4488-82ed-1fdafdb30bcc">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtNi0xLTEtMTY5NjA4_4f447966-23af-45c6-937a-bdf749ab9ec7">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb60c46f2cd493491ad50061773a9d2_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtMi0xLTEtMTY5NjA4_12cc80a6-88fc-49cc-b9c2-ab98362f444e">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14bc647bd66490ea555f0a1a8e9d50f_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtNC0xLTEtMTY5NjA4_7562cb25-5ef1-48f7-89f2-da740ce39210">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a3cb34cfce4c28be127d8715fd26f5_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtNi0xLTEtMTY5NjA4_98bc3132-def1-4eaa-849c-b53782560d53">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. In 2022, the valuation allowance decreased $<ix:nonFraction unitRef="usd" contextRef="icea89cae1b5a49169da66c58b3a977ca_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzI2MDE_6952d062-a285-41c3-a178-c490ffba1cb8">199</ix:nonFraction> million primarily due to book taxable income in Canada and the expiration of tax losses in the United States. In 2021, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i5d8f4b7199a04a1bb0f06da2481be68c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwOTk1MTE2NDE1MjM_4c94888e-9810-4a34-9aa1-22230d572692">30</ix:nonFraction>&#160;million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $<ix:nonFraction unitRef="usd" contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM1Nzg_4c609c4d-9ec8-431f-9549-136bab2fa053">5,878</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3502a33c4974412bb446b4520804d72c_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM1ODU_2f0e2ab7-7749-4515-ac41-10865ee4eb93">6,669</ix:nonFraction> million, respectively.&#160;As of December 31, 2022 and 2021, unclaimed ITCs available to offset future federal taxes in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM2OTk_6f01d275-c0f5-4ce3-925d-c65ab450c710">27</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3502a33c4974412bb446b4520804d72c_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM3MDY_a22de730-1a59-4e97-9287-c55a871530b3">31</ix:nonFraction> million, respectively, which expire in the years 2023 through 2043.&#160;In addition, as of December 31, 2022 and 2021, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="i23665fcb8d984723906982059409b87d_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM4OTg_84c849ac-955d-4188-b066-173d105fcec4">188</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cac628e4a8a43a0a0981c64688ec2f7_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM5MDU_530bccd5-f600-4178-802a-159be3c51c87">196</ix:nonFraction> million, respectively, which may be carried forward indefinitely. As of December 31, 2022 and 2021, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $<ix:nonFraction unitRef="usd" contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQwOTI_ba4552b6-8a74-48b7-96f7-153c6042189d">1,869</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3502a33c4974412bb446b4520804d72c_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQwOTk_8b2b1576-b753-4e0e-b293-59b2b2ca205a">1,965</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; federal taxable income in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="i0c140b9741d2496b919924cb9b494679_I20221231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQyNTY_0918cfba-3004-453d-b295-033fce5a268c">241</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQyNjM_d5f2dcb0-2478-410b-bd05-f3ca0940881a">266</ix:nonFraction> million, respectively, including acquired losses which expire in the years 2023 through 2033. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2022 and 2021 U.S. research and development credits available to offset future years&#8217; federal income taxes in the U.S. were approximately $<ix:nonFraction unitRef="usd" contextRef="i0c140b9741d2496b919924cb9b494679_I20221231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQ3NjE_096fab7a-fc84-4e15-8f31-48aac9763ec9">75</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQ3Njg_a3df2d44-3190-4c7e-88cf-bc1e6930ab65">119</ix:nonFraction> million, respectively, which includes acquired research and development credits and which expire in the years 2023 through 2042.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $<ix:nonFraction unitRef="usd" contextRef="i0a9bffc500cd4f18857b951c1603f412_I20221231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzUxNjc_b27bc2ec-3194-4c71-9b17-c7643bb32190">10,691</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie76d6ec50d164eb3bcb9478a77019aa0_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzUxNzQ_8c0253fb-7d67-466d-a31c-84ac88c63565">10,040</ix:nonFraction> million, respectively.&#160;As of December&#160;31, 2022, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2022, the Company estimates that there will be no tax liability </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if0963dc090794ba38c60cc0362637ad0" continuedAt="i089514ef5ca847f187e5df77353bc7cd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to unremitted earnings of its U.S. subsidiaries. However, future distributions could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, unrecognized tax benefits (including interest and penalties) were $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5MzE_0c6ffec4-f01b-46f5-bfa6-0d6aa6a3be7c">881</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5Mzg_3a0bc9ab-653e-4b73-a423-31404383b53b">927</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5NTE_9b4e12b0-9878-42de-bb5a-026a98d2ef69">384</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5NTg_d5265a79-97c4-4a6a-91ba-73d4c20f0b78">217</ix:nonFraction> million would affect the effective income tax rate, respectively. In 2022 and 2021, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2022 and 2021, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzMTY_8a4ecd58-2320-42ee-9fdb-44ed90505791">156</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzMjM_82f233cd-6cda-41ba-9a5f-0ac8c585c462">79</ix:nonFraction> million, respectively. The Company recognized a net reduction of $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzODQ_18bec631-c514-4e5c-8476-03e44dcccfbb">203</ix:nonFraction> million during 2022 and a net reduction of $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY0MjA_6174f832-d6ee-4c75-9d87-48999476c910">177</ix:nonFraction> million during 2021 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2022 and 2021, accrued interest and penalties related to unrecognized tax benefits were approximately $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY3MzQ_9265885c-8b8e-469a-a800-718f1fb41400">32</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY3NDE_e7a18268-c324-49cb-8235-cb04c2802967">41</ix:nonFraction> million, respectively. In 2022, the Company recognized a net decrease of approximately $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY4MjE_f9d9a260-4aa5-4a1f-a571-e0031457bf6e">9</ix:nonFraction> million and, in 2021, recognized an increase of $<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY4NjM_013f2d52-2554-4570-8ed1-54d7ef5c2464">8</ix:nonFraction> million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and <ix:nonFraction unitRef="subsidiary" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY5MjM_b4f5cc57-fc26-4ee3-b7d5-37ef99f18bc0">one</ix:nonFraction> or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2013 to 2021, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODE1_7347ea08-4a0f-48c4-8c49-1f0542a1cabd" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:82.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id57f6448d77d4f498fcb2c7411041826_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmNlZGM4MGQxMGE4NDVjZTkxZWU1OTMxODdiYTliNDNfNA_cb189b5b-6541-49fc-ad10-413335d487a4">2015</ix:nonNumeric> - <ix:nonNumeric contextRef="id573807c0c8f4975a352cd6f593b3ab3_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmNlZGM4MGQxMGE4NDVjZTkxZWU1OTMxODdiYTliNDNfOQ_5df252ab-ed64-43f9-b955-6039b90ce1f4">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib8aa63b12662497fb48a3704825ff944_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDg4ZjRlOGYxM2I5NDI4MWEzODEzZGI2Yzc5MWZkNjBfNA_5af39ebf-9012-4d0b-b37e-051f0004aea4">2012</ix:nonNumeric> - <ix:nonNumeric contextRef="ifd9c4983bcb5449091d89286c6560f44_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDg4ZjRlOGYxM2I5NDI4MWEzODEzZGI2Yzc5MWZkNjBfOQ_819ad7ca-8bbc-47c0-a3d4-bc3e9af61e33">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifb5e7e6a6a4b4b2fbad5eb1887c77136_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MzcyNDQ5YWJiNzc0NDFiYmJmMzYxM2NkZGUxOWFjOWRfNA_6be47eae-0cdb-443b-a9d9-33be7267563f">2014</ix:nonNumeric> - <ix:nonNumeric contextRef="i0a938ef7652a479b9208cc583c1cbeaf_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MzcyNDQ5YWJiNzc0NDFiYmJmMzYxM2NkZGUxOWFjOWRfOQ_9fa67ed6-cfc5-4534-8f72-10de3cd6c1a2">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf4cab1a9a354692a1713dfef6925e58_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NTlkOGE2YTBkYTJjNDMwYmIxMmFiMGNmOWM3Mjc1YmRfNA_1dc88ddc-edf4-4f0b-90eb-2c56e44b8846">2013</ix:nonNumeric> - <ix:nonNumeric contextRef="i01997882e0124cea82496489c90aa07b_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NTlkOGE2YTBkYTJjNDMwYmIxMmFiMGNmOWM3Mjc1YmRfOQ_826dd5e5-a57f-49ba-baa5-90d17f407578">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cb51eb021dc4b9b8b4658c2bc2a3b97_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzYtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGFkNzBhZDNhZDAyNGQ4Yjk4MTQzMDE3YWZlYmEwMGJfNA_684809db-297e-4aa8-aee2-4961db9fbf72">2018</ix:nonNumeric> - <ix:nonNumeric contextRef="i5e5f1133b38c4d24b01b931471fd8da0_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzYtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGFkNzBhZDNhZDAyNGQ4Yjk4MTQzMDE3YWZlYmEwMGJfOQ_136bb980-ee59-4058-b5ab-e120c242fe83">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89d1dfe888bd45a8883f343b6c477481_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzgtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NzUxZDU3NzYzZTU2NGUzNGIzODVlYWE0OTZkN2RhNTlfNA_a3603a57-9d4a-49fc-bbbd-1d204be1fcaf">2018</ix:nonNumeric> - <ix:nonNumeric contextRef="i5fd1521a412949fbbc1e51c170d1e007_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzgtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NzUxZDU3NzYzZTU2NGUzNGIzODVlYWE0OTZkN2RhNTlfOQ_134c29db-52b6-4e1d-9127-1af9ec945b16">2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16aed0f16ef84c42b74c7c39bd8a6462_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzktMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDY5MmRkYzcxYzNmNDYwNDgxYzdhNGI0YmExMTVjMTFfNA_deaa2ef1-b6c1-4a6f-b5d1-472d85360cf4">2017</ix:nonNumeric> - <ix:nonNumeric contextRef="id96036ac44ae4695a0fb252d5f81f219_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzktMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDY5MmRkYzcxYzNmNDYwNDgxYzdhNGI0YmExMTVjMTFfOQ_4317930e-d642-471b-a8ed-3593b6c73332">2021</ix:nonNumeric></span></div></td></tr></table></ix:nonNumeric></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#8217;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#8217;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company has contested this proposed tax deficiency through the IRS administrative appeals process, and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision has been recorded as of December 31, 2022. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU0OTc1NTgxNjMxMTU_98901891-ae3f-4d52-9784-286dd72855ee">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, as part of an alternative dispute resolution process with the IRS, the Company has reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized. The Company expects that the tentative settlement, if finalized without further modification, will affect the Company&#8217;s 2023 income tax provision, and while such settlement may be material to the Company&#8217;s results of operations or cash flows in the quarter in which it is recorded, will not be material to its results of operations or cash flows for the year ended December 31, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017. The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2023. The Company settled the tax years from 2005 through 2009 with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i089514ef5ca847f187e5df77353bc7cd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced net operating losses with a full valuation allowance by CAD <ix:nonFraction unitRef="cad" contextRef="ia889587b544748498683a9f94901e27e_I20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzk5MzI_67433a6a-0886-4aa2-9443-189c8471fb96">44</ix:nonFraction>&#160;million to close these years. The adjustment did not result in a material change to the provision for income taxes. The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD <ix:nonFraction unitRef="cad" contextRef="ie4f2bc454f0c4e1ca352bcd59e982748_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwMjQ5_bb6efc04-8749-4ce1-a74d-3d6dfeb34214">85</ix:nonFraction>&#160;million and CAD <ix:nonFraction unitRef="cad" contextRef="i4a9234e9d2a34cee8234f5493a02f5a8_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwMjYw_0553598f-07e8-427a-b38c-8903bfebc8ed">90</ix:nonFraction>&#160;million, respectively. The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013. The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD <ix:nonFraction unitRef="cad" contextRef="ic35b381adaa44c21ae46f412455f4ded_I20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwNTI2_f6188010-2e3d-4849-a262-d35ec8426676">21</ix:nonFraction>&#160;million for 2015 and CAD <ix:nonFraction unitRef="cad" contextRef="ibeb1927f7b53477f9d023db6485f371a_I20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwOTk1MTE2NDYzNDE_b217a18c-f47a-44cf-924b-149b9fa38931">23</ix:nonFraction>&#160;million for 2016. The adjustments for 2015 and 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022 the Company&#8217;s affiliate in Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#8211; 2019 for &#8364;<ix:nonFraction unitRef="eur" contextRef="i29b848aa660941a6becd4eec0de3f15d_D20221108-20221108" decimals="-5" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzE2NDkyNjc0NjU5NzQ_d008b8b8-5888-4eae-b97f-9e2a46cc73c0">271.7</ix:nonFraction>&#160;million. The Company is vigorously defending its position and no reserves have been recorded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia were under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office (&#8220;ATO&#8221;) issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="iab5fbd88668641d49bf8a11320bf0006_D20170808-20170808" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzExMTg1_48335a78-4276-479e-8789-e2fef88fdf62">117</ix:nonFraction> million, which includes penalties and interest. On April 13, 2022, the Company and the ATO entered into a settlement agreement resulting in an immaterial income tax provision.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzgx_fa5d0f44-940a-422e-b9bc-fda8f3e6c0d1" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2022, 2021 and 2020: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtMi0xLTEtMTY5NjA4_16ccc533-2bbe-47fd-ad69-eb8967a99900">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtNC0xLTEtMTY5NjA4_9dbbfcb8-9868-4a1f-ad00-ecf541fe54b6">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtNi0xLTEtMTY5NjA4_8f6d0cca-090c-49cf-993f-eeda893afe62">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItMi0xLTEtMTY5NjA4_d92caf58-c8a6-47e8-9755-0ca52eeef421">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItNC0xLTEtMTY5NjA4_936c68cd-ceb8-4a9d-adc6-c6b10c0d7a9d">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItNi0xLTEtMTY5NjA4_d0109bcf-4ec6-46e5-9ebe-2c30b90741f7">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtMi0xLTEtMTY5NjA4_aa7f473f-cada-4879-b8f4-da2def487a37">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtNC0xLTEtMTY5NjA4_455dd88d-3752-488b-8d36-4a8a3d352238">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtNi0xLTEtMTY5NjA4_871bf353-fabd-4512-807e-0322f854f5b0">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtMi0xLTEtMTY5NjA4_edf90b9c-57e7-474d-9a01-4d98a207317e">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtNC0xLTEtMTY5NjA4_8932a581-47fb-4c5a-b03a-755132b4649f">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtNi0xLTEtMTY5NjA4_5eda09cc-448b-4098-bdd6-7783d1ea09a8">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtMi0xLTEtMTY5NjA4_12c1fab9-0baf-466d-a898-59cd496c69c9">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtNC0xLTEtMTY5NjA4_cb1436dd-9144-4d6d-bfb5-0e20a446cb93">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtNi0xLTEtMTY5NjA4_25e9df86-0643-4b1f-9b15-fc4c5bcdf5d3">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtMi0xLTEtMTY5NjA4_efce9ce9-0394-4b2f-8e24-0853f47d1e1d">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtNC0xLTEtMTY5NjA4_7af63ca7-9401-49d7-98f6-e2cffccfe299">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtNi0xLTEtMTY5NjA4_35cf76bd-9450-4dad-8950-0ae97deebb69">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December&#160;31, 2022 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNjYz_c2836cf6-e5fe-4057-93e7-2d3a82febb5b">4</ix:nonFraction> million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_367"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwNDA_ba63cbcd-99b2-4b91-98ee-b18848237daa" continuedAt="i42d8a8a505bd46459ea23477a6f8625b" escape="true">LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i42d8a8a505bd46459ea23477a6f8625b" continuedAt="i53d50986b0384facb983e965ea2ad5b7"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwMzg_c9922600-77ae-449d-91b3-aa1301e5c675" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2022, 2021 and 2020 was calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtMi0xLTEtMTY5NjA4_8ea1f604-1aaa-4470-82eb-ac94b050d2c8">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtNC0xLTEtMTY5NjA4_e31521bb-1047-4a47-b2ed-5ae8bfb7d3b4">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtNi0xLTEtMTY5NjA4_be38cbc2-1c48-413b-a40d-9615898c575b">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItMi0xLTEtMTY5NjA4_467e5c95-13cf-4fb9-ad59-a24399b0be88"><ix:nonFraction unitRef="shares" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItMi0xLTEtMTY5NjA4_a1254015-0ee6-4f31-9e77-10fc39961c87">362.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNC0xLTEtMTY5NjA4_882dbe33-8b46-4adc-8d2f-bf25fec84a27"><ix:nonFraction unitRef="shares" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNC0xLTEtMTY5NjA4_f8709c2d-accd-48a5-a9b1-d51fc14ac6ef">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNi0xLTEtMTY5NjA4_30c06caf-655e-4111-a354-86ea2e527f4c"><ix:nonFraction unitRef="shares" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNi0xLTEtMTY5NjA4_65a891fa-0feb-4019-8627-3e2058670499">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtMi0xLTEtMTg5MjM0_074dedc6-4b93-4795-a2d1-9158444fa194"><ix:nonFraction unitRef="usdPerShare" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtMi0xLTEtMTg5MjM0_f1d23e70-0535-4a34-8a83-8e16d3366c7d">0.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNC0xLTEtMTg5MjM0_020ba721-cbbd-416b-8342-77e1a07b9c0a"><ix:nonFraction unitRef="usdPerShare" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNC0xLTEtMTg5MjM0_6157e492-a4d2-43da-a9c6-4fc459813e4d">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNi0xLTEtMTg5MjM0_2454d3cd-d555-49aa-97ff-1692159134fa"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNi0xLTEtMTg5MjM0_a9e8d7fd-813e-4f30-9172-1e9f74ede8df">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i53d50986b0384facb983e965ea2ad5b7"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwOTk1MTE2MjkwMjk_b88ddfd1-122a-4246-849e-ba6fdf5f3fbc">1,851,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ie20353a11f9f453cbff47b23ba9b5303_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzQ5NA_91222532-b6ba-4153-9670-fc598cd49823">4,932,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i32c1ed23b8494ad19285b0fa18785f85_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzUwMQ_e49f525b-8d4d-4c20-9c76-3ce1b1f5992f">3,154,000</ix:nonFraction> common shares for 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2022, 2021 and 2020, stock options, time-based RSUs and performance-based RSUs to purchase approximately <ix:nonFraction unitRef="shares" contextRef="iee43a25eaadf4d2d863f02a387856a5a_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY0NQ_8f6ae0af-231e-411e-b623-56ff29c5f044">14,396,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i9a3b000967c54376bcaa8d1227ab2fc7_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY0OQ_bf905067-c3ff-41c6-ab4c-dcf7bcfc70e5">3,428,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i89e7a814f74a4ae5ac92920a38079cc6_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY1Ng_cb71fd26-b31a-4d9e-8670-250a8e348b81">9,551,000</ix:nonFraction> common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2022 and 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i3dd34d570f3b45a0a89bc7b370627a8f_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzg3OQ_a10f02f1-83c1-4186-8be9-353ea4fab73e"><ix:nonFraction unitRef="shares" contextRef="iafb1e399c6334b55a693b8c539d5389b_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzg3OQ_d8721dda-8aa2-404b-8e0f-935d1d28fef9">156,000</ix:nonFraction></ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_370"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90ZXh0cmVnaW9uOjNkZjJhNWMyZTJhNDQ0NGM4MTJmYzg5NGJkN2FjMTA1XzY2_b77b54db-27b3-4a4f-9eca-f201a9056afa" continuedAt="ie1023052b69940c1bf2ecca6e8446cd5" escape="true">SUPPLEMENTAL CASH FLOW DISCLOSURES </ix:nonNumeric></span></div><ix:continuation id="ie1023052b69940c1bf2ecca6e8446cd5"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90ZXh0cmVnaW9uOjNkZjJhNWMyZTJhNDQ0NGM4MTJmYzg5NGJkN2FjMTA1XzY4_bc33241d-db7e-4222-8c65-8e7702b98989" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2022, 2021 and 2020 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItMi0xLTEtMTY5NjA4_060af702-a261-4b4d-989f-51c2d5016047">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItNC0xLTEtMTY5NjA4_e8802f41-77ba-4dd6-8578-475ef6608e69">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItNi0xLTEtMTY5NjA4_b63cb000-2697-465c-bcc1-a568b941a3ce">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtMi0xLTEtMTY5NjA4_66c08988-6c1f-4f61-ac50-13fc1f42fbdd">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtNC0xLTEtMTY5NjA4_01440dee-4592-40c3-a68c-24c06dca5c1d">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtNi0xLTEtMTY5NjA4_d4762bb2-6810-4fe4-b4da-703970ca7691">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_373"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxNDE_30a3456a-5804-4d12-a692-c8d658ba2319" continuedAt="ic35b99f0eae54de2b012fb95e80d0e9b" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="ic35b99f0eae54de2b012fb95e80d0e9b" continuedAt="i5681caa2ec72493184ef01754369175a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company&#8217;s subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:LegalSettlementsAndRelatedFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDQwNjc_12124347-671e-420d-8b28-6b7bb1f2d8a9">326</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. In February 2023, the Company&#8217;s subsidiary OraPharma, Inc. entered into a civil settlement agreement with the Department of Justice fully resolving this investigation. Under the terms of the settlement, OraPharma, Inc. has paid a settlement payment of $<ix:nonFraction unitRef="usd" contextRef="i20c9837df7684cbbb933fd9a731877c7_D20230201-20230223" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzU0OTc1NTgzMzg4MTE_dc4c7955-9c97-420d-b766-f03c838dbfb8">100,000</ix:nonFraction>, plus payment of additional immaterial amounts in applicable interest and other related costs, to resolve the civil False Claims Act (&#8220;FCA&#8221;) investigation. A related complaint brought by a former OraPharma employee pursuant to the FCA and certain state statutes will be dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Iowa &#8211; re OrthoDerm</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#8217;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Siliq</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is cooperating with this </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5681caa2ec72493184ef01754369175a" continuedAt="id6990d8d92194dda977509fbe6223dea"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1MzM_2c1ff0d6-08ee-42b6-93e4-10c94c3ac8e8">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1NDI_257371c9-37e5-491d-bd35-3b10cd6e52db">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="icae732543b524862bc31fb3dbb9b61d5_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1NTI_ea064ae8-ed19-47f3-9ced-645d8249784e">1,210</ix:nonFraction>&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#8217;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1Njc_5ec17d72-657d-4877-bea2-254356af5ee1">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034) (&#8220;T. Rowe.&#8221;); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127) (&#8220;Equity Trustees&#8221;); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128) (&#8220;Principal Funds&#8221;); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212) (&#8220;Bloombergsen&#8221;); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id6990d8d92194dda977509fbe6223dea" continuedAt="idb1093c9feab449c9568d895f5293ffc"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488) (&#8220;UC Regents&#8221;); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190); Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478); USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462); and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460). <ix:nonFraction unitRef="case" contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4OTY_1ef00f0c-6ae1-42a9-895a-9eba20c7690d">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5MDk_f160a83f-6402-4471-9005-fc899602aab6">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5MjY_b1db8f6a-2454-42c1-9628-6abd17be366c">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="iea1d9d4e5a1f4370a7144323d17979c8_D20160101-20161231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1ODQ_46773d84-f5a8-49d7-acda-b01ba21d5913">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="idb1093c9feab449c9568d895f5293ffc" continuedAt="i36d83d53affb434281a62f6610bb2ce0"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015) and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). The Company is also aware of <ix:nonFraction unitRef="action" contextRef="i99a775a1f0484870a58370f98e7e7bd6_D20220101-20221231" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1OTY_01f61783-76c2-47c9-a6a4-7b2650c8f304">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015) and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="i7097559c54d642c9938d351b2479cbdd_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MDU_ccdd62f6-6c43-4ec6-a8f3-5abf284d722f">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i1dbd4359a33044d39494365672dd2a82_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MTY_c45976fc-02de-4d36-ad36-1c4921380753">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i36d83d53affb434281a62f6610bb2ce0" continuedAt="ib769fe9fa4754d2eac785c08e07458bd"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="number_business" contextRef="i134d05f75047419881c27f05c3e5188c_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MjQ_e810f57a-aadd-4bd4-bf72-42258edf853a">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="i6a47c7281a5a4ca797223076080e2992_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MzM_744b583d-ee18-4e7d-8b97-14e4e15e9109">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="ia24e6b01a46e406cbeeb1ee5f895c977_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NDM_b5ddc7fa-d7b5-41ca-ac55-ed8a1a26da5d">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="id939f2c8095a466db826592c2f72f9f7_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NTE_b71510d6-33bb-4959-abde-725b4175fa71">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="id939f2c8095a466db826592c2f72f9f7_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NTk_5f3cd8ab-a9d3-4c2c-95c2-63897ee40d0b">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="ib4df41256cea4da189ae84ef1efc2dde_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDIzNTQ_3d6457cf-718b-45d2-a6d0-53b6ab1cb208">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib769fe9fa4754d2eac785c08e07458bd" continuedAt="i8b61e75a84ae4b889442728948df82d3"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="idb9217417cee498197ad26aaa5c98390_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2Njc_067e5d7a-73a6-418e-8bc2-1d81cf3143c6">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i34b9f8ec08464feea2782555631f70ea_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2Nzc_fcff3032-4854-46e4-ab14-1b0ff84fb685">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="i0963b261572a4ed8bec2d26c9a930742_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2ODY_be20f1db-7bd1-4e04-9770-61e6a87235d6">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="i8c21c165a2814f47b755c7aa53f9e73f_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2OTc_987e4817-ce73-4da4-bd9c-dfbc7ab83078">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i7f8128027f2f4ab58c24767a783dd7af_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI0MDQ_282949d7-e871-4871-a7ab-27dcd70c4dc3">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8b61e75a84ae4b889442728948df82d3" continuedAt="i6fb494937e244d588743f7c0c63fd744"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#8220;Consolidated State Case&#8221;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200 mg and 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Colazal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="id79311217c224c53ba11bdccb33324d8_D20200326-20200326" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3OTg_4d9ed478-12b2-4589-9ec0-7fbed2bf6f46">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 27 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i6fb494937e244d588743f7c0c63fd744" continuedAt="id0bd033d0991442c9bf7a1fc1381d9d9"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10, 2022, (the &#8220;Norwich Legal Decision&#8221;), finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#8217;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#8217;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="ifea8d20caee843099f9d0591402372e4_D20200828-20200828" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MTA_fc46fb6c-c9b3-4e05-b16c-f734ad940a56">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a <ix:nonNumeric contextRef="i278dafa9c31e41f38e93fbc21fe0ffb0_D20220721-20220721" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MTc_fc49ebfd-ef66-46b3-987f-21f5f2ffcc46">30</ix:nonNumeric>-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a <ix:nonNumeric contextRef="idf27d74757bd461caae17e74579bbe7f_D20200501-20200501" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MjY_5502feb1-83cf-49b1-b29c-4fe9ed5967e6">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a <ix:nonNumeric contextRef="i65a96a0fece84234b0dc8fea3877eca8_D20210401-20210430" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5NDU_fae3761c-3e5b-4b2a-a282-9a4935529761">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#8220;Auro&#8221;) alleging patent infringement by Auro&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id0bd033d0991442c9bf7a1fc1381d9d9" continuedAt="ia8ae9ddc889b44a29f22d07fc71788df"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#8217;s generic plecanatide tablets, 3 mg.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The filing of this suit triggered a <ix:nonNumeric contextRef="i08ebb4f96f1c4839a1c7d994f5ba8dce_D20230101-20230131" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MzE0ODE_c3346ca0-8e39-424e-adca-cbbc5e6a2f81">30</ix:nonNumeric>-month stay of the approval of the Auro ANDA for plecanatide tablets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against <ix:nonFraction unitRef="defendant" contextRef="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MDk_0449c0d1-4186-4e1b-b939-07f6b2510e49">19</ix:nonFraction> named defendants in <ix:nonFraction unitRef="proceeding" contextRef="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfProceedings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MTM_c064fe4c-c79d-4d94-a701-a5d824715d68">16</ix:nonFraction> proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. <ix:nonFraction unitRef="defendant" contextRef="i125a5a3114cb4f8f806bb33e49ba3344_D20220101-20221231" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MTY_6a17bf25-62a1-4822-92c9-3978276d0d06">Twelve</ix:nonFraction> of these proceedings were subsequently settled; <ix:nonFraction unitRef="defendant" contextRef="i8c4a7cbf453c49c3960027b1664103fb_D20220101-20221231" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3Mjg_19438be5-ff74-43b7-8454-054d3ce05ad5">two</ix:nonFraction> resulted in a default. As of the date of this filing, there are <ix:nonFraction unitRef="defendant" contextRef="i25f029dc1a644b39abdd1b72ba3c573f_D20230223-20230223" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NDg_045aeefd-7bfd-4827-b0a4-4a419338c1ca">two</ix:nonFraction> ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i4097e666fef649debbac3e331a2e144b_D20210910-20210910" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NTc_8a1261c0-41a9-44e2-b80d-c5588993ae77">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="ie319856acc814519a20ff1bbd24232a7_D20220202-20220202" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NjU_1d86fbb1-6448-4c93-8950-9b6bd817e4a3">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ia8ae9ddc889b44a29f22d07fc71788df" continuedAt="i37b4a04f08d84bf2b71cd6351e32ca4b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. <ix:nonFraction unitRef="lawsuit" contextRef="i70dad8274b624fa288d5880f291cefaa_D20220101-20221231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MzIzNTM_fc01fca1-5d9f-47c4-8c0e-ba1d0c216765">Three</ix:nonFraction> lawsuits are pending in Canada regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Apotex Inc. and Pharmascience Inc.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#8217;s IPR and joining it with Mylan&#8217;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#8217;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#8217;s petitions.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-six (<ix:nonFraction unitRef="case" contextRef="id902c97014ef4d54ad1d3eccc0cc5fa5_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3OTE_354b5719-6315-49d1-969a-73940c8bf59e">26</ix:nonFraction>) of such product liability suits currently remain pending. In <ix:nonFraction unitRef="case" contextRef="i24bd15be9a6b4930b6fa4d6deae79314_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MzU_14801e72-f699-498e-8983-5ba06f8b497e">three</ix:nonFraction> (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-five (<ix:nonFraction unitRef="case" contextRef="iaacdad21d98743ffac6109a55707e12d_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NDg_e2059e80-498c-48c1-b469-198ab4494ad2">25</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="ia3ed2bf0eb0249fdbb1fea6f1bf3256d_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NTE_5b482476-9d39-49c6-8ebc-500e2e7ca380">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="i4ec102f85ef9435f9389768c72affe6d_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NjI_07df151e-361b-4072-b219-998759539541">one</ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="i8b1a585708ab453a905d7caaf12d2868_I20221231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NzA_6fe66af7-4f94-47d2-bfd5-c9e96f85694d">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (<ix:nonNumeric contextRef="id6fd7f81bf2c4837ae0cd2c5aeed8804_D20211101-20211130" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4Nzk_3a080792-b788-4024-a740-b3afb6d8acdc">60</ix:nonNumeric>) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i37b4a04f08d84bf2b71cd6351e32ca4b" continuedAt="idcfe8718328549c18b3254a24786ce41"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a motion in the Bankruptcy Court to extend the <ix:nonNumeric contextRef="ie4bb3b3e1cbc48a8a7d48f7ba06845e6_D20211201-20211231" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4ODk_a4552aec-acdf-40aa-883a-990ff56e238f">60</ix:nonNumeric>-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#8217;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL has filed a petition for rehearing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the Third Circuit. If the bankruptcy case is ultimately dismissed, the Company&#8217;s position vis a vis J&amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pendency of the appeal, the Bankruptcy Court was considering competing motions by Debtor LTL to extend its exclusive period to file a chapter 11 plan and the talc claimants to terminate LTL&#8217;s exclusivity. In light of the Third Circuit&#8217;s decision, on January 31, 2023, the Bankruptcy Court adjourned any hearing on the exclusivity motions to March 20, 2023.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#8217;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#8217; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#8217; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#8217;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. That motion is pending. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="idcfe8718328549c18b3254a24786ce41" continuedAt="i40822e74860d4b2ea4c44ddf2fa2b2d4"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp; Johnson requested the court afford it sixty (<ix:nonNumeric contextRef="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxMzM_b4acb6f5-28a0-4479-aff5-9c885ab1a4bf">60</ix:nonNumeric>) days &#8211; until April 18, 2023, or seven (<ix:nonNumeric contextRef="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxNDM_a3f38de2-fb5b-4750-b2c4-1b99d6a1145b">7</ix:nonNumeric>) days following any lifting of the LTL Bankruptcy Court&#8217;s preliminary injunction &#8211; whichever comes earliest &#8211; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="i808a1d4b464940449c1d6cc1d68d3e33_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI5NTY_f3b9a00f-3a77-45f7-9411-af7e0dc8df84">23</ix:nonFraction>&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i40822e74860d4b2ea4c44ddf2fa2b2d4"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="ib662b0cd90234eab9ce6b4ef74639960_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI5NDM_9426bbb2-9985-4b03-825d-af34235c1cb8">30</ix:nonFraction>&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div></ix:continuation><div id="i57fbe32677504c888f142dd82b99b37f_376"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzQ0MTE_d2032fa9-dd48-4f81-ad84-17717275d211" continuedAt="i8a31d55b6eeb48a78609d54aff707ec5" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i8a31d55b6eeb48a78609d54aff707ec5" continuedAt="i4e96f3acd4cd40f08048796cf55a5606"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzg2_0a4c9b25-84c3-4a92-a9d0-f65a2af95d2e">42</ix:nonFraction> million as of December&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2022, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $<ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzQ0OQ_01408d9f-01bc-49c8-84d7-9de1d561c15d">250</ix:nonFraction> million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="idfa7f0c978d24ea089c5cb9062c953d1_I20221231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzkzNg_09488b62-5c46-4f38-9327-880cc355489d">35</ix:nonFraction> million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $<ix:nonFraction unitRef="usd" contextRef="ib717bd3b56334329b39872e4c89c7193_I20221231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzE0MjE_dac4b518-15aa-4e3d-afac-7a0c736cdd81">60</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, Bausch + Lomb has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i45faea11a7064b63813ba6b35593aff5_I20221231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzE5MzY_ee579529-a420-4076-8b55-f5630d9fec69">48</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., Bausch + Lomb has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i88b39b3e635847789adf70ed040317c0_I20221231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzI5NjI_d9b650cc-75a5-43cc-9ecf-381711802744">35</ix:nonFraction>&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), Bausch + Lomb may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2022, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4e96f3acd4cd40f08048796cf55a5606"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-81</span></div></div></div><div id="i57fbe32677504c888f142dd82b99b37f_379"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NTE_1ff2f85c-2ba3-4d80-958b-5e79bbe8a764" continuedAt="i8bc1d9b91fe249d7b28c7d14d6189f36" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i8bc1d9b91fe249d7b28c7d14d6189f36" continuedAt="i6fe34d6621b24e07bd989c87d89c9a3a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately <ix:nonFraction unitRef="number" contextRef="if1daf50b967543b5947399752d3b8bb1_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzU0OTc1NTgyNjY5Mg_3cd0e056-49a1-4ae1-b14a-eb0e97547695">80</ix:nonFraction>% of the Salix segment&#8217;s revenues.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical (&#8220;Solta&#8221;) aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NzI_353b9217-5b3b-4ce7-88ca-ed247d2d355f" escape="true">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="i6fe34d6621b24e07bd989c87d89c9a3a" continuedAt="id152d255ea6e41e8adf3f170694d27ae"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MjI_6514a5e6-4242-4999-b92f-3fa0d344f09b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItMS0xLTEtMTY5NjA4_2d2141e8-311a-40ee-9428-be0239cb7a35">2,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItMy0xLTEtMTY5NjA4_a0470d7a-8741-487f-aa93-e79e4c6bb85d">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItNS0xLTEtMTY5NjA4_3ad318e5-a0e2-46fd-921b-e75d2c1be5f5">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtMS0xLTEtMTY5NjA4_cd598e9b-c928-40f8-a59f-28be48f9ff6c">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtMy0xLTEtMTY5NjA4_bce2d264-296f-4760-b6c7-a56646725bfd">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtNS0xLTEtMTY5NjA4_9f63cb68-46a3-4d63-a66e-18aeb78fe2bd">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtMS0xLTEtMTY5NjA4_744d4373-8e8d-433d-88ee-460cd0fe1df7">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtMy0xLTEtMTY5NjA4_a90f02cc-4475-4e58-a8c6-47509e469a3b">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtNS0xLTEtMTY5NjA4_b97d3b0a-8f0b-489e-8193-c32cf1928911">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtMS0xLTEtMTY5NjA4_f007682e-71e0-4a42-93ca-6823de64db04">978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtMy0xLTEtMTY5NjA4_7b0e7aa7-11d5-430f-a50a-3e22b279be18">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtNS0xLTEtMTY5NjA4_70e95b04-bb3c-47ae-be23-341e69bb7e02">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtMS0xLTEtMTY5NjA4_399e2eff-2b87-4ea0-bfe7-bec0083737d6">3,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtMy0xLTEtMTY5NjA4_4dde6088-a88b-4451-a9c8-9e1cb972c7e0">3,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtNS0xLTEtMTY5NjA4_6cbf50e8-8d34-4b0a-91e6-8bc429de9d65">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctMS0xLTEtMTY5NjA4_e0bea19a-1419-4292-9d17-e73eefaaeea7">8,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctMy0xLTEtMTY5NjA4_38619838-c51e-4ce9-8980-e41ae1df7180">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctNS0xLTEtMTY5NjA4_0aba59f8-5af2-48a4-b9a6-a1e9fbfd9e8d">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktMS0xLTEtMTY5NjA4_66ded7fb-3838-4339-8fb1-10e27f6c831b">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktMy0xLTEtMTY5NjA4_9c0edb9a-88ce-488f-92d2-3866601f7f5c">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktNS0xLTEtMTY5NjA4_9b8d2075-b8d8-442c-ac63-63dc1c5738be">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTEtMS0xLTE2OTYwOA_eb1edc76-aa82-4479-a811-2f3dfb1fd460">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTMtMS0xLTE2OTYwOA_ed3c5a3b-ea08-4498-9ead-c66500994dd4">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTUtMS0xLTE2OTYwOA_25fa2dee-7a6e-48a2-aae2-026d2cef8574">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTEtMS0xLTE2OTYwOA_8cbb4887-c9c7-4842-aaeb-841a44778f77">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTMtMS0xLTE2OTYwOA_c65e4b23-99c7-4574-b771-a99317c08b10">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTUtMS0xLTE2OTYwOA_6362bf10-6fdc-400b-9891-4a1bfda284f9">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTEtMS0xLTE2OTYwOA_d1f2915c-ee7e-4567-b2cb-1e8d50f83d20">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTMtMS0xLTE2OTYwOA_f79e578e-d7d6-4a4a-9160-2b9d191cb7c4">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTUtMS0xLTE2OTYwOA_e9ebe814-e26e-4765-86ab-624b89d7a5d1">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTEtMS0xLTE2OTYwOA_8003c1bc-bef7-4ac6-ba82-4ab661d9916c">874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTMtMS0xLTE2OTYwOA_ac498412-98fd-43ac-935e-ed8fd57d80c1">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTUtMS0xLTE2OTYwOA_15a0f968-33b2-45a9-ae16-a579d94e3d70">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTEtMS0xLTE2OTYwOA_1f88ae4d-fb83-45e6-9d2a-751f52a8db28">3,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTMtMS0xLTE2OTYwOA_595909c0-f292-40ee-8019-7fe34e0f08b8">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTUtMS0xLTE2OTYwOA_a1edb4a1-6101-4b44-8ac2-e1f48883c58d">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTEtMS0xLTE2OTYwOA_efdeca8e-d4e2-4eac-bcda-f02edfda416b">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTMtMS0xLTE2OTYwOA_f50f3e0f-ff02-4f32-a163-1054a5d0a3ba">792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTUtMS0xLTE2OTYwOA_c6287f58-5b4e-468f-901f-2a4f49b29d32">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTEtMS0xLTE2OTYwOA_9b83a5d4-fd6a-46a2-9512-7954db7f61a7">1,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTMtMS0xLTE2OTYwOA_9a026d7f-2655-47dd-885d-162fdede8b47">1,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTUtMS0xLTE2OTYwOA_20c6abd8-3f8d-4af5-abb4-090a0a5685a8">1,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTEtMS0xLTE2OTYwOA_22315776-23f8-4f26-bf86-cb5768f7228a">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTMtMS0xLTE2OTYwOA_8060a5a0-f1fa-4bf7-918a-562eba639e69">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTUtMS0xLTE2OTYwOA_ccb35c74-42dd-4c8a-8ed8-31402575809b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTEtMS0xLTE2OTYwOA_da758daa-bafa-43a4-9fad-667a5000ed4b">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTMtMS0xLTE2OTYwOA_7e800959-84bc-4d8f-a132-d5bff23c4119">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTUtMS0xLTE2OTYwOA_4a2dc598-9ce2-4651-bd14-d16685b8eb46">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTEtMS0xLTE2OTYwOA_4344f246-995f-48e5-8b39-42310a2d901a">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTMtMS0xLTE2OTYwOA_143d671f-9286-4ee5-b9af-e737f81bc190">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTUtMS0xLTE2OTYwOA_afb6b6ba-21ca-4c8f-aade-f2a94a88b138">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTEtMS0xLTE2OTYwOA_ac0e351b-ea6a-4f4d-ad2c-ce4e7cc6fd91">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTMtMS0xLTE2OTYwOA_30eb09c5-8b30-4243-bac7-7a4f5b93609b">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTUtMS0xLTE2OTYwOA_9a041816-bc4e-4031-96ca-6a4f4f18147a">502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTEtMS0xLTE2OTYwOA_6e270776-60b8-4cb7-ac16-6c512aa3c2ac">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTMtMS0xLTE2OTYwOA_6721f330-bfe1-4430-9437-cfd945607ac0">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTUtMS0xLTE2OTYwOA_01ccacfa-6e7b-49d3-aa50-f7d27a710c55">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTEtMS0xLTE2OTYwOA_a3376892-8991-44b4-99c9-03559cb1abe0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTMtMS0xLTE2OTYwOA_ec041ea3-a180-474e-8f90-e31127d78eef">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTUtMS0xLTE2OTYwOA_4027da75-1aaa-44bf-8b9e-06ecbc483fb6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTEtMS0xLTE2OTYwOA_8a26b0f7-f30f-42bf-9e2f-b38bd32658aa">1,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTMtMS0xLTE2OTYwOA_81231e37-5113-41ad-a8dd-bc21af5b5dbd">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTUtMS0xLTE2OTYwOA_0f05711d-c152-4ee7-b6c8-256094283dcf">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTEtMS0xLTE2OTYwOA_054929c9-f86f-4c61-ab38-c2cfadcc3bcb">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTMtMS0xLTE2OTYwOA_f2106b54-c392-43a3-aac2-f73ed52a3d3c">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTUtMS0xLTE2OTYwOA_3187e7bf-ea70-4ed6-be64-86029de8d84a">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTEtMS0xLTE2OTYwOA_7c695501-4f99-4185-a24a-63ff9505ae14">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTMtMS0xLTE2OTYwOA_6d66ca83-3253-48c9-9540-630c68bed3fd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTUtMS0xLTE2OTYwOA_6d48d368-a3ae-48bb-9daf-730b1c1fedf5">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTEtMS0xLTE2OTYwOA_53bbe4ee-e755-48fb-b824-572b4feb8678">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTMtMS0xLTE2OTYwOA_21d6b156-95bd-42e2-a0d0-9f2e728e6d63">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTUtMS0xLTE2OTYwOA_3cd6b60a-bf4b-4f38-8b7a-661ecf592b9a">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NTM_faa90b75-0312-4123-a9a2-4487fa2871ec" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItMS0xLTEtMTY5NjA4_090d7f89-b491-4b6e-9cd2-07b40c8c695d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItMy0xLTEtMTY5NjA4_ee6773d1-d379-48ef-b979-4c79b9839109">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItNS0xLTEtMTY5NjA4_5ee5f39c-4686-4180-bd5d-7e9f808b11d9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtMS0xLTEtMTY5NjA4_ee64fa2a-d9f7-4e82-8afc-ebeb89c07b97">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtMy0xLTEtMTY5NjA4_da69d447-ea56-4402-9083-14261f8d5eec">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtNS0xLTEtMTY5NjA4_331f26c5-154f-4c32-addb-95dcfcc36b6d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtMS0xLTEtMTY5NjA4_54ee21e8-a146-4154-a692-6e270f0ca75b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtMy0xLTEtMTY5NjA4_a001a305-ffe4-4b30-b2ee-4fa013ebafc3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtNS0xLTEtMTY5NjA4_097e3cf4-4f69-48f4-9efd-f83c737f993c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtMS0xLTEtMTY5NjA4_eabbb93e-0bb6-4be5-a9ea-5eeec2b751f6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtMy0xLTEtMTY5NjA4_b7ffb8ee-75d1-461b-b19b-b3a497af1244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtNS0xLTEtMTY5NjA4_dde82acd-e771-4b7d-a9f3-81eb1704bc05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtMS0xLTEtMTY5NjA4_63a1a5d3-80fb-4c5a-890a-64db167873ae">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtMy0xLTEtMTY5NjA4_d3de827b-c4dc-4b39-afd5-9cd5fccb92c3">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtNS0xLTEtMTY5NjA4_039438a0-70ab-4880-a5fd-615e3efc3f94">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctMS0xLTEtMTY5NjA4_16611761-9620-4948-810f-a2cdf517ee27">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctMy0xLTEtMTY5NjA4_7e9ad944-9676-4f1e-9c34-bd806698d304">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctNS0xLTEtMTY5NjA4_a1a91d9a-ba83-40cb-ba24-a494f5eebeff">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtMS0xLTEtMTY5NjA4_994a7c23-4893-43e0-9158-d3232ad2b26e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtMy0xLTEtMTY5NjA4_4a627f21-7e86-4f24-9ce5-e56017a03852">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtNS0xLTEtMTY5NjA4_0ffbe883-b6a3-4da7-a0c8-cd21316b5eb2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktMS0xLTEtMTY5NjA4_d4371b7c-2ed3-4f46-be3b-f35227ed7690">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktMy0xLTEtMTY5NjA4_8c3286ff-3e21-464e-a3bd-e5847265e769">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktNS0xLTEtMTY5NjA4_129f94e2-4b32-4c44-80a1-f9b89c1cb0d7">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="id152d255ea6e41e8adf3f170694d27ae" continuedAt="ib3b51dc0484b462ca2b94deff6fe52ca"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company&#8217;s top <ix:nonFraction unitRef="product" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_1df62af4-991f-4c7e-a181-0644fe7ac16c"><ix:nonFraction unitRef="product" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_3021052a-e54e-4556-9fc4-13124c06f385"><ix:nonFraction unitRef="product" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_669663ae-9945-4d6b-84f1-b9335eca0119">ten</ix:nonFraction></ix:nonFraction></ix:nonFraction> products for the years 2022, 2021 and 2020 represented <ix:nonFraction unitRef="number" contextRef="id9d231d4c2ab49b88a385d4e4c1d3968_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3ODU_bbe13967-fd6e-4e4b-9326-01f65476afe4">49</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i3da3bcf08f654fea916793d2c53d072a_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3ODk_f5eb01d8-3095-4429-a27a-744a5992102f">43</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2fdaef4346ea429ab8f2ee8fecb44632_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3OTY_7646f007-ee63-4cbb-b47a-87aa04cbbb51">41</ix:nonFraction>% of total product sales, respectively. <ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0Njk_806d0159-b4b1-43cb-8610-5e7eabf58d48" continuedAt="ifc8ca8832f164a61a9edd7b48a769622" escape="true">Revenues by segment and product category were as&#160;follows: </ix:nonNumeric></span></div><ix:continuation id="ifc8ca8832f164a61a9edd7b48a769622"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:24.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb853490a8ee49a2aef8cfbf3f5a4de1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMS0xLTEtMTY5NjA4_17692a66-b0a7-4bd6-98c9-275c12cf8217">2,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d95ea31c71446ff881e3c3c83eb2a25_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMy0xLTEtMTY5NjA4_c0a5cc4b-785d-4669-a55f-b2cfb995f708">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca6b9323bd346c6b92ed1a1b30acf7f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItNS0xLTEtMTY5NjA4_b8618cf7-5b1b-4764-918c-a224769abb13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6deac1f013064d42938f9021d70b9b61_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItNy0xLTEtMTY5NjA4_209f8bc0-a066-440b-82b8-6b8008e4eb3c">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413ad399c5bb4928a8f7ac2c6f964ef9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItOS0xLTEtMTY5NjA4_1b6d4382-4533-48a1-89f5-9549efa09995">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie76b4f5598c542e8977f57517d459b26_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMTEtMS0xLTE2OTYwOA_01f34740-24ae-4061-9a75-b187adda5dda">3,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f4fddaf6544a54a803b97715d8b8b3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMS0xLTEtMTY5NjA4_ca776eee-4b88-42b8-9c13-cd1f3b7f4db1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47333b2e0a19447cbe86b126460626aa_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMy0xLTEtMTY5NjA4_cbd8da36-489b-42c9-9558-b1ee593b1d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be54156c43349909ea3602fe0d42877_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtNS0xLTEtMTY5NjA4_eb5bd11f-d728-4abc-a154-321110ca9828">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb70824cb234539868d27d67b554357_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtNy0xLTEtMTY5NjA4_44683027-7e33-40f8-8a7d-fcb99e53decb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia502c9842e5f4891ada76a5da18cdc8a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtOS0xLTEtMTY5NjA4_e4950897-4d7b-4373-a325-942d2ef8527e">1,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eaa6892d2db49f1aacde5bc7fa45a10_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMTEtMS0xLTE2OTYwOA_a0d5add5-0ddc-45d4-bc78-6be741c39fc7">1,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8e8b2dc20c42a1a2e9a6dadeb73a2c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMS0xLTEtMTY5NjA4_188befe4-01c8-4c8c-a24f-5fb6e048b3e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e2a9d241f34eeba2efe5bd5d76a0a1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMy0xLTEtMTY5NjA4_9aa5a15d-ffc6-4619-8739-9c090f2afab4">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63d862bb8366425a880c22f5380b0024_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtNS0xLTEtMTY5NjA4_9c9e3829-4f49-4e12-bc09-70cfbe8acce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7420a01c31714c0fa1134b1dabf8a3ec_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtNy0xLTEtMTY5NjA4_0c01ba03-dd53-491b-b5f2-ee96cf708103">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3abb30c5b704481e9f90a6b9c448bf3a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtOS0xLTEtMTY5NjA4_c217cc9b-9fc2-4fdf-8503-d97e9d89ad44">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6294656f6f1a45a794681c73c8296f8c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMTEtMS0xLTE2OTYwOA_0c96aec0-e47a-4079-8f61-96d75c85a586">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b09aa9c7b94449b67cecd0b45214cc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMS0xLTEtMTY5NjA4_fa8bb689-0f26-4f21-8e85-6313b5bbdaff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id206b5af67f845f58c6cd1d88e1b3a4e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMy0xLTEtMTY5NjA4_4fd4c26c-6ac2-49c3-9079-2e2db969f016">527</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d5a2c5a359458caf52d23f7b41228b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtNS0xLTEtMTY5NjA4_a6b23d4e-09a5-4d3d-99d6-4b66fa4bfa8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if159fdd5fead48bc90289f41c8322f11_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtNy0xLTEtMTY5NjA4_3d7180a0-9c4c-4ed9-b844-c0baf811d65f">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ee52ba866140689495745ea109e4fd_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtOS0xLTEtMTY5NjA4_77f6304a-9b8e-4709-8df3-9d0f68789faa">240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863f2f8de85147fda44457a636fe5c45_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMTEtMS0xLTE2OTYwOA_67a0937e-d58b-417c-a399-f9d9aa8b3d42">887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3715256e943148cdb22ee0f5bdb45137_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMS0xLTEtMTY5NjA4_c6e6f797-f761-412d-87b9-2f1cb6bde663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27712a14a4da4b038f73217c93180d68_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMy0xLTEtMTY5NjA4_4c12f2eb-b8f1-4509-8ee1-c337550a0070">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia596d06d5cf7420d91cbacaa63a7e5b5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtNS0xLTEtMTY5NjA4_cb537d42-7292-4213-9d88-34d846512e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9b8d6292204ceb88174f589a719bc8_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtNy0xLTEtMTY5NjA4_b3730ace-e2aa-4d35-9059-7383339cdf28">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4219dd6acfb54efb9311c9475b6e23e6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtOS0xLTEtMTY5NjA4_d3a45976-030a-44ec-94f7-f36ee527c372">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4aa6ffca7904bdeb3915ca156eb077d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMTEtMS0xLTE2OTYwOA_d02f41b0-3797-4546-b525-73f68a7e0d23">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMS0xLTEtMTY5NjA4_579955f7-0a36-4839-9ebf-da588493cc13">2,090</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMy0xLTEtMTY5NjA4_6eb64099-c004-437b-839d-d4da6d968763">988</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctNS0xLTEtMTY5NjA4_0ab90f57-80f6-4c8f-953f-c95a993792a1">300</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctNy0xLTEtMTY5NjA4_e20b56fa-c138-44c8-a4c6-67f4ce0d86f4">978</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctOS0xLTEtMTY5NjA4_2445f51a-5e0e-4cbc-8c66-baea71f5869b">3,768</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMTEtMS0xLTE2OTYwOA_6331db71-a859-4551-87f9-2d45814d6d99">8,124</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:24.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9483d11a5c444a2da894062077c18c91_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMS0xLTEtMTY5NjA4_9ec0dd65-f330-44e2-81bd-a24e6924abff">2,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia595e166454e4a1ba18f073f7077f6f2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMy0xLTEtMTY5NjA4_fd3b7a32-a02b-42e6-b275-a32eed0d0df3">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079da80c54a848e2aa47e7dbcab9ffb1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItNS0xLTEtMTY5NjA4_d30114fd-d638-4ab8-b48b-00cd0eb39217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6c31bfc35c5482fadce56e0fa82199d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItNy0xLTEtMTY5NjA4_caa48b39-3fb7-4928-9fbc-8cfab93ca090">924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a404c0e4ddc483fa3b4bfdba829dc37_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItOS0xLTEtMTY5NjA4_37db4976-283e-40ce-b830-e972c7dfb28f">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f17d0100c9f4f9aa8dbe75ac00e0ff4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMTEtMS0xLTE2OTYwOA_876448e0-21ee-43d4-a5c1-8a2241706a0e">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2776913bc0da414c927cea557f03e444_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMS0xLTEtMTY5NjA4_50648651-cfbf-438f-8b7d-c0d608a328a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e7fcc4d25bd4e2a964cb2338ff036d7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMy0xLTEtMTY5NjA4_43b00c37-5e0b-4efa-8a0c-7031e1c49ea9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90da407f7f24ea2a426ee198bfd832e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtNS0xLTEtMTY5NjA4_2b5ea0ae-50d1-49e2-8da3-8c43f6fa074b">308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacba9807dca4896944c3cb14d2c9965_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtNy0xLTEtMTY5NjA4_0e31a70c-5d8c-48b0-be02-e47fbd06aa91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce14bf04cd843c59432531a3a383d1d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtOS0xLTEtMTY5NjA4_d57eb984-e51c-4f65-8adc-f72e31216613">1,595</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0a21d5a4a145ef887145fc4fc218ee_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMTEtMS0xLTE2OTYwOA_b799a23b-6af1-4278-ae5d-97da6570947e">1,903</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf694cf9ac304e0d96169b4f91bcd66b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMS0xLTEtMTY5NjA4_5bdc3ffb-e161-44c8-ae49-283600d26634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be0fb17d5df42c29867d7fecd2c7ca2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMy0xLTEtMTY5NjA4_f025086f-3b79-4cc9-99de-2c0b8aeb145c">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db8a506550548a299d51ad491787e26_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtNS0xLTEtMTY5NjA4_f780a629-97ef-4c90-823d-c73d6e02e941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e9fb9964a742fcb99f6da99aa5fe35_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtNy0xLTEtMTY5NjA4_d5e3fea1-66f2-4430-ac11-bee0ac0c5433">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic263815e2d40493288266b33e37dac17_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtOS0xLTEtMTY5NjA4_37d550f9-e09e-4347-87c8-801ec6b9f7f6">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5940ce49e304337951488a51673e969_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMTEtMS0xLTE2OTYwOA_d5907757-e83a-4b37-80c3-d97d0c77c6f6">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54a0cc879b847ffbe785ec9a5afa987_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMS0xLTEtMTY5NjA4_7dca1b56-728f-4417-ba13-335608116452">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a43da1e3e4fffa44339a4a14cb01a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMy0xLTEtMTY5NjA4_78b00d2c-ba74-439a-b20c-9c9c432ab91c">738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89989032253542c28bdb051d0db5aa09_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtNS0xLTEtMTY5NjA4_d8eb40a8-4a51-4d77-b1e0-699142f8ff81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7610e8eccb34bc18c4be768f086e8dd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtNy0xLTEtMTY5NjA4_3a005a51-ab55-4e67-bd7e-7e1337e71408">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8a2661bf384208942b587c9911db16_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtOS0xLTEtMTY5NjA4_42cef912-cd5b-4e75-837d-fe2a7305d4da">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9e5472be5c451db5b0eff1fef54cfb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMTEtMS0xLTE2OTYwOA_fd650f7c-bbe8-42d1-b2f7-a025087abd5a">1,144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e3baf2a6764650b923ffaa42fce977_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMS0xLTEtMTY5NjA4_d8785314-4f81-4249-994e-4520bf36113a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8931f56328824e31b191e53741aba6ae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMy0xLTEtMTY5NjA4_0580c5f5-eeea-4681-ac83-f4db9292bc20">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4a3aeeec784319bdc81ce480a56718_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtNS0xLTEtMTY5NjA4_3b5c40bc-e586-4e83-b414-cefdfcc25f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5885f21d2149079bae27f669de3070_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtNy0xLTEtMTY5NjA4_b9a6fa54-83ef-4fd7-af9b-344a97a3b5d0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1702ecacf6b4d2d8df8794ce2cd972a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtOS0xLTEtMTY5NjA4_3b4f93f9-eb0b-48cb-8f0d-2150d7e4e586">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae851ca48674d748baf9c5b2236ce7f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMTEtMS0xLTE2OTYwOA_d9b73c67-d442-4372-9e5b-78d1f7a573d0">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMS0xLTEtMTY5NjA4_213a2257-e010-40e3-bb33-fd717aeb4f53">2,074</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMy0xLTEtMTY5NjA4_02f58d81-5817-4e8d-aecb-7ca9ea35ba5f">1,166</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctNS0xLTEtMTY5NjA4_d87e1313-feaf-4552-bb7c-5666a9cfb99c">308</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctNy0xLTEtMTY5NjA4_6b548baa-a0cc-497d-a832-5651ab8c54db">1,121</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctOS0xLTEtMTY5NjA4_5fafb9e3-0e24-4181-a2a5-f603ab561d8d">3,765</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMTEtMS0xLTE2OTYwOA_fb24064b-a9b8-46b4-af24-1e7d6bb91a12">8,434</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:24.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d622f630994275af93f8255a42e4e9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMS0xLTEtMTY5NjA4_e19c6973-391e-4018-9248-7dfc30d45295">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebef6967183a4000beed50717736f608_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMy0xLTEtMTY5NjA4_1582693f-ba68-47b2-8589-6f24d962e52b">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f9df991d2e45d79da2861c921c97f8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItNS0xLTEtMTY5NjA4_ef11da85-c0cb-443c-ab74-f866a49d1e45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f6371e887c4f53b390250e5b574807_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItNy0xLTEtMTY5NjA4_19d43e52-0539-412a-8ddf-db5a393aff9c">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414790932066409fa853afdc5c75d6ac_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItOS0xLTEtMTY5NjA4_d54113a0-8f19-461e-89f5-4a67e841c4d6">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210933c886d5414891a7858fd7293231_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMTEtMS0xLTE2OTYwOA_c0910ca1-a47a-4292-839c-2cfdcdbc3747">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0782133c89472a992a06cebb386638_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMS0xLTEtMTY5NjA4_b6285783-bf17-4674-97fb-e83fe36081dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d7ab2322e5421986e53954e29c023e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMy0xLTEtMTY5NjA4_0e3c05cd-c6e0-49c3-9fb6-f93a119f1905">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a29bd754c024342b29079e34fda7eea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtNS0xLTEtMTY5NjA4_bf9e6216-fa89-4738-9c27-73360f7a1fbb">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22303d42e3dc44f9bc0a9b6f8d915e17_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtNy0xLTEtMTY5NjA4_528400c6-265e-4961-8541-c27bc52939a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52852499987d44ba88be1554788eb30e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtOS0xLTEtMTY5NjA4_f500b21c-dd01-4266-b569-03125c82e050">1,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fdf48aa584499db19f9a47cf66ee0b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMTEtMS0xLTE2OTYwOA_5038c9d2-4369-41dc-bf1a-6cd5fcb2e954">1,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165688f9a68b45b9816d827111639efe_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMS0xLTEtMTY5NjA4_ec707a17-702a-49b6-9a5d-bc51901d1dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f22081fec247ddad4a592c3c9311fc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMy0xLTEtMTY5NjA4_63abdbdf-8945-428d-9d66-efd68c8ace2c">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f6805b61b17427ba6040ceb5f878cbb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtNS0xLTEtMTY5NjA4_68a7cb1a-752e-4e35-b14c-6f283482cd18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied66a5e8bad6417fa24276e949d9d54e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtNy0xLTEtMTY5NjA4_6cf9cf54-e3ce-4b47-b3b2-e9a502fc6297">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18258b56d6c404f9c117e6a1895e87b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtOS0xLTEtMTY5NjA4_c0df9e1f-9a27-4f27-85e6-da8053879999">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c1edf6e9fd47c09ba561d2d4f5fb45_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMTEtMS0xLTE2OTYwOA_3b477cca-1086-49f3-ba4b-ddb2f0e36dc8">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aed53df917a48138c9cdb27cea9d59a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMS0xLTEtMTY5NjA4_c5b61e71-27ac-45bc-b025-f671c75e6ccc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3c0300743443bebb82772ee9a1de17_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMy0xLTEtMTY5NjA4_833acd6f-a4ac-4899-9ea4-1721a1a2d2ee">775</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d30a1f1928e4154abdcb87a862c2799_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtNS0xLTEtMTY5NjA4_a7e76400-5f04-4d34-a962-81897019a602">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i410f367d50a54973b5eb040cfd166964_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtNy0xLTEtMTY5NjA4_5a05f44e-0a85-4d3a-995c-05df396ae1ee">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifabc22558a014281b9c2cb444e967f08_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtOS0xLTEtMTY5NjA4_60ad200a-52d5-4c99-a6cf-e4f6cc108ea4">254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6753cdad5c40adb3809316bce79647_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMTEtMS0xLTE2OTYwOA_8b004317-2416-47d4-a299-f33039d1bc36">1,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d99817ee7714f4d8639154cc1b22ccb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMS0xLTEtMTY5NjA4_53e63ec7-0d41-4828-82bc-78dc03172911">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2f801792d54e30b73e332c26636016_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMy0xLTEtMTY5NjA4_54b43675-c28f-41a2-b24e-0e86d44f30da">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc14b7106ace4ecfaf704ff0c5ede253_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtNS0xLTEtMTY5NjA4_f40636c4-5407-4574-8e8d-b857fb2ed70c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a2f472ad0740f09224cd8980cd10c6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtNy0xLTEtMTY5NjA4_cacaa1ac-d4d3-4f7b-9458-5f24c80c7ecf">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c691843b3b442e859dea2281143b48_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtOS0xLTEtMTY5NjA4_6fe8b9d7-c6df-4764-a8c4-e47bcee5cd50">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f907111c71342ffb50f8e77dabca249_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMTEtMS0xLTE2OTYwOA_9524e2a5-e717-425b-a039-6980c90e516c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMS0xLTEtMTY5NjA4_7eb0b995-7af0-49da-a415-35b6b657d3c2">1,904</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMy0xLTEtMTY5NjA4_110bc60a-2e2f-49fb-8f70-ca349e06d5c1">1,181</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctNS0xLTEtMTY5NjA4_6294ced7-0150-4a31-8fdf-b4f55cff9c41">253</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctNy0xLTEtMTY5NjA4_591be92d-7728-4088-a3fc-d88812114e41">1,274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctOS0xLTEtMTY5NjA4_5d7897ac-554e-485d-9411-d9f171675950">3,415</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMTEtMS0xLTE2OTYwOA_8069e08b-b77f-467f-9b2d-195b44d2c1f6">8,027</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="ib3b51dc0484b462ca2b94deff6fe52ca" continuedAt="i4d04df10c3f6474bbbd6b67b83c53506"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NDY_f248995a-1dcd-4e7f-88f9-0545969dd2fa" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5509eedbfcd4499ab1122c8107d4239_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtMS0xLTEtMTY5NjA4_c3482162-0ec2-4855-a69a-d4b98943de64">4,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a97db7f7054e388365a90a087bb5a6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtMy0xLTEtMTY5NjA4_e6b044bb-2672-4d56-9856-b5bc82a968d2">4,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd34fed22f422381e2ab562615f33e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtNS0xLTEtMTY5NjA4_b1e8e432-f045-41cb-96fb-33eb3867f499">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54e5dc2b3f045dea402afba64c50a72_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItMS0xLTEtMTY5NjA4_29ff5138-9466-473a-889c-bfe36dceb415">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c150c6fffe6495186bf61df0c286556_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItMy0xLTEtMTY5NjA4_48e0d10b-37fa-43f2-bff8-99780f2cc4fb">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40881288dfcd4d5f8699bf1f6a8b2dda_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItNS0xLTEtMTY5NjA4_683470bc-c76d-4be7-9ea8-9f7f4ac67eae">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ca09d20c2147509bcbb33af6032e74_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtMS0xLTEtMTY5NjA4_ab862696-eb68-4de4-af79-9c1feb565d1a">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia23a06260b684c668693d6e121b4629a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtMy0xLTEtMTY5NjA4_f0dc0e45-6a09-4a2d-bbc4-71781151077d">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie840834914ec48429fa235a8dc4f3d2f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtNS0xLTEtMTY5NjA4_115e52f8-62c3-4e90-acdd-91a081034ae9">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8ae97db4704ce7ade6a7925a3558e6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtMS0xLTEtMTY5NjA4_1bb0de4b-9cf6-47fa-9d49-f270199d6795">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884b037761c04998921745217361f61e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtMy0xLTEtMTY5NjA4_d83ac6e2-a7f2-4de9-8333-a81c60bcfd75">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98514049314c405da4e7a37f55ab7cbe_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtNS0xLTEtMTY5NjA4_985feded-39b2-465b-8d38-6fcbcc1482a2">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693f697c02b7481cb3047f296b40c30b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtMS0xLTEtMTY5NjA4_36a5ed54-c71d-49c9-b275-6d750587fc89">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6767d56cea04e58a135696afeaefc93_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtMy0xLTEtMTY5NjA4_2c2dfdff-7b73-4bb6-9173-471bce42c0ea">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6f8147a44e4a9992f6184af1c058f5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtNS0xLTEtMTY5NjA4_3150619d-1fda-4ed6-9da7-be797d3a0924">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49a7c59a5a1434eadff4dbbe1111a8e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtMS0xLTEtMTY5NjA4_dba96e1f-72ae-4fd4-8339-ea711c4ea994">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b7ce85a70745f3b0574cc6d9621b9f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtMy0xLTEtMTY5NjA4_f4645fe5-c692-4d69-912d-81d62c44087f">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6026773180f1437d92209ced4c2d11a4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtNS0xLTEtMTY5NjA4_fc0a30cd-8f05-4ddd-93fa-313c00b39b44">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9827e7af8fa146468a1dd0ec9ff82b94_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctMS0xLTEtMTY5NjA4_8401fd24-3eac-4b5d-987f-1890824dce8e">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c021e3945bd49d8a09d3bcdecca9997_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctMy0xLTEtMTY5NjA4_e6003858-4900-4c72-b51d-01b09eca1ff3">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia095099872674785b26d32c3d7479727_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctNS0xLTEtMTY5NjA4_5bdf460b-7ef2-4723-808e-9953608551b8">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c9a8e8837a4dd4bbd6b5d7dbdbade1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtMS0xLTEtMTY5NjA4_3c6e899a-40d5-4447-af98-0415abe1eaeb">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ed3916283a42a2919dd657f1cf7467_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtMy0xLTEtMTY5NjA4_a0b31f2e-9d14-47f2-879b-6cd6206ebc0e">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b13de71c9b467fbaed74e0a22f2208_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtNS0xLTEtMTY5NjA4_dd5270cd-9d8c-4062-9882-f8e7322feb6c">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7910566e68784de489fe82fff799babb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMS0xLTEtMjA0NTc3_dc73ae3d-f0bc-4fa4-85ea-caee742689bf">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3040f78c5bbe4353a9ac62b021035148_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMy0xLTEtMjA0NTc5_714e23b3-f4c3-40ea-9eda-cd805b305387">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e7baf1c6eb4c6fbd09d3daa5ddbf4c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktNS0xLTEtMjA0NTgx_40670ca8-b08c-466d-afe7-79903d1f8f2f">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db976941a0d4666bd6e1f2ba49f58ba_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTEtMS0xLTIwNDU3Nw_508a41b1-a5c1-45a3-92f7-8e6fbbfea5f0">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61760936cfa34d0f9b4aa7868541b7a5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTMtMS0xLTIwNDU3OQ_4916f2c6-b42f-4ad2-9991-0db147cc1636">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd26ef4e5ea4afc84ba00e232ce717f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTUtMS0xLTIwNDU4MQ_864f04fc-efe1-4306-82e0-80833f07521a">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73181f4bbbaf41faa1cdd2014a22c967_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTEtMS0xLTIwNDU3Nw_1e9efc8c-cafd-46e5-9150-5d21404d5f73">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0786250ca0c04b9db12a0fedb2ff1574_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTMtMS0xLTIwNDU3OQ_ac5e4d07-6644-4d0c-82e1-45ccb7640be1">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121eb01d5e11421ca0cc55f4358e2054_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTUtMS0xLTIwNDU4MQ_63ec43f7-3c83-4646-a5de-272d3b63806c">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee77d5bca934fc3a6b0ca93dcb21db4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMS0xLTEtMTY5NjA4_05291e18-1b45-4aca-b008-4e172a79834e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1273cfab17884bd791ec54e9980c98c5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMy0xLTEtMTY5NjA4_dd855932-9db5-458f-ac1b-e4099f853ba7">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18297ec700d4c0d9f6bab6013cd53e0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktNS0xLTEtMTY5NjA4_7a38d129-0851-4f13-8688-b5c97c7bf5e7">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bf70598ac04fe18dc183a56f3b216d_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTEtMS0xLTE2OTYwOA_6110ced4-a237-4b3e-a039-84ed1647986e">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79145fcaf1184069bcfc23b15cc6a8eb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTMtMS0xLTE2OTYwOA_b84efedd-972d-46d0-9151-a3561c9da374">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5a4355f0974bdca065bb27be79f476_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTUtMS0xLTE2OTYwOA_7fdba80c-0343-4126-bceb-9e9eb97e67f7">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06d30f1eb264b3fac209b850960d0be_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTEtMS0xLTE2OTYwOA_050779bf-b849-485f-9ea5-8eafd25a4943">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie73da62401a74fc195467ebcc7934a92_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTMtMS0xLTE2OTYwOA_70cd5776-675d-4a8f-a392-da1b0d788c85">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f7e3e748d041d1acbb6216d4655c28_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTUtMS0xLTE2OTYwOA_046478ac-e072-4e16-ac49-99a7908a8793">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTEtMS0xLTE2OTYwOA_5b2877fd-cc07-4804-aef3-ea17c53fafac">8,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTMtMS0xLTE2OTYwOA_563144eb-86d0-49c2-9a04-9a5cb3ddf6cc">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTUtMS0xLTE2OTYwOA_670a1536-7445-4f0e-afbc-883621aaf2fd">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MzQ_f27bb204-1468-43dc-8b5f-0f3dd61599dd" escape="true"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2022 and 2021 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:79.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369d1b4494f84c38a91722618c2cf34f_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEtMS0xLTEtMTY5NjA4_590755b9-ac08-4bb6-8cfb-3f7a8c4c3da5">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1987f37ff1840ed95338c32804401c0_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEtMy0xLTEtMTY5NjA4_b64ef661-c903-4410-bf5f-50fc080555b7">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf48590013554b98a5e052a00383ec48_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzItMS0xLTEtMTY5NjA4_ec7ca29e-32ac-4cab-a8f2-c02386d91d15">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760a6d7fc1f9409fb0004ef8b8b7dce9_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzItMy0xLTEtMTY5NjA4_aefbf825-0887-4ea1-9225-eba1c8556446">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1303985937d7476c974821a08256950b_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzMtMS0xLTEtMTY5NjA4_2c1b78c5-24c5-4729-b946-aead5d8e3dd0">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64031ed4889a463f9456655e410c4b3b_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzMtMy0xLTEtMTY5NjA4_efc13535-1269-4d9b-9309-1dd3fe5b9568">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4e3bbdcdd9403c9ada12b8321e0c39_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMS0xLTEtMjA0NTkx_766e59a7-72e4-46b0-9087-e248a75cf381">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcefb49efbb64a5d85dc32f0d8d4c60d_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMy0xLTEtMjA0NTkx_8762420d-ff43-4f0e-82d7-c099584be527">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df23a7c7aee42d4ae92346947a9d5d8_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMS0xLTEtMTY5NjA4_d0faded5-7a0b-46f6-904c-b2bee9eae2bf">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678b31ef25e240feb62147dc14a7ff6b_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMy0xLTEtMTY5NjA4_743c8fe1-8e7a-429b-8aef-3011ce5f26e6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf1d0feae3e4b1bacd61edd48477cd0_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzYtMS0xLTEtMTY5NjA4_2e5f0971-ec34-465d-b100-88348e4a5b6b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54abc6f54a194617920ce31c6643901c_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzYtMy0xLTEtMTY5NjA4_a5b5158d-1a0b-433e-bacc-b32ea5ed1921">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd0a8a5a2cb41e4a36e68bcd7a52224_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzctMS0xLTEtMTY5NjA4_2b7a961e-58b8-491c-bf21-f4c08e7c7afb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c46b45670f44dc39f81dd4b7a35274f_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzctMy0xLTEtMTY5NjA4_e3d1f5dc-936a-4a8c-8ff6-e5ec3ca23c19">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859c12825f9e40189f911741e94ae963_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzgtMS0xLTEtMTY5NjA4_15c3f615-80f2-4f4a-b2e8-8ef2fea1670b">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id690161da57c4e36a166af99a7b6395f_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzgtMy0xLTEtMTY5NjA4_add179e8-8954-426e-8312-972591377c23">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6727e28116b84a2b96efd2e5c433536b_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzktMS0xLTEtMTY5NjA4_d9f26ebd-6ec0-48f9-a8da-73ae98d59e82">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f01abf983a4e2a888777c7d9856df7_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzktMy0xLTEtMTY5NjA4_3194f09a-9f8e-4dd0-8c38-7821e7d68345">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ec6a0287cf469d8a40521df7bd0d92_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEwLTEtMS0xLTE2OTYwOA_1253a7ff-6df8-49f6-b1b3-7de7f954190a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52c57f85e61143298ba638df79853385_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEwLTMtMS0xLTE2OTYwOA_23237e57-2cd4-47e5-8d62-86c49af99ed2">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76b30129b7749b2bedad7175c4b9154_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzExLTEtMS0xLTE2OTYwOA_f630ec69-15cf-4b68-8a23-dbde550b448f">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4de5305b33748bab90c89fa03a2293a_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzExLTMtMS0xLTE2OTYwOA_cfbbf818-f57e-4e26-90ff-17ce86372520">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEyLTEtMS0xLTE2OTYwOA_839a069e-4f3d-47e2-ad42-e191bbabee50">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEyLTMtMS0xLTE2OTYwOA_c2ddd4cb-2cc7-4d7f-84e9-d07f5a2ae347">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="i4d04df10c3f6474bbbd6b67b83c53506"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MjQ_01d46952-17f7-40d5-9c2d-b147b4f23e9e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6353361e06042eabedeb74c21af8174_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtMS0xLTEtMTY5NjA4_fcbf0071-19c0-4bd7-8027-5a00d03c3ed0">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa738464b0a547659602f730d5711e8d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtMy0xLTEtMTY5NjA4_328fd6dc-e7a2-4c01-9528-58287ee4551e">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cdc5afe35b143799f38340807d6c40e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtNS0xLTEtMTY5NjA4_07897aa6-82a2-4ed5-8b90-9bf8f4923e51">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa065d85099a481aa7a155608fa5076e_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItMS0xLTEtMTY5NjA4_059a3b48-7e2e-41bb-8986-d7fa078911f9">15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b0b47abb6d8430b807a5fb4299b8bc7_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItMy0xLTEtMTY5NjA4_f9fe255a-6aae-43f3-91ea-334ea0db2311">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7665331a2b9c46119262f653ad0439d7_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItNS0xLTEtMTY5NjA4_c11b9790-22ab-40ed-9af5-8be1182c9a0b">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bfbab45127e4011bd04bc7151f71978_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtMS0xLTEtMTY5NjA4_8f3d0621-c523-4024-82d3-20c7a8d921fd">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a1cd06e58564300a92b6fa77154d967_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtMy0xLTEtMTY5NjA4_2c153669-b371-4136-aed8-d585086a811c">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd7c5e9fab0f4527a04532a1453031a0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtNS0xLTEtMTY5NjA4_126725db-52e7-4b02-8eb5-434437191e59">13</ix:nonFraction>%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-86</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>exhibit2112022ye.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1ece85ac3b974350a736e8bf0dfd5754_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit&#160;21.1</font></div><div style="margin-bottom:2pt;text-align:right"><font><br></font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Subsidiary Information </font></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">As of February&#160;23, 2023 </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction&#160;of<br>Incorporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Doing&#160;Business&#160;As</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Argentina S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Argentina S.R.L.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waicon Vision S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waicon Vision S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Australia) Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Australia) Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Australia Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Australia Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wirra Holdings Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wirra Holdings Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;Bausch &#38; Lomb Australia Holdings Pty </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Limited</font></div><div style="padding-left:6pt"><font><br></font></div><div style="padding-left:6pt"><font><br></font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Australia Holdings Pty  Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Australia Pty Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Australia Pty Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus Australia Pty. Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus Australia Pty. Ltd</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belarus</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Pharma S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Pharma S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss BH Dru&#353;tvo za trgovinu na veliko d.o.o. Sarajevo</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bosnia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss BH d.o.o. Sarajevo</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BL Ind&#250;stria &#211;tica Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BL Ind&#250;stria &#211;tica Ltda.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1375209 B.C. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Columbia<br>&#160;(Canada)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1375209 B.C. Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1261229 B.C. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British Columbia<br>&#160;(Canada)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1261229 B.C. Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss EOOD</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bulgaria</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss EOOD</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12279967 Canada Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12279967 Canada Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12283778 Canada Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12283778 Canada Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Corporation                            </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Corporation                            </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health, Canada Inc.&#47; Sant&#233; Bausch, Canada Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health, Canada Inc. &#47; Sant&#233; Bausch, Canada Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada GP Limited&#47; Commandit&#233; Valeant Canada Limit&#233;e</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada GP Limited&#47; Commandit&#233; Valeant Canada Limit&#233;e</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada Limited &#47; Valeant Canada Limit&#233;e</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada Limited &#47; Valeant Canada Limit&#233;e</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada S.E.C.&#47;Valeant Canada LP</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Canada S.E.C.&#47;Valeant Canada LP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V-BAC Holding Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">V-BAC Holding Corp.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Shanghai) Trading Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Shanghai) Trading Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Bausch &#38; Lomb Eyecare Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Bausch &#38; Lomb Eyecare Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda New Packing Materials Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda New Packing Materials Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda Pharmaceutical Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shandong Bausch &#38; Lomb Freda Pharmaceutical Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta (Shanghai) Health Management Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta (Shanghai) Health Management Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Pharmaceutical S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge Pharmaceutical S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmatech S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farmatech S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humax Pharmaceutical S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humax Pharmaceutical S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHARMASWISS dru&#353;tvo s ograni&#269;enom odgovorno&#353;&#263;u za trgovinu i usluge</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Croatia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHARMASWISS d.o.o.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Cesk&#225; republika s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss Cesk&#225; republika s.r.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Egypt LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Egypt LLC</font></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb France S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb France S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health France S.A.S.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health France S.A.S.</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoire Chauvin S.A.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratoire Chauvin S.A.S.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical France </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical France </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B L E P Holding GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B L E P Holding GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Gerhard Mann chem.-pharm. Fabrik Gesellschaft mit beschr&#228;nkter Haftung</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Gerhard Mann chem.-pharm. Fabrik GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Robert Winzer Pharma GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Robert Winzer Pharma GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grundst&#252;cksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grundst&#252;cksverwaltungsgesellschaft Dr.Gerhard Mann chem.- pharm. Fabrik GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Germany GmbH</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Germany GmbH</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Perfect Vision GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technolas Perfect Vision GmbH</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Hellas Single-Member Pharmaceuticals Soci&#233;t&#233; Anonyme</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Hellas </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Hong Kong) Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sino Concept Technology Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sino Concept Technology Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Hong Kong Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Hong Kong Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Magyarorsz&#225;g Korl&#225;tolt Felel&#245;ss&#233;g&#251; T&#225;rsas&#225;g</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hungary</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Magyarorsz&#225;g Kft</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb India Private Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb India Private Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Bausch Lomb Indonesia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indonesia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PT Bausch Lomb Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Ireland Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health HoldCo Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health HoldCo Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ireland Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Ireland Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Ireland Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Holdings Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Holdings Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb-IOM S.p.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb-IOM S.p.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Italy S.R.L.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Italy S.R.L.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.L.J. Company Limited </font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Japanese official name&#58; Bausch &#38; Lomb Japan kabushiki Kaisha)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.L.J. Company Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLP</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLP</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Pharma Kazakhstan LLP</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kazakhstan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Pharma Kazakhstan LLP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Korea Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Korea Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bescon Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bescon Co., Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Korea Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Korea Limited<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB PharmaSwiss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lithuania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAB PharmaSwiss</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Finance Luxembourg S.&#224; r.l.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Finance Luxembourg S.&#224; r.l.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Malaysia) Sdn. Bhd.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Malaysia Sdn. Bhd.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Malaysia Sdn. Bhd.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico Holdings S.A. de C.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb M&#233;xico Holdings S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Fedal, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Fedal, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Grossman, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratorios Grossman, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nysco de M&#233;xico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nysco de M&#233;xico, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tecnofarma, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tecnofarma, S.A. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Servicios y Administraci&#243;n, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Servicios y Administraci&#243;n, S. de R.L. de C.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Dutch Holdings B.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Dutch Holdings B.V.</font></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Netherlands B.V.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb Netherlands B.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb OPS B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch+Lomb OPS B.V.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natur Produkt Europe B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natur Produkt Europe B.V.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Dutch Holdings B.V.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Dutch Holdings B.V.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (New Zealand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (New Zealand) Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Farmac&#233;utica Panam&#225;, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Farmac&#233;utica Panam&#225;, S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Per&#250; S.R.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Per&#250; S.R.L.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Philippines Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Philippines Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Philippines Inc.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Philippines Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Poland sp&#243;&#322;ka z ograniczon&#261;  odpowiedzialno&#347;ci&#261;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch &#38; Lomb Poland sp. z.o.o.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Poland sp&#243;&#322;ka z ograniczon&#261; odpowiedzialno&#347;ci&#261;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Poland sp. z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emo-Farm sp&#243;&#322;ka z ograniczon&#261; odpowiedzialno&#347;ci&#261;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emo-Farm sp. z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Polfa Rzeszow Sp&#243;&#322;ka Akcyjna</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICN Polfa Rzeszow SA</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Przedsiebiorstwo Farmaceutyczne Jelfa Sp&#243;&#322;ka Akcyjna</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Przedsiebiorstwo Farmaceutyczne Jelfa SA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Poland sp. z.o.o.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Poland sp. z.o.o.</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Med sp&#243;&#322;ka z ograniczon&#261; odpowiedzialno&#347;ci&#261;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valeant Med sp. z o.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amoun Pharmaceutical Romania SRL</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amoun Pharmaceutical Romania SRL</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Romania SRL (f&#47;k&#47;a S.C. Valeant Pharma SRL)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Romania SRL (f&#47;k&#47;a Valeant Pharma SRL)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Limited Liability Company </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health LLC </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch RUMO Holdings Limited Liability Company</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch RUMO LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss d.o.o preduze&#263;e za proizvodnju, unutra&#353;nju, spoljnu trgovinu i zastupanje Beograd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss d.o.o, Belgrade</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Singapore) Private Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Singapore) Private Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Singapore Private Limited</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Singapore Private Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Slovakia s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Slovakia s.r.o.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss, trgovsko in proizvodno podjetje, d.o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovenia</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss d.o.o.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (South Africa) (Pty)  Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (South Africa) (Pty) Ltd</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soflens (Pty) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soflens (Pty) Ltd</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb S.A.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Iberia S.L. (fka Wanakie SA)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Iberia S.L.</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Nordic Aktiebolag</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Nordic AB</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Swiss AG</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Swiss AG</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss SA</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PharmaSwiss SA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Taiwan Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Taiwan Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Taiwan Limited</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Taiwan Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Thailand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb (Thailand) Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical (Thailand) Limited</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical (Thailand) Limited</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Sa&#287;lik ve Optik &#220;r&#252;nleri Ticaret Anonim &#350;irketi</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Sa&#287;lik ve Optik &#220;r&#252;nleri Tic.&#350;.&#222;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;Bausch Health&#34; Limited Liability Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;Bausch Health&#34; LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ukraine Limited Liability Company</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ukraine</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Ukraine Limited Liability Company</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Trading DWC-LLC</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bausch Health Trading DWC-LLC</font></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medpharma Pharmaceutical &#38; Chemical Industries LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UAE</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medpharma Pharma &#38; Chem Ind LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb U.K. Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb U.K. Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical UK Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical UK Limited</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterimedix Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterimedix Limited</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visioncare Devices, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visioncare Devices, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AcuFocus Holdings, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audrey Enterprise, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audrey Enterprise, LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Americas Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Americas Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb South Asia, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb South Asia, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Foundation, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Foundation, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Americas, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health Americas, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health US, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch Health US, LLC</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eye Essentials LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eye Essentials LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicis Pharmaceutical Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicis Pharmaceutical Corporation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Oceanside Pharmaceuticals, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Oceanside Pharmaceuticals, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">.</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OraPharma, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OraPharma, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreCision Dermatology, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PreCision Dermatology, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix Pharmaceuticals, Ltd.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santarus, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Santarus, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical Distribution, LLC</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Solta Medical Distribution, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics IP, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics IP, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Corp. USA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Corp. USA</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Vision Sciences Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unilens Vision Sciences Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRX Holdco LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VRX Holdco LLC</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Titanium, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Titanium, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergetics, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paragon BioTeck, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paragon BioTeck, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alden Optical Laboratories, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York (US)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alden Optical Laboratories, Inc.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Incorporated</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York (US)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch &#38; Lomb Incorporated</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In accordance with the instructions of Item&#160;601 of Regulation&#160;S-K, certain subsidiaries are omitted from the foregoing table.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit2312022ye.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7e2fc318ba9342d7b0985254a65fcbdd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:72.00pt 63.00pt 72.00pt 72.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-238084, 333-226786, 333-196120, 333-176205, 333-168254, 333-168629, 333-138697, and 333-266718 as amended, where applicable) of Bausch Health Companies Inc. of our report dated February&#160;23, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit3112022ye.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0608dcd52a834344b7112022d2fd1f08_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">THOMAS J. APPIO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit3122022ye.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0955b5bd6c98401bb4ff66710951e407_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom G. Vadaketh, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; TOM G.VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom G. Vadaketh</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit3212022ye.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2b28cd9803f344268c85994e312c549c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report of the Company on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 (the&#160;&#8220;Annual Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">THOMAS J. APPIO</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit3222022ye.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i03d9dd7d8149422487876a5dac8fce5c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I,  Tom G. Vadaketh, Executive Vice President, Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report of the Company on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 (the&#160;&#8220;Annual Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:49.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;23, 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">TOM G. VADAKETH</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom G. Vadaketh</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bhc-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AUDITINFORMATION" roleURI="http://www.bauschhealth.com/role/AUDITINFORMATION">
        <link:definition>0000002 - Document - AUDIT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000009 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>0000011 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000013 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>0000014 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT">
        <link:definition>0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>0000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>0000017 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>0000018 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>0000019 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bauschhealth.com/role/LEASES">
        <link:definition>0000020 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>0000021 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>0000023 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>0000024 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>0000025 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE">
        <link:definition>0000026 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURES" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES">
        <link:definition>0000027 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>0000028 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>0000030 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000033 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>0000034 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>0000035 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>0000036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000037 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>0000038 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>0000039 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.bauschhealth.com/role/LEASESTables">
        <link:definition>0000040 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>0000041 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>0000042 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>0000043 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>0000044 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables">
        <link:definition>0000045 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables">
        <link:definition>0000046 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESTables" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables">
        <link:definition>0000047 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000048 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>0000049 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>0000050 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
        <link:definition>0000051 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails">
        <link:definition>0000052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
        <link:definition>0000053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
        <link:definition>0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
        <link:definition>0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
        <link:definition>0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails">
        <link:definition>0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails">
        <link:definition>0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails">
        <link:definition>0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails">
        <link:definition>0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
        <link:definition>0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>0000063 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>0000064 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000065 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>0000066 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>0000067 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000068 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>0000069 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>0000070 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000071 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>0000072 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>0000073 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
        <link:definition>0000074 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
        <link:definition>0000075 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESSummaryofInventoriesNetDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails">
        <link:definition>0000076 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
        <link:definition>0000077 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails">
        <link:definition>0000078 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
        <link:definition>0000079 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1">
        <link:definition>0000079 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>0000080 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>0000081 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
        <link:definition>0000082 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>0000083 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>0000084 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>0000085 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSExchangeOfferDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails">
        <link:definition>0000086 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails">
        <link:definition>0000087 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>0000088 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>0000089 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>0000090 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>0000091 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
        <link:definition>0000092 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>0000093 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>0000094 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000095 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000096 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
        <link:definition>0000097 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1">
        <link:definition>0000097 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
        <link:definition>0000098 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
        <link:definition>0000099 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
        <link:definition>0000100 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
        <link:definition>0000101 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
        <link:definition>0000102 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails">
        <link:definition>0000103 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails">
        <link:definition>0000104 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseExpensesDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails">
        <link:definition>0000105 - Disclosure - LEASES - Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseAdditionalInformationDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails">
        <link:definition>0000106 - Disclosure - LEASES - Lease Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails">
        <link:definition>0000107 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails_1" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1">
        <link:definition>0000107 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000108 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>0000109 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>0000110 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONRSUsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails">
        <link:definition>0000111 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000112 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
        <link:definition>0000113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails">
        <link:definition>0000114 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETScheduleofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails">
        <link:definition>0000115 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails">
        <link:definition>0000116 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails">
        <link:definition>0000117 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails">
        <link:definition>0000118 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000119 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
        <link:definition>0000120 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000121 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
        <link:definition>0000122 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000123 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>0000124 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails">
        <link:definition>0000125 - Disclosure - LOSS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails">
        <link:definition>0000126 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails">
        <link:definition>0000127 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>0000128 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000129 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>0000130 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONCapitalExpendituresDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails">
        <link:definition>0000131 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
        <link:definition>0000132 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicInformationRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails">
        <link:definition>0000133 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
        <link:definition>0000134 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>0000135 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_AcquiredInProcessResearchAndDevelopmentMember" abstract="true" name="AcquiredInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_TradeReceivableNetPortionPastDue" abstract="false" name="TradeReceivableNetPortionPastDue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LegalSettlementsAndRelatedFees" abstract="false" name="LegalSettlementsAndRelatedFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorUnsecuredNotesDue2023Member" abstract="true" name="SeniorUnsecuredNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" abstract="false" name="IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueMay2027Member" abstract="true" name="RevolvingCreditFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" abstract="true" name="PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A8.50SeniorNotesDueJanuary2027Member" abstract="true" name="A8.50SeniorNotesDueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.25SeniorNotesDueJanuary2030Member" abstract="true" name="A5.25SeniorNotesDueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A2022OmnibusIncentivePlanRetentionProgramMember" abstract="true" name="A2022OmnibusIncentivePlanRetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NumberOfLargestWholesaleCustomers" abstract="false" name="NumberOfLargestWholesaleCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsPrepaidExpenses" abstract="false" name="DeferredTaxAssetsPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SurgicalReportingUnitMember" abstract="true" name="SurgicalReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NovaliqGmbHMember" abstract="true" name="NovaliqGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" abstract="true" name="VisionCareSurgicalAndOphthalmicReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" abstract="false" name="DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A6.125SeniorNotesdueApril2025Member" abstract="true" name="A6.125SeniorNotesdueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" abstract="true" name="CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_OtherEquipmentAndLeaseholdImprovementMember" abstract="true" name="OtherEquipmentAndLeaseholdImprovementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskPercentageofNetTradeReceivables" abstract="false" name="ConcentrationRiskPercentageofNetTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" abstract="true" name="SeniorSecuredNotes7.00PercentDueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueFebruary2027Member" abstract="true" name="TermLoanBFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxLossCarryforwards" abstract="false" name="DeferredTaxAssetsTaxLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NoncashCumulativeForeignCurrencyTranslationLoss" abstract="false" name="NoncashCumulativeForeignCurrencyTranslationLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEmployerContributionMaximumAge" abstract="false" name="DefinedBenefitPlanEmployerContributionMaximumAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" abstract="false" name="RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SOFRCDOREURIBORAndSONIARatesMember" abstract="true" name="SOFRCDOREURIBORAndSONIARatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ForeignCountryStateAndLocalMember" abstract="true" name="ForeignCountryStateAndLocalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IPOAndOverAllotmentOptionMember" abstract="true" name="IPOAndOverAllotmentOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetsLesseeAbstract" abstract="true" name="AssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ExchangeOfferMember" abstract="true" name="ExchangeOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CaliforniaProposition65RelatedMatterLitigationMember" abstract="true" name="CaliforniaProposition65RelatedMatterLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationUncertainTaxPositions" abstract="false" name="IncomeTaxReconciliationUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsTable" abstract="true" name="ScheduleOfCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_CertainEmployeesMember" abstract="true" name="CertainEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.875SeniorNotesdueMay2023Member" abstract="true" name="A5.875SeniorNotesdueMay2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_XifaxanBrandedProductsMember" abstract="true" name="XifaxanBrandedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" abstract="false" name="AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_A2022OmnibusIncentivePlanMember" abstract="true" name="A2022OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainContingencyStayOfApprovalPeriod" abstract="false" name="GainContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" abstract="false" name="IncomeTaxReconciliationDeferredIntercompanyProfit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" abstract="true" name="SeniorSecuredNotes6.50PercentDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EuropeInterbankOfferedRateEURIBORMember" abstract="true" name="EuropeInterbankOfferedRateEURIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" abstract="false" name="DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsMember" abstract="true" name="FairValueAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" abstract="false" name="DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" abstract="true" name="OmnibusIncentivePlan2014RetentionRSUGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ExtinguishmentOfDebtThirdPartyFees" abstract="false" name="ExtinguishmentOfDebtThirdPartyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" abstract="true" name="SeniorSecured1400NotesSecondLienDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SaleOfStockOverAllotmentTerm" abstract="false" name="SaleOfStockOverAllotmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PaymentForDebtAmortizationPrepaymentCost" abstract="false" name="PaymentForDebtAmortizationPrepaymentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" abstract="false" name="DefinedBenefitPlanNumberofDefinedBenefitPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" abstract="false" name="MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_NeurologyAndOtherReportingUnitMember" abstract="true" name="NeurologyAndOtherReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" abstract="true" name="USDollarBaseRateAndCanadianDollarPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriodTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes550DueMarch2023Member" abstract="true" name="SeniorNotes550DueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" abstract="false" name="DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" abstract="false" name="DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" abstract="false" name="PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CrossCurrencyFinalSettlementMember" abstract="true" name="CrossCurrencyFinalSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.375SeniorNotesdueMarch2020Member" abstract="true" name="A5.375SeniorNotesdueMarch2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2018And2019Member" abstract="true" name="TaxYear2018And2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" abstract="false" name="DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_TermFacilityDueMay2027Member" abstract="true" name="TermFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" abstract="false" name="AdditionalOperatingLeaseInformationLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" abstract="false" name="UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LiabilitiesLesseeAbstract" abstract="true" name="LiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AssetAcquisitionAndBusinessCombinationTable" abstract="true" name="AssetAcquisitionAndBusinessCombinationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaroPharmaceuticalsIncLitigationMember" abstract="true" name="TaroPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeDomain" abstract="true" name="TroubledDebtRestructuringDebtorTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ThreeLargestUSWholesalerCustomersMember" abstract="true" name="ThreeLargestUSWholesalerCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A9.25SeniorNotesDueApril2026Member" abstract="true" name="A9.25SeniorNotesDueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsSlaybackANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A1261229BCLtdMember" abstract="true" name="A1261229BCLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherIncomeExpenseNet" abstract="false" name="OtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationSettlementNumberOfObjectorsAppeals" abstract="false" name="LitigationSettlementNumberOfObjectorsAppeals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_PeriodReceivableOutstanding" abstract="false" name="PeriodReceivableOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" abstract="false" name="SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SellingGeneralAndAdministrativeExpenseMember" abstract="true" name="SellingGeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_A5.00SeniorNotesDueJanuary2028Member" abstract="true" name="A5.00SeniorNotesDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" abstract="false" name="GoodwillTransfersRelatedToSaleOfBusinessUnit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccumulatedLossesAvailableForFederalPurposes" abstract="false" name="AccumulatedLossesAvailableForFederalPurposes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" abstract="true" name="SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" abstract="false" name="ForeignCurrencyTransactionAndOtherGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NonExecutiveEligibleRecipientsMember" abstract="true" name="NonExecutiveEligibleRecipientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetImpairmentChargesMember" abstract="true" name="AssetImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" abstract="false" name="IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" abstract="true" name="InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PreserVisionAREDSPatentLitigationMember" abstract="true" name="PreserVisionAREDSPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ACertainInternationalBusinessMember" abstract="true" name="ACertainInternationalBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" abstract="false" name="RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" abstract="false" name="RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" abstract="false" name="PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NonU.S.DevelopedMarketsMember" abstract="true" name="NonU.S.DevelopedMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_AssetAcquisitionAndBusinessCombinationAxis" abstract="true" name="AssetAcquisitionAndBusinessCombinationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_CollaborativeAgreementMilestonePaymentsAggregate" abstract="false" name="CollaborativeAgreementMilestonePaymentsAggregate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" abstract="true" name="ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DivestituresOfNoncoreProductsPolicyTextBlock" abstract="false" name="DivestituresOfNoncoreProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" abstract="false" name="DebtInstrumentCreditSpreadAdjustmentOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_TaxBenefitRecognitionMeasurementPercentage" abstract="false" name="TaxBenefitRecognitionMeasurementPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RICOClassActionsLitigationMember" abstract="true" name="RICOClassActionsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" abstract="true" name="ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AssetAcquisitionAndBusinessCombinationLineItems" abstract="true" name="AssetAcquisitionAndBusinessCombinationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_A5.50SeniorNotesdueMarch2023Member" abstract="true" name="A5.50SeniorNotesdueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsLupinANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" abstract="false" name="AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnutilizedITInfrastructureImprovementProjectMember" abstract="true" name="UnutilizedITInfrastructureImprovementProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A1375209BCLtdMember" abstract="true" name="A1375209BCLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" abstract="false" name="DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A7.00SeniorUnsecuredNotesDue2028Member" abstract="true" name="A7.00SeniorUnsecuredNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueFebruary2027Member" abstract="true" name="RevolvingCreditFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" abstract="true" name="SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanPercentageAllocationofFund" abstract="false" name="DefinedBenefitPlanPercentageAllocationofFund" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A7.25SeniorUnsecuredNotesDue2029Member" abstract="true" name="A7.25SeniorUnsecuredNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfProceedings" abstract="false" name="GainContingencyNumberOfProceedings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriodOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DefaultJudgementMember" abstract="true" name="DefaultJudgementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_U.S.BroadMarketMember" abstract="true" name="U.S.BroadMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" abstract="false" name="DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" abstract="true" name="CapitalExpenditureAndDepreciationAndAmortizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_EquipmentOnOperatingLeaseMember" abstract="true" name="EquipmentOnOperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InvestmentGradeMember" abstract="true" name="InvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherAssetsFixedIncomeSecuritiesMember" abstract="true" name="OtherAssetsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2005ThroughTaxYear2009Member" abstract="true" name="TaxYear2005ThroughTaxYear2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeAxis" abstract="true" name="TroubledDebtRestructuringDebtorTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SOFRCDORAndEURIBORRatesMember" abstract="true" name="SOFRCDORAndEURIBORRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" abstract="true" name="ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NonU.S.OtherAssetsMember" abstract="true" name="NonU.S.OtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetAcquisitionAndBusinessCombinationDomain" abstract="true" name="AssetAcquisitionAndBusinessCombinationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" abstract="false" name="ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfDefendants" abstract="false" name="GainContingencyNumberOfDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EyenoviaIncMember" abstract="true" name="EyenoviaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" abstract="false" name="DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" abstract="true" name="BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixReportingUnitMember" abstract="true" name="SalixReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" abstract="true" name="ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" abstract="false" name="DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NorwichPharmaceuticalsIncLitigationMember" abstract="true" name="NorwichPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes4.502023Member" abstract="true" name="SeniorNotes4.502023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" abstract="false" name="MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" abstract="false" name="ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" abstract="false" name="PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" abstract="true" name="SeniorSecured1100NotesFirstLienDueSeptember2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AurobindoPharmaLimitedLitigationMember" abstract="true" name="AurobindoPharmaLimitedLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsLineItems" abstract="true" name="ScheduleOfCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CashDiscountsAndAllowancesSettlementPeriod" abstract="false" name="CashDiscountsAndAllowancesSettlementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PastDuePeriodForAccountsReceivableToBeNegligible" abstract="false" name="PastDuePeriodForAccountsReceivableToBeNegligible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" abstract="true" name="TermLoanBFacilityDueJune2025AndNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IPOFoundersGrantsMember" abstract="true" name="IPOFoundersGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bhc-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_457e67a6-2283-4028-ad0d-bc1106fd4e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b71c7fa-bdca-422e-8e27-2bbe0ec1d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_457e67a6-2283-4028-ad0d-bc1106fd4e13" xlink:to="loc_us-gaap_CommonStockValue_0b71c7fa-bdca-422e-8e27-2bbe0ec1d3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_223804cd-902f-4107-9807-943d45f0e4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_457e67a6-2283-4028-ad0d-bc1106fd4e13" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_223804cd-902f-4107-9807-943d45f0e4c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97a3cca3-275b-427b-9f68-ab332478ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_457e67a6-2283-4028-ad0d-bc1106fd4e13" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97a3cca3-275b-427b-9f68-ab332478ff8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc64b023-c4bb-4d50-aa55-f891b31e1ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_457e67a6-2283-4028-ad0d-bc1106fd4e13" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc64b023-c4bb-4d50-aa55-f891b31e1ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19b0fa95-3556-43f5-bf4c-fa78641cf983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_19b0fa95-3556-43f5-bf4c-fa78641cf983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_23930b66-bb96-4350-8c47-f4578f058fdb" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_23930b66-bb96-4350-8c47-f4578f058fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_27a82a74-6d57-4574-9092-210386d00d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_27a82a74-6d57-4574-9092-210386d00d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7dfe2a6b-1e09-4345-abb6-5f57f3560c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:to="loc_us-gaap_InventoryNet_7dfe2a6b-1e09-4345-abb6-5f57f3560c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b4c54df-b2f7-41c3-bb29-8fc1ba1c4424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e041b374-208a-4ca9-b419-52535188ee2b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b4c54df-b2f7-41c3-bb29-8fc1ba1c4424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbc1b06a-ea77-4598-a2b7-5025abe0efb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b3c1560-722c-448a-b185-2a89737d2f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbc1b06a-ea77-4598-a2b7-5025abe0efb7" xlink:to="loc_us-gaap_Liabilities_7b3c1560-722c-448a-b185-2a89737d2f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fca98508-af2f-4034-8542-eed78372c73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbc1b06a-ea77-4598-a2b7-5025abe0efb7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fca98508-af2f-4034-8542-eed78372c73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4524a2a3-f530-4fb7-ade5-a0494433960e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bbc1b06a-ea77-4598-a2b7-5025abe0efb7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4524a2a3-f530-4fb7-ade5-a0494433960e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ce40f5d5-00f4-4d08-914a-8e62ab8e1743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4a8b8643-6c94-4d5b-a28a-1d5b7d5cb214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce40f5d5-00f4-4d08-914a-8e62ab8e1743" xlink:to="loc_us-gaap_AccountsPayableCurrent_4a8b8643-6c94-4d5b-a28a-1d5b7d5cb214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5e10ac35-5574-4ba0-b251-447c24f87278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce40f5d5-00f4-4d08-914a-8e62ab8e1743" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5e10ac35-5574-4ba0-b251-447c24f87278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_fd53ba12-5a7f-4207-919a-8e55cd356a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ce40f5d5-00f4-4d08-914a-8e62ab8e1743" xlink:to="loc_us-gaap_LongTermDebtCurrent_fd53ba12-5a7f-4207-919a-8e55cd356a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a66f9f78-0eb2-44e3-b3ee-0c45e8c89eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:to="loc_us-gaap_LiabilitiesCurrent_a66f9f78-0eb2-44e3-b3ee-0c45e8c89eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_f3276fa0-2b33-4a56-9e38-7a5a16a9f674" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_f3276fa0-2b33-4a56-9e38-7a5a16a9f674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e23e6992-e6a1-4723-82ec-165769486aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e23e6992-e6a1-4723-82ec-165769486aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_527d6734-41f8-429d-b738-b73717ccb3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_527d6734-41f8-429d-b738-b73717ccb3b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_63f6c7ac-b3fe-4b59-bb66-767d798a5091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ccb5fc75-6024-4685-8380-3e071850c45c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_63f6c7ac-b3fe-4b59-bb66-767d798a5091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d9508fa9-debd-4f97-8ccd-496b8f8ef0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_AssetsCurrent_d9508fa9-debd-4f97-8ccd-496b8f8ef0a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_970a4fbc-a9e7-41ed-8a33-6abdfce0b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_970a4fbc-a9e7-41ed-8a33-6abdfce0b2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bb0af81c-a858-4e6c-8f93-10989265305e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bb0af81c-a858-4e6c-8f93-10989265305e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cbb067d7-35ca-417b-9c5d-9201452016a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_Goodwill_cbb067d7-35ca-417b-9c5d-9201452016a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9406326a-a5c9-4ef0-b7f7-9c7f59430020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9406326a-a5c9-4ef0-b7f7-9c7f59430020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_73d02569-3125-4d2a-9917-71f29ca74a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1b8aae75-1e6b-4bdf-b4f3-55c4bae38714" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_73d02569-3125-4d2a-9917-71f29ca74a2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51caac66-d4b5-4096-8148-8ccec25a6814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_48384286-0c48-4b2c-97bb-b937856b02b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51caac66-d4b5-4096-8148-8ccec25a6814" xlink:to="loc_us-gaap_StockholdersEquity_48384286-0c48-4b2c-97bb-b937856b02b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ec010521-91b6-4a4f-a7df-bd7537acded3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51caac66-d4b5-4096-8148-8ccec25a6814" xlink:to="loc_us-gaap_MinorityInterest_ec010521-91b6-4a4f-a7df-bd7537acded3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_56bb2602-a284-43ed-9493-02910f255dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17f8f7ef-6af6-43f7-93bf-5d80490931af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_56bb2602-a284-43ed-9493-02910f255dfd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17f8f7ef-6af6-43f7-93bf-5d80490931af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_377a71e7-9a67-4c5d-b8ae-3199a02cc794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_56bb2602-a284-43ed-9493-02910f255dfd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_377a71e7-9a67-4c5d-b8ae-3199a02cc794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_55a56017-eaef-4be1-ba43-0c8c380052b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bfb94777-187f-4bd6-8e91-cbdaca5191c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_55a56017-eaef-4be1-ba43-0c8c380052b5" xlink:to="loc_us-gaap_ProfitLoss_bfb94777-187f-4bd6-8e91-cbdaca5191c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eac92013-a520-4b80-b007-09d8c473a046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_55a56017-eaef-4be1-ba43-0c8c380052b5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eac92013-a520-4b80-b007-09d8c473a046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cea67024-c733-4a4c-b2ce-a033e24a5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aac866cd-4fff-4f52-8078-92f7f812dd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cea67024-c733-4a4c-b2ce-a033e24a5cb1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aac866cd-4fff-4f52-8078-92f7f812dd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9cf5cd32-2b61-4912-891a-6aec21babfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cea67024-c733-4a4c-b2ce-a033e24a5cb1" xlink:to="loc_us-gaap_CostsAndExpenses_9cf5cd32-2b61-4912-891a-6aec21babfb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3ed4efd8-0916-4af9-ba9b-6d439c658136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3ed4efd8-0916-4af9-ba9b-6d439c658136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1375c4d9-6253-42d5-b920-811aedac925b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1375c4d9-6253-42d5-b920-811aedac925b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7cbebf39-391b-4955-b8e5-477775f25d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7cbebf39-391b-4955-b8e5-477775f25d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_9110b620-34ed-4669-8083-aadde7fed834" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_9110b620-34ed-4669-8083-aadde7fed834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_e0c8328a-4eba-4c74-b9c3-39cc014cf8ff" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_e0c8328a-4eba-4c74-b9c3-39cc014cf8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_902d6d24-f012-4a0f-a1d7-9c09a97e945d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_us-gaap_AssetImpairmentCharges_902d6d24-f012-4a0f-a1d7-9c09a97e945d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_cb72d55e-2231-4b47-9c85-c390e378c8ac" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_cb72d55e-2231-4b47-9c85-c390e378c8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_d79d6659-6f39-49d5-aedf-1d6cc8af38e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bcdb1e55-0978-4003-8e8d-03ffdf4f54cf" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_d79d6659-6f39-49d5-aedf-1d6cc8af38e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef15740a-3f35-4c28-bd4e-09ce2c03d138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:to="loc_us-gaap_OperatingIncomeLoss_ef15740a-3f35-4c28-bd4e-09ce2c03d138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd81c4bc-d97a-4f86-bee0-468995ed8983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd81c4bc-d97a-4f86-bee0-468995ed8983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_70b516b7-8ec7-46ac-9627-0bb201d61fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:to="loc_us-gaap_InterestExpenseDebt_70b516b7-8ec7-46ac-9627-0bb201d61fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_431d93bd-418c-4a8c-8936-35d57d5fae59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_431d93bd-418c-4a8c-8936-35d57d5fae59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8cb40850-8889-4644-b142-1b23116f15e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_18eab167-bb1c-40e3-876d-7e6f11c73536" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8cb40850-8889-4644-b142-1b23116f15e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_46a70e1d-7a7a-4b19-acd5-4e5f817c62aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_46a70e1d-7a7a-4b19-acd5-4e5f817c62aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_8c270257-5910-4ed3-8c80-b9660e1e2ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_8c270257-5910-4ed3-8c80-b9660e1e2ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_b9defe3e-7c09-4a99-8c52-cefba7f7f30d" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_b9defe3e-7c09-4a99-8c52-cefba7f7f30d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_22e663af-98c2-4037-a4ad-1ba9425f7444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_22e663af-98c2-4037-a4ad-1ba9425f7444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_c196f603-d2f4-47d3-8d82-d269991ae79b" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d2c6509-2c81-462e-92ca-c231afb25e87" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_c196f603-d2f4-47d3-8d82-d269991ae79b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1ca992c-18b0-4191-b61a-4cbe73ace7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3d351591-e7f8-4d5f-aae4-a78d8255fbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1ca992c-18b0-4191-b61a-4cbe73ace7d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3d351591-e7f8-4d5f-aae4-a78d8255fbf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be6b4f67-ec24-4ea5-b8dc-75da8fea64ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a1ca992c-18b0-4191-b61a-4cbe73ace7d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_be6b4f67-ec24-4ea5-b8dc-75da8fea64ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f90de91-2fa7-48fd-9358-7de50b8cd4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_32536bfc-dbca-481d-b5a3-79bd873cef14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f90de91-2fa7-48fd-9358-7de50b8cd4d5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_32536bfc-dbca-481d-b5a3-79bd873cef14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad53d08e-17c4-4e0e-a878-d8ab4b5e650d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5f90de91-2fa7-48fd-9358-7de50b8cd4d5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad53d08e-17c4-4e0e-a878-d8ab4b5e650d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f9597c6b-abdc-4418-9b7f-307d84986d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9a8a50bf-6606-479c-9f40-5c204cac44e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f9597c6b-abdc-4418-9b7f-307d84986d46" xlink:to="loc_us-gaap_ProfitLoss_9a8a50bf-6606-479c-9f40-5c204cac44e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7043c096-bb92-4374-95c4-1b5c7e7746ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f9597c6b-abdc-4418-9b7f-307d84986d46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7043c096-bb92-4374-95c4-1b5c7e7746ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16fb0417-f3e9-454b-959a-53a9bdd18879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da42ae2a-24b5-49e0-ab8b-f863781c6571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16fb0417-f3e9-454b-959a-53a9bdd18879" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da42ae2a-24b5-49e0-ab8b-f863781c6571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6383d7c-3eda-4d5d-b43c-1802523bcd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16fb0417-f3e9-454b-959a-53a9bdd18879" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a6383d7c-3eda-4d5d-b43c-1802523bcd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36dccf75-cb90-4403-be89-925a231e0114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16fb0417-f3e9-454b-959a-53a9bdd18879" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36dccf75-cb90-4403-be89-925a231e0114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa0b1fef-8ff0-4598-8948-7ce2b918c491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16fb0417-f3e9-454b-959a-53a9bdd18879" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa0b1fef-8ff0-4598-8948-7ce2b918c491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bac53a5-b4de-4d2e-b7a1-23bc65dfa1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c76ecf4-3628-4cc8-a74a-7fa2068b5686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bac53a5-b4de-4d2e-b7a1-23bc65dfa1d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c76ecf4-3628-4cc8-a74a-7fa2068b5686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ca4ba4d9-2c71-4021-9028-cdd638984541" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8bac53a5-b4de-4d2e-b7a1-23bc65dfa1d4" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ca4ba4d9-2c71-4021-9028-cdd638984541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6187a8d0-c286-4e45-87eb-c8cfbeb35455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6187a8d0-c286-4e45-87eb-c8cfbeb35455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a1631f89-7321-48c7-a382-de442cf988f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a1631f89-7321-48c7-a382-de442cf988f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c205612-7ba8-41e2-928e-647df970367c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c205612-7ba8-41e2-928e-647df970367c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9d8dc170-c869-483f-aae8-b2612d17789d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9d8dc170-c869-483f-aae8-b2612d17789d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_30d761b6-c908-48e6-b333-9c892cd49c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_30d761b6-c908-48e6-b333-9c892cd49c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_6fa4c532-9f85-4296-8171-19c585a37bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_6fa4c532-9f85-4296-8171-19c585a37bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_01b85bb7-acbb-49d0-8305-9da8b7561870" xlink:href="bhc-20221231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3f0d3025-0398-43f0-90f9-bf88c169917f" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_01b85bb7-acbb-49d0-8305-9da8b7561870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_44b48d9f-6e4d-4502-8cb1-77e789463fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_ProfitLoss_44b48d9f-6e4d-4502-8cb1-77e789463fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_447d8d0c-9306-41f0-bd10-f8e08cf3540b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_DepreciationAndAmortization_447d8d0c-9306-41f0-bd10-f8e08cf3540b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0662542-b5b8-4c45-a475-98768adfdabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0662542-b5b8-4c45-a475-98768adfdabb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b36255e1-18b2-43cf-bd82-b09416066f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_AssetImpairmentCharges_b36255e1-18b2-43cf-bd82-b09416066f7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_8e6d435a-3d63-4831-93e2-67edff9aecde" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_8e6d435a-3d63-4831-93e2-67edff9aecde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_a7f70e27-68b5-4c9e-b76c-2ecef508626e" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_a7f70e27-68b5-4c9e-b76c-2ecef508626e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_37bdf586-c5bc-4e30-b6e3-e892cf48a564" xlink:href="bhc-20221231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_37bdf586-c5bc-4e30-b6e3-e892cf48a564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_6a2a58b9-103b-43b0-aec8-f927b1372883" xlink:href="bhc-20221231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_6a2a58b9-103b-43b0-aec8-f927b1372883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_21aace18-c28c-4ae3-b279-af256c7a6967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_21aace18-c28c-4ae3-b279-af256c7a6967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_c603ca86-7e26-4195-b871-6860d2b15dcb" xlink:href="bhc-20221231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_c603ca86-7e26-4195-b871-6860d2b15dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_79dd49a7-1582-49e5-8591-e3398018786b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_79dd49a7-1582-49e5-8591-e3398018786b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a128b119-677b-44da-9b64-6d6691e03a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_ShareBasedCompensation_a128b119-677b-44da-9b64-6d6691e03a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_9f57f47b-345f-415b-b8a0-606526a3e6ec" xlink:href="bhc-20221231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_DerivativeGainExcludedComponent_9f57f47b-345f-415b-b8a0-606526a3e6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d431fc9c-1db2-447b-9342-cd39460319cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d431fc9c-1db2-447b-9342-cd39460319cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_01817c12-c729-4bcb-b565-3ea115878fb2" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_01817c12-c729-4bcb-b565-3ea115878fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_a71a3d24-81e7-4448-bd61-b816450becdd" xlink:href="bhc-20221231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_a71a3d24-81e7-4448-bd61-b816450becdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_447de189-d160-469e-99dc-17a1f808b9e1" xlink:href="bhc-20221231.xsd#bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_447de189-d160-469e-99dc-17a1f808b9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77bb26ef-ba40-4723-8572-c53e5ba914e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_77bb26ef-ba40-4723-8572-c53e5ba914e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7caa5787-e258-4b59-9906-c61896320dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7caa5787-e258-4b59-9906-c61896320dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3fee0ff-7673-4f8e-b553-b417912973ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3fee0ff-7673-4f8e-b553-b417912973ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50614281-df01-468b-a249-92ee3e085c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70ff0459-d12c-4f36-9a25-319a6b6335c5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_50614281-df01-468b-a249-92ee3e085c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3adf262a-de52-453b-9651-ec42a3ef0e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3adf262a-de52-453b-9651-ec42a3ef0e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bd91f0a6-09cb-4f1e-ab58-94cfd1739b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bd91f0a6-09cb-4f1e-ab58-94cfd1739b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_941f1aa9-626e-4ea3-994c-be68be24dfe2" xlink:href="bhc-20221231.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_941f1aa9-626e-4ea3-994c-be68be24dfe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fff0a371-d09c-4003-8a05-3b7a09c08455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fff0a371-d09c-4003-8a05-3b7a09c08455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f82bca9a-b81f-4e0d-9501-0d6a8847c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f82bca9a-b81f-4e0d-9501-0d6a8847c181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eaf0b1e7-f506-49b7-926d-5107423b48d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_eaf0b1e7-f506-49b7-926d-5107423b48d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f5310b1a-2364-4ec2-a11d-2fe927d42c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7adf722-39bb-42da-8a72-21c9fa5e409f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f5310b1a-2364-4ec2-a11d-2fe927d42c9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9796c5dd-0d2f-4636-bf05-8c9635620dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_80cedf58-bd8f-49aa-a14d-a463ffb25543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9796c5dd-0d2f-4636-bf05-8c9635620dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_80cedf58-bd8f-49aa-a14d-a463ffb25543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7d019871-a4d0-4f07-8a1b-2983f35974b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9796c5dd-0d2f-4636-bf05-8c9635620dcb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7d019871-a4d0-4f07-8a1b-2983f35974b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b7003bef-b985-482a-bfd1-afe6650626a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_7be52cf0-c179-40ee-9159-9b6c46d7475c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7003bef-b985-482a-bfd1-afe6650626a0" xlink:to="loc_us-gaap_InventoryRawMaterials_7be52cf0-c179-40ee-9159-9b6c46d7475c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a1988dc8-b7ea-465c-9567-ebc07be29a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7003bef-b985-482a-bfd1-afe6650626a0" xlink:to="loc_us-gaap_InventoryWorkInProcess_a1988dc8-b7ea-465c-9567-ebc07be29a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bf274468-4bbb-47bb-bf4c-10bae0cc34ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_b7003bef-b985-482a-bfd1-afe6650626a0" xlink:to="loc_us-gaap_InventoryFinishedGoods_bf274468-4bbb-47bb-bf4c-10bae0cc34ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6a2290de-cdaa-44f3-b3cf-a467dcceebce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1431540d-2daa-4aeb-ab83-37c725bac5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6a2290de-cdaa-44f3-b3cf-a467dcceebce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1431540d-2daa-4aeb-ab83-37c725bac5af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5928eda5-ef5c-4b54-841c-c57d2ca805d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6a2290de-cdaa-44f3-b3cf-a467dcceebce" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5928eda5-ef5c-4b54-841c-c57d2ca805d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1fa9049e-ef0c-4be1-bf49-d48b8d7ac028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c9159515-0222-4a70-92a2-762db1d93dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1fa9049e-ef0c-4be1-bf49-d48b8d7ac028" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c9159515-0222-4a70-92a2-762db1d93dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e20c3fd1-3887-4f80-834a-68c12029d5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1fa9049e-ef0c-4be1-bf49-d48b8d7ac028" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e20c3fd1-3887-4f80-834a-68c12029d5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60e0ca9f-7daa-4ea5-ac3a-e39f4a13579e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f1ea1f1b-d0d4-416e-bee0-2aca84416112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60e0ca9f-7daa-4ea5-ac3a-e39f4a13579e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f1ea1f1b-d0d4-416e-bee0-2aca84416112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_993609c0-475b-4ce5-bd14-4207afc11132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_60e0ca9f-7daa-4ea5-ac3a-e39f4a13579e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_993609c0-475b-4ce5-bd14-4207afc11132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aecdd166-ad4a-4014-bfbc-54a09ba624ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b9bda699-bc6c-4a29-9430-f74b3d764dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aecdd166-ad4a-4014-bfbc-54a09ba624ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b9bda699-bc6c-4a29-9430-f74b3d764dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_13b1d4b3-53ee-4d06-9733-4c740f70832a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aecdd166-ad4a-4014-bfbc-54a09ba624ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_13b1d4b3-53ee-4d06-9733-4c740f70832a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45f1d13c-9bcc-4e93-bdbe-53193e2e63d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2122368c-0e93-41e8-a6b2-8b07798f0f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45f1d13c-9bcc-4e93-bdbe-53193e2e63d4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2122368c-0e93-41e8-a6b2-8b07798f0f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b15ad603-20f4-40a3-95bb-760e0fd5886c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45f1d13c-9bcc-4e93-bdbe-53193e2e63d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b15ad603-20f4-40a3-95bb-760e0fd5886c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a2538f95-df6c-4351-9117-84486f616850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a2538f95-df6c-4351-9117-84486f616850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_56f77d91-2014-4af0-9384-848268342685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_56f77d91-2014-4af0-9384-848268342685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_320869da-fbaa-4f21-932e-61b50711c47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_320869da-fbaa-4f21-932e-61b50711c47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2e75c06-017c-4a76-8f9a-2d3c7428a132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c2e75c06-017c-4a76-8f9a-2d3c7428a132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2d8fc560-6883-4906-befc-be3cafc05894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2d8fc560-6883-4906-befc-be3cafc05894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a1f96378-43ba-4b43-9ff1-0ba3a7d814e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_335392ef-6ef4-4af0-ab05-7337b897e1ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a1f96378-43ba-4b43-9ff1-0ba3a7d814e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LegalSettlementsAndRelatedFees_458142fc-23cb-4e25-906c-1c8314a34c75" xlink:href="bhc-20221231.xsd#bhc_LegalSettlementsAndRelatedFees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_bhc_LegalSettlementsAndRelatedFees_458142fc-23cb-4e25-906c-1c8314a34c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_3f8108a3-6181-4053-8800-8a57146de434" xlink:href="bhc-20221231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_bhc_AccruedProductRebateCurrent_3f8108a3-6181-4053-8800-8a57146de434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_e571020e-bf1c-48df-924c-064aafcb5e49" xlink:href="bhc-20221231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_bhc_AccruedProductReturnCurrent_e571020e-bf1c-48df-924c-064aafcb5e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_604f58cc-3d5c-4be6-923a-9880106f257c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_604f58cc-3d5c-4be6-923a-9880106f257c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_ba4b8484-4a09-4fd4-962f-9bd45e1d72af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_us-gaap_InterestPayableCurrent_ba4b8484-4a09-4fd4-962f-9bd45e1d72af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_85fc67a2-24c2-4e65-8b1a-97246e323a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_85fc67a2-24c2-4e65-8b1a-97246e323a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_577b1964-55e0-41ee-af0a-402fe9d075cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_fe6cf80e-1b64-4d2b-807c-a7fd0673dfcf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_577b1964-55e0-41ee-af0a-402fe9d075cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5641f0f7-c269-41b1-bb3d-b1438b8c90e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ec8c4ff6-18b1-4610-851c-93957fb69e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5641f0f7-c269-41b1-bb3d-b1438b8c90e7" xlink:to="loc_us-gaap_LongTermDebtCurrent_ec8c4ff6-18b1-4610-851c-93957fb69e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1afd7a30-ccd6-44ba-a78f-99c31f4df37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5641f0f7-c269-41b1-bb3d-b1438b8c90e7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1afd7a30-ccd6-44ba-a78f-99c31f4df37f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_099c3890-823a-48b4-913e-4af94ba0d6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d3a1533b-528d-4aa9-9eb5-a5f222415455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_099c3890-823a-48b4-913e-4af94ba0d6af" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d3a1533b-528d-4aa9-9eb5-a5f222415455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96469478-4a41-4ac5-bf0a-5a63204bd3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_099c3890-823a-48b4-913e-4af94ba0d6af" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96469478-4a41-4ac5-bf0a-5a63204bd3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_106286eb-92fe-4e31-b53f-366b1a14e160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_106286eb-92fe-4e31-b53f-366b1a14e160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0d39749e-c0d3-478c-afa5-d5c036c21244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0d39749e-c0d3-478c-afa5-d5c036c21244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7d52c1ed-21d9-4942-9143-f0b5a1b0c389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7d52c1ed-21d9-4942-9143-f0b5a1b0c389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fe45f73a-7ba4-4433-bbb4-7625f6a702cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fe45f73a-7ba4-4433-bbb4-7625f6a702cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_83aa5e6b-b7e6-4857-872d-fd3f323deb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_83aa5e6b-b7e6-4857-872d-fd3f323deb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_62fb8e63-5b57-4e63-a054-c79b10947f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_68ab2abf-a236-4f98-bbc8-bd58292f644c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_62fb8e63-5b57-4e63-a054-c79b10947f5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_abe57fd0-8b59-4b08-8cc0-e2eb19853b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_abe57fd0-8b59-4b08-8cc0-e2eb19853b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_cc4b0817-1e42-4ddd-b99f-dc9d82cbb6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_cc4b0817-1e42-4ddd-b99f-dc9d82cbb6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_538338ce-b645-403d-829c-b88f349fcbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_538338ce-b645-403d-829c-b88f349fcbb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_da72e92c-8d34-43c1-9f1f-60f5a25dc970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_da72e92c-8d34-43c1-9f1f-60f5a25dc970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e0bc649a-6565-406c-86c7-f1e822375c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e0bc649a-6565-406c-86c7-f1e822375c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_571d1b37-214c-43c0-a80d-0936e527c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_227a7859-bae5-4d47-8337-c351d6e29dab" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_571d1b37-214c-43c0-a80d-0936e527c548" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9ef834a4-40c2-4b25-839e-811dcf323d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_65a4ab5f-b29f-4307-ad63-2710329e1d04" xlink:href="bhc-20221231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9ef834a4-40c2-4b25-839e-811dcf323d9b" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_65a4ab5f-b29f-4307-ad63-2710329e1d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_1473b0fd-5424-497f-893d-69f1a17aa268" xlink:href="bhc-20221231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9ef834a4-40c2-4b25-839e-811dcf323d9b" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_1473b0fd-5424-497f-893d-69f1a17aa268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_362a0a4f-41be-4dfd-a696-4da1fb573b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9ef834a4-40c2-4b25-839e-811dcf323d9b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_362a0a4f-41be-4dfd-a696-4da1fb573b2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_282e12d4-79da-4a29-8abd-d225cb2988b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5da321fe-75ac-46bf-9df2-713505527a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_282e12d4-79da-4a29-8abd-d225cb2988b6" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_5da321fe-75ac-46bf-9df2-713505527a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3d1cd237-bbbb-46f8-be3b-e7fc683dcaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_282e12d4-79da-4a29-8abd-d225cb2988b6" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_3d1cd237-bbbb-46f8-be3b-e7fc683dcaf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8c0a6aef-618c-44bf-9f60-b603b3cbe9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1eb15c8-5d5c-43a7-8e8a-647c7ba4cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8c0a6aef-618c-44bf-9f60-b603b3cbe9e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d1eb15c8-5d5c-43a7-8e8a-647c7ba4cdde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b00e7fc-633b-475c-99d8-b452cc68cfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8c0a6aef-618c-44bf-9f60-b603b3cbe9e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b00e7fc-633b-475c-99d8-b452cc68cfad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a373471-cf3e-4391-9eac-a6d0931771b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30c0a2ce-c804-40fa-9014-8f3753431b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a373471-cf3e-4391-9eac-a6d0931771b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30c0a2ce-c804-40fa-9014-8f3753431b18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_38eaffc4-a5e4-4499-b506-3b16ddd3fc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a373471-cf3e-4391-9eac-a6d0931771b9" xlink:to="loc_us-gaap_OperatingLeaseLiability_38eaffc4-a5e4-4499-b506-3b16ddd3fc6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3030d09d-61e9-4fce-9bd5-3370cbd88ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3030d09d-61e9-4fce-9bd5-3370cbd88ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4cd324e3-1557-4408-933e-ba169ace265e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4cd324e3-1557-4408-933e-ba169ace265e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d300450e-b4f4-4770-b3d2-f3622986633b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d300450e-b4f4-4770-b3d2-f3622986633b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7407f30-8344-426d-99fa-ef3c7b894eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d7407f30-8344-426d-99fa-ef3c7b894eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3c10cb1e-8bd9-41bf-b531-54fab21c24c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3c10cb1e-8bd9-41bf-b531-54fab21c24c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6bdbaeea-d06b-4131-bab2-5cc6a85412f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2d42fb6c-df88-43c7-8b41-934bc93c431e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6bdbaeea-d06b-4131-bab2-5cc6a85412f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_159d249a-6068-43ad-a7b4-aacf6e3a1570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_27b4bed1-9ef2-4db8-b4a9-c994e336fa5f" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_159d249a-6068-43ad-a7b4-aacf6e3a1570" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_27b4bed1-9ef2-4db8-b4a9-c994e336fa5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_ca2eca80-badd-4b5f-bd83-cb01d87ee217" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_159d249a-6068-43ad-a7b4-aacf6e3a1570" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_ca2eca80-badd-4b5f-bd83-cb01d87ee217" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENETScheduleofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_9343f299-9782-4752-8535-b388936173d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_9343f299-9782-4752-8535-b388936173d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_37ee05a5-c674-4fc5-92f7-0516eaacb05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_37ee05a5-c674-4fc5-92f7-0516eaacb05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_34087a22-d502-483f-8fb7-b19327ac70b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_34087a22-d502-483f-8fb7-b19327ac70b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_45c344ab-4fe9-42ec-8d23-59c4eaba5118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_45c344ab-4fe9-42ec-8d23-59c4eaba5118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_cd3a19f0-1329-414b-89a7-aa64bf75a04a" xlink:href="bhc-20221231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e0dec24d-3cc7-4275-98e9-1c57c71761ef" xlink:to="loc_bhc_OtherIncomeExpenseNet_cd3a19f0-1329-414b-89a7-aa64bf75a04a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71caf516-81aa-48aa-bfa5-1ea1e0dabfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_990a4806-993a-4bbc-b1e7-a40777e2fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71caf516-81aa-48aa-bfa5-1ea1e0dabfbd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_990a4806-993a-4bbc-b1e7-a40777e2fcdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6040c815-4494-449b-b574-8a1dad20d114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71caf516-81aa-48aa-bfa5-1ea1e0dabfbd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6040c815-4494-449b-b574-8a1dad20d114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad3f3161-f0ab-4d57-88a3-ef0cf717da2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fd049143-c42f-4c66-855d-241390abfc36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad3f3161-f0ab-4d57-88a3-ef0cf717da2b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fd049143-c42f-4c66-855d-241390abfc36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1bb49307-3490-4237-a971-d3b37d3f3f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad3f3161-f0ab-4d57-88a3-ef0cf717da2b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1bb49307-3490-4237-a971-d3b37d3f3f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_104311f9-01d2-4ef6-a17b-4f741bee4c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d4cdc9f0-4536-40ed-8bc9-23de408a1546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_104311f9-01d2-4ef6-a17b-4f741bee4c2f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d4cdc9f0-4536-40ed-8bc9-23de408a1546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_80dbf0c0-8070-45c1-9180-c69d5bf3c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_104311f9-01d2-4ef6-a17b-4f741bee4c2f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_80dbf0c0-8070-45c1-9180-c69d5bf3c13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2341ed03-4d25-4a19-8beb-61237b55969f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7e82471f-b21a-4abf-99b2-ec1614f809ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2341ed03-4d25-4a19-8beb-61237b55969f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7e82471f-b21a-4abf-99b2-ec1614f809ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd7367f7-1cd9-4510-bcec-f804f0a1ff47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2341ed03-4d25-4a19-8beb-61237b55969f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd7367f7-1cd9-4510-bcec-f804f0a1ff47" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_6e97d584-3fd0-4289-b7a6-7215f594f3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_6e97d584-3fd0-4289-b7a6-7215f594f3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6c521d41-c20b-449d-bcec-9b85fb5ee1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6c521d41-c20b-449d-bcec-9b85fb5ee1bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_f26c22e5-f7f9-42f5-a4b4-d14deb2e1f23" xlink:href="bhc-20221231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_f26c22e5-f7f9-42f5-a4b4-d14deb2e1f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_cd5bcba7-b37c-472f-9fab-e1aa4d7301f3" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_cd5bcba7-b37c-472f-9fab-e1aa4d7301f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_cf1edca1-5b3d-40e6-9751-84cb54ca5e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_cf1edca1-5b3d-40e6-9751-84cb54ca5e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_61d5b563-7e17-4cf1-a1b9-d3fde6818e48" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_61d5b563-7e17-4cf1-a1b9-d3fde6818e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f596e2fb-bfcd-4628-a488-6ee962f8ee42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f596e2fb-bfcd-4628-a488-6ee962f8ee42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_0d2c1117-b2cf-4af0-91cb-3d40c85deb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_0d2c1117-b2cf-4af0-91cb-3d40c85deb5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_32174e22-95cb-41f1-837c-0be54b6746bc" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_32174e22-95cb-41f1-837c-0be54b6746bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_55d783fa-f27b-402c-a15d-f0e99f4dc6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a11f6878-27e6-4316-b206-ea5c8c93805d" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_55d783fa-f27b-402c-a15d-f0e99f4dc6a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bbacfb2f-65cb-4741-bd37-4c0cf67b613c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_33278222-5496-4f40-a2ed-bd4e1606f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bbacfb2f-65cb-4741-bd37-4c0cf67b613c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_33278222-5496-4f40-a2ed-bd4e1606f1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3674bac4-7a39-43ce-805b-d2b3a33ebf14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bbacfb2f-65cb-4741-bd37-4c0cf67b613c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3674bac4-7a39-43ce-805b-d2b3a33ebf14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_b8f0d93d-ce1a-4be4-8069-cc2438da0ace" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_b8f0d93d-ce1a-4be4-8069-cc2438da0ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7d89441f-ac74-4251-a676-01fba3125e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7d89441f-ac74-4251-a676-01fba3125e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_057445ed-7725-48d1-919a-8c4394f5e1fc" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_057445ed-7725-48d1-919a-8c4394f5e1fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_38eaa7b5-e7df-48b2-afbc-50dfabf61627" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_38eaa7b5-e7df-48b2-afbc-50dfabf61627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_ca237c1e-fc8f-4838-8510-f1ce91f44e1c" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_ca237c1e-fc8f-4838-8510-f1ce91f44e1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b805eb56-4ab7-4f85-97c8-b24c24ae0cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b805eb56-4ab7-4f85-97c8-b24c24ae0cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4aa8a0a3-6259-4373-a38c-ad95b1cc951d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4aa8a0a3-6259-4373-a38c-ad95b1cc951d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_ea8c8393-bc3c-4aae-ab8b-dc75ce855f16" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_ea8c8393-bc3c-4aae-ab8b-dc75ce855f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f00e4670-3c81-4e3f-a8ac-acbf315a1720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f00e4670-3c81-4e3f-a8ac-acbf315a1720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3d627fee-3470-411d-91ab-9239a86bbc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8d4b4207-55c7-464f-b398-2a93875625be" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3d627fee-3470-411d-91ab-9239a86bbc5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_0c84068c-5471-4873-ae80-76834b5c3dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a73b7e8c-641b-49b5-958c-401fde14c0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0c84068c-5471-4873-ae80-76834b5c3dcc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a73b7e8c-641b-49b5-958c-401fde14c0e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_1691acef-b2c6-4e08-bbef-02aee5e6670c" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0c84068c-5471-4873-ae80-76834b5c3dcc" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_1691acef-b2c6-4e08-bbef-02aee5e6670c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_81847fdb-621b-45cd-ab78-8fc7d4e1958d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_0c84068c-5471-4873-ae80-76834b5c3dcc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_81847fdb-621b-45cd-ab78-8fc7d4e1958d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0f9644d7-4bd8-4be0-b43c-9fa526c65a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c5e89a7f-16d1-4129-864e-02d2f35fd88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0f9644d7-4bd8-4be0-b43c-9fa526c65a90" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c5e89a7f-16d1-4129-864e-02d2f35fd88d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a0dfbbf6-4c7c-4c6a-837a-79c39c91988f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0f9644d7-4bd8-4be0-b43c-9fa526c65a90" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a0dfbbf6-4c7c-4c6a-837a-79c39c91988f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bhc-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i8c9900ab454a447dbe95cadfc4a78672_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5bb97809-b8c8-443b-8559-5412282f710e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5bb97809-b8c8-443b-8559-5412282f710e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_949e6ef5-8b44-484d-a58e-b7e6127e1ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_949e6ef5-8b44-484d-a58e-b7e6127e1ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_313a4280-05bd-474a-bed7-60896b6b6be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_313a4280-05bd-474a-bed7-60896b6b6be8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bee0eb3d-8b58-4a06-bf45-169256a77e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bee0eb3d-8b58-4a06-bf45-169256a77e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_a5e20ae6-7be5-43d4-b3e2-0565e58cb3ec" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_a5e20ae6-7be5-43d4-b3e2-0565e58cb3ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_df8d2568-5bde-4732-878d-7e3e75a997d2" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_df8d2568-5bde-4732-878d-7e3e75a997d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9ac41773-a44e-4d92-a96c-5cb3c42255a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_AssetImpairmentCharges_9ac41773-a44e-4d92-a96c-5cb3c42255a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_5c516331-a9ba-49b6-aa26-bd659ec5ddf8" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_5c516331-a9ba-49b6-aa26-bd659ec5ddf8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_12f70df3-0649-4e6f-9f5e-8a276fbfb949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_12f70df3-0649-4e6f-9f5e-8a276fbfb949" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_176ba277-6d17-4bc2-b26e-88efac156f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_CostsAndExpenses_176ba277-6d17-4bc2-b26e-88efac156f4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5b837661-6961-4b1d-bf9d-0605b0b483e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_OperatingIncomeLoss_5b837661-6961-4b1d-bf9d-0605b0b483e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_13d5e822-6160-4cb2-9ad9-ee849d122025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_13d5e822-6160-4cb2-9ad9-ee849d122025" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b47c34aa-6fe0-43c1-8b13-549dae0dbe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_InterestExpenseDebt_b47c34aa-6fe0-43c1-8b13-549dae0dbe61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dab5cd14-35d6-4a40-8334-578b89a03e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dab5cd14-35d6-4a40-8334-578b89a03e6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2e52e5fa-faa3-47c4-8df9-e0dce4e91bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2e52e5fa-faa3-47c4-8df9-e0dce4e91bc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96b45baf-e8a1-4499-aee5-eecb19704b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96b45baf-e8a1-4499-aee5-eecb19704b04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_697ce48d-b39a-4f04-97a2-58ad1d97cce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_697ce48d-b39a-4f04-97a2-58ad1d97cce9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1914e18f-1e54-4ae9-9397-df449ee9b180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_ProfitLoss_1914e18f-1e54-4ae9-9397-df449ee9b180" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d8907ea0-69c7-49cf-a941-c22da16089cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d8907ea0-69c7-49cf-a941-c22da16089cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_071189a7-b9dd-4c37-a724-86d47022ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_NetIncomeLoss_071189a7-b9dd-4c37-a724-86d47022ce73" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5fa979b8-2267-48d1-a106-f61d889b7858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_EarningsPerShareBasic_5fa979b8-2267-48d1-a106-f61d889b7858" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7b673528-43b3-4a0e-9f99-84784db3e9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7b673528-43b3-4a0e-9f99-84784db3e9f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_110163ea-6af9-40e8-baa4-48b0b4503559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_110163ea-6af9-40e8-baa4-48b0b4503559" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea835662-6d05-456d-ada5-cf8a4df3b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea835662-6d05-456d-ada5-cf8a4df3b3dd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:to="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c96d1c36-b59d-446b-bec8-bf55e31c4002_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:to="loc_srt_ProductsAndServicesDomain_c96d1c36-b59d-446b-bec8-bf55e31c4002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:to="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dfeb4ef8-43f4-4529-8252-41c9035cacb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:to="loc_us-gaap_ProductMember_dfeb4ef8-43f4-4529-8252-41c9035cacb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6547b431-1b02-43c9-b55e-a5070c4a30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6547b431-1b02-43c9-b55e-a5070c4a30a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="iecfebb389b8d40ebbe3c1c63f09a4c16_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_68d2cef9-13be-4010-8955-3840354faacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_CommonStockSharesIssued_68d2cef9-13be-4010-8955-3840354faacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569c0a8b-4139-4c6d-bf21-b76314c8c9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569c0a8b-4139-4c6d-bf21-b76314c8c9a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b2487661-b226-4d5d-84c7-ad2f4129fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b2487661-b226-4d5d-84c7-ad2f4129fbcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d51bf340-c871-4efe-a156-c4e79de119ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d51bf340-c871-4efe-a156-c4e79de119ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_df921915-217b-4d5d-9afc-0e4840580b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_df921915-217b-4d5d-9afc-0e4840580b7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5260f8ca-73f6-4494-b2ca-8a577ea31ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5260f8ca-73f6-4494-b2ca-8a577ea31ab1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d79dc674-7e88-468d-8167-1f9183a31f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d79dc674-7e88-468d-8167-1f9183a31f24" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_73e3fb7d-018d-441c-a56a-66055b5b965c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_73e3fb7d-018d-441c-a56a-66055b5b965c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b7f0603-c144-4ec1-969a-213b94630e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b7f0603-c144-4ec1-969a-213b94630e8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4429fffc-4769-4764-9f42-7b9864fd14ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4429fffc-4769-4764-9f42-7b9864fd14ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3ae9934b-385d-4ae0-bcd5-14343e260aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_ProfitLoss_3ae9934b-385d-4ae0-bcd5-14343e260aad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7724fc1d-5848-4c7c-bb14-167ae1dd3695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7724fc1d-5848-4c7c-bb14-167ae1dd3695" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_663acfc4-d306-404b-9e85-40bf7b7122d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a50abf5-6b0b-4a50-9555-0ec804af9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:to="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d851f178-953d-4ac9-89a1-9a7de3e44fc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:to="loc_us-gaap_EquityComponentDomain_d851f178-953d-4ac9-89a1-9a7de3e44fc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:to="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:to="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3af699d8-ce1c-4f10-aea1-656133c07298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_CommonStockMember_3af699d8-ce1c-4f10-aea1-656133c07298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fccdc70e-54e5-4705-b316-18a389faed09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fccdc70e-54e5-4705-b316-18a389faed09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b4681659-dfb2-46ab-afc9-a49ea55b2c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_RetainedEarningsMember_b4681659-dfb2-46ab-afc9-a49ea55b2c3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c02f4127-1d2e-458f-ad4b-212766a91770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c02f4127-1d2e-458f-ad4b-212766a91770" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e6c7abd7-d8ae-476b-b06e-4777a96fe00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e6c7abd7-d8ae-476b-b06e-4777a96fe00d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_205576d0-b2f0-478c-b080-0f45f9a63842_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_205576d0-b2f0-478c-b080-0f45f9a63842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4796dd9e-15bc-4e82-a3f9-6c6ef9a6e3a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4796dd9e-15bc-4e82-a3f9-6c6ef9a6e3a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended" id="i3c8cad6202954012a7f043a1ad85a6ba_DESCRIPTIONOFBUSINESSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b9f07a97-96b8-4ce8-9310-41de921a1f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b9f07a97-96b8-4ce8-9310-41de921a1f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:to="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9822fc03-e2d9-44af-85d4-86ff4d2b6830_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:to="loc_srt_OwnershipDomain_9822fc03-e2d9-44af-85d4-86ff4d2b6830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:to="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_575e3399-b32e-4eb6-b4b2-64f88581c4cf" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:to="loc_bhc_BauschLombMember_575e3399-b32e-4eb6-b4b2-64f88581c4cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i989d8576d70d43c5a5f7ef142fd1903b_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a6ae39a-734e-4e76-a7fd-7968ade0803a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a6ae39a-734e-4e76-a7fd-7968ade0803a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bc8c8d8d-8c2e-45ab-9a20-b584034ae431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bc8c8d8d-8c2e-45ab-9a20-b584034ae431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_88dd4968-c80f-48e6-8ce9-6b23e1e245a0" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_88dd4968-c80f-48e6-8ce9-6b23e1e245a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_a95031ca-9752-4396-a707-07fcaf746da4" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_a95031ca-9752-4396-a707-07fcaf746da4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64a83150-af5c-42db-9cbc-118de14699d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64a83150-af5c-42db-9cbc-118de14699d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_bd0cde7a-ef35-4458-9df2-97db5a244824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_bd0cde7a-ef35-4458-9df2-97db5a244824" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a80bb32b-c29d-4e97-aabe-db8f2d8f420b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a80bb32b-c29d-4e97-aabe-db8f2d8f420b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9006133e-0019-4af4-86f3-6bdb8ed9cd81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9006133e-0019-4af4-86f3-6bdb8ed9cd81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:href="bhc-20221231.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ddfa9f74-5c1a-4f66-a567-f5c809c8340b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:to="loc_us-gaap_IPOMember_ddfa9f74-5c1a-4f66-a567-f5c809c8340b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_187ae33a-7b4e-4526-9350-e474b448b654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_187ae33a-7b4e-4526-9350-e474b448b654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:to="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_99c4df25-14c5-446b-91bf-a8b8b0a05522_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:to="loc_srt_OwnershipDomain_99c4df25-14c5-446b-91bf-a8b8b0a05522_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:to="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2666b61c-5bd2-4cc7-b6c0-63b6a16de958" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:to="loc_bhc_BauschLombMember_2666b61c-5bd2-4cc7-b6c0-63b6a16de958" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended" id="ic6f3c5829eeb411293a2cc13e3f0b76a_SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_1c0a5be3-edd2-4615-b8e0-ecf8b0c85a57" xlink:href="bhc-20221231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_1c0a5be3-edd2-4615-b8e0-ecf8b0c85a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_c0bfc1ad-7375-40d9-8e54-1f3047ca73ac" xlink:href="bhc-20221231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_c0bfc1ad-7375-40d9-8e54-1f3047ca73ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_6d5ece1d-3626-4818-8fc4-77c75eab009d" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_6d5ece1d-3626-4818-8fc4-77c75eab009d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_045d2b20-dc68-4f45-a838-8741abb6972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_045d2b20-dc68-4f45-a838-8741abb6972b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2277d71b-93c1-48d5-9fba-60ef56293adb" xlink:href="bhc-20221231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2277d71b-93c1-48d5-9fba-60ef56293adb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_b45b4da0-0693-4ae1-ba81-7870fd65ea4a" xlink:href="bhc-20221231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_PeriodReceivableOutstanding_b45b4da0-0693-4ae1-ba81-7870fd65ea4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_52abaf41-bc4c-4ebc-9546-cad398e17bea" xlink:href="bhc-20221231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_52abaf41-bc4c-4ebc-9546-cad398e17bea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8b939b85-b77d-41c9-8870-76fbdf377b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:to="loc_us-gaap_AccountsReceivableMember_8b939b85-b77d-41c9-8870-76fbdf377b91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fb06a026-64a4-4f15-8329-dd6181852d7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:to="loc_srt_NameOfMajorCustomerDomain_fb06a026-64a4-4f15-8329-dd6181852d7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:to="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_a5fdbf68-3e3b-4d50-ac9e-10155814a812" xlink:href="bhc-20221231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_a5fdbf68-3e3b-4d50-ac9e-10155814a812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d48a5ad4-a197-4cc1-acec-530082223d01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d48a5ad4-a197-4cc1-acec-530082223d01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_56f8dfb8-1218-4ff1-96d0-6b1f3d7dd4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_56f8dfb8-1218-4ff1-96d0-6b1f3d7dd4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8917d2fa-c74c-4a8f-b11c-80ef029dc462_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:to="loc_srt_SegmentGeographicalDomain_8917d2fa-c74c-4a8f-b11c-80ef029dc462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:to="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_62b47a6e-78a6-4a03-bd47-a9884444477c" xlink:href="bhc-20221231.xsd#bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:to="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_62b47a6e-78a6-4a03-bd47-a9884444477c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended" id="i092f6ac88fe64dc59fc5db194cea273e_SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c795db2d-d44a-4332-862a-b493e77ad015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c795db2d-d44a-4332-862a-b493e77ad015" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:to="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b910320-5824-4f7b-8473-46b72b9caed8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:to="loc_srt_RangeMember_0b910320-5824-4f7b-8473-46b72b9caed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:to="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_883557fe-38fd-4d20-9c78-5bb8506af49b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:to="loc_srt_MinimumMember_883557fe-38fd-4d20-9c78-5bb8506af49b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae01a2f4-26a1-4c42-9159-e2fd10373729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:to="loc_srt_MaximumMember_ae01a2f4-26a1-4c42-9159-e2fd10373729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce958865-c399-4929-b819-96d82f0c73a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce958865-c399-4929-b819-96d82f0c73a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_723fdf52-0464-4ee1-b00e-9620a138e5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_LandImprovementsMember_723fdf52-0464-4ee1-b00e-9620a138e5f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_281a457b-0ef2-4df1-afa2-bc46a95812f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_281a457b-0ef2-4df1-afa2-bc46a95812f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e559de1b-b29a-4322-ac04-38c6cb58cc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e559de1b-b29a-4322-ac04-38c6cb58cc9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_da7ed1b5-55a5-45c4-bbe1-79ebe59549db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_da7ed1b5-55a5-45c4-bbe1-79ebe59549db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_b98b5cd3-4db7-425e-afde-d617f05f742c" xlink:href="bhc-20221231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_b98b5cd3-4db7-425e-afde-d617f05f742c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3e4d52d8-beb6-48cb-9b72-8e29bc4753cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3e4d52d8-beb6-48cb-9b72-8e29bc4753cd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended" id="if7b4471bd991486dba86f486057648ac_SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99922bc2-8094-431c-adce-d73a982fa19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99922bc2-8094-431c-adce-d73a982fa19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:to="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d52f03d5-d8e1-4aec-b06c-5c52c2492d18_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:to="loc_srt_RangeMember_d52f03d5-d8e1-4aec-b06c-5c52c2492d18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:to="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5b9c5df-518b-4167-9a8b-118c28750f09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:to="loc_srt_MinimumMember_b5b9c5df-518b-4167-9a8b-118c28750f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2cc8c17c-9c38-4c57-801c-eba9fe09a761" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:to="loc_srt_MaximumMember_2cc8c17c-9c38-4c57-801c-eba9fe09a761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fda4bb68-0899-45d5-8c64-a02961fea0d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fda4bb68-0899-45d5-8c64-a02961fea0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_cb260426-a5d5-4cd2-9688-ca4b14820e70" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_ProductBrandsMember_cb260426-a5d5-4cd2-9688-ca4b14820e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7a37fb4c-7465-4988-a474-cbbaa7236312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_us-gaap_TradeNamesMember_7a37fb4c-7465-4988-a474-cbbaa7236312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_7e9d98a4-7e42-4e42-ad81-2f9c7153ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_us-gaap_ContractualRightsMember_7e9d98a4-7e42-4e42-ad81-2f9c7153ddb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ce0b19c3-7702-4a26-93b6-c1eef44bfe87" xlink:href="bhc-20221231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_PartnerRelationshipsMember_ce0b19c3-7702-4a26-93b6-c1eef44bfe87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_f88d3456-ec44-45e2-8cd0-38d38959ea97" xlink:href="bhc-20221231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_OutLicensedTechnologyMember_f88d3456-ec44-45e2-8cd0-38d38959ea97" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended" id="ic41794c9a31a462dbd2873b372e0145a_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3ae0da2-7ecd-4f35-a43f-92dfb007ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3ae0da2-7ecd-4f35-a43f-92dfb007ceb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_8d27e7a9-c0f7-4181-a938-10e7d15e95de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_8d27e7a9-c0f7-4181-a938-10e7d15e95de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b5015dc-9f7b-4533-ad97-7d9926f554e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b5015dc-9f7b-4533-ad97-7d9926f554e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6c86172-75f2-4d5a-ab06-538296cb7614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_17f5ece1-d16a-47c3-bb5f-f0ad998df111_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_17f5ece1-d16a-47c3-bb5f-f0ad998df111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_31bda5c7-ced5-4f48-ae80-658576537fca" xlink:href="bhc-20221231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_31bda5c7-ced5-4f48-ae80-658576537fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_b68e4b90-c57b-47f8-adc1-d778c9772283" xlink:href="bhc-20221231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_b68e4b90-c57b-47f8-adc1-d778c9772283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_4cfd9f81-cbae-4f05-be64-5a1c5d591cf2" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForRebatesMember_4cfd9f81-cbae-4f05-be64-5a1c5d591cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_859633fc-146d-45ff-96e4-6a32c7f55df8" xlink:href="bhc-20221231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForChargebacksMember_859633fc-146d-45ff-96e4-6a32c7f55df8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_b9c6ab63-8ddb-497e-8fdf-ee33be66037a" xlink:href="bhc-20221231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForDistributionFeesMember_b9c6ab63-8ddb-497e-8fdf-ee33be66037a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="ic998b0ce5c5b42caa3ee77656f43b9c5_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8034afba-c5ac-41a3-8e23-0acdc8e42cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8034afba-c5ac-41a3-8e23-0acdc8e42cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_90e1218d-f054-4a5a-9392-e1a7ed6d2f3c" xlink:href="bhc-20221231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_90e1218d-f054-4a5a-9392-e1a7ed6d2f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5b8448bd-2b36-4fb7-acca-e9e34d834691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5b8448bd-2b36-4fb7-acca-e9e34d834691" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_e8a4bcca-df2a-40c2-896f-f18bfce0e05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_e8a4bcca-df2a-40c2-896f-f18bfce0e05b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7cd1fb3-96de-4c9b-ae69-20a10a940838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7cd1fb3-96de-4c9b-ae69-20a10a940838" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_d82d3aae-e3a1-4e66-b0d7-3377ebf65cba" xlink:href="bhc-20221231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_d82d3aae-e3a1-4e66-b0d7-3377ebf65cba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a5923549-93a8-48c5-ac91-8c887721abea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a5923549-93a8-48c5-ac91-8c887721abea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_5e395771-09e4-4f99-9635-796eaf2943d5" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_5e395771-09e4-4f99-9635-796eaf2943d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_a67e5bbf-e367-44f8-ba03-b27506212a55" xlink:href="bhc-20221231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_a67e5bbf-e367-44f8-ba03-b27506212a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e1f5909-84a9-4b7b-b479-afd187603e90_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:to="loc_srt_RangeMember_6e1f5909-84a9-4b7b-b479-afd187603e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:to="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87b38656-e9ca-48b7-80db-81a05a5aef3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:to="loc_srt_MinimumMember_87b38656-e9ca-48b7-80db-81a05a5aef3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92f46c5c-f018-41c2-94c6-652ca9517e01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:to="loc_srt_MaximumMember_92f46c5c-f018-41c2-94c6-652ca9517e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fad7249-e746-490e-b0b6-6d1337610281_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:to="loc_srt_ProductsAndServicesDomain_0fad7249-e746-490e-b0b6-6d1337610281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:to="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_43d52fba-04e1-4b78-9949-5fe333f0c4e5" xlink:href="bhc-20221231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:to="loc_bhc_PriceAppreciationCreditMember_43d52fba-04e1-4b78-9949-5fe333f0c4e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended" id="ic897770a6f3c481288ea9812b32eaeba_SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_db7d83b5-1f55-46ed-87e1-004671c27d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_db7d83b5-1f55-46ed-87e1-004671c27d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3fb6078-dd1a-4ba3-884c-6674ad061416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3fb6078-dd1a-4ba3-884c-6674ad061416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:to="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:to="loc_srt_RangeMember_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:to="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c227b54c-31f5-4ff0-958f-a9c22c84de25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:to="loc_srt_MinimumMember_c227b54c-31f5-4ff0-958f-a9c22c84de25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b03e5a31-754a-48b8-9bba-099b494e1ab3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:to="loc_srt_MaximumMember_b03e5a31-754a-48b8-9bba-099b494e1ab3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended" id="ie763e729fae7454594b835e4912f5036_SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5be90d4-3f38-4476-9886-66cec5fd7d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5be90d4-3f38-4476-9886-66cec5fd7d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_34715f67-defa-4600-8947-0e07522beae9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_34715f67-defa-4600-8947-0e07522beae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a240301d-01af-4f41-910c-b0900a4af0f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a240301d-01af-4f41-910c-b0900a4af0f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_15734290-f31c-4866-96b8-48e26b386af9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:to="loc_us-gaap_EquityComponentDomain_15734290-f31c-4866-96b8-48e26b386af9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:to="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19eff5ec-73e9-482c-8f52-8fa71b4a5993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:to="loc_us-gaap_RetainedEarningsMember_19eff5ec-73e9-482c-8f52-8fa71b4a5993" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="i50a3f08ad22a40c6b619534d1dc9932d_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a2ae4a01-ac98-488a-90c5-6b08df0040da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a2ae4a01-ac98-488a-90c5-6b08df0040da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0293b5a2-0ce4-4d3d-a3ed-b8955bec6ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_InventoryNet_0293b5a2-0ce4-4d3d-a3ed-b8955bec6ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_37dafb47-96dd-4669-a86a-a0984a9c5520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_37dafb47-96dd-4669-a86a-a0984a9c5520" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_580da42e-edb4-4186-a9e9-42808c9deaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_580da42e-edb4-4186-a9e9-42808c9deaf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cc8d572-4ed2-46b6-99ea-28029efdafc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_Goodwill_6cc8d572-4ed2-46b6-99ea-28029efdafc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a629ced9-6515-4c38-a2c7-36f77a34e514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a629ced9-6515-4c38-a2c7-36f77a34e514" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6081d7b8-5852-450f-a3fc-8958f922fcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6081d7b8-5852-450f-a3fc-8958f922fcf6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5b89c536-1466-449c-81d0-ce45102a1e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5b89c536-1466-449c-81d0-ce45102a1e31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_72c921c0-c41a-4c10-b790-a2e9a532a063" xlink:href="bhc-20221231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_72c921c0-c41a-4c10-b790-a2e9a532a063" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2d94762d-7937-45ad-b7bf-afb9157a694e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:to="loc_dei_EntityDomain_2d94762d-7937-45ad-b7bf-afb9157a694e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:to="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_979e5e42-42f0-43aa-8b2b-c1c9821ccbb7" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:to="loc_bhc_BauschLombMember_979e5e42-42f0-43aa-8b2b-c1c9821ccbb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7_default" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_2582b039-5f3d-4344-8ed1-673b2052b384" xlink:href="bhc-20221231.xsd#bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:to="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_2582b039-5f3d-4344-8ed1-673b2052b384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f11e7acc-9082-4119-872a-bae2f59b5a8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f11e7acc-9082-4119-872a-bae2f59b5a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_0854ae34-78ec-4fae-bb9b-9d294791c724" xlink:href="bhc-20221231.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:to="loc_bhc_AssetImpairmentChargesMember_0854ae34-78ec-4fae-bb9b-9d294791c724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_f0ca14de-1a81-4d2e-aab2-2a9c73b6b00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_f0ca14de-1a81-4d2e-aab2-2a9c73b6b00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8c170aba-0684-4be3-a411-5e2247382d81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8c170aba-0684-4be3-a411-5e2247382d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e7c95f71-5676-4228-a989-e9a3c8b4c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e7c95f71-5676-4228-a989-e9a3c8b4c4c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_340f0fe4-97f9-45cf-b04b-7d140b42b147_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_340f0fe4-97f9-45cf-b04b-7d140b42b147_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_3a514df7-fa56-4fcb-9e59-7cd8513154c6" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_3a514df7-fa56-4fcb-9e59-7cd8513154c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="i57e08727a9c0478d92c713ed5abae2da_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c17c53a6-286a-42e1-9208-95dd86221482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringReserve_c17c53a6-286a-42e1-9208-95dd86221482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_fea6cb30-f1b7-4ca6-ad49-4cb935e940f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_fea6cb30-f1b7-4ca6-ad49-4cb935e940f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_0d27153e-d2ee-4f10-9c12-09cdaf0495c3" xlink:href="bhc-20221231.xsd#bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_0d27153e-d2ee-4f10-9c12-09cdaf0495c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f1e13ef0-07b7-424f-91bd-3897c31da8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_PaymentsForRestructuring_f1e13ef0-07b7-424f-91bd-3897c31da8b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2c4c5e9b-615f-42ba-9f48-cc8709a08528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringCharges_2c4c5e9b-615f-42ba-9f48-cc8709a08528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d04b617-d027-4a1c-ae00-64cef99e098e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d04b617-d027-4a1c-ae00-64cef99e098e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_dbae514c-93b8-4802-9c1d-b6f7976f0656_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_dbae514c-93b8-4802-9c1d-b6f7976f0656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_94ef97da-5212-4fc3-bbfa-f6829392fb0c" xlink:href="bhc-20221231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_94ef97da-5212-4fc3-bbfa-f6829392fb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_b2bc3b9b-9d17-4903-9749-6b8cd0d528c0" xlink:href="bhc-20221231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_b2bc3b9b-9d17-4903-9749-6b8cd0d528c0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ie99fb2e740f3400a8e27a4ee256681c2_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d3c1bfe-018a-40ab-9aca-058547952fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d3c1bfe-018a-40ab-9aca-058547952fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_1b451252-a825-489e-a111-e63453628ab7" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_1b451252-a825-489e-a111-e63453628ab7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6d897619-97cb-4abd-9991-f7296ce2f515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_us-gaap_DerivativeAssets_6d897619-97cb-4abd-9991-f7296ce2f515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_d76a034a-703a-47e0-b47a-f41658b64869" xlink:href="bhc-20221231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_d76a034a-703a-47e0-b47a-f41658b64869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4a4d80db-3f61-4546-b14f-e38da42e1be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:to="loc_us-gaap_DerivativeLiabilities_4a4d80db-3f61-4546-b14f-e38da42e1be9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b47adf7c-1318-4ed5-84f7-87d261b56717_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b47adf7c-1318-4ed5-84f7-87d261b56717_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0a704e-4a2b-48bc-bb1e-94eae423591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0a704e-4a2b-48bc-bb1e-94eae423591f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aeb18773-3b70-4b14-8b86-049385590fe8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aeb18773-3b70-4b14-8b86-049385590fe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75e070fa-7e94-4bb9-8960-3678027383b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75e070fa-7e94-4bb9-8960-3678027383b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eaec7d04-34cb-40b9-9f79-1e6871b1d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eaec7d04-34cb-40b9-9f79-1e6871b1d81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4d99263d-927c-4c3d-9a41-bc905d63357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4d99263d-927c-4c3d-9a41-bc905d63357f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cb681537-c48c-45b4-9afa-f6955f9fd734_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cb681537-c48c-45b4-9afa-f6955f9fd734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:to="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1a92948b-4e14-416b-9805-0e7a185667ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1a92948b-4e14-416b-9805-0e7a185667ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_510eb5c4-a57d-4d5f-ae24-6b8197204291_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_510eb5c4-a57d-4d5f-ae24-6b8197204291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_b8359a1b-2eb6-43ea-affa-623160285da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:to="loc_us-gaap_CurrencySwapMember_b8359a1b-2eb6-43ea-affa-623160285da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c5a0d2e7-f587-4e17-8757-4ae736cd44b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c5a0d2e7-f587-4e17-8757-4ae736cd44b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0bb6d527-44dc-4be4-9ee6-611b87be1627_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:to="loc_us-gaap_HedgingDesignationDomain_0bb6d527-44dc-4be4-9ee6-611b87be1627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:to="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8380d4f8-85cc-4582-9f39-dea63e1a065c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:to="loc_us-gaap_NondesignatedMember_8380d4f8-85cc-4582-9f39-dea63e1a065c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b4772e7a-1bc6-4427-8363-c9f79bc4f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b4772e7a-1bc6-4427-8363-c9f79bc4f66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ba47443-2d0a-4279-a892-dd2037b0b51f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:to="loc_dei_EntityDomain_4ba47443-2d0a-4279-a892-dd2037b0b51f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:to="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_4a553dbb-b4a6-436d-ba0d-560f80681fc9" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:to="loc_bhc_BauschLombMember_4a553dbb-b4a6-436d-ba0d-560f80681fc9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="ie0dd4251bbf34b3d8969730ec0c98a03_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_ec7d4b58-8c85-4aa1-b2f6-b8bcc722ce71" xlink:href="bhc-20221231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_ec7d4b58-8c85-4aa1-b2f6-b8bcc722ce71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d62867e1-c6fc-4f97-a2f2-d489356ce643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d62867e1-c6fc-4f97-a2f2-d489356ce643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ab6976e6-1b70-4541-9fe5-ede466403374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ab6976e6-1b70-4541-9fe5-ede466403374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_809ec73c-6984-4dfc-93aa-348c463149fb" xlink:href="bhc-20221231.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_809ec73c-6984-4dfc-93aa-348c463149fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_b4be1d51-5c62-4e84-972f-87e4f2f29e5b" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_b4be1d51-5c62-4e84-972f-87e4f2f29e5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_18e58cda-ff22-4339-b580-eca78eea9b1b" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_18e58cda-ff22-4339-b580-eca78eea9b1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0ff08aff-5bba-4429-8996-338e10fb0286_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:to="loc_dei_EntityDomain_0ff08aff-5bba-4429-8996-338e10fb0286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:to="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c5644ba5-1090-4c3d-acce-a8d2c02971b8" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:to="loc_bhc_BauschLombMember_c5644ba5-1090-4c3d-acce-a8d2c02971b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:to="loc_srt_LitigationCaseTypeDomain_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:to="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_d2aa6716-19bd-4093-954a-b688ab87ef82" xlink:href="bhc-20221231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_d2aa6716-19bd-4093-954a-b688ab87ef82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1d82e076-d0fd-41a2-bc10-18aa16ab1818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:to="loc_us-gaap_LitigationStatusDomain_1d82e076-d0fd-41a2-bc10-18aa16ab1818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:to="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_60be3031-37fd-450d-954e-20bba72f65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:to="loc_us-gaap_SettledLitigationMember_60be3031-37fd-450d-954e-20bba72f65bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b478faeb-4b4a-4a1d-828c-0c053123e182_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:to="loc_srt_SegmentGeographicalDomain_b478faeb-4b4a-4a1d-828c-0c053123e182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:to="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_7b201b24-5e50-44f1-b86e-eb1cd482199d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:to="loc_stpr_NJ_7b201b24-5e50-44f1-b86e-eb1cd482199d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="ifab3ee48462240248712707d0dc1b3f2_FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1bdab469-dbda-4fc2-92a9-38b50a45bebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1bdab469-dbda-4fc2-92a9-38b50a45bebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d0f4cfe6-48a6-46d9-9cff-bd851d83c9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d0f4cfe6-48a6-46d9-9cff-bd851d83c9e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1618223a-16b8-4e33-b125-d91c3d4cc684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1618223a-16b8-4e33-b125-d91c3d4cc684" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cc2af617-6f1d-4162-a4e1-ad2e90fce232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cc2af617-6f1d-4162-a4e1-ad2e90fce232" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c4708f14-4aee-49f9-89bd-5f6ffa452cc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c4708f14-4aee-49f9-89bd-5f6ffa452cc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:to="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_b293196f-ee41-4f23-a129-3021e6172b21" xlink:href="bhc-20221231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_b293196f-ee41-4f23-a129-3021e6172b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c80f8a87-157a-417c-a196-59458b2c708c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c80f8a87-157a-417c-a196-59458b2c708c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_03d38411-b44f-4e44-b932-c917440aa2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_03d38411-b44f-4e44-b932-c917440aa2ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1a57bd02-ef2f-4904-b875-c6060bb6b241_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:to="loc_us-gaap_HedgingDesignationDomain_1a57bd02-ef2f-4904-b875-c6060bb6b241_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:to="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_535e8a4c-ac06-4132-be0e-6b7aacf0ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_535e8a4c-ac06-4132-be0e-6b7aacf0ebda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c2cc47eb-50ec-4927-81b1-8b78993e1e7c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:to="loc_dei_EntityDomain_c2cc47eb-50ec-4927-81b1-8b78993e1e7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:to="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_9744f85d-d586-4349-a54b-053663356067" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:to="loc_bhc_BauschLombMember_9744f85d-d586-4349-a54b-053663356067" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i210b5afcef1e4448b8e3e881bef4d9e4_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_632b834c-604c-4f04-8991-10271ae22f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_632b834c-604c-4f04-8991-10271ae22f15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8c787def-e4c6-4fdb-a6b1-39ad079f6697_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8c787def-e4c6-4fdb-a6b1-39ad079f6697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8f1a737f-21e2-4f78-8b1e-4927989166f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8f1a737f-21e2-4f78-8b1e-4927989166f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_eabca688-21a5-4250-b339-c58806897287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_eabca688-21a5-4250-b339-c58806897287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6856222b-a6fd-4bcb-83d1-323f5575ec9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6856222b-a6fd-4bcb-83d1-323f5575ec9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_69b1ad11-71ef-4574-8398-45b705f5462b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:to="loc_us-gaap_CurrencySwapMember_69b1ad11-71ef-4574-8398-45b705f5462b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f48a31d8-651f-4edd-b121-29ca90e45640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f48a31d8-651f-4edd-b121-29ca90e45640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0cc50552-5792-4b8f-8e13-cb62a260bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0cc50552-5792-4b8f-8e13-cb62a260bfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ac086476-0116-4b2b-81bb-dd1c1b84fe86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:to="loc_us-gaap_HedgingDesignationDomain_ac086476-0116-4b2b-81bb-dd1c1b84fe86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:to="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1613bbc-06c5-477d-907f-70a5cb3c3d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1613bbc-06c5-477d-907f-70a5cb3c3d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_446318d7-ba6f-43ec-979d-42f96af5de8b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:to="loc_dei_EntityDomain_446318d7-ba6f-43ec-979d-42f96af5de8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:to="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_32ffc42f-f8fc-411e-b754-0aedd83ffd66" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:to="loc_bhc_BauschLombMember_32ffc42f-f8fc-411e-b754-0aedd83ffd66" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i1c4d5f78d1c64a2c810c945952982e5b_FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d6168829-8ce2-4f24-beb1-82b4ef0da071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d6168829-8ce2-4f24-beb1-82b4ef0da071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_406c4dc5-4b38-49ba-b465-2fdf5611495c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_406c4dc5-4b38-49ba-b465-2fdf5611495c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_adf48f51-fbbc-45bc-9e85-4161ebce24c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_adf48f51-fbbc-45bc-9e85-4161ebce24c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_cb3f5b21-0270-4037-9ad3-f36145aa3796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:to="loc_us-gaap_CurrencySwapMember_cb3f5b21-0270-4037-9ad3-f36145aa3796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f059a565-753a-434b-9bd7-a720e1c35132_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f059a565-753a-434b-9bd7-a720e1c35132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:to="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_350985de-c9f5-40a4-9524-d1840c0b1a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_350985de-c9f5-40a4-9524-d1840c0b1a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_73d0f252-0188-400f-ade0-e52a4b7c8fe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:to="loc_us-gaap_HedgingDesignationDomain_73d0f252-0188-400f-ade0-e52a4b7c8fe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:to="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dc6e453d-f2e8-4238-bf4b-7d757d10af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dc6e453d-f2e8-4238-bf4b-7d757d10af5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_875c2ed3-0efc-49e5-b44b-725db415cb5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_875c2ed3-0efc-49e5-b44b-725db415cb5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_dc11b953-4000-45ad-9daa-c7f35863bd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:to="loc_us-gaap_InterestExpenseMember_dc11b953-4000-45ad-9daa-c7f35863bd49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i2d91c4034247401790f094bd40f8174d_FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8ac6f0cd-187f-4d12-973d-a95d7806b739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8ac6f0cd-187f-4d12-973d-a95d7806b739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:to="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_37120243-d027-4d84-9a74-637eeed36172_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:to="loc_us-gaap_HedgingDesignationDomain_37120243-d027-4d84-9a74-637eeed36172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:to="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4bbfda78-19c7-4a74-a312-6f2cc1cc31f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:to="loc_us-gaap_NondesignatedMember_4bbfda78-19c7-4a74-a312-6f2cc1cc31f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_856e6c98-340a-4314-b5b9-5ae2171d98c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_856e6c98-340a-4314-b5b9-5ae2171d98c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_dfddb581-7e16-48b9-9db9-1226e90646be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:to="loc_us-gaap_ForeignExchangeContractMember_dfddb581-7e16-48b9-9db9-1226e90646be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i3266e6a3533a481684c04a978008b3b8_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_15e38786-330f-4219-bb56-c495e5905640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_15e38786-330f-4219-bb56-c495e5905640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bd9fbc24-8ee5-485c-b78c-19ebcd73ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bd9fbc24-8ee5-485c-b78c-19ebcd73ac09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d550e5e8-efcb-47ab-95d8-d30f15be95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeLiabilities_d550e5e8-efcb-47ab-95d8-d30f15be95f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1fd454ef-ac4e-4513-9993-768e966d9c77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1fd454ef-ac4e-4513-9993-768e966d9c77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_8fdb37f7-13a5-4565-847c-162633f8c7f6" xlink:href="bhc-20221231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_8fdb37f7-13a5-4565-847c-162633f8c7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_31f5eba9-bb2a-4341-b70e-3ab3a34c274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_31f5eba9-bb2a-4341-b70e-3ab3a34c274f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8d845ffd-92a2-4860-a96c-b25a6f0a4c41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8d845ffd-92a2-4860-a96c-b25a6f0a4c41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9a49d323-0c29-4608-ac81-3c2c182c0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9a49d323-0c29-4608-ac81-3c2c182c0636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:to="loc_us-gaap_HedgingDesignationDomain_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:to="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5c59fd7c-2264-4edc-8b5b-55b788feb42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:to="loc_us-gaap_NondesignatedMember_5c59fd7c-2264-4edc-8b5b-55b788feb42c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="i110d3ecfb5e04c76948a6e29b214e50d_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_59472664-3a35-436c-84c7-6f54e85091d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_59472664-3a35-436c-84c7-6f54e85091d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_783d0519-c87d-4987-87ae-8a698802225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_783d0519-c87d-4987-87ae-8a698802225e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_721060c8-2fdd-4057-9acb-21db0c650318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:to="loc_us-gaap_ForeignExchangeContractMember_721060c8-2fdd-4057-9acb-21db0c650318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:to="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_df90a487-e1a6-40d6-8c41-28a4c512b1b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:to="loc_us-gaap_HedgingDesignationDomain_df90a487-e1a6-40d6-8c41-28a4c512b1b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:to="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c40e5f5c-5ed3-42f7-a4e9-90969367b7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:to="loc_us-gaap_NondesignatedMember_c40e5f5c-5ed3-42f7-a4e9-90969367b7d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="i69c9b33c1dc94f969b02632a11dc9cb7_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_86e73425-0faf-4171-a42a-89e737dae16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_86e73425-0faf-4171-a42a-89e737dae16e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd695bf1-bf5b-4894-bf8a-7a6eef285b54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd695bf1-bf5b-4894-bf8a-7a6eef285b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_28a83be3-e237-48bf-b911-e99b050d6e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_28a83be3-e237-48bf-b911-e99b050d6e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_82abdf05-d127-4890-8ab9-045c3fbc3292_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_82abdf05-d127-4890-8ab9-045c3fbc3292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9385e892-b224-4e7a-8fea-70a7fbabd42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9385e892-b224-4e7a-8fea-70a7fbabd42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_7dac22b9-519a-4d1f-a825-5aadc59e0999" xlink:href="bhc-20221231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_7dac22b9-519a-4d1f-a825-5aadc59e0999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_202dd8ad-b026-452e-a04e-b036f85728b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_202dd8ad-b026-452e-a04e-b036f85728b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab245087-ad0d-457a-836d-bc5cde546c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab245087-ad0d-457a-836d-bc5cde546c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:to="loc_srt_RangeMember_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:to="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0b35084f-900d-4043-b115-7876308e63b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:to="loc_srt_MinimumMember_0b35084f-900d-4043-b115-7876308e63b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bed62b5b-02b5-4254-b39f-76f09d6a331c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:to="loc_srt_MaximumMember_bed62b5b-02b5-4254-b39f-76f09d6a331c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended" id="i093bd88e515c4bae92ae4dbb66dd17ba_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a7cf61b1-03f6-4f92-9578-0ba32771fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a7cf61b1-03f6-4f92-9578-0ba32771fea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_137acec1-3ca8-40c0-bae6-5a945ac0d51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_137acec1-3ca8-40c0-bae6-5a945ac0d51a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_f3d2861b-b615-4fde-95ca-53b6136be68e" xlink:href="bhc-20221231.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_f3d2861b-b615-4fde-95ca-53b6136be68e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_205611ce-17ea-46fd-9ea4-e12488df24ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_205611ce-17ea-46fd-9ea4-e12488df24ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_633f186c-81c4-4762-9391-da7ee89d3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_633f186c-81c4-4762-9391-da7ee89d3ab2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d2c2564b-b443-4b86-b566-ecf7aa43664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b6560e57-bc22-43b9-b872-aa5c697e991d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b6560e57-bc22-43b9-b872-aa5c697e991d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_005581dd-bb8d-4b17-a2a9-beaef5636636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_005581dd-bb8d-4b17-a2a9-beaef5636636" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_498493cd-4fd0-45f8-9a4f-e307cb97e33a" xlink:href="bhc-20221231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_498493cd-4fd0-45f8-9a4f-e307cb97e33a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_2b25e6db-b4bd-440f-85bd-1990f937a38b" xlink:href="bhc-20221231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:to="loc_bhc_FairValueAdjustmentsMember_2b25e6db-b4bd-440f-85bd-1990f937a38b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended" id="i747d18a8a1674aaba26fb7f51969da8b_FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f086e718-5c9b-4d8f-98e3-fc33c526e731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f086e718-5c9b-4d8f-98e3-fc33c526e731" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_06e225c9-07e3-446d-aac3-82424bc13e09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_06e225c9-07e3-446d-aac3-82424bc13e09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_bfa79598-beb0-4df7-8e38-11f0ade9e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_bfa79598-beb0-4df7-8e38-11f0ade9e1c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8f433da-611d-4525-936c-d43885d20feb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a8f433da-611d-4525-936c-d43885d20feb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94256545-40fd-45b7-81f6-be3ce433e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94256545-40fd-45b7-81f6-be3ce433e52b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i8d71e05b4ad743b2ba9e4b59da3c00f6_PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_257769b3-d055-449a-b838-db8f3b5b9900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_257769b3-d055-449a-b838-db8f3b5b9900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb55e32f-928f-439b-9d70-dd2479695ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb55e32f-928f-439b-9d70-dd2479695ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5d0acfe-c422-4c50-a68b-991f77718377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5d0acfe-c422-4c50-a68b-991f77718377" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0bd7616b-3a03-4499-af09-93b2cb067efb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0bd7616b-3a03-4499-af09-93b2cb067efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_22e4448b-cf61-4af6-a2e7-ee2cdc8070ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_LandMember_22e4448b-cf61-4af6-a2e7-ee2cdc8070ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_7ec26ba0-d89e-41f3-aa91-8fe04528e7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_7ec26ba0-d89e-41f3-aa91-8fe04528e7fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02cc3bb8-4dd2-4ef0-82df-402b7e096602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02cc3bb8-4dd2-4ef0-82df-402b7e096602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_3c4e503d-5517-47fd-afcd-a7e21c5a6ae2" xlink:href="bhc-20221231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_3c4e503d-5517-47fd-afcd-a7e21c5a6ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_4f6e3c1e-3df4-4ae0-a4d8-df8e4653ece0" xlink:href="bhc-20221231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_4f6e3c1e-3df4-4ae0-a4d8-df8e4653ece0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_25f68db8-eace-4a7e-bb3d-36a1da7f27b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_ConstructionInProgressMember_25f68db8-eace-4a7e-bb3d-36a1da7f27b5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i7e246748260e4a84a642e3cfba1bd121_INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82a0066d-1e9e-46ae-9077-893f0e868295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82a0066d-1e9e-46ae-9077-893f0e868295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40e1e1b4-cafa-4159-9b5d-c0f17c438655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40e1e1b4-cafa-4159-9b5d-c0f17c438655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd174ca3-5b73-4ea4-9539-0f1bd7bb89d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd174ca3-5b73-4ea4-9539-0f1bd7bb89d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20335e86-fd40-46a9-aff1-b46026fd4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20335e86-fd40-46a9-aff1-b46026fd4d20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3e0d137-e079-4068-972f-f220359ac092_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3e0d137-e079-4068-972f-f220359ac092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_a909a9bc-5637-441a-abbe-56e8c317f3ae" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_ProductBrandsMember_a909a9bc-5637-441a-abbe-56e8c317f3ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d767646a-dd51-4121-ab9c-d94ed77c8e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_us-gaap_TradeNamesMember_d767646a-dd51-4121-ab9c-d94ed77c8e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_72a7c4dd-afb5-4731-b7c7-586265aa014f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_us-gaap_ContractualRightsMember_72a7c4dd-afb5-4731-b7c7-586265aa014f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_7baec522-310b-49bd-bb82-6b38aca0468d" xlink:href="bhc-20221231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_PartnerRelationshipsMember_7baec522-310b-49bd-bb82-6b38aca0468d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_348833c7-5e32-4584-9c4b-1d48dd6ec5e5" xlink:href="bhc-20221231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_OutLicensedTechnologyMember_348833c7-5e32-4584-9c4b-1d48dd6ec5e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_45785d16-4b0b-45b2-ae4c-4e67f222f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_45785d16-4b0b-45b2-ae4c-4e67f222f4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c3d633a-6f37-44be-812a-450d72d0ef87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c3d633a-6f37-44be-812a-450d72d0ef87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_807acb45-6986-43aa-aef3-8d2b5481c927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:to="loc_us-gaap_TrademarksMember_807acb45-6986-43aa-aef3-8d2b5481c927" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="i98e9b2d2ea3f4944b5bbd3ac2711451f_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fe463d6d-6217-4a91-ae1f-770933233abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_AssetImpairmentCharges_fe463d6d-6217-4a91-ae1f-770933233abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_acdfdf56-ebf4-4c62-90f8-e4dba4dcb09c" xlink:href="bhc-20221231.xsd#bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_acdfdf56-ebf4-4c62-90f8-e4dba4dcb09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ca1e2201-414f-465b-9807-53ce302640dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ca1e2201-414f-465b-9807-53ce302640dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70a5e253-a13c-4ba5-8fa5-89c5576113e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70a5e253-a13c-4ba5-8fa5-89c5576113e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c96c4f1-1767-4dbc-b6f3-3267596451a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c96c4f1-1767-4dbc-b6f3-3267596451a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d3fb4269-302f-45b4-8ca1-081964edd603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d3fb4269-302f-45b4-8ca1-081964edd603" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f854705e-b3e4-4db0-8798-5d2b021c2855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f854705e-b3e4-4db0-8798-5d2b021c2855" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d8e76d4f-65ee-4f73-95ba-6fba7717ac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d8e76d4f-65ee-4f73-95ba-6fba7717ac1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d519a8aa-514a-4a04-b703-e07ad1816291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d519a8aa-514a-4a04-b703-e07ad1816291" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_4d568fa2-7c65-4164-8c39-a5e205d9d33f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_4d568fa2-7c65-4164-8c39-a5e205d9d33f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_de113014-0e46-4780-a61d-ce75b62bef51" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_de113014-0e46-4780-a61d-ce75b62bef51" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_4e97dbe8-fbc6-4dee-a6a7-6acf8b2d73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_4e97dbe8-fbc6-4dee-a6a7-6acf8b2d73fa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_c44819da-4933-4c2f-8fdd-32ee3845891f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_c44819da-4933-4c2f-8fdd-32ee3845891f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_1a8be0c9-63e6-4cd3-a602-5dd51afccda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_NumberOfReportingUnits_1a8be0c9-63e6-4cd3-a602-5dd51afccda0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4679e418-e327-43ad-a966-5651752f494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_Goodwill_4679e418-e327-43ad-a966-5651752f494d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_77d23f36-dae3-443b-8071-963877e82609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_77d23f36-dae3-443b-8071-963877e82609" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d3489566-71ab-45b4-8477-953082615a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d3489566-71ab-45b4-8477-953082615a81" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cce91724-371c-4fd2-b21d-923c1ca09bbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cce91724-371c-4fd2-b21d-923c1ca09bbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d809d32e-646e-4efd-bf73-05be676727c8" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_ProductBrandsMember_d809d32e-646e-4efd-bf73-05be676727c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e2085fca-a010-409b-845f-644dc62448e9" xlink:href="bhc-20221231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e2085fca-a010-409b-845f-644dc62448e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_bbd00f65-d071-4237-a08f-7e3aed7bc2bd" xlink:href="bhc-20221231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_bbd00f65-d071-4237-a08f-7e3aed7bc2bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a9b05432-202d-4713-abe7-ff174fdc9454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a9b05432-202d-4713-abe7-ff174fdc9454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_edf18849-8e15-4071-a214-daf6de950057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_edf18849-8e15-4071-a214-daf6de950057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c15237c4-3b23-4851-ab53-5d085e9888ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c15237c4-3b23-4851-ab53-5d085e9888ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f347c686-b9a4-479e-827b-47d552cfcfed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f347c686-b9a4-479e-827b-47d552cfcfed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_cd55ae46-2d87-42f3-890d-9ee7b4aff1c9" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_cd55ae46-2d87-42f3-890d-9ee7b4aff1c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_b12ddae0-20be-4f81-aeb7-b6a79e587872" xlink:href="bhc-20221231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:to="loc_bhc_ACertainInternationalBusinessMember_b12ddae0-20be-4f81-aeb7-b6a79e587872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63cfbd71-2870-4b67-b0b2-22c496471fc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_63cfbd71-2870-4b67-b0b2-22c496471fc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_c89fce59-42f0-41ea-bc84-42b7f5198a36" xlink:href="bhc-20221231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_c89fce59-42f0-41ea-bc84-42b7f5198a36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09ee9b2e-421e-450f-899c-50711f231330_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:to="loc_srt_RangeMember_09ee9b2e-421e-450f-899c-50711f231330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:to="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cb6bca6c-4b6d-4703-8518-820af5e2f35a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:to="loc_srt_MinimumMember_cb6bca6c-4b6d-4703-8518-820af5e2f35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cbcacf0-0013-4a43-b060-402319a283b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:to="loc_srt_MaximumMember_6cbcacf0-0013-4a43-b060-402319a283b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:to="loc_us-gaap_ReportingUnitDomain_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:to="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_a5c27741-26e7-4cca-a02f-6ac69c6f97a3" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_a5c27741-26e7-4cca-a02f-6ac69c6f97a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e44a08ba-8575-4587-b9ed-a1b63c2c095f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e44a08ba-8575-4587-b9ed-a1b63c2c095f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_38bbf1f3-641e-431c-b238-4f13ca167d62" xlink:href="bhc-20221231.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_38bbf1f3-641e-431c-b238-4f13ca167d62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_f8d00716-0781-4772-9052-f0ec95bf4870" xlink:href="bhc-20221231.xsd#bhc_SalixReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_SalixReportingUnitMember_f8d00716-0781-4772-9052-f0ec95bf4870" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember_d52f43d9-2a51-47c3-8d31-aa2351063491" xlink:href="bhc-20221231.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_NeurologyAndOtherReportingUnitMember_d52f43d9-2a51-47c3-8d31-aa2351063491" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SurgicalReportingUnitMember_8b724453-d565-4104-a985-bd5ac4b8d8de" xlink:href="bhc-20221231.xsd#bhc_SurgicalReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_SurgicalReportingUnitMember_8b724453-d565-4104-a985-bd5ac4b8d8de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7edd03d0-40f6-4d0e-a7aa-464b94099e83_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:to="loc_dei_EntityDomain_7edd03d0-40f6-4d0e-a7aa-464b94099e83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:to="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ad074cde-4107-49b4-82a5-380bd153f12b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:to="loc_bhc_BauschLombMember_ad074cde-4107-49b4-82a5-380bd153f12b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cc309076-d482-4291-8dad-8215e0f286ae_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:to="loc_srt_ProductsAndServicesDomain_cc309076-d482-4291-8dad-8215e0f286ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:to="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_765a5e76-7cac-4bb6-bb19-26a8c3c1a28b" xlink:href="bhc-20221231.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:to="loc_bhc_XifaxanBrandedProductsMember_765a5e76-7cac-4bb6-bb19-26a8c3c1a28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9680e2c-a159-49ca-afc0-cab1e53878dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b9680e2c-a159-49ca-afc0-cab1e53878dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_5941c6ef-8971-46d9-919b-34ed757ad841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_5941c6ef-8971-46d9-919b-34ed757ad841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_134a90e9-6ff4-4b60-bd7c-77f5139e866b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_134a90e9-6ff4-4b60-bd7c-77f5139e866b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e041263f-7d9f-458d-83f5-526768fba23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e041263f-7d9f-458d-83f5-526768fba23e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:to="loc_us-gaap_SegmentDomain_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:to="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_38c60f2f-281d-4585-a380-2b0c472dc85b" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:to="loc_bhc_SalixSegmentMember_38c60f2f-281d-4585-a380-2b0c472dc85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_00830986-ed14-4d05-aef1-6c2b8ac53a80" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_00830986-ed14-4d05-aef1-6c2b8ac53a80" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended" id="id8b897b60b2c40c7ba21c3c31e9386fe_INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:to="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_423a4e2f-8309-4e53-9b51-02d7f1a070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_Goodwill_423a4e2f-8309-4e53-9b51-02d7f1a070e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_b08611d1-3a8e-41e0-9434-bf325dcdaf06" xlink:href="bhc-20221231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_b08611d1-3a8e-41e0-9434-bf325dcdaf06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e0f53516-cc2e-43c1-bdef-bb23ff548899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e0f53516-cc2e-43c1-bdef-bb23ff548899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c049001a-8c8c-4038-b1e3-9e0beb65ae60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c049001a-8c8c-4038-b1e3-9e0beb65ae60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1d48fd9e-ba4c-4838-bfe5-7b237f7322a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1d48fd9e-ba4c-4838-bfe5-7b237f7322a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5ae40e0a-5a5d-4035-b485-ed9e0bf6fd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5ae40e0a-5a5d-4035-b485-ed9e0bf6fd58" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d0fadcc0-e645-4d4f-8115-ff7526bdc3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d0fadcc0-e645-4d4f-8115-ff7526bdc3fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_155716b5-3b4f-4f22-9e29-6ea78b1630f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_84c7b8c7-588a-4434-bae8-83bc59599ed7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:to="loc_us-gaap_SegmentDomain_84c7b8c7-588a-4434-bae8-83bc59599ed7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:to="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_ca2c9d9e-b65f-4d59-96aa-19412d94ed41" xlink:href="bhc-20221231.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_BauschLombInternationalMember_ca2c9d9e-b65f-4d59-96aa-19412d94ed41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2f22e343-8c05-4577-a933-b615463f951a" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_BauschLombMember_2f22e343-8c05-4577-a933-b615463f951a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_23f7f0dd-b48f-4b5f-9203-38e512c1445f" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_SalixSegmentMember_23f7f0dd-b48f-4b5f-9203-38e512c1445f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_38475537-81d1-40b9-859b-6ddfccc7aca2" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_InternationalRxMember_38475537-81d1-40b9-859b-6ddfccc7aca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_157b7e6c-1193-4d68-8bff-c568192f6279" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_157b7e6c-1193-4d68-8bff-c568192f6279" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_64fb5ae1-71b7-49e1-9e88-462f6cc52973" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_64fb5ae1-71b7-49e1-9e88-462f6cc52973" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_dfa0f59c-307e-4d8f-b393-145d3c52703a" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_dfa0f59c-307e-4d8f-b393-145d3c52703a" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="i82cb9e75f95f49678f893098f4a45b91_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0e002145-00d6-4024-9527-3ca0b54914c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0e002145-00d6-4024-9527-3ca0b54914c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3cc4dd5e-ba87-43b1-a4ad-969a571965c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3cc4dd5e-ba87-43b1-a4ad-969a571965c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_38fac790-f998-4c23-b094-7f18d0646d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebt_38fac790-f998-4c23-b094-7f18d0646d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aaf77706-e282-4030-b731-56aeb19d6f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebtCurrent_aaf77706-e282-4030-b731-56aeb19d6f5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_77688b34-ad0b-4e68-be7a-e4d2cbe2182d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_77688b34-ad0b-4e68-be7a-e4d2cbe2182d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6f28d934-82c4-48fc-ba46-303a25e4625e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:to="loc_us-gaap_CreditFacilityDomain_6f28d934-82c4-48fc-ba46-303a25e4625e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:to="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dea23afc-cbc3-48e5-98d7-4dde73941895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dea23afc-cbc3-48e5-98d7-4dde73941895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d08b64c7-6aa8-439e-8325-e90bab96361e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d08b64c7-6aa8-439e-8325-e90bab96361e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_054345cf-f3f2-434f-b0f7-a923e475f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:to="loc_us-gaap_SecuredDebtMember_054345cf-f3f2-434f-b0f7-a923e475f0e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_719a67ff-08e3-402d-8465-3af51ddbca74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:to="loc_us-gaap_UnsecuredDebtMember_719a67ff-08e3-402d-8465-3af51ddbca74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e5ca2b6b-f4be-49fb-ac5a-5287870a3646_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e5ca2b6b-f4be-49fb-ac5a-5287870a3646_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_813d735a-a12e-4af8-a262-1003213b8aab" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_813d735a-a12e-4af8-a262-1003213b8aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_2ad19069-e34c-4987-b477-75e9fdc96ca6" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_2ad19069-e34c-4987-b477-75e9fdc96ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_ae8d92f1-0545-4508-9ad0-4f13ec11bf82" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_ae8d92f1-0545-4508-9ad0-4f13ec11bf82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_e2307e87-f75b-4b48-8760-71c826acda58" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_e2307e87-f75b-4b48-8760-71c826acda58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_4a9d0add-5f23-4de1-b634-0d9650bd31c0" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_4a9d0add-5f23-4de1-b634-0d9650bd31c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_40774d3d-c6bb-4579-b628-0eb3de2948b5" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_40774d3d-c6bb-4579-b628-0eb3de2948b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_2014f272-534b-4157-9a62-e0a2dbe326f1" xlink:href="bhc-20221231.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermFacilityDueMay2027Member_2014f272-534b-4157-9a62-e0a2dbe326f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_174639b4-3aa9-42e6-af71-c92252591d77" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_174639b4-3aa9-42e6-af71-c92252591d77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_40ef7c8e-a1f8-417d-a1fb-bc746f241324" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_40ef7c8e-a1f8-417d-a1fb-bc746f241324" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_145afe00-b83d-4851-b4c9-86222dcc38c2" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_145afe00-b83d-4851-b4c9-86222dcc38c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_de710d55-2d19-4f26-b709-b38cedefe66d" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_de710d55-2d19-4f26-b709-b38cedefe66d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_5adc6b53-cb1f-446b-b93a-280ad51cf7d9" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_5adc6b53-cb1f-446b-b93a-280ad51cf7d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_31a45f60-25c8-4539-aee5-23a01146d132" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_31a45f60-25c8-4539-aee5-23a01146d132" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d52763ff-e58c-4be2-92f3-c5de34387302" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d52763ff-e58c-4be2-92f3-c5de34387302" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_2498a1fe-2c9b-4bf0-b793-c57bd918262d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_2498a1fe-2c9b-4bf0-b793-c57bd918262d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_9f5e90ce-527a-49fa-b1d4-e431588b0451" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_9f5e90ce-527a-49fa-b1d4-e431588b0451" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_8fb78562-dc35-46af-96b0-4500304a135e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_8fb78562-dc35-46af-96b0-4500304a135e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_245d5308-5971-465b-b1b5-b113e9dcbd63" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_245d5308-5971-465b-b1b5-b113e9dcbd63" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_880c7f03-1032-427d-8906-4c59aef28817" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_880c7f03-1032-427d-8906-4c59aef28817" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_234c50ba-cc49-46eb-9425-6db9c81948cf" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_234c50ba-cc49-46eb-9425-6db9c81948cf" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_ab8559fe-9137-46fb-b857-fef41f39113e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_ab8559fe-9137-46fb-b857-fef41f39113e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_147bf087-fdfe-4a07-9875-952d24f82dcc" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_147bf087-fdfe-4a07-9875-952d24f82dcc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_ef0a4a2b-5d06-438b-bf11-9517b126fbac" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_ef0a4a2b-5d06-438b-bf11-9517b126fbac" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_86878693-b17b-466e-aa58-fc4351902c81" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_86878693-b17b-466e-aa58-fc4351902c81" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_6b367a1d-54eb-47c0-a0f1-e6c5af17165c" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_6b367a1d-54eb-47c0-a0f1-e6c5af17165c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_a188d3d6-cb92-4100-8119-9abfb6864ea1" xlink:href="bhc-20221231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_OtherLongTermDebtMember_a188d3d6-cb92-4100-8119-9abfb6864ea1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5d4f5185-060d-4fbd-a03a-58fdcbf38f14_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:to="loc_dei_EntityDomain_5d4f5185-060d-4fbd-a03a-58fdcbf38f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:to="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8a4d6694-711f-4b6f-9dc4-73c568149045" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:to="loc_bhc_BauschLombMember_8a4d6694-711f-4b6f-9dc4-73c568149045" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="i6a8e0523a35d4118ae6123bfd9c72339_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_50a0e6f8-744a-44e0-9408-8299948e1ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_50a0e6f8-744a-44e0-9408-8299948e1ae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_a1e1f4ec-6c86-4fca-bbce-ee2d51b6a05e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_a1e1f4ec-6c86-4fca-bbce-ee2d51b6a05e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5acd45bf-72b4-4aad-94e6-c998b9279e22" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5acd45bf-72b4-4aad-94e6-c998b9279e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_eacc0821-3145-43f2-b85f-b71df976cb3b" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_eacc0821-3145-43f2-b85f-b71df976cb3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c6a8b730-b5c5-4450-b0ad-16a04092fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c6a8b730-b5c5-4450-b0ad-16a04092fae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9fe07d6b-308c-4d25-821b-19d26f5530fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:to="loc_us-gaap_CreditFacilityDomain_9fe07d6b-308c-4d25-821b-19d26f5530fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:to="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_b17894d8-39a7-462e-8bc2-8cd498a0b562" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_b17894d8-39a7-462e-8bc2-8cd498a0b562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6217ce2b-477b-4c03-8ad3-0ddf895a6c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6217ce2b-477b-4c03-8ad3-0ddf895a6c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cdd723e9-9b08-4b0b-a03f-09c35c073bb1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cdd723e9-9b08-4b0b-a03f-09c35c073bb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a69b963d-f398-44a3-9a47-d02a99acd46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:to="loc_us-gaap_SecuredDebtMember_a69b963d-f398-44a3-9a47-d02a99acd46d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d2188982-f205-4b04-8d8f-39989ae5c69e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:to="loc_dei_EntityDomain_d2188982-f205-4b04-8d8f-39989ae5c69e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:to="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_cefa27cd-4583-44fc-ac90-669b3c9453e5" xlink:href="bhc-20221231.xsd#bhc_A1261229BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:to="loc_bhc_A1261229BCLtdMember_cefa27cd-4583-44fc-ac90-669b3c9453e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7639a574-7fc7-4b64-b3f7-8444ebff38ea_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:to="loc_srt_OwnershipDomain_7639a574-7fc7-4b64-b3f7-8444ebff38ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:to="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_50b12be9-4248-4392-9b40-4ebafe99f006" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:to="loc_bhc_BauschLombMember_50b12be9-4248-4392-9b40-4ebafe99f006" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended" id="ibf47caafc6a44895b4e5591acf7e98d8_FINANCINGARRANGEMENTSExchangeOfferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_954f2df4-6f51-4988-b1ef-f1969b3de3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_954f2df4-6f51-4988-b1ef-f1969b3de3ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a452cb4c-91e3-4adf-9ebf-d26bd20b9509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a452cb4c-91e3-4adf-9ebf-d26bd20b9509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_32628e69-913e-48f1-8542-06c4a9a79363" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_32628e69-913e-48f1-8542-06c4a9a79363" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e7f7237f-f322-4c83-9505-037c18460877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e7f7237f-f322-4c83-9505-037c18460877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1e72d7db-a031-4365-8281-a26f60e12a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1e72d7db-a031-4365-8281-a26f60e12a7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3edaefba-41ba-4ced-96e4-da6870fc5473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3edaefba-41ba-4ced-96e4-da6870fc5473" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_d27d7557-eddc-4e73-8b83-4ced5da7ca34" xlink:href="bhc-20221231.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_d27d7557-eddc-4e73-8b83-4ced5da7ca34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd78edf1-5ccf-4fc4-9273-57e9dfce8b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd78edf1-5ccf-4fc4-9273-57e9dfce8b28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d87e6516-6047-415f-9367-1af11c101313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d87e6516-6047-415f-9367-1af11c101313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_533ece37-08e8-43f6-9c47-dc85fbefbee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:to="loc_us-gaap_UnsecuredDebtMember_533ece37-08e8-43f6-9c47-dc85fbefbee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8e624afe-fded-45af-b013-548253589a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:to="loc_us-gaap_SecuredDebtMember_8e624afe-fded-45af-b013-548253589a92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0cdcb63-01d2-49d3-a3cb-7bc764185e63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0cdcb63-01d2-49d3-a3cb-7bc764185e63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_bcfe611d-fd25-405a-95b0-5d1da58102df" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_bcfe611d-fd25-405a-95b0-5d1da58102df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_3954f05a-c042-4b34-9942-96e5e63f6583" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_3954f05a-c042-4b34-9942-96e5e63f6583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d3e5b022-7898-4292-a500-a91bee25d685" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d3e5b022-7898-4292-a500-a91bee25d685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_297099dc-069c-49bb-86e8-35c43f558454" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_297099dc-069c-49bb-86e8-35c43f558454" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_0be20820-2338-40a4-a2df-90053ad56b2f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_0be20820-2338-40a4-a2df-90053ad56b2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_1236fe2a-56c0-428d-82c4-491ec6382b79" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_1236fe2a-56c0-428d-82c4-491ec6382b79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_d2c5b19f-a728-4030-9ea1-022dd0f9c60c" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_d2c5b19f-a728-4030-9ea1-022dd0f9c60c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f9c66c52-7ddd-4ccd-adcd-f4d1e622a18a" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f9c66c52-7ddd-4ccd-adcd-f4d1e622a18a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29_default" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_643c31dc-45d5-4d08-b6b4-fcbe48f4933a" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:to="loc_bhc_ExchangeOfferMember_643c31dc-45d5-4d08-b6b4-fcbe48f4933a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3907b006-ac1f-46be-a128-5aab7052a74f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:to="loc_srt_OwnershipDomain_3907b006-ac1f-46be-a128-5aab7052a74f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:to="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_91109587-e70a-434c-9a23-a085d4edb27b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:to="loc_bhc_BauschLombMember_91109587-e70a-434c-9a23-a085d4edb27b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a0d713e9-36fe-4ac3-966c-91507d6225e7_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:to="loc_dei_EntityDomain_a0d713e9-36fe-4ac3-966c-91507d6225e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:to="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_91d3f36c-a316-48d5-af3b-316e6015517c" xlink:href="bhc-20221231.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:to="loc_bhc_A1375209BCLtdMember_91d3f36c-a316-48d5-af3b-316e6015517c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="extended" id="ic24bcbd9995742428c2a021d331280e5_FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df3ef924-a8cb-4968-830c-9813ab0724ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df3ef924-a8cb-4968-830c-9813ab0724ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d51a44-20f9-4520-95aa-72bc34aca0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d51a44-20f9-4520-95aa-72bc34aca0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_967ec9e9-eedf-4222-b397-60ca7838b766_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_967ec9e9-eedf-4222-b397-60ca7838b766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_c4691181-ffb9-4159-981f-d0e2465e61e9" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_c4691181-ffb9-4159-981f-d0e2465e61e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_a176b373-c21e-4272-90d3-d1aa2a3fddf6" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_a176b373-c21e-4272-90d3-d1aa2a3fddf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_2f6c0d8d-48ee-4868-bbd3-7bcdc304afae" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_2f6c0d8d-48ee-4868-bbd3-7bcdc304afae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_9b0936d1-2f0a-4372-b21c-d85e6b8c5485" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_9b0936d1-2f0a-4372-b21c-d85e6b8c5485" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_f1b512d0-cd5b-4e77-b8d5-73926778cd00" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_f1b512d0-cd5b-4e77-b8d5-73926778cd00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_c93e2ecf-3763-40e3-916c-60d0eb73bfd1" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_c93e2ecf-3763-40e3-916c-60d0eb73bfd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4d7922ea-2bce-4d42-a3b8-eadc1e97f36d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4d7922ea-2bce-4d42-a3b8-eadc1e97f36d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_24bb7398-b79d-4672-8191-37a3702b2e50" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_24bb7398-b79d-4672-8191-37a3702b2e50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_18032b8c-16d4-4f8b-92ff-b1012b9da376" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_18032b8c-16d4-4f8b-92ff-b1012b9da376" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4c9a1519-4227-4732-b6e8-04278c804ff3" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4c9a1519-4227-4732-b6e8-04278c804ff3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3cc78849-e560-4b27-8e50-4b727407db2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3cc78849-e560-4b27-8e50-4b727407db2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c9c093ed-6f42-4b5e-acaa-1da8a9ceab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:to="loc_us-gaap_UnsecuredDebtMember_c9c093ed-6f42-4b5e-acaa-1da8a9ceab6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f_default" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_2e27f0dc-24ac-41c8-821e-6fa13307f26d" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:to="loc_bhc_ExchangeOfferMember_2e27f0dc-24ac-41c8-821e-6fa13307f26d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i9bb2a86e97584a4892de1ead24b97e1d_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fef58597-73ff-45bf-9604-0e085325591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fef58597-73ff-45bf-9604-0e085325591d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_17f434ed-ae73-4b37-9942-2c1694005718" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_17f434ed-ae73-4b37-9942-2c1694005718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_abcd8ea4-daa3-4173-a078-e1a9e3544a35" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_abcd8ea4-daa3-4173-a078-e1a9e3544a35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_eb59e3a3-9338-4664-b1e6-58d0e6ccc78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_eb59e3a3-9338-4664-b1e6-58d0e6ccc78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ee27452e-c04d-43c4-9382-2f4cc0c52b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LongTermDebt_ee27452e-c04d-43c4-9382-2f4cc0c52b37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_61b030b1-e77d-4ab6-beb2-304b52470ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_61b030b1-e77d-4ab6-beb2-304b52470ada" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_9a8e045e-cfd9-4f82-b25b-1dc2d49d4546" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_9a8e045e-cfd9-4f82-b25b-1dc2d49d4546" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3bae0582-9362-4332-9e1d-47596a9fde30" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3bae0582-9362-4332-9e1d-47596a9fde30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fef01529-99ca-4406-8f8f-40f8ea9bfde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fef01529-99ca-4406-8f8f-40f8ea9bfde3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_9547a8cb-f2e5-4240-b107-94f8af286260" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_9547a8cb-f2e5-4240-b107-94f8af286260" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_382df9a3-f3cc-4ed7-bf53-faf918a276eb" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_382df9a3-f3cc-4ed7-bf53-faf918a276eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_4cc32597-7b53-4c43-84ac-5aaf5c3c32ce" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_4cc32597-7b53-4c43-84ac-5aaf5c3c32ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_03f58643-46d1-4a08-9ea6-eeab61bd33c3" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_03f58643-46d1-4a08-9ea6-eeab61bd33c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_eaa511f3-2d3a-4dea-9fc0-eeba18f800ee" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_eaa511f3-2d3a-4dea-9fc0-eeba18f800ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_a2de81b6-e5f0-41c9-9466-ddb54211ac01" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_a2de81b6-e5f0-41c9-9466-ddb54211ac01" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_bd660124-e752-4137-bd66-7e5f531f3e05" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_bd660124-e752-4137-bd66-7e5f531f3e05" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_37f235cf-156d-44e7-80a2-1589253c2366" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_37f235cf-156d-44e7-80a2-1589253c2366" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_78f4a6ae-40df-4bc7-80d4-b73ced5052ec" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_78f4a6ae-40df-4bc7-80d4-b73ced5052ec" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_6f3be177-5643-4afa-9bb3-9904fb5d7fd0" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_6f3be177-5643-4afa-9bb3-9904fb5d7fd0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_112c50a9-010e-41ff-944a-664a1dff9f5e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_112c50a9-010e-41ff-944a-664a1dff9f5e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_f6373ae1-60d7-40c7-9e72-859a26d6d823" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_f6373ae1-60d7-40c7-9e72-859a26d6d823" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_5594548e-c232-4fbd-bb8e-4a13bdf4a4fc" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_5594548e-c232-4fbd-bb8e-4a13bdf4a4fc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_56feca14-82b0-42ee-bbf6-2b3ca58e3ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentTerm_56feca14-82b0-42ee-bbf6-2b3ca58e3ac9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2c0585dd-20e4-4c40-8a3a-428e1672264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2c0585dd-20e4-4c40-8a3a-428e1672264d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_79289cbd-d6da-4c7a-a6cf-48370f103368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_79289cbd-d6da-4c7a-a6cf-48370f103368" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63ff2c44-ef10-489b-9252-53397f57b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63ff2c44-ef10-489b-9252-53397f57b38b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8dbb9dac-0a82-4192-8ee5-e7dd0697a2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8dbb9dac-0a82-4192-8ee5-e7dd0697a2c2" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_6c2ff629-0e26-4478-983a-3c77a63c9b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_6c2ff629-0e26-4478-983a-3c77a63c9b24" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:to="loc_us-gaap_CreditFacilityDomain_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:to="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1b1bd92f-7bae-49e5-b5ac-88ed1eac6604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1b1bd92f-7bae-49e5-b5ac-88ed1eac6604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a63f505b-b7ce-4c26-a2dc-2902698193b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:to="loc_us-gaap_LetterOfCreditMember_a63f505b-b7ce-4c26-a2dc-2902698193b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba77d675-b8cc-4469-8674-16238dced847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba77d675-b8cc-4469-8674-16238dced847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_14e61fd8-aeac-4624-b239-8dc5fd5d5588" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_14e61fd8-aeac-4624-b239-8dc5fd5d5588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_f6360395-68ea-41f4-ad25-d296c8d1c51a" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_f6360395-68ea-41f4-ad25-d296c8d1c51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_bda4a7d3-7fe5-441b-9833-a9480aca8612" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_bda4a7d3-7fe5-441b-9833-a9480aca8612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_79fd71b0-6f74-47ea-8893-0a740090d1c5" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_79fd71b0-6f74-47ea-8893-0a740090d1c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_52aa988a-228b-409f-b8fb-43b4b9ee4805" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_52aa988a-228b-409f-b8fb-43b4b9ee4805" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_964b79c3-1456-4a5d-a28d-99305d84117b" xlink:href="bhc-20221231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_964b79c3-1456-4a5d-a28d-99305d84117b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_857a68fb-ab1b-4c0c-a6ae-9202d22bacd4" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_857a68fb-ab1b-4c0c-a6ae-9202d22bacd4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_cc16a8ed-c495-4644-b909-4c9d4924f14b" xlink:href="bhc-20221231.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermFacilityDueMay2027Member_cc16a8ed-c495-4644-b909-4c9d4924f14b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_951b2b17-4a82-4758-9881-0565cf3b217f" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_951b2b17-4a82-4758-9881-0565cf3b217f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_022005bd-12b3-48ba-860c-99f324ceb5d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:to="loc_us-gaap_VariableRateDomain_022005bd-12b3-48ba-860c-99f324ceb5d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:to="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e5b72b9c-a835-4e25-995f-778ae3261970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e5b72b9c-a835-4e25-995f-778ae3261970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_daa4f4fc-0279-4d56-a788-07c57088e973" xlink:href="bhc-20221231.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_daa4f4fc-0279-4d56-a788-07c57088e973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_7097b3bb-f28b-4f84-b39b-37a6990d2e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_7097b3bb-f28b-4f84-b39b-37a6990d2e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_9cac2bfb-d992-42b1-be62-93a7fe6471b5" xlink:href="bhc-20221231.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_9cac2bfb-d992-42b1-be62-93a7fe6471b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_91f0420b-847c-470d-ab80-032187846431" xlink:href="bhc-20221231.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_91f0420b-847c-470d-ab80-032187846431" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_ef9c1af7-15b4-4e1e-909a-c76b29b12a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_BaseRateMember_ef9c1af7-15b4-4e1e-909a-c76b29b12a73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_7d776b5c-3b2b-499f-8f90-8b0c01ee4e17" xlink:href="bhc-20221231.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_7d776b5c-3b2b-499f-8f90-8b0c01ee4e17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_deb97ce3-3fb4-406d-a4ec-c6c6a0502cf3" xlink:href="bhc-20221231.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_deb97ce3-3fb4-406d-a4ec-c6c6a0502cf3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69f9f290-e439-4648-ac49-77daf6a63f81_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:to="loc_srt_RangeMember_69f9f290-e439-4648-ac49-77daf6a63f81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:to="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d17360a6-8788-4953-9b60-4f3b8b7c850b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:to="loc_srt_MinimumMember_d17360a6-8788-4953-9b60-4f3b8b7c850b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f0d01d3-b310-4efd-9885-56a6d73c9459" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:to="loc_srt_MaximumMember_7f0d01d3-b310-4efd-9885-56a6d73c9459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_783747e5-7fc0-4c32-860d-bd363cc7c978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_783747e5-7fc0-4c32-860d-bd363cc7c978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f1d11338-c009-420a-a66e-aa11962f6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:to="loc_us-gaap_SecuredDebtMember_f1d11338-c009-420a-a66e-aa11962f6d0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_df1f32b3-e2d4-4db9-8163-115e78557a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:to="loc_us-gaap_UnsecuredDebtMember_df1f32b3-e2d4-4db9-8163-115e78557a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8302470-517b-4e54-979f-e13997ba4ccf_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:to="loc_dei_EntityDomain_b8302470-517b-4e54-979f-e13997ba4ccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:to="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_57c82984-2493-4123-bff3-ce01cc37ffae" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:to="loc_bhc_BauschLombMember_57c82984-2493-4123-bff3-ce01cc37ffae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_4334d46f-9baa-4818-af67-566c028f23a4" xlink:href="bhc-20221231.xsd#bhc_A1261229BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:to="loc_bhc_A1261229BCLtdMember_4334d46f-9baa-4818-af67-566c028f23a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f28ca8a0-d6a7-40ab-a938-b210e4a378b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:to="loc_srt_OwnershipDomain_f28ca8a0-d6a7-40ab-a938-b210e4a378b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:to="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_87b57b4c-73f7-4d14-a2dd-26f60608e16b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:to="loc_bhc_BauschLombMember_87b57b4c-73f7-4d14-a2dd-26f60608e16b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i9406fd308276405aae7650d6d3b66fad_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2e0d318-14e0-4906-874e-cd9b16ac5954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2e0d318-14e0-4906-874e-cd9b16ac5954" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_ec527d12-01b8-457f-8606-e23bbde5fe9e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_ec527d12-01b8-457f-8606-e23bbde5fe9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4981d8f1-0353-4528-b2ff-7371d6176a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4981d8f1-0353-4528-b2ff-7371d6176a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_13adfcb6-3637-47b8-966a-9c6e3c7f2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_13adfcb6-3637-47b8-966a-9c6e3c7f2bfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_483b2a59-59fb-4e56-ad7c-5ab11834ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_483b2a59-59fb-4e56-ad7c-5ab11834ddd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcac5249-aeee-41f3-bbf4-7940e0c37d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcac5249-aeee-41f3-bbf4-7940e0c37d7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b3d49116-ce0a-4a99-a9b1-9db01c2b2756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b3d49116-ce0a-4a99-a9b1-9db01c2b2756" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9fc8300-03d6-4e18-9733-56e89c57d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9fc8300-03d6-4e18-9733-56e89c57d91b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35b97b9e-f619-45ab-81c2-f74578339381_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35b97b9e-f619-45ab-81c2-f74578339381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_df1b4b6e-c349-4e55-ae7d-24d33366a431" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_df1b4b6e-c349-4e55-ae7d-24d33366a431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_18e50e0d-5b34-498d-8462-a7a1fea73989" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_18e50e0d-5b34-498d-8462-a7a1fea73989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_ca231209-c5bc-4dea-a615-fa657c096a2d" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_ca231209-c5bc-4dea-a615-fa657c096a2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_fde6e11b-f2ab-4390-91d6-bcdc954aa2b9" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_fde6e11b-f2ab-4390-91d6-bcdc954aa2b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f9d6d4a2-dd84-4938-acc0-c30eef67293b" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f9d6d4a2-dd84-4938-acc0-c30eef67293b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_2ae2d3a7-de92-4223-9537-f99bf6ba0f17" xlink:href="bhc-20221231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_2ae2d3a7-de92-4223-9537-f99bf6ba0f17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b310641b-b2b5-4c5b-ac58-c648641f1319" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b310641b-b2b5-4c5b-ac58-c648641f1319" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_e04da999-4411-4e28-9256-050f37c1db8b" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_e04da999-4411-4e28-9256-050f37c1db8b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_fc141c9d-c054-4507-9e09-deef22dd51af" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_fc141c9d-c054-4507-9e09-deef22dd51af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_4f1de0f5-df58-44a8-91f3-7792e0645d25" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_4f1de0f5-df58-44a8-91f3-7792e0645d25" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_4e912738-15ac-43ed-b97b-9db2c419d8c1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_4e912738-15ac-43ed-b97b-9db2c419d8c1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_8377b664-9d68-4f14-b5ea-95a6b20e7093" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_8377b664-9d68-4f14-b5ea-95a6b20e7093" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_98bdc963-9375-4e9a-b36c-3da760987f76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_98bdc963-9375-4e9a-b36c-3da760987f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a859e5cd-7b9b-48e6-af6c-25276cb20ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:to="loc_us-gaap_SecuredDebtMember_a859e5cd-7b9b-48e6-af6c-25276cb20ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4517889c-3a39-418b-ab1e-19d2a3782db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:to="loc_us-gaap_UnsecuredDebtMember_4517889c-3a39-418b-ab1e-19d2a3782db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5c8839c4-66f3-4e19-a1d3-9b3320d76795_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_5c8839c4-66f3-4e19-a1d3-9b3320d76795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1e0afa07-63df-477c-a0f1-efe0b8fe5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1e0afa07-63df-477c-a0f1-efe0b8fe5ed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_44264761-6d99-4558-af6c-0dee1982bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_44264761-6d99-4558-af6c-0dee1982bddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61ac9729-f72f-4ed4-a224-6eb4e7b6d896_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:to="loc_srt_RangeMember_61ac9729-f72f-4ed4-a224-6eb4e7b6d896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:to="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4cd69a1d-31c7-49bc-9e94-6f75daf4fde2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:to="loc_srt_MaximumMember_4cd69a1d-31c7-49bc-9e94-6f75daf4fde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_29874df1-7008-4788-9e3d-abbcf28f81be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:to="loc_srt_OwnershipDomain_29874df1-7008-4788-9e3d-abbcf28f81be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:to="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3671f76b-9ae3-48d2-aba6-4ad11caf90f1" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:to="loc_bhc_BauschLombMember_3671f76b-9ae3-48d2-aba6-4ad11caf90f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_71e5a9bd-ab97-49f4-8d71-0b29dbc11363_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:to="loc_dei_EntityDomain_71e5a9bd-ab97-49f4-8d71-0b29dbc11363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:to="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_d67b6e6c-a729-4556-b50e-b381b9bbb0e2" xlink:href="bhc-20221231.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:to="loc_bhc_A1375209BCLtdMember_d67b6e6c-a729-4556-b50e-b381b9bbb0e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="if280fbcc06164a14b8f38ea2643594c2_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_dc90e7ab-6a9e-4530-861f-502ff4707319" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_dc90e7ab-6a9e-4530-861f-502ff4707319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3171bde3-be12-4daf-9e49-178987c974f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3171bde3-be12-4daf-9e49-178987c974f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25827ccd-df5e-4628-a818-f3de0df99fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25827ccd-df5e-4628-a818-f3de0df99fd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_433d96ae-3767-4918-8d2f-d20bbc126794" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_433d96ae-3767-4918-8d2f-d20bbc126794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_57bd9e45-623b-4afb-a5b2-89e73f059d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_57bd9e45-623b-4afb-a5b2-89e73f059d7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2216a388-1695-4bc0-8032-2217241377cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2216a388-1695-4bc0-8032-2217241377cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2138dcd4-abfc-4b21-b8ba-b96fdf78de0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2138dcd4-abfc-4b21-b8ba-b96fdf78de0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_b4a16438-467d-4daf-9506-c52260145a6e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_b4a16438-467d-4daf-9506-c52260145a6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_95bb84f4-e051-4221-be64-58bde3915bf9" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_95bb84f4-e051-4221-be64-58bde3915bf9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_853ce126-294e-41c7-bee0-04cec3dce235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_853ce126-294e-41c7-bee0-04cec3dce235" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64f5df14-833c-4b54-bdf1-ae7baf26d58b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64f5df14-833c-4b54-bdf1-ae7baf26d58b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2e8d415e-f1cf-4ae9-8287-e6862faf70c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:to="loc_us-gaap_UnsecuredDebtMember_2e8d415e-f1cf-4ae9-8287-e6862faf70c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1d50a413-fcc2-402b-9bba-3c0338f1b264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:to="loc_us-gaap_SecuredDebtMember_1d50a413-fcc2-402b-9bba-3c0338f1b264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f21f9239-099d-4a93-b3ee-8ab74c140178_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f21f9239-099d-4a93-b3ee-8ab74c140178_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_79f1a57d-f584-495e-953e-c2e9e52ff8e7" xlink:href="bhc-20221231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_79f1a57d-f584-495e-953e-c2e9e52ff8e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_f968dc42-41d8-48fb-a365-614404088c9a" xlink:href="bhc-20221231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_f968dc42-41d8-48fb-a365-614404088c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_2dca0d1e-30a7-47b1-97ed-2b1212e4a793" xlink:href="bhc-20221231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_2dca0d1e-30a7-47b1-97ed-2b1212e4a793" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_1d0402d0-b832-4061-b027-60d7faa521dc" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes4.502023Member_1d0402d0-b832-4061-b027-60d7faa521dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_7db6b8ff-0744-4b3b-a4a0-a12674b1bf34" xlink:href="bhc-20221231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_7db6b8ff-0744-4b3b-a4a0-a12674b1bf34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_610efa59-c9a9-4830-9a02-6421002aa261" xlink:href="bhc-20221231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_610efa59-c9a9-4830-9a02-6421002aa261" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_55be26b4-ebe4-4033-bacb-e353dc87248f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_55be26b4-ebe4-4033-bacb-e353dc87248f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_7f07e58f-9a2a-4265-9b29-1c6e16c58918" xlink:href="bhc-20221231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_7f07e58f-9a2a-4265-9b29-1c6e16c58918" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_98580bdc-7cd7-45b5-bc15-7ffd27214193" xlink:href="bhc-20221231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_98580bdc-7cd7-45b5-bc15-7ffd27214193" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_438dc019-bff0-4041-a3c3-03c6fc70ae9d" xlink:href="bhc-20221231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_438dc019-bff0-4041-a3c3-03c6fc70ae9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_0c21dd80-93a1-49d0-9a94-a9e2eaf32ac2" xlink:href="bhc-20221231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_0c21dd80-93a1-49d0-9a94-a9e2eaf32ac2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_54b024e9-fe6f-45f0-bebc-cd1cd60adf9a" xlink:href="bhc-20221231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_54b024e9-fe6f-45f0-bebc-cd1cd60adf9a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_fd33e6f8-38b1-4a06-9bb0-5c8b7ddc5976" xlink:href="bhc-20221231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_fd33e6f8-38b1-4a06-9bb0-5c8b7ddc5976" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_a1f7ebde-9cf6-4e01-95ea-7549420da8f8" xlink:href="bhc-20221231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_a1f7ebde-9cf6-4e01-95ea-7549420da8f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_8db7f3f0-46d5-4982-a21f-7596a690325d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_8db7f3f0-46d5-4982-a21f-7596a690325d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_27900475-02e5-4dbf-9bae-169a89d587d1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_27900475-02e5-4dbf-9bae-169a89d587d1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_15d7ba33-3184-457d-9593-02ad04a1b63f" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_15d7ba33-3184-457d-9593-02ad04a1b63f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_1f0e1c57-4067-4025-8f5d-244279b4c91e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_1f0e1c57-4067-4025-8f5d-244279b4c91e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_75a6d503-8432-4a12-8c75-5c56df9dea2f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_75a6d503-8432-4a12-8c75-5c56df9dea2f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_17f9e71a-3c38-4de8-9812-b05ca50f654d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_17f9e71a-3c38-4de8-9812-b05ca50f654d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_952fb3af-ff6f-4fc6-90ba-633247d3fc5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_952fb3af-ff6f-4fc6-90ba-633247d3fc5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6c59082d-f216-4857-9e22-1b52ae9e2045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6c59082d-f216-4857-9e22-1b52ae9e2045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c38a7c5e-4893-4457-8c76-359b15f6eb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c38a7c5e-4893-4457-8c76-359b15f6eb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_717f4373-774a-4f06-9c47-1077dee0d163_default" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_717f4373-774a-4f06-9c47-1077dee0d163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_ae1c289b-9db8-4aad-bd32-6a055ccaf328" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:to="loc_bhc_ExchangeOfferMember_ae1c289b-9db8-4aad-bd32-6a055ccaf328" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended" id="i82f9ad6b4f054ab2b1ac0c7ac43007f6_FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c13f4097-61fc-4447-90c0-c937a864c103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c13f4097-61fc-4447-90c0-c937a864c103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_42157c18-a321-4bd2-80be-f82b8b6e6984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_42157c18-a321-4bd2-80be-f82b8b6e6984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_859870b4-153f-464f-b959-ce2cf407acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_859870b4-153f-464f-b959-ce2cf407acd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_403180ac-4f8d-4786-8fef-187453bcb06b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_403180ac-4f8d-4786-8fef-187453bcb06b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_12e19e7e-ff93-413b-86e6-80a3f81389e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:to="loc_us-gaap_UnsecuredDebtMember_12e19e7e-ff93-413b-86e6-80a3f81389e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended" id="i68f6c54f60914ae88f2bb16b527b0040_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_3f58611a-d760-40d4-96de-2b5fb5fd781a" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_3f58611a-d760-40d4-96de-2b5fb5fd781a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_cec4a9f2-ed75-44ff-ac63-6cdbca1b299a" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_cec4a9f2-ed75-44ff-ac63-6cdbca1b299a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9cfe6c06-78e2-4c66-8f4e-6f0c11cc68c6" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9cfe6c06-78e2-4c66-8f4e-6f0c11cc68c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_359601c8-b58c-46c5-a95b-a57131a8aeae" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_359601c8-b58c-46c5-a95b-a57131a8aeae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ad98a9b8-795b-445e-b7d7-2b9acc0f7fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ad98a9b8-795b-445e-b7d7-2b9acc0f7fdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_aed012fa-5ab7-4bdb-b538-1c986c86cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_aed012fa-5ab7-4bdb-b538-1c986c86cbfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_a367b846-9576-4218-b1c3-02449f850f03" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_a367b846-9576-4218-b1c3-02449f850f03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_43281018-ee28-4681-af74-f7618d0bef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_43281018-ee28-4681-af74-f7618d0bef2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_e1ce9406-b4f4-4134-9d6b-6eb9c74ee9d1" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_e1ce9406-b4f4-4134-9d6b-6eb9c74ee9d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_f58198f8-aa69-4d71-b0da-afd302f88636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_f58198f8-aa69-4d71-b0da-afd302f88636" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c447c476-1486-4435-9f0c-0bb53805ca67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c447c476-1486-4435-9f0c-0bb53805ca67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e6496e3e-2b61-42ba-92bf-001d187e923d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e6496e3e-2b61-42ba-92bf-001d187e923d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8ae779aa-c034-4136-aa65-09f98b657075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8ae779aa-c034-4136-aa65-09f98b657075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bb409de9-88bd-4d21-8918-7e107a19eb3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bb409de9-88bd-4d21-8918-7e107a19eb3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:to="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_dda38f2c-5d38-49bd-ad1c-c78de8f1b6e2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:to="loc_country_IE_dda38f2c-5d38-49bd-ad1c-c78de8f1b6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:to="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_146bb9a2-daf5-46ae-b172-3b8f65e92fb9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:to="loc_country_US_146bb9a2-daf5-46ae-b172-3b8f65e92fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a84b74e1-cad8-497a-a73a-eeef9729d694_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a84b74e1-cad8-497a-a73a-eeef9729d694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4115838c-09b1-43c6-972e-e5e8e46de9de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:to="loc_srt_ScenarioForecastMember_4115838c-09b1-43c6-972e-e5e8e46de9de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i85941c1e90eb4ab08d99af39a60ae022_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_602e3481-c229-408b-aab5-d234f4594ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_602e3481-c229-408b-aab5-d234f4594ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_be43e085-92b5-4b8e-9d34-ae30e877a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_be43e085-92b5-4b8e-9d34-ae30e877a692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4de43f1e-ab6e-498a-a25e-b7f61c532f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4de43f1e-ab6e-498a-a25e-b7f61c532f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:to="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b856b50e-109b-4f5c-85c3-150202e44b36" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:to="loc_country_US_b856b50e-109b-4f5c-85c3-150202e44b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6897ac5f-5d20-43a7-a346-6e9f6c663ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:to="loc_us-gaap_ForeignPlanMember_6897ac5f-5d20-43a7-a346-6e9f6c663ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_862e1c3a-c40e-4b5c-9849-3b8f3e32475a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_862e1c3a-c40e-4b5c-9849-3b8f3e32475a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c5a732c9-e3ad-4003-beb1-b4e7fbd76de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c5a732c9-e3ad-4003-beb1-b4e7fbd76de6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b29ae8f-3e51-4198-8d73-127b170f1393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b29ae8f-3e51-4198-8d73-127b170f1393" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i5cf99aee40164eef91ce3491a79807e0_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_16ae9a27-06c8-4d73-8a98-70056d6177c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_16ae9a27-06c8-4d73-8a98-70056d6177c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_38905e52-c2b8-4d39-bea8-be5631d98e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_38905e52-c2b8-4d39-bea8-be5631d98e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_283192d0-d50a-49e9-af7a-b9b9d8168cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_283192d0-d50a-49e9-af7a-b9b9d8168cc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_792d07ba-4a8b-4821-aa9c-b296d0b39b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_792d07ba-4a8b-4821-aa9c-b296d0b39b26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fea0299e-90d3-488d-a459-762866017b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fea0299e-90d3-488d-a459-762866017b48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_56b1c0ad-8567-482c-92db-fc1d3f193a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_56b1c0ad-8567-482c-92db-fc1d3f193a5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_67ca1ad6-721d-484e-bc07-6ae487bc2453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_67ca1ad6-721d-484e-bc07-6ae487bc2453" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_66f2ffab-a15f-4da8-9933-274cab3f6e53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_66f2ffab-a15f-4da8-9933-274cab3f6e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:to="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b7809d68-7444-42e9-a751-54e1db5275eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:to="loc_country_US_b7809d68-7444-42e9-a751-54e1db5275eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9882ed52-a626-4db8-8d47-d65c06920744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:to="loc_us-gaap_ForeignPlanMember_9882ed52-a626-4db8-8d47-d65c06920744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_070c0b58-86c1-4dd1-b946-53e9d4f81034_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_070c0b58-86c1-4dd1-b946-53e9d4f81034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_66e57944-2d8f-4898-bf4a-a6fe4232245a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_66e57944-2d8f-4898-bf4a-a6fe4232245a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_614b85d8-271e-4e42-ae51-7e1809da1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_614b85d8-271e-4e42-ae51-7e1809da1aff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended" id="ie8f25f4417a1428d94050eacb0c6cb0a_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f91107ac-fb7b-4333-8959-1d16a0d19111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f91107ac-fb7b-4333-8959-1d16a0d19111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dda7f35e-defa-44ea-b64c-99a0132bd451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dda7f35e-defa-44ea-b64c-99a0132bd451" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_83431585-ee97-43aa-ac62-b976880151ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_83431585-ee97-43aa-ac62-b976880151ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_4b5591fd-1867-4ae4-8dd6-4da4e7d1b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_4b5591fd-1867-4ae4-8dd6-4da4e7d1b8f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_35b252ea-1c73-48eb-9d9b-6fd9ddd83354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_35b252ea-1c73-48eb-9d9b-6fd9ddd83354" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_34609ecf-a1c3-4aff-b815-fdffc6c4e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_34609ecf-a1c3-4aff-b815-fdffc6c4e40e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6e2291d9-df2d-4ebf-b781-52652a1a580b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6e2291d9-df2d-4ebf-b781-52652a1a580b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_53728cb6-345f-4945-aea5-3cfe4f082713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b31cc6b0-ce0b-4d41-a3f4-8e66b59015ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b31cc6b0-ce0b-4d41-a3f4-8e66b59015ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b6d1e97d-3977-4410-875c-2bbdc297233a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b6d1e97d-3977-4410-875c-2bbdc297233a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5a1245c6-d52e-4b62-b095-4b47d48abf05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5a1245c6-d52e-4b62-b095-4b47d48abf05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6220a863-8b75-4ee9-afb1-8d515afae036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6220a863-8b75-4ee9-afb1-8d515afae036" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_38696b77-b7f6-482e-8498-f0ac34c6af72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_38696b77-b7f6-482e-8498-f0ac34c6af72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_89394b81-7f94-4a29-83fe-eccf25a81192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_89394b81-7f94-4a29-83fe-eccf25a81192" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dec0cce4-8b6c-430c-a644-6bcc04b36aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a2d3f290-0454-4056-9244-fcdc1c668845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a2d3f290-0454-4056-9244-fcdc1c668845" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_e00d27ec-f3df-43b3-8cf4-447ae3cd3205" xlink:href="bhc-20221231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_e00d27ec-f3df-43b3-8cf4-447ae3cd3205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_45ab2b06-67f0-4e76-9638-2c5999ca1212" xlink:href="bhc-20221231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_45ab2b06-67f0-4e76-9638-2c5999ca1212" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_735fbe4c-d707-4127-aab3-e35cac8e1a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_735fbe4c-d707-4127-aab3-e35cac8e1a3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8fd03f03-1725-4901-9469-2029efa40857_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8fd03f03-1725-4901-9469-2029efa40857_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:to="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abbfef35-6723-4f5a-8368-94d355baf44d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:to="loc_country_US_abbfef35-6723-4f5a-8368-94d355baf44d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1fd771e4-58b6-4db4-be71-b671e6957f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:to="loc_us-gaap_ForeignPlanMember_1fd771e4-58b6-4db4-be71-b671e6957f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_31f740d8-8b93-45cb-bc4f-99c21b127aaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_31f740d8-8b93-45cb-bc4f-99c21b127aaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_73f74d56-90d8-4e10-96b4-39df8a4e44f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_73f74d56-90d8-4e10-96b4-39df8a4e44f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c8127fc9-eacb-4824-a3eb-dc76dfe3179c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c8127fc9-eacb-4824-a3eb-dc76dfe3179c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended" id="ie8e3278386c14e50b31ea83693014363_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78912db1-3f29-493d-b77e-bf7a835ae1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78912db1-3f29-493d-b77e-bf7a835ae1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_6a19191b-973d-4752-9eb3-835c9fadc288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_6a19191b-973d-4752-9eb3-835c9fadc288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d7eeed7b-dea9-4331-9ff4-d7306b15d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d7eeed7b-dea9-4331-9ff4-d7306b15d06e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b33b0e30-1ec7-41f4-b33b-c713a4215917_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b33b0e30-1ec7-41f4-b33b-c713a4215917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:to="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b5b50e34-d163-4e7e-89fb-f151fdbd2823" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:to="loc_country_US_b5b50e34-d163-4e7e-89fb-f151fdbd2823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_15239644-0d3f-496b-8cf0-1b23282d4a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:to="loc_us-gaap_ForeignPlanMember_15239644-0d3f-496b-8cf0-1b23282d4a78" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended" id="i6415e8689c2d4c328f0f0dfcde2a88e3_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ee1d1471-7b43-46dc-b048-fc9309af1471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ee1d1471-7b43-46dc-b048-fc9309af1471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_290dd821-2e82-401a-8957-e342850702be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_290dd821-2e82-401a-8957-e342850702be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c2b90e74-a65e-4343-b38b-3552136031a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c2b90e74-a65e-4343-b38b-3552136031a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_749a9dfc-c3aa-460b-9be4-7917b462ad05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_749a9dfc-c3aa-460b-9be4-7917b462ad05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8ffe7fbe-2493-4b6a-ad58-9aec60c951fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8ffe7fbe-2493-4b6a-ad58-9aec60c951fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_83a299c3-e2b9-4116-afd1-8af779d554f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_83a299c3-e2b9-4116-afd1-8af779d554f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b1b03995-9388-4512-b7ae-3612b35b4ac0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b1b03995-9388-4512-b7ae-3612b35b4ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_567f6298-8e59-497e-bf6b-f3507daf3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_567f6298-8e59-497e-bf6b-f3507daf3f7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_513675a1-acc7-4f9a-b374-7d8e02c6da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_513675a1-acc7-4f9a-b374-7d8e02c6da3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c99fca70-de5c-495e-af59-a41819d891f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c99fca70-de5c-495e-af59-a41819d891f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:to="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8d32672-dc73-477f-9366-4556b4d7b604" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:to="loc_country_US_f8d32672-dc73-477f-9366-4556b4d7b604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7d20e9d3-9951-4af9-976f-fd04759668e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:to="loc_us-gaap_ForeignPlanMember_7d20e9d3-9951-4af9-976f-fd04759668e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended" id="i8c175d670b0149d8b7f2af8d33e8f1e1_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_6dffbbab-7161-422f-bb5f-2a99c3a54a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_6dffbbab-7161-422f-bb5f-2a99c3a54a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_aeb18b95-07f5-4719-bf4b-c4c51e6252c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_aeb18b95-07f5-4719-bf4b-c4c51e6252c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c35d5032-458f-46e8-a9ea-a7f74d264169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c35d5032-458f-46e8-a9ea-a7f74d264169" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_2325fee9-1f38-401d-a4f4-e3043955afae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_2325fee9-1f38-401d-a4f4-e3043955afae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1e6755cc-673e-4267-a2d9-f2608f3c4858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1e6755cc-673e-4267-a2d9-f2608f3c4858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_a73ffc7f-5234-4733-aefd-c9d1d116f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_a73ffc7f-5234-4733-aefd-c9d1d116f36b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_696bda6e-e3be-477b-a99a-b5a2640b7959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_696bda6e-e3be-477b-a99a-b5a2640b7959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4afd378f-8104-4c19-9f69-f95a8750f7be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4afd378f-8104-4c19-9f69-f95a8750f7be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a7d8d70a-33bd-4f45-aff9-82fb5f908976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a7d8d70a-33bd-4f45-aff9-82fb5f908976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_79a68616-d991-41f0-aa4e-b91114715ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_79a68616-d991-41f0-aa4e-b91114715ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bbdff44f-657d-450b-9753-e86b5f6b2d0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bbdff44f-657d-450b-9753-e86b5f6b2d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:to="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b133bcfc-2e4d-4b87-8c7a-585970a8b14c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:to="loc_country_US_b133bcfc-2e4d-4b87-8c7a-585970a8b14c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_56a30834-5463-4618-a4b6-c79929ffda55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:to="loc_us-gaap_ForeignPlanMember_56a30834-5463-4618-a4b6-c79929ffda55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended" id="i4e291571199b484fa599d55c9d692bcd_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_a6f47eb5-9f6f-4003-beaf-e4cb88b1d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_a6f47eb5-9f6f-4003-beaf-e4cb88b1d2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b02d822f-80ba-4b70-9303-254cd708535a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b02d822f-80ba-4b70-9303-254cd708535a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3776a90b-4e29-4b6f-ac6b-9c9229d93d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3776a90b-4e29-4b6f-ac6b-9c9229d93d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed968605-be7b-4643-a72f-99e0c8aaed15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ed968605-be7b-4643-a72f-99e0c8aaed15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:to="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b94039db-630e-4464-ab2d-f6dad164c519" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:to="loc_country_US_b94039db-630e-4464-ab2d-f6dad164c519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5ea57ec8-39fa-4caf-8031-33f7ed4ba5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:to="loc_us-gaap_ForeignPlanMember_5ea57ec8-39fa-4caf-8031-33f7ed4ba5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_4b41576f-f380-467b-b7e7-0eb3cbaced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_4b41576f-f380-467b-b7e7-0eb3cbaced23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_91a3fbf5-a4b3-4237-8639-647e57430b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_91a3fbf5-a4b3-4237-8639-647e57430b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_1b8e413e-edae-4fa6-b019-1feb71052c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_1b8e413e-edae-4fa6-b019-1feb71052c61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_1ea0301e-11a4-40ae-9cbf-3c420f4a0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_1ea0301e-11a4-40ae-9cbf-3c420f4a0ec8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended" id="i7d611ea3cc7544cc854cc3884e140dd1_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0029437-f0b0-4b84-a612-5bfcf0c01458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0029437-f0b0-4b84-a612-5bfcf0c01458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_bd13d8d6-0d09-48c3-82ca-b77375d6143b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_bd13d8d6-0d09-48c3-82ca-b77375d6143b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_8a944e21-fee7-404a-92e1-5d8c5336059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_8a944e21-fee7-404a-92e1-5d8c5336059c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_7d4e2b7f-a639-45f4-8043-208f8fb09d29" xlink:href="bhc-20221231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_U.S.BroadMarketMember_7d4e2b7f-a639-45f4-8043-208f8fb09d29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_c93132a1-059b-4c7a-917f-7253e0066e9d" xlink:href="bhc-20221231.xsd#bhc_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_EmergingMarketsMember_c93132a1-059b-4c7a-917f-7253e0066e9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_dca97654-ef50-40fa-bfba-e39bc0e8e1fe" xlink:href="bhc-20221231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_dca97654-ef50-40fa-bfba-e39bc0e8e1fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_bd64c7b3-f9c5-4d50-884f-c22766b9e817" xlink:href="bhc-20221231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_bd64c7b3-f9c5-4d50-884f-c22766b9e817" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_7b74da11-d6f9-48c7-b9f5-60f6156ea900" xlink:href="bhc-20221231.xsd#bhc_InvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:to="loc_bhc_InvestmentGradeMember_7b74da11-d6f9-48c7-b9f5-60f6156ea900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_911f77bd-f8f8-407a-baa7-766ce9743f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_911f77bd-f8f8-407a-baa7-766ce9743f51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_4749f55a-909e-4a4c-8b57-026a13152406" xlink:href="bhc-20221231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_4749f55a-909e-4a4c-8b57-026a13152406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d99ff95-7036-44a4-ac5e-9bbd493113f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d99ff95-7036-44a4-ac5e-9bbd493113f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_00d234ba-7fe4-4f99-9347-884f83f3e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_00d234ba-7fe4-4f99-9347-884f83f3e075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6db80133-988d-4945-a983-1639c8c7542d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6db80133-988d-4945-a983-1639c8c7542d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72aaadb7-a8a3-492b-b28e-22060c4da0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72aaadb7-a8a3-492b-b28e-22060c4da0ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_06a67732-8854-407c-ad17-090d3ab9f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_06a67732-8854-407c-ad17-090d3ab9f9c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf7f49f3-657f-4199-98b3-3a6507ffc9a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf7f49f3-657f-4199-98b3-3a6507ffc9a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_baf86216-060b-4450-b3d3-16ecdd1aee85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_baf86216-060b-4450-b3d3-16ecdd1aee85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_53b089da-36f0-4754-943f-1d5e393b1d94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_53b089da-36f0-4754-943f-1d5e393b1d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:to="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e51c6697-8899-4d50-ae0f-e855ad260739" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:to="loc_country_US_e51c6697-8899-4d50-ae0f-e855ad260739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_235cae61-6447-4101-9a32-3535a4fc1bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:to="loc_us-gaap_ForeignPlanMember_235cae61-6447-4101-9a32-3535a4fc1bd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i04fa4b67bc4946e980e33898da888f24_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ccab8241-08da-4933-9b19-6a9334bbc27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ccab8241-08da-4933-9b19-6a9334bbc27d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_50ae5f8f-8e6b-4804-a46c-4b16f70e15e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_50ae5f8f-8e6b-4804-a46c-4b16f70e15e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_495f3f7c-0dfc-438d-89e7-96a66e74f029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_495f3f7c-0dfc-438d-89e7-96a66e74f029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ba11c4c-5c5b-4b22-9e9a-73173609f249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ba11c4c-5c5b-4b22-9e9a-73173609f249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0d7137eb-6fee-480b-a342-8ddc3d365f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0d7137eb-6fee-480b-a342-8ddc3d365f4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e9e18fee-8888-4ac2-991e-193416f339bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e9e18fee-8888-4ac2-991e-193416f339bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_ea35d340-6077-4695-ad2a-478262a0a6b1" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_ea35d340-6077-4695-ad2a-478262a0a6b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b397f419-86b6-46f6-af5f-bde17a761d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b397f419-86b6-46f6-af5f-bde17a761d49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c853b151-6315-4683-8c52-b3ed075037fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c853b151-6315-4683-8c52-b3ed075037fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_94db0473-37f1-4ddc-8459-64eddb9022f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_94db0473-37f1-4ddc-8459-64eddb9022f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2bffd66-345c-4f09-8b90-91cdf265fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2bffd66-345c-4f09-8b90-91cdf265fd90" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_974d8331-e66c-49c8-9870-689804ee83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_974d8331-e66c-49c8-9870-689804ee83d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_a896181c-f5e7-4e8a-b00f-73f0bd572acc" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_a896181c-f5e7-4e8a-b00f-73f0bd572acc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_492e1c84-a87e-4fc1-a394-8fe343ddc19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_492e1c84-a87e-4fc1-a394-8fe343ddc19b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_936585a0-0712-428c-b7b5-2d01c913e205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_936585a0-0712-428c-b7b5-2d01c913e205" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d2e9d8b-105a-4b96-b5d7-2747065b544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d2e9d8b-105a-4b96-b5d7-2747065b544a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_12f1a0bf-afd4-4791-9ad0-5b1d5fa6b188" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_12f1a0bf-afd4-4791-9ad0-5b1d5fa6b188" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4caed5bc-4970-4eba-9662-3ef2ebd6d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4caed5bc-4970-4eba-9662-3ef2ebd6d26b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_ab567625-8be2-4f8a-97ca-93ca74df247f" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_ab567625-8be2-4f8a-97ca-93ca74df247f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_98c225aa-69c4-4729-a1fb-17f8edd9ebb6" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_98c225aa-69c4-4729-a1fb-17f8edd9ebb6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_798d74f7-6665-4a3b-b29f-e382327a6b9a" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_798d74f7-6665-4a3b-b29f-e382327a6b9a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_44c10ac5-a2ba-4c49-9f5c-e195a8c3e5d9" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_44c10ac5-a2ba-4c49-9f5c-e195a8c3e5d9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_23b2e187-591d-49b4-ad9c-edf23e321f3d" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_23b2e187-591d-49b4-ad9c-edf23e321f3d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_31a89bb6-6b16-480e-82dc-fb7da387f052" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_31a89bb6-6b16-480e-82dc-fb7da387f052" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_d6a3d119-781e-4a2f-b982-27560dde8403" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_fef5eca6-2104-479a-80d1-9cd875301312" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_fef5eca6-2104-479a-80d1-9cd875301312" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15d5416d-0dfd-4909-b3c3-bde1f6b06a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15d5416d-0dfd-4909-b3c3-bde1f6b06a2f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9a5dd47a-5454-4c5a-b4a2-2db4a634f976_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:to="loc_us-gaap_PlanNameDomain_9a5dd47a-5454-4c5a-b4a2-2db4a634f976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:to="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_6b50e840-2518-440b-803e-e8c9707ff856" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_6b50e840-2518-440b-803e-e8c9707ff856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_f62829ab-72aa-4740-a513-de1c0f079382" xlink:href="bhc-20221231.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_IPOFoundersGrantsMember_f62829ab-72aa-4740-a513-de1c0f079382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_c7abdd7e-7fce-457c-b100-18b23fa7bebf" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:to="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_c7abdd7e-7fce-457c-b100-18b23fa7bebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c71aea1-e444-4693-8d84-4b79ae0f0504_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2c71aea1-e444-4693-8d84-4b79ae0f0504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_1beac531-6dc1-4c97-96af-84710e5ba20c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:to="loc_srt_ExecutiveOfficerMember_1beac531-6dc1-4c97-96af-84710e5ba20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_27b4be76-0f5b-487d-b307-8cf4446e5d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_27b4be76-0f5b-487d-b307-8cf4446e5d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_32ec6c96-ab12-467f-a2c0-58eb52b15884" xlink:href="bhc-20221231.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_32ec6c96-ab12-467f-a2c0-58eb52b15884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_e7b46ec8-8ac3-4949-b95d-4fab9db5264d" xlink:href="bhc-20221231.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_e7b46ec8-8ac3-4949-b95d-4fab9db5264d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_a090ba4e-04b5-4b00-9efa-5da9dacb54d9" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_a090ba4e-04b5-4b00-9efa-5da9dacb54d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainEmployeesMember_3f094069-1a07-40ff-bcee-b27a4d95546e" xlink:href="bhc-20221231.xsd#bhc_CertainEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_CertainEmployeesMember_3f094069-1a07-40ff-bcee-b27a4d95546e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:href="bhc-20221231.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bfb06713-cac7-45e8-ac3a-f5a948a90529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bfb06713-cac7-45e8-ac3a-f5a948a90529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa570a20-78a9-487d-9c6f-4c0aab854d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa570a20-78a9-487d-9c6f-4c0aab854d0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_db3cbd99-e0bc-4d0e-8140-4b17820cd3a6" xlink:href="bhc-20221231.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_TimeBasedRSUMember_db3cbd99-e0bc-4d0e-8140-4b17820cd3a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_037fa58d-8b67-4624-8dad-4a47ebbc2bfb" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_037fa58d-8b67-4624-8dad-4a47ebbc2bfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_8963e2fd-74d3-4254-a33a-53df447df45c" xlink:href="bhc-20221231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_8963e2fd-74d3-4254-a33a-53df447df45c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_8950740c-8b26-4634-b06a-a16cfb6ab60b" xlink:href="bhc-20221231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_8950740c-8b26-4634-b06a-a16cfb6ab60b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_349749d2-176c-4b61-8082-7768be34cc2d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:to="loc_dei_EntityDomain_349749d2-176c-4b61-8082-7768be34cc2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:to="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8baff32d-fc95-472c-ac99-3a9453024b18" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:to="loc_bhc_BauschLombMember_8baff32d-fc95-472c-ac99-3a9453024b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4320c1d3-2a92-493a-9427-e1293e9d2846_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:to="loc_us-gaap_VestingDomain_4320c1d3-2a92-493a-9427-e1293e9d2846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:to="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3b969881-ce79-4bbf-85cd-bd8c41a3daff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3b969881-ce79-4bbf-85cd-bd8c41a3daff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_984c67c4-76ef-46c1-b614-36d9d5e18553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_984c67c4-76ef-46c1-b614-36d9d5e18553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_51caf965-5eec-4320-84ca-346425e5bbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_51caf965-5eec-4320-84ca-346425e5bbf7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i94ea2545d59549489bd68ffbe81ee4c4_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_25f36c35-2c65-453f-935f-e662984013f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:to="loc_us-gaap_ShareBasedCompensation_25f36c35-2c65-453f-935f-e662984013f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b62a514c-1242-471a-938e-892394089df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b62a514c-1242-471a-938e-892394089df2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9450321e-b2c5-4446-b3d1-e743076b803a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9450321e-b2c5-4446-b3d1-e743076b803a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0ff2d2f-f3b7-4054-b585-e0c046e7f784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0ff2d2f-f3b7-4054-b585-e0c046e7f784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a285a4a-6296-4977-b0fa-66ff8858692c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a285a4a-6296-4977-b0fa-66ff8858692c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aa7e68fa-fe91-4e2e-883a-3ec681ce0502_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aa7e68fa-fe91-4e2e-883a-3ec681ce0502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a7d48ec1-7e89-4287-bb80-bc5c8b687a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a7d48ec1-7e89-4287-bb80-bc5c8b687a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_a099e230-5e9c-4545-b516-6aab7eea666e" xlink:href="bhc-20221231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_a099e230-5e9c-4545-b516-6aab7eea666e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3b40827b-0e1c-4a42-b55c-9117178b3161_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:to="loc_us-gaap_PlanNameDomain_3b40827b-0e1c-4a42-b55c-9117178b3161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:to="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_07326d05-2c79-48c4-bd44-70876c19d592" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_07326d05-2c79-48c4-bd44-70876c19d592" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended" id="i9c552ddaf0244f20afdee628d3b7308c_SHAREBASEDCOMPENSATIONStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_f3641741-fb9f-4038-be7e-9aecc3346203" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_f3641741-fb9f-4038-be7e-9aecc3346203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c99ca97-281a-4109-8851-c754a6ea1929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c99ca97-281a-4109-8851-c754a6ea1929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c35f0ec-63f3-4e9d-ab3e-e6cd805f567c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c35f0ec-63f3-4e9d-ab3e-e6cd805f567c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ac40c386-a2cb-4f72-90ed-dade3fff9bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ac40c386-a2cb-4f72-90ed-dade3fff9bc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0815108-7952-4a49-add9-3f97b9256f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0815108-7952-4a49-add9-3f97b9256f96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c0b3060-0574-44d5-81d3-a146785afeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c0b3060-0574-44d5-81d3-a146785afeb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195b9c1b-aee4-4e1e-b491-a22957bfd9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195b9c1b-aee4-4e1e-b491-a22957bfd9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7c88269a-5161-4390-9e82-62bf3ecbd09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7c88269a-5161-4390-9e82-62bf3ecbd09a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7a21969-66c0-4063-807f-78b781e215a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7a21969-66c0-4063-807f-78b781e215a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8de1dbf5-7dda-4fe6-a066-af413b2f3b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8de1dbf5-7dda-4fe6-a066-af413b2f3b7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0380ed48-9b6f-4fa6-9460-5cf5bc69762c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_560d62b5-7f0a-48d2-92f6-01a506907119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_560d62b5-7f0a-48d2-92f6-01a506907119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_95397365-577d-4356-914e-b683ea4666b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_95397365-577d-4356-914e-b683ea4666b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62f96973-dca1-4603-9875-a98a19e4100e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62f96973-dca1-4603-9875-a98a19e4100e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_294485ab-ccc9-45a5-b728-57455a05525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_294485ab-ccc9-45a5-b728-57455a05525d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44bd8183-5594-446d-8675-7a1b54ade7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44bd8183-5594-446d-8675-7a1b54ade7fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6f0fd882-50a8-4280-bf76-7aca0cbe74e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6f0fd882-50a8-4280-bf76-7aca0cbe74e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f6fe8c8d-b622-47bc-b5cb-e8635a3d12ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a27a2d2d-02bc-44bd-bcb8-7105758f533c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a27a2d2d-02bc-44bd-bcb8-7105758f533c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c8f97ccc-045e-440e-b77a-41d471cdea17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c8f97ccc-045e-440e-b77a-41d471cdea17" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf932698-9e86-4ee7-9d70-0b33449e9491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf932698-9e86-4ee7-9d70-0b33449e9491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ebfe423d-34bd-4924-ae7a-c08a0770d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ebfe423d-34bd-4924-ae7a-c08a0770d0de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_da44935d-8639-4e6f-89d5-a0cd1f2dd509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_da44935d-8639-4e6f-89d5-a0cd1f2dd509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9b966895-c231-43c1-8833-f7b10ce05636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9b966895-c231-43c1-8833-f7b10ce05636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38376a11-5c75-48c2-881a-02cb2d3bc817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38376a11-5c75-48c2-881a-02cb2d3bc817" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70528000-bb5c-4627-b4fc-6b0f16ddf202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70528000-bb5c-4627-b4fc-6b0f16ddf202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6679c78f-2a1d-4454-b947-5baea5fabb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6679c78f-2a1d-4454-b947-5baea5fabb4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_408dbddb-de07-43d7-8f11-35ff43e83659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_408dbddb-de07-43d7-8f11-35ff43e83659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9764ce8c-b51f-4f81-87f8-63b5f7e1ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9764ce8c-b51f-4f81-87f8-63b5f7e1ca61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec79342b-f734-4214-87b0-b3cdadb816d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec79342b-f734-4214-87b0-b3cdadb816d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f64d817-3f51-4d72-93e7-e6a18c03c531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f64d817-3f51-4d72-93e7-e6a18c03c531" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_ef2e201d-4907-4e35-8c78-8a6bbe968033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:to="loc_us-gaap_VestingDomain_ef2e201d-4907-4e35-8c78-8a6bbe968033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:to="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8ab39188-306b-4e5b-807e-a8b9e8019b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8ab39188-306b-4e5b-807e-a8b9e8019b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9fe594fd-9bd6-4c1c-83ae-4a311a538d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9fe594fd-9bd6-4c1c-83ae-4a311a538d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901dfad3-8718-4522-8b44-5c387c932080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901dfad3-8718-4522-8b44-5c387c932080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a775897-12fc-4d18-b264-091d4523382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a775897-12fc-4d18-b264-091d4523382b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eea634fb-0181-4cbb-88b4-1713992f12af_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:to="loc_dei_EntityDomain_eea634fb-0181-4cbb-88b4-1713992f12af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:to="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_61049084-8387-4ee6-938c-78c027e6ce52" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:to="loc_bhc_BauschLombMember_61049084-8387-4ee6-938c-78c027e6ce52" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended" id="i7494c940268a46cb9b9635ae3edacdf6_SHAREBASEDCOMPENSATIONRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_396c36af-f33f-459f-a12b-27b79163c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_396c36af-f33f-459f-a12b-27b79163c52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dac229e-c8a2-4298-9a48-1c6d18d1220d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dac229e-c8a2-4298-9a48-1c6d18d1220d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10cc6275-ea1c-491a-b622-a4b4151c175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10cc6275-ea1c-491a-b622-a4b4151c175b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d8ee405c-9d2f-47b6-b592-e9f3609010fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d8ee405c-9d2f-47b6-b592-e9f3609010fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95303f30-54c8-4c39-b52d-630beaa83a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95303f30-54c8-4c39-b52d-630beaa83a35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_c88299de-05d2-490b-8cfe-650e6d9fceef" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_c88299de-05d2-490b-8cfe-650e6d9fceef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ec88277-a901-41ee-a162-f54b62853df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ec88277-a901-41ee-a162-f54b62853df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68673c53-e643-46a7-b1a8-e82b2c83ae5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68673c53-e643-46a7-b1a8-e82b2c83ae5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a3b7890-19ff-421d-b5a9-1f356266f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a3b7890-19ff-421d-b5a9-1f356266f0fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cc2572e-1f71-410e-b5ff-3ba46325675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cc2572e-1f71-410e-b5ff-3ba46325675c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c3d6cc5-3a35-4ccc-b8d9-e7feccb57e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2895b7a-bee2-48e3-832f-40922e97323f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2895b7a-bee2-48e3-832f-40922e97323f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d4bbd3c-96e5-4496-81e8-581ece3d8638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d4bbd3c-96e5-4496-81e8-581ece3d8638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_41947701-3aba-4901-b276-6cef82e12aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_41947701-3aba-4901-b276-6cef82e12aae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3b1f5e9-0699-4073-91b3-64df573d8b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3b1f5e9-0699-4073-91b3-64df573d8b91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52071c17-622e-4dcc-9a76-6fd9f89b591b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1c8e7c7-e701-4be7-955b-f5b704ae3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1c8e7c7-e701-4be7-955b-f5b704ae3c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_194aa211-e3db-442f-a255-59f19ee922bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_194aa211-e3db-442f-a255-59f19ee922bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f489d32-aa1b-4183-b6bf-2fc44b296424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f489d32-aa1b-4183-b6bf-2fc44b296424" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:to="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c60529c-db90-44d5-afe3-21569a017c58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c60529c-db90-44d5-afe3-21569a017c58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_416d128f-7668-4037-a39f-133a1769e384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_416d128f-7668-4037-a39f-133a1769e384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_629a523e-d8b3-48c7-9226-f9e83061b311" xlink:href="bhc-20221231.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_bhc_TimeBasedRSUMember_629a523e-d8b3-48c7-9226-f9e83061b311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_d0b7e752-18e9-4f5f-8450-6c6a310f4037" xlink:href="bhc-20221231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_d0b7e752-18e9-4f5f-8450-6c6a310f4037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:to="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ffed4673-feef-45ac-aa8c-660dd9fdc804_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:to="loc_dei_EntityDomain_ffed4673-feef-45ac-aa8c-660dd9fdc804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:to="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c4a58384-a7ac-48fe-8195-5fd7d710315b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:to="loc_bhc_BauschLombMember_c4a58384-a7ac-48fe-8195-5fd7d710315b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i66b14955f74a483b899a4c782f3001c7_ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f32939b8-bd7e-43ed-8d9f-d905f372094a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f32939b8-bd7e-43ed-8d9f-d905f372094a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:to="loc_us-gaap_EquityComponentDomain_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:to="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a7c32968-f282-411a-80a8-c38891f5994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a7c32968-f282-411a-80a8-c38891f5994d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_14110f12-dad6-4315-bd67-4e3b23d6885f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_14110f12-dad6-4315-bd67-4e3b23d6885f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b304c608-6bdd-4bfd-ad0c-dd9a3c4a19b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b304c608-6bdd-4bfd-ad0c-dd9a3c4a19b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended" id="i157731af7ada4ccfa83395e080457219_ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bbb52ff4-65c5-4266-882f-ffb3cb459049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bbb52ff4-65c5-4266-882f-ffb3cb459049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_37ee13a6-005d-4d88-988d-7a0c8d67e268_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:to="loc_us-gaap_EquityComponentDomain_37ee13a6-005d-4d88-988d-7a0c8d67e268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:to="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df22e784-e3f6-41bc-988b-9a7bdfd72941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df22e784-e3f6-41bc-988b-9a7bdfd72941" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended" id="i85f1c19e305b403482aae3cf2e61902c_OTHEREXPENSENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_49be7f30-05ab-455e-9270-fbaf0e18eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_49be7f30-05ab-455e-9270-fbaf0e18eb0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a515074b-a508-45d3-ab71-90983428790a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a515074b-a508-45d3-ab71-90983428790a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_14880004-8c07-417c-aa65-5c70a0f43dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_14880004-8c07-417c-aa65-5c70a0f43dd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8fce1c57-e246-476e-87bb-48f354a7788f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8fce1c57-e246-476e-87bb-48f354a7788f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_820cf0b9-c82b-4f17-ad81-5e3f81fe6504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_820cf0b9-c82b-4f17-ad81-5e3f81fe6504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_9dad45a7-5bd6-4cb0-8a9c-d9a248b59bf2" xlink:href="bhc-20221231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_9dad45a7-5bd6-4cb0-8a9c-d9a248b59bf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cbcfe7d-c12d-4e44-bf20-0a12521288fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cbcfe7d-c12d-4e44-bf20-0a12521288fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_c2113646-7302-4d22-82e9-8ae0b4b7d676" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_c2113646-7302-4d22-82e9-8ae0b4b7d676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e7c3ad64-b757-4c47-b6ee-972542de7fd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e7c3ad64-b757-4c47-b6ee-972542de7fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_667ae2a0-ec24-44d7-b23b-f427fe5fd039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_667ae2a0-ec24-44d7-b23b-f427fe5fd039" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended" id="iaa642e6548374b9a8bb93606a05b4ed5_INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_885469bc-628f-4e67-97ee-88a48116714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_885469bc-628f-4e67-97ee-88a48116714d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_cff7c9fd-5085-4c1a-9864-b7945d2c3d09" xlink:href="bhc-20221231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_cff7c9fd-5085-4c1a-9864-b7945d2c3d09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_d4851162-ab3b-47f8-b162-88ba28bec44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_d4851162-ab3b-47f8-b162-88ba28bec44b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_30b8010b-794d-4852-956f-16ca43952d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_489b7b56-49e3-4034-81a4-2fa4a21c0db3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_489b7b56-49e3-4034-81a4-2fa4a21c0db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7c06ba27-5c56-4b9f-ab2a-54da309f89bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7c06ba27-5c56-4b9f-ab2a-54da309f89bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i4b0258f1d4c84d619fd1252574595802_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eadc128c-2f5f-44c1-99a9-f80e44f14080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eadc128c-2f5f-44c1-99a9-f80e44f14080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_2893330e-6114-421b-94e6-1b6ddad70f79" xlink:href="bhc-20221231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_2893330e-6114-421b-94e6-1b6ddad70f79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_8da5aef5-8d58-42e1-b872-4b9e6f44e156" xlink:href="bhc-20221231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_8da5aef5-8d58-42e1-b872-4b9e6f44e156" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27458778-ed2f-44ea-b549-ec5bea33134e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27458778-ed2f-44ea-b549-ec5bea33134e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7241831-2ac2-4997-afd7-af3a5e91461b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7241831-2ac2-4997-afd7-af3a5e91461b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_1d3a34ed-4358-4cac-bd67-97ce2cbd61cf" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_1d3a34ed-4358-4cac-bd67-97ce2cbd61cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_987fdf90-7f6f-4248-8c9f-2b9596b23ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_987fdf90-7f6f-4248-8c9f-2b9596b23ddb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_75166305-a2d0-4980-8dfa-4cf841595242" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_75166305-a2d0-4980-8dfa-4cf841595242" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_5a5cccee-c713-4bae-b77d-9b761232a33f" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_5a5cccee-c713-4bae-b77d-9b761232a33f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_07592841-5279-4c97-a114-e6495d28a9f5" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_07592841-5279-4c97-a114-e6495d28a9f5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dee05cae-30d1-4118-b55a-c96062bb727a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dee05cae-30d1-4118-b55a-c96062bb727a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_69f1f43e-c16d-4fc4-8ec0-077cd816ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_69f1f43e-c16d-4fc4-8ec0-077cd816ff16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f08b922d-826a-4032-8158-11501c9849ae" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f08b922d-826a-4032-8158-11501c9849ae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b15fad99-2169-444f-b3e9-30c47d80d3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b15fad99-2169-444f-b3e9-30c47d80d3b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_c4d03ced-6c89-4ac5-a753-754aac791baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_c4d03ced-6c89-4ac5-a753-754aac791baa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_64813bfd-7d8d-44aa-8844-14ef702b80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_64813bfd-7d8d-44aa-8844-14ef702b80e6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0e7d2a8e-2581-4bed-8970-b9753bd28ffb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0e7d2a8e-2581-4bed-8970-b9753bd28ffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_8acc60e8-741f-4542-9741-40499285e0c3" xlink:href="bhc-20221231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_8acc60e8-741f-4542-9741-40499285e0c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e9b369c1-f1c1-46c0-946f-752a8d9ec8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_DomesticCountryMember_e9b369c1-f1c1-46c0-946f-752a8d9ec8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_c94fefe3-4f6d-4a7a-a39c-d860aea9a30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_ForeignCountryMember_c94fefe3-4f6d-4a7a-a39c-d860aea9a30b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_9c7673e4-5781-4a83-ad06-0cf729d7fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_9c7673e4-5781-4a83-ad06-0cf729d7fc2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_b2ec0a1e-f844-489c-a165-38776fa855bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_b2ec0a1e-f844-489c-a165-38776fa855bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_be3be5da-ebdc-46b8-99cf-b8a60ca56bfd" xlink:href="bhc-20221231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_be3be5da-ebdc-46b8-99cf-b8a60ca56bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7ea25a68-aac4-4409-ae24-739228885154_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:to="loc_us-gaap_TaxPeriodDomain_7ea25a68-aac4-4409-ae24-739228885154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:to="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_8a6122dc-ec5a-4f68-b3b3-47f3455b8803" xlink:href="bhc-20221231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_8a6122dc-ec5a-4f68-b3b3-47f3455b8803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_3f270f86-dc3f-400c-a2a2-8252e0a4a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2012Member_3f270f86-dc3f-400c-a2a2-8252e0a4a81f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_2eea0437-1e23-4f45-becf-f35df370064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2013Member_2eea0437-1e23-4f45-becf-f35df370064b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2015Member_283df42d-8872-4b9e-8169-76f86efa88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2015Member_283df42d-8872-4b9e-8169-76f86efa88ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2016Member_4c596920-c9eb-4b76-91a0-6df2c345abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2016Member_4c596920-c9eb-4b76-91a0-6df2c345abf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018And2019Member_3f6aad6e-cd55-452a-ad0f-45b7585b9d13" xlink:href="bhc-20221231.xsd#bhc_TaxYear2018And2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_bhc_TaxYear2018And2019Member_3f6aad6e-cd55-452a-ad0f-45b7585b9d13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_d4f88aee-9327-4fd1-b636-ff5b4ada7461_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_d4f88aee-9327-4fd1-b636-ff5b4ada7461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_152b9456-18a2-4fc3-90dd-4b59e3b6d168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_152b9456-18a2-4fc3-90dd-4b59e3b6d168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_975ef9e2-eca7-423d-a2e0-e1d05b70283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_975ef9e2-eca7-423d-a2e0-e1d05b70283b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_f9625fb9-6018-4c8b-9495-fefc83b64e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_f9625fb9-6018-4c8b-9495-fefc83b64e43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_636a1838-175c-45e9-a646-437683e1464c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_636a1838-175c-45e9-a646-437683e1464c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_695fc4bb-1185-4559-ba7f-15b04089939f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:to="loc_srt_ScenarioForecastMember_695fc4bb-1185-4559-ba7f-15b04089939f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f55af004-6465-492b-a849-ec14be5091f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f55af004-6465-492b-a849-ec14be5091f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_47c5e6b9-14da-4436-b452-eb2ada101f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:to="loc_us-gaap_SubsequentEventMember_47c5e6b9-14da-4436-b452-eb2ada101f52" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended" id="if774d5501cbb4468bc2f1a5a1a8b4cec_INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_a915132c-5a47-4665-877b-cbd88fd3c780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:to="loc_us-gaap_OpenTaxYear_a915132c-5a47-4665-877b-cbd88fd3c780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4a04a610-6171-463c-afaa-d6abb1c0e6af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4a04a610-6171-463c-afaa-d6abb1c0e6af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_abedd2c0-2876-4792-a166-26dc00a9422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_DomesticCountryMember_abedd2c0-2876-4792-a166-26dc00a9422f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_907db38e-ba75-45aa-b16f-7832a12b63e4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_CA_907db38e-ba75-45aa-b16f-7832a12b63e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_c2907509-d801-4f7b-8d6e-54e49233b7c9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_DE_c2907509-d801-4f7b-8d6e-54e49233b7c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ff7b17f6-0ce5-4e31-a24a-b477750527eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_FR_ff7b17f6-0ce5-4e31-a24a-b477750527eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_db768a61-866c-4f5d-9129-37d1f57adc12" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_IE_db768a61-866c-4f5d-9129-37d1f57adc12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_e4437edc-e80d-45da-8fca-bf82b194097d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_e4437edc-e80d-45da-8fca-bf82b194097d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_b0951b67-7a25-4061-ab05-7d19bfaa16d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_b0951b67-7a25-4061-ab05-7d19bfaa16d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:to="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bade871e-2af1-4f23-a5bf-9f65b720e436_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:to="loc_srt_RangeMember_bade871e-2af1-4f23-a5bf-9f65b720e436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:to="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f9738757-5d36-4ea8-b3cd-862c74c547b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:to="loc_srt_MinimumMember_f9738757-5d36-4ea8-b3cd-862c74c547b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_133b6a89-8dea-4a67-87f1-bf6142a10a35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:to="loc_srt_MaximumMember_133b6a89-8dea-4a67-87f1-bf6142a10a35" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended" id="i68e522bf00154526a309b2b1ec363dc8_LOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92334be5-5ee5-492d-b723-dfed4c4e8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92334be5-5ee5-492d-b723-dfed4c4e8e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d268e054-b08f-49f4-aee6-f1b618e9e301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d268e054-b08f-49f4-aee6-f1b618e9e301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_0d14b071-3dba-4385-b0bd-2c7f37aee65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:to="loc_us-gaap_StockCompensationPlanMember_0d14b071-3dba-4385-b0bd-2c7f37aee65d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:href="bhc-20221231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_567dc37b-3eac-49c2-b80d-c78ba35045f5" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_567dc37b-3eac-49c2-b80d-c78ba35045f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended" id="i548c4a2fa38240588e57e9ce6ccb7e3d_LEGALPROCEEDINGSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LegalSettlementsAndRelatedFees_df236e00-e4d8-4804-997a-8d7528217b60" xlink:href="bhc-20221231.xsd#bhc_LegalSettlementsAndRelatedFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LegalSettlementsAndRelatedFees_df236e00-e4d8-4804-997a-8d7528217b60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_4574be78-2b99-4306-bc63-415585446b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_4574be78-2b99-4306-bc63-415585446b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25d96e0-9f30-4ef9-a882-2e89579fd933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25d96e0-9f30-4ef9-a882-2e89579fd933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_629b67fd-9434-406c-a712-b38648dc614c" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_629b67fd-9434-406c-a712-b38648dc614c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_27b83574-f952-4d91-91fd-4b402c77a1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_27b83574-f952-4d91-91fd-4b402c77a1bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_d422e5fa-fb64-4542-882b-df16dfc75117" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_d422e5fa-fb64-4542-882b-df16dfc75117" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_3e90d0ac-b531-41fd-9362-e425c6588e42" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_3e90d0ac-b531-41fd-9362-e425c6588e42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_74c850fd-348f-4745-a4cd-0536b83fbebb" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_74c850fd-348f-4745-a4cd-0536b83fbebb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_1397d920-6072-4007-920b-4352f8d2d4c5" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_1397d920-6072-4007-920b-4352f8d2d4c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_6cbfcb8c-1ebe-4397-8803-10a543607d58" xlink:href="bhc-20221231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_6cbfcb8c-1ebe-4397-8803-10a543607d58" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dc213cb0-3899-4999-a7d3-01a31aaa25a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dc213cb0-3899-4999-a7d3-01a31aaa25a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_b854111c-6ac3-4189-b28f-9a18ce7fae93" xlink:href="bhc-20221231.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_b854111c-6ac3-4189-b28f-9a18ce7fae93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_9e4084a6-cd0a-4996-b0f4-efeda6184828" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_9e4084a6-cd0a-4996-b0f4-efeda6184828" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_317c3566-e95f-4384-b9a1-6b7ed8f60807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_317c3566-e95f-4384-b9a1-6b7ed8f60807" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_537dbecb-7cdb-4935-a2c4-d95ba0209203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_537dbecb-7cdb-4935-a2c4-d95ba0209203" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_aaf0c21a-605a-4777-99ec-1bb6d1a3ff62" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_aaf0c21a-605a-4777-99ec-1bb6d1a3ff62" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_0e0312c0-8e49-43a8-8680-de868e036bc5" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_0e0312c0-8e49-43a8-8680-de868e036bc5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5f2255c1-e6cd-43b2-a8ae-7a02c719f0cf" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5f2255c1-e6cd-43b2-a8ae-7a02c719f0cf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_13801d69-6853-411c-a1ef-e5beda37799e" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_13801d69-6853-411c-a1ef-e5beda37799e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_e4981cf9-749c-4d8a-8847-d6e6bd138eed" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_e4981cf9-749c-4d8a-8847-d6e6bd138eed" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_aa3ca70d-2ee1-468f-af88-713fd219b5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_aa3ca70d-2ee1-468f-af88-713fd219b5f2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a29b13be-756d-4abe-abe6-66f0fa3cfb56_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:to="loc_srt_LitigationCaseTypeDomain_a29b13be-756d-4abe-abe6-66f0fa3cfb56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:to="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_69ff9c2c-2f64-4424-aaf7-414fc7fa6c6a" xlink:href="bhc-20221231.xsd#bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_69ff9c2c-2f64-4424-aaf7-414fc7fa6c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_2a14b460-ac22-4a96-b8fd-efbb07dd5708" xlink:href="bhc-20221231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_2a14b460-ac22-4a96-b8fd-efbb07dd5708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_dd97b800-f82c-4e0a-a7a4-17dc427c744e" xlink:href="bhc-20221231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_dd97b800-f82c-4e0a-a7a4-17dc427c744e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_0312ea3e-674e-4376-8a44-2f7fbcdfe431" xlink:href="bhc-20221231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_RICOClassActionsLitigationMember_0312ea3e-674e-4376-8a44-2f7fbcdfe431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_08a0f272-0123-4dd9-a85a-fc420b294a9c" xlink:href="bhc-20221231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_08a0f272-0123-4dd9-a85a-fc420b294a9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_d0a9ad83-148c-4227-95f6-3554684bfe58" xlink:href="bhc-20221231.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_d0a9ad83-148c-4227-95f6-3554684bfe58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_9967729a-7a87-4121-97b6-2280038a16b3" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_9967729a-7a87-4121-97b6-2280038a16b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52d38fdc-4666-424b-a11c-4ff21e9f883b" xlink:href="bhc-20221231.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52d38fdc-4666-424b-a11c-4ff21e9f883b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_03b75b49-4abe-46fe-ba0d-c589013d61e0" xlink:href="bhc-20221231.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_8c302994-ae90-4eca-8961-9aea95455ee6" xlink:href="bhc-20221231.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_8c302994-ae90-4eca-8961-9aea95455ee6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_c7b2c4e2-26dd-4a16-a358-31159ca5726c" xlink:href="bhc-20221231.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PadagisLitigationMember_c7b2c4e2-26dd-4a16-a358-31159ca5726c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_63d9c545-a7cc-45bb-aee1-6c589cf520e9" xlink:href="bhc-20221231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_63d9c545-a7cc-45bb-aee1-6c589cf520e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember_17ceaf88-9766-4660-8111-a3970c3a2d59" xlink:href="bhc-20221231.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_AurobindoPharmaLimitedLitigationMember_17ceaf88-9766-4660-8111-a3970c3a2d59" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_a794df80-3ac3-4274-a108-57b66f12172a" xlink:href="bhc-20221231.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_a794df80-3ac3-4274-a108-57b66f12172a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_da07e5d1-773d-4efd-82e4-9b53332b6a41" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_da07e5d1-773d-4efd-82e4-9b53332b6a41" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_bd8c302f-66f3-484f-8407-a9c95e25b101" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_bd8c302f-66f3-484f-8407-a9c95e25b101" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_aea4082f-c74b-4148-9fc8-61ebef85247b" xlink:href="bhc-20221231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ApotexIncLitigationMember_aea4082f-c74b-4148-9fc8-61ebef85247b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_030a0368-51e7-45a4-a337-da81eaa59786" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_030a0368-51e7-45a4-a337-da81eaa59786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_6220109e-19ba-4108-90fe-f1a67f507011" xlink:href="bhc-20221231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_6220109e-19ba-4108-90fe-f1a67f507011" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_a5dc8fbb-8b2a-4f56-b01a-fb06b58c03a0" xlink:href="bhc-20221231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_a5dc8fbb-8b2a-4f56-b01a-fb06b58c03a0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_2a9130d8-5f14-4734-8fd1-90604f15ca39" xlink:href="bhc-20221231.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_2a9130d8-5f14-4734-8fd1-90604f15ca39" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:to="loc_srt_SegmentGeographicalDomain_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:to="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_a74fd8bb-fbfc-4e12-b893-ad42771dde8d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:to="loc_stpr_NJ_a74fd8bb-fbfc-4e12-b893-ad42771dde8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:to="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_2f26f3a7-4eab-41fc-9526-65e3dff9bec3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:to="loc_stpr_CA-BC_2f26f3a7-4eab-41fc-9526-65e3dff9bec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_beab4e79-9b4b-447d-a7ee-7e4e725278f5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:to="loc_stpr_CA-QC_beab4e79-9b4b-447d-a7ee-7e4e725278f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b8332490-467a-48ca-b207-d546e9c89d5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b8332490-467a-48ca-b207-d546e9c89d5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_447a9eaf-1a93-43d4-bbdc-86d8040cbbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_447a9eaf-1a93-43d4-bbdc-86d8040cbbd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_0dc6fc1b-0b3f-424b-afd9-6ce96bd2537c" xlink:href="bhc-20221231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_0dc6fc1b-0b3f-424b-afd9-6ce96bd2537c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d56176a1-3559-4caa-9786-e181574a9414_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:to="loc_us-gaap_LitigationStatusDomain_d56176a1-3559-4caa-9786-e181574a9414_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:to="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4bf3d8ce-075b-4dc8-bc17-c867e6d544d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_us-gaap_PendingLitigationMember_4bf3d8ce-075b-4dc8-bc17-c867e6d544d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_b2cf0ff0-25b8-4fae-a4a9-0e08d0537cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_us-gaap_SettledLitigationMember_b2cf0ff0-25b8-4fae-a4a9-0e08d0537cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_f7be8179-b100-4e58-9686-d4198b437fc1" xlink:href="bhc-20221231.xsd#bhc_DefaultJudgementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_bhc_DefaultJudgementMember_f7be8179-b100-4e58-9686-d4198b437fc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_74b6457b-7753-49d4-879f-32cb51b1aafd" xlink:href="bhc-20221231.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_74b6457b-7753-49d4-879f-32cb51b1aafd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_209e4431-f07e-462c-b862-3c2b69527371_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_209e4431-f07e-462c-b862-3c2b69527371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_c65625e4-a61f-42ed-a67c-e384901089c2" xlink:href="bhc-20221231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_c65625e4-a61f-42ed-a67c-e384901089c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3d9291d9-181d-458e-a05c-597c910639f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3d9291d9-181d-458e-a05c-597c910639f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e73dcee7-3bfb-4e1a-b8ba-6b304acca4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:to="loc_us-gaap_SubsequentEventMember_e73dcee7-3bfb-4e1a-b8ba-6b304acca4cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1bfe4b96-bf53-415c-b881-06072ce8a538_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:to="loc_dei_EntityDomain_1bfe4b96-bf53-415c-b881-06072ce8a538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:to="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_72fde0de-b72c-488f-b014-6a638435317d" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:to="loc_bhc_BauschLombMember_72fde0de-b72c-488f-b014-6a638435317d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="i137a1bd04a344a98b749d3ef759a6570_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_54dfc962-2691-4e59-9dc1-90b626c9d210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:to="loc_us-gaap_ContractualObligation_54dfc962-2691-4e59-9dc1-90b626c9d210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_56cd10dc-1515-48e7-8823-9da7d6bfc093" xlink:href="bhc-20221231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_56cd10dc-1515-48e7-8823-9da7d6bfc093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:to="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_332d7303-bd62-43cb-a947-dcda3c92de84_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_332d7303-bd62-43cb-a947-dcda3c92de84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_06de28ce-58b3-4ef7-8f6e-e59aaee7980a" xlink:href="bhc-20221231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_06de28ce-58b3-4ef7-8f6e-e59aaee7980a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_e185ac25-3592-40ab-8499-28f9404e002e" xlink:href="bhc-20221231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_e185ac25-3592-40ab-8499-28f9404e002e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_dfd56213-7304-46f4-bc62-2ceed971083e" xlink:href="bhc-20221231.xsd#bhc_NovaliqGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_NovaliqGmbHMember_dfd56213-7304-46f4-bc62-2ceed971083e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_989e4f2d-0bf8-4121-b28f-d7eaee493c46" xlink:href="bhc-20221231.xsd#bhc_EyenoviaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_EyenoviaIncMember_989e4f2d-0bf8-4121-b28f-d7eaee493c46" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="ic471eeea953a4a968ad58a0268c25e50_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_df1ecff2-04a1-4cbf-a2de-c60b7e4489c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_df1ecff2-04a1-4cbf-a2de-c60b7e4489c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bf39c052-00c2-4b90-addf-79596dcce49c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:to="loc_us-gaap_SegmentDomain_bf39c052-00c2-4b90-addf-79596dcce49c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:to="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_25950a6e-696b-4ed4-9953-d125f0b3193a" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:to="loc_bhc_SalixSegmentMember_25950a6e-696b-4ed4-9953-d125f0b3193a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c133104a-d4ac-493a-a5db-0c14c4630165_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:to="loc_srt_ProductsAndServicesDomain_c133104a-d4ac-493a-a5db-0c14c4630165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:to="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_e2c864bb-fcfb-4dc1-a5f8-cd4fab5b17a5" xlink:href="bhc-20221231.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:to="loc_bhc_XifaxanBrandedProductsMember_e2c864bb-fcfb-4dc1-a5f8-cd4fab5b17a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f02e7a5-d765-41fe-ab51-649213b863c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f02e7a5-d765-41fe-ab51-649213b863c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9eadc55e-ccec-437f-b53f-fad41ad31407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9eadc55e-ccec-437f-b53f-fad41ad31407" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_21202ebf-584a-4cc4-8140-d6e1abee2006_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_21202ebf-584a-4cc4-8140-d6e1abee2006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4eb7880a-d569-4d11-88c8-4b8ba5682fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4eb7880a-d569-4d11-88c8-4b8ba5682fa6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="i76b74c1417234ad2855a894fd4205b6f_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880547cd-fece-492b-9c95-fab66b92e859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880547cd-fece-492b-9c95-fab66b92e859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_99b918fc-ad34-4401-96bf-5c071a1475e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_99b918fc-ad34-4401-96bf-5c071a1475e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_be2f9c58-f8ee-4290-883c-8daf7d9b7a23" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_be2f9c58-f8ee-4290-883c-8daf7d9b7a23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_04744bb3-eec9-44f1-8911-686701e5ff5c" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_04744bb3-eec9-44f1-8911-686701e5ff5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3936aeba-c2bd-47de-9620-6caa4376ba01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_AssetImpairmentCharges_3936aeba-c2bd-47de-9620-6caa4376ba01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7e611386-af2e-44b7-9681-24468fb173f3" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7e611386-af2e-44b7-9681-24468fb173f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8805a4d7-4630-4174-9ddf-fe602fdbd990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8805a4d7-4630-4174-9ddf-fe602fdbd990" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a0b159b2-76f3-461e-9e76-09abaa12688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a0b159b2-76f3-461e-9e76-09abaa12688c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bf6d1f52-7a6c-49ef-9d38-266b3a7ce7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_InterestExpenseDebt_bf6d1f52-7a6c-49ef-9d38-266b3a7ce7a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aa8051ac-fb8a-449b-b340-23534ee91cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aa8051ac-fb8a-449b-b340-23534ee91cc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_61bf09ec-4419-447b-8b63-136d5733bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_61bf09ec-4419-447b-8b63-136d5733bc00" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d31d4d2-6a57-4d2f-9aa8-7c2232e5ad06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d31d4d2-6a57-4d2f-9aa8-7c2232e5ad06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:to="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:to="loc_srt_ConsolidationItemsDomain_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:to="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_df367fd8-0968-4f7d-8d03-793097e1bf67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:to="loc_us-gaap_OperatingSegmentsMember_df367fd8-0968-4f7d-8d03-793097e1bf67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ddc12982-d4bf-42a9-90ce-c69916c1dcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ddc12982-d4bf-42a9-90ce-c69916c1dcec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2735c64b-375b-4335-b015-d909b01191a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:to="loc_us-gaap_SegmentDomain_2735c64b-375b-4335-b015-d909b01191a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:to="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_91d18519-700b-49fd-8ce1-043b0d23c964" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_SalixSegmentMember_91d18519-700b-49fd-8ce1-043b0d23c964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_eab1ec99-90ea-4cf4-9965-5a95a76f7d7c" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_InternationalRxMember_eab1ec99-90ea-4cf4-9965-5a95a76f7d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_28f48c5a-2721-46c7-a2d9-00705d238d58" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_SoltaMedicalSegmentMember_28f48c5a-2721-46c7-a2d9-00705d238d58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_f9da7fa9-6150-4f58-b9c9-05bb3d467232" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_f9da7fa9-6150-4f58-b9c9-05bb3d467232" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_97cc523a-26a7-469d-9aee-4b4be8a3e83e" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_BauschLombMember_97cc523a-26a7-469d-9aee-4b4be8a3e83e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONCapitalExpendituresDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" xlink:type="extended" id="if469262cba1d491eafbc1d3e046066c3_SEGMENTINFORMATIONCapitalExpendituresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:href="bhc-20221231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_db48d879-c436-4e1b-84b7-a4acb69c3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_db48d879-c436-4e1b-84b7-a4acb69c3ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:to="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_84ab77a6-afc2-416c-bd47-27dc01e17078_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:to="loc_srt_ConsolidationItemsDomain_84ab77a6-afc2-416c-bd47-27dc01e17078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:to="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_62a31d62-301d-4835-9ab0-12f0658b43a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:to="loc_us-gaap_OperatingSegmentsMember_62a31d62-301d-4835-9ab0-12f0658b43a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_04077e0e-7c89-40ab-950d-68c4649dfa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_04077e0e-7c89-40ab-950d-68c4649dfa20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:to="loc_us-gaap_SegmentDomain_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:to="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_b73de39b-165f-46fb-b7a2-f8c39fa52702" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_SalixSegmentMember_b73de39b-165f-46fb-b7a2-f8c39fa52702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_1e964f93-65f8-4aa8-9c8d-5e633ed07ae3" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_InternationalRxMember_1e964f93-65f8-4aa8-9c8d-5e633ed07ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_bface64c-1647-438a-8811-f3f7806819fa" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_bface64c-1647-438a-8811-f3f7806819fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a8054d26-f597-40f0-9556-cdd254cf2be3" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a8054d26-f597-40f0-9556-cdd254cf2be3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_baa30d9e-102a-4365-ae5b-07234e3bddd7" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_BauschLombMember_baa30d9e-102a-4365-ae5b-07234e3bddd7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended" id="i01c7f6dbde164f98b45b47240b7f02cd_SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_f99e7d72-8652-49b4-8be3-e48189e373a5" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_f99e7d72-8652-49b4-8be3-e48189e373a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c73b218b-ebe8-4a0c-a450-093c33af4e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c73b218b-ebe8-4a0c-a450-093c33af4e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_145a3118-a2dd-4a36-8c31-1ef2b980f56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_145a3118-a2dd-4a36-8c31-1ef2b980f56a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4dc1a2f4-217a-4010-a906-efd962da111e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4dc1a2f4-217a-4010-a906-efd962da111e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_4f757316-22f4-404c-96a7-ed182bdb3b64" xlink:href="bhc-20221231.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:to="loc_bhc_RevenuesNetMember_4f757316-22f4-404c-96a7-ed182bdb3b64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_731dc01c-2323-40a9-be69-4945c25e2d43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_731dc01c-2323-40a9-be69-4945c25e2d43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f80193c2-56c0-4f35-b95d-f99903a1040b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f80193c2-56c0-4f35-b95d-f99903a1040b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8886edc4-5591-4a2b-8362-a769052d2ffa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:to="loc_us-gaap_SegmentDomain_8886edc4-5591-4a2b-8362-a769052d2ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:to="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_c34269cd-f329-4111-aa60-60f0638b98cc" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_SalixSegmentMember_c34269cd-f329-4111-aa60-60f0638b98cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_1ce10fe2-bf6c-4db5-bc04-9a107f6708d0" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_InternationalRxMember_1ce10fe2-bf6c-4db5-bc04-9a107f6708d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_7f772be1-355b-47fa-8162-cef54a8d0ca3" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_SoltaMedicalSegmentMember_7f772be1-355b-47fa-8162-cef54a8d0ca3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a69212c5-c4bc-4e08-9134-d4d4e725a4af" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a69212c5-c4bc-4e08-9134-d4d4e725a4af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f5886882-6e22-442b-bb41-754b019a7132" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_BauschLombMember_f5886882-6e22-442b-bb41-754b019a7132" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41163220-d060-449e-a494-3182083b6155_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:to="loc_srt_ProductsAndServicesDomain_41163220-d060-449e-a494-3182083b6155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:to="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_c922100d-733d-42ae-ac70-ebc3d7bbf4b6" xlink:href="bhc-20221231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_PharmaceuticalProductsMember_c922100d-733d-42ae-ac70-ebc3d7bbf4b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_add23b32-f4ea-49b3-8495-f3d8c7230bce" xlink:href="bhc-20221231.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_DeviceProductsMember_add23b32-f4ea-49b3-8495-f3d8c7230bce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_2a9e229d-9be1-4704-a473-89cbc5902886" xlink:href="bhc-20221231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_OvertheCounterProductsMember_2a9e229d-9be1-4704-a473-89cbc5902886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_b194b25a-941f-48f2-b807-dcbc1005d6e1" xlink:href="bhc-20221231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_b194b25a-941f-48f2-b807-dcbc1005d6e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_4362231d-e503-467e-a1b5-d89979db7867" xlink:href="bhc-20221231.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_OtherRevenuesMember_4362231d-e503-467e-a1b5-d89979db7867" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:to="loc_srt_NameOfMajorCustomerDomain_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:to="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_af813b8e-5377-486b-bcb5-b25dff6a30e0" xlink:href="bhc-20221231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:to="loc_bhc_CustomerTopTenProductsMember_af813b8e-5377-486b-bcb5-b25dff6a30e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended" id="i90eeb245b2e3413b9115d9fb1ff1858e_SEGMENTINFORMATIONGeographicInformationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1386244-ef03-4314-a1ad-50ed818a4568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1386244-ef03-4314-a1ad-50ed818a4568" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:to="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4e7ad99b-5b74-467a-bf1b-ea6359b3142c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:to="loc_srt_SegmentGeographicalDomain_4e7ad99b-5b74-467a-bf1b-ea6359b3142c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:to="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_3500c916-ff5f-4f65-af31-0e9fb5ba7de4" xlink:href="bhc-20221231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_3500c916-ff5f-4f65-af31-0e9fb5ba7de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_077c2eca-501e-41ef-be62-7313ce0b30a3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_CN_077c2eca-501e-41ef-be62-7313ce0b30a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_40b00bde-f0c3-4a16-a5d8-b7103707c07d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_CA_40b00bde-f0c3-4a16-a5d8-b7103707c07d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_829aa66b-8639-4735-a908-835d7eed8b15" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_PL_829aa66b-8639-4735-a908-835d7eed8b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_38a20039-6b01-47db-bb36-52fa0d3b0d9a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_MX_38a20039-6b01-47db-bb36-52fa0d3b0d9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_ffd3a67e-9819-494c-9202-2205c36cbed2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_JP_ffd3a67e-9819-494c-9202-2205c36cbed2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_9bfc894e-dec2-4579-9d4d-0a0999bcc703" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_FR_9bfc894e-dec2-4579-9d4d-0a0999bcc703" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_921824af-d521-43db-b7db-d0f9c8fdc24e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_RU_921824af-d521-43db-b7db-d0f9c8fdc24e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_d906cfbf-cbba-4651-b6d6-6cce68eb7042" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_DE_d906cfbf-cbba-4651-b6d6-6cce68eb7042" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_fe3057c2-31e2-4d62-8f1d-7585f0b4ad17" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_GB_fe3057c2-31e2-4d62-8f1d-7585f0b4ad17" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_7c712c81-4933-44ef-9909-52b5aed4dd8c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_ES_7c712c81-4933-44ef-9909-52b5aed4dd8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_d4dd0c36-325c-4ab1-8323-3f37ba6a2875" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_KR_d4dd0c36-325c-4ab1-8323-3f37ba6a2875" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_88cd5c47-0edf-47ae-b7a7-a61c4e3cec40" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_IT_88cd5c47-0edf-47ae-b7a7-a61c4e3cec40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_99066e05-b060-4f37-9560-7414db6c6bd0" xlink:href="bhc-20221231.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_bhc_OtherCountriesMember_99066e05-b060-4f37-9560-7414db6c6bd0" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended" id="i0f30275675c54b539585766ccca55e5f_SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_98a85093-6082-42df-8b1b-d6e05bdac034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:to="loc_us-gaap_NoncurrentAssets_98a85093-6082-42df-8b1b-d6e05bdac034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:to="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d62fa678-230e-479b-8451-c1822f6acf88_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:to="loc_srt_SegmentGeographicalDomain_d62fa678-230e-479b-8451-c1822f6acf88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:to="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_0cc81ca5-2919-4440-9550-68963b6f26a5" xlink:href="bhc-20221231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_0cc81ca5-2919-4440-9550-68963b6f26a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_3750124c-0d0a-4bd1-b9db-bce9ff6b668a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_IE_3750124c-0d0a-4bd1-b9db-bce9ff6b668a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_49647eab-3d9b-4cc2-94f5-244cb0ab9430" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_CA_49647eab-3d9b-4cc2-94f5-244cb0ab9430" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_d77a965f-6aa5-439f-b20c-17659eb41fbf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_DE_d77a965f-6aa5-439f-b20c-17659eb41fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_7dc02061-1bed-42c9-8517-5477cb36eb43" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_PL_7dc02061-1bed-42c9-8517-5477cb36eb43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_9f9a6991-9b15-44ad-9486-539d8f4dc761" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_MX_9f9a6991-9b15-44ad-9486-539d8f4dc761" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_972139ba-210d-49e6-9b8a-76bfe6b0dfc0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_FR_972139ba-210d-49e6-9b8a-76bfe6b0dfc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_a4758204-f721-420b-9a6b-7b3b146b8c89" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_CN_a4758204-f721-420b-9a6b-7b3b146b8c89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_c9df035a-c1f0-42f3-a24f-d063bd8ffe58" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_RS_c9df035a-c1f0-42f3-a24f-d063bd8ffe58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_9c8febd8-6d82-4c28-9494-1d56d57c885b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_IT_9c8febd8-6d82-4c28-9494-1d56d57c885b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_96de32ad-1496-4a9f-9f51-e7441e9ac120" xlink:href="bhc-20221231.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_bhc_OtherCountriesMember_96de32ad-1496-4a9f-9f51-e7441e9ac120" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="icd9b198b85204be190c02cd5864916a7_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ab495404-a0dd-448c-bf7a-08aaad76533c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ab495404-a0dd-448c-bf7a-08aaad76533c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8e0df741-3cf6-4609-b3c1-088b8c67641d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8e0df741-3cf6-4609-b3c1-088b8c67641d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_88c8956f-ae32-447a-92a9-3f40ade8b579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_88c8956f-ae32-447a-92a9-3f40ade8b579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c003ca59-ef6e-4719-9f90-8be60959c5b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c003ca59-ef6e-4719-9f90-8be60959c5b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_4f71218b-d8c0-4ef0-b6b6-4978cba315f2" xlink:href="bhc-20221231.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:to="loc_bhc_RevenuesNetMember_4f71218b-d8c0-4ef0-b6b6-4978cba315f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4fd0b090-bfd1-448d-be2a-4f57e38490a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_4fd0b090-bfd1-448d-be2a-4f57e38490a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_4dcbc858-8f63-4766-8bfe-e6bd8058ed41" xlink:href="bhc-20221231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_4dcbc858-8f63-4766-8bfe-e6bd8058ed41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_f1b22523-4a5b-4586-b132-1f12e5ece931" xlink:href="bhc-20221231.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_McKessonCorporationMember_f1b22523-4a5b-4586-b132-1f12e5ece931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_cccb02cd-1992-432a-b395-9bf44c55e4b5" xlink:href="bhc-20221231.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_CardinalHealthIncMember_cccb02cd-1992-432a-b395-9bf44c55e4b5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bhc-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_7c7fd055-608f-44a3-9b2f-95d4a4235b7e_terseLabel_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation</link:label>
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_label_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation [Member]</link:label>
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_documentation_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:href="bhc-20221231.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:to="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9dd5c44b-f167-4824-80fe-181c7baae2dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a2da4079-3344-4f52-a002-5c8ecd785c92_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_31966eb6-301d-41c9-9d5f-907c0525297e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_a81d2adf-385c-4862-9742-4f12f0f0ef46_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_4d75448b-e700-4138-b25a-98dd49a67835_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1f9b1a07-0872-4abf-9947-0e6ff9f21012_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_00b6bd76-1e37-4bd9-a0a6-22465471e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e3944ef3-a9dc-483b-b33a-d9719437e5ad_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ee956258-fc53-4f7c-b953-681181bc2bca_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_eddd26fa-cb59-422a-bdf6-2850db7fae66_terseLabel_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:to="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_cc15d432-47f9-4a1e-a455-f055f5af41e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4a7a431d-f280-43b8-b2c3-20c66f1e2c06_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e3886c61-345b-4878-af89-ad2b8e125859_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_ba67bdcd-7d65-40b8-8db4-c30af4db8873_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_db3e1a96-c39c-49e4-af18-ac3423d17c5b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c66dae12-3dfa-47e0-8439-deae6838fce8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_2084857c-ee37-4840-8634-317b6718276d_terseLabel_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments in terms of collaboration and license agreements, aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_label_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone Payments, Aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_documentation_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:href="bhc-20221231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:to="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_73d71184-13d2-48e3-a298-603a6b4a74ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_e2b9735f-dde1-44e5-b80e-581a90fa5d4e_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quebec</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_0e7e0ef0-3082-4c08-b833-304b904034f5_terseLabel_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:href="bhc-20221231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:to="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_a63048da-f111-4b57-86de-8cbd5ec4851b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0069b9ad-3e2b-4e44-ad7b-216b3d85a590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a785fa79-892c-4f25-90fb-1d5f973d2c3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7c231e7-3a5b-4012-9f53-5e51ee4e3628_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bf5860a8-4208-41ea-9408-0faa71b8c05b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e2a1aa05-e87c-4117-a76d-d392e6bbc69b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b5529f96-33d4-439e-9275-05958b006d01_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_fdf95c8f-aae5-4e62-9c57-d70bbc699206_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_7872c53b-aabe-4a52-8d69-97fac7decccd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxLineItems_70e32f27-6ab7-4838-a569-ba18c34ef36b_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_label_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxLineItems" xlink:to="lab_bhc_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a4584be5-1808-42a1-9308-c86f5ede499a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2f4b481c-fedf-41ee-a0dc-d01de4432259_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_25f8a925-fc3c-4958-8936-e48789bf6101_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_07e8d164-d5b4-4ce0-b4b7-232e9f4ef29f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_48baaa4b-3ce4-49a2-ac34-4548e78303c3_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_c394e141-2465-4427-a2bb-abe54a1b1c3f_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20221231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_080b2da8-c1d5-4866-bc96-e2c95e4cb4ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_34b76eae-7ebb-4692-80c2-49e69b1cdec5_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:href="bhc-20221231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:to="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_6ed7a934-cc9f-41e1-870f-43f1235120e2_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_f362ed49-6443-40af-86e9-5848b7d720af_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e3ac8ee4-fb89-4fdb-9b7d-ec7162e13d01_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f048e7b9-6921-46ca-ae61-bce0c8252a9f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ad7e4b1e-c52a-4b0b-bfdd-52f7145ca8b2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_20a109f5-7210-4091-af03-02c544403fe0_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b60f9fc5-a91f-4a9b-b831-06ede1c16b62_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_73a67931-46f8-4333-a795-40be293f4cf3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_854c51a0-8939-4b54-bde7-96651820b9c6_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_e632da4f-3c43-4deb-9039-91285f536a5a_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_c1b2ee2f-b9c3-4007-a9b6-5b1235df07ef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_bb28c27a-468e-42ad-8f17-5c961878c4d4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9bdf40e4-c5e2-422f-93e3-f339f8dc81c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9ce5e357-56c7-4c45-a64d-7b5cf140c4e5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cde4f65d-bb23-40f6-b4d5-a5a1fb132ccf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_7aa3ff59-6abf-46af-b3f8-8620023cfde5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_645d99f6-ebb9-4692-b513-b67f321cd492_terseLabel_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_label_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:href="bhc-20221231.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:to="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_64af9471-aed7-46b2-86fb-4869c163e655_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_7a314744-1c03-4ab6-8848-88d33b616500_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_29e2a6c0-4919-47d7-ae84-7a97de8c126a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_9c0f2f9a-8abb-4d3f-bd03-e8071d61707a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_24484129-8aa1-4ea1-9886-9c743b9b7894_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_5c417a30-247d-4676-aa84-43a3d4786782_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of open tax years by jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_74f4138c-b7c2-4970-a6c6-eb03b8fec245_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f2a97633-ee6c-42d2-bac2-38a786400bdf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5552364b-383e-41e5-8814-0f4e3237ecd7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_489a9aa6-b5ac-45ed-a83b-7db7ae0ba2b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_7bec3a62-d9c3-4ec2-8a75-56754bd569a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_a834dada-1d84-425f-aa37-c271c5fa2257_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_19c170ec-adb5-41a2-b848-b2c5c601a9a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_bf94ba38-1b67-4f3f-8b1c-a5258c0a1610_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payments</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_19bec491-cb71-4eac-bcfb-becb6b0eed49_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_b79af686-723e-4388-b95b-6d358236c974_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_b56cefbd-a3eb-440c-8715-3a9b59e3f327_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0f8f085a-79df-4bf3-b195-5106b524cc4a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_6f3b0904-4345-40e2-9a65-21cbeb96334a_terseLabel_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_label_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet" xlink:href="bhc-20221231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherIncomeExpenseNet" xlink:to="lab_bhc_OtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dc7a4a40-14e6-46fe-b9b3-a0cb89d1ef43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_c8c8475b-d9f9-4ed9-9066-5a93650a5339_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside basis differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2e47be0a-9645-4209-bc9d-7b06046b01eb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InvestmentGradeMember_49dc4f9b-b843-4c1b-bba8-21b0de453a8b_terseLabel_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment grade</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_label_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_documentation_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember" xlink:href="bhc-20221231.xsd#bhc_InvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InvestmentGradeMember" xlink:to="lab_bhc_InvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_f2d4ea2d-e6ee-4dbc-a834-1ac92c37c03b_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_919cce4e-2bcc-4255-97c8-0c064f45ee49_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_2f6f21c4-9936-40ae-b6ec-3826106f7582_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gain</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_ac2fe16e-0bb7-45f8-83ce-7a984fea17a9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_e1477cc6-6331-43ba-8f82-50e372cddb61_terseLabel_en-US" xlink:label="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:href="bhc-20221231.xsd#bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c45c784b-1ae6-419c-8400-4d8abd1cce04_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aae64100-75c0-48d4-aee0-c0c1d61a3757_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d92ac046-7ccf-4b8e-8ccb-e75027614c49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5f5847a0-c0d7-4387-b455-123ad1ad9484_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_fa605e2f-4e8c-4bf5-9a5e-f2b537827369_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_422f81d5-08b9-4764-b4ca-db353adaa4dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_82cc147a-7d20-4bc1-81d1-c582cc5936cf_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_859e7a47-a5e5-41b8-a334-f870983ab193_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:to="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_ce0a74eb-5396-4e4e-8470-2128854594bc_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20221231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_12d7e6a7-a5ee-4a32-b692-46a51ba8f251_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bc25ed5a-6fdd-4172-b7c5-95a8f77a8642_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1a41c884-35a4-404f-b067-f3fc2c830140_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_7a096b48-8e5b-4ee8-b97c-5ee2d9ccaa4d_terseLabel_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General and Administrative Expense [Member]</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The allocation (or location) of expense to (in) selling, general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:href="bhc-20221231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43a1d3db-b866-40be-937a-6529a787afcc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_63423104-a218-4254-b55e-7cb9719b868e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_fe4d4871-7b15-45f0-923d-9371b984742e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments for the pension benefit plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2016Member_a55a22e5-e6ac-4d08-b4ae-aa2d366676c7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2016</link:label>
    <link:label id="lab_us-gaap_TaxYear2016Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2016 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2016Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2016Member" xlink:to="lab_us-gaap_TaxYear2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_468226f4-4f1e-4131-b0b5-389b52bc829b_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Intermediate Holdco Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:to="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_de27585d-f0ca-4597-a398-fd9e98f17401_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b32ae70a-1ee2-43f1-a122-eb1a5ac238f3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1af2472b-ca2f-47e6-a3aa-aef016bfd468_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_11b87a2d-2f95-4bed-8f19-1c23e7051f91_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_af52949c-52f7-4339-a384-93785875ee4b_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20221231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_218dfe11-b2db-429c-900f-8ebc4c7c9203_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5dbaa663-ce69-4a1a-a6a1-5d41bfb78a93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5e087a10-54d9-4d9a-9b7d-acb4571c7c54_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_5af8389f-6763-4119-9af5-f39ef47e5b20_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aced465c-8293-46db-b894-7e0d9d88a1c6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_a53a4188-e906-4147-b317-46fe274e0932_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland</link:label>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_label_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:to="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_4ec9d7ff-fea1-4f7f-a934-b45f4e0a7740_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_228bc724-d6ff-491f-aac1-d8b99f256329_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_979f9632-7a5e-4864-b9e5-0986edc04065_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_74dc7914-5447-4769-acaa-4adae81ff248_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a67a3c15-9e2e-4538-9950-05f21dbf2303_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_5ee3836b-f575-43d2-90c5-0b4b05a2ca09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bb833177-5304-4d01-9876-23911d96b178_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9962d084-de09-4181-b1d2-91f9aded39d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c213874-0777-412f-b532-b833d93dbdb9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_cce8737a-1b17-41e6-b9c3-972481b264d6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_db697f23-bc96-4160-a5ae-8a9dde061e30_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:to="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_d68d2df8-0c7b-4996-ba57-34517a834959_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20221231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_7c203596-6900-4aa0-9abd-ba3a6ca6f181_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_08038e21-3bb3-4075-9991-7df4acc74088_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:to="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_78d5150d-3382-42e1-99f3-5a244db7d497_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents allegedly infringed upon, number</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4ad1e350-3fc5-402b-85a4-54a402c2ad35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_6ed5de51-78b6-4839-a4bc-92914ae9b044_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread adjustment (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_label_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:to="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_7cb5d5ed-e8bc-4977-adf8-be9f16f071bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_18d38a01-9c0d-46a3-8fa9-10f6fd78ed80_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20221231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_35339786-0219-46c3-842e-0394bf0c3d58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against the allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_47eb423b-67e6-4ef5-82eb-f80f70c1aa3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b12dc33d-0db5-496c-9d67-428c9b289f63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_35ef73c8-e386-4e21-902d-fd52a93d0725_terseLabel_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement period for cash discounts and allowances</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_label_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_documentation_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:href="bhc-20221231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:to="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_283cc57a-b32a-43f2-bd8d-7b1ee54645a0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5b455999-c225-4b2a-ae1c-d9dafac81a33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8f1aa55a-2594-4ac1-8957-81a0c177099e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e38a8edc-f135-477a-9f00-5c398334418a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_564968ce-befe-45d8-88ea-492f37464183_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_e3c92570-d71e-4a78-9376-fb66fd60fb94_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_7ae34993-a516-4adc-9697-3a93229c08dd_netLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Unsecured Senior Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7017eca4-86b4-4716-b848-97e07af93dcb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b6cde2c0-89a0-49d8-9b82-49c7dc45e253_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_71efe074-d50c-4388-9b04-b92cbf78cbda_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a75ccce7-1084-4721-9196-f6f28a74ff6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_af320f2d-7aac-46e0-9c6e-735a24bea7d1_terseLabel_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer [Member]</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:to="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_a78b227c-130e-4f7c-ae6e-a70b39605a0e_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to tax attributes</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:href="bhc-20221231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_20616dd7-98ee-48b3-ae12-5e9a54d676ac_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_0c6f8b0f-1e7f-44dd-a7c4-def143681aad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2018And2019Member_fb316373-ab67-4a91-a0b9-fcf1da756231_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2018And2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2018 and 2019</link:label>
    <link:label id="lab_bhc_TaxYear2018And2019Member_label_en-US" xlink:label="lab_bhc_TaxYear2018And2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2018 And 2019 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2018And2019Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2018And2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2018 And 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018And2019Member" xlink:href="bhc-20221231.xsd#bhc_TaxYear2018And2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2018And2019Member" xlink:to="lab_bhc_TaxYear2018And2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d900c5d4-c801-4646-86e9-6a8c200170d1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable operating lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_dfaea557-be94-4902-b8dd-93a7d592b1f8_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded pension benefit plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d3f9b077-642c-4c07-bd34-3d2098f32e33_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1808275f-b292-467d-a80c-d61b4700c82c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_281ea574-6732-40a1-83d0-e3525eb5b506_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_dc84ea7e-ad0e-4da9-951c-73d9cb19849a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_5f458cbe-1e4b-495b-9bf9-130ec30c2caf_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Current</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:to="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_16ad3416-dd9d-4fc4-8a49-97c366be4890_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fd40ad31-0a65-4559-b0af-ef30a753ddc0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_5289aa86-3932-4fb4-b219-e0717fa5c865_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4888f9a5-ccdc-4843-8a8c-4c33eaa11b2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_4661c001-d56d-41c7-baf3-463eaf6d14da_terseLabel_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Unsecured Notes Due January 2028</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:href="bhc-20221231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:to="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_27397bc0-58da-46f1-8738-745cf857f719_terseLabel_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Over-Allotment Option</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_label_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option [Member]</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_documentation_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:href="bhc-20221231.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:to="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_a6fb9a81-337e-4037-bb61-865e7808e428_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_1dcc0d63-f60b-4cff-8037-073bb528e5ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_50071298-c101-4f39-9183-bd4860770044_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of (provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_7599cad4-2478-4976-8e18-30701c9a8740_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0f2e39d4-4fcf-489e-9514-e18482920ac7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d266a015-06c3-4915-b948-23fd42d2da42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_82aae258-f001-4b75-8279-21ad477f784e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_e5cd68ff-9738-4627-b892-f90b47dcbd0e_verboseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_7e5c5092-5d93-4195-bad9-03e6241d22ac_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_786e1f6a-5967-49da-b1e1-d981acc8785c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_a450db42-4257-482d-9cdd-dba51f81b043_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_00980ba9-52f9-48c8-be48-d79e78451422_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of debt exchanged</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_24a043cb-bbdf-4035-8deb-36995e86166b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_a3ba57aa-7593-4726-ae4b-b999d8487626_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_adce42d8-9c75-4d72-abe8-33e660e6c811_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_98f741b5-2ab5-4756-b191-110f5d2b919b_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:href="bhc-20221231.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_33c03591-ea25-4712-9a3c-03b58f6bdf16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_55877da4-24e6-43a7-b96f-118f2e359a7a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_e31da913-6f3b-446f-9d39-9dd07e9d72c9_terseLabel_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member" xlink:href="bhc-20221231.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermFacilityDueMay2027Member" xlink:to="lab_bhc_TermFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_324d13c8-7e09-44d3-b8ba-08abb3d09380_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment included in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_39740e06-9e26-478c-81f6-605e276a3b10_verboseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock options that will vest on the anniversaries from the date of grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_9ea5b490-e4a4-4bc5-ad9d-75f02edc402c_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of stock options that will vest in the future period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_29eb407f-0ef6-4e2c-8e92-08a52be73ef3_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_9a118f59-1096-4b1f-aa51-673fab8cf08f_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rates</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0d9c9e59-9208-483c-bded-d2b45a1881bc_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2012Member_5be9023a-3008-4489-82ac-e724f2ba1d7a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012</link:label>
    <link:label id="lab_us-gaap_TaxYear2012Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2012Member" xlink:to="lab_us-gaap_TaxYear2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_5f04e664-984f-41d8-9980-2ffbff1dac44_terseLabel_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_label_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_documentation_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:href="bhc-20221231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:to="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_216f7a7d-559f-4ea7-ace4-8721ae290cd0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d28b4b23-b2d8-4d5c-abb5-68c6f33c6fc9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d071bec7-e0d3-4a59-b40d-e0be795e2af4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_24880d66-f447-411f-9019-fab0bd5a25a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to accumulated deficit (less than)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4bc489a9-3573-4be4-b18c-46457650746a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_ac5a46e0-766d-449c-9d72-67f5a8a984c2_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_d56d2d94-7d3b-4bcb-9105-2c66fc6eb35c_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_16ec9862-cf8f-4d1d-9742-eb886fcf4306_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a5138791-6bc9-4f21-aef7-4ee0f935369f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2228b3de-3080-49eb-8a79-7c79c9d3e827_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible amount of share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_4d5b1471-c71b-4147-946e-d43c7f71fb45_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5553a8f-65f8-4f84-ba56-762d8f204d84_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_a30d9587-030c-4a47-8280-da44cbdd18ce_terseLabel_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures:</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_label_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditure and Depreciation and Amortization [Abstract]</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_documentation_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the capital expenditures, depreciation and amortization by segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:href="bhc-20221231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:to="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_325ddd19-0976-4002-b1b0-86ba594b0797_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2d6f95fc-a2bb-4480-b671-5b5382df8af4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a236fbe4-2595-43d1-b73e-38e6e25b1b4f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_5cb8b3e8-a0e0-48c8-91ca-7e406dca7849_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_4ee8dcc7-450d-40cb-866e-73be65c90b83_terseLabel_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_label_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:href="bhc-20221231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:to="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_033b72bc-03a3-439f-91c5-eb86447770c8_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_68cefff0-e45c-4af7-a2d6-99a8b226ef73_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20221231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_ef4b7396-ea02-4449-985f-cbeb970d49bb_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination program criteria, if circumstances met, number of shares that will vest (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Equity Instruments Other Than Options, Number Of Shares Vesting</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Equity Instruments Other Than Options, Number Of Shares Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_63424ae8-b1a9-4e32-b28b-2d562a49c6bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3a38bc8c-63b7-4d81-a070-5e127a8550c6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_19c618bd-9eed-472b-926e-b732b50519af_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_55112f38-7372-4a7c-a69d-2aa1b5ce74bf_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_939167b0-4d58-4160-b157-87f4fc2429e6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares held</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6fc1a6c2-0160-4d72-866f-fe9e0ae16d02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7b71893f-5417-4938-8e68-3703f78cf44a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5e3b526d-0cad-466b-947a-47dd8c956496_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_9bfc7be4-4db3-4ce7-b484-a57da82382b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2b3c7ea9-737c-4461-9a04-dac7edc2151a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, one-time award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00f6e9dd-e233-496c-bb48-d950a11a79a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_5447196d-10e2-4a70-b55c-808455e6a93f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_c2651d45-7053-490f-a984-1b3c9147673b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated company contributions in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_1926f233-c61a-4d14-ac2c-1004b46d1119_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a9215b5b-3a93-4493-aaed-ff4c3d748808_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_32065ef3-24a9-428d-9663-e00cb3866f05_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3fcfec8a-b43a-411e-931a-3a14060ee25d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0cf828c7-e97f-45d3-ac82-1c002b334a8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e10cb9ba-7690-4879-897f-1db67d7ca792_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_0f92b985-bdb9-40a0-aee3-13c396d5591b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70208fc9-6d46-4009-b5c3-94d313abf7eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ae19bc5c-8d78-481c-bba1-857a6b172de5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_d512463f-49d8-40d9-964d-8aa4922f9d28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_7fe7d2d8-dc06-45cd-92e7-67cd39ae4b0b_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f13457f1-754e-4f7b-97d0-2433dda7e5ea_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_342d523e-e91e-402e-adeb-c7ca55b521c9_terseLabel_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers and Other Members of Leadership</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_label_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership [Member]</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_documentation_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:href="bhc-20221231.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:to="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_5fb39b1b-3088-4507-9ec6-da7275aa5caf_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20221231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_1eb83991-393e-4914-a1f5-d6719f79a0ef_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, award type, percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_aea3d9ca-439f-4661-9715-4aba98c65273_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ddf71ca2-12b1-4d6f-a295-7afadc380f33_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_179ab399-4699-4d05-9353-df7f333f5013_terseLabel_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_label_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_documentation_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:href="bhc-20221231.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:to="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_3119b99a-99d5-4bc2-86a9-cd2a64c8c38d_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:to="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_eea15257-21de-478a-9cbb-cb240859fd1c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_dae53b0e-11dd-428c-a8e7-c40fb8c152ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_53dfb4a1-c632-426d-9cfc-741c35ae14b9_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:href="bhc-20221231.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_95cb1c42-11dc-497b-8ff8-613b61d841a7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_821228fd-7958-43f5-90c7-70ffc3b1c46c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_7b278c2e-b623-449f-ad5d-b010dc18beb7_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_a891db4c-9c49-4f5f-97e1-4094e2944caf_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan, Retention RSU Grant</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:to="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6ff0abba-9f23-4f4a-b8c2-82186217e5d7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9ed561ee-f81f-48c7-ab18-b7e5319be429_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_234ce482-d0ab-47ae-826a-9da7d78700ce_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_06b3deaf-6e5f-41cb-bdbb-afadbbf91f41_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f48044df-c9e1-47b4-985b-0832c3c880a2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_0a57c2f3-66a5-4884-a287-7b12b1fe7114_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfDefendants" xlink:to="lab_bhc_GainContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_ff99d291-26a7-426c-b05e-d6c2686ac5a2_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_1e6644da-c851-4884-a080-0ba3e7258a3e_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:to="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_98734f7b-74d5-4c18-bfe4-3fad062d3e8d_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20221231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_532a4355-c9d4-4d32-aeb5-3db03f171f1c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_159e3ed2-48ef-489f-9033-b19e1e2b3ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_170c299f-e82c-415c-ad2d-4716ef7fffa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_67cfa838-a9ad-497a-8252-c6c6b1373b94_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_22f57018-5f63-4791-9813-f07621bba034_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_ef6d8095-4ff1-479b-93c0-56dc6b6d7906_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes due 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f4f77388-0537-45b1-b0fa-3120b8e75ed5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_783bcdc6-b76e-4f4b-a3d8-93dbdb6ae1e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e3590338-ba68-4a70-a1a4-ef584d3eba9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_a5f33a4a-7570-4fae-a60e-9021c2d0fed9_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_80dcfeaf-935c-4d69-97dd-27a04efa3f5b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_faead416-614a-4259-ba32-8dfd398aca4c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_12d7b226-f09e-4a6a-944a-ad1ec023e626_terseLabel_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_label_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:href="bhc-20221231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:to="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6a3507b2-8e2f-4dff-834e-c7d6bd9b224d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_e8a98cf7-c53d-4d63-9862-a08d1a7861ad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) recognized in interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_05504166-7736-4eda-8a27-a0ad41618e7d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held For Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_2878f97b-6c99-4b80-9757-f16a4ce98690_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_d8e17a93-125a-4a01-b27d-74874b456815_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20221231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_d82733d0-9ab7-4092-a99c-4e4ee712e1d9_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20221231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_8a60ec08-7a2c-48fd-8fc7-725eba148908_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_b88a8235-f9f6-43e8-a1e7-86c2290ee50a_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63b2345a-a9cd-4bfa-a7ee-5a8902d9f1b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_91869522-43a9-442a-91b4-631cc2a78d85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement loss recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_59973827-a77d-42cf-b097-99735e8bff7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_a0fa0e2d-12a8-4f6c-81d9-69d6f2e54b23_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_87f0d7a4-0b97-474f-a67a-5096615052b4_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B&amp;L Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_d2b37edd-925f-4a92-9e2f-7efb5dc65870_negatedLabel_en-US" xlink:label="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_label_en-US" xlink:label="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction And Other Gain (Loss), Before Tax</link:label>
    <link:label id="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_documentation_en-US" xlink:label="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction And Other Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:href="bhc-20221231.xsd#bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:to="lab_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_49ca9484-f734-48fd-9ee3-eee069d15c68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_c57fcc33-1248-45eb-8561-e9530b5bac2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before benefit of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_eca8fa2b-88db-4133-b411-89f12e85e10d_terseLabel_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:href="bhc-20221231.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_fa34ddb0-f993-4633-8bb5-fbec513a967b_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f356b80d-8f4e-4107-b224-2595ac6a6de1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_598534e3-f8fb-4e40-bccf-3160074094fb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_5b97821e-232f-43f4-b46f-d4c22ccdb644_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to commitments of the entity during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsTable" xlink:to="lab_bhc_ScheduleOfCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_bf9570fd-23e5-4ee2-bf82-24bc3cea735f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_683a355a-d229-4c89-8e61-068d6403a673_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5edb520b-3480-4c1d-a7b7-52737807c8bb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_731968ff-7d17-4e04-9044-e588a2a41ded_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_df72eced-7dc3-494b-8024-9e6be326c4dc_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20221231.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_06d28df9-6915-407e-8da0-ddc04264ea29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_0e0ac971-2bfa-43c7-8b57-cccb466f1467_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_d0e72bf2-03c3-4365-a61d-cbb0fbc5b831_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_c5914322-71f4-4a76-8629-8a0bc4c99471_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fade2150-c146-406a-88f9-d9a00f24c5ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_a54b7586-193b-4d63-9898-8c6e6508ece6_terseLabel_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale reclassified to goodwill</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_documentation_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:href="bhc-20221231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:to="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ce394172-69cd-4b73-a6d8-775fcafceb39_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_cee872e4-b3b7-4f68-b438-9f430900b46e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_cbafa57c-6b20-41eb-9994-c7d0123b48d4_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate, percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_a6be32ab-d973-4a1d-9a75-b16ddbdfdeb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0da9332-61a6-4303-acc5-3e29712d7cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8adef50f-bb4b-428b-84f7-7987cea0de27_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_be9f783d-d366-4fac-96a7-849c08fed773_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_8b2c12bc-9ce1-4727-9b1a-674085c9ac9b_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Unsecured Notes Due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20221231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_3ad515f2-e4b3-43c8-be56-baa474ee7765_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8f53db84-b77e-4f64-abce-beea8b8c7929_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_0c12e29c-060c-468c-8d4b-3b2ce91104d8_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_ffc793b0-d7ba-4f92-a42a-cd8baa507367_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes due 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_b408623a-4636-4cac-93b4-eecc5c234c26_verboseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Research and Development [Member]</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:href="bhc-20221231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:to="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_cb893fd0-bf4c-42b2-b7f7-a262109c14b9_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20221231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4f4d82a0-f956-4659-a858-45913aea63c0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eb1d7046-04ba-49ed-b6eb-79f8554fe564_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_48621649-86d6-477c-8bed-e19e757574ef_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_d1147bdc-0589-4fc5-b193-697095471306_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_60d99b24-c639-40ad-910e-c27da129e80d_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87dfa43d-5bd9-42da-a801-ccb373728e76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_1b21f075-a798-47cf-bd89-3d69e5549466_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5b32e487-2712-4dc7-ba9c-5bf6c2da80d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_fc3b32b5-52de-435a-b77c-68261e1cbd09_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:href="bhc-20221231.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:to="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_15f35c0c-5ab5-464f-98c9-1497ae187d41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_15e8adc8-1db6-41b3-bfd4-db0ee077c959_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c0f2bf9f-8df6-4c8f-8556-e18ee8a21126_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c4f29461-980f-405c-8395-e03246b60158_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_75e494c3-e953-4b3c-874c-09f0de763429_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_8c7d96a2-e27c-4a93-88e8-b440c52ffd9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d3ff6d32-8e4e-47c2-a3ce-3e8e9fb13dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_add6e55a-cc9e-4d71-bae5-990340ab6c32_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_21ffab60-15ea-42b1-8571-4cf7ce300ee5_terseLabel_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_label_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_documentation_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:href="bhc-20221231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:to="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_02f926a4-5830-4196-aa0c-578a80e49a03_terseLabel_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_label_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants [Member]</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_documentation_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember" xlink:href="bhc-20221231.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOFoundersGrantsMember" xlink:to="lab_bhc_IPOFoundersGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_39094ad1-cd86-4c97-8918-9bd928207b24_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_dbd2cbe9-2f68-4ab2-bd8a-7e3cc65ab817_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_da64708b-b315-4ec8-b0df-1daf4d816109_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_24980d65-4644-4e93-bb9b-d6de12f7739e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_8c3ad0c3-edcf-44f7-83c6-60f7f1c5edd1_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_af55d6fc-d29f-4a78-bf2e-666575467ad3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_314fa130-bca9-4a3a-8cff-732d430cdf6c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_67d65391-e683-4030-b350-e21950bd3cb2_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_5b9592f5-5d60-4154-8afb-c8c0877281ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_8c96b9bd-f88d-499c-a57d-a41b5f0b0821_terseLabel_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities included in:</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract" xlink:href="bhc-20221231.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LiabilitiesLesseeAbstract" xlink:to="lab_bhc_LiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a709a191-108d-420b-be1e-69b3f6e829df_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings and other matters</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c7782d8-c29b-4111-8987-2cd325304a50_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_a3059acd-87b8-4052-9af2-cf3bd8b752a3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_U.S.BroadMarketMember_72961cc6-d81a-4728-81c6-829094f8a500_terseLabel_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. broad market</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_label_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_documentation_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember" xlink:href="bhc-20221231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_U.S.BroadMarketMember" xlink:to="lab_bhc_U.S.BroadMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_18e4c7f3-eef8-4b16-9bed-81fdefd97285_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_5883c257-9b8b-4dd7-a90c-6b5c93363529_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_ce62702a-025f-4e78-930b-3d34ced84a7d_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_fccdc847-d321-4eaa-85b7-7f41c45a5f9c_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_6dd0cf50-de99-43bc-8a5a-0d5a3a9aeefe_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.250% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_b2045aae-107c-42d2-9cbe-5ce877127f16_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes due 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_8a384f0c-86d2-494a-89c1-a375859397bc_terseLabel_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_label_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units [Member]</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_documentation_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:href="bhc-20221231.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:to="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_caa8821b-f0f1-41e3-a441-a89a057e290b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748&#160;issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_333d12ae-7965-46f7-8c08-fa17bd7bc222_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20221231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_a775aaeb-b423-4c2f-b74a-4e1e618764be_verboseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, Time-based RSUs, Performance-based RSUs</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20221231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a5f16b90-b349-477a-a9a4-41546a0dc083_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_3dfd342c-f67f-4ffd-ad33-ba25421fc66a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:to="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_b0da34b0-0052-4953-a5b0-4b14392805a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_121639a2-3805-41b8-ae2d-2d3f8b0d0bdc_netLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_1e7256dd-93f7-4c7e-9c82-93980f3d5dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d6a9e3c9-a4e6-435b-91c5-6969a9c0519a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_99ae47ae-b727-48f5-8328-5d43517e043b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_55f9b57f-6320-4c5e-b673-3b7539cc6f7a_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5a482e1c-711b-4626-b3d5-e7d8353a3126_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_8c662961-e91b-47c6-a10e-429920151834_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_26aad134-864c-4e4b-a80a-28652895a1b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_fd464a5f-29c6-4c66-ad1c-dda1c8f670c3_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_8b5e38ac-0390-49d1-ade2-f3a58fb991a7_verboseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23021612-ed5c-402e-9a8d-21ed28419d77_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3096c4a1-4d7f-4604-bc57-b8b962f74b80_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca107841-d4f6-4e78-99f6-dead2f538c16_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_91d37385-e5e4-49e6-9778-203a680d4688_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_dd360383-31ed-4c87-9989-f43e1a232c88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_f0c4678d-c36b-4dc5-909c-93e132db194f_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fe3eac49-f2c5-499c-ad45-661ddca55fca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e00e43fe-751d-415a-8f14-22a600cd1c87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_9cfb537b-1ac9-4174-b097-5db29950fe05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a8eef085-e396-4535-bb8d-1efb28855eb2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_d6b655f2-c4f7-461d-b25f-d615a7c66e6c_terseLabel_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology and Other Reporting Unit</link:label>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_label_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology And Other Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology And Other Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember" xlink:href="bhc-20221231.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NeurologyAndOtherReportingUnitMember" xlink:to="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_4989f905-5387-4829-a4be-9278b3289997_terseLabel_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_label_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_documentation_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:to="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_e5698d65-598f-440c-86ff-cd58c2b39bcf_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_d3d849ba-7e6f-49d2-90f4-16d8caaac621_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ad87ebaa-4e16-4c5c-adeb-680cb39665fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2678e8b2-f623-44c5-9395-bd6a02043b3b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_07072f96-9eaf-4ae6-b0ad-86beb5d2a896_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6da3b505-d024-4a8c-a88a-e655c2df4c51_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Lives (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28145e79-e005-4eff-a06e-35c503825e3e_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1dcea0ac-c593-4806-8c5b-21dda54cfc4a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AuditInformationAbstract_1f9ca637-7087-4f48-bd42-5c552d6547e8_terseLabel_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bhc_AuditInformationAbstract_label_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bhc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bhc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AuditInformationAbstract" xlink:href="bhc-20221231.xsd#bhc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AuditInformationAbstract" xlink:to="lab_bhc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a57d6d5f-e195-4e4b-a6b0-234c10d0fdb1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4b443c24-e18a-45cf-a7d2-8a5f5c365de5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_32eebb98-9c21-42df-994a-c53be68f4c32_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_a7be24e3-f35a-4e02-a9f1-42789ce43239_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_018c2c4f-e7f6-42eb-b718-ae98e207b99b_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_01c30238-4cd1-47f3-9599-999754e43191_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recognized in accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8eee80ff-6e7f-4e89-9c25-b8eb97f69988_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7f16ba2b-df8f-49d0-95c6-1e33de36a4a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_92896f83-3531-4365-9858-5005a58b57b5_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20221231.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_826b17ae-9114-4a75-a931-94bd45ad8ff5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_ef294dd2-3553-4234-a404-e4761767382d_negatedTerseLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20221231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_db8f267c-4a84-43c2-8d25-5553e28aa306_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsLesseeAbstract_d71839d8-e036-4a97-91fd-18b54ca55469_terseLabel_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in:</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_label_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract" xlink:href="bhc-20221231.xsd#bhc_AssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsLesseeAbstract" xlink:to="lab_bhc_AssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b4afecb6-4b2a-4937-8725-1a5e14acc471_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee, unutilized commitments, percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f94170d5-3354-4d5b-b255-a5b8dce399ad_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefaultJudgementMember_e28c8bd7-d2ef-4c0b-9c63-b2882349cb31_terseLabel_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_label_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement [Member]</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_documentation_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember" xlink:href="bhc-20221231.xsd#bhc_DefaultJudgementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefaultJudgementMember" xlink:to="lab_bhc_DefaultJudgementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_196059f9-3fb5-40be-8e1f-782fbd63ae75_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_bb3d10b1-61f6-419d-9469-58c7f9a34a28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a1eccae6-cc66-44fb-8f4d-d78fde6345d8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_0510d4a6-2d20-49dc-bca6-19bbc5be2d97_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_af22652f-7807-44a4-970f-dcbc946fea1a_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Research and Development</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1327d69e-f920-4725-8396-ff698b5b2396_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_52715c33-25a2-4a50-98a5-22522e7ed616_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_cb5c64f1-1f48-49e6-bb47-7c63d1050d9f_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_21ef2f37-56d9-44db-9553-2d8cb80d55f6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_b3f09861-badb-4b0f-abac-fc5f5b327aab_terseLabel_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_label_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_documentation_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember" xlink:href="bhc-20221231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ACertainInternationalBusinessMember" xlink:to="lab_bhc_ACertainInternationalBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d4942ea0-736f-47df-91ad-85a8a29e524a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_663f6550-59c1-4910-97f0-69fd42fb9954_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5c907cff-4421-495a-8c8e-680beb6adf0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_91bfc571-ae67-4d2c-9258-8dd1d15a1493_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d83ba1f7-ee7e-4bda-ade5-5e2e5c87a8bd_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b5be608f-077d-44ae-a8c6-80864cdeccff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a9ee5644-ae64-4adb-8960-76695127169d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_932eb3d7-84a9-45c1-bf73-b5bf6c0d28e6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_3a668e99-b78f-45a5-9346-7a8919fa924e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension and postretirement benefit plan adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7970985b-8617-4ba1-8d55-034569be354a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_003d1da3-26e6-48de-a52e-3dce90db4cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Company share volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_975cf6d9-fb04-4c0b-9f6e-996600c2d9c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_68160ba1-a658-4d18-9e55-62cad751096f_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfProceedings" xlink:to="lab_bhc_GainContingencyNumberOfProceedings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_7c9a34b8-3499-4dff-93e8-bd025aeddb1b_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Years</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_6dda827c-d2ec-44dd-9682-ad5adaa7a47b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_d8609fb2-fff1-4c1a-8edd-1fc780ec196d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fe430c88-6f18-4141-932a-a3977f69a31f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_06f356d2-9878-4612-a282-8f3ba21ca7bf_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_ad4caa92-c2fc-448b-aa80-250ca3994312_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage for amortization of net actuarial gains and losses</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:to="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NovaliqGmbHMember_2e4fe7f3-01e3-45ab-8c50-b38e0f40aa32_terseLabel_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_label_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_documentation_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember" xlink:href="bhc-20221231.xsd#bhc_NovaliqGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NovaliqGmbHMember" xlink:to="lab_bhc_NovaliqGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_533828d1-96de-4e38-b34b-15a947fd463d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ad86b4e7-8558-4b90-a1e0-da8b4d32d667_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_90bdeb3c-b358-4b8a-951f-0fe84d9a0a76_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f2b62871-6ab5-4c27-a7cc-9b09d23c30a8_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_36a6834c-2a5c-402b-a7b6-89dab7074557_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationTable_8f18feb3-804d-4d27-acd0-f824d7da673f_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationTable_label_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Table]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationTable_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:to="lab_bhc_AssetAcquisitionAndBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2eefd347-6dd1-4772-bca0-48f1547d0e02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_1ad5679d-e2ed-49c1-be43-4dc6030232dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1fd50184-82ae-4cb4-a9b7-9beecc077f7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_9cb603a5-98f9-4f67-bf06-8dbf990bb823_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_a36845b6-2d26-4ec8-bdab-a4316ca13d36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_612ac886-c306-435b-8323-18e7dd09a2e4_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_02a5c8ef-c975-4ff1-ba75-0fa4f4133a09_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20221231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_88ec0b79-8fa8-4e20-857f-6d67e901db0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_cdfc20a1-b2fe-41fa-9df2-4dc23803f927_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-lease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2bb82c51-c969-4f7c-8903-3d2b6151a35d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c0668836-38b9-417e-bd28-c04c18915d30_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6239d13c-991e-478e-9a09-723e4ca02bbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_a73dbd58-205b-4b9f-b0d3-90193c390a2e_terseLabel_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Federal and Provincial</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_label_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Country State and Local [Member]</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_documentation_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember" xlink:href="bhc-20221231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ForeignCountryStateAndLocalMember" xlink:to="lab_bhc_ForeignCountryStateAndLocalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_3fe28016-f583-4d76-adca-f6c9452e40bf_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_836bc453-72ba-44aa-8782-99f962914a69_verboseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities:</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_fd66fe63-f16e-4403-a52b-617a2d0864fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized actuarial (losses) gains</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_73c55de8-1016-4991-b98f-b811d40703b0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in NOLs</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Increase (Decrease) in Liability from Prior Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:to="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_963e6433-6d9d-402c-b620-e2ad531755fb_terseLabel_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes due 2023</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_label_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:href="bhc-20221231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:to="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3d60ba92-845d-4dfb-90d9-8081f8d1a15d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_6a2db6cb-e94b-4de8-88e4-887f3f7afb6b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_8daa2f94-da27-4016-8d7f-4e510b6af264_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_05ada23e-5caf-4250-85ae-a01c74f99882_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_fcaa3b15-a460-48e3-a5b8-28edcc698185_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_32119a4e-99d3-417c-8388-6a13f5e27290_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4a3bf391-c72f-42cb-aeaa-d1d39a41455a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of foreign currency translation losses upon disposal of assets held for sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a0c82621-2e6e-4186-bcd5-fff9ccbbef09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_fc45cc79-25bf-448a-9160-41e04a11c2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d2ad5f1e-99b5-4bd6-bba4-b488baca3912_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, amount paid</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_68952d9f-77e5-4919-b7b2-1f602060dde9_terseLabel_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash cumulative foreign currency translation loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_label_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_documentation_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:href="bhc-20221231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:to="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_8c7c5518-82d1-41f7-9b8d-5471b7ba1cac_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 through Tax Year 2009</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_label_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:href="bhc-20221231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:to="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_216452a5-f3f6-47d2-abcc-42378f9ea55c_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20221231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_fad7246d-10ad-40fc-ac21-3ac802c0c70e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_a9197b60-77ad-40c5-b3bf-043fae1399e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_bbaad948-deb2-4f33-9340-3f517bd85fe2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5bd772a9-5296-4c66-9650-3d232f420e22_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_81be4ab7-f114-46e0-b0b0-7175210dbd0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_7b1ab7b4-3f4c-470e-9794-5ae0902e25f1_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_62bfb89a-0a55-4027-9712-bac1d2299100_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_07e1296f-2996-4bdc-85a8-bd13f7bbc0c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A1261229BCLtdMember_fc1d9191-07cf-4f17-9661-14aa4825f331_terseLabel_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd.</link:label>
    <link:label id="lab_bhc_A1261229BCLtdMember_label_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd. [Member]</link:label>
    <link:label id="lab_bhc_A1261229BCLtdMember_documentation_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember" xlink:href="bhc-20221231.xsd#bhc_A1261229BCLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A1261229BCLtdMember" xlink:to="lab_bhc_A1261229BCLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_a3bb5c3a-c20d-45c5-af60-65a93d045139_negatedTerseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization or settlement recognition of net loss</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:to="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12416957-7158-422a-a82e-965bbc52330a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_73960892-82f8-4dda-be58-b26d011d56ec_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_3141f359-8063-4805-9029-fd00bdf26af2_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_058eb877-51c2-485f-bc4f-337db65c3f2f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_8a646370-1101-4b05-94a7-2d10387144fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, percentage of actual plan asset allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_b38e1ca7-5c9e-4ea6-8d6a-13495b2c0ced_terseLabel_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from B+L initial public offering, net of costs</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_label_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_documentation_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:href="bhc-20221231.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:to="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_6997d653-4bde-4c72-99fb-054dd1b12d89_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20221231.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_a35197fd-bef9-4b68-b061-62a507908b7b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_94e762c2-6a22-4b42-9c4c-7db7394008ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_a0bb8241-ba57-44ae-867a-5a5ce6ab98ec_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net (loss) gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_3a0564fd-b509-4d67-8d80-a78038c7d600_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_6dff0191-6520-4c32-90f6-3e9baeb14a9e_verboseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_487ada1b-7d02-4e15-a8e7-52890a2d6700_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_e4b26204-02df-477a-b451-43d7182afcef_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e5602405-820c-4d68-8695-e832976fd116_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_ab1690d4-d831-4cb3-a81e-a2884c001afc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0dfb8033-fac3-4f2e-8f63-989e730bca6a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_d08eab7c-492f-4420-b2b8-f4c8e715a762_terseLabel_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to pooled scientific research and experimental development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="bhc-20221231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_0c651a7e-9434-4e70-bf46-12df2b61521e_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental credit facility borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_aa51a5ba-f81e-412a-9b84-83ee6c88cc8f_verboseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_2d79e445-03c6-4636-9ed2-a79256ddaca2_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20221231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_78266890-38cb-4bc3-b190-0006b510ac9b_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_bfb86b17-8927-427b-843d-b8090738911c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4433cef6-a930-42e5-b100-0246b1759c57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_24220067-b611-412f-a87c-01454dc08e87_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_c21501de-cd1c-4d9a-8053-23420a487b27_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_3bb2a6f9-ba9c-4051-9c5c-42de7babe3c3_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of outstanding principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_label_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:to="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_2b4a0922-d7fe-4202-a361-aea2bd379de8_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_33f05186-7ebf-40c9-8c59-9cf6e2e1781d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_4be63f91-9868-4a0f-81d8-59e569c46840_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9f090a98-9db6-408d-ab91-3e55ab47c622_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_be4f8339-d321-404d-a9df-1fc5107b6f4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_cc08d725-7aeb-45a2-b45a-5d79f61fb1b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_352e84eb-cd2a-434b-a39b-ec901f7c1dd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_a052583a-12eb-4fc7-a817-9d26fe0f311a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_3784271e-246b-49f8-b457-1a11170020b5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_29d0040d-3974-4288-8239-65685c9252db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill reclassified to assets held for sale (Note 3)</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_28fa2782-cd3f-4f92-80da-d6fad3a392e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2cc1a1b6-e7bb-43cf-bcc3-a5e753349fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_922dfec7-afca-476d-b598-637b2766ec80_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_8cbe1b48-8fcd-4ca7-b923-d9e668ed74ce_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_221c8b78-d849-4457-8871-d7db58f87887_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">14.00% Second Lien Senior Notes2 Due October 2030</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:to="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_943b5d10-29ec-4e34-b19e-d593620afde7_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_1491f66f-2157-4db3-b1dc-719571285e00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_33f518c8-63e4-4a16-9018-b0c691d1e9f6_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_1cf21bcd-a834-4672-bd7f-f308302bb9e5_terseLabel_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of net trade receivables that is past due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_label_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_documentation_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue" xlink:href="bhc-20221231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TradeReceivableNetPortionPastDue" xlink:to="lab_bhc_TradeReceivableNetPortionPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_44b46c0f-51b6-4b64-931f-34ff9ef8afcd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2941282-fb7b-4b3c-b1b7-ffeb0ca25263_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_349d4929-98fd-4057-ada0-aa7384122749_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_dcb39e8c-5c9e-4182-b831-35f4b15931ba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_74689595-925b-43e3-8e11-88292ad9d77e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5a99a518-f3a8-4075-8b40-df2d0f8a01fe_netLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f7fff851-9e86-4dfe-827d-441943d47140_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7f65d027-7d74-41fb-a5e9-c22ab86444f8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2b96266d-8c90-4509-8598-c3b3240fd769_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f6ec00c-fb52-4db6-a375-6b9ee041561c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_97041564-df36-474b-a5f2-43fc5a8553d5_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6200e6b7-164c-40dd-90ce-05268b85703c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_936d8f67-066e-4c97-a8ed-0fd308cb2a16_terseLabel_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:href="bhc-20221231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_87423190-1425-4783-a1a0-7ff22f3c5f46_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b4b1b5b9-5c5f-4de7-b12c-7e454a07b657_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c2d02e1f-f3cf-485d-bfec-5f6496bcab79_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c244e4b6-b5b5-41e0-89ec-17112970704e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_bb8e0d1a-66d5-4b00-9795-7a97f006437a_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_a0df7075-7047-4715-b1d1-52425aec0c84_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period two</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_ef1132f1-d30f-4ea5-9e06-389bce18cb0c_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:to="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_68e3ac05-beca-4148-b24d-e2cfdf930e7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_d3dbeed6-a428-4287-b18f-dfaddfa051b0_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20221231.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_995cc9d6-968e-4f9c-a330-4c6b209ca846_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_64c9924f-dad1-4c76-bf11-66e9489d938c_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20221231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1af73eb4-fa32-4fb8-8456-f558c59f2900_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_7fda4cf5-c68c-480a-af0e-deb0db4dea5e_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_label_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_documentation_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:to="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_5d841834-b929-4f2c-b410-f9218e97d9bc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7af8e762-4dad-4e97-8bc5-205a1ab7a372_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_1bf0a483-2782-4a82-a830-76de32e30613_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b0b5b2d0-26d2-4534-a720-17b9c912e378_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of external customers that accounted for 10% or more of total revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0ee8b5cf-10bc-44d1-b67e-44babfc121c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e5ece72e-7e80-4e9b-b25d-a7bb98f3085c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_656b81ba-9b78-4ffa-9e87-2335b62400d1_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_54942690-2b1b-4a11-a299-6224b37fdf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_ef92c691-0aa0-47e2-a209-4a00ed7c77d3_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1743747b-77ba-4933-87ea-77ffa1a99aa8_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_021094d2-5bdb-4b38-9120-218d58888cea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c519ea94-2487-4776-8084-2a1e34aba289_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_0ed46bd0-7232-44fd-8424-84cc47705a48_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3dc074b8-3816-4d04-b9a7-df906ffab849_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_05674a07-80a5-4366-8883-af166cd03123_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20221231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_9e2b915e-9f9e-46a1-98cb-0ba77a8b1431_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_d1531576-82df-4059-8fd9-25a95c207143_terseLabel_en-US" xlink:label="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:href="bhc-20221231.xsd#bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_03b5e196-d67a-447d-a8ac-79f5d1ee14d8_terseLabel_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Products</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_label_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures Of Non-core Products [Policy Text Block]</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_documentation_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Non-core Products [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:href="bhc-20221231.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:to="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_9016a33f-f04c-453c-8a03-7901fc04b728_terseLabel_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party fees</link:label>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_label_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment Of Debt, Third Party Fees</link:label>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_documentation_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment Of Debt, Third Party Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:href="bhc-20221231.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:to="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_361185b0-6446-4b51-92f0-91e21cb94322_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c4fa6d59-7ff4-4b9e-98c4-a5b4966dc3f2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_2d0cfc60-2717-4b83-88cb-c5ef7a03dbbf_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:href="bhc-20221231.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:to="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6574055a-5e1b-4fa2-aeca-d9490c27246d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_a8a0a36b-91d3-434c-a547-614e724f245e_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b510a2f9-f730-474a-92ff-1d1a1cd996fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_fca88aa1-7ad9-4653-8ae9-81fdba4b49cf_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_74ed5340-7517-415a-8686-506d7597535a_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.500% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_076ddd47-a19d-4b4d-978e-976a42295062_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_972fd601-eeef-4986-8f4f-da996bc8b2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77f692c0-c014-4d74-975a-dc3240754731_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_be837d56-dc97-4e5c-9b1d-0ae640254c42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in variable consideration provision, adjustment</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a475b422-417d-4349-b1ec-767518a802f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of (provision for) benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d8178018-3272-4110-b930-4668a11c8b01_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b8db221b-cc1e-4dff-90c3-55704048ccbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fb2d5e00-2c68-4c71-9c9b-afbfe878c3d3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_32133c43-6a5b-44a5-9afe-cb3523a8e445_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_e190152c-3f4c-4e60-80e2-68e955fbbfbb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_183b0923-38e3-44b4-9b65-0b249e1ca43c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_9ca518a4-761c-4c6c-89db-975af7fac12a_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20221231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_26a55346-35f6-4015-a520-0aea2166d63d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_eb8a2577-323b-4580-a187-311c64021b03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6c7f86c1-4109-44e8-93f2-05e797401b20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_53530c96-18c2-496f-81c0-83ee40438453_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_68df4f5b-59eb-4f59-86d0-d537fe80a34a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_087976e7-2e5e-4c38-9fc3-52fdeb48107c_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_457f94b0-b602-4273-a03b-683acb2d40b7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_22698ce9-818b-4d90-b47b-ff6e4aa3109a_terseLabel_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:href="bhc-20221231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4aa5123d-70a7-4165-b5dc-33b3152eaeb5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_a5ffa9bc-fb71-4985-ac48-ac640e9c2bba_terseLabel_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due period for receivables to be negligible (less than)</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_label_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past Due Period for Accounts Receivable to be Negligible</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_documentation_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the past due period for which accounts receivables are negligible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:href="bhc-20221231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:to="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_9d1c5c40-d8bd-4412-ac9a-651d48dac025_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_eac830ee-feb1-4cd4-afcc-a0c597b99f5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_4cfad5b5-4e1c-42ed-a2d7-acbd313d4800_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_9b3741e1-92c1-48b2-93b4-602a4396b42c_verboseLabel_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plant, equipment and technology</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_label_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Basis Difference of Convertible Notes</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_documentation_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:to="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_30344959-6449-4a38-b0b6-cbb8705aa159_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share Attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4a338d86-b295-4808-aa98-7333661f00cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_02c75489-3136-4e72-8fb1-c7fb7d06786b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bae460b4-2dae-49bd-80fb-dec310710c48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_766e6436-c85e-4e29-8ea5-a2c27f3f5c7e_terseLabel_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Unsecured Notes Due May 2023</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_label_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_documentation_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:href="bhc-20221231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:to="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_66236bca-131a-47c5-a8bf-36c8ce8b0df6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_181053e8-2628-47f4-a997-83cb750ce806_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_d93781f1-601c-4147-8f15-5b2efff82ae5_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_5c2f5b86-4adb-49e6-ae9e-76e848b2c3d2_terseLabel_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period net trade receivable balance outstanding (more than)</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_label_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Receivable Outstanding</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_documentation_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time the accounts receivable has been outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding" xlink:href="bhc-20221231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PeriodReceivableOutstanding" xlink:to="lab_bhc_PeriodReceivableOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_02a0f8f9-5604-4cbf-9e89-fa94f49ae3b1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_3e7ef03b-cafd-47d4-b67d-448b380d435d_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20221231.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a4fbd7c5-c52e-4e9e-87d8-523404b32d0d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_5c2b09c6-8122-46b2-b22d-5c39c31f101a_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_7b587d8d-6e75-4560-9f69-c775e3506c60_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d3b47857-08a9-429a-8140-b13e9e579429_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_426b47b2-0b64-486e-9fbf-d04ef2a2e3ba_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20221231.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_adb78592-9ce2-47be-913d-d2a4cd604c3e_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 and November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_03c626a2-7dc7-4d0b-a291-06baad57e2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b01db199-ff45-40e2-bec0-3b509a3e3ad1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1d57d3a9-0af6-4fc1-8797-9e79918820af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_86a30cd5-f5df-44d3-9950-c4a03c039745_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_79c4e622-5f95-4613-8457-7c2dda2f3618_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_1699a6ad-f095-43c8-907d-caee03d9d9c3_terseLabel_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed investment tax credits and research and development credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_label_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Tax Credits and Research and Development Credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_documentation_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of unclaimed tax credits and research and development credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:href="bhc-20221231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:to="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_3c415b8d-3353-4b7e-b21d-1001da7cbf1d_terseLabel_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Benefit from income taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_label_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_documentation_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:href="bhc-20221231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:to="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_546f9844-513f-4478-a48d-b495f3a09c58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca0abd73-5182-40fa-b175-8c0ac241ec12_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_20ac893b-6cc4-4b14-afcb-db9c410000ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_7bae8f51-31c6-462d-8f77-bbe48cf9f12f_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_274e1c22-8025-4250-a879-773ce2a4b050_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c0a3e4d2-0b80-469d-90a4-dac68dcf8032_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c4978fdc-fd27-43ad-897b-44670d6f0c47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_0fdc3b2d-8bdb-4924-a1b2-e4629bd80a5f_terseLabel_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash, number of objectors' appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_label_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_documentation_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:href="bhc-20221231.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:to="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5eec6990-6554-4cc6-926a-2122e67d9873_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7357d66d-d1dd-4ef0-91df-3c7b8bafb05f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_c356ed6b-aad4-43a1-bcb3-b7efc5827307_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Acquisition-Related Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_97247301-05e3-43c6-96a0-6d116c41996a_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_label_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember" xlink:href="bhc-20221231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.OtherAssetsMember" xlink:to="lab_bhc_NonU.S.OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_de2eaafb-fa9d-4549-83e1-a92f40b36cbc_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20221231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_670820b4-d189-4fd5-9c34-173023ce7b5a_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e79c9252-a9ca-4fd3-bb05-a11cb7d963ad_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_54b2e946-5162-49ef-831c-c8daf3ebb5b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_b24af071-8c03-42e2-ab37-b5e20eea67d2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining restructuring liabilities</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_c996c0f8-f269-44d8-9ce9-cedb8917d217_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_0631497e-449a-4d35-9327-e98fac82b6b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_41a07e1b-7ac0-4cc9-be12-1888b6730595_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0c20935b-2101-40e1-8570-4d6f1ec310a5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_88270116-1ad8-4ab0-ac92-fa4540f5f817_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Loss Carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on tax loss carryforwards available to the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:to="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9f01e23c-eb06-4fd3-8855-989cbf7b9a0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_c697dcd7-5da4-4267-9dc4-969dddacf716_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of current year</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f6b58277-9370-4880-9cc9-be15b8ca1491_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_9895175f-c1ff-4fb8-a1b6-f7b0fc6d9cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f2610cd-9f9d-4a99-8e0d-b24c5a86d390_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_c172802b-5676-4c88-a77f-baae2b6fb32e_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables accounted for by largest wholesale customers</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_label_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:to="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4f83c08e-19fe-4c02-96b6-2bb5381dace7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db59c274-5ff9-4a29-ad85-b46e2b7a945b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_674f2fb6-96d3-4502-a301-abe3358358ce_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EyenoviaIncMember_c7d61e45-1a93-4005-b048-f76b4ab680ca_terseLabel_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_label_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc. [Member]</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_documentation_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember" xlink:href="bhc-20221231.xsd#bhc_EyenoviaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EyenoviaIncMember" xlink:to="lab_bhc_EyenoviaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_cc56cdb0-5fcd-4cda-94fc-805aba1e93b6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_565d8104-0f5c-4250-805a-fd6d26cdf853_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5d0b6d5c-9df6-4f75-8b7f-ab0bdab88c64_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States - Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_355bd366-3f9d-407f-9133-32a9705dd313_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20221231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_29951907-95aa-4a2c-bf8d-ab403cd352db_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Options Vested in Period, Total Fair Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total fair value of stock options vested during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_8e678d51-ff28-46a3-a2aa-4c9bf7a93c43_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20221231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8ec4b0b4-6f91-4e6e-8a70-195995e09192_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_898f5751-f87b-4286-a0a3-c478b996b2a7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_168aec9f-d825-4500-85ec-79f818f81152_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_394c3b6a-719f-4624-a0c5-956a4ff36334_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_08b25ef3-87fb-4b2b-8e41-827dd3fbe68e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of aggregate maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0e9e8957-f1a6-4102-aab1-ed479300895f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_312cca9a-cd58-4561-9c7b-968832ea34a7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_d0ee68f0-7dec-4e7e-bfa3-4830030bb1fc_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Effective Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_cabbde41-d6b0-423b-a24f-c82f93faf806_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_cb118ed2-937a-419f-ba10-25b34a7b5db5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_3c030a2c-b326-4c4e-aab2-55b554b504f1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_24c53483-fb5b-43f1-9404-d66b458089ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_98bd9c91-3c34-4d6c-9175-9e1a53bfa64b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_f51226ee-1469-41b4-9b3a-54d35afee414_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_24955c6d-06c9-4950-a246-698ae138eb52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_e9e463b2-bc56-4af7-be36-bbd24c8dc077_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a1be5f4c-7e32-4cb6-8fc8-fdd5698b118b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of vesting rights</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d13a4ccd-9d8d-4af4-8be2-9ad251be9905_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c66a2067-02a7-408d-9eb9-de814b64539d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_73fe34a6-d316-4349-9251-ff9426e1968d_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000 % Senior Notes Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:to="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_17dad60b-8212-4e19-9ee3-b8c1266a00fe_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_90305be6-463c-4c85-ac23-c31c830bafb4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_fe36a01c-0526-4506-94c4-603539218b7e_terseLabel_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation</link:label>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_label_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation [Member]</link:label>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_documentation_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember" xlink:href="bhc-20221231.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AurobindoPharmaLimitedLitigationMember" xlink:to="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_4001f7ef-a085-463c-aefb-50e8ab2786ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_a835f6a7-4074-4a81-82b2-a5c2506b04ad_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_adba14dd-0d0c-40bc-92f9-0041f55229bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_eee205a2-ea8f-4731-802b-a6837fd11437_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_45ffcd39-4e18-4c10-9865-9cc75e02574a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1aeeb6c6-6e75-4307-91b6-b160d6fc7aea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b1f5d7e7-82da-4a0a-9052-8640cf6f5ab6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_449036b1-10c2-4d13-b53c-41570073bc15_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of property, plant and equipment</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_9245cad8-2c24-44cd-8aac-b79d47c306b3_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e92e2be8-f9a9-4fcd-b112-570cf58377c0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1eb3a655-11c0-4182-b823-5a9d555e9828_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c93f82dd-be07-469a-9df1-2f1936a32ba1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_109e9d4e-6344-400a-9d6f-22cb6ce58820_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_b525a012-2fd5-4e5f-b33d-3337d3e0424c_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments / Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixReportingUnitMember_0f913e31-3d26-40cb-bc4a-36bb15dc22c2_terseLabel_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_label_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember" xlink:href="bhc-20221231.xsd#bhc_SalixReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixReportingUnitMember" xlink:to="lab_bhc_SalixReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_3aee3b0b-1b63-422d-bb6e-df6639fa0698_terseLabel_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes Due March 2020</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_label_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_documentation_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:href="bhc-20221231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:to="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_72d53168-8748-49ba-bcaf-442b510c74d9_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d5cebc36-1fdd-4ff2-9a5c-939bbf6b621e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_55cb74b0-6dc9-4b76-8320-850b61248f71_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries of amounts previously written off</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d4f7d7c8-439c-41a2-9816-b205010fbaab_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_bfec0fc6-f42c-4ae3-a8dc-9f29c334cc27_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:href="bhc-20221231.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:to="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_5a3f13b6-cfaf-4350-a3ba-0a1d1acd8897_terseLabel_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps, final settlement</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_label_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement [Member]</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_documentation_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:href="bhc-20221231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:to="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_2579473d-9fa4-4c98-bd80-d69a113a0b47_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_c702294e-bec2-42f9-881f-10df886b43a9_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_bfcb0504-4d8d-4b54-9a6b-fd38649eaf7e_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_72dd4e19-4d11-44c8-a204-9286a5e2666c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems_647836ea-6dc1-4733-9513-648804d95669_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Line Items]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems_label_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Line Items]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:to="lab_bhc_AssetAcquisitionAndBusinessCombinationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_682c645f-4566-4632-bb2e-52eb23d56229_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from B+L initial public offering, net of costs (Note 2)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_24059b86-cfa6-40ef-8aba-e9ab5dcacc1f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_8086dd8d-562e-4043-9f84-32992f4136c2_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit on intra-entity transfers</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Deferred Intercompany Profit</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:to="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_51cf36f3-ae77-48f5-acb9-e97b7131114f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_0f8291af-8974-4ea9-95c3-076f436a8899_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Research and Experimental Development pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Scientific Research and Experimental Development Pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:to="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_325880d0-8ae5-4dc5-b130-cc516bcc6b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b3128b74-6a6b-471b-8574-9b368423a2b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_a868a00e-0445-45b0-8afe-096fbbc96b51_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_67f7ba68-492b-4da5-82b7-871143b67414_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_080513e5-e922-4f82-9d74-986df957a245_verboseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_602eb6f5-19f9-427d-b303-b9a309da22ad_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_5c9604d6-ef6b-4d29-bb20-a245ddb07e82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_41ca6a78-aff1-4c19-a0d9-cfa4a3c803c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_6850463f-693a-46a5-a15c-8f0b346c976e_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_bc8c8a16-c2bf-4dfd-b566-28e203fc8e7b_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_bf13a0b5-f98c-4be0-99c3-54e9dbc8c5ee_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c388c7ae-57db-47b2-b678-00d95fca3068_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c19f97a0-4286-449d-92e5-f0af5e652a43_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_67d7b568-949c-417a-ba37-64c618f95059_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_7e90e5fc-08ff-42a9-a0d4-c4484712c9b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual asset allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_a4baa7a1-b957-40be-9940-cf455eb08cee_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, grants in period (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_b4846c5a-c4b7-47d5-a5ad-69524fac3e34_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_7e73f8bd-5bbc-444e-b3b7-8d0b72806ef4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected benefit from income taxes at Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_953faddc-9b57-4942-8148-967a37e6960e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f20d9089-16e5-41c9-bcf7-ff2c5e7d3895_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_a4c010f9-c33a-4f5c-854a-d1aafaea4b04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_ca6876b7-e71b-4c7f-9c2e-1d86be1a9fb8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_461c28af-beca-4f24-8274-28bf79dcc380_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_c6ebe51b-00d9-4f6e-a4d5-887f563607c6_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_8ab162b4-66c1-4f2e-b5bb-1fc5534c71ba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c62c6ff4-ec5d-44f1-a25c-4ad464061eff_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_0915c21d-60ce-45a9-be7d-93369c6276f8_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmergingMarketsMember_e32ddec1-8a42-4775-9798-de5e2e0770e4_verboseLabel_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_label_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_documentation_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember" xlink:href="bhc-20221231.xsd#bhc_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmergingMarketsMember" xlink:to="lab_bhc_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a3499f33-425e-4145-87ea-305c9c0d49cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b39df83a-0fe5-480c-a9e5-732d7884e66f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_55666255-f01b-4af7-abe7-6c59f2a6b9d8_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_5a36f954-c96f-41c8-a93e-3595479e5eaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2128d16f-406b-410e-b979-c87060ec14a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Method and assumptions on valuation of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a8982cc-e432-4ec6-a5c6-802aa1c2dfd2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_6857d4dd-3029-4da8-a6cc-de31e2683c85_terseLabel_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:href="bhc-20221231.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_9a609935-5aea-4c65-bb2f-f73f12d2fdf0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_8b29fb15-3257-430a-906c-de8e0229e2f9_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_label_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:to="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_63cdc9c6-5458-4920-b21a-d6358598d994_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_c3810fac-0d5f-4353-8af7-7feb6e11f743_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit concentration</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5c0c5bf1-5694-427a-9421-d98ea803902e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6c3f7199-d033-4deb-8f21-17eea19bf592_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_d37319df-de1b-4567-a353-879417fb4331_terseLabel_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="bhc-20221231.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e730b8be-7c7f-4416-a3db-57464dbd48a1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac1fdcab-8dbb-4e4a-a9e7-4efea68fb305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_cd40a9a8-2e60-49f2-b176-eba267904109_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_ccbfde30-6219-4d61-8496-beba73ce8cdb_terseLabel_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of largest wholesale customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_label_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Largest Wholesale Customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_documentation_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of largest wholesale customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:href="bhc-20221231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:to="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_08375bce-07d5-43fb-b032-11cc99a8d489_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_48a0dcf4-b369-4742-95a2-20400a66b650_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_63ba8e13-0d8b-4f27-8af6-fe6b007808a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_79627cc3-1652-44c2-8e93-f0c7c02ad00e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_14fbfed1-0686-419a-8540-3769776a3fb8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_44ede08b-8acd-4fb4-9b20-318d7b1f79eb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0acb415-e116-49f1-aef6-08b379d6e835_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1ac32ea0-5ec9-4bcd-bfc8-76e6c170d638_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b06ae132-f9da-4e53-8cc1-6d75f791c2bb_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_52d1ad58-cf5d-4b61-8fdd-abae29ce53ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3096acf0-1a81-42bc-ad4e-f8271b2f0c39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_281dc492-e364-4966-aece-cb0d77e1f10d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_1bce217d-9c7e-4b2b-a02d-88b107042fcc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_b94a5d97-2135-4346-bacd-8a37ffebece8_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_e2645e40-7fda-4cad-acf1-036f43b8ee3d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_a637ca0b-823b-4109-8aab-3e44aae9612c_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_03131144-b263-427b-93e0-84d42b726fcd_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:href="bhc-20221231.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:to="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_0bf5e59c-f9dc-4183-be02-79cbb4d318bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ac20446f-9132-49c2-859b-8820c2acd939_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_cfbc0e93-8b6e-4435-905a-869b8b12ab17_negatedTerseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_c92c019d-a356-4d01-b2f4-4a052a9057e4_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_6ed39af0-7b09-4bf8-bd28-9973dad22313_verboseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ac58a351-169d-43a2-9d79-e43ba3adc6ad_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_93706cd9-37b6-4823-ae66-f350f4e5d500_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20221231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_fecd43ee-9b43-472c-8c8a-06e4b7dfa765_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20221231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a2a58f50-c8a7-4ae0-bcfc-0ddbcf1bed7b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6d10b232-cd46-4e3a-8d11-8077a25f4b88_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3d96e3cc-6130-474c-b55d-69e896378888_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_9a9b047e-de9f-485e-bc49-fd2e6f3214ae_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional suits filed, but not served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_fb4d1cbe-22c4-457e-a472-fa7401cae5e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible portion of Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_39ee0f6d-98cf-4045-b032-add3112b4c30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_bff5622e-cd3d-40ca-ad55-c3aa512ce469_verboseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_98fdfff7-b12c-41ce-9dc9-a5c3b613fb59_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_2d1ed1bc-e1eb-4544-924e-009ce58a8592_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028-2032</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_effb7cad-5418-44e5-8694-8ad1a076dfc4_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_4c0d1a7d-be79-40da-807b-b58861036dfb_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares, term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_label_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_documentation_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:to="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5985269b-53fd-41ca-b76a-e985f181ca66_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6d26d20f-9f8b-42c7-8b59-52eb73c2b6cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_aba16706-e5dc-4910-b910-fd8f16b4c7cf_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis_bf639d69-0630-4378-a34a-b285915fb959_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Axis]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis_label_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Axis]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:to="lab_bhc_AssetAcquisitionAndBusinessCombinationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_416d911c-6d4d-4c7b-a80b-8316df565502_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_6bbedefe-0b59-4aef-a42f-7beb505ef3d6_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_5bb36dd0-206b-4908-ae12-09ef3ff32405_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_0bae3509-e9ff-4c17-9fe8-df03c31bd2f8_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20221231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainEmployeesMember_442dd637-56fd-4e37-a0d7-7b00a6fd69af_terseLabel_en-US" xlink:label="lab_bhc_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Employees</link:label>
    <link:label id="lab_bhc_CertainEmployeesMember_label_en-US" xlink:label="lab_bhc_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Employees [Member]</link:label>
    <link:label id="lab_bhc_CertainEmployeesMember_documentation_en-US" xlink:label="lab_bhc_CertainEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainEmployeesMember" xlink:href="bhc-20221231.xsd#bhc_CertainEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainEmployeesMember" xlink:to="lab_bhc_CertainEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_8786967d-71e4-44d2-a10f-053719254ee7_verboseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_0ac00069-7263-4750-9bba-56d0535f0588_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3331db28-484a-4464-a22a-756c3b1e93e5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a883a85c-8a92-49c4-8c76-91e7c1c07425_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2013Member_89e0d7cc-623c-4dd6-8efb-857f01a276de_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013</link:label>
    <link:label id="lab_us-gaap_TaxYear2013Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2013Member" xlink:to="lab_us-gaap_TaxYear2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_3fa83376-c739-4859-8e99-b33a289fad6a_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_label_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:to="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_e903b09b-335f-4d3e-a51b-d7d5baae41d0_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:to="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_58afb9f4-9ca0-4869-9356-82d014860c80_terseLabel_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_label_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients [Member]</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_documentation_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:href="bhc-20221231.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:to="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_94907ba0-c538-402d-9926-cf13e42ea781_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7e3b0b77-111f-40f9-9e42-0f7585c3b3b8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_ca3c379e-7eef-4a36-b34c-7a6caca3bea7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5dc38b51-3c15-44bd-83e1-2b70727321d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5ae8697f-2db0-4616-b266-6cdc3ac652af_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c746b244-325a-4a1e-b905-d2529d5ecb0f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_85784317-9032-4af4-b8f0-9b3a93d41814_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_5ee3c7c7-e37f-46c1-bee6-5925854310ef_terseLabel_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_label_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program [Member]</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_documentation_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:to="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_ad012b4d-8015-4636-9b65-b1cd2110b537_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b18552b1-28e4-4315-8261-0b4eda11d89d_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_17b579d9-4e2b-4e66-93dc-f29cd52ab062_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_e1702d66-6e08-4242-b092-6f1fe4a37ac9_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_51b1318a-3396-4127-ba0f-689b734cd26d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_c76f587c-6b4a-4f2f-aee5-8b6802c64017_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net decrease for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_3c227bdd-0d06-40e4-9d4e-c26d687c1a5c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_50fd4a9f-59ad-4c8c-b016-e623422ef32d_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20221231.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_7058d5b1-4970-4b32-acd8-0a0dcd5748dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandImprovementsMember_ddd29a19-ef92-4769-83c3-a3f7c504731a_terseLabel_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land improvements</link:label>
    <link:label id="lab_us-gaap_LandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovementsMember" xlink:to="lab_us-gaap_LandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_86b89dd3-2ef4-4d91-afaf-3c5ca21509ee_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_955bcb55-d7c1-4ea5-a9e8-379d0f48ac76_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_93eca2bd-5572-49ef-8824-60f4970c306e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b80be1e7-6405-4b0b-a83d-7ccabb472649_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f587e6be-183d-4c72-b509-d6799684c316_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d4196df0-7a52-49f0-b81f-bbe6866143e8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07dcfe68-b475-4846-8512-3e6b3d51ef1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4a5024c7-2127-4f8c-b93e-065e219f3a4c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_cc807cae-bf2d-4c7a-97ff-8109ef6ed775_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_95f3df0b-612c-433e-90d7-a514722dfe06_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_17a30448-40ba-4d3c-8387-9b13f31c736a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a5ae6077-9a6e-4e21-be5c-ac785dedbdba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1efe4a43-93b9-49b5-acd9-8701bd3b83c6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e52641fa-8388-4075-8cf3-6734b9b86b27_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_fcc0f1e3-3794-411b-904c-6f8a19cf977a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_7135d157-ccac-45ad-8c28-a0913dcd6854_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution maximum age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:to="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ea5a8bfa-e224-4e99-9e8d-72d40a15bd88_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d74091c4-2d28-4b4b-8b4f-c213c7ffc4f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_83d0439b-8732-476f-818a-f9d3f8e35e4e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7a0b2d2c-9d0a-4ed8-9275-1eb67e29a19a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_57b61b2f-1b6b-40f0-b0ba-67b8f2f0bf2a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_4f18ca68-3380-4ccf-a655-b8e2202315d8_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20221231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_aba80569-5281-4a36-9fc6-72761cb0beef_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_862aed96-cca1-43ac-b0f0-c12aa17f9fa1_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20221231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_63277dba-d5fe-445d-a5fd-84418ad11a35_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_21af8fbc-760d-41ef-898f-5211501ef769_terseLabel_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer [Member]</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:to="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_4dcea247-95f6-4df8-8147-60e13aa251f0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of lease expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5c7f7f0f-22ca-4c8a-8556-7ad356c163e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_1195f664-f434-4dfd-9d8a-ebeb078f239f_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_be342815-09b4-4443-b5a1-b1acc086f672_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested time-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_5269046a-57e3-4456-aa8d-49885d5c6198_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20221231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b19d37ae-e1fb-428d-8479-42b163ee3052_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_208a871a-436d-42da-97f9-40333a42542a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_1cb080de-5d71-4ce7-b8e8-dfa55c52678a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested performance-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b6609d09-5be2-413a-9489-c3b89e6fc9e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_575bb5bf-5e27-4af6-b923-a67a19545d40_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_15b7ed1f-7050-47d7-82af-f6fdcf70e771_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_09bd6fbc-32ae-4fbe-81d7-7cb68e443173_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_4e600f07-f833-49dd-81cf-cd62910d3565_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_185d07e5-018d-451e-88f3-9f0dc5e9d9c2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_36d567d1-2bc5-4b90-8966-76e39ec08291_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8b104bdf-e357-4713-866b-13f9703b3ea9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_7e5e5f0f-63b4-4340-bd31-f23e15f6f365_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3c2f30a8-ada3-4bd8-acdc-a0ce5d038501_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3509e3c9-bf48-49a5-aa83-21c3a7aa37cc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_64863d68-131c-48bd-8aa4-bbda351f2b4f_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_974e148b-5a08-4e92-abac-2ca7a395f63e_verboseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_76d8de7e-5eb7-4077-9bd6-2b5ba9946044_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_19169bbb-e510-4a67-ba57-4f752da0a20c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_667562cb-c1ef-44ec-ba72-aedd4699f047_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_35749a3f-24e3-4387-8615-e58626f83b1a_verboseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20221231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7ff01963-1de5-4377-a303-dcc85376f825_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net trade receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_0f26825c-e808-4c23-a3f9-8ae0685c3da3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_4d12c184-140f-4d0c-b7c8-b39e4324d700_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_99ba9f6c-abfa-4fd8-aace-bf954646418b_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government bond funds</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f26f15d5-69a0-4a09-9bdd-d265c2e38146_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_781a08a3-a33d-4cb5-9d18-05b3a3664683_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_cc82259a-deae-475c-b2b6-1ab2951ef006_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_24bad189-25fe-48af-89c7-05e457b579d6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_063c2a14-6365-479a-82c2-b23903e3d5f7_terseLabel_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Unsecured Notes Due January 2027</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_label_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:href="bhc-20221231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:to="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_064dec26-9a52-49a4-89d8-f99e81c6e60e_terseLabel_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three largest U.S. wholesaler customers</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_label_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest US Wholesaler Customers [Member]</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_documentation_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the three largest U.S. wholesaler customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:href="bhc-20221231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:to="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_03aca0e8-84eb-4452-b2c5-92b81afb5842_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20221231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_5084daf0-e688-4b89-a513-d810c4eed2cc_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_b16f0eef-4217-4e9a-b4d2-f375dc404072_terseLabel_en-US" xlink:label="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela</link:label>
    <link:label id="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_label_en-US" xlink:label="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine And Venezuela [Member]</link:label>
    <link:label id="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_documentation_en-US" xlink:label="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine And Venezuela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:href="bhc-20221231.xsd#bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:to="lab_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_aab5e116-b579-4d64-9c5f-094b8270b2f2_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used to calculate the fair values of performance-based RSUs</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ed4a3144-2ed1-49bb-b3af-d1bc8f422ecc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0fdac83b-97b1-439b-8e4a-69345f60f42d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8be83be-ed99-49c5-a447-8ff52a99e69c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_30c94b46-aa1e-4ed0-aa48-8092eeaef6c0_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_160c84c7-0432-4c16-a269-695d6cdedb8e_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes due 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_e9bea1fb-9104-4c89-822f-d19be4518cea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of underfunded plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a450960f-069d-45b4-a3ec-81b28169aa31_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d3a57a38-451a-45f6-b042-ff9fc635c16b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c1782ad2-490f-4efe-ad54-64e9cb4cb4e0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_6dc775ed-9717-4a31-b9eb-b3a8068861bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5e2c3054-91b3-4782-93fc-a7dcd17a56f9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_f6d46833-729c-4151-87e6-f7826764bae1_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_91a9408e-ffcf-4c67-a7be-69bb4230fb3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b099925a-6408-4ef5-a2cf-bcd8d562e15a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_1521970e-5b9b-4bcc-9c28-4af6b1d58a9f_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_0d94b9c5-071e-41f4-8a37-18de101cc5c0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_22de854a-5f11-4ead-85dc-c162b5aab620_terseLabel_en-US" xlink:label="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts-OraPharma Litigation</link:label>
    <link:label id="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_label_en-US" xlink:label="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation By The U.S. Attorney&#8217;s Office For The District of Massachusetts-OraPharma Litigation [Member]</link:label>
    <link:label id="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_documentation_en-US" xlink:label="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation By The U.S. Attorney&#8217;s Office For The District of Massachusetts-OraPharma Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:href="bhc-20221231.xsd#bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:to="lab_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_b7b9eec2-c975-4be9-b982-36b34790436d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes4.502023Member" xlink:to="lab_bhc_SeniorNotes4.502023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_3ee27318-be56-4d1e-b26d-c03332d4dea8_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_74a7fe78-9220-4b94-85fb-0a846438b1c8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_aa222f0c-4f52-4c83-8f52-3b3a6b76c539_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_574daaf9-ffba-49c6-90ef-bbf34802a856_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_386ab510-9d0c-4e4d-9c7c-cee2aef6657f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7da01433-699c-47f2-99f6-4203613d1bf5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_713b690b-2cfc-4609-abb9-f81e10c2d8aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a5eaf7b8-1606-4f2a-8739-d3f8d8dbda2b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1c90cf9f-f46e-443b-8c7a-e7f0afbb46ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_411023e2-5461-445e-a75c-b19436026daf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fb68ca28-dff1-4a42-a12f-d519a7a4cdfd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_5d651d4d-9883-4121-bd22-60725bff8c4a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_7d3322ec-a0d0-41e0-9f30-969121115fb4_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_3cd09f27-e584-4a4c-af27-eab9b929e461_terseLabel_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum period to classify uncertain tax position liabilities as long term liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_label_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_documentation_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:href="bhc-20221231.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:to="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bf1ef727-b8f3-4102-a974-a53033c0f137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_93e7714b-aa58-4b6a-a3a0-eb7b402db75e_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79f0cd94-e50a-4084-8b91-6918cc9a0a1f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2015Member_d7012e50-e534-438f-be9a-01f163e90c52_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015</link:label>
    <link:label id="lab_us-gaap_TaxYear2015Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2015Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2015Member" xlink:to="lab_us-gaap_TaxYear2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_0771f238-8bb9-4ac5-8ad5-865c467a13ae_terseLabel_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Unsecured Notes Due April 2026</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_label_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_documentation_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:href="bhc-20221231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:to="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_6889d6ed-6063-478b-9c3a-76ce93561f0c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_6e2c321c-0c4f-4bb6-8223-17bb56ee9c8a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_c733bbe4-8d92-4db0-b038-c96d1d45649d_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20221231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_e9f21ada-1083-47eb-aa10-3b02a26a30e2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_117652e8-f53b-42d5-9287-695052183eeb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e5675958-084d-4a98-8455-2be6316496f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3a950da8-8866-4a6b-ae70-8fd524801896_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_870d57b1-fa34-404c-b64a-0b1ddbd5ee8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2480f1c1-73b5-43af-a74b-81a8c97580bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cb7a038e-2247-4da1-99cb-2a1161896af1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7fbc46fc-ce56-4a19-add3-96a24bd566a9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_96c292fb-4bf2-4e71-89e2-258d15b0ab65_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b2c75c36-ed0b-45ea-8780-f5528c08e8be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised in the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9893e469-bfb6-413c-8f3a-857f06930add_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_06bf5c30-d1cb-432d-a0d7-784d381a27f5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_b2575847-6563-4dce-be2b-460cbbce9ea5_terseLabel_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_label_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products [Member]</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_documentation_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember" xlink:href="bhc-20221231.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_XifaxanBrandedProductsMember" xlink:to="lab_bhc_XifaxanBrandedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_421a36c1-c4fa-416c-91ea-50c92d0a759d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c03bf047-7531-4a7b-8c2a-6d0e18f3e385_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_02f469b6-fd03-4ed8-9cad-790e12a4976a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_a4ab7115-631e-4178-98e0-2c1f8c2b1c9a_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due March 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.50%, Due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:to="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_ec9c3d1e-7a95-4bc5-9641-8fcd287d7625_terseLabel_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg</link:label>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_label_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg Inland Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:to="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_fe415512-3f4f-432c-a9c2-6ce16adb4bc6_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_35ae4f3a-ffdd-4f02-988d-d4b5361401c1_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_265bf405-1558-4734-ba14-ef35e111bd1a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_183673f3-bb29-4751-8bb1-f08584af5614_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_cb96b641-e04a-48b4-a6d4-862517149712_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_c5b4f8df-132b-45e3-8bbd-01e876c29fd5_terseLabel_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Unsecured Notes Due January 2030</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_label_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:href="bhc-20221231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:to="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_95f508d8-c1a6-40cb-beba-0ba2cd2cfdbb_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20221231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d7d592a-0074-41b1-8874-b82eb3292e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_440042fd-b41b-42c4-b53a-f91a2d973c56_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage due to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_3a13d28f-4127-443f-b835-619e56bfdc9a_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, change in discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_bafe613a-ae3e-4159-951d-69c1fd944d14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_f6cf1673-b1a6-4e45-937a-2ab218558bbf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_55884596-5d46-4aec-bb0b-08ddb6201efd_terseLabel_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_label_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_documentation_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:href="bhc-20221231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:to="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_00576d02-ccee-4ece-922d-bae5f09d431b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e510df9b-d948-4156-a973-76c57a842a22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A1375209BCLtdMember_9e38c278-2a5a-46aa-823b-2ad282b7db03_terseLabel_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intermediate Holdco</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_label_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd. [Member]</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_documentation_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember" xlink:href="bhc-20221231.xsd#bhc_A1375209BCLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A1375209BCLtdMember" xlink:to="lab_bhc_A1375209BCLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d1884601-ec52-4cb3-8164-efe438557a6c_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ee9f07b3-8156-440a-871b-2dbb52579a98_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_62147f75-675c-4029-8b64-20a6ba52f9de_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible decrease in unrecognized tax benefits realized in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_da5c4ff1-249f-4104-82a7-a674a45dbd58_terseLabel_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairments</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_label_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_documentation_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember" xlink:href="bhc-20221231.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetImpairmentChargesMember" xlink:to="lab_bhc_AssetImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_e643ba55-4b09-4bb3-bc93-8276210d9c92_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_ef37b425-6d2c-4187-b17a-65d41b6b64b9_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes due 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0eebce20-d2f0-484c-8865-b89cccc655f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b4079503-c348-4780-853e-f5c6cfe9856d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27dfb750-5816-4259-add1-029b8ed832ff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges to date</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c0ba02cd-4edc-4de4-82c6-603dccee5a74_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_7de75e1e-5414-46d9-85aa-6fbe8f2d8e5b_terseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency impact</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:to="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9c24822c-7bdf-4c8c-aab7-d6dc06fdf7f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6409e17a-fecd-4003-8aef-677a3d7ffc8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4d98f6af-d63b-4a4f-b012-69181755cd85_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_e6e99a3d-5b4a-493f-94f3-ce9db8b143a3_terseLabel_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_label_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation [Member]</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_documentation_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:href="bhc-20221231.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:to="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_7d5cda4c-98dc-492e-85f3-b69cdc84a9d7_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_6d2a470a-cc9e-46a8-8cb8-c5b3fbf0b5f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_6a8bb1ed-ec5a-49bd-9de7-f04c28531ca7_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage allocation of fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:to="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4e78fcfd-83cf-43c2-847d-b5a80182fc51_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_e2132524-4356-4ff1-ba6d-235373a6c07e_terseLabel_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Unsecured Notes Due March 2023</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_label_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:href="bhc-20221231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:to="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9a16a419-5bc5-4018-aa20-d835ca866c96_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_700b4086-f041-48f4-9856-13afc8ee283f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69afbef1-2c3d-4d1f-9daa-711c73e2b127_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_825d08a0-9932-4b9c-b853-be193edc4452_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of the approval period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_bac2b638-a857-45ea-8c7b-5ebcba36e550_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, if rate not ascertainable (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_label_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:to="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_eabc8887-9587-4647-8b51-5e89c4de0e98_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b3f83856-8d12-42ea-a7ad-a1dddd56557f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f782b731-b3b0-494e-b236-ef6b7bc974cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_5325a5b7-e036-4ce9-b932-c71cea6df247_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_862eccb0-e2a1-4752-af24-b89dc5f02738_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_a9d6cfc5-17d9-4bcb-a045-44b466c58d4e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining mandatory quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7d555eae-a979-407d-8553-e43ccc6039e3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_a09caef2-d545-4248-9622-ca028f9c1bbb_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_fe5ea7cf-c3c6-4e4c-93ad-f8e88241d21c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock_f1f55816-0bc5-43f1-9a6c-d45ad7fa4681_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Licensing Agreements, And Divestiture Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Licensing Agreements, And Divestiture Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:to="lab_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_1d14f673-c5bf-4bcf-9328-cb820c3efff9_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_8984e6f9-a0bf-48a5-8e9a-0b38e44fc927_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_01bb71cf-a65e-4559-9535-3d0558106e0f_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_379eb608-51eb-430b-8edf-86e60cd24a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment write-down</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_0ad83e0b-8387-49d0-bdcc-0b7a0e7c147e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e0d69972-bf16-4376-bd60-95e42305fe72_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6a87227e-6fe4-4eb8-b8d6-6bddc2df1234_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_52174cf3-dfaa-4051-817b-e5dbfdd49426_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4027bfa9-39dc-44f8-975e-85ac66e4436d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_25237e14-8280-4035-9ed9-dc6f8008b940_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember" xlink:href="bhc-20221231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsMember" xlink:to="lab_bhc_FairValueAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_02f80b5f-1032-4e38-8732-60f8588435c5_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2891b497-0d75-48d4-a0c5-dcd5d64c9b04_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67990cc9-d9e8-4825-8cbd-6934a8a528c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_6d636724-ba37-48d7-a29f-6e5f5fb228b4_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_f0da2c7e-a056-4358-affe-c210b237bc4e_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain_8a96a6e6-ccc5-48af-89fd-f33f36df3b72_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Domain]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain_label_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Domain]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition And Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:to="lab_bhc_AssetAcquisitionAndBusinessCombinationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_95b876c1-0961-4c18-80a0-2edfe7b7f4fe_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_6d4511d4-2c41-4789-91e7-44405c49ad07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial gain (loss) arising during the year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4af785f4-fd2b-4e2d-a5a6-68fa18f96636_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26662874-7bb2-419f-980d-2580427dc585_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_e911ff48-3975-466c-9953-0b035729c548_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1b20dc85-035f-46c1-ab36-3218b1c9db91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a28760f7-80f1-495f-8fab-5fa5f7816de6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExchangeOfferMember_ea1686c4-a9e4-4368-be0d-d150d8e96ad8_terseLabel_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_label_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer [Member]</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_documentation_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExchangeOfferMember" xlink:to="lab_bhc_ExchangeOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f05b58c5-5eee-42e1-94c0-dc8354e3989c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_afb68f91-ed8b-479c-b58c-be1dafa216a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration adjustments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_16ffb32d-7704-4f7c-be17-79d78422fdb8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_1ee74fc8-7a96-4433-9b0c-249e2abf166e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_37dac57a-59e9-43fc-ab8d-67d87fa93dbd_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes due 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_a6362dc0-68b8-4c11-9147-b45d114abb2b_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember" xlink:href="bhc-20221231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsLitigationMember" xlink:to="lab_bhc_RICOClassActionsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_884b9809-52cc-46c1-bddb-33fd1bb302e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b36e0b21-0a68-4ec5-ab96-68159178f896_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af223ca9-1a19-4f1f-832d-eefabd2bc156_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a464212b-6614-40c1-9126-6f39af548437_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c4a31507-e44a-47ca-b31c-5e86033618a2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn under credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ddbc73a2-6199-49f4-accc-ee68a8311fb4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_38120f74-328c-4fc9-b9fb-68e7aab7a77d_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Senior Notes Due March 2022</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:to="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d7ab1db5-685c-4c1c-b0bf-6a2bfeaf6aba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_e0baef6e-b2cc-4a08-9085-0efba4113717_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_29e462f5-2ab3-498a-8a44-ce9bf722cd6a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6b01fc48-334e-42fb-9bf8-8beeca7485e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and by product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e34d45a1-65ef-4e45-a663-09f48a9e7b11_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_4db398bd-dfcf-47ea-b4ac-efd94735042f_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common shares issuable upon vesting (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_80dce5ae-a808-4cac-971e-dd9d78212e5c_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_205cc13c-b123-41ac-84a6-5dba78683681_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20221231.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_0240bce2-5112-4b09-8864-85c4f474de16_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7c2747dd-6dac-46a0-a00b-253a9fb97332_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_195df30e-ad21-4768-8f97-2d6d22d53886_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_20cd34f4-7844-4f86-9b97-75c88aa19f35_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_cad93474-9b8f-4aeb-9833-bdf650acb08b_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_eb600f17-77f5-473b-b592-a17d474c4664_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_39b03208-338a-4ba5-8712-73a817b7e74c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_93f48e3c-8d58-40e9-ab65-bc023da05b9f_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the change in projected benefit obligations, change in plan assets and funded status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_fcc6791e-9170-4206-b09e-773cd95f6a68_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_7d9095e9-a4b4-472e-befe-5a23d883e3fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_11a7c790-4f80-4d10-a071-ddc8c86870de_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_3b733df2-f170-4d85-b537-ca4c6fb7532f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_018d38eb-f1d8-4fce-82c7-0c9dd86ca958_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_d396d186-3bc3-43f9-8f51-4e36fb141b65_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20221231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1ef7303e-8fb7-4f4f-9d76-8c686690d6e1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bb972649-1afa-4214-8849-d041989c6288_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_005052ce-c18b-4e44-bdf5-34acff326d5a_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_8aebe101-fb46-4bc0-828f-8c4eff8b936d_verboseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_2fe755c6-50f1-4dbe-93b6-b2529df0df4b_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_67895ac4-c2e0-4bbb-b707-6b4affacd8ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_078bc09c-770f-4c2e-bbce-93f07cb70041_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9de76ea2-49fc-4abb-93c5-49ca0a5394cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_63722b80-12c4-429f-beb1-1e9d022b90b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0697c962-9c05-4a74-934d-8a07873d7a09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c57b8df6-7436-4c12-86f4-78838a1d4935_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_11cadab0-f92c-4ce3-bd86-7d60f9386a28_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_af934d83-4c3d-4f1b-959e-985780d23650_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b1136cc6-746d-4664-8c1b-519181879cb7_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_e2475057-55a4-441f-8900-9ed722c9699b_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4404b34b-4e55-4ebf-89f2-529e39f42bcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e472b68e-2865-4d1a-9215-86cd13a45fec_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5bda5c75-f109-4831-8d8b-992068d7dd5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_b4edf459-5862-4754-816c-6ea69fea98d2_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_e3ba0050-fe07-43d2-a58c-1aa56c503d50_terseLabel_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated losses available for federal and provincial purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_label_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Losses Available for Federal Purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_documentation_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to accumulated losses available for federal and provincial purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:href="bhc-20221231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:to="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47179bee-293a-424f-b5cd-d964c77d3fec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_cc8f252d-b7d3-4858-a0df-77e90e97e2c8_terseLabel_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment on operating lease</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_label_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease [Member]</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_documentation_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:href="bhc-20221231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:to="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_b266f40b-63fe-4218-9471-1811cb81fd30_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_a4637092-3e60-4334-9064-548ed73b0f31_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20221231.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9116debc-8d69-43c0-81c2-2707f11837d6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_c8d9747d-f486-43f6-8a91-838d1144f06e_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a02163bc-fa91-4098-ae2c-1e3c79e63944_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_fb1e055b-6d65-4323-9e50-74ee36e5e8e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_849e859f-628d-41d9-ab9e-c704e7d5ffeb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f884900f-e080-47e6-8093-8c8aa48f418c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_fb3a7b82-9040-46c5-b921-5f603185cb18_terseLabel_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency</link:label>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_label_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_626f5db6-15c9-4905-8956-4a24bab16da1_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_71f69de9-9f4c-4ea8-9ac8-6993c3a6e030_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_3173197a-3774-4c64-a744-497245e0f07e_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_d62e746c-be56-4720-aa8b-91493ca75563_negatedTerseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04f67164-ec61-40d3-ada5-a3d6d0bd5f6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_5c2ea8fb-f95a-42e5-80bd-1ab6e1e52676_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_94b82d5b-c8b6-4e53-98c4-f89b1170b31a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_acf0ebc4-b389-4be0-ba1a-c53a461d352b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_64f3ae19-751b-4847-844d-a3bc0a65a149_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital expenditures, depreciation and amortization by segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d3f296a5-94e1-42d7-913b-6c185a77d2dc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f57e468b-7047-4b8d-9a88-77311a102336_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_d1ada53b-e03e-4228-bcb9-3f6659c88586_terseLabel_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_label_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_documentation_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:href="bhc-20221231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:to="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_c8776b5b-87e6-4952-bf9a-ff89d3ad48f7_terseLabel_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment, outstanding debt</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_label_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:to="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_dbc0d4f5-c09d-4a77-95ab-c222522a6a46_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_25d36057-b847-46fd-8f7f-4b1a69b5c53c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_4fea8976-7188-43a6-a879-9a907f28eb1c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_2d2c845b-4483-4bdb-9e0b-7aea6b9851f7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_413b9305-9429-4df9-ad60-592706ff2000_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_0891eef1-51d0-4233-b6cc-0f712e4c6f9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_bf064390-7cc0-4f9d-92ba-983273ce2937_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5df97415-8a84-443d-b69f-58e7af40a187_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_710f98db-6ec5-43af-8f6f-d3487a13ce8d_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_299fd9ed-19b1-4d16-8352-9a398197c303_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_a5f809d6-83c5-420c-bbe3-e6d7258ccc03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_5129a981-4660-4bfb-aa45-ce9fedfc1841_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_6a99bb1d-d1cd-4f8d-9fd9-527927ce925d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c90ee7d0-0b5a-4487-8ee7-9fb467930c77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_655dfe78-9c4a-4ba7-adf9-ea1752993c45_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cc32ad97-2f24-4c05-80dd-4ed8cfb17123_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Notes&#160;20 and 21)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e0a3d6b8-66f2-4c71-a533-19d5eefca33c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_856a0d7c-b3aa-423a-a412-037db1c9b0cd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76c18011-f204-42b4-b22f-52870717788f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_0d5e9206-d38f-4300-a70e-80c514111d2c_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_fdf5c089-2bd6-4464-9b9e-051290f3f048_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20221231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_42d4a6b9-e6e6-48ed-bea9-da47a2cc3534_terseLabel_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment and leasehold improvements</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_label_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equipment and Leasehold Improvement [Member]</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_documentation_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents other equipment and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:href="bhc-20221231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:to="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_178bde69-35ed-4a41-90d4-bc31453a4ca7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e4217279-f328-489a-98ee-6e46db7d07fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_ec733562-d014-4cd6-b5d1-a1bb04ba5009_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_3a9b90a7-a8c0-4fe0-9a23-582e9423c743_terseLabel_en-US" xlink:label="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Bio Teck Inc. Asset Acquisition and Total Titanium Inc. Business Combination</link:label>
    <link:label id="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_label_en-US" xlink:label="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Bio Teck Inc. Asset Acquisition And Total Titanium Inc. Business Combination [Member]</link:label>
    <link:label id="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_documentation_en-US" xlink:label="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paragon Bio Teck Inc. Asset Acquisition And Total Titanium Inc. Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:href="bhc-20221231.xsd#bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:to="lab_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_91add625-0e9c-47ea-9b2f-07ddede85330_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7096b939-9a06-4c38-9d71-ff48953d5f02_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_38301781-3fae-4164-bdcf-daa658b1f60d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_2f46634b-51f7-41b8-9cc8-70b685a66c0d_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivables and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20221231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e96c75ce-1af0-4e0e-bee9-7b2ae0a32325_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_ab8a1778-3b1d-4cef-8240-84742efb562e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_24243683-6a7d-4652-8586-f748a60edc16_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SurgicalReportingUnitMember_0742dec2-31be-4be9-938b-9aa6e0318528_terseLabel_en-US" xlink:label="lab_bhc_SurgicalReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Reporting Unit</link:label>
    <link:label id="lab_bhc_SurgicalReportingUnitMember_label_en-US" xlink:label="lab_bhc_SurgicalReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_SurgicalReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_SurgicalReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SurgicalReportingUnitMember" xlink:href="bhc-20221231.xsd#bhc_SurgicalReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SurgicalReportingUnitMember" xlink:to="lab_bhc_SurgicalReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_2544223a-f2a4-4d18-b787-f7c387e64678_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_70e26c22-3bbf-4329-b824-11654321c49e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_6da018ef-1718-47c4-9c01-03d9be6ba642_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_c339e9e1-4f01-40dd-81b4-3f9f82d91ce2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_ba7e0fe1-0160-4a02-9410-4db2d770de06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:to="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a7139357-8af8-4b53-96a8-6a7b8711394c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_f84d7596-a571-4c79-b847-7b7eeb295261_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_ffe8f038-2e4d-45d5-b7cf-ba73be45673a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_52c443e5-35f1-4346-853b-da78d6b7c6c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_8c3b77ae-4fb4-4778-bc36-409e7eb8f899_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_4b76980f-0f9c-4ef4-8e88-08bf7c785262_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_01f14704-f8d6-4130-b5a0-e8730390152e_terseLabel_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_label_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_documentation_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:href="bhc-20221231.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:to="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c3ffb887-e78a-461b-8bbc-b039ccbe38de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2441324e-0109-440c-9bd2-706f5a22d729_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_f7ae9d43-e320-40c2-8bc7-76e72c9d4680_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Uncertain Tax Positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:to="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_08bb9a36-fd6d-4753-84a0-bd33953e72da_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_89a8b298-0bd5-472d-8885-c94b84f34a13_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_302410c0-7d9e-4a55-a57c-b11359c4ac46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e2b993f1-9eb6-4726-8d0c-0d387cad8296_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bc8be0d6-664a-42eb-aaa8-3b875fe2573e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_d1b5ba56-dec4-4cdf-99ce-c99a6dd7d785_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted</link:label>
    <link:label id="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Troubled Debt Restructuring Note, Debtor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:to="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_06c93542-b880-477f-ad8f-636ea0e8771e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period one</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period One</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a0743b48-1d43-4ae3-8fbd-0d4bcab851a0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_a8b0f884-beee-4151-86fd-d426c4a7cc45_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1742cf0b-159b-4304-9e7c-b1ae4a9bb5ec_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_5df906b7-1c3f-4499-8f02-86c6b32ce41e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_57c7f288-414e-4773-aca6-e875bf698e78_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_666c1f23-9a0b-461a-a80c-e39adbcf0929_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1a38e24a-ee1d-4cba-a049-cfc8ef140920_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0c49c2b-a868-4017-aff3-f92f58e3689e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_004b146b-40b6-45c6-a71b-0aae2bbe3fee_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_650db8a5-38ed-44aa-b896-38ce8e2b52e3_terseLabel_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Unsecured Notes due April 2025</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_label_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_documentation_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:href="bhc-20221231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:to="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f2dd1194-e9b8-4721-ae6c-26c3c5056a62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ca82af62-2b96-4313-937c-fd78b3b1fd22_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3ed0b56f-f665-4d52-8d7a-2758582c96e8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_400fbe84-4d11-4f40-b049-00d3d2c319dc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_2a3313bd-a338-4bb5-9d61-d58cdbbd328b_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide developed markets</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_label_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:href="bhc-20221231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:to="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d4810539-f516-4301-9057-cb7bcfcfcaf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_d9f44e36-b71c-4135-86c6-7965cd2ff58b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_26d3858e-b3ed-48c1-9d21-c4b9ce67b009_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4c5d4024-72c5-4b90-bd6b-44251d8dcb1e_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_35047fda-5d1f-4a8c-abd2-9072d3e04e62_terseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective effect of application of new accounting standard</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_label_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:href="bhc-20221231.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:to="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_1157c57a-8011-4978-95b2-478c3ab871df_terseLabel_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognition, measurement percentage (greater than)</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_label_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_documentation_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:href="bhc-20221231.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:to="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_299a7669-e6d7-4046-ab9b-64d37ed62f39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_da9844ba-720a-4eea-9e40-41cb1dc46e65_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20221231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_5ba08fdd-9962-4b39-a7b6-d7f6ea3fcab1_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discounts and deferred financing costs</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Debt Discounts And Deferred Financing Costs</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Debt Discounts And Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:to="lab_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b68dda3a-ec53-4d0c-88d8-921436c03684_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_875d2ff1-ecf9-445d-aec8-711428f4ba6f_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_89b9043c-0a81-4e6e-97f5-457515a3cc9c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6fcf47b7-f8ad-4b10-98bb-edce27655488_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RS_f92453b3-4c30-4280-8ab7-012527e1b4a9_terseLabel_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serbia</link:label>
    <link:label id="lab_country_RS_label_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SERBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RS" xlink:to="lab_country_RS" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_e17ee767-5162-41bb-a171-dd09048f81ce_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_77089548-b0dc-46a4-9b09-0d325308b5eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_fdb119c7-85b0-4571-ba2e-64a4371641f6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_cc765653-3b61-4660-89af-2f2aa87735fc_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0973e837-e456-4e43-9ec7-090c3f771735_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_455a36f1-27e4-4d1f-be1a-16ebb1f3cc0e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_3029031f-7ce2-466a-9693-65d2b0567e61_terseLabel_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EURIBOR</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_label_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR) [Member]</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_documentation_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:href="bhc-20221231.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:to="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_0cb5c103-fd9b-40be-9c3c-1e14911cc32a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ccad0f71-dd9e-4e54-90e9-2cc49d043cf1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating lease future payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_2896c788-d7f2-4133-bb42-f32c4d7eca11_negatedLabel_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party fees paid in connection with the Exchange Offer</link:label>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:to="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1539fc41-09c4-4ae3-b8ef-4b6370d22e14_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_042ed7cc-f36a-49e4-9385-f5d545b20141_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit accrual, interest percentage earned on cash balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:to="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_222ac436-8f59-4b48-bf06-0264a52c2c16_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_7d9cb95e-24b8-49b2-a6c5-5b5fb41ba825_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9641c161-b51f-41b3-b5ca-a869d0bf6626_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_23eed082-de0a-487d-ad07-cb81da04f453_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_7edd9f71-f35e-4510-9fd6-22e6bf4fd55e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_059b13ff-1606-4a78-bedf-f1a685d12209_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f380c2d6-8853-4c4d-92b9-2fef113a5147_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_d6c54eb1-5276-4bf7-a016-5623567e1275_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination program criteria, if circumstances met, number of shares that will remain eligible to vest (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Options, Number Of Shares Eligible To Vest</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Options, Number Of Shares Eligible To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_f84890f9-50d1-4c77-a7d1-2b7cbd581a33_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_63df3ac2-6583-4df7-9b02-e01312344d4a_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20221231.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_9624f371-a366-457b-92c8-20fee7e14c1b_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_9081d4d4-c137-48df-9de7-c9b6e250df71_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_fa7a6026-cf80-4959-b323-57c4839e9710_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_490adca8-9d05-445b-8198-af2cc865a73c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_765c76d6-5e97-4452-b982-fc300bb6baa6_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_7fadf30f-0a62-4c2a-8b0d-51253768a90b_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of intangible assets</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_afaccfd4-c37b-4f8a-be7b-8fdcd06fcce9_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_b871d11d-18b7-4162-8df6-9ae6bcafd8f0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_4da3ea4d-9434-42f9-b313-072756805256_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20221231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_693610dd-3a89-4550-b751-1a904bdb9b43_terseLabel_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_label_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project [Member]</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_documentation_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:href="bhc-20221231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:to="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d1f0a9de-0469-42fa-8492-943c4d7854a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_b9ada57c-38cc-4bf0-9567-815f8fe6f274_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_741309dd-864c-4e07-a1e9-47cb9fd01d24_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_2eb740cc-6a57-445f-bdda-c2d6a589cdcf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Net Periodic (Benefit) Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6f46f57a-8bb4-4618-98ec-6eb05229aef1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_63c4120a-2cf1-44d3-9440-0fcf78a5ad11_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1067709c-23b2-4457-8f03-a0fda7872842_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_52577d36-4c09-417b-80ef-7180231e83ce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_950acb7f-8523-4fd4-90fb-ac76efa64391_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20221231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5376eedd-5e93-426e-88bf-c7db9f3a4a48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant-Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_e41b64d1-4782-4b63-8493-ac0fd3513ba1_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_b5cf5427-5970-4741-a638-7f0b09546fe1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8bf633ab-ceb6-4a00-8d66-10f39b21b5c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_80596c9a-e90d-43e4-a781-2609cb4f2109_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_61cd788c-479a-443c-9d88-b689f8a32fef_terseLabel_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other operating lease information</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:to="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_c20d0ab9-91a1-4553-96ac-f5823e205924_terseLabel_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of right-of-use assets and right-of-use liabilities</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="bhc-20221231.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxTable_90c10d73-fa67-4872-beb5-e59dafae0cea_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_label_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_documentation_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information relating to income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxTable" xlink:to="lab_bhc_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3ac56fb4-bd0a-495c-8de5-764e2af4fe10_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_320e7f3f-4a3e-4f34-a0bc-d8d1f915ca34_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_505a2ca8-e5c9-4e4b-875f-f24a3d8eb253_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_04228338-7d50-4318-baf0-fde6b8aaea9f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_3c8a6ca1-cd8e-48d8-8466-788d84463147_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_c3c09a7c-85aa-4734-8a44-a9f4fc4fa4db_verboseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20221231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_685a1796-d86b-4a65-ae4a-bc2683388ad2_verboseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_0ecd2bc9-5d6f-4828-a0e6-ae2287adaeb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_ad8d2ece-d715-4014-b159-bd114093f739_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance related to foreign tax credits and NOLs</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Change in Operating Losses Valuation Allowance</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:to="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_036b840c-85f9-4bce-88bd-67650715e538_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">11.00% First Lien Senior Notes Due September 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:to="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_6d06e657-d26d-45aa-b4f5-d4322c424eeb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_587f808e-c6ed-49d0-a374-d3272a07ecd0_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_53ec3711-f8d5-4e88-b028-abf7631ae420_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_e2fdde27-817e-4adc-b016-74f53d5ab19f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_44dd79f1-cbae-4e0f-92fb-e3d4c061b495_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_7bfeb4d1-63bd-4362-801c-eb33c1add6e0_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e0652498-95f4-48ab-a386-1908edcb9b26_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_b06a1e13-f897-4e8b-9e21-eb286cd46d9d_terseLabel_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, SOFR</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_label_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:href="bhc-20221231.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:to="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LegalSettlementsAndRelatedFees_117359a1-515b-4158-ad0f-5ab2e0569ddf_terseLabel_en-US" xlink:label="lab_bhc_LegalSettlementsAndRelatedFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_LegalSettlementsAndRelatedFees_label_en-US" xlink:label="lab_bhc_LegalSettlementsAndRelatedFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlements And Related Fees</link:label>
    <link:label id="lab_bhc_LegalSettlementsAndRelatedFees_documentation_en-US" xlink:label="lab_bhc_LegalSettlementsAndRelatedFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlements And Related Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LegalSettlementsAndRelatedFees" xlink:href="bhc-20221231.xsd#bhc_LegalSettlementsAndRelatedFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LegalSettlementsAndRelatedFees" xlink:to="lab_bhc_LegalSettlementsAndRelatedFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_b7b7f4fb-b90d-4288-9b62-b174292861ba_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_67f2524e-39b6-4148-ac20-3494c02234c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bhc-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1adcffcc-ca21-44b5-8eb2-7bf5be171f20,g:c9908e17-16d9-4082-b14a-6499a1a7512d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20221231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1581553c-4699-4a53-be01-404ef85f6aa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentType_1581553c-4699-4a53-be01-404ef85f6aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cf464498-18dc-4ca8-96bf-2c505bb8b54c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentAnnualReport_cf464498-18dc-4ca8-96bf-2c505bb8b54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bb5df57a-0cab-42d0-b211-13b621c64647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentPeriodEndDate_bb5df57a-0cab-42d0-b211-13b621c64647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3f835d09-36dd-4a7c-b987-3b98e6fb8aa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_CurrentFiscalYearEndDate_3f835d09-36dd-4a7c-b987-3b98e6fb8aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9a678d87-2d18-42ba-94fb-c0b0ad1de242" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentTransitionReport_9a678d87-2d18-42ba-94fb-c0b0ad1de242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1261b8a3-76e3-466b-8267-cdb72a8ceb17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityFileNumber_1261b8a3-76e3-466b-8267-cdb72a8ceb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_eceab8f2-ddcd-458c-998c-c15a21b1c7fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityRegistrantName_eceab8f2-ddcd-458c-998c-c15a21b1c7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19cc0d70-41bd-4ff4-bb4c-ec595e7b12e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19cc0d70-41bd-4ff4-bb4c-ec595e7b12e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_650ba67b-c697-481c-8c97-13901ff146a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityAddressCountry_650ba67b-c697-481c-8c97-13901ff146a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d17ee84b-afc8-4d9e-989a-fd5adc3b21c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityTaxIdentificationNumber_d17ee84b-afc8-4d9e-989a-fd5adc3b21c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b9750efd-84fb-42f4-b063-6d2e8e5cdb17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityAddressAddressLine1_b9750efd-84fb-42f4-b063-6d2e8e5cdb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c5b3bd1b-71de-44ea-97b6-03c80c176166" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityAddressCityOrTown_c5b3bd1b-71de-44ea-97b6-03c80c176166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b285a198-4d86-4a35-b782-487ca51ef44b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityAddressStateOrProvince_b285a198-4d86-4a35-b782-487ca51ef44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a23d11e2-1974-4a2e-8611-cc18a2923e5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityAddressPostalZipCode_a23d11e2-1974-4a2e-8611-cc18a2923e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9a105545-77fd-4f98-bae5-c45bf1750d95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_CityAreaCode_9a105545-77fd-4f98-bae5-c45bf1750d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fe36335b-759a-4037-8ba6-0f9166e23350" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_LocalPhoneNumber_fe36335b-759a-4037-8ba6-0f9166e23350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_aafd9cb7-b93a-4479-a486-933ff4573827" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_Security12bTitle_aafd9cb7-b93a-4479-a486-933ff4573827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2257e7c7-c4d1-413b-b60d-92cb97b39521" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_TradingSymbol_2257e7c7-c4d1-413b-b60d-92cb97b39521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8d17d6c3-4763-49e1-ad7d-2f0d3fe594ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_SecurityExchangeName_8d17d6c3-4763-49e1-ad7d-2f0d3fe594ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6c0267a2-7b4a-4650-8028-db089072e885" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6c0267a2-7b4a-4650-8028-db089072e885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_19e24cbc-bd94-4b56-97a5-9ea3a6ef55ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityVoluntaryFilers_19e24cbc-bd94-4b56-97a5-9ea3a6ef55ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_20a38701-2d08-471c-be5a-94bfdd00d670" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityCurrentReportingStatus_20a38701-2d08-471c-be5a-94bfdd00d670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bf87d6c0-b53b-4258-b1f8-95177c99120b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityInteractiveDataCurrent_bf87d6c0-b53b-4258-b1f8-95177c99120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_11cd1d20-668c-44d5-b264-435d3b820e95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityFilerCategory_11cd1d20-668c-44d5-b264-435d3b820e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8ba7e26b-2496-4dea-9757-558fe2ee3e3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntitySmallBusiness_8ba7e26b-2496-4dea-9757-558fe2ee3e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c3bf468d-1ab3-485f-90cc-dba7e6e45905" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityEmergingGrowthCompany_c3bf468d-1ab3-485f-90cc-dba7e6e45905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_54397baa-5bef-45de-84d9-5c9608751253" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_IcfrAuditorAttestationFlag_54397baa-5bef-45de-84d9-5c9608751253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2f6b5d9e-7e17-498d-bd99-49bfe248894d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityShellCompany_2f6b5d9e-7e17-498d-bd99-49bfe248894d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_4fb80179-dcac-4a00-903f-57cb24fd9c6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityPublicFloat_4fb80179-dcac-4a00-903f-57cb24fd9c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2062055b-6011-4ad9-9a78-3ef54310de7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2062055b-6011-4ad9-9a78-3ef54310de7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_602bc200-1a73-4e1f-9cb4-0fb9bd644844" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_602bc200-1a73-4e1f-9cb4-0fb9bd644844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_82993251-56d8-4e26-90de-e0cdfaf9a857" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_EntityCentralIndexKey_82993251-56d8-4e26-90de-e0cdfaf9a857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_25655f13-e194-4754-ab71-7fb711d187ee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentFiscalYearFocus_25655f13-e194-4754-ab71-7fb711d187ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_679d5b71-ba18-4a30-ac67-14e7f9c7214d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_DocumentFiscalPeriodFocus_679d5b71-ba18-4a30-ac67-14e7f9c7214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_50416698-a5a7-4066-8041-453bb4587f04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d05725ea-8967-4c30-9492-3f7d02154a94" xlink:to="loc_dei_AmendmentFlag_50416698-a5a7-4066-8041-453bb4587f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/AUDITINFORMATION" xlink:type="simple" xlink:href="bhc-20221231.xsd#AUDITINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/AUDITINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AuditInformationAbstract_f5c8f614-f281-4038-a3fd-9147bed704d2" xlink:href="bhc-20221231.xsd#bhc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_6a2b0678-63a2-4d1e-98ac-adb6218f6205" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_f5c8f614-f281-4038-a3fd-9147bed704d2" xlink:to="loc_dei_AuditorFirmId_6a2b0678-63a2-4d1e-98ac-adb6218f6205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_fcbed019-dc1b-4d09-bc25-e3ca7fbf2593" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_f5c8f614-f281-4038-a3fd-9147bed704d2" xlink:to="loc_dei_AuditorName_fcbed019-dc1b-4d09-bc25-e3ca7fbf2593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_85901364-7e45-4555-8671-93303d9c5aa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AuditInformationAbstract_f5c8f614-f281-4038-a3fd-9147bed704d2" xlink:to="loc_dei_AuditorLocation_85901364-7e45-4555-8671-93303d9c5aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:to="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_152334ec-8794-47bc-a41a-e8acc4e62f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_152334ec-8794-47bc-a41a-e8acc4e62f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_94a92b05-5a90-45d1-ac10-f45afaf42c73" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_94a92b05-5a90-45d1-ac10-f45afaf42c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_06791c2a-c402-4ae3-ba19-2312b30aafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_06791c2a-c402-4ae3-ba19-2312b30aafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ef94f3b8-2bd9-4fb4-8654-1e3d513cc63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_us-gaap_InventoryNet_ef94f3b8-2bd9-4fb4-8654-1e3d513cc63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_169b9969-499a-4ad7-9468-51a057f2113e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_169b9969-499a-4ad7-9468-51a057f2113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_89f9a369-a2c1-4534-a8c0-e1c7e374ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7f498ba9-3ab3-4ed8-be27-54357f6a378b" xlink:to="loc_us-gaap_AssetsCurrent_89f9a369-a2c1-4534-a8c0-e1c7e374ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3aef1074-4527-43cf-9366-27be721b0a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3aef1074-4527-43cf-9366-27be721b0a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_773b817a-1152-47b2-8172-bf1e9513b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_773b817a-1152-47b2-8172-bf1e9513b7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c7364852-4652-41e0-944f-169816f79203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_Goodwill_c7364852-4652-41e0-944f-169816f79203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_0399bae6-cfc4-4d49-b0e0-3f5347f5b0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_0399bae6-cfc4-4d49-b0e0-3f5347f5b0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b9ad0593-a971-4783-97db-8204cfa63051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b9ad0593-a971-4783-97db-8204cfa63051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f16dea6-0dbf-4d30-9cf3-0a331a9478f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_00ccd6f9-5c7a-4a93-92a5-283a532b0895" xlink:to="loc_us-gaap_Assets_9f16dea6-0dbf-4d30-9cf3-0a331a9478f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:to="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f21b29ba-f612-4fa3-ba45-5b18e615d33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:to="loc_us-gaap_AccountsPayableCurrent_f21b29ba-f612-4fa3-ba45-5b18e615d33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_07f37465-ae1e-4857-afe7-72bb0343ece1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_07f37465-ae1e-4857-afe7-72bb0343ece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7f966504-91ec-4d9a-8ac0-2b23b69286cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:to="loc_us-gaap_LongTermDebtCurrent_7f966504-91ec-4d9a-8ac0-2b23b69286cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6fe06850-52c2-496f-a2a6-775422557faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_21e8c8f1-65fa-49f7-bd30-ebc0f97f70ff" xlink:to="loc_us-gaap_LiabilitiesCurrent_6fe06850-52c2-496f-a2a6-775422557faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_6d85e03d-8849-485a-b9ee-54683624b309" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_6d85e03d-8849-485a-b9ee-54683624b309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f83a14ee-2eea-4650-95fc-1a3c326040ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f83a14ee-2eea-4650-95fc-1a3c326040ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ac71b28d-c349-4e24-8eeb-d59717aa84e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ac71b28d-c349-4e24-8eeb-d59717aa84e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_38b66d03-50fc-473b-9719-60c92724637d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_38b66d03-50fc-473b-9719-60c92724637d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_07f9a510-bc52-4f30-989f-619ba847d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_06759d09-56c8-4b28-aeb8-0ff1696f8ca5" xlink:to="loc_us-gaap_Liabilities_07f9a510-bc52-4f30-989f-619ba847d3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ffea100b-c2bb-4d91-9357-ccb51b78cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ffea100b-c2bb-4d91-9357-ccb51b78cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7abed515-4721-47f6-9d18-b64f57225cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_CommonStockValue_7abed515-4721-47f6-9d18-b64f57225cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_83b95e31-defc-4f28-936d-bb2fea6254b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_83b95e31-defc-4f28-936d-bb2fea6254b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cde5326f-e088-4e12-a81d-3c0aa799af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cde5326f-e088-4e12-a81d-3c0aa799af0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72aa10f6-7e69-48a5-896d-2b0b7abd09a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_72aa10f6-7e69-48a5-896d-2b0b7abd09a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f9fb111-80a3-40c5-b40e-e9824cde98cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_StockholdersEquity_2f9fb111-80a3-40c5-b40e-e9824cde98cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_662890dc-48a2-488e-8e26-5c3f29563ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_MinorityInterest_662890dc-48a2-488e-8e26-5c3f29563ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86569a6f-b7cc-4e80-97fc-864537c29ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_485e9c5c-6186-49d7-a3c1-ec35b9d054d1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86569a6f-b7cc-4e80-97fc-864537c29ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c1b5bf7-e48c-417e-b26b-6ab9618ed4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e30906ae-d03b-441d-a0ca-ea50b11fc8d2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2c1b5bf7-e48c-417e-b26b-6ab9618ed4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_605f815b-9c7d-4b69-b1b7-7e99c7aa2080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_18e02a43-ba29-4e82-8c36-e9875bd4828f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_605f815b-9c7d-4b69-b1b7-7e99c7aa2080" xlink:to="loc_us-gaap_CommonStockSharesIssued_18e02a43-ba29-4e82-8c36-e9875bd4828f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9da75c17-dc80-4794-adb2-e3327f63859c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_605f815b-9c7d-4b69-b1b7-7e99c7aa2080" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9da75c17-dc80-4794-adb2-e3327f63859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_53163f70-0b8d-4ca6-8f44-bff12dac2549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_53163f70-0b8d-4ca6-8f44-bff12dac2549" xlink:to="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:to="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c96d1c36-b59d-446b-bec8-bf55e31c4002" xlink:to="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dfeb4ef8-43f4-4529-8252-41c9035cacb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:to="loc_us-gaap_ProductMember_dfeb4ef8-43f4-4529-8252-41c9035cacb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6547b431-1b02-43c9-b55e-a5070c4a30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7c36d003-fcb3-4f3a-97cf-c2f3a9850500" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6547b431-1b02-43c9-b55e-a5070c4a30a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_85fd8fe6-f812-40a5-ac87-2ced8e6466cc" xlink:to="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5bb97809-b8c8-443b-8559-5412282f710e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8a6a6713-3823-4048-9488-10f78888d97a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5bb97809-b8c8-443b-8559-5412282f710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_949e6ef5-8b44-484d-a58e-b7e6127e1ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_949e6ef5-8b44-484d-a58e-b7e6127e1ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_313a4280-05bd-474a-bed7-60896b6b6be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_313a4280-05bd-474a-bed7-60896b6b6be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bee0eb3d-8b58-4a06-bf45-169256a77e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bee0eb3d-8b58-4a06-bf45-169256a77e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_a5e20ae6-7be5-43d4-b3e2-0565e58cb3ec" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_a5e20ae6-7be5-43d4-b3e2-0565e58cb3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_df8d2568-5bde-4732-878d-7e3e75a997d2" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_df8d2568-5bde-4732-878d-7e3e75a997d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9ac41773-a44e-4d92-a96c-5cb3c42255a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_AssetImpairmentCharges_9ac41773-a44e-4d92-a96c-5cb3c42255a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_5c516331-a9ba-49b6-aa26-bd659ec5ddf8" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_5c516331-a9ba-49b6-aa26-bd659ec5ddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_12f70df3-0649-4e6f-9f5e-8a276fbfb949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_12f70df3-0649-4e6f-9f5e-8a276fbfb949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_176ba277-6d17-4bc2-b26e-88efac156f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_dbcbe872-9ca7-48c6-8900-08cc7f383a0f" xlink:to="loc_us-gaap_CostsAndExpenses_176ba277-6d17-4bc2-b26e-88efac156f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5b837661-6961-4b1d-bf9d-0605b0b483e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_OperatingIncomeLoss_5b837661-6961-4b1d-bf9d-0605b0b483e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_13d5e822-6160-4cb2-9ad9-ee849d122025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_13d5e822-6160-4cb2-9ad9-ee849d122025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b47c34aa-6fe0-43c1-8b13-549dae0dbe61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_InterestExpenseDebt_b47c34aa-6fe0-43c1-8b13-549dae0dbe61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dab5cd14-35d6-4a40-8334-578b89a03e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dab5cd14-35d6-4a40-8334-578b89a03e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2e52e5fa-faa3-47c4-8df9-e0dce4e91bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2e52e5fa-faa3-47c4-8df9-e0dce4e91bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96b45baf-e8a1-4499-aee5-eecb19704b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96b45baf-e8a1-4499-aee5-eecb19704b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_697ce48d-b39a-4f04-97a2-58ad1d97cce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_697ce48d-b39a-4f04-97a2-58ad1d97cce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1914e18f-1e54-4ae9-9397-df449ee9b180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_ProfitLoss_1914e18f-1e54-4ae9-9397-df449ee9b180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d8907ea0-69c7-49cf-a941-c22da16089cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d8907ea0-69c7-49cf-a941-c22da16089cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_071189a7-b9dd-4c37-a724-86d47022ce73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_NetIncomeLoss_071189a7-b9dd-4c37-a724-86d47022ce73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5fa979b8-2267-48d1-a106-f61d889b7858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_EarningsPerShareBasic_5fa979b8-2267-48d1-a106-f61d889b7858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7b673528-43b3-4a0e-9f99-84784db3e9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7b673528-43b3-4a0e-9f99-84784db3e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_110163ea-6af9-40e8-baa4-48b0b4503559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_110163ea-6af9-40e8-baa4-48b0b4503559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea835662-6d05-456d-ada5-cf8a4df3b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cc297efb-a8de-47a9-8ada-62e6c58482b6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea835662-6d05-456d-ada5-cf8a4df3b3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_35f59da3-caa9-4161-ad6b-5a3d27fad6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:to="loc_us-gaap_ProfitLoss_35f59da3-caa9-4161-ad6b-5a3d27fad6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_50162aa4-dd27-47a5-827e-af6f86c50d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_50162aa4-dd27-47a5-827e-af6f86c50d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_50162aa4-dd27-47a5-827e-af6f86c50d77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_c0d403b7-b671-415e-8e18-729f577b935a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_c0d403b7-b671-415e-8e18-729f577b935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_2f1d9c60-86be-4fe1-a631-0481da7e9311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_2f1d9c60-86be-4fe1-a631-0481da7e9311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ae9ebea9-9f9b-4a34-9c8e-373a9d2ffbc2" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ae9ebea9-9f9b-4a34-9c8e-373a9d2ffbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_2f7bddd2-a929-477a-9b4a-89f0e808062d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_2f7bddd2-a929-477a-9b4a-89f0e808062d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_0e41d86c-e12b-4546-8d8a-e789ac0e6571" xlink:href="bhc-20221231.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_0e41d86c-e12b-4546-8d8a-e789ac0e6571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c363b0e1-c7fd-4233-a086-8e5cd459ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_cbbf2b46-c559-440a-952e-9181ef849ede" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c363b0e1-c7fd-4233-a086-8e5cd459ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cdd3086f-3002-4faa-8f75-78ac2829020c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_50162aa4-dd27-47a5-827e-af6f86c50d77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cdd3086f-3002-4faa-8f75-78ac2829020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f34b7a72-3434-4482-af15-77ffab961b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_50162aa4-dd27-47a5-827e-af6f86c50d77" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f34b7a72-3434-4482-af15-77ffab961b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5a64cd64-9e83-4f91-8ea6-ebd981fe5545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5a64cd64-9e83-4f91-8ea6-ebd981fe5545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1567edd8-8283-4860-973e-3ce733a9f632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1567edd8-8283-4860-973e-3ce733a9f632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e08ae7c5-3f5b-493b-913a-1dd728169b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdb39bbd-7bf7-4d69-91a9-1e4a8a8510d0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e08ae7c5-3f5b-493b-913a-1dd728169b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb5c4ae4-d57c-44a5-b4ad-db6eb7a39c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb5c4ae4-d57c-44a5-b4ad-db6eb7a39c6c" xlink:to="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d851f178-953d-4ac9-89a1-9a7de3e44fc1" xlink:to="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:to="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3af699d8-ce1c-4f10-aea1-656133c07298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_CommonStockMember_3af699d8-ce1c-4f10-aea1-656133c07298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fccdc70e-54e5-4705-b316-18a389faed09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fccdc70e-54e5-4705-b316-18a389faed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b4681659-dfb2-46ab-afc9-a49ea55b2c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_RetainedEarningsMember_b4681659-dfb2-46ab-afc9-a49ea55b2c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c02f4127-1d2e-458f-ad4b-212766a91770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_06bd8463-2f90-4533-9c89-be8397b2a0fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c02f4127-1d2e-458f-ad4b-212766a91770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e6c7abd7-d8ae-476b-b06e-4777a96fe00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8eab000b-26c0-4770-96f4-1e44a1b543cd" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e6c7abd7-d8ae-476b-b06e-4777a96fe00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_205576d0-b2f0-478c-b080-0f45f9a63842" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4796dd9e-15bc-4e82-a3f9-6c6ef9a6e3a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9570d7e5-85bd-4881-b082-f6f849e2b977" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4796dd9e-15bc-4e82-a3f9-6c6ef9a6e3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cb390b6d-a878-4665-8622-bf2fe1e00234" xlink:to="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5cbd086f-eee5-47a1-9044-71364ec04504" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_68d2cef9-13be-4010-8955-3840354faacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_CommonStockSharesIssued_68d2cef9-13be-4010-8955-3840354faacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569c0a8b-4139-4c6d-bf21-b76314c8c9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_569c0a8b-4139-4c6d-bf21-b76314c8c9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b2487661-b226-4d5d-84c7-ad2f4129fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b2487661-b226-4d5d-84c7-ad2f4129fbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d51bf340-c871-4efe-a156-c4e79de119ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d51bf340-c871-4efe-a156-c4e79de119ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_df921915-217b-4d5d-9afc-0e4840580b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_df921915-217b-4d5d-9afc-0e4840580b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5260f8ca-73f6-4494-b2ca-8a577ea31ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5260f8ca-73f6-4494-b2ca-8a577ea31ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d79dc674-7e88-468d-8167-1f9183a31f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d79dc674-7e88-468d-8167-1f9183a31f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_73e3fb7d-018d-441c-a56a-66055b5b965c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_73e3fb7d-018d-441c-a56a-66055b5b965c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b7f0603-c144-4ec1-969a-213b94630e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1b7f0603-c144-4ec1-969a-213b94630e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4429fffc-4769-4764-9f42-7b9864fd14ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4429fffc-4769-4764-9f42-7b9864fd14ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3ae9934b-385d-4ae0-bcd5-14343e260aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_ProfitLoss_3ae9934b-385d-4ae0-bcd5-14343e260aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7724fc1d-5848-4c7c-bb14-167ae1dd3695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7724fc1d-5848-4c7c-bb14-167ae1dd3695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_663acfc4-d306-404b-9e85-40bf7b7122d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_CommonStockSharesIssued_663acfc4-d306-404b-9e85-40bf7b7122d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a50abf5-6b0b-4a50-9555-0ec804af9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b0eb6caa-3107-4b32-9cb1-52752e055ab1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a50abf5-6b0b-4a50-9555-0ec804af9bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_45714692-a1a7-473b-bd26-31669361419a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_45714692-a1a7-473b-bd26-31669361419a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b2cd439-848f-44c2-9732-5d7c0bcc05ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_45714692-a1a7-473b-bd26-31669361419a" xlink:to="loc_us-gaap_ProfitLoss_0b2cd439-848f-44c2-9732-5d7c0bcc05ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_45714692-a1a7-473b-bd26-31669361419a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d3e4db65-edc5-4594-a4c1-0b1efc91c78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_DepreciationAndAmortization_d3e4db65-edc5-4594-a4c1-0b1efc91c78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9cd78860-b225-4f2d-96c7-b743abce1b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9cd78860-b225-4f2d-96c7-b743abce1b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d97de1a6-9692-41e7-a845-377e80939222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_AssetImpairmentCharges_d97de1a6-9692-41e7-a845-377e80939222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_5dedf664-8a80-4859-a1ef-fc8140b4e87f" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_5dedf664-8a80-4859-a1ef-fc8140b4e87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_008e3f78-2dea-49f9-a690-9406b53a4ba3" xlink:href="bhc-20221231.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_008e3f78-2dea-49f9-a690-9406b53a4ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_2501aef1-e643-4201-8ce9-f407241d7cdb" xlink:href="bhc-20221231.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_2501aef1-e643-4201-8ce9-f407241d7cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_96804447-6d04-4036-97f1-9d6241107e6d" xlink:href="bhc-20221231.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_96804447-6d04-4036-97f1-9d6241107e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_42c25d14-b082-4d6a-a48f-556540567782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_42c25d14-b082-4d6a-a48f-556540567782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_cc82f712-687e-47fb-bea5-5681d06301c5" xlink:href="bhc-20221231.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_cc82f712-687e-47fb-bea5-5681d06301c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_5793e236-9f7c-44a5-88d7-c10a78c402b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_5793e236-9f7c-44a5-88d7-c10a78c402b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e0709e5e-51ca-4202-87c9-615f0fe474af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_ShareBasedCompensation_e0709e5e-51ca-4202-87c9-615f0fe474af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_39734775-b178-45cc-8e3d-1db5b3ca6cd1" xlink:href="bhc-20221231.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_DerivativeGainExcludedComponent_39734775-b178-45cc-8e3d-1db5b3ca6cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d691a37-6529-43e7-bdad-43fb82cf50d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d691a37-6529-43e7-bdad-43fb82cf50d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_a9f49055-1745-483a-a730-7840c529af19" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_a9f49055-1745-483a-a730-7840c529af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_236d0c87-45bc-4ba0-9b95-ca90f08f173c" xlink:href="bhc-20221231.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_236d0c87-45bc-4ba0-9b95-ca90f08f173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_53a8214f-91a5-45e3-bfb9-b18deee05c4b" xlink:href="bhc-20221231.xsd#bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax_53a8214f-91a5-45e3-bfb9-b18deee05c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_45f0f4cb-6745-43f3-bad7-d1ecf4649d0b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ade9e235-f0ca-42e9-a039-98738ce254b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ade9e235-f0ca-42e9-a039-98738ce254b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e9101151-82ef-411f-ae5e-50db54917a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e9101151-82ef-411f-ae5e-50db54917a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81b1a2f2-31b3-4365-9d6c-af391e751328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_81b1a2f2-31b3-4365-9d6c-af391e751328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_677dc50f-59ad-4945-ac4d-f83a45de2ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0a27fec-5735-4c51-83d2-a71711d305fd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_677dc50f-59ad-4945-ac4d-f83a45de2ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ba26557-6d23-42e7-979c-6d0ae69378e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_45714692-a1a7-473b-bd26-31669361419a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ba26557-6d23-42e7-979c-6d0ae69378e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2be89f6a-eadd-4a94-aa82-27a7ddc6e407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2be89f6a-eadd-4a94-aa82-27a7ddc6e407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5f3514cc-5563-4bd1-b874-1045cddf05ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5f3514cc-5563-4bd1-b874-1045cddf05ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcf0578d-1ac8-4866-ae86-d31456d45835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fcf0578d-1ac8-4866-ae86-d31456d45835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21c3e7d0-5869-4dd8-8522-47d91fd4a931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_21c3e7d0-5869-4dd8-8522-47d91fd4a931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6ed211b9-5f00-4038-81cc-4a1bf7669c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6ed211b9-5f00-4038-81cc-4a1bf7669c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_333a6409-ba21-4297-8d60-d724294f7fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_333a6409-ba21-4297-8d60-d724294f7fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_5ac5d726-9f74-4f12-9777-f2f5ba00168f" xlink:href="bhc-20221231.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_5ac5d726-9f74-4f12-9777-f2f5ba00168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b964883e-c988-4d0b-a532-a27c002e397b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_f74235db-5777-42a7-a967-6d537ac801e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b964883e-c988-4d0b-a532-a27c002e397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67fa57b1-d2e1-4864-90cf-5197610e0abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_67fa57b1-d2e1-4864-90cf-5197610e0abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_08b4d9ec-3c07-4e6e-b43c-4708eaa83f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_08b4d9ec-3c07-4e6e-b43c-4708eaa83f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_df7ccf4e-30de-4f28-87d0-82eb9decbae8" xlink:href="bhc-20221231.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_df7ccf4e-30de-4f28-87d0-82eb9decbae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d340bc39-4063-4f1c-a13c-aa20c603f152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d340bc39-4063-4f1c-a13c-aa20c603f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e7170b7a-6f46-40c2-b82a-42025b2f6951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e7170b7a-6f46-40c2-b82a-42025b2f6951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1ec49163-8ad5-40a9-a392-8e7bf8b34354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1ec49163-8ad5-40a9-a392-8e7bf8b34354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_23bcf0fc-7b49-4413-b5c3-43b7800e081b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_23bcf0fc-7b49-4413-b5c3-43b7800e081b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bad8d6cf-ab8d-48ad-a0e1-0fb7618bc35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_599f65e3-5b97-401a-9e36-f35033f2c6aa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bad8d6cf-ab8d-48ad-a0e1-0fb7618bc35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c43809e2-ba4f-465f-be41-af84bdae356b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c43809e2-ba4f-465f-be41-af84bdae356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b8586b-7d9b-47ea-b6e0-58c08d4448b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a3b8586b-7d9b-47ea-b6e0-58c08d4448b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b7664be4-4f07-458c-9175-71dac06ed912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b7664be4-4f07-458c-9175-71dac06ed912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_655a6712-fa0a-4da5-a38c-d7bcaa5bb4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_655a6712-fa0a-4da5-a38c-d7bcaa5bb4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8376a2f5-82e4-4a98-b526-8fc335d18fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8376a2f5-82e4-4a98-b526-8fc335d18fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_6559d7c4-f5f9-4a77-b029-c67999058dbc" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_6559d7c4-f5f9-4a77-b029-c67999058dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54cb3494-c84f-473e-927e-5cde4097e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_86b0d7a9-2e60-40f0-b1c8-80f77ef8622b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54cb3494-c84f-473e-927e-5cde4097e9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20221231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc9b0e49-43de-4efe-811e-a7da4c6ac9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_c91c28dd-f115-4b74-978a-6db257dcb35b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc9b0e49-43de-4efe-811e-a7da4c6ac9e7" xlink:to="loc_us-gaap_NatureOfOperations_c91c28dd-f115-4b74-978a-6db257dcb35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_600a3df3-e4b9-4b70-b2ce-f9c2641e42ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b6283ab2-7f88-4fd6-b218-e21dcd297f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_600a3df3-e4b9-4b70-b2ce-f9c2641e42ee" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b6283ab2-7f88-4fd6-b218-e21dcd297f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e3b87cec-2f8c-4652-b441-973e016d02cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock_5c1809e3-77ab-43b3-afeb-e874de410db6" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e3b87cec-2f8c-4652-b441-973e016d02cf" xlink:to="loc_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock_5c1809e3-77ab-43b3-afeb-e874de410db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_15f6d157-40a6-48d3-8af5-3e9cdf511635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_127b1585-1185-40ab-bc5c-fc692de0b9ba" xlink:href="bhc-20221231.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_15f6d157-40a6-48d3-8af5-3e9cdf511635" xlink:to="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_127b1585-1185-40ab-bc5c-fc692de0b9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cf86cfb8-0bd5-4e64-9a92-9d4a71868691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_127a4777-581c-4db8-8c7f-a8b52e2969a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cf86cfb8-0bd5-4e64-9a92-9d4a71868691" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_127a4777-581c-4db8-8c7f-a8b52e2969a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20221231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_963f3dbe-84c5-4d91-adf0-8537e21b59d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d23e2384-09b3-436a-b9a8-dae832382b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_963f3dbe-84c5-4d91-adf0-8537e21b59d2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d23e2384-09b3-436a-b9a8-dae832382b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0838d257-96d2-4094-8cf0-6ad788645d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_32c3ce74-c887-482c-a3db-0f084ad06877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0838d257-96d2-4094-8cf0-6ad788645d22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_32c3ce74-c887-482c-a3db-0f084ad06877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c565697-1620-4e73-afff-c6450212a6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_75f6e8b1-555d-4e9b-91ad-90f7db4c8801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4c565697-1620-4e73-afff-c6450212a6a6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_75f6e8b1-555d-4e9b-91ad-90f7db4c8801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c2482983-43e8-446f-a46e-dd079b8df8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_316fd895-0bd7-4f96-9552-ae2bb22be4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c2482983-43e8-446f-a46e-dd079b8df8d0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_316fd895-0bd7-4f96-9552-ae2bb22be4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_057e2eca-8420-4afe-98b4-e1e17f5b0f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cce4cca2-a8af-4347-bfdf-4651bccabae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_057e2eca-8420-4afe-98b4-e1e17f5b0f68" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cce4cca2-a8af-4347-bfdf-4651bccabae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_31d04f5d-d0c5-4301-bc39-256caef3b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0234cbd9-1ea8-4d65-aa0f-282ec47acfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_31d04f5d-d0c5-4301-bc39-256caef3b3af" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0234cbd9-1ea8-4d65-aa0f-282ec47acfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASES" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_08034868-6d8d-44cc-a52b-7eb7ede26aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e7c2543c-26d5-4654-91a2-fe4c1d4ac829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_08034868-6d8d-44cc-a52b-7eb7ede26aca" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e7c2543c-26d5-4654-91a2-fe4c1d4ac829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9fdba88-734a-475d-9512-4b1e7beb45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3a918f7c-44ef-439a-b940-946cfe6ffdde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f9fdba88-734a-475d-9512-4b1e7beb45c4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3a918f7c-44ef-439a-b940-946cfe6ffdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_732498f1-ce6b-48b7-83f1-f7c80aff866f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_d7aa690d-bee0-4451-9445-c271d5d8f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_732498f1-ce6b-48b7-83f1-f7c80aff866f" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_d7aa690d-bee0-4451-9445-c271d5d8f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_763024a3-3c7e-47c4-95f2-aaaad228dae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7c685abe-1dfe-4df3-b3ad-3b1100cfe870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_763024a3-3c7e-47c4-95f2-aaaad228dae3" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7c685abe-1dfe-4df3-b3ad-3b1100cfe870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f5bb15a4-4e6b-4e4b-b45e-7928ee8e2078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_92d7e9f9-bee5-45f3-a558-b93799a3963e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f5bb15a4-4e6b-4e4b-b45e-7928ee8e2078" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_92d7e9f9-bee5-45f3-a558-b93799a3963e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_860bba5b-c3e0-444a-a485-8df2ef83b8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_45434d6a-13da-4295-bde1-77fa88f86a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_860bba5b-c3e0-444a-a485-8df2ef83b8ba" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_45434d6a-13da-4295-bde1-77fa88f86a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20221231.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_75bf7d10-dd1a-4cfb-a005-60df57179b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5941168d-b793-48a2-ab20-2964f6397257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_75bf7d10-dd1a-4cfb-a005-60df57179b89" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5941168d-b793-48a2-ab20-2964f6397257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="simple" xlink:href="bhc-20221231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_c048a6f1-492a-4f28-be9e-167c5dc63150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c46e252f-8783-4714-a92b-b4679e23c45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c048a6f1-492a-4f28-be9e-167c5dc63150" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c46e252f-8783-4714-a92b-b4679e23c45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d47e854-35e5-4f9b-873a-8d7a4d9a3d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_89245999-732e-42b0-a8fd-9925e9a34ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d47e854-35e5-4f9b-873a-8d7a4d9a3d58" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_89245999-732e-42b0-a8fd-9925e9a34ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bhc-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085ac96a-3faf-4131-8336-05857141ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4aa51079-05c4-4481-882a-fce405001a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_085ac96a-3faf-4131-8336-05857141ab59" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4aa51079-05c4-4481-882a-fce405001a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5a7dae33-bd26-4420-9c17-26c7dba40c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_6081c3e7-4258-4f2e-9ee4-fe43f5ea971b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5a7dae33-bd26-4420-9c17-26c7dba40c97" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_6081c3e7-4258-4f2e-9ee4-fe43f5ea971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_43a74cad-2c22-470c-9c0e-73d4a00e4ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_43a74cad-2c22-470c-9c0e-73d4a00e4ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_adebf620-9d54-437a-9aac-e6297bde6942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_UseOfEstimates_adebf620-9d54-437a-9aac-e6297bde6942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d4aecb26-f017-4d9b-834e-e53f6cbf547b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d4aecb26-f017-4d9b-834e-e53f6cbf547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_d7dbd299-834f-4fb1-b090-7874cc9a74a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_d7dbd299-834f-4fb1-b090-7874cc9a74a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_74a3c529-228d-49f7-be79-1583e01023ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_74a3c529-228d-49f7-be79-1583e01023ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_75444d35-1640-4ea9-8cf6-65eab821b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_75444d35-1640-4ea9-8cf6-65eab821b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_011d511f-b55a-4257-8715-45e6b3a19341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_011d511f-b55a-4257-8715-45e6b3a19341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0f77fdc0-4557-4d6b-a92a-e2d652c4cbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0f77fdc0-4557-4d6b-a92a-e2d652c4cbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_6503062d-75a5-40f9-942d-d9206aacdd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_6503062d-75a5-40f9-942d-d9206aacdd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_4b83443a-285f-4883-b3f3-b431677c6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_4b83443a-285f-4883-b3f3-b431677c6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_05aa8bbe-62f9-421c-af6a-578fa9d58a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_05aa8bbe-62f9-421c-af6a-578fa9d58a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8bf50bc5-6546-4255-bf47-f201ed324096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8bf50bc5-6546-4255-bf47-f201ed324096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_2067f573-edd6-4d53-9db0-5f6dbc6ca9c3" xlink:href="bhc-20221231.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_2067f573-edd6-4d53-9db0-5f6dbc6ca9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_7afe588a-9e35-4d52-b651-64b39689406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_7afe588a-9e35-4d52-b651-64b39689406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_31fcc9ae-9c6a-46dc-a13d-8a255379cfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_31fcc9ae-9c6a-46dc-a13d-8a255379cfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_343e010c-d17a-47eb-a51f-95403635a8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_343e010c-d17a-47eb-a51f-95403635a8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_77bb056e-cf9f-40bc-b6c5-8be389f00665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_77bb056e-cf9f-40bc-b6c5-8be389f00665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_97e072ab-c11e-442a-a408-2ec31c6caffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_97e072ab-c11e-442a-a408-2ec31c6caffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9b0d6f8e-d9e5-4a1a-ab6a-9e339c30c978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9b0d6f8e-d9e5-4a1a-ab6a-9e339c30c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ddd304c7-f5c7-46f2-8715-b3ca1f2b6f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ddd304c7-f5c7-46f2-8715-b3ca1f2b6f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_7bc8050a-4ee2-4000-9ae5-1fad897b9c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_7bc8050a-4ee2-4000-9ae5-1fad897b9c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c0aa2ba3-f628-42be-85fd-c0c80091517c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_c0aa2ba3-f628-42be-85fd-c0c80091517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b9deae95-c0d0-4795-be7f-a0e09b550077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b9deae95-c0d0-4795-be7f-a0e09b550077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock_fef5340a-ac6e-4230-84ce-4d3391a29e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_InterestExpensePolicyTextBlock_fef5340a-ac6e-4230-84ce-4d3391a29e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a05f028b-b7ce-4e68-880a-a5cc330a371a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a05f028b-b7ce-4e68-880a-a5cc330a371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_af51b978-71d7-4bd6-818a-d65007c4509c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_af51b978-71d7-4bd6-818a-d65007c4509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bd0fa0fc-d768-4a36-8303-bf42f41abaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bd0fa0fc-d768-4a36-8303-bf42f41abaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_3d214d8a-8832-4008-97fb-3c43bd86afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_3d214d8a-8832-4008-97fb-3c43bd86afa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_789092e4-de49-4bb3-bed7-92c6873c651b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_789092e4-de49-4bb3-bed7-92c6873c651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e280d1d-e70e-44f6-ab09-fe95d6727313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2e280d1d-e70e-44f6-ab09-fe95d6727313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_28925467-dbf8-49aa-b7d8-c19e65c24680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7412c51f-8453-43a6-8b9f-552738bc22f0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_28925467-dbf8-49aa-b7d8-c19e65c24680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d0043019-7454-4297-884e-cffe2da1677e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_eb46ea56-3066-41df-a140-43e18daaea9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0043019-7454-4297-884e-cffe2da1677e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_eb46ea56-3066-41df-a140-43e18daaea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_b5b1e610-8584-47f6-b7f7-4fc1244a1eff" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0043019-7454-4297-884e-cffe2da1677e" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_b5b1e610-8584-47f6-b7f7-4fc1244a1eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_e2539335-d2ff-4404-a7f2-3de1e2a0a7c0" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0043019-7454-4297-884e-cffe2da1677e" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_e2539335-d2ff-4404-a7f2-3de1e2a0a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_41b4f100-a5d7-48da-96f6-07420ae0caa6" xlink:href="bhc-20221231.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0043019-7454-4297-884e-cffe2da1677e" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_41b4f100-a5d7-48da-96f6-07420ae0caa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_91e958ce-143c-4c6a-a20f-2628c5813a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_91e958ce-143c-4c6a-a20f-2628c5813a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_84bf812f-0c53-437e-9549-5401e67df443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_84bf812f-0c53-437e-9549-5401e67df443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7b85b700-c7cf-4911-896b-5c786e1b3dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7b85b700-c7cf-4911-896b-5c786e1b3dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_f2986d54-9237-4d1a-8cbd-651ec4d777a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_f2986d54-9237-4d1a-8cbd-651ec4d777a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a4d067a0-a327-4036-8958-a412fbd9dd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d78fc5d-d650-4551-baad-3e369234e31f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a4d067a0-a327-4036-8958-a412fbd9dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bbfeb4b0-be36-4c61-9e24-e1741fd19634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b5aae5ae-b81e-498c-8b90-8fbcfe9ad16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bbfeb4b0-be36-4c61-9e24-e1741fd19634" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b5aae5ae-b81e-498c-8b90-8fbcfe9ad16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_05e5e242-dac7-4a37-bc04-767c4daed04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_60901f2d-a963-4e37-bb6a-22dc79356573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_05e5e242-dac7-4a37-bc04-767c4daed04e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_60901f2d-a963-4e37-bb6a-22dc79356573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fec4c42-0c9a-4671-8c87-8c79d1e49a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8b42a142-ec3a-49f9-8678-a3b236be679a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fec4c42-0c9a-4671-8c87-8c79d1e49a4b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8b42a142-ec3a-49f9-8678-a3b236be679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_a91a46e5-1531-4fbd-8799-d243ffaa0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fec4c42-0c9a-4671-8c87-8c79d1e49a4b" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_a91a46e5-1531-4fbd-8799-d243ffaa0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_455766af-d83d-45cc-9b11-793014a9d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fec4c42-0c9a-4671-8c87-8c79d1e49a4b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_455766af-d83d-45cc-9b11-793014a9d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_155dfffd-f5a2-453c-b49c-892c190a5164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fec4c42-0c9a-4671-8c87-8c79d1e49a4b" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_155dfffd-f5a2-453c-b49c-892c190a5164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a37ad65d-5227-4759-850c-b4c36270bf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d097c594-792c-4eee-984b-0a9e30de96b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a37ad65d-5227-4759-850c-b4c36270bf78" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d097c594-792c-4eee-984b-0a9e30de96b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c4ac8b67-b212-461d-97ed-bbd72931ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_bdbdda6a-df7c-4d33-adb1-e6e8bca54746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c4ac8b67-b212-461d-97ed-bbd72931ebce" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_bdbdda6a-df7c-4d33-adb1-e6e8bca54746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_594a9477-36eb-46bc-80e7-56b7ee409326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c4ac8b67-b212-461d-97ed-bbd72931ebce" xlink:to="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_594a9477-36eb-46bc-80e7-56b7ee409326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_68b66d8f-4d38-42b8-b042-d99b0a245527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c4ac8b67-b212-461d-97ed-bbd72931ebce" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_68b66d8f-4d38-42b8-b042-d99b0a245527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_d6254d22-9d92-4e00-9506-add378ba8db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_d6254d22-9d92-4e00-9506-add378ba8db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4be3a61e-ece1-44be-b5c9-7e3cf25c4940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4be3a61e-ece1-44be-b5c9-7e3cf25c4940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_1d67723f-dc8d-4ad0-b0fd-348660c12c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_1d67723f-dc8d-4ad0-b0fd-348660c12c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_69f53e93-2a86-4fdf-ac5d-8d9aed5c6287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_69f53e93-2a86-4fdf-ac5d-8d9aed5c6287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_9a6ab4b5-9f3b-4747-8a4c-746a5bd0d490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_9a6ab4b5-9f3b-4747-8a4c-746a5bd0d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_056800a4-4e84-4bed-8b88-e23a13972c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_056800a4-4e84-4bed-8b88-e23a13972c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_82b0f368-7431-4b42-b729-71a047d42229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_82b0f368-7431-4b42-b729-71a047d42229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_3d27a70a-2980-4946-ad6a-10984c48d025" xlink:href="bhc-20221231.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8a02eaf8-b080-4149-a4a7-fa6a1e9c8b40" xlink:to="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_3d27a70a-2980-4946-ad6a-10984c48d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0a40fc4-5c48-4da8-b002-2b7a508c9a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_5dd045d7-4dc9-48cb-ba86-4ef006d2fdb4" xlink:href="bhc-20221231.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0a40fc4-5c48-4da8-b002-2b7a508c9a0e" xlink:to="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_5dd045d7-4dc9-48cb-ba86-4ef006d2fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2d7ece7f-14e5-49eb-9d1e-90f16db4c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0a40fc4-5c48-4da8-b002-2b7a508c9a0e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2d7ece7f-14e5-49eb-9d1e-90f16db4c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_061a41aa-89ab-4a74-89b6-e57dfcbf0ba4" xlink:href="bhc-20221231.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0a40fc4-5c48-4da8-b002-2b7a508c9a0e" xlink:to="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_061a41aa-89ab-4a74-89b6-e57dfcbf0ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_01f8ff0b-a58f-4c10-8667-827f4e9e410b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0a40fc4-5c48-4da8-b002-2b7a508c9a0e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_01f8ff0b-a58f-4c10-8667-827f4e9e410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_eaea3973-4fe4-4db7-b04a-91736818d0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_eaea3973-4fe4-4db7-b04a-91736818d0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb2c5c76-45aa-4da3-9cae-0f3ced13b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb2c5c76-45aa-4da3-9cae-0f3ced13b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2711eb07-87da-40f7-9e5b-33c6f518057b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2711eb07-87da-40f7-9e5b-33c6f518057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_42cdaa38-ddd5-481a-9aaa-a370b85386c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_42cdaa38-ddd5-481a-9aaa-a370b85386c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_31685536-9bfe-4054-87aa-a36cbce44d4a" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_31685536-9bfe-4054-87aa-a36cbce44d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_80d7c8eb-ab51-4362-bbe5-1a9852866a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be7809e5-4c2e-4bca-b17b-3c9eeabd36df" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_80d7c8eb-ab51-4362-bbe5-1a9852866a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_74835e41-98ac-44b8-a32a-096afe5c16fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_abb5b1a0-49df-4f6c-a78e-ae2d2230e52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_74835e41-98ac-44b8-a32a-096afe5c16fc" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_abb5b1a0-49df-4f6c-a78e-ae2d2230e52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_034dd189-ef17-48cf-820d-3c6b4a4d691e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_45d463c1-5acd-4bf7-bccd-d6de8b4896b4" xlink:href="bhc-20221231.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_034dd189-ef17-48cf-820d-3c6b4a4d691e" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_45d463c1-5acd-4bf7-bccd-d6de8b4896b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_6e3d6476-3d78-4709-9c18-528159615636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_8e534c57-0fc6-4569-bf08-5fce16227b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_6e3d6476-3d78-4709-9c18-528159615636" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_8e534c57-0fc6-4569-bf08-5fce16227b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_63c43f89-ed5a-4100-91f5-1a62ea908714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_63c43f89-ed5a-4100-91f5-1a62ea908714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_33cf6bc5-de7a-494a-9822-c7367c8b924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_33cf6bc5-de7a-494a-9822-c7367c8b924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79f2884e-8fcf-4c3d-9fc6-55ed425666a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_79f2884e-8fcf-4c3d-9fc6-55ed425666a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_982c06c4-1cac-4b3f-ab09-f5f117be9645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_982c06c4-1cac-4b3f-ab09-f5f117be9645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_f0e5c299-38cf-467b-99c8-e00a6bd0ead2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_f0e5c299-38cf-467b-99c8-e00a6bd0ead2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80c7c617-5476-46e1-83a1-57dc29569604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68453912-5859-4e16-bce7-0bd2fca3f202" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_80c7c617-5476-46e1-83a1-57dc29569604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20221231.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_03268361-03e6-4912-9a91-c86bf57b2bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9864c04e-3118-4316-8ef1-4af10a4c9132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_03268361-03e6-4912-9a91-c86bf57b2bc1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9864c04e-3118-4316-8ef1-4af10a4c9132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b2a049f5-fa44-4569-b0e6-6b5f64b98170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_23b5cdc5-1f2a-49a4-b0b1-71b19c65a204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b2a049f5-fa44-4569-b0e6-6b5f64b98170" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_23b5cdc5-1f2a-49a4-b0b1-71b19c65a204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_abbafd18-c5a0-4536-8165-75a9ffd9cc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_abbafd18-c5a0-4536-8165-75a9ffd9cc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_d57aaecb-d046-4896-90d0-09e049deb6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_d57aaecb-d046-4896-90d0-09e049deb6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ae2f7ebd-98a8-4647-95e0-1ed451648c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ae2f7ebd-98a8-4647-95e0-1ed451648c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_c22b54d1-047e-492d-84e1-c6d116acfbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_c22b54d1-047e-492d-84e1-c6d116acfbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_a5d6971f-ae5a-4cb9-9604-8ed1386424b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_a5d6971f-ae5a-4cb9-9604-8ed1386424b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_41febec7-c578-4246-96f2-09e103b44276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b3a2ed06-a844-4ef3-9138-a86282fe738b" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_41febec7-c578-4246-96f2-09e103b44276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59e6737e-11f0-46da-91c5-8be06c532b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_0f68b89b-eb1f-45fc-9257-bff8b60da763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59e6737e-11f0-46da-91c5-8be06c532b9c" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_0f68b89b-eb1f-45fc-9257-bff8b60da763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59e6737e-11f0-46da-91c5-8be06c532b9c" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:to="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9822fc03-e2d9-44af-85d4-86ff4d2b6830" xlink:to="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_575e3399-b32e-4eb6-b4b2-64f88581c4cf" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_cfbb5d27-7924-4254-af29-5a99fb2b4edd" xlink:to="loc_bhc_BauschLombMember_575e3399-b32e-4eb6-b4b2-64f88581c4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_9d8edf69-9ef4-4e14-bfce-e958b9f7cbfa" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b9f07a97-96b8-4ce8-9310-41de921a1f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_216002ee-73b0-456a-a6ce-731f58260c96" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b9f07a97-96b8-4ce8-9310-41de921a1f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c158d91-e059-4fd3-86f2-0c61d5168da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c158d91-e059-4fd3-86f2-0c61d5168da0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9006133e-0019-4af4-86f3-6bdb8ed9cd81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:href="bhc-20221231.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0f1bea76-2ca8-49e5-abd2-78e8d21b236b" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ddfa9f74-5c1a-4f66-a567-f5c809c8340b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:to="loc_us-gaap_IPOMember_ddfa9f74-5c1a-4f66-a567-f5c809c8340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_187ae33a-7b4e-4526-9350-e474b448b654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_285acd6d-b7d8-4d74-a21f-c795925d201d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_187ae33a-7b4e-4526-9350-e474b448b654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:to="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_99c4df25-14c5-446b-91bf-a8b8b0a05522" xlink:to="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2666b61c-5bd2-4cc7-b6c0-63b6a16de958" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e23e7db5-f0b1-4253-8ab9-99a773f7f691" xlink:to="loc_bhc_BauschLombMember_2666b61c-5bd2-4cc7-b6c0-63b6a16de958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_bca0b5d5-4939-4790-a4ab-d75a1aba3edd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a6ae39a-734e-4e76-a7fd-7968ade0803a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4a6ae39a-734e-4e76-a7fd-7968ade0803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bc8c8d8d-8c2e-45ab-9a20-b584034ae431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bc8c8d8d-8c2e-45ab-9a20-b584034ae431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_88dd4968-c80f-48e6-8ce9-6b23e1e245a0" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_88dd4968-c80f-48e6-8ce9-6b23e1e245a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_a95031ca-9752-4396-a707-07fcaf746da4" xlink:href="bhc-20221231.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_a95031ca-9752-4396-a707-07fcaf746da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64a83150-af5c-42db-9cbc-118de14699d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64a83150-af5c-42db-9cbc-118de14699d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_bd0cde7a-ef35-4458-9df2-97db5a244824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_bd0cde7a-ef35-4458-9df2-97db5a244824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a80bb32b-c29d-4e97-aabe-db8f2d8f420b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_70605241-15f7-45f9-b7f6-c0de62ec68bc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a80bb32b-c29d-4e97-aabe-db8f2d8f420b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5992054b-640b-4a43-bf14-11a66f919013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5992054b-640b-4a43-bf14-11a66f919013" xlink:to="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_85df26e8-0ae4-4e6d-8333-fa4b5cac4f31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8b939b85-b77d-41c9-8870-76fbdf377b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e76617da-013d-49e9-b625-0dd43014efd7" xlink:to="loc_us-gaap_AccountsReceivableMember_8b939b85-b77d-41c9-8870-76fbdf377b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fb06a026-64a4-4f15-8329-dd6181852d7c" xlink:to="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_a5fdbf68-3e3b-4d50-ac9e-10155814a812" xlink:href="bhc-20221231.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_74d0a59c-4343-497b-9209-da1a72ddf843" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_a5fdbf68-3e3b-4d50-ac9e-10155814a812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d48a5ad4-a197-4cc1-acec-530082223d01" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_56f8dfb8-1218-4ff1-96d0-6b1f3d7dd4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2cefe157-7a8c-4fde-9875-f42a90e2a45f" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_56f8dfb8-1218-4ff1-96d0-6b1f3d7dd4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8917d2fa-c74c-4a8f-b11c-80ef029dc462" xlink:to="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_62b47a6e-78a6-4a03-bd47-a9884444477c" xlink:href="bhc-20221231.xsd#bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a4528bcb-8419-4435-9db4-9a12aa0a9392" xlink:to="loc_bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember_62b47a6e-78a6-4a03-bd47-a9884444477c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_98e6c552-d0cb-4ac2-b82f-ac9cd734f35d" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_1c0a5be3-edd2-4615-b8e0-ecf8b0c85a57" xlink:href="bhc-20221231.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_1c0a5be3-edd2-4615-b8e0-ecf8b0c85a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_c0bfc1ad-7375-40d9-8e54-1f3047ca73ac" xlink:href="bhc-20221231.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_c0bfc1ad-7375-40d9-8e54-1f3047ca73ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_6d5ece1d-3626-4818-8fc4-77c75eab009d" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_6d5ece1d-3626-4818-8fc4-77c75eab009d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_045d2b20-dc68-4f45-a838-8741abb6972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_045d2b20-dc68-4f45-a838-8741abb6972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2277d71b-93c1-48d5-9fba-60ef56293adb" xlink:href="bhc-20221231.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_2277d71b-93c1-48d5-9fba-60ef56293adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_b45b4da0-0693-4ae1-ba81-7870fd65ea4a" xlink:href="bhc-20221231.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_PeriodReceivableOutstanding_b45b4da0-0693-4ae1-ba81-7870fd65ea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_52abaf41-bc4c-4ebc-9546-cad398e17bea" xlink:href="bhc-20221231.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5a5eebef-ce4f-4e82-95df-c59317eae97c" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_52abaf41-bc4c-4ebc-9546-cad398e17bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82f66a99-f516-46eb-af14-b09b12733d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_892bfc4a-f094-4ada-a915-2af92ed5d99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82f66a99-f516-46eb-af14-b09b12733d63" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_892bfc4a-f094-4ada-a915-2af92ed5d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82f66a99-f516-46eb-af14-b09b12733d63" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_b5012b8b-4869-4f67-aea6-2e9b21da22b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_b5012b8b-4869-4f67-aea6-2e9b21da22b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_a3091caf-fae6-4367-b4c4-ab0288ca8cda" xlink:href="bhc-20221231.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_a3091caf-fae6-4367-b4c4-ab0288ca8cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a2924bd1-2d6a-4621-b4ea-defa9a904611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a2924bd1-2d6a-4621-b4ea-defa9a904611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_44556105-4637-4742-baf7-7449a48bb5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_44556105-4637-4742-baf7-7449a48bb5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_4cbf8660-6e73-4a32-b207-8b38d4893321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_4cbf8660-6e73-4a32-b207-8b38d4893321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_24f46ea1-a1a1-4790-a17a-43fe8caf73ec" xlink:href="bhc-20221231.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_24f46ea1-a1a1-4790-a17a-43fe8caf73ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_52f36bab-2220-4b1b-b8ad-aef0fa4bb0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_45e4c056-5cd9-4fee-b9b5-63183db17f33" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_52f36bab-2220-4b1b-b8ad-aef0fa4bb0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8200609-8946-4036-ba24-270f62130c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8200609-8946-4036-ba24-270f62130c19" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:to="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b910320-5824-4f7b-8473-46b72b9caed8" xlink:to="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_883557fe-38fd-4d20-9c78-5bb8506af49b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:to="loc_srt_MinimumMember_883557fe-38fd-4d20-9c78-5bb8506af49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae01a2f4-26a1-4c42-9159-e2fd10373729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f680734-b5fc-41df-9408-1786212b48a0" xlink:to="loc_srt_MaximumMember_ae01a2f4-26a1-4c42-9159-e2fd10373729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce958865-c399-4929-b819-96d82f0c73a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_723fdf52-0464-4ee1-b00e-9620a138e5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_LandImprovementsMember_723fdf52-0464-4ee1-b00e-9620a138e5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_281a457b-0ef2-4df1-afa2-bc46a95812f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_281a457b-0ef2-4df1-afa2-bc46a95812f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e559de1b-b29a-4322-ac04-38c6cb58cc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e559de1b-b29a-4322-ac04-38c6cb58cc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_da7ed1b5-55a5-45c4-bbe1-79ebe59549db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_da7ed1b5-55a5-45c4-bbe1-79ebe59549db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_b98b5cd3-4db7-425e-afde-d617f05f742c" xlink:href="bhc-20221231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_b98b5cd3-4db7-425e-afde-d617f05f742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3e4d52d8-beb6-48cb-9b72-8e29bc4753cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_61ad7e47-2b31-4e9a-a8e0-9b3ad457ecfa" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_3e4d52d8-beb6-48cb-9b72-8e29bc4753cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_024b7079-4132-4de3-8697-aacd9281fd63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c795db2d-d44a-4332-862a-b493e77ad015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cd3fa2c2-0ec2-4500-8eea-7c54f84987a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c795db2d-d44a-4332-862a-b493e77ad015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7c247ce1-b5f1-40e0-9260-3aff75b0e177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c247ce1-b5f1-40e0-9260-3aff75b0e177" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:to="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d52f03d5-d8e1-4aec-b06c-5c52c2492d18" xlink:to="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5b9c5df-518b-4167-9a8b-118c28750f09" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:to="loc_srt_MinimumMember_b5b9c5df-518b-4167-9a8b-118c28750f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2cc8c17c-9c38-4c57-801c-eba9fe09a761" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39f71b72-6d1b-4b4a-ba7e-68c8abfb4a71" xlink:to="loc_srt_MaximumMember_2cc8c17c-9c38-4c57-801c-eba9fe09a761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fda4bb68-0899-45d5-8c64-a02961fea0d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_cb260426-a5d5-4cd2-9688-ca4b14820e70" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_ProductBrandsMember_cb260426-a5d5-4cd2-9688-ca4b14820e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7a37fb4c-7465-4988-a474-cbbaa7236312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_us-gaap_TradeNamesMember_7a37fb4c-7465-4988-a474-cbbaa7236312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_7e9d98a4-7e42-4e42-ad81-2f9c7153ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_us-gaap_ContractualRightsMember_7e9d98a4-7e42-4e42-ad81-2f9c7153ddb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ce0b19c3-7702-4a26-93b6-c1eef44bfe87" xlink:href="bhc-20221231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_PartnerRelationshipsMember_ce0b19c3-7702-4a26-93b6-c1eef44bfe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_f88d3456-ec44-45e2-8cd0-38d38959ea97" xlink:href="bhc-20221231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7dd5c77c-00de-4db5-a2b3-e6d4064aa4f1" xlink:to="loc_bhc_OutLicensedTechnologyMember_f88d3456-ec44-45e2-8cd0-38d38959ea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_27516f3c-af18-4fb8-814f-372ae462b99c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99922bc2-8094-431c-adce-d73a982fa19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b9d245a-b473-4997-b5ec-e3b0cb0e62fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99922bc2-8094-431c-adce-d73a982fa19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d0eca93b-e221-4908-a138-f5c70e8969a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d0eca93b-e221-4908-a138-f5c70e8969a4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_17f5ece1-d16a-47c3-bb5f-f0ad998df111" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_31bda5c7-ced5-4f48-ae80-658576537fca" xlink:href="bhc-20221231.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_31bda5c7-ced5-4f48-ae80-658576537fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_b68e4b90-c57b-47f8-adc1-d778c9772283" xlink:href="bhc-20221231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_b68e4b90-c57b-47f8-adc1-d778c9772283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_4cfd9f81-cbae-4f05-be64-5a1c5d591cf2" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForRebatesMember_4cfd9f81-cbae-4f05-be64-5a1c5d591cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_859633fc-146d-45ff-96e4-6a32c7f55df8" xlink:href="bhc-20221231.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForChargebacksMember_859633fc-146d-45ff-96e4-6a32c7f55df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_b9c6ab63-8ddb-497e-8fdf-ee33be66037a" xlink:href="bhc-20221231.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0e1ad40-d4f1-43c0-9509-bf883644e3dc" xlink:to="loc_bhc_ReserveForDistributionFeesMember_b9c6ab63-8ddb-497e-8fdf-ee33be66037a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_80bc09e3-879d-4b78-a026-35e237a2d825" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_094b783e-5932-47e9-bfdb-bf7fe4aa0c25" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3ae0da2-7ecd-4f35-a43f-92dfb007ceb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3ae0da2-7ecd-4f35-a43f-92dfb007ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_8d27e7a9-c0f7-4181-a938-10e7d15e95de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_8d27e7a9-c0f7-4181-a938-10e7d15e95de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b5015dc-9f7b-4533-ad97-7d9926f554e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_0b5015dc-9f7b-4533-ad97-7d9926f554e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6c86172-75f2-4d5a-ab06-538296cb7614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a089d01b-b92f-4605-8369-5de3a8fa3cdf" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6c86172-75f2-4d5a-ab06-538296cb7614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4c97d647-f93b-496e-b2fe-8c31924862ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4c97d647-f93b-496e-b2fe-8c31924862ae" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a5923549-93a8-48c5-ac91-8c887721abea" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_5e395771-09e4-4f99-9635-796eaf2943d5" xlink:href="bhc-20221231.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_5e395771-09e4-4f99-9635-796eaf2943d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_a67e5bbf-e367-44f8-ba03-b27506212a55" xlink:href="bhc-20221231.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_27951c55-dd6b-4120-a238-663629062fd2" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_a67e5bbf-e367-44f8-ba03-b27506212a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6e1f5909-84a9-4b7b-b479-afd187603e90" xlink:to="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87b38656-e9ca-48b7-80db-81a05a5aef3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:to="loc_srt_MinimumMember_87b38656-e9ca-48b7-80db-81a05a5aef3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92f46c5c-f018-41c2-94c6-652ca9517e01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ba209ab-af29-4aba-bb71-c5588a494038" xlink:to="loc_srt_MaximumMember_92f46c5c-f018-41c2-94c6-652ca9517e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0fad7249-e746-490e-b0b6-6d1337610281" xlink:to="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_43d52fba-04e1-4b78-9949-5fe333f0c4e5" xlink:href="bhc-20221231.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_080284c0-7014-45ca-80ec-146082866b86" xlink:to="loc_bhc_PriceAppreciationCreditMember_43d52fba-04e1-4b78-9949-5fe333f0c4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a56e91ca-b863-4fbe-bf48-2670e87dc3af" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8034afba-c5ac-41a3-8e23-0acdc8e42cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8034afba-c5ac-41a3-8e23-0acdc8e42cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_90e1218d-f054-4a5a-9392-e1a7ed6d2f3c" xlink:href="bhc-20221231.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_90e1218d-f054-4a5a-9392-e1a7ed6d2f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5b8448bd-2b36-4fb7-acca-e9e34d834691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5b8448bd-2b36-4fb7-acca-e9e34d834691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_e8a4bcca-df2a-40c2-896f-f18bfce0e05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_e8a4bcca-df2a-40c2-896f-f18bfce0e05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7cd1fb3-96de-4c9b-ae69-20a10a940838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7cd1fb3-96de-4c9b-ae69-20a10a940838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_d82d3aae-e3a1-4e66-b0d7-3377ebf65cba" xlink:href="bhc-20221231.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_bf1c618a-a97d-42a6-afcf-32b3bb1dc3a4" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_d82d3aae-e3a1-4e66-b0d7-3377ebf65cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_155a8757-3bc2-4119-a9b2-14725cb76011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_155a8757-3bc2-4119-a9b2-14725cb76011" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:to="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c4d7c760-ab24-4eb2-9aa4-cc951a9d3925" xlink:to="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c227b54c-31f5-4ff0-958f-a9c22c84de25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:to="loc_srt_MinimumMember_c227b54c-31f5-4ff0-958f-a9c22c84de25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b03e5a31-754a-48b8-9bba-099b494e1ab3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_133dd924-ec9d-4669-b24f-300f2484beab" xlink:to="loc_srt_MaximumMember_b03e5a31-754a-48b8-9bba-099b494e1ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7935a521-5a96-4069-a12e-d475b017fdc1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_db7d83b5-1f55-46ed-87e1-004671c27d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_db7d83b5-1f55-46ed-87e1-004671c27d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3fb6078-dd1a-4ba3-884c-6674ad061416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a1c38fea-5929-494b-9fc9-85d7bd6fe87d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3fb6078-dd1a-4ba3-884c-6674ad061416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82367713-8ede-4e02-a0bd-1f3d46cd1451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_f3d77bb4-8efd-4a24-8f6c-6f7c97a9c65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82367713-8ede-4e02-a0bd-1f3d46cd1451" xlink:to="loc_us-gaap_AdvertisingExpense_f3d77bb4-8efd-4a24-8f6c-6f7c97a9c65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fb476a0-2cc7-43fc-a67d-22ce55d08df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_fb9cc6e0-891f-4f1a-9a9c-ba298f411c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fb476a0-2cc7-43fc-a67d-22ce55d08df4" xlink:to="loc_us-gaap_InterestCostsCapitalized_fb9cc6e0-891f-4f1a-9a9c-ba298f411c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e0ca8e31-aa91-4113-9e6b-954672bbe0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_1e96fe7c-8886-4cb0-9db5-0b9a538e5b40" xlink:href="bhc-20221231.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0ca8e31-aa91-4113-9e6b-954672bbe0d5" xlink:to="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_1e96fe7c-8886-4cb0-9db5-0b9a538e5b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_a732bc8d-1ee2-4482-8f2f-ac1b7862e8ac" xlink:href="bhc-20221231.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0ca8e31-aa91-4113-9e6b-954672bbe0d5" xlink:to="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_a732bc8d-1ee2-4482-8f2f-ac1b7862e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c9a436c-4899-4343-9919-8bb65320bc10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_2bc49c09-bb90-4ecb-b3e2-def532956ede" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c9a436c-4899-4343-9919-8bb65320bc10" xlink:to="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_2bc49c09-bb90-4ecb-b3e2-def532956ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c692b0a-70ae-4186-846f-b2d4c4337e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c692b0a-70ae-4186-846f-b2d4c4337e0d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_34715f67-defa-4600-8947-0e07522beae9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a240301d-01af-4f41-910c-b0900a4af0f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_45c7bdfb-e9a2-4034-9f05-a947b8ff7f4b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a240301d-01af-4f41-910c-b0900a4af0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15734290-f31c-4866-96b8-48e26b386af9" xlink:to="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19eff5ec-73e9-482c-8f52-8fa71b4a5993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d4f92b3-bcb9-4f9f-a5fb-ec87aafb336b" xlink:to="loc_us-gaap_RetainedEarningsMember_19eff5ec-73e9-482c-8f52-8fa71b4a5993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6f6ca342-73b2-4f10-bef4-be20e1abb9dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5be90d4-3f38-4476-9886-66cec5fd7d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7efbba53-cc72-4634-9623-fad84ebbc249" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d5be90d4-3f38-4476-9886-66cec5fd7d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0fd29e76-f12e-4230-a63c-5ee8ffe01034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0fd29e76-f12e-4230-a63c-5ee8ffe01034" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2d94762d-7937-45ad-b7bf-afb9157a694e" xlink:to="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_979e5e42-42f0-43aa-8b2b-c1c9821ccbb7" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d4c284b5-bfe4-4fab-8916-a510cf169bab" xlink:to="loc_bhc_BauschLombMember_979e5e42-42f0-43aa-8b2b-c1c9821ccbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationAxis_5c63bdcc-3be0-431f-91af-d7a3e7b5cee7" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_2582b039-5f3d-4344-8ed1-673b2052b384" xlink:href="bhc-20221231.xsd#bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationDomain_62649600-9625-41cd-b1a9-a5b10196d03d" xlink:to="loc_bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember_2582b039-5f3d-4344-8ed1-673b2052b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f11e7acc-9082-4119-872a-bae2f59b5a8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_0854ae34-78ec-4fae-bb9b-9d294791c724" xlink:href="bhc-20221231.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:to="loc_bhc_AssetImpairmentChargesMember_0854ae34-78ec-4fae-bb9b-9d294791c724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_f0ca14de-1a81-4d2e-aab2-2a9c73b6b00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4989c497-4261-4ce1-a1c6-065a5c57e953" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_f0ca14de-1a81-4d2e-aab2-2a9c73b6b00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8c170aba-0684-4be3-a411-5e2247382d81" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e7c95f71-5676-4228-a989-e9a3c8b4c4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0692c955-bec2-488c-9823-9ac1a3d8732f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e7c95f71-5676-4228-a989-e9a3c8b4c4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_340f0fe4-97f9-45cf-b04b-7d140b42b147" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_3a514df7-fa56-4fcb-9e59-7cd8513154c6" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b04aa24b-155f-4d23-8b84-515c97c4afb4" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_3a514df7-fa56-4fcb-9e59-7cd8513154c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:href="bhc-20221231.xsd#bhc_AssetAcquisitionAndBusinessCombinationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationTable_761f72c3-186e-4c8a-80eb-e595ec06ee45" xlink:to="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a2ae4a01-ac98-488a-90c5-6b08df0040da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a2ae4a01-ac98-488a-90c5-6b08df0040da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0293b5a2-0ce4-4d3d-a3ed-b8955bec6ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_InventoryNet_0293b5a2-0ce4-4d3d-a3ed-b8955bec6ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_37dafb47-96dd-4669-a86a-a0984a9c5520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_37dafb47-96dd-4669-a86a-a0984a9c5520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_580da42e-edb4-4186-a9e9-42808c9deaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_580da42e-edb4-4186-a9e9-42808c9deaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6cc8d572-4ed2-46b6-99ea-28029efdafc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_Goodwill_6cc8d572-4ed2-46b6-99ea-28029efdafc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a629ced9-6515-4c38-a2c7-36f77a34e514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a629ced9-6515-4c38-a2c7-36f77a34e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6081d7b8-5852-450f-a3fc-8958f922fcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_6081d7b8-5852-450f-a3fc-8958f922fcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5b89c536-1466-449c-81d0-ce45102a1e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_5b89c536-1466-449c-81d0-ce45102a1e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_72c921c0-c41a-4c10-b790-a2e9a532a063" xlink:href="bhc-20221231.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAndBusinessCombinationLineItems_fa7422d1-939c-4dfd-9ab4-36e14d6d38d8" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_72c921c0-c41a-4c10-b790-a2e9a532a063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a1c8da2e-eb0b-4eda-8ffc-5820650fc085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a1c8da2e-eb0b-4eda-8ffc-5820650fc085" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_dbae514c-93b8-4802-9c1d-b6f7976f0656" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_94ef97da-5212-4fc3-bbfa-f6829392fb0c" xlink:href="bhc-20221231.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_94ef97da-5212-4fc3-bbfa-f6829392fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_b2bc3b9b-9d17-4903-9749-6b8cd0d528c0" xlink:href="bhc-20221231.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_44d7ec64-72d6-4036-b420-7026fc94491a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_b2bc3b9b-9d17-4903-9749-6b8cd0d528c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b0bc5887-2b7a-4783-ac2c-331cfcd0537c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_c17c53a6-286a-42e1-9208-95dd86221482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringReserve_c17c53a6-286a-42e1-9208-95dd86221482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_fea6cb30-f1b7-4ca6-ad49-4cb935e940f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_fea6cb30-f1b7-4ca6-ad49-4cb935e940f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_0d27153e-d2ee-4f10-9c12-09cdaf0495c3" xlink:href="bhc-20221231.xsd#bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_0d27153e-d2ee-4f10-9c12-09cdaf0495c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f1e13ef0-07b7-424f-91bd-3897c31da8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_PaymentsForRestructuring_f1e13ef0-07b7-424f-91bd-3897c31da8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2c4c5e9b-615f-42ba-9f48-cc8709a08528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_RestructuringCharges_2c4c5e9b-615f-42ba-9f48-cc8709a08528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d04b617-d027-4a1c-ae00-64cef99e098e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_648ec5e1-5ae2-48a7-bf29-9eb96b40cf69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d04b617-d027-4a1c-ae00-64cef99e098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c1735bbf-a005-49c5-aa25-377627e260fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c1735bbf-a005-49c5-aa25-377627e260fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b47adf7c-1318-4ed5-84f7-87d261b56717" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0a704e-4a2b-48bc-bb1e-94eae423591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b5468cbf-3bbc-4285-b5f3-dc4b955af134" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0a704e-4a2b-48bc-bb1e-94eae423591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aeb18773-3b70-4b14-8b86-049385590fe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_75e070fa-7e94-4bb9-8960-3678027383b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_75e070fa-7e94-4bb9-8960-3678027383b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eaec7d04-34cb-40b9-9f79-1e6871b1d81e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eaec7d04-34cb-40b9-9f79-1e6871b1d81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4d99263d-927c-4c3d-9a41-bc905d63357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0b314d3-ac8e-40f6-8c40-83bd728a0f77" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4d99263d-927c-4c3d-9a41-bc905d63357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_cb681537-c48c-45b4-9afa-f6955f9fd734" xlink:to="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1a92948b-4e14-416b-9805-0e7a185667ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_45b630a7-13fd-4db2-8932-c8eea0e57f48" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1a92948b-4e14-416b-9805-0e7a185667ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_510eb5c4-a57d-4d5f-ae24-6b8197204291" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_b8359a1b-2eb6-43ea-affa-623160285da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:to="loc_us-gaap_CurrencySwapMember_b8359a1b-2eb6-43ea-affa-623160285da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c5a0d2e7-f587-4e17-8757-4ae736cd44b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6a1f5afc-f0bd-453b-b2cb-8ec71c433ba6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c5a0d2e7-f587-4e17-8757-4ae736cd44b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_0bb6d527-44dc-4be4-9ee6-611b87be1627" xlink:to="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8380d4f8-85cc-4582-9f39-dea63e1a065c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:to="loc_us-gaap_NondesignatedMember_8380d4f8-85cc-4582-9f39-dea63e1a065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b4772e7a-1bc6-4427-8363-c9f79bc4f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_909e7474-de24-4701-9984-a1bed8b6e489" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b4772e7a-1bc6-4427-8363-c9f79bc4f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4ba47443-2d0a-4279-a892-dd2037b0b51f" xlink:to="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_4a553dbb-b4a6-436d-ba0d-560f80681fc9" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_891bd921-8b60-4d14-afa1-0f47fda52a5f" xlink:to="loc_bhc_BauschLombMember_4a553dbb-b4a6-436d-ba0d-560f80681fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bb924bf-f594-4c1a-84be-66813b74a234" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d3c1bfe-018a-40ab-9aca-058547952fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2d3c1bfe-018a-40ab-9aca-058547952fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_1b451252-a825-489e-a111-e63453628ab7" xlink:href="bhc-20221231.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_1b451252-a825-489e-a111-e63453628ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6d897619-97cb-4abd-9991-f7296ce2f515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_4f3a872d-dfd0-406d-ade0-206ce458948a" xlink:to="loc_us-gaap_DerivativeAssets_6d897619-97cb-4abd-9991-f7296ce2f515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b80f419f-ce5b-4671-a11e-965852d07e7f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_d76a034a-703a-47e0-b47a-f41658b64869" xlink:href="bhc-20221231.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_d76a034a-703a-47e0-b47a-f41658b64869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4a4d80db-3f61-4546-b14f-e38da42e1be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_71c3a41a-4da7-4398-836c-d99fd1ad1b43" xlink:to="loc_us-gaap_DerivativeLiabilities_4a4d80db-3f61-4546-b14f-e38da42e1be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dba67113-c9ca-4d58-9a59-e73535f6ee18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dba67113-c9ca-4d58-9a59-e73535f6ee18" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0ff08aff-5bba-4429-8996-338e10fb0286" xlink:to="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c5644ba5-1090-4c3d-acce-a8d2c02971b8" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_69a002d0-8ecb-46a5-a1e1-d4d78b966179" xlink:to="loc_bhc_BauschLombMember_c5644ba5-1090-4c3d-acce-a8d2c02971b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a24c1bd4-ebf2-4171-a45f-96da5d2c76e6" xlink:to="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_d2aa6716-19bd-4093-954a-b688ab87ef82" xlink:href="bhc-20221231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_075bf1d3-c8c6-4f45-889d-31930e568742" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_d2aa6716-19bd-4093-954a-b688ab87ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_1d82e076-d0fd-41a2-bc10-18aa16ab1818" xlink:to="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_60be3031-37fd-450d-954e-20bba72f65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_fe73f711-282a-4cd0-be8a-d45497d6df49" xlink:to="loc_us-gaap_SettledLitigationMember_60be3031-37fd-450d-954e-20bba72f65bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b478faeb-4b4a-4a1d-828c-0c053123e182" xlink:to="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_7b201b24-5e50-44f1-b86e-eb1cd482199d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9224e3ba-c799-4054-bc0c-9beee50ac008" xlink:to="loc_stpr_NJ_7b201b24-5e50-44f1-b86e-eb1cd482199d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0f8d0c31-37ee-4372-aaf6-16c328a3a031" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_ec7d4b58-8c85-4aa1-b2f6-b8bcc722ce71" xlink:href="bhc-20221231.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_ec7d4b58-8c85-4aa1-b2f6-b8bcc722ce71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d62867e1-c6fc-4f97-a2f2-d489356ce643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d62867e1-c6fc-4f97-a2f2-d489356ce643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ab6976e6-1b70-4541-9fe5-ede466403374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ab6976e6-1b70-4541-9fe5-ede466403374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_809ec73c-6984-4dfc-93aa-348c463149fb" xlink:href="bhc-20221231.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_809ec73c-6984-4dfc-93aa-348c463149fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_b4be1d51-5c62-4e84-972f-87e4f2f29e5b" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_b4be1d51-5c62-4e84-972f-87e4f2f29e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_18e58cda-ff22-4339-b580-eca78eea9b1b" xlink:href="bhc-20221231.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1b1b011-15ec-49c8-8b39-7a27dd7a96ed" xlink:to="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_18e58cda-ff22-4339-b580-eca78eea9b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cce724e7-6d9a-4074-a1cf-cf3de4202e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cce724e7-6d9a-4074-a1cf-cf3de4202e58" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4708f14-4aee-49f9-89bd-5f6ffa452cc6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2a2e088-4af5-41c3-ab45-436d9b553872" xlink:to="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_b293196f-ee41-4f23-a129-3021e6172b21" xlink:href="bhc-20221231.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencySwapMember_ade47b70-c547-4843-b7aa-c9653954aca3" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_b293196f-ee41-4f23-a129-3021e6172b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c80f8a87-157a-417c-a196-59458b2c708c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_03d38411-b44f-4e44-b932-c917440aa2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_e24b9b0f-cc81-4ed9-b52e-384b93d9c3b4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_03d38411-b44f-4e44-b932-c917440aa2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1a57bd02-ef2f-4904-b875-c6060bb6b241" xlink:to="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_535e8a4c-ac06-4132-be0e-6b7aacf0ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e110f371-4046-4617-910a-4273242d4624" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_535e8a4c-ac06-4132-be0e-6b7aacf0ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c2cc47eb-50ec-4927-81b1-8b78993e1e7c" xlink:to="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_9744f85d-d586-4349-a54b-053663356067" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3f7e537d-ca80-4608-8d83-b48e975d2cc5" xlink:to="loc_bhc_BauschLombMember_9744f85d-d586-4349-a54b-053663356067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65acf688-97f7-4a02-8d14-dfd0a7748a48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1bdab469-dbda-4fc2-92a9-38b50a45bebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1bdab469-dbda-4fc2-92a9-38b50a45bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d0f4cfe6-48a6-46d9-9cff-bd851d83c9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d0f4cfe6-48a6-46d9-9cff-bd851d83c9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1618223a-16b8-4e33-b125-d91c3d4cc684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1618223a-16b8-4e33-b125-d91c3d4cc684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cc2af617-6f1d-4162-a4e1-ad2e90fce232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d612d3cb-d7cd-4fe0-9cd7-8bcdc75f16b2" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cc2af617-6f1d-4162-a4e1-ad2e90fce232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_95729580-a16e-4d03-93e3-d573f89ee24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_95729580-a16e-4d03-93e3-d573f89ee24b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8c787def-e4c6-4fdb-a6b1-39ad079f6697" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8f1a737f-21e2-4f78-8b1e-4927989166f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8f1a737f-21e2-4f78-8b1e-4927989166f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_eabca688-21a5-4250-b339-c58806897287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_09fe3482-9382-4f75-948c-18d612cf044f" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_eabca688-21a5-4250-b339-c58806897287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6856222b-a6fd-4bcb-83d1-323f5575ec9b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_69b1ad11-71ef-4574-8398-45b705f5462b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d8ad6b8d-b7ca-422a-963c-f31b50f8bda5" xlink:to="loc_us-gaap_CurrencySwapMember_69b1ad11-71ef-4574-8398-45b705f5462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f48a31d8-651f-4edd-b121-29ca90e45640" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_0cc50552-5792-4b8f-8e13-cb62a260bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2fd4a285-21f9-43cc-b894-755c491f1e0c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_0cc50552-5792-4b8f-8e13-cb62a260bfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac086476-0116-4b2b-81bb-dd1c1b84fe86" xlink:to="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1613bbc-06c5-477d-907f-70a5cb3c3d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_5d3f0404-94cc-4a36-b88f-fe0c13cbe7db" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1613bbc-06c5-477d-907f-70a5cb3c3d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_446318d7-ba6f-43ec-979d-42f96af5de8b" xlink:to="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_32ffc42f-f8fc-411e-b754-0aedd83ffd66" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e883692-5a23-466d-adab-2e6f769dd2d3" xlink:to="loc_bhc_BauschLombMember_32ffc42f-f8fc-411e-b754-0aedd83ffd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_eaba13ea-9fdc-422b-950a-53d7026db9ec" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_632b834c-604c-4f04-8991-10271ae22f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1515373-740d-4e07-88c3-9d38fa1c2c0a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_632b834c-604c-4f04-8991-10271ae22f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77f6fd5f-f86f-4dee-b173-4aa5d9d926b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77f6fd5f-f86f-4dee-b173-4aa5d9d926b9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_adf48f51-fbbc-45bc-9e85-4161ebce24c6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_cb3f5b21-0270-4037-9ad3-f36145aa3796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b991854a-8c18-4039-92b0-8af6912f2f5e" xlink:to="loc_us-gaap_CurrencySwapMember_cb3f5b21-0270-4037-9ad3-f36145aa3796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f059a565-753a-434b-9bd7-a720e1c35132" xlink:to="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_350985de-c9f5-40a4-9524-d1840c0b1a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_94ac29e9-731a-465c-bad1-3c0a9aef6d7b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_350985de-c9f5-40a4-9524-d1840c0b1a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_73d0f252-0188-400f-ade0-e52a4b7c8fe4" xlink:to="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dc6e453d-f2e8-4238-bf4b-7d757d10af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_714b3eeb-35d1-41ef-af45-c1dee9edcb4b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_dc6e453d-f2e8-4238-bf4b-7d757d10af5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_875c2ed3-0efc-49e5-b44b-725db415cb5f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_dc11b953-4000-45ad-9daa-c7f35863bd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd6a9d58-7cad-461e-800b-87a800d94851" xlink:to="loc_us-gaap_InterestExpenseMember_dc11b953-4000-45ad-9daa-c7f35863bd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_82db499b-f6b9-464c-a66b-cd6a6aa7d02e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d6168829-8ce2-4f24-beb1-82b4ef0da071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d6168829-8ce2-4f24-beb1-82b4ef0da071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_406c4dc5-4b38-49ba-b465-2fdf5611495c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7b4a1c9f-431a-41b6-a2ec-87e75d47632c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_406c4dc5-4b38-49ba-b465-2fdf5611495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_87f4e041-0ac6-4088-8233-02de9af1b991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_87f4e041-0ac6-4088-8233-02de9af1b991" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:to="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_37120243-d027-4d84-9a74-637eeed36172" xlink:to="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4bbfda78-19c7-4a74-a312-6f2cc1cc31f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c7b308e6-3198-4c30-8ce1-c9b90e2164bc" xlink:to="loc_us-gaap_NondesignatedMember_4bbfda78-19c7-4a74-a312-6f2cc1cc31f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_856e6c98-340a-4314-b5b9-5ae2171d98c0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_dfddb581-7e16-48b9-9db9-1226e90646be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95886e3c-2583-407d-862f-f2fbb45d6033" xlink:to="loc_us-gaap_ForeignExchangeContractMember_dfddb581-7e16-48b9-9db9-1226e90646be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_21caafd0-4242-4493-bf44-124cd6e1da09" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8ac6f0cd-187f-4d12-973d-a95d7806b739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_021e0e5a-5320-4b4f-b3e8-f34ec326a53b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8ac6f0cd-187f-4d12-973d-a95d7806b739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8c82d868-7894-4361-8cc2-d30ef688985e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8c82d868-7894-4361-8cc2-d30ef688985e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1fd454ef-ac4e-4513-9993-768e966d9c77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_8fdb37f7-13a5-4565-847c-162633f8c7f6" xlink:href="bhc-20221231.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_8fdb37f7-13a5-4565-847c-162633f8c7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_31f5eba9-bb2a-4341-b70e-3ab3a34c274f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_474d6993-083e-41b3-82ec-ad7520fd05b7" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_31f5eba9-bb2a-4341-b70e-3ab3a34c274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8d845ffd-92a2-4860-a96c-b25a6f0a4c41" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9a49d323-0c29-4608-ac81-3c2c182c0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e39dd83a-2017-47f4-b620-2ae69878a951" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9a49d323-0c29-4608-ac81-3c2c182c0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2ce06b1a-6542-402a-9e8b-4ffb7eb21afd" xlink:to="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_5c59fd7c-2264-4edc-8b5b-55b788feb42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_33513f18-f62c-4f7d-a45b-8e229d372192" xlink:to="loc_us-gaap_NondesignatedMember_5c59fd7c-2264-4edc-8b5b-55b788feb42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d179bab9-5a18-4e23-9f21-27166cdbff20" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_15e38786-330f-4219-bb56-c495e5905640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_15e38786-330f-4219-bb56-c495e5905640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bd9fbc24-8ee5-485c-b78c-19ebcd73ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_bd9fbc24-8ee5-485c-b78c-19ebcd73ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d550e5e8-efcb-47ab-95d8-d30f15be95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4aaec127-295e-44e6-9598-ac1a6f40ce58" xlink:to="loc_us-gaap_DerivativeLiabilities_d550e5e8-efcb-47ab-95d8-d30f15be95f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c67f4f92-2e3f-40fb-b65d-8a134ffc2a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c67f4f92-2e3f-40fb-b65d-8a134ffc2a2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2cf7e4d2-e9e2-4ac4-ba38-fc4dae7da7b9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_721060c8-2fdd-4057-9acb-21db0c650318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faa63772-51ce-4a77-9cc7-4404ecb6a455" xlink:to="loc_us-gaap_ForeignExchangeContractMember_721060c8-2fdd-4057-9acb-21db0c650318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:to="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_df90a487-e1a6-40d6-8c41-28a4c512b1b5" xlink:to="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c40e5f5c-5ed3-42f7-a4e9-90969367b7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_82ea8ec5-ba6c-40b1-90f8-30f29f1932ad" xlink:to="loc_us-gaap_NondesignatedMember_c40e5f5c-5ed3-42f7-a4e9-90969367b7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_676213b8-bd9c-49a9-965a-c4e7d165b76d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_59472664-3a35-436c-84c7-6f54e85091d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_59472664-3a35-436c-84c7-6f54e85091d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_783d0519-c87d-4987-87ae-8a698802225e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2ebd5860-7972-4cd7-a20f-219142b2be27" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_783d0519-c87d-4987-87ae-8a698802225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_681329a2-cfae-4402-9398-193c9961cb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_681329a2-cfae-4402-9398-193c9961cb64" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_dd695bf1-bf5b-4894-bf8a-7a6eef285b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_28a83be3-e237-48bf-b911-e99b050d6e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_036d49b5-136a-4011-a994-6445c563e8a3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_28a83be3-e237-48bf-b911-e99b050d6e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_82abdf05-d127-4890-8ab9-045c3fbc3292" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9385e892-b224-4e7a-8fea-70a7fbabd42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9385e892-b224-4e7a-8fea-70a7fbabd42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_7dac22b9-519a-4d1f-a825-5aadc59e0999" xlink:href="bhc-20221231.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_02115e39-e1c3-4b03-b0ac-99c065176085" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_7dac22b9-519a-4d1f-a825-5aadc59e0999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_202dd8ad-b026-452e-a04e-b036f85728b9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab245087-ad0d-457a-836d-bc5cde546c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f193391-b308-4bc5-bc86-58a87e30c1cb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab245087-ad0d-457a-836d-bc5cde546c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_34c1a9c7-29e4-4594-b4e5-b9d858b1bdfd" xlink:to="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0b35084f-900d-4043-b115-7876308e63b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:to="loc_srt_MinimumMember_0b35084f-900d-4043-b115-7876308e63b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bed62b5b-02b5-4254-b39f-76f09d6a331c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_91414ccf-80ef-4008-8055-66f0e89ea865" xlink:to="loc_srt_MaximumMember_bed62b5b-02b5-4254-b39f-76f09d6a331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6d0eaf84-4adb-4ed4-9549-cf05c8a04b92" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_86e73425-0faf-4171-a42a-89e737dae16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a57465f5-4457-4156-8d53-c63341ee23d0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_86e73425-0faf-4171-a42a-89e737dae16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cedbb4b0-ec58-47d9-ab0b-f64ee9661fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cedbb4b0-ec58-47d9-ab0b-f64ee9661fb5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_be4e93f6-e672-429a-b3b7-fe21f1bbd5a7" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_498493cd-4fd0-45f8-9a4f-e307cb97e33a" xlink:href="bhc-20221231.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_498493cd-4fd0-45f8-9a4f-e307cb97e33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_2b25e6db-b4bd-440f-85bd-1990f937a38b" xlink:href="bhc-20221231.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8ff98e80-f9d5-40a1-99b6-b44a62b5dea9" xlink:to="loc_bhc_FairValueAdjustmentsMember_2b25e6db-b4bd-440f-85bd-1990f937a38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6e95493e-568e-4dfb-a292-bc3e1ef24f10" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a7cf61b1-03f6-4f92-9578-0ba32771fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a7cf61b1-03f6-4f92-9578-0ba32771fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_137acec1-3ca8-40c0-bae6-5a945ac0d51a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_137acec1-3ca8-40c0-bae6-5a945ac0d51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_f3d2861b-b615-4fde-95ca-53b6136be68e" xlink:href="bhc-20221231.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_f3d2861b-b615-4fde-95ca-53b6136be68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_205611ce-17ea-46fd-9ea4-e12488df24ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_205611ce-17ea-46fd-9ea4-e12488df24ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_633f186c-81c4-4762-9391-da7ee89d3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_633f186c-81c4-4762-9391-da7ee89d3ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d2c2564b-b443-4b86-b566-ecf7aa43664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9802058b-ad70-4661-806b-fae838ece584" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d2c2564b-b443-4b86-b566-ecf7aa43664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b6560e57-bc22-43b9-b872-aa5c697e991d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b6560e57-bc22-43b9-b872-aa5c697e991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_005581dd-bb8d-4b17-a2a9-beaef5636636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_682bea85-af8f-48b5-8473-f32069cb77d3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_005581dd-bb8d-4b17-a2a9-beaef5636636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_81fde31e-51d1-4e6a-ad3b-7cfde8278d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_81fde31e-51d1-4e6a-ad3b-7cfde8278d55" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_06e225c9-07e3-446d-aac3-82424bc13e09" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_bfa79598-beb0-4df7-8e38-11f0ade9e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_be295011-ce5a-4e30-b040-b236f9d2bc82" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_bfa79598-beb0-4df7-8e38-11f0ade9e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a8f433da-611d-4525-936c-d43885d20feb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94256545-40fd-45b7-81f6-be3ce433e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ea70eb7-a18d-4964-bcd6-827598995f84" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94256545-40fd-45b7-81f6-be3ce433e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3cac16da-bd25-4ad7-be87-74a3bf252b3b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_f086e718-5c9b-4d8f-98e3-fc33c526e731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f564c16-ed69-459a-a699-e3fcc155bfb8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_f086e718-5c9b-4d8f-98e3-fc33c526e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_35e80513-00ee-4faa-86ae-5b49c71c3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_955d3e91-563f-41af-b85b-12bcc4d4dc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_35e80513-00ee-4faa-86ae-5b49c71c3ed1" xlink:to="loc_us-gaap_InventoryRawMaterials_955d3e91-563f-41af-b85b-12bcc4d4dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3bf2bb20-9eb7-417b-b819-9cc836294ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_35e80513-00ee-4faa-86ae-5b49c71c3ed1" xlink:to="loc_us-gaap_InventoryWorkInProcess_3bf2bb20-9eb7-417b-b819-9cc836294ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_dc339d42-9e75-4d5a-8675-9255ceea2c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_35e80513-00ee-4faa-86ae-5b49c71c3ed1" xlink:to="loc_us-gaap_InventoryFinishedGoods_dc339d42-9e75-4d5a-8675-9255ceea2c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_107283a8-a740-40ba-891d-0e504087f4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_35e80513-00ee-4faa-86ae-5b49c71c3ed1" xlink:to="loc_us-gaap_InventoryNet_107283a8-a740-40ba-891d-0e504087f4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66d1b86d-7f62-4634-b014-06fd90508d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_66d1b86d-7f62-4634-b014-06fd90508d0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd7616b-3a03-4499-af09-93b2cb067efb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_22e4448b-cf61-4af6-a2e7-ee2cdc8070ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_LandMember_22e4448b-cf61-4af6-a2e7-ee2cdc8070ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_7ec26ba0-d89e-41f3-aa91-8fe04528e7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_7ec26ba0-d89e-41f3-aa91-8fe04528e7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_02cc3bb8-4dd2-4ef0-82df-402b7e096602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_02cc3bb8-4dd2-4ef0-82df-402b7e096602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_3c4e503d-5517-47fd-afcd-a7e21c5a6ae2" xlink:href="bhc-20221231.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_3c4e503d-5517-47fd-afcd-a7e21c5a6ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_4f6e3c1e-3df4-4ae0-a4d8-df8e4653ece0" xlink:href="bhc-20221231.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_4f6e3c1e-3df4-4ae0-a4d8-df8e4653ece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_25f68db8-eace-4a7e-bb3d-36a1da7f27b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2b13c5c4-0d1b-4140-a9e9-599bf2711b59" xlink:to="loc_us-gaap_ConstructionInProgressMember_25f68db8-eace-4a7e-bb3d-36a1da7f27b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c088f85b-a95f-4ce1-8bef-be713308caea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_257769b3-d055-449a-b838-db8f3b5b9900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_257769b3-d055-449a-b838-db8f3b5b9900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb55e32f-928f-439b-9d70-dd2479695ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb55e32f-928f-439b-9d70-dd2479695ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5d0acfe-c422-4c50-a68b-991f77718377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_55c1abca-f747-4fb0-9d35-52f9f2db23fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5d0acfe-c422-4c50-a68b-991f77718377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PROPERTYPLANTANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1c9f7d01-27f8-4545-82a9-5663ac473225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3c122dd6-844f-42a6-b536-b1b75c7ba472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1c9f7d01-27f8-4545-82a9-5663ac473225" xlink:to="loc_us-gaap_Depreciation_3c122dd6-844f-42a6-b536-b1b75c7ba472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53decd47-96fb-4ae8-8e72-5bb84506503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53decd47-96fb-4ae8-8e72-5bb84506503d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3e0d137-e079-4068-972f-f220359ac092" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_a909a9bc-5637-441a-abbe-56e8c317f3ae" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_ProductBrandsMember_a909a9bc-5637-441a-abbe-56e8c317f3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d767646a-dd51-4121-ab9c-d94ed77c8e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_us-gaap_TradeNamesMember_d767646a-dd51-4121-ab9c-d94ed77c8e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_72a7c4dd-afb5-4731-b7c7-586265aa014f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_us-gaap_ContractualRightsMember_72a7c4dd-afb5-4731-b7c7-586265aa014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_7baec522-310b-49bd-bb82-6b38aca0468d" xlink:href="bhc-20221231.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_PartnerRelationshipsMember_7baec522-310b-49bd-bb82-6b38aca0468d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_348833c7-5e32-4584-9c4b-1d48dd6ec5e5" xlink:href="bhc-20221231.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce34e80b-9e9c-4fcd-96ff-329106882a99" xlink:to="loc_bhc_OutLicensedTechnologyMember_348833c7-5e32-4584-9c4b-1d48dd6ec5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0072d2fd-2852-4587-ac90-c308bef19ae9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82a0066d-1e9e-46ae-9077-893f0e868295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_82a0066d-1e9e-46ae-9077-893f0e868295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40e1e1b4-cafa-4159-9b5d-c0f17c438655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_40e1e1b4-cafa-4159-9b5d-c0f17c438655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd174ca3-5b73-4ea4-9539-0f1bd7bb89d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_dd174ca3-5b73-4ea4-9539-0f1bd7bb89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20335e86-fd40-46a9-aff1-b46026fd4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_293bfa40-5249-4df9-bc55-4ff4505d3d95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_20335e86-fd40-46a9-aff1-b46026fd4d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53decd47-96fb-4ae8-8e72-5bb84506503d" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9c3d633a-6f37-44be-812a-450d72d0ef87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_807acb45-6986-43aa-aef3-8d2b5481c927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d158d638-7f79-47b8-a2b1-bc39bc2bbd58" xlink:to="loc_us-gaap_TrademarksMember_807acb45-6986-43aa-aef3-8d2b5481c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_03e0a4b2-0b3a-46b6-a4b8-19d88fc1db12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_45785d16-4b0b-45b2-ae4c-4e67f222f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7f7eef03-dce4-489d-8ba4-29d77b217f70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_45785d16-4b0b-45b2-ae4c-4e67f222f4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2c065e4b-53c6-42dd-bb5a-944a7cb763b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53decd47-96fb-4ae8-8e72-5bb84506503d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2c065e4b-53c6-42dd-bb5a-944a7cb763b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8c61a951-8d6d-4398-b6dc-f1a8cf05aa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53decd47-96fb-4ae8-8e72-5bb84506503d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8c61a951-8d6d-4398-b6dc-f1a8cf05aa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d5c7d49-a207-4da4-ab65-fe17c1a5762b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9d5c7d49-a207-4da4-ab65-fe17c1a5762b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cce91724-371c-4fd2-b21d-923c1ca09bbe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_d809d32e-646e-4efd-bf73-05be676727c8" xlink:href="bhc-20221231.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_ProductBrandsMember_d809d32e-646e-4efd-bf73-05be676727c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e2085fca-a010-409b-845f-644dc62448e9" xlink:href="bhc-20221231.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e2085fca-a010-409b-845f-644dc62448e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_bbd00f65-d071-4237-a08f-7e3aed7bc2bd" xlink:href="bhc-20221231.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e693e1b-ec0d-49f9-b37d-d8f44d232b58" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_bbd00f65-d071-4237-a08f-7e3aed7bc2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a9b05432-202d-4713-abe7-ff174fdc9454" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_edf18849-8e15-4071-a214-daf6de950057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_edf18849-8e15-4071-a214-daf6de950057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c15237c4-3b23-4851-ab53-5d085e9888ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_50ef8049-0a7d-417c-ad59-ecbfc4296150" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_c15237c4-3b23-4851-ab53-5d085e9888ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f347c686-b9a4-479e-827b-47d552cfcfed" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_cd55ae46-2d87-42f3-890d-9ee7b4aff1c9" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_cd55ae46-2d87-42f3-890d-9ee7b4aff1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_b12ddae0-20be-4f81-aeb7-b6a79e587872" xlink:href="bhc-20221231.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_799da36b-c021-4ed2-8034-893a6043cd62" xlink:to="loc_bhc_ACertainInternationalBusinessMember_b12ddae0-20be-4f81-aeb7-b6a79e587872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_63cfbd71-2870-4b67-b0b2-22c496471fc9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_c89fce59-42f0-41ea-bc84-42b7f5198a36" xlink:href="bhc-20221231.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b965e851-d606-4570-a073-ce033df87e21" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_c89fce59-42f0-41ea-bc84-42b7f5198a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_09ee9b2e-421e-450f-899c-50711f231330" xlink:to="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cb6bca6c-4b6d-4703-8518-820af5e2f35a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:to="loc_srt_MinimumMember_cb6bca6c-4b6d-4703-8518-820af5e2f35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cbcacf0-0013-4a43-b060-402319a283b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58fd9187-b599-49ff-bdf9-95e954c4f157" xlink:to="loc_srt_MaximumMember_6cbcacf0-0013-4a43-b060-402319a283b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_9c6dacf2-71dc-4ee4-b2e0-8db5f29bc7b0" xlink:to="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_a5c27741-26e7-4cca-a02f-6ac69c6f97a3" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_a5c27741-26e7-4cca-a02f-6ac69c6f97a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e44a08ba-8575-4587-b9ed-a1b63c2c095f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_e44a08ba-8575-4587-b9ed-a1b63c2c095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_38bbf1f3-641e-431c-b238-4f13ca167d62" xlink:href="bhc-20221231.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_38bbf1f3-641e-431c-b238-4f13ca167d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_f8d00716-0781-4772-9052-f0ec95bf4870" xlink:href="bhc-20221231.xsd#bhc_SalixReportingUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_SalixReportingUnitMember_f8d00716-0781-4772-9052-f0ec95bf4870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember_d52f43d9-2a51-47c3-8d31-aa2351063491" xlink:href="bhc-20221231.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_NeurologyAndOtherReportingUnitMember_d52f43d9-2a51-47c3-8d31-aa2351063491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SurgicalReportingUnitMember_8b724453-d565-4104-a985-bd5ac4b8d8de" xlink:href="bhc-20221231.xsd#bhc_SurgicalReportingUnitMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_66dccc04-7c40-4acd-b29a-55e40a4ea316" xlink:to="loc_bhc_SurgicalReportingUnitMember_8b724453-d565-4104-a985-bd5ac4b8d8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7edd03d0-40f6-4d0e-a7aa-464b94099e83" xlink:to="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ad074cde-4107-49b4-82a5-380bd153f12b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e3b46139-def3-4aa0-8007-54a40bc7aa21" xlink:to="loc_bhc_BauschLombMember_ad074cde-4107-49b4-82a5-380bd153f12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cc309076-d482-4291-8dad-8215e0f286ae" xlink:to="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_765a5e76-7cac-4bb6-bb19-26a8c3c1a28b" xlink:href="bhc-20221231.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62e82fc7-61b5-4c07-8cd0-aaf504af770a" xlink:to="loc_bhc_XifaxanBrandedProductsMember_765a5e76-7cac-4bb6-bb19-26a8c3c1a28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b9680e2c-a159-49ca-afc0-cab1e53878dc" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_5941c6ef-8971-46d9-919b-34ed757ad841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c20eafe-649b-4edf-81f5-4de5e3af870e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_5941c6ef-8971-46d9-919b-34ed757ad841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_134a90e9-6ff4-4b60-bd7c-77f5139e866b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e041263f-7d9f-458d-83f5-526768fba23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_31c71e31-1e42-4b5f-8834-32150123cde4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e041263f-7d9f-458d-83f5-526768fba23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6f0a6be2-13a6-4468-bd79-2e81bbfbaa47" xlink:to="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_38c60f2f-281d-4585-a380-2b0c472dc85b" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:to="loc_bhc_SalixSegmentMember_38c60f2f-281d-4585-a380-2b0c472dc85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_00830986-ed14-4d05-aef1-6c2b8ac53a80" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a2a6eb4-4e76-40f1-9988-12b80235f2cc" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_00830986-ed14-4d05-aef1-6c2b8ac53a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9d29ce8d-00f2-4285-9907-ee44c533b1df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fe463d6d-6217-4a91-ae1f-770933233abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_AssetImpairmentCharges_fe463d6d-6217-4a91-ae1f-770933233abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_acdfdf56-ebf4-4c62-90f8-e4dba4dcb09c" xlink:href="bhc-20221231.xsd#bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_acdfdf56-ebf4-4c62-90f8-e4dba4dcb09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ca1e2201-414f-465b-9807-53ce302640dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ca1e2201-414f-465b-9807-53ce302640dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70a5e253-a13c-4ba5-8fa5-89c5576113e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70a5e253-a13c-4ba5-8fa5-89c5576113e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c96c4f1-1767-4dbc-b6f3-3267596451a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c96c4f1-1767-4dbc-b6f3-3267596451a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d3fb4269-302f-45b4-8ca1-081964edd603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_d3fb4269-302f-45b4-8ca1-081964edd603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f854705e-b3e4-4db0-8798-5d2b021c2855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_f854705e-b3e4-4db0-8798-5d2b021c2855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d8e76d4f-65ee-4f73-95ba-6fba7717ac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d8e76d4f-65ee-4f73-95ba-6fba7717ac1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d519a8aa-514a-4a04-b703-e07ad1816291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d519a8aa-514a-4a04-b703-e07ad1816291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_4d568fa2-7c65-4164-8c39-a5e205d9d33f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_4d568fa2-7c65-4164-8c39-a5e205d9d33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_de113014-0e46-4780-a61d-ce75b62bef51" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_de113014-0e46-4780-a61d-ce75b62bef51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_4e97dbe8-fbc6-4dee-a6a7-6acf8b2d73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_4e97dbe8-fbc6-4dee-a6a7-6acf8b2d73fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_c44819da-4933-4c2f-8fdd-32ee3845891f" xlink:href="bhc-20221231.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_c44819da-4933-4c2f-8fdd-32ee3845891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_1a8be0c9-63e6-4cd3-a602-5dd51afccda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_NumberOfReportingUnits_1a8be0c9-63e6-4cd3-a602-5dd51afccda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4679e418-e327-43ad-a966-5651752f494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_Goodwill_4679e418-e327-43ad-a966-5651752f494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_77d23f36-dae3-443b-8071-963877e82609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_77d23f36-dae3-443b-8071-963877e82609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d3489566-71ab-45b4-8477-953082615a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_48340d1c-f7c4-4a6f-a693-3af87ff2e445" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d3489566-71ab-45b4-8477-953082615a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4564ed32-78d8-4550-8ecd-458747012299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4564ed32-78d8-4550-8ecd-458747012299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_19a452e3-4fc6-4fe4-8606-db09cb845387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_19a452e3-4fc6-4fe4-8606-db09cb845387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e61dc592-3e41-43b5-8c8d-7a586aed2d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e61dc592-3e41-43b5-8c8d-7a586aed2d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ac31497d-353a-44d4-a399-940c55e43198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ac31497d-353a-44d4-a399-940c55e43198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfb5468b-0735-4da6-a050-ba4a1ceeac71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfb5468b-0735-4da6-a050-ba4a1ceeac71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a003df79-d565-4a5b-b940-a9154866d4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a003df79-d565-4a5b-b940-a9154866d4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2c4d76d3-1a6c-4b3c-942d-cfa96d45a5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2c4d76d3-1a6c-4b3c-942d-cfa96d45a5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7887c76f-fcc1-482e-9997-d77ac90c4f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fbb0b0c-f7c2-4958-84d5-71845834544d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7887c76f-fcc1-482e-9997-d77ac90c4f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_359db537-6955-47cf-82e1-14fad38dfcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_359db537-6955-47cf-82e1-14fad38dfcbd" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_84c7b8c7-588a-4434-bae8-83bc59599ed7" xlink:to="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_ca2c9d9e-b65f-4d59-96aa-19412d94ed41" xlink:href="bhc-20221231.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_BauschLombInternationalMember_ca2c9d9e-b65f-4d59-96aa-19412d94ed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2f22e343-8c05-4577-a933-b615463f951a" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_BauschLombMember_2f22e343-8c05-4577-a933-b615463f951a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_23f7f0dd-b48f-4b5f-9203-38e512c1445f" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_SalixSegmentMember_23f7f0dd-b48f-4b5f-9203-38e512c1445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_38475537-81d1-40b9-859b-6ddfccc7aca2" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_InternationalRxMember_38475537-81d1-40b9-859b-6ddfccc7aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_157b7e6c-1193-4d68-8bff-c568192f6279" xlink:href="bhc-20221231.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_157b7e6c-1193-4d68-8bff-c568192f6279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_64fb5ae1-71b7-49e1-9e88-462f6cc52973" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_64fb5ae1-71b7-49e1-9e88-462f6cc52973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_dfa0f59c-307e-4d8f-b393-145d3c52703a" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f50053cb-75dd-401e-96f1-9890f8c1053e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_dfa0f59c-307e-4d8f-b393-145d3c52703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_fd86478b-8808-45d6-b135-0e545ce3d87d" xlink:to="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4116a3f2-4f17-498d-b30b-c29111884d31" xlink:to="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_423a4e2f-8309-4e53-9b51-02d7f1a070e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_Goodwill_423a4e2f-8309-4e53-9b51-02d7f1a070e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_b08611d1-3a8e-41e0-9434-bf325dcdaf06" xlink:href="bhc-20221231.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_b08611d1-3a8e-41e0-9434-bf325dcdaf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e0f53516-cc2e-43c1-bdef-bb23ff548899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e0f53516-cc2e-43c1-bdef-bb23ff548899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c049001a-8c8c-4038-b1e3-9e0beb65ae60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c049001a-8c8c-4038-b1e3-9e0beb65ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1d48fd9e-ba4c-4838-bfe5-7b237f7322a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1d48fd9e-ba4c-4838-bfe5-7b237f7322a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_5ae40e0a-5a5d-4035-b485-ed9e0bf6fd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_5ae40e0a-5a5d-4035-b485-ed9e0bf6fd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d0fadcc0-e645-4d4f-8115-ff7526bdc3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d0fadcc0-e645-4d4f-8115-ff7526bdc3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_155716b5-3b4f-4f22-9e29-6ea78b1630f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_b46a2b0b-5771-480e-a1e1-9290ec27eeb2" xlink:to="loc_us-gaap_Goodwill_155716b5-3b4f-4f22-9e29-6ea78b1630f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LegalSettlementsAndRelatedFees_52812e89-de9c-4c50-9d9a-2d02e339be2a" xlink:href="bhc-20221231.xsd#bhc_LegalSettlementsAndRelatedFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_bhc_LegalSettlementsAndRelatedFees_52812e89-de9c-4c50-9d9a-2d02e339be2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_1e9280f1-8efd-47d8-b279-e63e62af90da" xlink:href="bhc-20221231.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_bhc_AccruedProductRebateCurrent_1e9280f1-8efd-47d8-b279-e63e62af90da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_7c15869b-59c6-4399-a6e2-f61785415d71" xlink:href="bhc-20221231.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_bhc_AccruedProductReturnCurrent_7c15869b-59c6-4399-a6e2-f61785415d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b25a0dfe-e3c3-4ff6-954a-d4449cde6258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_b25a0dfe-e3c3-4ff6-954a-d4449cde6258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_3895a955-5138-40fc-b2eb-b88375f97490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_us-gaap_InterestPayableCurrent_3895a955-5138-40fc-b2eb-b88375f97490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b7346620-4abd-4dff-93b9-30d911021be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b7346620-4abd-4dff-93b9-30d911021be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7f0ee03d-9cca-4c06-8e83-e912157d673a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7f0ee03d-9cca-4c06-8e83-e912157d673a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2c2bcf7b-2b5a-46a9-ba8a-a366087331c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1918dada-e99a-49e2-bd8a-30a3a317e9b5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2c2bcf7b-2b5a-46a9-ba8a-a366087331c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65839272-e1ea-41a7-ba8a-30ab1e0e7070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65839272-e1ea-41a7-ba8a-30ab1e0e7070" xlink:to="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6f28d934-82c4-48fc-ba46-303a25e4625e" xlink:to="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_dea23afc-cbc3-48e5-98d7-4dde73941895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a238414-ad02-40ea-81b9-a6eaac942d89" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_dea23afc-cbc3-48e5-98d7-4dde73941895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d08b64c7-6aa8-439e-8325-e90bab96361e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_054345cf-f3f2-434f-b0f7-a923e475f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:to="loc_us-gaap_SecuredDebtMember_054345cf-f3f2-434f-b0f7-a923e475f0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_719a67ff-08e3-402d-8465-3af51ddbca74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9f0d00c5-8343-40aa-867b-012dd3e68c83" xlink:to="loc_us-gaap_UnsecuredDebtMember_719a67ff-08e3-402d-8465-3af51ddbca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e5ca2b6b-f4be-49fb-ac5a-5287870a3646" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_813d735a-a12e-4af8-a262-1003213b8aab" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_813d735a-a12e-4af8-a262-1003213b8aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_2ad19069-e34c-4987-b477-75e9fdc96ca6" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_2ad19069-e34c-4987-b477-75e9fdc96ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_ae8d92f1-0545-4508-9ad0-4f13ec11bf82" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_ae8d92f1-0545-4508-9ad0-4f13ec11bf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_e2307e87-f75b-4b48-8760-71c826acda58" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_e2307e87-f75b-4b48-8760-71c826acda58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_4a9d0add-5f23-4de1-b634-0d9650bd31c0" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_4a9d0add-5f23-4de1-b634-0d9650bd31c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_40774d3d-c6bb-4579-b628-0eb3de2948b5" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_40774d3d-c6bb-4579-b628-0eb3de2948b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_2014f272-534b-4157-9a62-e0a2dbe326f1" xlink:href="bhc-20221231.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_TermFacilityDueMay2027Member_2014f272-534b-4157-9a62-e0a2dbe326f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_174639b4-3aa9-42e6-af71-c92252591d77" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_174639b4-3aa9-42e6-af71-c92252591d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_40ef7c8e-a1f8-417d-a1fb-bc746f241324" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_40ef7c8e-a1f8-417d-a1fb-bc746f241324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_145afe00-b83d-4851-b4c9-86222dcc38c2" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_145afe00-b83d-4851-b4c9-86222dcc38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_de710d55-2d19-4f26-b709-b38cedefe66d" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_de710d55-2d19-4f26-b709-b38cedefe66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_5adc6b53-cb1f-446b-b93a-280ad51cf7d9" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_5adc6b53-cb1f-446b-b93a-280ad51cf7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_31a45f60-25c8-4539-aee5-23a01146d132" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_31a45f60-25c8-4539-aee5-23a01146d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d52763ff-e58c-4be2-92f3-c5de34387302" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d52763ff-e58c-4be2-92f3-c5de34387302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_2498a1fe-2c9b-4bf0-b793-c57bd918262d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_2498a1fe-2c9b-4bf0-b793-c57bd918262d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_9f5e90ce-527a-49fa-b1d4-e431588b0451" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_9f5e90ce-527a-49fa-b1d4-e431588b0451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_8fb78562-dc35-46af-96b0-4500304a135e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_8fb78562-dc35-46af-96b0-4500304a135e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_245d5308-5971-465b-b1b5-b113e9dcbd63" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_245d5308-5971-465b-b1b5-b113e9dcbd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_880c7f03-1032-427d-8906-4c59aef28817" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_880c7f03-1032-427d-8906-4c59aef28817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_234c50ba-cc49-46eb-9425-6db9c81948cf" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_234c50ba-cc49-46eb-9425-6db9c81948cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_ab8559fe-9137-46fb-b857-fef41f39113e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_ab8559fe-9137-46fb-b857-fef41f39113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_147bf087-fdfe-4a07-9875-952d24f82dcc" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_147bf087-fdfe-4a07-9875-952d24f82dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_ef0a4a2b-5d06-438b-bf11-9517b126fbac" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_ef0a4a2b-5d06-438b-bf11-9517b126fbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_86878693-b17b-466e-aa58-fc4351902c81" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_86878693-b17b-466e-aa58-fc4351902c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_6b367a1d-54eb-47c0-a0f1-e6c5af17165c" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_6b367a1d-54eb-47c0-a0f1-e6c5af17165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_a188d3d6-cb92-4100-8119-9abfb6864ea1" xlink:href="bhc-20221231.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c050e5ce-d186-4d17-9f3d-47630fd34c9f" xlink:to="loc_bhc_OtherLongTermDebtMember_a188d3d6-cb92-4100-8119-9abfb6864ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5d4f5185-060d-4fbd-a03a-58fdcbf38f14" xlink:to="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8a4d6694-711f-4b6f-9dc4-73c568149045" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5ef2cbce-ffbd-4f68-972b-df141f64dd6e" xlink:to="loc_bhc_BauschLombMember_8a4d6694-711f-4b6f-9dc4-73c568149045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7d3c05f-1695-43e5-b153-6fb1eb1a7f8b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0e002145-00d6-4024-9527-3ca0b54914c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0e002145-00d6-4024-9527-3ca0b54914c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3cc4dd5e-ba87-43b1-a4ad-969a571965c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3cc4dd5e-ba87-43b1-a4ad-969a571965c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_38fac790-f998-4c23-b094-7f18d0646d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebt_38fac790-f998-4c23-b094-7f18d0646d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_aaf77706-e282-4030-b731-56aeb19d6f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebtCurrent_aaf77706-e282-4030-b731-56aeb19d6f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_77688b34-ad0b-4e68-be7a-e4d2cbe2182d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02bffa7a-3650-4cba-8cb9-0cdf53ee3476" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_77688b34-ad0b-4e68-be7a-e4d2cbe2182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b848bd80-ceee-4932-b26d-3c28e68bdb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b848bd80-ceee-4932-b26d-3c28e68bdb9e" xlink:to="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9fe07d6b-308c-4d25-821b-19d26f5530fa" xlink:to="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_b17894d8-39a7-462e-8bc2-8cd498a0b562" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_b17894d8-39a7-462e-8bc2-8cd498a0b562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_6217ce2b-477b-4c03-8ad3-0ddf895a6c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2275b516-26a8-4952-9b10-87075b63cd90" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_6217ce2b-477b-4c03-8ad3-0ddf895a6c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3b6dbc9e-cde7-425b-bd2a-d07fac7e6d6c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cdd723e9-9b08-4b0b-a03f-09c35c073bb1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb01e35a-0662-4c32-a3d0-699394946c23" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cdd723e9-9b08-4b0b-a03f-09c35c073bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e53ab130-f8e8-4fcf-a2cd-3b1d454024fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a69b963d-f398-44a3-9a47-d02a99acd46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bed16e4b-55b8-4303-bfb2-f2f5963906bd" xlink:to="loc_us-gaap_SecuredDebtMember_a69b963d-f398-44a3-9a47-d02a99acd46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d2188982-f205-4b04-8d8f-39989ae5c69e" xlink:to="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_cefa27cd-4583-44fc-ac90-669b3c9453e5" xlink:href="bhc-20221231.xsd#bhc_A1261229BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_bbdfc130-222d-4261-940c-a73baf224510" xlink:to="loc_bhc_A1261229BCLtdMember_cefa27cd-4583-44fc-ac90-669b3c9453e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_7639a574-7fc7-4b64-b3f7-8444ebff38ea" xlink:to="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_50b12be9-4248-4392-9b40-4ebafe99f006" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_2cdc26cf-e6f7-44fd-a24f-eafc8d749ca1" xlink:to="loc_bhc_BauschLombMember_50b12be9-4248-4392-9b40-4ebafe99f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f5024f6f-b963-4c9e-a90f-6924fb211d4d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_50a0e6f8-744a-44e0-9408-8299948e1ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_50a0e6f8-744a-44e0-9408-8299948e1ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_a1e1f4ec-6c86-4fca-bbce-ee2d51b6a05e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_a1e1f4ec-6c86-4fca-bbce-ee2d51b6a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5acd45bf-72b4-4aad-94e6-c998b9279e22" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5acd45bf-72b4-4aad-94e6-c998b9279e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_eacc0821-3145-43f2-b85f-b71df976cb3b" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_eacc0821-3145-43f2-b85f-b71df976cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c6a8b730-b5c5-4450-b0ad-16a04092fae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_250fe6e6-ff37-4a2e-9c4e-a5b6a20d8923" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c6a8b730-b5c5-4450-b0ad-16a04092fae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c1fb6d67-645d-47e4-a5c5-3fbe51642155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1fb6d67-645d-47e4-a5c5-3fbe51642155" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d87e6516-6047-415f-9367-1af11c101313" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_533ece37-08e8-43f6-9c47-dc85fbefbee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:to="loc_us-gaap_UnsecuredDebtMember_533ece37-08e8-43f6-9c47-dc85fbefbee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_8e624afe-fded-45af-b013-548253589a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1665ef4-c531-457a-bee5-2605949c0e9b" xlink:to="loc_us-gaap_SecuredDebtMember_8e624afe-fded-45af-b013-548253589a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0cdcb63-01d2-49d3-a3cb-7bc764185e63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_bcfe611d-fd25-405a-95b0-5d1da58102df" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_bcfe611d-fd25-405a-95b0-5d1da58102df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_3954f05a-c042-4b34-9942-96e5e63f6583" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_3954f05a-c042-4b34-9942-96e5e63f6583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d3e5b022-7898-4292-a500-a91bee25d685" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_d3e5b022-7898-4292-a500-a91bee25d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_297099dc-069c-49bb-86e8-35c43f558454" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_297099dc-069c-49bb-86e8-35c43f558454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_0be20820-2338-40a4-a2df-90053ad56b2f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_0be20820-2338-40a4-a2df-90053ad56b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_1236fe2a-56c0-428d-82c4-491ec6382b79" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_1236fe2a-56c0-428d-82c4-491ec6382b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_d2c5b19f-a728-4030-9ea1-022dd0f9c60c" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_d2c5b19f-a728-4030-9ea1-022dd0f9c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f9c66c52-7ddd-4ccd-adcd-f4d1e622a18a" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9a66be15-8a4c-4441-9470-c0d126985ece" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f9c66c52-7ddd-4ccd-adcd-f4d1e622a18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f1b3f1eb-1cc4-4cc0-9896-614a2b91aa29" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_643c31dc-45d5-4d08-b6b4-fcbe48f4933a" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_891a1147-96f4-4f6d-82cc-3b9b08d16219" xlink:to="loc_bhc_ExchangeOfferMember_643c31dc-45d5-4d08-b6b4-fcbe48f4933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3907b006-ac1f-46be-a128-5aab7052a74f" xlink:to="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_91109587-e70a-434c-9a23-a085d4edb27b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_402b7c0d-dd1f-4178-b6d1-1a3ec480a56a" xlink:to="loc_bhc_BauschLombMember_91109587-e70a-434c-9a23-a085d4edb27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a0d713e9-36fe-4ac3-966c-91507d6225e7" xlink:to="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_91d3f36c-a316-48d5-af3b-316e6015517c" xlink:href="bhc-20221231.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a7050691-52d3-4380-8111-07ac3caf6de4" xlink:to="loc_bhc_A1375209BCLtdMember_91d3f36c-a316-48d5-af3b-316e6015517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_33007c6c-b261-4e0e-81c1-16e53a5e2e3a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_954f2df4-6f51-4988-b1ef-f1969b3de3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_954f2df4-6f51-4988-b1ef-f1969b3de3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a452cb4c-91e3-4adf-9ebf-d26bd20b9509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a452cb4c-91e3-4adf-9ebf-d26bd20b9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_32628e69-913e-48f1-8542-06c4a9a79363" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_32628e69-913e-48f1-8542-06c4a9a79363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e7f7237f-f322-4c83-9505-037c18460877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e7f7237f-f322-4c83-9505-037c18460877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1e72d7db-a031-4365-8281-a26f60e12a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1e72d7db-a031-4365-8281-a26f60e12a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3edaefba-41ba-4ced-96e4-da6870fc5473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3edaefba-41ba-4ced-96e4-da6870fc5473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_d27d7557-eddc-4e73-8b83-4ced5da7ca34" xlink:href="bhc-20221231.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_d27d7557-eddc-4e73-8b83-4ced5da7ca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd78edf1-5ccf-4fc4-9273-57e9dfce8b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0d22f7f3-2c21-40ed-b0a2-ff7ec7f34207" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd78edf1-5ccf-4fc4-9273-57e9dfce8b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_66cfbbc0-e38d-4ad1-a559-23d17367cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cfbbc0-e38d-4ad1-a559-23d17367cb1d" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_967ec9e9-eedf-4222-b397-60ca7838b766" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_c4691181-ffb9-4159-981f-d0e2465e61e9" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_c4691181-ffb9-4159-981f-d0e2465e61e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_a176b373-c21e-4272-90d3-d1aa2a3fddf6" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_a176b373-c21e-4272-90d3-d1aa2a3fddf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_2f6c0d8d-48ee-4868-bbd3-7bcdc304afae" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_2f6c0d8d-48ee-4868-bbd3-7bcdc304afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_9b0936d1-2f0a-4372-b21c-d85e6b8c5485" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_9b0936d1-2f0a-4372-b21c-d85e6b8c5485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_f1b512d0-cd5b-4e77-b8d5-73926778cd00" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_f1b512d0-cd5b-4e77-b8d5-73926778cd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_c93e2ecf-3763-40e3-916c-60d0eb73bfd1" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_c93e2ecf-3763-40e3-916c-60d0eb73bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4d7922ea-2bce-4d42-a3b8-eadc1e97f36d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4d7922ea-2bce-4d42-a3b8-eadc1e97f36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_24bb7398-b79d-4672-8191-37a3702b2e50" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_24bb7398-b79d-4672-8191-37a3702b2e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_18032b8c-16d4-4f8b-92ff-b1012b9da376" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_18032b8c-16d4-4f8b-92ff-b1012b9da376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4c9a1519-4227-4732-b6e8-04278c804ff3" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c5c93c9c-53f2-48d5-aa1b-292d06d2b5a5" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4c9a1519-4227-4732-b6e8-04278c804ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3cc78849-e560-4b27-8e50-4b727407db2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c9c093ed-6f42-4b5e-acaa-1da8a9ceab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4366ac6-aa66-470f-a41b-43e09f935633" xlink:to="loc_us-gaap_UnsecuredDebtMember_c9c093ed-6f42-4b5e-acaa-1da8a9ceab6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_d0d2cfbb-1d55-4fba-b9ee-617c33d20f7f" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_2e27f0dc-24ac-41c8-821e-6fa13307f26d" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_21fcd7e4-2fdd-432c-a2f4-de21e84a19fa" xlink:to="loc_bhc_ExchangeOfferMember_2e27f0dc-24ac-41c8-821e-6fa13307f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_2c08cfce-7b3f-4197-8fec-3db9eb45db4a" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df3ef924-a8cb-4968-830c-9813ab0724ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_df3ef924-a8cb-4968-830c-9813ab0724ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d51a44-20f9-4520-95aa-72bc34aca0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0f9d7eb1-04c6-452a-884e-fdf2a6d953b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d51a44-20f9-4520-95aa-72bc34aca0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_53bf262b-079c-4547-b76f-b77fa695f689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_53bf262b-079c-4547-b76f-b77fa695f689" xlink:to="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f55b869a-52fa-4e92-8f2a-90eb42c5c8f0" xlink:to="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1b1bd92f-7bae-49e5-b5ac-88ed1eac6604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1b1bd92f-7bae-49e5-b5ac-88ed1eac6604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a63f505b-b7ce-4c26-a2dc-2902698193b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c4b7b5c0-4d36-4153-878d-bc10ca692a5a" xlink:to="loc_us-gaap_LetterOfCreditMember_a63f505b-b7ce-4c26-a2dc-2902698193b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba77d675-b8cc-4469-8674-16238dced847" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_14e61fd8-aeac-4624-b239-8dc5fd5d5588" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_14e61fd8-aeac-4624-b239-8dc5fd5d5588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_f6360395-68ea-41f4-ad25-d296c8d1c51a" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_f6360395-68ea-41f4-ad25-d296c8d1c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_bda4a7d3-7fe5-441b-9833-a9480aca8612" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_bda4a7d3-7fe5-441b-9833-a9480aca8612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_79fd71b0-6f74-47ea-8893-0a740090d1c5" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_79fd71b0-6f74-47ea-8893-0a740090d1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_52aa988a-228b-409f-b8fb-43b4b9ee4805" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_52aa988a-228b-409f-b8fb-43b4b9ee4805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_964b79c3-1456-4a5d-a28d-99305d84117b" xlink:href="bhc-20221231.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_964b79c3-1456-4a5d-a28d-99305d84117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_857a68fb-ab1b-4c0c-a6ae-9202d22bacd4" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_857a68fb-ab1b-4c0c-a6ae-9202d22bacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_cc16a8ed-c495-4644-b909-4c9d4924f14b" xlink:href="bhc-20221231.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_TermFacilityDueMay2027Member_cc16a8ed-c495-4644-b909-4c9d4924f14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_951b2b17-4a82-4758-9881-0565cf3b217f" xlink:href="bhc-20221231.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_08a657fd-49ee-4810-8750-7f7972601d6b" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_951b2b17-4a82-4758-9881-0565cf3b217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_022005bd-12b3-48ba-860c-99f324ceb5d3" xlink:to="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e5b72b9c-a835-4e25-995f-778ae3261970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e5b72b9c-a835-4e25-995f-778ae3261970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_daa4f4fc-0279-4d56-a788-07c57088e973" xlink:href="bhc-20221231.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_daa4f4fc-0279-4d56-a788-07c57088e973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_7097b3bb-f28b-4f84-b39b-37a6990d2e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_7097b3bb-f28b-4f84-b39b-37a6990d2e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_9cac2bfb-d992-42b1-be62-93a7fe6471b5" xlink:href="bhc-20221231.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_9cac2bfb-d992-42b1-be62-93a7fe6471b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_91f0420b-847c-470d-ab80-032187846431" xlink:href="bhc-20221231.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_91f0420b-847c-470d-ab80-032187846431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_ef9c1af7-15b4-4e1e-909a-c76b29b12a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_us-gaap_BaseRateMember_ef9c1af7-15b4-4e1e-909a-c76b29b12a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_7d776b5c-3b2b-499f-8f90-8b0c01ee4e17" xlink:href="bhc-20221231.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_7d776b5c-3b2b-499f-8f90-8b0c01ee4e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_deb97ce3-3fb4-406d-a4ec-c6c6a0502cf3" xlink:href="bhc-20221231.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3d4da750-09be-4444-893f-bcf7b4e51b8a" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_deb97ce3-3fb4-406d-a4ec-c6c6a0502cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_69f9f290-e439-4648-ac49-77daf6a63f81" xlink:to="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d17360a6-8788-4953-9b60-4f3b8b7c850b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:to="loc_srt_MinimumMember_d17360a6-8788-4953-9b60-4f3b8b7c850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7f0d01d3-b310-4efd-9885-56a6d73c9459" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00944742-d1c5-437a-b6e3-d8026c2c0800" xlink:to="loc_srt_MaximumMember_7f0d01d3-b310-4efd-9885-56a6d73c9459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_783747e5-7fc0-4c32-860d-bd363cc7c978" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_f1d11338-c009-420a-a66e-aa11962f6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:to="loc_us-gaap_SecuredDebtMember_f1d11338-c009-420a-a66e-aa11962f6d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_df1f32b3-e2d4-4db9-8163-115e78557a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_49d215eb-5374-41fd-9154-556d9009041b" xlink:to="loc_us-gaap_UnsecuredDebtMember_df1f32b3-e2d4-4db9-8163-115e78557a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b8302470-517b-4e54-979f-e13997ba4ccf" xlink:to="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_57c82984-2493-4123-bff3-ce01cc37ffae" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:to="loc_bhc_BauschLombMember_57c82984-2493-4123-bff3-ce01cc37ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_4334d46f-9baa-4818-af67-566c028f23a4" xlink:href="bhc-20221231.xsd#bhc_A1261229BCLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b38bf8ef-63ec-4ddd-ae05-296d620b80c1" xlink:to="loc_bhc_A1261229BCLtdMember_4334d46f-9baa-4818-af67-566c028f23a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_f28ca8a0-d6a7-40ab-a938-b210e4a378b9" xlink:to="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_87b57b4c-73f7-4d14-a2dd-26f60608e16b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_47ba1a9d-cea6-4a69-b354-d3fe86f9fbee" xlink:to="loc_bhc_BauschLombMember_87b57b4c-73f7-4d14-a2dd-26f60608e16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7e89021e-5344-4f07-9f1e-9416284557ed" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fef58597-73ff-45bf-9604-0e085325591d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fef58597-73ff-45bf-9604-0e085325591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_17f434ed-ae73-4b37-9942-2c1694005718" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_17f434ed-ae73-4b37-9942-2c1694005718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_abcd8ea4-daa3-4173-a078-e1a9e3544a35" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_abcd8ea4-daa3-4173-a078-e1a9e3544a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_eb59e3a3-9338-4664-b1e6-58d0e6ccc78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_eb59e3a3-9338-4664-b1e6-58d0e6ccc78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ee27452e-c04d-43c4-9382-2f4cc0c52b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LongTermDebt_ee27452e-c04d-43c4-9382-2f4cc0c52b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_61b030b1-e77d-4ab6-beb2-304b52470ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_61b030b1-e77d-4ab6-beb2-304b52470ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_9a8e045e-cfd9-4f82-b25b-1dc2d49d4546" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_9a8e045e-cfd9-4f82-b25b-1dc2d49d4546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3bae0582-9362-4332-9e1d-47596a9fde30" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_3bae0582-9362-4332-9e1d-47596a9fde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fef01529-99ca-4406-8f8f-40f8ea9bfde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fef01529-99ca-4406-8f8f-40f8ea9bfde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_9547a8cb-f2e5-4240-b107-94f8af286260" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_9547a8cb-f2e5-4240-b107-94f8af286260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_382df9a3-f3cc-4ed7-bf53-faf918a276eb" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_382df9a3-f3cc-4ed7-bf53-faf918a276eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_4cc32597-7b53-4c43-84ac-5aaf5c3c32ce" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_4cc32597-7b53-4c43-84ac-5aaf5c3c32ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_03f58643-46d1-4a08-9ea6-eeab61bd33c3" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_03f58643-46d1-4a08-9ea6-eeab61bd33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_eaa511f3-2d3a-4dea-9fc0-eeba18f800ee" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_eaa511f3-2d3a-4dea-9fc0-eeba18f800ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_a2de81b6-e5f0-41c9-9466-ddb54211ac01" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_a2de81b6-e5f0-41c9-9466-ddb54211ac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_bd660124-e752-4137-bd66-7e5f531f3e05" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_bd660124-e752-4137-bd66-7e5f531f3e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_37f235cf-156d-44e7-80a2-1589253c2366" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_37f235cf-156d-44e7-80a2-1589253c2366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_78f4a6ae-40df-4bc7-80d4-b73ced5052ec" xlink:href="bhc-20221231.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_78f4a6ae-40df-4bc7-80d4-b73ced5052ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_6f3be177-5643-4afa-9bb3-9904fb5d7fd0" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_6f3be177-5643-4afa-9bb3-9904fb5d7fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_112c50a9-010e-41ff-944a-664a1dff9f5e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_112c50a9-010e-41ff-944a-664a1dff9f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_f6373ae1-60d7-40c7-9e72-859a26d6d823" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_f6373ae1-60d7-40c7-9e72-859a26d6d823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_5594548e-c232-4fbd-bb8e-4a13bdf4a4fc" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_5594548e-c232-4fbd-bb8e-4a13bdf4a4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_56feca14-82b0-42ee-bbf6-2b3ca58e3ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentTerm_56feca14-82b0-42ee-bbf6-2b3ca58e3ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2c0585dd-20e4-4c40-8a3a-428e1672264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2c0585dd-20e4-4c40-8a3a-428e1672264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_79289cbd-d6da-4c7a-a6cf-48370f103368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_79289cbd-d6da-4c7a-a6cf-48370f103368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63ff2c44-ef10-489b-9252-53397f57b38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63ff2c44-ef10-489b-9252-53397f57b38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8dbb9dac-0a82-4192-8ee5-e7dd0697a2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_8dbb9dac-0a82-4192-8ee5-e7dd0697a2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_6c2ff629-0e26-4478-983a-3c77a63c9b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2a289339-12f9-49dc-97bf-effdd1666ea4" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_6c2ff629-0e26-4478-983a-3c77a63c9b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b87342e5-d6b9-46cd-a600-0950f592c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b87342e5-d6b9-46cd-a600-0950f592c3aa" xlink:to="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_35b97b9e-f619-45ab-81c2-f74578339381" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_df1b4b6e-c349-4e55-ae7d-24d33366a431" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_df1b4b6e-c349-4e55-ae7d-24d33366a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_18e50e0d-5b34-498d-8462-a7a1fea73989" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_18e50e0d-5b34-498d-8462-a7a1fea73989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_ca231209-c5bc-4dea-a615-fa657c096a2d" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_ca231209-c5bc-4dea-a615-fa657c096a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_fde6e11b-f2ab-4390-91d6-bcdc954aa2b9" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_fde6e11b-f2ab-4390-91d6-bcdc954aa2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f9d6d4a2-dd84-4938-acc0-c30eef67293b" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_f9d6d4a2-dd84-4938-acc0-c30eef67293b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_2ae2d3a7-de92-4223-9537-f99bf6ba0f17" xlink:href="bhc-20221231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_2ae2d3a7-de92-4223-9537-f99bf6ba0f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b310641b-b2b5-4c5b-ac58-c648641f1319" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b310641b-b2b5-4c5b-ac58-c648641f1319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_e04da999-4411-4e28-9256-050f37c1db8b" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_e04da999-4411-4e28-9256-050f37c1db8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_fc141c9d-c054-4507-9e09-deef22dd51af" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_fc141c9d-c054-4507-9e09-deef22dd51af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_4f1de0f5-df58-44a8-91f3-7792e0645d25" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_4f1de0f5-df58-44a8-91f3-7792e0645d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_4e912738-15ac-43ed-b97b-9db2c419d8c1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_4e912738-15ac-43ed-b97b-9db2c419d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_8377b664-9d68-4f14-b5ea-95a6b20e7093" xlink:href="bhc-20221231.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d6be198b-597e-4bbc-93fc-31aec203df86" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_8377b664-9d68-4f14-b5ea-95a6b20e7093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_98bdc963-9375-4e9a-b36c-3da760987f76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a859e5cd-7b9b-48e6-af6c-25276cb20ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:to="loc_us-gaap_SecuredDebtMember_a859e5cd-7b9b-48e6-af6c-25276cb20ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4517889c-3a39-418b-ab1e-19d2a3782db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7d9b7888-215b-4565-97e4-75b913b396c1" xlink:to="loc_us-gaap_UnsecuredDebtMember_4517889c-3a39-418b-ab1e-19d2a3782db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_5c8839c4-66f3-4e19-a1d3-9b3320d76795" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1e0afa07-63df-477c-a0f1-efe0b8fe5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1e0afa07-63df-477c-a0f1-efe0b8fe5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_44264761-6d99-4558-af6c-0dee1982bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_51283a48-d4d6-41e4-a557-7a74b5f418c5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_44264761-6d99-4558-af6c-0dee1982bddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_61ac9729-f72f-4ed4-a224-6eb4e7b6d896" xlink:to="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4cd69a1d-31c7-49bc-9e94-6f75daf4fde2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a9f03ea-9a71-43c8-b361-b09dbd682ce9" xlink:to="loc_srt_MaximumMember_4cd69a1d-31c7-49bc-9e94-6f75daf4fde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_29874df1-7008-4788-9e3d-abbcf28f81be" xlink:to="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3671f76b-9ae3-48d2-aba6-4ad11caf90f1" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_bba8627d-6a0a-4fdd-a8e2-55674e692cd0" xlink:to="loc_bhc_BauschLombMember_3671f76b-9ae3-48d2-aba6-4ad11caf90f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_71e5a9bd-ab97-49f4-8d71-0b29dbc11363" xlink:to="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_d67b6e6c-a729-4556-b50e-b381b9bbb0e2" xlink:href="bhc-20221231.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ab592f60-467b-4208-b96a-7ede56c36c98" xlink:to="loc_bhc_A1375209BCLtdMember_d67b6e6c-a729-4556-b50e-b381b9bbb0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca8881d4-012c-445e-b5b5-50d389f0982a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2e0d318-14e0-4906-874e-cd9b16ac5954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a2e0d318-14e0-4906-874e-cd9b16ac5954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_ec527d12-01b8-457f-8606-e23bbde5fe9e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_ec527d12-01b8-457f-8606-e23bbde5fe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4981d8f1-0353-4528-b2ff-7371d6176a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4981d8f1-0353-4528-b2ff-7371d6176a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_13adfcb6-3637-47b8-966a-9c6e3c7f2bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_13adfcb6-3637-47b8-966a-9c6e3c7f2bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_483b2a59-59fb-4e56-ad7c-5ab11834ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_483b2a59-59fb-4e56-ad7c-5ab11834ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcac5249-aeee-41f3-bbf4-7940e0c37d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fcac5249-aeee-41f3-bbf4-7940e0c37d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b3d49116-ce0a-4a99-a9b1-9db01c2b2756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b3d49116-ce0a-4a99-a9b1-9db01c2b2756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9fc8300-03d6-4e18-9733-56e89c57d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed5c8ef2-4f2a-404c-a2a5-84725d31fa11" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f9fc8300-03d6-4e18-9733-56e89c57d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d121f62e-5cad-459c-8a45-3ef07ef7e2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d121f62e-5cad-459c-8a45-3ef07ef7e2b0" xlink:to="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64f5df14-833c-4b54-bdf1-ae7baf26d58b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2e8d415e-f1cf-4ae9-8287-e6862faf70c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:to="loc_us-gaap_UnsecuredDebtMember_2e8d415e-f1cf-4ae9-8287-e6862faf70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1d50a413-fcc2-402b-9bba-3c0338f1b264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c352ca7-ea83-4440-b612-36e1636fab68" xlink:to="loc_us-gaap_SecuredDebtMember_1d50a413-fcc2-402b-9bba-3c0338f1b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f21f9239-099d-4a93-b3ee-8ab74c140178" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_79f1a57d-f584-495e-953e-c2e9e52ff8e7" xlink:href="bhc-20221231.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_79f1a57d-f584-495e-953e-c2e9e52ff8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_f968dc42-41d8-48fb-a365-614404088c9a" xlink:href="bhc-20221231.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_f968dc42-41d8-48fb-a365-614404088c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_2dca0d1e-30a7-47b1-97ed-2b1212e4a793" xlink:href="bhc-20221231.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_2dca0d1e-30a7-47b1-97ed-2b1212e4a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_1d0402d0-b832-4061-b027-60d7faa521dc" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes4.502023Member_1d0402d0-b832-4061-b027-60d7faa521dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_7db6b8ff-0744-4b3b-a4a0-a12674b1bf34" xlink:href="bhc-20221231.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_7db6b8ff-0744-4b3b-a4a0-a12674b1bf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_610efa59-c9a9-4830-9a02-6421002aa261" xlink:href="bhc-20221231.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_610efa59-c9a9-4830-9a02-6421002aa261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_55be26b4-ebe4-4033-bacb-e353dc87248f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_55be26b4-ebe4-4033-bacb-e353dc87248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_7f07e58f-9a2a-4265-9b29-1c6e16c58918" xlink:href="bhc-20221231.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_7f07e58f-9a2a-4265-9b29-1c6e16c58918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_98580bdc-7cd7-45b5-bc15-7ffd27214193" xlink:href="bhc-20221231.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_98580bdc-7cd7-45b5-bc15-7ffd27214193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_438dc019-bff0-4041-a3c3-03c6fc70ae9d" xlink:href="bhc-20221231.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_438dc019-bff0-4041-a3c3-03c6fc70ae9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_0c21dd80-93a1-49d0-9a94-a9e2eaf32ac2" xlink:href="bhc-20221231.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_0c21dd80-93a1-49d0-9a94-a9e2eaf32ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_54b024e9-fe6f-45f0-bebc-cd1cd60adf9a" xlink:href="bhc-20221231.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_54b024e9-fe6f-45f0-bebc-cd1cd60adf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_fd33e6f8-38b1-4a06-9bb0-5c8b7ddc5976" xlink:href="bhc-20221231.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_fd33e6f8-38b1-4a06-9bb0-5c8b7ddc5976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_a1f7ebde-9cf6-4e01-95ea-7549420da8f8" xlink:href="bhc-20221231.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_a1f7ebde-9cf6-4e01-95ea-7549420da8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_8db7f3f0-46d5-4982-a21f-7596a690325d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_8db7f3f0-46d5-4982-a21f-7596a690325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_27900475-02e5-4dbf-9bae-169a89d587d1" xlink:href="bhc-20221231.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_27900475-02e5-4dbf-9bae-169a89d587d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_15d7ba33-3184-457d-9593-02ad04a1b63f" xlink:href="bhc-20221231.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_15d7ba33-3184-457d-9593-02ad04a1b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_1f0e1c57-4067-4025-8f5d-244279b4c91e" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_1f0e1c57-4067-4025-8f5d-244279b4c91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_75a6d503-8432-4a12-8c75-5c56df9dea2f" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_75a6d503-8432-4a12-8c75-5c56df9dea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_17f9e71a-3c38-4de8-9812-b05ca50f654d" xlink:href="bhc-20221231.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c7006532-c393-46d4-89d6-96796a776636" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_17f9e71a-3c38-4de8-9812-b05ca50f654d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_952fb3af-ff6f-4fc6-90ba-633247d3fc5b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6c59082d-f216-4857-9e22-1b52ae9e2045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6c59082d-f216-4857-9e22-1b52ae9e2045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c38a7c5e-4893-4457-8c76-359b15f6eb76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_64f5f599-b868-4430-843e-b4240137520f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c38a7c5e-4893-4457-8c76-359b15f6eb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:href="bhc-20221231.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_717f4373-774a-4f06-9c47-1077dee0d163" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_ae1c289b-9db8-4aad-bd32-6a055ccaf328" xlink:href="bhc-20221231.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_67fdb1df-fccd-4f93-9d94-ded1042f715d" xlink:to="loc_bhc_ExchangeOfferMember_ae1c289b-9db8-4aad-bd32-6a055ccaf328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_798882da-7c06-45ff-bf61-b63c31a7dc4b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_dc90e7ab-6a9e-4530-861f-502ff4707319" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_dc90e7ab-6a9e-4530-861f-502ff4707319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3171bde3-be12-4daf-9e49-178987c974f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3171bde3-be12-4daf-9e49-178987c974f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25827ccd-df5e-4628-a818-f3de0df99fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_25827ccd-df5e-4628-a818-f3de0df99fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_433d96ae-3767-4918-8d2f-d20bbc126794" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_433d96ae-3767-4918-8d2f-d20bbc126794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_57bd9e45-623b-4afb-a5b2-89e73f059d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_57bd9e45-623b-4afb-a5b2-89e73f059d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2216a388-1695-4bc0-8032-2217241377cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2216a388-1695-4bc0-8032-2217241377cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2138dcd4-abfc-4b21-b8ba-b96fdf78de0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2138dcd4-abfc-4b21-b8ba-b96fdf78de0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_b4a16438-467d-4daf-9506-c52260145a6e" xlink:href="bhc-20221231.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_b4a16438-467d-4daf-9506-c52260145a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_95bb84f4-e051-4221-be64-58bde3915bf9" xlink:href="bhc-20221231.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_95bb84f4-e051-4221-be64-58bde3915bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_853ce126-294e-41c7-bee0-04cec3dce235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c3177347-4170-432d-a0ed-0a736f32c856" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_853ce126-294e-41c7-bee0-04cec3dce235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c0ede34-064c-43cf-91fe-fdb197d058a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_e7876b21-3d18-4ebf-97aa-31792b0d8509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c0ede34-064c-43cf-91fe-fdb197d058a4" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_e7876b21-3d18-4ebf-97aa-31792b0d8509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2a0a2ce0-cadc-40de-95e5-fa4b3dc43989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2a0a2ce0-cadc-40de-95e5-fa4b3dc43989" xlink:to="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_403180ac-4f8d-4786-8fef-187453bcb06b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_12e19e7e-ff93-413b-86e6-80a3f81389e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4bbff150-d51e-47dc-a470-f99c7c316241" xlink:to="loc_us-gaap_UnsecuredDebtMember_12e19e7e-ff93-413b-86e6-80a3f81389e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8fa4471e-54ff-4ea6-a961-260943f8df56" xlink:to="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c13f4097-61fc-4447-90c0-c937a864c103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c13f4097-61fc-4447-90c0-c937a864c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_42157c18-a321-4bd2-80be-f82b8b6e6984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_42157c18-a321-4bd2-80be-f82b8b6e6984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_859870b4-153f-464f-b959-ce2cf407acd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_147605e1-341b-49f3-b344-9e18e5e6d653" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_859870b4-153f-464f-b959-ce2cf407acd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5a331c7d-f2cf-4f36-9da8-41b9d7e22636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5a331c7d-f2cf-4f36-9da8-41b9d7e22636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_94fe6e1a-4799-448c-9885-04b306cc3194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_94fe6e1a-4799-448c-9885-04b306cc3194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0dfaaeb9-eac6-4047-8654-abd70dde4166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0dfaaeb9-eac6-4047-8654-abd70dde4166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_22d9ba5f-7571-41c0-97d5-e93b9a82f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_22d9ba5f-7571-41c0-97d5-e93b9a82f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e62e0279-5a95-405b-805e-2f4d04c06dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e62e0279-5a95-405b-805e-2f4d04c06dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5512b90c-6509-4026-bcc4-6575d0908ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_5512b90c-6509-4026-bcc4-6575d0908ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7f328a5b-ea24-45ae-bd9c-c78ba315b435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7f328a5b-ea24-45ae-bd9c-c78ba315b435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_feda9425-e3a5-4156-be02-235adebb6f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_feda9425-e3a5-4156-be02-235adebb6f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7a079c06-1a45-4313-86a6-83c7bf3eaf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_106d0d97-13bc-4b01-93e9-43807ec7f1ec" xlink:to="loc_us-gaap_LongTermDebt_7a079c06-1a45-4313-86a6-83c7bf3eaf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_59f210b8-4e31-4dc9-b994-a9b0444786ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_59f210b8-4e31-4dc9-b994-a9b0444786ac" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c447c476-1486-4435-9f0c-0bb53805ca67" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e6496e3e-2b61-42ba-92bf-001d187e923d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e6496e3e-2b61-42ba-92bf-001d187e923d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8ae779aa-c034-4136-aa65-09f98b657075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_47f3abc0-54d8-4a9d-aace-4b6e007c2394" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_8ae779aa-c034-4136-aa65-09f98b657075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bb409de9-88bd-4d21-8918-7e107a19eb3e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:to="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_dda38f2c-5d38-49bd-ad1c-c78de8f1b6e2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_c72951d1-acac-4bd5-b03d-82b8c5d71b21" xlink:to="loc_country_IE_dda38f2c-5d38-49bd-ad1c-c78de8f1b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9ec6f05c-25a5-4f2a-9efc-57d4695b6759" xlink:to="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_146bb9a2-daf5-46ae-b172-3b8f65e92fb9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_2c1b698f-fd6a-4860-99fd-cf8a6921bdf4" xlink:to="loc_country_US_146bb9a2-daf5-46ae-b172-3b8f65e92fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a84b74e1-cad8-497a-a73a-eeef9729d694" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4115838c-09b1-43c6-972e-e5e8e46de9de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2ddd5438-ebc9-4f58-a5b0-c71638896499" xlink:to="loc_srt_ScenarioForecastMember_4115838c-09b1-43c6-972e-e5e8e46de9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_ed0d3e91-097e-4093-b29e-1cbac34ec08c" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_3f58611a-d760-40d4-96de-2b5fb5fd781a" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_3f58611a-d760-40d4-96de-2b5fb5fd781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_cec4a9f2-ed75-44ff-ac63-6cdbca1b299a" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_cec4a9f2-ed75-44ff-ac63-6cdbca1b299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9cfe6c06-78e2-4c66-8f4e-6f0c11cc68c6" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_9cfe6c06-78e2-4c66-8f4e-6f0c11cc68c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_359601c8-b58c-46c5-a95b-a57131a8aeae" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_359601c8-b58c-46c5-a95b-a57131a8aeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ad98a9b8-795b-445e-b7d7-2b9acc0f7fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_ad98a9b8-795b-445e-b7d7-2b9acc0f7fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_aed012fa-5ab7-4bdb-b538-1c986c86cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_aed012fa-5ab7-4bdb-b538-1c986c86cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_a367b846-9576-4218-b1c3-02449f850f03" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_a367b846-9576-4218-b1c3-02449f850f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_43281018-ee28-4681-af74-f7618d0bef2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_43281018-ee28-4681-af74-f7618d0bef2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_e1ce9406-b4f4-4134-9d6b-6eb9c74ee9d1" xlink:href="bhc-20221231.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_e1ce9406-b4f4-4134-9d6b-6eb9c74ee9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_f58198f8-aa69-4d71-b0da-afd302f88636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ff559447-225f-4189-b9ae-5c6fcdc2a252" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_f58198f8-aa69-4d71-b0da-afd302f88636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4149dd82-073d-4925-ba0c-a5fded44dcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4149dd82-073d-4925-ba0c-a5fded44dcb7" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4de43f1e-ab6e-498a-a25e-b7f61c532f5a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:to="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b856b50e-109b-4f5c-85c3-150202e44b36" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_a52e73e5-c7d1-4bf6-ab23-3f1ee82da91d" xlink:to="loc_country_US_b856b50e-109b-4f5c-85c3-150202e44b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6897ac5f-5d20-43a7-a346-6e9f6c663ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8277f1f0-5a5d-44df-af3d-528ff4b673ee" xlink:to="loc_us-gaap_ForeignPlanMember_6897ac5f-5d20-43a7-a346-6e9f6c663ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_862e1c3a-c40e-4b5c-9849-3b8f3e32475a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c5a732c9-e3ad-4003-beb1-b4e7fbd76de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c5a732c9-e3ad-4003-beb1-b4e7fbd76de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b29ae8f-3e51-4198-8d73-127b170f1393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4d23e2b5-7493-46f8-9cc9-a4c3aa18ca1a" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3b29ae8f-3e51-4198-8d73-127b170f1393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7ad6ae02-449a-4c09-ab8c-d80774ea00b6" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_602e3481-c229-408b-aab5-d234f4594ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_602e3481-c229-408b-aab5-d234f4594ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_be43e085-92b5-4b8e-9d34-ae30e877a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_f12a7936-8978-4ff6-a900-a36af24c202a" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_be43e085-92b5-4b8e-9d34-ae30e877a692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ba168bc8-fe94-4d65-b3d5-5e453b048593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ba168bc8-fe94-4d65-b3d5-5e453b048593" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_66f2ffab-a15f-4da8-9933-274cab3f6e53" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:to="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b7809d68-7444-42e9-a751-54e1db5275eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e0bca927-84d1-497e-9677-3883e510e61b" xlink:to="loc_country_US_b7809d68-7444-42e9-a751-54e1db5275eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_9882ed52-a626-4db8-8d47-d65c06920744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a4b0c05-0a02-4dbb-9cd9-68a2960ec965" xlink:to="loc_us-gaap_ForeignPlanMember_9882ed52-a626-4db8-8d47-d65c06920744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_070c0b58-86c1-4dd1-b946-53e9d4f81034" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_66e57944-2d8f-4898-bf4a-a6fe4232245a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_66e57944-2d8f-4898-bf4a-a6fe4232245a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_614b85d8-271e-4e42-ae51-7e1809da1aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_89eba75c-1075-41fe-b971-3af944317f78" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_614b85d8-271e-4e42-ae51-7e1809da1aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_19d26bb4-d13d-41f4-a7b8-6aa1a5fccbde" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_16ae9a27-06c8-4d73-8a98-70056d6177c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_16ae9a27-06c8-4d73-8a98-70056d6177c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_38905e52-c2b8-4d39-bea8-be5631d98e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_38905e52-c2b8-4d39-bea8-be5631d98e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_283192d0-d50a-49e9-af7a-b9b9d8168cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_283192d0-d50a-49e9-af7a-b9b9d8168cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_792d07ba-4a8b-4821-aa9c-b296d0b39b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_792d07ba-4a8b-4821-aa9c-b296d0b39b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fea0299e-90d3-488d-a459-762866017b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_fea0299e-90d3-488d-a459-762866017b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_56b1c0ad-8567-482c-92db-fc1d3f193a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_56b1c0ad-8567-482c-92db-fc1d3f193a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_67ca1ad6-721d-484e-bc07-6ae487bc2453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_38d2f770-afa7-4259-9f8d-8a5ba0715348" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_67ca1ad6-721d-484e-bc07-6ae487bc2453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c355cb4e-cabe-423c-96f4-ec0a7d4da12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c355cb4e-cabe-423c-96f4-ec0a7d4da12d" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8fd03f03-1725-4901-9469-2029efa40857" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:to="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_abbfef35-6723-4f5a-8368-94d355baf44d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_30a996d5-7d37-4536-9863-d7486fcfb8f0" xlink:to="loc_country_US_abbfef35-6723-4f5a-8368-94d355baf44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_1fd771e4-58b6-4db4-be71-b671e6957f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb717957-8651-4a78-a843-bcb95cee11a7" xlink:to="loc_us-gaap_ForeignPlanMember_1fd771e4-58b6-4db4-be71-b671e6957f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_31f740d8-8b93-45cb-bc4f-99c21b127aaf" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_73f74d56-90d8-4e10-96b4-39df8a4e44f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_73f74d56-90d8-4e10-96b4-39df8a4e44f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c8127fc9-eacb-4824-a3eb-dc76dfe3179c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_35af62ae-3948-4051-89dd-106b84f2afe2" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c8127fc9-eacb-4824-a3eb-dc76dfe3179c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4084ecc7-11c6-40d0-a793-d6e7f0a4291f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f91107ac-fb7b-4333-8959-1d16a0d19111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_f91107ac-fb7b-4333-8959-1d16a0d19111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dda7f35e-defa-44ea-b64c-99a0132bd451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dda7f35e-defa-44ea-b64c-99a0132bd451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_83431585-ee97-43aa-ac62-b976880151ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_83431585-ee97-43aa-ac62-b976880151ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_4b5591fd-1867-4ae4-8dd6-4da4e7d1b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_4b5591fd-1867-4ae4-8dd6-4da4e7d1b8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_35b252ea-1c73-48eb-9d9b-6fd9ddd83354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_35b252ea-1c73-48eb-9d9b-6fd9ddd83354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_34609ecf-a1c3-4aff-b815-fdffc6c4e40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_34609ecf-a1c3-4aff-b815-fdffc6c4e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6e2291d9-df2d-4ebf-b781-52652a1a580b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_6e2291d9-df2d-4ebf-b781-52652a1a580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_53728cb6-345f-4945-aea5-3cfe4f082713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_22f8ae63-09ff-4bc8-a8da-c4992a57f0f7" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_53728cb6-345f-4945-aea5-3cfe4f082713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b31cc6b0-ce0b-4d41-a3f4-8e66b59015ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b31cc6b0-ce0b-4d41-a3f4-8e66b59015ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b6d1e97d-3977-4410-875c-2bbdc297233a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_b6d1e97d-3977-4410-875c-2bbdc297233a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5a1245c6-d52e-4b62-b095-4b47d48abf05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5a1245c6-d52e-4b62-b095-4b47d48abf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6220a863-8b75-4ee9-afb1-8d515afae036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_6220a863-8b75-4ee9-afb1-8d515afae036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_38696b77-b7f6-482e-8498-f0ac34c6af72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_38696b77-b7f6-482e-8498-f0ac34c6af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_89394b81-7f94-4a29-83fe-eccf25a81192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_89394b81-7f94-4a29-83fe-eccf25a81192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dec0cce4-8b6c-430c-a644-6bcc04b36aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_285d254b-e349-481a-9d94-b8dccb2bddb3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_dec0cce4-8b6c-430c-a644-6bcc04b36aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a2d3f290-0454-4056-9244-fcdc1c668845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a2d3f290-0454-4056-9244-fcdc1c668845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4ffc2d8a-7ace-4b02-a14e-5e377ab68c99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_e00d27ec-f3df-43b3-8cf4-447ae3cd3205" xlink:href="bhc-20221231.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_e00d27ec-f3df-43b3-8cf4-447ae3cd3205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_45ab2b06-67f0-4e76-9638-2c5999ca1212" xlink:href="bhc-20221231.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_45ab2b06-67f0-4e76-9638-2c5999ca1212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_735fbe4c-d707-4127-aab3-e35cac8e1a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_7558766b-6266-4d6d-b68c-c26addaa2b9b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_735fbe4c-d707-4127-aab3-e35cac8e1a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b57e8c53-7e9e-4b1d-9b24-7eda499571fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b57e8c53-7e9e-4b1d-9b24-7eda499571fd" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b33b0e30-1ec7-41f4-b33b-c713a4215917" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:to="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b5b50e34-d163-4e7e-89fb-f151fdbd2823" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_dc584641-3860-4475-9f73-db9dd63090f4" xlink:to="loc_country_US_b5b50e34-d163-4e7e-89fb-f151fdbd2823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_15239644-0d3f-496b-8cf0-1b23282d4a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_68cb6dbb-11ba-4199-817c-8fae77b64e67" xlink:to="loc_us-gaap_ForeignPlanMember_15239644-0d3f-496b-8cf0-1b23282d4a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4860dc39-889d-4179-9814-9861d4e98e2a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_57b793fd-c352-4d33-b116-6ed9b86c8a8e" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78912db1-3f29-493d-b77e-bf7a835ae1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_78912db1-3f29-493d-b77e-bf7a835ae1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_6a19191b-973d-4752-9eb3-835c9fadc288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_6a19191b-973d-4752-9eb3-835c9fadc288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d7eeed7b-dea9-4331-9ff4-d7306b15d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_c9f838c4-1907-4f0d-a565-273a4f761383" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_d7eeed7b-dea9-4331-9ff4-d7306b15d06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c88a1fa2-e590-47f8-8b36-4129cb00a9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c88a1fa2-e590-47f8-8b36-4129cb00a9d6" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b1b03995-9388-4512-b7ae-3612b35b4ac0" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_567f6298-8e59-497e-bf6b-f3507daf3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_567f6298-8e59-497e-bf6b-f3507daf3f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_513675a1-acc7-4f9a-b374-7d8e02c6da3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1fa9a552-b51b-44ec-abf5-dbd53c7b80c1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_513675a1-acc7-4f9a-b374-7d8e02c6da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c99fca70-de5c-495e-af59-a41819d891f1" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:to="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8d32672-dc73-477f-9366-4556b4d7b604" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_edaf2f1f-881f-4b34-9044-feff027767e1" xlink:to="loc_country_US_f8d32672-dc73-477f-9366-4556b4d7b604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7d20e9d3-9951-4af9-976f-fd04759668e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_940a44cf-fbda-4c3d-b2b3-b38cc0e3ae02" xlink:to="loc_us-gaap_ForeignPlanMember_7d20e9d3-9951-4af9-976f-fd04759668e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_b0bd00ba-5550-434e-bbaa-6cef8b71cd7c" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ee1d1471-7b43-46dc-b048-fc9309af1471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_ee1d1471-7b43-46dc-b048-fc9309af1471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_290dd821-2e82-401a-8957-e342850702be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_290dd821-2e82-401a-8957-e342850702be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c2b90e74-a65e-4343-b38b-3552136031a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_c2b90e74-a65e-4343-b38b-3552136031a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_749a9dfc-c3aa-460b-9be4-7917b462ad05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_749a9dfc-c3aa-460b-9be4-7917b462ad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8ffe7fbe-2493-4b6a-ad58-9aec60c951fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_8ffe7fbe-2493-4b6a-ad58-9aec60c951fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_83a299c3-e2b9-4116-afd1-8af779d554f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_ad0fa375-9b5a-41ce-8e35-d49d01d1bf15" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_83a299c3-e2b9-4116-afd1-8af779d554f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fd121a7f-f0e3-4ac2-a68b-775d5fe72cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fd121a7f-f0e3-4ac2-a68b-775d5fe72cfb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4afd378f-8104-4c19-9f69-f95a8750f7be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a7d8d70a-33bd-4f45-aff9-82fb5f908976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a7d8d70a-33bd-4f45-aff9-82fb5f908976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_79a68616-d991-41f0-aa4e-b91114715ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d9fe7025-a8d6-4378-8472-4b8e716ab01e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_79a68616-d991-41f0-aa4e-b91114715ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbdff44f-657d-450b-9753-e86b5f6b2d0a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:to="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b133bcfc-2e4d-4b87-8c7a-585970a8b14c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_d94d2cc7-aa99-4b64-bf2d-3ed559b74410" xlink:to="loc_country_US_b133bcfc-2e4d-4b87-8c7a-585970a8b14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_56a30834-5463-4618-a4b6-c79929ffda55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0e313016-5d5f-4a6b-9446-e23af7842a63" xlink:to="loc_us-gaap_ForeignPlanMember_56a30834-5463-4618-a4b6-c79929ffda55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_94595a25-c3ab-4a81-96b9-45609ae9cb96" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_6dffbbab-7161-422f-bb5f-2a99c3a54a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_6dffbbab-7161-422f-bb5f-2a99c3a54a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_aeb18b95-07f5-4719-bf4b-c4c51e6252c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_aeb18b95-07f5-4719-bf4b-c4c51e6252c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c35d5032-458f-46e8-a9ea-a7f74d264169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_c35d5032-458f-46e8-a9ea-a7f74d264169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_2325fee9-1f38-401d-a4f4-e3043955afae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_a20f6030-7971-4337-8985-ee5c999b7dfe" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_2325fee9-1f38-401d-a4f4-e3043955afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19cd95fb-d4cf-4a07-b63c-6dc3b0d55e86" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1e6755cc-673e-4267-a2d9-f2608f3c4858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1e6755cc-673e-4267-a2d9-f2608f3c4858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_a73ffc7f-5234-4733-aefd-c9d1d116f36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_a73ffc7f-5234-4733-aefd-c9d1d116f36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_696bda6e-e3be-477b-a99a-b5a2640b7959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_88d97ab9-d4bd-4362-95e4-a690974c3ed7" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_696bda6e-e3be-477b-a99a-b5a2640b7959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_29a72f0f-7828-4d37-9f9a-c5c01ac76c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_29a72f0f-7828-4d37-9f9a-c5c01ac76c29" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_b02d822f-80ba-4b70-9303-254cd708535a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_3776a90b-4e29-4b6f-ac6b-9c9229d93d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_4983686b-cf11-4b68-bee3-b075755dc7a3" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_3776a90b-4e29-4b6f-ac6b-9c9229d93d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ed968605-be7b-4643-a72f-99e0c8aaed15" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:to="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b94039db-630e-4464-ab2d-f6dad164c519" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_709260eb-11bc-4a41-b7c3-3dff7766f214" xlink:to="loc_country_US_b94039db-630e-4464-ab2d-f6dad164c519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_5ea57ec8-39fa-4caf-8031-33f7ed4ba5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6751dbe8-d067-40af-9832-451bcee347df" xlink:to="loc_us-gaap_ForeignPlanMember_5ea57ec8-39fa-4caf-8031-33f7ed4ba5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f6b2cdef-e0d4-4ee7-a118-ce35c281cc49" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_4b41576f-f380-467b-b7e7-0eb3cbaced23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_4b41576f-f380-467b-b7e7-0eb3cbaced23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_91a3fbf5-a4b3-4237-8639-647e57430b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_91a3fbf5-a4b3-4237-8639-647e57430b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_1b8e413e-edae-4fa6-b019-1feb71052c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_1b8e413e-edae-4fa6-b019-1feb71052c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_1ea0301e-11a4-40ae-9cbf-3c420f4a0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c6d6167b-b4ad-4932-8913-a6fbe3ff94c0" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_1ea0301e-11a4-40ae-9cbf-3c420f4a0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2de8b4b6-1dc9-4240-b3e0-09faec3c51c8" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_a6f47eb5-9f6f-4003-beaf-e4cb88b1d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_78632abc-ec4d-4c33-80e6-7ee964b51faa" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_a6f47eb5-9f6f-4003-beaf-e4cb88b1d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af7f91a4-5507-423c-8929-3b382acd27f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_af7f91a4-5507-423c-8929-3b382acd27f8" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_bd13d8d6-0d09-48c3-82ca-b77375d6143b" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_8a944e21-fee7-404a-92e1-5d8c5336059c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_8a944e21-fee7-404a-92e1-5d8c5336059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_7d4e2b7f-a639-45f4-8043-208f8fb09d29" xlink:href="bhc-20221231.xsd#bhc_U.S.BroadMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_U.S.BroadMarketMember_7d4e2b7f-a639-45f4-8043-208f8fb09d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_c93132a1-059b-4c7a-917f-7253e0066e9d" xlink:href="bhc-20221231.xsd#bhc_EmergingMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_EmergingMarketsMember_c93132a1-059b-4c7a-917f-7253e0066e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_dca97654-ef50-40fa-bfba-e39bc0e8e1fe" xlink:href="bhc-20221231.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_dca97654-ef50-40fa-bfba-e39bc0e8e1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_bd64c7b3-f9c5-4d50-884f-c22766b9e817" xlink:href="bhc-20221231.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_8b01e380-d2b1-4f67-8a4e-69a80439d271" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_bd64c7b3-f9c5-4d50-884f-c22766b9e817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_7b74da11-d6f9-48c7-b9f5-60f6156ea900" xlink:href="bhc-20221231.xsd#bhc_InvestmentGradeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:to="loc_bhc_InvestmentGradeMember_7b74da11-d6f9-48c7-b9f5-60f6156ea900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_911f77bd-f8f8-407a-baa7-766ce9743f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_644f67ce-0285-48ea-93f7-e304ace2a962" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_911f77bd-f8f8-407a-baa7-766ce9743f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_4749f55a-909e-4a4c-8b57-026a13152406" xlink:href="bhc-20221231.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_d236df7a-9133-40d3-ac17-35fed39db979" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_4749f55a-909e-4a4c-8b57-026a13152406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d99ff95-7036-44a4-ac5e-9bbd493113f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_00d234ba-7fe4-4f99-9347-884f83f3e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_00d234ba-7fe4-4f99-9347-884f83f3e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6db80133-988d-4945-a983-1639c8c7542d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6db80133-988d-4945-a983-1639c8c7542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72aaadb7-a8a3-492b-b28e-22060c4da0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_850eec16-a56f-4a66-9b2c-c170a07dd25c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72aaadb7-a8a3-492b-b28e-22060c4da0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_c0e9e2e9-00d7-4d76-9f26-e0ddf4b2542a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_06a67732-8854-407c-ad17-090d3ab9f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_75a3d90b-36f2-42bc-9253-497070244d60" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_06a67732-8854-407c-ad17-090d3ab9f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf7f49f3-657f-4199-98b3-3a6507ffc9a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_baf86216-060b-4450-b3d3-16ecdd1aee85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3aba798-2bfd-4e7e-a250-eb83fa49db63" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_baf86216-060b-4450-b3d3-16ecdd1aee85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_53b089da-36f0-4754-943f-1d5e393b1d94" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:to="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e51c6697-8899-4d50-ae0f-e855ad260739" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_95cef791-60f9-4ef7-88ab-f4e7fc1c01e4" xlink:to="loc_country_US_e51c6697-8899-4d50-ae0f-e855ad260739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_235cae61-6447-4101-9a32-3535a4fc1bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3963f283-9674-4b0c-80e4-fc3a8533e5a6" xlink:to="loc_us-gaap_ForeignPlanMember_235cae61-6447-4101-9a32-3535a4fc1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e1f928f1-1f5a-40d8-9c7f-b07db3d66150" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0029437-f0b0-4b84-a612-5bfcf0c01458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_00bf7634-64ea-44a4-ac92-2b8e3bc212c8" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0029437-f0b0-4b84-a612-5bfcf0c01458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa59c395-c328-4eae-9801-4f8525b39950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract_4ab94a07-dca9-4624-88d0-58c151bccc90" xlink:href="bhc-20221231.xsd#bhc_AssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa59c395-c328-4eae-9801-4f8525b39950" xlink:to="loc_bhc_AssetsLesseeAbstract_4ab94a07-dca9-4624-88d0-58c151bccc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_44da4117-6076-4bb4-a3bb-03bc6033b8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetsLesseeAbstract_4ab94a07-dca9-4624-88d0-58c151bccc90" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_44da4117-6076-4bb4-a3bb-03bc6033b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d9a2551e-e7f7-4806-a586-904d68b326a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetsLesseeAbstract_4ab94a07-dca9-4624-88d0-58c151bccc90" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d9a2551e-e7f7-4806-a586-904d68b326a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:href="bhc-20221231.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa59c395-c328-4eae-9801-4f8525b39950" xlink:to="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca34860a-9fbe-470e-9e84-a8558477493d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca34860a-9fbe-470e-9e84-a8558477493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_fb00530a-f526-4d33-ba44-9be504655a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_fb00530a-f526-4d33-ba44-9be504655a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea92954c-e8b1-42e3-86c9-8539607828ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ea92954c-e8b1-42e3-86c9-8539607828ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_cb41184d-8748-409a-80bb-19b2b737d74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_cb41184d-8748-409a-80bb-19b2b737d74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1a0f7caf-37ee-4466-b3b8-d531bf3b848d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_ab7a1007-150b-4d8e-8f94-326f14bd9517" xlink:to="loc_us-gaap_OperatingLeaseLiability_1a0f7caf-37ee-4466-b3b8-d531bf3b848d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b0a0c254-8f20-425b-a61a-3f4c40f79944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5c614fc2-1a1a-4a26-8f9a-46070ccebbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0a0c254-8f20-425b-a61a-3f4c40f79944" xlink:to="loc_us-gaap_FinanceLeaseLiability_5c614fc2-1a1a-4a26-8f9a-46070ccebbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_ac2dac58-5c98-4499-a6f6-434ac198f967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0a0c254-8f20-425b-a61a-3f4c40f79944" xlink:to="loc_us-gaap_SubleaseIncome_ac2dac58-5c98-4499-a6f6-434ac198f967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_d90e20ac-084a-4fab-97f9-29b51f5bd348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b0a0c254-8f20-425b-a61a-3f4c40f79944" xlink:to="loc_us-gaap_ShortTermLeaseCost_d90e20ac-084a-4fab-97f9-29b51f5bd348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6c5140fe-8a8f-4d49-953f-18e5cd9e050e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9c6cd1d2-be27-4798-9d2e-6ad2057a256d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c5140fe-8a8f-4d49-953f-18e5cd9e050e" xlink:to="loc_us-gaap_OperatingLeaseCost_9c6cd1d2-be27-4798-9d2e-6ad2057a256d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_449d43a1-1959-41ba-93ce-840b5f840eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c5140fe-8a8f-4d49-953f-18e5cd9e050e" xlink:to="loc_us-gaap_VariableLeaseCost_449d43a1-1959-41ba-93ce-840b5f840eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3534a94b-9703-414c-9610-9e130ee68315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_593a6d1c-a11e-475f-b834-912a694ae825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3534a94b-9703-414c-9610-9e130ee68315" xlink:to="loc_us-gaap_OperatingLeasePayments_593a6d1c-a11e-475f-b834-912a694ae825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_68286ba8-78db-4952-9130-a609e3a4b26b" xlink:href="bhc-20221231.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3534a94b-9703-414c-9610-9e130ee68315" xlink:to="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_68286ba8-78db-4952-9130-a609e3a4b26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eb44c383-db0d-4b0f-8c8b-18e069e49401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3534a94b-9703-414c-9610-9e130ee68315" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eb44c383-db0d-4b0f-8c8b-18e069e49401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e389c969-7eda-487d-a210-0fa009f06bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3534a94b-9703-414c-9610-9e130ee68315" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e389c969-7eda-487d-a210-0fa009f06bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9ce0c435-5650-4b58-ae01-165137751824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9ce0c435-5650-4b58-ae01-165137751824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_28766874-8313-4524-994d-3d6d90dd1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_28766874-8313-4524-994d-3d6d90dd1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f636631-ce54-49c5-88ee-805a7803f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f636631-ce54-49c5-88ee-805a7803f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be214a85-5524-4b19-8c79-7dc2735346a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be214a85-5524-4b19-8c79-7dc2735346a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d2621d6f-3d02-4eab-aff3-d78105800274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d2621d6f-3d02-4eab-aff3-d78105800274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9dd834dc-bab1-4e39-a253-e23831f98cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9dd834dc-bab1-4e39-a253-e23831f98cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08b60d8c-8d19-4f22-97ab-c94670bab8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08b60d8c-8d19-4f22-97ab-c94670bab8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4474ec05-b124-4ac6-bc44-cc394094b958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4474ec05-b124-4ac6-bc44-cc394094b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_04868c7a-916d-466c-b274-841bfa6778ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_OperatingLeaseLiability_04868c7a-916d-466c-b274-841bfa6778ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_25d217c0-6900-4a95-bc67-9902b2457307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_25d217c0-6900-4a95-bc67-9902b2457307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9238405-e217-45ff-bbf9-832dd3e13b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf98d3c-3c4f-4ee8-8428-a454002acb52" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c9238405-e217-45ff-bbf9-832dd3e13b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb42fe0f-4bcf-473d-8c3c-8f78cddff736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eb42fe0f-4bcf-473d-8c3c-8f78cddff736" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9a5dd47a-5454-4c5a-b4a2-2db4a634f976" xlink:to="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_6b50e840-2518-440b-803e-e8c9707ff856" xlink:href="bhc-20221231.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_cf51627e-2368-4c4d-99bf-b85f7c253306" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_6b50e840-2518-440b-803e-e8c9707ff856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_f62829ab-72aa-4740-a513-de1c0f079382" xlink:href="bhc-20221231.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_IPOFoundersGrantsMember_f62829ab-72aa-4740-a513-de1c0f079382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_787c6def-78b2-4539-9b3c-12570e3cca1c" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_c7abdd7e-7fce-457c-b100-18b23fa7bebf" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember_1c8c90f4-6c22-4f09-8cfe-284dc71a0937" xlink:to="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_c7abdd7e-7fce-457c-b100-18b23fa7bebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2c71aea1-e444-4693-8d84-4b79ae0f0504" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_1beac531-6dc1-4c97-96af-84710e5ba20c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:to="loc_srt_ExecutiveOfficerMember_1beac531-6dc1-4c97-96af-84710e5ba20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_27b4be76-0f5b-487d-b307-8cf4446e5d7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_634163f6-1808-4757-be17-ce2cc7a7716e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_27b4be76-0f5b-487d-b307-8cf4446e5d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_32ec6c96-ab12-467f-a2c0-58eb52b15884" xlink:href="bhc-20221231.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_32ec6c96-ab12-467f-a2c0-58eb52b15884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_e7b46ec8-8ac3-4949-b95d-4fab9db5264d" xlink:href="bhc-20221231.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_e7b46ec8-8ac3-4949-b95d-4fab9db5264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_a090ba4e-04b5-4b00-9efa-5da9dacb54d9" xlink:href="bhc-20221231.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_a090ba4e-04b5-4b00-9efa-5da9dacb54d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainEmployeesMember_3f094069-1a07-40ff-bcee-b27a4d95546e" xlink:href="bhc-20221231.xsd#bhc_CertainEmployeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69022037-82a0-45fb-930b-04e09dca503e" xlink:to="loc_bhc_CertainEmployeesMember_3f094069-1a07-40ff-bcee-b27a4d95546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc5e8a3a-fd2c-41c0-a87f-7516e51c3c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:href="bhc-20221231.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bfb06713-cac7-45e8-ac3a-f5a948a90529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bfb06713-cac7-45e8-ac3a-f5a948a90529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa570a20-78a9-487d-9c6f-4c0aab854d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_0c95b616-80b4-40f9-8a89-db715322de5d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa570a20-78a9-487d-9c6f-4c0aab854d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_db3cbd99-e0bc-4d0e-8140-4b17820cd3a6" xlink:href="bhc-20221231.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_TimeBasedRSUMember_db3cbd99-e0bc-4d0e-8140-4b17820cd3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_037fa58d-8b67-4624-8dad-4a47ebbc2bfb" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_037fa58d-8b67-4624-8dad-4a47ebbc2bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_8963e2fd-74d3-4254-a33a-53df447df45c" xlink:href="bhc-20221231.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_8963e2fd-74d3-4254-a33a-53df447df45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_8950740c-8b26-4634-b06a-a16cfb6ab60b" xlink:href="bhc-20221231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_704e4d26-37ea-49dc-9889-7d933dbfa890" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_8950740c-8b26-4634-b06a-a16cfb6ab60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_349749d2-176c-4b61-8082-7768be34cc2d" xlink:to="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8baff32d-fc95-472c-ac99-3a9453024b18" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b52fd46d-54cf-48c9-a688-c99f21d3a865" xlink:to="loc_bhc_BauschLombMember_8baff32d-fc95-472c-ac99-3a9453024b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_4320c1d3-2a92-493a-9427-e1293e9d2846" xlink:to="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3b969881-ce79-4bbf-85cd-bd8c41a3daff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3b969881-ce79-4bbf-85cd-bd8c41a3daff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_984c67c4-76ef-46c1-b614-36d9d5e18553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_984c67c4-76ef-46c1-b614-36d9d5e18553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_51caf965-5eec-4320-84ca-346425e5bbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_229da44a-6187-4f2a-86d0-0b63cf7f90df" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_51caf965-5eec-4320-84ca-346425e5bbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e6db84-eb4d-4caa-b54d-dc59b4cfe276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ccab8241-08da-4933-9b19-6a9334bbc27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ccab8241-08da-4933-9b19-6a9334bbc27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_50ae5f8f-8e6b-4804-a46c-4b16f70e15e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_50ae5f8f-8e6b-4804-a46c-4b16f70e15e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_495f3f7c-0dfc-438d-89e7-96a66e74f029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_495f3f7c-0dfc-438d-89e7-96a66e74f029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ba11c4c-5c5b-4b22-9e9a-73173609f249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ba11c4c-5c5b-4b22-9e9a-73173609f249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0d7137eb-6fee-480b-a342-8ddc3d365f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0d7137eb-6fee-480b-a342-8ddc3d365f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e9e18fee-8888-4ac2-991e-193416f339bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e9e18fee-8888-4ac2-991e-193416f339bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_ea35d340-6077-4695-ad2a-478262a0a6b1" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_ea35d340-6077-4695-ad2a-478262a0a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b397f419-86b6-46f6-af5f-bde17a761d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b397f419-86b6-46f6-af5f-bde17a761d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c853b151-6315-4683-8c52-b3ed075037fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c853b151-6315-4683-8c52-b3ed075037fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_94db0473-37f1-4ddc-8459-64eddb9022f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_94db0473-37f1-4ddc-8459-64eddb9022f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2bffd66-345c-4f09-8b90-91cdf265fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a2bffd66-345c-4f09-8b90-91cdf265fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_974d8331-e66c-49c8-9870-689804ee83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_974d8331-e66c-49c8-9870-689804ee83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_a896181c-f5e7-4e8a-b00f-73f0bd572acc" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_a896181c-f5e7-4e8a-b00f-73f0bd572acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_492e1c84-a87e-4fc1-a394-8fe343ddc19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_492e1c84-a87e-4fc1-a394-8fe343ddc19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_936585a0-0712-428c-b7b5-2d01c913e205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_936585a0-0712-428c-b7b5-2d01c913e205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d2e9d8b-105a-4b96-b5d7-2747065b544a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7d2e9d8b-105a-4b96-b5d7-2747065b544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_12f1a0bf-afd4-4791-9ad0-5b1d5fa6b188" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_12f1a0bf-afd4-4791-9ad0-5b1d5fa6b188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4caed5bc-4970-4eba-9662-3ef2ebd6d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4caed5bc-4970-4eba-9662-3ef2ebd6d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_ab567625-8be2-4f8a-97ca-93ca74df247f" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_ab567625-8be2-4f8a-97ca-93ca74df247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_98c225aa-69c4-4729-a1fb-17f8edd9ebb6" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_98c225aa-69c4-4729-a1fb-17f8edd9ebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_798d74f7-6665-4a3b-b29f-e382327a6b9a" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_798d74f7-6665-4a3b-b29f-e382327a6b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_44c10ac5-a2ba-4c49-9f5c-e195a8c3e5d9" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_44c10ac5-a2ba-4c49-9f5c-e195a8c3e5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_23b2e187-591d-49b4-ad9c-edf23e321f3d" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting_23b2e187-591d-49b4-ad9c-edf23e321f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_31a89bb6-6b16-480e-82dc-fb7da387f052" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest_31a89bb6-6b16-480e-82dc-fb7da387f052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_d6a3d119-781e-4a2f-b982-27560dde8403" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_fef5eca6-2104-479a-80d1-9cd875301312" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_fef5eca6-2104-479a-80d1-9cd875301312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15d5416d-0dfd-4909-b3c3-bde1f6b06a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fcca6522-3afb-4515-bc24-34fca2e8f252" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15d5416d-0dfd-4909-b3c3-bde1f6b06a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21a50128-56e5-42e8-bb47-33f01737e2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21a50128-56e5-42e8-bb47-33f01737e2fa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9450321e-b2c5-4446-b3d1-e743076b803a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0ff2d2f-f3b7-4054-b585-e0c046e7f784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0ff2d2f-f3b7-4054-b585-e0c046e7f784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a285a4a-6296-4977-b0fa-66ff8858692c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_983ec3ad-6486-4e3b-97c2-6ca7a4c8267d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a285a4a-6296-4977-b0fa-66ff8858692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_aa7e68fa-fe91-4e2e-883a-3ec681ce0502" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a7d48ec1-7e89-4287-bb80-bc5c8b687a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a7d48ec1-7e89-4287-bb80-bc5c8b687a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_a099e230-5e9c-4545-b516-6aab7eea666e" xlink:href="bhc-20221231.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3cc35348-3bd1-4428-b141-8c4999f5d620" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_a099e230-5e9c-4545-b516-6aab7eea666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3b40827b-0e1c-4a42-b55c-9117178b3161" xlink:to="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_07326d05-2c79-48c4-bd44-70876c19d592" xlink:href="bhc-20221231.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_02fe2c95-81e7-46a8-bc6d-25dacfbe17aa" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_07326d05-2c79-48c4-bd44-70876c19d592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e53e5e9a-08fe-4d74-a64f-1a2620ec75af" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_25f36c35-2c65-453f-935f-e662984013f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:to="loc_us-gaap_ShareBasedCompensation_25f36c35-2c65-453f-935f-e662984013f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b62a514c-1242-471a-938e-892394089df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2eb4dcf1-d977-4d23-9f3a-ea9a3b6a9e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b62a514c-1242-471a-938e-892394089df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9408757-2af4-484c-a441-7362bd27ca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9408757-2af4-484c-a441-7362bd27ca1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_ef2e201d-4907-4e35-8c78-8a6bbe968033" xlink:to="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8ab39188-306b-4e5b-807e-a8b9e8019b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8ab39188-306b-4e5b-807e-a8b9e8019b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9fe594fd-9bd6-4c1c-83ae-4a311a538d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d147513b-eab2-47bf-b7eb-f522f2c06340" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9fe594fd-9bd6-4c1c-83ae-4a311a538d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_901dfad3-8718-4522-8b44-5c387c932080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1a775897-12fc-4d18-b264-091d4523382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5cec2bf-1414-466a-849d-342c4ab2fd14" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1a775897-12fc-4d18-b264-091d4523382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_eea634fb-0181-4cbb-88b4-1713992f12af" xlink:to="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_61049084-8387-4ee6-938c-78c027e6ce52" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1485a6c-e9e9-4caa-b9d7-6739e81fb377" xlink:to="loc_bhc_BauschLombMember_61049084-8387-4ee6-938c-78c027e6ce52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad02d344-f975-4cc3-8acc-e3c02c7ad78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_f3641741-fb9f-4038-be7e-9aecc3346203" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_f3641741-fb9f-4038-be7e-9aecc3346203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c99ca97-281a-4109-8851-c754a6ea1929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0c99ca97-281a-4109-8851-c754a6ea1929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c35f0ec-63f3-4e9d-ab3e-e6cd805f567c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c35f0ec-63f3-4e9d-ab3e-e6cd805f567c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ac40c386-a2cb-4f72-90ed-dade3fff9bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ac40c386-a2cb-4f72-90ed-dade3fff9bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0815108-7952-4a49-add9-3f97b9256f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e0815108-7952-4a49-add9-3f97b9256f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c0b3060-0574-44d5-81d3-a146785afeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ad2b7d5e-cc0e-41f8-97aa-a8d15b4c999a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c0b3060-0574-44d5-81d3-a146785afeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195b9c1b-aee4-4e1e-b491-a22957bfd9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_195b9c1b-aee4-4e1e-b491-a22957bfd9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7c88269a-5161-4390-9e82-62bf3ecbd09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7c88269a-5161-4390-9e82-62bf3ecbd09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7a21969-66c0-4063-807f-78b781e215a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7a21969-66c0-4063-807f-78b781e215a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8de1dbf5-7dda-4fe6-a066-af413b2f3b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8de1dbf5-7dda-4fe6-a066-af413b2f3b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0380ed48-9b6f-4fa6-9460-5cf5bc69762c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_553b73fc-8999-4c77-a314-700b777f8d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0380ed48-9b6f-4fa6-9460-5cf5bc69762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_560d62b5-7f0a-48d2-92f6-01a506907119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_560d62b5-7f0a-48d2-92f6-01a506907119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_95397365-577d-4356-914e-b683ea4666b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_95397365-577d-4356-914e-b683ea4666b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62f96973-dca1-4603-9875-a98a19e4100e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62f96973-dca1-4603-9875-a98a19e4100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_294485ab-ccc9-45a5-b728-57455a05525d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_294485ab-ccc9-45a5-b728-57455a05525d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44bd8183-5594-446d-8675-7a1b54ade7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44bd8183-5594-446d-8675-7a1b54ade7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6f0fd882-50a8-4280-bf76-7aca0cbe74e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_6f0fd882-50a8-4280-bf76-7aca0cbe74e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f6fe8c8d-b622-47bc-b5cb-e8635a3d12ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_60ba9309-1bfd-42ea-8cae-fd6993baf923" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f6fe8c8d-b622-47bc-b5cb-e8635a3d12ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a27a2d2d-02bc-44bd-bcb8-7105758f533c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a27a2d2d-02bc-44bd-bcb8-7105758f533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c8f97ccc-045e-440e-b77a-41d471cdea17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c8f97ccc-045e-440e-b77a-41d471cdea17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf932698-9e86-4ee7-9d70-0b33449e9491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cf932698-9e86-4ee7-9d70-0b33449e9491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ebfe423d-34bd-4924-ae7a-c08a0770d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ebfe423d-34bd-4924-ae7a-c08a0770d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_da44935d-8639-4e6f-89d5-a0cd1f2dd509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_040c3f1a-e946-4fc4-843d-800fe023d0fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_da44935d-8639-4e6f-89d5-a0cd1f2dd509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9b966895-c231-43c1-8833-f7b10ce05636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9b966895-c231-43c1-8833-f7b10ce05636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38376a11-5c75-48c2-881a-02cb2d3bc817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_38376a11-5c75-48c2-881a-02cb2d3bc817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70528000-bb5c-4627-b4fc-6b0f16ddf202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ee0e65e4-e252-43b8-ac98-f5825a91d7c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_70528000-bb5c-4627-b4fc-6b0f16ddf202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a2631fe-9bf1-4d37-ae60-986f9a65723f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6679c78f-2a1d-4454-b947-5baea5fabb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6679c78f-2a1d-4454-b947-5baea5fabb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_408dbddb-de07-43d7-8f11-35ff43e83659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_408dbddb-de07-43d7-8f11-35ff43e83659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9764ce8c-b51f-4f81-87f8-63b5f7e1ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9764ce8c-b51f-4f81-87f8-63b5f7e1ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec79342b-f734-4214-87b0-b3cdadb816d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec79342b-f734-4214-87b0-b3cdadb816d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f64d817-3f51-4d72-93e7-e6a18c03c531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_171afac1-3da6-4926-9f74-6df184330219" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7f64d817-3f51-4d72-93e7-e6a18c03c531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4db8685-e718-4195-915f-ef25b268df77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4db8685-e718-4195-915f-ef25b268df77" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:to="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4c60529c-db90-44d5-afe3-21569a017c58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_416d128f-7668-4037-a39f-133a1769e384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_416d128f-7668-4037-a39f-133a1769e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_629a523e-d8b3-48c7-9226-f9e83061b311" xlink:href="bhc-20221231.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_bhc_TimeBasedRSUMember_629a523e-d8b3-48c7-9226-f9e83061b311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f3b644c-7f82-4a23-95d5-196ce564a118" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_d0b7e752-18e9-4f5f-8450-6c6a310f4037" xlink:href="bhc-20221231.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_d23ef2a2-1fe6-4f9c-ab2b-8f52a9cbb5c0" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_d0b7e752-18e9-4f5f-8450-6c6a310f4037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:to="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ffed4673-feef-45ac-aa8c-660dd9fdc804" xlink:to="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c4a58384-a7ac-48fe-8195-5fd7d710315b" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1a28df1-828c-41b6-a0eb-f5490381103d" xlink:to="loc_bhc_BauschLombMember_c4a58384-a7ac-48fe-8195-5fd7d710315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acbd48e2-0837-4ce5-b3b9-fc6f5bf0c603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_396c36af-f33f-459f-a12b-27b79163c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_396c36af-f33f-459f-a12b-27b79163c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dac229e-c8a2-4298-9a48-1c6d18d1220d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dac229e-c8a2-4298-9a48-1c6d18d1220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10cc6275-ea1c-491a-b622-a4b4151c175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_10cc6275-ea1c-491a-b622-a4b4151c175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d8ee405c-9d2f-47b6-b592-e9f3609010fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d8ee405c-9d2f-47b6-b592-e9f3609010fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95303f30-54c8-4c39-b52d-630beaa83a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_95303f30-54c8-4c39-b52d-630beaa83a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_c88299de-05d2-490b-8cfe-650e6d9fceef" xlink:href="bhc-20221231.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_c88299de-05d2-490b-8cfe-650e6d9fceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ec88277-a901-41ee-a162-f54b62853df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ec88277-a901-41ee-a162-f54b62853df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68673c53-e643-46a7-b1a8-e82b2c83ae5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_68673c53-e643-46a7-b1a8-e82b2c83ae5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a3b7890-19ff-421d-b5a9-1f356266f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a3b7890-19ff-421d-b5a9-1f356266f0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cc2572e-1f71-410e-b5ff-3ba46325675c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4cc2572e-1f71-410e-b5ff-3ba46325675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c3d6cc5-3a35-4ccc-b8d9-e7feccb57e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4b90a39f-5dc7-4d50-95a8-2d44c2397b24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c3d6cc5-3a35-4ccc-b8d9-e7feccb57e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2895b7a-bee2-48e3-832f-40922e97323f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2895b7a-bee2-48e3-832f-40922e97323f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d4bbd3c-96e5-4496-81e8-581ece3d8638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d4bbd3c-96e5-4496-81e8-581ece3d8638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_41947701-3aba-4901-b276-6cef82e12aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_41947701-3aba-4901-b276-6cef82e12aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3b1f5e9-0699-4073-91b3-64df573d8b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e3b1f5e9-0699-4073-91b3-64df573d8b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52071c17-622e-4dcc-9a76-6fd9f89b591b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0b505869-320f-4fdb-947b-c68490ab83cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52071c17-622e-4dcc-9a76-6fd9f89b591b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_675937a2-6457-455c-b0b6-aca59cbf8f65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1c8e7c7-e701-4be7-955b-f5b704ae3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1c8e7c7-e701-4be7-955b-f5b704ae3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_194aa211-e3db-442f-a255-59f19ee922bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_194aa211-e3db-442f-a255-59f19ee922bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f489d32-aa1b-4183-b6bf-2fc44b296424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_31257554-9c91-4972-94ce-83c9fdfbc548" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f489d32-aa1b-4183-b6bf-2fc44b296424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bb18be93-5cf7-45fc-9084-9330e4b962bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bb18be93-5cf7-45fc-9084-9330e4b962bc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4fab6b8e-9e1f-4ad5-a163-c8cb673d371b" xlink:to="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a7c32968-f282-411a-80a8-c38891f5994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a7c32968-f282-411a-80a8-c38891f5994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_14110f12-dad6-4315-bd67-4e3b23d6885f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_14110f12-dad6-4315-bd67-4e3b23d6885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b304c608-6bdd-4bfd-ad0c-dd9a3c4a19b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1b629183-6711-4273-8b83-7b9153608821" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b304c608-6bdd-4bfd-ad0c-dd9a3c4a19b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c2623779-0321-4630-b4f5-c9724609b012" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f32939b8-bd7e-43ed-8d9f-d905f372094a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_1937ddc4-f782-4351-b676-dee3765b2b50" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f32939b8-bd7e-43ed-8d9f-d905f372094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ef4d7ba0-7f2e-4a90-ad1e-0a08e5d8be98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef4d7ba0-7f2e-4a90-ad1e-0a08e5d8be98" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37ee13a6-005d-4d88-988d-7a0c8d67e268" xlink:to="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df22e784-e3f6-41bc-988b-9a7bdfd72941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1f4d0046-eebe-452a-a204-812d8836b91d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df22e784-e3f6-41bc-988b-9a7bdfd72941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_835c087b-7a54-405e-a63d-4528e5956ea1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bbb52ff4-65c5-4266-882f-ffb3cb459049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_8c1cf0c0-ce79-4e6f-b3bd-979d0a9d5781" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bbb52ff4-65c5-4266-882f-ffb3cb459049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_b7733d7d-81fd-433b-8c6a-55824a786d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_9a82c0f7-c162-42ad-891c-ebff9bc50202" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b7733d7d-81fd-433b-8c6a-55824a786d96" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_9a82c0f7-c162-42ad-891c-ebff9bc50202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_32a4fd53-adc8-4b1f-b919-ba2cc6942371" xlink:href="bhc-20221231.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b7733d7d-81fd-433b-8c6a-55824a786d96" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_32a4fd53-adc8-4b1f-b919-ba2cc6942371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_12b9b5f0-0c9f-454d-a714-026f71de53a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_b7733d7d-81fd-433b-8c6a-55824a786d96" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_12b9b5f0-0c9f-454d-a714-026f71de53a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENETScheduleofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_25c73890-a7c3-4d65-831d-e0b50560e5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_25c73890-a7c3-4d65-831d-e0b50560e5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c3ea6f68-13fe-455d-a4ae-751c44f411a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c3ea6f68-13fe-455d-a4ae-751c44f411a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_922afa40-cd29-46b9-9430-cae478399724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_922afa40-cd29-46b9-9430-cae478399724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0f17ce12-f1f8-4e36-94de-2253f339e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_0f17ce12-f1f8-4e36-94de-2253f339e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_040cb795-72f6-4808-9d64-aa109ccd3b39" xlink:href="bhc-20221231.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_bhc_OtherIncomeExpenseNet_040cb795-72f6-4808-9d64-aa109ccd3b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c919f16d-b9f1-44da-bba6-02e7cce3b436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e619efd7-8ff6-426b-85a8-331b58fc95db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c919f16d-b9f1-44da-bba6-02e7cce3b436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_31da9fe2-7e4e-448a-8b7d-b38afee0395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_31da9fe2-7e4e-448a-8b7d-b38afee0395c" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_820cf0b9-c82b-4f17-ad81-5e3f81fe6504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_9dad45a7-5bd6-4cb0-8a9c-d9a248b59bf2" xlink:href="bhc-20221231.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f104130-345f-4376-a128-a769fb0343d1" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_9dad45a7-5bd6-4cb0-8a9c-d9a248b59bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3cbcfe7d-c12d-4e44-bf20-0a12521288fd" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_c2113646-7302-4d22-82e9-8ae0b4b7d676" xlink:href="bhc-20221231.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5519dbda-fe29-4e61-88d7-468e308ea055" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_c2113646-7302-4d22-82e9-8ae0b4b7d676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7c3ad64-b757-4c47-b6ee-972542de7fd4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_667ae2a0-ec24-44d7-b23b-f427fe5fd039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3a108fdc-dfb9-4b72-a195-0aa5d5ddc73a" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_667ae2a0-ec24-44d7-b23b-f427fe5fd039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_eb1ab871-7f05-452d-bfec-570753b4b6c8" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_49be7f30-05ab-455e-9270-fbaf0e18eb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_49be7f30-05ab-455e-9270-fbaf0e18eb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a515074b-a508-45d3-ab71-90983428790a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a515074b-a508-45d3-ab71-90983428790a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_14880004-8c07-417c-aa65-5c70a0f43dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_14880004-8c07-417c-aa65-5c70a0f43dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8fce1c57-e246-476e-87bb-48f354a7788f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_9385bb9b-10f8-4ee1-802d-5152d6e82080" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8fce1c57-e246-476e-87bb-48f354a7788f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a06ceef2-992a-40e4-89cd-7af071ed6b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5e7f6e37-1dbd-40e7-aad1-ccd4f3007292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a06ceef2-992a-40e4-89cd-7af071ed6b1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5e7f6e37-1dbd-40e7-aad1-ccd4f3007292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_09e0d598-7aa4-4256-b46a-85d78625e18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5e7f6e37-1dbd-40e7-aad1-ccd4f3007292" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_09e0d598-7aa4-4256-b46a-85d78625e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6b4ad4a8-4cfd-473a-98ae-18648ec8eba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5e7f6e37-1dbd-40e7-aad1-ccd4f3007292" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_6b4ad4a8-4cfd-473a-98ae-18648ec8eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfba7d4f-aa04-4deb-9a84-6c5815e9ea20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5e7f6e37-1dbd-40e7-aad1-ccd4f3007292" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cfba7d4f-aa04-4deb-9a84-6c5815e9ea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4853bdb-8c2d-488d-8124-736af8b3dbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a06ceef2-992a-40e4-89cd-7af071ed6b1e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4853bdb-8c2d-488d-8124-736af8b3dbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c5a20cc-1140-4678-bfc3-a91110f8e16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4853bdb-8c2d-488d-8124-736af8b3dbff" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c5a20cc-1140-4678-bfc3-a91110f8e16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_75fe5995-6f59-440d-8a7f-f555bf80bc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4853bdb-8c2d-488d-8124-736af8b3dbff" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_75fe5995-6f59-440d-8a7f-f555bf80bc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3f9423fa-1998-4c93-bef5-d36917a4f37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4853bdb-8c2d-488d-8124-736af8b3dbff" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3f9423fa-1998-4c93-bef5-d36917a4f37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4df6607-e66a-48e9-a21c-496e152c2e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a06ceef2-992a-40e4-89cd-7af071ed6b1e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4df6607-e66a-48e9-a21c-496e152c2e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a6c5e556-f64e-4717-b97a-a31af63457b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4df6607-e66a-48e9-a21c-496e152c2e4b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a6c5e556-f64e-4717-b97a-a31af63457b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a99a3e3f-89b2-43d2-aa5c-f3aac9a159b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4df6607-e66a-48e9-a21c-496e152c2e4b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a99a3e3f-89b2-43d2-aa5c-f3aac9a159b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aeb81004-e645-492e-a19a-2d3e738dcff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f4df6607-e66a-48e9-a21c-496e152c2e4b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aeb81004-e645-492e-a19a-2d3e738dcff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5984edab-9ed3-429f-8957-3db15fef3717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a06ceef2-992a-40e4-89cd-7af071ed6b1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5984edab-9ed3-429f-8957-3db15fef3717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f9214b8b-09fe-4191-9e31-981649cbfef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9bc24eba-b493-419c-951c-905763ce0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9214b8b-09fe-4191-9e31-981649cbfef4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9bc24eba-b493-419c-951c-905763ce0ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e44e810b-a3fc-49ba-842e-f884847c006f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9214b8b-09fe-4191-9e31-981649cbfef4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e44e810b-a3fc-49ba-842e-f884847c006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f9214b8b-09fe-4191-9e31-981649cbfef4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_f9a6d78c-6513-4d8d-af89-617b2fb92409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_f9a6d78c-6513-4d8d-af89-617b2fb92409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1a2f87fd-b351-4afd-ae46-5f5618127c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1a2f87fd-b351-4afd-ae46-5f5618127c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_185c43e5-2dc5-4ec3-9088-8fa76563c3df" xlink:href="bhc-20221231.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_185c43e5-2dc5-4ec3-9088-8fa76563c3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_3799122a-92ad-46c5-8ed2-ee50f8304aa9" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_3799122a-92ad-46c5-8ed2-ee50f8304aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5c254b87-485f-4abb-a7fb-0253eb979200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5c254b87-485f-4abb-a7fb-0253eb979200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_1d2c7e21-e556-44ae-a0b2-702adf7a6da5" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_1d2c7e21-e556-44ae-a0b2-702adf7a6da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bdd99ffa-818a-4d2a-8a7e-c39bbc7679cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bdd99ffa-818a-4d2a-8a7e-c39bbc7679cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_693d576e-b5db-441c-8248-db9496d0976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_693d576e-b5db-441c-8248-db9496d0976a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_a0c67791-1622-4c81-9f79-08e2fe35fe0e" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_a0c67791-1622-4c81-9f79-08e2fe35fe0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_72c5a427-8fda-4677-b3b4-ab446920c6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_72c5a427-8fda-4677-b3b4-ab446920c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8740c837-9d50-44e4-93a9-bca7972000e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_cf15afe0-4c6d-48a1-ae5e-26019e23da0a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8740c837-9d50-44e4-93a9-bca7972000e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_acfebd78-fef7-48f2-bb1e-e7719418078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_acfebd78-fef7-48f2-bb1e-e7719418078e" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_4a348902-00e0-45e1-9da6-d2914a293e2e" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_4a348902-00e0-45e1-9da6-d2914a293e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3715ad6b-d03b-424e-9734-0f9b6d8d648d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_3715ad6b-d03b-424e-9734-0f9b6d8d648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_df37b89a-dcf3-4aee-86ba-4bde7106becd" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts_df37b89a-dcf3-4aee-86ba-4bde7106becd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_3b167785-e6c0-4a70-ab18-99cb74f5f742" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_3b167785-e6c0-4a70-ab18-99cb74f5f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_cf8d36f9-e522-4357-b1d0-ee5e73d3664f" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_cf8d36f9-e522-4357-b1d0-ee5e73d3664f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6625004f-ec82-44ed-bc2f-2c24ba26bd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6625004f-ec82-44ed-bc2f-2c24ba26bd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e8bd9d74-b535-4f13-817d-6f91c22a0933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e8bd9d74-b535-4f13-817d-6f91c22a0933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_3674818b-9dfd-4d1a-80a8-b051bf673c1b" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_3674818b-9dfd-4d1a-80a8-b051bf673c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ae33abd7-eb0c-4b1d-913e-62ecd0e7ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ae33abd7-eb0c-4b1d-913e-62ecd0e7ff8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a3cc0813-f7eb-452d-9989-da45fc975b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a3cc0813-f7eb-452d-9989-da45fc975b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_af8cfab2-2ca9-48ea-bb9f-9073de0f6e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_af8cfab2-2ca9-48ea-bb9f-9073de0f6e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ccfce3e6-9920-49f4-8223-ce2036c2a24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ccfce3e6-9920-49f4-8223-ce2036c2a24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7512dc11-ddb1-4b65-abf5-306257ade54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7d4f1d72-4d3b-49c7-b6d7-2e0bd9861c61" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7512dc11-ddb1-4b65-abf5-306257ade54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_acfebd78-fef7-48f2-bb1e-e7719418078e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1c9eda45-13a0-45c9-a1df-df0baee9749f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1c9eda45-13a0-45c9-a1df-df0baee9749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_8bf8e392-3437-442e-ba72-b975b83ef6e1" xlink:href="bhc-20221231.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_8bf8e392-3437-442e-ba72-b975b83ef6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_57250c92-c920-4a2d-8fc2-0f7a4a72619e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_57250c92-c920-4a2d-8fc2-0f7a4a72619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e39aebf4-b5f8-4901-b270-26ff585b992c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_5e64a63b-f35d-4235-b2b6-007ce94d6c96" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e39aebf4-b5f8-4901-b270-26ff585b992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9cb1c3fc-b5f3-41de-b2bc-7e10cfc9a3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_acfebd78-fef7-48f2-bb1e-e7719418078e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9cb1c3fc-b5f3-41de-b2bc-7e10cfc9a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0a9ea50-d35d-4f2f-a20a-05495b336fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0a9ea50-d35d-4f2f-a20a-05495b336fac" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_489b7b56-49e3-4034-81a4-2fa4a21c0db3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7c06ba27-5c56-4b9f-ab2a-54da309f89bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_fb5c1e48-fbab-4940-8ed6-06adea94e0da" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7c06ba27-5c56-4b9f-ab2a-54da309f89bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_502fbbe8-12cf-4ff5-905f-ff0488979e38" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_06f72b3e-5e7c-4443-8570-90cb86604515" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_885469bc-628f-4e67-97ee-88a48116714d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_885469bc-628f-4e67-97ee-88a48116714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_cff7c9fd-5085-4c1a-9864-b7945d2c3d09" xlink:href="bhc-20221231.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_cff7c9fd-5085-4c1a-9864-b7945d2c3d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_d4851162-ab3b-47f8-b162-88ba28bec44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_d4851162-ab3b-47f8-b162-88ba28bec44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_30b8010b-794d-4852-956f-16ca43952d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_149cb9a4-8cf7-46d8-ae82-7b470939facb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_30b8010b-794d-4852-956f-16ca43952d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a1b89957-110e-4ccd-a9a0-ee4ee3017cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a1b89957-110e-4ccd-a9a0-ee4ee3017cde" xlink:to="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0e7d2a8e-2581-4bed-8970-b9753bd28ffb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_8acc60e8-741f-4542-9741-40499285e0c3" xlink:href="bhc-20221231.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_8acc60e8-741f-4542-9741-40499285e0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e9b369c1-f1c1-46c0-946f-752a8d9ec8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_DomesticCountryMember_e9b369c1-f1c1-46c0-946f-752a8d9ec8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_c94fefe3-4f6d-4a7a-a39c-d860aea9a30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_ForeignCountryMember_c94fefe3-4f6d-4a7a-a39c-d860aea9a30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_9c7673e4-5781-4a83-ad06-0cf729d7fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ed7d7993-d8b4-42bc-9081-254a94b12b52" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_9c7673e4-5781-4a83-ad06-0cf729d7fc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_b2ec0a1e-f844-489c-a165-38776fa855bf" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_be3be5da-ebdc-46b8-99cf-b8a60ca56bfd" xlink:href="bhc-20221231.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_58b24768-b1cb-4c37-bb55-beb624a2c6e4" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_be3be5da-ebdc-46b8-99cf-b8a60ca56bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_7ea25a68-aac4-4409-ae24-739228885154" xlink:to="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_8a6122dc-ec5a-4f68-b3b3-47f3455b8803" xlink:href="bhc-20221231.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_8a6122dc-ec5a-4f68-b3b3-47f3455b8803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_3f270f86-dc3f-400c-a2a2-8252e0a4a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2012Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2012Member_3f270f86-dc3f-400c-a2a2-8252e0a4a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_2eea0437-1e23-4f45-becf-f35df370064b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2013Member_2eea0437-1e23-4f45-becf-f35df370064b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2015Member_283df42d-8872-4b9e-8169-76f86efa88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2015Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2015Member_283df42d-8872-4b9e-8169-76f86efa88ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2016Member_4c596920-c9eb-4b76-91a0-6df2c345abf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2016Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_us-gaap_TaxYear2016Member_4c596920-c9eb-4b76-91a0-6df2c345abf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018And2019Member_3f6aad6e-cd55-452a-ad0f-45b7585b9d13" xlink:href="bhc-20221231.xsd#bhc_TaxYear2018And2019Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_a21b756d-29c4-4a0e-bbd0-240a26a4e260" xlink:to="loc_bhc_TaxYear2018And2019Member_3f6aad6e-cd55-452a-ad0f-45b7585b9d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_d4f88aee-9327-4fd1-b636-ff5b4ada7461" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_152b9456-18a2-4fc3-90dd-4b59e3b6d168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_152b9456-18a2-4fc3-90dd-4b59e3b6d168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_975ef9e2-eca7-423d-a2e0-e1d05b70283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_975ef9e2-eca7-423d-a2e0-e1d05b70283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_f9625fb9-6018-4c8b-9495-fefc83b64e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_98265d75-f276-47cb-8308-fed611917293" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_f9625fb9-6018-4c8b-9495-fefc83b64e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_636a1838-175c-45e9-a646-437683e1464c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_695fc4bb-1185-4559-ba7f-15b04089939f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_62082407-9810-455f-a106-988a48bc0198" xlink:to="loc_srt_ScenarioForecastMember_695fc4bb-1185-4559-ba7f-15b04089939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f55af004-6465-492b-a849-ec14be5091f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_47c5e6b9-14da-4436-b452-eb2ada101f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fd694417-c070-4eca-b742-23bc38833850" xlink:to="loc_us-gaap_SubsequentEventMember_47c5e6b9-14da-4436-b452-eb2ada101f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_2def37fe-27c7-4d29-9f63-e5d2a1fc0c50" xlink:to="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eadc128c-2f5f-44c1-99a9-f80e44f14080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_eadc128c-2f5f-44c1-99a9-f80e44f14080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_2893330e-6114-421b-94e6-1b6ddad70f79" xlink:href="bhc-20221231.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_2893330e-6114-421b-94e6-1b6ddad70f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_8da5aef5-8d58-42e1-b872-4b9e6f44e156" xlink:href="bhc-20221231.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_8da5aef5-8d58-42e1-b872-4b9e6f44e156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27458778-ed2f-44ea-b549-ec5bea33134e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27458778-ed2f-44ea-b549-ec5bea33134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7241831-2ac2-4997-afd7-af3a5e91461b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7241831-2ac2-4997-afd7-af3a5e91461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_1d3a34ed-4358-4cac-bd67-97ce2cbd61cf" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_1d3a34ed-4358-4cac-bd67-97ce2cbd61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_987fdf90-7f6f-4248-8c9f-2b9596b23ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_987fdf90-7f6f-4248-8c9f-2b9596b23ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_75166305-a2d0-4980-8dfa-4cf841595242" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_75166305-a2d0-4980-8dfa-4cf841595242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_5a5cccee-c713-4bae-b77d-9b761232a33f" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_5a5cccee-c713-4bae-b77d-9b761232a33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_07592841-5279-4c97-a114-e6495d28a9f5" xlink:href="bhc-20221231.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_07592841-5279-4c97-a114-e6495d28a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dee05cae-30d1-4118-b55a-c96062bb727a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_dee05cae-30d1-4118-b55a-c96062bb727a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_69f1f43e-c16d-4fc4-8ec0-077cd816ff16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_69f1f43e-c16d-4fc4-8ec0-077cd816ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f08b922d-826a-4032-8158-11501c9849ae" xlink:href="bhc-20221231.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f08b922d-826a-4032-8158-11501c9849ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b15fad99-2169-444f-b3e9-30c47d80d3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b15fad99-2169-444f-b3e9-30c47d80d3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_c4d03ced-6c89-4ac5-a753-754aac791baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_c4d03ced-6c89-4ac5-a753-754aac791baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_64813bfd-7d8d-44aa-8844-14ef702b80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_fb76ff21-a3ad-4ff8-9dc0-47e10943cb6d" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_64813bfd-7d8d-44aa-8844-14ef702b80e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82d90b72-4893-4a11-9881-407d64945d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82d90b72-4893-4a11-9881-407d64945d09" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4a04a610-6171-463c-afaa-d6abb1c0e6af" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_abedd2c0-2876-4792-a166-26dc00a9422f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_DomesticCountryMember_abedd2c0-2876-4792-a166-26dc00a9422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_907db38e-ba75-45aa-b16f-7832a12b63e4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_CA_907db38e-ba75-45aa-b16f-7832a12b63e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_c2907509-d801-4f7b-8d6e-54e49233b7c9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_DE_c2907509-d801-4f7b-8d6e-54e49233b7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ff7b17f6-0ce5-4e31-a24a-b477750527eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_FR_ff7b17f6-0ce5-4e31-a24a-b477750527eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_db768a61-866c-4f5d-9129-37d1f57adc12" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_country_IE_db768a61-866c-4f5d-9129-37d1f57adc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_e4437edc-e80d-45da-8fca-bf82b194097d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_e4437edc-e80d-45da-8fca-bf82b194097d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_b0951b67-7a25-4061-ab05-7d19bfaa16d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_484c2d8e-5c44-4f83-a2b7-219773823ebe" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_b0951b67-7a25-4061-ab05-7d19bfaa16d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:to="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bade871e-2af1-4f23-a5bf-9f65b720e436" xlink:to="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f9738757-5d36-4ea8-b3cd-862c74c547b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:to="loc_srt_MinimumMember_f9738757-5d36-4ea8-b3cd-862c74c547b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_133b6a89-8dea-4a67-87f1-bf6142a10a35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb09bffe-f045-4ac4-8ff8-2452f4537fd7" xlink:to="loc_srt_MaximumMember_133b6a89-8dea-4a67-87f1-bf6142a10a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_74c4fdc4-3be2-4164-b997-34edaac662c2" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_a915132c-5a47-4665-877b-cbd88fd3c780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_55be95e0-daf3-462e-9009-3258026e8165" xlink:to="loc_us-gaap_OpenTaxYear_a915132c-5a47-4665-877b-cbd88fd3c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_78c45770-c2a4-485a-a0e2-bbbe0c5619f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78c45770-c2a4-485a-a0e2-bbbe0c5619f5" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_71e59a51-680d-4845-b7d4-07be56c98e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_71e59a51-680d-4845-b7d4-07be56c98e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6d63f6ee-94a3-4ec0-8434-13d9ea3419ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6d63f6ee-94a3-4ec0-8434-13d9ea3419ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8f10dec8-eefe-4276-a4c5-50b271b8942b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8f10dec8-eefe-4276-a4c5-50b271b8942b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4f54a61f-aeb9-4133-959d-a0892dbb5d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4f54a61f-aeb9-4133-959d-a0892dbb5d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_33e3a2b8-5fee-4b6c-b030-259f36964041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_33e3a2b8-5fee-4b6c-b030-259f36964041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d7a0ae93-b719-4a16-ad71-b203caebee27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e10f11c7-deab-4409-bd91-b7d5a84803b2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d7a0ae93-b719-4a16-ad71-b203caebee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adc7a0e9-6f7b-44b5-b324-2cf605c436ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:to="loc_us-gaap_NetIncomeLoss_adc7a0e9-6f7b-44b5-b324-2cf605c436ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ceff5af-ab63-4fcf-a352-d817c9066d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5ceff5af-ab63-4fcf-a352-d817c9066d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cf23944-f5ce-469d-9d0b-8a9ad163c69b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cf23944-f5ce-469d-9d0b-8a9ad163c69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cd6f59b7-d492-4913-b106-3dbc8b3a01db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:to="loc_us-gaap_EarningsPerShareBasic_cd6f59b7-d492-4913-b106-3dbc8b3a01db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_806afd75-1262-4008-b25e-b66badc6e151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df22693a-84a2-41e0-9149-72d2b419d9fb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_806afd75-1262-4008-b25e-b66badc6e151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_948a0764-6e61-4490-bdbd-0e8714a5457c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_948a0764-6e61-4490-bdbd-0e8714a5457c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d268e054-b08f-49f4-aee6-f1b618e9e301" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_0d14b071-3dba-4385-b0bd-2c7f37aee65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:to="loc_us-gaap_StockCompensationPlanMember_0d14b071-3dba-4385-b0bd-2c7f37aee65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:href="bhc-20221231.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4e86c39-65ba-4560-adb5-20b54614e3f9" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_567dc37b-3eac-49c2-b80d-c78ba35045f5" xlink:href="bhc-20221231.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_4301b97d-1d0c-4b51-b53b-a3199907f5a5" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_567dc37b-3eac-49c2-b80d-c78ba35045f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41be6f4b-9994-4899-9a46-88edb0c8c9a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92334be5-5ee5-492d-b723-dfed4c4e8e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f8793cd7-73d9-4196-87d0-7273a1306759" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92334be5-5ee5-492d-b723-dfed4c4e8e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_c0a173c5-20dc-46c2-8f6d-d1482ac5ede4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb3bded9-7d03-496e-99f8-ac9b0701c9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c0a173c5-20dc-46c2-8f6d-d1482ac5ede4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb3bded9-7d03-496e-99f8-ac9b0701c9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1dd1acf7-0f99-4ac5-8265-bf018467a69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb3bded9-7d03-496e-99f8-ac9b0701c9f7" xlink:to="loc_us-gaap_InterestPaidNet_1dd1acf7-0f99-4ac5-8265-bf018467a69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_daa0fe7c-4802-40fe-8395-81e39b633963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_cb3bded9-7d03-496e-99f8-ac9b0701c9f7" xlink:to="loc_us-gaap_IncomeTaxesPaid_daa0fe7c-4802-40fe-8395-81e39b633963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6c7c57cb-4d05-4964-9859-aa69f0f88746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6c7c57cb-4d05-4964-9859-aa69f0f88746" xlink:to="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a29b13be-756d-4abe-abe6-66f0fa3cfb56" xlink:to="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_69ff9c2c-2f64-4424-aaf7-414fc7fa6c6a" xlink:href="bhc-20221231.xsd#bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember_69ff9c2c-2f64-4424-aaf7-414fc7fa6c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_2a14b460-ac22-4a96-b8fd-efbb07dd5708" xlink:href="bhc-20221231.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_2a14b460-ac22-4a96-b8fd-efbb07dd5708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_dd97b800-f82c-4e0a-a7a4-17dc427c744e" xlink:href="bhc-20221231.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_dd97b800-f82c-4e0a-a7a4-17dc427c744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_0312ea3e-674e-4376-8a44-2f7fbcdfe431" xlink:href="bhc-20221231.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_RICOClassActionsLitigationMember_0312ea3e-674e-4376-8a44-2f7fbcdfe431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_08a0f272-0123-4dd9-a85a-fc420b294a9c" xlink:href="bhc-20221231.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_08a0f272-0123-4dd9-a85a-fc420b294a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_d0a9ad83-148c-4227-95f6-3554684bfe58" xlink:href="bhc-20221231.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_d0a9ad83-148c-4227-95f6-3554684bfe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_9967729a-7a87-4121-97b6-2280038a16b3" xlink:href="bhc-20221231.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_5027d557-308d-4c24-ae2d-a021119a3ef5" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_9967729a-7a87-4121-97b6-2280038a16b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52d38fdc-4666-424b-a11c-4ff21e9f883b" xlink:href="bhc-20221231.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_52d38fdc-4666-424b-a11c-4ff21e9f883b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_03b75b49-4abe-46fe-ba0d-c589013d61e0" xlink:href="bhc-20221231.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_8c302994-ae90-4eca-8961-9aea95455ee6" xlink:href="bhc-20221231.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_8c302994-ae90-4eca-8961-9aea95455ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_c7b2c4e2-26dd-4a16-a358-31159ca5726c" xlink:href="bhc-20221231.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PadagisLitigationMember_c7b2c4e2-26dd-4a16-a358-31159ca5726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_63d9c545-a7cc-45bb-aee1-6c589cf520e9" xlink:href="bhc-20221231.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_63d9c545-a7cc-45bb-aee1-6c589cf520e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember_17ceaf88-9766-4660-8111-a3970c3a2d59" xlink:href="bhc-20221231.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_AurobindoPharmaLimitedLitigationMember_17ceaf88-9766-4660-8111-a3970c3a2d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_a794df80-3ac3-4274-a108-57b66f12172a" xlink:href="bhc-20221231.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_a794df80-3ac3-4274-a108-57b66f12172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_da07e5d1-773d-4efd-82e4-9b53332b6a41" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_da07e5d1-773d-4efd-82e4-9b53332b6a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_bd8c302f-66f3-484f-8407-a9c95e25b101" xlink:href="bhc-20221231.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_bd8c302f-66f3-484f-8407-a9c95e25b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_aea4082f-c74b-4148-9fc8-61ebef85247b" xlink:href="bhc-20221231.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ApotexIncLitigationMember_aea4082f-c74b-4148-9fc8-61ebef85247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_030a0368-51e7-45a4-a337-da81eaa59786" xlink:href="bhc-20221231.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_28c0f62c-6033-4ae3-9a75-6b3a29d71182" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_030a0368-51e7-45a4-a337-da81eaa59786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_6220109e-19ba-4108-90fe-f1a67f507011" xlink:href="bhc-20221231.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_6220109e-19ba-4108-90fe-f1a67f507011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_a5dc8fbb-8b2a-4f56-b01a-fb06b58c03a0" xlink:href="bhc-20221231.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_a5dc8fbb-8b2a-4f56-b01a-fb06b58c03a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_2a9130d8-5f14-4734-8fd1-90604f15ca39" xlink:href="bhc-20221231.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_756524b9-a6b6-4a82-ab78-b7a8a87ffd77" xlink:to="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_2a9130d8-5f14-4734-8fd1-90604f15ca39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9bf0b9ae-c47a-4c3a-bd5a-d5dcb0a926d0" xlink:to="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_a74fd8bb-fbfc-4e12-b893-ad42771dde8d" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:to="loc_stpr_NJ_a74fd8bb-fbfc-4e12-b893-ad42771dde8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_744ec7a8-1392-4bc9-a23d-c566d53216a0" xlink:to="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_2f26f3a7-4eab-41fc-9526-65e3dff9bec3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:to="loc_stpr_CA-BC_2f26f3a7-4eab-41fc-9526-65e3dff9bec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_beab4e79-9b4b-447d-a7ee-7e4e725278f5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_438bdb5a-26b8-4318-b37e-5b7c0b0238c3" xlink:to="loc_stpr_CA-QC_beab4e79-9b4b-447d-a7ee-7e4e725278f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b8332490-467a-48ca-b207-d546e9c89d5f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_447a9eaf-1a93-43d4-bbdc-86d8040cbbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_447a9eaf-1a93-43d4-bbdc-86d8040cbbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_0dc6fc1b-0b3f-424b-afd9-6ce96bd2537c" xlink:href="bhc-20221231.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_870d8806-3546-4e82-80f3-0ad7a269fbcc" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_0dc6fc1b-0b3f-424b-afd9-6ce96bd2537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_d56176a1-3559-4caa-9786-e181574a9414" xlink:to="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4bf3d8ce-075b-4dc8-bc17-c867e6d544d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_us-gaap_PendingLitigationMember_4bf3d8ce-075b-4dc8-bc17-c867e6d544d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_b2cf0ff0-25b8-4fae-a4a9-0e08d0537cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_us-gaap_SettledLitigationMember_b2cf0ff0-25b8-4fae-a4a9-0e08d0537cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_f7be8179-b100-4e58-9686-d4198b437fc1" xlink:href="bhc-20221231.xsd#bhc_DefaultJudgementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_bhc_DefaultJudgementMember_f7be8179-b100-4e58-9686-d4198b437fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_74b6457b-7753-49d4-879f-32cb51b1aafd" xlink:href="bhc-20221231.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_37b80a7f-a4be-48e8-81f8-723b9c143218" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_74b6457b-7753-49d4-879f-32cb51b1aafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_209e4431-f07e-462c-b862-3c2b69527371" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_c65625e4-a61f-42ed-a67c-e384901089c2" xlink:href="bhc-20221231.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95253da5-d8da-49df-aa44-8f3d790733ae" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_c65625e4-a61f-42ed-a67c-e384901089c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3d9291d9-181d-458e-a05c-597c910639f6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e73dcee7-3bfb-4e1a-b8ba-6b304acca4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fdf1fd62-d085-44e5-a350-95cfcb13b07f" xlink:to="loc_us-gaap_SubsequentEventMember_e73dcee7-3bfb-4e1a-b8ba-6b304acca4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1bfe4b96-bf53-415c-b881-06072ce8a538" xlink:to="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_72fde0de-b72c-488f-b014-6a638435317d" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a328f91f-4214-4e05-bae7-5963966816bd" xlink:to="loc_bhc_BauschLombMember_72fde0de-b72c-488f-b014-6a638435317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_912d481a-4326-4bdb-b89d-821ee389e62c" xlink:to="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LegalSettlementsAndRelatedFees_df236e00-e4d8-4804-997a-8d7528217b60" xlink:href="bhc-20221231.xsd#bhc_LegalSettlementsAndRelatedFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LegalSettlementsAndRelatedFees_df236e00-e4d8-4804-997a-8d7528217b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_4574be78-2b99-4306-bc63-415585446b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_4574be78-2b99-4306-bc63-415585446b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25d96e0-9f30-4ef9-a882-2e89579fd933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25d96e0-9f30-4ef9-a882-2e89579fd933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_629b67fd-9434-406c-a712-b38648dc614c" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_629b67fd-9434-406c-a712-b38648dc614c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_27b83574-f952-4d91-91fd-4b402c77a1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_27b83574-f952-4d91-91fd-4b402c77a1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_d422e5fa-fb64-4542-882b-df16dfc75117" xlink:href="bhc-20221231.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_d422e5fa-fb64-4542-882b-df16dfc75117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_3e90d0ac-b531-41fd-9362-e425c6588e42" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_3e90d0ac-b531-41fd-9362-e425c6588e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_74c850fd-348f-4745-a4cd-0536b83fbebb" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_74c850fd-348f-4745-a4cd-0536b83fbebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_1397d920-6072-4007-920b-4352f8d2d4c5" xlink:href="bhc-20221231.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_1397d920-6072-4007-920b-4352f8d2d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_6cbfcb8c-1ebe-4397-8803-10a543607d58" xlink:href="bhc-20221231.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_6cbfcb8c-1ebe-4397-8803-10a543607d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dc213cb0-3899-4999-a7d3-01a31aaa25a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dc213cb0-3899-4999-a7d3-01a31aaa25a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_b854111c-6ac3-4189-b28f-9a18ce7fae93" xlink:href="bhc-20221231.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_b854111c-6ac3-4189-b28f-9a18ce7fae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_9e4084a6-cd0a-4996-b0f4-efeda6184828" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_9e4084a6-cd0a-4996-b0f4-efeda6184828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_317c3566-e95f-4384-b9a1-6b7ed8f60807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_317c3566-e95f-4384-b9a1-6b7ed8f60807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_537dbecb-7cdb-4935-a2c4-d95ba0209203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_537dbecb-7cdb-4935-a2c4-d95ba0209203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_aaf0c21a-605a-4777-99ec-1bb6d1a3ff62" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_aaf0c21a-605a-4777-99ec-1bb6d1a3ff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_0e0312c0-8e49-43a8-8680-de868e036bc5" xlink:href="bhc-20221231.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_0e0312c0-8e49-43a8-8680-de868e036bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5f2255c1-e6cd-43b2-a8ae-7a02c719f0cf" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5f2255c1-e6cd-43b2-a8ae-7a02c719f0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_13801d69-6853-411c-a1ef-e5beda37799e" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_13801d69-6853-411c-a1ef-e5beda37799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_e4981cf9-749c-4d8a-8847-d6e6bd138eed" xlink:href="bhc-20221231.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_e4981cf9-749c-4d8a-8847-d6e6bd138eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_aa3ca70d-2ee1-468f-af88-713fd219b5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7beca216-cd52-4f8f-b5db-763a32241051" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_aa3ca70d-2ee1-468f-af88-713fd219b5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d38c6f5-270d-4837-a5d3-f7d500c3555f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d38c6f5-270d-4837-a5d3-f7d500c3555f" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:to="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_332d7303-bd62-43cb-a947-dcda3c92de84" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_06de28ce-58b3-4ef7-8f6e-e59aaee7980a" xlink:href="bhc-20221231.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_06de28ce-58b3-4ef7-8f6e-e59aaee7980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_e185ac25-3592-40ab-8499-28f9404e002e" xlink:href="bhc-20221231.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_e185ac25-3592-40ab-8499-28f9404e002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_dfd56213-7304-46f4-bc62-2ceed971083e" xlink:href="bhc-20221231.xsd#bhc_NovaliqGmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_NovaliqGmbHMember_dfd56213-7304-46f4-bc62-2ceed971083e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_989e4f2d-0bf8-4121-b28f-d7eaee493c46" xlink:href="bhc-20221231.xsd#bhc_EyenoviaIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_832806f9-9ea1-46c7-960c-100d14fc42af" xlink:to="loc_bhc_EyenoviaIncMember_989e4f2d-0bf8-4121-b28f-d7eaee493c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:href="bhc-20221231.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_12aa6936-889e-4b9c-a5d7-cb1b975afdec" xlink:to="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_54dfc962-2691-4e59-9dc1-90b626c9d210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:to="loc_us-gaap_ContractualObligation_54dfc962-2691-4e59-9dc1-90b626c9d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_56cd10dc-1515-48e7-8823-9da7d6bfc093" xlink:href="bhc-20221231.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_3bd5f80f-c617-4669-ad28-08277f71fe89" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_56cd10dc-1515-48e7-8823-9da7d6bfc093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_29eacb7f-cb60-47a1-a67e-a83c76631a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_29eacb7f-cb60-47a1-a67e-a83c76631a83" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bf39c052-00c2-4b90-addf-79596dcce49c" xlink:to="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_25950a6e-696b-4ed4-9953-d125f0b3193a" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_48309c25-a64c-4fca-956e-99fbbad58bf3" xlink:to="loc_bhc_SalixSegmentMember_25950a6e-696b-4ed4-9953-d125f0b3193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c133104a-d4ac-493a-a5db-0c14c4630165" xlink:to="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_e2c864bb-fcfb-4dc1-a5f8-cd4fab5b17a5" xlink:href="bhc-20221231.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9da10639-d404-4085-b84f-743f35a96056" xlink:to="loc_bhc_XifaxanBrandedProductsMember_e2c864bb-fcfb-4dc1-a5f8-cd4fab5b17a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4f02e7a5-d765-41fe-ab51-649213b863c9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9eadc55e-ccec-437f-b53f-fad41ad31407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5752ea37-cbf2-46de-a173-a8d44f616c22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9eadc55e-ccec-437f-b53f-fad41ad31407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_21202ebf-584a-4cc4-8140-d6e1abee2006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4eb7880a-d569-4d11-88c8-4b8ba5682fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e9f3f67b-1e66-4b17-8611-b06d815244b3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4eb7880a-d569-4d11-88c8-4b8ba5682fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e9a14a4a-14ee-4312-a5c2-56670807948f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_df1ecff2-04a1-4cbf-a2de-c60b7e4489c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_f6bc5372-b364-4f4c-85ff-f09ea9bd8688" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_df1ecff2-04a1-4cbf-a2de-c60b7e4489c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_113874fe-7363-46f0-a92e-95ea48995972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_113874fe-7363-46f0-a92e-95ea48995972" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:to="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c7bb6ce5-f5f5-4573-8e06-6fc4dc43c3bf" xlink:to="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_df367fd8-0968-4f7d-8d03-793097e1bf67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:to="loc_us-gaap_OperatingSegmentsMember_df367fd8-0968-4f7d-8d03-793097e1bf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ddc12982-d4bf-42a9-90ce-c69916c1dcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_554edbf4-40f9-4f95-bdb3-0202208d21bd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ddc12982-d4bf-42a9-90ce-c69916c1dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2735c64b-375b-4335-b015-d909b01191a0" xlink:to="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_91d18519-700b-49fd-8ce1-043b0d23c964" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_SalixSegmentMember_91d18519-700b-49fd-8ce1-043b0d23c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_eab1ec99-90ea-4cf4-9965-5a95a76f7d7c" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_InternationalRxMember_eab1ec99-90ea-4cf4-9965-5a95a76f7d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_28f48c5a-2721-46c7-a2d9-00705d238d58" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_SoltaMedicalSegmentMember_28f48c5a-2721-46c7-a2d9-00705d238d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_f9da7fa9-6150-4f58-b9c9-05bb3d467232" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_f9da7fa9-6150-4f58-b9c9-05bb3d467232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_97cc523a-26a7-469d-9aee-4b4be8a3e83e" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24e245a5-7bf9-4312-a178-d1118c8b4913" xlink:to="loc_bhc_BauschLombMember_97cc523a-26a7-469d-9aee-4b4be8a3e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_040544d8-3110-4728-ad86-9d6a8d84cea4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880547cd-fece-492b-9c95-fab66b92e859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880547cd-fece-492b-9c95-fab66b92e859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_99b918fc-ad34-4401-96bf-5c071a1475e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_99b918fc-ad34-4401-96bf-5c071a1475e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_be2f9c58-f8ee-4290-883c-8daf7d9b7a23" xlink:href="bhc-20221231.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_be2f9c58-f8ee-4290-883c-8daf7d9b7a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_04744bb3-eec9-44f1-8911-686701e5ff5c" xlink:href="bhc-20221231.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_04744bb3-eec9-44f1-8911-686701e5ff5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3936aeba-c2bd-47de-9620-6caa4376ba01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_AssetImpairmentCharges_3936aeba-c2bd-47de-9620-6caa4376ba01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7e611386-af2e-44b7-9681-24468fb173f3" xlink:href="bhc-20221231.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7e611386-af2e-44b7-9681-24468fb173f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8805a4d7-4630-4174-9ddf-fe602fdbd990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8805a4d7-4630-4174-9ddf-fe602fdbd990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a0b159b2-76f3-461e-9e76-09abaa12688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a0b159b2-76f3-461e-9e76-09abaa12688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bf6d1f52-7a6c-49ef-9d38-266b3a7ce7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_InterestExpenseDebt_bf6d1f52-7a6c-49ef-9d38-266b3a7ce7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aa8051ac-fb8a-449b-b340-23534ee91cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aa8051ac-fb8a-449b-b340-23534ee91cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_61bf09ec-4419-447b-8b63-136d5733bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_61bf09ec-4419-447b-8b63-136d5733bc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d31d4d2-6a57-4d2f-9aa8-7c2232e5ad06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1b71b844-cf99-444f-9140-a8030fe017ba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d31d4d2-6a57-4d2f-9aa8-7c2232e5ad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONCapitalExpendituresDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_96bf0639-5a02-41af-9ce7-6d9838c4cb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_96bf0639-5a02-41af-9ce7-6d9838c4cb74" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:to="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_84ab77a6-afc2-416c-bd47-27dc01e17078" xlink:to="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_62a31d62-301d-4835-9ab0-12f0658b43a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:to="loc_us-gaap_OperatingSegmentsMember_62a31d62-301d-4835-9ab0-12f0658b43a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_04077e0e-7c89-40ab-950d-68c4649dfa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_bcd3b7e3-13b0-41c0-aea6-1f0375cc989d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_04077e0e-7c89-40ab-950d-68c4649dfa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cd4ac9f-c6b5-44b6-ab4b-97ad9b8e0add" xlink:to="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_b73de39b-165f-46fb-b7a2-f8c39fa52702" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_SalixSegmentMember_b73de39b-165f-46fb-b7a2-f8c39fa52702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_1e964f93-65f8-4aa8-9c8d-5e633ed07ae3" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_InternationalRxMember_1e964f93-65f8-4aa8-9c8d-5e633ed07ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_bface64c-1647-438a-8811-f3f7806819fa" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_bface64c-1647-438a-8811-f3f7806819fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a8054d26-f597-40f0-9556-cdd254cf2be3" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a8054d26-f597-40f0-9556-cdd254cf2be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_baa30d9e-102a-4365-ae5b-07234e3bddd7" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93fb9236-8b43-4184-a17b-c1bcd0d4574e" xlink:to="loc_bhc_BauschLombMember_baa30d9e-102a-4365-ae5b-07234e3bddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_58eab177-b4a2-4a9d-a86a-da51efcb4b2e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:href="bhc-20221231.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_abc3efd3-bab1-4d1a-ae31-b32c46084663" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_db48d879-c436-4e1b-84b7-a4acb69c3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_bc58c04f-ba04-499b-9968-55352d1293dd" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_db48d879-c436-4e1b-84b7-a4acb69c3ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3d6826b5-e499-4639-955a-305dae386331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3d6826b5-e499-4639-955a-305dae386331" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4dc1a2f4-217a-4010-a906-efd962da111e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_4f757316-22f4-404c-96a7-ed182bdb3b64" xlink:href="bhc-20221231.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ea39a47c-0fb2-4f86-8ced-30bbd7a6d2c6" xlink:to="loc_bhc_RevenuesNetMember_4f757316-22f4-404c-96a7-ed182bdb3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_731dc01c-2323-40a9-be69-4945c25e2d43" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f80193c2-56c0-4f35-b95d-f99903a1040b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9f35b22e-2271-4e58-adab-00259945d2f8" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f80193c2-56c0-4f35-b95d-f99903a1040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8886edc4-5591-4a2b-8362-a769052d2ffa" xlink:to="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_c34269cd-f329-4111-aa60-60f0638b98cc" xlink:href="bhc-20221231.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_SalixSegmentMember_c34269cd-f329-4111-aa60-60f0638b98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_1ce10fe2-bf6c-4db5-bc04-9a107f6708d0" xlink:href="bhc-20221231.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_InternationalRxMember_1ce10fe2-bf6c-4db5-bc04-9a107f6708d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_7f772be1-355b-47fa-8162-cef54a8d0ca3" xlink:href="bhc-20221231.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_SoltaMedicalSegmentMember_7f772be1-355b-47fa-8162-cef54a8d0ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a69212c5-c4bc-4e08-9134-d4d4e725a4af" xlink:href="bhc-20221231.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a69212c5-c4bc-4e08-9134-d4d4e725a4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f5886882-6e22-442b-bb41-754b019a7132" xlink:href="bhc-20221231.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_256feeb9-e646-4fe6-990e-0a9463061322" xlink:to="loc_bhc_BauschLombMember_f5886882-6e22-442b-bb41-754b019a7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_41163220-d060-449e-a494-3182083b6155" xlink:to="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_c922100d-733d-42ae-ac70-ebc3d7bbf4b6" xlink:href="bhc-20221231.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_PharmaceuticalProductsMember_c922100d-733d-42ae-ac70-ebc3d7bbf4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_add23b32-f4ea-49b3-8495-f3d8c7230bce" xlink:href="bhc-20221231.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_DeviceProductsMember_add23b32-f4ea-49b3-8495-f3d8c7230bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_2a9e229d-9be1-4704-a473-89cbc5902886" xlink:href="bhc-20221231.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_OvertheCounterProductsMember_2a9e229d-9be1-4704-a473-89cbc5902886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_b194b25a-941f-48f2-b807-dcbc1005d6e1" xlink:href="bhc-20221231.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_b194b25a-941f-48f2-b807-dcbc1005d6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_4362231d-e503-467e-a1b5-d89979db7867" xlink:href="bhc-20221231.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3702bc10-3603-401d-9d6b-9d651af56ed7" xlink:to="loc_bhc_OtherRevenuesMember_4362231d-e503-467e-a1b5-d89979db7867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e3d9ea7d-4fa6-48ed-bce9-07a508a34a91" xlink:to="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_af813b8e-5377-486b-bcb5-b25dff6a30e0" xlink:href="bhc-20221231.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_674b37c7-9348-49b4-bd18-f0b1e118e360" xlink:to="loc_bhc_CustomerTopTenProductsMember_af813b8e-5377-486b-bcb5-b25dff6a30e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f4ef7285-0eed-4029-902a-4e9ff060444e" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_f99e7d72-8652-49b4-8be3-e48189e373a5" xlink:href="bhc-20221231.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_f99e7d72-8652-49b4-8be3-e48189e373a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c73b218b-ebe8-4a0c-a450-093c33af4e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c73b218b-ebe8-4a0c-a450-093c33af4e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_145a3118-a2dd-4a36-8c31-1ef2b980f56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_43cd1861-9639-4fd9-aa44-63974ae322b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_145a3118-a2dd-4a36-8c31-1ef2b980f56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6eb16df0-6e3b-49ef-873f-e7245675daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6eb16df0-6e3b-49ef-873f-e7245675daf9" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:to="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4e7ad99b-5b74-467a-bf1b-ea6359b3142c" xlink:to="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_3500c916-ff5f-4f65-af31-0e9fb5ba7de4" xlink:href="bhc-20221231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_3500c916-ff5f-4f65-af31-0e9fb5ba7de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_077c2eca-501e-41ef-be62-7313ce0b30a3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_CN_077c2eca-501e-41ef-be62-7313ce0b30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_40b00bde-f0c3-4a16-a5d8-b7103707c07d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_CA_40b00bde-f0c3-4a16-a5d8-b7103707c07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_829aa66b-8639-4735-a908-835d7eed8b15" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_PL_829aa66b-8639-4735-a908-835d7eed8b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_38a20039-6b01-47db-bb36-52fa0d3b0d9a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_MX_38a20039-6b01-47db-bb36-52fa0d3b0d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_ffd3a67e-9819-494c-9202-2205c36cbed2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_JP_ffd3a67e-9819-494c-9202-2205c36cbed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_9bfc894e-dec2-4579-9d4d-0a0999bcc703" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_FR_9bfc894e-dec2-4579-9d4d-0a0999bcc703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_921824af-d521-43db-b7db-d0f9c8fdc24e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_RU_921824af-d521-43db-b7db-d0f9c8fdc24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_d906cfbf-cbba-4651-b6d6-6cce68eb7042" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_DE_d906cfbf-cbba-4651-b6d6-6cce68eb7042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_fe3057c2-31e2-4d62-8f1d-7585f0b4ad17" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_GB_fe3057c2-31e2-4d62-8f1d-7585f0b4ad17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_7c712c81-4933-44ef-9909-52b5aed4dd8c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_ES_7c712c81-4933-44ef-9909-52b5aed4dd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_d4dd0c36-325c-4ab1-8323-3f37ba6a2875" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_KR_d4dd0c36-325c-4ab1-8323-3f37ba6a2875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_88cd5c47-0edf-47ae-b7a7-a61c4e3cec40" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_country_IT_88cd5c47-0edf-47ae-b7a7-a61c4e3cec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_99066e05-b060-4f37-9560-7414db6c6bd0" xlink:href="bhc-20221231.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_04743aec-e374-4840-b541-211844cca73c" xlink:to="loc_bhc_OtherCountriesMember_99066e05-b060-4f37-9560-7414db6c6bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b9e472fd-09b4-4278-845d-3c963f182d0c" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1386244-ef03-4314-a1ad-50ed818a4568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_9e19427b-14b1-4095-86a5-c1a0413afae4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1386244-ef03-4314-a1ad-50ed818a4568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_da491bf2-fd5b-4bc8-b272-3f8876398e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_da491bf2-fd5b-4bc8-b272-3f8876398e3e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:to="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d62fa678-230e-479b-8451-c1822f6acf88" xlink:to="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_0cc81ca5-2919-4440-9550-68963b6f26a5" xlink:href="bhc-20221231.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_0cc81ca5-2919-4440-9550-68963b6f26a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_3750124c-0d0a-4bd1-b9db-bce9ff6b668a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_IE_3750124c-0d0a-4bd1-b9db-bce9ff6b668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_49647eab-3d9b-4cc2-94f5-244cb0ab9430" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_CA_49647eab-3d9b-4cc2-94f5-244cb0ab9430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_d77a965f-6aa5-439f-b20c-17659eb41fbf" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_DE_d77a965f-6aa5-439f-b20c-17659eb41fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_7dc02061-1bed-42c9-8517-5477cb36eb43" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_PL_7dc02061-1bed-42c9-8517-5477cb36eb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_9f9a6991-9b15-44ad-9486-539d8f4dc761" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_MX_9f9a6991-9b15-44ad-9486-539d8f4dc761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_972139ba-210d-49e6-9b8a-76bfe6b0dfc0" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_FR_972139ba-210d-49e6-9b8a-76bfe6b0dfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_a4758204-f721-420b-9a6b-7b3b146b8c89" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_CN_a4758204-f721-420b-9a6b-7b3b146b8c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_c9df035a-c1f0-42f3-a24f-d063bd8ffe58" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RS"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_RS_c9df035a-c1f0-42f3-a24f-d063bd8ffe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_9c8febd8-6d82-4c28-9494-1d56d57c885b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_country_IT_9c8febd8-6d82-4c28-9494-1d56d57c885b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_96de32ad-1496-4a9f-9f51-e7441e9ac120" xlink:href="bhc-20221231.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7013ba16-8d55-4ee2-84e2-679d7b0ce544" xlink:to="loc_bhc_OtherCountriesMember_96de32ad-1496-4a9f-9f51-e7441e9ac120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_f2da7f65-6f70-4b4c-a360-b98f379c2f5f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_98a85093-6082-42df-8b1b-d6e05bdac034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b0476de2-0c07-4d5a-9c86-4a936b9a7a33" xlink:to="loc_us-gaap_NoncurrentAssets_98a85093-6082-42df-8b1b-d6e05bdac034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20221231.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_998f9d78-c1c7-4a2b-9d6a-2ffd1b8d2475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_998f9d78-c1c7-4a2b-9d6a-2ffd1b8d2475" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0df741-3cf6-4609-b3c1-088b8c67641d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_88c8956f-ae32-447a-92a9-3f40ade8b579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a55aa566-64f9-4c33-935b-b46cd744b21c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_88c8956f-ae32-447a-92a9-3f40ade8b579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c003ca59-ef6e-4719-9f90-8be60959c5b9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_4f71218b-d8c0-4ef0-b6b6-4978cba315f2" xlink:href="bhc-20221231.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c2f5adf6-0b9b-43a8-916c-6bf906d4bcae" xlink:to="loc_bhc_RevenuesNetMember_4f71218b-d8c0-4ef0-b6b6-4978cba315f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4fd0b090-bfd1-448d-be2a-4f57e38490a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_4dcbc858-8f63-4766-8bfe-e6bd8058ed41" xlink:href="bhc-20221231.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_4dcbc858-8f63-4766-8bfe-e6bd8058ed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_f1b22523-4a5b-4586-b132-1f12e5ece931" xlink:href="bhc-20221231.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_McKessonCorporationMember_f1b22523-4a5b-4586-b132-1f12e5ece931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_cccb02cd-1992-432a-b395-9bf44c55e4b5" xlink:href="bhc-20221231.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cedc08d7-9c71-4ac7-ac8f-d25fdbc4d79f" xlink:to="loc_bhc_CardinalHealthIncMember_cccb02cd-1992-432a-b395-9bf44c55e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_799842aa-eb89-49e1-afed-ee9890b7affd" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ab495404-a0dd-448c-bf7a-08aaad76533c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_453a37d4-05d4-4b91-83ea-664f69f9c1db" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ab495404-a0dd-448c-bf7a-08aaad76533c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>bhc-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bhc-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (T W # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  ,C_P#BJ/\ A-/#W_0=TS_P,C_^*J;_ (1G1_\ H$V/_@,G^%'_  C.C_\
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M#)_A1_PC.C_] FQ_\!D_PH A_P"$T\/?]!W3/_ R/_XJC_A-/#W_ $'=,_\
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M)_A1_P (SH__ $";'_P&3_"@"'_A-/#W_0=TS_P,C_\ BJ/^$T\/?]!W3/\
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M_P# R/\ ^*H_X33P]_T'=,_\#(__ (JIO^$9T?\ Z!-C_P" R?X4?\(SH_\
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M_ R/_P"*J;_A&='_ .@38_\ @,G^%'_",Z/_ - FQ_\  9/\* (?^$T\/?\
M0=TS_P #(_\ XJC_ (33P]_T'=,_\#(__BJF_P"$9T?_ *!-C_X#)_A1_P (
MSH__ $";'_P&3_"@"'_A-/#W_0=TS_P,C_\ BJ/^$T\/?]!W3/\ P,C_ /BJ
MF_X1G1_^@38_^ R?X4?\(SH__0)L?_ 9/\* (?\ A-/#W_0=TS_P,C_^*H_X
M33P]_P!!W3/_  ,C_P#BJF_X1G1_^@38_P#@,G^%'_",Z/\ ] FQ_P# 9/\
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M^$9T?_H$V/\ X#)_A1_PC.C_ /0)L?\ P&3_  H A_X33P]_T'=,_P# R/\
M^*H_X33P]_T'=,_\#(__ (JIO^$9T?\ Z!-C_P" R?X4?\(SH_\ T";'_P !
MD_PH A_X33P]_P!!W3/_  ,C_P#BJ/\ A-/#W_0=TS_P,C_^*J;_ (1G1_\
MH$V/_@,G^%'_  C.C_\ 0)L?_ 9/\* (?^$T\/?]!W3/_ R/_P"*KR[Q]\1/
M$7BSXBZ9\/\ X>:SI^FW4FGMJVHZ^T:7@M;<2>6JQ1D[6<MU#=B/K7J__",Z
M/_T";'_P&3_"O+OBM\,=4TW7+;X@^ KO3]%\1:38RV]S:W<!^R7]IGS#'($P
M00P)!'.<<C - %?PQXD\=_#WXJ:)X.\9ZW;^,--\1PW#Z;K,5BEG-%/ GF21
M21H=NW9R#U)_''ME>+_#_P"'OB_Q1XVTCX@?$'5-*GN["S=-'TG0XY%MK7SD
M DE9I/F+LORD<CWX%>T4 %%%% !1110 4444 %%%% !1110 4444 <;X!_Y#
MWCW_ +#P_P#2&TKLJXWP#_R'O'O_ &'A_P"D-I794 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XR_P"1/UW_
M *\)_P#T6U;-8WC+_D3]=_Z\)_\ T6U $OA?_D6=(_Z\X?\ T 5J5E^%_P#D
M6=(_Z\X?_0!6I0 4444 %%%% !1110 4444 %%%% !1110!QO@'_ )#WCW_L
M/#_TAM*[*N-\ _\ (>\>_P#8>'_I#:5V5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>,O^1/UW_KPG_]%M6S
M6-XR_P"1/UW_ *\)_P#T6U $OA?_ )%G2/\ KSA_] %:E9?A?_D6=(_Z\X?_
M $ 5J4 %%%% !1110 4444 %%%% !1110 4444 <;X!_Y#WCW_L/#_TAM*[*
MN-\ _P#(>\>_]AX?^D-I794 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM*[*N-\ _P#(>\>_]AX?^D-I794 %%%% !1110 4444 %%%% !1110 4444
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M3X7R7DNH>.6OX(+:[.N_O(K:9IHU_P!!M,8<HA/&/X1_6N[KC? /_(>\>_\
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M "'O'O\ V'A_Z0VE=E7&^ ?^0]X]_P"P\/\ TAM*[*@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?"__ "+.D?\ 7G#_ .@"M2LOPO\ \BSI'_7G#_Z *U* "BBB@ HHHH ****
M"BBB@ HHHH **** .-\ _P#(>\>_]AX?^D-I795QO@'_ )#WCW_L/#_TAM*[
M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY#WCW_L/#_TAM*[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Y=Y:_AL0V=G;Z?;QV]K!';6\8PD4*!%4>@ X%3445Y.^K/5V"BBBD 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **P_&?CGP]\.O#]QKGBC6['P_I$'^LO-1N%AC!YPN6/+''"CD
M]A7PY\:/^"O'@?PY/)I/PRT"]\=ZLS>5%>W"M:V1<G VJ1YLG/;:F<C#5Z>#
MRW%Y@[8:FY>?3[WH1*<8[L^_ZS==\3:/X7M/M6LZK8Z1;?\ /:^N$A3_ +Z8
M@5^84=]^WI^U!$LD"S?#;0+H9#H$T54#=""=UWC'<9K9\._\$==4\1W7]J?$
M?XMW&H:G,<SKIUH\[L?^OF=]S?C'7L_V-A,-_ON,C%]HIS?X;&?M)2^&)]PZ
MA^U;\%]+F,5S\6/!:2CJBZ];,1]0'.*DTO\ :F^#6M2+'9?%;P9-*QPL7]O6
MJNQ]E+@FOF/3?^".OP8M80+K7_&=[+W8WUL@_ "W_J:CU;_@CC\'+N%_L'B3
MQEI\V/E+7EK*@/J5-N"?^^A2^KY%M]8GZ\J"]3L?<^FZI9ZQ:)=6%W!?6K_=
MFMI%D1OHP)!JU7YAZE_P2!\7>#[I[[X<_&62QNNJ+<VLUBX],S02,3]=@K,_
MX2+]NW]E?C4+*X^)OAZWZR21_P!M*RCJ2\96Z QW? [^M/\ L7"XC_<L9&3[
M23@_QW#VDE\43]3Z*^ /@S_P5W\$^(;Q-(^)WAV^\!ZHK^5)>VX:[LPP.#O4
M 2Q'/;:^,')%?<'@GQ_X:^)&AQ:QX5U[3O$.ER?=NM-N4G0'^Z2I.&]5.".X
MKQL9EF,R]VQ--Q\^GWK0TC.,MF;]%%%>86%%%% !114-U>06-N\]S-';P(,M
M)*X55'N3TH FHKRWQ9^U%\*?!8<:EXZTEI$^]#8S?:Y ?0K"&(/UKQ7Q=_P4
MI\!:3OCT#0=9U^5>DDH2TA;Z,2S?FE>?5S#"4?XE1???\$>77S3!8?\ BU4O
MG=_<M3Z\HK\^=;_;D^,OBVQ:Z\,^";/P_I#?\Q.Z@DE2/TS<2%(1^(KQ+QI\
M6?'OC/>OC+XKRF-C^\TS29VF# ^B6X6W;Z&05Y5;/J$/X<7+\%][_P CHR^6
M89W+ER7 U<1YQ@^7YRV7S/T]\:?&SP%\.]Z^(O%NDZ7,G6VDN5:?\(ERY_ 5
M\_\ CS_@I#X T%9(O#.EZEXJN!]V1E^QVY_X$X+_ /D.O@^TT;2T_P"0=X:U
MOQ!(.5GOB;>!O]Z*(%A^$PKKM!L/'FGS9T:TT?P< -T<UM#'YZ^RSXDG'XO6
M$<7FV.=L+0=GVBY?B[1/J?\ 4W/^7FS;&87+X]JE:,JGRC#FN_+1GO5Q\?OV
ME_C;"S^$?# \)Z*__+^ELL*;/4W-R=IQZH :X^X^ &EZOJ*ZC\9/C]HQNP=S
MV=KJ?]I70!ZKN9OD_!6''%<#<?"_7_&=U#+XB\5ZIKMXQRT<C27#D_[+NQ)_
M[YKOO"O['.IZHRM!X5U6[5CE9-1;R$^N3L!'YUWPX:S7$6EC()+_ *>5$E_X
M#'8XY9#P)AW?,,WKXZ:^S1I-1OY.;2_0].\&>-/V2_@X\3:.#XEU:,\7ESIT
M]Y/N]5,D:QJ?= *],;]N3P]>?\@GP?XDN%[37T<-I&?<9D9L?\!KEO!O[$]]
M:JAO+O3-#C/5+*'SI/H3\HS^)KV'PS^S!X)T'8]W;W&M7"\[KV4[,^R+@8]C
MFOI,-EV%P<;5JZ?]VG&R_P# I7O]QA6Q>5TH>QR3+7"/\U:I?_R2E&%GZR9Y
M5XD_;/U$6.++1;'1I&R/.N[HW'_?(VIS^=>%>-/C=XU\<LZ"R\3>*-QX@M+*
M5+;_ +Y5<?B%-?HQI.AZ;H-OY&F:?:Z?!_SSM85C7\E J]775QTZ:Y<!&-/^
M\US2^]NR^YF. HY?&?M,VI2K_P!U5/9P]&E%R?\ X&C\N_#MW\8K*Z-S:_!F
MZU!,YC_M30[V0#\-R*WXK7J%K\9OVK%MTM['X<1V$"#"11:&T:J/0!GP*^]*
M*^9KX?&8J7-7Q<Y?=^70_2*'%63X./)ALCP\5YJ4G\VW=_,^$/\ A8W[8=Y_
MJ_"_D?\ </ME_P#0FH_X3G]LA>OA_/\ VY6?_P 57W?17-_9<_\ H(J??_P#
MI_UYPRVR;"_^"W_\D?"'_"??MC+U\.9_[<;3_P"*H_X6=^V!:\R>$_.'I_9L
M#?\ H+5]WT4?V9/_ *")_?\ \ /]><,]\FPO_@M__)'PA_POC]K"S_UOP[\_
M'_4$E;_T!Z/^&IOVGK'FX^$?FJ.I_P"$;U _JLE?=]5-2U:RT>W,]_=P6<(_
MY:3R!!^9J9X&I3BYRQ4DEU=BH\8Y;5:C+)*#;[*2_)GPW_PW#\:=-_Y"7PDV
M8Z_\2Z]A_P#0LT?\/'_%&F_\A/X6[,=?]-EA_P#0H37U!XA_:$\,Z1N2R\_5
MYA_SP79'GW9OZ UR)^)'Q%\??)X>T@Z?:OTGCCSQ_P!=9/E_( U\9BN(L-AY
M^QPV,E6J?RTX*;^]:?B?14,1E.(C[3%9!3IP[NM.FOU?X'C5C_P4^TZ3'VSX
M?74'KY&JK)_.):Z&Q_X*9> Y,?;/"_B*#U\A8)?YR+7H2_LZZQXLF%SXLUJ.
M=FY*L#<O],M@#\,UT6F_LI_#.T"F\\-6FKR#^*^B1AG_ '5 'YYKKP&*XEQ<
MKRH\D.\W%/\ \!BFT<^*QOA]!6>!GS=J=6<E]\[)GC][_P %)_ K9%AH>K^S
M7JI'C\$+_P ZQ+K_ (*"V.HMBWOK33%/3=8S.WXD@C]*^B+S]E_X37RXD^'V
M@J.G[FT6(_\ CN*Y^^_8G^"VH9W^"88SZP7UU'C\%E KKQN49SC-L:XKM&T?
MQ4+_ (F&&S7P^I_'@JZ?K"7_ *5*WX'C-G^U _BEL-\2M-TY6Z>=*MMC\D!K
MI]-U;_A)L8^-/AN?=_RR3Q)O;_OC(K>OO^"??P?N\^5INIV6?^>&HR''_?>Z
MN8U+_@FG\.KC)LM?\26;'L\T$JC\/*!_6O _U1Q#_P!YJ3J^M67^2/5_M;@R
MIIAJU2AZT8/_ -)9V>G_  9O]> -OX[M;X'G-O,TW\FJ]_PSAJ:\KXIY_P"N
M##_V>O%-0_X)A6+-NT[XA75L1ROVC2UD_595JC_PP?\ %KPSSX7^+ A*_=_T
MJ[LO_19?%'^J. C_ !<#)^?M9/\ 4.;*:W^ZY_%/M/#N/XZH]Y_X9YUU/N>*
MO_'9!_[-1_PH;Q5#S#XLPPZ?O)5_D:\%_P"%5_M?>$/^0=XO.M[>G_$TBN,_
M^!2C]:/^%K?M>^#>=2\('7 G4?V7%<;O_ 5A^E+_ %;R2'QX6K'_ +>G_P#)
M#_L?,J_^YYMA*OES1C+[G']3WK_A5WQ.L?\ CW\5^:HZ+_:$_P#)EQ1_8?QC
ML/\ 4ZA]IQ_TVA;_ -#%>"K_ ,%!OB%X28+XQ^%8@*\/C[18?I*CUUFA?\%,
MO!5UM&K^%=<TXGJ;1H;E1^;(?TJXY+DZ=J6,K4GY5)+\TSGK<,<7TX\[R^E6
MCWC[.5_NE?\  ]-_X2CXOZ1_Q\Z3]MQU_P!&23/_ 'Z(H_X7MXNTO_D*^$]F
M.O[F:#_T+-0^'_VZO@WKVU7\2RZ5*W2/4+&9/S9591^=>E^'_C1X!\5;1I'C
M30;]VZ10ZC$9/Q3=N'Y5WT\EQ'_,%G%3_MYQJ?G8^1QF'QN#O_:.3.*_P3@O
MOM8X:R_:<L7(%YH5Q!Z^3.LG\PM=#8_M">$+S'FS7=E_UWMR<?\ ?!:N]N](
MT[5D!N;*UO$89!FB5P1^(KG[[X2^$-0SYN@VJ9_YX P_^@$5U_4N*L/_  L9
M3J_XX<O_ *0>!]9R.K\>'G#_  RO_P"E$MC\4?">HX\G7[)2>@FD\H_^/XKH
M;/4+74$WVMS#<K_>AD#C]*\WOOV=O"EUGR3?61[>3.&'_CP-<]=_LRI&_F:?
MXAEA8?=$UOD_]]*P_E1_:'%&'_BX&G5_P5.7_P!+#ZKDE;^'B90_Q0O_ .DG
MN-%>#_\ "JOB/H?.F^)_/C'2,7DJ_P#CK#;^M'V_XR:'_K;<W\:]/W<$N?\
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M\A[Q[_V'A_Z0VE=E7&^ ?^0]X]_[#P_](;2NRH **** "BBB@ HHHH ****
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MXGNP#\K73_(&;I\@RB\?>(W'WLOR>MCI^_[D.K:_)=?ZU/.K9AAJ'Q35_O\
MR.J_::_X*7:AXF\0?\*T_9UL9O$GB&_<VG_"16\!E_>$X*V<>/G(&?WK#: "
M0",,-7]EW_@F';V.I+X]^/-T?&/B^ZD-RVB7$YN;:.0\[KF0D_:)/49V>N_J
M#]FOX,^(?@KHDEM\-O!DEOJ-XNVY\27UHKWEP/[OG2@(B?[" #@$Y/->V?\
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M%W?_ '3(ZL3]%->3^)/C)\ ?!6^/3E\1^/[Q>,H19VI([;RJN!]%:NV\'_\
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MBFY\9>)6LA%9RRVL=K!91.H+".),@,<X+=QGBO7:9.^K"BBB@04444 %%%%
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MW;>ARG[*OP"^+OQZ^S>*O'[+\._!#;9;73;.U"ZAJ:'!!S+N,,1'\> S#[H
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MC3]CC5K+QS^UM^U/XT\.7L&K>$-0O=#L[35;&426MW/!:.)O+=25?:6'(/\
M&".M?7VK2ZA#9EM,M;:[NMPQ'=W+0)CN=RQN<^VV@#FO /\ R'O'O_8>'_I#
M:5V5?(WC?Q'\5=)\;>+F\/Z?J2VLFH(;B'0X3>QK-]E@!PYB5L[/+_A']:\H
M\5?'3XE: 3_:\?CJR!_B-G- #]#\HKH_V.G%2KXJ$/)O5>J-L-@\SQT^3!8.
M=3S25GZ79^B%(S!023@>IK\J]6_:<U7<1=W/B1R>UW=.,_FYKF;K]H)KJ3,F
MFSW SUFO#G_T$USO&Y)'66.7RC)_DCZ&?!G&4:?M(Y14:]8W^Y-O\#]:KKQ%
MI5EG[1J=G!C_ )ZW"+_,UEW'Q,\(VF?.\4:.A'\)OXL_ENK\Q-#^.G@^1E&K
MZ/K<?K]BN(6_+>JUZ#H/QD^ =T0M^OCVVD[[H;5D_P#'"3^E7',,@?\ S%M_
M]NM?F?)XO <1X'7%9=4I+O.%1+[W%(^Y[CXW>!+7._Q/8G_KFY?_ -!!K,N/
MVC_AY;Y_XG_FGTCM)S^NS%?-NA_$3]ER\VB;Q%JD#G^&^@NE_,I'C]:]"T.^
M_9CO]I@\1:"2>AOM8EA_21UKLCB\BE\-:4O1Q/GEC\1-\JJ4D_\ $[G>7'[4
M_@2'.RXOI_\ KG:D?^A$5F7'[7GA"/B+3M8F/_7&)1_Z,_I6QH?A7X,:CM_L
MO_A&-0ST\F^CN,_^/FNSM/AKX.@56M_#&B@=0ZV,1/Y[:ZHULKWA"4OFOT.N
M*Q]355(?)7/'[G]L;2ES]G\.7DO_ %TN$3^0-4&_:]U"])%AX-WGMF[:3]!&
M*^A;7P[I5EC[/IEG!CIY5NB_R%:"J%  &!Z"J^M8".V'OZR97U;'2WQ%O2*/
MFG_AH;XE:E_R#? N[/3_ $&YF_D11_PGOQUU;_CW\._8\]/]!"8_[^-7TO11
M_:%"/P8>/SNP^HUI?'B)?*R/FC^SOV@]8_UMS]B1O^FEI'C_ +XYI/\ A2OQ
M?UGG4/&OD(>J?VE<'_QU5V_K7TQ11_:U2/P4X1](A_9=-_'4G+UD?-*?LCZI
MJ3!]6\9>8W4[;9Y3^;./Y5MZ=^Q_X;AP;W6=3NB.HA\N('\U;^=>]T5$LWQL
ME;VEO1)?H7'*L''7DOZMO]3RS3OV9_ %A@OI4UZP_BN+J3^2D#]*ZG2_A7X/
MT<AK3PUID;CH[6RNP_X$P)KJJ:[K&I9V"JHR68X KBGC,14^.HW\V=D,+AZ?
MPTTODAL,,=O&(XHUBC7HJ* !^ J2N*\1?&OP!X25SJ_C30K!EZQ2:A%YGX(&
MW'\!7DOBG]O[X0^'5D%IJE_X@E7^#3;%P"?3=+L4_4$UY-7&8>C_ !*B7S,J
MV.PF'_BU8KYK\CZ/HKX'\7?\%+=8O+>]?P?X%BAM[6,R2WVJS/.L:?WW2,*$
M'N7Q7S;XB_;S^*GQ2UZ#0-(\3ZE>:C>R>3;:3X0M-DLC'^%&C&]O^^SP*PHX
MR6,;6!HSJV_EB[+U>R/(EG^&D[8:$JC_ +J=OO=C]./CM^TAX*_9[T%KWQ+?
M/-J,D9>ST.P42WUYSCY(\\+G@NQ"CN:_)_\ :8_:2^*/[6>I-8:K.O@KP DN
M^#P_:2>:S ?=><@CSG[X)55[*#DGZL^#/_!/?Q!XVB'B+XM:M=Z1<71$ITFV
MG6XOFR!S/.=RJWJJ[_\ >!XKZE\)_LV_"#X/68OH?#FDVQAY.IZTXG=3_>WS
M$A#_ +N*[,-F69X-N5"E"G)?:D^=K_"E[J^=_47_  L8]J-."I)]_>E]RT^1
M\ ?LWZ=\2/"OAUM)^!WP[;1Y+Y!'>^*Y;83WEW[-=S@0HG<(BKCKR>:]RT/]
M@/QQ\1M0CU?XK_$"::=N3;V\KWDX!_A\V3"I]%##I7T9XN_:Z^$7@E72Y\9Z
M?>RQCB#2<WA/^R#$&4'ZD5X;XP_X*9:#;L\/A3P?J&J2'Y4FU.=+9=WKL3>6
M'XJ:^:QE;"UJCK9GBG6F]]=/NCL?<97X6Y_G-I3P]6JO[W[N'JK\J_%GM_PZ
M_9#^%?PT\J6Q\,0:G?Q\B^UC_2Y<^H##8I]U45ZY=WEII-D\]S/#96D*_-),
MXCC11ZD\ 5\#_P#"[?VI_C-\OA?PO-X>L)UPDUKIPMXV7U$]T2,^ZD>U2V/[
M"/Q5^)UU'??$GX@K%NY\N2>74IT_V<,51?\ @+$"G2S!\O)@,*VN]E%?U]Q^
MAT?#W+\GC;-\RH8=+>,/WD_G&-OU/I/QQ^V-\)/ GFQW/BVWU6Z3_EVT=3=L
MQ]-Z?(#]6%>"^+?^"E1O;@V/@7P-<7MQ(VV&;59?F;_MA%DG\'KTKP3_ ,$^
M/A7X7\N35(=1\4W(')U"Z,<6[U"1;./9BU>]>$_ 'AGP);F#PYX?TW0XBH5A
M86J0EP/[Q4 M]3FM_99KB/CJ1IKR5W^/Z,Z/KG V4_[OAJN,FNM27LX?)1]Z
MWE)'PXUY^UO\<\^5%>>#M+D.?D5=)5 ?0M_I!'T)K8\,_P#!-O4-7O#J'CWQ
MW)=74C;I8]-C:5W^L\O.?^ 5]U44UDE&;YL3.51^;_RU_$RJ>(^:48.CE%&E
MA(?].X*_SD[W?G9'A'@O]B?X2^"_+=?#QUBY3GS]5F:8Y]=O"C\J]CT?POH_
MA^-4TS2[.P51@?9X%0X^H%:E%>E1R_"8=\U*E%/O;7[]SX''YSF6:2YL=B)U
M'_>DW^%[!1117H'C!1110 4444 %%%% !1110 4444 %%%% !1110!R/Q,^$
MG@[XR>'7T+QKX=L?$6F-RL5Y'EHF/\4;C#QM_M(0?>O@#XJ?\$K?$GP[UX^,
M/V>O'%]I&JVY+Q:5?7;03KR"4BNDQD'^Y( ,#ES7Z6T5Z^!S;%Y?I1G[KWB]
M8OY&<H1EN?EKH/\ P47^._[-NH6N@?'KX;7&HP*?+74V@-C=2@#!99%!MY^G
M\ 7/.6KZT^%?_!1;X$?%2WMQ'XSA\,:C+@-I_B9?L3H3V,C$PG_@,AKZ'US0
M=,\3:7/INL:=::KITXVRVE] LT,@]&1@01]17RK\3/\ @EQ\"/B$\]Q8Z+?>
M#+Z7+&;P_=E(]W_7&0/&![*J_AUKUOK63X[_ 'FBZ4N\-8_^ O;Y$<M2.SN?
M5VEZM8ZY8Q7NG7EO?V<HS'<6LJR1N/4,I(-6Z_,'4/\ @DW\2_A[?37/PI^-
M+:=N.]%N&N=,D![!I+=GW'WVCZ5&OP!_;Y\*XBL/B,=70<>8==2?];E :G^Q
M\%5UP^-A;^\G$/:26\3]0J9+,D$;R2NL<:C<SL< #U)K\P6^"O\ P4!\09AN
M_'9TY.GF#6+:+\<PH338O^"5GQC^)DB3?%'XW"Z9CN=1+=ZNWKC,[Q '^7O1
M_8^#IZU\=!+^[>7Y6#VDGM$^R/BM^W5\$/@]YT.M>.]/OM1CX.FZ*3?S[O[K
M"+*H?]]EKY!\<?\ !4SX@?%_6G\+_L_?#>^N+V8834+ZU-Y> 9^^+>,F.,#^
M\[.N,Y Q7LOPK_X)-_!?P(T5SXB&J>/+Y3N_XF=P8+8'VBAVDCV=F%?6O@WP
M#X9^'>DKIGA;P_IGAW3AC_1M+M([="1W(0#)]SS5>WR7 ZT:<JTN\M(_<M7Z
M,+5);NQ^;?@__@F]\8_VB?$%MXI_:(^(%Y;1_>&E0W0N[U5."8UQF"V!_P!@
M.,C[HZU]\_!7]G'X=?L^Z/\ 8/ WAFTTAW0)/?D>;>7/_729LNPSSMSM'8"O
M2J*\W'9QB\='V=25H+:,=(KY?YW+C3C'5;A1117B&@4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7YQ?MW_ +$.K^'/$3_'?X(B?2?$^G3?VCJF
MEZ6-LC.O+7=NH_CZ^9'C#C) SN#?H[17IY?F%;+:WMJ7HT]FNS(E%35F?+7[
M"_[:NF?M4^#6L=4\C3?B%I,2_P!I:>AVI<IP!=0C^X3@,O\  QQT*D_4M?F5
M^W%^RIKW[/7CJ+]HGX(>9I$EA.;S6M-LDRMJQ^_<*@X,#@D2Q]!DG[I.WZ\_
M9!_:T\/?M7?#Q=5LO+T[Q/IX2+6=%WY:VD(X=,\M$^"5;V(/(->KF> I2I+,
M< OW,MUUA+L_+L_^!>(2=^26Y[S1117RYL%%%% !1110 4444 %8WC+_ )$_
M7?\ KPG_ /1;5LUC>,O^1/UW_KPG_P#1;4 2^%_^19TC_KSA_P#0!6I67X7_
M .19TC_KSA_] %:E !1110 4444 %%%% '$^._@GX"^)VN:!K/BSPCI/B#5=
M!N/M.FW=]:K)) ^UEQD_>7YRVQLKO5'QN16'1>)O"VB^-=#NM%\0Z18:]HUT
M%%QI^IVR7-O,%8,H>-P5;#*I&1U /:M2B@#"\3> _#7C3P[_ &!XA\.Z3KNA
M?)_Q*]3L8KBU^3!3]TZE?EP,<<8XI6\#>&W\(_\ "*-X?TMO"WV867]AFRC^
MQ>0!@1>1MV;,<;<8]JW** ,?PGX-T#P'H<.C>&=#TWP[H\+,T6GZ3:1VMO&6
M8LQ6.,!0222<#DFMBBB@#C? /_(>\>_]AX?^D-I795QO@'_D/>/?^P\/_2&T
MKLJ ,'7? 7AGQ1(7UCP]I>J2$8\R\LHY6_-E)KR;Q9^Q-\)O%;23'0[C2[MO
M^7BQO9/E^D<A>,?]\5[O16<J5.?QQ3]4G^9VX?'8K".^'JR@_P"[)K\F?#WB
MS_@F19W#22>&OB!<0-U2'7M)BN%^FZV:WP/?!_&O#_&/_!/WXV^&6DET[2?#
M7C.$?<BT;5WL9C]5ND*@_P#;0U^J-%9_4\#+2IAH->G+_P"D.+_$^IPW&W$N
M#M[+'U/G+F_]*YC\./%W@?X@_#?S7\6_"[QGH,"?>N(+#[9;C'_3="J'\ZX2
MS^)WABX5M^I_8_\ 8NK63?\ ^.*P'YU_0%7"^.O@3\.?B9YA\5^!O#^OROUN
M+[38I)A[B0KN!]P:G^Q>'ZVE3#SA_@G^DU+\6>S/Q&SW$)1S"-'$K_I[1A+\
ME$_$^S\0:-?6YDAU?2RN<#S+Z.-S]$9@WZ5U5I;^(]!M5NK6/5M/B;E;B'S(
MT;W! &?SK] ?'/\ P2K^ 7B_S'L-'U;PG._/F:+J3E<^NR?S5 ]@!7A.O?\
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M\?-^=?'&H:]\![7)M/BYJMT1TV^$9E_G,*Y#5OB9\*;-F6V\2>*M2<='3PY
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M+.D?]></_H K4K+\+_\ (LZ1_P!></\ Z *U* "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF*?0 4444 %%%% !1110 4457OM0M=+LYKN]N8;2TA4O+/.X1$4=2S'@#ZT
M6**Q/#OCCPYXP:8:#X@TO6S#@RC3KV.XV9Z;MC''XUMT %%%% !1110 4444
M %%%,>9(V17=5:1MJ!C@L<$X'J< G\#0 ^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BF23)"H:1U12P4%C@9)  ^I) _&GT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5C>,O^1/UW_KPG_\ 1;5LUS?Q
M&U:QT7P+KMSJ-[;V%O\ 8YD\ZZE6--Q0@#+$#)/ % &AX7_Y%G2/^O.'_P!
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M'QY_T+_AW_P>W'_R'1_:/CS_ *%_P[_X/;C_ .0ZZZB@#D?[1\>?]"_X=_\
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MUG> ?@+X"^&&I2:AX:\.0V%^Z[/M4DTL\BKW"M*S%0>^W&:[^@#D?[1\>?\
M0O\ AW_P>W'_ ,AT?VCX\_Z%_P ._P#@]N/_ )#KKJ* .1_M'QY_T+_AW_P>
MW'_R'1_:/CS_ *%_P[_X/;C_ .0ZZZB@#D?[1\>?]"_X=_\ ![<?_(=']H^/
M/^A?\._^#VX_^0ZZZB@#D?[1\>?]"_X=_P#![<?_ "'67J]KX\U74-$NO[%\
M.Q?V;>-=[?[:G/F9MYH=N?LG'^NW9Y^[COD>A44 <C_:/CS_ *%_P[_X/;C_
M .0Z/[1\>?\ 0O\ AW_P>W'_ ,AUUU% '(_VCX\_Z%_P[_X/;C_Y#H_M'QY_
MT+_AW_P>W'_R'7744 <C_:/CS_H7_#O_ (/;C_Y#H_M'QY_T+_AW_P 'MQ_\
MAUUU% '(_P!H^//^A?\ #O\ X/;C_P"0Z/[1\>?]"_X=_P#![<?_ "'7744
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MOV"OV</ %Q\?_B'\8/ NAMX<\#:/>3^%O"UC'=SSB[,8"7=\[S2.Y#ME8UR
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M3P/XV\ W7B/XNZGXR\$?#R>YN/"?A>71X+-K)Y#\AGNHV+7&Q?55R0,;5RC
M'V%1110 4444 %%%% !1110 4444 %%%% !1110!\ _MP>'?B"O[0?P'US7?
M%EJW@9OBEH-GH7A73K<J%^97DO+J5N7G+^;&JC*+'@@[G<5J_P#!0#X,_#R:
M;7OB=\9?%5[KFAPZ"VB^$/ MNTL#0ZJYR)X/+F'GS,V,@IM" ;]RQKM^BOV@
M?V?O^%ZZI\,+S^WO[$_X0GQ;9>*=GV/[1]L^SL3Y&?,3R]V?O_-C^Z:\I^/G
M[%WCOXP?M":3\4]$^-">$KG0;9;;0]-G\)P:I%IQ*_O95$T_EM([DMYGEA@
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M4Z1QHH55'L  *M4 %%%% !1110 4444 %%%% !1110 4444 ?,'_  4(\/\
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M^)>O?M(:Y\8_#WQ\3PWKUY";&PCG\%VVI?V99<!8(6GG*KQG+HBEB\F?OL"
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M'$CKR05D4@E2*^K*\\^"?@KQ]X%\-WME\0OB1_PL[5I;LS0:I_85OI/D0E$
MA\J%BK88.VX\_/CL*]#H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/P[^%>M> M.GL?$GB0^.=+.JZ#-X<TS[6+N,IOAC6/>)3)*2BH A&7&XH,D
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M^M.<?\_O_)8__(F'L:?8_+__ (<F?]5F_P#+6_\ NRC_ (<F?]5F_P#+6_\
MNROU HI_ZTYQ_P _O_)8_P#R(>QI]C\PK?\ X(H^3<1R?\+G<;&#9C\,;6X/
M8_;.#[UVO_!2KX/Z_<_"7X&Z'HW@SQ#\6+/PSJD":G8Z7;7$L][;0VZ(_FO
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M:#4F6\M;(WR21!4%S"R N%:3Y-_J<<<<[X;_ &+4\&_M,?'KP9\/O".H^$_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>(?M
M7?M1Z=^R]X-TC4&\/:AXQ\2:]J":5H?AW2^)KZY89"Y"L0.B_*CL6= %.<@
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MX3OM)L];U_2]&O-7N!::=;ZA>1P27LYP!%"KL#(YR/E7)Y% &U1110 4444
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MX/TP:=H.D6.B:>)'F%IIULEO%O=B[ML0 ;F8EB<9)))J&W\$^';3Q9=>*8-
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M7Q+U[2KKX>>/O^$5T^WMO*N+/^T;FR\R7>Q\S= K;N"HP?[M>+_\,G_M.?\
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MPLTSPEX+^&D@T>XU/1[V">XN[*[G8SK<*EW+N8M-.RE450\O/48]Y_;G\4?
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MG\8^"?#OBR:T5DMY-<TFWO6A5B"P0RHVT$@9 ZX%1^"?@O\ #[X9W\]]X/\
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067297648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,507,122,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,037,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Part&#160;III incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#8217;s fiscal year ended December&#160;31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065614992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUDIT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067489264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,247<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">11,547<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,686<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,941<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,334<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,426<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes&#160;20 and 21)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748&#160;issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">10,391<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,186)<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,056)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; deficit</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">952<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity (deficit)</a></td>
<td class="nump">260<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity (deficit)</a></td>
<td class="nump">$ 25,686<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065518000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">361,898,846<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">361,898,846<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065337744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,124<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Expenses</a></td>
<td class="nump">7,670<span></span>
</td>
<td class="nump">7,984<span></span>
</td>
<td class="nump">7,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(1,464)<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">875<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(83)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(937)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (225)<span></span>
</td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">358,900<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">358,900<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,046<span></span>
</td>
<td class="nump">$ 8,342<span></span>
</td>
<td class="nump">$ 7,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065070528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (212)<span></span>
</td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Pension and postretirement benefit plan adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Net actuarial gain (loss) arising during the year</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax', window );">Amortization of prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition', window );">Amortization or settlement recognition of net loss</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Income tax (expense) benefit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax', window );">Foreign currency impact</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension and postretirement benefit plan adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(468)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (494)<span></span>
</td>
<td class="num">$ (1,079)<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063371392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity (Deficit)</div></th>
<th class="th">
<div>Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity (Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 10,172<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="num">$ (7,452)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(8,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Release of foreign currency translation losses upon disposal of assets held for sale</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from B+L initial public offering, net of costs (Note 2)</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">361,898,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,391<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="num">$ (9,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,056)<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067301648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (212)<span></span>
</td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt discounts and debt issuance costs</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairment</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivables and inventories</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Additions to accrued legal settlements</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(1,572)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(875)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities', window );">Third party fees paid in connection with the Exchange Offer</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(728)<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets and other assets</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(218)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(303)<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">6,836<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(7,846)<span></span>
</td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(5,642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty', window );">Proceeds from B+L initial public offering, net of costs</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes related to share-based awards</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(474)<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Transaction And Other Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related To Litigation Settlement, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Initial Public Offering, Net Of Costs, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066308912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068637232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 89% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International, Diversified (dentistry, neurology, medical dermatology and generic pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these audited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Suspended Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221; or &#8220;Solta Medical&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company&#8217;s Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualified for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company&#8217;s three largest U.S. wholesaler customers accounted for approximately 46% of net trade receivables. In addition, as of December 31, 2022 and 2021, the Company&#8217;s net trade receivable balance from Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela amounted to $136 million and $78&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2022, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2022, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company&#8217;s cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for additional details regarding the Company&#8217;s cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $33 million, $35 million and $39&#160;million as of December 31, 2022, 2021 and 2020, respectively. The activity in the allowance for credit losses for trade receivables was as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8220;B&amp;L Trademark&#8221;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors, including rising interest rates and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of modified debt accounted for as a troubled debt restructuring consists of all future undiscounted cash flows, both principal and contractual future interest, associated with such debt. The excess of the carrying value over the principal amount of such debt is recorded as a premium and is reduced as stated interest payments are made on such debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2022 and 2021.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $40 million and $36 million as of December 31, 2022 and 2021, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2022 and 2021 were $131&#160;million in each period, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21 million and $28 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160;The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product mix and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2022 and 2021 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $10 million and $17 million for the years 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company&#8217;s global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTI3_ff4eb31c-416c-4e09-84fe-f967761f1790">thirty</span> to ninety days.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDc5_7ac9b54d-f1f9-4a3c-9aa7-dc857eb1ddf1">one</span> to twenty years, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTcz_3643a3d1-f7d7-4998-afc9-5317fb44ffa9">one</span> to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company&#8217;s lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sale of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $518 million, $515 million and $451 million, for 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company&#8217;s cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2022 and 2021 was $66 million and $60&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive loss. Other comprehensive loss includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company&#8217;s results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company&#8217;s disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance was effective for the Company beginning January 1, 2021.&#160;The application of this guidance did not have a material effect on the Company&#8217;s financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160;Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities </span></div>as of March 12, 2020, through December 31, 2024. For the years presented, the Company has not entered into any contract modifications in which the optional expedients were applied.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066320704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock', window );">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragon BioTeck, Inc.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2022, Bausch + Lomb acquired Paragon BioTeck, Inc., an eye-care focused drug development company, having a primary emphasis on the early detection of ocular diseases. The acquisition of Paragon Bioteck has been accounted for as an asset acquisition. The primary assets in the transaction, the trademarks, represented substantially all of the fair value of the gross assets acquired. There are no future sales milestones associated with this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Titanium</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2022, Bausch + Lomb acquired Total Titanium, Inc., a privately held ophthalmic microsurgical instrument and machined parts manufacturing company. The transaction was completed to assist in driving revenue growth as well as increasing manufacturing capacity. The fair value of the acquisition has been accounted for as a business combination. Additional contingent payments may be payable upon reaching key future milestone achievements related to sales and employee retention.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these transactions, recorded within the Consolidated Balance Sheet are Trade receivables, net of $1&#160;million, Inventories, net of $1&#160;million, Property, plant and equipment of $2&#160;million, Intangibles, net of $43&#160;million, Goodwill of $5&#160;million and Deferred tax liabilities, net of $11&#160;million. Supplemental pro forma information related to revenue and earnings for 2022 were not provided for the aforementioned transaction as they did not have a material impact on the Company&#8217;s operations. Refer to Note 21, &#8220;COMMITMENTS AND CONTINGENCIES&#8221; for further detail regarding potential future milestone payments related to previously entered transactions and agreements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Consolidated Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Licensing Agreements, And Divestiture Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065595264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2022 was $12 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $30&#160;million, $18&#160;million and $11&#160;million of restructuring and integration-related costs and made payments of $41&#160;million, $19&#160;million and $18 million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022 and 2021, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2022 and 2021 are Separation and IPO costs of $33&#160;million and $32&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2022 and 2021 are Separation-related and IPO-related costs of $94&#160;million and $132&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities And Initial Public Offering Costs Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065515664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:25.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of December 31, 2022 includes $380&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding certain U.S. securities litigation, which was subject to one objector&#8217;s appeal of the final court approval and the Glumetza Antitrust Litigation. With respect to the U.S. Securities Litigation, the period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the securities litigation settlement and judgment have become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company&#8217;s rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company&#8217;s Consolidated Balance Sheets, by $1,210&#160;million during the third quarter of 2022. See &#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for additional details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss. As of December 31, 2021, there were no cross-currency swaps.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps (the &#8220;2022 Cross-Currency Swaps&#8221;), with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2022 and 2021: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest settlement of the 2022 Cross-Currency Swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 Cross-Currency Swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022 and 2021, the Company received $0 and $27&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company entered into foreign currency exchange contracts. As of December&#160;31, 2022, these contracts had an aggregate outstanding notional amount of $455&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at December&#160;31, 2022.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2022 and 2021:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2022 and 2021 was $14,011 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152514448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152514448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $179 million, $177 million and $180 million for 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152360752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses, research and development expenses. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2022 were $15&#160;million and included: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $1,216&#160;million and $1,194&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets as of September 30, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on these factors, no impairment to the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was identified as of December 31, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was required. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets included in the audited Consolidated Balance Sheets had a carrying value of $2,693&#160;million and an estimated remaining useful life of 60 months as of December 31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale as discussed in Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company&#8217;s core businesses and (iv) $1&#160;million related to Acquired IPR&amp;D not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity (&#8220;LOE&#8221;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:22.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 Interim Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy led to significant volatility in the global equity markets and the Company was able to continue its operations with limited disruptions. In performing its assessment during 2020, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and made adjustments to the long-term forecasts used in previous goodwill impairment assessments, for these and other matters. After completing this assessment, the Company believed that, with the exception of the Ortho Dermatologics reporting unit, its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, did not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company&#8217;s forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the then respective quarter of 2020 which reflected current market conditions and current trends in business performance. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2020 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International Rx segment consisted of the International Rx reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The Company&#8217;s latest forecasts for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit&#8217;s results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit&#8217;s assets and were not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit as of March 31, 2022. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate had increased 1% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value tests utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Ortho Dermatologics reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Ortho Dermatologics reporting unit had remaining goodwill of $480&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 20, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately 80% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology and Other </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts, and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -2.5% and a discount rate of 10.25%, in the estimation of the reporting unit&#8217;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#8217;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $622&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $1,439&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of 2.0% and 3.0% and discount rates of 9.50% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Ortho Dermatologics and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in the third quarter of 2022, the Ortho Dermatologics reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company evaluated the reporting unit&#8217;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Ortho Dermatologics reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, given the reporting unit&#8217;s limited headroom, any changes or other potential future developments may adversely impact the estimated fair value of the Ortho Dermatologics reporting unit in one or more future periods requiring an impairment to goodwill to be recognized. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it was to occur.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022, and as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#8217;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, it is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix reporting unit in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December&#160;31, 2022 were $5,004 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219239446352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072177360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2022 and 2021 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $9,600&#160;million (although such availability is subject to the Company&#8217;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s indentures. In connection therewith, Bausch + Lomb and its subsidiaries, are now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the relevant Bausch Health indentures, and the earnings and debt of Bausch + Lomb, as defined in the relevant indentures, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221; and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the 9.25% Senior Notes due 2026, 8.50% Senior Notes due 2027, 5.00% Senior Notes due 2028, 7.00% Senior Notes due 2028 and 7.25% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#8217;s Consolidated Balance Sheet.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, the Company recorded a gain of $570&#160;million, net of third party fees of $25&#160;million, in connection with the Exchange Offer. The premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225&#160;million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000&#160;million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts of $4,565&#160;million and $1,500&#160;million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of December 31, 2022, the Company had drawn $470&#160;million and $25&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $500&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility may be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of December 31, 2022, the principal amount outstanding under the B+L Term Facility was $2,488&#160;million and $2,439&#160;million net of issuance costs. As of December 31, 2022, Bausch + Lomb had no outstanding borrowings, $24&#160;million of issued and outstanding letters of credit and remaining availability of $476&#160;million under its Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at December&#160;31, 2022 was 7.84% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, and the first installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $106&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million, aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.750% Senior Secured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the &#8220;January 2027 Unsecured Notes&#8221;) and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the &#8220;August 2027 Secured Notes&#8221;), respectively, in a private placement. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at the redemption prices set forth in the indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.125% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.00% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of 11.00% per year that is payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 11.00% First Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 14.00% Second Lien Secured Notes mature on October 15, 2030, and have stated interest of 14.00% per year that is payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.00% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of 9.00% per year that is interest payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of December 31, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#8217;s outstanding 9.00% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp., a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the &#8220;March 2020 Unsecured Notes&#8221;), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#8364;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the &#8220;Euro Notes&#8221;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and, together with the March 2020 Unsecured Notes&#8221;, the May 2023 Unsecured Notes and the Euro Notes) in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes. Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the April 2025 Unsecured Notes were redeemed and discharged in the second quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.000% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement. The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes, at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $541&#160;million in aggregate principal balance of the December 2025 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.250% Senior Unsecured Notes due 2026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $752&#160;million in aggregate principal balance of the April 2026 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">8.500% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $1,099&#160;million in aggregate principal balance of the 8.500% January 2027 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the &#8220;7.000% January 2028 Unsecured Notes&#8221;) and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the &#8220;May 2029 Unsecured Notes&#8221;), respectively, in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $540&#160;million and $373&#160;million in aggregate principal balance of the 7.000% January 2028 Unsecured Notes and 7.250% May 2029 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the &#8220;5.000% January 2028 Unsecured Notes&#8221;) and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the &#8220;January 2030 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 5.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $710&#160;million and $332&#160;million in aggregate principal balance of the 5.000% January 2028 Unsecured Notes and 5.250% January 2030 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.250% Senior Unsecured Notes due 2029</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the &#8220;6.250% February 2029 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company&#8217;s June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2020 Refinancing Transactions&#8221;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $540&#160;million in aggregate principal balance of the 6.250% February 2029 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the &#8220;5.000% February 2029 Unsecured Notes&#8221;) and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the &#8220;February 2031 Unsecured Notes&#8221;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2020 Refinancing Transactions&#8221;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, $371&#160;million and $336&#160;million in aggregate principal balance of the 5.000% February 2029 Unsecured Notes and 5.250% February 2031 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of December 31, 2022 and 2021 was 7.74% and 5.88%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements for 2022 and in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 and December 2022, the Company repurchased and retired certain outstanding Senior Notes with an aggregate par value of $927&#160;million in the open market, for an aggregate cost of $550&#160;million. In connection with these repurchases, the Company recognized a gain of $369&#160;million, net of write-offs of debt premiums, discounts and deferred </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance costs, on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company completed the Exchange Offer and recorded a net gain on extinguishment of debt of $570&#160;million as described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $64&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2022 Amended Credit Agreement, there is no Excess Cash Flow payment due for 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152360752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8220;B&amp;L&#8221;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company&#8217;s employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2022 and 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2022 and 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2023, the Company expects to contribute $0, $4 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2022 was 4.50%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was 2.75% for 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 expected rate of return for the U.S. pension benefit plan will be 6.00%. The 2023 expected rate of return for the Ireland pension benefit plans will be 4.25%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plan Assets </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2022 and 2021:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for details on the Company&#8217;s fair value measurements based on a three-tier hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2022 and 2021.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 92% and 95% of the non-U.S. commingled funds in 2022 and 2021, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans and the Company matches a portion of the employee contributions. The Company contributed $47 million, $44 million and $43 million to these plans during the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152470256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company&#8217;s operating leases are included in the Consolidated Balance Sheet as of December 31, 2022 and 2021 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, 2021 and 2020 the Company&#8217;s finance leases were not material and for the years 2022, 2021 and 2020 sub-lease income and short-term lease expense were not material. Lease expense for the years 2022, 2021 and 2020 include:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152540384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, Bausch Health further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 18,226,000 common shares were available for future grants as of December&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of Bausch Health&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NDM_93af1e70-6189-47b5-bbc3-e0e2bb7a586f">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expense related to stock options and&#160;RSUs for the years 2022, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc1MDMxNjk_b501e15b-da5b-47c2-acd7-f8740cbbba2e">ten</span>th anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2022, 2021 and 2020 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2022, 2021 and 2020 were $6.60, $10.92 and $6.60, respectively. The total intrinsic values of stock options exercised in 2022, 2021 and 2020 were $1 million, $15 million and $2 million, respectively. Proceeds received on the exercise of stock options in 2022, 2021 and 2020 were $3 million, $22 million and $5 million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $14 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2022, 2021 and 2020 were $15&#160;million, $15&#160;million and $15&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2022: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $94 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years. The total fair value of time-based RSUs vested in 2022, 2021 and 2020 were $80 million, $69 million and $66 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2022, 2021 and 2020 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no TSR performance-based RSUs granted in 2022. The fair values of TSR performance-based RSUs granted during 2021 and 2020 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">369,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of ROTC performance-based RSUs with a weighted-average grant date fair value of $9.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $7 million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.4 years. A maximum of approximately 1,104,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2022. The total fair value of performance-based RSUs vested in 2022 was $31&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, Bausch + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to Bausch + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, Bausch + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were B+L IPO Founder Grants. The IPO Founder grants in the form of stock options have a three-year graded vesting period and the IPO Founder RSUs vest 50% in the second year and 50% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, Bausch + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#8220;CEO&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original three-year vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the two-year anniversary of the CEO&#8217;s termination of service date (such applicable date, the &#8220;Unrestricted Date&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original three-year vesting period associated with such grants) upon the Unrestricted Date and will remain exercisable for two years following this date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, Bausch + Lomb entered into an Amended and Restated Separation Agreement (the &#8220;A&amp;R Separation Agreement&#8221;) in connection with the departure of Bausch + Lomb&#8217;s CEO. Under the A&amp;R Separation Agreement, Bausch + Lomb&#8217;s CEO agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board determines in its discretion or his successor is appointed, but no later than June 30, 2023. On the CEO&#8217;s termination date, in lieu of pro-rated vesting, partial vesting of a set number of the CEO&#8217;s IPO Founder Grants, in the amount of: (a) 315,592 of the CEO&#8217;s IPO Founder Grants in the form of restricted stock units will accelerate and vest, but the shares received upon settlement will still remain fully restricted and nontransferable until the Unrestricted Date and (b) </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,248,496 of the CEO&#8217;s IPO Founder Grants in the form of stock options will remain eligible to vest upon the Unrestricted Date and remain exercisable for two years following the Unrestricted Date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes Bausch + Lomb&#8217;s named executive officers (other than the CEO) and certain other employees. This program provides these Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by Bausch + Lomb without &#8220;cause&#8221; or the executive&#8217;s resignation for &#8220;good reason&#8221;, in each case within the one-year anniversary of Bausch + Lomb&#8217;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original three-year vesting period associated with such grants). However, the IPO Founder Grants in the form of RSUs (while settled in connection with the termination of employment) will not be transferrable until, and the IPO Founder Grants in the form of stock options will not be exercisable until, the earliest to occur of: (i) the date the spinoff distribution is completed, (ii) a &#8220;change in control&#8221; (as defined in the applicable retention award letter), (iii) the date the Board of Directors of the Company determines that it will no longer pursue the spinoff distribution and (iv) the two-year anniversary of the executive&#8217;s termination of employment and the IPO Founder Grants in the form of stock options will be exercisable for two years following the later of this date and the termination date Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately 850,000 RSUs under the retention program pursuant to Bausch + Lomb&#8217;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNDI_bd3faf2e-8d53-4f0a-9ea0-1f5a151830e1">three</span> anniversaries of the grant date based on continuous employment with Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 17,500,000 Bausch + Lomb common shares were available for future grants as of December&#160;31, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the B+L Plan generally expire on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NTY_abbdaf34-1a0a-4131-b1a8-ee77e636b7d4">ten</span>th anniversary of the grant date. The exercise price of any stock option granted under the B+L Plan will not be less than the closing price per common share preceding the date of grant. Stock options generally vest 33% each year over a three-year period, on the anniversary of the date of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan for the year 2022 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns associated with historical stock options granted to Bausch + Lomb employees under BHC&#8217;s long-term incentive plan. The expected volatility was determined based on implied and historical volatility of Bausch + Lomb&#8217;s selected peer companies. Bausch + Lomb will continue to leverage BHC&#8217;s historical stock option experience and peer company data until it has sufficient experience with its own equity awards and market data. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected Bausch + Lomb annual dividend rate at the time of grant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradable, fully transferable stock options without vesting restrictions, which significantly differ from Bausch + Lomb&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under Bausch + Lomb&#8217;s Plan during 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2022 were $3.84. There were no stock options exercised in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $4&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. There were no stock options that vested during 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan generally vest 33% a year over a three-year period with the exception of IPO Founder RSUs which vest 50% in the second year and 50% in the third year after the grant. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Bausch + Lomb&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, Bausch + Lomb may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity under Bausch + Lomb&#8217;s Plan during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $41&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. The total fair value of time-based RSUs vested in 2022 was not material.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while Bausch + Lomb did not grant performance-based RSUs during 2022, certain Bausch + Lomb employees continued to participate in BHC&#8217;s performance-based RSUs granted prior to May 5, 2022. As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $4&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066421072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS <div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2022 and 2021 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066532560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2022, 2021 and 2020 consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072215376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2022, 2021 and 2020 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gain on sales of assets includes $25&#160;million related to the achievement of a milestone related to a certain product and a $26&#160;million loss upon completion of the Amoun Sale during 2021.</span></div>In 2020, Acquired in-process research and development costs of $32 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219069984816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before income taxes for 2022, 2021 and 2020 consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of (Provision for) benefit from income taxes for 2022, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (Provision for) benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before income taxes for 2022, 2021 and 2020 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other consists of immaterial adjustments affecting the tax provision such as those related to the filing of tax returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2022, 2021 and 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. In 2022, the valuation allowance decreased $199 million primarily due to book taxable income in Canada and the expiration of tax losses in the United States. In 2021, the valuation allowance decreased by $30&#160;million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $5,878 million and $6,669 million, respectively.&#160;As of December 31, 2022 and 2021, unclaimed ITCs available to offset future federal taxes in Canada were approximately $27 million and $31 million, respectively, which expire in the years 2023 through 2043.&#160;In addition, as of December 31, 2022 and 2021, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $188 million and $196 million, respectively, which may be carried forward indefinitely. As of December 31, 2022 and 2021, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,869 million and $1,965 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; federal taxable income in the U.S. of approximately $241 million and $266 million, respectively, including acquired losses which expire in the years 2023 through 2033. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2022 and 2021 U.S. research and development credits available to offset future years&#8217; federal income taxes in the U.S. were approximately $75 million and $119 million, respectively, which includes acquired research and development credits and which expire in the years 2023 through 2042.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $10,691 million and $10,040 million, respectively.&#160;As of December&#160;31, 2022, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2022, the Company estimates that there will be no tax liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to unremitted earnings of its U.S. subsidiaries. However, future distributions could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, unrecognized tax benefits (including interest and penalties) were $881 million and $927 million, of which $384 million and $217 million would affect the effective income tax rate, respectively. In 2022 and 2021, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2022 and 2021, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $156 million and $79 million, respectively. The Company recognized a net reduction of $203 million during 2022 and a net reduction of $177 million during 2021 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2022 and 2021, accrued interest and penalties related to unrecognized tax benefits were approximately $32 million and $41 million, respectively. In 2022, the Company recognized a net decrease of approximately $9 million and, in 2021, recognized an increase of $8 million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2013 to 2021, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2021</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2021</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2021</span></div></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#8217;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#8217;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company has contested this proposed tax deficiency through the IRS administrative appeals process, and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision has been recorded as of December 31, 2022. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, as part of an alternative dispute resolution process with the IRS, the Company has reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized. The Company expects that the tentative settlement, if finalized without further modification, will affect the Company&#8217;s 2023 income tax provision, and while such settlement may be material to the Company&#8217;s results of operations or cash flows in the quarter in which it is recorded, will not be material to its results of operations or cash flows for the year ended December 31, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017. The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2023. The Company settled the tax years from 2005 through 2009 with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years. The adjustment did not result in a material change to the provision for income taxes. The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively. The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013. The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and CAD 23&#160;million for 2016. The adjustments for 2015 and 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022 the Company&#8217;s affiliate in Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#8211; 2019 for &#8364;271.7&#160;million. The Company is vigorously defending its position and no reserves have been recorded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia were under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office (&#8220;ATO&#8221;) issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest. On April 13, 2022, the Company and the ATO entered into a settlement agreement resulting in an immaterial income tax provision.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2022, 2021 and 2020: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December&#160;31, 2022 could decrease by approximately $4 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066421072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2022, 2021 and 2020 was calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,851,000, 4,932,000 and 3,154,000 common shares for 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2022, 2021 and 2020, stock options, time-based RSUs and performance-based RSUs to purchase approximately 14,396,000, 3,428,000 and 9,551,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2022 and 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066447008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW DISCLOSURES</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW DISCLOSURES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2022, 2021 and 2020 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066532560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company&#8217;s subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $326 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. In February 2023, the Company&#8217;s subsidiary OraPharma, Inc. entered into a civil settlement agreement with the Department of Justice fully resolving this investigation. Under the terms of the settlement, OraPharma, Inc. has paid a settlement payment of $100,000, plus payment of additional immaterial amounts in applicable interest and other related costs, to resolve the civil False Claims Act (&#8220;FCA&#8221;) investigation. A related complaint brought by a former OraPharma employee pursuant to the FCA and certain state statutes will be dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Iowa &#8211; re OrthoDerm</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#8217;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Siliq</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is cooperating with this </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#8217;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034) (&#8220;T. Rowe.&#8221;); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127) (&#8220;Equity Trustees&#8221;); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128) (&#8220;Principal Funds&#8221;); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212) (&#8220;Bloombergsen&#8221;); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488) (&#8220;UC Regents&#8221;); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190); Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478); USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462); and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015) and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015) and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#8220;Consolidated State Case&#8221;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200 mg and 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Colazal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 27 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10, 2022, (the &#8220;Norwich Legal Decision&#8221;), finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#8217;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#8217;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a 30-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#8220;Auro&#8221;) alleging patent infringement by Auro&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#8217;s generic plecanatide tablets, 3 mg.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The filing of this suit triggered a 30-month stay of the approval of the Auro ANDA for plecanatide tablets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. Three lawsuits are pending in Canada regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Apotex Inc. and Pharmascience Inc.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#8217;s IPR and joining it with Mylan&#8217;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#8217;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#8217;s petitions.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#8217;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL has filed a petition for rehearing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the Third Circuit. If the bankruptcy case is ultimately dismissed, the Company&#8217;s position vis a vis J&amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pendency of the appeal, the Bankruptcy Court was considering competing motions by Debtor LTL to extend its exclusive period to file a chapter 11 plan and the talc claimants to terminate LTL&#8217;s exclusivity. In light of the Third Circuit&#8217;s decision, on January 31, 2023, the Bankruptcy Court adjourned any hearing on the exclusivity motions to March 20, 2023.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#8217;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#8217; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#8217; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#8217;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. That motion is pending. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp; Johnson requested the court afford it sixty (60) days &#8211; until April 18, 2023, or seven (7) days following any lifting of the LTL Bankruptcy Court&#8217;s preliminary injunction &#8211; whichever comes earliest &#8211; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152536864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $42 million as of December&#160;31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2022, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $250 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, Bausch + Lomb has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., Bausch + Lomb has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), Bausch + Lomb may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2022, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066245168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical (&#8220;Solta&#8221;) aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company&#8217;s top ten products for the years 2022, 2021 and 2020 represented 49%, 43% and 41% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2022 and 2021 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067458352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company&#8217;s Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and Acquisition-Related Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Fair Value of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualified for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div>The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with </span></div>reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela have been weak in recent years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for Credit Losses</a></td>
<td class="text">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock', window );">Divestitures of Products</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div>Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8220;B&amp;L Trademark&#8221;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit&#8217;s carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors, including rising interest rates and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. </span></div>The carrying value of modified debt accounted for as a troubled debt restructuring consists of all future undiscounted cash flows, both principal and contractual future interest, associated with such debt. The excess of the carrying value over the principal amount of such debt is recorded as a premium and is reduced as stated interest payments are made on such debt.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, gastroenterology (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2022 and 2021.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $40 million and $36 million as of December 31, 2022 and 2021, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2022 and 2021 were $131&#160;million in each period, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21 million and $28 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160;The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product mix and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2022 and 2021 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $10 million and $17 million for the years 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div>The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div>Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sale of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company&#8217;s cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share Attributable to Bausch Health Companies Inc.</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. </span></div>Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive loss. Other comprehensive loss includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div>If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company&#8217;s results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company&#8217;s disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance was effective for the Company beginning January 1, 2021.&#160;The application of this guidance did not have a material effect on the Company&#8217;s financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160;Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities </span></div>as of March 12, 2020, through December 31, 2024. For the years presented, the Company has not entered into any contract modifications in which the optional expedients were applied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures of Non-core Products [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DivestituresOfNoncoreProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068660160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables was as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of property, plant and equipment</a></td>
<td class="text">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of estimated useful lives of intangible assets</a></td>
<td class="text">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2022 and 2021.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063683280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:25.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.242%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2022 and 2021: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2022 and 2021:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI https://asc.fasb.org/extlink&amp;oid=127000641&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068541600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066253840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,920)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062788224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2022, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:22.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.338%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072400928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2022 and 2021 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072391024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2022 and 2021 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock', window );">Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of aggregate maturities of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of troubled debt restructuring which results when the debtor restructures the terms of its debt with a creditor due to the debtor's financial difficulties and the creditor grants certain concessions to obtain payment it might not otherwise receive. Includes a description of the principal changes in terms, the major features of settlement for each restructuring, the aggregate gain on restructuring and the related income tax effect, the per share amount of the total gain on restructuring, net of related income tax effect, and the total gain (loss) on transfers of assets recognized during the period. After the troubled debt restructuring has occurred debtors discuss the extent and amount to which amounts contingently payable are included in the carrying amount of restructured payables, and the conditions under which those amounts would become payable or would be forgiven when there is at least a reasonable possibility that a liability for contingent payments will be incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15765-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062798000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of amounts recognized in accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial (losses) gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Components of the change in projected benefit obligations, change in plan assets and funded status</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2022 and 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of underfunded plans</a></td>
<td class="text">Information for the underfunded pension benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Future benefit payments for the pension benefit plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2022, 2021 and 2020 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Actual asset allocations</a></td>
<td class="text">The following presents the actual asset allocation as of December 31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock', window );">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2022 and 2021.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071375072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Summary of right-of-use assets and right-of-use liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company&#8217;s operating leases are included in the Consolidated Balance Sheet as of December 31, 2022 and 2021 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of lease expenses</a></td>
<td class="text">Lease expense for the years 2022, 2021 and 2020 include:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock', window );">Summary of other operating lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2022, 2021 and 2020 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of operating lease future payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Operating Lease Information, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063724752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expense related to stock options and&#160;RSUs for the years 2022, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2022, 2021 and 2020 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>2022 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under Bausch + Lomb&#8217;s Plan during 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of non-vested time-based RSU activity</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2022: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity under Bausch + Lomb&#8217;s Plan during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair values of performance-based RSUs</a></td>
<td class="text">The fair values of TSR performance-based RSUs granted during 2021 and 2020 were estimated with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of non-vested performance-based RSU activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2022: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066402096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2022 and 2021 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066548960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs for the years 2022, 2021 and 2020 consists of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066503408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2022, 2021 and 2020 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071810320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before income taxes for 2022, 2021 and 2020 consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of (provision for) benefit from income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of (Provision for) benefit from income taxes for 2022, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of (provision for) benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to income (loss) before income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (Provision for) benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before income taxes for 2022, 2021 and 2020 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2022 and 2021 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discounts and deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2022, 2021 and 2020: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of open tax years by jurisdiction</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2021</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2021</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 - 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2021</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2022, 2021 and 2020: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066449184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2022, 2021 and 2020 was calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065363504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow disclosures</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2022, 2021 and 2020 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067471232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of capital expenditures, depreciation and amortization by segment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and by product category</a></td>
<td class="text">Revenues by segment and product category were as&#160;follows: <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"/><td style="width:24.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenues by geographic region</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of long-lived assets by geographic region</a></td>
<td class="text"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2022 and 2021 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of external customers that accounted for 10% or more of total revenues</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219070494912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">89.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065075488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,898,846<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">310,449,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember', window );">IPO and Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares sold, net proceeds</a></td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">B+L IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">4,550,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SaleOfStockOverAllotmentTerm', window );">Underwriters option to purchase additional shares, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Additional Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockOverAllotmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Over-Allotment, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockOverAllotmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061483472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents', window );">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables', window );">Percentage of net trade receivables accounted for by largest wholesale customers</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember', window );">Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net trade receivable</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible', window );">Past due period for receivables to be negligible (less than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PeriodReceivableOutstanding', window );">Period net trade receivable balance outstanding (more than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TradeReceivableNetPortionPastDue', window );">Portion of net trade receivables that is past due</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade receivables | Three largest U.S. wholesaler customers | Credit concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_NumberOfLargestWholesaleCustomers', window );">Number of largest wholesale customers | wholesaler</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Percentage of Net Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskPercentageofNetTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NumberOfLargestWholesaleCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of largest wholesale customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NumberOfLargestWholesaleCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the past due period for which accounts receivables are negligible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PastDuePeriodForAccountsReceivableToBeNegligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PeriodReceivableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time the accounts receivable has been outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PeriodReceivableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TradeReceivableNetPortionPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade Receivable, Net, Portion Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TradeReceivableNetPortionPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068388320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, beginning of period</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate', window );">Retrospective effect of application of new accounting standard</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against the allowance</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries of amounts previously written off</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, end of period</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068405808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063386336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062747968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(5,524)<span></span>
</td>
<td class="num">(5,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,910<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,508)<span></span>
</td>
<td class="num">(2,297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,038)<span></span>
</td>
<td class="num">(2,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061616224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,910<span></span>
</td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CashDiscountsAndAllowancesSettlementPeriod', window );">Settlement period for cash discounts and allowances</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">$ 5,571<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,124<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reduction in variable consideration provision, adjustment</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CashDiscountsAndAllowancesSettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Discounts And Allowances, Settlement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CashDiscountsAndAllowancesSettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068592592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066541280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219164429456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071771840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TaxBenefitRecognitionMeasurementPercentage', window );">Tax benefit recognition, measurement percentage (greater than)</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities', window );">Minimum period to classify uncertain tax position liabilities as long term liabilities</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TaxBenefitRecognitionMeasurementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit Recognition, Measurement Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TaxBenefitRecognitionMeasurementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066442784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage', window );">Threshold percentage for amortization of net actuarial gains and losses</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062129632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="num">$ (260)<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (605)<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="nump">$ 9,186<span></span>
</td>
<td class="nump">$ 8,961<span></span>
</td>
<td class="nump">$ 8,013<span></span>
</td>
<td class="nump">7,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063501872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems', window );"><strong>Asset Acquisition And Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,044<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
<td class="nump">$ 13,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems', window );"><strong>Asset Acquisition And Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss', window );">Noncash cumulative foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember', window );">Asset Impairments | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems', window );"><strong>Asset Acquisition And Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other (Income) Expense | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems', window );"><strong>Asset Acquisition And Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Paragon Bio Teck Inc. Asset Acquisition and Total Titanium Inc. Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems', window );"><strong>Asset Acquisition And Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetAcquisitionAndBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition And Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetAcquisitionAndBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Cumulative Foreign Currency Translation Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NoncashCumulativeForeignCurrencyTranslationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetAcquisitionAndBusinessCombinationAxis=bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetAcquisitionAndBusinessCombinationAxis=bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065041936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">restructuring and integration-related costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining restructuring liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061987984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068577392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>appeal</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount paid</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LitigationSettlementNumberOfObjectorsAppeals', window );">Settlement, escrow fund included in restricted cash, number of objectors' appeals | appeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent', window );">Decrease in restricted cash and other settlement deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent', window );">Decrease in accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LitigationSettlementNumberOfObjectorsAppeals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number of Objectors' Appeals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LitigationSettlementNumberOfObjectorsAppeals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062927872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Net proceeds, cross-currency swaps</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember', window );">Cross-currency swaps, final settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062915136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - Bausch + Lomb - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065292400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in Other comprehensive loss</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072321760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 455,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063615440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Accrued and other current liabilities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066567968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain related to changes in fair value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071646496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted-Average Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061546768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</a></td>
<td class="text">Acquisition-related contingent consideration adjustments<span></span>
</td>
<td class="text">Acquisition-related contingent consideration adjustments<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments / Settlements</a></td>
<td class="num">$ (28)<span></span>
</td>
<td class="num">$ (99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign currency translation adjustment included in other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember', window );">Fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067295840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Non-recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 14,011<span></span>
</td>
<td class="nump">$ 22,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068545952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Summary of Inventories, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 1,090<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219067519600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,520<span></span>
</td>
<td class="nump">$ 3,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,920)<span></span>
</td>
<td class="num">(1,820)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,951<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember', window );">Other equipment and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember', window );">Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063282480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063520960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,436<span></span>
</td>
<td class="nump">$ 25,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(21,334)<span></span>
</td>
<td class="num">(20,180)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,102<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,134<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">B&amp;L Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,840<span></span>
</td>
<td class="nump">20,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(17,196)<span></span>
</td>
<td class="num">(16,169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3,644<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 899<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(542)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,347<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,251)<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219050841712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 234,000,000<span></span>
</td>
<td class="nump">$ 114,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">impairments<span></span>
</td>
<td class="text">impairments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,124,000,000<span></span>
</td>
<td class="nump">$ 8,434,000,000<span></span>
</td>
<td class="nump">8,027,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,102,000,000<span></span>
</td>
<td class="nump">5,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,000,000<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,547,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,547,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">13,044,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">$ 13,126,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090,000,000<span></span>
</td>
<td class="nump">2,074,000,000<span></span>
</td>
<td class="nump">1,904,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">$ 1,267,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,216,000,000<span></span>
</td>
<td class="nump">$ 1,194,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,693,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,693,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember', window );">Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember', window );">Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember', window );">Neurology and Other Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="nump">$ 622,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_SurgicalReportingUnitMember', window );">Surgical Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,004,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,004,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | A Certain International Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,644,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,644,000,000<span></span>
</td>
<td class="nump">4,673,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,673,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember', window );">Unutilized IT Infrastructure Improvement Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_SurgicalReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_SurgicalReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071673728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated aggregate amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,102<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062393872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457,000,000<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
<td class="nump">$ 13,126,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91,000,000)<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(824,000,000)<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,547,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">13,044,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
<td class="nump">5,786,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,246,000,000<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789,000,000<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(798,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,000,000<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(824,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,238,000,000<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Transfers Related To Sale of Business Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061422864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LegalSettlementsAndRelatedFees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 2,988<span></span>
</td>
<td class="nump">$ 4,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LegalSettlementsAndRelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlements And Related Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LegalSettlementsAndRelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219048041312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 19,110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,870,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">20,766,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">432,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,334,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">2,437,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,392,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,488,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.500% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,680,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,672,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | Senior Secured 6.125% Notes Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 987,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.750% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,583,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 11.00% First Lien Senior Notes Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,826,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 14.00% Second Lien Senior Notes2 Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 711,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 9.00% Intermediate Holdco Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,423,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 959,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 951,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.250% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 741,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 737,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 643,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 644,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 171,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 170,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 433,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 429,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 821,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 813,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 452,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 448,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 337,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 334,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 779,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 771,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 462,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">458,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066623520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember', window );">1261229 B.C. Ltd. | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes Due January 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1261229BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219047874000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Exchange Offer (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (64,000,000)<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="num">$ (27,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875,000,000<span></span>
</td>
<td class="num">$ (62,000,000)<span></span>
</td>
<td class="num">$ (59,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ExtinguishmentOfDebtThirdPartyFees', window );">Third party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer | Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,594,000,000<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Notes due 2026 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes due 2027 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal', window );">Reduction of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt instrument, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,835,000,000<span></span>
</td>
<td class="nump">1,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 11.00% First Lien Senior Notes Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 11.00% First Lien Senior Notes Due September 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 14.00% Second Lien Senior Notes2 Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 14.00% Second Lien Senior Notes2 Due October 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 9.00% Intermediate Holdco Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 9.00% Intermediate Holdco Senior Notes Due January 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ExtinguishmentOfDebtThirdPartyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment Of Debt, Third Party Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ExtinguishmentOfDebtThirdPartyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219058682880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details) - Existing Unsecured Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member', window );">9.00% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member', window );">9.00% Senior Notes due 2025 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 541,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member', window );">9.25% Senior Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member', window );">9.25% Senior Notes due 2026 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member', window );">8.50% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member', window );">8.50% Senior Notes due 2027 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member', window );">7.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member', window );">7.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member', window );">5.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member', window );">5.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member', window );">7.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member', window );">7.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member', window );">6.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member', window );">6.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member', window );">5.00% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member', window );">5.00% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member', window );">5.25% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member', window );">5.25% Senior Notes due 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member', window );">5.25% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member', window );">5.25% Senior Notes due 2031 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219045755232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 20,766,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,766,000,000<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">19,110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,110,000,000<span></span>
</td>
<td class="nump">22,870,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember', window );">1261229 B.C. Ltd. | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,829,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">994,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">2,392,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Remaining mandatory quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">2,437,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,437,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Federal Funds Effective Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate Factor, SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember', window );">New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">2,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Remaining mandatory quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 2,488,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,488,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate Factor, SOFR | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Incremental credit facility borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage', window );">Incremental borrowings interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | EURIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability</a></td>
<td class="nump">476,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.275%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Credit Spread Adjustment on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1261229BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219047310576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,846,000,000<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (875,000,000)<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (570,000,000)<span></span>
</td>
<td class="num">$ (369,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member', window );">6.50% Senior Notes Due March 2022 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member', window );">7.000 % Senior Notes Due March 2024 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member', window );">5.500% Senior Notes Due November 2025 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member', window );">5.750% Senior Notes Due August 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member', window );">8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">7.00% Senior Notes Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes Due September 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes Due September 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes2 Due October 2030 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes2 Due October 2030 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes2 Due October 2030 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes Due January 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219051379136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 26, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,846,000,000<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (875,000,000)<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (570,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member', window );">Term Loan B Facility Due June 2025 and November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentForDebtAmortizationPrepaymentCost', window );">Repayment, outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (570,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (369,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Unsecured Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.375% Senior Notes Due March 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Unsecured Notes Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Senior Unsecured Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes Due December 2025 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Unsecured Notes Due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Unsecured Notes Due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Unsecured Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Unsecured Notes Due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due February 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due February 2031 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.50% Senior Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtAmortizationPrepaymentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Amortization Prepayment Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtAmortizationPrepaymentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066515008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">7.74%<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072001856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,846,000,000<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (64,000,000)<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="num">$ (27,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000,000<span></span>
</td>
<td class="num">$ (62,000,000)<span></span>
</td>
<td class="num">$ (59,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="nump">$ 927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="nump">$ 369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219070784448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">6,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">19,110<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 20,766<span></span>
</td>
<td class="nump">$ 22,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062962656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>defined_benefit_plan</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>defined_benefit_plan</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod', window );">Future benefit payments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance', window );">Benefit accrual, interest percentage earned on cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.23%<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans', window );">Number of defined benefit plans | defined_benefit_plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended', window );">Number of defined benefit plans amended | defined_benefit_plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanPercentageAllocationofFund', window );">Percentage allocation of fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge', window );">Employer contribution maximum age</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Employer Contribution, Maximum Age</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEmployerContributionMaximumAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Estimated Future Benefit Payments, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans Amended</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanPercentageAllocationofFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Percentage Allocation of Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanPercentageAllocationofFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072409168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial (losses) gains</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial (losses) gains</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial (losses) gains</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062757264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061708784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial gain</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071516144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063659664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2023</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2024</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2026</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2027</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2028-2032</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063038720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.69%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">3.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.41%<span></span>
</td>
<td class="nump">2.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">5.23%<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.53%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">6.67%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">3.71%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.57%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.39%<span></span>
</td>
<td class="nump">2.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065353872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) - Pension Benefit Plans<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219050855456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Pension Benefit Plans | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level 1 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;2 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;3 | Pension Benefit Plans | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072442784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AssetsLesseeAbstract', window );"><strong>Right-of-use assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other non-current assets</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LiabilitiesLesseeAbstract', window );"><strong>Lease liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061518240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sub-lease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219066277120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease costs</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068558304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061422704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Future Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219049994304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2022</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Incentive stock plan, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on the anniversaries from the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on the anniversaries from the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued', window );">Maximum common shares issuable upon vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_CertainEmployeesMember', window );">Certain Employees | Performance-Based Restricted Stock Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer, Excluding The Chief Executive Officer | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Chief Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest', window );">Involuntary termination program criteria, if circumstances met, number of shares that will remain eligible to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Chief Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting', window );">Involuntary termination program criteria, if circumstances met, number of shares that will vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Incentive stock plan, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | RSUs | Bausch + Lomb | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Equity Instruments Other Than Options, Number Of Shares Vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Options, Number Of Shares Eligible To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of stock options vested during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of stock options that will vest in the future period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_CertainEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_CertainEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219049982368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219049950144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected stock option life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">37.80%<span></span>
</td>
<td class="nump">50.20%<span></span>
</td>
<td class="nump">38.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">End of the period (in shares)</a></td>
<td class="nump">10,800,000<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end of the period (in shares)</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 27.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">23.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">19.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in dollars per share)</a></td>
<td class="nump">28.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">End of the period (in dollars per share)</a></td>
<td class="nump">26.83<span></span>
</td>
<td class="nump">$ 27.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">26.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 27.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end of the period</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end of the period</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised in the period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected stock option life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">31.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">End of the period (in shares)</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in dollars per share)</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">End of the period (in dollars per share)</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end of the period</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end of the period</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of stock options that will vest in the future period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219047829536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - RSUs (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(3,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">26.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">24.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 15.97<span></span>
</td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">17.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 16.67<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued', window );">Maximum common shares issuable upon vesting (in shares)</a></td>
<td class="nump">1,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 33.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">9.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">30.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">34.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 29.83<span></span>
</td>
<td class="nump">$ 33.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Company share volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062714064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,038)<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (2,056)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062793520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062770128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063597040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_OtherIncomeExpenseNet', window );">Other, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061777072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember', window );">Amoun | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219047818928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Benefit from Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of loss before benefit of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="num">$ (323)<span></span>
</td>
<td class="num">$ (410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(256)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(271)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Domestic</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">$ (83)<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072336128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canadian statutory rate</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (129)<span></span>
</td>
<td class="num">$ (1,024)<span></span>
</td>
<td class="num">$ (934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>(Provision for) benefit from income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Expected benefit from income taxes at Canadian statutory rate</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible amount of share-based compensation</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount', window );">Adjustments to tax attributes</a></td>
<td class="nump">53<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance', window );">Change in valuation allowance related to foreign tax credits and NOLs</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differences</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible portion of Goodwill impairments</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit', window );">Tax benefit on intra-entity transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">$ (83)<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationDeferredIntercompanyProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071506240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 2,872<span></span>
</td>
<td class="nump">$ 2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Provisions</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts', window );">Debt discounts and deferred financing costs</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool', window );">Scientific Research and Experimental Development pool</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxAssetsPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,377<span></span>
</td>
<td class="nump">4,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(2,023)<span></span>
</td>
<td class="num">(2,222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes', window );">Plant, equipment and technology</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Outside basis differences</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,964<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Debt Discounts And Deferred Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on tax loss carryforwards available to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219063267440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">5,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,910<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes', window );">Charged to Benefit from income taxes</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061860400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> &#8364; in Millions, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 08, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net decrease for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net increase (decrease) recognized in interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns', window );">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Possible decrease in unrecognized tax benefits realized in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member', window );">Tax Year 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial | Pooled Scientific Research and Experimental Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2005 through Tax Year 2009 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2012 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2015 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2016 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Tax Year 2018 and 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to) | &#8364;</a></td>
<td class="nump">&#8364; 271.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccumulatedLossesAvailableForFederalPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the details pertaining to accumulated losses available for federal and provincial purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccumulatedLossesAvailableForFederalPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unclaimed tax credits and research and development credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2018And2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2018And2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219071402112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068603824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of year</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(85)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219070784432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (225)<span></span>
</td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">358,900<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">362,000<span></span>
</td>
<td class="nump">358,900<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219068612624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Stock options, Time-based RSUs, Performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">14,396<span></span>
</td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219072347328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Other payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 1,540<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219056861232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Narrative (Details)<br> $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>defendant</div>
</th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jul. 21, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 26, 2020</div></th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Feb. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>defendant </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>defendant </div>
<div>group </div>
<div>case </div>
<div>action </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>number_business</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LegalSettlementsAndRelatedFees', window );">Legal matters and related fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="nump">$ 1,890,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember', window );">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts-OraPharma Litigation | Settled Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of additional suits filed, but not served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember', window );">RICO Class Actions Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember', window );">Perrigo Israel Pharmaceuticals, Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember', window );">Norwich Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember', window );">Taro Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember', window );">Aurobindo Pharma Limited Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfProceedings', window );">Number of proceedings | proceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Pending Litigation | Subsequent Event | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Settled Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Default Judgement | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember', window );">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember', window );">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Patents allegedly infringed upon, number | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod', window );">Stay of approval, motion to extend, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation | Pending Litigation, Agreed Stipulations Of Dismissal Submitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation | British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower To Shower Product Liability Litigation | Quebec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember', window );">California Proposition 65 Related Matter Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne', window );">Stay of approval, motion to extend, period one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo', window );">Stay of approval, motion to extend, period two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfProceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Proceedings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfProceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LegalSettlementsAndRelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlements And Related Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LegalSettlementsAndRelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219065083104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Capital expenditures</a></td>
<td class="nump">$ 42,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member', window );">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember', window );">Novaliq GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember', window );">Eyenovia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CollaborativeAgreementMilestonePaymentsAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_EyenoviaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219165376320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062277216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,124<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(824)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,464)<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (64)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,124<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (828)<span></span>
</td>
<td class="num">$ (792)<span></span>
</td>
<td class="num">$ (619)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219070726800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the capital expenditures, depreciation and amortization by segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219062087456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenues by Product Category (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue | product</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,124<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,572<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,453<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Revenues | Product Concentration Risk | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219044919376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographic Information, Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,124<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061584288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RS', window );">Serbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219061613184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Customer concentration - Revenues<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140219152546704">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>bhc-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20221231.xsd" xlink:type="simple"/>
    <context id="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fc68bd369cd4500b13aaae303a6c383_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i76ecf876aad94246b25154ba566eebd1_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="ica54d07af4a0484896e86ce0129c4df1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0a1a172f25a841aeaa5ee92611763bda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic504eef7811a496cb440f3d265414631_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia072a195239645fa87f61a77ca261bca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i352ec3a38f244bdbafd755de208aa067_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia31a4f763ded4502b9e4fa2d840d63f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28edfd63f7b14bc8bcd18527c6781606_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e70e662458f40bb8c987a1572e53027_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie42242da77914d51bc567ec579238930_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc69aab44eb84be4ac14baf7ef6a6ac2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b5355a46f96463087fd4837bdefc2b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaad43210cdbd45f0b0a9a371bd0993dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5b0ddd5ab97433abadd6e743429df67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f603a5a47f6490291f143a008712675_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b88f1ca9e1a48ad9446d9187ae673ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd1162a0c4e547519003679dc043973a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7beef9cf290b4312a60d7c32efde693f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i744ebc157dbb4a0b86ccfabc060e848f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d9756007b6d4f3d84623153c2dddeff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9599e56128940a0955ca4ff88d8639a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i687d9364584e4a7ca7034a3483a95a7d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9effac2c66724eed803dffd7950879ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia08ca18a2f12467bae0a8b8c719d3561_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b2c612fd89643298310e38a8883f365_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4869d1047a0141b19a3fbf5790033030_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcee2b5169a8459c8cbccfe68bebb595_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea9dde3b1c18435faec13820801e4e34_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4522c45ac1c44145a7ecea556295fe2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if48c23e1700a4f49ba421b5d2cbc0242_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03c547eba26f449dbd67bd40c78e03b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic85093372ad449739b9c5caf68d08cbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89640c6de2df463b91359c26584e4b54_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i666af66f47b4407393455522d3f67aab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d90679865d741fea3690267adba920e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i286802cacb2b47a7aac5819b6b1ae881_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifcfc9710ac6749858b8d7495fde87d13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i414d863f79fc4e20a1c5842fb6a72ba3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i35ad12432cad49608f2807386679107d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9854d974005d4f129d1f349b2e8e9e0e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i571caf526a3f498d9102359d54985610_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i664418729e77455ea311715c8025ba3c_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="ie4af7206f3dc4cb7ae55779f23145348_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="ibb85da3e8b8943f38dca2d158d722362_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i4538c7b5b4ca4fdeab03c2bf4233e8d9_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i285925d86568407da8a3757803694323_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i83b9870676f542a6aac864bbace50b24_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie91578972bdb40a3af61e355b78d5073_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f9466cb58824868850dfff1f0fc66e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic15bd253c0ab41118c4045afdf0da935_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1524d212be2e451fb87eaa66b46428f1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9f0642352c64cc196cfc2d1d9b89a93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if32df11a6c7b427ea3edf23629b832da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica86b1d3841f48b0a4940ae2217f149d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i829741d1c6804070b7cafb83060ea664_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i073d5fbb37a74b6896df8b862273a349_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6fddaa647d224e77a75b08d87ff4b3b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7338914353884cdba4212e42f3f0a816_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ce6f99808e4460581a8ecf630ae0e44_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba264d87eb1844f383743044281eca57_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58b60e4e1ba344759f420bb9dbb9e07f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id33f7392918d41c58f5a2c8261fd0cfd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idafb37adc38a40a1bddab0dddf725726_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42fbedcd6cef45eda7bf77d1487a41c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i95efbf91ff384469ba31cc31eabf84f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43679a56867547b585e61a8bebd30a9b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0f5735466294af0bf44c228f9e7909e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08e3ff0b63c54e8195b04d98b1f2ea94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35c9ecdf3caa44afb7674f4ff6cfa6bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab447034f3cb4a3f80c5615de06f525e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice1298ccb8014e2e952b7df5ed8488c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ec7611adc424942b82f55c3fddc6e0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03f3ba9f79754b2ea2362524743f75b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa6fc4c28dfc4f42aa151ae93e67746a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcd7e5042c154abd8c3fb0ba3a5333b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i719c1c8681de42628cd8a33f7cf93c13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ffab7018d0f4f64a53a07c03c589447_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9afa3f38b75645c38047038819ab8039_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0af36779781240ea8b5a9fc2a8a18c0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9b3071dbd0b4c22a7410dae4bf7b27e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5f6251d34e449328ee02711fb471754_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22b3dad0951e4afdafdd9832d60755e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a778a0ae49a449791a3ba321887c7e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1634ddcaf934a68ad0cbcba62dae846_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12975a1db9344dbda6b24ceb8ae4993b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc88addf22a44ee8b85946edc015b2db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i879910dcddad4e1ba3539787593b400e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20afac804c4041ed899b450f18e9dc96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3066bc5404d6492ba2a9b0f3e2e60f4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac38adbc92884946ae5f917cf58ca323_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d9a436ca4734f6f94506b064f541daf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc7ef7f347f1406097fd27ec7b96cc69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bhc:AssetAcquisitionAndBusinessCombinationAxis">bhc:ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f28cdba1c984df9bb56e87ea0c43627_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d21286a1db84d29b25753aac5f56c63_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idefdc69a4d2748c3a652f4a956103762_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i524d6ebfb9f44cdab7f8e33886bbb169_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebf28d9434964d1dba31bb27dbb684d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide1f360554f7411582424cb25e12139f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i955e95f8176a41949983431111fba814_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic539170d6fff4d05972a7397e5960010_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3360f8949ed24c0b940f86ac34748add_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96ca3e5e97be45d19824357bc3ee379e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccec48614f5d4821a0e8b30e1252d2b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17110427cd8e4e619785b7b0d32f0f70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbc775b178554f5cbfa0bd80dfded44e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85324249cb304f399a6dfe976b7fe743_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a3da17c145a49f8b5870436902391af_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2117911a26c0491389f1d3defbed0a7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id71f74f577b3494b8e2ac929500c8376_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i019d338e616445d7a5081ae3d42d3429_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c2af8e02fe54c78b7f35ee1a9e11c90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id050355187a44ec58d9dae39638c996e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0359fde753a243faa8a6b23ba6f302f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic910749763294350870635de86bbe6aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46e9550a1a424a89b1dee40213b0de3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32b90092334445a8849506fc89a086ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7a4eaca0ff74acda11e62ff530e7678_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia5f44a4aff374a1ca74b044ad084bef4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i000ff44669fd472ba78d6de1cb550d21_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i686c1137885f4b3fa7d3a9b34364ed73_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i73819dbe86f345268ddb7db8c71128b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f6823e843294bcd88d2a409c815988c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1694f371b3534c56984cb0cfe3ef6fdb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9a242b4bc754037b318a7c4cdf5b1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i681759bbcf4146c19403440ab8bc7434_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8dd1a2af87dd427db7a4b552da531b07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id964973a928249758deda08b15dea7a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib2804a8dc9ae48539fdb9519f6b3726f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b4a269030174bbb968a2388290df2a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i496ec6bb7c5c49b189881126f8ba44cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2232f920079d4878afb7b64f68af1b49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a2a0cc3ed3047c0ad4ecaa58c71ceab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab2851d6501645e39f0bde92ff897991_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife4532439f68449aa15050571c32b49c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie158e865d7084cd7820657aac3a943d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17f6b23e952b4a29adb188680f77e15f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib48f720a184c4ef7a34f2bd1ad005549_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8dd91ce28d94179ac8fb005c89c2151_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib340705dabb047c38f3e490247c25c10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6298df68baef4a31a4dfad39a62b592c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21918f466bf24354a1c6d6444bc04589_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic90a06531e4448a48622699307e4ff02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d01deeac67f4ce7862d6b348bdaf675_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec2d9d196bf448729e83961b2b2b79ef_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a29668b30ec453bbf648449343ac881_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i536a23a0ae454cadbc22242f347ae91a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i301added27ee4e56a32e9279750f97a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6a10a38645a4e64ba544a15e76a1aac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i046977fe683b41e79f01810b4a036c3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd74bed9d620431aa82e098aceab060b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5251c4b7112b46c6b9fc7a4f6cb910a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f238094cdda40f1b2d7750a45917f53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic47f900acdec465e98ce7071671bb8e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cbea40e3c0740518b9890e6748531fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f9e292759354aeda24365245bac9d90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb6b4338793a4025bda029ab360f1d32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1da1f0ee4e9641a2a9e84287bf32dc6e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic24b70b9839e4a32ae3eb6fcc78cbb99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic51c16e7f763491085dd8ffc5944f6eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabdd5d523d9a4a00884669c513d28162_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i93aa5bfa4146474da5d319dd6afdca60_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72736a422df241408c61594fa909e273_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b9fae444f1343bc9673dcae7bca4e9d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9f982f471504a4d886d0828ec908c63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d556e8c69b5410fac594e6bc3f63165_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84a2da26e9934eb883d8c56c01e510d0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id13d7cff51ec4364a60ff99c788582e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ideec9371c4594543a2df71f87382e5d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1289ce27c69445a4b28904e412ddc6b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia83781ceb47d40ad91cb275c07538fe6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c7187691ddb4f3baf53a15b1e780054_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03171de550654b9094b2686785213340_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i654780d358bc47d9b9208fc7318b418b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied86354202574859ba53d8251730ef25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i076eb2797d7b4496a5587e804a530855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8779797f0c542ae8f67e21fea46bf5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81dc99f8258b4049aee820556d44657d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i90d4fc2538f545c38a76406207865da4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9971091867b4c49bc0d165d080d95a5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2847dfc8dcef4913b6cf4a248d8cb28d_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6ec174dd9a974db9a84eee065064aebc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia131f8f45b8e4955bded72abc02da48e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9fd14aff977d4b488fc11c018551212d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5894755ae0f14e1abd383f2cc912473b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd356ccb740d484fac8d36718bbab19d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0672a8f98ecd4dec9b3ca1e0bb2cd304_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6cf428232eff4699b8da41866a4f1306_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fc58ca927074377a059e6afb1cdbc07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida153af5024646c5860c4d0e1d881318_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd69ca9b861e4a609f1e5f5da66792b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d069e331e9d4278a420482bdaf3f937_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7dd4d61250f445c8a4800bb452ccef13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0924cb562dd24071ba12d72afe82bbec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ddf60ecd98b4f768f11e6a38f661960_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa0deab0ec61405097152c610065909b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff63ef6faace45498e346825d00e01a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1576ddc62d446f3a6d5e4978c7937d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f6defc1abe0499b87b8d9ba0729620e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie978af0fcc4247feacd32583a9786a9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2db8916c81ee460fac6b5d6d2d6a779f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i052132743b504af0bdf4f85716745c47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5770479e5eef445e811659815d6ded32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94689023eb444f91a13a7e4d47e5db0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fd0757d629c4245891c0a910034923c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id815a410db39410abd908f92b68de9ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d74453ca604456b90988495dfb2c935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82bb7cbf3457475e9a924170769182c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9856ff949f043bc9821f51eec5c0ca9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0699fe85526c4352aebcd5347c7b8ffb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibde1691268ac403c8e6b3decd6654cb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieda7752d38634982add22e8fe5ee38e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibceccba7710c415bad87fdec58072ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf06d2028b254481bcde95fc6c3cc519_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e057f632e184647ae17542d539bd24a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i619f20c616f04a608422a936c94246b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1732052987b04886a0b885788267de2e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ica053b1634ce477da9107e88d8f63295_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c413cdb1b164432877c83f54ab2b752_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ad4945bf5b946aeac343ddf77e3ca2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccc6df613d904efa9a6c5d3e9e8453e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idd76bc2237554c19bf5f7b2da6fedd79_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i84ddd8e4ef73432abf45d8222d362bc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91663006f1f64ef9b72e553828a29c56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff8822a2ac32419c8920e934ce9eb11e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e14db2c7cd143aa8caf8a8b3aee8506_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b234d01c94442fe91530027b0f6530b_D20200331-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib8020b17bcc3445ea7163d7ebd53a470_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a0c24b9ab774864babd19a173d572a2_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i34640daea4d7462a9d9640c91a9681d6_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="if89e8badccef47d0a7d7bc1e901ceebf_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i90e6ce0d73164ddf964bb0ea4fa23010_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib099140ae6db41829838038f01c73b6b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i96ab98d4a236452a8fb70057836d164c_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91c967a98aaf490f85d7f7da1b415ab3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iac26985514b44cee99c565494437c9bf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7dab83ba8be74e6ea0cc6457f87cc786_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idbdf52fd4b1141df99e98d44fc5f54cc_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieae8581e17154d79af15b43340cf71ed_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i723051ff458540289de98a13ff5b824e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d4c382c97644eb7a14b499b2e665d51_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i25b53b103dc24a0eb09366a47de8f0f4_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ic3ecaaa094ed49849e4e48a5f2f59700_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iab863accad34439cad8d1a61aba863c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i71a29147694c4aa784a0508f3b8b0b83_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if1860ad2ed2945a9a9f05e0807ab6a99_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i90c3ea7a8793435088d6fb6d8ae58077_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib1b89ed8a12b41e9b73c9ba2e0663772_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7598aed7ec34bddb36dd9a1f40c947e_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide546e7ecff04d7b8671f8b40f6612e1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i42871f56c57941c385528783c1e999c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i263addd715b04b329673b5c1f5ccba82_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0dad95c441654101809dec4ce04cb340_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7647535adfe442f6b2bad4ec71e6c424_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i48916ae978b944169cbdc730b06bc6fb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0a7459d4547245ad9a36ea070c5f5ec3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f86b5f573824c0b99316ea9e59d1842_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9cf2cce057f44b058a16380acebfee7b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99e03f7f94044004815a278acfe122e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1c4915118e4c47e39d266ed6aa6df20d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3237e29dcce54fe4a18404bf646a22a3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if150371b70684386a5836a8b20ae71bf_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i72666ab0833443e986330313e8a4c321_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3567189e676429991222cd3e3e1213b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie84c3447e94e4cf08b00cd1500e214d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba65689930cd459f9a5372d1a52fcc18_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i40adc4228d5649c8b5ea39c9bb7e19b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SurgicalReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e26e58975e443e0b51918f03cee7d5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2961e7ea8ce40b29f24b00453ac5571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i780fe08a52e14ab1bac7e028c782c9c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90c8e00c14544d52a42942914e81c273_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2604b11090a343939a4cfcab0196957a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3aaac0c0174b4c27bd54436507088ceb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59050beb6a5f4285ae430ef5a8f35377_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffc26a76728a46aab695daedd417d9fc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8163e10398b746e7a5edad1b5513c5c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e127eb541b94518be190909675ed289_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba6f95a9036b477e8cb580382038f606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb29815fc9674a7c99be25fdb001b3a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07aa5fc5a9e841de925a2df849619500_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd3f8766f9504fd1bf68133e1f140db2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8aaccccd91c84bd69bb27eb24388fe86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i409f129e0bfc49478eb8d9d221ae81ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9ac2987c7a84f5eb6926a647891d84f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41d7411313624b009890802c2b02341a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0e1627198084241927fb3193e16c19e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief9aaa9954e64952b709312f105f0242_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d26b379509d423eb7d0672c56517477_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf79ff56bc204a2c9936be929b812f08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc62ed95df4c4f718a9ab78fe220331a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd671799f9f141918a55117de2700d25_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88d3d40cb3df41cb9891422a15f11c46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07fe67aba19647d8a1e332514379f9d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a1fad0f4ca745f2846087891acdaa52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3871b29377e94ec5b038d5daba56ff08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie524823ade0a444c94da1bd1ed833f9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i378ff1b395ad4dbdafa627b96247ff1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i881d1e751ebe415e99bf6d231a16fcfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia76d935f691748a49d6a2c6eca7e979e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic646016282634f4faf802c21a106b8cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3678917bb79c4121986b9218d5ffed64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia59d52dbecab4068a233f40b5bbb55aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib01229077aac498c8cda3d570f0e07b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25e40adf4f7647f89d1e9fa9364e241d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1486c4b57084e97aee9abcf914db494_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0745c7074bc48f0ade1f704c884d877_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ca0d50d36f246238babe463a6168a0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5af86776c3d44c6e88302711b8c5846e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedd85d5e6a46425692fc6df9be6d1548_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e536bc640ae47de8bac8ed86aa24e83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i721f7910e79b40e1aebc37232add279e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8438d9428d694b1b806321debd8fbf57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1261229BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="i470227bdb89e493fb8816f0ffa6ac326_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i336001093a5145dc9bdc0d6e370b605d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9dd991f205a44e65bd6187fabb7e37c4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iddcdaaed0902414c803acc0f1fab8685_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i875efb41d7fe43c6bb3f59c8192b9d6a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8bb07bff0ebd439fb019a10f099085be_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia1517f47c4054556b04ca7e9f7836241_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if9afad4d704c441b8aca72f314828730_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia9830466dc5e4c1b9a52f500da56a52d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0ed6355aa8404cc9862ff4ff062d0399_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5769552bffcc48e19f81962c26dee7ad_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice52a066605a4e9897aa4694669ec4cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e844fc59da8465586a93905777c04be_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf91aadd30904af7ab5ff5c49b173483_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i5f74ab6a22d445758697179f2d0c1807_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i3cb3d1e5412446dc811ba962259a01d4_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i523d17064ca94b16900c15d5f8c804de_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="id0475cb4c7ac43abbf4df21604027a97_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i9cfb98dcef094732bcafe6f62012d336_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9c9ce2c21b474762a7da6161958145b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic42bbc3c6bf3452bb704930c76f7dde5_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i377918284ec1474f8fdb964743a3854e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i20b85ff842a240e69cd341f8a97baf08_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i02adb91ce4244dcfb8903780127e4950_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2371a67c1d5d4ce6bb8affa16d99a8ee_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="icfc22bae41d747e1bf892fd0aff2bac1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i12b21613190a42c48428381118250a85_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i08144428b8f74cbfa6a5eb11eec200bc_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic2b61046449c4453948b31ac17dcf49f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib987a52fcaed4951afb151a82a0665fe_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i279595da75be49f6a0842b392c5e04e2_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5ba9e35b10d64b8f8d73e9204b9ccbf3_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4e403587348b4dbd9a36b1f6aa5ca65a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4085e18b60c748e48cf892810f08a0c3_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08ca66a8836a40cb85dd578b9e98529f_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="id7b201553ea840b8882b868dc71cc5f0_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i19e771793b9549488be559466ddda99e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic889bd7bbe3b4f05a299372748c68b3d_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="idb3e0b748c154802a58a1beafbe2cff5_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i15c6d66c35ee4080bdc94c23a19b52a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie320b639a3cd47dc961878584dd8c3af_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8abed56d79f84c52a16d613195c7f1dc_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5222261a43e242bd96ba62a6d53496dc_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia4b348dc7be84fe6845f94845ff52de8_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i08b9fcb7582349bdaf4dcf63e1033674_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia1d957402ceb40b8a787c5e4f4236ebf_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8c1cf2c8c91a4a85aba037eee43e16a0_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i12a3c2097c9343febaf0889f97fafd58_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3678fe7d442d4e65a3e4b646e9a46587_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1d8fc1d36257456c85af865931829d7d_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i7bf08cd8ce2848bfb0ffd1ba61fd6396_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia1587227fe18483fbd9cf40bd7d77115_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6ce57f96608f474f8f53043e82f4429e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i34b6aa60fd3b4cb8a9c35ca0b87ae3bd_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4684fb9c9da34175aa3d87f334fea43d_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie357a3d3d5a5421cbd36adeb99212916_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iccfcad9639644d1aa8dd1ea244c8e451_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9cab5412f0764a9597e25ac424d2566b_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i71bde11f22654ef58395cb62e46066e8_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-17</instant>
        </period>
    </context>
    <context id="ieedc4eac3b8d4a698d8cb9a05c341498_I20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="ic538128a88704c54a42c782f1c49cea7_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i2e218676fac849289a6c340912b014b8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8aacff91d3fd4e97930a57ce23252d07_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i157619cd6dcb473cb47ad7bdd54e90f3_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i044da1c8e8644f5d923942355e34d8ff_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i1eb6552099344d328f3d1d048ca4608d_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i90b481eb38c945c59569b06b12fbff6f_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i3bfc736c31a94604bb0c70ced892d8b7_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="i0ae7bb4dd25840828cd9d3be1c5cf334_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="iccd58703f4d64effbac9da3441381c5d_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="i88775d2b6196454d8a77ee9d6235695d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0698b60423314874943ed0139e7bdff1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a449c4bfa5041418ee1aa7972a1256e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d7729b9b40f4da1b234f69afa941cbe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc9e2bcfdfc8462abc99097872f4c5a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff3554474d984129a7b72717cf870c74_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="idd69ab9daab24aac824807091b8a5671_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8c469d793b6f4ee882b2681b6838c579_I20150130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-30</instant>
        </period>
    </context>
    <context id="ic8228270dba34df8adb389c08897a92f_D20200101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1a3b96fbff084df6af99651fb95d52b6_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="ib7a80fb088e54c2f87adcda10dca8eba_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="id8bda88c9492434b8ad71e6d24f403d9_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i1f42826c47ed4f49b649fda634dc4a0a_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i2c4e650a31d242bbb5c5d585c03cb333_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="idb5cda3faa264c738c116577d2729461_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e615859d6bb4a4e90467e2add18e800_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idadc1532b7b04afba0801fa41303f107_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="ia297817a7541403aa01709acbd44a471_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-26</instant>
        </period>
    </context>
    <context id="i6bb93a16e162462585252110ee36a962_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fa832e82c1d49a2a3ff00d4b061892e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i669d24178a614762a12dfff0155fe19e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibfed71661ee944d49ddb49203d8a286a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i50380855fc2e44f5b6be1ffc1d533681_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i9882b34fe6474ac8b75496ebe2306941_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i9df3f1e3d2554c78ad4cbb459875b7bf_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i18218eacfbb142faaa9a5d87297b9a13_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i696a075a54064b0997717cd8d8a32b6c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9cc611b24a90474d83f2f66f38a20f88_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ib223f403a7154cc18ac343122c9c3e06_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i3fe5dc0384494154a1e6d8f92d81bdcd_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="id10012d6ae2a4a9a8da2d30e73d8fbe6_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i3fc3ea4063504440ada3d5c75d466bff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1e135d7f019a49849b913e4b90edfb2d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if81f73f3e85d440bab9c87b07c094950_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="i274a447de4c946398cf00b10748b1942_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="if254b82a71434782ad56911693096e5f_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="iecbd9075b4a94899961c7585f2aed5b7_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i0d9a11ba7b5b4f3ba097f6f466955097_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i35ebc47cf5eb41e4b68a050da347702f_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i0457826532364f8e9c2bd5bce176537a_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i64c9aae9869547b990b47d9f024d2b7e_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i6f524e92b57548fcb59a5560034d56ea_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i40215fdad1084cdd819206c295150373_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i7a746c21c7a14bc3bc2a6e2b9323019a_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="ifdadcd473052481b9f108756b569bcf5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i700f313b8feb4a02af4dbbaaf4864a43_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icc4a098d6f0545d9a3df6e94e3949b54_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i28625644c7474c10beae0b5bf10ac394_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i24e7ab6a195b4f8a8f49a061d91b6087_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f6923561a7e494dbd4b2c015eaf76da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16516120cd164448a3c89f1ebb6cd381_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if96b54eac8a34eb6b8925e566ef51275_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6738f26e1aaf424082202a7be5272d77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ce272f013fa44ac973752d5610d84eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea04213dece64c3497dd259bdea83001_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d0e93f49dae408e8c386793727d9086_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfa7c677eed24732a11e7ab6f1654f25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02ae9ff0984e482c8f536551e5df3d8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i901b9016f0344620b9f6802621dd347c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbb4a6b3049041e6a53d4e6874579447_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c981d7a36cd45b285c23ca5fdc44f66_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="ia086606e46a34f71bfb9e605f2e6266e_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i7def2285ac5140d38d1f9ffcf8a7126e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i890e5bee618d469cab458bb423035b53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfd01159712142d2a14941af601cba4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10c9b32cd0a64bd9a48e14dc09730b3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib186ad161aa040e7a1a0cfe3d0b2add9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a7b19941aba4839893beff2b2339518_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if909172682784a94b3a8faea6d1af750_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6097557c0fd439483e7592516150539_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if82393cee0c6403aad0994b42e1b3e03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21af5dc5f9dd4f15985aaa4c4bfd5822_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ecb8307bf5d4aff94f54ff6b76837d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb616bbdc2974979a68ab30bf4d7f508_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37d55bf5477448368b255cbbc9f9ac2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id842fbc0d8ad486aaae75003e4167df9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba3108451ff34c44bdccaa78adf4e451_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a0fdbd98ed940e8bb4f138e20fe4aad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b66f09a9c794304941a8e256c67d221_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id46544209ecf4725a093aaefe444ca63_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7cd997e52074902b6b0f11a459c1455_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddfe10a628844d85a9f16739ece8b000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e72c38588c34bcebd41f5dee9e6e442_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80c26c19111d4d8f9acc24b805792584_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebcb27b8c53e41a4a7f03c7a9ce24b16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4aff83b9c634a5894b070163727d3ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bfb9a5fc6b5416cabb3992fd6d9866a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c83ee90555c4d4388fe2aad369a07ca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie94c6b830d4d4e83b5455bc50c831168_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i596d5259e41b4516a9b8bd8bff994b04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d65fd0099884d129c8955aeded2ab3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59f1bfdacbdc49e58897e6ed02cc3ba3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eff69c67fc94f7ea63429c1b535269f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i06cde57fea89421ca93bc357400547db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fcca6398a69456491cd915adc6cf018_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1025885b5b041c495101b7c543c11f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4749a66112794a748f77060b21d3a4ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60d3fed8097a4daeab0e728d1fa59dec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c4325c973be4bb49485892fb209d262_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbdd4eaf78224b6ba6820bf1639d0b9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib57fb1d627d84572b6935e5a91bc1ddb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icce670f0334749faaec2717ea665b0a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf1b1a26770b4939981b10056497e10c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2ffcdeee6044901ab85b83bfab8de15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia469039e78794b72b821fd03d9c90ec4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i943e5fbfcbe84d65b033540f48279c89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i940816bafd874e0ebc01474cfb7a3a65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8b2464e33b44bf28fa58498386246b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0537dc089def43d3936e05d8a4ff751b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i166bc7feb587436bbb13eac98a8a0cbd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icba4611dcd504efcb55fd69027047b6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4161b216dc5142939aa46e36e819cc8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12cd435007f84ea6a463f1c697369c5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea6ff1609d90414882841cc6046a9951_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0966710236bc43c2af312375aaf2ff7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if627813ab5da419892b99795959e6aa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20160fde44604a6aaa038ff97269bd4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i838299195fbf4b9a822896bdc73e1fa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia604d8b17aee4a76b705119871e72bb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1a13cdeaf0a4538ae66a0cb4eaac793_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8cd29133231149b7b1b8a8ee26abb9c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9487a86efc54fb68c486f5b06c683f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaeac84c7747644e18df3b02f9009bcf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7d0aeff6b0247bbb772f435284fb4ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i022e7bc0a5b44851ae8856c5d2c73a9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25e42f7f8fb44b94a825edd38ce13b8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b44a8ef5108400eb1f8766f7e0fcec7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ec9432798a24a7081587f93c9df9218_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5c542d4e97f492fb79c2d7ea87bc43c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54c92c43460b4f029f30adcfddd56c4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib87b5c5cd3884bc6a0c85db52ded0201_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba16f047558a4012b26c69b39abe5903_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85986033cb94474b99f01b19273837dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5849250174794a5294b9599a5268d9ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34e897629c0e405197197192231ed87e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i586cba0ddcd34f2182b8f7a26689b550_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37a90c8afe5049298baf47464adba23f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3b750ecf0264c51acd1b84640243687_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d1ee6e5579e4fbbac27d5f4d6d6c071_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7beb776c2d084696af8546fb16fbfb0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e418ec04bde4a42807126013e7f6e28_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id064c3e553534ddf8d58196348abc463_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iadc34f3620a04953983302095d065919_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e718d2c489345649ae9f4b875a944c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b786c529ecc420a98bfcc8623fd3887_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i192fabe7c1564743b0a4bfd0ec76367f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2583535030e04ec19d33ff6aa980c232_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6dbace4328d64e68ae9985b0db92a939_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54976a88d71c4f29a87ce8b7fbb1f390_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if368c75fe2714137b5b2bec4f478ed08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i874f6ee73d0b4d708cde5f122a628b5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71ab17d153f94ce28b4f3c1f077f073e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib78598f7e1204321a742adcc1939f548_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84605640b59c4cdfaca45e277d8f930e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0da8fd5fa784526af1d7dcba6682ea3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80a9b377100548608bea1fb0de4c4b8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d15c8b03fa84bebadf0ca964ff394c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8a9caf7ad8a43c2a1cf9ec9bf2be638_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6f47aed6238c4f0d8374cffa9d1ccc3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i943967018a284fddb2383dd48804e6ce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica42099d7cb54b18ab0758ac46934fdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53b4988948464da080807bfacdb2fd60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0e958e564b34a8ea6e5d23a9dd1d9bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia15ca0c069774a069fc140fe27c34672_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17e7bb314271400dadeec64d6689bab1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i68a1b6f04f9843a3a430cc23faab2335_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i460709745cf1459d8d83a3ef3c4c4028_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i807af49d13d7419ca0ef798eab13affb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11a95e634eae482ba0ca850423b7cbd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ada76f87a244e6ba2a626f4f5d2f68c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4bb0efe5f2746f4ab125458e68b1cbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i643e656337e04c8482c55cf8750c1308_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if34397ecd5a048799f2dbb74323fe7fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0933dfd2b3014b3982966e76c30667ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id83bd552fb8241e68b041b00d4deb904_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5317bcb7e0b4df8aa18bb103e434600_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2c0591c4a3a4e679502344b5b1c1371_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e710e9f1a5d4373996e9b7fcded1add_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i229dc35bd984450fa43d45f7faba215d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i951ceb7ff1d646c9b3fef0581a1b618f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id767817a5a2e453c9618655dde1bbe6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90326ac3a5c64cfaa3de8f4582846b0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a56c8726ff045a281148a00e040766e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4dc9006276854ef785d74a884a2fbd50_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6026f5c4ae10476cb57fa85da364cc1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1aa0fc165cad4c259a0114c60066cc26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd34b48ca86f4bb9a48ea67c0a464fdf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f30f4d8fd4e467cb57e4293e32ca3d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d49fa28b18849f4835a0e22941c0d50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="ic07679a14e86417f8712f8cbb82b60ff_D20200428-20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="iad4afe550a6c481c97793e197c5bce51_D20220621-20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-21</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="ic7b69fb3977c4adc9d0e3708349c1838_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ff6893c5f5d415f9e29b9f99c2ebded_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i090655bf437c47a08f93010b3050db91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b78b13259aa479f924ecd7471c6be3d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62e3c2748eaf4aafa359630b13935a24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if00b7cd8fe45432a9a85664c569eeb15_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8d64492eb2e4908a69e9f58b7558e25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0946c8396b744fe99205ccf1dee3017f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iede2de5499f441559e821dbcad622021_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60f0f7903cd849f3b7151828b60fac8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a380354c968473db359c0f5368d07a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia45df334731c4a1288356ac1f33c7415_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia355745004ed4515ab1169c8dee886ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2a6f01dc7e7849e1afb697e1681e7989_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic888605118c2447e80ad019de50268f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f438587dede4b58b5187b50c6366f8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2492e7b35404d8e87840515f9d9a6c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae249c92a22044b9807b386e185de759_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaee78b80f312454f958d6185baba0299_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d52467dd2c048db873fab55177a674a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8820b0a3beb24bed91da8f3c82e42606_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58c7a9138ff04e618e86f8caa65ef150_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i371264615c75420297fa60d12cdd7590_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i976c4ead5b5e43388410dab98e1380f6_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i4c08f6b4a1bb4b97b88bd4703a8f0c70_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i8eae6ead96a941d1b21a4d5924929d5c_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i798f17f8800a4c818af00babd1be3910_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i92c83dd26ed54f1789ce908d1c7409fc_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i52e72a61294341d795cb93013ab5a0ea_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ifee915a0af56457092546e18d9f5b2b1_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ibba9807196544553bf6afedfc7ef764f_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="iba13317aa60c47fdbe720638efeb8a32_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i4972cc1494f64143a33a8f5939165fb1_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i9246f8b8e1204a3b9c57cd2cd7d1f32b_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="ia300b8d00c054934a733fe79c976c8df_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="icff6d6c9c84647b1b1dce247dcafc619_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="icad5cc2f654041548ac38459ec8e3737_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i158545ece5364e96bdae2027c13c3e8d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57057d66fc88405090a8ce98ca6c8e2c_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ia60f66139de8490cb251cef704102616_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2f724b3f1785466b94b544893b47c1bb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i15e52757684147129eded077c6efccfd_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ic466f5201e554473806f5d23207321c7_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i2d0ac44894434f3c838f08217170a230_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i496a8139703848748c2af0e1c60eba9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida5ab484db4f47cea101682d1dc38960_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56e87d37abd4499ea01e8038522b296c_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="if701cbfe1c6a4dcd881783198bdf3bf1_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ic3174916bf904c96b87d8033569c321d_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ib7365ac3a4d640af8c0c8f6f469cd387_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i6d68de5df36c4a3eaab2e8b8f62dbb07_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i694231e10d404b83a250ebe6cbae790f_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i6757e09e35d643fa9be873511bd89c4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i337510976d6d4c44a85e9ccfb0130e9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b929374818a40479322ab79af8f337f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d4815a98c184418bbffa029558875ff_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba32dedd928944da83299aa3d3ed3346_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="i1a4ddffae3344372a182a6c72cc2f5fc_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ied619ca0067f4cbabf0c52c7b99335ca_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ibd0b6c724836415c81fb64b147921edd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaab69c0d93144f0a90dcb5aceff25294_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22321ba60ab64391a853e3a1ffd653d5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0e2ee13540d244e58ee59a9ca76630cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9476d0eb2004c5589302c03748dd6c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id01756a362e44beb92a479cf33c85af9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f95881b6ece465992d0a8b5672f70a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdc8cd56812542429247ba8cba9a093a_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3c97c4ec64941ccb13c8842880f03f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id14bc647bd66490ea555f0a1a8e9d50f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54a3cb34cfce4c28be127d8715fd26f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8dabfb23996479799c6a595815ba441_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4eb60c46f2cd493491ad50061773a9d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icea89cae1b5a49169da66c58b3a977ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d8f4b7199a04a1bb0f06da2481be68c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76a003bd56204fbfb30cc08651a430f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3502a33c4974412bb446b4520804d72c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23665fcb8d984723906982059409b87d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8cac628e4a8a43a0a0981c64688ec2f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c140b9741d2496b919924cb9b494679_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a9bffc500cd4f18857b951c1603f412_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie76d6ec50d164eb3bcb9478a77019aa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id57f6448d77d4f498fcb2c7411041826_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id573807c0c8f4975a352cd6f593b3ab3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib8aa63b12662497fb48a3704825ff944_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd9c4983bcb5449091d89286c6560f44_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifb5e7e6a6a4b4b2fbad5eb1887c77136_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a938ef7652a479b9208cc583c1cbeaf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf4cab1a9a354692a1713dfef6925e58_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01997882e0124cea82496489c90aa07b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cb51eb021dc4b9b8b4658c2bc2a3b97_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e5f1133b38c4d24b01b931471fd8da0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89d1dfe888bd45a8883f343b6c477481_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fd1521a412949fbbc1e51c170d1e007_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16aed0f16ef84c42b74c7c39bd8a6462_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id96036ac44ae4695a0fb252d5f81f219_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia889587b544748498683a9f94901e27e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie4f2bc454f0c4e1ca352bcd59e982748_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a9234e9d2a34cee8234f5493a02f5a8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic35b381adaa44c21ae46f412455f4ded_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeb1927f7b53477f9d023db6485f371a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29b848aa660941a6becd4eec0de3f15d_D20221108-20221108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2018And2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="iab5fbd88668641d49bf8a11320bf0006_D20170808-20170808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-08</startDate>
            <endDate>2017-08-08</endDate>
        </period>
    </context>
    <context id="ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie20353a11f9f453cbff47b23ba9b5303_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32c1ed23b8494ad19285b0fa18785f85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee43a25eaadf4d2d863f02a387856a5a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a3b000967c54376bcaa8d1227ab2fc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89e7a814f74a4ae5ac92920a38079cc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dd34d570f3b45a0a89bc7b370627a8f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iafb1e399c6334b55a693b8c539d5389b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20c9837df7684cbbb933fd9a731877c7_D20230201-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="icae732543b524862bc31fb3dbb9b61d5_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea1d9d4e5a1f4370a7144323d17979c8_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i99a775a1f0484870a58370f98e7e7bd6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7097559c54d642c9938d351b2479cbdd_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i1dbd4359a33044d39494365672dd2a82_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i134d05f75047419881c27f05c3e5188c_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i6a47c7281a5a4ca797223076080e2992_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="ia24e6b01a46e406cbeeb1ee5f895c977_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="id939f2c8095a466db826592c2f72f9f7_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="ib4df41256cea4da189ae84ef1efc2dde_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="idb9217417cee498197ad26aaa5c98390_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i34b9f8ec08464feea2782555631f70ea_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i0963b261572a4ed8bec2d26c9a930742_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i8c21c165a2814f47b755c7aa53f9e73f_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i7f8128027f2f4ab58c24767a783dd7af_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="id79311217c224c53ba11bdccb33324d8_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="ifea8d20caee843099f9d0591402372e4_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i278dafa9c31e41f38e93fbc21fe0ffb0_D20220721-20220721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="idf27d74757bd461caae17e74579bbe7f_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i65a96a0fece84234b0dc8fea3877eca8_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i08ebb4f96f1c4839a1c7d994f5ba8dce_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:AurobindoPharmaLimitedLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i125a5a3114cb4f8f806bb33e49ba3344_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c4a7cbf453c49c3960027b1664103fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i25f029dc1a644b39abdd1b72ba3c573f_D20230223-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="i4097e666fef649debbac3e331a2e144b_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="ie319856acc814519a20ff1bbd24232a7_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i70dad8274b624fa288d5880f291cefaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id902c97014ef4d54ad1d3eccc0cc5fa5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24bd15be9a6b4930b6fa4d6deae79314_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaacdad21d98743ffac6109a55707e12d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3ed2bf0eb0249fdbb1fea6f1bf3256d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ec102f85ef9435f9389768c72affe6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b1a585708ab453a905d7caaf12d2868_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6fd7f81bf2c4837ae0cd2c5aeed8804_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ie4bb3b3e1cbc48a8a7d48f7ba06845e6_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CaliforniaProposition65RelatedMatterLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i808a1d4b464940449c1d6cc1d68d3e33_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib662b0cd90234eab9ce6b4ef74639960_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="idfa7f0c978d24ea089c5cb9062c953d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib717bd3b56334329b39872e4c89c7193_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45faea11a7064b63813ba6b35593aff5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88b39b3e635847789adf70ed040317c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1daf50b967543b5947399752d3b8bb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i579071a879594866a10f896450838c2b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9d231d4c2ab49b88a385d4e4c1d3968_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3da3bcf08f654fea916793d2c53d072a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2fdaef4346ea429ab8f2ee8fecb44632_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb853490a8ee49a2aef8cfbf3f5a4de1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d95ea31c71446ff881e3c3c83eb2a25_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ca6b9323bd346c6b92ed1a1b30acf7f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6deac1f013064d42938f9021d70b9b61_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i413ad399c5bb4928a8f7ac2c6f964ef9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie76b4f5598c542e8977f57517d459b26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5f4fddaf6544a54a803b97715d8b8b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47333b2e0a19447cbe86b126460626aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0be54156c43349909ea3602fe0d42877_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5fb70824cb234539868d27d67b554357_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia502c9842e5f4891ada76a5da18cdc8a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1eaa6892d2db49f1aacde5bc7fa45a10_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd8e8b2dc20c42a1a2e9a6dadeb73a2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55e2a9d241f34eeba2efe5bd5d76a0a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i63d862bb8366425a880c22f5380b0024_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7420a01c31714c0fa1134b1dabf8a3ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3abb30c5b704481e9f90a6b9c448bf3a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6294656f6f1a45a794681c73c8296f8c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic7b09aa9c7b94449b67cecd0b45214cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id206b5af67f845f58c6cd1d88e1b3a4e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08d5a2c5a359458caf52d23f7b41228b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if159fdd5fead48bc90289f41c8322f11_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28ee52ba866140689495745ea109e4fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i863f2f8de85147fda44457a636fe5c45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3715256e943148cdb22ee0f5bdb45137_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27712a14a4da4b038f73217c93180d68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia596d06d5cf7420d91cbacaa63a7e5b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2e9b8d6292204ceb88174f589a719bc8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4219dd6acfb54efb9311c9475b6e23e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4aa6ffca7904bdeb3915ca156eb077d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9483d11a5c444a2da894062077c18c91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia595e166454e4a1ba18f073f7077f6f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i079da80c54a848e2aa47e7dbcab9ffb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6c31bfc35c5482fadce56e0fa82199d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a404c0e4ddc483fa3b4bfdba829dc37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f17d0100c9f4f9aa8dbe75ac00e0ff4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2776913bc0da414c927cea557f03e444_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e7fcc4d25bd4e2a964cb2338ff036d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie90da407f7f24ea2a426ee198bfd832e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icacba9807dca4896944c3cb14d2c9965_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ce14bf04cd843c59432531a3a383d1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe0a21d5a4a145ef887145fc4fc218ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf694cf9ac304e0d96169b4f91bcd66b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1be0fb17d5df42c29867d7fecd2c7ca2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5db8a506550548a299d51ad491787e26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37e9fb9964a742fcb99f6da99aa5fe35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic263815e2d40493288266b33e37dac17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5940ce49e304337951488a51673e969_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib54a0cc879b847ffbe785ec9a5afa987_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d6a43da1e3e4fffa44339a4a14cb01a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89989032253542c28bdb051d0db5aa09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7610e8eccb34bc18c4be768f086e8dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica8a2661bf384208942b587c9911db16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifa9e5472be5c451db5b0eff1fef54cfb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48e3baf2a6764650b923ffaa42fce977_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8931f56328824e31b191e53741aba6ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c4a3aeeec784319bdc81ce480a56718_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b5885f21d2149079bae27f669de3070_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1702ecacf6b4d2d8df8794ce2cd972a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ae851ca48674d748baf9c5b2236ce7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4d622f630994275af93f8255a42e4e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iebef6967183a4000beed50717736f608_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86f9df991d2e45d79da2861c921c97f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0f6371e887c4f53b390250e5b574807_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i414790932066409fa853afdc5c75d6ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i210933c886d5414891a7858fd7293231_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd0782133c89472a992a06cebb386638_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7d7ab2322e5421986e53954e29c023e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a29bd754c024342b29079e34fda7eea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22303d42e3dc44f9bc0a9b6f8d915e17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52852499987d44ba88be1554788eb30e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0fdf48aa584499db19f9a47cf66ee0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i165688f9a68b45b9816d827111639efe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6f22081fec247ddad4a592c3c9311fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f6805b61b17427ba6040ceb5f878cbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied66a5e8bad6417fa24276e949d9d54e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia18258b56d6c404f9c117e6a1895e87b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8c1edf6e9fd47c09ba561d2d4f5fb45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3aed53df917a48138c9cdb27cea9d59a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e3c0300743443bebb82772ee9a1de17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d30a1f1928e4154abdcb87a862c2799_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i410f367d50a54973b5eb040cfd166964_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifabc22558a014281b9c2cb444e967f08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e6753cdad5c40adb3809316bce79647_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d99817ee7714f4d8639154cc1b22ccb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d2f801792d54e30b73e332c26636016_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc14b7106ace4ecfaf704ff0c5ede253_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99a2f472ad0740f09224cd8980cd10c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5c691843b3b442e859dea2281143b48_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f907111c71342ffb50f8e77dabca249_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5509eedbfcd4499ab1122c8107d4239_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i38a97db7f7054e388365a90a087bb5a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96fd34fed22f422381e2ab562615f33e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if54e5dc2b3f045dea402afba64c50a72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c150c6fffe6495186bf61df0c286556_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40881288dfcd4d5f8699bf1f6a8b2dda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01ca09d20c2147509bcbb33af6032e74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia23a06260b684c668693d6e121b4629a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie840834914ec48429fa235a8dc4f3d2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b8ae97db4704ce7ade6a7925a3558e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i884b037761c04998921745217361f61e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98514049314c405da4e7a37f55ab7cbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i693f697c02b7481cb3047f296b40c30b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6767d56cea04e58a135696afeaefc93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a6f8147a44e4a9992f6184af1c058f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib49a7c59a5a1434eadff4dbbe1111a8e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0b7ce85a70745f3b0574cc6d9621b9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6026773180f1437d92209ced4c2d11a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9827e7af8fa146468a1dd0ec9ff82b94_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c021e3945bd49d8a09d3bcdecca9997_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia095099872674785b26d32c3d7479727_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36c9a8e8837a4dd4bbd6b5d7dbdbade1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i26ed3916283a42a2919dd657f1cf7467_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5b13de71c9b467fbaed74e0a22f2208_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7910566e68784de489fe82fff799babb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3040f78c5bbe4353a9ac62b021035148_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01e7baf1c6eb4c6fbd09d3daa5ddbf4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7db976941a0d4666bd6e1f2ba49f58ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61760936cfa34d0f9b4aa7868541b7a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bd26ef4e5ea4afc84ba00e232ce717f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73181f4bbbaf41faa1cdd2014a22c967_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0786250ca0c04b9db12a0fedb2ff1574_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i121eb01d5e11421ca0cc55f4358e2054_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ee77d5bca934fc3a6b0ca93dcb21db4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1273cfab17884bd791ec54e9980c98c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if18297ec700d4c0d9f6bab6013cd53e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1bf70598ac04fe18dc183a56f3b216d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79145fcaf1184069bcfc23b15cc6a8eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c5a4355f0974bdca065bb27be79f476_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie06d30f1eb264b3fac209b850960d0be_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie73da62401a74fc195467ebcc7934a92_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5f7e3e748d041d1acbb6216d4655c28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i369d1b4494f84c38a91722618c2cf34f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1987f37ff1840ed95338c32804401c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf48590013554b98a5e052a00383ec48_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i760a6d7fc1f9409fb0004ef8b8b7dce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1303985937d7476c974821a08256950b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i64031ed4889a463f9456655e410c4b3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd4e3bbdcdd9403c9ada12b8321e0c39_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcefb49efbb64a5d85dc32f0d8d4c60d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3df23a7c7aee42d4ae92346947a9d5d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i678b31ef25e240feb62147dc14a7ff6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddf1d0feae3e4b1bacd61edd48477cd0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54abc6f54a194617920ce31c6643901c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fd0a8a5a2cb41e4a36e68bcd7a52224_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c46b45670f44dc39f81dd4b7a35274f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i859c12825f9e40189f911741e94ae963_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id690161da57c4e36a166af99a7b6395f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6727e28116b84a2b96efd2e5c433536b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18f01abf983a4e2a888777c7d9856df7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44ec6a0287cf469d8a40521df7bd0d92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i52c57f85e61143298ba638df79853385_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id76b30129b7749b2bedad7175c4b9154_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4de5305b33748bab90c89fa03a2293a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6353361e06042eabedeb74c21af8174_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaa738464b0a547659602f730d5711e8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cdc5afe35b143799f38340807d6c40e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa065d85099a481aa7a155608fa5076e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b0b47abb6d8430b807a5fb4299b8bc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7665331a2b9c46119262f653ad0439d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bfbab45127e4011bd04bc7151f71978_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a1cd06e58564300a92b6fa77154d967_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd7c5e9fab0f4527a04532a1453031a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="wholesaler">
        <measure>bhc:wholesaler</measure>
    </unit>
    <unit id="appeal">
        <measure>bhc:appeal</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="defined_benefit_plan">
        <measure>bhc:defined_benefit_plan</measure>
    </unit>
    <unit id="subsidiary">
        <measure>bhc:subsidiary</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="number_business">
        <measure>bhc:number_business</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="defendant">
        <measure>bhc:defendant</measure>
    </unit>
    <unit id="proceeding">
        <measure>bhc:proceeding</measure>
    </unit>
    <unit id="lawsuit">
        <measure>bhc:lawsuit</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y18zLTEtMS0xLTE2OTYwOA_2e824ff0-355a-48c8-8b38-cd7407c8fbe6">0000885590</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y180LTEtMS0xLTE2OTYwOA_ff632a02-30c2-430a-b042-a88c4bf40be1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y181LTEtMS0xLTE2OTYwOA_88fd21e5-4b70-4022-829a-604ad8f6f5e1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl80L2ZyYWc6MmU4NWE3ODg1NzdkNDNkN2ExNTYyYWJlNzQ4M2U5NTUvdGFibGU6NjJmZTMzMjNkYmE3NDM2NDgyNzMwNzI5NDNkNTgwN2MvdGFibGVyYW5nZTo2MmZlMzMyM2RiYTc0MzY0ODI3MzA3Mjk0M2Q1ODA3Y182LTEtMS0xLTE2OTYwOA_48af0d3d-9227-4ee1-be9f-7ef405368584">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i0b5355a46f96463087fd4837bdefc2b9_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMC0xLTEtMTc5NzE2_2939de66-932c-4e6b-ad04-11490b474fee">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="i20afac804c4041ed899b450f18e9dc96_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTI3_ff4eb31c-416c-4e09-84fe-f967761f1790">P30D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iac38adbc92884946ae5f917cf58ca323_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDc5_7ac9b54d-f1f9-4a3c-9aa7-dc857eb1ddf1">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iac38adbc92884946ae5f917cf58ca323_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTcz_3643a3d1-f7d7-4998-afc9-5317fb44ffa9">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i28625644c7474c10beae0b5bf10ac394_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDMvZnJhZzowNWQzNWRkN2Y4YTQ0ZWRiYjI2MmI2ZmZiYjBlZDQ3NC90YWJsZTo5Nzk4ODUwZTc2YjY0NDY0YTZhODUzZTlkNDA3NzU3ZS90YWJsZXJhbmdlOjk3OTg4NTBlNzZiNjQ0NjRhNmE4NTNlOWQ0MDc3NTdlXzAtMS0xLTEtMTY5NjA4_d8394bad-084c-46d9-9338-e40cd6061742"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4ff6893c5f5d415f9e29b9f99c2ebded_D20220905-20220905"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NDM_93af1e70-6189-47b5-bbc3-e0e2bb7a586f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc1MDMxNjk_b501e15b-da5b-47c2-acd7-f8740cbbba2e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNDI_bd3faf2e-8d53-4f0a-9ea0-1f5a151830e1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NTY_abbdaf34-1a0a-4131-b1a8-ee77e636b7d4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iba32dedd928944da83299aa3d3ed3346_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjA0_55974b33-e4c2-4c2e-9a34-2e9068d74704"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1a4ddffae3344372a182a6c72cc2f5fc_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjEy_a0978419-85e2-41cb-9484-209b4ac8d8d0"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ied619ca0067f4cbabf0c52c7b99335ca_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjIw_f462411f-aaf1-409b-86d4-2144fd669537"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibd0b6c724836415c81fb64b147921edd_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjI4_e6349cae-54be-48eb-acbc-821e8fc19139"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iaab69c0d93144f0a90dcb5aceff25294_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjM2_d9f519c3-a4ae-4f72-8c05-f94176e2f277"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i22321ba60ab64391a853e3a1ffd653d5_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yNzk2L2ZyYWc6NjEwOTUwMDA1ZWNjNDlhZjkzYTc3YjBjNTk1NzhlMjIvdGV4dHJlZ2lvbjo2MTA5NTAwMDVlY2M0OWFmOTNhNzdiMGM1OTU3OGUyMl8xNjQ5MjY3NDQyNjQ0_22051d0a-83ca-4eed-856b-f295062bbaaa"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjI5_360555b5-2bbb-4a36-90b2-2cabca0ceaf8">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8wLTAtMS0xLTE2OTYwOA_efa04582-9abb-414d-bb6d-17d9487b3216">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8xLTItMS0xLTE2OTYwOA_fe351237-b680-48e1-9a71-8b8278279fbf">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8xLTItMS0xLTE2OTYwOA_403a7df3-ba14-46c3-bde7-e2bb9db1f857">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OWYyNWRkOTQyYTA2NDYwNDg3MjE5NjA2ZDgxNThjYTgvdGFibGVyYW5nZTo5ZjI1ZGQ5NDJhMDY0NjA0ODcyMTk2MDZkODE1OGNhOF8zLTAtMS0xLTE2OTYwOA_ba7eeb7a-4777-496b-b313-6e0f5692aad8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMw_726e3b82-d90b-41cd-ae45-161dd5f7400d">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM3_446b0b61-3dbb-450d-99bc-afe4ee7c9b23">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTAtMS0xLTE2OTYwOA_99582be6-e221-4b80-891a-db2e75753f94">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTQtMS0xLTE2OTYwOA_025b3556-3ba8-4182-912d-4460335e4099">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6NmM2MmE5OTk0ZTUzNGYxMjk2ODQ1MzNlYWU5MmViOTAvdGFibGVyYW5nZTo2YzYyYTk5OTRlNTM0ZjEyOTY4NDUzM2VhZTkyZWI5MF8wLTctMS0xLTE2OTYwOA_d1c7068e-ccf3-4e2b-a983-0fbbd6bdca69">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMx_3637086d-2681-4865-9355-7c34e2f5173e">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM4_08aca0f3-0b34-4c62-85ff-fdd7e24a4d58">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM5_03dfe834-b386-4a93-bcb9-a9fda38fda1d">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMy_2837d5c8-3b21-4e94-8bfd-8be223dddf1f">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQw_449e3088-d747-4906-afe9-7b3c0ca784bb">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQx_f8c55d4a-0bdd-4235-a035-b07b33a8d5c3">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQ0_833e30aa-a914-40cc-86c1-8551e43689f7">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTAtMS0xLTE2OTYwOA_182efb26-506e-42e1-a7af-c4b8b5c58654">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTEtMS0xLTE2OTYwOA_4d07ce5c-a4c3-491a-90ce-4878dad7c9b2">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6OGI1NTE1YzhiYzIzNDY5Yzg2NzFkMjA0ODRiNjk1NDEvdGFibGVyYW5nZTo4YjU1MTVjOGJjMjM0NjljODY3MWQyMDQ4NGI2OTU0MV8xLTItMS0xLTE2OTYwOA_f1242615-c111-4115-91a7-580dc0a746bc">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjMz_de23f8ce-f0b1-4d36-bed9-e241fc54d4ed">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM0_0a453464-fd60-4057-8d32-6d687de71370">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjI4_db937546-85f1-4d5b-a1bb-fe7646a71b55">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjQy_bcef411a-a0a5-4852-8a23-abb6fcf8cbe5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTAtMS0xLTE2OTYwOA_6d63f3e4-296f-4d95-a606-8c5ceb52aa03">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTctMS0xLTE2OTYwOA_2f938ea7-5484-4a28-a05b-e1749614b23b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGFibGU6YjIxNzI4MzUwOWZjNDk5MjhiZWQyODFkYTI0MTYyNzMvdGFibGVyYW5nZTpiMjE3MjgzNTA5ZmM0OTkyOGJlZDI4MWRhMjQxNjI3M18wLTktMS0xLTE2OTYwOA_b2602c93-f63f-4e16-a3c2-81eba0649eb5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM1_2863bcaa-f60e-44c0-bc03-af65a7df44ef">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18xNjQ5MjY3NDQ3MjI3_069d7c41-832d-4ccb-9622-a20e724d58c9">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6fc68bd369cd4500b13aaae303a6c383_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18yNzU0_443ec42a-85cc-44bd-a526-76d9896e69a3"
      unitRef="usd">2507122217</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i76ecf876aad94246b25154ba566eebd1_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18yOTM2_c576461b-f909-4cae-bfd6-433cfde2a13f"
      unitRef="shares">362037191</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8xL2ZyYWc6YTY2ZTVlY2NjY2IxNGZlZGExODgyMDkxMmU0OGYxMzcvdGV4dHJlZ2lvbjphNjZlNWVjY2NjYjE0ZmVkYTE4ODIwOTEyZTQ4ZjEzN18zMjM2_239e0549-2be0-4683-b37a-79523f157c8b">Part&#160;III incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2023 Annual Meeting of Shareholders. Such proxy statement will be filed no later than 120&#160;days after the close of the registrant&#x2019;s fiscal year ended December&#160;31, 2022.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODMvZnJhZzpjMmVjZWVjNmZkOTk0MjM2YTNiMGY0ZDMzNGY3ZWY3Mi90YWJsZTo1Nzc0MzhkZjIxNTA0OGQ4OTNhMTU4MWE3MzAyYjUxMS90YWJsZXJhbmdlOjU3NzQzOGRmMjE1MDQ4ZDg5M2ExNTgxYTczMDJiNTExXzItMC0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTllNWZkOWQ3MjAxNDM1YmE5Yzg2YWY0NjkzYzg2YmFfNzE_1da03a03-9a32-4dde-b3cc-74e15211ef5a">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODkvZnJhZzowOTcwNTYyM2M4MWU0ZGZjOTI0MjlmNDQ1OTMyNGY2NC90ZXh0cmVnaW9uOjA5NzA1NjIzYzgxZTRkZmM5MjQyOWY0NDU5MzI0ZjY0XzE3MDg4_5fc16266-650a-45dd-bbf0-256a43a1a9c5">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yODkvZnJhZzowOTcwNTYyM2M4MWU0ZGZjOTI0MjlmNDQ1OTMyNGY2NC90ZXh0cmVnaW9uOjA5NzA1NjIzYzgxZTRkZmM5MjQyOWY0NDU5MzI0ZjY0XzE3MDkw_df34e038-65ce-44fa-b703-c3d8b6f61e60">Florham Park, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzQtMi0xLTEtMTY5NjA4_ac6d0ddf-3c80-459c-99e6-ff7129269eb8"
      unitRef="usd">564000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzQtNC0xLTEtMTY5NjA4_9354e81f-d7c5-435b-ba5e-2c611bd58fe7"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzUtMi0xLTEtMTY5NjA4_5cb3f4ad-f865-44be-9f25-b0ab98678884"
      unitRef="usd">27000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzUtNC0xLTEtMTY5NjA4_3d38d40c-db8e-44ad-9c16-91050690bcf0"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzYtMi0xLTEtMTY5NjA4_e568a811-1e75-48ec-a6f9-6dc8d5c75968"
      unitRef="usd">1790000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzYtNC0xLTEtMTY5NjA4_50e0e12f-be92-4d8f-9784-7aee415b1385"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzctMi0xLTEtMTY5NjA4_35c61c2e-c851-45d1-9165-9a764e7de026"
      unitRef="usd">1090000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzctNC0xLTEtMTY5NjA4_3525fc8a-02b0-45a4-90e1-757735993f83"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzgtMi0xLTEtMTY5NjA4_af8fc1f8-8a38-4f8f-81d2-f44e712fb860"
      unitRef="usd">776000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzgtNC0xLTEtMTY5NjA4_62dbb50f-4508-453e-85ae-f3fca8c1b05e"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzktMi0xLTEtMTY5NjA4_c0a9c83e-ba0c-4266-9b1b-0c377f168405"
      unitRef="usd">4247000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzktNC0xLTEtMTY5NjA4_18f86aa3-ef4e-45e1-bfa5-3b026f859e0e"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEwLTItMS0xLTE2OTYwOA_6f27af42-3044-4125-86a6-adf60e52deb4"
      unitRef="usd">1600000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEwLTQtMS0xLTE2OTYwOA_8fd40ab7-a812-466a-8c27-04bf8900ac2f"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzExLTItMS0xLTE2OTYwOA_ef1e9611-bb9d-4edb-8977-a502956c0d58"
      unitRef="usd">5800000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzExLTQtMS0xLTE2OTYwOA_8b7cb339-c919-4b80-a06c-fea08d60325b"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEyLTItMS0xLTE2OTYwOA_4f39d349-65ba-4ca5-817a-975decdf79b0"
      unitRef="usd">11547000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEyLTQtMS0xLTE2OTYwOA_f7d7b8ac-74be-4c68-b15a-7c56f5cec87e"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEzLTItMS0xLTE2OTYwOA_a64a1852-aa7b-467a-a159-ff27cabe043b"
      unitRef="usd">2166000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzEzLTQtMS0xLTE2OTYwOA_c3075745-8e8a-47a2-8c21-cb48e6f0517f"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE0LTItMS0xLTE2OTYwOA_f0b0b181-2723-4970-9471-9060ed07d6ed"
      unitRef="usd">326000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE0LTQtMS0xLTE2OTYwOA_ade9f53e-e0d2-437b-8239-e62edeb5b400"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE1LTItMS0xLTE2OTYwOA_c640148d-6343-4673-84d3-41f8e9a2f57a"
      unitRef="usd">25686000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE1LTQtMS0xLTE2OTYwOA_16658233-696e-4b84-b16d-3f8846f2dee3"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE4LTItMS0xLTE2OTYwOA_f9720cb5-e90b-462e-beb8-c916efa99035"
      unitRef="usd">521000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE4LTQtMS0xLTE2OTYwOA_3593523d-274d-461d-bbd2-8460bd4c772a"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE5LTItMS0xLTE2OTYwOA_2370dbae-5ffe-4bcb-bd3f-38e9fc1bb814"
      unitRef="usd">2988000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzE5LTQtMS0xLTE2OTYwOA_088260f1-40cc-44df-a4ad-3b64cd28320d"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTItMS0xLTE3MTI4OQ_8a5d20d7-fad5-4528-9a20-18752ed38857"
      unitRef="usd">432000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTQtMS0xLTE3OTQ0NQ_c4feb5a6-83c9-4ee9-880a-e8aed99eeb03"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTItMS0xLTE2OTYwOA_f1b2211d-a600-46cf-8805-9464753668b0"
      unitRef="usd">3941000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIwLTQtMS0xLTE2OTYwOA_9a9a1cc3-6559-4e4a-bf95-e0214e8cb0a7"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIxLTItMS0xLTE2OTYwOA_bf1f150d-4c84-4356-b59b-882710bb10cc"
      unitRef="usd">208000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIxLTQtMS0xLTE2OTYwOA_562aa1ef-5190-4edc-946b-9af14d2d22e7"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIyLTItMS0xLTE2OTYwOA_bd13a912-d41e-41a9-91f5-504f606178fc"
      unitRef="usd">20334000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIyLTQtMS0xLTE2OTYwOA_c3acbe7b-afba-415f-b4ad-fa870a0fe88c"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIzLTItMS0xLTE2OTYwOA_61044d76-4101-438d-8970-2e39ce776694"
      unitRef="usd">202000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzIzLTQtMS0xLTE2OTYwOA_47a038db-dcff-4e58-b9f0-b82568a3b32c"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI0LTItMS0xLTE2OTYwOA_18e896af-1857-40d8-b87c-ef9557f243bc"
      unitRef="usd">741000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI0LTQtMS0xLTE2OTYwOA_d23f8ea9-bfd5-48c2-8747-f0b44d56210b"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI1LTItMS0xLTE2OTYwOA_3c061888-345f-46b4-8d8c-e56b93331053"
      unitRef="usd">25426000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI1LTQtMS0xLTE2OTYwOA_45766ed9-6674-44db-a84e-8a0981dcdab2"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI2LTItMS0xLTE2OTYwOA_35f88275-ccb7-4f79-8030-c9b8a059382b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI2LTQtMS0xLTE2OTYwOA_566b8c01-2cea-4c94-8c1a-be566b8d3cd6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzYy_bbb042f9-6576-4faa-b429-c94a0a242183"
      unitRef="shares">361898846</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzYy_f0734da7-b3b7-4297-88f3-38fd355d2718"
      unitRef="shares">361898846</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzY5_59355c67-cc00-472b-af4e-6bc870402bab"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmU2MzljMTZkNTBjMDRmZDlhYTUxYWUyM2I4MjY4OGY4XzY5_6f13473f-a992-4474-ab82-c85d3f7d167b"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTItMS0xLTE2OTYwOA_6f53aa88-6c18-46b0-aeda-5dbb8c9a2a05"
      unitRef="usd">10391000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI4LTQtMS0xLTE2OTYwOA_54d367ee-01fe-45e5-aeda-57a5c51dde44"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI5LTItMS0xLTE2OTYwOA_5df41696-35dd-4c98-b55d-6453ee10ff2c"
      unitRef="usd">159000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzI5LTQtMS0xLTE2OTYwOA_a67d6c63-1fc1-4552-a47d-58e912724705"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMwLTItMS0xLTE2OTYwOA_9d9d6242-d4b8-4871-8a65-00ad97f0cdd4"
      unitRef="usd">-9186000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMwLTQtMS0xLTE2OTYwOA_2cc39520-f8db-4964-b1de-73f84dcafeac"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMxLTItMS0xLTE2OTYwOA_6cb92171-9bd7-4319-bbbf-f9a7e8da51f5"
      unitRef="usd">-2056000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMxLTQtMS0xLTE2OTYwOA_307fe095-5d5b-4623-b6fd-a60df178f1c6"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMyLTItMS0xLTE2OTYwOA_b5383492-fbd7-4439-b3fc-f353824e30bd"
      unitRef="usd">-692000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMyLTQtMS0xLTE2OTYwOA_646099c6-01aa-4358-bf48-0c339435c113"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMzLTItMS0xLTE2OTYwOA_31c8a3c6-51f7-4ed7-a76d-e7e91ecc4f32"
      unitRef="usd">952000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzMzLTQtMS0xLTE2OTYwOA_3f24a50f-5803-4a77-b565-88f3653266f3"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM0LTItMS0xLTE2OTYwOA_2f63f134-7c30-4c27-a89c-52bcb6e91581"
      unitRef="usd">260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM0LTQtMS0xLTE2OTYwOA_037625c4-0158-45c5-8975-18929bd07fdf"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM1LTItMS0xLTE2OTYwOA_aae82288-dacf-4cfa-850d-09c1185e5f0f"
      unitRef="usd">25686000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTUvZnJhZzo3ZThlMWM4ZjhhYTk0MGZhYWM0ZGUyMzY5ZmQ2ZTNkOC90YWJsZTo1YTUyOTgyYjRhN2Y0ZWJhYTY1ZjAyMDIzNWIxZTQzYi90YWJsZXJhbmdlOjVhNTI5ODJiNGE3ZjRlYmFhNjVmMDIwMjM1YjFlNDNiXzM1LTQtMS0xLTE2OTYwOA_07f4836a-cbc6-4de0-b1d9-77b411bc4777"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtMS0xLTEtMTY5NjA4_93ef4266-6114-4fb7-aefb-854a9ccb694e"
      unitRef="usd">8046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtMy0xLTEtMTY5NjA4_d02c4bac-5966-44c2-9ace-108df2be9cd2"
      unitRef="usd">8342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMtNS0xLTEtMTY5NjA4_52e44209-8902-44e1-8d14-e74a84b544ac"
      unitRef="usd">7924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtMS0xLTEtMTY5NjA4_72af3a5f-cd84-4cd7-bfb5-8969dca9f024"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtMy0xLTEtMTY5NjA4_59cb5417-dd27-4d1d-ab50-69ec8177700a"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzQtNS0xLTEtMTY5NjA4_5ceef2f8-eefb-4070-99b1-cc1bca44427d"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtMS0xLTEtMTY5NjA4_03a7c9ae-98f3-42d0-9821-cf36c0956bb7"
      unitRef="usd">8124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtMy0xLTEtMTY5NjA4_3e412892-c466-4b6d-ba78-a2b96f6b5bb9"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzUtNS0xLTEtMTY5NjA4_07fa5f4a-188b-4fe7-90e8-8ea92422ea7c"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i96f24ee503034b4ab64c035269ad0686_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctMS0xLTEtMTY5NjA4_c325d17c-14d5-4947-8c6b-e6711868564a"
      unitRef="usd">2336000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieb4fa373a33d4416ad975331156f8e2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctMy0xLTEtMTY5NjA4_f1793d4d-9d3e-4ffd-800e-91d5308e4a80"
      unitRef="usd">2361000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ief7623c7ce0d4d56bab88f6b945638da_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzctNS0xLTEtMTY5NjA4_030a6ea6-449c-4ebd-9809-1c547979d0cd"
      unitRef="usd">2202000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic14eb20d5d00463180ac90ff51d5d8d0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtMS0xLTEtMTY5NjA4_cf8cbd62-d079-432b-912c-8cb835a6f091"
      unitRef="usd">28000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i16ce0280789a4872adda1029add7f5bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtMy0xLTEtMTY5NjA4_31b88fdf-48fe-4d94-983f-0e4883a6bed5"
      unitRef="usd">33000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i68f7e4fc620647879fcb878cd35f8213_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzgtNS0xLTEtMTY5NjA4_4e0de6ac-07e6-4ac9-adbf-eddf2437bfab"
      unitRef="usd">47000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktMS0xLTEtMTY5NjA4_24dac994-1676-402e-be43-e8e8f06b6bd6"
      unitRef="usd">2625000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktMy0xLTEtMTY5NjA4_71b9c52f-47ec-47ca-8a72-f98b38928ed4"
      unitRef="usd">2624000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzktNS0xLTEtMTY5NjA4_91d9f56a-9c03-4059-8c42-56da561c6379"
      unitRef="usd">2367000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTEtMS0xLTE2OTYwOA_b9e7a7a2-292c-4223-8c05-edb045e65cea"
      unitRef="usd">529000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTMtMS0xLTE2OTYwOA_faff6b98-13af-4f27-9eed-6c1a6269422a"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEwLTUtMS0xLTE2OTYwOA_40d893fc-a075-45d7-b7ee-616f4f6760da"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTEtMS0xLTE2OTYwOA_68e1622b-4a7e-4762-96bd-09b315f3710a"
      unitRef="usd">1215000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTMtMS0xLTE2OTYwOA_a9f46f74-f77e-4f6a-a780-99a4f7742af5"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzExLTUtMS0xLTE2OTYwOA_f8a20886-a370-4d0d-a534-457a8e0ee9b5"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTEtMS0xLTE2OTYwOA_17eef924-3fc7-45d5-a7fe-f45661f65a57"
      unitRef="usd">824000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTMtMS0xLTE2OTYwOA_3d7566b8-48da-46f1-8265-384318a5b011"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEyLTUtMS0xLTE2OTYwOA_a51929ef-828e-44e7-8d3b-d0a5cdfa81a0"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTEtMS0xLTE2OTYwOA_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTMtMS0xLTE2OTYwOA_bb166372-19b5-4873-8286-13042a66b5f6"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzEzLTUtMS0xLTE2OTYwOA_4cc0dfd6-f8f3-46d6-8461-cac87df7ad73"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTEtMS0xLTE2OTYwOA_9e7f5d05-9384-4a3d-9662-4e6c96f62636"
      unitRef="usd">63000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTMtMS0xLTE2OTYwOA_c6ad5c2b-09db-4c54-bf5c-aaf62601a899"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE0LTUtMS0xLTE2OTYwOA_79e771b6-5e16-4dfa-bc2a-4ba3dc240198"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTEtMS0xLTE2OTYwOA_a5b68590-e864-456a-bd3b-63b7b51d8bfb"
      unitRef="usd">-35000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTMtMS0xLTE2OTYwOA_85f75121-7c62-4d7e-b8f6-ac884e144328"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE1LTUtMS0xLTE2OTYwOA_5fd0177b-6f61-4033-b283-43448e63f5c5"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTEtMS0xLTE2OTYwOA_9610c08d-7bec-44bb-bb86-0a28071cc988"
      unitRef="usd">7670000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTMtMS0xLTE2OTYwOA_627eda17-5415-4cb5-bd70-5db35cf60a77"
      unitRef="usd">7984000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE2LTUtMS0xLTE2OTYwOA_05be6cb9-361b-4d4e-9cde-65eae0938711"
      unitRef="usd">7351000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTEtMS0xLTE2OTYwOA_ef948fff-a12f-4611-9634-cfccd35d0767"
      unitRef="usd">454000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTMtMS0xLTE2OTYwOA_f22c3fa6-219a-460b-8846-b38e01600852"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE3LTUtMS0xLTE2OTYwOA_68afa60d-4844-484e-9dc9-5c4bd333ecc7"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTEtMS0xLTE2OTYwOA_0030c4cb-95e8-4aee-9687-0d01e02c2fca"
      unitRef="usd">14000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTMtMS0xLTE2OTYwOA_dab70423-56a0-453d-8970-d6d55f8df5f4"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE4LTUtMS0xLTE2OTYwOA_54e642f0-bdd3-4f45-9359-e2ba3d08870d"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTEtMS0xLTE2OTYwOA_7352e363-b6c2-4c90-ac29-d3a29ae84c7c"
      unitRef="usd">1464000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTMtMS0xLTE2OTYwOA_198034be-ce63-4b38-ba4b-09d091b10ae0"
      unitRef="usd">1426000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzE5LTUtMS0xLTE2OTYwOA_47bc1925-93db-40ca-9038-5ab0987288f4"
      unitRef="usd">1534000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTEtMS0xLTE2OTYwOA_4a02e589-f95f-4990-ae98-c69e615f921e"
      unitRef="usd">875000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTMtMS0xLTE2OTYwOA_4478786f-c25e-4143-9d0b-b59822795c3c"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIwLTUtMS0xLTE2OTYwOA_e4d74243-d6d1-4e9a-8733-8b7fccbabadb"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTEtMS0xLTE2OTYwOA_cf821268-4f8c-4751-b56e-3d91e133bbb5"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTMtMS0xLTE2OTYwOA_a7e1b2fb-1db4-49ca-9c52-c8f0323ebeae"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIxLTUtMS0xLTE2OTYwOA_ef72c913-2f3d-4389-bbe0-783c830438c3"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTEtMS0xLTE2OTYwOA_ea7e4d89-1c9a-4c18-b086-0253213b42d8"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTMtMS0xLTE2OTYwOA_7d12da12-b08c-48ee-82f8-70077f74decc"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIyLTUtMS0xLTE2OTYwOA_13a558d1-5502-4957-9b9c-6e35d3e6e58c"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTEtMS0xLTE2OTYwOA_bbe26775-ded9-495f-83f2-7fa8ad43378d"
      unitRef="usd">83000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTMtMS0xLTE2OTYwOA_cfe01621-7ec9-4f4b-8c03-9c4d113b4d6c"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzIzLTUtMS0xLTE2OTYwOA_872ec6c8-8cb9-4152-ab4c-639eca258877"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTEtMS0xLTE2OTYwOA_e854f6a8-eb53-4c0d-a8b9-1184816d3d1c"
      unitRef="usd">-212000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTMtMS0xLTE2OTYwOA_055abd8a-745b-41eb-8db1-247689c47164"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI0LTUtMS0xLTE2OTYwOA_8b230bbb-3254-47f0-b65e-52507093b17a"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTEtMS0xLTE2OTYwOA_780be002-7593-43e2-8efb-7e8acb7d2c7c"
      unitRef="usd">13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTMtMS0xLTE2OTYwOA_05698ebe-5f81-423c-93b3-22219872745a"
      unitRef="usd">11000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI1LTUtMS0xLTE2OTYwOA_8e0728ab-67f2-4ebd-94f8-7deff9595f15"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTEtMS0xLTE2OTYwOA_189c56a4-655f-4e4d-933b-c80d2020a833"
      unitRef="usd">-225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTMtMS0xLTE2OTYwOA_ba8802d3-4081-4d13-8516-a18df5b209c9"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI2LTUtMS0xLTE2OTYwOA_d675aa28-8da8-4945-81c8-73d7a24754c6"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTEtMS0xLTE4OTE0OQ_074dedc6-4b93-4795-a2d1-9158444fa194"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTEtMS0xLTE4OTE0OQ_f1d23e70-0535-4a34-8a83-8e16d3366c7d"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTMtMS0xLTE4OTE0OQ_020ba721-cbbd-416b-8342-77e1a07b9c0a"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTMtMS0xLTE4OTE0OQ_6157e492-a4d2-43da-a9c6-4fc459813e4d"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTUtMS0xLTE4OTE0OQ_2454d3cd-d555-49aa-97ff-1692159134fa"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzI5LTUtMS0xLTE4OTE0OQ_a9e8d7fd-813e-4f30-9172-1e9f74ede8df"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTEtMS0xLTE2OTYwOA_467e5c95-13cf-4fb9-ad59-a24399b0be88"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTEtMS0xLTE2OTYwOA_a1254015-0ee6-4f31-9e77-10fc39961c87"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTMtMS0xLTE2OTYwOA_882dbe33-8b46-4adc-8d2f-bf25fec84a27"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTMtMS0xLTE2OTYwOA_f8709c2d-accd-48a5-a9b1-d51fc14ac6ef"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTUtMS0xLTE2OTYwOA_30c06caf-655e-4111-a354-86ea2e527f4c"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8yOTgvZnJhZzpjMzNkZGVlZWRiNTY0NTk0YjZkOWNjNzM4ZmFhOGI2Mi90YWJsZTo4YTc2N2MzYjExNTQ0MjgxODYxZjQyM2M4YTE1YjMyNC90YWJsZXJhbmdlOjhhNzY3YzNiMTE1NDQyODE4NjFmNDIzYzhhMTViMzI0XzMwLTUtMS0xLTE2OTYwOA_65a891fa-0feb-4019-8627-3e2058670499"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItMS0xLTEtMTY5NjA4_ba981429-5910-4460-8a9a-2573ccf435b1"
      unitRef="usd">-212000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItMy0xLTEtMTY5NjA4_5bd94db1-fefa-4395-945d-cbbbc51cbf31"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzItNS0xLTEtMTY5NjA4_c27a2e55-315b-487a-850b-45544a127173"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtMS0xLTEtMTY5NjA4_de822d4c-1a95-453a-a04a-bc6f4e655556"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtMy0xLTEtMTY5NjA4_f44d0c5b-2c80-470d-87f5-b1a8c1d185ab"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzUtNS0xLTEtMTY5NjA4_db052499-2de7-4ec4-bfd6-f2a0c6c2a9b6"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtMS0xLTEtMTY5NjA4_7c431916-7531-4019-9d8d-732fd12ba1ae"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtMy0xLTEtMTY5NjA4_21c558ad-8c2a-4348-96c9-a69a7f16fef3"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzYtNS0xLTEtMTY5NjA4_24b35a1b-f7be-440c-b9b2-a984fc888f40"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctMS0xLTEtMTY5NjA4_69da70f7-40dd-4086-bdc1-45f9917ee321"
      unitRef="usd">-10000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctMy0xLTEtMTY5NjA4_6ed2fc71-ecae-4f76-a495-a007751e2426"
      unitRef="usd">-10000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzctNS0xLTEtMTY5NjA4_95bfe2aa-890a-41ec-acc3-623e5c22f221"
      unitRef="usd">-1000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtMS0xLTEtMTY5NjA4_1c4ae4d3-cec7-457f-8df7-26843308983a"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtMy0xLTEtMTY5NjA4_9508f7cb-b043-4276-b59b-3801f50afcc6"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzgtNS0xLTEtMTY5NjA4_79d2b183-b9a1-4cca-bfd9-26e88103d76d"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktMS0xLTEtMTY5NjA4_ec31e053-1011-4bfd-a081-edae93949a59"
      unitRef="usd">1000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktMy0xLTEtMTY5NjA4_0fde5529-f63a-42c4-803a-c042b420c3e9"
      unitRef="usd">-3000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzktNS0xLTEtMTY5NjA4_d162d7dd-8cdd-4e0d-bad4-a486fabd13ff"
      unitRef="usd">0</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTEtMS0xLTE2OTYwOA_8958ff33-8b7d-4732-91f5-471e549538b6"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTMtMS0xLTE2OTYwOA_3fa3c831-60e7-4394-8ce1-103634ee808d"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEwLTUtMS0xLTE2OTYwOA_52a5114b-d644-427e-8cb8-a3509e048d89"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTEtMS0xLTE2OTYwOA_978eb50a-7e0f-4626-aedd-ad6dce496fbd"
      unitRef="usd">-257000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTMtMS0xLTE2OTYwOA_79b6f164-9419-428b-84dc-3a3305333df6"
      unitRef="usd">-158000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzExLTUtMS0xLTE2OTYwOA_b4e8f2dd-4a12-4836-a15d-3840fe9097d1"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTEtMS0xLTE2OTYwOA_65453037-da36-4544-bb78-01d01afd9b89"
      unitRef="usd">-256000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTMtMS0xLTE2OTYwOA_a0812da2-7afc-42a7-9ca9-b16a32e45ef9"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEyLTUtMS0xLTE2OTYwOA_39a9d4e3-4580-4211-9030-b1e24edc02fb"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTEtMS0xLTE2OTYwOA_c5bc8679-69aa-499d-ba3f-6410109b6b8b"
      unitRef="usd">-468000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTMtMS0xLTE2OTYwOA_cd44fddf-d956-43a1-a039-75826743447b"
      unitRef="usd">-1067000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzEzLTUtMS0xLTE2OTYwOA_b779c2b1-43f3-470b-b728-f934d0aed89c"
      unitRef="usd">-604000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTEtMS0xLTE2OTYwOA_31b6ac9f-6f86-453b-bc44-dcf3f3b15c50"
      unitRef="usd">26000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTMtMS0xLTE2OTYwOA_7b2dc1f0-43c9-4c99-ba33-94e483b583c8"
      unitRef="usd">12000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE0LTUtMS0xLTE2OTYwOA_2d56bab2-412c-4fbf-9edf-6d1220feae9e"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTEtMS0xLTE2OTYwOA_e6ec0c16-dee5-44a4-9275-48f9f319fc58"
      unitRef="usd">-494000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTMtMS0xLTE2OTYwOA_09d5f84c-d366-4963-97c2-bca738714642"
      unitRef="usd">-1079000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDEvZnJhZzpjYmJkM2E5ZWZjN2Y0MDM2OWQ2OTg2N2UyMzg3NmU0Zi90YWJsZTpmNDdlZTI2ZTZlMDQ0NGNhOWY4Y2UwYWUxOTNmZmE0OC90YWJsZXJhbmdlOmY0N2VlMjZlNmUwNDQ0Y2E5ZjhjZTBhZTE5M2ZmYTQ4XzE1LTUtMS0xLTE2OTYwOA_b149f415-01a5-4821-b3cb-c7b1fe159384"
      unitRef="usd">-607000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i352ec3a38f244bdbafd755de208aa067_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMi0xLTEtMTY5NjA4_1a3ae807-8f30-4529-9455-3f28935568e7"
      unitRef="shares">352600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i352ec3a38f244bdbafd755de208aa067_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtNC0xLTEtMTY5NjA4_ffeba8c2-458a-4929-8c8f-7e62346d0898"
      unitRef="usd">10172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia31a4f763ded4502b9e4fa2d840d63f8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtNi0xLTEtMTY5NjA4_bbef3009-fd78-492c-98c0-4d9cb288c5de"
      unitRef="usd">429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28edfd63f7b14bc8bcd18527c6781606_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtOC0xLTEtMTY5NjA4_e5ab3a7e-d3b9-4263-b0c7-764c7a82cb37"
      unitRef="usd">-7452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e70e662458f40bb8c987a1572e53027_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTAtMS0xLTE2OTYwOA_1675c33a-33b0-40e4-bd3b-41b72f0c8c2b"
      unitRef="usd">-2086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie42242da77914d51bc567ec579238930_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTItMS0xLTE2OTYwOA_265ce0e2-fd4e-42bd-8187-304db7aee6a1"
      unitRef="usd">1063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc69aab44eb84be4ac14baf7ef6a6ac2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTQtMS0xLTE2OTYwOA_c6b328cd-94ca-4f8e-a94a-3592aaf4a3b4"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzMtMTYtMS0xLTE2OTYwOA_e6f13aa6-c491-42e3-ab8e-97d5b49500e9"
      unitRef="usd">1136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtOC0xLTEtMTc5NzA0_a77686f7-3ce0-4318-a322-61e3e17d158a"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaad43210cdbd45f0b0a9a371bd0993dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTItMS0xLTE3OTcwNA_36e44774-3871-4d63-9356-d183db9d7647"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5b0ddd5ab97433abadd6e743429df67_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTYtMS0xLTE3OTcwNA_780f42a4-d968-4aca-ab5d-2058a7cc4007"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMi0xLTEtMTY5NjA4_b6ba0af1-d56a-48e3-8aa6-8d061af7ba69"
      unitRef="shares">2800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e0d74d7f2424f6088ab3b2f9a91b2c2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtNC0xLTEtMTY5NjA4_1361ba85-9166-4289-8e9b-a1b0a32519cf"
      unitRef="usd">55000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtNi0xLTEtMTY5NjA4_e3d14607-3619-4b31-a8ef-83689488e4ee"
      unitRef="usd">-50000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTItMS0xLTE2OTYwOA_ea907e3d-1cbc-4bb0-8b26-8e98ebde8632"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzQtMTYtMS0xLTE2OTYwOA_0518a02a-01a2-44b2-a8d3-d711a7d4c576"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtNi0xLTEtMTY5NjA4_2a92cddf-1212-4827-99b8-bc5fffdb1fbe"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtMTItMS0xLTE2OTYwOA_92767e22-bd0a-477d-977b-dd33a16a36aa"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzUtMTYtMS0xLTE2OTYwOA_4201b51b-bc85-47cf-b6be-acd35667b472"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib2bb31f8ab7c497a9392130f621366e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtNi0xLTEtMTY5NjA4_58eeff58-1d9b-48f2-838c-181f980e923d"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtMTItMS0xLTE2OTYwOA_f5ff7337-8c2d-485d-9980-ce6903acf643"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzYtMTYtMS0xLTE2OTYwOA_1b98f45c-bf89-46a2-9bf2-49cf3e475321"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzctMTQtMS0xLTE2OTYwOA_cd2e0568-7563-4f38-a776-0ef9afc0a4a8"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzctMTYtMS0xLTE2OTYwOA_ad6efa0f-e5a4-4888-ad03-c49d6876b206"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i0b88f1ca9e1a48ad9446d9187ae673ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtOC0xLTEtMTY5NjA4_483c87e3-1d30-485e-a356-b86afcc58295"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTItMS0xLTE2OTYwOA_ccca44c6-68cb-4fb6-9d5c-3cc45cfb43a9"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTQtMS0xLTE2OTYwOA_351a529c-3301-4493-9a00-0328fa74eded"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzgtMTYtMS0xLTE2OTYwOA_9bf7d6e1-b903-4ca4-b001-db9fbe6d34cc"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibd1162a0c4e547519003679dc043973a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTAtMS0xLTE2OTYwOA_316f905b-102e-42bb-bcc9-0129b34acffd"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f603a5a47f6490291f143a008712675_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTItMS0xLTE2OTYwOA_a9c12e62-d091-4231-b454-03e218b5dfec"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibd36418561e24592ac91f70f0695a95f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTQtMS0xLTE2OTYwOA_0c256a0a-9d3f-4ad1-825c-deca1a9779a2"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzktMTYtMS0xLTE2OTYwOA_be9a4f01-435e-4e49-8558-df26a7e92cd2"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7beef9cf290b4312a60d7c32efde693f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTItMS0xLTE2OTYwOA_cbfa90d1-be7c-4b2f-b1dc-f9696e48986d"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7beef9cf290b4312a60d7c32efde693f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTQtMS0xLTE2OTYwOA_557ed271-7b0d-475f-be6b-abf45ef5c172"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i744ebc157dbb4a0b86ccfabc060e848f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTYtMS0xLTE2OTYwOA_7f82667d-80ff-4677-9362-07a02d007254"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d9756007b6d4f3d84623153c2dddeff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTgtMS0xLTE2OTYwOA_18a6fcb5-3085-4dd0-b51d-4ea63ebb8ea0"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9599e56128940a0955ca4ff88d8639a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTEwLTEtMS0xNjk2MDg_4152e921-b559-42c5-a822-5bc801986130"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i687d9364584e4a7ca7034a3483a95a7d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTEyLTEtMS0xNjk2MDg_8e499a74-096b-436a-a9d1-7f4d9b755490"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9effac2c66724eed803dffd7950879ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTE0LTEtMS0xNjk2MDg_95768e73-96c8-47d0-afb2-ee225b1a97a4"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEwLTE2LTEtMS0xNjk2MDg_ad0969cb-ab0f-4c6f-ac62-d171bf832e25"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTItMS0xLTE2OTYwOA_43c8fd1a-547f-4698-8e23-eb238d8bc0e8"
      unitRef="shares">4000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i99d1629036634f5f9e7660f8d632c2ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTQtMS0xLTE2OTYwOA_56138d7c-6ca6-4210-8f05-bad10024bc83"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTYtMS0xLTE2OTYwOA_3a256ad1-704f-456e-9e0b-ad9d9e51a168"
      unitRef="usd">-68000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTEyLTEtMS0xNjk2MDg_9a51dfa1-3db8-447e-9f1e-10bb0b75afc2"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEyLTE2LTEtMS0xNjk2MDg_68339b4a-b7c0-4a49-a9f1-d5075020a907"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTYtMS0xLTE2OTYwOA_1b73b051-34c0-4477-ba55-d751ed12cc7d"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTEyLTEtMS0xNjk2MDg_98de21a9-ac55-40fc-a394-1602e92016c0"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzEzLTE2LTEtMS0xNjk2MDg_03e03fef-2c93-45ff-8157-60980d243fd9"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i859ba47d5b1142969af84ec7b5cdb83f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTYtMS0xLTE2OTYwOA_e63fefc7-5e3c-4f04-ad5b-f45bc4ffa3e1"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTEyLTEtMS0xNjk2MDg_6e108b13-466c-4e97-b42b-e8eb292a024b"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE0LTE2LTEtMS0xNjk2MDg_9b9e8844-2020-4a12-aa77-7df4e071941d"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTEwLTEtMS0xNzk3MDY_862b1ff5-706d-4ab2-8514-0d1aad4c30c0"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTEyLTEtMS0xNzk3MDY_de586aac-a265-463f-ae2c-64c6a7ddb8d3"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE2LTEtMS0xNzk3MDY_2248998b-6ecc-4328-a857-199f52f56860"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE0LTEtMS0xNjk2MDg_9d426ef4-339a-4a0f-92f9-a443381ff88e"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE1LTE2LTEtMS0xNjk2MDg_6a595392-11f4-43ff-9ba7-cf72c8e099bf"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i1b2c612fd89643298310e38a8883f365_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTgtMS0xLTE2OTYwOA_80a5dd62-b18e-404c-8b60-5fb38c87a013"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTEyLTEtMS0xNjk2MDg_2b4c5b8a-b052-4cfd-986a-1c5441a38ae8"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTE0LTEtMS0xNjk2MDg_ebe432eb-0dc6-4aa6-b27d-5f70c4e846ea"
      unitRef="usd">11000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE2LTE2LTEtMS0xNjk2MDg_d1a7b296-9e22-407b-8e3b-72c9ef0fbcac"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa0b7dcc5ae64357baa477ce8586380e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTEwLTEtMS0xNjk2MDg_79767c6a-682c-48a9-a012-10fff5f15585"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8dbf1b22810a44e78cb58abc0401ff42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTEyLTEtMS0xNjk2MDg_d7013c90-6c5e-4480-ae4c-f8fbbc21ba80"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id5d1a890a66a4f989ca318a2d1747f79_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTE0LTEtMS0xNjk2MDg_528a2c72-86ce-4607-a845-53f8f940ade7"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE3LTE2LTEtMS0xNjk2MDg_ca75da20-781e-4254-adbf-1499dcc631eb"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4869d1047a0141b19a3fbf5790033030_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTItMS0xLTE2OTYwOA_845c1c62-3d02-446f-949a-e4f6213521b0"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4869d1047a0141b19a3fbf5790033030_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTQtMS0xLTE2OTYwOA_082b9972-f504-4ea0-9fbd-1929c87320a6"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcee2b5169a8459c8cbccfe68bebb595_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTYtMS0xLTE2OTYwOA_943251f3-451c-4235-80e2-4e5d7bca4a31"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea9dde3b1c18435faec13820801e4e34_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTgtMS0xLTE2OTYwOA_394b6360-d9a2-4bc3-a6fb-3dc88c952a8e"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4522c45ac1c44145a7ecea556295fe2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTEwLTEtMS0xNjk2MDg_444cbc7a-69b3-4cc5-beec-5ce7bbf74e47"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if48c23e1700a4f49ba421b5d2cbc0242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTEyLTEtMS0xNjk2MDg_05631cf1-290e-4db1-bb96-7f3554920e8d"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03c547eba26f449dbd67bd40c78e03b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTE0LTEtMS0xNjk2MDg_bcce9663-ef4b-4dce-9af9-cf270b20211c"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE4LTE2LTEtMS0xNjk2MDg_792032ed-fa88-417f-b3f4-5560e548f1c3"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTYtMS0xLTE3OTcxMA_fb483163-7285-4772-a26c-aa519efd6ec9"
      unitRef="usd">-327000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEwLTEtMS0xNzk3MTA_d94066d6-589e-4546-9ef0-f8c6bc26df65"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEyLTEtMS0xNzk3MTA_0c24b066-af53-4e8f-a1ef-3359cbe4ed3a"
      unitRef="usd">-190000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE0LTEtMS0xNzk3MTA_fd45ff5e-481f-4223-b6a9-1b16a1bbf53b"
      unitRef="usd">865000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE2LTEtMS0xNzk3MTA_c1a45580-b858-4c67-a73c-75caf146b414"
      unitRef="usd">675000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTItMS0xLTE2OTYwOA_664b6bcd-3f3d-41e9-a249-cdf32da43e56"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if780a5cd9e874dc6bef5bf2bdd0adfc0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTQtMS0xLTE2OTYwOA_0501e575-4083-4806-b79d-77e61024789c"
      unitRef="usd">74000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTYtMS0xLTE2OTYwOA_92840c40-a4fb-4cf9-98a9-8fb9fde28dc1"
      unitRef="usd">-71000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTEyLTEtMS0xNjk2MDg_31696484-39ab-4b8c-9adf-7d98f4ca805c"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzE5LTE2LTEtMS0xNjk2MDg_91568d00-cb9d-42c8-9849-4d2d18aeb259"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTYtMS0xLTE2OTYwOA_89146f2c-443a-4ada-9b35-19cedbd93673"
      unitRef="usd">126000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTEyLTEtMS0xNjk2MDg_da294cd6-ca60-44b4-84e2-a18fe252c414"
      unitRef="usd">126000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIwLTE2LTEtMS0xNjk2MDg_3df5aae5-89c3-4fd0-b0fc-f80d82a6d744"
      unitRef="usd">126000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i505aec9fc1ff4436bb83f3a942a506c5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTYtMS0xLTE2OTYwOA_942c0c8d-443e-4a00-b89c-fdc048608b74"
      unitRef="usd">31000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTEyLTEtMS0xNjk2MDg_be284137-f455-4fa9-8a08-b752bdc9a9e6"
      unitRef="usd">31000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIxLTE2LTEtMS0xNjk2MDg_405d5014-af2e-4c52-8add-4ca7e0082f40"
      unitRef="usd">31000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIzLTE0LTEtMS0xNjk2MDg_344a7c6e-bf07-4017-b8bc-62fa6eb70ff6"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzIzLTE2LTEtMS0xNjk2MDg_e838fc2f-7671-45a2-841f-012a53f1a293"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ic85093372ad449739b9c5caf68d08cbe_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTgtMS0xLTE2OTYwOA_1d8c2f43-2946-44af-8404-d8aaea1a404c"
      unitRef="usd">-225000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTEyLTEtMS0xNjk2MDg_f7da9a79-98d8-4189-8e86-847e0198115a"
      unitRef="usd">-225000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTE0LTEtMS0xNjk2MDg_df4e59d7-ac68-4c99-a33d-97a032c6647a"
      unitRef="usd">13000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI0LTE2LTEtMS0xNjk2MDg_e00e7b55-9a99-4be8-9d3c-dca740e00596"
      unitRef="usd">-212000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d8cb3d06ca5456da7e91e0e517d331d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTEwLTEtMS0xNjk2MDg_f379a791-e610-43a6-ae51-edee26f75561"
      unitRef="usd">-269000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iae0b544924bb4de4b1f563f25895279d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTEyLTEtMS0xNjk2MDg_bc653cf7-55c0-4900-bf95-bd63330b76c3"
      unitRef="usd">-269000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i20ea5c999ba04320ae5c6a6eb1bc09ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTE0LTEtMS0xNjk2MDg_202516b1-fffe-4850-ae89-9fbe06747fc9"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI1LTE2LTEtMS0xNjk2MDg_3cbe7e39-cabf-4fbc-a4cc-8f2253cf17bb"
      unitRef="usd">-256000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i89640c6de2df463b91359c26584e4b54_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTItMS0xLTE2OTYwOA_05f8fc9f-6c4e-4cce-9a8a-f4f4cf7ca141"
      unitRef="shares">361900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89640c6de2df463b91359c26584e4b54_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTQtMS0xLTE2OTYwOA_0d4496d6-9e14-4764-b458-00e465f304ec"
      unitRef="usd">10391000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i666af66f47b4407393455522d3f67aab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTYtMS0xLTE2OTYwOA_838831e2-0dd3-4247-876a-b30b05e5cfc5"
      unitRef="usd">159000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d90679865d741fea3690267adba920e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTgtMS0xLTE2OTYwOA_f5cbac72-9391-4d6f-a104-7b85865d9327"
      unitRef="usd">-9186000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i286802cacb2b47a7aac5819b6b1ae881_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTEwLTEtMS0xNjk2MDg_83a8aad3-38a8-4993-9658-9359122595dc"
      unitRef="usd">-2056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcfc9710ac6749858b8d7495fde87d13_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTEyLTEtMS0xNjk2MDg_7d025dfa-c425-4105-91b8-36b5998f34b8"
      unitRef="usd">-692000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i414d863f79fc4e20a1c5842fb6a72ba3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTE0LTEtMS0xNjk2MDg_ad040ee5-db5c-445a-85a1-b9f7f946e987"
      unitRef="usd">952000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDQvZnJhZzo4YzIzM2FmMzZlYjQ0ZjhjODllZTAwZjdkMjQyNTc4ZC90YWJsZTpjZGUxNzI2ZTYzMzU0ZDEwODg2ODBkNmQ5NjVmY2UxMC90YWJsZXJhbmdlOmNkZTE3MjZlNjMzNTRkMTA4ODY4MGQ2ZDk2NWZjZTEwXzI2LTE2LTEtMS0xNjk2MDg_048615b5-f6eb-49ac-af1d-746a4e13507f"
      unitRef="usd">260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtMi0xLTEtMTY5NjA4_ba981429-5910-4460-8a9a-2573ccf435b1"
      unitRef="usd">-212000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtNC0xLTEtMTY5NjA4_5bd94db1-fefa-4395-945d-cbbbc51cbf31"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMtNi0xLTEtMTY5NjA4_c27a2e55-315b-487a-850b-45544a127173"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtMi0xLTEtMTY5NjA4_cea72393-38be-4336-a6cc-ae1c1a4e1043"
      unitRef="usd">1394000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtNC0xLTEtMTY5NjA4_b39ef577-00ca-4c6d-b7c8-11114fc3f566"
      unitRef="usd">1552000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUtNi0xLTEtMTY5NjA4_43b65728-dfbe-4528-9638-08d35afa2191"
      unitRef="usd">1825000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtMi0xLTEtMTY5NjA4_838be25c-a503-4518-8371-04c16aa76af5"
      unitRef="usd">99000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtNC0xLTEtMTY5NjA4_cb90e45c-8a32-49ae-a428-b9e8d10688d2"
      unitRef="usd">55000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzYtNi0xLTEtMTY5NjA4_532d64f7-aed8-417b-9dd7-8c39154070fe"
      unitRef="usd">61000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctMi0xLTEtMTY5NjA4_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctNC0xLTEtMTY5NjA4_bb166372-19b5-4873-8286-13042a66b5f6"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzctNi0xLTEtMTY5NjA4_4cc0dfd6-f8f3-46d6-8461-cac87df7ad73"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtMi0xLTEtMTY5NjA4_17eef924-3fc7-45d5-a7fe-f45661f65a57"
      unitRef="usd">824000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtNC0xLTEtMTY5NjA4_cc8ae32c-2906-4cb0-9413-0dae29542196"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzgtNi0xLTEtMTY5NjA4_b924cc6a-8708-4c3b-8ed5-e89c37d4f0dd"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktMi0xLTEtMTY5NjA4_1dde2730-9b87-4082-b494-65c7b70fefd4"
      unitRef="usd">29000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktNC0xLTEtMTY5NjA4_5b72fb9f-a9f6-46ec-8451-7afaac2975aa"
      unitRef="usd">11000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzktNi0xLTEtMTY5NjA4_af72793d-69b3-4be3-b08d-27687d784e36"
      unitRef="usd">48000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTItMS0xLTE2OTYwOA_a030d8e8-dfa3-4459-a0e5-ea2402367adf"
      unitRef="usd">51000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTQtMS0xLTE2OTYwOA_9099abd8-e45d-48c8-bab1-a2fc51c8325d"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEwLTYtMS0xLTE2OTYwOA_b6b3c8ea-31e4-4a1e-acbe-8d87d2c91438"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTItMS0xLTE2OTYwOA_8ea3e725-8b63-4b51-a7f2-97daa4b9f137"
      unitRef="usd">-176000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTQtMS0xLTE2OTYwOA_4d8274dc-bf6e-49fd-90c3-9d6dbca5d8d7"
      unitRef="usd">-225000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzExLTYtMS0xLTE2OTYwOA_f77384d8-9748-4a81-a49e-f5273c15e434"
      unitRef="usd">-475000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTItMS0xLTE2OTYwOA_919a99f1-a739-4d9c-a380-9f1cd84ff9fc"
      unitRef="usd">5000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTQtMS0xLTE2OTYwOA_2e8cb237-d3db-4a5f-b09f-a6e30e4d204e"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEyLTYtMS0xLTE2OTYwOA_ffcfd1e7-525d-4d34-bf8b-eee9c66ab086"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTItMS0xLTE2OTYwOA_ac17c885-8e1c-4447-bc3b-59e8cded3900"
      unitRef="usd">-9000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTQtMS0xLTE2OTYwOA_0189c598-d572-4d04-a7e1-b405e1b4f378"
      unitRef="usd">-569000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzEzLTYtMS0xLTE2OTYwOA_4ca99d68-ee14-4981-8f8a-1668f0d6c655"
      unitRef="usd">-442000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTItMS0xLTE2OTYwOA_6f49ec95-5cab-4e69-bfc7-22df1a958310"
      unitRef="usd">1572000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTQtMS0xLTE2OTYwOA_7ede46ed-0f75-499c-a536-5ffe6eeac428"
      unitRef="usd">351000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE0LTYtMS0xLTE2OTYwOA_a0267a8c-3273-4cd5-93db-ae7e644ccb28"
      unitRef="usd">168000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTItMS0xLTE2OTYwOA_c422a9c7-f2f7-494d-825f-46bb43306d3c"
      unitRef="usd">126000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTQtMS0xLTE2OTYwOA_895faae0-089a-443f-8d7d-053467060c16"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE1LTYtMS0xLTE2OTYwOA_e7e4017c-c1ac-4a9e-8fec-83b9a0d79b0c"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTItMS0xLTE2OTYwOA_ae55b261-03b6-4d32-872a-541a61bd546a"
      unitRef="usd">6000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTQtMS0xLTE2OTYwOA_3eb7cbc2-bff6-4cad-b7e6-6ffef1d30226"
      unitRef="usd">20000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE3LTYtMS0xLTE2OTYwOA_db983d07-e638-4b04-bcb6-76dcec7e7c60"
      unitRef="usd">23000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTItMS0xLTE2OTYwOA_9f93dd14-11ea-497f-b169-a77d5e39817b"
      unitRef="usd">875000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTQtMS0xLTE2OTYwOA_eb991c00-c18e-4eb0-b1bd-48a977a28a00"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE4LTYtMS0xLTE2OTYwOA_ad598499-8b03-4f17-b3e6-ece8c587ec9e"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTItMS0xLTE3MTMwNw_d40febbb-d8d9-4adc-ad27-ded869270d93"
      unitRef="usd">34000000</bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities>
    <bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTQtMS0xLTE3OTczNw_c2f08c34-9665-486b-9e39-11400255b250"
      unitRef="usd">0</bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities>
    <bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTYtMS0xLTE3OTczNw_e3030244-f4d1-42e9-b2d9-d975675ad652"
      unitRef="usd">0</bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTItMS0xLTE2OTYwOA_3ead9d46-cf9c-487f-88da-2ac6abe974a3"
      unitRef="usd">2000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTQtMS0xLTE2OTYwOA_dd49a9a8-ff1f-482d-90a8-16e16948095d"
      unitRef="usd">16000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzE5LTYtMS0xLTE2OTYwOA_dba7a963-7728-4fa1-ba2e-9ae44779e7d0"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTItMS0xLTE2OTYwOA_101f2d20-c076-493e-a37f-2dd07d4eb1a9"
      unitRef="usd">-3000000</bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax>
    <bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTQtMS0xLTE2OTYwOA_63c50634-d570-4d1f-8210-fd9078ce56d9"
      unitRef="usd">35000000</bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax>
    <bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIwLTYtMS0xLTE2OTYwOA_7f8e1eb5-b0b2-4a88-a9b5-4f6f7973f8ae"
      unitRef="usd">10000000</bhc:ForeignCurrencyTransactionAndOtherGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTItMS0xLTE2OTYwOA_92d34cb1-8145-4d93-a344-cb814c95e1a4"
      unitRef="usd">57000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTQtMS0xLTE2OTYwOA_dbf5e460-0ef8-4009-b33f-4e9478fd3d9f"
      unitRef="usd">229000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIyLTYtMS0xLTE2OTYwOA_818ceddf-6af5-4966-a36f-8234535b1e52"
      unitRef="usd">-170000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTItMS0xLTE2OTYwOA_8ec133c4-357b-4d9d-a1fa-a3ec8a041da7"
      unitRef="usd">198000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTQtMS0xLTE2OTYwOA_c033b66e-00ed-4162-85ce-0bed23474926"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzIzLTYtMS0xLTE2OTYwOA_a3e181f2-c75b-4f7f-a456-2d4fff48a327"
      unitRef="usd">77000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTItMS0xLTE2OTYwOA_3b3e61e8-b9fa-4949-ac73-da985f93926f"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTQtMS0xLTE2OTYwOA_5b5573cf-6e9d-49ad-a300-88771a0e2625"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI0LTYtMS0xLTE2OTYwOA_1629e58d-1d6f-40f7-a151-a4334c804c2a"
      unitRef="usd">-12000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTItMS0xLTE2OTYwOA_0b282640-7f29-4951-9eb5-87dc01868595"
      unitRef="usd">-75000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTQtMS0xLTE2OTYwOA_23ef705f-7cad-4eb0-953c-60908d4ebc21"
      unitRef="usd">121000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI1LTYtMS0xLTE2OTYwOA_4d305449-ff38-4261-8a6c-d21508fd727d"
      unitRef="usd">-471000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTItMS0xLTE2OTYwOA_984735dd-e20a-4c46-b145-096fa118435e"
      unitRef="usd">-728000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTQtMS0xLTE2OTYwOA_4de96915-10de-4c42-88fa-84f156dd7370"
      unitRef="usd">1426000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI2LTYtMS0xLTE2OTYwOA_d6c7fd57-da70-4e47-872a-3f1078d1e43c"
      unitRef="usd">1111000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTItMS0xLTE2OTYwOA_2b30b8a3-b64a-49f8-b31d-bb3f28752135"
      unitRef="usd">45000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTQtMS0xLTE2OTYwOA_40340aea-3a74-428f-8ed9-e8cd540d2495"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI4LTYtMS0xLTE2OTYwOA_fc8cecc5-fd7e-4823-be37-4ffacb30714d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTItMS0xLTE2OTYwOA_dfce5807-8574-4dc5-8806-404b0259f221"
      unitRef="usd">50000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTQtMS0xLTE2OTYwOA_d2689134-ff94-439e-a179-1923e43ab30d"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzI5LTYtMS0xLTE2OTYwOA_9e41db87-3b08-49b8-80dc-fd99b6d93426"
      unitRef="usd">7000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTItMS0xLTE2OTYwOA_38e8ee9a-ac25-4b21-ad9b-cd41c37259ff"
      unitRef="usd">218000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTQtMS0xLTE2OTYwOA_42604880-d577-4247-81e7-e71e9e8308d1"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMwLTYtMS0xLTE2OTYwOA_1765ca82-e36d-41bb-98ba-2d5580541019"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTItMS0xLTE2OTYwOA_3739eb4a-b9c7-467c-88e3-8a73773b3f7f"
      unitRef="usd">17000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTQtMS0xLTE2OTYwOA_24534ec9-7c1c-4995-b873-7ed1975a1365"
      unitRef="usd">19000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMxLTYtMS0xLTE2OTYwOA_b2eb56a0-5ace-4728-9f9c-8ed20b1b1f9e"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTItMS0xLTE2OTYwOA_e40b4112-fad9-4416-8da2-210c8eeb1d28"
      unitRef="usd">22000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTQtMS0xLTE2OTYwOA_5e4008ca-efd2-4b73-9d05-1f74781fcda9"
      unitRef="usd">15000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMyLTYtMS0xLTE2OTYwOA_a031e3a4-a7dc-4bc9-9993-25cf7f62dead"
      unitRef="usd">8000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTItMS0xLTE2OTYwOA_2e16f5df-d713-45fb-8e49-7dbf69785a4d"
      unitRef="usd">5000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTQtMS0xLTE2OTYwOA_ce4a5808-8e9a-4f00-a8eb-51a2226d54f3"
      unitRef="usd">669000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzMzLTYtMS0xLTE2OTYwOA_7e75b674-07bc-4704-8729-403bc5f736f2"
      unitRef="usd">21000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTItMS0xLTE2OTYwOA_329322f9-b5e2-40b8-8326-255343f95000"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTQtMS0xLTE2OTYwOA_1faa674c-d7cb-4766-b60a-af44b2651bf1"
      unitRef="usd">27000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM0LTYtMS0xLTE2OTYwOA_f7c26f63-74b1-4ce3-ac46-5f07b1b2d76b"
      unitRef="usd">23000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTItMS0xLTE2OTYwOA_09deb267-d507-4f17-86e0-550289518dc4"
      unitRef="usd">-303000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTQtMS0xLTE2OTYwOA_8b13b771-3a3a-49c6-99fb-d72954a35e6c"
      unitRef="usd">409000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM1LTYtMS0xLTE2OTYwOA_a6cce20a-05b8-4142-88bf-2d3d80c09acd"
      unitRef="usd">-261000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTItMS0xLTE2OTYwOA_adda07c7-b7a4-4201-83e3-ec97b93f774d"
      unitRef="usd">6836000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTQtMS0xLTE2OTYwOA_ee078d60-f997-419e-865a-6e19581791b5"
      unitRef="usd">2100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM3LTYtMS0xLTE2OTYwOA_337793a5-3b7d-492b-be26-4c44e4040372"
      unitRef="usd">3455000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTItMS0xLTE2OTYwOA_6d12d6bd-db8e-4cd8-a79c-7afd4a088e23"
      unitRef="usd">7846000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTQtMS0xLTE2OTYwOA_8ac7e08c-a68f-4cd4-9c54-a79812950562"
      unitRef="usd">3440000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzM4LTYtMS0xLTE2OTYwOA_544befcd-2bc7-4a5a-ad2b-aed9d57298b4"
      unitRef="usd">5642000000</us-gaap:RepaymentsOfLongTermDebt>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTItMS0xLTE3MTM0NQ_84b34851-0932-410a-a084-26690951e270"
      unitRef="usd">675000000</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTQtMS0xLTE3OTc0Mw_91f1df3e-f38e-4875-960c-3165d7075dfb"
      unitRef="usd">0</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQwLTYtMS0xLTE3OTc0Mw_146eedc8-05f4-4b2f-8228-efbaf58b65ba"
      unitRef="usd">0</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTItMS0xLTE2OTYwOA_c76666eb-c6c1-49a4-88a9-d51dc4552a92"
      unitRef="usd">31000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTQtMS0xLTE2OTYwOA_5038ea7c-1ec8-4ef7-80e7-7196578a12a1"
      unitRef="usd">52000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQxLTYtMS0xLTE2OTYwOA_b9138e08-e452-4c27-ac39-7a4f76ffc8e7"
      unitRef="usd">30000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTItMS0xLTE2OTYwOA_e90bf8ba-a9a2-4b3f-8d96-6d0235b1837e"
      unitRef="usd">26000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTQtMS0xLTE2OTYwOA_9721b989-8b00-47c9-b838-138c66f23244"
      unitRef="usd">83000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQyLTYtMS0xLTE2OTYwOA_07df6af1-476b-4471-b1db-792d0e2c3907"
      unitRef="usd">35000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTItMS0xLTE2OTYwOA_f9f12fbf-a17e-43ce-9db3-8a85b4821d59"
      unitRef="usd">71000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTQtMS0xLTE2OTYwOA_2b8e45a3-c527-4264-b663-24d7495e2167"
      unitRef="usd">48000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQzLTYtMS0xLTE2OTYwOA_9d9ea72d-af0d-4bb6-8015-65a38f976bc3"
      unitRef="usd">39000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTItMS0xLTE2OTYwOA_c34b63c5-ae1e-4cab-86f8-ce836162fa14"
      unitRef="usd">-11000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTQtMS0xLTE2OTYwOA_c77fb692-a76b-43e5-a7a5-e7673e342550"
      unitRef="usd">10000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ0LTYtMS0xLTE2OTYwOA_cd224ac0-2f21-41f7-8b0b-18d4c2f48f41"
      unitRef="usd">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTItMS0xLTE2OTYwOA_cb621696-f1af-4f86-9d95-fa3f91d18bc6"
      unitRef="usd">-474000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTQtMS0xLTE2OTYwOA_419df6ef-4eba-4ab9-be86-74756d1111b9"
      unitRef="usd">-1513000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ1LTYtMS0xLTE2OTYwOA_59c922e5-f4f0-448f-a59b-dc099248f0b4"
      unitRef="usd">-2294000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTItMS0xLTE2OTYwOA_460910e1-1dcd-4d73-94a5-6b57c5dac03c"
      unitRef="usd">-23000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTQtMS0xLTE2OTYwOA_a5c7e7e9-eb0d-446f-a488-443faf47d004"
      unitRef="usd">-19000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ2LTYtMS0xLTE2OTYwOA_b6eed6d0-5720-4788-b781-6b710e4d6463"
      unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTItMS0xLTE2OTYwOA_89687c7d-e33a-40e2-b73a-d14ff83d183a"
      unitRef="usd">-1528000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTQtMS0xLTE2OTYwOA_1ea97607-7e82-4db4-a10b-681b08c1734f"
      unitRef="usd">303000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ3LTYtMS0xLTE2OTYwOA_ab31cdac-4697-49a4-9185-9d76b727234e"
      unitRef="usd">-1428000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTItMS0xLTE2OTYwOA_9ce12bc3-31c6-4f3f-9e2c-e0d4bf2e1c37"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTQtMS0xLTE2OTYwOA_ea7d7842-b82d-4a71-a0bc-1cbb7fc505d4"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ4LTYtMS0xLTE2OTYwOA_7d575ce0-18a0-42da-8517-cc785d0adcfb"
      unitRef="usd">3244000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTItMS0xLTE2OTYwOA_27f799cf-e2a2-452b-a568-613b35e49423"
      unitRef="usd">591000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTQtMS0xLTE2OTYwOA_9ad6badb-995e-4262-a759-b5fcf07fb0bf"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzQ5LTYtMS0xLTE2OTYwOA_386ad3c3-ebf0-4a52-bba7-68b2d32f0bab"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTItMS0xLTE2OTYwOA_ac6d0ddf-3c80-459c-99e6-ff7129269eb8"
      unitRef="usd">564000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTQtMS0xLTE2OTYwOA_9354e81f-d7c5-435b-ba5e-2c611bd58fe7"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUxLTYtMS0xLTE2OTYwOA_5d2e77b9-dad0-41a8-86fd-206cf9457380"
      unitRef="usd">605000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTItMS0xLTE2OTYwOA_5cb3f4ad-f865-44be-9f25-b0ab98678884"
      unitRef="usd">27000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTQtMS0xLTE2OTYwOA_3d38d40c-db8e-44ad-9c16-91050690bcf0"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUyLTYtMS0xLTE2OTYwOA_d6ed8d13-4fec-49b6-9ab1-c414044dd32c"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTItMS0xLTE2OTYwOA_5b46ef98-1540-4c83-a054-1bf7dd3cba5e"
      unitRef="usd">591000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTQtMS0xLTE2OTYwOA_6649e5d2-5fe2-4f03-94e8-abf30122ff90"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMDcvZnJhZzoyMTRlYjM0ZWVhOGU0OTU1YjYwOTYzMTMyZjNiNDRhNy90YWJsZTo0YmE2ZjRkNTQzNjg0MTBkOTNiZTA1NGExYmMwNTY0Yy90YWJsZXJhbmdlOjRiYTZmNGQ1NDM2ODQxMGQ5M2JlMDU0YTFiYzA1NjRjXzUzLTYtMS0xLTE2OTYwOA_6e68a0a6-bc9d-4d0e-a458-226145b35d8a"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzEwOTY_c1d4af01-9330-413c-b6a3-cef914ebabdf">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or &#x201c;Bausch Health&#x201d;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#x201c;GI&#x201d;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical aesthetic devices and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#x2019;s products are marketed directly or indirectly in approximately 100 countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i35ad12432cad49608f2807386679107d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzE2NDkyNjc0NDQwNTI_38778cec-8ef6-4e0c-b174-2753a6309002"
      unitRef="number">0.89</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTMvZnJhZzozNjY1ZTk3OTlkOGY0Mjg2YThjNTMyNzQzMWY0NDYwOC90ZXh0cmVnaW9uOjM2NjVlOTc5OWQ4ZjQyODZhOGM1MzI3NDMxZjQ0NjA4XzE2NDkyNjc0NDQwNDc_cf0b75ef-e3b7-410d-a6d7-5e45304e86f0"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTYy_bbe16f0c-4512-45e2-a629-2abe0824dafb">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#x201c;B+L Separation&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#x201c;IPO&#x201d;) of Bausch + Lomb (the &#x201c;B+L IPO&#x201d;) was declared effective on May 5, 2022, and Bausch + Lomb&#x2019;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#x201c;Selling Shareholder&#x201d;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 89% of Bausch + Lomb&#x2019;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d;) on the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#x2019;s Salix, International, Diversified (dentistry, neurology, medical dermatology and generic pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these audited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Suspended Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#x201c;Solta IPO&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#x201c;Solta&#x201d; or &#x201c;Solta Medical&#x201d;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company&#x2019;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#x2019;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus, and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#x2019;s business, financial condition, cash flows and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company&#x2019;s Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb&#x2019;s cross-currency swaps qualified for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#x2019;s trade receivables outstanding in these countries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company&#x2019;s three largest U.S. wholesaler customers accounted for approximately 46% of net trade receivables. In addition, as of December 31, 2022 and 2021, the Company&#x2019;s net trade receivable balance from Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela amounted to $136 million and $78&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2022, a portion of which is comprised of public hospitals. Based on an analysis of credit risk, including an analysis of bad debt experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2022, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company&#x2019;s cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote. See Note 5, &#x201c;FAIR VALUE MEASUREMENTS&#x201d; for additional details regarding the Company&#x2019;s cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $33 million, $35 million and $39&#160;million as of December 31, 2022, 2021 and 2020, respectively. The activity in the allowance for credit losses for trade receivables was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x201c;B&amp;amp;L Trademark&#x201d;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors, including rising interest rates and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of modified debt accounted for as a troubled debt restructuring consists of all future undiscounted cash flows, both principal and contractual future interest, associated with such debt. The excess of the carrying value over the principal amount of such debt is recorded as a premium and is reduced as stated interest payments are made on such debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, gastroenterology (&#x201c;GI&#x201d;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $40 million and $36 million as of December 31, 2022 and 2021, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2022 and 2021 were $131&#160;million in each period, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21 million and $28 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160;The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product mix and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2022 and 2021 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements (&#x201c;DSAs&#x201d;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $10 million and $17 million for the years 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company&#x2019;s global payment terms are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTI3_ff4eb31c-416c-4e09-84fe-f967761f1790"&gt;thirty&lt;/span&gt; to ninety days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDc5_7ac9b54d-f1f9-4a3c-9aa7-dc857eb1ddf1"&gt;one&lt;/span&gt; to twenty years, some of which include termination options and options to extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTcz_3643a3d1-f7d7-4998-afc9-5317fb44ffa9"&gt;one&lt;/span&gt; to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company&#x2019;s lease agreements contain material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee. The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sale of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $518 million, $515 million and $451 million, for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company&#x2019;s cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2022 and 2021 was $66 million and $60&#160;million, respectively, and is included in Property, plant and equipment, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive loss. Other comprehensive loss includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Benefit Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company&#x2019;s results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company&#x2019;s disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance was effective for the Company beginning January 1, 2021.&#160;The application of this guidance did not have a material effect on the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160;Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities &lt;/span&gt;&lt;/div&gt;as of March 12, 2020, through December 31, 2024. For the years presented, the Company has not entered into any contract modifications in which the optional expedients were applied.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjEw_ab7694cc-e717-401b-a235-40ed879d637a">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9854d974005d4f129d1f349b2e8e9e0e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5NzM_3d01fe22-b992-486b-aeb3-fa00c67fa892"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i571caf526a3f498d9102359d54985610_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5ODU_72b100e5-0d44-4d54-9e5e-44329e376422"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <bhc:SaleOfStockOverAllotmentTerm
      contextRef="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyMjk_cffea732-b06a-4e81-82a6-26c34d851234">P30D</bhc:SaleOfStockOverAllotmentTerm>
    <bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance
      contextRef="ibf6b4147574f4b87a69f77a2a8310114_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyMTk_6486c715-10ce-47bd-bce9-c677f7090657"
      unitRef="shares">5250000</bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i664418729e77455ea311715c8025ba3c_D20220601-20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNDM_9a540386-7401-4df6-811a-1dae435a7ea2"
      unitRef="shares">4550357</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie4af7206f3dc4cb7ae55779f23145348_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTE5OTM_ed631fb7-578a-475d-984d-ecada0416dbe"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibb85da3e8b8943f38dca2d158d722362_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwOTk1MTE2OTIwMDE_3f35289a-35c9-4931-8eb9-3ead2630dfd5"
      unitRef="shares">310449643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i4538c7b5b4ca4fdeab03c2bf4233e8d9_D20220601-20220601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNjk_fc16d1c3-8eba-457d-8515-9c5c766bec8f"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i285925d86568407da8a3757803694323_D20220601-20220601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE2NDkyNjc1MDcyNTU_03b6ce4e-4d17-46a3-8162-900a310437ed"
      unitRef="usd">675000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:UseOfEstimates
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDE4_eeee03fe-24cc-4ce1-a020-b05a87e05452">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company&#x2019;s Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjA0_47c3e150-1ffd-4930-a0dc-58a3545138e4">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTgz_7ea750c8-73c5-45e8-9082-e356dbc0e9e4">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition. Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjUw_0a269a98-5fdd-4ed1-b526-8144e772f870">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjA4_47291656-c9e4-4ad0-afb4-1bb4908f8b6f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb&#x2019;s cross-currency swaps qualified for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTg3_eae3fa0f-bcac-4fc6-8729-3a7457ac3226">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEwNjAy_5c3f5865-3042-443b-b426-bd12cb964763">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTky_69b1234e-9151-4f80-baa6-bd18e246d488">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with &lt;/span&gt;&lt;/div&gt;reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela have been weak in recent years.</us-gaap:ConcentrationRiskCreditRisk>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzExMDYy_a5d26158-a9c3-4120-aac3-20a7efd8c834">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <bhc:NumberOfLargestWholesaleCustomers
      contextRef="i83b9870676f542a6aac864bbace50b24_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyNjAx_24ad25a1-02d3-424c-b873-6c720a790990"
      unitRef="wholesaler">3</bhc:NumberOfLargestWholesaleCustomers>
    <bhc:ConcentrationRiskPercentageofNetTradeReceivables
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyNjY2_81950fd8-f860-4e3a-bc75-a9a51119c659"
      unitRef="number">0.46</bhc:ConcentrationRiskPercentageofNetTradeReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie91578972bdb40a3af61e355b78d5073_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyODY3_2c0f0906-e856-457b-9e10-bd709522be64"
      unitRef="usd">136000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3f9466cb58824868850dfff1f0fc66e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyODc0_3db44387-9bbf-4a16-8a75-15ee5ae6c6af"
      unitRef="usd">78000000</us-gaap:AccountsReceivableNetCurrent>
    <bhc:PastDuePeriodForAccountsReceivableToBeNegligible
      contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEyOTM4_38906f33-2ada-48d0-87c4-9f0820a5ad19">P90D</bhc:PastDuePeriodForAccountsReceivableToBeNegligible>
    <bhc:PeriodReceivableOutstanding
      contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMDQ0_a2da58f4-24a1-43c4-9399-181be279c881">P90D</bhc:PeriodReceivableOutstanding>
    <bhc:TradeReceivableNetPortionPastDue
      contextRef="ie91578972bdb40a3af61e355b78d5073_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMDY0_71e99516-eed5-4ad8-9023-c5bf869f57b3"
      unitRef="usd">2000000</bhc:TradeReceivableNetPortionPastDue>
    <bhc:PeriodReceivableOutstanding
      contextRef="i2fbfc7690ec64d868c5ee02800d03797_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzEzMzcw_bf3aadfe-6a82-4113-b84e-b7ff65790596">P90D</bhc:PeriodReceivableOutstanding>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTA5_2452b79e-4001-4744-8c5b-0c680cff7689">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MTk1_6b8a01c4-b6a4-4f9f-b2a4-cbc0e590b68d"
      unitRef="usd">33000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MTk5_595b0f6e-447d-4a78-835f-1e367c229467"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzE1MjA2_a0be026d-ef0d-4736-a039-0ae00da6316e"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDcw_9be1ae17-c450-43a9-a150-4f40c787b4af">The activity in the allowance for credit losses for trade receivables was as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtMS0xLTEtMTY5NjA4_f669fe1f-8eb4-43d9-ab38-a344209fd399"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtMy0xLTEtMTY5NjA4_e1b74fc3-7600-4f80-8bd2-b75f18bd4df0"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzEtNS0xLTEtMTY5NjA4_d25f6fae-b9c2-4204-b9c7-8d239a07953d"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItMS0xLTEtMTY5NjA4_c90abe9a-6777-4568-a467-5f80ff0a0ae4"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItMy0xLTEtMTY5NjA4_45af9eb6-fddf-46ad-a869-a8253cf9d9a0"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzItNS0xLTEtMTY5NjA4_21adff16-837f-46aa-b288-80bd9b31eaea"
      unitRef="usd">1000000</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtMS0xLTEtMTY5NjA4_c4bc7417-039f-4ea8-bc85-03d68005b41b"
      unitRef="usd">5000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtMy0xLTEtMTY5NjA4_bdb1e41f-fb5f-4ac7-9f6c-15c9d6e51711"
      unitRef="usd">-2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzMtNS0xLTEtMTY5NjA4_bd85ac87-13c1-4a32-bb69-19983315c86b"
      unitRef="usd">2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtMS0xLTEtMTY5NjA4_73d4096b-8427-411f-aa6e-ed3bf4830ac5"
      unitRef="usd">6000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtMy0xLTEtMTY5NjA4_d52488a5-a24f-4616-8714-c365a970791a"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzQtNS0xLTEtMTY5NjA4_45be36f4-d6a7-4729-98a3-59ec4b7b0cb7"
      unitRef="usd">12000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtMS0xLTEtMTY5NjA4_ab55f6a1-a8c9-48a8-b3e9-98e4b124826a"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtMy0xLTEtMTY5NjA4_67308d4c-339a-4ecf-9bf0-d854fde2f142"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzUtNS0xLTEtMTY5NjA4_0b0e1446-f726-4a98-8fbd-760183e33b41"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtMS0xLTEtMTY5NjA4_893fcb12-89cd-4ee7-9fe7-4083edb3aa7e"
      unitRef="usd">3000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtMy0xLTEtMTY5NjA4_ec4063dc-ae32-49db-bafe-e9282611aa9d"
      unitRef="usd">1000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzYtNS0xLTEtMTY5NjA4_f3842161-dbeb-483a-8b01-9678e92a8766"
      unitRef="usd">3000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctMS0xLTEtMTY5NjA4_6b8a01c4-b6a4-4f9f-b2a4-cbc0e590b68d"
      unitRef="usd">33000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctMy0xLTEtMTY5NjA4_7e681143-84f6-4e0a-9463-5ae6e783f32c"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTphYTk4ZGUxYjM1NmU0NDlkYTM3OTdlZjhkNmJhNmVmOC90YWJsZXJhbmdlOmFhOThkZTFiMzU2ZTQ0OWRhMzc5N2VmOGQ2YmE2ZWY4XzctNS0xLTEtMTY5NjA4_bcccc805-ab91-47bc-9b6b-10c6d25f590c"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQz_b5dd6121-6acc-496e-8dd5-69d0c65091c7">Inventories&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTE2_86b43457-ee65-4876-8598-7a09f28f5847">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTIz_51a6e9e6-578e-4f7a-ac79-c4b95028aafb">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmQ2ZTg1ZWMwMDUzNDVmOTlmMzhhMTQxYzcwNDIxNDlfNA_b28b5193-8480-43ca-8b0a-8db09df9f8ac">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic15bd253c0ab41118c4045afdf0da935_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmQ2ZTg1ZWMwMDUzNDVmOTlmMzhhMTQxYzcwNDIxNDlfOQ_c4b414c1-45ca-4c12-83e1-cd9905ff1e68">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1524d212be2e451fb87eaa66b46428f1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246N2I0YzJkYWYzZDVhNDgxZDkxNjYwMDljYTE5N2IyMDdfMTA_a225e206-ed7a-4687-8875-1c75f5f0b7ef">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id9f0642352c64cc196cfc2d1d9b89a93_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NDFkYzI1YTM0NjQ2NDM3YThkNWNlMzM4YjIyNTg2NjFfNA_e7ddc8a5-e1e6-4cc7-a36b-99283203a669">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if32df11a6c7b427ea3edf23629b832da_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NDFkYzI1YTM0NjQ2NDM3YThkNWNlMzM4YjIyNTg2NjFfOQ_7c54a46a-c164-4f6b-852f-405c2660afa9">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ica86b1d3841f48b0a4940ae2217f149d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGQ4MGQwZTAyYTVlNGFmYTkyMjU5MGY4Y2YzMTdlNjZfNA_40946f9e-80d6-4cad-bc97-c078370aac11">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i829741d1c6804070b7cafb83060ea664_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGQ4MGQwZTAyYTVlNGFmYTkyMjU5MGY4Y2YzMTdlNjZfOQ_89d4e7da-5673-44ea-aad8-d66b3527f0ed">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i073d5fbb37a74b6896df8b862273a349_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246Zjk5ZGE2OWZjZWQyNDk3ZmI5ZWViNWFiYWYzZGNhYmZfMTA_38b7044c-e414-4c37-b230-5a1c6061ef83">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6fddaa647d224e77a75b08d87ff4b3b3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTowNGVmZWE0N2I1MzQ0NTcwYjYxNjg3MWY5MDJiMWRjMi90YWJsZXJhbmdlOjA0ZWZlYTQ3YjUzNDQ1NzBiNjE2ODcxZjkwMmIxZGMyXzUtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZjUzZjJiNWY0NmNkNGRiN2I0NWM5MjFjMDRhZjJiNDNfMzE_c53acef2-4cf3-4623-bf6b-c9dbe11a76ab">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTUx_3e5b4b16-c4a3-4ad5-ad02-856f623619bc">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDI4_dd713bab-4a84-4b10-a627-f1651cc8d760">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7338914353884cdba4212e42f3f0a816_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZmQwM2Y4ZGM5OWNlNDU2NGEyNWUyZWE3YjRkYzMyNDlfNA_895fb916-8b6f-4da1-9b43-d03f13d5e006">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0ce6f99808e4460581a8ecf630ae0e44_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzAtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZmQwM2Y4ZGM5OWNlNDU2NGEyNWUyZWE3YjRkYzMyNDlfOQ_0f5fe397-73ec-44fa-8795-f1f9959fa56f">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iba264d87eb1844f383743044281eca57_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NWRhY2QxNWNhNmNhNDMyOWE0Nzg3NTgwNDAxZTk1YzBfNA_5cbad66d-ca05-402c-b753-cdba09f980d4">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i58b60e4e1ba344759f420bb9dbb9e07f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NWRhY2QxNWNhNmNhNDMyOWE0Nzg3NTgwNDAxZTk1YzBfOQ_183f46b3-1687-43a2-94df-a555010199ac">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id33f7392918d41c58f5a2c8261fd0cfd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTdkMTYzNWUwMzlmNGZlNmFlOTc3ZTNlMTExZDJkYTdfNA_18011c84-b006-42d0-a06b-26dac02827af">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idafb37adc38a40a1bddab0dddf725726_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZTdkMTYzNWUwMzlmNGZlNmFlOTc3ZTNlMTExZDJkYTdfOQ_461bc9b3-b598-495e-9423-32ef92dff8da">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i42fbedcd6cef45eda7bf77d1487a41c0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDgyNGU4NDRlY2NlNDc0OWEzZDI1MzNhZDhmMWRhZGNfNA_ed8d0130-74c6-4929-9d8c-78f738320e79">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i95efbf91ff384469ba31cc31eabf84f4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDgyNGU4NDRlY2NlNDc0OWEzZDI1MzNhZDhmMWRhZGNfOQ_17bcddf8-1a40-4adc-b4ac-a4f0ff9cc608">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i43679a56867547b585e61a8bebd30a9b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246YmY2YmFhMGJjNjAzNGFkYTlhYzJhYmY0NmY5MjRkZjRfNA_c6fc69ad-6551-498f-aeaf-c6908b000186">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if0f5735466294af0bf44c228f9e7909e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpkMDg4MjljZjBhODk0YTk1ODQwZmY3MmM5ZThkZWU3YS90YWJsZXJhbmdlOmQwODgyOWNmMGE4OTRhOTU4NDBmZjcyYzllOGRlZTdhXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246YmY2YmFhMGJjNjAzNGFkYTlhYzJhYmY0NmY5MjRkZjRfOQ_45704082-b148-46a8-930e-9cc40855a6ee">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <bhc:DivestituresOfNoncoreProductsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTI0_c5e9874d-7980-477a-a256-240dd18fbd4f">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;</bhc:DivestituresOfNoncoreProductsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTI5_eb39246b-0c3b-4457-bb37-ac0235a3b1e2">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjU1_f365aed3-bedf-488a-be74-33c270123fbf">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x201c;B&amp;amp;L Trademark&#x201d;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTMw_766b0e95-1d45-4053-be59-982c5f33cd56">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors, including rising interest rates and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDU3_9a41fa7f-85a4-4d96-b5ad-95606e43cc18">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility. &lt;/span&gt;&lt;/div&gt;The carrying value of modified debt accounted for as a troubled debt restructuring consists of all future undiscounted cash flows, both principal and contractual future interest, associated with such debt. The excess of the carrying value over the principal amount of such debt is recorded as a premium and is reduced as stated interest payments are made on such debt.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDk3_128669b7-a3a8-481d-8aea-52d2ec8539cb">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTc5_ff90b253-5c2f-456e-baa7-c363f450636e">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye health, gastroenterology (&#x201c;GI&#x201d;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale. Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below. The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $40 million and $36 million as of December 31, 2022 and 2021, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics. The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information. These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products. Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2022 and 2021 were $131&#160;million in each period, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21 million and $28 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160;The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant. As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product mix and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2022 and 2021 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products. Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale. That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart. The Company has Distribution Services Agreements (&#x201c;DSAs&#x201d;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty. Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes. Additionally, price appreciation credits are generated when the Company increases a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $10 million and $17 million for the years 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQ1_e6bfe8a8-971c-4ac1-ac72-49d8d07f1bc9">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i08e3ff0b63c54e8195b04d98b1f2ea94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMi0xLTEtMTY5NjA4_494b98e3-e6c9-452e-a20f-f0dcebc42bb3"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i35c9ecdf3caa44afb7674f4ff6cfa6bf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtNC0xLTEtMTY5NjA4_99d01828-a556-447b-8377-a55288cbab6b"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iab447034f3cb4a3f80c5615de06f525e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtNi0xLTEtMTY5NjA4_4d57d1da-66ec-4b71-9020-ae2cdb033104"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ice1298ccb8014e2e952b7df5ed8488c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtOC0xLTEtMTY5NjA4_f126cdcf-2ae8-4986-8352-603f6a355c91"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2ec7611adc424942b82f55c3fddc6e0c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMTAtMS0xLTE2OTYwOA_02dde61e-2710-4765-8ba0-c4bafbff775a"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzEtMTItMS0xLTE2OTYwOA_77f59811-53ac-4cc2-9d75-8faf85b3774b"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMi0xLTEtMTY5NjA4_d6d867cc-e463-4301-9297-e1f4e5595562"
      unitRef="usd">625000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItNC0xLTEtMTY5NjA4_07c72923-7006-4837-98e8-a0dc1cb21b74"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItNi0xLTEtMTY5NjA4_65aa9de1-029f-46de-b010-747b5726f31d"
      unitRef="usd">2462000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItOC0xLTEtMTY5NjA4_b1d3780e-9295-4adf-b2c5-4c106e22dc9d"
      unitRef="usd">1999000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMTAtMS0xLTE2OTYwOA_a05d3e84-3d72-457a-b093-6040c959ec55"
      unitRef="usd">211000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzItMTItMS0xLTE2OTYwOA_00f23e63-6dd6-4d76-a4c6-12cd1f6f971d"
      unitRef="usd">5428000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i944c81103c344e2389a0354c7176c5b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMi0xLTEtMTY5NjA4_bdf27bbc-8348-45b6-aa67-7a85a5abede6"
      unitRef="usd">593000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtNC0xLTEtMTY5NjA4_2e26c13d-b68b-4700-913b-4d8b08b4582a"
      unitRef="usd">224000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i89b8dd414ac44881aa01d8c684677000_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtNi0xLTEtMTY5NjA4_09f4d17a-a920-425a-9216-0395c21cbcca"
      unitRef="usd">2297000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i4bd4a396c8154937b48ccbcb37844020_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtOC0xLTEtMTY5NjA4_04dc3312-f501-4b84-8d73-469290dd2f44"
      unitRef="usd">2013000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie3b1bf380cf24687a6ab739885cb703a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMTAtMS0xLTE2OTYwOA_cf4c0013-6ae9-497b-9304-11ae8a246d5d"
      unitRef="usd">251000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzMtMTItMS0xLTE2OTYwOA_e96f145f-e12f-4860-8fe2-215bb434b1b3"
      unitRef="usd">5378000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i03f3ba9f79754b2ea2362524743f75b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMi0xLTEtMTY5NjA4_096b5c49-4df1-4b89-b303-2335ebeaa023"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iaa6fc4c28dfc4f42aa151ae93e67746a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtNC0xLTEtMTY5NjA4_c000d0a0-94b3-4dd1-a63f-85188e6e7eca"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibcd7e5042c154abd8c3fb0ba3a5333b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtNi0xLTEtMTY5NjA4_af769179-01a4-4d25-a947-ab957425418e"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i719c1c8681de42628cd8a33f7cf93c13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtOC0xLTEtMTY5NjA4_51fe56fa-ceb2-44d7-8741-2d500255531c"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2ffab7018d0f4f64a53a07c03c589447_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMTAtMS0xLTE2OTYwOA_a5bb3364-50e8-414b-8448-56cd2f27ac38"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzQtMTItMS0xLTE2OTYwOA_34126a7c-9582-47e3-a0d0-e20471d557c0"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMi0xLTEtMTY5NjA4_d8f26d02-1372-428c-adc1-53031235e703"
      unitRef="usd">571000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtNC0xLTEtMTY5NjA4_d608d20a-97a5-4193-86f5-796291abca4c"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtNi0xLTEtMTY5NjA4_d800e88f-01b6-4d76-9ce6-17d2b44b6504"
      unitRef="usd">2587000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtOC0xLTEtMTY5NjA4_68120421-1219-4da6-961b-e0e76f99ce0d"
      unitRef="usd">2064000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9afa3f38b75645c38047038819ab8039_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMTAtMS0xLTE2OTYwOA_91c5eb1e-2152-4af8-888b-e8605d89727f"
      unitRef="usd">218000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzUtMTItMS0xLTE2OTYwOA_cde888f6-19b2-4afa-abcd-480df174234d"
      unitRef="usd">5571000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i25a6e72128cb46408f358906d6cca26d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMi0xLTEtMTY5NjA4_4e3e7a25-db8a-4808-a5b1-c9c7ca9c4c86"
      unitRef="usd">605000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtNC0xLTEtMTY5NjA4_1639a179-6416-4ab5-bbc9-d14c17d7c5ef"
      unitRef="usd">186000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icfb7fada74874a92adef903d1aa46d02_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtNi0xLTEtMTY5NjA4_a3af2318-a27d-4566-9e42-ee7e606626f5"
      unitRef="usd">2508000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib4af5b8e21f74db586578b1ee56ba0c6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtOC0xLTEtMTY5NjA4_e7bbec91-57e2-46f7-ade6-4688f9bb9e1b"
      unitRef="usd">2038000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9afa3f38b75645c38047038819ab8039_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMTAtMS0xLTE2OTYwOA_f3ae2dff-de21-48eb-b2b0-fa9376d9356a"
      unitRef="usd">187000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzYtMTItMS0xLTE2OTYwOA_a67f5dce-70e4-47b4-a3c9-2c689afdbf42"
      unitRef="usd">5524000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0af36779781240ea8b5a9fc2a8a18c0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMi0xLTEtMTY5NjA4_b45571e6-5a31-4d17-913a-b815cab12c38"
      unitRef="usd">188000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie9b3071dbd0b4c22a7410dae4bf7b27e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctNC0xLTEtMTY5NjA4_f18a0edb-9cb6-498b-a755-89a0c6c8db2a"
      unitRef="usd">427000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib5f6251d34e449328ee02711fb471754_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctNi0xLTEtMTY5NjA4_3c8335dd-36c0-4b78-8ccb-981f4e98611f"
      unitRef="usd">1023000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i22b3dad0951e4afdafdd9832d60755e6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctOC0xLTEtMTY5NjA4_367b73ad-094c-41f2-8a9c-7836cbe501e6"
      unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5a778a0ae49a449791a3ba321887c7e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMTAtMS0xLTE2OTYwOA_ccf2d8db-7753-4baf-b8da-03e3e73b35fb"
      unitRef="usd">76000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90YWJsZTpmM2RhMjZhODIyZTk0ODk1OWE1YjAyNTAyNWI5YmExYi90YWJsZXJhbmdlOmYzZGEyNmE4MjJlOTQ4OTU5YTViMDI1MDI1YjliYTFiXzctMTItMS0xLTE2OTYwOA_9003aed2-ec87-4b1c-b9a5-15e8f8c995c3"
      unitRef="usd">1910000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic1634ddcaf934a68ad0cbcba62dae846_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI2OTQ3_3c89bfef-ec52-4fed-8efe-9f3f4a0eece1"
      unitRef="usd">40000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i12975a1db9344dbda6b24ceb8ae4993b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI2OTU0_497f8447-4682-4959-8d4f-af28abf2f7dd"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:CashDiscountsAndAllowancesSettlementPeriod
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzI5NDUz_ddf974de-ff1f-48a9-bcc8-bb1465a7b871">P1M</bhc:CashDiscountsAndAllowancesSettlementPeriod>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMTc3_859e9cf4-acde-423a-98d9-20010aef4e19"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMTc3_b745aa0f-e1a8-4b3f-9364-3f00f6d01d79"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i8cb22790a09946568e706e1fa09edcd0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMzE5_62ddc654-c407-4d59-9456-2bcbc7614241"
      unitRef="usd">-21000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i0c4d6febee424de7b7e85dcd5d13a7bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzMzMzI2_9d9e111c-05c2-4b7c-98f9-c6a2f2d25719"
      unitRef="usd">-28000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc88addf22a44ee8b85946edc015b2db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5MTA5_da81a542-be2c-4a9c-b9ca-3c64c2262c32"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i879910dcddad4e1ba3539787593b400e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5MTE2_2be397bf-8b0c-4dd8-a6fe-662b5b6d6b68"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="i3066bc5404d6492ba2a9b0f3e2e60f4e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzM5OTMz_4eae5ac7-68da-460a-a657-fc758f423b02">P90D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3d9a436ca4734f6f94506b064f541daf_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMDg1_dff224df-09ee-49bc-a68a-d14bfccc10c8">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i3d9a436ca4734f6f94506b064f541daf_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQwMTc5_26d12a7e-2aed-4a34-ac69-bff62b68c6be">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTgw_f284532f-db47-490a-bc73-82e5bf9202ba">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTQz_95db29ab-e9f7-43e4-8cea-7afe5305b8a3">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sale of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDQ2_c159cbee-d61a-4b31-862e-0a5c204fd83f">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjU3_d9763f59-761b-4214-a06d-46c914766d85"
      unitRef="usd">518000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjYx_c23b0bdf-e45b-4d67-9ace-5461ee20445f"
      unitRef="usd">515000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ0NjY4_15915bb1-8f14-4652-96fb-03596ab420fb"
      unitRef="usd">451000000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDc1_c86803fc-85a9-46ce-a29c-d12cc81b3c1a">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDgz_5dc10af9-de21-4a97-a3cd-e56629ef1462">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company&#x2019;s cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:InterestCostsCapitalized
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ2NTky_cb5ca372-f5fa-47c1-b11f-acfd08ba9404"
      unitRef="usd">66000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ2NTk5_0e459049-2c10-44f9-abb7-8c14061d0956"
      unitRef="usd">60000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MjIx_b7a06343-331a-4b3e-be3d-e95435fa0cd7">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <bhc:TaxBenefitRecognitionMeasurementPercentage
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ3Njgz_deae431a-df4f-4b0c-babf-aeb4069a7bcf"
      unitRef="number">0.50</bhc:TaxBenefitRecognitionMeasurementPercentage>
    <bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzQ3ODQ2_788f707c-75f3-4cf4-8759-b8dd28849916">P1Y</bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTc3_94ca78bd-02b2-4adf-afe7-4b095b4f588b">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. &lt;/span&gt;&lt;/div&gt;Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MTM4_84757d0f-3d75-4c14-a639-011e044099ec">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive loss. Other comprehensive loss includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDE0_d7ba23eb-9208-4601-9576-1511c8944a9d">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDk0_8a719ee8-7a9e-4442-b1aa-4c457c10abea">Employee Benefit Plans The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzUwNTY0_b49b0194-2219-48ca-9e45-0e7b1137017e"
      unitRef="number">0.10</bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzU0MDI3_d5a74000-d324-4b77-993c-1db58ccd4e86">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses. The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company&#x2019;s results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company&#x2019;s disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance was effective for the Company beginning January 1, 2021.&#160;The application of this guidance did not have a material effect on the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160;Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities &lt;/span&gt;&lt;/div&gt;as of March 12, 2020, through December 31, 2024. For the years presented, the Company has not entered into any contract modifications in which the optional expedients were applied.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide2fd41a841048ed9b2fa9f9b0744e68_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTYvZnJhZzoyMDU5Nzc3NDg5YjI0OTlhOTllNDU0OGIyYTVkZjM3ZC90ZXh0cmVnaW9uOjIwNTk3Nzc0ODliMjQ5OWE5OWU0NTQ4YjJhNWRmMzdkXzUxNTU1_22b38246-9d5f-49a2-aa72-fa85aa09f052"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bhc:AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzY1Nzk_06270414-a497-428d-8784-57711486ac07">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paragon BioTeck, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2022, Bausch + Lomb acquired Paragon BioTeck, Inc., an eye-care focused drug development company, having a primary emphasis on the early detection of ocular diseases. The acquisition of Paragon Bioteck has been accounted for as an asset acquisition. The primary assets in the transaction, the trademarks, represented substantially all of the fair value of the gross assets acquired. There are no future sales milestones associated with this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Total Titanium&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2022, Bausch + Lomb acquired Total Titanium, Inc., a privately held ophthalmic microsurgical instrument and machined parts manufacturing company. The transaction was completed to assist in driving revenue growth as well as increasing manufacturing capacity. The fair value of the acquisition has been accounted for as a business combination. Additional contingent payments may be payable upon reaching key future milestone achievements related to sales and employee retention.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these transactions, recorded within the Consolidated Balance Sheet are Trade receivables, net of $1&#160;million, Inventories, net of $1&#160;million, Property, plant and equipment of $2&#160;million, Intangibles, net of $43&#160;million, Goodwill of $5&#160;million and Deferred tax liabilities, net of $11&#160;million. Supplemental pro forma information related to revenue and earnings for 2022 were not provided for the aforementioned transaction as they did not have a material impact on the Company&#x2019;s operations. Refer to Note 21, &#x201c;COMMITMENTS AND CONTINGENCIES&#x201d; for further detail regarding potential future milestone payments related to previously entered transactions and agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun Pharmaceutical Company S.A.E. (&#x201c;Amoun&#x201d;) for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International Rx segment (previously included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Consolidated Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.&lt;/span&gt;&lt;/div&gt;</bhc:AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3Njc_80d4d129-d323-4490-a905-778adc823455"
      unitRef="usd">1000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3Nzk_a39dafe2-f1be-40b2-b5ba-ea7cf5a97599"
      unitRef="usd">1000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk3OTE_81245ccf-616b-4170-b909-130541966aae"
      unitRef="usd">2000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4MDM_09ed35c1-6cbc-4601-bc0a-26bbe682b8a6"
      unitRef="usd">43000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4MTY_c5741357-b352-47a8-8b3e-60340268ae86"
      unitRef="usd">5000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="idc7ef7f347f1406097fd27ec7b96cc69_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzEwOTk1MTE2Njk4Mjg_45459ca5-f052-4207-b77c-0dbfa4e13feb"
      unitRef="usd">11000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i7f28cdba1c984df9bb56e87ea0c43627_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzQ3NzE_fbd42408-1721-4161-84bf-d2f838f662fa"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i6d21286a1db84d29b25753aac5f56c63_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzU3MTY_ff26ddc7-6e65-4cc3-91f3-fcd001d3023d"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="idefdc69a4d2748c3a652f4a956103762_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzU4MDQ_95451280-57b6-48f3-8402-1379c6c6679b"
      unitRef="usd">88000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i524d6ebfb9f44cdab7f8e33886bbb169_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYwMzE_c12d32a2-2127-4f77-a1fe-bab4f156d1da"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYxNTE_8966fc2c-e234-44ad-9354-e8498cbb1106"
      unitRef="usd">210000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <bhc:NoncashCumulativeForeignCurrencyTranslationLoss
      contextRef="i9d4b89ad9dcb4fbf898113d44d330b61_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMTkvZnJhZzplOGMxZjNhZTFjNzM0ZjhjODZkZDU4N2NkMWQ1OWI2OS90ZXh0cmVnaW9uOmU4YzFmM2FlMWM3MzRmOGM4NmRkNTg3Y2QxZDU5YjY5XzYyMzc_8caa6444-a9fb-40ca-a31e-b98dcc2679a5"
      unitRef="usd">340000000</bhc:NoncashCumulativeForeignCurrencyTranslationLoss>
    <bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIzODI_6be903ca-8969-4b3b-99b0-2e3551d9a699">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and integration costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2022 was $12 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $30&#160;million, $18&#160;million and $11&#160;million of restructuring and integration-related costs and made payments of $41&#160;million, $19&#160;million and $18 million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation costs, Separation-related costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022 and 2021, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2022 and 2021 are Separation and IPO costs of $33&#160;million and $32&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2022 and 2021 are Separation-related and IPO-related costs of $94&#160;million and $132&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="iebf28d9434964d1dba31bb27dbb684d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY1OA_02e83f20-4f18-4d3c-abdc-20503babc1d1"
      unitRef="usd">12000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY4Mw_07571652-7011-4d00-ae9c-23a35b8682b4"
      unitRef="usd">30000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY4Nw_64dfef02-477f-47cd-a824-b37352e6d049"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzY5NA_21376adb-3577-4d4d-b1b2-5261de337fa4"
      unitRef="usd">11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <bhc:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE2NDkyNjc0NDU3MDk_0606c3ba-99d4-4052-9fd9-143598f22791">restructuring and integration-related costs</bhc:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:PaymentsForRestructuring
      contextRef="i22a7fd37bcc94d12a267548ed184b222_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc2NQ_ee278414-4ef2-43f2-b96f-b9d7a47d3086"
      unitRef="usd">41000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ib304a40e58ef4e0b9305a86397648f6e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc2OQ_48f005b1-2f0e-4e5e-a56a-06f12e575bb7"
      unitRef="usd">19000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4f6d46c0ff90442aa741379575bd6b3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzc3Ng_36f45a0d-eb14-493d-bc8b-2b67cc34fefb"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE3MTU_1c7bfdac-1ae8-4028-bb75-c00e6c3d22b7"
      unitRef="usd">33000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzE3MjI_daae52ff-abd6-40ab-9e8c-f0dcaa503897"
      unitRef="usd">32000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i327d87b02b0640feb60097a33ef1d913_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIyMzY_de3e47da-4ee6-4e1e-9858-a896837fae9e"
      unitRef="usd">94000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaaf0466880b84be8854c3689ada1d2d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjIvZnJhZzowYjBkZjVhMDJlN2I0YWU2OTBjN2ZiMzNkMjNhNzA5Yi90ZXh0cmVnaW9uOjBiMGRmNWEwMmU3YjRhZTY5MGM3ZmIzM2QyM2E3MDliXzIyNDM_f2f16f67-00c9-458c-b67d-6b1683ea0625"
      unitRef="usd">132000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MzI_7c694c80-9e46-4dc6-ad57-8c227e29caee">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of December 31, 2022 includes $380&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, Restricted cash and other settlement deposits included $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding certain U.S. securities litigation, which was subject to one objector&#x2019;s appeal of the final court approval and the Glumetza Antitrust Litigation. With respect to the U.S. Securities Litigation, the period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the securities litigation settlement and judgment have become &#x201c;final&#x201d;, as no more appeals can be filed. As a result, the Company&#x2019;s rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company&#x2019;s Consolidated Balance Sheets, by $1,210&#160;million during the third quarter of 2022. See &#x201c;U.S. Securities Litigation - Opt -Out Litigation&#x201d; of Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d; for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss. As of December 31, 2021, there were no cross-currency swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps (the &#x201c;2022 Cross-Currency Swaps&#x201d;), with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#x2019;s investment in certain Bausch + Lomb euro-denominated subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest settlement of the 2022 Cross-Currency Swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 Cross-Currency Swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022 and 2021, the Company received $0 and $27&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Company entered into foreign currency exchange contracts. As of December&#160;31, 2022, these contracts had an aggregate outstanding notional amount of $455&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#x2019;s relative fair value at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of December&#160;31, 2022 and 2021 was $14,011 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjM_9a9568ff-7ca1-401a-998f-03fdb4ee9ea4">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.242%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ide1f360554f7411582424cb25e12139f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMi0xLTEtMTY5NjA4_bd36812a-2284-4734-98cd-4fbb236a8f0f"
      unitRef="usd">94000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i955e95f8176a41949983431111fba814_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtNC0xLTEtMTY5NjA4_7f1a0822-c482-4b33-bfd8-90930a412ecb"
      unitRef="usd">85000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic539170d6fff4d05972a7397e5960010_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtNi0xLTEtMTY5NjA4_3054d63f-f597-434a-a19e-47db73c05c09"
      unitRef="usd">9000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtOC0xLTEtMTY5NjA4_12ec3b7e-cb49-47d7-a347-87ac1883abec"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTAtMS0xLTE2OTYwOA_846c5c95-2d23-41d3-8309-80e0e526c897"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTItMS0xLTE2OTYwOA_ddadc037-d1bc-4315-93f4-5962cf5227c3"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTQtMS0xLTE2OTYwOA_0a70424c-119c-4ffb-ad48-7053327c2e10"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzMtMTYtMS0xLTE2OTYwOA_4bbc36ab-5523-474b-bcaa-416205b62542"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ide1f360554f7411582424cb25e12139f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMi0xLTEtMTY5NjA4_d5702d0e-31c2-4116-ad58-220dcd6a64a2"
      unitRef="usd">27000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i955e95f8176a41949983431111fba814_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtNC0xLTEtMTY5NjA4_60c15d26-236c-4914-9b9a-0bd0b33f9fe4"
      unitRef="usd">27000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ic539170d6fff4d05972a7397e5960010_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtNi0xLTEtMTY5NjA4_fc45a433-a157-4d7d-84ae-047716a3b5c2"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtOC0xLTEtMTY5NjA4_e2c8eff1-2e5d-486f-a950-d4d94ae16f48"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTAtMS0xLTE2OTYwOA_7d169576-f7cf-47be-9c69-c370b5a8d437"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTItMS0xLTE2OTYwOA_2583047c-4943-407f-9110-be013e838121"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTQtMS0xLTE2OTYwOA_7474be01-b6aa-457d-968a-af355073f430"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzQtMTYtMS0xLTE2OTYwOA_ae2b3a78-2814-41ac-a64b-b4c68f5b4bdf"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMi0xLTEtMTY5NjA4_97d505d7-d4c9-4d97-8047-f5d41efe6369"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtNC0xLTEtMTY5NjA4_0ddc5ac4-7ab5-44a7-9682-ff9d66e2f130"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtNi0xLTEtMTY5NjA4_b0b7e9fb-e8c2-4991-87d5-bb6819c797d2"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtOC0xLTEtMTY5NjA4_1fb6b30a-f95b-4327-b08f-09a2438f968b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTAtMS0xLTE2OTYwOA_a4433082-5283-487c-9dbd-ab90bf839ff3"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTItMS0xLTE2OTYwOA_fad02fde-0027-4d8f-b428-c201c326e1a7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTQtMS0xLTE2OTYwOA_f152eac9-1c6c-4c68-a4df-39049d85a293"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i85324249cb304f399a6dfe976b7fe743_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzUtMTYtMS0xLTE2OTYwOA_729e275b-da08-42b7-b396-90ac9dedffa5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ide1f360554f7411582424cb25e12139f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMi0xLTEtMTY5NjA4_3198768f-80d6-45d7-a58b-02311bed435e"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i955e95f8176a41949983431111fba814_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctNC0xLTEtMTY5NjA4_1a1e4f2f-1350-4100-956f-12d6dfe03361"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ic539170d6fff4d05972a7397e5960010_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctNi0xLTEtMTY5NjA4_6a4c7f74-fecb-4ef5-a079-0fcc76799914"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i3360f8949ed24c0b940f86ac34748add_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctOC0xLTEtMTY5NjA4_f7b719b0-bd3d-4bba-87fd-7618db3e2902"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i96ca3e5e97be45d19824357bc3ee379e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTAtMS0xLTE2OTYwOA_d7379a36-0bef-4c0c-bd03-1ac0194e046b"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="iccec48614f5d4821a0e8b30e1252d2b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTItMS0xLTE2OTYwOA_b096fb1d-6c3c-4eec-89ec-d70670501ee8"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i17110427cd8e4e619785b7b0d32f0f70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTQtMS0xLTE2OTYwOA_40815bdc-0f64-41ae-ac4d-05da897d436b"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ibbc775b178554f5cbfa0bd80dfded44e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzctMTYtMS0xLTE2OTYwOA_b88b97df-8217-4bd7-aff6-3302f7278643"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i8a3da17c145a49f8b5870436902391af_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMi0xLTEtMjAzMzA4_3071fc09-5bdb-42b4-ba21-731f4e3aedf7"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2117911a26c0491389f1d3defbed0a7d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtNC0xLTEtMjAzMzA4_f42ea785-68d5-4d5c-be42-3ffd9034201f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id71f74f577b3494b8e2ac929500c8376_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtNi0xLTEtMjAzMzA4_4cb3c97c-f66e-4f1e-9c70-88a64d44aba5"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i019d338e616445d7a5081ae3d42d3429_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtOC0xLTEtMjAzMzA4_fa097157-f494-4b3d-8ec2-6d8289b8db22"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4c2af8e02fe54c78b7f35ee1a9e11c90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTAtMS0xLTIwMzMwOA_bc100d42-8d06-4045-aeee-2184a1495478"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id050355187a44ec58d9dae39638c996e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTItMS0xLTIwMzMwOA_e8397c68-8d27-4893-913a-2c02c1933188"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0359fde753a243faa8a6b23ba6f302f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTQtMS0xLTIwMzMwOA_66be8146-97cb-4e59-a4a3-39195c4ec430"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic910749763294350870635de86bbe6aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzgtMTYtMS0xLTIwMzMwOA_7b79f619-4118-42dd-b42f-fb3dc15cca06"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i555f2fd9b2bb4e569f7adcc19ee4d3f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMi0xLTEtMjAzMzA4_376eafc5-befd-46b7-86c6-c7a99289a27a"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i399dedc9804b4c02a9afcf58d1f1ff0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktNC0xLTEtMjAzMzA4_a5715b91-2e05-4203-890a-24a0f7d63529"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3511fa8243aa41d9bb2d2e8679f3cb9c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktNi0xLTEtMjAzMzA4_55db2cd1-9c84-4a3d-aa95-4b5eaa6f0fc8"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icb6a9f29e3fd4527808a0df8ae4fa6a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktOC0xLTEtMjAzMzA4_04d582bd-ccb4-4355-8dc8-d8e9b4f52585"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3be6bd54d3804fe28dd9fe889d4be1a2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTAtMS0xLTIwMzMwOA_0ab9cb15-cff5-434f-82e8-083bd1ed2745"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4aa6947ab17c4737a3eed6b0202d89bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTItMS0xLTIwMzMwOA_190d0a41-2a77-4af9-b17d-dc69b03aba4f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie92cfb60859d4ec0a1605dcfa905ba1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTQtMS0xLTIwMzMwOA_f267b2ec-f147-4c55-9f3d-2d183d422204"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i85324249cb304f399a6dfe976b7fe743_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmOGNkMjJiODg2YmI0NWY2OGQ3YjBjM2ViMGRjOTgxYS90YWJsZXJhbmdlOmY4Y2QyMmI4ODZiYjQ1ZjY4ZDdiMGMzZWIwZGM5ODFhXzktMTYtMS0xLTIwMzMwOA_c64aa301-3dd9-4a75-a5e2-0c292377ce9f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzEzODk_f73e2c97-3d6d-4a65-88d1-668f7e444b01">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i46e9550a1a424a89b1dee40213b0de3d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2NDg_90306d6e-7e6e-4e60-978c-bf4bd122a63a"
      unitRef="usd">380000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i32b90092334445a8849506fc89a086ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2NjI_1a4b39d4-a0d0-4a12-9f17-090db4450e79"
      unitRef="usd">1510000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LitigationSettlementNumberOfObjectorsAppeals
      contextRef="ic7a4eaca0ff74acda11e62ff530e7678_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2Nzc_858a9a5c-8210-4759-8f82-95f5b0796ac3"
      unitRef="appeal">1</bhc:LitigationSettlementNumberOfObjectorsAppeals>
    <bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent
      contextRef="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2ODY_121e0990-8d01-4617-b1cc-1473b3d1a364"
      unitRef="usd">-1210000000</bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent>
    <bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ic90053e48f4b475c87f96f34d162504a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc2ODY_9680efa4-7381-47fa-9eff-10228c190ebc"
      unitRef="usd">-1210000000</bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia5f44a4aff374a1ca74b044ad084bef4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDI4Mg_9faa5b80-e5b2-46e6-b82c-c6f0a7d5e057"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDcwNA_1c49bfde-e8af-42e9-8c2d-c48ea36c5c31"
      unitRef="usd">4000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDc0Mw_ce9ef390-ae7d-4981-9b44-87471a6e5c57"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i000ff44669fd472ba78d6de1cb550d21_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU0OTc1NTgzNDgxMQ_18d5484c-dd39-45ad-a512-ef0dd86b43cc"
      unitRef="usd">2000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i686c1137885f4b3fa7d3a9b34364ed73_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzE2NDkyNjc0NTc3MDI_5d23e0e5-890b-4e43-8489-def85e1726b1"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjA_04c90120-d69b-4b3e-b8ed-7f539c2625cd">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i73819dbe86f345268ddb7db8c71128b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzEtMS0xLTEtMTY5NjA4_3dc3e81b-1471-4a18-a4e5-0edcd1a87ccd"
      unitRef="usd">45000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i2f6823e843294bcd88d2a409c815988c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzEtMy0xLTEtMTY5NjA4_e7a58358-9470-4a30-b947-e16189fe0f10"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i1694f371b3534c56984cb0cfe3ef6fdb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzItMS0xLTEtMTY5NjA4_13ebe43a-7068-4e7b-a4af-5f6e13e41bad"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ia9a242b4bc754037b318a7c4cdf5b1fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzItMy0xLTEtMTY5NjA4_027b9312-1bc3-4079-b0cf-8045670a5bfa"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i681759bbcf4146c19403440ab8bc7434_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzMtMS0xLTEtMTY5NjA4_53a3cc97-0989-4494-a52f-416c216e21e6"
      unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i8dd1a2af87dd427db7a4b552da531b07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpmMDAwZWJjNGViYWY0MzU4OTRhNmM0Y2U2ZjljNWI1YS90YWJsZXJhbmdlOmYwMDBlYmM0ZWJhZjQzNTg5NGE2YzRjZTZmOWM1YjVhXzMtMy0xLTEtMTY5NjA4_63b37e45-f0cc-4445-b393-1d6bb5d19388"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MTE_d7cabdab-5690-4207-8b3e-3ca2ca874d19">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="id964973a928249758deda08b15dea7a2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzEtMS0xLTEtMTY5NjA4_8f84aed7-3740-4f25-a191-307811ad907f"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib2804a8dc9ae48539fdb9519f6b3726f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzEtMy0xLTEtMTY5NjA4_58325246-b98a-4e9f-8f7e-981bcc566941"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i5b4a269030174bbb968a2388290df2a9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzItMS0xLTEtMTY5NjA4_bcadff0c-2cae-4ff3-8648-9aace39b2be1"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i496ec6bb7c5c49b189881126f8ba44cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyNjQ0OWNmYjk1Y2I0ODNiYmM5NzllNmUzYWZiNzU1Ny90YWJsZXJhbmdlOjI2NDQ5Y2ZiOTVjYjQ4M2JiYzk3OWU2ZTNhZmI3NTU3XzItMy0xLTEtMTY5NjA4_ab358728-47b0-4934-9f22-85f6608c2ddd"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i2232f920079d4878afb7b64f68af1b49_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzMyOTg1MzQ5MDQ1NDM_6e1c546b-e0fb-4865-8005-f39c5fe6fa73"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i4a2a0cc3ed3047c0ad4ecaa58c71ceab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzMyMjY_491fccaa-d8c4-4257-8a21-55b439b5f2a9"
      unitRef="usd">27000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iab2851d6501645e39f0bde92ff897991_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzM1NzE_b28f864a-d7c6-4739-84f5-52d59e3cf52d"
      unitRef="usd">455000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ife4532439f68449aa15050571c32b49c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzEtMS0xLTEtMTY5NjA4_770bac45-06be-4515-b80c-668e39a025bf"
      unitRef="usd">-4000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ie158e865d7084cd7820657aac3a943d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzEtMy0xLTEtMTY5NjA4_13ff19d3-55ca-414e-bd18-dc9c13c52ec2"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i17f6b23e952b4a29adb188680f77e15f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzItMS0xLTEtMTY5NjA4_5018af59-8fe2-4449-bb91-5d7892f91a87"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib48f720a184c4ef7a34f2bd1ad005549_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzItMy0xLTEtMTY5NjA4_c337fa7c-5fce-4440-b702-16f212285b8b"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="iab2851d6501645e39f0bde92ff897991_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzMtMS0xLTEtMTY5NjA4_28a38559-23e2-4e9f-b751-92e885de7d19"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic8dd91ce28d94179ac8fb005c89c2151_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZToyMDY0ZmY3OGM5Yjc0N2I0ODkwN2FmYzU0YTBhYzZlMy90YWJsZXJhbmdlOjIwNjRmZjc4YzliNzQ3YjQ4OTA3YWZjNTRhMGFjNmUzXzMtMy0xLTEtMTY5NjA4_49eacb9d-f04f-4a8d-b89a-892136c0e372"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4Mjg_c2debf8c-dfea-4047-9525-74b34e272335">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzEtMS0xLTEtMTY5NjA4_0a6eb30b-ef83-4d1f-9373-8778e6762511"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ib340705dabb047c38f3e490247c25c10_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzEtMy0xLTEtMTY5NjA4_3620151e-d963-415b-be01-74ccb52c1150"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzItMS0xLTEtMTY5NjA4_c0fd6a7f-7382-4183-aab7-72c5a984a470"
      unitRef="usd">20000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="ib340705dabb047c38f3e490247c25c10_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYWZlMzc0YjdlZTI0YWM0YWJjNmE5YWJkZWM3OGMwZS90YWJsZXJhbmdlOmRhZmUzNzRiN2VlMjRhYzRhYmM2YTlhYmRlYzc4YzBlXzItMy0xLTEtMTY5NjA4_0ae42b1d-6cce-4951-b021-7164a489a976"
      unitRef="usd">17000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6298df68baef4a31a4dfad39a62b592c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ3NTY_22143c4d-db96-4462-8e7a-589ee95e68c6"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i21918f466bf24354a1c6d6444bc04589_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ3NjI_44201a20-f07c-4d88-b311-8f87a94972ba"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic90a06531e4448a48622699307e4ff02_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzQ4MjA_2e9659ab-db57-4818-aa6c-affb4a448dc3"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU4MjI_3b5fd58a-39f3-4141-8f90-ca0c894dad80">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEtNC0xLTEtMTY5NjA4_b026e669-887b-4280-8a07-c75720b558f4"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEtOC0xLTEtMTY5NjA4_02e9c034-8d7d-4583-9c72-c46ff0f98a74"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d01deeac67f4ce7862d6b348bdaf675_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzMtMi0xLTEtMTY5NjA4_0a801896-03cb-4c9c-8230-c72309f35719"
      unitRef="usd">16000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iec2d9d196bf448729e83961b2b2b79ef_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzMtNi0xLTEtMTY5NjA4_5e818052-cdbe-48a3-ac32-82198cbdd4d6"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i9a29668b30ec453bbf648449343ac881_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzQtMi0xLTEtMTY5NjA4_2222f192-7d07-4846-bf42-f83da8173e6b"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i536a23a0ae454cadbc22242f347ae91a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzQtNi0xLTEtMTY5NjA4_ceb474c5-f7c5-447e-ada5-a77ab3375fed"
      unitRef="usd">-6000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtMC0xLTEtMTY5NjA4_2fc25c3a-fe81-45c4-b834-9c67fe5e649f">Acquisition-related contingent consideration adjustments</bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtMC0xLTEtMTY5NjA4_f6b220cf-2591-4f65-821e-819255473f18">Acquisition-related contingent consideration adjustments</bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtNC0xLTEtMTY5NjA4_a7428265-829f-4b69-9165-c198a560e7ac"
      unitRef="usd">28000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzUtOC0xLTEtMTY5NjA4_7bd7a770-50a0-472a-959c-4ee8914fc993"
      unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzYtNC0xLTEtMTY5NjA4_de43908e-f6f9-4e68-9da9-0d4975a19257"
      unitRef="usd">28000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzYtOC0xLTEtMTY5NjA4_7d05787b-9aca-4fb1-a3f5-0748be1f796e"
      unitRef="usd">99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzctNC0xLTEtMTY5NjA4_9e15dff9-ffb8-4324-bda1-5d44f93084db"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzctOC0xLTEtMTY5NjA4_de45ca4c-fb1f-4095-a811-24a5fec64d8b"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzgtNC0xLTEtMTY5NjA4_90929267-a141-457e-9a1c-db14967e62c0"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzgtOC0xLTEtMTY5NjA4_bf28397b-3853-4801-83d0-b754ad18a3a2"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzktNC0xLTEtMTY5NjA4_433b5870-1884-411b-9c9d-6aaedee9f878"
      unitRef="usd">34000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzktOC0xLTEtMTY5NjA4_7c9adcf2-3efc-4572-862b-6fb434bdc769"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEwLTQtMS0xLTE2OTYwOA_78479711-21fa-4312-bd90-ad9a3602b10d"
      unitRef="usd">207000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90YWJsZTpkYzUyNDE0Y2VmOGY0ZjBjYjJlNmM0Yjk5NjUxMWRkNy90YWJsZXJhbmdlOmRjNTI0MTRjZWY4ZjRmMGNiMmU2YzRiOTk2NTExZGQ3XzEwLTgtMS0xLTE2OTYwOA_fa7353e7-ca34-4be9-a982-644f6545758a"
      unitRef="usd">202000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i301added27ee4e56a32e9279750f97a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU2ODg_2f0a5410-c182-4ced-a355-019418be2c2d"
      unitRef="usd">14011000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id6a10a38645a4e64ba544a15e76a1aac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjUvZnJhZzphNjAxMWZkM2UzZmE0MDRkYjhkMDg3NTFkNzlmYWJiYS90ZXh0cmVnaW9uOmE2MDExZmQzZTNmYTQwNGRiOGQwODc1MWQ3OWZhYmJhXzU2OTU_e744dcfe-897b-4f00-8d32-0b8d58eca889"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90ZXh0cmVnaW9uOmUzMGYzMmEwNGU4NTQzNWViODlkZmI3MjE4MGZmMTJkXzUz_f87b22b0-f6fd-49fd-a722-495716c82e75">INVENTORIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90ZXh0cmVnaW9uOmUzMGYzMmEwNGU4NTQzNWViODlkZmI3MjE4MGZmMTJkXzQ4_89d1c123-d0ed-4f80-aebe-479b1b24876d">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzEtMi0xLTEtMTY5NjA4_04253d12-62d2-477a-b659-161c5602228d"
      unitRef="usd">326000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzEtNC0xLTEtMTY5NjA4_db7ca277-7f03-4631-9ef4-6fe70ea7339f"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzItMi0xLTEtMTY5NjA4_ff5aba9b-9fad-48bf-88d5-644cf5a001e1"
      unitRef="usd">98000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzItNC0xLTEtMTY5NjA4_f80b78fd-4ac3-4abf-acf4-a04cf0a0b7de"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzMtMi0xLTEtMTY5NjA4_cb3d49ab-1bd4-4be7-9a24-4534c4b4eb97"
      unitRef="usd">666000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzMtNC0xLTEtMTY5NjA4_cd50c462-0fae-4af8-87d5-760e1d3372d7"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzQtMi0xLTEtMTY5NjA4_a5670c8d-c2d8-414b-add6-f73981da568f"
      unitRef="usd">1090000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMjgvZnJhZzplMzBmMzJhMDRlODU0MzVlYjg5ZGZiNzIxODBmZjEyZC90YWJsZToxNjE2NDI0NzIxZDU0MGUxYTIwOTEwNzRiZTJmYTEwNS90YWJsZXJhbmdlOjE2MTY0MjQ3MjFkNTQwZTFhMjA5MTA3NGJlMmZhMTA1XzQtNC0xLTEtMTY5NjA4_a30ca7ba-8046-42bb-a790-3a4320fb77db"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzE2Mg_92ee0894-0a83-4d7d-afd6-38f739de4573">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $179 million, $177 million and $180 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzE1Nw_9e16f508-08ad-4dd9-a876-7a8a2a99abc3">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i046977fe683b41e79f01810b4a036c3a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzEtMi0xLTEtMTY5NjA4_e353779f-dca9-4dab-9c97-c1ee402219bc"
      unitRef="usd">71000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd74bed9d620431aa82e098aceab060b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzEtNC0xLTEtMTY5NjA4_e9273849-6322-4f32-b6e5-d0df04989415"
      unitRef="usd">74000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5251c4b7112b46c6b9fc7a4f6cb910a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzItMi0xLTEtMTY5NjA4_115e024a-0892-4238-9edd-99c7946f11ea"
      unitRef="usd">798000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3f238094cdda40f1b2d7750a45917f53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzItNC0xLTEtMTY5NjA4_e7e0a4bc-2916-4609-a6fd-f21aab4c0f99"
      unitRef="usd">675000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic47f900acdec465e98ce7071671bb8e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzMtMi0xLTEtMTY5NjA4_0358efef-2bcb-471e-a787-648c6b1d8f9b"
      unitRef="usd">1951000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3cbea40e3c0740518b9890e6748531fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzMtNC0xLTEtMTY5NjA4_e637b9a5-e67d-47e6-808b-914b28cc220e"
      unitRef="usd">1678000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f9e292759354aeda24365245bac9d90_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzQtMi0xLTEtMTY5NjA4_5b0377cc-d91d-45b1-9839-131dba4993bf"
      unitRef="usd">342000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icb6b4338793a4025bda029ab360f1d32_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzQtNC0xLTEtMTY5NjA4_63e3a00b-2d8a-4a24-94ae-f59450d20822"
      unitRef="usd">342000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1da1f0ee4e9641a2a9e84287bf32dc6e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzUtMi0xLTEtMTY5NjA4_52d142c3-0e7f-49e7-a356-2fdc45734546"
      unitRef="usd">78000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic24b70b9839e4a32ae3eb6fcc78cbb99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzUtNC0xLTEtMTY5NjA4_e736eab6-0219-49d6-8222-e9e2943757dd"
      unitRef="usd">73000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic51c16e7f763491085dd8ffc5944f6eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzYtMi0xLTEtMTY5NjA4_4a2097ce-609c-4322-ac7f-e84acb60fea1"
      unitRef="usd">280000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iabdd5d523d9a4a00884669c513d28162_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzYtNC0xLTEtMTY5NjA4_d82e4f5f-baa6-47c5-9c3b-4819bd8a93d7"
      unitRef="usd">576000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzctMi0xLTEtMTY5NjA4_1c8da833-650b-46fc-a371-04211f240c1c"
      unitRef="usd">3520000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzctNC0xLTEtMTY5NjA4_6587e31c-c449-4ce3-8206-eefd434c2ef6"
      unitRef="usd">3418000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzgtMi0xLTEtMTY5NjA4_25055da6-d8da-4ff5-94dc-b754f4652c2e"
      unitRef="usd">1920000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzgtNC0xLTEtMTY5NjA4_2a4b1058-3034-4b64-9f7a-15a398c0ac61"
      unitRef="usd">1820000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzktMi0xLTEtMTY5NjA4_e30f6057-11d4-4849-ab40-e8ab2fac63ad"
      unitRef="usd">1600000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90YWJsZToxNTRhYzcxOWUzNjY0MDk4Yjc2MmMwZjM3NWZjYmQ3Yy90YWJsZXJhbmdlOjE1NGFjNzE5ZTM2NjQwOThiNzYyYzBmMzc1ZmNiZDdjXzktNC0xLTEtMTY5NjA4_0505a31a-f2e6-4edf-b020-e5e2f5ef0f12"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzEwNg_4519d49b-a124-44ef-b9fe-24dcceac2bd4"
      unitRef="usd">179000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzExMA_42489959-5d3f-4c8a-89b7-522bd30385bf"
      unitRef="usd">177000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzEvZnJhZzpmOGNiMTQ0OTdhNzg0OGFkODFjYWIwYTc1ZDRmNGZiNS90ZXh0cmVnaW9uOmY4Y2IxNDQ5N2E3ODQ4YWQ4MWNhYjBhNzVkNGY0ZmI1XzExNw_76730ad4-83ec-4c6c-b356-dfc9e5837fc0"
      unitRef="usd">180000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDEz_36ac6e42-12b9-42df-965b-c0796f78c4b4">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses, research and development expenses. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2022 were $15&#160;million and included: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating inflammatory bowel syndrome with diarrhea (&#x201c;IBS-D&#x201d;) were invalid (the &#x201c;Norwich Legal Decision&#x201d;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues were $1,216&#160;million and $1,194&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#x2019;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets as of September 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Based on these factors, no impairment to the carrying value of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets was identified as of December 31, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets was required. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets included in the audited Consolidated Balance Sheets had a carrying value of $2,693&#160;million and an estimated remaining useful life of 60 months as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; could be material to the results of operations of the Company in the period or periods in which they were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale as discussed in Note 3, &#x201c;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#x201d;, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company&#x2019;s core businesses and (iv) $1&#160;million related to Acquired IPR&amp;amp;D not in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Periodically, the Company&#x2019;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity (&#x201c;LOE&#x201d;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#x2019;s own branded generic or through a third-party). This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually assesses the useful lives related to the Company&#x2019;s long-lived assets to reflect the most current assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#x2019;s terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit&#x2019;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#x2019;s and a market participant&#x2019;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company&#x2019;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 Interim Impairment Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative impacts of the COVID-19 pandemic on the global economy led to significant volatility in the global equity markets and the Company was able to continue its operations with limited disruptions. In performing its assessment during 2020, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and made adjustments to the long-term forecasts used in previous goodwill impairment assessments, for these and other matters. After completing this assessment, the Company believed that, with the exception of the Ortho Dermatologics reporting unit, its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, did not indicate that the fair value of any reporting unit may be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company&#x2019;s forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. The quantitative fair value tests utilized the Company&#x2019;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the then respective quarter of 2020 which reflected current market conditions and current trends in business performance. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Annual Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020). The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the fourth quarter of 2020 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International Rx, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International Rx segment consisted of the International Rx reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#x2019;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International Rx reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International Rx reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International Rx and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2021 Impairment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the second quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2021 and September 30, 2021 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The Company&#x2019;s latest forecasts for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit&#x2019;s results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit&#x2019;s assets and were not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the fourth quarter of 2021 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2022 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2022 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2022 Interim Assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit as of March 31, 2022. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#x2019;s discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate had increased 1% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period May 6, 2022 (the time Bausch + Lomb&#x2019;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#x2019;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value tests utilized the Company&#x2019;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value tests utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;September 30, 2022 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections for the Ortho Dermatologics reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#x2019;s discounted cash flow model for the Ortho Dermatologics reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Ortho Dermatologics reporting unit had remaining goodwill of $480&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salix &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues represent approximately 80% of the Salix reporting unit&#x2019;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues are indicators that the Salix reporting unit&#x2019;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#x2019;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#x2019;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#x2019;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Annual Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurology and Other &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#x2019;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts, and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -2.5% and a discount rate of 10.25%, in the estimation of the reporting unit&#x2019;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#x2019;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $622&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $1,439&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of 2.0% and 3.0% and discount rates of 9.50% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than 25%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Ortho Dermatologics and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the impairment of goodwill in the third quarter of 2022, the Ortho Dermatologics reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit during the period October 1, 2022 through December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company evaluated the reporting unit&#x2019;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#x2019;s latest business strategies. This evaluation supported management&#x2019;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Ortho Dermatologics reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, given the reporting unit&#x2019;s limited headroom, any changes or other potential future developments may adversely impact the estimated fair value of the Ortho Dermatologics reporting unit in one or more future periods requiring an impairment to goodwill to be recognized. Any such impairment could be material to the Company&#x2019;s results of operations in the period in which it was to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salix &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022, and as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#x2019;s assessment as to a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#x2019;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#x2019;s latest business strategies. This evaluation supported management&#x2019;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. However, it is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix reporting unit in one or more future periods. Any such impairment could be material to the Company&#x2019;s results of operations in the period in which it were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through December&#160;31, 2022 were $5,004 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDMz_fe0f8fe3-26c0-4381-b581-ac89b4ca1ef2">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDM2_e9e75ba3-7eab-4ea8-98c3-bd2b7dab42f8">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMS0xLTEtMTY5NjA4_632dfe7c-458c-42ab-b3dc-ce388562a567">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMy0xLTEtMTY5NjA4_83ad21b3-8b85-4dcb-9ab5-274a1f125acf"
      unitRef="usd">20840000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtNS0xLTEtMTY5NjA4_49ebd07e-d095-46a7-88d5-59a2f1a0939e"
      unitRef="usd">17196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i93aa5bfa4146474da5d319dd6afdca60_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtNy0xLTEtMTY5NjA4_b893c60c-6dab-45c9-922b-c6643bc616f1"
      unitRef="usd">3644000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i72736a422df241408c61594fa909e273_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtOS0xLTEtMTY5NjA4_578ad635-acbc-4dd1-961f-334cea00412d"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i72736a422df241408c61594fa909e273_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMTEtMS0xLTE2OTYwOA_522894d3-9d32-48b3-b99f-b6c160a626f5"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i72736a422df241408c61594fa909e273_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzMtMTMtMS0xLTE2OTYwOA_8ab872ed-ac89-4aef-8dc7-26a7bb0e4554"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0b9fae444f1343bc9673dcae7bca4e9d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMS0xLTEtMTY5NjA4_b6d406c0-1aee-4ed6-8c00-feef8c045029">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMy0xLTEtMTY5NjA4_7bfdd079-9827-4e43-b909-c018e2862374"
      unitRef="usd">899000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtNS0xLTEtMTY5NjA4_ed3880f3-de29-4618-b90e-a819dc051378"
      unitRef="usd">542000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia9f982f471504a4d886d0828ec908c63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtNy0xLTEtMTY5NjA4_2d88e4fe-77bd-465a-808e-8fc72e1d27fb"
      unitRef="usd">357000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtOS0xLTEtMTY5NjA4_a7d03196-5b27-4f13-bee2-73c0eaae72af"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMTEtMS0xLTE2OTYwOA_b9599d95-67ac-41c2-9d68-365afa4683f8"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9d556e8c69b5410fac594e6bc3f63165_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzQtMTMtMS0xLTE2OTYwOA_4d630e8d-446f-4f69-9728-ea21320cc979"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i84a2da26e9934eb883d8c56c01e510d0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMS0xLTEtMTY5NjA4_0c2d3d9a-d06c-41c4-a8d0-83f0d1e8d722">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMy0xLTEtMTY5NjA4_a8c8d88f-a538-424d-a67e-68d6d9fc4451"
      unitRef="usd">3347000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtNS0xLTEtMTY5NjA4_674a61f1-eb1b-40de-9a99-ad214ee34e01"
      unitRef="usd">3251000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id13d7cff51ec4364a60ff99c788582e5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtNy0xLTEtMTY5NjA4_6e794bb1-494f-45f7-91bb-b2f5837f3ddd"
      unitRef="usd">96000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtOS0xLTEtMTY5NjA4_5be3887a-ac67-423e-aa18-4db94654e659"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMTEtMS0xLTE2OTYwOA_05776d65-0abf-452b-b431-da51a02f84aa"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ideec9371c4594543a2df71f87382e5d9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzUtMTMtMS0xLTE2OTYwOA_b1e693e1-d84c-4e14-879b-3ef3989f96a9"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1289ce27c69445a4b28904e412ddc6b4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMS0xLTEtMTY5NjA4_214075b2-2970-43b5-a47a-75d0e364e117">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMy0xLTEtMTY5NjA4_0cd27640-472d-4716-9c06-bbee7e9ff726"
      unitRef="usd">149000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtNS0xLTEtMTY5NjA4_db261d44-003a-483b-965d-8b39add35cef"
      unitRef="usd">149000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia83781ceb47d40ad91cb275c07538fe6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtNy0xLTEtMTY5NjA4_7df0aa41-07ef-4254-8714-bf79822dea2a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtOS0xLTEtMTY5NjA4_615294c9-d261-4809-a059-0c3233f4203a"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMTEtMS0xLTE2OTYwOA_58b3a24e-3143-41c5-9145-5d9ebf73a47e"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4c7187691ddb4f3baf53a15b1e780054_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzYtMTMtMS0xLTE2OTYwOA_d82b3a6e-0659-4d98-9bfe-e902680218e6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i03171de550654b9094b2686785213340_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMS0xLTEtMTY5NjA4_71cdb605-6f83-4760-8616-888218e30b3d">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMy0xLTEtMTY5NjA4_69591950-86c5-4d3a-b721-853b78db9a65"
      unitRef="usd">201000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctNS0xLTEtMTY5NjA4_688415b5-c42b-479a-86cb-ec6d3b88c9f8"
      unitRef="usd">196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i654780d358bc47d9b9208fc7318b418b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctNy0xLTEtMTY5NjA4_e50e2cc8-10cb-4198-9c79-bdda953d5a1c"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ied86354202574859ba53d8251730ef25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctOS0xLTEtMTY5NjA4_c53641f4-cf9a-4ca6-8aae-45e048ca0e45"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ied86354202574859ba53d8251730ef25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMTEtMS0xLTE2OTYwOA_b79ebf08-bd28-4f81-a640-53da7aadfa37"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ied86354202574859ba53d8251730ef25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzctMTMtMS0xLTE2OTYwOA_b63d7392-e45f-401c-a021-9c125eb3479b"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMy0xLTEtMTY5NjA4_578d9697-bbfc-4245-a3f9-8b41db4d4b99"
      unitRef="usd">25436000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtNS0xLTEtMTY5NjA4_bdc047a6-8e4c-43e4-9699-2a260b0d6eb1"
      unitRef="usd">21334000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtNy0xLTEtMTY5NjA4_9951b5b9-5aa4-4994-b0ad-18ee2b47033c"
      unitRef="usd">4102000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtOS0xLTEtMTY5NjA4_d25227a6-30a6-4d24-8700-f00406b0ef17"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMTEtMS0xLTE2OTYwOA_28d867d7-f4cc-4072-b376-7b466b3e575c"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzgtMTMtMS0xLTE2OTYwOA_ed39d62a-c409-45ad-8f8e-5e73bed36b0f"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i076eb2797d7b4496a5587e804a530855_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTMtMS0xLTE2OTYwOA_311aa6c5-689d-48bd-8806-a9d16c3c57d9"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i076eb2797d7b4496a5587e804a530855_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTctMS0xLTE2OTYwOA_c1a2c8d3-e8c8-4adc-a107-9527924627af"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic8779797f0c542ae8f67e21fea46bf5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTktMS0xLTE2OTYwOA_bfb1d6a7-77e2-4d06-8e63-1ea1217c58b1"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic8779797f0c542ae8f67e21fea46bf5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzEwLTEzLTEtMS0xNjk2MDg_a02535d9-f75a-4a2a-bb21-4aebf56e4b40"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTMtMS0xLTE2OTYwOA_7e18eec6-5125-43b6-97ac-93cadf363924"
      unitRef="usd">27134000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTUtMS0xLTE2OTYwOA_2d3fb085-9878-4d6b-b932-b04f08ef0f7e"
      unitRef="usd">21334000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTctMS0xLTE2OTYwOA_8a0a08a6-a02c-4205-accc-a79af41fd2d3"
      unitRef="usd">5800000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTktMS0xLTE2OTYwOA_a2dd47d1-0f37-4092-bf04-14d68897cfa8"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTExLTEtMS0xNjk2MDg_cd1f4e3e-1987-4e31-95cf-563262730f8c"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTo0NWI5ZjZkZjM3ZmM0NjQzOWEyOWE2M2RhNTJjNTQzMy90YWJsZXJhbmdlOjQ1YjlmNmRmMzdmYzQ2NDM5YTI5YTYzZGE1MmM1NDMzXzExLTEzLTEtMS0xNjk2MDg_b696569d-4c3f-4efa-9a83-1acb5767b72d"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE2ODY3NTk_5890b0cb-31ff-42d7-96b1-8df7ce48d3d0"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2MzQ_15fa253c-9263-43de-8457-d80059a6d3d4">impairments</bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2MzY_9e23bbdb-1648-4150-bed7-af5ea71e7ead"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i81dc99f8258b4049aee820556d44657d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTU2NDk_9fcc4ee2-06c1-4344-a817-b515ef811455"
      unitRef="usd">5000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTk5NzQ_a4e0b411-2cb5-436f-8d2f-742c6d6acd6c"
      unitRef="usd">1216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90d4fc2538f545c38a76406207865da4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1MDAwMDU_8cb5e1d2-3df6-48c0-8194-9eb34a666530"
      unitRef="usd">1194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ic9971091867b4c49bc0d165d080d95a5_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0OTg3NjM_28bf6c37-bfc5-41fb-a3e1-79c7cb4e954b"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i2847dfc8dcef4913b6cf4a248d8cb28d_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1MDAwMjM_183a3c6e-cb2c-444b-b7a8-4f4b3cadf64f"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ec174dd9a974db9a84eee065064aebc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTkyMTU2Mw_a72bc7d0-a8d2-4694-b9e2-85cf1da6fde9"
      unitRef="usd">2693000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i169507177c8d4101a372b9c100f98ae2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTkyMTYwOQ_f13dab8b-2ee6-49f3-9d42-1aaeef1a7199">P60M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1Mjk_854cbdb9-52ff-474b-a4df-36a71ada4875">impairments</bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ia131f8f45b8e4955bded72abc02da48e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzYwNg_8e5021a4-95d5-4581-9af7-99f7acc1ee0b"
      unitRef="usd">105000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzY5NQ_c1fd5b8f-b31c-4c98-ae4a-6d12e7e1cbc5"
      unitRef="usd">88000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i9fd14aff977d4b488fc11c018551212d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1Xzc4Mw_735c1a08-be37-4e6e-8fa1-2283d62a0e11"
      unitRef="usd">23000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i5894755ae0f14e1abd383f2cc912473b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1Xzg2NQ_1e8497db-0e10-4d00-91f5-32398c6bfeb0"
      unitRef="usd">18000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="ibd356ccb740d484fac8d36718bbab19d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMTA_30b7e1c0-7837-47bd-ad27-64ea76fd87c8"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0672a8f98ecd4dec9b3ca1e0bb2cd304_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMjM_8948107d-7a27-4af0-8e83-ab862f2bc77f"
      unitRef="usd">16000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6cf428232eff4699b8da41866a4f1306_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzMzY_2984d71c-4c80-420d-b023-d1105a287b5a"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6fc58ca927074377a059e6afb1cdbc07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNDg_74acf6ca-0c76-428e-92bc-eebb5e9b4ff2"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDEy_67a8c962-1893-4ea6-ad0b-5c78961563b1">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMi0xLTEtMTY5NjA4_6dae1cad-6937-41b9-8251-c5a9a2eef52d"
      unitRef="usd">1027000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtNC0xLTEtMTY5NjA4_f405818b-9fee-4004-a1e8-36c9a246a3d7"
      unitRef="usd">904000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtNi0xLTEtMTY5NjA4_632adbea-6fcd-4246-8fab-e3e24fdef84e"
      unitRef="usd">798000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtOC0xLTEtMTY5NjA4_8bf86cfd-5767-4ba6-a94d-5f6a36cec11a"
      unitRef="usd">670000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTAtMS0xLTE2OTYwOA_3b177a16-21eb-4a1b-9c6f-caa5cb5729e5"
      unitRef="usd">633000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTItMS0xLTE2OTYwOA_8b41d5b1-c00d-4e93-8691-9b0351b0dbf9"
      unitRef="usd">70000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTpmNzk1ZDIyZTNkNzU0ZTE3YjUzYzRiYTE0NGUyNGJhYy90YWJsZXJhbmdlOmY3OTVkMjJlM2Q3NTRlMTdiNTNjNGJhMTQ0ZTI0YmFjXzEtMTQtMS0xLTE2OTYwOA_08d9cc4d-4afe-4dcb-9346-208b5aa19e04"
      unitRef="usd">4102000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDQ3_a1bfc2b2-6f8e-412a-a3d1-f0d20513699e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ida153af5024646c5860c4d0e1d881318_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMi0xLTEtMTY5NjA4_b9ec54ee-f0ea-41f7-92c6-99ffe0771f8f"
      unitRef="usd">5786000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibd69ca9b861e4a609f1e5f5da66792b9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtNC0xLTEtMTc5ODI5_622f22ef-bd63-4f4a-bed9-4c177c3b874e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2d069e331e9d4278a420482bdaf3f937_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtNi0xLTEtMTY5NjA4_c08990d7-690a-43aa-9f24-acc76e1cfbab"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7dd4d61250f445c8a4800bb452ccef13_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtOC0xLTEtMTc5ODQx_2d5623a9-ec28-42fd-9e32-a77a1ec6c320"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0924cb562dd24071ba12d72afe82bbec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTAtMS0xLTE2OTYwOA_09709b08-f27a-4197-8971-d5375f5555dd"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5ddf60ecd98b4f768f11e6a38f661960_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTItMS0xLTE3OTg1Nw_a0b7219d-c7a3-4665-97d8-e9c2f1f0dfda"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaa0deab0ec61405097152c610065909b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTItMS0xLTE2OTYwOA_c207599a-81a0-4f15-9c2d-c7fed9f30221"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEtMTQtMS0xLTE2OTYwOA_e15923f3-b009-4967-b043-4aad3c30bfac"
      unitRef="usd">13126000000</us-gaap:Goodwill>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMi0xLTEtMTc5ODMx_f960e0ef-725e-41e9-88fb-13dd78d1f2fe"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItNC0xLTEtMTc5ODI5_7ffefa99-6c0e-44a6-b9f8-a8dd4152f494"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItNi0xLTEtMTY5NjA4_4a5124e4-8825-471b-995d-ebb79d11bb71"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItOC0xLTEtMTc5ODQx_0f1e7e8f-6fee-4f25-9a4f-35ed5f3241f8"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTAtMS0xLTE3OTg0NQ_4a2742c8-d04d-4f47-9609-df9faee255d7"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTItMS0xLTE3OTg1Nw_d410fa9f-c61f-4aa4-b4a6-418741fef4ba"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTQtMS0xLTE3OTg1OQ_8f0bc7e8-326a-4124-b1ab-70565e1bac90"
      unitRef="usd">0</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzItMTQtMS0xLTE2OTYwOA_01a19da5-78c4-498c-a7c0-8ce6f0005f4e"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMi0xLTEtMTY5NjA4_bae6cef6-85a0-485e-8ba0-4416cdfd31e1"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtNC0xLTEtMTc5ODI5_b0d6f73a-83d0-4404-a320-a8ebe26c4b0d"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtNi0xLTEtMTc5ODM1_81bd02d8-5ed4-40ff-a7eb-82230c49fe41"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtOC0xLTEtMTc5ODQx_c3736914-7711-4550-b8ca-3c724b5c6be3"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTAtMS0xLTE3OTg0NQ_ec767026-0f88-4e0a-b65a-587f7f877ba1"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTItMS0xLTE3OTg1Nw_96ed4b2b-8eb0-40af-beaa-7c12618b627f"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTQtMS0xLTE3OTg1OQ_014bbc2f-5fd3-486c-9362-0768901cfcbd"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzMtMTQtMS0xLTE2OTYwOA_92ccf373-ff67-4da0-a9dd-8b888bea498d"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iff63ef6faace45498e346825d00e01a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMi0xLTEtMTY5NjA4_209a0380-33fd-459c-92d0-eab011d0798e"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtNC0xLTEtMTc5ODI5_1390fc9e-a53a-4818-9d51-84a23a42b242"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtNi0xLTEtMTc5ODM1_dd16f4be-7531-4f67-981a-ee573db01792"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtOC0xLTEtMTc5ODQx_829ee60c-3476-4a93-9dce-9c8995fa3db6"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic202cd1610e947c8acff5f7dfe996d0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTAtMS0xLTE3OTg0NQ_03a85a91-a233-4bb4-b50a-aaec3c138c26"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTItMS0xLTE3OTg1Nw_975805a3-45dd-4d47-9e3b-1e6c0cb7ab66"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTQtMS0xLTE3OTg1OQ_4c80898c-cdeb-4ea4-b8ff-649fa34139b0"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzQtMTQtMS0xLTE2OTYwOA_e09fb6a3-8a20-4e67-ad56-4289d073d283"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ia1576ddc62d446f3a6d5e4978c7937d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMi0xLTEtMTY5NjA4_8606fe1a-d543-418c-b1bf-f65ad8c64be1"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4f6defc1abe0499b87b8d9ba0729620e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtNC0xLTEtMTc5ODI5_92f47779-27cc-4b8f-bd5e-64a02c1cc98a"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie978af0fcc4247feacd32583a9786a9f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtNi0xLTEtMTY5NjA4_aa4b89e8-47a5-49cc-be5f-e1c27785101c"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2db8916c81ee460fac6b5d6d2d6a779f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtOC0xLTEtMTc5ODQx_47c71a09-a428-41ba-9219-ae50a4cfc4f7"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i052132743b504af0bdf4f85716745c47_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTAtMS0xLTE2OTYwOA_b2bf154a-c98c-49d7-aa61-d21a2ce1f326"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5770479e5eef445e811659815d6ded32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTItMS0xLTE3OTg1Nw_4b248c14-ac1e-4142-bb9b-fedbbc60ae8b"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i94689023eb444f91a13a7e4d47e5db0c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTItMS0xLTE2OTYwOA_1d221512-f320-4642-8d17-e42333059be7"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzUtMTQtMS0xLTE2OTYwOA_2c73d785-c389-4c55-af74-ae5b167994ce"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMi0xLTEtMTY5NjA4_4074f0e1-12a9-49a9-ac77-e329e47fcd43"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtNC0xLTEtMTc5ODI5_2c28bc79-b831-4a97-836c-bac09e3501b7"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtNi0xLTEtMTc5ODM3_0aaecf65-c6a8-4226-a2d1-bf32fc462b0d"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtOC0xLTEtMTc5ODQx_c4e1eb7b-2363-4313-ac00-c102397ba27e"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTAtMS0xLTE3OTg0Nw_c6412202-fb1b-4dca-8552-0aec5be4d42d"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTItMS0xLTE3OTg1Nw_4960ebdb-bc86-4504-a813-e406e7c1c91c"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTQtMS0xLTE3OTg2MQ_68143581-d548-4a02-8b26-c4bbbc40dff1"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzYtMTQtMS0xLTE2OTYwOA_f4b07c44-ca59-4f46-a695-7ee4d194e769"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMi0xLTEtMTY5NjA4_64a4bcf4-2d79-4b8e-8348-32e15eadc517"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctNC0xLTEtMTc5ODI5_cd272321-6a16-46c6-9248-faaec1da398b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctNi0xLTEtMTc5ODM3_a2e78c18-1d36-4650-b4a3-4f98a2b4f9ab"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctOC0xLTEtMTc5ODQx_3189f624-70f9-447e-878b-018f0299329f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTAtMS0xLTE3OTg1NQ_70a8ef04-2080-47eb-8737-8b22808589cc"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTItMS0xLTE3OTg1Nw_9f669b8b-369e-4d74-959b-355eb8c0508e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTQtMS0xLTE3OTg2MQ_6f992392-914e-4c91-901e-a002909e47e9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzctMTQtMS0xLTE2OTYwOA_42af7b5d-b7d1-480e-9e39-51c0c405939f"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4bffb3bc0b814a68a85e69638cf26d76_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMi0xLTEtMTY5NjA4_2f0443df-bc2f-4f48-8f72-1de46b874e45"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtNC0xLTEtMTc5ODI5_1fffc726-338c-4154-a7a6-c64af3621577"
      unitRef="usd">-77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtNi0xLTEtMTc5ODM3_4d3d6fdc-ba90-41cc-8891-f13ba8781c94"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtOC0xLTEtMTc5ODQx_768f1557-87d2-480d-ae3f-69dd8989a35e"
      unitRef="usd">-62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id815a410db39410abd908f92b68de9ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTAtMS0xLTE3OTg0OQ_4faafbf6-245e-450a-87ea-e427dcc2ced7"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTItMS0xLTE3OTg1Nw_3ae4dfd7-9858-460f-b9c3-f1986577a60f"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTQtMS0xLTE3OTg2MQ_e3f55f61-f3d4-4893-9fba-414650b58ba5"
      unitRef="usd">21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzgtMTQtMS0xLTE2OTYwOA_e7a3fa02-1c18-487a-890f-5d53e6f5e26c"
      unitRef="usd">-118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i82bb7cbf3457475e9a924170769182c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMi0xLTEtMTY5NjA4_c98a0c9e-f302-4a3a-a185-6c59ae21123d"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id9856ff949f043bc9821f51eec5c0ca9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktNC0xLTEtMTc5ODI5_19b0a99c-1ab2-4fbc-8d61-6b49cf2aa443"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0699fe85526c4352aebcd5347c7b8ffb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktNi0xLTEtMTY5NjA4_15d17848-ad68-4285-8da8-335dea20b45c"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibde1691268ac403c8e6b3decd6654cb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktOC0xLTEtMTc5ODQx_a0d82769-2229-4930-9a56-7d0fe42f592e"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieda7752d38634982add22e8fe5ee38e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTAtMS0xLTE2OTYwOA_f52efa19-2a9b-41e2-a887-5e39cca37f37"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibceccba7710c415bad87fdec58072ed1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTItMS0xLTE3OTg1Nw_ce7b1e16-ad7a-4128-9e05-08f652bed1be"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaf06d2028b254481bcde95fc6c3cc519_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTItMS0xLTE2OTYwOA_9ddecf99-84d2-4fe7-ab01-5a270e4bcd1f"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzktMTQtMS0xLTE2OTYwOA_449745e5-a866-40d0-8a11-8ec99144af6e"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTItMS0xLTE2OTYwOA_0feb4cfa-6a18-4257-b12d-8837d28e4526"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTQtMS0xLTE2OTYwOA_fccf5964-87f5-4b0b-a564-5b5058333014"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTYtMS0xLTE3OTgzOQ_18ec76b9-a319-4987-afa4-d8de69818134"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTgtMS0xLTE2OTYwOA_e2a2721b-90ce-4f73-a520-d962b5c77e11"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEwLTEtMS0xNzk4NTE_c4c4cd1e-b2d4-4579-aa1a-4c096272148c"
      unitRef="usd">-798000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEyLTEtMS0xNzk4NTc_47019b2b-4ff8-494d-9893-e75775b061fb"
      unitRef="usd">115000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTEyLTEtMS0xNjk2MDg_85dcb331-21ec-4ba9-a55b-7ac4b5d6b461"
      unitRef="usd">683000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEwLTE0LTEtMS0xNjk2MDg_8767db35-026a-471a-b58b-4b8f7e15bcea"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTItMS0xLTIwMzMxNQ_425bc67b-45f2-42bf-9d61-9de56b24e97e"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTQtMS0xLTIwMzMxNQ_9eca9ed6-f2b4-4793-9bab-73b9cd87ddfc"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTYtMS0xLTIwMzMxNQ_9d2ad67e-3a06-4a30-b478-81ccfeb46653"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTgtMS0xLTIwMzMxNQ_20ad4004-092c-486b-abf6-9814ac1a6ddd"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEwLTEtMS0yMDMzMTU_6549dd8b-ce96-4d8e-bb04-fc868f4305cf"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEyLTEtMS0yMDMzMTU_735b817b-f960-4bba-a01a-44f18bedcc97"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0yMDMzMTU_b6671f8b-5679-401c-ab9d-12ec7e72693b"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE2LTEtMS0yMDMzMTU_e2dcb421-13dd-43e2-8c21-bca722f13fa7"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTItMS0xLTE2OTYwOA_cae9e80f-c42e-4eef-b2c4-31b4c8c33897"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTQtMS0xLTE3OTgzMw_1340698d-2a01-4903-9903-f49d4c0b00cf"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTYtMS0xLTE3OTgzOQ_442c59a9-872c-4b80-b87f-f17f0686f980"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTgtMS0xLTE3OTg0Mw_173b0ce4-be3c-4e6c-bfc9-f60aa4fafc6d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEwLTEtMS0xNjk2MDg_4942a68a-b990-4cbb-87e3-c1847749fbb9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTEyLTEtMS0xNzk4NTc_5e295253-4ab8-4707-b8d7-9807eda75399"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0xNzk4NjM_fce26811-b73e-4b69-a382-01a9505c839c"
      unitRef="usd">824000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzExLTE0LTEtMS0xNjk2MDg_ed83d435-7d96-4977-aaf2-74030b914bf5"
      unitRef="usd">824000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8e057f632e184647ae17542d539bd24a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTItMS0xLTE2OTYwOA_e37f91f7-a908-423e-912f-f3bc9930f26a"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTQtMS0xLTE2OTYwOA_252b8127-fd5c-4846-ab71-20b87c4b34a1"
      unitRef="usd">-77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTYtMS0xLTE3OTgzOQ_6c82ffc3-5209-4044-a975-64ce4833caf2"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTgtMS0xLTE2OTYwOA_917e70c6-f500-4b74-b25f-144abc3e66a8"
      unitRef="usd">-36000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1732052987b04886a0b885788267de2e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEwLTEtMS0xNzk4NTM_d2ad9164-5af7-490f-ba99-b41efc79b813"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEyLTEtMS0xNzk4NTc_d417eaaa-99ab-4f1b-8cb7-634a926ca85c"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTEyLTEtMS0xNjk2MDg_e85359c6-b654-4b5a-8d0f-460fe36b2ba7"
      unitRef="usd">22000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEyLTE0LTEtMS0xNjk2MDg_2272f13c-3ac3-4308-b159-e5715ca455ea"
      unitRef="usd">-91000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i6c413cdb1b164432877c83f54ab2b752_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTItMS0xLTE2OTYwOA_da3fe3ac-6c7e-476f-80de-b8cf42726dd4"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1ad4945bf5b946aeac343ddf77e3ca2b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTQtMS0xLTE2OTYwOA_fe897d29-8401-4118-9b85-440d10c051d3"
      unitRef="usd">5246000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iccc6df613d904efa9a6c5d3e9e8453e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTYtMS0xLTE2OTYwOA_66d83aa8-fac0-46e8-ac68-56042669efb2"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idd76bc2237554c19bf5f7b2da6fedd79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTgtMS0xLTE2OTYwOA_d5c0ad89-3e50-4224-aac6-74d9db187865"
      unitRef="usd">789000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i84ddd8e4ef73432abf45d8222d362bc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEwLTEtMS0xNjk2MDg_55ce874e-172a-4b5d-a5a2-41073ee96558"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i91663006f1f64ef9b72e553828a29c56_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEyLTEtMS0xNzk4NTc_61516f7d-b6f2-4a2e-a0c9-91749522fc54"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iff8822a2ac32419c8920e934ce9eb11e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTEyLTEtMS0xNjk2MDg_a4679444-a251-44c6-93a6-02b3a09fcfd6"
      unitRef="usd">2238000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90YWJsZTowODdlZTNmMDE1NjI0YWQxYWIwZjVmNTYzOGZlYmExYi90YWJsZXJhbmdlOjA4N2VlM2YwMTU2MjRhZDFhYjBmNWY1NjM4ZmViYTFiXzEzLTE0LTEtMS0xNjk2MDg_80549f87-8181-4fca-a8b8-544499289653"
      unitRef="usd">11547000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8e14db2c7cd143aa8caf8a8b3aee8506_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwNDgy_eea7ba67-1b3e-4351-9eb6-30ee19a33d2c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3b234d01c94442fe91530027b0f6530b_D20200331-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzExNDk0_210f5f30-4d34-4936-87c9-848f0d536d14"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib8020b17bcc3445ea7163d7ebd53a470_D20200630-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzExNDk0_928c9323-cb66-4684-a3e2-1641bed15407"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i2a0c24b9ab774864babd19a173d572a2_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyODc5_3d406d89-580e-4936-ae10-453e88770d6f"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i34640daea4d7462a9d9640c91a9681d6_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyOTIw_8fab8333-aa93-4829-ae06-50c6982d0d0a"
      unitRef="number">0.0950</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="if89e8badccef47d0a7d7bc1e901ceebf_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEyOTI3_473a7a9d-480f-4b08-9451-f0dcc0e95dd8"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i2a0c24b9ab774864babd19a173d572a2_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEzMTA2_97198071-921b-4139-8aa6-1d8b495dffc0"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i90e6ce0d73164ddf964bb0ea4fa23010_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEzMTY3_de74003a-aee6-48c4-aebc-d92fbc470e9e"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1Njg3_77ad0cef-f60d-4d11-a5ac-933f9df40275"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1Njkz_d864bbc2-0ad3-48c9-8a88-fcbd782d6164"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ib79cdb4e5d924ef3bd936a7d77c8f807_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1NzM0_86e58f5e-76cd-4506-9ba8-d1cede69541b"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ie4dcbaaf2e5d4ae885ae162f534e08c2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1NzQx_acbb5c0e-cafe-4eea-84d5-42bc6d6bce50"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ib099140ae6db41829838038f01c73b6b_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1OTIw_608b2a98-69a0-4efe-b962-cec8f0345244"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i96ab98d4a236452a8fb70057836d164c_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE1OTUw_29b23a05-dd14-4e13-b3c0-8060fa89999f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i91c967a98aaf490f85d7f7da1b415ab3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MTk4_1e1691d2-6634-4ba9-af63-fc45c583fb2e"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="iac26985514b44cee99c565494437c9bf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MjM5_f7a6e7ec-c32b-4458-8409-f5dc34030516"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i7dab83ba8be74e6ea0cc6457f87cc786_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4MjQ2_56e91197-6c8e-473f-a67d-d40d24acbd73"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idbdf52fd4b1141df99e98d44fc5f54cc_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE4NDQ5_16d27b78-fa70-42f0-8ad4-4e5dd553cc88"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ieae8581e17154d79af15b43340cf71ed_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTAw_ad868069-d6f1-46f7-99ab-06f40e69217b"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i723051ff458540289de98a13ff5b824e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTA3_5c08a39b-2270-4573-b9bd-55800e217de2"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ieae8581e17154d79af15b43340cf71ed_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTQ4_86493441-ac89-40a4-9ad6-fbb054846233"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i723051ff458540289de98a13ff5b824e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNTU1_2c7bd09a-d0b1-4f33-8c2b-d05c132f57f4"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i5d4c382c97644eb7a14b499b2e665d51_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNzM0_6313d08c-d41f-43be-af9b-62e4b6c6b129"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i25b53b103dc24a0eb09366a47de8f0f4_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIwNzY0_cca8d60c-4990-47af-9ce7-69199eec1b96"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzNzEx_6f97acaa-d15e-4226-b86a-d3d7928e9f13"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzNzM3_0ace43f4-e9d5-402b-9ff8-871e8953a703"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i3aeea5c3a94e47bc8d50f086f2156afc_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzOTE2_e27dd9d7-e256-453a-a40d-0104e12a2c96"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic3ecaaa094ed49849e4e48a5f2f59700_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzIzOTc3_5201700c-60dc-47a5-bc3f-e7c5bfd9c0c9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="iab863accad34439cad8d1a61aba863c1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1NzA_48640298-495d-43a8-80c9-2d215303c96d"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjA_def0d5f4-8c87-419d-b2a4-289ea076f399"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjQ_9e9e1e70-9d28-4964-a9cf-52811c0767fe"
      unitRef="number">0.09</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i71a29147694c4aa784a0508f3b8b0b83_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNjg_24ca871d-0bec-4ea4-abb3-5f67a24e9d9e"
      unitRef="number">0.02</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if1860ad2ed2945a9a9f05e0807ab6a99_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzNzE_ac4ffef9-1d30-4003-b419-e7e96df6bd47"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODA_9f485bd9-9f0a-42de-8a57-3cbd60ae3446"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODQ_08482a14-c954-4437-8985-7d84d9adde4c"
      unitRef="number">0.10</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
      contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzODk_4625d481-c787-40ea-bed9-7a7dc789be37"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib1b89ed8a12b41e9b73c9ba2e0663772_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODEzOTM_f8cfda5b-cdbf-41fe-a9c6-12a87a0111bf"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="ie7598aed7ec34bddb36dd9a1f40c947e_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MDU_4941557a-9997-4412-99b5-c84c650fda92"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ide546e7ecff04d7b8671f8b40f6612e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MTY_2e3e6439-551f-4ed8-a1a2-6efdf1d84ae3"
      unitRef="number">0.02</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i42871f56c57941c385528783c1e999c2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MjA_06e21138-26cb-48f2-ac02-3cd3cdd230a4"
      unitRef="number">0.03</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ide546e7ecff04d7b8671f8b40f6612e1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MjQ_5494beca-8ca0-46da-8284-53247ef01d1e"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i42871f56c57941c385528783c1e999c2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0MzA_f0fe0e91-9538-4f14-890f-8d6c6b363838"
      unitRef="number">0.115</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i263addd715b04b329673b5c1f5ccba82_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0Mzc_5c78d324-73ab-4a46-896d-c125e5c0731a"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0dad95c441654101809dec4ce04cb340_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NDE_fca787b3-2828-452a-99a3-d0062b726865"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NTk_1efbd917-0c16-4383-bca6-5bf5eb933476"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i90c3ea7a8793435088d6fb6d8ae58077_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NjM_74a07880-6f71-4ebd-ae5c-b6c85a6af3c0"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0NzI_e33116e9-f894-4c7c-b3c0-49a875cf42ce"
      unitRef="number">0.105</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i48916ae978b944169cbdc730b06bc6fb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0Nzk_8b926f4a-58fa-4179-8881-a72f0c911441"
      unitRef="usd">119000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i7647535adfe442f6b2bad4ec71e6c424_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3NDI_9088eb82-df26-4a40-a870-0f5d81370b3e"
      unitRef="usd">480000000</us-gaap:Goodwill>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0a7459d4547245ad9a36ea070c5f5ec3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTM_74313222-a71f-4ada-a6db-ed4d59ab4660"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6f86b5f573824c0b99316ea9e59d1842_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTM_7ed318dd-77e3-415a-9859-4c850c7ce951"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9cf2cce057f44b058a16380acebfee7b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE0OTg_7eaf20c3-20ce-4ee1-bfe0-c9c074a0632e"
      unitRef="number">0.025</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i99e03f7f94044004815a278acfe122e8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MDQ_db676392-241a-407a-8988-38d112f3b28b"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i1c4915118e4c47e39d266ed6aa6df20d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MTE_edb3fb2b-5b9c-4bed-b630-2989946d8343"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3237e29dcce54fe4a18404bf646a22a3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MTc_b0de0f52-3c1b-4d8e-9507-aecbf6742f84"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i9cf2cce057f44b058a16380acebfee7b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc0ODE1MjY_523cddd6-8931-4272-90db-ecfa778932d3"
      unitRef="number">0.05</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1NTg3MjY_e79cba4e-149d-4ed7-a001-500b7366237a"
      unitRef="number">-0.025</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzE2NDkyNjc1NTg3MzM_f2968623-4329-4d3c-b12f-b088457b6d51"
      unitRef="number">0.1025</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if150371b70684386a5836a8b20ae71bf_D20221001-20221001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE3NDQ4MDc_d642f0ba-76a0-4dfe-8a03-64b144b3122a"
      unitRef="usd">622000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ibb28c3e988cf4fad8e220d6ce81bee83_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzEwOTk1MTE3NDQ4MjE_66753578-c360-4399-9e86-01ff1f6da98b"
      unitRef="usd">1439000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i72666ab0833443e986330313e8a4c321_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3ODc_43a589a3-3442-4cbd-a48c-33282a1056ed"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ic3567189e676429991222cd3e3e1213b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3OTM_3dc5d343-4b4a-43ab-9bad-e775a6195b84"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i72666ab0833443e986330313e8a4c321_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU3OTk_cc7b014d-2249-4dc6-8782-26d4d349ce68"
      unitRef="number">0.0950</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ic3567189e676429991222cd3e3e1213b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MDY_f6373663-0d07-4b26-94a6-014f0d547de3"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ie84c3447e94e4cf08b00cd1500e214d6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MTQ_a7347b90-b59c-43bb-affb-31112197c8af"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iba65689930cd459f9a5372d1a52fcc18_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzU0OTc1NTgyNDU4MTg_e65549dd-50e7-49f9-a2b1-bf1faee3459d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i40adc4228d5649c8b5ea39c9bb7e19b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzQvZnJhZzo3ZWZjNDQwYmI4ZGM0MDk1OTFmYzU3YmQxNDk1ZWU2NS90ZXh0cmVnaW9uOjdlZmM0NDBiYjhkYzQwOTU5MWZjNTdiZDE0OTVlZTY1XzI0NDA2_65837740-a9e4-47b9-8d9b-286adf59010d"
      unitRef="usd">5004000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90ZXh0cmVnaW9uOjNkOTQ1YTNjMWYxODQ1NWFiZmUxMTVkYjU5ODhkODJjXzY1_07e906bf-4167-46fe-a08f-90372e1774ca">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90ZXh0cmVnaW9uOjNkOTQ1YTNjMWYxODQ1NWFiZmUxMTVkYjU5ODhkODJjXzc1_46a6b7ad-ed27-44ae-bc3d-6c8f32b128fb">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:LegalSettlementsAndRelatedFees
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzEtMi0xLTEtMTY5NjA4_12124347-671e-420d-8b28-6b7bb1f2d8a9"
      unitRef="usd">326000000</bhc:LegalSettlementsAndRelatedFees>
    <bhc:LegalSettlementsAndRelatedFees
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzEtNC0xLTEtMTY5NjA4_b0417a47-f222-4ee5-936d-a0a84367ee5f"
      unitRef="usd">1890000000</bhc:LegalSettlementsAndRelatedFees>
    <bhc:AccruedProductRebateCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzItMi0xLTEtMTY5NjA4_d56cfb8d-06bd-41ff-b4c7-7e34ae3c4013"
      unitRef="usd">983000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzItNC0xLTEtMTY5NjA4_d1efe7a2-2cd7-42bb-82d8-1ecdfb129723"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzMtMi0xLTEtMTY5NjA4_5ba6707c-bd16-45e3-85c6-30c5b8c048b2"
      unitRef="usd">427000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzMtNC0xLTEtMTY5NjA4_60466004-7b56-46a7-a848-e9a32413e3ea"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzQtMi0xLTEtMTY5NjA4_bccf929b-da82-42d0-b179-a67f7f0558ad"
      unitRef="usd">300000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzQtNC0xLTEtMTY5NjA4_64549322-fba4-4b9c-8656-c7bfea8cf41b"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzUtMi0xLTEtMTY5NjA4_2a4e70a9-d0a4-4a8b-b927-79979cc77dfd"
      unitRef="usd">208000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzUtNC0xLTEtMTY5NjA4_d45d4847-46f4-4691-9abe-8830b1c7836d"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzYtMi0xLTEtMTY5NjA4_e1690229-088e-4804-b6c1-43c2c568ceb0"
      unitRef="usd">30000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzYtNC0xLTEtMTY5NjA4_b0541d1e-bfbb-48c3-9fc0-d15ec4ab4cd0"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzctMi0xLTEtMTY5NjA4_0a737564-0c2c-4d31-ac0c-d0610dac51c5"
      unitRef="usd">714000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzctNC0xLTEtMTY5NjA4_b3647e33-18e2-4aee-82c9-d3ddaf7bfddc"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzgtMi0xLTEtMTY5NjA4_23c5af79-91f2-4d90-a45c-ea21d294b6bb"
      unitRef="usd">2988000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zMzcvZnJhZzozZDk0NWEzYzFmMTg0NTVhYmZlMTE1ZGI1OTg4ZDgyYy90YWJsZTo4ZjY4ZGNmMzRjZDk0MTIyYTBlMzYxYTAwMWMwZDA2Yi90YWJsZXJhbmdlOjhmNjhkY2YzNGNkOTQxMjJhMGUzNjFhMDAxYzBkMDZiXzgtNC0xLTEtMTY5NjA4_bad3e622-5da3-44a1-aae3-1eb2052875a1"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNzA_248f7863-e5b7-4cff-9d04-5b5706d7cca6">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December 31, 2022, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $9,600&#160;million (although such availability is subject to the Company&#x2019;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#x2019;s indentures. In connection therewith, Bausch + Lomb and its subsidiaries, are now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the relevant Bausch Health indentures, and the earnings and debt of Bausch + Lomb, as defined in the relevant indentures, are also not included in the calculation of the Company&#x2019;s financial maintenance covenant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#x201c;Exchange Offer&#x201d;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#x201c;Existing Unsecured Senior Notes&#x201d;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#x201c;11.00% First Lien Secured Notes&#x201d;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#x201c;14.00% Second Lien Secured Notes&#x201d; and, together with the 11.00% First Lien Secured Notes, the &#x201c;New BHC Secured Notes&#x201d;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#x201c;9.00% Intermediate Holdco Secured Notes&#x201d; and, together with the New BHC Secured Notes, the &#x201c;New Secured Notes&#x201d;) issued by 1375209 B.C. Ltd. (&#x201c;Intermediate Holdco&#x201d;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25% Senior Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50% Senior Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the 9.25% Senior Notes due 2026, 8.50% Senior Notes due 2027, 5.00% Senior Notes due 2028, 7.00% Senior Notes due 2028 and 7.25% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#x2019;s Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2022, the Company recorded a gain of $570&#160;million, net of third party fees of $25&#160;million, in connection with the Exchange Offer. The premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#x201c;2018 Restated Credit Agreement&#x201d;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225&#160;million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;) in an aggregate principal amount in excess of $1,000&#160;million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and term loan facilities of original principal &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts of $4,565&#160;million and $1,500&#160;million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the &#x201c;November 2025 Term Loan B Facility&#x201d;), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#x201c;Second Amendment&#x201d;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#x201c;2022 Amended Credit Agreement&#x201d;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#x201c;2027 Term Loan B Facility&#x201d;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#x201c;2027 Revolving Credit Facility&#x201d;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;), along with certain of the Company&#x2019;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of December 31, 2022, the Company had drawn $470&#160;million and $25&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#x201c;term SOFR rate&#x201d;) for the interest period relevant to such borrowing&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#x201c;EURIBOR&#x201d;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $500&#160;million through December 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#x201c;restricted&#x201d; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#x2019;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#x2019;s financial maintenance covenant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the B+L Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#x201c;B+L Credit Agreement&#x201d;, and the credit facilities thereunder, the &#x201c;B+L Credit Facilities&#x201d;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#x201c;B+L Term Facility&#x201d;) and a five-year revolving credit facility of $500&#160;million (the &#x201c;B+L Revolving Credit Facility&#x201d; and such financing, the &#x201c;B+L Debt Financing&#x201d;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility may be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of December 31, 2022, the principal amount outstanding under the B+L Term Facility was $2,488&#160;million and $2,439&#160;million net of issuance costs. As of December 31, 2022, Bausch + Lomb had no outstanding borrowings, $24&#160;million of issued and outstanding letters of credit and remaining availability of $476&#160;million under its Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a Canadian Dollar Offered Rate (&#x201c;CDOR&#x201d;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#x201c;SONIA&#x201d;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#x2019;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;amp;P, Moody&#x2019;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#x201c;IG Trigger&#x201d;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on Bausch + Lomb&#x2019;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at December&#160;31, 2022 was 7.84% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, and the first installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $106&#160;million through March 2027, with the remaining term loan balance being due in May 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). In connection with the closing of the B+L IPO, the redemption of the Company&#x2019;s 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and the related indenture, the &#x201c;April 2025 Unsecured Notes Indenture&#x201d;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively pari passu with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#x201c;March 2022 Secured Notes&#x201d;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Secured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million, aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#x201c;November 2025 Secured Notes&#x201d;), in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.750% Senior Secured Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the &#x201c;January 2027 Unsecured Notes&#x201d;) and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the &#x201c;August 2027 Secured Notes&#x201d;), respectively, in a private placement. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at the redemption prices set forth in the indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.125% Senior Secured Notes due 2027 - February 2022 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New BHC Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 11.00% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of 11.00% per year that is payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 11.00% First Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 14.00% Second Lien Secured Notes mature on October 15, 2030, and have stated interest of 14.00% per year that is payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.00% Intermediate Holdco Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of 9.00% per year that is interest payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of December 31, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#x2019;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redemption of April 2025 Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#x2019;s outstanding 9.00% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Unsecured Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2015, VRX Escrow Corp., a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the &#x201c;March 2020 Unsecured Notes&#x201d;), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#x20ac;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the &#x201c;Euro Notes&#x201d;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and, together with the March 2020 Unsecured Notes&#x201d;, the May 2023 Unsecured Notes and the Euro Notes) in a private placement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2020 Unsecured Notes accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500% per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes. Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, the April 2025 Unsecured Notes were redeemed and discharged in the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.000% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) in a private placement. The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the December 2025 Unsecured Notes, at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $541&#160;million in aggregate principal balance of the December 2025 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.250% Senior Unsecured Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#x201c;April 2026 Unsecured Notes&#x201d;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#x201c;March 2018 Refinancing Transactions&#x201d;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $752&#160;million in aggregate principal balance of the April 2026 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;8.500% Senior Unsecured Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#x2019;s existing January 2027 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption. On September 30, 2022, $1,099&#160;million in aggregate principal balance of the 8.500% January 2027 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the &#x201c;7.000% January 2028 Unsecured Notes&#x201d;) and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the &#x201c;May 2029 Unsecured Notes&#x201d;), respectively, in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, $540&#160;million and $373&#160;million in aggregate principal balance of the 7.000% January 2028 Unsecured Notes and 7.250% May 2029 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the &#x201c;5.000% January 2028 Unsecured Notes&#x201d;) and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the &#x201c;January 2030 Unsecured Notes&#x201d;) in a private placement. The proceeds and cash on hand was used to repurchase certain unsecured notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on the 5.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes and the January 2030 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes or the January 2030 Unsecured Notes prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, $710&#160;million and $332&#160;million in aggregate principal balance of the 5.000% January 2028 Unsecured Notes and 5.250% January 2030 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.250% Senior Unsecured Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the &#x201c;6.250% February 2029 Unsecured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company&#x2019;s June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;May 2020 Refinancing Transactions&#x201d;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, $540&#160;million in aggregate principal balance of the 6.250% February 2029 Unsecured Notes were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the &#x201c;5.000% February 2029 Unsecured Notes&#x201d;) and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the &#x201c;February 2031 Unsecured Notes&#x201d;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#x20ac;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;December 2020 Refinancing Transactions&#x201d;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, $371&#160;million and $336&#160;million in aggregate principal balance of the 5.000% February 2029 Unsecured Notes and 5.250% February 2031 Unsecured Notes, respectively, were validly tendered and accepted by the Company in connection with the Exchange Offer noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company&#x2019;s outstanding debt obligations as of December 31, 2022 and 2021 was 7.74% and 5.88%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#x2019;s financial statements for 2022 and in future periods will not be representative of the weighted average stated rate of interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on Extinguishment of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022 and December 2022, the Company repurchased and retired certain outstanding Senior Notes with an aggregate par value of $927&#160;million in the open market, for an aggregate cost of $550&#160;million. In connection with these repurchases, the Company recognized a gain of $369&#160;million, net of write-offs of debt premiums, discounts and deferred &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance costs, on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company completed the Exchange Offer and recorded a net gain on extinguishment of debt of $570&#160;million as described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $64&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2022 Amended Credit Agreement, there is no Excess Cash Flow payment due for 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzM0Mjg0_697d06b0-dc7d-4441-b06a-c4b62d9eaa1b">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2022 and 2021 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e26e58975e443e0b51918f03cee7d5e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtNC0xLTEtMTY5NjA4_ebea29bb-ffe6-473b-8d88-2f0583937892"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9e26e58975e443e0b51918f03cee7d5e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtNi0xLTEtMTY5NjA4_d4282406-28c5-419f-8eb0-887cb8ededff"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id2961e7ea8ce40b29f24b00453ac5571_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtOC0xLTEtMTY5NjA4_ef96f4e9-ad79-4a11-95a8-a542dabe6d7a"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id2961e7ea8ce40b29f24b00453ac5571_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzMtMTAtMS0xLTE2OTYwOA_1b2c74a6-9dab-443e-8641-054c7011ea74"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i780fe08a52e14ab1bac7e028c782c9c0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtNC0xLTEtMTY5NjA4_e1853570-8d07-466a-b8f2-6df6319300f0"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i780fe08a52e14ab1bac7e028c782c9c0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtNi0xLTEtMTY5NjA4_4e3b495f-3749-4015-bea5-dcc4f92c8ab7"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i90c8e00c14544d52a42942914e81c273_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtOC0xLTEtMTY5NjA4_787d62fe-30c6-47b3-a586-3f5c1d5a8336"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i90c8e00c14544d52a42942914e81c273_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzQtMTAtMS0xLTE2OTYwOA_6bb12fce-0e72-410a-9bae-da874688ad0c"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2604b11090a343939a4cfcab0196957a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtNC0xLTEtMTY5NjA4_2f17fc4f-e36d-4618-a39a-84c860366e5d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2604b11090a343939a4cfcab0196957a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtNi0xLTEtMTY5NjA4_efda17d4-c594-44a2-bcc8-b9dea6515b6f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3aaac0c0174b4c27bd54436507088ceb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtOC0xLTEtMTY5NjA4_7db3ad99-b041-4d6a-998d-28a3a11b3644"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3aaac0c0174b4c27bd54436507088ceb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzUtMTAtMS0xLTE2OTYwOA_4f1c81b5-d4e0-4175-8540-0a1296022c29"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNC0xLTEtMTc4NDk1_fbc9702d-1fe2-41d8-89dd-40152e12c095"
      unitRef="usd">470000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNi0xLTEtMTc4NDk3_c644e1ad-049b-41d7-9a62-f5048aabbf7a"
      unitRef="usd">470000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtOC0xLTEtMTc4NDk5_cd4394c4-08e1-43d0-a8ac-d3a347a1498e"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2ee2bb6115f54d87b9beee1bb4b50dde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMTAtMS0xLTE3ODUwMQ_4c09053c-6d61-4e5a-951f-a5a7852ca0a5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iffc26a76728a46aab695daedd417d9fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNC0xLTEtMTc4NDk1_1b7501e9-f504-49be-bbc8-76f2f608f213"
      unitRef="usd">2437000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iffc26a76728a46aab695daedd417d9fc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNi0xLTEtMTc4NDk3_65b79b08-e390-4e90-aef1-06a167ba0b34"
      unitRef="usd">2392000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktOC0xLTEtMTc4NDk5_70e02824-a2b5-4725-aeec-763607e902fb"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ieb0b1a9f064243269f4c66a77f1ba44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMTAtMS0xLTE3ODUwMQ_a55813bb-c39b-491c-9f83-bc55120fb372"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTQtMS0xLTE3ODUwMw_d677d1f1-e8b8-4726-9c85-6f2633ca566a"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTYtMS0xLTE3ODUwMw_9bc1b00d-7610-4747-8387-5bd53add73c3"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e127eb541b94518be190909675ed289_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTgtMS0xLTE3ODUwMw_729aae0c-a101-43fe-8712-3965cb1de6f5"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9e127eb541b94518be190909675ed289_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzExLTEwLTEtMS0xNzg1MDM_ace14d5e-23d3-4030-b295-94718c979ebd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTQtMS0xLTE3ODUwMw_4b133578-5364-4b36-97e7-ea09e2b544ba"
      unitRef="usd">2488000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTYtMS0xLTE3ODUwMw_b28b4674-9524-4fe8-9d9c-5694ee006fbd"
      unitRef="usd">2439000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iba6f95a9036b477e8cb580382038f606_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTgtMS0xLTE3ODUwMw_b64b1582-a8d0-4572-a199-9bd3eb1b2bd2"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iba6f95a9036b477e8cb580382038f606_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTEwLTEtMS0xNzg1MDM_54a9d2ad-d105-4b8d-8ed8-cfa67267ea24"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMC0xLTEtMTY5NjA4L3RleHRyZWdpb246MGMyNTFkMDVlZWUyNDBmMzhiYzk5YTQwNGQ1NmQwYWZfNA_8cc8436f-729d-49a7-a14f-faadd2e71134"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNC0xLTEtMTY5NjA4_984c8924-c5c6-4118-b8c3-412db0d94fd2"
      unitRef="usd">1680000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifb29815fc9674a7c99be25fdb001b3a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtNi0xLTEtMTY5NjA4_1e611f07-6d74-481a-9088-6e84990d0062"
      unitRef="usd">1672000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07aa5fc5a9e841de925a2df849619500_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtOC0xLTEtMTY5NjA4_7dab57bb-4ad2-4a56-8b74-a0adc592fca4"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i07aa5fc5a9e841de925a2df849619500_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzgtMTAtMS0xLTE2OTYwOA_a48a90f2-702b-45b9-8b9f-0965e0dde967"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTAtMS0xLTE3MDc1Mi90ZXh0cmVnaW9uOmM1ZjRmOGQyODgyNTRhOWVhZjFmMDM1YzY1ZjdhMzAxXzQ_1d622a30-6072-4e69-b6fd-00fdbe966284"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTQtMS0xLTE3ODUwNg_caabb19e-bb9a-4812-aad9-d5ee6f77333f"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifd3f8766f9504fd1bf68133e1f140db2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTYtMS0xLTE3ODUwNg_4f2d38cb-aa32-4992-b53e-30d05ba7e8e7"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8aaccccd91c84bd69bb27eb24388fe86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTgtMS0xLTE3ODUwNg_a9e605e2-9daf-4d5e-81ee-891597b885c4"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8aaccccd91c84bd69bb27eb24388fe86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTEwLTEtMS0xNzg1MDY_62cbf4d8-f1e2-47f3-af5d-0ef2366be161"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMC0xLTEtMTY5NjA4L3RleHRyZWdpb246MDg5ZmJjMDg1YzY0NDAwNWI0MjA2MDBjMGM2MTZmNDdfNA_59814e61-b226-426f-8a9f-fbd665cfb5c6"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNC0xLTEtMTY5NjA4_18503b41-ceb6-474d-879c-3cbffb64b5be"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i409f129e0bfc49478eb8d9d221ae81ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktNi0xLTEtMTY5NjA4_66d6bd84-916c-43a3-95d8-712bc95c7f97"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9ac2987c7a84f5eb6926a647891d84f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktOC0xLTEtMTY5NjA4_adc8e1dd-9710-43c2-990c-1cd1cb5d157b"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia9ac2987c7a84f5eb6926a647891d84f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzktMTAtMS0xLTE2OTYwOA_5347b3fd-3c08-40cc-87a8-b2a26c45285a"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41d7411313624b009890802c2b02341a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjA2MDNmZjJkYjgyOTQ4NjY5Y2RkYTg0OWE3Yjg0MmYxXzQ_3e539cbe-46ae-4f01-ad45-131b047697bc"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i41d7411313624b009890802c2b02341a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTQtMS0xLTE2OTYwOA_32719070-72fa-45ee-807a-7c79b20226e2"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i41d7411313624b009890802c2b02341a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTYtMS0xLTE2OTYwOA_1a8aaf99-151c-40db-901b-d14ba5570a48"
      unitRef="usd">1583000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTgtMS0xLTE2OTYwOA_e6a4d49c-aff9-4fe9-890a-65d6db0fafe2"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0b3a76a023c9402bad2d13c268a5ae6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEwLTEwLTEtMS0xNjk2MDg_1e49ebc4-e7aa-43a5-8f1d-03ea96b320ec"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTAtMS0xLTE3MDc2MS90ZXh0cmVnaW9uOjMyMjllZWVlNzFmYTRjYzA4OGRkMjQ3NGU2OGYwMWNiXzQ_c0549f31-0753-43a0-a857-6a5b09642778"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTQtMS0xLTE3ODUwOQ_4b49c953-fb89-4496-9f30-0bee3606adfa"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTYtMS0xLTE3ODUwOQ_cd965b24-3bd2-4602-9a96-a8f10e3878e4"
      unitRef="usd">2826000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ief9aaa9954e64952b709312f105f0242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTgtMS0xLTE3ODUwOQ_8d09c51b-ed97-4d41-8cf3-b46299a9e6e7"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ief9aaa9954e64952b709312f105f0242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTEwLTEtMS0xNzg1MDk_f340f72f-52d3-4ec8-866a-c5d57f1a5467"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTAtMS0xLTE3MDc2MS90ZXh0cmVnaW9uOjg3NWY1NmUwOTU1MDQzMjhhMzljOThmM2E3MWUyZTZmXzQ_9072abfd-ee57-44d1-9686-87ff40a06beb"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTQtMS0xLTE3ODUxMw_89045c35-f359-447b-8482-3feb02172db5"
      unitRef="usd">352000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTYtMS0xLTE3ODUxMw_83642f1f-f124-4e92-a257-4f9b18ebba78"
      unitRef="usd">711000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf79ff56bc204a2c9936be929b812f08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTgtMS0xLTE3ODUxMw_1c3f28a6-b73d-4e3d-a225-ab7d00d54d14"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaf79ff56bc204a2c9936be929b812f08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTEwLTEtMS0xNzg1MTM_ee405513-d831-4962-9baa-8800bfe7844b"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTAtMS0xLTE3MDc2OC90ZXh0cmVnaW9uOjRhMDY1NDlmNmUwYTQyODU5YmE1ZmNmMDhmZDgwZTU5XzQ_fe7516b8-aabc-4d0a-8a5f-f928ce5adfbe"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTQtMS0xLTE3ODUxMw_3667a206-85c5-40c9-9289-209594652355"
      unitRef="usd">999000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTYtMS0xLTE3ODUxMw_f2ce8548-45ac-4145-b024-a13dc099ca15"
      unitRef="usd">1423000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifd671799f9f141918a55117de2700d25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTgtMS0xLTE3ODUxMw_36147125-0506-478f-9aff-b5204a8cceee"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifd671799f9f141918a55117de2700d25_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTEwLTEtMS0xNzg1MTM_6c5d282e-05c7-4e64-87ff-a7b45f96afa0"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjlkYWNmOTIyNGNkYjQ5ODI4NzU0NWUwNTJjMTFjYzYxXzQ_f4d44a92-e693-4042-8de5-d943130fdf10"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTQtMS0xLTE2OTYwOA_976e32c6-7669-441e-b16d-4a4b2076ebeb"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTYtMS0xLTE2OTYwOA_ebeff1b4-8dc3-4bc8-b5ce-f55821e7b356"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07fe67aba19647d8a1e332514379f9d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTgtMS0xLTE2OTYwOA_e1385576-a302-4638-b384-727877ead957"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i07fe67aba19647d8a1e332514379f9d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEyLTEwLTEtMS0xNjk2MDg_d0d21fda-3be2-49d9-98f2-4e1c74f534d1"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmMxY2MxMWMwYzMwYjQ0ZDJiODE2YmQ5M2VkYjEwNTY4XzQ_2f75a0bf-aea2-468b-880a-80f2fd0bce62"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTQtMS0xLTE2OTYwOA_b64f7a8b-cc49-474c-9cfd-b36b806d3e10"
      unitRef="usd">959000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7a1fad0f4ca745f2846087891acdaa52_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTYtMS0xLTE2OTYwOA_436932d6-6d9b-43bb-8104-887fb5ac7781"
      unitRef="usd">951000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3871b29377e94ec5b038d5daba56ff08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTgtMS0xLTE2OTYwOA_233363c9-1304-4873-9bc5-632a77a8a855"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3871b29377e94ec5b038d5daba56ff08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzEzLTEwLTEtMS0xNjk2MDg_1076cfb6-5e4d-412b-83b8-7d24fb90c434"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjhhYWJiYzgxMzE3MzQ1YjliZjIzZjE4NGFiNTFjZDUyXzQ_0cc6e12c-320c-4bb1-9c60-2b1ef5dfd8f0"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTQtMS0xLTE2OTYwOA_ddc52934-ae7a-4da6-a1f6-6ac5c8d20097"
      unitRef="usd">741000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i44092c2d59ca47e785d0f7ca9b8a26d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTYtMS0xLTE2OTYwOA_c0514e1b-6558-46a8-bb8c-9d004c9405b1"
      unitRef="usd">737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie524823ade0a444c94da1bd1ed833f9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTgtMS0xLTE2OTYwOA_9def6f5a-ece8-4507-bd04-afc8652da2a8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie524823ade0a444c94da1bd1ed833f9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE0LTEwLTEtMS0xNjk2MDg_a8626f89-15e9-4420-ae5d-4786358d0283"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmM1YTQwNmNmYTg1OTQxYzM5MTYzYTk4ZTUyMTk4MzYwXzQ_090411ed-08bb-4401-b15a-d19444eb5b6c"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTQtMS0xLTE2OTYwOA_ef086f43-a15b-4c3a-9f94-7254414f2c71"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i378ff1b395ad4dbdafa627b96247ff1e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTYtMS0xLTE2OTYwOA_f7879c9a-f3f2-425a-8ac7-568555bad59d"
      unitRef="usd">644000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTgtMS0xLTE2OTYwOA_6c1f74d1-88c5-4b59-aaf0-ed0e2f7666ce"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5ee6fb2cb388473e9a06e36a4d178bad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE1LTEwLTEtMS0xNjk2MDg_1afa0636-824d-4af0-bf5c-bca21a97d173"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjlkNGRkOTdmMDc0ZDRmYmY4YzAyYjM0NDYzODA3NGEyXzQ_c2ff696f-821d-4f49-8f8c-994ab6506e57"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTQtMS0xLTE2OTYwOA_8b845ce4-45d8-4f00-be0a-0937225a8a33"
      unitRef="usd">171000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i881d1e751ebe415e99bf6d231a16fcfb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTYtMS0xLTE2OTYwOA_e35e1ddd-6eb2-44bc-87a4-11965c11dc5b"
      unitRef="usd">170000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia76d935f691748a49d6a2c6eca7e979e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTgtMS0xLTE2OTYwOA_17ad6bf5-c36f-411e-b9bf-292efff3ae47"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia76d935f691748a49d6a2c6eca7e979e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE2LTEwLTEtMS0xNjk2MDg_36a1eedd-7fa8-4654-8ecc-7299ef0e51ab"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic646016282634f4faf802c21a106b8cc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjFlMDBjZGM1ODk5MjQ0YzBiMGNmM2E3OTgxMDA0ZDQxXzQ_41083b44-16d5-4ddc-beae-6c8d6cec7e39"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic646016282634f4faf802c21a106b8cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTQtMS0xLTE2OTYwOA_68c3954e-e6f5-4905-a922-cba16fed95f3"
      unitRef="usd">433000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic646016282634f4faf802c21a106b8cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTYtMS0xLTE2OTYwOA_a945c3a9-e512-4bae-aea6-0c11ee105fcc"
      unitRef="usd">429000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3678917bb79c4121986b9218d5ffed64_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTgtMS0xLTE2OTYwOA_5fa43f8f-ec20-4590-aa47-ea973aadda28"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3678917bb79c4121986b9218d5ffed64_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE3LTEwLTEtMS0xNjk2MDg_62de0fcf-50a8-4fdf-bf87-f67bd223ee10"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmRiMTIwZThlMmIzNjQ2NzI4ZDdlMTQ4YzVmYzNiOGFiXzQ_90a0bfdc-378e-41e4-99ca-57b9054ff5a8"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTQtMS0xLTE2OTYwOA_c336f664-2fa9-4b91-9bb3-1ae3ec4363b9"
      unitRef="usd">821000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia59d52dbecab4068a233f40b5bbb55aa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTYtMS0xLTE2OTYwOA_5c26cc6f-7a91-446e-9a1f-1ff528ab8d48"
      unitRef="usd">813000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib01229077aac498c8cda3d570f0e07b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTgtMS0xLTE2OTYwOA_94f2f489-8ec7-4d4e-8434-1a6d4af10f49"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib01229077aac498c8cda3d570f0e07b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE4LTEwLTEtMS0xNjk2MDg_663b75b3-507f-41c0-b5af-48faba868498"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmExODM2ODhiOGYzMDRlZGFhYmNkNjJkY2Y0M2Y5NTQzXzQ_083527f6-777b-47d1-af85-36fcf5af5b28"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTQtMS0xLTE2OTYwOA_95401792-fe1d-4058-9101-6fe1fa0d84ae"
      unitRef="usd">452000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i25e40adf4f7647f89d1e9fa9364e241d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTYtMS0xLTE2OTYwOA_c73cd80f-d9de-4442-8b19-ed9af619304c"
      unitRef="usd">448000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if1486c4b57084e97aee9abcf914db494_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTgtMS0xLTE2OTYwOA_60f48664-71b8-490d-9e4a-8aa494495976"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if1486c4b57084e97aee9abcf914db494_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzE5LTEwLTEtMS0xNjk2MDg_090face3-d4aa-4437-97c4-dd5c991d54ff"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjQ3NDU4NWJlNjM4MTRmY2E4Zjg5ZmE4ZGQ0Y2RkODQyXzQ_988ca696-435a-43fe-95b0-97657bd31c09"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTQtMS0xLTE2OTYwOA_2e4cff11-6e9a-4fb1-bb7c-6f96c8a437a7"
      unitRef="usd">337000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib0745c7074bc48f0ade1f704c884d877_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTYtMS0xLTE2OTYwOA_97e4fbd3-d29c-4609-9898-ad6ebe402927"
      unitRef="usd">334000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTgtMS0xLTE2OTYwOA_b075e6ec-b97c-4b13-be03-a999b54fb38f"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i237d51b6084e4cc4b0e22eddf5c549e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIwLTEwLTEtMS0xNjk2MDg_da67cfe4-a4a0-4805-8a34-4912e4aea2cd"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOmE2NTViYWE3YjQ2NTRhMjNhZDI3ZGQyYmUxNWU4ODNkXzQ_f098739f-f19f-475b-93ef-170186a29149"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTQtMS0xLTE2OTYwOA_0354fcdf-e3db-4301-99c1-ae928ea65021"
      unitRef="usd">779000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1ca0d50d36f246238babe463a6168a0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTYtMS0xLTE2OTYwOA_4e427621-be8d-41f3-a030-30307a048fe5"
      unitRef="usd">771000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5af86776c3d44c6e88302711b8c5846e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTgtMS0xLTE2OTYwOA_a209b19f-fb73-4300-aba8-4fb78ced024e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5af86776c3d44c6e88302711b8c5846e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIxLTEwLTEtMS0xNjk2MDg_17a15151-0f3d-4afd-8b50-69a60954b0bc"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTAtMS0xLTE2OTYwOC90ZXh0cmVnaW9uOjMxM2I3MWZmYzQwNTRjOTBhODQyZmE5MGFkNjRjN2E2XzQ_1b9b5217-0b0e-4213-a1be-ca704d7f2a98"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTQtMS0xLTE2OTYwOA_afd6da7a-a450-4df2-9a94-fdfacba5aaac"
      unitRef="usd">462000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iedd85d5e6a46425692fc6df9be6d1548_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTYtMS0xLTE2OTYwOA_bd53ef9d-bf36-49d7-89b7-e1298c3d3add"
      unitRef="usd">458000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6e536bc640ae47de8bac8ed86aa24e83_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTgtMS0xLTE2OTYwOA_ae8111d2-dea2-4daf-afc9-8d3502cced00"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6e536bc640ae47de8bac8ed86aa24e83_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIyLTEwLTEtMS0xNjk2MDg_165fa76e-1f18-4381-acc9-ce0baaf24d16"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i721f7910e79b40e1aebc37232add279e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTQtMS0xLTE2OTYwOA_cf6486f3-ae63-46d1-be48-1839d6577d1b"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i721f7910e79b40e1aebc37232add279e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTYtMS0xLTE2OTYwOA_26a1967c-8436-448f-90dc-17198e579b1a"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTgtMS0xLTE2OTYwOA_1cd2adbc-09c5-4878-bdf4-9b62eda8c83b"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i966cfc4542104c7bb4d87d6f61dd44fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzIzLTEwLTEtMS0xNjk2MDg_9c26b9c3-38d1-4bea-ab5f-751d403e5eec"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTQtMS0xLTE2OTYwOA_40920591-6c8c-46fe-93ea-0221fc69d49b"
      unitRef="usd">19110000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTYtMS0xLTE2OTYwOA_e8e97b28-4a65-48d0-9307-8afd71685b24"
      unitRef="usd">20766000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTgtMS0xLTE2OTYwOA_b84588c3-4778-49b3-9da5-4053dec3a5ad"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI0LTEwLTEtMS0xNjk2MDg_f63b4419-5a4d-4911-bf06-6492326ec1ac"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI1LTYtMS0xLTE2OTYwOA_8a5d20d7-fad5-4528-9a20-18752ed38857"
      unitRef="usd">432000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI1LTEwLTEtMS0xNjk2MDg_222a91ef-7c29-44da-82e6-6b15af4cb493"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI2LTYtMS0xLTE2OTYwOA_6ce7e82d-83cc-4741-b311-7a0b93de1cb9"
      unitRef="usd">20334000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo4N2FiNjE1NjAzNzc0OGIyOWM2MzEwZjZhMTE0YmU0NS90YWJsZXJhbmdlOjg3YWI2MTU2MDM3NzQ4YjI5YzYzMTBmNmExMTRiZTQ1XzI2LTEwLTEtMS0xNjk2MDg_c3acbe7b-afba-415f-b4ad-fa870a0fe88c"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1Mzg_3581e7c3-af60-46aa-aeb0-caf1e6ef4e47"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="i8438d9428d694b1b806321debd8fbf57_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1NDU_8fa3a286-cc0c-4b6c-9be8-9777c52fa4a3"
      unitRef="usd">9600000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1NjI_a3ff92fd-b7ef-42be-8fa2-67001d6f103c"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="ibf2a5732a52d4a44ac56d7f09ded569e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1Njg_27ef165d-fe64-4efa-9b3a-720ecfdf1313"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMjA_4be2aa54-0036-4961-b563-8f02fbe2b704"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i470227bdb89e493fb8816f0ffa6ac326_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTI3Nzg_ee3e3775-cb0a-4b71-b051-e07b34d4aae2"
      unitRef="usd">5594000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMTE_d9677b97-7ef9-4098-8732-d82d7cec06f9"
      unitRef="usd">3125000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal
      contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMjc_ce393058-3113-46de-bf35-f43f4fa7dc90"
      unitRef="usd">2469000000</bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNDM_d1acf2f8-bf44-4677-b33f-006ffad55539"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNTk_8fed4677-c025-4049-82ab-cbee440ceaf6"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNjc_93b7e33d-d5ba-4560-94b2-ae176e553368"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwNzU_deddb99e-0748-45a6-9450-ba6a1c3b33d0"
      unitRef="usd">352000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwODk_3c3b81a5-8363-4221-9dd9-59dbfb2cca3a"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idf77ab3f41434fb29ed4bc1efe8548d8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwOTc_bc76758c-423c-4d00-8d75-3330a9ea12ec"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9dd991f205a44e65bd6187fabb7e37c4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMDU_61adbe93-a60e-4677-b9a8-dae8473d2442"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMTM_cbaa3472-cd46-4d7c-b5c5-053e29cdf733"
      unitRef="usd">999000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMjc_14356b2b-934a-4776-b9af-1e52cfff2ea7"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iddcdaaed0902414c803acc0f1fab8685_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxMzQ_00aed306-221e-4153-902b-06ffb8594509"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i875efb41d7fe43c6bb3f59c8192b9d6a_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNDE_3d97800b-bd8b-4c3b-abf0-d6ddf37a0bab"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAwMDk_b7fe6ffb-a247-4b09-83e6-760430c38a16">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25% Senior Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50% Senior Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8bb07bff0ebd439fb019a10f099085be_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEtMC0xLTEtMTcwODc1L3RleHRyZWdpb246YTVmMmM1ZTljZWFhNDliMjg0ZDE4OTc4OGM0NGJlODZfNA_0b8e7e61-4c3a-43ce-9f25-9df024b42a96"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i8bb07bff0ebd439fb019a10f099085be_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEtMi0xLTEtMTc4NjQ3_1c583e90-4f28-475b-80fa-ce253e49b55a"
      unitRef="usd">541000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzItMC0xLTEtMTcwODc1L3RleHRyZWdpb246NjY0OWIzMTM1YmZiNDgwOGFhOGUzMzAzNmI2NDE4MTVfNA_2a426f2c-b461-4b20-834c-3e587306a68c"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzItMi0xLTEtMTc4NjQ3_2776cb21-2419-4f17-bb04-f33e9d6892fc"
      unitRef="usd">752000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzMtMC0xLTEtMTcwODc1L3RleHRyZWdpb246MDQ1N2E4YzAyYzQxNDhhYWE0ZWMyYmIzOThkMjhkOTFfNA_6ba528a9-1256-44a2-aea7-5541face57f8"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzMtMi0xLTEtMTc4NjQ3_99cdc9d1-964f-4e3e-984c-776979403f8a"
      unitRef="usd">1099000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9afad4d704c441b8aca72f314828730_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzQtMC0xLTEtMTcwODc1L3RleHRyZWdpb246ZWE4YzJlNTVlYzcwNGJlMzg3NjA1NzdhMjc5YzcyMWZfNA_2d5b341f-6027-432b-b7c0-14095622bc61"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if9afad4d704c441b8aca72f314828730_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzQtMi0xLTEtMTc4NjQ3_c40b817d-8ceb-4a43-8c89-7b3bbe753552"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzUtMC0xLTEtMTcwODc1L3RleHRyZWdpb246OTQ1YTg0OWY3ZmVkNGNiY2I5NzllZmJmOWY5Y2M4ODVfNA_c4dfced8-5678-499a-b37f-4d45cca52b1e"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzUtMi0xLTEtMTc4NjQ3_e1422766-32be-42ea-92d9-1c85bba376c3"
      unitRef="usd">710000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzYtMC0xLTEtMTcwODc1L3RleHRyZWdpb246Mjk5ZWIxNmNhNWIyNDNjMjkyNGYzZmNkNjNiNWQ5NGRfNA_b7f8a934-1338-43ab-8c11-291a3f6acd6d"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzYtMi0xLTEtMTc4NjQ3_376988a6-87e5-4c24-b691-353aeb9007be"
      unitRef="usd">373000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzctMC0xLTEtMTcwODc1L3RleHRyZWdpb246ZjA5OTE5Y2Q5NDBmNDQ5NGFlOTNkOTlmZTU5ODUwNjZfNA_7035d803-ceab-4f19-8501-718fe2cc4725"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzctMi0xLTEtMTc4NjQ3_417c4f7a-f506-4177-a49b-3d4498494ef8"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzgtMC0xLTEtMTcwODc1L3RleHRyZWdpb246Yjg3ZmZkYTEzOTIxNDQxM2JjYjRiMWRmMzAzZjQ3OTBfNA_988cfd79-8a6f-489c-b726-26f18fcead04"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzgtMi0xLTEtMTc4NjQ3_2c16277f-b296-4057-aafc-91ca34f3b944"
      unitRef="usd">371000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5769552bffcc48e19f81962c26dee7ad_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzktMC0xLTEtMTcwODc1L3RleHRyZWdpb246YmY4OTJiM2YyYjBmNGEyMmE1YzEzNWViNmYzZDdmNGNfNA_3f4a4a92-1b98-4d5b-8f1c-9d8baecdaff4"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i5769552bffcc48e19f81962c26dee7ad_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzktMi0xLTEtMTc4NjQ3_23bb142c-cae7-40f4-962c-453f7d1eaea4"
      unitRef="usd">332000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEwLTAtMS0xLTE3MDg3NS90ZXh0cmVnaW9uOmM4YTA2ZjYxNTFlNzQ3ZmI4MzI4MTE3MzQ4YWNjOTJhXzQ_40982d25-55e6-446c-b05b-8b1aa06fd9ab"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzEwLTItMS0xLTE3ODY0Nw_97625692-3a04-4fa5-8d64-2ebd323f0608"
      unitRef="usd">336000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i470227bdb89e493fb8816f0ffa6ac326_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTpjYzI0YWY1MzU0NWM0OTUxOGM3NTc3NGI0NzEzYWUyOS90YWJsZXJhbmdlOmNjMjRhZjUzNTQ1YzQ5NTE4Yzc1Nzc0YjQ3MTNhZTI5XzExLTItMS0xLTE3ODY0Nw_8c48e9b9-e785-4da1-b2f9-3c78b2d6a913"
      unitRef="usd">5594000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f82a9dc3866412a9deea77bc5ae99a7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNDg_7c92c90d-c532-4eaa-82ed-5f35b03fb1f4"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia1517f47c4054556b04ca7e9f7836241_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNTU_2831e523-7b5d-473e-9f10-b207043ddf7e"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib42ba09a64844ca680f1d3c3cd60e33e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNjI_3b6948f6-dd3b-4f1e-a43a-f1a1a00cc2e7"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9afad4d704c441b8aca72f314828730_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNjk_a24df9e0-bd37-48e2-a639-7df8636c6f8c"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8745bbc0c8fc49fd9f490819ba267c4a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxNzY_cad46d1d-63fe-4dd0-8e59-6e21044d43d8"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8e844fc59da8465586a93905777c04be_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxODM_3d629f48-0ff9-4110-9931-fbf772ba8a85"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:ExtinguishmentOfDebtThirdPartyFees
      contextRef="i8e844fc59da8465586a93905777c04be_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAxOTc_2d5971f2-f1bb-4411-88fc-1ca95f66723f"
      unitRef="usd">25000000</bhc:ExtinguishmentOfDebtThirdPartyFees>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i336001093a5145dc9bdc0d6e370b605d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyMTA_4bf0c6a5-c999-4dcf-97ef-5de8f97fff27"
      unitRef="usd">1835000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaf91aadd30904af7ab5ff5c49b173483_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyMjg_a6983c87-a45b-49e7-8f84-e88aa73fc760"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i5f74ab6a22d445758697179f2d0c1807_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNDQ_e25a6df8-b41d-4fd9-ade5-120f79f0d226">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="iaf91aadd30904af7ab5ff5c49b173483_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNTM_c70c53f9-c28e-4705-9180-642dde2236c9"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3cb3d1e5412446dc811ba962259a01d4_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyNjk_a0e2a643-b22b-4a44-ac6c-a3f5f4aeb61f"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i523d17064ca94b16900c15d5f8c804de_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAyODU_d6ae81a9-7839-463c-a86b-29801feee11a"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id0475cb4c7ac43abbf4df21604027a97_I20220510"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMDE_f5dff486-e95e-44fa-9e5c-a9a73244eb1a"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMTc_e6af45a4-571a-490f-9939-fbc5fd6b79f5"
      unitRef="usd">975000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMzE_b7be15e7-264b-48a3-9369-391dd1e67d0b">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzMzk_b7477e8c-5f2c-4e7a-94be-e61dd8494d9d"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59050beb6a5f4285ae430ef5a8f35377_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyMTAzNTU_17bb6b7d-176a-43e2-8865-5474eb298475"
      unitRef="usd">470000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9c9ce2c21b474762a7da6161958145b1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEwOTk1MTE3Mzc1MDE_620617e9-b78e-4e7a-9fad-e6e11729810e"
      unitRef="usd">25000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic42bbc3c6bf3452bb704930c76f7dde5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNTM_723d7d1b-390a-47a7-b8a6-3add103241c3"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="i377918284ec1474f8fdb964743a3854e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNjA_724d9824-5dd9-4c63-a2f3-f4d3de094983"
      unitRef="number">0.0150</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i20b85ff842a240e69cd341f8a97baf08_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNjc_7b6ccbb5-a90b-4538-88a9-40adc68f8113"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxNzQ_b5563180-8447-434e-a118-f1eb2ef11b2f"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i02adb91ce4244dcfb8903780127e4950_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxODI_dfd43e0b-1108-4c45-9a97-b7950ef1e822"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i8a2132eaf78b49258c63546c8cf381a5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxOTA_21c95e59-60cb-4463-b1af-c89bb877d119"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i2371a67c1d5d4ce6bb8affa16d99a8ee_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMxOTc_86445fe8-1eb3-4427-8580-b2c0921e7166"
      unitRef="number">0.0025</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i377918284ec1474f8fdb964743a3854e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMDQ_db9aa685-6d44-4c4e-bfb8-43d826bc0f6a"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icfc22bae41d747e1bf892fd0aff2bac1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMTE_90129778-29ee-45fa-b499-527a7b8b5b56"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i12b21613190a42c48428381118250a85_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMTg_6f63a14d-828f-4aee-b9bf-d46aca3b5cdd"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i08144428b8f74cbfa6a5eb11eec200bc_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMjU_267cf219-7794-44d5-908d-945bf49007b4"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic2b61046449c4453948b31ac17dcf49f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMzI_f1e16594-9116-470a-bd57-e094467c6035"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib987a52fcaed4951afb151a82a0665fe_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyMzk_8427555a-ec8c-4a29-8cc5-bea1cbdad828"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i279595da75be49f6a0842b392c5e04e2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNDY_dca58585-78c6-4e3d-bd0d-a8621f5bf35c"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i5ba9e35b10d64b8f8d73e9204b9ccbf3_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNTM_a657876c-a26d-40e2-8e40-d72d076619ee"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNjA_68c4bf6d-5aa9-4a26-8845-cb779804204e"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNjY_54e33537-e1b8-433d-afc9-87c2f94393c1"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNzI_a724ab55-5839-402c-9835-63b22bd1c422"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i91cf750bd43f4040a31cffc04ba04ac2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyNzc_21bb2963-30e2-43c1-9fc7-ac0b1c20457f"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="id0475cb4c7ac43abbf4df21604027a97_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyODM_84a48adf-85aa-4db9-9b2a-07807fd05536"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i4e403587348b4dbd9a36b1f6aa5ca65a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMyOTA_603c21fe-9385-458b-a64c-1180c1dc7286"
      unitRef="usd">125000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="i4085e18b60c748e48cf892810f08a0c3_D20221231-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMDQ_4ff7c2c2-30c0-4c37-b4ea-02fed41de1bb"
      unitRef="usd">500000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMTg_e02c17c2-0486-4ef9-bd6d-d79c77e847f9"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage
      contextRef="i930bf880830b42ef8ff40d2fbedff278_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMzQ_2a354a56-4ee7-461d-ac7e-0de5fb871bea"
      unitRef="number">0.40</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i08ca66a8836a40cb85dd578b9e98529f_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzMzk_60b511ff-569a-4b22-80f8-24eaa49d7932"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="id7b201553ea840b8882b868dc71cc5f0_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNDU_0de25925-fc50-4b2a-b6d2-e548d60f5c40"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i9cfb98dcef094732bcafe6f62012d336_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNTE_bf354181-2671-4eaf-9315-b3e5a1b243aa"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="i19e771793b9549488be559466ddda99e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNTc_30d1fb5c-1949-4356-8937-17ecb002fe11"
      unitRef="number">7.60</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i8e4df79210ba43ca9c084ace43296d31_D20221129-20221129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk5MTc_51daf64e-6534-45f2-b88b-a0b3f07de93d"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic889bd7bbe3b4f05a299372748c68b3d_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzNjM_5a26ff1c-4cd7-4429-b792-06d91b5eeb03"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzODg_d9119925-1942-402b-97ea-f788af4227f0">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTMzOTk_65397b26-dbeb-4c46-a1d8-6330a8cf9b77">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idb3e0b748c154802a58a1beafbe2cff5_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MDE_1c021bc3-1f72-4b3f-a54d-ee5d29ba68d0"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MTU_34d95d2f-eb08-4719-be49-62cb607e23fa"
      unitRef="usd">2488000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0MzE_36b9a4b0-60fa-4cb6-9e6d-c5d9ae3d42d9"
      unitRef="usd">2439000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk4ODE_d6f079ef-874a-47b2-9ca3-f272e6c54240"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i15c6d66c35ee4080bdc94c23a19b52a0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk4OTA_47e49d3c-e8dd-4982-9fd5-c3c3f70ed4bb"
      unitRef="usd">24000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i8163e10398b746e7a5edad1b5513c5c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzU0OTc1NTgyNDk5MDM_6d29601e-f9a1-4bcf-938f-e95da670417d"
      unitRef="usd">476000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie320b639a3cd47dc961878584dd8c3af_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NDc_dcc12549-ce01-464e-b8da-aaf7299c2592"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8abed56d79f84c52a16d613195c7f1dc_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NTU_994e8efa-d192-4ca1-b625-ffab6e647ee6"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i5222261a43e242bd96ba62a6d53496dc_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NjI_c891623a-fd62-4d27-9111-639bc6821a6a"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia4b348dc7be84fe6845f94845ff52de8_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0Njk_910372f4-2960-48c1-9b22-bbf294c79249"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i08b9fcb7582349bdaf4dcf63e1033674_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0NzY_a374d381-8a48-4637-96db-d3b2f4d114e0"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia1d957402ceb40b8a787c5e4f4236ebf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0ODM_6388da4e-88d9-4e20-9437-e9752d3792ec"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8c1cf2c8c91a4a85aba037eee43e16a0_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0OTA_c089f806-c7e5-4ea8-a2ce-046156135af4"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i12a3c2097c9343febaf0889f97fafd58_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM0OTc_60da778f-f0bf-45b5-a552-a9a5cb3b8e09"
      unitRef="number">0.00015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3678fe7d442d4e65a3e4b646e9a46587_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MDU_d19d990f-287d-40a3-8867-0cb92791bb49"
      unitRef="number">0.00475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1d8fc1d36257456c85af865931829d7d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MTM_634e498c-de56-4645-b0a9-c5b23550e321"
      unitRef="number">0.01015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7bf08cd8ce2848bfb0ffd1ba61fd6396_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MjE_02fa632b-9844-443e-b435-a822c4607157"
      unitRef="number">0.01475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1Mjk_8f2a013e-ccb6-4e7c-9235-de8569171e0c"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ia1587227fe18483fbd9cf40bd7d77115_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1MzY_ce90b262-b578-4990-be3f-b762f0edbe31"
      unitRef="number">0.00110</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i6ce57f96608f474f8f53043e82f4429e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NDQ_25842606-23f5-4d23-8970-f51badf58070"
      unitRef="number">0.00275</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NTI_b14ddb79-0723-4a74-bf53-6b7c01c666c6"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i34b6aa60fd3b4cb8a9c35ca0b87ae3bd_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NTk_e822dd17-949c-4bc4-b4f5-c55d9e0ffff3"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4684fb9c9da34175aa3d87f334fea43d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NjY_406abacd-e2b5-4a3b-a557-3c96137578cb"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie357a3d3d5a5421cbd36adeb99212916_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1NzM_5925f64d-ad23-4db7-bd1e-253a77da44e3"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i77b3ae6dedf445a6b244a95db0040812_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1ODA_42d06870-3d9b-43bf-a724-d21754032e18"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4dd332b0a3d24ce2ab53e7a3886d2afa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1ODc_a97c14a9-efb7-45ed-93bd-0fa746e51413"
      unitRef="number">0.0784</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM1OTQ_096ed541-250f-48b5-bdbc-a8e95500ed0d"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MDA_107b5d8e-c5d4-4c7c-8aa8-8d7a8c528a57"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MDY_4775fbaf-bee7-49e6-ae03-0c83ffc583ef"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i6c18029690914024bc7fe9e7eb1f2e7a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MTE_431a6db9-0dab-482c-9d54-df92f694f208"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ic889bd7bbe3b4f05a299372748c68b3d_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MTc_9acf272a-77f3-463a-94b5-398085465ecb"
      unitRef="number">0.0100</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="ia92f6aaec2f0435ea1ee6916d308bbee_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2MjQ_ac47aa00-c635-4a1a-b95f-27db7d09ef60"
      unitRef="usd">25000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="iccfcad9639644d1aa8dd1ea244c8e451_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2Mzc_8d7d2688-31ea-454e-8c97-c79b08e544e8"
      unitRef="usd">106000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88d3d40cb3df41cb9891422a15f11c46_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE1OTc_5179969b-2913-4700-b9fe-fa63336d10ab"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MDU_311f1f44-ad05-4a66-a879-20d4e3fc2b05"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNDI0_a568efd5-1df3-416f-8731-3902342c27d7"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNDYx_f1a4cd88-0eac-4ac2-b681-c94bb2fba4f4"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNTI5_d1bacd87-242e-45e5-8659-717f395aa45d"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9cab5412f0764a9597e25ac424d2566b_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNTYy_a568efd5-1df3-416f-8731-3902342c27d7"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNjQy_010b335d-7ada-4060-a41b-989eb1088972"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i71bde11f22654ef58395cb62e46066e8_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzExNjc1_f1a4cd88-0eac-4ac2-b681-c94bb2fba4f4"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMTQy_198b6a3a-9286-47c0-adf8-bee6b96b13bd"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMjE1_96789e1f-03f0-4ff9-a7e4-be6168b69001"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieedc4eac3b8d4a698d8cb9a05c341498_I20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMjY1_aea3d4dc-9e12-4df6-a079-80fdc81b8180"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i861e04d76d3c48ab84c635bc2fbce9ab_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyMzAw_198b6a3a-9286-47c0-adf8-bee6b96b13bd"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyNjc3_a4244f0d-363f-4720-8610-77a4ef3f4486"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2e218676fac849289a6c340912b014b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyNzk4_7fc81555-efb7-4e69-a6ac-9784c3df82f1"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8aacff91d3fd4e97930a57ce23252d07_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyODMx_6e273eb6-aedb-4d7d-bf2b-6d20400b32e4"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyOTEy_d90b5a5c-c39e-426b-990c-abe804454f9e"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic538128a88704c54a42c782f1c49cea7_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzEyOTQ1_e3a3dfdd-e9db-4a3e-9a9e-061b5a504d10"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0NzU0_3a55634f-9557-4b80-bb08-f78898f5046e"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0ODYw_83b08718-068d-4f2f-9b2a-23e46041739d"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6dc5eabc6be94f9d8799367fe05ffaad_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE0ODkz_3a55634f-9557-4b80-bb08-f78898f5046e"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i157619cd6dcb473cb47ad7bdd54e90f3_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE1MDg0_372659b0-22c6-46e9-900a-441fe60d5476"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i044da1c8e8644f5d923942355e34d8ff_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE1NDg1_977d46c3-661e-4ad9-83e2-a9392563df58"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i1eb6552099344d328f3d1d048ca4608d_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2MDQw_b5eca4fa-a104-48f3-b99c-f2ab5e1ac8b0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i90b481eb38c945c59569b06b12fbff6f_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2MjY1_b3f55f0b-d3e7-49d2-a486-82329c06b740"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MTE_381ab1fe-3bdc-451e-97f0-27b24c9e269b"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MTk_f78a92df-cd28-4a2e-99d1-ec614201c6af"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2MzU_614de583-cf75-419e-aee7-7b28a0ba0a51"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3bfc736c31a94604bb0c70ced892d8b7_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NDM_7b29dbe5-26db-44ab-a58f-4b671173abf8"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0ae7bb4dd25840828cd9d3be1c5cf334_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NTE_70b86d30-89e4-43fb-9876-42974927eb4e"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="iccd58703f4d64effbac9da3441381c5d_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NTc_0cd2d037-bda7-41c2-981d-4dc862253057"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NTE_c449a57e-e673-4363-9739-903c1099acff"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NTk_fd35e2ba-fb76-44c1-9e03-a81d9fd8c9d8"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2Njc_1ad27d7b-5822-4d4c-8d65-0b60f193bb86"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i88775d2b6196454d8a77ee9d6235695d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2NzU_223f2f75-fbae-4db5-a9c8-a97e89fe457b"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0e1627198084241927fb3193e16c19e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2ODE_df1858db-47e9-4edf-99b3-6c8c248029bd"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2ODk_b14318f5-74d5-40ff-a99e-745b166ce835"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM2OTc_a256653e-547d-4834-bea4-a7db65dafd15"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MDU_c57401d7-f1bb-48d1-bbae-9d1f393e1c9b"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MTM_d3eb0acc-1d46-4d8b-98f3-e3cc703af5cd"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MjE_c4421d8e-67de-4b27-aad0-0d5d34d4bdba"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0698b60423314874943ed0139e7bdff1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3Mjk_55da5599-3cba-47ce-a237-836cbff87c8a"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3MzU_a38575c1-ec9f-4330-a68b-776cca3ef886"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i7a449c4bfa5041418ee1aa7972a1256e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NDM_6748978b-d7e3-43e7-885f-109d6458fcb6"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NDg_977638df-b4a1-4e37-9724-bef53a092b47"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d26b379509d423eb7d0672c56517477_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NTY_888f4561-855d-4c93-ab9a-101a59972635"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NjQ_1c5f6853-0b5e-450e-9742-82c34b1438b8"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3NzE_393a7aba-c53a-47d0-bcc4-628c0c9363d3"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3Nzg_d960d0f9-83eb-4b63-953b-e31dbfae913f"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3ODU_c97140b4-4697-4da7-a734-e13393684e7a"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3OTI_4804980f-70fd-41f1-be33-b7e6c5d85196"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM3OTk_4d7959bc-1f85-4e80-b8c4-303c19257761"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i7d7729b9b40f4da1b234f69afa941cbe_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MTM_80f01a09-8bcb-45d4-bdbc-951317c87bfd"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MDY_162f23ad-2432-4cbe-9bf4-c924f11ebd92"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4MjA_87beabd2-acbb-4501-b671-fc30cba0ac14"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc62ed95df4c4f718a9ab78fe220331a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4Mjc_6992bbbc-7cbd-4284-9f0e-6cc933fb1e57"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ibc9e2bcfdfc8462abc99097872f4c5a1_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3MzIw_0a7f4130-0c23-457e-a656-ddf7ce3dca29"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="iff3554474d984129a7b72717cf870c74_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMjU_abc063c6-43b0-4924-913d-7834545bb5de"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff3554474d984129a7b72717cf870c74_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyMzk_24d7587d-93a8-41ac-9080-bfbf1835e629"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="iff3554474d984129a7b72717cf870c74_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyNDY_bb12d31b-a832-41de-9ad2-1ff624c45148"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="idd69ab9daab24aac824807091b8a5671_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTg1MzQ5OTAyNjI_a55771d2-32db-46f0-8064-f4e35fc5cdb0"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NDM0_86e4421c-ad60-4c36-a7b8-979feb424ade"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NTA5_f91314f4-55df-4011-a892-cdf064cd0ed0"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c469d793b6f4ee882b2681b6838c579_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3NjU2_86e4421c-ad60-4c36-a7b8-979feb424ade"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic8228270dba34df8adb389c08897a92f_D20200101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE3ODk3_f6bcd1ee-8b6c-41e2-bbdf-62961e227619"
      unitRef="usd">169000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1a3b96fbff084df6af99651fb95d52b6_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MDEx_e7897059-04a1-4f68-966c-248c80716794"
      unitRef="usd">233000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTA1_ad5efd57-7063-427a-9afb-fdec4cb5d41b"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTQx_75550855-2b2c-4986-b2cf-fcd11a183d4c"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MTc3_a2f08c7a-64d3-4e98-9513-a7049312cff1"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MjE2_36289daa-76e5-4e24-bf32-eed8851002ac"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4MzY5_9041e3c5-f5b0-45ab-86d5-2da8dadbb33a"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NDAy_eaaa52c4-4272-4eb9-9111-9c7c689ae59d"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NDcz_db5a1a91-3ec6-4a30-b59f-ec1d3b1f2a03"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NTMy_5c1380df-f295-4d74-91d1-3a79ce51a356"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NTY1_320acecc-5677-4e83-b1d5-9d5f1c21edd9"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NjIz_20ae2649-423f-4d13-a7f7-b760aa083955"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4NjU2_cae417be-2496-4896-a49e-b74da7a69d03"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9d4d9fbd8c2b412ba5609b5db57a3ea4_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE4ODU5_63c0505e-7a54-404a-84da-c51a3d4c0dcd"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib7a80fb088e54c2f87adcda10dca8eba_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MDI1_8068ecb6-9e56-4c02-a402-fe8c260f00d7"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8bda88c9492434b8ad71e6d24f403d9_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MDMy_6c1e8343-49e2-4bb8-99c8-f19c2a6c7e84"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1f42826c47ed4f49b649fda634dc4a0a_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5MTk1_b073eb03-9ed7-4d5d-a2fc-fffcca4d6ddd"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i2c4e650a31d242bbb5c5d585c03cb333_I20200116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5NjQ2_88d43419-02ed-4a07-8e80-bd59259a1e35"
      unitRef="usd">1240000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="idb5cda3faa264c738c116577d2729461_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE5ODI1_1e95c224-08a9-4081-82b1-77afad5b5b54"
      unitRef="usd">208000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1e615859d6bb4a4e90467e2add18e800_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwMTYw_f18649ea-a29f-48f9-a589-97b36f479e11"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idadc1532b7b04afba0801fa41303f107_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwMzk2_e5228871-1cc6-4432-ace2-cb30fa94730e"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idadc1532b7b04afba0801fa41303f107_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwNDcz_b11f0eb8-f48d-43aa-aa9a-d81894522c29"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idadc1532b7b04afba0801fa41303f107_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwNTA2_210e12b6-cd3f-4898-8dbb-4a6f9a9051e0"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idadc1532b7b04afba0801fa41303f107_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIwODgx_f4419b1b-f42d-42d5-aa58-8cedd1351c0a"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia297817a7541403aa01709acbd44a471_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5ODM_c8ce78e6-3508-4503-969e-59b5b164d530"
      unitRef="usd">541000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxNzk2_331930e8-2695-448b-b30d-beb55cd843ad"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxODYx_07c76e78-3393-49c1-bda3-36ea77bb808d"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIxODk3_331930e8-2695-448b-b30d-beb55cd843ad"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIyMDYw_e3312b81-1d4f-4947-ba74-ba1fee92418c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iefa2df21bacf4eceb62fe61ff33ee4ee_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIyMzE5_331930e8-2695-448b-b30d-beb55cd843ad"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i6bb93a16e162462585252110ee36a962_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5NTM_0c51565c-e277-4bf9-b5db-4186ea33f187"
      unitRef="usd">752000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e218676fac849289a6c340912b014b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzMTgx_86a087d8-9e6d-44cd-b7a0-ad9a896ae083"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5fa832e82c1d49a2a3ff00d4b061892e_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzMjcw_61e46650-90d8-43ff-800b-e86294b15efd"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e218676fac849289a6c340912b014b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNDIz_86a087d8-9e6d-44cd-b7a0-ad9a896ae083"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2e218676fac849289a6c340912b014b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNTUx_7fc81555-efb7-4e69-a6ac-9784c3df82f1"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e218676fac849289a6c340912b014b8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzIzNTg0_86a087d8-9e6d-44cd-b7a0-ad9a896ae083"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i669d24178a614762a12dfff0155fe19e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5Njc_55df0481-d674-4f93-abde-985272bec09f"
      unitRef="usd">1099000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibfed71661ee944d49ddb49203d8a286a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNjM_31191404-cc2e-4680-923d-797f94003df1"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NTI4_2d2d9ad5-facc-41a1-9a30-e95384258716"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NTY3_3b899dd2-9a6b-4b95-a838-b5332e69ca60"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0Njc5_6910b970-ea00-4ba5-a973-2e6a7ff83f8e"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NzEy_2d2d9ad5-facc-41a1-9a30-e95384258716"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0NzYx_cae1fdfd-13b4-46c7-a807-cdbd84374f78"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0ODA0_b4fe1f72-30d6-416d-9b8b-393877ae4928"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI0ODM3_3b899dd2-9a6b-4b95-a838-b5332e69ca60"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI1Njkz_a6351379-e763-4040-ba49-5eaea5eaa5a8"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MDAz_3693ef92-85b2-4642-955c-f319c55030f2"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i9df3f1e3d2554c78ad4cbb459875b7bf_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MTQ1_28314832-f509-4d6a-8b46-a92d86c50374"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i18218eacfbb142faaa9a5d87297b9a13_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2MTQ1_8b4b1dc5-69a2-464e-9c40-7937744d62c2"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i696a075a54064b0997717cd8d8a32b6c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MDk_f35201a2-c0b0-43df-bd20-7681aa49f522"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i9cc611b24a90474d83f2f66f38a20f88_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MjM_b9eb1234-c0ad-49e7-992f-ea3a0cda377d"
      unitRef="usd">373000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50380855fc2e44f5b6be1ffc1d533681_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5Mzc_a9b5bbf7-01c8-4cd1-be53-e3aa1876a771"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9882b34fe6474ac8b75496ebe2306941_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5NDU_a7581650-be62-428c-8008-0b1251bb845c"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NTE0_fb111677-8a1a-4156-b940-e4634fab8baf"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NTUz_ff4bd4b7-6997-44e2-9981-25c814706c1f"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2Njg5_2f2c748a-e916-452e-a8e6-ebf5241583fa"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2NzIy_855f55e2-9aef-43d8-be34-890e154f391e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2Nzcx_18cd6c21-5371-4ae7-a3f5-c6e612d3342a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2ODE0_6803ed10-62e0-48d6-904e-9d93689340cc"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI2ODQ3_5a83fa9d-9f8c-4f7c-b913-871c15b0a760"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI3NTk3_18cd6c21-5371-4ae7-a3f5-c6e612d3342a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI3NzYy_18cd6c21-5371-4ae7-a3f5-c6e612d3342a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MDI4_18cd6c21-5371-4ae7-a3f5-c6e612d3342a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i3fe5dc0384494154a1e6d8f92d81bdcd_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MTI2_1f6c8083-aabf-495e-8970-4f43fe5975f1"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id10012d6ae2a4a9a8da2d30e73d8fbe6_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4MTI2_3a620a45-eba3-404c-9edc-e3619f1b4236"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i3fc3ea4063504440ada3d5c75d466bff_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4NjU_3c91c027-fbae-4a0b-ba2c-786ea40c2795"
      unitRef="usd">710000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i1e135d7f019a49849b913e4b90edfb2d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4Nzk_43b73b74-9192-46e7-a49f-ff83f78bc164"
      unitRef="usd">332000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i504d7ca4dc5b4a8fa55aaa9f922a00c0_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM4OTM_75c36869-4be0-4f5f-9e20-1fff909a3a78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib223f403a7154cc18ac343122c9c3e06_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5MDE_a798784a-b23f-477a-b393-d9494f7a0027"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NDE3_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NTI0_22d00e50-8102-4720-8114-e2242e122688"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NTU3_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NjA3_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i274a447de4c946398cf00b10748b1942_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4NzI1_0aef5546-acd9-4123-b2dc-bbd5d3fff8da"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <bhc:PaymentForDebtAmortizationPrepaymentCost
      contextRef="if254b82a71434782ad56911693096e5f_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI4ODEy_89e2fade-30c9-4b33-a7c9-ddf06da5f47a"
      unitRef="usd">303000000</bhc:PaymentForDebtAmortizationPrepaymentCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iecbd9075b4a94899961c7585f2aed5b7_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5MjE3_d1b1e547-3677-492c-bd19-7aa465517431"
      unitRef="usd">-27000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5MzUy_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NDE2_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NTQ3_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0d9a11ba7b5b4f3ba097f6f466955097_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5NjQw_f0b9bb6e-9d90-4df3-ada5-29cadbe67864"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i35ebc47cf5eb41e4b68a050da347702f_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5ODU0_a264ec91-fefc-49d1-99fb-a7d74b72d745"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzI5OTEw_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMDM0_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMTU2_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMjQy_6fe9169c-ad4f-4e33-a57d-25b832b91816"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ia9830466dc5e4c1b9a52f500da56a52d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTM5OTc_c5532106-5aa4-4e4c-b748-67b78aaaa810"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if81f73f3e85d440bab9c87b07c094950_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMTE_d46dba89-c3e5-4b6f-a66b-80071b9f8487"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwMzY2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNDA1_7a2ddfb8-846b-4889-9466-9ecb7304c3aa"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNTIx_b2d9b729-7e10-459d-b60f-e1cd3b9407a9"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNTU0_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjA0_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjQz_79cb67cc-bb20-4032-b51d-a65260c39375"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwNjc2_7a2ddfb8-846b-4889-9466-9ecb7304c3aa"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i6f524e92b57548fcb59a5560034d56ea_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwODk4_0a4cf65d-d48c-42a3-bb41-4d7d18118c52"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i40215fdad1084cdd819206c295150373_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMwOTI1_cadfc032-dad2-437c-86a3-80ff29e5205d"
      unitRef="usd">233000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7a746c21c7a14bc3bc2a6e2b9323019a_D20201203-20201203"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxMjQ3_ff01b560-8420-4236-83f1-c894960dc74e"
      unitRef="usd">-7000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxMzgy_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNDQ2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNTk1_7a2ddfb8-846b-4889-9466-9ecb7304c3aa"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxNzI2_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMxODE5_419fb918-12cf-40ae-a1ac-fed21e629376"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i203f4f5fcee3421fa9933d730e146a97_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMDM1_f1cd33ce-7b6b-4370-9189-3c56fc5dc6d8"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMDkx_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMjE1_c7bcec0e-3463-4bb2-8c5d-6f05bb4c5b30"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyMzM3_5d5050d8-a1a5-4ac7-95cf-c4e1fec4586e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyNDIz_32cda7bb-1747-4009-b24f-577fcb61c42a"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyNjg0_8df2d438-317a-4c4c-a756-7b00a1c5180a"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ieb35bce15b1e49fe91c882043f4a193e_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMyOTAw_900e5b44-aff4-4c97-b6d6-d3ed1eff5875"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i0ed6355aa8404cc9862ff4ff062d0399_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMTk_b7ce7d13-37e5-4fcf-9a0b-5e5c8f7ec5aa"
      unitRef="usd">371000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ice52a066605a4e9897aa4694669ec4cc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwMzM_8eadecf0-0c9a-4e76-9963-fc0d360cafe7"
      unitRef="usd">336000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0457826532364f8e9c2bd5bce176537a_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNDc_a9c8d6c6-03c7-461e-897b-670b830b46d2"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i64c9aae9869547b990b47d9f024d2b7e_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1MTQwNTU_a5affc76-e4a2-4797-8b41-f980b9096885"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMzNTQw_b58ed975-53ce-405d-a3ac-f359f57cc0bb"
      unitRef="number">0.0774</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzMzNTQ3_5efdd0e7-b959-4d83-8a8b-821aec75d038"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ifdadcd473052481b9f108756b569bcf5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NjI_7d66a73d-41f4-4193-a3af-be13f50190c9"
      unitRef="usd">927000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2NzY_63244f71-c9c2-49a4-81ca-62ec2131dce8"
      unitRef="usd">550000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i440a6ed8c3ec4590b6102589534a1d6b_D20220601-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE2OTA_dc3d8067-6970-4677-8e3c-95f9efc5da15"
      unitRef="usd">369000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i700f313b8feb4a02af4dbbaaf4864a43_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE3MDQ_2ed1834e-ba9e-42a2-be36-dd5b7e608871"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="icc4a098d6f0545d9a3df6e94e3949b54_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzE2NDkyNjc1NDE3MTg_fb275e4f-f955-4134-8bfe-d001e8bb9e0d"
      unitRef="usd">-64000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90ZXh0cmVnaW9uOjFlNTI3ZGU1MzRlZTRmN2ZhZWE5OGRkZjZmZGJhOTRjXzM0MjU2_50e9a270-ec29-4b6d-af0c-20c861f843bb">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzEtMS0xLTEtMTY5NjA4_a706fa4f-f1b5-4344-9e47-d976ee5c9a34"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzItMS0xLTEtMTY5NjA4_d519d961-8dd6-45b7-9fc0-de4c4b444558"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzMtMS0xLTEtMTY5NjA4_202e6856-7376-4dbe-ae5c-b33ed91ab14e"
      unitRef="usd">2789000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzQtMS0xLTEtMTY5NjA4_a8b5c6ed-7394-41e2-b0a1-6917dcdce918"
      unitRef="usd">891000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzUtMS0xLTEtMTY5NjA4_f9c677b1-9883-496a-aedc-277a69491774"
      unitRef="usd">6938000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzYtMS0xLTEtMTY5NjA4_1a0961c4-b290-4313-9bf1-563b6d69b7df"
      unitRef="usd">8192000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzctMS0xLTEtMTY5NjA4_e4551eb2-1d80-4439-9a9d-9354ad9551ec"
      unitRef="usd">19110000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzgtMS0xLTEtMTY5NjA4_8fef4f4c-1f34-4b7a-92b3-f09944e51491"
      unitRef="usd">-1656000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDAvZnJhZzoxZTUyN2RlNTM0ZWU0ZjdmYWVhOThkZGY2ZmRiYTk0Yy90YWJsZTo3MzU2YTExMmM1YTQ0YTMwOTE2NTI3MGExZmZiZDdlNS90YWJsZXJhbmdlOjczNTZhMTEyYzVhNDRhMzA5MTY1MjcwYTFmZmJkN2U1XzktMS0xLTEtMTY5NjA4_e8e97b28-4a65-48d0-9307-8afd71685b24"
      unitRef="usd">20766000000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzOTg_d708f385-a9d8-4127-891a-ccfcb4d54a43">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp;amp; Lomb Holdings Incorporated (&#x201c;B&amp;amp;L&#x201d;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan. The U.S. postretirement benefit plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the B&amp;amp;L benefit plans, outside of the U.S., a limited group of the Company&#x2019;s employees are covered by defined benefit pension plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Pension Benefit Plans and Postretirement Benefit Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2022 and 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Benefit Obligation, Change in Plan Assets and Funded Status &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#x2019;s defined benefit plan in Ireland to a defined contribution plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of the Company&#x2019;s pension benefit plans were underfunded as of December 31, 2022 and 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2023, the Company expects to contribute $0, $4 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#x2019;s U.S. pension plan for 2022 was 4.50%. The expected return on plan assets for the Company&#x2019;s Ireland pension plans was 2.75% for 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 expected rate of return for the U.S. pension benefit plan will be 6.00%. The 2023 expected rate of return for the Ireland pension benefit plans will be 4.25%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Benefit Plan Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Plan Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#x201c;FAIR VALUE MEASUREMENTS&#x201d; for details on the Company&#x2019;s fair value measurements based on a three-tier hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 92% and 95% of the non-U.S. commingled funds in 2022 and 2021, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Contribution Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans and the Company matches a portion of the employee contributions. The Company contributed $47 million, $44 million and $43 million to these plans during the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance
      contextRef="i24e7ab6a195b4f8a8f49a061d91b6087_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzY3Mg_1ec1e233-fb3f-4209-af36-094e61399bb8"
      unitRef="number">0.0450</bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance>
    <bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans
      contextRef="i8f6923561a7e494dbd4b2c015eaf76da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzcxNg_55e26615-08e9-4839-a47f-6a6af9589028"
      unitRef="defined_benefit_plan">2</bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans>
    <bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended
      contextRef="i16516120cd164448a3c89f1ebb6cd381_D20141201-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzOA_f69c43cb-746d-44a4-b845-59d5f9048502"
      unitRef="defined_benefit_plan">1</bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended>
    <bhc:DefinedBenefitPlanEmployerContributionMaximumAge
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzE0MjM_3399b7fc-7602-4946-a66e-26125aa32a23">P65Y</bhc:DefinedBenefitPlanEmployerContributionMaximumAge>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0Mjc_a6255919-ba08-4532-b147-481ccbcd6a20">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2022 and 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial (losses) gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMi0xLTEtMTY5NjA4_eed5d28a-bf95-409a-837e-237ad47cf60f"
      unitRef="usd">-35000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtNC0xLTEtMTY5NjA4_c9139263-75e7-41ca-bf49-88e5a069dcd3"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtNi0xLTEtMTY5NjA4_df1c8d59-377f-471f-a4a8-e9424f7bd2c3"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtOC0xLTEtMTY5NjA4_6a05e694-8807-4d84-8b15-6eaa841fb8b8"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMTAtMS0xLTE2OTYwOA_e47e6aef-dbe3-4cec-bb72-ead21b45a5cd"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzMtMTItMS0xLTE2OTYwOA_182b9d9b-66f0-46e0-910b-95fd4fa525b9"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMi0xLTEtMTY5NjA4_812b2870-9b76-4757-af35-cf8db92862a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtNC0xLTEtMTY5NjA4_3755b302-3270-4ab6-b720-53a9297352a3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtNi0xLTEtMTY5NjA4_fb6308c0-da79-48d7-9bf4-84ddc3d09553"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtOC0xLTEtMTY5NjA4_743dac0a-952e-49f9-97e2-76baa2f16fc0"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMTAtMS0xLTE2OTYwOA_632a7910-f087-410a-aa74-b3e9ea04c724"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo4OGNlODE0M2E5ZGE0NGM5YmFhNzI5Y2NmMDc0ZDVlZS90YWJsZXJhbmdlOjg4Y2U4MTQzYTlkYTQ0YzliYWE3MjljY2YwNzRkNWVlXzQtMTItMS0xLTE2OTYwOA_9e53fff4-1d10-4dd5-8f80-0a94ed14950e"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MDg_bf408f8c-6032-450a-96dc-c03c8141bdf7">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMi0xLTEtMTY5NjA4_f769a719-c709-46f1-8246-d85ede05ed1f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtNC0xLTEtMTY5NjA4_8da62794-da43-4a31-ae7c-978f9b44139a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtNi0xLTEtMTY5NjA4_6e42a9ad-841b-4c29-99ff-ea577a75ea83"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtOC0xLTEtMTY5NjA4_b855e4c2-da59-4d08-b559-7b75f1584eb9"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTAtMS0xLTE2OTYwOA_dad7027f-e43d-492d-b5c4-efc6f4a0e4ca"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTItMS0xLTE2OTYwOA_7e370462-ad23-48b3-9b40-c88a76ceba47"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTQtMS0xLTE2OTYwOA_879d91a5-6ebd-4fa3-ab2a-dcd20d061af9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTYtMS0xLTE2OTYwOA_bf2df45b-3a02-412a-a776-b2c1b00fdabe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzMtMTgtMS0xLTE2OTYwOA_5fd34237-b8a9-4a5b-b558-1895b8b3e0b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMi0xLTEtMTY5NjA4_ac507fbf-446d-4c0a-89b5-a415f95b054e"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtNC0xLTEtMTY5NjA4_c6cd4b24-6fce-4f48-90e6-0ee664b31123"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtNi0xLTEtMTY5NjA4_5c54a370-0c1d-436b-b610-a2d5f963cda2"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtOC0xLTEtMTY5NjA4_5a7dfaf3-cdd0-494d-9a52-fa0a18309c8f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTAtMS0xLTE2OTYwOA_27489259-8350-49c4-9408-d1ec83bd9145"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTItMS0xLTE2OTYwOA_2518a640-df9c-4682-8b90-978993c3b22c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTQtMS0xLTE2OTYwOA_b7effb68-52ef-4dbd-81bb-a4001e2acc79"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTYtMS0xLTE2OTYwOA_7d918f92-566b-4f0b-becc-842451d84c13"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzQtMTgtMS0xLTE2OTYwOA_9e13dcb0-4307-45c8-b1bb-f8b23f2e374b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMi0xLTEtMTY5NjA4_2fc0433f-d46e-40fb-98ce-c72766e40450"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtNC0xLTEtMTY5NjA4_bd3729df-0d10-4919-9da1-70b80c2a93bc"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtNi0xLTEtMTY5NjA4_06a07d1d-0217-4c17-9334-afae6b48e56f"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtOC0xLTEtMTY5NjA4_be2cbf9a-6479-48db-a3c9-da0e4e169dbb"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTAtMS0xLTE2OTYwOA_1f30b0c9-28f0-4b05-a729-930ee56ee5d8"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTItMS0xLTE2OTYwOA_7f1e3f4d-5c5b-47cf-8604-f8d6bf91910c"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTQtMS0xLTE2OTYwOA_452c1069-4c49-47cb-9141-a12d0f34c251"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTYtMS0xLTE2OTYwOA_0b8d7c94-8ba2-4bcd-8b29-47aff3491854"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzUtMTgtMS0xLTE2OTYwOA_70844ce7-8ee6-4d34-ad98-9d5d6bc5346e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMi0xLTEtMTY5NjA4_ca0d533a-9eae-474c-9169-00f2d578f503"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtNC0xLTEtMTY5NjA4_551daec4-4e49-498c-8590-47e85b4158d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtNi0xLTEtMTY5NjA4_ae9a90c8-7e27-443d-b893-5906d4d08383"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtOC0xLTEtMTY5NjA4_8213f73d-5ed1-490c-8827-5e9f4c47a518"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTAtMS0xLTE2OTYwOA_fa2337f0-2120-424f-b5c3-bcffe043c075"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTItMS0xLTE2OTYwOA_01c21fb6-0dec-4c1e-9d64-51b830db075b"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTQtMS0xLTE2OTYwOA_2f8339bf-78c3-42b4-bc56-39e343ef9586"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTYtMS0xLTE2OTYwOA_bd5d3ecb-f41b-466b-9f66-35bbf9f55106"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzYtMTgtMS0xLTE2OTYwOA_3695363c-7eed-47a2-98bb-16b198bd8ec5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMi0xLTEtMTY5NjA4_173e0070-985c-4967-8512-30aba9d97e1f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctNC0xLTEtMTY5NjA4_bf6983eb-4d91-4201-a2df-a3be7c6d2a94"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctNi0xLTEtMTY5NjA4_6bf293ea-97d4-4dcb-b34c-d7d6799140c6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctOC0xLTEtMTY5NjA4_b600af3f-61ee-4af3-943f-608cd7976163"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTAtMS0xLTE2OTYwOA_482a9f49-dfe1-456c-be9b-e3d3f79ccedf"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTItMS0xLTE2OTYwOA_19404ffb-5e52-4918-acee-8474e78d36ea"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTQtMS0xLTE2OTYwOA_f8cf9017-02ff-4411-ac16-a44157f42c0f"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTYtMS0xLTE2OTYwOA_80fb8fe0-4c6d-4776-b85b-3f73cca678b5"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzctMTgtMS0xLTE2OTYwOA_433979c4-7edc-490c-b679-cae5d9cfe017"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMi0xLTEtMTY5NjA4_625018bc-8503-45aa-8b53-d9ecd310b14a"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtNC0xLTEtMTY5NjA4_7bf00178-9eba-4263-88de-124abc1ba0b2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtNi0xLTEtMTY5NjA4_07db7a2b-a931-46af-a7fc-7675fc3f928b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtOC0xLTEtMTY5NjA4_fdd65c4a-0bfa-4a58-85d0-35e21fed2964"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTAtMS0xLTE2OTYwOA_af5cef01-a37a-437a-a553-2eb11259b743"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTItMS0xLTE2OTYwOA_0e18b360-d624-4d99-bfae-b8bd2e9032b5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTQtMS0xLTE2OTYwOA_49b6c700-ddfd-4cc5-80eb-032eb0c35d08"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTYtMS0xLTE2OTYwOA_9d5a8791-8224-4f61-b6d0-6135a1c5b356"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzgtMTgtMS0xLTE2OTYwOA_634eb40e-9c18-49e6-a729-7beba2c6cb75"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTItMS0xLTE2OTYwOA_b97a00db-34c3-44ea-9a4f-8fe64cb9e367"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTQtMS0xLTE2OTYwOA_4f26c397-d44c-4508-bce8-8bb165c50948"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTYtMS0xLTE2OTYwOA_922adb13-775e-4ffd-b471-908914935f0a"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTgtMS0xLTE2OTYwOA_22003849-596a-437b-9da9-f7c945955289"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTEwLTEtMS0xNjk2MDg_1a4bbad3-47af-4262-8f42-5543f2d3332e"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTEyLTEtMS0xNjk2MDg_2adac560-334b-470a-9d88-f0bcc810494a"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE0LTEtMS0xNjk2MDg_7e2ca78b-411b-4f60-b5c3-7b21cfc02901"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE2LTEtMS0xNjk2MDg_2e245f40-0a08-41f7-bad8-d88450a67d05"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToxY2VkNmNjMzZjZmQ0NTgxODA3YTUxZDAzNDNiN2VhZi90YWJsZXJhbmdlOjFjZWQ2Y2MzNmNmZDQ1ODE4MDdhNTFkMDM0M2I3ZWFmXzEwLTE4LTEtMS0xNjk2MDg_ef590664-2f52-4a17-b1a9-07fbad1ae6d8"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MzA_b2a83639-1466-4e49-979c-8ad2a157f274">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMi0xLTEtMTY5NjA4_8337be31-7e78-4fb8-92a7-147b5e51ef10"
      unitRef="usd">220000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4d0e93f49dae408e8c386793727d9086_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtNC0xLTEtMTY5NjA4_6a8818a0-5d25-4912-85b3-0f1d9697dae3"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtNi0xLTEtMTY5NjA4_6aa5af47-d239-4e59-b270-ddf826467fd6"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtOC0xLTEtMTY5NjA4_0f5ecd9b-e470-4e32-80f8-5eb7a3989753"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMTAtMS0xLTE2OTYwOA_d553710a-a4e5-4b81-b05a-f9cc17e2a031"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ibfa7c677eed24732a11e7ab6f1654f25_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzQtMTItMS0xLTE2OTYwOA_af2924d2-5c3b-4165-8528-d74e24ef0a0b"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMi0xLTEtMTY5NjA4_a233f4f7-8830-4759-8349-8e251d9ad326"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtNC0xLTEtMTY5NjA4_25d73ac1-1542-442d-bd6d-8b8789d50348"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtNi0xLTEtMTY5NjA4_81d7cdd0-9c09-457f-9f28-eedb82ac1fa1"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtOC0xLTEtMTY5NjA4_1c8d7e5e-9b10-45c4-878f-5557b45032d4"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMTAtMS0xLTE2OTYwOA_b80a42ad-c4c2-49bd-aba0-2805fdfe8448"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzUtMTItMS0xLTE2OTYwOA_7e872f10-4995-498d-aad1-ca0c1c99b5da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMi0xLTEtMTY5NjA4_18eb01d5-ec54-4722-85d8-f75ddacf3fbd"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtNC0xLTEtMTY5NjA4_b1d13ab9-17cf-4457-ba40-46aca652c271"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtNi0xLTEtMTY5NjA4_f9ebaa99-e885-413a-8eab-d56b87260819"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtOC0xLTEtMTY5NjA4_244e1a28-91ce-4909-85fb-57fe82e94d2b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMTAtMS0xLTE2OTYwOA_32e9665e-5b37-4901-a3de-59e953b4e91c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzYtMTItMS0xLTE2OTYwOA_d51dada2-9c57-4186-876e-8860ef5fb3b0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMi0xLTEtMTY5NjA4_84fd56e8-22e6-4c4d-92be-306860d90cd5"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtNC0xLTEtMTY5NjA4_87b65910-dc7e-4b4c-8b99-ec44fed4d7c7"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtNi0xLTEtMTY5NjA4_07df6c3d-2356-49b8-bfbf-d7e7e45a41e5"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtOC0xLTEtMTY5NjA4_381aeac7-cb63-40cd-b282-7dfd4f3b5136"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMTAtMS0xLTE2OTYwOA_dc068465-4090-4607-bbca-63172b375f5f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzgtMTItMS0xLTE2OTYwOA_be02fa0d-8492-4513-8b1f-a2202468be82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMi0xLTEtMTY5NjA4_9c36a412-b6ce-4353-9747-3f8b8d5ad419"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktNC0xLTEtMTY5NjA4_e7a53690-ad31-4a64-8e03-832af4bbd773"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktNi0xLTEtMTY5NjA4_47a3c3dd-0a4e-4b57-8160-2c8d7bb216e4"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktOC0xLTEtMTY5NjA4_911ade8a-1e51-4cc4-94fb-d4235436b95f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMTAtMS0xLTE2OTYwOA_e8da97a4-9e21-4345-ad00-048232a1adcf"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzktMTItMS0xLTE2OTYwOA_d85dbbb8-b3fc-4bd4-8d6f-31881cb55710"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTItMS0xLTE2OTYwOA_5d626a8f-bdf0-45d3-9fbc-5d7ad993a991"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTQtMS0xLTE2OTYwOA_a1f6d533-c560-4f04-b26b-6d740474d21a"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTYtMS0xLTE2OTYwOA_3943748a-cbd9-4364-9908-c59ebe2f14f9"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTgtMS0xLTE2OTYwOA_25a364d5-0cc2-4ae7-97e0-f2bf198740e5"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTEwLTEtMS0xNjk2MDg_4b13fc54-643a-4e29-aa17-31a71098949f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEwLTEyLTEtMS0xNjk2MDg_650c713c-f7f6-461f-83aa-992b42d8bbb2"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTItMS0xLTE2OTYwOA_1c3458d9-932e-4724-adf3-a7f2b8f59495"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTQtMS0xLTE2OTYwOA_c656cbc2-ee36-4c24-b055-cd7e9ed92f0a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTYtMS0xLTE2OTYwOA_7b633a72-abca-47ab-9731-471fbc21a0b3"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTgtMS0xLTE2OTYwOA_3a256e34-6551-4463-861e-d927107be43d"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTEwLTEtMS0xNjk2MDg_af39e3de-4d98-4e6b-a6a7-28f6f40b0dc1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzExLTEyLTEtMS0xNjk2MDg_316fd283-f286-4beb-a36c-44305ba9900c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTItMS0xLTE2OTYwOA_3fd52400-e4fe-43c3-a8ee-10dad00ec772"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTQtMS0xLTE2OTYwOA_61f017d9-e372-44a6-b44e-efc258fa48b4"
      unitRef="usd">220000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTYtMS0xLTE2OTYwOA_c0b43d79-bfc6-4f4f-9c40-438a92893364"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTgtMS0xLTE2OTYwOA_7d9adf64-789f-4b80-9fce-fb473db7456f"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTEwLTEtMS0xNjk2MDg_dc72df34-5a18-4b0f-9cf8-c6992f507dd7"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzEyLTEyLTEtMS0xNjk2MDg_77d7535d-a6f0-4105-87a6-3d7eef775517"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTItMS0xLTE2OTYwOA_36b84ca0-4d17-415f-ba79-ad55729b025e"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4d0e93f49dae408e8c386793727d9086_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTQtMS0xLTE2OTYwOA_7de2b4e4-dd3f-43ad-9e62-57a9ecc5a9ba"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTYtMS0xLTE2OTYwOA_a2bdb351-bfef-4d0a-97e8-b420e88747a7"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ff9d680d8794e55b84ea6090b5b5f93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTgtMS0xLTE2OTYwOA_7d216c01-7a3f-4eb2-a5c8-00a4b096d353"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTEwLTEtMS0xNjk2MDg_b33b8ba5-a0ab-4709-aeca-6a975f01d615"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibfa7c677eed24732a11e7ab6f1654f25_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE1LTEyLTEtMS0xNjk2MDg_d7099b96-ab61-4b92-a57f-f30e4b3e01e4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTItMS0xLTE2OTYwOA_cc2c2a55-2420-470d-8703-68363a069992"
      unitRef="usd">-44000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTQtMS0xLTE2OTYwOA_3099697c-6399-4674-a1d9-d6cf2bc62138"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTYtMS0xLTE2OTYwOA_4e44dd61-c553-4bd3-a717-b7bb1dcf5903"
      unitRef="usd">-41000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTgtMS0xLTE2OTYwOA_07939094-a5bb-43fe-8af7-f0aaf80bf158"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTEwLTEtMS0xNjk2MDg_426df5f4-12a2-4833-9278-fc56e0ed304e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE2LTEyLTEtMS0xNjk2MDg_013eccb0-981a-437e-ad0a-bf9d280dadff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTItMS0xLTE2OTYwOA_48a8a385-ae20-4ffc-b994-296953c38faf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTQtMS0xLTE2OTYwOA_43d01525-e849-4131-86dc-cf3afc07d6d9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTYtMS0xLTE2OTYwOA_76cf3b1e-2339-4184-a797-3bb35da6efb7"
      unitRef="usd">25000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTgtMS0xLTE2OTYwOA_6bf84ee6-96da-47a7-9250-bf9c13c27bc6"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTEwLTEtMS0xNjk2MDg_ad38e992-70ae-47ec-b025-2c70b16230b6"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE4LTEyLTEtMS0xNjk2MDg_842caf8a-e5a7-4f18-a711-bd61fc6facbe"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTItMS0xLTE2OTYwOA_235cbb2e-0528-4cae-a660-b2c89536b250"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTQtMS0xLTE2OTYwOA_457b28ba-9118-4f07-aedc-d909779ebbeb"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTYtMS0xLTE2OTYwOA_3246bf06-118b-49f0-acfd-5e230ba75551"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTgtMS0xLTE2OTYwOA_20b9273a-32dd-483c-83ee-c1e0cd856ad3"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTEwLTEtMS0xNjk2MDg_2113fde5-e7d0-4908-82be-2c2a68811b40"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzE5LTEyLTEtMS0xNjk2MDg_33c5a1fd-1ead-44a8-ad27-9ebe794938cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTItMS0xLTE2OTYwOA_ceed5d0a-2d20-4f50-97ac-d029f7d62910"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTQtMS0xLTE2OTYwOA_103ff14a-f2ba-455d-985d-7555739a1781"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTYtMS0xLTE2OTYwOA_893c322c-d79e-4c61-b59b-65fff0ca015d"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTgtMS0xLTE2OTYwOA_281b7e3e-77f8-4676-afe4-b098e1e12c9b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTEwLTEtMS0xNjk2MDg_1ab635c2-9142-41f9-910b-aad27556652a"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIwLTEyLTEtMS0xNjk2MDg_5eed5b18-cc95-4ff0-93b4-a31cd9920716"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTItMS0xLTE2OTYwOA_39d1e428-d1c9-485f-9ce7-edf116c17564"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTQtMS0xLTE2OTYwOA_f4f2beb6-fdcd-4e77-a93b-a04b6c706955"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTYtMS0xLTE2OTYwOA_195cd979-0207-4609-a73b-1fd148fbe6e7"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTgtMS0xLTE2OTYwOA_32f6c479-5d7d-40c8-8fb4-6120877ddeba"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTEwLTEtMS0xNjk2MDg_82027250-12b8-47ca-880a-f1dc6fcbe0fd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIxLTEyLTEtMS0xNjk2MDg_15018c9e-3f2f-4a70-a261-498afa7f4338"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTItMS0xLTE2OTYwOA_6c57df2f-f4f7-4349-8f1a-b3f9318a98d5"
      unitRef="usd">162000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTQtMS0xLTE2OTYwOA_145971d1-1385-4042-bdbd-4add97e1de8d"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTYtMS0xLTE2OTYwOA_b9c74d4e-45be-4d38-a0cd-87fa116eab20"
      unitRef="usd">93000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTgtMS0xLTE2OTYwOA_1faade55-13e6-4696-b16f-400667ad75ba"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTEwLTEtMS0xNjk2MDg_e774a0a0-8709-4ef7-a170-35f6bbfd84e4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIyLTEyLTEtMS0xNjk2MDg_9afeca02-c0bc-470d-92e6-2805e01e1ec7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTItMS0xLTE2OTYwOA_1eb90bb6-f0da-4030-a6b0-752ee0a8ef9b"
      unitRef="usd">-10000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTQtMS0xLTE2OTYwOA_56c8c0c7-4935-4c99-95f5-91232d5f946f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTYtMS0xLTE2OTYwOA_6681e55a-fdaf-485e-a741-aa4c71aab89a"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTgtMS0xLTE2OTYwOA_1a6e544d-4c71-49b9-bf39-0176b9f1b92e"
      unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTEwLTEtMS0xNjk2MDg_632df2ce-2c5a-4877-8fcf-8ac0f229e33b"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzIzLTEyLTEtMS0xNjk2MDg_5d0bf5f6-93ab-4a43-afb0-1a6c32b51192"
      unitRef="usd">-35000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTItMS0xLTE2OTYwOA_95c99294-8c61-42b9-9279-9ecc2c8ce8ae"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTQtMS0xLTE2OTYwOA_b2f4f312-d46d-4462-b439-e9e0d84a21e0"
      unitRef="usd">4000000</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTYtMS0xLTE2OTYwOA_ddc15bf7-e40d-4094-8060-6910ba562dab"
      unitRef="usd">22000000</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTgtMS0xLTE2OTYwOA_ecdcb815-d11b-479a-a4e8-d36e94fa786a"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTEwLTEtMS0xNjk2MDg_fcd8be3a-7496-430c-b105-2cbf8364455d"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI2LTEyLTEtMS0xNjk2MDg_2e16fb3b-a039-4e7a-9259-1ea336847447"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTItMS0xLTE2OTYwOA_e5b2b82c-4674-46fe-a87f-bbe7440c307b"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTQtMS0xLTE2OTYwOA_728b0c77-d75e-4a2d-9df5-599c42950a85"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTYtMS0xLTE2OTYwOA_07782651-84e5-4496-8538-7be15fa3d361"
      unitRef="usd">3000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTgtMS0xLTE2OTYwOA_ef4a66bf-3138-49b5-9a92-8ec54a8beb9a"
      unitRef="usd">2000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTEwLTEtMS0xNjk2MDg_a895e95d-5530-4630-86e9-337f98f33ce7"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI3LTEyLTEtMS0xNjk2MDg_b4f7c608-809c-4df9-bcce-26ea1e888a48"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTItMS0xLTE2OTYwOA_da2a76fe-e3cf-4be1-b0ea-2983fc5c2108"
      unitRef="usd">10000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTQtMS0xLTE2OTYwOA_9e48a15a-6cc3-49af-8097-92123996dcd3"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTYtMS0xLTE2OTYwOA_cabf8771-a494-40a7-9e36-f70c3b17de73"
      unitRef="usd">38000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTgtMS0xLTE2OTYwOA_42a7e1e1-1202-4b12-886a-c3f4ec78538d"
      unitRef="usd">51000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTEwLTEtMS0xNjk2MDg_f12293bd-2b14-46e1-837a-427557339e95"
      unitRef="usd">23000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjE0MWJmNWI0ZTY0NmY2ODQ2YTczMGU4ZDc4MGU1NC90YWJsZXJhbmdlOjkyMTQxYmY1YjRlNjQ2ZjY4NDZhNzMwZThkNzgwZTU0XzI4LTEyLTEtMS0xNjk2MDg_26fb8830-afbd-4ac7-a290-6c66ef4f8eee"
      unitRef="usd">31000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MzE_27f177d0-b154-407f-a290-c359b0a333ae">Information for the underfunded pension benefit plans is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItMi0xLTEtMTY5NjA4_b0ba418e-37a1-4f6a-bcfe-b6e6b6724011"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i901b9016f0344620b9f6802621dd347c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItNC0xLTEtMTY5NjA4_739027df-9040-4b68-9fab-1b454dd6f61e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItNi0xLTEtMTY5NjA4_24b07080-d558-4ffc-ade9-6826066bb475"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzItOC0xLTEtMTY5NjA4_2fd75a39-0072-4f94-9d20-d64cf8d72e17"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtMi0xLTEtMTY5NjA4_4bdb3241-c90b-4315-9e2a-f0d2d8cfb780"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i901b9016f0344620b9f6802621dd347c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtNC0xLTEtMTY5NjA4_0c8dc66f-1389-4833-9511-bbcb029c4776"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtNi0xLTEtMTY5NjA4_7263b13d-6ea5-487c-98de-32774719ae0d"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzMtOC0xLTEtMTY5NjA4_ca153e50-fa01-49e8-a033-2602c3bc15fa"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtMi0xLTEtMTY5NjA4_3c511fe8-4511-4f80-8fb5-bd646ac0b1ba"
      unitRef="usd">162000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i901b9016f0344620b9f6802621dd347c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtNC0xLTEtMTY5NjA4_adff2e2b-5b2f-4980-809f-6a86a89233e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i02ae9ff0984e482c8f536551e5df3d8f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtNi0xLTEtMTY5NjA4_8da1564d-f3c7-43c5-9dd9-24dba90a6e0d"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ifbb4a6b3049041e6a53d4e6874579447_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTpkMjk3NDQ2NDU1ODg0MWI0ODY1NDE4MjJlNmVjZDdmMC90YWJsZXJhbmdlOmQyOTc0NDY0NTU4ODQxYjQ4NjU0MTgyMmU2ZWNkN2YwXzQtOC0xLTEtMTY5NjA4_f5bf7fe8-79f1-4bea-9905-74d14faedbe7"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQwMzE_7706bbb7-cb45-48a1-88b9-126f96b41002"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzE2NDkyNjc0NTExODI_020abd4e-2297-4ade-ab45-6bb07cfd1c78"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQwNDI_725d1cf9-519a-4f5f-a01f-697f0116d27c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0Mjg_bb98549b-6443-4743-8299-89f7af160586">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzQ0MDM_b522cbe2-0321-4e40-9867-ce3763c12dff">P10Y</bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItMi0xLTEtMTY5NjA4_5597e84f-1751-4e1a-81bb-efedd7870e7c"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItNC0xLTEtMTY5NjA4_691376e7-0ae9-4165-af96-97073e92e44f"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzItNi0xLTEtMTY5NjA4_772ec6a6-bcf9-4462-a7db-71de0a8c1b0f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtMi0xLTEtMTY5NjA4_2c6b77af-2d97-49e0-bf7d-9ec2b1b361e7"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtNC0xLTEtMTY5NjA4_ba34a06d-03de-46cc-9446-4c303d6eacf1"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzMtNi0xLTEtMTY5NjA4_23a874b6-cf80-44d7-843c-dc2b35f1bf0c"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtMi0xLTEtMTY5NjA4_65169090-5c22-4344-a7c0-1883a473e97b"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtNC0xLTEtMTY5NjA4_16194dba-96ed-4031-97a1-3ffe1e4a13a5"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzQtNi0xLTEtMTY5NjA4_ae98de83-d723-41b0-bdb2-71e218eac917"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtMi0xLTEtMTY5NjA4_4460cef9-4654-4980-bc62-445d13919693"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtNC0xLTEtMTY5NjA4_2ee7942d-0d56-4876-9ab8-65b219943540"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzUtNi0xLTEtMTY5NjA4_5ef0ed1f-06fe-4781-9946-064ad55b1297"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtMi0xLTEtMTY5NjA4_b5910e17-2739-4a81-9086-5f9fb860da35"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtNC0xLTEtMTY5NjA4_aeb395bb-14c4-417b-8056-223ce549f237"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzYtNi0xLTEtMTY5NjA4_0767299b-d4d3-4e6a-8123-e0d1b32b9b8b"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctMi0xLTEtMTY5NjA4_404a7a58-fa41-4bfb-997b-a600d6347d0f"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctNC0xLTEtMTY5NjA4_9886fcb8-edeb-4da9-a654-81eaccbe15db"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo0ZDQzZmZjODZhZGM0ZTE2OWNlMGRmNGJhMzE5OTU4Yi90YWJsZXJhbmdlOjRkNDNmZmM4NmFkYzRlMTY5Y2UwZGY0YmEzMTk5NThiXzctNi0xLTEtMTY5NjA4_4492a638-3336-4eac-b206-5de03a5d5680"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MDU_396b1186-1931-48c8-a663-b8cec0a3f707">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMi0xLTEtMTY5NjA4_72df5fda-fcd4-4b1b-9bf7-5c0608725ce8"
      unitRef="number">0.0269</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtNC0xLTEtMTY5NjA4_d8849762-c1a3-47ec-9bcd-03d1739b2d0a"
      unitRef="number">0.0225</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtNi0xLTEtMTY5NjA4_c1a4cd0e-1077-4079-bc11-ac331e6efa23"
      unitRef="number">0.0316</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtOC0xLTEtMTY5NjA4_54bfedab-608c-4ca3-9076-294cee44add9"
      unitRef="number">0.0257</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMTAtMS0xLTE2OTYwOA_ffc90187-36ba-4a30-a586-fb5df9c019ad"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzQtMTItMS0xLTE2OTYwOA_3ce0c81f-307d-416c-be1a-f04bcad8d294"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMi0xLTEtMTY5NjA4_705e49bc-229e-4335-a549-454249fdcaf8"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtNC0xLTEtMTY5NjA4_111b6a52-a838-4c39-9f87-7e7a1edafc88"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtNi0xLTEtMTY5NjA4_09dd077f-15be-43a3-87ff-bbabf4e2ec39"
      unitRef="number">0.0625</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtOC0xLTEtMTY5NjA4_66d61c5b-9cab-46cb-9f61-b6cb1133c19a"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMTAtMS0xLTE2OTYwOA_59f5330a-a790-4551-8686-7028545119c1"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzUtMTItMS0xLTE2OTYwOA_26b2a8d4-89ff-406a-affc-8eda17a5478a"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMi0xLTEtMTY5NjA4_0d42724f-9e6c-4d9b-a672-bf736ee6266f"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtNC0xLTEtMTY5NjA4_9084bbd9-ecd1-4508-be92-94de95f50344"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtNi0xLTEtMTY5NjA4_a6f73b43-d9f3-4ee2-bb2d-68c02566335c"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtOC0xLTEtMTY5NjA4_04f8393e-e999-467b-b456-8bf38ed1b8a2"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib5eaafaa19764caf8723567f0db63a45_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMTAtMS0xLTE2OTYwOA_22b5a026-af2b-4437-83e8-df1b641618a8"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i0275551d7f5a41d4ab94d3d4ec8daba6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzYtMTItMS0xLTE2OTYwOA_34dee60b-55b9-4e9f-8a87-923757efe95a"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctMi0xLTEtMTY5NjA4_f89eaf74-cb13-42cc-ba9f-6c89f7e56d48"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="iea04213dece64c3497dd259bdea83001_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctNC0xLTEtMTY5NjA4_2f81522a-4911-4a49-8b82-93d2faa6aa6a"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i001200bc6eba44f09dc4b185a051e828_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzctNi0xLTEtMTY5NjA4_50598120-c133-4c10-aa96-4d1f03ab3053"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktMi0xLTEtMTY5NjA4_16610d4c-f8da-4bcc-bec5-2681a1aedb12"
      unitRef="number">0.0460</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktNC0xLTEtMTY5NjA4_6dd5b546-fccd-434e-9e2f-c1d8bcf8d080"
      unitRef="number">0.0137</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzktNi0xLTEtMTY5NjA4_59da1a72-633a-4618-824b-0d89eda6ed8f"
      unitRef="number">0.0168</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTItMS0xLTE2OTYwOA_bf606d75-3db2-4d9e-8160-43f4396e967c"
      unitRef="number">0.0523</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTQtMS0xLTE2OTYwOA_1bdfdfeb-dd24-497e-b26c-d17ba3848b52"
      unitRef="number">0.0274</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEwLTYtMS0xLTE2OTYwOA_45d987c0-8944-4ee8-94e8-5d04fd0deb6a"
      unitRef="number">0.0298</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTItMS0xLTE2OTYwOA_83a80952-53ff-4a2c-ba51-6636828aa475"
      unitRef="number">0.0353</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTQtMS0xLTE2OTYwOA_470784d0-e084-416c-a624-9c1455870697"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzExLTYtMS0xLTE2OTYwOA_179d60c8-6ace-4848-b41a-c9c8c3305d93"
      unitRef="number">0.0305</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="iba688778d3d44a359ab88f515d6148b0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTItMS0xLTE2OTYwOA_ba8c546d-bec1-4b9b-9c0f-1c0688d32a64"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i5ff4978ff8634524a6682241f44bc4f4_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTQtMS0xLTE2OTYwOA_cb1cbd7a-3ce3-4c24-901e-5d87f48f7bb4"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i4c247001aaaa4e20a53b52ddecc897a8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZToyMzgyYmE5ZjhhNzQ0YmYwODc5MzhlOGI2YjdjNzhlNi90YWJsZXJhbmdlOjIzODJiYTlmOGE3NDRiZjA4NzkzOGU4YjZiN2M3OGU2XzEyLTYtMS0xLTE2OTYwOA_8d1cbecf-5aae-4cfd-b95a-71cc333adb70"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtMi0xLTEtMTY5NjA4_6995655a-24da-4c48-908b-d73eeb90f26e"
      unitRef="number">0.0541</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtNC0xLTEtMTY5NjA4_ceae4c98-3688-4cda-9616-45786c104f26"
      unitRef="number">0.0269</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtNi0xLTEtMTY5NjA4_6be485cd-7348-4bff-ba2d-c1f0cfef4dc1"
      unitRef="number">0.0539</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzUtOC0xLTEtMTY5NjA4_2207ff1e-1055-431c-9320-99a973193c4d"
      unitRef="number">0.0257</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtMi0xLTEtMTY5NjA4_a9ef5780-fcb0-4405-82e8-561e9f9c5bad"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtNC0xLTEtMTY5NjA4_17aef501-cea0-491d-b583-b8387dcd6607"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i7ce272f013fa44ac973752d5610d84eb_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtNi0xLTEtMTY5NjA4_6734a791-fb1d-482e-b2a4-4dbc28028d62"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="icd7fe17c8c254fd4932b34fd4fa8868a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzYtOC0xLTEtMTY5NjA4_b6f217e8-2c49-429c-9bd6-a46fcd98ffce"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzctMi0xLTEtMTY5NjA4_4c4f9de3-780c-41f4-adcd-75f8dd21b697"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i3a0eb5fe97494204bc49eb34d0410b4d_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzctNC0xLTEtMTY5NjA4_46fb06dd-ecf2-4309-8dcc-ea3d75c12464"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzktMi0xLTEtMTY5NjA4_86d0f6ad-c450-47c9-b666-2ffd11ebb44d"
      unitRef="number">0.0667</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzktNC0xLTEtMTY5NjA4_d268b006-80d9-4b39-badf-fb41bc30ff6c"
      unitRef="number">0.0172</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzEwLTItMS0xLTE2OTYwOA_42644ba6-3bb1-4d4b-b668-2f2e27aaea83"
      unitRef="number">0.0371</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzEwLTQtMS0xLTE2OTYwOA_e5a08855-4191-4506-ace2-326ccab8c685"
      unitRef="number">0.0263</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="if96b54eac8a34eb6b8925e566ef51275_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzExLTItMS0xLTE2OTYwOA_b5b644c2-4018-4a08-86ba-dc22082e9a08"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i6738f26e1aaf424082202a7be5272d77_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5YzAzODJmYjQ0Njk0M2FiODVhYjcwOWJmNzdhMzRmMi90YWJsZXJhbmdlOjljMDM4MmZiNDQ2OTQzYWI4NWFiNzA5YmY3N2EzNGYyXzExLTQtMS0xLTE2OTYwOA_59e53e33-bd15-4677-a182-ea7f710c3371"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU0OTI_705e49bc-229e-4335-a549-454249fdcaf8"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU1NzU_8167e7f8-641c-4f3b-a04f-a3d90d498942"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i6c981d7a36cd45b285c23ca5fdc44f66_D20230101-20231231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU4Nzg_815a5618-74b7-47d0-a093-3067a171e601"
      unitRef="number">0.0600</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ia086606e46a34f71bfb9e605f2e6266e_D20230101-20231231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzU5NTk_178ceb54-4b82-4cab-ae23-64fa4754b6f8"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzk0MTk_33f72322-a8a6-499a-bd09-aac21589860f">The following presents the actual asset allocation as of December 31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i7def2285ac5140d38d1f9ffcf8a7126e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzItMi0xLTEtMTY5NjA4_8948aacd-8dc3-4b73-aef4-f0243934e64f"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i890e5bee618d469cab458bb423035b53_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzItNC0xLTEtMTY5NjA4_f94219c5-223f-4e04-bdfc-43e6b6bf27d3"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="idfd01159712142d2a14941af601cba4b_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzMtMi0xLTEtMTY5NjA4_76661634-6d08-4015-9298-3ceff5200e41"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i10c9b32cd0a64bd9a48e14dc09730b3d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzMtNC0xLTEtMTY5NjA4_51db6a2f-f5c7-4e54-8cac-303672608d7f"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib186ad161aa040e7a1a0cfe3d0b2add9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzQtMi0xLTEtMTY5NjA4_9e8ab924-5a1a-45ee-9759-341b2cb761ef"
      unitRef="number">0.59</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i3a7b19941aba4839893beff2b2339518_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzQtNC0xLTEtMTY5NjA4_c11247de-de22-4088-a3ed-f6f2ad34917f"
      unitRef="number">0.69</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if909172682784a94b3a8faea6d1af750_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzYtMi0xLTEtMTY5NjA4_59563e50-de71-4654-9810-916eda4af55c"
      unitRef="number">0.06</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ic6097557c0fd439483e7592516150539_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzYtNC0xLTEtMTY5NjA4_65b4160c-5f4b-4db4-a666-a90885d5729c"
      unitRef="number">0.09</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if82393cee0c6403aad0994b42e1b3e03_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzctMi0xLTEtMTY5NjA4_1deac76c-ad2b-4d9a-ba63-4934d1bdc266"
      unitRef="number">0.23</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i21af5dc5f9dd4f15985aaa4c4bfd5822_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzctNC0xLTEtMTY5NjA4_6ab6909e-08bc-425f-9b66-6d08f93164bb"
      unitRef="number">0.31</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i3ecb8307bf5d4aff94f54ff6b76837d3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzgtMi0xLTEtMTY5NjA4_c45c81d0-5071-4a3b-bf45-16dd433bee35"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ifb616bbdc2974979a68ab30bf4d7f508_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzgtNC0xLTEtMTY5NjA4_606bf1fa-a04b-463d-8dde-09a250be37eb"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i37d55bf5477448368b255cbbc9f9ac2d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzktMi0xLTEtMTY5NjA4_a841eedf-26eb-4e7d-a8b1-0508c200d089"
      unitRef="number">0.26</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="id842fbc0d8ad486aaae75003e4167df9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTphMDY3Y2I0OGMxYWU0ODljYmVhN2U1NzgyMGRkNTVmYS90YWJsZXJhbmdlOmEwNjdjYjQ4YzFhZTQ4OWNiZWE3ZTU3ODIwZGQ1NWZhXzktNC0xLTEtMTY5NjA4_b08714c2-e922-4619-999e-67f40cb520ed"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzODU_62776645-d163-43d5-9c9e-2a351ad6f25f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba3108451ff34c44bdccaa78adf4e451_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMi0xLTEtMTY5NjA4_a36aebf1-2e6d-45b8-990d-668670248f28"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a0fdbd98ed940e8bb4f138e20fe4aad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtNC0xLTEtMTY5NjA4_8be214a7-6af4-48e0-bde2-710f127d462f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b66f09a9c794304941a8e256c67d221_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtNi0xLTEtMTY5NjA4_bb68533c-ac2d-4087-baa8-4d9fb740bfd3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id46544209ecf4725a093aaefe444ca63_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtOC0xLTEtMTY5NjA4_b6c3c902-343d-45c6-9f9d-67682ea18261"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib7cd997e52074902b6b0f11a459c1455_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTAtMS0xLTE2OTYwOA_aca6688b-579e-4d70-a89b-720b1263f7ee"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iddfe10a628844d85a9f16739ece8b000_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTItMS0xLTE2OTYwOA_b1981f42-637f-47af-ba81-214c950c4473"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e72c38588c34bcebd41f5dee9e6e442_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTQtMS0xLTE2OTYwOA_592b7731-faf3-41b9-8fa8-eb0840f2afed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80c26c19111d4d8f9acc24b805792584_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzMtMTYtMS0xLTE2OTYwOA_942e8901-168d-488b-bdf9-b221d364fc25"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebcb27b8c53e41a4a7f03c7a9ce24b16_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMi0xLTEtMTY5NjA4_170d775a-8514-488d-b1f8-0bc60e5e1629"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie4aff83b9c634a5894b070163727d3ad_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtNC0xLTEtMTY5NjA4_eb5556d9-2452-40a0-afa8-9b6317e03c3a"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1bfb9a5fc6b5416cabb3992fd6d9866a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtNi0xLTEtMTY5NjA4_3c071664-ed0a-4fde-94c5-35679df3a90e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8c83ee90555c4d4388fe2aad369a07ca_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtOC0xLTEtMTY5NjA4_aa4aa84b-64e3-4a8e-81a0-07364290b790"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie94c6b830d4d4e83b5455bc50c831168_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTAtMS0xLTE2OTYwOA_a2c08ede-130c-4cd2-b2e2-776de7c0cf25"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i596d5259e41b4516a9b8bd8bff994b04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTItMS0xLTE2OTYwOA_74ea4084-eaad-459c-ba5e-0bafbb7ea1fa"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d65fd0099884d129c8955aeded2ab3e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTQtMS0xLTE2OTYwOA_f81b0813-760e-4fe4-9216-829ad2c80f8f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i59f1bfdacbdc49e58897e6ed02cc3ba3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzYtMTYtMS0xLTE2OTYwOA_72730de7-5398-40d2-9d9b-a8bdcf1df742"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9eff69c67fc94f7ea63429c1b535269f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMi0xLTEtMTY5NjA4_5b19eaa4-44ab-48fa-be70-957b6bd82428"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06cde57fea89421ca93bc357400547db_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctNC0xLTEtMTY5NjA4_0fab27a9-145f-419c-a8a4-9839c5c78f26"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fcca6398a69456491cd915adc6cf018_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctNi0xLTEtMTY5NjA4_e8b402ca-d072-4c5d-8fe7-f9b3bb352a5a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie1025885b5b041c495101b7c543c11f2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctOC0xLTEtMTY5NjA4_cd7e3d94-5703-450e-b18d-061b91f109fc"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4749a66112794a748f77060b21d3a4ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTAtMS0xLTE2OTYwOA_c3d6b631-7d13-4865-b97d-93961b4865be"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60d3fed8097a4daeab0e728d1fa59dec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTItMS0xLTE2OTYwOA_051e03aa-495a-4419-b9f1-72c8aa2399bc"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c4325c973be4bb49485892fb209d262_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTQtMS0xLTE2OTYwOA_b42dffc8-1076-44dd-8147-653a9bafd906"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbdd4eaf78224b6ba6820bf1639d0b9b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzctMTYtMS0xLTE2OTYwOA_73655479-9763-4182-bd7b-d56f34de258d"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib57fb1d627d84572b6935e5a91bc1ddb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMi0xLTEtMTY5NjA4_7f211f5d-b0ad-4b40-adab-90b8620ed624"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icce670f0334749faaec2717ea665b0a2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtNC0xLTEtMTY5NjA4_9ae3cf5c-e399-471c-9b0d-12b7bf5936f1"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibf1b1a26770b4939981b10056497e10c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtNi0xLTEtMTY5NjA4_2afbb2af-445f-4853-9776-09fb04508ccb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2ffcdeee6044901ab85b83bfab8de15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtOC0xLTEtMTY5NjA4_d5f6e201-8554-46b4-92a8-e1bd1731ba85"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia469039e78794b72b821fd03d9c90ec4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTAtMS0xLTE2OTYwOA_d1008dc0-9a51-4671-8720-79f14bcd2cb2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i943e5fbfcbe84d65b033540f48279c89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTItMS0xLTE2OTYwOA_26f2ce49-e9da-423f-886e-266c2a088d1c"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i940816bafd874e0ebc01474cfb7a3a65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTQtMS0xLTE2OTYwOA_55f6e0fa-c3e8-4dd9-8420-29ef7a51fa5d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8b2464e33b44bf28fa58498386246b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzgtMTYtMS0xLTE2OTYwOA_aee2ce96-3c47-4ddd-aab6-70db9f1d6525"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0537dc089def43d3936e05d8a4ff751b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMi0xLTEtMTY5NjA4_5d11bf1a-9ab3-49da-bd72-61f9ddfadcd1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i166bc7feb587436bbb13eac98a8a0cbd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktNC0xLTEtMTY5NjA4_8a5095d0-75d8-482d-b552-2c3fc516f471"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icba4611dcd504efcb55fd69027047b6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktNi0xLTEtMTY5NjA4_f65e626f-ccd2-4281-9a46-a0463ff4b8ca"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4161b216dc5142939aa46e36e819cc8d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktOC0xLTEtMTY5NjA4_4525c800-460e-4678-bcad-28c45d1b4d68"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i12cd435007f84ea6a463f1c697369c5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTAtMS0xLTE2OTYwOA_17d69908-8239-410a-a618-80102e3086f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iea6ff1609d90414882841cc6046a9951_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTItMS0xLTE2OTYwOA_ffc58850-888e-4b3f-b7a9-c262635c51d4"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0966710236bc43c2af312375aaf2ff7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTQtMS0xLTE2OTYwOA_7eb086d4-6cc6-478f-8037-4d3f0b3c762c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if627813ab5da419892b99795959e6aa9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzktMTYtMS0xLTE2OTYwOA_9af9a1b0-a24f-4ae3-a0d0-8d77d52f4b79"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i20160fde44604a6aaa038ff97269bd4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTItMS0xLTE2OTYwOA_fc4a1d15-8609-4c64-8206-2f1b38d209f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i838299195fbf4b9a822896bdc73e1fa9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTQtMS0xLTE2OTYwOA_9427305d-58a7-4a85-a0fe-c9a4206af27a"
      unitRef="usd">95000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia604d8b17aee4a76b705119871e72bb9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTYtMS0xLTE2OTYwOA_09fa8335-c952-4e15-be1c-6ee9f8fa91e0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1a13cdeaf0a4538ae66a0cb4eaac793_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTgtMS0xLTE2OTYwOA_c51164c9-9d4b-4e72-9178-cfcef03bafd6"
      unitRef="usd">95000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8cd29133231149b7b1b8a8ee26abb9c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTEwLTEtMS0xNjk2MDg_b4c5a567-1186-4df1-8e5c-d7668293fd2d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9487a86efc54fb68c486f5b06c683f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTEyLTEtMS0xNjk2MDg_937f491c-0db3-4adf-849c-a13127a4ea2a"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaeac84c7747644e18df3b02f9009bcf8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTE0LTEtMS0xNjk2MDg_1fe604ab-470e-4c28-9a9e-9f3ca108c066"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic7d0aeff6b0247bbb772f435284fb4ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzExLTE2LTEtMS0xNjk2MDg_4f19b728-fc36-4d3d-b7ba-b2acbc12378d"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i022e7bc0a5b44851ae8856c5d2c73a9b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTItMS0xLTE2OTYwOA_90804b57-f74f-45fe-b57c-27ec02d55009"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i25e42f7f8fb44b94a825edd38ce13b8e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTQtMS0xLTE2OTYwOA_b13f30ce-4578-4608-9c1f-33b44fa7f55a"
      unitRef="usd">160000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3b44a8ef5108400eb1f8766f7e0fcec7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTYtMS0xLTE2OTYwOA_81d308cf-5e9d-489d-8f9f-c478444712ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7ec9432798a24a7081587f93c9df9218_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTgtMS0xLTE2OTYwOA_1272a53b-bc75-4bf0-a1ae-1aa78e0e1289"
      unitRef="usd">162000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5c542d4e97f492fb79c2d7ea87bc43c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTEwLTEtMS0xNjk2MDg_b6259dd5-ec1a-4499-b026-34188902582c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54c92c43460b4f029f30adcfddd56c4f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTEyLTEtMS0xNjk2MDg_7430fb5e-dcbd-4589-9bbd-8ff914fb6f77"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib87b5c5cd3884bc6a0c85db52ded0201_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTE0LTEtMS0xNjk2MDg_c33bcea4-9236-4060-9ef7-9db789ace242"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba16f047558a4012b26c69b39abe5903_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo3OWIwMGEyNzZlMjk0MzM0YTMxM2NjZTZhZGZhNGRmMS90YWJsZXJhbmdlOjc5YjAwYTI3NmUyOTQzMzRhMzEzY2NlNmFkZmE0ZGYxXzEyLTE2LTEtMS0xNjk2MDg_0881427b-6bdd-44b1-96bb-f712774c1939"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85986033cb94474b99f01b19273837dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMi0xLTEtMTY5NjA4_7af821be-f9c9-4c95-bfd5-48cb90298b45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5849250174794a5294b9599a5268d9ae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtNC0xLTEtMTY5NjA4_771286fe-c06a-48f9-87d0-ef15ba7e7cd0"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i34e897629c0e405197197192231ed87e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtNi0xLTEtMTY5NjA4_da254bf5-6104-44f4-88b1-18da4821ca08"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i586cba0ddcd34f2182b8f7a26689b550_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtOC0xLTEtMTY5NjA4_ef2c2c51-a298-4854-beaf-ff3b53dcf8bd"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37a90c8afe5049298baf47464adba23f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTAtMS0xLTE2OTYwOA_32addd28-4c65-4d13-87f6-298d4fe86595"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if3b750ecf0264c51acd1b84640243687_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTItMS0xLTE2OTYwOA_881d9a9d-d461-4b3f-988b-9e2116892191"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d1ee6e5579e4fbbac27d5f4d6d6c071_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTQtMS0xLTE2OTYwOA_d7e2fc29-f37f-492e-8500-8e4fd4b2b65e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7beb776c2d084696af8546fb16fbfb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzMtMTYtMS0xLTE2OTYwOA_c5c8a9bb-da6d-4791-99b8-3d3f604be130"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8e418ec04bde4a42807126013e7f6e28_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMi0xLTEtMTY5NjA4_6cd6293b-e291-4863-b98f-62d4841228a1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id064c3e553534ddf8d58196348abc463_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtNC0xLTEtMTY5NjA4_f9e8667d-31a9-4460-ace5-a7d1c3bacdfc"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iadc34f3620a04953983302095d065919_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtNi0xLTEtMTY5NjA4_f1a830ff-207f-482e-b21b-df0de6b31a7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2e718d2c489345649ae9f4b875a944c6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtOC0xLTEtMTY5NjA4_475ed940-58ad-4824-874e-15d0d28badcc"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b786c529ecc420a98bfcc8623fd3887_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTAtMS0xLTE2OTYwOA_8223e66b-4309-44c7-add1-2d7d7698f0af"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i192fabe7c1564743b0a4bfd0ec76367f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTItMS0xLTE2OTYwOA_47694244-af6a-4c9d-8f58-5b0ae4414cd7"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2583535030e04ec19d33ff6aa980c232_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTQtMS0xLTE2OTYwOA_c126948a-778e-49d6-a32c-a0d38dbb2c66"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6dbace4328d64e68ae9985b0db92a939_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzYtMTYtMS0xLTE2OTYwOA_e6da70a4-7b1f-40d9-b726-cb5b854e3b73"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i54976a88d71c4f29a87ce8b7fbb1f390_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMi0xLTEtMTY5NjA4_8e3d0d64-2a5d-4f65-85a4-82e2d622a1ae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if368c75fe2714137b5b2bec4f478ed08_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctNC0xLTEtMTY5NjA4_f9d3455d-7568-4d29-a9ea-e9875b658db8"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i874f6ee73d0b4d708cde5f122a628b5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctNi0xLTEtMTY5NjA4_71333336-d1ac-451f-8522-3d4bb279e526"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i71ab17d153f94ce28b4f3c1f077f073e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctOC0xLTEtMTY5NjA4_59bafd51-d2f1-4f57-8cbd-0362c7c12a43"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib78598f7e1204321a742adcc1939f548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTAtMS0xLTE2OTYwOA_bb898a14-669a-44ad-a340-3b7a526982b6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i84605640b59c4cdfaca45e277d8f930e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTItMS0xLTE2OTYwOA_7b7b59d8-fd51-48e4-875c-cfc2540df4d9"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie0da8fd5fa784526af1d7dcba6682ea3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTQtMS0xLTE2OTYwOA_6522f165-42f1-4162-bc52-221c5ef77c9e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80a9b377100548608bea1fb0de4c4b8f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzctMTYtMS0xLTE2OTYwOA_de61265e-1c8c-4cf3-aec6-1d908cf5e8c5"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2d15c8b03fa84bebadf0ca964ff394c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMi0xLTEtMTY5NjA4_66d2d705-faad-4f54-a0d0-da60cca7e176"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8a9caf7ad8a43c2a1cf9ec9bf2be638_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktNC0xLTEtMTY5NjA4_c4e4e2d0-eab2-4ab6-932e-9889f69af988"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f47aed6238c4f0d8374cffa9d1ccc3b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktNi0xLTEtMTY5NjA4_196263cb-ab9f-4088-bfea-4bca7206adf0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i943967018a284fddb2383dd48804e6ce_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktOC0xLTEtMTY5NjA4_61b29532-4820-4542-9b14-f897021f9745"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica42099d7cb54b18ab0758ac46934fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTAtMS0xLTE2OTYwOA_fd034ea4-5fd0-4342-8de4-41344ae758c5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53b4988948464da080807bfacdb2fd60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTItMS0xLTE2OTYwOA_57c97137-415d-4800-b4bf-3f992dab5ec0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id0e958e564b34a8ea6e5d23a9dd1d9bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTQtMS0xLTE2OTYwOA_3dc4d25c-9b0e-4b7b-8cf0-ed5df8328e3e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia15ca0c069774a069fc140fe27c34672_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzktMTYtMS0xLTE2OTYwOA_4b9eeeca-0658-47e4-bbe2-cee9e74fcd3e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17e7bb314271400dadeec64d6689bab1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTItMS0xLTE2OTYwOA_dd190d16-c066-4bc6-b87b-02d41f8c2491"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i68a1b6f04f9843a3a430cc23faab2335_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTQtMS0xLTE2OTYwOA_35948f58-675a-4c5b-b029-a6ab626b6f17"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i460709745cf1459d8d83a3ef3c4c4028_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTYtMS0xLTE2OTYwOA_0bba6266-fceb-4598-8d18-7bb3159d9f71"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i807af49d13d7419ca0ef798eab13affb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTgtMS0xLTE2OTYwOA_eefa413b-78da-4989-874b-0fb904de8a65"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11a95e634eae482ba0ca850423b7cbd2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTEwLTEtMS0xNjk2MDg_9ba62bae-cd22-4fa5-a4ae-35faab0b886b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0ada76f87a244e6ba2a626f4f5d2f68c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTEyLTEtMS0xNjk2MDg_7ade16ef-e162-4cd6-a6d1-d78485311baa"
      unitRef="usd">65000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id4bb0efe5f2746f4ab125458e68b1cbd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTE0LTEtMS0xNjk2MDg_6a2165bf-1660-4f3c-bb06-793bddd8a2d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i643e656337e04c8482c55cf8750c1308_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzExLTE2LTEtMS0xNjk2MDg_93b0d1ab-3d1d-4149-90c0-f9d426ceb3ae"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if34397ecd5a048799f2dbb74323fe7fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTItMS0xLTE2OTYwOA_91deeaba-67ec-4e5e-9624-28e3dd159e6d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0933dfd2b3014b3982966e76c30667ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTQtMS0xLTE2OTYwOA_45081570-6486-4637-a58d-12de93a62fb5"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id83bd552fb8241e68b041b00d4deb904_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTYtMS0xLTE2OTYwOA_6c0cac42-7965-4bb3-9b30-e46dc6982262"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5317bcb7e0b4df8aa18bb103e434600_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTgtMS0xLTE2OTYwOA_5b364ad6-d863-415b-a7d6-ce5d81f0cca6"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2c0591c4a3a4e679502344b5b1c1371_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTEwLTEtMS0xNjk2MDg_5d27b7a1-d067-47d0-9bdd-13b423ab56da"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e710e9f1a5d4373996e9b7fcded1add_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTEyLTEtMS0xNjk2MDg_2a657731-a05c-4630-b45e-11f9924a69ee"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i229dc35bd984450fa43d45f7faba215d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTE0LTEtMS0xNjk2MDg_6c1708e6-ba33-4f1e-806f-5294c8c891f8"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i951ceb7ff1d646c9b3fef0581a1b618f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEyLTE2LTEtMS0xNjk2MDg_161daaa1-18b3-4328-93b0-b32ca11ddff9"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id767817a5a2e453c9618655dde1bbe6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTItMS0xLTE2OTYwOA_0c8aae34-bd78-4acc-930c-f3e585ee6e53"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90326ac3a5c64cfaa3de8f4582846b0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTQtMS0xLTE2OTYwOA_7acff833-e9f1-4bfc-a6d7-c38012371073"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a56c8726ff045a281148a00e040766e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTYtMS0xLTE2OTYwOA_d50402af-9139-44d5-8262-1a6b7f0a1bf6"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4dc9006276854ef785d74a884a2fbd50_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTgtMS0xLTE2OTYwOA_a7a87dc5-2757-4254-98c5-69bfbf7f10b9"
      unitRef="usd">94000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6026f5c4ae10476cb57fa85da364cc1a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTEwLTEtMS0xNjk2MDg_60870fe9-4046-47b8-9c93-af53af7db335"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1aa0fc165cad4c259a0114c60066cc26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTEyLTEtMS0xNjk2MDg_e6a622ec-2597-482a-8c09-6640b382874b"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd34b48ca86f4bb9a48ea67c0a464fdf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTE0LTEtMS0xNjk2MDg_48047d22-0c91-45bd-bf2a-d51b7474dade"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f30f4d8fd4e467cb57e4293e32ca3d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90YWJsZTo5MjY4NWZmNDBjZDA0Nzk4ODc5Zjk5NTgxNGRmNWM2OC90YWJsZXJhbmdlOjkyNjg1ZmY0MGNkMDQ3OTg4NzlmOTk1ODE0ZGY1YzY4XzEzLTE2LTEtMS0xNjk2MDg_68acad19-0421-4754-bdc6-be25625b4c40"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="i60fc8747794e4f648be7ba64676863f0_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzg1OTE_2bf81483-81fb-4519-a7c5-e308c6c5d07e"
      unitRef="number">0.92</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="i8d49fa28b18849f4835a0e22941c0d50_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzg1OTg_a6b3210c-ea46-4f6e-8ef1-894943971068"
      unitRef="number">0.95</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMjI_73626834-85ba-4b10-8b46-492a2c9728bf"
      unitRef="usd">47000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMjY_ff6ac971-aa0f-461b-a1aa-95faacda7f0a"
      unitRef="usd">44000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDYvZnJhZzo5MmIwMDQ2NmMxZTI0YTdhYWVlYTcxNmI2MmM1MjRjMS90ZXh0cmVnaW9uOjkyYjAwNDY2YzFlMjRhN2FhZWVhNzE2YjYyYzUyNGMxXzkzMzM_db7a59f4-3506-4c0f-b198-75e1a4d6c755"
      unitRef="usd">43000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNA_d871689d-e86f-42c2-8581-7de7b78e5240">LEASES&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company&#x2019;s operating leases are included in the Consolidated Balance Sheet as of December 31, 2022 and 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, 2021 and 2020 the Company&#x2019;s finance leases were not material and for the years 2022, 2021 and 2020 sub-lease income and short-term lease expense were not material. Lease expense for the years 2022, 2021 and 2020 include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bhc:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNQ_d6d433a4-a636-4478-8796-cb167921e6a4">&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company&#x2019;s operating leases are included in the Consolidated Balance Sheet as of December 31, 2022 and 2021 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_84fa6b41-c95f-4d87-8960-b43177e365d6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMC0xLTEtMTY5NjA4_a923cf40-6b0c-4704-b373-7694a7d01543"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_37d845cd-41f5-43b7-92e5-dd314c9a301c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMC0xLTEtMTY5NjA4_b0c0500d-91da-417e-8084-d539d4370286"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_108c5430-cd27-49f8-b9ae-90aceff73b86"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMC0xLTEtMTY5NjA4_774d0076-0888-427b-b991-eb83cf6f3ae5"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMS0xLTEtMTY5NjA4_09c5874c-8de5-42cd-b65c-27e3b46550ce"
      unitRef="usd">221000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzItMy0xLTEtMTY5NjA4_366ca798-31f9-4354-8e33-ce03e951a67b"
      unitRef="usd">247000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMS0xLTEtMTY5NjA4_873cd13b-1924-4a0f-9866-4c2531d43c57"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzQtMy0xLTEtMTY5NjA4_17d7cfcb-8d1f-49fd-a943-f15d631f1b04"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMS0xLTEtMTY5NjA4_bf822d62-8a7d-4b2a-b2dd-f35e1fb8e59e"
      unitRef="usd">184000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzUtMy0xLTEtMTY5NjA4_642f7af6-e046-4314-af8b-8b0dde4a07f9"
      unitRef="usd">214000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzYtMS0xLTEtMTY5NjA4_cf544acd-7a03-44a1-985a-56c95c7a6402"
      unitRef="usd">234000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTozNmNjYmE3OWZlYzU0ZTU3YjMzNjU4YTMzODhiNTc3MC90YWJsZXJhbmdlOjM2Y2NiYTc5ZmVjNTRlNTdiMzM2NThhMzM4OGI1NzcwXzYtMy0xLTEtMTY5NjA4_7528ed17-d66a-4fa1-9bb1-c980d87fefb8"
      unitRef="usd">264000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_102ca61d-037a-4e60-9af8-e7ede42dfc6d"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_7409e9f7-9d89-4b14-b6f9-8fd2ebff920d"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzIxNQ_e623c275-b3b2-411c-bc87-61b0ea4192f0"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:SubleaseIncome
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_34526e1a-789d-4a37-866f-5853c00d3dfa"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_4b2d68b4-522c-4df8-8308-df42c9dc86ea"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_5cce738a-0e20-4fff-8652-ca1e12e80b26"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:ShortTermLeaseCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_8d9f14e1-6ab7-4217-b446-fef286a01397"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_aee2adba-c6da-48f2-b988-f83634ce9dac"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzMxMQ_d5e9e8fe-e6e7-4807-8927-6389aed12936"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNg_1a3c3487-bb3a-4cee-b730-a8e678695a51">Lease expense for the years 2022, 2021 and 2020 include:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtMS0xLTEtMTY5NjA4_60bb9b8c-fe30-425b-af05-af123b7e6aa9"
      unitRef="usd">62000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtMy0xLTEtMTY5NjA4_c1653096-865c-4f7c-a173-714217e00473"
      unitRef="usd">67000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzEtNS0xLTEtMTY5NjA4_a6e6b351-68c2-4665-8f78-bf570c02818b"
      unitRef="usd">65000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItMS0xLTEtMTY5NjA4_b5c6ea7e-1893-4d53-8051-be6262631039"
      unitRef="usd">15000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItMy0xLTEtMTY5NjA4_015d3c37-ff09-456e-b524-f91a584277d1"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTo3YjZiMzZhYzViMTE0YzUxYTAzOGUzNzdkNGQzNDM1OS90YWJsZXJhbmdlOjdiNmIzNmFjNWIxMTRjNTFhMDM4ZTM3N2Q0ZDM0MzU5XzItNS0xLTEtMTY5NjA4_3f84f939-5fc2-4d4d-9f7e-c2bf3911e74e"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwNw_0ab181ca-c112-43c2-84e0-b0b02ee4c3f1">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2022, 2021 and 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtMS0xLTEtMTY5NjA4_8ec6584c-4d7d-458c-a885-9c530cb6999e"
      unitRef="usd">70000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtMy0xLTEtMTY5NjA4_46afb3f7-135f-452a-869d-10872b9f800f"
      unitRef="usd">76000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzEtNS0xLTEtMTY5NjA4_c834c6be-fa6f-4c86-b204-9f2972f4167d"
      unitRef="usd">74000000</us-gaap:OperatingLeasePayments>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItMS0xLTEtMTY5NjA4_4a327afd-5e15-4785-9f3d-69379045df03"
      unitRef="usd">28000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItMy0xLTEtMTY5NjA4_15074fd3-a6bb-4a52-b8ed-59ae103ae1d5"
      unitRef="usd">46000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzItNS0xLTEtMTY5NjA4_5a05033d-c7e6-4a6b-9b1c-fa018f9ab78d"
      unitRef="usd">39000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtMS0xLTEtMTY5NjA4_9ee7f040-9fea-4334-84c1-ecaebdfecfc1">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtMy0xLTEtMTY5NjA4_1e36d52c-1b93-48a8-832f-16b7e969f5cf">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzMtNS0xLTEtMTY5NjA4_31f171fc-8c1c-4b5f-8b80-2d98c352bd9c">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtMS0xLTEtMTY5NjA4_eedc5161-86d1-4de9-8a4d-38fde0db6545"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtMy0xLTEtMTY5NjA4_c85db72d-f9f6-472c-a4f5-caec9de7c143"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZTpiMDE0Mjc5ZjkxNTI0MWZhYWFmYWFhZDU5YTQyZThmNy90YWJsZXJhbmdlOmIwMTQyNzlmOTE1MjQxZmFhYWZhYWFkNTlhNDJlOGY3XzQtNS0xLTEtMTY5NjA4_d06ec30d-9e53-400d-808f-ab14de3c7724"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90ZXh0cmVnaW9uOmJkMTE4ZTNmNWUxNDQzYjliOGJlM2EwZGVjYzhmMjZiXzYwOA_a578d11c-b4e9-48c8-89c2-8e0bf51b7771">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzEtMi0xLTEtMTY5NjA4_0005391e-48ea-4426-a7f3-5c2cdcea8e7b"
      unitRef="usd">63000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzItMi0xLTEtMTY5NjA4_95c7a45b-04c0-41dc-a540-5afc5e37312d"
      unitRef="usd">49000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzMtMi0xLTEtMTY5NjA4_ce842c25-b322-4be2-8139-974f2fd11ceb"
      unitRef="usd">42000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzQtMi0xLTEtMTY5NjA4_eec2d1e3-44cb-41d1-9109-8e462f5fa599"
      unitRef="usd">36000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzUtMi0xLTEtMTY5NjA4_323ae119-2732-4d72-bba5-fe5de26af794"
      unitRef="usd">34000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzYtMi0xLTEtMTY5NjA4_5717085c-6ba1-4264-890e-fcec7e5d29cf"
      unitRef="usd">63000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzctMi0xLTEtMTY5NjA4_b25c41b6-8745-4ef4-ada4-3ea98cb862bf"
      unitRef="usd">287000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzgtMi0xLTEtMTY5NjA4_da05665b-5402-4539-814f-bee53fd2ade6"
      unitRef="usd">53000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzktMi0xLTEtMTY5NjA4_f76d4a98-edfb-4ffc-9e11-868867a00fa5"
      unitRef="usd">234000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzEwLTItMS0xLTE2OTYwOA_d6a12664-9bcf-457e-9226-dec269f61c46"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNDkvZnJhZzpiZDExOGUzZjVlMTQ0M2I5YjhiZTNhMGRlY2M4ZjI2Yi90YWJsZToxYjFjMjkwNWE1Yjk0OGFiYjk5NzA2MmMwMDUyOGJkMi90YWJsZXJhbmdlOjFiMWMyOTA1YTViOTQ4YWJiOTk3MDYyYzAwNTI4YmQyXzExLTItMS0xLTE2OTYwOA_8656016c-1fc2-4a94-af27-990d0ad00aee"
      unitRef="usd">184000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjEw_3633204c-ec52-4418-9b8d-6ed208e72725">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch Health&#x2019;s Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, shareholders approved Bausch Health&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;), which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 28, 2020, Bausch Health further amended and restated the Amended and Restated 2014 Plan (the &#x201c;Further Amended and Restated 2014 Plan&#x201d;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#x201c;SARs&#x201d;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#x201c;underwater&#x201d; stock option or SAR and (iv) other housekeeping and/or clerical changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#x201c;Amended and Restated 2014 Plan&#x201d;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 18,226,000 common shares were available for future grants as of December&#160;31, 2022. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to retain and incentivize certain members of Bausch Health&#x2019;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#x201c;Retention RSU Grant&#x201d;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NDM_93af1e70-6189-47b5-bbc3-e0e2bb7a586f"&gt;three&lt;/span&gt; anniversaries of the grant date based on continuous employment with Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company&#x2019;s share-based compensation expense related to stock options and&#160;RSUs for the years 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc1MDMxNjk_b501e15b-da5b-47c2-acd7-f8740cbbba2e"&gt;ten&lt;/span&gt;th anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2022, 2021 and 2020 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#x2019;s exercise price and expected annual dividend rate at the time of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#x2019;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of all stock options granted in 2022, 2021 and 2020 were $6.60, $10.92 and $6.60, respectively. The total intrinsic values of stock options exercised in 2022, 2021 and 2020 were $1 million, $15 million and $2 million, respectively. Proceeds received on the exercise of stock options in 2022, 2021 and 2020 were $3 million, $22 million and $5 million,&#160;respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $14 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years. The total fair value of stock options vested in 2022, 2021 and 2020 were $15&#160;million, $15&#160;million and $15&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#x2019;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#x2019;s common shares on the vesting date. The Company&#x2019;s current intent is to settle vested RSUs through the issuance of common&#160;shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested time-based RSU represents the right of a holder to receive one of the Company&#x2019;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#x2019;s common shares on the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $94 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years. The total fair value of time-based RSUs vested in 2022, 2021 and 2020 were $80 million, $69 million and $66 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#x2019;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#x2019;s performance is below a specified performance level, no common shares will be&#160;paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each TSR performance-based RSU granted during 2022, 2021 and 2020 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#x2019;s common shares on the date of grant. Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#x2019;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest. If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no TSR performance-based RSUs granted in 2022. The fair values of TSR performance-based RSUs granted during 2021 and 2020 were estimated with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, the Company granted approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;369,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance-based RSUs, consisting of ROTC performance-based RSUs with a weighted-average grant date fair value of $9.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per RSU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $7 million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.4 years. A maximum of approximately 1,104,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2022. The total fair value of performance-based RSUs vested in 2022 was $31&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch + Lomb Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to May 5, 2022, Bausch + Lomb participated in Bausch Health&#x2019;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#x201c;B+L Plan&#x201d;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2022, in connection with the B+L IPO, Bausch + Lomb granted certain awards to certain eligible recipients (the &#x201c;IPO Founder Grants&#x201d;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to Bausch + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, Bausch + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were B+L IPO Founder Grants. The IPO Founder grants in the form of stock options have a three-year graded vesting period and the IPO Founder RSUs vest 50% in the second year and 50% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2022, Bausch + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#x201c;CEO&#x201d;). Under the terms of the separation agreement, the CEO&#x2019;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original three-year vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the two-year anniversary of the CEO&#x2019;s termination of service date (such applicable date, the &#x201c;Unrestricted Date&#x201d;). Under the terms of the separation agreement, the CEO&#x2019;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original three-year vesting period associated with such grants) upon the Unrestricted Date and will remain exercisable for two years following this date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2022, Bausch + Lomb entered into an Amended and Restated Separation Agreement (the &#x201c;A&amp;amp;R Separation Agreement&#x201d;) in connection with the departure of Bausch + Lomb&#x2019;s CEO. Under the A&amp;amp;R Separation Agreement, Bausch + Lomb&#x2019;s CEO agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board determines in its discretion or his successor is appointed, but no later than June 30, 2023. On the CEO&#x2019;s termination date, in lieu of pro-rated vesting, partial vesting of a set number of the CEO&#x2019;s IPO Founder Grants, in the amount of: (a) 315,592 of the CEO&#x2019;s IPO Founder Grants in the form of restricted stock units will accelerate and vest, but the shares received upon settlement will still remain fully restricted and nontransferable until the Unrestricted Date and (b) &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,248,496 of the CEO&#x2019;s IPO Founder Grants in the form of stock options will remain eligible to vest upon the Unrestricted Date and remain exercisable for two years following the Unrestricted Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes Bausch + Lomb&#x2019;s named executive officers (other than the CEO) and certain other employees. This program provides these Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by Bausch + Lomb without &#x201c;cause&#x201d; or the executive&#x2019;s resignation for &#x201c;good reason&#x201d;, in each case within the one-year anniversary of Bausch + Lomb&#x2019;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original three-year vesting period associated with such grants). However, the IPO Founder Grants in the form of RSUs (while settled in connection with the termination of employment) will not be transferrable until, and the IPO Founder Grants in the form of stock options will not be exercisable until, the earliest to occur of: (i) the date the spinoff distribution is completed, (ii) a &#x201c;change in control&#x201d; (as defined in the applicable retention award letter), (iii) the date the Board of Directors of the Company determines that it will no longer pursue the spinoff distribution and (iv) the two-year anniversary of the executive&#x2019;s termination of employment and the IPO Founder Grants in the form of stock options will be exercisable for two years following the later of this date and the termination date Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately 850,000 RSUs under the retention program pursuant to Bausch + Lomb&#x2019;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNDI_bd3faf2e-8d53-4f0a-9ea0-1f5a151830e1"&gt;three&lt;/span&gt; anniversaries of the grant date based on continuous employment with Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 17,500,000 Bausch + Lomb common shares were available for future grants as of December&#160;31, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted under the B+L Plan generally expire on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NTY_abbdaf34-1a0a-4131-b1a8-ee77e636b7d4"&gt;ten&lt;/span&gt;th anniversary of the grant date. The exercise price of any stock option granted under the B+L Plan will not be less than the closing price per common share preceding the date of grant. Stock options generally vest 33% each year over a three-year period, on the anniversary of the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan for the year 2022 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected stock option life was determined based on historical exercise and forfeiture patterns associated with historical stock options granted to Bausch + Lomb employees under BHC&#x2019;s long-term incentive plan. The expected volatility was determined based on implied and historical volatility of Bausch + Lomb&#x2019;s selected peer companies. Bausch + Lomb will continue to leverage BHC&#x2019;s historical stock option experience and peer company data until it has sufficient experience with its own equity awards and market data. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock option. The expected dividend yield was determined based on the stock option&#x2019;s exercise price and expected Bausch + Lomb annual dividend rate at the time of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradable, fully transferable stock options without vesting restrictions, which significantly differ from Bausch + Lomb&#x2019;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under Bausch + Lomb&#x2019;s Plan during 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of all stock options granted in 2022 were $3.84. There were no stock options exercised in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $4&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. There were no stock options that vested during 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan generally vest 33% a year over a three-year period with the exception of IPO Founder RSUs which vest 50% in the second year and 50% in the third year after the grant. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Bausch + Lomb&#x2019;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are credited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent provided for in a RSU agreement, Bausch + Lomb may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#x2019;s common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#x2019;s common shares on the vesting date. The Company&#x2019;s current intent is to settle vested RSUs through the issuance of common&#160;shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested RSU represents the right of a holder to receive one of the Company&#x2019;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#x2019;s common shares on the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity under Bausch + Lomb&#x2019;s Plan during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $41&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.5 years. Unrecognized compensation does not include IPO Founder Grants as they are linked to the completion of the Separation and expense recognition will begin near the time of the separation. The total fair value of time-based RSUs vested in 2022 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, while Bausch + Lomb did not grant performance-based RSUs during 2022, certain Bausch + Lomb employees continued to participate in BHC&#x2019;s performance-based RSUs granted prior to May 5, 2022. As of December 31, 2022, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $4&#160;million, which will be amortized over the weighted-average remaining requisite service period of approximately 0.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQyMw_88e47ac9-5fd9-4d9c-b39c-7a54f417531c"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iacbac47da7b145158fb0f7e8d5b7e2fa_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzc4Mw_df7f6ee4-a195-4e8e-af4a-530bf0389a9a"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic07679a14e86417f8712f8cbb82b60ff_D20200428-20200428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzIyMTQ_e02b4931-cecc-4d3c-88ab-058b7cafedf5"
      unitRef="shares">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iad4afe550a6c481c97793e197c5bce51_D20220621-20220621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5MzI_c13e0c3c-5f28-4334-832f-9dae25a9a2a7"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic7b69fb3977c4adc9d0e3708349c1838_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzMwMjE_4c0921dd-c726-4ef7-a078-c20ff5269354"
      unitRef="shares">18226000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjQ2_a17bdeaf-7f25-4a79-bc28-6a1dfa2eb156">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company&#x2019;s share-based compensation expense related to stock options and&#160;RSUs for the years 2022, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtMi0xLTEtMTY5NjA4_cf2bf457-ea6d-4413-a878-4a7f283725a6"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtNC0xLTEtMTY5NjA4_2d9f90d4-01a6-4e40-913d-09cc03fd35d2"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzEtNi0xLTEtMTY5NjA4_029f5108-89ce-4f91-9da5-e35d02aa56ae"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItMi0xLTEtMTY5NjA4_af962139-2264-42ab-a546-48a18fa90222"
      unitRef="usd">111000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7b78b13259aa479f924ecd7471c6be3d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItNC0xLTEtMTY5NjA4_a4af2c15-99b6-4314-b7b5-4548b76a5d32"
      unitRef="usd">113000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i62e3c2748eaf4aafa359630b13935a24_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzItNi0xLTEtMTY5NjA4_58b6c9b7-0533-4247-9735-f854c4f049c5"
      unitRef="usd">90000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtMi0xLTEtMTY5NjA4_fd78823b-0c9b-4ed9-85ae-3fcd232e81c0"
      unitRef="usd">126000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtNC0xLTEtMTY5NjA4_244850ad-c101-458e-9910-8039d1a47008"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzMtNi0xLTEtMTY5NjA4_2334ecd4-e699-452b-ba57-a124c8232a88"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if00b7cd8fe45432a9a85664c569eeb15_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtMi0xLTEtMTY5NjA4_09c92296-12e9-4c01-a6c1-9254449ec067"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia8d64492eb2e4908a69e9f58b7558e25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtNC0xLTEtMTY5NjA4_2ee7e11f-9c70-48da-a891-711aaee009fd"
      unitRef="usd">10000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0946c8396b744fe99205ccf1dee3017f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzUtNi0xLTEtMTY5NjA4_729d775c-a2bb-4b9d-bdf3-d2f3e196134a"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iede2de5499f441559e821dbcad622021_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtMi0xLTEtMTY5NjA4_48949181-5c38-4ad2-a939-c081b662c617"
      unitRef="usd">114000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i60f0f7903cd849f3b7151828b60fac8b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtNC0xLTEtMTY5NjA4_6352b1f0-39af-40b8-a40e-feeb09ad2ee8"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2a380354c968473db359c0f5368d07a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzYtNi0xLTEtMTY5NjA4_d01a3bc9-e8cb-458c-8a22-1db1c98f2b90"
      unitRef="usd">94000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctMi0xLTEtMTY5NjA4_f7751b18-b9a4-4886-8d79-0ad3cb184d62"
      unitRef="usd">126000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctNC0xLTEtMTY5NjA4_0151946e-6c3d-4bfd-9c4b-158fe5b8006b"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4NzFkZTc0NWVhMmI0NjA4OWM0ZTFkNzgwMzFhMjRiNy90YWJsZXJhbmdlOjg3MWRlNzQ1ZWEyYjQ2MDg5YzRlMWQ3ODAzMWEyNGI3XzctNi0xLTEtMTY5NjA4_3cdd15a2-3b54-47de-9a41-cb6fa35fef3c"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="ia45df334731c4a1288356ac1f33c7415_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQ1OTg_8f847938-1b6e-4613-a6f3-d11182b6b1da"
      unitRef="number">0.33</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="ia355745004ed4515ab1169c8dee886ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQ2MDU_73dccad0-929d-4f7b-bf21-a4d593858ced"
      unitRef="number">0.25</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2a6f01dc7e7849e1afb697e1681e7989_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjU1_c9be6ae3-42a9-45d5-853c-4248fa9d0570">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic888605118c2447e80ad019de50268f8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjMy_3d1ed1f6-7437-43a8-8087-e7b86185d949">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjE3_cae9223f-1e37-49d6-868d-3ec4f71bb541">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2022, 2021 and 2020 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;2022 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtMi0xLTEtMTY5NjA4_4279d211-547a-4e83-9edf-7f95ed738c2d">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtNC0xLTEtMTY5NjA4_bd2868e4-7ddb-4828-8f9f-12d4975191c8">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzEtNi0xLTEtMTY5NjA4_eeab039e-5020-4b06-ac18-6cbd8541aa9b">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItMi0xLTEtMTY5NjA4_c1ada56a-89a4-476d-9471-8cbaa947849b"
      unitRef="number">0.378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItNC0xLTEtMTY5NjA4_2949657f-fd12-4b55-8c09-a10ec97b29db"
      unitRef="number">0.502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzItNi0xLTEtMTY5NjA4_bf8c4d7e-be04-4e14-9ceb-523332a012d9"
      unitRef="number">0.387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtMi0xLTEtMTY5NjA4_4256283e-ed30-4350-a2e6-bbe9b0d34d95"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtNC0xLTEtMTY5NjA4_f3282774-8ddd-4e09-b7e7-bfe7594d5b2d"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzMtNi0xLTEtMTY5NjA4_03a74bc8-73b3-48e5-99d8-9157c3b0def1"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtMi0xLTEtMTY5NjA4_058beb2f-17d9-4d96-98ed-f1cc168c00a2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtNC0xLTEtMTY5NjA4_a27c5ecc-b5d3-443d-aa6c-8b2d7cbb3196"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplM2M0N2U5N2ZiZDY0MjZjOTZkZDViYWE4YmIxYzkyNC90YWJsZXJhbmdlOmUzYzQ3ZTk3ZmJkNjQyNmM5NmRkNWJhYThiYjFjOTI0XzQtNi0xLTEtMTY5NjA4_6598eb43-092f-4d8e-8e62-9e42a092ba39"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjM0_e7ce2fad-df4d-4475-87b8-7a759e80c613">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under Bausch + Lomb&#x2019;s Plan during 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzEtMi0xLTEtMTY5NjA4_128b4c5e-9b25-4de8-acbe-3994765295a3"
      unitRef="shares">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5777011b7c77426a9a5f0ba168f3b6d8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzEtNC0xLTEtMTY5NjA4_6792fa42-af95-411d-9d7c-69a7683d6649"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzItMi0xLTEtMTY5NjA4_b5d57eb1-66b6-4240-979c-6bbe52754f30"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzItNC0xLTEtMTY5NjA4_6c2f1f2d-a8fc-4d3f-800a-ab464731a90c"
      unitRef="usdPerShare">23.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzMtMi0xLTEtMTY5NjA4_52b40e02-9486-4893-983c-e2934e93443b"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzMtNC0xLTEtMTY5NjA4_fad7266e-ead3-4fb0-85af-5531da3d6854"
      unitRef="usdPerShare">19.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzQtMi0xLTEtMTY5NjA4_50e79726-79ec-4672-bf83-890a9ab2030b"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzQtNC0xLTEtMTY5NjA4_eff084cf-5a2f-4110-9342-2df0804c95c5"
      unitRef="usdPerShare">28.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtMi0xLTEtMTY5NjA4_31154aaa-f0e4-4c8d-b630-4bf0daa86ec8"
      unitRef="shares">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtNC0xLTEtMTY5NjA4_c41913d8-cbed-47f0-9ef7-caffb2c4f257"
      unitRef="usdPerShare">26.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtNi0xLTEtMTY5NjA4_35bb6a75-dcb9-4ab7-918f-234da037466e">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzUtOC0xLTEtMTY5NjA4_83c1e84f-fe5c-4038-b83a-03d585942301"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtMi0xLTEtMTY5NjA4_fd1b493f-600b-461b-9c02-ab6f18f2ac22"
      unitRef="shares">10300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtNC0xLTEtMTY5NjA4_129798b5-7bdb-46b3-b2f8-ea7952982f6f"
      unitRef="usdPerShare">26.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtNi0xLTEtMTY5NjA4_1a59f766-bcf1-48f0-b541-551d25f8db8e">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzYtOC0xLTEtMTY5NjA4_ff192376-1cf1-4bb4-a5a9-d5bf5a149bfc"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctMi0xLTEtMTY5NjA4_e632a28f-c4f9-44fc-a647-16043c637cd0"
      unitRef="shares">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctNC0xLTEtMTY5NjA4_c8af5121-481e-47cc-bf20-5557071c8aef"
      unitRef="usdPerShare">27.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctNi0xLTEtMTY5NjA4_cc08fba2-a755-457a-9cce-61f32cbd9520">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo2OWVkMTk5MmVmMjY0NTBjYWZjNGNjMzg4Y2Q1MDQ4MS90YWJsZXJhbmdlOjY5ZWQxOTkyZWYyNjQ1MGNhZmM0Y2MzODhjZDUwNDgxXzctOC0xLTEtMTY5NjA4_c80bffc8-d788-49ad-9f13-db26df2cebe7"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwNzI_416d6438-e879-4125-8906-2bd4e6da9af6"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwNzY_bcd75772-3e5b-4a05-976c-82f1a5001d9e"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYwODM_30167043-66c1-49fb-a050-2d2178063cbb"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNjY_e5c1f3b6-ee56-40de-a437-c21a96feccba"
      unitRef="usd">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNzA_27a51d6a-cadf-405a-b72e-48acd5ff0124"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYxNzc_20a074b5-9cea-4a3b-9161-82dd0565951c"
      unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNTc_8ecbcafa-d9d5-4f4b-8aa5-65346e0dd1e9"
      unitRef="usd">3000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNjE_feb70b48-fc09-4940-89b3-79aa37ef9e41"
      unitRef="usd">22000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYyNjg_b5d49170-6846-4b98-a02b-c355462ee2b4"
      unitRef="usd">5000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9f438587dede4b58b5187b50c6366f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzYzOTI_fc212a39-2198-4217-8b4d-870ea65f681e"
      unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzY0OTg_e06e09a3-b782-403a-a99a-c9cfdc38d762">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM0Mg_253e43fe-d56c-4127-bad1-c14cf9bbf9a1"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="if7542fcc53f34c2f9ae3e3644f650b4a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM1NQ_7ff304c2-0676-49f1-9683-c541c3dbfd59"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i090655bf437c47a08f93010b3050db91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTg3NTM2OA_17d39930-d02a-45f7-8faf-ef94b971b68c"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzY2ODM_26c03b42-0f0b-4456-a237-42f2a7058d4c"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjM4_f27baae6-1f75-4a8b-b579-e771917dfacf">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjQ5_fb481732-c7d8-4662-a39f-02386ba03acf">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity under Bausch + Lomb&#x2019;s Plan during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if2492e7b35404d8e87840515f9d9a6c5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzEtMi0xLTEtMTY5NjA4_b1695ca0-28e1-4629-98e1-1cdd5cb184fb"
      unitRef="shares">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if2492e7b35404d8e87840515f9d9a6c5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzEtNC0xLTEtMTY5NjA4_175509c8-cb02-4572-a319-3bbf7aef4cdd"
      unitRef="usdPerShare">28.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzItMi0xLTEtMTY5NjA4_e3be2369-4a6a-4831-a4e8-de83ad79de95"
      unitRef="shares">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzItNC0xLTEtMTY5NjA4_3310fef1-d0af-4325-b782-1d13a9257631"
      unitRef="usdPerShare">11.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzMtMi0xLTEtMTY5NjA4_3cd2ed16-4d1c-4cb8-b3a5-9b586fdfeb70"
      unitRef="shares">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzMtNC0xLTEtMTY5NjA4_08100fe7-3193-40c5-9e0e-33a14da78d36"
      unitRef="usdPerShare">26.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzQtMi0xLTEtMTY5NjA4_e1e8b902-2fac-4983-90ad-c2b0acff35c0"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzQtNC0xLTEtMTY5NjA4_160ed7c5-cee5-421d-8486-2a429dd19832"
      unitRef="usdPerShare">24.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iae249c92a22044b9807b386e185de759_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzUtMi0xLTEtMTY5NjA4_9fb5ab79-3877-45cd-9fb4-d4bc58d7d4aa"
      unitRef="shares">8300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iae249c92a22044b9807b386e185de759_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphMTM5NGNhOTIyOTI0ZmIxYWJmNWNiYjY2N2NkZTE2Mi90YWJsZXJhbmdlOmExMzk0Y2E5MjI5MjRmYjFhYmY1Y2JiNjY3Y2RlMTYyXzUtNC0xLTEtMTY5NjA4_68c24b85-bc3a-44fd-98c5-f53174cedb30"
      unitRef="usdPerShare">15.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iae249c92a22044b9807b386e185de759_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg0OTU_bd350da4-f7c9-48e7-8b59-d69f9e98b7db"
      unitRef="usd">94000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2MDE_0ef293b8-4b90-4715-ab23-a2303690ae9d">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2Njk_828b1786-5d23-49ee-9b11-574a9395ce9c"
      unitRef="usd">80000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iaee78b80f312454f958d6185baba0299_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2NzM_505c8f47-af62-4e07-b999-ebc5bfcf8338"
      unitRef="usd">69000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i0d52467dd2c048db873fab55177a674a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzg2ODA_e18f1cf7-e264-4591-a660-f78433ec536f"
      unitRef="usd">66000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8820b0a3beb24bed91da8f3c82e42606_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk2OTE_a6789100-5433-42cf-9318-0b08f178bf0b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjA5_8205e5db-5472-4c7f-a451-15b594ef5425">The fair values of TSR performance-based RSUs granted during 2021 and 2020 were estimated with the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzEtNC0xLTEtMTY5NjA4_6d6090be-b022-4de8-8c02-a0c05672a0da">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzEtNi0xLTEtMTY5NjA4_86d5443a-aa45-420d-899f-e773f89a233d">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzItNC0xLTEtMTY5NjA4_960bb68b-8717-4feb-8cf6-9ea16c9fc37f"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzItNi0xLTEtMTY5NjA4_d32e0220-c716-4054-b5ce-478d9119fe03"
      unitRef="number">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i501a37a78c3741f4b5a83cf9bbe206aa_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzMtNC0xLTEtMTY5NjA4_e10974bc-fdee-4092-a385-e2c989fd0bf0"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibfc7bb3beec9427ba45036b1e0141a0d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphYmJkMDk2NjI2ZDk0OGZhYjI0ZGMxNjRmNGM0NjQ0ZS90YWJsZXJhbmdlOmFiYmQwOTY2MjZkOTQ4ZmFiMjRkYzE2NGY0YzQ2NDRlXzMtNi0xLTEtMTY5NjA4_7cfff11d-733e-47c5-a51e-4b2fa6dfbcc7"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMjIw_891db957-1c0d-4acb-a5cd-1809d5154598">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzEtMi0xLTEtMTY5NjA4_6cb43cd1-3f5a-4417-b8bd-2096ac2ba477"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3d8f6c73a3ea45778a765ceb3a3792d5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzEtNC0xLTEtMTY5NjA4_3a75b919-939e-4c95-b2c1-07e37dc2439c"
      unitRef="usdPerShare">33.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzItMi0xLTEtMTY5NjA4_1ae359ba-f902-42ff-9f5d-d38eaf220424"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzItNC0xLTEtMTY5NjA4_32c5bb8e-5685-4051-b9df-0ebfec60639c"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzMtMi0xLTEtMTY5NjA4_bddc113d-2cb8-4a3d-82ac-19f2b6cd4137"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzMtNC0xLTEtMTY5NjA4_32d93a84-5dda-4dda-9d30-f354987006dd"
      unitRef="usdPerShare">30.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtMi0xLTEtMTkyNzU2_b213e4b2-601c-44e2-9701-15e8441a91db"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtNC0xLTEtMTkyNzU4_7fdef447-dd86-495e-ae63-5f5e356a7dde"
      unitRef="usdPerShare">34.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtMi0xLTEtMTY5NjA4_ca94502a-45bd-4e0d-bb61-bc8558bb6576"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo4ZjdlZTA1YWVhMDU0YzJjODNlMjIxZDQ4Nzk1NGY3NS90YWJsZXJhbmdlOjhmN2VlMDVhZWEwNTRjMmM4M2UyMjFkNDg3OTU0Zjc1XzQtNC0xLTEtMTY5NjA4_84d5b542-56f7-448e-bac1-beca1c6d6254"
      unitRef="usdPerShare">29.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwNDg3_0396e60b-c048-4e31-a79d-8f0ca8abe06c"
      unitRef="shares">369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i371264615c75420297fa60d12cdd7590_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwNzM3_c7b6e8c3-060e-497d-bc5c-d421a11ee8a3"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwOTcy_3c76fad7-59a6-416d-a182-3697a669763b"
      unitRef="usd">7000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMDc4_f00146b6-a313-47be-b2b8-64982a5ab308">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued
      contextRef="i58c7a9138ff04e618e86f8caa65ef150_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzExMTE2_e07e2097-2fba-49a1-9abc-bd78ce7d30e2"
      unitRef="shares">1104000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i58cfa955bd014572ab40caa917331ebd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzEwOTk1MTE2ODkzODU_7654039a-188b-4d69-9ea0-00a93749a94e"
      unitRef="usd">31000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i976c4ead5b5e43388410dab98e1380f6_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NTU_79956789-12ed-41ca-aae6-941ff12f1b10"
      unitRef="shares">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5NjY_2fef6eb2-c6d5-4b68-bae6-ac5f66222d3f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5OTI_25fd3fea-3472-4c07-871f-3ae2c9c67f3e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4c08f6b4a1bb4b97b88bd4703a8f0c70_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODA5OTQ_a2581b57-caca-4c76-b0fa-35156bc9e2c5"
      unitRef="shares">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="i8eae6ead96a941d1b21a4d5924929d5c_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMDU_5e16adc7-e855-4f04-9400-cd06ed45ac63"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="i798f17f8800a4c818af00babd1be3910_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMTA_7b80252a-6bdf-4cef-8adb-8304f7808aa3"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="i92c83dd26ed54f1789ce908d1c7409fc_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMTU_b1a4cff2-16d1-46d6-8924-59a80ebc1aa2"
      unitRef="shares">5700000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="i52e72a61294341d795cb93013ab5a0ea_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwMjY_7e08704c-c8c8-45aa-b8d5-16aa0ddb2d27"
      unitRef="shares">4300000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifee915a0af56457092546e18d9f5b2b1_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNDY_9c36c729-23cc-4200-9a26-f4d7e2bbe1c8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibba9807196544553bf6afedfc7ef764f_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNDg_580faf06-b250-4d61-9476-81e638706f89"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iba13317aa60c47fdbe720638efeb8a32_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNTM_75301352-2908-4b9a-a77b-ef152d368249"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4972cc1494f64143a33a8f5939165fb1_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNjc_617a9de8-214b-41db-a80d-f77839edd0f8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod
      contextRef="i9246f8b8e1204a3b9c57cd2cd7d1f32b_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwNzc_9e42aa76-ad93-4400-9dd7-12c9fda7c1e8">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia300b8d00c054934a733fe79c976c8df_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwODg_4946830c-3fa6-431d-96d6-19e90898018f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod
      contextRef="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEwOTg_b03163e0-a1e0-41ff-94e1-19cc8e28812f">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting
      contextRef="icff6d6c9c84647b1b1dce247dcafc619_I20221222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MDA_3055ee27-4f77-47c7-9bdb-c10b1e651195"
      unitRef="shares">315592</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest
      contextRef="icad5cc2f654041548ac38459ec8e3737_I20221222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MDk_4ad09fb7-305d-4e4f-b451-e9a4585c965b"
      unitRef="shares">1248496</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod
      contextRef="i99e1d88c22364cb6b56da87897b7c942_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3MTk_a21bba2f-67a9-4abe-b82e-6009b413e3c0">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod
      contextRef="i158545ece5364e96bdae2027c13c3e8d_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMjE_7a52c7ff-0b85-40cd-b47d-337e21423e6e">P1Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i57057d66fc88405090a8ce98ca6c8e2c_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMzI_6e3d9ce5-026b-466e-86b0-b06ae8df4811">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod
      contextRef="ia60f66139de8490cb251cef704102616_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NDE_b9f97913-b78b-4e92-b9f4-86d41605e4e2">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod
      contextRef="ia60f66139de8490cb251cef704102616_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NDI_79129784-f171-428e-a063-f97b35a533ff">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i45ea2f1b931c406ab59cf4fbb9067e9a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExMzQ_cefc0585-931b-47fd-bd47-747dd65cb5b4"
      unitRef="shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2f724b3f1785466b94b544893b47c1bb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNTQ_71ecf785-67fc-41c9-a8f0-1f2e82488e98"
      unitRef="shares">17500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i15e52757684147129eded077c6efccfd_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_3d8d190a-cc75-41ef-8504-298de74d7dde"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic466f5201e554473806f5d23207321c7_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_b38bb77c-e16d-4db7-870f-971b7690e919"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2d0ac44894434f3c838f08217170a230_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExNzA_b39a7177-a1a6-4a2e-98de-0f1e7c7a6ceb"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i087f57f630cd4065a0d2aa83440554be_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODExOTk_e50eeea9-abe7-4576-a69b-b1f222f8858f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzEtNi0xLTEtMTgwNDk0_4d6a892e-3e0c-4131-8eb1-ebefa25dad3d">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzItNi0xLTEtMTgwNDk0_44023514-fca8-4ccb-98e7-9f597d99eae8"
      unitRef="number">0.315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzMtNi0xLTEtMTgwNDk0_d0d17830-6be6-4558-8a29-7f0b83495d48"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTphZWJmYWVlN2ViZjA0NmQ4YTM1ZTA0ZjZiNWJjMmFkNC90YWJsZXJhbmdlOmFlYmZhZWU3ZWJmMDQ2ZDhhMzVlMDRmNmI1YmMyYWQ0XzQtNi0xLTEtMTgwNDk0_b4543137-35c8-4098-85cb-c13e99d477b5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i496a8139703848748c2af0e1c60eba9d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzEtMi0xLTEtMTgwNTAw_c48bd599-5a3c-45db-89e2-2c9d60a8881f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i496a8139703848748c2af0e1c60eba9d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzEtNC0xLTEtMTgwNTAy_d8c22855-313f-4ef1-abd9-03c3ab4cc6e7"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzItMi0xLTEtMTgwNTAw_529ea439-5332-4ad9-9134-c679288acf7f"
      unitRef="shares">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzItNC0xLTEtMTgwNTAy_0ac47cef-c3e7-43b8-8465-79582c00d969"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzMtMi0xLTEtMTgwNTAw_f57ec692-859e-42fd-9dd4-426a0957d8b5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzMtNC0xLTEtMTgwNTAy_2d5b062c-a8e9-40e2-9aa1-cd0b0eb0525f"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzQtMi0xLTEtMTgwNTAw_20d8602b-864f-43e3-ba2a-c54e42bb09ce"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzQtNC0xLTEtMTgwNTAy_5babaf03-cbd2-4928-927e-6c32f52bbc04"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtMi0xLTEtMTgwNTAw_a01f8506-e3f5-4894-9234-148251bb27a0"
      unitRef="shares">6300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtNC0xLTEtMTgwNTAy_9253626a-201b-431f-9256-6febc3e2faae"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtNi0xLTEtMTgwNTA0_70f904e9-9cc2-4c46-a8ae-d2bb80aa0169">P9Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzUtOC0xLTEtMTgwNTA2_25ca5ed0-7d8d-4e11-b25e-dedf148843d4"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtMi0xLTEtMTgwNTAw_66a9b924-01e2-4d64-ac32-9422055d0104"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtNC0xLTEtMTgwNTAy_c71c25ed-c876-45b5-aba8-9f56ffc66f66"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtNi0xLTEtMTgwNTA0_e9f79e42-03ef-4828-9d71-e2ca7bad405f">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzYtOC0xLTEtMTgwNTA2_90c06989-0126-4c07-8de8-3ceccb0c0623"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctMi0xLTEtMTgwNTAw_79e9fbd3-48ab-48b8-aa06-e8258bafdc0c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctNC0xLTEtMTgwNTAy_1ff8a2d5-2d0d-4f3f-88d9-8a718fa03608"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctNi0xLTEtMTgwNTA0_312b29a7-9780-423d-9d0c-f6f75c7fc12d">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTo5MWRjZTExZTU2YjY0OWExOGRiMGU5ZjMyODk3YjAyMi90YWJsZXJhbmdlOjkxZGNlMTFlNTZiNjQ5YTE4ZGIwZTlmMzI4OTdiMDIyXzctOC0xLTEtMTgwNTA2_a92928bb-3113-4984-9f6c-1852fe2dbd0f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxNTU_3a917275-403e-4464-89d8-0b293d1c243b"
      unitRef="usdPerShare">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NjY_39b958ba-08e4-4304-b9ec-f58e118fba15"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ida5ab484db4f47cea101682d1dc38960_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxNjM_29266a51-6cd2-457c-8c34-73f2bf8e1c07"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6ee5ecfc73f9483b9bbb30db9ede4fd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEyMjQ_9e748450-62bb-4b4e-ad90-d7724936d8a9">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i56e87d37abd4499ea01e8038522b296c_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_57506c91-bcfd-4e19-adc7-6757c1b7df84"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if701cbfe1c6a4dcd881783198bdf3bf1_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_c553065c-c1fc-4c48-84c7-a0ded6c3cc8a"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic3174916bf904c96b87d8033569c321d_D20220505-20220505"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3NzU_e4b7f706-665d-4418-952a-9d81efee4c3d"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib7365ac3a4d640af8c0c8f6f469cd387_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3Nzk_65292be1-6ed1-4b07-97da-c1e99950aa62">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6d68de5df36c4a3eaab2e8b8f62dbb07_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzQzOTgwNDY1NTY1ODQ_e311c8c0-7e0f-43ac-b35a-f72e2a6f0804"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i694231e10d404b83a250ebe6cbae790f_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3ODU_b27e6042-1b6c-4fdc-a92a-51e928852e2d"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6757e09e35d643fa9be873511bd89c4c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzEtMi0xLTEtMTgwNTc0_7e70f2c2-36ba-4bcc-abfb-a5ca991f44b2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6757e09e35d643fa9be873511bd89c4c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzEtNC0xLTEtMTgwNTc2_ffc973c8-e9a4-4bcc-b997-29c20ef6d75f"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzItMi0xLTEtMTgwNTc0_8cb8cff8-5b99-4110-a959-8d4d41ae1785"
      unitRef="shares">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzItNC0xLTEtMTgwNTc2_723c966d-e3c5-4606-847e-eaed0c402ec4"
      unitRef="usdPerShare">16.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzMtMi0xLTEtMTgwNTc0_9f514bf7-7988-46c0-98d3-254cff35b919"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzMtNC0xLTEtMTgwNTc2_2cadddb4-f7cd-4456-9df8-bee3d2cddc64"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtMi0xLTEtMTg3MTkx_c95b1f70-84c4-459b-b234-41258b85b09e"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtNC0xLTEtMTg3MTk0_9de3f468-9375-4035-b4e1-653f4fe6d7a1"
      unitRef="usdPerShare">17.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtMi0xLTEtMTgwNTc0_3e64c7e6-afea-4983-9ce4-5122cc511bff"
      unitRef="shares">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90YWJsZTplZWFlODg3ZGMyODI0YjBkOGQ5Y2UyMGJiMTQ5ZWY4My90YWJsZXJhbmdlOmVlYWU4ODdkYzI4MjRiMGQ4ZDljZTIwYmIxNDllZjgzXzQtNC0xLTEtMTgwNTc2_b64ebf6f-2060-4bba-88d2-0881ce806fc6"
      unitRef="usdPerShare">16.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i337510976d6d4c44a85e9ccfb0130e9f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODIxOTU_6906dd69-80d1-41f8-8f03-d2aa438f7b36"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3e6e4343504d471fa05fbeb7590e9bc5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzE2NDkyNjc0ODEyNzA_7d4efb6c-4172-4979-a387-18b46efc4123">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0b929374818a40479322ab79af8f337f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk3OTE_e5e757a4-67a1-4529-9b3a-f73d3a483bbc"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8d4815a98c184418bbffa029558875ff_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTIvZnJhZzoyZDg0MDc2NTMwMDE0Y2NmYTc3OTNmZDM1MmYwYmM0Yi90ZXh0cmVnaW9uOjJkODQwNzY1MzAwMTRjY2ZhNzc5M2ZkMzUyZjBiYzRiXzU0OTc1NTgxOTk4MDI_e937dd3a-26ec-44dc-b062-0b6864f22c45">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzQxOA_aa539f3a-cdfb-44f2-a9d1-7fefc569b65c">ACCUMULATED OTHER COMPREHENSIVE LOSS &lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2022 and 2021 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in the Company&#x2019;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzQyNg_fe22913a-550e-4eaa-aa97-0b56c353bd68">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2022 and 2021 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e2ee13540d244e58ee59a9ca76630cb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzEtMi0xLTEtMTY5NjA4_a7351712-4cf6-4fb6-8d67-848309ac6d81"
      unitRef="usd">-2038000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9476d0eb2004c5589302c03748dd6c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzEtNC0xLTEtMTY5NjA4_e080250c-3df6-4448-bb83-b135a44cdba8"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id01756a362e44beb92a479cf33c85af9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzItMi0xLTEtMTY5NjA4_38c1e6b1-2b0b-4ee1-afbe-634d59df8dc8"
      unitRef="usd">-18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f95881b6ece465992d0a8b5672f70a8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzItNC0xLTEtMTY5NjA4_68aa2821-6dcd-4a32-919d-8518fc1c536e"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i286802cacb2b47a7aac5819b6b1ae881_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzMtMi0xLTEtMTY5NjA4_b81a8eb8-2c1c-448c-a271-ace4ffc706cf"
      unitRef="usd">-2056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4522c45ac1c44145a7ecea556295fe2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90YWJsZTplZGNjOTczYmMwZGQ0NzliODMyNTE3MDI3NGE4YWU5Zi90YWJsZXJhbmdlOmVkY2M5NzNiYzBkZDQ3OWI4MzI1MTcwMjc0YThhZTlmXzMtNC0xLTEtMTY5NjA4_80204a43-770f-4fd0-be30-5220e99e03c6"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibdc8cd56812542429247ba8cba9a093a_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTUvZnJhZzo3MTJkNWNjNjc4OTU0MzI1YTI3MThmZjhjMGFlN2M3OC90ZXh0cmVnaW9uOjcxMmQ1Y2M2Nzg5NTQzMjVhMjcxOGZmOGMwYWU3Yzc4XzE2NDkyNjc0NDI0MTU_7117b752-e3cb-40ac-a757-4778f5acbe87"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90ZXh0cmVnaW9uOmUzMTUwNDRkYzY0YTQ4ZjVhOWYyYzhhNjM4NDRkODM4XzI4Nw_184ee076-4628-4165-af2a-3bb19b1bcb75">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2022, 2021 and 2020 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90ZXh0cmVnaW9uOmUzMTUwNDRkYzY0YTQ4ZjVhOWYyYzhhNjM4NDRkODM4XzI4Ng_bca7aab7-1de1-4c3d-9ae1-b89a09dd2e04">Research and development costs for the years 2022, 2021 and 2020 consists of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtMi0xLTEtMTY5NjA4_a1df3580-487f-4ff4-ac4b-956d3147aa2a"
      unitRef="usd">500000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtNC0xLTEtMTY5NjA4_f8546d36-68d8-4473-b5fe-b8e2864f74d8"
      unitRef="usd">440000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzEtNi0xLTEtMTY5NjA4_253a0e3b-0783-49b7-b069-06a579999382"
      unitRef="usd">420000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItMi0xLTEtMTY5NjA4_ecba8e62-c4e7-452e-9385-95f9a501bc53"
      unitRef="usd">29000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItNC0xLTEtMTY5NjA4_33618a04-f884-41ee-b3b6-df15ec37c1f1"
      unitRef="usd">25000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzItNi0xLTEtMTY5NjA4_c9ed7981-ea43-45f7-ac5a-2d6bcfaf966a"
      unitRef="usd">32000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtMi0xLTEtMTY5NjA4_34bfe495-dfc6-4332-957e-e2bc39f1b702"
      unitRef="usd">529000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtNC0xLTEtMTY5NjA4_411083d4-c414-4725-bf97-b2d0bfe326cc"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNTgvZnJhZzplMzE1MDQ0ZGM2NGE0OGY1YTlmMmM4YTYzODQ0ZDgzOC90YWJsZTphYTlmYTYyZmE3YWQ0Yzc3YjA4YjRiYTFlOWZmMzA1MC90YWJsZXJhbmdlOmFhOWZhNjJmYTdhZDRjNzdiMDhiNGJhMWU5ZmYzMDUwXzMtNi0xLTEtMTY5NjA4_09424f01-e048-4d23-a17d-b06849c65302"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzk4Nw_b46b2542-96b7-401b-9840-8bac5258b8a4">OTHER EXPENSE, NET&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2022, 2021 and 2020 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sale of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net gain on sales of assets includes $25&#160;million related to the achievement of a milestone related to a certain product and a $26&#160;million loss upon completion of the Amoun Sale during 2021.&lt;/span&gt;&lt;/div&gt;In 2020, Acquired in-process research and development costs of $32 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements.</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzk4NQ_6e2c58c9-1bc6-44f3-84a6-eb6f5fcac397">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2022, 2021 and 2020 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sale of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItMi0xLTEtMTY5NjA4_12c9e791-9c1e-4884-b7d0-bb172f1c9e4c"
      unitRef="usd">-9000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItNC0xLTEtMTY5NjA4_3dcdacaf-6ce6-4a71-afaf-faac288fc1f7"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzItNi0xLTEtMTY5NjA4_841509f3-7c08-4836-8076-355f261adea1"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtMi0xLTEtMTY5NjA4_8b75fe51-55a3-482d-877e-2a0731cbde43"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtNC0xLTEtMTY5NjA4_202ee63d-6a73-4689-8865-c5dcb864ea4e"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzMtNi0xLTEtMTY5NjA4_c52be17c-7a40-401b-8995-854a8c1e1b77"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtMi0xLTEtMTY5NjA4_607647c2-7000-409b-9989-0ef7fe85a861"
      unitRef="usd">5000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtNC0xLTEtMTY5NjA4_7b3665a4-9c0e-4f84-947f-9de9d585af83"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzQtNi0xLTEtMTY5NjA4_a8e0f038-5de7-4e6f-9614-4c4a01b0c71e"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtMi0xLTEtMTY5NjA4_a44105ce-cbf4-4dcb-8b90-8b5d48d78455"
      unitRef="usd">29000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtNC0xLTEtMTY5NjA4_909b7cf1-0674-4f0a-a80d-d5fb26f6fb09"
      unitRef="usd">11000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzUtNi0xLTEtMTY5NjA4_55f761d5-25c9-45d4-9216-82a3cfe47865"
      unitRef="usd">48000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <bhc:OtherIncomeExpenseNet
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtMi0xLTEtMTY5NjA4_05203c28-ce78-4d43-a0b7-ed5626ae41c8"
      unitRef="usd">1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtNC0xLTEtMTY5NjA4_f0b1cbf9-5720-412a-b15d-c40e06c4b794"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzYtNi0xLTEtMTY5NjA4_5c448ad8-3b71-45af-ae7a-32a64aff4c5e"
      unitRef="usd">1000000</bhc:OtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctMi0xLTEtMTY5NjA4_0dc3ad24-ce15-4d7e-8308-1a26eb2501a0"
      unitRef="usd">-35000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctNC0xLTEtMTY5NjA4_418426c9-243a-4f1d-bc34-483e6111d7c7"
      unitRef="usd">-373000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90YWJsZTpjMTg1ZWYzYWM3NGY0MmE5OGY4NmE4YzJjODFkYzAyYy90YWJsZXJhbmdlOmMxODVlZjNhYzc0ZjQyYTk4Zjg2YThjMmM4MWRjMDJjXzctNi0xLTEtMTY5NjA4_7f3169fc-d280-4376-b0d0-18e722bb5033"
      unitRef="usd">-502000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2Mjg3NzE_3dcdacaf-6ce6-4a71-afaf-faac288fc1f7"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2Mjg3Nzc_841509f3-7c08-4836-8076-355f261adea1"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib3c97c4ec64941ccb13c8842880f03f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzE2NDkyNjc0NDMyODA_694fb24f-47e4-42e6-81c4-befc7694107f"
      unitRef="usd">25000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i33a71834a2c2461da62fcc9c1c83566e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzE2NDkyNjc0NDMzMDU_9bfd3340-1f27-4897-b87c-192a7241b576"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjEvZnJhZzo1ZmQwNDIxMzgyODI0Nzc4OTY3NGZhNDk5ZmQ4OWU4Mi90ZXh0cmVnaW9uOjVmZDA0MjEzODI4MjQ3Nzg5Njc0ZmE0OTlmZDg5ZTgyXzEwOTk1MTE2MjkwMTA_c52be17c-7a40-401b-8995-854a8c1e1b77"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODE2_9594934c-eab6-40df-831c-98fec1c9701e">INCOME TAXES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before income taxes for 2022, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of (Provision for) benefit from income taxes for 2022, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (Provision for) benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before income taxes for 2022, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision for) benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other consists of immaterial adjustments affecting the tax provision such as those related to the filing of tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discounts and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter. Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law. The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#x201c;ATI&#x201d;), (ii) providing a rule for a partnership&#x2019;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation. For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results. While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies. In 2022, the valuation allowance decreased $199 million primarily due to book taxable income in Canada and the expiration of tax losses in the United States. In 2021, the valuation allowance decreased by $30&#160;million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#x2019; federal and provincial taxable income in Canada of approximately $5,878 million and $6,669 million, respectively.&#160;As of December 31, 2022 and 2021, unclaimed ITCs available to offset future federal taxes in Canada were approximately $27 million and $31 million, respectively, which expire in the years 2023 through 2043.&#160;In addition, as of December 31, 2022 and 2021, pooled SR&amp;amp;ED expenditures available to offset against future taxable income in Canada were approximately $188 million and $196 million, respectively, which may be carried forward indefinitely. As of December 31, 2022 and 2021, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,869 million and $1,965 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#x2019; federal taxable income in the U.S. of approximately $241 million and $266 million, respectively, including acquired losses which expire in the years 2023 through 2033. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2022 and 2021 U.S. research and development credits available to offset future years&#x2019; federal income taxes in the U.S. were approximately $75 million and $119 million, respectively, which includes acquired research and development credits and which expire in the years 2023 through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the Company had accumulated taxable losses available to offset future years&#x2019; taxable income in Ireland of approximately $10,691 million and $10,040 million, respectively.&#160;As of December&#160;31, 2022, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries. The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated. As of December 31, 2022, the Company estimates that there will be no tax liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;attributable to unremitted earnings of its U.S. subsidiaries. However, future distributions could be subject to U.S. withholding tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, unrecognized tax benefits (including interest and penalties) were $881 million and $927 million, of which $384 million and $217 million would affect the effective income tax rate, respectively. In 2022 and 2021, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2022 and 2021, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $156 million and $79 million, respectively. The Company recognized a net reduction of $203 million during 2022 and a net reduction of $177 million during 2021 in the unrecognized tax benefits related to tax positions taken in the prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2022 and 2021, accrued interest and penalties related to unrecognized tax benefits were approximately $32 million and $41 million, respectively. In 2022, the Company recognized a net decrease of approximately $9 million and, in 2021, recognized an increase of $8 million of interest and&#160;penalties, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2013 to 2021, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Service (the &#x201c;IRS&#x201d;) completed its examinations of the Company&#x2019;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#x2019;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#x2019;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#x2019;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company has contested this proposed tax deficiency through the IRS administrative appeals process, and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision has been recorded as of December 31, 2022. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, as part of an alternative dispute resolution process with the IRS, the Company has reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized. The Company expects that the tentative settlement, if finalized without further modification, will affect the Company&#x2019;s 2023 income tax provision, and while such settlement may be material to the Company&#x2019;s results of operations or cash flows in the quarter in which it is recorded, will not be material to its results of operations or cash flows for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently under examination by the Canada Revenue Agency (&#x201c;CRA&#x201d;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017. The Company believes that the CRA will open an audit cycle for the years 2018 &#x2013; 2019 in 2023. The Company settled the tax years from 2005 through 2009 with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years. The adjustment did not result in a material change to the provision for income taxes. The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively. The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013. The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and CAD 23&#160;million for 2016. The adjustments for 2015 and 2016 will reduce NOLs currently offset by a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 8, 2022 the Company&#x2019;s affiliate in Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#x2013; 2019 for &#x20ac;271.7&#160;million. The Company is vigorously defending its position and no reserves have been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Australia were under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office (&#x201c;ATO&#x201d;) issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest. On April 13, 2022, the Company and the ATO entered into a settlement agreement resulting in an immaterial income tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December&#160;31, 2022 could decrease by approximately $4 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzgy_1abe34c8-e494-4517-a690-b2eb5311e536">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before income taxes for 2022, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtMi0xLTEtMTY5NjA4_2f95ada8-dda8-45f5-98ab-c2a12264aeee"
      unitRef="usd">64000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtNC0xLTEtMTY5NjA4_18567352-7db9-4263-a389-59efc7e2784d"
      unitRef="usd">-323000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzEtNi0xLTEtMTY5NjA4_086db271-bda5-49e5-9045-6371186e9b58"
      unitRef="usd">-410000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItMi0xLTEtMTY5NjA4_d0ccabbf-93b6-4549-a55a-f7e09573979f"
      unitRef="usd">-193000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItNC0xLTEtMTY5NjA4_36154b39-5f9c-46e0-8393-5706e9e33bca"
      unitRef="usd">-701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzItNi0xLTEtMTY5NjA4_dc7d86ff-247f-484b-a27b-c6b70015915d"
      unitRef="usd">-524000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtMi0xLTEtMTY5NjA4_3c5009bd-33b2-4a5b-bc9d-f65abe183799"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtNC0xLTEtMTY5NjA4_e6463f25-5cb1-461f-a1ee-6de2d33374fb"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxYjVmMzZlMDJiN2Q0ZmUyOTI0ZWY1Y2U5NGE1ZmMyYy90YWJsZXJhbmdlOjFiNWYzNmUwMmI3ZDRmZTI5MjRlZjVjZTk0YTVmYzJjXzMtNi0xLTEtMTY5NjA4_ade5324c-3b73-4bed-8486-9ed008c830ac"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzkx_3917b006-b668-40dd-9430-75c63ac6e496">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of (Provision for) benefit from income taxes for 2022, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItMi0xLTEtMTY5NjA4_467f5cf7-8f91-4a2e-b59a-a749e2d45bc6"
      unitRef="usd">15000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItNC0xLTEtMTY5NjA4_f2fb6c3a-de28-450d-81a1-ac0159a10953"
      unitRef="usd">23000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzItNi0xLTEtMTY5NjA4_8cea1518-4ba1-4bcf-86dd-036a64d25ffe"
      unitRef="usd">8000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtMi0xLTEtMTY5NjA4_64b382ef-d94b-4a69-9143-10ff9d08ba3c"
      unitRef="usd">256000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtNC0xLTEtMTY5NjA4_a7ae243d-a63e-4ac3-bf75-39886481b3d4"
      unitRef="usd">-74000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzMtNi0xLTEtMTY5NjA4_d6c67398-9df6-4c31-9c46-acb30c556b73"
      unitRef="usd">216000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtMi0xLTEtMTY5NjA4_e058ea5b-a25b-4191-8886-053d9fba64f1"
      unitRef="usd">271000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtNC0xLTEtMTY5NjA4_5c4b0d74-9027-45b7-9cec-acd069271db1"
      unitRef="usd">-51000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzQtNi0xLTEtMTY5NjA4_7293c8e1-c077-44bb-834f-768175bb8ad1"
      unitRef="usd">224000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtMi0xLTEtMTY5NjA4_03d1541b-a51b-4f7c-a7be-e4a08dc4d136"
      unitRef="usd">-14000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtNC0xLTEtMTY5NjA4_2fbe9dee-e960-41e5-9b59-8cee4eab3bcc"
      unitRef="usd">-20000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzYtNi0xLTEtMTY5NjA4_477d9e2e-ef99-4a34-ac1e-93a5c30e6326"
      unitRef="usd">-9000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctMi0xLTEtMTY5NjA4_c45288c1-f58c-4add-9e17-64d943021d82"
      unitRef="usd">-174000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctNC0xLTEtMTY5NjA4_c0c44cc5-8b9a-4ef1-a739-010059d803f3"
      unitRef="usd">-16000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzctNi0xLTEtMTY5NjA4_239fc324-79b2-4a90-91c9-6b403aefc905"
      unitRef="usd">-590000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtMi0xLTEtMTY5NjA4_2651ff91-e309-4dbe-a9d1-0e2b10905714"
      unitRef="usd">-188000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtNC0xLTEtMTY5NjA4_db8b04c4-eb61-4aeb-9b4c-4f5d6896c117"
      unitRef="usd">-36000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzgtNi0xLTEtMTY5NjA4_16cec0c6-6aa7-4e91-aafa-f382784eeff6"
      unitRef="usd">-599000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktMi0xLTEtMTY5NjA4_eada04c8-b3ed-4bfd-b656-d938cbc32449"
      unitRef="usd">83000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktNC0xLTEtMTY5NjA4_93084cac-4428-4e49-8b70-5af0b15df4b7"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToxMWUwNjQwZGZlZGU0ZGRhYmEwZDMzYjVkYjNhZDgzMy90YWJsZXJhbmdlOjExZTA2NDBkZmVkZTRkZGFiYTBkMzNiNWRiM2FkODMzXzktNi0xLTEtMTY5NjA4_1ec65331-0249-4832-9fbf-f4b2251b5d67"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzg5_706e41af-9269-4288-ba7a-8479a31ce78b">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (Provision for) benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before income taxes for 2022, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision for) benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_3b344862-7aa0-422e-99c8-c899163ad178"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_89c40325-d24b-4f3d-b182-bf324e1634f9"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzIyMw_f80c91cc-d583-4e99-88e2-13cb4d4d4814"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtMi0xLTEtMTY5NjA4_59b8f0b7-19c5-4f9a-84c5-a83a03b184f8"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtNC0xLTEtMTY5NjA4_d54125f2-3e29-4f24-b95a-a99245cdf6f1"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEtNi0xLTEtMTY5NjA4_df04d0ec-6add-4bb3-a7d6-b3c182e661b2"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtMi0xLTEtMTY5NjA4_52c0a5ca-6503-4d0b-a8da-b449c2c0dc98"
      unitRef="usd">-35000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtNC0xLTEtMTY5NjA4_6fc2284f-a658-43e4-a025-d9ff6bce522d"
      unitRef="usd">-275000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzMtNi0xLTEtMTY5NjA4_0f645a8e-8827-472c-860d-6f28edd78c89"
      unitRef="usd">-251000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtMi0xLTEtMTY5NjA4_a37ad6d3-b698-4d5d-86f0-acfaaa0b6400"
      unitRef="usd">19000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtNC0xLTEtMTY5NjA4_7e97051b-0f8d-46c5-8e64-8e5375445731"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzQtNi0xLTEtMTY5NjA4_85a1b818-a280-4f00-b1ac-983ae6eaa2ad"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtMi0xLTEtMTY5NjA4_86397086-5ba2-4471-8374-7e934a7c5857"
      unitRef="usd">-53000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtNC0xLTEtMTY5NjA4_b5572b3e-89fb-4664-946f-361cadd39597"
      unitRef="usd">59000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzUtNi0xLTEtMTY5NjA4_ef873b9e-1eb7-4ac2-a42b-0eff4d9d1a91"
      unitRef="usd">-26000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtMi0xLTEtMTY5NjA4_59de652e-bc21-4e93-b463-595474a5cad0"
      unitRef="usd">-100000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtNC0xLTEtMTY5NjA4_352d67fc-aea3-4027-b089-697345290b5a"
      unitRef="usd">-28000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzYtNi0xLTEtMTY5NjA4_0d87913d-ca58-4b13-812a-e43e201a310b"
      unitRef="usd">-62000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctMi0xLTEtMTY5NjA4_7046b9ff-3050-4b8e-90b9-bde49d71be0e"
      unitRef="usd">-24000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctNC0xLTEtMTY5NjA4_93846d8f-4880-4485-b057-fbfe563bc282"
      unitRef="usd">-40000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzctNi0xLTEtMTY5NjA4_1426a477-c09d-4d15-973a-64b199c8e3e7"
      unitRef="usd">-687000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtMi0xLTEtMTY5NjA4_e0e87131-5cef-41dd-8293-0e2b6dee9fac"
      unitRef="usd">50000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtNC0xLTEtMTY5NjA4_4d4ea763-7fb6-451c-97d7-1faae1f24203"
      unitRef="usd">-112000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzgtNi0xLTEtMTY5NjA4_1f9b46cf-0b58-408c-a1fc-108d0b61052b"
      unitRef="usd">163000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktMi0xLTEtMTY5NjA4_0848e327-1c9c-4242-a50e-a8131018acb3"
      unitRef="usd">57000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktNC0xLTEtMTY5NjA4_fd4a9823-695a-4e9b-9b06-d3234219dc65"
      unitRef="usd">198000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzktNi0xLTEtMTY5NjA4_d1585e23-7145-4d33-a991-55545111181c"
      unitRef="usd">128000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTItMS0xLTE2OTYwOA_ccf4c86b-dc40-4464-8fbe-4cb7fa138868"
      unitRef="usd">175000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTQtMS0xLTE2OTYwOA_4647eb2c-9d18-484b-b809-b1df4c8395b8"
      unitRef="usd">99000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEwLTYtMS0xLTE2OTYwOA_ecf8c50e-ca1b-40bc-9c49-1dae678db63e"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTItMS0xLTE2OTYwOA_ce14564b-f195-4887-bc79-5a228585519c"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTQtMS0xLTE2OTYwOA_9fee0135-7b56-4e2b-afd3-68b64558e0b0"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzExLTYtMS0xLTE2OTYwOA_ae57d995-1b78-42af-9b32-44bddb490bab"
      unitRef="usd">338000000</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTItMS0xLTE2OTYwOA_5c702a32-21d3-4f62-9b68-faf5179120f3"
      unitRef="usd">-6000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTQtMS0xLTE2OTYwOA_0ff3c74d-9f20-453c-a1e6-b38a5c2ed77b"
      unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEyLTYtMS0xLTE2OTYwOA_d56b1512-823c-4bdb-b19d-052d9f3c9465"
      unitRef="usd">13000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTItMS0xLTE2OTYwOA_ec6b4c99-a466-44eb-9573-9523f138d383"
      unitRef="usd">83000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTQtMS0xLTE2OTYwOA_116d28f9-3687-4857-993c-d539254dd4f4"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTozMGVlZTQzNjI5MTM0ZjNiOGYzMjM3NWIwNzI0ZmY3OS90YWJsZXJhbmdlOjMwZWVlNDM2MjkxMzRmM2I4ZjMyMzc1YjA3MjRmZjc5XzEzLTYtMS0xLTE2OTYwOA_9de06775-dc70-4b17-9cdc-d49e0e328ca1"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODI5_337362f4-c675-4fee-a5de-dddbf0c8df96">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2022 and 2021 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt discounts and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzItMi0xLTEtMTY5NjA4_b2329514-b88b-4b14-add5-d573c4c08fa4"
      unitRef="usd">2872000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzItNC0xLTEtMTY5NjA4_9ed1a7e5-be7b-46da-be40-da9778957978"
      unitRef="usd">2973000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzMtMi0xLTEtMTY5NjA4_b9e33c5c-9352-457f-a4d0-ea263a1cd8c3"
      unitRef="usd">859000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzMtNC0xLTEtMTY5NjA4_50e87ac9-7145-4db4-87b9-49575d10ae8a"
      unitRef="usd">991000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtMi0xLTEtMjAzNTkw_ff46398e-b57f-4a6e-a84a-c1d1dd261930"
      unitRef="usd">370000000</bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts>
    <bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtNC0xLTEtMjAzNTky_593a346a-7965-4af8-94aa-49ea702efd17"
      unitRef="usd">0</bhc:DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtMi0xLTEtMTY5NjA4_0fee1acb-5cc5-484f-ab86-851eb3be7af7"
      unitRef="usd">140000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzQtNC0xLTEtMTY5NjA4_d9ab0934-573d-431b-9f83-f91b4009bf63"
      unitRef="usd">173000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzUtMi0xLTEtMTY5NjA4_5660acb6-228b-47a7-94ba-79bb8f9f6499"
      unitRef="usd">48000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzUtNC0xLTEtMTY5NjA4_74c4dcc0-cb4b-49f4-892e-4528bb9db64a"
      unitRef="usd">52000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzYtMi0xLTEtMTY5NjA4_e1db80cc-6031-4bd4-a061-0d80dc57a910"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzYtNC0xLTEtMTY5NjA4_7bbc75f3-e5e2-4de4-8a1f-11ae55d8a5e8"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzctMi0xLTEtMTY5NjA4_757e93fd-b44f-420a-af80-7ded14df1257"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzctNC0xLTEtMTY5NjA4_a0f0da94-1887-4d42-a718-8d15aea4e7c5"
      unitRef="usd">3000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzgtMi0xLTEtMTY5NjA4_b6611304-e176-4aeb-9ad4-08a9d3883140"
      unitRef="usd">26000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzgtNC0xLTEtMTY5NjA4_719fff9f-9b89-4f1d-89f5-d45c931802af"
      unitRef="usd">26000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzktMi0xLTEtMTY5NjA4_265abe07-a065-44bb-85bb-af40a8962483"
      unitRef="usd">22000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzktNC0xLTEtMTY5NjA4_e746c78d-7d2b-4e43-9b4d-becf03b7e47e"
      unitRef="usd">17000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEwLTItMS0xLTE2OTYwOA_a65b7850-3d60-414a-979a-f1cf5d8e3b37"
      unitRef="usd">24000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEwLTQtMS0xLTE2OTYwOA_6b14fc75-74bf-4941-afdf-006bc5648e7f"
      unitRef="usd">38000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzExLTItMS0xLTE2OTYwOA_0f45ffaf-bbe2-4031-885b-887aa5bb75cd"
      unitRef="usd">4377000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzExLTQtMS0xLTE2OTYwOA_e5bc28d3-37c8-4433-9360-33b7db59081c"
      unitRef="usd">4287000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEyLTItMS0xLTE2OTYwOA_76574d90-e161-48c7-9d5e-0213b8cf3a47"
      unitRef="usd">2023000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEyLTQtMS0xLTE2OTYwOA_bc577b26-234d-4719-a133-7fdff0a5d651"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEzLTItMS0xLTE2OTYwOA_4b744db8-96fe-4f96-b788-6dc9d11bd576"
      unitRef="usd">2354000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzEzLTQtMS0xLTE2OTYwOA_8d15f468-4810-4f88-acdc-8b5db315d90a"
      unitRef="usd">2065000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE1LTItMS0xLTE2OTYwOA_bb574bf0-c6c9-4920-b11f-ba1ade0c3a00"
      unitRef="usd">191000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE1LTQtMS0xLTE2OTYwOA_5b872b72-26ae-4900-a250-f5c23120a118"
      unitRef="usd">188000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE2LTItMS0xLTE2OTYwOA_1dcfb0b7-2ecc-4bb2-8297-fe62efce48eb"
      unitRef="usd">74000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE2LTQtMS0xLTE2OTYwOA_1af2382b-be13-41aa-a11f-959547d0bc00"
      unitRef="usd">44000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE3LTItMS0xLTE2OTYwOA_8a9ba9df-425b-4ef9-9183-722ac75624eb"
      unitRef="usd">125000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE3LTQtMS0xLTE2OTYwOA_578612e9-df43-4492-bbf2-313a78ce3956"
      unitRef="usd">110000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE5LTItMS0xLTE2OTYwOA_604ff789-954f-4999-9282-bad02b19dbcc"
      unitRef="usd">390000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzE5LTQtMS0xLTE2OTYwOA_6deefc69-5bc0-4fef-a6b8-6d185a199d48"
      unitRef="usd">342000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzIwLTItMS0xLTE2OTYwOA_23bb4368-f3dd-4b88-aa43-41cc4cfcecca"
      unitRef="usd">1964000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplMGE1NTg1OTg4YTI0OGNiYTJiMWE3NTIzNGYyYmEzNi90YWJsZXJhbmdlOmUwYTU1ODU5ODhhMjQ4Y2JhMmIxYTc1MjM0ZjJiYTM2XzIwLTQtMS0xLTE2OTYwOA_a1ea3a6b-91fa-452f-9ab8-ef565f452da6"
      unitRef="usd">1723000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id14bc647bd66490ea555f0a1a8e9d50f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtMi0xLTEtMTY5NjA4_8ddaa84e-f185-4340-a8fb-a25be889675b"
      unitRef="usd">2222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i54a3cb34cfce4c28be127d8715fd26f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtNC0xLTEtMTY5NjA4_c7947b2b-577d-4365-8f76-181dc43413de"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id8dabfb23996479799c6a595815ba441_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzEtNi0xLTEtMTY5NjA4_5c375681-4e4e-4442-83e1-0940ddae39b5"
      unitRef="usd">2831000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItMi0xLTEtMTY5NjA4_1e2f4cf1-0d43-4b24-b350-3d25bcca562e"
      unitRef="usd">-124000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItNC0xLTEtMTY5NjA4_26d7e1b9-b694-41ed-b672-f61eda8bdf63"
      unitRef="usd">-63000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzItNi0xLTEtMTY5NjA4_6d7fd28b-f444-4303-b4f3-d9ef5af5fd6b"
      unitRef="usd">-773000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if91f8514c2a74ed6bfd45a7ac343ed95_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtMi0xLTEtMTY5NjA4_c27e8b41-dbf7-4232-9b45-469ce6e77318"
      unitRef="usd">-75000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie95cd39d0c354636b5bf2277670b58b4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtNC0xLTEtMTY5NjA4_14b344e0-282a-4488-82ed-1fdafdb30bcc"
      unitRef="usd">33000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6f03aad51cc042b2bfaaf18c21f744b1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzMtNi0xLTEtMTY5NjA4_4f447966-23af-45c6-937a-bdf749ab9ec7"
      unitRef="usd">194000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4eb60c46f2cd493491ad50061773a9d2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtMi0xLTEtMTY5NjA4_12cc80a6-88fc-49cc-b9c2-ab98362f444e"
      unitRef="usd">2023000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id14bc647bd66490ea555f0a1a8e9d50f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtNC0xLTEtMTY5NjA4_7562cb25-5ef1-48f7-89f2-da740ce39210"
      unitRef="usd">2222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i54a3cb34cfce4c28be127d8715fd26f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTowYjExMjkzNWE3MzE0NGVlYmMzYTMxODgzZjlhZTQ3Zi90YWJsZXJhbmdlOjBiMTEyOTM1YTczMTQ0ZWViYzNhMzE4ODNmOWFlNDdmXzQtNi0xLTEtMTY5NjA4_98bc3132-def1-4eaa-849c-b53782560d53"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="icea89cae1b5a49169da66c58b3a977ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzI2MDE_6952d062-a285-41c3-a178-c490ffba1cb8"
      unitRef="usd">-199000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5d8f4b7199a04a1bb0f06da2481be68c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwOTk1MTE2NDE1MjM_4c94888e-9810-4a34-9aa1-22230d572692"
      unitRef="usd">-30000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM1Nzg_4c609c4d-9ec8-431f-9549-136bab2fa053"
      unitRef="usd">5878000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i3502a33c4974412bb446b4520804d72c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM1ODU_2f0e2ab7-7749-4515-ac41-10865ee4eb93"
      unitRef="usd">6669000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM2OTk_6f01d275-c0f5-4ce3-925d-c65ab450c710"
      unitRef="usd">27000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i3502a33c4974412bb446b4520804d72c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM3MDY_a22de730-1a59-4e97-9287-c55a871530b3"
      unitRef="usd">31000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i23665fcb8d984723906982059409b87d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM4OTg_84c849ac-955d-4188-b066-173d105fcec4"
      unitRef="usd">188000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i8cac628e4a8a43a0a0981c64688ec2f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzM5MDU_530bccd5-f600-4178-802a-159be3c51c87"
      unitRef="usd">196000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i76a003bd56204fbfb30cc08651a430f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQwOTI_ba4552b6-8a74-48b7-96f7-153c6042189d"
      unitRef="usd">1869000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3502a33c4974412bb446b4520804d72c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQwOTk_8b2b1576-b753-4e0e-b293-59b2b2ca205a"
      unitRef="usd">1965000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i0c140b9741d2496b919924cb9b494679_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQyNTY_0918cfba-3004-453d-b295-033fce5a268c"
      unitRef="usd">241000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQyNjM_d5f2dcb0-2478-410b-bd05-f3ca0940881a"
      unitRef="usd">266000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i0c140b9741d2496b919924cb9b494679_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQ3NjE_096fab7a-fc84-4e15-8f31-48aac9763ec9"
      unitRef="usd">75000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i251b5dd528e34cdb844ff9da5b1d6b41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzQ3Njg_a3df2d44-3190-4c7e-88cf-bc1e6930ab65"
      unitRef="usd">119000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i0a9bffc500cd4f18857b951c1603f412_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzUxNjc_b27bc2ec-3194-4c71-9b17-c7643bb32190"
      unitRef="usd">10691000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="ie76d6ec50d164eb3bcb9478a77019aa0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzUxNzQ_8c0253fb-7d67-466d-a31c-84ac88c63565"
      unitRef="usd">10040000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5MzE_0c6ffec4-f01b-46f5-bfa6-0d6aa6a3be7c"
      unitRef="usd">881000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5Mzg_3a0bc9ab-653e-4b73-a423-31404383b53b"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5NTE_9b4e12b0-9878-42de-bb5a-026a98d2ef69"
      unitRef="usd">384000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU5NTg_d5265a79-97c4-4a6a-91ba-73d4c20f0b78"
      unitRef="usd">217000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzMTY_8a4ecd58-2320-42ee-9fdb-44ed90505791"
      unitRef="usd">156000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzMjM_82f233cd-6cda-41ba-9a5f-0ac8c585c462"
      unitRef="usd">79000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzYzODQ_18bec631-c514-4e5c-8476-03e44dcccfbb"
      unitRef="usd">203000000</bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY0MjA_6174f832-d6ee-4c75-9d87-48999476c910"
      unitRef="usd">177000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY3MzQ_9265885c-8b8e-469a-a800-718f1fb41400"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY3NDE_e7a18268-c324-49cb-8235-cb04c2802967"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY4MjE_f9d9a260-4aa5-4a1f-a571-e0031457bf6e"
      unitRef="usd">-9000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY4NjM_013f2d52-2554-4570-8ed1-54d7ef5c2464"
      unitRef="usd">8000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzY5MjM_b4f5cc57-fc26-4ee3-b7d5-37ef99f18bc0"
      unitRef="subsidiary">1</bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyODE1_7347ea08-4a0f-48c4-8c49-1f0542a1cabd">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="id57f6448d77d4f498fcb2c7411041826_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmNlZGM4MGQxMGE4NDVjZTkxZWU1OTMxODdiYTliNDNfNA_cb189b5b-6541-49fc-ad10-413335d487a4">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="id573807c0c8f4975a352cd6f593b3ab3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzEtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MmNlZGM4MGQxMGE4NDVjZTkxZWU1OTMxODdiYTliNDNfOQ_5df252ab-ed64-43f9-b955-6039b90ce1f4">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ib8aa63b12662497fb48a3704825ff944_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDg4ZjRlOGYxM2I5NDI4MWEzODEzZGI2Yzc5MWZkNjBfNA_5af39ebf-9012-4d0b-b37e-051f0004aea4">2012</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ifd9c4983bcb5449091d89286c6560f44_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzItMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDg4ZjRlOGYxM2I5NDI4MWEzODEzZGI2Yzc5MWZkNjBfOQ_819ad7ca-8bbc-47c0-a3d4-bc3e9af61e33">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ifb5e7e6a6a4b4b2fbad5eb1887c77136_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MzcyNDQ5YWJiNzc0NDFiYmJmMzYxM2NkZGUxOWFjOWRfNA_6be47eae-0cdb-443b-a9d9-33be7267563f">2014</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i0a938ef7652a479b9208cc583c1cbeaf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzMtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246MzcyNDQ5YWJiNzc0NDFiYmJmMzYxM2NkZGUxOWFjOWRfOQ_9fa67ed6-cfc5-4534-8f72-10de3cd6c1a2">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="icf4cab1a9a354692a1713dfef6925e58_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NTlkOGE2YTBkYTJjNDMwYmIxMmFiMGNmOWM3Mjc1YmRfNA_1dc88ddc-edf4-4f0b-90eb-2c56e44b8846">2013</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i01997882e0124cea82496489c90aa07b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzQtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NTlkOGE2YTBkYTJjNDMwYmIxMmFiMGNmOWM3Mjc1YmRfOQ_826dd5e5-a57f-49ba-baa5-90d17f407578">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i4cb51eb021dc4b9b8b4658c2bc2a3b97_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzYtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGFkNzBhZDNhZDAyNGQ4Yjk4MTQzMDE3YWZlYmEwMGJfNA_684809db-297e-4aa8-aee2-4961db9fbf72">2018</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5e5f1133b38c4d24b01b931471fd8da0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzYtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246OGFkNzBhZDNhZDAyNGQ4Yjk4MTQzMDE3YWZlYmEwMGJfOQ_136bb980-ee59-4058-b5ab-e120c242fe83">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i89d1dfe888bd45a8883f343b6c477481_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzgtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NzUxZDU3NzYzZTU2NGUzNGIzODVlYWE0OTZkN2RhNTlfNA_a3603a57-9d4a-49fc-bbbd-1d204be1fcaf">2018</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5fd1521a412949fbbc1e51c170d1e007_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzgtMi0xLTEtMTY5NjA4L3RleHRyZWdpb246NzUxZDU3NzYzZTU2NGUzNGIzODVlYWE0OTZkN2RhNTlfOQ_134c29db-52b6-4e1d-9127-1af9ec945b16">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i16aed0f16ef84c42b74c7c39bd8a6462_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzktMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDY5MmRkYzcxYzNmNDYwNDgxYzdhNGI0YmExMTVjMTFfNA_deaa2ef1-b6c1-4a6f-b5d1-472d85360cf4">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="id96036ac44ae4695a0fb252d5f81f219_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZToyNGU3OGRhNTc3MDM0ZjVjOTVlYWJhYTJkMjU4ODlhMC90YWJsZXJhbmdlOjI0ZTc4ZGE1NzcwMzRmNWM5NWVhYmFhMmQyNTg4OWEwXzktMi0xLTEtMTY5NjA4L3RleHRyZWdpb246ZDY5MmRkYzcxYzNmNDYwNDgxYzdhNGI0YmExMTVjMTFfOQ_4317930e-d642-471b-a8ed-3593b6c73332">2021</us-gaap:OpenTaxYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzU0OTc1NTgxNjMxMTU_98901891-ae3f-4d52-9784-286dd72855ee"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="ia889587b544748498683a9f94901e27e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzk5MzI_67433a6a-0886-4aa2-9443-189c8471fb96"
      unitRef="cad">-44000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ie4f2bc454f0c4e1ca352bcd59e982748_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwMjQ5_bb6efc04-8749-4ce1-a74d-3d6dfeb34214"
      unitRef="cad">85000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i4a9234e9d2a34cee8234f5493a02f5a8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwMjYw_0553598f-07e8-427a-b38c-8903bfebc8ed"
      unitRef="cad">90000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="ic35b381adaa44c21ae46f412455f4ded_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwNTI2_f6188010-2e3d-4849-a262-d35ec8426676"
      unitRef="cad">-21000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="ibeb1927f7b53477f9d023db6485f371a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEwOTk1MTE2NDYzNDE_b217a18c-f47a-44cf-924b-149b9fa38931"
      unitRef="cad">-23000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i29b848aa660941a6becd4eec0de3f15d_D20221108-20221108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzE2NDkyNjc0NjU5NzQ_d008b8b8-5888-4eae-b97f-9e2a46cc73c0"
      unitRef="eur">271700000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="iab5fbd88668641d49bf8a11320bf0006_D20170808-20170808"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzExMTg1_48335a78-4276-479e-8789-e2fef88fdf62"
      unitRef="usd">117000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNzgx_fa5d0f44-940a-422e-b9bc-fda8f3e6c0d1">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtMi0xLTEtMTY5NjA4_16ccc533-2bbe-47fd-ad69-eb8967a99900"
      unitRef="usd">927000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtNC0xLTEtMTY5NjA4_9dbbfcb8-9868-4a1f-ad00-ecf541fe54b6"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzEtNi0xLTEtMTY5NjA4_8f6d0cca-090c-49cf-993f-eeda893afe62"
      unitRef="usd">1002000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItMi0xLTEtMTY5NjA4_d92caf58-c8a6-47e8-9755-0ca52eeef421"
      unitRef="usd">156000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItNC0xLTEtMTY5NjA4_936c68cd-ceb8-4a9d-adc6-c6b10c0d7a9d"
      unitRef="usd">79000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzItNi0xLTEtMTY5NjA4_d0109bcf-4ec6-46e5-9ebe-2c30b90741f7"
      unitRef="usd">66000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtMi0xLTEtMTY5NjA4_aa7f473f-cada-4879-b8f4-da2def487a37"
      unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtNC0xLTEtMTY5NjA4_455dd88d-3752-488b-8d36-4a8a3d352238"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzMtNi0xLTEtMTY5NjA4_871bf353-fabd-4512-807e-0322f854f5b0"
      unitRef="usd">171000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtMi0xLTEtMTY5NjA4_edf90b9c-57e7-474d-9a01-4d98a207317e"
      unitRef="usd">127000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtNC0xLTEtMTY5NjA4_8932a581-47fb-4c5a-b03a-755132b4649f"
      unitRef="usd">129000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzQtNi0xLTEtMTY5NjA4_5eda09cc-448b-4098-bdd6-7783d1ea09a8"
      unitRef="usd">209000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtMi0xLTEtMTY5NjA4_12c1fab9-0baf-466d-a898-59cd496c69c9"
      unitRef="usd">85000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtNC0xLTEtMTY5NjA4_cb1436dd-9144-4d6d-bfb5-0e20a446cb93"
      unitRef="usd">169000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzUtNi0xLTEtMTY5NjA4_25e9df86-0643-4b1f-9b15-fc4c5bcdf5d3"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtMi0xLTEtMTY5NjA4_efce9ce9-0394-4b2f-8e24-0853f47d1e1d"
      unitRef="usd">881000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtNC0xLTEtMTY5NjA4_7af63ca7-9401-49d7-98f6-e2cffccfe299"
      unitRef="usd">927000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia08ca18a2f12467bae0a8b8c719d3561_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90YWJsZTplNmY1MzM3OTg5NTM0MWY1OTc3ZDNiMjU4Yjk1OGQyYS90YWJsZXJhbmdlOmU2ZjUzMzc5ODk1MzQxZjU5NzdkM2IyNThiOTU4ZDJhXzYtNi0xLTEtMTY5NjA4_35cf76bd-9450-4dad-8950-0ae97deebb69"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjQvZnJhZzpiMjUwZjIxNWRjY2Q0ZjE5OTE0MDcyZDY4Mzg4NWE0My90ZXh0cmVnaW9uOmIyNTBmMjE1ZGNjZDRmMTk5MTQwNzJkNjgzODg1YTQzXzEyNjYz_c2836cf6-e5fe-4057-93e7-2d3a82febb5b"
      unitRef="usd">4000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwNDA_ba63cbcd-99b2-4b91-98ee-b18848237daa">LOSS PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2022, 2021 and 2020 was calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, 2021 and 2020, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,851,000, 4,932,000 and 3,154,000 common shares for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2022, 2021 and 2020, stock options, time-based RSUs and performance-based RSUs to purchase approximately 14,396,000, 3,428,000 and 9,551,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2022 and 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwMzg_c9922600-77ae-449d-91b3-aa1301e5c675">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc. for 2022, 2021 and 2020 was calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtMi0xLTEtMTY5NjA4_8ea1f604-1aaa-4470-82eb-ac94b050d2c8"
      unitRef="usd">-225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtNC0xLTEtMTY5NjA4_e31521bb-1047-4a47-b2ed-5ae8bfb7d3b4"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzEtNi0xLTEtMTY5NjA4_be38cbc2-1c48-413b-a40d-9615898c575b"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItMi0xLTEtMTY5NjA4_467e5c95-13cf-4fb9-ad59-a24399b0be88"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItMi0xLTEtMTY5NjA4_a1254015-0ee6-4f31-9e77-10fc39961c87"
      unitRef="shares">362000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNC0xLTEtMTY5NjA4_882dbe33-8b46-4adc-8d2f-bf25fec84a27"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNC0xLTEtMTY5NjA4_f8709c2d-accd-48a5-a9b1-d51fc14ac6ef"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNi0xLTEtMTY5NjA4_30c06caf-655e-4111-a354-86ea2e527f4c"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzItNi0xLTEtMTY5NjA4_65a891fa-0feb-4019-8627-3e2058670499"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtMi0xLTEtMTg5MjM0_074dedc6-4b93-4795-a2d1-9158444fa194"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtMi0xLTEtMTg5MjM0_f1d23e70-0535-4a34-8a83-8e16d3366c7d"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNC0xLTEtMTg5MjM0_020ba721-cbbd-416b-8342-77e1a07b9c0a"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNC0xLTEtMTg5MjM0_6157e492-a4d2-43da-a9c6-4fc459813e4d"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNi0xLTEtMTg5MjM0_2454d3cd-d555-49aa-97ff-1692159134fa"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90YWJsZToxNDA4NDNhZDBjOGU0NDRlODliNDczN2VlN2Q0ZjAyZC90YWJsZXJhbmdlOjE0MDg0M2FkMGM4ZTQ0NGU4OWI0NzM3ZWU3ZDRmMDJkXzYtNi0xLTEtMTg5MjM0_a9e8d7fd-813e-4f30-9172-1e9f74ede8df"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzEwOTk1MTE2MjkwMjk_b88ddfd1-122a-4246-849e-ba6fdf5f3fbc"
      unitRef="shares">1851000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie20353a11f9f453cbff47b23ba9b5303_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzQ5NA_91222532-b6ba-4153-9670-fc598cd49823"
      unitRef="shares">4932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i32c1ed23b8494ad19285b0fa18785f85_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzUwMQ_e49f525b-8d4d-4c20-9c76-3ce1b1f5992f"
      unitRef="shares">3154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iee43a25eaadf4d2d863f02a387856a5a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY0NQ_8f6ae0af-231e-411e-b623-56ff29c5f044"
      unitRef="shares">14396000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a3b000967c54376bcaa8d1227ab2fc7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY0OQ_bf905067-c3ff-41c6-ab4c-dcf7bcfc70e5"
      unitRef="shares">3428000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89e7a814f74a4ae5ac92920a38079cc6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzY1Ng_cb71fd26-b31a-4d9e-8670-250a8e348b81"
      unitRef="shares">9551000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3dd34d570f3b45a0a89bc7b370627a8f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzg3OQ_a10f02f1-83c1-4186-8be9-353ea4fab73e"
      unitRef="shares">156000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iafb1e399c6334b55a693b8c539d5389b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNjcvZnJhZzo4MTlhZGM4YjNiNDM0ZmY0YTA1MDVkMWE3NmQzMjgxMi90ZXh0cmVnaW9uOjgxOWFkYzhiM2I0MzRmZjRhMDUwNWQxYTc2ZDMyODEyXzg3OQ_d8721dda-8aa2-404b-8e0f-935d1d28fef9"
      unitRef="shares">156000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90ZXh0cmVnaW9uOjNkZjJhNWMyZTJhNDQ0NGM4MTJmYzg5NGJkN2FjMTA1XzY2_b77b54db-27b3-4a4f-9eca-f201a9056afa">SUPPLEMENTAL CASH FLOW DISCLOSURES &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2022, 2021 and 2020 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90ZXh0cmVnaW9uOjNkZjJhNWMyZTJhNDQ0NGM4MTJmYzg5NGJkN2FjMTA1XzY4_bc33241d-db7e-4222-8c65-8e7702b98989">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2022, 2021 and 2020 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItMi0xLTEtMTY5NjA4_060af702-a261-4b4d-989f-51c2d5016047"
      unitRef="usd">1540000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItNC0xLTEtMTY5NjA4_e8802f41-77ba-4dd6-8578-475ef6608e69"
      unitRef="usd">1419000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzItNi0xLTEtMTY5NjA4_b63cb000-2697-465c-bcc1-a568b941a3ce"
      unitRef="usd">1474000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtMi0xLTEtMTY5NjA4_66c08988-6c1f-4f61-ac50-13fc1f42fbdd"
      unitRef="usd">266000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtNC0xLTEtMTY5NjA4_01440dee-4592-40c3-a68c-24c06dca5c1d"
      unitRef="usd">240000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzAvZnJhZzozZGYyYTVjMmUyYTQ0NDRjODEyZmM4OTRiZDdhYzEwNS90YWJsZTphOGE5ZTBiYjQxMjc0ODZiOWVlMzRhN2Y2ZmYxNGRkMS90YWJsZXJhbmdlOmE4YTllMGJiNDEyNzQ4NmI5ZWUzNGE3ZjZmZjE0ZGQxXzMtNi0xLTEtMTY5NjA4_d4762bb2-6810-4fe4-b4da-703970ca7691"
      unitRef="usd">162000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxNDE_30a3456a-5804-4d12-a692-c8d658ba2319">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company&#x2019;s subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2022, the Company&#x2019;s Consolidated Balance Sheets includes accrued current loss contingencies of $326 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney&#x2019;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters. In February 2023, the Company&#x2019;s subsidiary OraPharma, Inc. entered into a civil settlement agreement with the Department of Justice fully resolving this investigation. Under the terms of the settlement, OraPharma, Inc. has paid a settlement payment of $100,000, plus payment of additional immaterial amounts in applicable interest and other related costs, to resolve the civil False Claims Act (&#x201c;FCA&#x201d;) investigation. A related complaint brought by a former OraPharma employee pursuant to the FCA and certain state statutes will be dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Iowa &#x2013; re OrthoDerm&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#x2019;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Jublia&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Siliq&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is cooperating with this &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#x201c;Securities Class Action Settlement&#x201d;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#x201c;Timber Hill&#x201d;) filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#x2019;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor Rx Services, LLC (&#x201c;Philidor&#x201d;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#x2019;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034) (&#x201c;T. Rowe.&#x201d;); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127) (&#x201c;Equity Trustees&#x201d;); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128) (&#x201c;Principal Funds&#x201d;); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212) (&#x201c;Bloombergsen&#x201d;); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#x201c;BlueMountain&#x201d;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#x201c;Janus Aspen&#x201d;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#x201c;Lord Abbett&#x201d;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#x201c;Pentwater&#x201d;); Public Employees&#x2019; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#x201c;Mississippi&#x201d;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488) (&#x201c;UC Regents&#x201d;); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#xf6;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) (&#x201c;NYCERS&#x201d;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#x201c;Hound Partners&#x201d;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#x201c;Senzar&#x201d;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#x201c;Catalyst&#x201d;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#x201c;Aly&#x201d;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#x201c;Connecticut&#x201d;); Delaware Public Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#x201c;Delaware&#x201d;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190); Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478); USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462); and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#x2019;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015) and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015) and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario Superior Court) (filed November 16, 2015).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#x2019; Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#x2019;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;) (discussed in further detail below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#x2019; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#x201c;Company&#x201d;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits cover products of both Bausch + Lomb and the Company&#x2019;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail above), Humana Inc. (&#x201c;Humana&#x201d;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed above, were deemed asserted in the State Court Action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#x2019; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#x201c;Consolidated State Case&#x201d;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 200 mg and 550 mg, Arazlo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Colazal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Nuvessa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 27 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10, 2022, (the &#x201c;Norwich Legal Decision&#x201d;), finding that the U.S. Patents protecting the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#x201c;HE&#x201d;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#x2019;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#x2019;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#x201c;Taro&#x201d;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#x2019;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and triggering a 30-month stay of the approval of the Taro ANDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion. Following a three-day trial in October 2022, on December 1, 2022, the District Court issued a final decision in favor of Bausch, finding the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents valid and infringed by Padagis. The District Court dismissed the lawsuit on February 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#x201c;Auro&#x201d;) alleging patent infringement by Auro&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#x2019;s generic plecanatide tablets, 3 mg.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The filing of this suit triggered a 30-month stay of the approval of the Auro ANDA for plecanatide tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; AREDS Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#x201c;AMD&#x201d;). The PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp;amp; Lomb Incorporated (&#x201c;B&amp;amp;L Inc.&#x201d;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation against Certain Ocuvite and PreserVision &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, ZeaVision, LLC (&#x201c;ZeaVision&#x201d;) filed a complaint for patent infringement against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#x2019;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2021, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#x201c;Slayback&#x201d;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#x2019;s generic drops, for which an ANDA has been filed by Slayback. B&amp;amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#x201c;Eye Therapies&#x201d;). On September 10, 2021, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2022, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#x201c;Lupin&#x201d;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#x2019;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;B&amp;amp;L Inc. remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and B&amp;amp;L Inc. intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inter Partes Review Proceedings at the U.S. Patent and Trademark Office&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company&#x2019;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#x2019;s branded pharmaceutical products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. Three lawsuits are pending in Canada regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against Apotex Inc. and Pharmascience Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#x2019;s IPR and joining it with Mylan&#x2019;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#x2019;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#x2019;s petitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#x201c;Bankruptcy Court&#x201d;), and substantially all cases related to Johnson &amp;amp; Johnson&#x2019;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#x2019;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#x2019;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL has filed a petition for rehearing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;en banc &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the Third Circuit. If the bankruptcy case is ultimately dismissed, the Company&#x2019;s position vis a vis J&amp;amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the pendency of the appeal, the Bankruptcy Court was considering competing motions by Debtor LTL to extend its exclusive period to file a chapter 11 plan and the talc claimants to terminate LTL&#x2019;s exclusivity. In light of the Third Circuit&#x2019;s decision, on January 31, 2023, the Bankruptcy Court adjourned any hearing on the exclusivity motions to March 20, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#x2019;s expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;it&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#x2019;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#x2019;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#x2019; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#x2019;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#x2019; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#x2019; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#x2019;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. That motion is pending. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#x2019; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp;amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp;amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp;amp; Johnson requested the court afford it sixty (60) days &#x2013; until April 18, 2023, or seven (7) days following any lifting of the LTL Bankruptcy Court&#x2019;s preliminary injunction &#x2013; whichever comes earliest &#x2013; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <bhc:LegalSettlementsAndRelatedFees
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDQwNjc_12124347-671e-420d-8b28-6b7bb1f2d8a9"
      unitRef="usd">326000000</bhc:LegalSettlementsAndRelatedFees>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i20c9837df7684cbbb933fd9a731877c7_D20230201-20230223"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzU0OTc1NTgzMzg4MTE_dc4c7955-9c97-420d-b766-f03c838dbfb8"
      unitRef="usd">100000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1MzM_2c1ff0d6-08ee-42b6-93e4-10c94c3ac8e8"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i6a43711c51a14d18b5c6502856d0f770_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1NDI_257371c9-37e5-491d-bd35-3b10cd6e52db"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="icae732543b524862bc31fb3dbb9b61d5_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1NTI_ea064ae8-ed19-47f3-9ced-645d8249784e"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1Njc_5ec17d72-657d-4877-bea2-254356af5ee1"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4OTY_1ef00f0c-6ae1-42a9-895a-9eba20c7690d"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5MDk_f160a83f-6402-4471-9005-fc899602aab6"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i2d7d3df70b014498965986c54af8ce71_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5MjY_b1db8f6a-2454-42c1-9628-6abd17be366c"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iea1d9d4e5a1f4370a7144323d17979c8_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1ODQ_46773d84-f5a8-49d7-acda-b01ba21d5913"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="i99a775a1f0484870a58370f98e7e7bd6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc1OTY_01f61783-76c2-47c9-a6a4-7b2650c8f304"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7097559c54d642c9938d351b2479cbdd_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MDU_ccdd62f6-6c43-4ec6-a8f3-5abf284d722f"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i1dbd4359a33044d39494365672dd2a82_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MTY_c45976fc-02de-4d36-ad36-1c4921380753"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i134d05f75047419881c27f05c3e5188c_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MjQ_e810f57a-aadd-4bd4-bf72-42258edf853a"
      unitRef="number_business">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i6a47c7281a5a4ca797223076080e2992_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2MzM_744b583d-ee18-4e7d-8b97-14e4e15e9109"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="ia24e6b01a46e406cbeeb1ee5f895c977_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NDM_b5ddc7fa-d7b5-41ca-ac55-ed8a1a26da5d"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="id939f2c8095a466db826592c2f72f9f7_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NTE_b71510d6-33bb-4959-abde-725b4175fa71"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="id939f2c8095a466db826592c2f72f9f7_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2NTk_5f3cd8ab-a9d3-4c2c-95c2-63897ee40d0b"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="ib4df41256cea4da189ae84ef1efc2dde_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDIzNTQ_3d6457cf-718b-45d2-a6d0-53b6ab1cb208"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="idb9217417cee498197ad26aaa5c98390_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2Njc_067e5d7a-73a6-418e-8bc2-1d81cf3143c6"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i34b9f8ec08464feea2782555631f70ea_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2Nzc_fcff3032-4854-46e4-ab14-1b0ff84fb685"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i0963b261572a4ed8bec2d26c9a930742_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2ODY_be20f1db-7bd1-4e04-9770-61e6a87235d6"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i8c21c165a2814f47b755c7aa53f9e73f_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc2OTc_987e4817-ce73-4da4-bd9c-dfbc7ab83078"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7f8128027f2f4ab58c24767a783dd7af_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI0MDQ_282949d7-e871-4871-a7ab-27dcd70c4dc3"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="id79311217c224c53ba11bdccb33324d8_D20200326-20200326"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3OTg_4d9ed478-12b2-4589-9ec0-7fbed2bf6f46">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="ifea8d20caee843099f9d0591402372e4_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MTA_fc46fb6c-c9b3-4e05-b16c-f734ad940a56">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i278dafa9c31e41f38e93fbc21fe0ffb0_D20220721-20220721"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MTc_fc49ebfd-ef66-46b3-987f-21f5f2ffcc46">P30D</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="idf27d74757bd461caae17e74579bbe7f_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MjY_5502feb1-83cf-49b1-b29c-4fe9ed5967e6">P30D</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i65a96a0fece84234b0dc8fea3877eca8_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc5NDU_fae3761c-3e5b-4b2a-a282-9a4935529761">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i08ebb4f96f1c4839a1c7d994f5ba8dce_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MzE0ODE_c3346ca0-8e39-424e-adca-cbbc5e6a2f81">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MDk_0449c0d1-4186-4e1b-b939-07f6b2510e49"
      unitRef="defendant">19</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfProceedings
      contextRef="i8ae1521745fc421d9ac0af24e8c54e68_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MTM_c064fe4c-c79d-4d94-a701-a5d824715d68"
      unitRef="proceeding">16</bhc:GainContingencyNumberOfProceedings>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i125a5a3114cb4f8f806bb33e49ba3344_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3MTY_6a17bf25-62a1-4822-92c9-3978276d0d06"
      unitRef="defendant">12</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i8c4a7cbf453c49c3960027b1664103fb_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3Mjg_19438be5-ff74-43b7-8454-054d3ce05ad5"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i25f029dc1a644b39abdd1b72ba3c573f_D20230223-20230223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NDg_045aeefd-7bfd-4827-b0a4-4a419338c1ca"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i4097e666fef649debbac3e331a2e144b_D20210910-20210910"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NTc_8a1261c0-41a9-44e2-b80d-c5588993ae77">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="ie319856acc814519a20ff1bbd24232a7_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3NjU_1d86fbb1-6448-4c93-8950-9b6bd817e4a3">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i70dad8274b624fa288d5880f291cefaa_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MzIzNTM_fc01fca1-5d9f-47c4-8c0e-ba1d0c216765"
      unitRef="lawsuit">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="id902c97014ef4d54ad1d3eccc0cc5fa5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc3OTE_354b5719-6315-49d1-969a-73940c8bf59e"
      unitRef="case">26</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i24bd15be9a6b4930b6fa4d6deae79314_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4MzU_14801e72-f699-498e-8983-5ba06f8b497e"
      unitRef="case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iaacdad21d98743ffac6109a55707e12d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NDg_e2059e80-498c-48c1-b469-198ab4494ad2"
      unitRef="case">25</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia3ed2bf0eb0249fdbb1fea6f1bf3256d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NTE_5b482476-9d39-49c6-8ebc-500e2e7ca380"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4ec102f85ef9435f9389768c72affe6d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NjI_07df151e-361b-4072-b219-998759539541"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8b1a585708ab453a905d7caaf12d2868_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4NzA_6fe66af7-4f94-47d2-bfd5-c9e96f85694d"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="id6fd7f81bf2c4837ae0cd2c5aeed8804_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4Nzk_3a080792-b788-4024-a740-b3afb6d8acdc">P60D</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriod
      contextRef="ie4bb3b3e1cbc48a8a7d48f7ba06845e6_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2MTc4ODk_a4552aec-acdf-40aa-883a-990ff56e238f">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne
      contextRef="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxMzM_b4acb6f5-28a0-4479-aff5-9c885ab1a4bf">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo
      contextRef="ib5c2c5897b654f21b2ac6f2201723b6d_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzE2NDkyNjc2NDkxNDM_a3f38de2-fb5b-4750-b2c4-1b99d6a1145b">P7D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i808a1d4b464940449c1d6cc1d68d3e33_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI5NTY_f3b9a00f-3a77-45f7-9411-af7e0dc8df84"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ib662b0cd90234eab9ce6b4ef74639960_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzMvZnJhZzpiNGY2NDg2ZjNjZDM0YjQwOTA5N2QxYzRlZjIzNjk0MC90ZXh0cmVnaW9uOmI0ZjY0ODZmM2NkMzRiNDA5MDk3ZDFjNGVmMjM2OTQwXzEwOTk1MTE4MDI5NDM_9426bbb2-9985-4b03-825d-af34235c1cb8"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzQ0MTE_d2032fa9-dd48-4f81-ad84-17717275d211">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has commitments related to capital expenditures of approximately $42 million as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2022, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $250 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35 million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a December 2019 agreement with Novaliq GmbH, Bausch + Lomb has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an October 2020 agreement with Eyenovia, Inc., Bausch + Lomb has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), Bausch + Lomb may be required to make development and sales-based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2022, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, no material amounts were accrued for the Company&#x2019;s obligations under these indemnification provisions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzg2_0a4c9b25-84c3-4a92-a9d0-f65a2af95d2e"
      unitRef="usd">42000000</us-gaap:ContractualObligation>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzQ0OQ_01408d9f-01bc-49c8-84d7-9de1d561c15d"
      unitRef="usd">250000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="idfa7f0c978d24ea089c5cb9062c953d1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzkzNg_09488b62-5c46-4f38-9327-880cc355489d"
      unitRef="usd">35000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="ib717bd3b56334329b39872e4c89c7193_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzE0MjE_dac4b518-15aa-4e3d-afac-7a0c736cdd81"
      unitRef="usd">60000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i45faea11a7064b63813ba6b35593aff5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzE5MzY_ee579529-a420-4076-8b55-f5630d9fec69"
      unitRef="usd">48000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i88b39b3e635847789adf70ed040317c0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzYvZnJhZzpkZWE3MTIzODY2MTI0ZTJjOTc5NjkzYjFiZTk2ODBkZi90ZXh0cmVnaW9uOmRlYTcxMjM4NjYxMjRlMmM5Nzk2OTNiMWJlOTY4MGRmXzI5NjI_d9b650cc-75a5-43cc-9ecf-381711802744"
      unitRef="usd">35000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NTE_1ff2f85c-2ba3-4d80-958b-5e79bbe8a764">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products. Sales of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product line represented approximately 80% of the Salix segment&#x2019;s revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta Medical (&#x201c;Solta&#x201d;) aesthetic medical devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological products) and (iv) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Capital Expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Product and by Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues for the Company&#x2019;s top ten products for the years 2022, 2021 and 2020 represented 49%, 43% and 41% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2022 and 2021 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if1daf50b967543b5947399752d3b8bb1_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzU0OTc1NTgyNjY5Mg_3cd0e056-49a1-4ae1-b14a-eb0e97547695"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NzI_353b9217-5b3b-4ce7-88ca-ed247d2d355f">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MjI_6514a5e6-4242-4999-b92f-3fa0d344f09b">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItMS0xLTEtMTY5NjA4_2d2141e8-311a-40ee-9428-be0239cb7a35"
      unitRef="usd">2090000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItMy0xLTEtMTY5NjA4_a0470d7a-8741-487f-aa93-e79e4c6bb85d"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzItNS0xLTEtMTY5NjA4_3ad318e5-a0e2-46fd-921b-e75d2c1be5f5"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtMS0xLTEtMTY5NjA4_cd598e9b-c928-40f8-a59f-28be48f9ff6c"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtMy0xLTEtMTY5NjA4_bce2d264-296f-4760-b6c7-a56646725bfd"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzMtNS0xLTEtMTY5NjA4_9f63cb68-46a3-4d63-a66e-18aeb78fe2bd"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtMS0xLTEtMTY5NjA4_744d4373-8e8d-433d-88ee-460cd0fe1df7"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtMy0xLTEtMTY5NjA4_a90f02cc-4475-4e58-a8c6-47509e469a3b"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzQtNS0xLTEtMTY5NjA4_b97d3b0a-8f0b-489e-8193-c32cf1928911"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtMS0xLTEtMTY5NjA4_f007682e-71e0-4a42-93ca-6823de64db04"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtMy0xLTEtMTY5NjA4_7b0e7aa7-11d5-430f-a50a-3e22b279be18"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzUtNS0xLTEtMTY5NjA4_70e95b04-bb3c-47ae-be23-341e69bb7e02"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtMS0xLTEtMTY5NjA4_399e2eff-2b87-4ea0-bfe7-bec0083737d6"
      unitRef="usd">3768000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtMy0xLTEtMTY5NjA4_4dde6088-a88b-4451-a9c8-9e1cb972c7e0"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzYtNS0xLTEtMTY5NjA4_6cbf50e8-8d34-4b0a-91e6-8bc429de9d65"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctMS0xLTEtMTY5NjA4_e0bea19a-1419-4292-9d17-e73eefaaeea7"
      unitRef="usd">8124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctMy0xLTEtMTY5NjA4_38619838-c51e-4ce9-8980-e41ae1df7180"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzctNS0xLTEtMTY5NjA4_0aba59f8-5af2-48a4-b9a6-a1e9fbfd9e8d"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktMS0xLTEtMTY5NjA4_66ded7fb-3838-4339-8fb1-10e27f6c831b"
      unitRef="usd">1489000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktMy0xLTEtMTY5NjA4_9c0edb9a-88ce-488f-92d2-3866601f7f5c"
      unitRef="usd">1493000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzktNS0xLTEtMTY5NjA4_9b8d2075-b8d8-442c-ac63-63dc1c5738be"
      unitRef="usd">1338000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTEtMS0xLTE2OTYwOA_eb1edc76-aa82-4479-a811-2f3dfb1fd460"
      unitRef="usd">324000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTMtMS0xLTE2OTYwOA_ed3c5a3b-ea08-4498-9ead-c66500994dd4"
      unitRef="usd">403000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEwLTUtMS0xLTE2OTYwOA_25fa2dee-7a6e-48a2-aae2-026d2cef8574"
      unitRef="usd">386000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTEtMS0xLTE2OTYwOA_8cbb4887-c9c7-4842-aaeb-841a44778f77"
      unitRef="usd">135000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTMtMS0xLTE2OTYwOA_c65e4b23-99c7-4574-b771-a99317c08b10"
      unitRef="usd">167000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzExLTUtMS0xLTE2OTYwOA_6362bf10-6fdc-400b-9891-4a1bfda284f9"
      unitRef="usd">131000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTEtMS0xLTE2OTYwOA_d1f2915c-ee7e-4567-b2cb-1e8d50f83d20"
      unitRef="usd">612000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTMtMS0xLTE2OTYwOA_f79e578e-d7d6-4a4a-9160-2b9d191cb7c4"
      unitRef="usd">722000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEyLTUtMS0xLTE2OTYwOA_e9ebe814-e26e-4765-86ab-624b89d7a5d1"
      unitRef="usd">814000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTEtMS0xLTE2OTYwOA_8003c1bc-bef7-4ac6-ba82-4ab661d9916c"
      unitRef="usd">874000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTMtMS0xLTE2OTYwOA_ac498412-98fd-43ac-935e-ed8fd57d80c1"
      unitRef="usd">958000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzEzLTUtMS0xLTE2OTYwOA_15a0f968-33b2-45a9-ae16-a579d94e3d70"
      unitRef="usd">909000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTEtMS0xLTE2OTYwOA_1f88ae4d-fb83-45e6-9d2a-751f52a8db28"
      unitRef="usd">3434000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTMtMS0xLTE2OTYwOA_595909c0-f292-40ee-8019-7fe34e0f08b8"
      unitRef="usd">3743000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE0LTUtMS0xLTE2OTYwOA_a1edb4a1-6101-4b44-8ac2-e1f48883c58d"
      unitRef="usd">3578000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTEtMS0xLTE2OTYwOA_efdeca8e-d4e2-4eac-bcda-f02edfda416b"
      unitRef="usd">-828000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTMtMS0xLTE2OTYwOA_f50f3e0f-ff02-4f32-a163-1054a5d0a3ba"
      unitRef="usd">-792000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE1LTUtMS0xLTE2OTYwOA_c6287f58-5b4e-468f-901f-2a4f49b29d32"
      unitRef="usd">-619000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTEtMS0xLTE2OTYwOA_9b83a5d4-fd6a-46a2-9512-7954db7f61a7"
      unitRef="usd">1215000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTMtMS0xLTE2OTYwOA_9a026d7f-2655-47dd-885d-162fdede8b47"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE2LTUtMS0xLTE2OTYwOA_20c6abd8-3f8d-4af5-abb4-090a0a5685a8"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTEtMS0xLTE2OTYwOA_22315776-23f8-4f26-bf86-cb5768f7228a"
      unitRef="usd">824000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTMtMS0xLTE2OTYwOA_8060a5a0-f1fa-4bf7-918a-562eba639e69"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE3LTUtMS0xLTE2OTYwOA_ccb35c74-42dd-4c8a-8ed8-31402575809b"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTEtMS0xLTE2OTYwOA_da758daa-bafa-43a4-9fad-667a5000ed4b"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTMtMS0xLTE2OTYwOA_7e800959-84bc-4d8f-a132-d5bff23c4119"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE4LTUtMS0xLTE2OTYwOA_4a2dc598-9ce2-4651-bd14-d16685b8eb46"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTEtMS0xLTE2OTYwOA_4344f246-995f-48e5-8b39-42310a2d901a"
      unitRef="usd">63000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTMtMS0xLTE2OTYwOA_143d671f-9286-4ee5-b9af-e737f81bc190"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzE5LTUtMS0xLTE2OTYwOA_afb6b6ba-21ca-4c8f-aade-f2a94a88b138"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTEtMS0xLTE2OTYwOA_ac0e351b-ea6a-4f4d-ad2c-ce4e7cc6fd91"
      unitRef="usd">-35000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTMtMS0xLTE2OTYwOA_30eb09c5-8b30-4243-bac7-7a4f5b93609b"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIwLTUtMS0xLTE2OTYwOA_9a041816-bc4e-4031-96ca-6a4f4f18147a"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTEtMS0xLTE2OTYwOA_6e270776-60b8-4cb7-ac16-6c512aa3c2ac"
      unitRef="usd">454000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTMtMS0xLTE2OTYwOA_6721f330-bfe1-4430-9437-cfd945607ac0"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIxLTUtMS0xLTE2OTYwOA_01ccacfa-6e7b-49d3-aa50-f7d27a710c55"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTEtMS0xLTE2OTYwOA_a3376892-8991-44b4-99c9-03559cb1abe0"
      unitRef="usd">14000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTMtMS0xLTE2OTYwOA_ec041ea3-a180-474e-8f90-e31127d78eef"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIyLTUtMS0xLTE2OTYwOA_4027da75-1aaa-44bf-8b9e-06ecbc483fb6"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTEtMS0xLTE2OTYwOA_8a26b0f7-f30f-42bf-9e2f-b38bd32658aa"
      unitRef="usd">1464000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTMtMS0xLTE2OTYwOA_81231e37-5113-41ad-a8dd-bc21af5b5dbd"
      unitRef="usd">1426000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzIzLTUtMS0xLTE2OTYwOA_0f05711d-c152-4ee7-b6c8-256094283dcf"
      unitRef="usd">1534000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTEtMS0xLTE2OTYwOA_054929c9-f86f-4c61-ab38-c2cfadcc3bcb"
      unitRef="usd">875000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTMtMS0xLTE2OTYwOA_f2106b54-c392-43a3-aac2-f73ed52a3d3c"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI0LTUtMS0xLTE2OTYwOA_3187e7bf-ea70-4ed6-be64-86029de8d84a"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTEtMS0xLTE2OTYwOA_7c695501-4f99-4185-a24a-63ff9505ae14"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTMtMS0xLTE2OTYwOA_6d66ca83-3253-48c9-9540-630c68bed3fd"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI1LTUtMS0xLTE2OTYwOA_6d48d368-a3ae-48bb-9daf-730b1c1fedf5"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTEtMS0xLTE2OTYwOA_53bbe4ee-e755-48fb-b824-572b4feb8678"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTMtMS0xLTE2OTYwOA_21d6b156-95bd-42e2-a0d0-9f2e728e6d63"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkN2FhYmI1OTk2NGI0ZGE3ODIyMWFhYWRjNDdlMjdlYS90YWJsZXJhbmdlOmQ3YWFiYjU5OTY0YjRkYTc4MjIxYWFhZGM0N2UyN2VhXzI2LTUtMS0xLTE2OTYwOA_3cd6b60a-bf4b-4f38-8b7a-661ecf592b9a"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NTM_faa90b75-0312-4123-a9a2-4487fa2871ec">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i579071a879594866a10f896450838c2b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItMS0xLTEtMTY5NjA4_090d7f89-b491-4b6e-9cd2-07b40c8c695d"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i806ad6775cdd401db25bf8bcf8d2f003_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItMy0xLTEtMTY5NjA4_ee6773d1-d379-48ef-b979-4c79b9839109"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i475d1b5bd23a4eb499a764efdf0fea9f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzItNS0xLTEtMTY5NjA4_5ee5f39c-4686-4180-bd5d-7e9f808b11d9"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i5e7845c0cc3646d2a0b91a5bc49beb07_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtMS0xLTEtMTY5NjA4_ee64fa2a-d9f7-4e82-8afc-ebeb89c07b97"
      unitRef="usd">21000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i1de05f52dacd445f89714dd163c68d58_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtMy0xLTEtMTY5NjA4_da69d447-ea56-4402-9083-14261f8d5eec"
      unitRef="usd">22000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i275e88de64ed4a75ada23f0c4febbff1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzMtNS0xLTEtMTY5NjA4_331f26c5-154f-4c32-addb-95dcfcc36b6d"
      unitRef="usd">29000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4a6b5dceac294cecb2e7e9087976c072_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtMS0xLTEtMTY5NjA4_54ee21e8-a146-4154-a692-6e270f0ca75b"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8ce0a40f3a0841fa87b050f6b4a9d13a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtMy0xLTEtMTY5NjA4_a001a305-ffe4-4b30-b2ee-4fa013ebafc3"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib698048181c94709b3c1c1578494e7b9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzQtNS0xLTEtMTY5NjA4_097e3cf4-4f69-48f4-9efd-f83c737f993c"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i529f309c95bd4e5da0ccd75dfc3951f5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtMS0xLTEtMTY5NjA4_eabbb93e-0bb6-4be5-a9ea-5eeec2b751f6"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i65968ca0d4ac4eb3b372ad823dd2ccbd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtMy0xLTEtMTY5NjA4_b7ffb8ee-75d1-461b-b19b-b3a497af1244"
      unitRef="usd">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ifc87bda4e3064afcb7e05ead72acdcb3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzUtNS0xLTEtMTY5NjA4_dde82acd-e771-4b7d-a9f3-81eb1704bc05"
      unitRef="usd">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ife0876dc776241b8b42e86268dbecb47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtMS0xLTEtMTY5NjA4_63a1a5d3-80fb-4c5a-890a-64db167873ae"
      unitRef="usd">178000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i970e384a5c5446a98c971db7e5ac2819_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtMy0xLTEtMTY5NjA4_d3de827b-c4dc-4b39-afd5-9cd5fccb92c3"
      unitRef="usd">201000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie8cf9741201f48e3ac26857311f3513c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzYtNS0xLTEtMTY5NjA4_039438a0-70ab-4880-a5fd-615e3efc3f94"
      unitRef="usd">253000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctMS0xLTEtMTY5NjA4_16611761-9620-4948-810f-a2cdf517ee27"
      unitRef="usd">206000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0a1dc1ce443e4dcaab9bbab0406bc531_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctMy0xLTEtMTY5NjA4_7e9ad944-9676-4f1e-9c34-bd806698d304"
      unitRef="usd">227000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i37c70a173ea248f2bf41cdd082ac0410_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzctNS0xLTEtMTY5NjA4_a1a91d9a-ba83-40cb-ba24-a494f5eebeff"
      unitRef="usd">289000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia36c406e8935420c9a9b0ba811d0b94c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtMS0xLTEtMTY5NjA4_994a7c23-4893-43e0-9158-d3232ad2b26e"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ib1c2273cc4fb45e8b2526f1f395d7e7e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtMy0xLTEtMTY5NjA4_4a627f21-7e86-4f24-9ce5-e56017a03852"
      unitRef="usd">42000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i286bf4f9e9a145f9aaaf18635129a3be_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzgtNS0xLTEtMTY5NjA4_0ffbe883-b6a3-4da7-a0c8-cd21316b5eb2"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktMS0xLTEtMTY5NjA4_d4371b7c-2ed3-4f46-be3b-f35227ed7690"
      unitRef="usd">220000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktMy0xLTEtMTY5NjA4_8c3286ff-3e21-464e-a3bd-e5847265e769"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpkMWVlNzhkYzBiMDk0MmY4YTRiM2U3ZjcwNjgxMmYzNS90YWJsZXJhbmdlOmQxZWU3OGRjMGIwOTQyZjhhNGIzZTdmNzA2ODEyZjM1XzktNS0xLTEtMTY5NjA4_129f94e2-4b32-4c44-80a1-f9b89c1cb0d7"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_1df62af4-991f-4c7e-a181-0644fe7ac16c"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_3021052a-e54e-4556-9fc4-13124c06f385"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3NDQ_669663ae-9945-4d6b-84f1-b9335eca0119"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id9d231d4c2ab49b88a385d4e4c1d3968_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3ODU_bbe13967-fd6e-4e4b-9326-01f65476afe4"
      unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3da3bcf08f654fea916793d2c53d072a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3ODk_f5eb01d8-3095-4429-a27a-744a5992102f"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2fdaef4346ea429ab8f2ee8fecb44632_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzI3OTY_7646f007-ee63-4cbb-b47a-87aa04cbbb51"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0Njk_806d0159-b4b1-43cb-8610-5e7eabf58d48">Revenues by segment and product category were as&#160;follows: &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.635%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb853490a8ee49a2aef8cfbf3f5a4de1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMS0xLTEtMTY5NjA4_17692a66-b0a7-4bd6-98c9-275c12cf8217"
      unitRef="usd">2090000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d95ea31c71446ff881e3c3c83eb2a25_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMy0xLTEtMTY5NjA4_c0a5cc4b-785d-4669-a55f-b2cfb995f708"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ca6b9323bd346c6b92ed1a1b30acf7f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItNS0xLTEtMTY5NjA4_b8618cf7-5b1b-4764-918c-a224769abb13"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6deac1f013064d42938f9021d70b9b61_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItNy0xLTEtMTY5NjA4_209f8bc0-a066-440b-82b8-6b8008e4eb3c"
      unitRef="usd">826000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i413ad399c5bb4928a8f7ac2c6f964ef9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItOS0xLTEtMTY5NjA4_1b6d4382-4533-48a1-89f5-9549efa09995"
      unitRef="usd">481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie76b4f5598c542e8977f57517d459b26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzItMTEtMS0xLTE2OTYwOA_01f34740-24ae-4061-9a75-b187adda5dda"
      unitRef="usd">3676000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5f4fddaf6544a54a803b97715d8b8b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMS0xLTEtMTY5NjA4_ca776eee-4b88-42b8-9c13-cd1f3b7f4db1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47333b2e0a19447cbe86b126460626aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMy0xLTEtMTY5NjA4_cbd8da36-489b-42c9-9558-b1ee593b1d97"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0be54156c43349909ea3602fe0d42877_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtNS0xLTEtMTY5NjA4_eb5bd11f-d728-4abc-a154-321110ca9828"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fb70824cb234539868d27d67b554357_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtNy0xLTEtMTY5NjA4_44683027-7e33-40f8-8a7d-fcb99e53decb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia502c9842e5f4891ada76a5da18cdc8a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtOS0xLTEtMTY5NjA4_e4950897-4d7b-4373-a325-942d2ef8527e"
      unitRef="usd">1572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eaa6892d2db49f1aacde5bc7fa45a10_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzMtMTEtMS0xLTE2OTYwOA_a0d5add5-0ddc-45d4-bc78-6be741c39fc7"
      unitRef="usd">1872000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd8e8b2dc20c42a1a2e9a6dadeb73a2c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMS0xLTEtMTY5NjA4_188befe4-01c8-4c8c-a24f-5fb6e048b3e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55e2a9d241f34eeba2efe5bd5d76a0a1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMy0xLTEtMTY5NjA4_9aa5a15d-ffc6-4619-8739-9c090f2afab4"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63d862bb8366425a880c22f5380b0024_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtNS0xLTEtMTY5NjA4_9c9e3829-4f49-4e12-bc09-70cfbe8acce8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7420a01c31714c0fa1134b1dabf8a3ec_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtNy0xLTEtMTY5NjA4_0c01ba03-dd53-491b-b5f2-ee96cf708103"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3abb30c5b704481e9f90a6b9c448bf3a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtOS0xLTEtMTY5NjA4_c217cc9b-9fc2-4fdf-8503-d97e9d89ad44"
      unitRef="usd">1453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6294656f6f1a45a794681c73c8296f8c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzQtMTEtMS0xLTE2OTYwOA_0c96aec0-e47a-4079-8f61-96d75c85a586"
      unitRef="usd">1611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7b09aa9c7b94449b67cecd0b45214cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMS0xLTEtMTY5NjA4_fa8bb689-0f26-4f21-8e85-6313b5bbdaff"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id206b5af67f845f58c6cd1d88e1b3a4e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMy0xLTEtMTY5NjA4_4fd4c26c-6ac2-49c3-9079-2e2db969f016"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08d5a2c5a359458caf52d23f7b41228b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtNS0xLTEtMTY5NjA4_a6b23d4e-09a5-4d3d-99d6-4b66fa4bfa8d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if159fdd5fead48bc90289f41c8322f11_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtNy0xLTEtMTY5NjA4_3d7180a0-9c4c-4ed9-b844-c0baf811d65f"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28ee52ba866140689495745ea109e4fd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtOS0xLTEtMTY5NjA4_77f6304a-9b8e-4709-8df3-9d0f68789faa"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i863f2f8de85147fda44457a636fe5c45_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzUtMTEtMS0xLTE2OTYwOA_67a0937e-d58b-417c-a399-f9d9aa8b3d42"
      unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3715256e943148cdb22ee0f5bdb45137_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMS0xLTEtMTY5NjA4_c6e6f797-f761-412d-87b9-2f1cb6bde663"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27712a14a4da4b038f73217c93180d68_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMy0xLTEtMTY5NjA4_4c12f2eb-b8f1-4509-8ee1-c337550a0070"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia596d06d5cf7420d91cbacaa63a7e5b5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtNS0xLTEtMTY5NjA4_cb537d42-7292-4213-9d88-34d846512e45"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e9b8d6292204ceb88174f589a719bc8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtNy0xLTEtMTY5NjA4_b3730ace-e2aa-4d35-9059-7383339cdf28"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4219dd6acfb54efb9311c9475b6e23e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtOS0xLTEtMTY5NjA4_d3a45976-030a-44ec-94f7-f36ee527c372"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4aa6ffca7904bdeb3915ca156eb077d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzYtMTEtMS0xLTE2OTYwOA_d02f41b0-3797-4546-b525-73f68a7e0d23"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i619f20c616f04a608422a936c94246b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMS0xLTEtMTY5NjA4_579955f7-0a36-4839-9ebf-da588493cc13"
      unitRef="usd">2090000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0586098957b14b9ab47f7e2894edca74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMy0xLTEtMTY5NjA4_6eb64099-c004-437b-839d-d4da6d968763"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica053b1634ce477da9107e88d8f63295_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctNS0xLTEtMTY5NjA4_0ab90f57-80f6-4c8f-953f-c95a993792a1"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d1ea27dbb854164a19128a797f55348_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctNy0xLTEtMTY5NjA4_e20b56fa-c138-44c8-a4c6-67f4ce0d86f4"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72a11c235a0345a7a4c1bad4c070fa42_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctOS0xLTEtMTY5NjA4_2445f51a-5e0e-4cbc-8c66-baea71f5869b"
      unitRef="usd">3768000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTpmMjM3ZTQ3ZDA3NTQ0N2Q5YWM4YjdiNjNjZWI2ZjEzNy90YWJsZXJhbmdlOmYyMzdlNDdkMDc1NDQ3ZDlhYzhiN2I2M2NlYjZmMTM3XzctMTEtMS0xLTE2OTYwOA_6331db71-a859-4551-87f9-2d45814d6d99"
      unitRef="usd">8124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9483d11a5c444a2da894062077c18c91_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMS0xLTEtMTY5NjA4_9ec0dd65-f330-44e2-81bd-a24e6924abff"
      unitRef="usd">2066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia595e166454e4a1ba18f073f7077f6f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMy0xLTEtMTY5NjA4_fd3b7a32-a02b-42e6-b275-a32eed0d0df3"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i079da80c54a848e2aa47e7dbcab9ffb1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItNS0xLTEtMTY5NjA4_d30114fd-d638-4ab8-b48b-00cd0eb39217"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6c31bfc35c5482fadce56e0fa82199d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItNy0xLTEtMTY5NjA4_caa48b39-3fb7-4928-9fbc-8cfab93ca090"
      unitRef="usd">924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a404c0e4ddc483fa3b4bfdba829dc37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItOS0xLTEtMTY5NjA4_37db4976-283e-40ce-b830-e972c7dfb28f"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f17d0100c9f4f9aa8dbe75ac00e0ff4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzItMTEtMS0xLTE2OTYwOA_876448e0-21ee-43d4-a5c1-8a2241706a0e"
      unitRef="usd">3763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2776913bc0da414c927cea557f03e444_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMS0xLTEtMTY5NjA4_50648651-cfbf-438f-8b7d-c0d608a328a4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e7fcc4d25bd4e2a964cb2338ff036d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMy0xLTEtMTY5NjA4_43b00c37-5e0b-4efa-8a0c-7031e1c49ea9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie90da407f7f24ea2a426ee198bfd832e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtNS0xLTEtMTY5NjA4_2b5ea0ae-50d1-49e2-8da3-8c43f6fa074b"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icacba9807dca4896944c3cb14d2c9965_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtNy0xLTEtMTY5NjA4_0e31a70c-5d8c-48b0-be02-e47fbd06aa91"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce14bf04cd843c59432531a3a383d1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtOS0xLTEtMTY5NjA4_d57eb984-e51c-4f65-8adc-f72e31216613"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe0a21d5a4a145ef887145fc4fc218ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzMtMTEtMS0xLTE2OTYwOA_b799a23b-6af1-4278-ae5d-97da6570947e"
      unitRef="usd">1903000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf694cf9ac304e0d96169b4f91bcd66b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMS0xLTEtMTY5NjA4_5bdc3ffb-e161-44c8-ae49-283600d26634"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1be0fb17d5df42c29867d7fecd2c7ca2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMy0xLTEtMTY5NjA4_f025086f-3b79-4cc9-99de-2c0b8aeb145c"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5db8a506550548a299d51ad491787e26_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtNS0xLTEtMTY5NjA4_f780a629-97ef-4c90-823d-c73d6e02e941"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37e9fb9964a742fcb99f6da99aa5fe35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtNy0xLTEtMTY5NjA4_d5e3fea1-66f2-4430-ac11-bee0ac0c5433"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic263815e2d40493288266b33e37dac17_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtOS0xLTEtMTY5NjA4_37d550f9-e09e-4347-87c8-801ec6b9f7f6"
      unitRef="usd">1389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5940ce49e304337951488a51673e969_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzQtMTEtMS0xLTE2OTYwOA_d5907757-e83a-4b37-80c3-d97d0c77c6f6"
      unitRef="usd">1532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54a0cc879b847ffbe785ec9a5afa987_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMS0xLTEtMTY5NjA4_7dca1b56-728f-4417-ba13-335608116452"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d6a43da1e3e4fffa44339a4a14cb01a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMy0xLTEtMTY5NjA4_78b00d2c-ba74-439a-b20c-9c9c432ab91c"
      unitRef="usd">738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89989032253542c28bdb051d0db5aa09_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtNS0xLTEtMTY5NjA4_d8eb40a8-4a51-4d77-b1e0-699142f8ff81"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7610e8eccb34bc18c4be768f086e8dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtNy0xLTEtMTY5NjA4_3a005a51-ab55-4e67-bd7e-7e1337e71408"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica8a2661bf384208942b587c9911db16_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtOS0xLTEtMTY5NjA4_42cef912-cd5b-4e75-837d-fe2a7305d4da"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa9e5472be5c451db5b0eff1fef54cfb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzUtMTEtMS0xLTE2OTYwOA_fd650f7c-bbe8-42d1-b2f7-a025087abd5a"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48e3baf2a6764650b923ffaa42fce977_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMS0xLTEtMTY5NjA4_d8785314-4f81-4249-994e-4520bf36113a"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8931f56328824e31b191e53741aba6ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMy0xLTEtMTY5NjA4_0580c5f5-eeea-4681-ac83-f4db9292bc20"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c4a3aeeec784319bdc81ce480a56718_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtNS0xLTEtMTY5NjA4_3b5c40bc-e586-4e83-b414-cefdfcc25f45"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b5885f21d2149079bae27f669de3070_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtNy0xLTEtMTY5NjA4_b9a6fa54-83ef-4fd7-af9b-344a97a3b5d0"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1702ecacf6b4d2d8df8794ce2cd972a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtOS0xLTEtMTY5NjA4_3b4f93f9-eb0b-48cb-8f0d-2150d7e4e586"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ae851ca48674d748baf9c5b2236ce7f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzYtMTEtMS0xLTE2OTYwOA_d9b73c67-d442-4372-9e5b-78d1f7a573d0"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib31b16430fd943b4ac70f1ab52dd9589_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMS0xLTEtMTY5NjA4_213a2257-e010-40e3-bb33-fd717aeb4f53"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief1300f3d25d4e788d2e8917057162f2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMy0xLTEtMTY5NjA4_02f58d81-5817-4e8d-aecb-7ca9ea35ba5f"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2b0041cc618467b9e39bff2ee9ce549_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctNS0xLTEtMTY5NjA4_d87e1313-feaf-4552-bb7c-5666a9cfb99c"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d74453ca604456b90988495dfb2c935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctNy0xLTEtMTY5NjA4_6b548baa-a0cc-497d-a832-5651ab8c54db"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd0757d629c4245891c0a910034923c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctOS0xLTEtMTY5NjA4_5fafb9e3-0e24-4181-a2a5-f603ab561d8d"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToyY2U3YTZhZGU0OTI0MmM1YmVmOTZmNTU1ODQ1YThkNC90YWJsZXJhbmdlOjJjZTdhNmFkZTQ5MjQyYzViZWY5NmY1NTU4NDVhOGQ0XzctMTEtMS0xLTE2OTYwOA_fb24064b-a9b8-46b4-af24-1e7d6bb91a12"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4d622f630994275af93f8255a42e4e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMS0xLTEtMTY5NjA4_e19c6973-391e-4018-9248-7dfc30d45295"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebef6967183a4000beed50717736f608_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMy0xLTEtMTY5NjA4_1582693f-ba68-47b2-8589-6f24d962e52b"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86f9df991d2e45d79da2861c921c97f8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItNS0xLTEtMTY5NjA4_ef11da85-c0cb-443c-ab74-f866a49d1e45"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0f6371e887c4f53b390250e5b574807_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItNy0xLTEtMTY5NjA4_19d43e52-0539-412a-8ddf-db5a393aff9c"
      unitRef="usd">1020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i414790932066409fa853afdc5c75d6ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItOS0xLTEtMTY5NjA4_d54113a0-8f19-461e-89f5-4a67e841c4d6"
      unitRef="usd">506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i210933c886d5414891a7858fd7293231_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzItMTEtMS0xLTE2OTYwOA_c0910ca1-a47a-4292-839c-2cfdcdbc3747"
      unitRef="usd">3680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd0782133c89472a992a06cebb386638_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMS0xLTEtMTY5NjA4_b6285783-bf17-4674-97fb-e83fe36081dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7d7ab2322e5421986e53954e29c023e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMy0xLTEtMTY5NjA4_0e3c05cd-c6e0-49c3-9fb6-f93a119f1905"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a29bd754c024342b29079e34fda7eea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtNS0xLTEtMTY5NjA4_bf9e6216-fa89-4738-9c27-73360f7a1fbb"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22303d42e3dc44f9bc0a9b6f8d915e17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtNy0xLTEtMTY5NjA4_528400c6-265e-4961-8541-c27bc52939a0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52852499987d44ba88be1554788eb30e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtOS0xLTEtMTY5NjA4_f500b21c-dd01-4266-b569-03125c82e050"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0fdf48aa584499db19f9a47cf66ee0b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzMtMTEtMS0xLTE2OTYwOA_5038c9d2-4369-41dc-bf1a-6cd5fcb2e954"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i165688f9a68b45b9816d827111639efe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMS0xLTEtMTY5NjA4_ec707a17-702a-49b6-9a5d-bc51901d1dab"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6f22081fec247ddad4a592c3c9311fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMy0xLTEtMTY5NjA4_63abdbdf-8945-428d-9d66-efd68c8ace2c"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f6805b61b17427ba6040ceb5f878cbb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtNS0xLTEtMTY5NjA4_68a7cb1a-752e-4e35-b14c-6f283482cd18"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied66a5e8bad6417fa24276e949d9d54e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtNy0xLTEtMTY5NjA4_6cf9cf54-e3ce-4b47-b3b2-e9a502fc6297"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia18258b56d6c404f9c117e6a1895e87b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtOS0xLTEtMTY5NjA4_c0df9e1f-9a27-4f27-85e6-da8053879999"
      unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8c1edf6e9fd47c09ba561d2d4f5fb45_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzQtMTEtMS0xLTE2OTYwOA_3b477cca-1086-49f3-ba4b-ddb2f0e36dc8"
      unitRef="usd">1430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aed53df917a48138c9cdb27cea9d59a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMS0xLTEtMTY5NjA4_c5b61e71-27ac-45bc-b025-f671c75e6ccc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e3c0300743443bebb82772ee9a1de17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMy0xLTEtMTY5NjA4_833acd6f-a4ac-4899-9ea4-1721a1a2d2ee"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d30a1f1928e4154abdcb87a862c2799_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtNS0xLTEtMTY5NjA4_a7e76400-5f04-4d34-a962-81897019a602"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i410f367d50a54973b5eb040cfd166964_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtNy0xLTEtMTY5NjA4_5a05f44e-0a85-4d3a-995c-05df396ae1ee"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifabc22558a014281b9c2cb444e967f08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtOS0xLTEtMTY5NjA4_60ad200a-52d5-4c99-a6cf-e4f6cc108ea4"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e6753cdad5c40adb3809316bce79647_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzUtMTEtMS0xLTE2OTYwOA_8b004317-2416-47d4-a299-f33039d1bc36"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d99817ee7714f4d8639154cc1b22ccb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMS0xLTEtMTY5NjA4_53e63ec7-0d41-4828-82bc-78dc03172911"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d2f801792d54e30b73e332c26636016_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMy0xLTEtMTY5NjA4_54b43675-c28f-41a2-b24e-0e86d44f30da"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc14b7106ace4ecfaf704ff0c5ede253_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtNS0xLTEtMTY5NjA4_f40636c4-5407-4574-8e8d-b857fb2ed70c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99a2f472ad0740f09224cd8980cd10c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtNy0xLTEtMTY5NjA4_cacaa1ac-d4d3-4f7b-9458-5f24c80c7ecf"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5c691843b3b442e859dea2281143b48_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtOS0xLTEtMTY5NjA4_6fe8b9d7-c6df-4764-a8c4-e47bcee5cd50"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f907111c71342ffb50f8e77dabca249_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzYtMTEtMS0xLTE2OTYwOA_9524e2a5-e717-425b-a039-6980c90e516c"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i146edb1f75664d0f8f52ee6af249dd17_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMS0xLTEtMTY5NjA4_7eb0b995-7af0-49da-a415-35b6b657d3c2"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eed543b11e94cf8ae7823f1f8b132d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMy0xLTEtMTY5NjA4_110bc60a-2e2f-49fb-8f70-ca349e06d5c1"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fb9fc2b088144e0aab629871d17311e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctNS0xLTEtMTY5NjA4_6294ced7-0150-4a31-8fdf-b4f55cff9c41"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a0004b3b8ca4446a0786bf8c6407ba6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctNy0xLTEtMTY5NjA4_591be92d-7728-4088-a3fc-d88812114e41"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie77fc902f0b244af80da18b9479e878f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctOS0xLTEtMTY5NjA4_5d7897ac-554e-485d-9411-d9f171675950"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo1NTY4Zjc3MTUxYTQ0MjZkYjY1MjJhNjFjNmUwNGU5NS90YWJsZXJhbmdlOjU1NjhmNzcxNTFhNDQyNmRiNjUyMmE2MWM2ZTA0ZTk1XzctMTEtMS0xLTE2OTYwOA_8069e08b-b77f-467f-9b2d-195b44d2c1f6"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0NDY_f248995a-1dcd-4e7f-88f9-0545969dd2fa">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2022, 2021 and 2020 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5509eedbfcd4499ab1122c8107d4239_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtMS0xLTEtMTY5NjA4_c3482162-0ec2-4855-a69a-d4b98943de64"
      unitRef="usd">4836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38a97db7f7054e388365a90a087bb5a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtMy0xLTEtMTY5NjA4_e6b044bb-2672-4d56-9856-b5bc82a968d2"
      unitRef="usd">4887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96fd34fed22f422381e2ab562615f33e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEtNS0xLTEtMTY5NjA4_b1e8e432-f045-41cb-96fb-33eb3867f499"
      unitRef="usd">4791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if54e5dc2b3f045dea402afba64c50a72_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItMS0xLTEtMTY5NjA4_29ff5138-9466-473a-889c-bfe36dceb415"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c150c6fffe6495186bf61df0c286556_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItMy0xLTEtMTY5NjA4_48e0d10b-37fa-43f2-bff8-99780f2cc4fb"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40881288dfcd4d5f8699bf1f6a8b2dda_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzItNS0xLTEtMTY5NjA4_683470bc-c76d-4be7-9ea8-9f7f4ac67eae"
      unitRef="usd">341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01ca09d20c2147509bcbb33af6032e74_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtMS0xLTEtMTY5NjA4_ab862696-eb68-4de4-af79-9c1feb565d1a"
      unitRef="usd">351000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia23a06260b684c668693d6e121b4629a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtMy0xLTEtMTY5NjA4_f0dc0e45-6a09-4a2d-bbc4-71781151077d"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie840834914ec48429fa235a8dc4f3d2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzMtNS0xLTEtMTY5NjA4_115e52f8-62c3-4e90-acdd-91a081034ae9"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b8ae97db4704ce7ade6a7925a3558e6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtMS0xLTEtMTY5NjA4_1bb0de4b-9cf6-47fa-9d49-f270199d6795"
      unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i884b037761c04998921745217361f61e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtMy0xLTEtMTY5NjA4_d83ac6e2-a7f2-4de9-8333-a81c60bcfd75"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98514049314c405da4e7a37f55ab7cbe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzQtNS0xLTEtMTY5NjA4_985feded-39b2-465b-8d38-6fcbcc1482a2"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i693f697c02b7481cb3047f296b40c30b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtMS0xLTEtMTY5NjA4_36a5ed54-c71d-49c9-b275-6d750587fc89"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6767d56cea04e58a135696afeaefc93_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtMy0xLTEtMTY5NjA4_2c2dfdff-7b73-4bb6-9173-471bce42c0ea"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a6f8147a44e4a9992f6184af1c058f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzUtNS0xLTEtMTY5NjA4_3150619d-1fda-4ed6-9da7-be797d3a0924"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib49a7c59a5a1434eadff4dbbe1111a8e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtMS0xLTEtMTY5NjA4_dba96e1f-72ae-4fd4-8339-ea711c4ea994"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0b7ce85a70745f3b0574cc6d9621b9f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtMy0xLTEtMTY5NjA4_f4645fe5-c692-4d69-912d-81d62c44087f"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6026773180f1437d92209ced4c2d11a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzYtNS0xLTEtMTY5NjA4_fc0a30cd-8f05-4ddd-93fa-313c00b39b44"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9827e7af8fa146468a1dd0ec9ff82b94_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctMS0xLTEtMTY5NjA4_8401fd24-3eac-4b5d-987f-1890824dce8e"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c021e3945bd49d8a09d3bcdecca9997_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctMy0xLTEtMTY5NjA4_e6003858-4900-4c72-b51d-01b09eca1ff3"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia095099872674785b26d32c3d7479727_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzctNS0xLTEtMTY5NjA4_5bdf460b-7ef2-4723-808e-9953608551b8"
      unitRef="usd">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36c9a8e8837a4dd4bbd6b5d7dbdbade1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtMS0xLTEtMTY5NjA4_3c6e899a-40d5-4447-af98-0415abe1eaeb"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26ed3916283a42a2919dd657f1cf7467_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtMy0xLTEtMTY5NjA4_a0b31f2e-9d14-47f2-879b-6cd6206ebc0e"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5b13de71c9b467fbaed74e0a22f2208_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzgtNS0xLTEtMTY5NjA4_dd5270cd-9d8c-4062-9882-f8e7322feb6c"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7910566e68784de489fe82fff799babb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMS0xLTEtMjA0NTc3_dc73ae3d-f0bc-4fa4-85ea-caee742689bf"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3040f78c5bbe4353a9ac62b021035148_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMy0xLTEtMjA0NTc5_714e23b3-f4c3-40ea-9eda-cd805b305387"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01e7baf1c6eb4c6fbd09d3daa5ddbf4c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktNS0xLTEtMjA0NTgx_40670ca8-b08c-466d-afe7-79903d1f8f2f"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7db976941a0d4666bd6e1f2ba49f58ba_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTEtMS0xLTIwNDU3Nw_508a41b1-a5c1-45a3-92f7-8e6fbbfea5f0"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61760936cfa34d0f9b4aa7868541b7a5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTMtMS0xLTIwNDU3OQ_4916f2c6-b42f-4ad2-9991-0db147cc1636"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bd26ef4e5ea4afc84ba00e232ce717f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEwLTUtMS0xLTIwNDU4MQ_864f04fc-efe1-4306-82e0-80833f07521a"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73181f4bbbaf41faa1cdd2014a22c967_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTEtMS0xLTIwNDU3Nw_1e9efc8c-cafd-46e5-9150-5d21404d5f73"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0786250ca0c04b9db12a0fedb2ff1574_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTMtMS0xLTIwNDU3OQ_ac5e4d07-6644-4d0c-82e1-45ccb7640be1"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i121eb01d5e11421ca0cc55f4358e2054_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzExLTUtMS0xLTIwNDU4MQ_63ec43f7-3c83-4646-a5de-272d3b63806c"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ee77d5bca934fc3a6b0ca93dcb21db4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMS0xLTEtMTY5NjA4_05291e18-1b45-4aca-b008-4e172a79834e"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1273cfab17884bd791ec54e9980c98c5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktMy0xLTEtMTY5NjA4_dd855932-9db5-458f-ac1b-e4099f853ba7"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if18297ec700d4c0d9f6bab6013cd53e0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzktNS0xLTEtMTY5NjA4_7a38d129-0851-4f13-8688-b5c97c7bf5e7"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1bf70598ac04fe18dc183a56f3b216d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTEtMS0xLTE2OTYwOA_6110ced4-a237-4b3e-a039-84ed1647986e"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79145fcaf1184069bcfc23b15cc6a8eb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTMtMS0xLTE2OTYwOA_b84efedd-972d-46d0-9151-a3561c9da374"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5a4355f0974bdca065bb27be79f476_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzEzLTUtMS0xLTE2OTYwOA_7fdba80c-0343-4126-bceb-9e9eb97e67f7"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie06d30f1eb264b3fac209b850960d0be_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTEtMS0xLTE2OTYwOA_050779bf-b849-485f-9ea5-8eafd25a4943"
      unitRef="usd">887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie73da62401a74fc195467ebcc7934a92_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTMtMS0xLTE2OTYwOA_70cd5776-675d-4a8f-a392-da1b0d788c85"
      unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f7e3e748d041d1acbb6216d4655c28_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE0LTUtMS0xLTE2OTYwOA_046478ac-e072-4e16-ac49-99a7908a8793"
      unitRef="usd">1112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTEtMS0xLTE2OTYwOA_5b2877fd-cc07-4804-aef3-ea17c53fafac"
      unitRef="usd">8124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic504eef7811a496cb440f3d265414631_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTMtMS0xLTE2OTYwOA_563144eb-86d0-49c2-9a04-9a5cb3ddf6cc"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072a195239645fa87f61a77ca261bca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2N2Q4Mzk4ZWI4Nzc0YmMxYTVkZWQ5NWI5YzA5M2U3OS90YWJsZXJhbmdlOjY3ZDgzOThlYjg3NzRiYzFhNWRlZDk1YjljMDkzZTc5XzE1LTUtMS0xLTE2OTYwOA_670a1536-7445-4f0e-afbc-883621aaf2fd"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MzQ_f27bb204-1468-43dc-8b5f-0f3dd61599dd">&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2022 and 2021 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i369d1b4494f84c38a91722618c2cf34f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEtMS0xLTEtMTY5NjA4_590755b9-ac08-4bb6-8cfb-3f7a8c4c3da5"
      unitRef="usd">725000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic1987f37ff1840ed95338c32804401c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEtMy0xLTEtMTY5NjA4_b64ef661-c903-4410-bf5f-50fc080555b7"
      unitRef="usd">743000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ibf48590013554b98a5e052a00383ec48_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzItMS0xLTEtMTY5NjA4_ec7ca29e-32ac-4cab-a8f2-c02386d91d15"
      unitRef="usd">363000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i760a6d7fc1f9409fb0004ef8b8b7dce9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzItMy0xLTEtMTY5NjA4_aefbf825-0887-4ea1-9225-eba1c8556446"
      unitRef="usd">336000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1303985937d7476c974821a08256950b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzMtMS0xLTEtMTY5NjA4_2c1b78c5-24c5-4729-b946-aead5d8e3dd0"
      unitRef="usd">126000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i64031ed4889a463f9456655e410c4b3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzMtMy0xLTEtMTY5NjA4_efc13535-1269-4d9b-9309-1dd3fe5b9568"
      unitRef="usd">123000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icd4e3bbdcdd9403c9ada12b8321e0c39_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMS0xLTEtMjA0NTkx_766e59a7-72e4-46b0-9087-e248a75cf381"
      unitRef="usd">89000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ibcefb49efbb64a5d85dc32f0d8d4c60d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMy0xLTEtMjA0NTkx_8762420d-ff43-4f0e-82d7-c099584be527"
      unitRef="usd">87000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i3df23a7c7aee42d4ae92346947a9d5d8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMS0xLTEtMTY5NjA4_d0faded5-7a0b-46f6-904c-b2bee9eae2bf"
      unitRef="usd">65000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i678b31ef25e240feb62147dc14a7ff6b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzQtMy0xLTEtMTY5NjA4_743c8fe1-8e7a-429b-8aef-3011ce5f26e6"
      unitRef="usd">75000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iddf1d0feae3e4b1bacd61edd48477cd0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzYtMS0xLTEtMTY5NjA4_2e5f0971-ec34-465d-b100-88348e4a5b6b"
      unitRef="usd">46000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i54abc6f54a194617920ce31c6643901c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzYtMy0xLTEtMTY5NjA4_a5b5158d-1a0b-433e-bacc-b32ea5ed1921"
      unitRef="usd">45000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7fd0a8a5a2cb41e4a36e68bcd7a52224_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzctMS0xLTEtMTY5NjA4_2b7a961e-58b8-491c-bf21-f4c08e7c7afb"
      unitRef="usd">44000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0c46b45670f44dc39f81dd4b7a35274f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzctMy0xLTEtMTY5NjA4_e3d1f5dc-936a-4a8c-8ff6-e5ec3ca23c19"
      unitRef="usd">39000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i859c12825f9e40189f911741e94ae963_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzgtMS0xLTEtMTY5NjA4_15c3f615-80f2-4f4a-b2e8-8ef2fea1670b"
      unitRef="usd">26000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id690161da57c4e36a166af99a7b6395f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzgtMy0xLTEtMTY5NjA4_add179e8-8954-426e-8312-972591377c23"
      unitRef="usd">30000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i6727e28116b84a2b96efd2e5c433536b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzktMS0xLTEtMTY5NjA4_d9f26ebd-6ec0-48f9-a8da-73ae98d59e82"
      unitRef="usd">23000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i18f01abf983a4e2a888777c7d9856df7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzktMy0xLTEtMTY5NjA4_3194f09a-9f8e-4dd0-8c38-7821e7d68345"
      unitRef="usd">25000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i44ec6a0287cf469d8a40521df7bd0d92_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEwLTEtMS0xLTE2OTYwOA_1253a7ff-6df8-49f6-b1b3-7de7f954190a"
      unitRef="usd">20000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i52c57f85e61143298ba638df79853385_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEwLTMtMS0xLTE2OTYwOA_23237e57-2cd4-47e5-8d62-86c49af99ed2"
      unitRef="usd">21000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id76b30129b7749b2bedad7175c4b9154_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzExLTEtMS0xLTE2OTYwOA_f630ec69-15cf-4b68-8a23-dbde550b448f"
      unitRef="usd">73000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic4de5305b33748bab90c89fa03a2293a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzExLTMtMS0xLTE2OTYwOA_cfbbf818-f57e-4e26-90ff-17ce86372520"
      unitRef="usd">74000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ica54d07af4a0484896e86ce0129c4df1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEyLTEtMS0xLTE2OTYwOA_839a069e-4f3d-47e2-ad42-e191bbabee50"
      unitRef="usd">1600000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0a1a172f25a841aeaa5ee92611763bda_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZToxOWE5ZGMwMDMwMzI0YjYzODk3MjA3MWU5YzcxOTU0Yi90YWJsZXJhbmdlOjE5YTlkYzAwMzAzMjRiNjM4OTcyMDcxZTljNzE5NTRiXzEyLTMtMS0xLTE2OTYwOA_c2ddd4cb-2cc7-4d7f-84e9-d07f5a2ae347"
      unitRef="usd">1598000000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90ZXh0cmVnaW9uOmUzZDczMDY3ZGQzZTRmZTlhZGE1MWUzOTUxY2RlOTQ3XzM0MjQ_01d46952-17f7-40d5-9c2d-b147b4f23e9e">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6353361e06042eabedeb74c21af8174_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtMS0xLTEtMTY5NjA4_fcbf0071-19c0-4bd7-8027-5a00d03c3ed0"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa738464b0a547659602f730d5711e8d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtMy0xLTEtMTY5NjA4_328fd6dc-e7a2-4c01-9528-58287ee4551e"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3cdc5afe35b143799f38340807d6c40e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzEtNS0xLTEtMTY5NjA4_07897aa6-82a2-4ed5-8b90-9bf8f4923e51"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifa065d85099a481aa7a155608fa5076e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItMS0xLTEtMTY5NjA4_059a3b48-7e2e-41bb-8986-d7fa078911f9"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b0b47abb6d8430b807a5fb4299b8bc7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItMy0xLTEtMTY5NjA4_f9fe255a-6aae-43f3-91ea-334ea0db2311"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7665331a2b9c46119262f653ad0439d7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzItNS0xLTEtMTY5NjA4_c11b9790-22ab-40ed-9af5-8be1182c9a0b"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3bfbab45127e4011bd04bc7151f71978_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtMS0xLTEtMTY5NjA4_8f3d0621-c523-4024-82d3-20c7a8d921fd"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7a1cd06e58564300a92b6fa77154d967_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtMy0xLTEtMTY5NjA4_2c153669-b371-4136-aed8-d585086a811c"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibd7c5e9fab0f4527a04532a1453031a0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU3ZmJlMzI2Nzc1MDRjODg4ZjE0MmRkODJiOTliMzdmL3NlYzo1N2ZiZTMyNjc3NTA0Yzg4OGYxNDJkZDgyYjk5YjM3Zl8zNzkvZnJhZzplM2Q3MzA2N2RkM2U0ZmU5YWRhNTFlMzk1MWNkZTk0Ny90YWJsZTo2NGI1NDRkNzE2YTY0YzYyODgwYzI4NWZlMTM2YjA3Yy90YWJsZXJhbmdlOjY0YjU0NGQ3MTZhNjRjNjI4ODBjMjg1ZmUxMzZiMDdjXzMtNS0xLTEtMTY5NjA4_126725db-52e7-4b02-8eb5-434437191e59"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>151
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MS!ERLIA=PFLV"+IW#1C]&J/_(8PUY7")H5D=(8NAI!HPE84M&=-$4)'E,FI
M&]1H@P^A+67L?N8EO&:'>28QI9Q$% \W9&U:QP^#!V^7X/RSVN* >]=!%(EE
M(7159O5JW:0F56W^"Z\ZW(KBG@E%,M@9:;MU:SXB5EVCFFB9NTK=2FWJW@U3
MTV@!;8#9WTFI3Q-[0-VZPW=02P,$%     @ J8175EGX?+Z!!@  -QL  !@
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MA)[( Q*\O4:T0_ +D6O*%6*P,EC_]&R D6P&2V-H4;O>7 IM.MUM2S.+0=H
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M/*\N-XPFK-0 ]?]'SN7KC7[!_FNKQ=]02P,$%     @ J8175GW!_DF5!
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MI>E3E7@E26#Q@MOVN=,IZ#JU=->)D)K]1])]%M+)2C(!.S_$D(44A9)&3-N
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MXVA9WNUWRQP6%7;]<D%CD_GND2R.=R4-KMW32R0L2WQ$:\EF:TUF,61!@;B
M=JZE@),&;,",:PK[OWTFMBUC5QDZBZA<Y@4V4?,([J[&P/5%1G7@*K W9 T'
M>W1+2:R7:=E/.*/*E/R75F*_6FJV>N6JPZ;";J=7AK;(?+=3PF[L'343*A?I
MD5W!ZEISG1W6BM;BL\!U>A@NM=^8SP7I$7;G)OO6<$_D@G&%8CH'E^YE![HD
ML^-[=J/%*CW0SH2&XW'Z=TE)1*41P/.Y$'I[8UY0?$09_@]02P,$%     @
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M>8H>4/GBA:\H-!F9#4>0TJ=E>I_VIZW]T>MV/K9 W5\HS8+2;%8W=IFI/!-
MRCI0F@NE>5":CZ)5$ZZTBIG>*H:N_6%UW].0CQ90I_AI00LJ:)]HE4=)#>5,
M4+B_8RJ/_U#W%TKSH#0?1:L&>.G^,KW[VV7E#ZM[=)3)-P3K]3I'< M)"RII
M0VF+-AUPH)(NE.9!:3Z*5GW,8.G@&GH'%[GRQU#X9_(UW9F^/5VSH8VD!96T
MH;1%FPXX4$D72O.@-!]%JV9#Z=4:3WBU/[J>P5!XA[06^E#[%DJSH#0;2EM
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M7D)1#+$2JRDY4C(GR!3I3OR'QGHW8:8'2&.F?4CCR()8TQ#VX]!5FJK84O!
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MBM%%::\$D>&-G;U!5CC]?SDSE105%Z(2,[%"(1R)<GAGD_!KH4]'[]3;:U6
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M"N^#5YIP\,3-^.#P05"P11HVGV6OZ*!<U_2JR?\LREGVCN3;@BR>SQU9\?3
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M(M=)U6U5]X*KC.H5V:A:V8BY0%PW2$2XSD-!<J\*4.IKK6 CJ=-4RYO.Q#&
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M."R6JFSD=<%U,%M()<8 1['4(-#T5RYAU=#N(UO':9)0]E)30W?46([VFT0
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M9J_[>7_0&Q*CP(;ISTHZKQ/Y^28ER*_(UM%CTKXZMYX(^W:L0^UX^2D[?'9
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MW-J'?ZCDSQN2E]G2\Z=XB'O?'/=$5OM@JW08%E3:Q&_YF.+0.?#^X#L'1NG
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M<J(D;(\&X/W(8)?AAA8H/TR]^ ]02P,$%     @ J8175K7&50-P @  4@4
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MLU"69M!O*WKT4+L .E\J9;>&NZ!_1O,_4$L#!!0    ( *F$5U9)\N"/'0,
M ,<&   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*55;6_3,!#^*Z<P
MH2%5RTM?THVV4KL5,6D;96P@A/C@)M?&X-B9[:S;O^?LM*&@;1+B0VV?<_?X
MN?/YZ6BC]$]3(%IX*(4TXZ"PMCH)0Y,56#)SI"J4]&6E=,DLF7H=FDHCRWU0
M*<(DB@9AR;@,)B._M]"3D:JMX!(7&DQ=EDP_SE"HS3B(@]W&-5\7UFV$DU'%
MUO@)[6VUT&2%+4K.2Y2&*PD:5^-@&I_,>L[?.WSFN#%[:W"9+)7ZZ8SS?!Q$
MCA *S*Q#8#3=XRD*X8"(QMT6,VB/=('[ZQWZ.Y\[Y;)D!D^5^,)S6XR#80 Y
MKE@M[+7:O,=M/GV'EREA_ B;QK=')V:UL:K<!I-=<MG,[&%;A[V 8?1,0+(-
M2#SOYB#/\HQ9-AEIM0'MO G-+7RJ/IK(<>DNY9/5])53G)TLKC\LYM<W7SNP
MN)A>W<#TZ@SF'V_/%Y?SJYM1:.D(YQAF6[A9 Y<\ Q<G<*FD+0S,98[YGP A
M<6L))CN"L^1%Q#/,CJ ;=R")DN0%O&Z;<-?C=9]+6%-#:_M("0LF+3"9P_RN
MYA5UFH5OTZ6QFEKE^U.Y-\B]IY'=\SDQ%<MP'-#[,*CO,9B\?A4/HK<O\.ZU
MO'LOH?_[1?T''-P42$WV0VG(5%DI2:4QH%90M<6KVN)A6SSF?>C"L%RB;B_-
M>]$B)C!ZS,:2UPD<<DG]+ 0]3?.F\?,^%\[[ -+8#3V8U5SD7*Z-1^$E,;C'
MTO-)CX<P2/MPR;*"LM./?]&).\?]F,9!.H0/MB!&>U3)4R"]YD*)OV"[O<3_
M?C<%B8=+FUGBT40!0:9=."7N5M>-OE ^A+*FFS>0#"/HIP/H=OI)1&,O'L(T
MR^JR%LQB3K)!'9)QY@,/B6@2O7'ST,T'CG,4^;E/.9[M.^,#R3$1V%"Q#^+T
M>%?#CK/2G>7S.XB)Q6Z#Y-L7N=-4>7LE48>$U53HI5$\'CW5I^&>N)2HUUY"
M#=UE+6VC,^UNJ]+31IQ^NS<2?\GTFDM#-5Q1:'24]@/0C6PVAE65EZJELB1\
M?EG0/PUJYT#?5TK9G>$.:/^[)K\ 4$L#!!0    ( *F$5U8@DVH[,B   *.'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;.T]:7/;.)9_!>5)3]FU
MC"U*\M4YJIS8G?%4KHG3W5NUM1\H$I(PH4@U#SN:7[_O $" I X[1V=KYD,<
MB0?P\.X+T-.[O/A4SJ6LQ.=%FI7/]N95M?SYZ*B,YW(1E8?Y4F9P9YH7BZB"
MK\7LJ%P6,DKHI45Z-!P,3HX6D<KVGC^E:^^+YT_SNDI5)M\7HJP7BZA8O9!I
M?O=L+]PS%SZHV;S""T?/GRZCF;R1U:_+]P5\.[*C)&HALU+EF2CD]-G>1?CS
MBS$^3P_\IN1=Z7P6N)))GG_"+]?)L[T! B13&5<X0@3_W<J7,DUQ( #C#SWF
MGIT27W0_F]%_H;7#6B91*5_FZ>\JJ>;/]L[V1"*G49U6'_*[OTF]GF,<+\[3
MDOZ*.W[V>+0GXKJL\H5^&2!8J(S_CSYK/#@OG W6O##4+PP);IZ(H+R,JNCY
MTR*_$P4^#:/A!UHJO0W J0R)<E,5<%?!>]7SZ[<?+]Z^NG[Q^DI<W-Q<?;P1
M%V\OQ:MW[RY_OW[]^NE1!7/@DT>Q'N\%CS=<,UXX%&_RK)J7XBI+9.(/< 3
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MBJF2K201=ZZ*1/Q1@U\-3 AHTNH8A0>#Q!)TWG0*<@1CEC!R5*B\]$&)P"D
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M@^P:L 9T_>X&0\4LJ1U6U,*DOM@FLMR3$YSU2+W+H&5?B DOHEH!D5B 5VZ
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M70F#X<FI=V48G(=C$<*C0*"+/F_1<PN )RT6PZ8<O.O_\(HE6GO<7E=UG\.
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MPG9L/_,JJY893;<8PT7I(UUUU1LD;*_,ZWPQT6V]U#9CFG#][ID/=/WVH)<
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MCW]TQWRI\B4.";Q<5?F"/J*3) M\ .Y/<S X^@M.@,=J$WC/_P]02P,$%
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MNJ+&CMH!:'^AE-TM7(#]KV+P&U!+ P04    " "IA%=6OK_B$^@@  !GB
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6S5/6ESVT:6?Z5+HTQ)-1!-
M\! E7U62;"?:2FR7[<Q^V-H/(-DB,08!#@[)FE^_[^@3%TG9R>Q4);)$HKM?
MOW[WT7CYD.5?B[64I?BV2=+BU=&Z++?/GSTK%FNYB8I!MI4I?'.7Y9NHA#_S
MU;-BF\MH28,VR;/1<'C^;!/%Z='KE_39Q_SURZPJDSB5'W-15)M-E#]>RR1[
M>'44'ND//L6K=8D?/'O]<ANMY&=9_K[]F,-?S\PLRW@CTR+.4I'+NU='5^'S
MZPD^3P_\/98/A?.[P)W,L^PK_G&[?'4T1(!D(A<ESA#!/_?R1B8)3@1@_%/-
M>626Q('N[WKV=[1WV,L\*N1-EOQWO"S7KXXNCL12WD554G[*'GZ1:C]3G&^1
M)07]% _\[&AV)!95468;-1@@V,0I_QM]4WAP!EP,.P:,U( 1P<T+$91OHC)Z
M_3+/'D2.3\-L^ MME48#<'&*A_*YS.';&,:5K]_=OK]Z?W/[_F=Q]>G3U?N?
MW_[V]OV7SR^?E3 W/O%LH>:YYGE&'?.$(_%;EI;K0KQ-EW+I3_ ,@#*0C31D
MUZ/>&=_(Q4",PT",AJ-1SWQCL],QS3?NG&]>BC=QL4BRHLJE^)^K>5'F0!7_
MV[9;GFO2/A=RRO-B&RWDJR-@A4+F]_+H]5__$IX/7_1 .C&03OIF/^!,>N=I
MA[)]<O$QC]-%O(T2$6VR*BT+D=T!=0/*LGD2KR)DH4)$Z5)L]WHR!7D"G\.Z
MF[C:%(%8 N;Y<9PD+HHJ2A=2++("/Z))X,3E9BYS<^KT*/P2PF,@!@I>JUQ+
M<9<E($[B=/6<'Z2'3N(46"1)$(!3\5M45GE</CI;NR* Q7N&[:.![8T'VZV&
M[89@^\[AGV4:9SG\LP"B6XH;^!&7XEVTB).XC&6!&P@OQ"=9E%%I'[A:Y5*"
M\"MQ:V/X^CY+[F&_M0D>Q7]5J>1GCL5?_W(Q"D<OO-]&%U/U4S\Y%5]DOA&_
M9E$JKIL33<U@_>\HN!A=PL_9;"3>9_=\1MT3^8_4)[N\G(C+BPD?VQ7L<-FQ
MZ5G/IM_)>5Z!#N'G)K,A_5]?RG^J%5;_D5$P&>//\>6H,=GUWWYM'AY]V@WF
M;Y&:N#Y9V^0$7W,HP'1Q09!=-H;5:.M]5B(]30?3X? G_]/:H83!^<40?\*)
MAL%LBK_/8('S03B:UH?Z. J#X7 ()]C<U'0 $]4'7U4K4&(\%, 2D\MS]>]4
M3 87L\9JF@PO$+PA C:]&#N_P\]P@/M[%^<P\:^Q3&LS?);;TNP5IYG-)D3#
MYPV0P\E H2H#SFV9Z\.BS'BF\5",IR,Q"\,F2=,DMVD))P@$ &PL?LF2Y2*K
M;RU*-1XO@ \N ;0)\&W'J?Z>%OZYJL.Y @&<=#'J.1PE_)P,"2B RLA4&G Y
MO83_0T0DH7-R,8('1WAL9MIS,9N$8C:>.4]=B@LF*F<+,W$^&</_$TM!TXF8
M\;+>5L,9K C\B4_-8,RTY9G)>"PF(T3)B.8:C2]@PP292W\ " CZBW#L &<F
M]!^<P&E-)A>:8"]A;9Y/L=:E&,,>Q^.)@FL$T]#W%BXX\]GL$OX/';AF^CEG
MN7$H)N>PW-0L!RC[ (HJ%W^/\CBK"@$&DOGO2U:".DFR='6&-,/:$W5'1D..
M17@9A"&<Y#"8G9^C^ ;R!02.\( GXE=9 #G<5'F.HG*;Y63?@DKJG'$RM@+M
M?9:>+7:./<;%$3G'>M4;D"!I!(-NLLTVB4G%?0%5O$O!B1/0[F G@W&R%'/T
M DX#TN'M$K7Y-.T#!\2@*U)0ZO#4"H#)4Y2Y91,$YC9W(IQA*8M%'L_A+S 3
M<%09S1,IHCE,I2#:EY$[8&QGW,, 04NG!%]*V?Y(7M'=78S^!W@O-#Z5*_YC
MH4Z$[8YB*Q?Q70S32OA8FV7DG@SPH JYSTQ@ZR354@9HW %VF7S*-6 :#!U:
MIIK_ SPJ469B(7,"]9]5E,#*"\=(E-\6((7QS\"9O%Q')7AR8';'.,-:$BU%
MZ2/1YNP%C)VS^M-'KO^&O<0P 2Q>Q' P.5)*F3U'<*M< -)7P(FPAH0A2Z H
M6!DX# EF#D95"@SS0BS :843A8>W<+Y =0G(>T 3N(9%(4MX8@N281G?QT!F
M2_IB$6UC9%4XBL57' FG"A9* /]NJWRQ!G>0/RUC\"@:3P.X6;Z,4S+L?& V
MT5=I$!BG]X"4C=1'R5C7B(*Q !A]^T+(= 6^,E+.1N8KF>.I+/Y9Q45LL)T6
M61(OG<.(-E&RBC;\R0L!3D]:W,$"=)S@#QLX-![H!,U"]'RTX/D>XG)-=)0@
M>Q0#<=5NNC-#L8<@HOLH3HC([[+6?8D*D)/3$"2%T?#%O(H3_ @\[J^RI _#
M%YIAZE2S 4O;3(OT[$@*CU<?87A6N-^?B@=X(-IN\^Q;#"B2R:,XOB1K0[D2
M,$,"HZK5&LYSL=:;8;J,"Y<AVF!;6&G)N!,CD#+/T881=_$W@ K("$Z2V"1'
ME.=X4*?$L[OLX#9!E!29%B*P,5@#>&\1 UEBB*9$3EQ8AB>61'(&$D)L.3O
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M6&%(<<BN[V<A!R#;O[\4X]F8 IY=W_?/C^-#"DRV?H_!Z_&HY_L0OC]7<4G
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MJP6*/8J3'J[&N5 05$6A<QB#W2GEG0_8,.2.ZJH/*5><4)P_O&C:H-I::LM
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M=1&G?+H>S?Y!_-:"N1.GR"?"Z%Q&>GQ(IV:18,G7@=.2LB*MAG;[P^1&;24
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M?FV-2<SW7D*@8%/2Q;^\%]?DM<*I"E"XUIJQND<=MZ6JD@"O8K@7&/4>H?V
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MWNL_RFR+4XIY5I;9AGY=RPA<*GP OK_+ $SU!R[PD.5?";S7_P=02P,$%
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M*.XL&Q* $H"&ZJ14.!7AP"X*&)\7(@ "XCI@0F$W&K8C\S58PHAX &O+G<%
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ML&4TL1#\X3X H([+&.CU6VFP(PO$FAE60DJF0#+%>5\].."RK@%'Q@29WE!
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M-C @L:P& WD6BKV\:SF:!N)/B)V1BF@WT('-R8G!DPD&-C-P;G /$=+<WL]
M]>W]W'E^>NR/QKZ8C\1XCI2$F*R,-ZQ"*$./U)56X7'58'$&E*8%46ED?P4H
M=WM.#?MM$XM6>OY':C"-$M_^+/P:5O]HT$<3M*_(4=/^C?BH<RH_<IO*'\[.
MQ&NX ,U?B_$0:(W?IG.ZC,[HX6@"ESHEQWE@G;LC56PRP>CI<(27&</MRT^_
M&E"8! *-V"W8MLBSV6U_(M-LQ4V&<T2B>6F*9)LLD^$,T?>&XSE=9J<OI\!T
M"-*-U)M/Z'*&<_?O=#R<\A1:%0B.&/9MIV_[?X:4F;NV;'4DJ_VTFPXG'F_F
MC 1A?%:+U!]C^,L8O)^SL^&,60K!Q_-LF9N=C'\'/Z@I9$4%FRO'2,AGA.:1
M#@Z !TPW572 CAG<V487X.ACF?W @7$:JH@C%.IE5"MQ33^()(7MN :D/ \8
M)5"S&CUCFE$3DCQ^;0R'38P[X+!%J]&#^">C_5,D;]..;[91?6C=62,ZP-T>
M84!U56;I3^R^5N-L -\HCAZ)%7K+A"26NN*5)^1N$ZQ?G5>@YK@PA[/X4 ($
M9,569#K_@<6F6)=QSA:?=D'K&E;PUAVC3BT-APXOH!#Z49CZ*+/P.$K3'X =
MSWH)!VBVC/*T$P1$@ABBZ@3S&VX=B;7.(?ZD1IT%F*_U!@L/IN/!>3=[N9VH
MH"E4>,0@"=N[[);3OCKW#JOKLAN*MG/TX%]<H%-&"#88VNGK:CE>)&SH_*ZW
M[W+GF:J*DI2<&K$F"'C.A (L_*41);K)-BP98:A0]V6C+81>F#-30HJ=SZI#
M56 3F\I#%46J,)$ZPNT^/.^,8B?5XXDZ%:_99(<X#C&<@7]^_3L@MLG?RI$-
MU FX>X#:Y8ELS>RN"RL;OF<HY@^*Y!:"SAQ/?V OFA4.,%NE]6$B#J^0A@V^
M2:ZC\1P)0P*K;_O3]C=N%ZN*7"\QFZC2"C0JD)W26N@9\.^*#4VN0&!8#";D
MQ/'C6C_13J@!Z(R8HDLD]]B*C/N7P[CLK',YBC;&WI[E)A3;X6PN%OD4Y.$,
MI"-3G,PL'OL#(IM\,]H2<1NMW#95;0Z=T+F M;*L= ^<P #35:O$J:]<!4H6
M09XMP=A)#CWR<KD$#>"!L/<0=X\0Y;9247N2HI:\ME2%F@I-2\V& - IT"!*
M:D<"9)FM&H1PVL]D/\,RX.W!S(5MF9/J8FY)QV941D4:-/4/*9ID'#.$Z,.L
M'%2](H,7UF>"M089IT,,EJAX*J#$DUZP,#J/M,Q=CV.P:C!MBQ4X],4Z:0X=
MT%A094-,9Q:SC&Z7.HL/P=^R-P>[RR4^/J)43=@ :](\A0O"-8O2J4;,)V$G
M5B_[RFIMGC &M'=[*F0'OPQ3-:JE 3F*NCSN#+3+8PH,80I2$K+5)^(.ZPJ?
M2UH4KDK4 !@9ZR)B^01V^2<S^X7!&U86W;-TK3)F4R-(V1&C;H>VAFP5Y%DE
M#4.HVDI/B;QYBLN!+=2IF5W'!N!]C.*%\'2%JF_C%0@@$R9*78%N2AF5*M13
MP0>RP%L!9 #[DR+&2PQD\DU*U:]H.["X-,B* 0W*D8ZJ@X\8CIG%>4UGPM#:
M-AZ$7#%'+4E&>"3+0@^U70D#JBU +D*@@:O\RVX3.>3*XZ^V\NAZ++<@94X'
MA?LKMG7\SB9#!\H>5K41 A[5U _F.*"*HL:I'*K 8!$.^RA+Y(QS4 =U'':;
MD8'F(9*/^2]4\8B28Z*ZYAD^<\RM=;II*.X5GB#%M&T@S)'?Z_.;K^+7\T_?
MK\3GJ_/[[WS\^=X< 28;'J))B>S)V!V5=RCCK)B[>4VQSI0Z!MIG()K@Y;-@
M;8I_G6UBUOX&C1O6R00'V^=/R-AJ&LEYPRY3V-\%TYC6%L\KM-EPFBJF+9[J
M9%,6=:')D,&93YO-S+'-I&9V7O'Q$Z8J@C'F>]\><6ILJ3O@RL6QDZ1W4*3]
MQ&L5^NSR=FF^CL4W8L7^7_OC&&Y==9[:,6=(NG[S4,0P7HX4M_<AK]^)A$R/
M@]3>*H$%,9YTWL[<VZM892NDKLVUZW[#[MW,N?M;FD7A(SJP.D=NP_ FG;<S
M]_9+;8:=B:/G;WL"OS?BII;F589]!3OI;-IUZTV;]X8ILV8+$5LQS"K?;Q[T
MP5YLGRRV(MW_@CPVQ;#&>K;GFS=M?WV1(/:*DM=Q-W;N7B)*OM=U.VW<_GZ)
M\#ON7,S^IZ[&4+&%@U0/\PJGB>?AD>M*,_I$VL?_OJ.'4UAT/#=2=>K9HTAT
MF,6K6HPD=O/I+C<IMZ9@"9PMD$M'%)U3Z!:J39IK4\:/TT1MK6W T#\KZYY=
MRZ%3DMZ$@*'F$[5^\NJ-D"RC-,D>Z0SY11+^-8>(J6 @,*F*-?@-C&Y,.&RB
M0(YGUQ,YVLX4HQA6D;$!8@/A9O3Q6YD6E0S96 3/,H>P&A60&F1H2W=U>G93
M+B(=<,01XNL%WVP3FM/$.NPJJ/M9SV[-M(A!ZD2':GA;M&&LWB'KY ,$%Q0%
M$+Z\!T.WGK 97YIQV - SOS7!/EL^MIRL^I8!NU=FH.63@]_MRFY,XD6-8W:
M9\)ZHD,EFFYHKX&$3PQP/TV;H6M-WA78V8QB_898<)/1'% Q0@TY*O<_\S7,
MM#U#C97GC(+1/HFB ,=$-/QB$Y\905_[ X R@_#44Q*L<;(IV Y(%AMUV4QA
MP(Y!$4H#[/FC.;!QZ1[88!_A1MZ8;.1IEO<?\*@(Q2\56$90%-+W4MIW^R)+
MKNP;"LVW## K?^00SFF?MX^JH*KC.SVHI";^:[9NJ_Q!%I@H[YYUL:LV3PTT
MN^$U MBMGUO7B)W\=BM_W.KEV^VY1^2Y]<SIW8XW;O4T6_K0]2KGB?,F+GH_
M>M\X9V+S2[G5T^J5YG-^D[<>SN]#?Y;H/',1J25,'0WGTP-("ND=8_Y2I!MZ
MKW>1%D4:T^T:)$QE. !^7Z8@C^8++E"]Z/WA_P%02P,$%     @ J8175IY/
MI'=;!   T@H  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULA59M;]LV
M$/XK!S4K-J!^D2R_-+4-)&F&%6C7H.G:#\,^T-+)(BJ1'DG%R;_?'2FK3J)X
M7TXD=??PN1<>N=QK\\.6B [NZTK9550ZMSL?C6Q68BWL4.]0T9]"FUHXFIKM
MR.X,BMP;U=4H&8]GHUI(%:V7?NW&K)>Z<954>&/ -G4MS,,E5GJ_BN+HL/!%
M;DO'"Z/U<B>V>(ONK]V-H=FH0\EEC<I*K<!@L8HNXO/+E/6]PC>)>WLT!O9D
MH_4/GGS(5]&8"6&%F6,$09\[O,*J8B"B\6^+&75;LN'Q^(#^N_>=?-D(BU>Z
M^BYS5ZZB100Y%J*IW!>]_P-;?Z:,E^G*>@G[H!N3<M98I^O6F!C44H6ON&_C
M<&2P&+]@D+0&B><=-O(LWPLGUDNC]V!8F]!XX%WUUD1.*D[*K3/T5Y*=6W^\
MOKB]OEV.'&'QRBAK[2Z#7?*"79S )ZU<:>%:Y9@_!A@1B8Y)<F!RF9Q$?(_9
M$";Q&TC&27(";])Y-O%XDY<\0TJ6A;\O-M892OX_?4X&B+0?@@_$N=V)#%<1
M5;Q%<X?1^O6K>#9^=X)@VA%,3Z&?"/U)NWY6 0S\H1KH8M!8!&$M.@M"Y5!Q
M,*"28B,KZ23%A7[J3 J'.56<*\&5"%>ZW@GU\/K5(HGG[RS0T3?"2;4-]F1D
M$*3*JH923H/62%E=R=Q#78I*J SAUC<401 %4&*QWJ#IDNL9T2!FA4)7U!CL
M.?Q*>+6L*CJK]K>@YW7Z7#KB< Z?B84!I=4@:XQ!Y0Y:9Y"0/<ET#A^?!> 1
MQD66F8;&S$Q[O /6L<D93,=!/-_S6"]>I)#$*7S53E0]L2=*DY3E+(6+_AB]
M:0,4(C7N34\AE0]VFYP]4G:4=M0>'!I).[,U]6UO_(#"V%YHVVP&@2.%1-?H
M_]A2&S<@G+KEC_=T#]#WV2[#-K8'A?_?L(W\RRGW6I\?%Q]DVOJ<SA(6<Q93
M^":(PJ;"IZ7::<=3%DD0(6M2A;LL7"N5KUNGGQ<[.])+WSZNVYQ&[.HI9ZZ$
M+6$G).7#Z/IHKXQ_%(SD]Q.U;M3C O?!K(E28[#F2J-RZ2NI.9?F?,8B[3TT
M>N/HD@Z8>)^50FU#MA3=G4_C]Z1<%R12QIZ\A>_^IL-\(.[(AC"(%P'_M/55
M,QNF;0G,ATDWFK6C9QBYM!F[#L0"R7@*OY",O4Q(OGA,BL918"BV#QP<"PU=
M1_YD9GPVJK[B"*%&D96,R>$MZ&5 YR#+$'-6"R11^<G1IKX(N(A0%.2E[X<G
M>]B$RW3"HQ32M_R=0NH+8P:3&7_G0*W@ZT](T@YM(UEPU[*$^J'>-<[GC130
M.IA.X(8[/X7K3E0-LAM/D] %A%M-P+EJ6]6.CC87/_6Q/X\ZV&'YS/>OO@MN
M=/3.J-%L_6O*@D]<>')TJ]V#[2*\4WZJA]?>)V&V4EDB6Y#I>#B?1F#""RI,
MG-[Y5\M&.WH#^6%)CTXTK$#_"ZW=8<(;=,_8]7]02P,$%     @ J8175B5S
M+1EC&   \64  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL[5UI<QLW
MTOXK**V3DFI'(]Z2XJ-*DI5-4G'DDN3-AZW] )(@B=?#&68.R<JOWSX #.:B
M:-FQL_OF@V61Q "-/I_N!J@7]TGZ/ELIE8L/ZRC.7NZM\GSSW=%1-ENIM<S"
M9*-B^&21I&N9P\MT>91M4B7G]- Z.AKT>I.CM=3QWJL7]-[;]-6+I,@C':NW
MJ<B*]5JF#^<J2NY?[O7W[!O7>KG*\8VC5R\V<JEN5/YN\S:%5T=NEKE>JSC3
M22Q2M7BY=];_[GR$XVG /[6ZS[S?!>YDFB3O\<6/\Y=[/21(16J6XPP2_KM3
M%RJ*<"(@XS<SYYY;$A_T?[>S?T][A[U,9:8NDNA7/<]7+_=.]L1<+601Y=?)
M_0_*[&>,\\V2**.?XI['CH9[8E9D>;(V#P,%:QWS__*#X8/WP$FOXX&!>6!
M=/-"1.5KF<M7+]+D7J0X&F;#7VBK]#00IV,4RDV>PJ<:GLM?W?QP=GUY>'YV
M<_E:7%R]>7OYR\W9[8]7O[PXRF%V'',T,S.=\TR#CIGZ _$FB?-5)B[CN9I7
M)S@"LAQM TO;^6#KC*_5+!3#?B &O<%@RWQ#M]<AS3?LVNM*INKP'&0X%V_E
M ZA6+L[25,9+1;__ZVR:Y2GHR;_;=L]SC]KG1MOY+MO(F7JY!\:1J?1.[;WZ
M]F_]2>_Y%LI'CO+1MMD_2DI/FTF<RP(L7OR@9)2OOOW;R:!__#P3/R?Q\O!6
MI6OQ8SP#'H$%B;>1C.&E>",?0#+]42 R9.PJB>8JS83<;-+D#EC</B,^(:[6
ML9X667W2_7RE!(X<])[3.'R77O>?'P3B?J5AOE1M(N#S7.#@BV2]D?&#/WM_
MQ]G[E=D%^#>Q*/(B54+]5NC\0<A[F<XSL00%R6&YZ8._8BANRQ<"M";.%BI-
M#5FS9+T&ET-\ 8[<21W)::1$ 9:1T@A'@,@3^P;OEV<&$]?K8BWB8CV%1Y)%
M;<Y\)7,8]""F2N@L*W#A1&QDFNN9!IKRK+H8SRWN98;;DQ&.[I\$O5X/_U4G
M#\0F*C)ZLFOYMHT8M0=.%3D,,%3)>"[B).<GH@<=+P7$ABR']_%WPV0<M6V]
MJ8+7--[Q$@66JB)30BYR>,;.! *$ES!8@M0"'+90FGZ=25"(*,)?U8?9"NU^
M+A*,4" X) ]>MFW,$M=4MMZQN&1EP<\@5$D*-:48K8*D:JFSG%88]-JY[F\Z
M3V;O:8/(1*2Z39B\0E6V<HT;8:[#G#GR0*C%0E'P$V>;5$=BV$.7VC\!'0C@
MB01% C/C],!B$+^.9Q#@@;/;1"*+?)6D^G=8X'%*+VLD#$[(JP,A%2\!%I@2
M):W[P#G/O ^N[0<E#WP;_][,M?T1ZP"8F[L]@PR*BKEB&UDD$4 ;4DY\"D-)
M]IW8UP>?R+X=:5E)- \5.ZF1JT*UG<\UJB,8>W\8C-LM77H.VWBX%/U?!B;C
MT5[U\'FK.<@X1L>R5+%*X?\U0!)DRDI%8&5Q0_#[VG!(?5#I3(.VP0!@ *Y&
M^I]LD'KV#;0^4:IFFHTL1;R5B7TC[9NSZ\PY\WL=1>@9I\0.&$Q..4HR),@M
M@V]Z;JEFC?S0'+@-#@(TM$H4B Q7)'=C(\1^*HT9 ??-\Y',<H%4*W)W$"CH
M?YSV@'@ 3/ $A9+0&:TPBV2J%T09.GO0*'G0PAFB@O:+7A;VK"*]U-9!(@D;
M W5@QW-]I^>@34B^^QW%?2<C5%N:<7_*<KFE]^BMBG>#%VN=Y\KQ\#P!SXLO
M7FO8:)ZDF?W$NC_PO$ =1' -2@_1P5,GHWXR ABAU'N,2^RO!/M-E!8%C06]
M :R\TTF110^.[48!2)+WP-?4J$&%649@O$%]=V \'E"3J?=*;<A\X_D1#)M%
M"M8$87"(R'SO]5,1@U\SD/2CG9<S6K*[K)AFP'O@,6RF]1G?F^WJQ6Y05YTC
M\N>CUZ63^#3G](A3:GJ@?J<':@2@$'P%Z 0 ()@5> ,X93"8M$3,>X5.H8((
M#(0CW<B0RZB68'VT3YM+5&,S:$!6@A?<D ,O-<R5"#2!;/$@-$R>3,'2V"28
M+_@F#3UDOS/SK09 :PP[JVH,^FXI(@39B%E0.@:QPOYA#VNR&&)X,OT_HX-H
M";!RS)Y!59:L85:D6,4:^+*6L31ICINR[L 7"22<Z+CTFOP0S(]; JC&#F4F
M-SH'61893$6,DA#Y9K0_0N<1XE8=Y_ /'VZ9+T]P M_\4P4" _.\,XKEF,%"
MVK(YJXPZV\K!&7A*P%[DDO3:SE5QI('_R?7-._:#&Y52T0-F]#X*Q=O6]RD2
MH,1333%GP1# T$QP_0[L1!0;JD6LM+I3UBW/5(H\,U&.XU,EUL$>V)+,3#BL
MC&U=/+6A\?;FNDRB*.QV4)4C%76B/#: *J1+E;<2T:)/5K1Q4X4L:==7MQ<N
M:K-O1OJ(ID41@?&#[E)6(_'%%C*7B8P\PB#O?<\&0!'J[S^+&P7S$#M#S%Z3
ME+0G02KQ>5S<*@\X/C?OFEP'^9'VA-886*0D@J.5WD#Z(=<!;AN6S-GSC&W$
M^-3 ZL":1,*16O0M1M71 5JZ 57-"N,O%J!0*2LU^UEO4R7=H7CGW'MC[N 3
M)F8_;<U6 F?4(1H<JR&.Q0@%6I\[PP0/C-C.BW_7CB*P-O$/G,PISJYAB5U*
MRTP&01GH"HI&"@B;[1\-X3^8)XH(UZ-4%5BOE=!"IQFBX12$=EO)!7(*25SK
M!'W*;%T --@A+8!X6::!B2S_*F@J%:PKI*@/^#L**Y+6VS?P(?DF"P4?E$PS
MHXGPLT\C$(Z;4)J9#5#^ KH/3,&)#N@1?H)&WU26>2;Z8^\'K=B'Y+G?'XI3
M&/P8_?#48$(_3_!G;XRB TH1R !]<_"44;(A@S>/T)H#&HP_^F!I0&F\#%SV
M0=%IOH9 A"4]4E?W;!_4H0_I[^GH*;3QWJ_,WJN<J(>FMBK"(\BIU$$@ <R>
MW"=D=Z1=4J<"H'+!U0(851.X77]'></JA+'F!BBYA =^IZD@U%N4<1[)V?O#
MFQF$&%R=%CRTX'R=S%54 HO2"NZI*J[FAQ+B.Z$& %9KIO:[NE9= L\]'V"
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M'#&\[D\<6I_0>_U^.!I9N+L_#'L'C(C'8_&]C\_']/XHG PK"S7Q\ EAZC[
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M?8()&MXG!M-X63=2S= (G)'+$TQ!]!&'%+>?I?4<Y9ES4Y6K5-_*]>;Y=>M
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M,G>#A&P(;:R#7<$)EW1[A:!"-*<!Z$%4650WDFZZUBBS#=!A2$.N?<7FWZD
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M%!$].'S-#%W/BDO8TL"&\QCX@K#E37Z/9#0G&RL'WB3B'3KVYN<OX=_*&3!
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M&-+AD7G#"R;3.SH4#IS%0?PXRN5=IM#(Q5Q\*>F<35[KH#.%\WR8<$P/ZU_
ME)) $"60S12<64J]\HFWLFP6=71=WHE<_:G3?X0KWA*3-,03#D)7#NH" 1OQ
M)WO?IM$PXA>;4'\<E,F+VIX3PZ-2KIPJ*.L9'A!H05D+AO7;=0PFFVK"RPQE
M!89:)O2QF((.XZ02<W#\D )KUKS9&X7=BSX7MB[,!+O#BHZYMEO6DY M-,#P
M+!;+N*HIKAW&C34GJ"Q5O6C#^FB&*H'6TXV#P,6"<3N#9,5)-R]@RQG:93[W
M18:A)WA+KY<"ZIK R2@+A0; G!653;7"W#3UK5S4NA9AT)V=R@]EZN5-C*;K
M)BF\?+R& ]1^"XB@YNW,GP^?O7%4L[9N3R<@PE)H!A:M6UU190R(H+C,2U8=
M^Y5QG;?-JAT5FU6;E+I;GUF7EXETQ\Y**@?G0HMNL:<'SQGGJ_LVWMOVZH%]
M-X9D[,=@XL"*0BJU5HS5" 1'9I)5_7 \A0#9R_7WW)TF&_R8*8*(KS>12[R=
MFCW&->LRT4%WWY^!9YW&B(-H?MS-*]A(6NR'&.-.X@0!='&58%O&BU)E!FF]
M<#\%:28(=7L^]G%&>S_Z07-PJ->,[M(-^G;7(*I<3:+3!\C ND=!]*\FO>-:
M&*<9"I=,Y4I,X$ Z"I.20" S"T\%$!M6DNLYK"9I0Q$>*( E+>BL27\ACUZ(
M,\X\I63&]?4DG0>I)1JY=%X-)2E61LH,\*CNBI)*/,!>$KE(E<C7E/!?Y;HP
MLE+?^[5IH#IQ6CH<G/ZPG"2NG( 45JF7Q3W0/!LEYPAS-</P#EBP2L1 6C5:
M(#3*WQLYD<D#:4VT)<=9AK6/?H2B)W!]"\[KV>$YA@;"(MT>0. 9QLFO0(FL
MZEC1HIN/ANS?BB7*S=DJ[Y_T=YAL]^AP<'1VL#L87-S @&9I,#D63)0\>\],
MQVZF))BIX^ET)QP.3D=/G7!TX"9,=Z)KK;FP<"'PWMIS'1R?G#YRKI8LY[GD
M#JJ?)DE4_Y)H<SY@&39N'R!S=WBR.Q@.3PX/8"=)Z.11^ZG!8'=P#% -3DX/
M=H?'Z)XS':T#S980&[03[6U/=T!@-V 2BF;W8Y%2A>QCH'3SGPPP6O+X^0V!
M=8XW49,"5K\HBY:%[_RL86LJ[_!XV]9R>8?]N AP @OCXPIM"4B2H'T229O.
M4\&]'WR#GRQY9O,6O^+!2^Q  -(6U$;'!; %<7BF7N4/<;P"&OTF,S##'^;W
ML[/AD_C=G80(J$'!G+?--YF#8(SNUW+$X.CXY-GLKCTHO6C0Z[(D=+$[!W*_
M\$P-*_FU/.5S_E8)P!NJ,KK7KQ(+R45NJ!+KK\CTYK#'89@R4/UR)1A7BN$A
M?=!TH*NEP'X&\(,ML/+<2!V5@+M8]8[_=S#CN98 @8<'KI2W9QK$W+5V<&6K
M?F%.OYKT>T10D>M>]%[@\1U[ KZ7QV);ER^L+4W"3)OT>N)>[H^IU@HKDZFC
M0<-G4GM&B3VS9<3>SPF;6VCB2.MWD&IUOA"0Y[WD?A]T.,KRORJ[@0@#81#C
MX/,<#3!HJ?[4$^AB6WO0,7#-M/S4T/G>/)]/X\E_ 5>:B'7,<H@P=5VJ.Y5S
ML3T?B[L)^A1,,3L@(GM4*/=H9.A[A'Y9LVR=E5:]FV0B'&YY<QK8#Q*$!6;@
MN2LR;<P#7MVB"R.(H,)\[I?R'8;>C&[M$9X_WWSR/ R5Z!7%(:/;!<7!X1_=
MV:=>4\[?PH[QB5WOB8OQ971V2 ?-X6_WK'GNZR;]&C7& 8/>>.9L9[H%AHEO
M.F=N"O=MLX#JF87X_ROU]Q=A-7T'0*(-PZEB$S4'1>BMS4"W!X]CA:'@/E,]
M]D]1<=DB&^G.+J<SD=IDY\=;!T#X));**=%2]5=TML1!U3XLP,*+W%$^P,>U
MOE[''CQWP'8&$;>PS0@L^;$D"\K'>R6J?_B]+ICF)0W(V'M0W/W8 G.'%3J@
M;LO,*6O^!;/F8VRH%'T&/7['1*+]))/)WF3L=VW.X1 3)<.CH]WAJ34ENL%8
M#ZPG!F,-,8:Q6!N-.O6WES2Q6ZD]\V'<3$"B$_C^AO>N[&1W.#@X.3R#E8$U
M[^\3S>-S.*4&.@D ;].YH<)%P8:J.<EH&!:',V9&)QI;=>UR,LFY?Y))7)#0
M,2K$6$@!ZN1W[)!668UH_']]G&-!)*TYS(OT#4_M@=!6T,I6AF/&1D]I4<[R
MWLU)9ZN#&35'NN(?+J[X*L$$T@4?_6E*EXO.;K^Z I78<'3 Z#W<_5AN=E+@
M!_%U_/0P1LO6M4W1V!9 RA#U6IY_!FZ!Z\]%4\'6<9F$GIG;$6&[F@<DP=')
M: 3\,GRY).C:&^ND@0Y;Z5"K87Y#;$'GJ6M]%((9&%""!Q^)BMC974=!OJY9
M*RN.!X>'L/;C_UM9X;-H$"+OIW??CO>81/MZ&C6YKS_ZV((EB@85'98P:;II
MM2';=/(>(?"M]$< O8=C"YY)Q.">IS*A;C::,OD.&@)H$%&\P>67V./A0YTQ
M4J.-Z_(Y#>M[G/F!:'-&GL(?7M,?SUDY)63:%(K#&!:T6'S#3*F6F3[EK3N8
M[;H.YG*YGCC:C7+TF3SZM93"MO+1XG5!!Q_0N,0STSP ]JVQU90MZOR8-7-9
M_VD;Z'0/:I$QSHT'G=V+#9F,2<J[D;5.)9WHO6@W 5C.)*'!H&UI&F/"=-KB
M-NT4M.#A'C<&O6W)0&07;.C#+--QTCP]@TUGZE)]X^GMUFC^HA/%N,/]ZH.0
M$U.0S%L.N40 /=<>P@1D;]/QT@UB),QJV5R3P5LJ,\4;0ZK%8$>?ZP]:EYR8
M=_E8NO.XM+2MO!92@:0VO6)8$1E*H\9=1G3WQZT\A?R MD.N/A?Y-WSC;P40
M]%,+=#9JN!%HM\'QT>G9\3%%60<[@6L2FXB-TUB^0G$GN.PAOCXQVI&1%B<M
M(=FK6T/K_T<JU_['V^FQEA.VJ:&LXNJ'>T7Q8)+<%34.CF00 +,YKRM]!VL!
M0E?N4?FJGJY4YSH 0\W/. 1^S"V_7)7!L6O94$K9E[KZ\:?O;"$,E@/L8N !
M=WT[C&T3!*Y;;;8*CA'NZ%X=O6IW*E.,[_97DJRM(K%&-V+2-F%Z\!RPL7?=
M8O!\^*HP[5_IK+@&T1V=!P*UC380BV84C:;=2<F5"MCVHULK-/*"O#; <>9'
M=(,CE^X4*BO.JE_'VC[(GIF14)MP[A<MN2LK[A"M?"X4M_9<*B06.G -Z]*+
MI/A+26U%=0N3B=\[ +6VC0R'O2MU7SS3O0WD:DW+P*BY?GM*,)0@'+!=]=VK
M:'NX0Z KJK:NF<Y 36&K?-VXI;&N!F:4]0W=(V7U.L+"-$XD$Y"5Z0KH'?O7
MAX)Y,^$-<)D70 T(<U+ UF/0A4Y]P+U#'DW< Y),/ Q&H]2#2F CM%0&><$5
MA]M'>@44%DJ]D^%Y)3G2!_X4,!<K>H<]L^%FCVT[(]YKNZV5WCD<$%#4U-2"
MB6+ZM-#2<(O>.1%>P=<6"BY1[8#-%!B<DOC1;2$YN(/]9-- 6Q@Q&_)0DU/+
MFBFB-A5S0?3)OK7NW >FVP0ED>-P?[9N_'?8BO]^QZ;>?7437AB119GR=8*?
M'W!F06W+,6 3,M ^.4@SS,&8R'@8GPP-$UWH1,_<<J,>4Z%?4)]?:?N:>GW9
MK6514I]NW6:#$T'Z;+C]=5USNC"H2R%*OZ^K[@'6%URU"]-*-37"/N&J*:0^
MTP7>.B/MQS;V=(,=6E &K#!6V.C0]"1;TX'K)5UHE(NQ^07\NI?N)['$GO+!
MMIWXZ1>;E-/&3J9?<,%M'=NE<1,;7&"K@+?2W5^ E*:.V^0Y>.J,[)BU 6C;
M;M=V=\*K_3%HZZ8LJ3H0)#/L"LV[,EG%F#*_J%-VAX<N+8OZ9-?4GYIU*AO^
MQDXH8>5SJWWJTWI%/N?L)!B^XZN/_6=K..AK'GWM^C\=O!J>[E[\#C;NX=G!
MCLT.Z@6&NPPL^:URG99A#9PEYY18Q9J0%2:9I+9#DK>57NM='0KS2KPKVU#!
M_(Z^/\ANM$]TW;XR7;!:UV_*XOLJ^MW*XOX<+)W,:+=@<552V<J( \_0,5W:
M*V-@4VU!W9 B!J3?P"TT&Z);[*HO[?$I%W/G(]XNL(X(L^=/>!7]\%K3:]O)
M>Z),^.?0[013KE=#P+L!Q(W$J5OWD=%A+RF*#^2Z9MUKP;.FF9UN;LDE9%3L
MW4I]4V.MT(>X?7\1A1V0_4R'J7>KN<&O_V4.;VQ>MSWYPGU,4"5?Y?S%'M-C
MUHM2_%K4DHH&S7GF]I=-8O-PV!BP_\L!'VP7^5O7\DZ95H5KVH.,\QS+5OAC
M$OZW)/YF67\EP55CY[O]08-!W"ZG053:3/'M.%18AUY+L@!?CVH\;W"!]Y^#
MY^'_6SQC,N,)>#:ET"UF/-HE7[+-C.O+5WLR\7UY^,I!9=*C!@MK9\4'V%P,
M_,Q.#M[&D;B<U5?1>KPU\F%#>8M%V^9B4=T7C;T8+5"R_MLMH="MN=&!AU:8
M?_5,1(-)H+_PT(/O?I'[#'P[,P8C-#BIG8V^*?.T_=BL/JB8P6^K1+JL4S;@
M82) 5I?^BHTDS<:HZ4(/>WEWAVXI]LAOJ/_"3R-PU'6WQB!>9/G96SFCJZ\5
M[.9%!X:B7PK]V#WE=XPYM]<^"&^,XK M[&G\X('YSA.?,.[ +@\=J$?:;SUR
M@3'\'&M69.H]&J^UN#L6ONR)L'J6)JS&-O[?_RS+1-)S>;UBGC+MY#QI\8Q#
M:6%1(0+U\E-IFXOBP])V%QPT44,R6%BBX!=J].?#7%;#7?(HRP01O8^HT$R:
M)Y KZ#-_T?;ICG/M[<?)>DPJ"JQC@"0O\EW3@]L6Z./I;IU3L1[/K<C4][9?
MP%V1UMXD YF"G0(CS(VYM$W%E$V)B9+*-6['0*,YF%70Y]=TQLJS6SW&Y6R\
M'T5S0;,X.!D!.A.8NYI*,D$U-].)<HR[^+Z0RV7C7F,T%B-,?KU97W@VK"A!
M=T6'VRQ-XC=73+22/41;BFIZ)!,^RIJ#6Z9VM?.L9< @NCBEMA$FI^+%&O-6
M*D!O-29+IUZA A<QN=(L+C34C]%T;4!,PL4C2O-R?W<YC[PLTI A%F(E2W^!
M_/4E^J0)UN?K8S48WO%RG9V]Z:7C<(O6X!U9 61]SP!Q-Z]L#Z'2][;TB,ST
MK>&KV&L,BA]\R8TJ<+2"Z+,\S'6#?K#=)FB#G#'A^2IH:F_2UTF[;V);S?4<
M4;3U@1WH[%MZ908%8#BY\KS-;UJLF"2L7S8P\G7Y^C'Z$EF$&?-1+*^[(R^]
M76!/9!#P"_F#!7]GD2T^[=QOEL-Q$+\XX^/[((AV__'S./"N'S6:Z]WMA78J
MFUAG-<C]/#RCB5,@@KZVY]FO-@[?39"#5;N"\4S8&]4ZZ6AICHE3=^/<J\3%
M0Q* Y4PT><)U3:Y0V@S3DXHO],<Y(O?MF,28ICH10+N7@CU<M$+FK76OLQ2U
M3<E;-@.=AR2#%01L(K0A,D$YNW;P/>]%A@/I#^;I:C02E%2Y&J!I+SHOM"VJ
MA1D>:;:2PA?Z'%[2P7/M#ILDF-/$N,M&$ ?RI"T]0E8YW<@JKO#0!,ZMV&*O
M0@^^;0]_[[2.)7=-M7$&/)8*;9/%?I'7NI2B#E8%WX.A"7E0SHBZR!)&C!O^
MDD?NM>.N,:-%G]/$2CN/AVBL7;0;KS0"'"]5D>_W'O<Y"245I:4AH:.YS4=4
M^:.)] H\.25[-ZC5<9\C\7(9'$GO)=3VA\1:!&-JXSS[]J>#07]/^78W^>O6
M2<_62JDBX.'EM@!T5-U1]>N@CKL%T21*O-85V*@JU9\ZQ!*<#0BS7M^C("%Q
M;W?")8GTWF\HIV]]=/399?-*ISHV%,Y?AXI[,Q/W6CJ^!V\;3OB&GY$P.IER
MOO+S:^NF0H>9983TDQ8NT!H*APX3QUH,>UF'5IMDZ_+[!;D/#=M&6& @)$%1
ME,O[K3I)-J:=7AKCRH=$F"HGYTAC0M">EH[,QUY8B<%DN_JF+E'NWPS_E'JK
M.'+4MXC^'&$7_#SE')U,O;/EP=/K.+3U$: P._C(Z<VY#/X<3U\V4-OLF_*!
MEMJ<&NTPMV>!/_@-B\?85WO11ZW+;_B;+?V/]86#PM3>=2(%R;$U'JXI6K'/
M.>\TK'+^[59_Q8534,#HZ_)MY)S:SG3PCM=CMS6DU:A4/QO<U._[;O?F:8,T
MW[HIS:A.E9N0=\>E!PD,S"<6LR=Y]&50_H(=;U#6V&2V9TVY7;0M42\_6;BH
M# 4M(Z*65XX<6JO>1![QL]*K[P4WJO-#"S<RSZM5=B_0AMH&.*/1":90AL>[
MT>?+7?RE[0I@)&&M26EZ^83&9:ROHF!JYB2\Z"/H)L;=Y/_"1V4.8,V(O\DD
MU0(/#^):^WL34W0^*.LJ4Z@8]CO!@<KT3\DBHQ2*/K;,WS(JU5TT4:GY:,J=
M#C7KSQZ3>P9@%G.NH2F\ U/&/E^$FQAB+O:/?%,<P>1_\;MB_4?*^R($L0M1
MF!2_,:8QKH/Q8'U=6"7Z^/%,:#C6U!0'E7ED>9/\N5"U+3'X6BSQ:*Y;6*"!
M[/=0@+P((]C2!O_2$7MKEZ%EC:Q9!PY8&V6MD5GH8ZH#:9=KW0MR%7.\Z MI
M\_G0::=.@K^W8+G;AY&SNRUNL_X(MS>-;O##-L1-,Y4)<&T7,V6<E,V.B2]2
MO"^IX[.A>,D\WL=81UYX00;;QRBHR]1MJ[Z:'STDPGL)/XCSE]Q6!POA^F/)
M;_;K=V_V507_)/"W+);P;X7?CK\4M7CW!ACB3EX X?$W$^NW6\,M[RJL;/IV
M:SQ\-1YM[<.;[O%W;Q; 8Y]!(P.*HDQ.X=7!WLG1%A^3,K_4Q0*'1.\8N(]^
MG('U($M\ .Y/"Y F^A><8%F4WPB\=_\#4$L#!!0    ( *F$5U9E;$@#!0@
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MH/,"/%\85+WV"Q_0O2H]^A-02P,$%     @ J8175AU<0;I@"P  IQT  !D
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MCX#\3>YN\M5-3->&/L)D4:3"&I1N#5P,?\^3LZ+@=E;R,#!UV:0D#+G+Z[1
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MG^3":E5WKG?$HJ;[E;K$]8$N5Z"2[Y&II.^L<Z+NP(_-#7 <ZGQ@+<#6\XZ
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M)$(>-OMPRZH\ZOWXD)4<T/T15%R[H0ORP/SG4^B<94"R+:>1; H[/5>LU9<
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M#9,V>,U"T;=2M<9AU*;GYJQ&JJ(9W!?8F.1W*]C9QM!'LAB]E.65P=)L@_'
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M/5Z>T!J\0.J_H*]>+XXQ1]YSL"ZU'@1<Q>:ZNG6<R5")@P@_8S"JY?"B#E_
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MQ%BHH#'I 30">F2;TZ9!'8+\^)PFRJE@$,,\N00N<G0-X]$E+.M9@_%)O4Y
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MD B0R-H.VT/SY'U78_\8I9K1Q2X^@-A,8!P43H\[* EY^AC=GH&8Y]-R4&Y
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MML!>:.P+/QT-C^$HQ)^/?/<\4TNT!@41TI)0&4"7+X5JC%S#"L5:3L#GJ"2
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M@SCM/@S[0,LGFZM$NB05U_OUNZ->;"6RXJP%^L$R2=T=[X[/O8BG:Z6_F"6
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MPJ_LN(>/49]&^',V^V]Q-!S@HS_"AS?:>7$'B&<16#0V(&'D"H5.PYP,UD:
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M[(9+X'@&1(#O0Z5L/J$-BCO#\7]02P,$%     @ J8175KC-^W^* @  ;04
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M].8ANF=ZQ:4!@4LJC<XNS@/0C;F;B565-]1"6;*G#PMZ#U&[!-I?*F5W$W=
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MIL>I)L936M J90[\2JLU?G-!K:EK2SA.(GS?E;MIN"0<W8,0QXOB>Q#/&9$
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MGAK<W(Z&H\O;T2<8/CX.1Y^N[Z]'ST_P[IF.,R;?G_45&M&B_;@&O*@ [0.
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MLHH88(*"G9\[O-@OO=C_!B_6'K:FR8HAT,'Q_C V+UQ +"*^TAI.7U<[5H"
M+K',,$F35%&5-2:)3IG:DT0]*L ;%#OXFS-X\01T)*GEE/]Y#KDN)9V7,RI8
M?RQG5'G9--T%6_$DX<D*]?3,J,24 ,$#LX.OVQ,\3W7$P%3A3.N!!<. "SC<
MQ_1AZ"C"QLY]8+[C(BQ@I'"=P\!0UDT;RL,BF%CYJ.* <9=E$L7<"8_ 4]!;
M^AYVF.21!YSD.I.2)<$S@2(L22.C)!K^ ;6QD>DP#.!(S,#[;[I5RP 8A5*M
ML:W5:EF.5JD]1FU6+(A8N#18NZ%<DB<:9;H0JZ"PR5JV[8*E0*UCCUB3Z6$
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MX])\W[#K;CX3^4#1=BF)V!*&CJ#(ZQ%IOKPP-TIL]-<."Z&4B'5SS4"7$CO
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MAF[5Q@#F-#6%_[S6_^Y"O3NAMY;3>Q7874Z_.O=V*O7_2+>)R )31")IGY%
MA5AT-5-+VN;;4FJC]B.%\_8+L(7D2<JR"4O3#1C2^SD"%%A:C>$V\$%Z'.KR
MC..D"E76B\20\*%.HP*]+R*TEW+I0@'3%M&A6^I*>]D5@6.JRWA* NCM2/WQ
MF']CFFT1.MRX'ZL4B(9N 5$+4'2U5V7KT?5%XVE[O_8TO;VE_ 2>TE"O5#.(
M1F^SI,=L>_/7OGBS#+=M4^.]J4)WH21RF";@]YDQ?O5""ZRO7T_^ U!+ P04
M    " "IA%=6NE]?M]D"  !I!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6RM56UOVC 0_BNG;)J*U"4AO(PR0(*.J976#<%>/DS[8)*#6'7LS'9*
M]^]W=B!C&T6:M"_QG7WW^+FS_62T4_K>Y(@6'@LAS3C(K2V'4632' MF0E6B
MI)6-T@6SY.IM9$J-+/-)A8B2..Y'!>,RF(S\W$)/1JJR@DM<:#!543#]8X9"
M[<9!.SA,+/DVMVXBFHQ*ML45VD_E0I,7-2@9+U :KB1HW(R#:7LXZ[IX'_"9
MX\X<V> J62MU[YS;;!S$CA *3*U#8#0\X#4*X8"(QO<]9M!LZ1*/[0/Z6U\[
MU;)F!J^5^,(SFX^#00 9;E@E[%+M;G!?3\_AI4H8_X5='=M- D@K8U6Q3R8&
M!9?UR![W?3A*&,1/)"3[A,3SKC?R+-\PRR8CK7:@732A.<.7ZK.)')?N4%96
MTRJG/#MY]V&U@L5\":N;Z7(.%Q_96J!IC2)+X"XD2O= LQHH>0*HG<"=DC8W
M,)<99K\#1,2JH98<J,V2LXAO, VAT[Z$)$Z2,WB=IM2.Q^L\@3=G6G*Y-;!
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M##/Z5:"R!V@_E=(\36S[ZGX^P6]02P,$%     @ J8175K_K5BK\!   8B$
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M$D\1$R$5TQ")^90X4U4,19YIC( J/$Q7D# Y1Z7785\5%92-.5IZ<%9X8$Z
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M-0YS/,_K:C!2E:9Y@@EC4WI^X*/7$OHJ(CI$^':9%XW,BTZ9=U)L6-FZF *
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MF/6C0#Y",/[S#]R//GBH=ANJW0J]\PI5IU+1J 2-2M^O37<TTY"I_[8Q[[;
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M18C/]!,?!".68 1^>#HB_;#0A?/F)Q9,!.;)SS>_>PP(2S:-H\46:7NM A\
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M*KPUB]/L$YR*6&<$UH=4L%W16#+814G^3;X5B:@T@-..!JAH@)H-)AT-<-$
M9QW-F67=NB."+.:<G0!7T1)-_<ARD[66O8D2-8Q/@LM_(]E.+)Z6[^^7[Y;!
MS?TG<!,$'S_??UK>OP</'_]<!LNW3^ 2/-(C30Y4?J_9)HE4\B_ %\(CLHHI
M")@<T9!RD@W* V?'2(UP"E[?44&B./U-0GQ^N@.O7_T&7H$H 1^B.%81\[&0
M_!6+\;K@>IMS11U<(0(?6"*V*7B;A#2L XQEQ\O>HY?>WR(KXAU=OP$87@#D
M(&0@%)S?'%KHX'(P<(:'NP;C;0">Y$(-#S&] !!=.OZ%[/*1RG4C5.Z^D/B0
M9_HFE@N0)&N: I*$<G!2RH_RXN]'%L= SO 3X>$_IASG%"9F"DHUKM(]6=/K
MD92%#'2T^/47.'5^-^5G(+!:MB9EMB8V],4MB54"+L"*;J(DB9(-8,_@.R7<
MU.T<R\VPE+8=%W VQ?/QL=H=4Q#4036:;DG3M=(,#IRKX=M3'K$0[%^6B(ED
MCC2M/-]U/=@@:0B:H)F9Y+0D.;62?"#?U1S+)].:TS 2Q@4Z;3W[TG71I,'0
M%(6]#HI>2=$[;[BII&@9:*_U<.A#I\'0$%2=#36"LY+@S$KP+DK7[/"21+U
M322M2'T7X4!@M4[[9:?]'R]9_I#9&@BLEBWHZ'+K#"A:!5AUGB)5J&ISV1 $
M?<<\EV'%%\#!9*N JDE22[8,05/D=M!$FB8:1+@*F)HF31VWR=$0Y?H=N@!U
M68?6.GBV=!4P=5F:-3FV@ZISHDY1UU)H+Z:/5!QXARFSMNR[_(9"J_=3%V/H
M_GB]@E9'T#MC Z'5,Z:= ;1;@YZ*U:[]DUE+L=I!KM<E!=H?0+M!Z*58!@.
M6XIE#ZK3U"X!VFW"V8HU:VN1-"E-CH8H5#%D=9*ZJD-K&3Q?L?SV<".OR=$0
M-.M0+*0K*;)7TD>Z(L+LKNPM^ZZ_H=#J_=2%&,$?KUC(:@9Z9VP@M'K&M"=
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M ?+_9\;$RX5Z0'DJO_@/4$L#!!0    ( *F$5U9Z8B5R0@4  -8>   9
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M^DE7)!I'; +%5]8CYEQIQ['#2O]$0)@$O;[@7.T"LT'W6XK_ %!+ P04
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M(;E[YZ=0(3.-1E*.A1IU1G^2%YP4)%J+&FS)Y,'[:^M=^GI.S.LDZ@V&X?H
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MTBA[2FV=R9;YS3R_SF>3^0-,9K.[Q_E#/K^!Q=VW?)9?+>$S7/&6R1=$F*+
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MT>#L) #5^:H+C&S]+*^DL<[PR\8^1:A<@CVOI#3[P#7H'[?L+U!+ P04
M" "IA%=6 E":C+P#  !U%0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6S%F.]OFS@8Q_\5BYNF5NK*KT"3+D'*@.V0MBQ:UMV+:2]<<!+?#.9LI]E)
M]\?/!LI"2U&B\]0WB0W/]V/[^<(CX^F>LN]\BY  /W)2\)FQ%:*\-DV>;E$.
M^24M42'OK"G+H9!=MC%YR1#,*E%.3,>R?#.'N#"":75MR8(IW0F""[1D@._R
M'+)_WR!"]S/#-NXO?,*;K5 7S&!:P@U:(7%3+IGLF2TEPSDJ.*8%8&@],^;V
M=6P[2E!%?,%HSP_:0"WEEM+OJI-D,\-2,T($I4(AH/R[0R$B1)'D//YIH$8[
MIA(>MN_I;ZO%R\7<0HY"2O["F=C.C+$!,K2&.R(^T?V?J%F0IW@I);SZ!?LF
MUC) NN."YHU8SB#'1?T/?S2).!#8HR<$3B-PCA6XC< ]5C!J!*-C!5XCJ)9N
MUFNO$A=! 8,IHWO 5+2DJ4:5_4HM\X4+]:"L!)-WL=2)8)6\6R1ODW"^^ SF
M8?CQ9O$Y6;P#RX_ODS")5^ 5F&>TK#RE:["0QL_3E.X*@8L-6 E89)!E')Q%
M2$!,^+D4W*PB</;B'+P N  ?,"%2S*>FD+-58YII,[,W]<R<)V86H?02N/8%
M<"S'Z9&'Q\OM'GETO-SJD<='R^U)5VY*AUJ;G-8FI^*Y3_ >)'[):"';*9*O
MK." ,A!N8;%!*N.=,%RDN"0(?'TO@2 1*.??^JRH1Q_UCZZ*U34O88IFAJQ&
M'+$[9 0O_[!]ZW6?,3IAD4Y8K G6L=!M+72'Z$%2I+*2<P0$E>4QW>4[ @7*
M5%7#*1;@C"#.@9 ^GO<Y5,.]"JZJ_UWPRO'EDWEWF/G'0>ZH&Q+U<'S+ZP;%
M/4&V[?IM5"<!HS8!H\$$S \6'=6+[EOH(.341U$G+-()BS7!.DYXK1/>LU83
M3Z>%.F&13EBL"=:QT&\M]']G-?$?O> 3>^P_J":/@\83WWY03WJ"+-M]4$_J
M(/\@Z&KD.?WEY*K-P-5@!L)ZS7*;">+U6NX[+\ 2,4PSM5&YW[1<R-;?<A>E
MGNR^/ P.<>J3JA,6Z83%FF =G\:M3^-G+39CG1;JA$4Z8;$F6,?"26OAY'<6
MFT'XJ0[IA$4Z8?'D49&S^RN<;?WZ.+/TUCCP'SARFS4\\JFN:*5%6FFQ+EK7
MPX,/;/M9ZU\SO"XC==(BK;18%ZUKY*]/<'OP\_#_5L%A^LD^:?W(UDJ+&YHW
M4 G-@Q,K=2#Y ;(-+C@@:"TUUN65%+/ZC*_N"%I6AUBW5 B:5\TM@AEB*D#>
M7U,J[COJ7*P]:0U^ E!+ P04    " "IA%=6R'"(E2<'  "<.P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,RYX;6R]FVMOVS84AO\*X15#BZ6Q1=^[Q$!B
M76:@<;/8Z3X,^\#(M$U4$EV2S@78CQ\E*Y9U"6MU)_F26!+/0XKO,4F]ILX>
MN/@FUY0J]!@&D3QOK)7:?&HVI;^F(9&G?$,C?67)14B4/A2KIMP(2A9)4!@T
M<:O5:X:$18W167+N6HS.^%8%+*+7 LEM&!+Q=$D#_G#>L!K/)V[8:JWB$\W1
MV8:LZ(RJV\VUT$?-/67!0AI)QB,DZ/*\<6%]\O @#DA*?&7T01Y\1O&MW''^
M+3Z8+,X;K;A%-*"^BA%$_[NG8QH$,4FWXWL*;>SKC ,//S_3W>3F]<W<$4G'
M//B++=3ZO#%HH 5=DFV@;OC#'S2]H6[,\WD@D[_H(2W;:B!_*Q4/TV#=@I!%
MN__D,>V(@P"K\T( 3@-P,:#[0D [#6@7 WHO!'32@,ZQ =TTH'OL/?32@-ZQ
M ?TTH)^(M>O=1!J;*#(Z$_P!B;BTIL4?$GV3:*T(B^)4G"FAKS(=IT87XS]O
M)[/)?/)E.CM!GR=C9SJ;3#UTX=TXSI4SG<_0Q=1&]N2K,YM/YK<W#OJ(ID0(
M$J<0>F]315@@/^BSMS,;O7_W ;U#+$)7+ ATJLFSIM*MC.MJ^FF+QKL6X1=:
MU$97/%)KB9QH01<5\;8YWL(_ CAF .X8 $W=O_M.QL^=?(F-Q"LB3E';.D&X
MA:VJ'C&'V]3?A[>J.N3X\*K:G?\7[AX?CBO"O:/#K:%!BO8^W]L)K_U2ODNI
MQ_<+__N6298,AA?1 EUNI2XG)1KS\(Y%)+GP]V=]#DT4#>4_%0V_W%74J:XH
MGD(^R0WQZ7E#SQ&2BGO:&/WZB]5K_5Z5 9 P&Q+F0,)<2)@'!,OE46>?1QT3
M?3079$'U7.Q3=D_N BI/4$1559H8.773!!)F[V#=!!8O6>Y'5K_?/6O>'\I_
M3"&WJM"PE2_D ;4])U=W+U?7*-<DNJ>1XH(9A#(2Z@H%";-WL-Y!]PZ'[8).
M1Y1QRV6L5DDFH);G9.KM9>H99;H6>HTMU-,)V@0D4HCHL9GJH7JC%[_J1>&,
MS+K"0<+L7KG#N\-!0;EC"KD5A7JMHG1 ;<])U]]+U__!-TR1:,7T4(A(/,>^
M_#TS<NK*!0FS^Z5.[@T[1;F.*>26"W4');F VIZ3:["7:V"4R^-\\:#7Z%4"
M&2/K"C0H3PWM5J>3[PI[4$YOW.GV"UU_5"FWHI35[11*>57MLG!O7RK7J\-]
MKPZ-O6K3)16"+I BCRA@Y(X%>I%IF'.,N+I=#0FSA^4,QL."'D>4<<ME](-
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M^0'ZJ&_(:L(1>T'&X,\_[+;U5QE[=8)Y-8'EF'539MTJ],$2<<&.OC@R'.W
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MD..#CPYDHONM] 3NU^S 5IL=MM!TLDJ@8+C9T;=$P%![(V?8N@."E=3 K^J
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M(M<5U/,U8_+E1CNH#B4G_P-02P,$%     @ J8175GC*E$$F!0  DRD  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULS9K;;N,V$(9?A5"+8A?-K@X^
M):ECP+$.:R )@KA)+XI>,-+8%E8279*V=X%]^)*2(EN.HMKH%$@N$DGF_Y'4
M_.#0$PZWC'\52P!)OJ5))JZ,I92K2],4X1)2*CZS%63JDSGC*97JEB],L>)
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M)1%]J.E#QZJMKZ.ULE25OEG0,XC:!=#\1BE[[+C2;![6Y"]02P,$%     @
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M:&5E=',O<VAE970W,BYX;6RM54UOVS@0_2L#M2A:((EL.4Z[J2W 7VD#Q-G
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M.OO(C&S=R^N%,ZO0#A^-X^8:I@4_?VB] _]?&.-V"[]!\Z"F_P)02P,$%
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M%T!I \S^4@B]F]A&T_Q7DK]02P,$%     @ J8175A6AWSB0 @  V@8  !D
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M:PT#H-00:1E_:TZG26F F^,/]GOK77N980D#3E](II9]Y\I!&<SQBJH)+W]
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M970W.2YX;6RU6FUSVC@0_BL:KM-I9YK:DHR!EC!#7IIC)DTS);W.S<U]<+
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M;'Y^MUBLGK_8#O!U4?RRV\WW_P]02P,$%     @ J8175B>JPA;. @  ?PD
M !D   !X;"]W;W)K<VAE971S+W-H965T.#$N>&ULK99O;]HP$,:_BI554RMM
MS?\$.HA$@79(+:U*N[YVX0A6G3BS#;3[]+.3-*.0A@KM#;'C>Y[\[G!R[JP9
M?Q8+ (E>$IJ*KK&0,CLS33%=0(+%*<L@52MSQA,LU93'IL@XX%DN2JCI6%9@
M)IBD1M3)[]WRJ,.6DI(4;CD2RR3!_/4<*%MW#=MXNW%'XH74-\RHD^$8)B ?
MLENN9F;E,B,)I(*P%'&8=XV>?=9OZ_@\X!>!M=@8(YW)$V//>C*:=0U+ P&%
MJ=0.6%U6T =*M9'"^%UZ&M4CM7!S_.9^D>>N<GG" OJ,/I*97'2-EH%F,,=+
M*N_8^B>4^?C:;\JHR'_1NHRU##1="LF24JP($I(65_Q2UF%#8'L?")Q2X'Q6
MX)8"-T^T(,O3&F")HPYG:\1UM'+3@[PVN5IE0U+]+TXD5ZM$Z60T&M_WQI>C
M\ZLAZDTFP_L)ZHT'Z/+F9O XNKI"WU$O85R2/S@O^O!%[1X!Z'@ $A,J3E3
MPV2 CH].T!$B*;HFE*I T3&E@M./,*<ER'D!XGP ,H#I*7+M;\BQ'*=&WO^\
MW'XO-U5)JKHX55V<W,_]P&\H)%&;!&8(QS&'6 T1WBP%%*6H2[1P]NJ=]6MY
M)C(\A:ZAWCL!? 5&]/6+'5@_ZM+^3V;OBN!617";W"-52[<NP4+EYRK]F5A%
MMN6$'7.U"=YH?2"X5X%[^\"].O!"%6R MRUOB[O1^4!NO^+V]W'[==S^#G?8
M;FUQ-SH?R!U4W,$^[J"..]CA#D)KB[O1^4#NL.(.]W&'==SA+K?K;G$W.A_(
MW:JX6XW<]PM0+7LN@=?1MW9WRW;1&^T/A&]7\.U&^+$ZF_0QYZ\DC75[6::R
M+HOVSD?&4U^9K3QV@WS'_Y=LP6=NM$=]-+G&/":I0!3F2F:=ADK/BW9?3"3+
M\H[YQ*3JO_EPH4Y(P'6 6I\S)M\FN@E79Z[H+U!+ P04    " "IA%=6$-64
M:&D+  !NB   &0   'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6R]G6M3VT@6
MAO^*RKNUE:F=Q-;=9($J0.HL4[E5F-GYK-B-K8ILL9((F7^_DG'<-#HZ4J]?
M,1\F8$X_DL]KVLUC74X?\N);N9:RLGYLLFUY-EE7U=W;Z;1<K.4F*=_D=W);
M_^0V+S9)57];K*;E72&3Y6[0)ILZLUDPW23I=G)^NGOL<W%^FM]76;J5GPNK
MO-]LDN*O2YGE#V<3>_+S@2_I:ETU#TS/3^^2E;R1U1]WGXOZN^F!LDPW<ENF
M^=8JY.W9Y,)^*^:[ ;N*_Z3RH7SRM=4\E:]Y_JWYYGIY-IDU>R0SN:@:1%+_
M\UU>R2QK2/5^_'</G1RVV0Q\^O5/NM@]^?K)?$U*>95G?Z;+:GTVF4^LI;Q-
M[K/J2_[P;[E_0G[#6^19N?N_]?!8&WH3:W%?5OEF/[C>@TVZ??PW^;%OQ),!
M=M< 9S_ &3K W0]PGP\(.@9X^P'>T '^?H _=$"P'Q#L>O_8K%VGHZ1*SD^+
M_,$JFNJ:UGRQBVLWNFYPNFU>63=54?\TK<=5Y]<??[_X^.[Z\GUL7=S<Q+_?
M6!<?(^O=IT_1G]?OWUNOK9OZM;R\SZ25WUKO\GSYD&:9]2J259)FY2]UP1\W
MD?7J[[^<3JMZ=QKH=+'?=/2X::=CT[9C?<BWU;JTXNU2+G7 M'X>AR?C_'PR
MEPY+_.U^^\9R9[]:SLRQB1VZXH=_2(IZN-TY/.*'1W)Q&.X0P^/APZFMB^'#
M9TPOW<,+P]WQW [>U3K9KJ25;JUJ+:U%4A1_I=N5E6SR^VW5O!A6^Q<#L:N7
MCVB/1C>3Y=OR+EG(LTD]&Y:R^"XGY__XFQW,_D6%AH1%2%B,A D03 O;.X3M
M<?3SRR1+M@MI)=4N[:]RE6ZW3=QUSLT#=[)(\R65-,LU31H)BQYA_@[6O+]^
MKR<<SP]GN_].I]^?!DG4NC//HVH%56L[P;-:+0;_$(//QG!1EK(JK;7,EE:]
M:+#*I)YW"[G(DK),;U.YM*J<_;UC\:9I(&$1$A8C8>(1%CS-<\Z%&1S"#-@P
M#V^6SP-,J)1??<PK:;G4V^@ENQW35)&P" F+D3 1M%)][=C/?_FU7,-#KB&;
M:[V@K9>K6TO^6#R^12;;I977LV1!9<>R3+-#PJ*PW:$3FYP=B4J[]3ORV/9V
MJ<UW?7[H^ISM^A>99'77Z[]I=HN/4JYV7W*3(0LT;3T2%LU;77K>\MX* =HA
M+8R30Q@G_/O4<IDV?Q>65-O9H:9M1\*BDU93??+UCMRH ,&TG.R9^NMNQB9U
MO;E+TJ+Y5:&BV@_VNU]F5_TET;Y$FQ_F#KEXBJE:+S@AYQ+^J?V_K7ORA[%M
MLB:6S2S?MQKFD:8O?B@MVM/TN=GWZ 4Q5=RU>A94,;%\UG-P5 Y.3P[WY6)M
M_=-ZGV^^3JWK;26+;=),/PDY[?,XXPR0M A*BZ$T@:+I,2O=8(_H&VRH<(#2
M(B@MAM($BJ9GKJR#/99VX,'&@4/%PY[&+>^(DGINI7T#63MG?8.MA(,]LG'@
M^<9!0)T#E!9#:<(VU0ZV\@[V2XD'?D/&X4+5 Y060VG"-K</MM(/-M(_\##C
M"*$&PF[;@M9$V5LBB)(>YV KZ6##K0-/-&XXU#O8_>*!*'G=_=8TAH2PE86P
MC] 0_%CC'* BPFZ;B%8.4 F!HNF?RBH+X1QC(?C!IDE!:9'3]A7/D^HO$:A]
MTMNO3(:#-QD\TC@4J,EPVKZA%4IOB2!*B(E.;[F2%HZ!M"#["[444%H$I<50
MFD#1]%R5I7!&M!0.U%) :1&4%D-I D73,U>6PAG+4O!@X\"AEL(AM()+?ZH7
M$[6MV90KT1NOY(0SLIS@^<;]A\H)*"V&TH33EA-=82HKX;R4E> W9)PJU$I
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MAN1Z&1\D5[-$^<FDU^]/IL,!ZMT-T/WC]7""^M/)9'CWB&Y&O:O1S>AQ-'Q
MYP.0F%#Q"7U!TX<!.C_[A,X0R=$MH52MANC84L%H23O=!;ZJ GM' @\@O4"^
M^QEYCN<9W/OO=W??NMNJ!'4=O+H.7JGG']$;XQ<\HR 0SN>HEZ9\C:E /WLS
M(;G::K],"5:*@5E1G[]+4> 4NI8Z8 +X!JSDXP>W[7PUI?N?Q-XD[]?)^Z?4
MDQM88JIVE93 JPIPH%C"'"T C&M;Z;5*/=TI-HGOM3OVIIG1H8T;Q4YM](8T
MJ$F#DZ1CSN;K5"J^F>(SHE4"[4;8./+WT PV3F0F:]5DK7>2R34W'XC60=3
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MRN.GX&-#B7WQ<70CE!)QL;D#%H+4)^#QK< JHFSH[ZW5!_GI?U!+ P04
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M@VJ6TOQ.<7ER<I+G\B9HFHQJ*:H)5).HIE!-HYI!-4MI?I>XP#D)!\XO/C5
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M;"]W;W)K<VAE971S+W-H965T.#<N>&ULM9UK;]O(%8;_"J%>D 5:BW=:J2W
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MD# "P5@RLT,R,_&U<E.EC1%DFZK6A+)RBL8G:E-<-OF\2DLG=;:Z6-2I=0K
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M5<OR75O,M6=!G[-R'QX_>NY#5^Y13:*:0C6-:H;2W,RV*_<C=N5^A*[<HYI
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M'%Q(;(9CW1#JVAM"_=-^I^G*3K7X5LXNR^7>W3Q>/>II7UWK^$1[1:@6H)I
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MWPRN'NX7=[>K@Y>OX/9F]O5_IW^MOA5;!ZC**P>HJP/4YP>HKQPP6ATP.O2
M\>J \:$O:;(Z8'+H"&>K \X.'>%\=<#YH2-<K ZX./2 R]4!EX<>H S79VYX
M\"'?3O:+L_WJ(>O3K1Q\OI7U"5<./N/*^I0K+\[YJX>L3[IR\%E7UJ==>7'>
M7SUD?>*5@\^\LC[URL'G7EF??.7YV7_\QNS_*5R???7YV7_]D/795P\^^^JW
M'_:#S[ZZ/OOJP6=?79]]]>"SKZ[/OGKPV5?79U\]^.RKZ[.O'GSVU?795Y_.
M_KNOOXB??HMKT\7T_<_SNS\'\\?G+[W'!T]3P=/QRU_>-[/'>2M=S)=_>[,\
M;O'>L ,1_&8'YD DB0A,W=>#+!W\:Y"VLYN[^2"?W;=7#_/V>A#<+=K[P0]:
MNYC>?+[_Y\_O%LOA'Y%W5ZNAK*]#J:\,I0S\N]GBT_U GUVWUWN.=^3'C[J.
M=^7'GW<=[W6\_LXWX'< J@1XMSQQW\Z>NCY[OZI2T9_^/5"&/P[4H:H.\E0;
M_/ _]IV8W^2*\S![.QA>/#&*A-'DC-9>+9G1$S.4,'KW>U+/.A7C@!<S>OK6
M*)<2QCS@Q8PZ%4NNI.V7]8N1GB?[D/>D='YK'.;5N(>_&AGCR9G@[H]OKT;V
MIGSFU02',[(?A9 Y4U''#^9T^8.I7'2^J;C/#Z:>)X,?_N,?%Z.S\7_NPY)#
M7E/WSV?:]8,U7W^'I#]9V0',UU]=RN6>P_.#SY-RL>?PXH!?G*M?,A>2-U$>
M\":^_LJ3,M4!;^;KOQ;E7,+4AY\9&=,<\J;.GYB)A!&BC]/UCU=T3)A/_WI7
M9^R55[4S$8^^Q:C1DSMZ]7O_^V)@S^X7\X?E_ZE?#/Z7MWS"P%ZTM_?_>\_+
M_/6K-MZO/7Y6\=/]E^E5^\N;+_/VOIW_T;YY_Q__4,Z&_[EO=B<QC<1T$C-(
MS"0QB\1L$G-(S"4QC\1\$@M(+"2QB,1B$DM(+"6QC,1R$BM(K"2QBL1J$FM(
M3 A4H^;TG?PQ_I8_QC+]?=)>M[=?GM8!OLQOKMK!EW9^M0PBTX_MX/JA'2SN
M!E>?IK/EGVYF@ZN[V6)^]WGPP_1^,%T_<U^:^E4Z:-^80F(:B>DD9I"826(6
MB=DDYI"82V(>B?E?L8LG['%!\8_WRMNA\O.[/[;C!SEB2&(1B<4DEI!82F(9
MB>4D5I!826(5B=4DUI"8D$_IO>,'I.W$C\FW^#'IB!]?IG\_?O!Q/[C[,/A\
M-_OXKT4[OQU<M[\O]N4*J=8W5Y"81F(ZB1DD9I*816(VB3DDYI*81V+^5VRR
ME2O.+\9GPZ?_/$L7+Y\Z&H^'^YX:OGSJY&RL[GMJ1+Z;F,02$DM)+".QG,0*
M$BM)K"*QFL0:$A/RV;9W,H"TG61P]BT9G$F3@7=WO\P$LT'[U^)F]O'AYO[3
MT_K(,B6\E@W.7OS:.1OO^Z7SV\LGCB[V/5&3OL*^<_K+4=7S?:,:Y*@FB5DD
M9I.80V(NB7DDYK_\-_2OB_/)WOGZZU//MG\:]D[!X<LG3B[WSM7D.XE)+"&Q
ME,0R$LM)K""QDL0J$JM)K"$Q(9__>L_5D+8S5Y]_FZO/I7.U_M=JC2#\\*&=
M[YN;I<?W_?_M)*:1F$YB!HF9)&:1F$UB#HFY).:1F$]B 8F%)!:16$QB"8FE
M)):16$YB!8F5)%:16$UB#8D)^2S>.W% VD[BN/B6."Z>=&K;Y 69/TA,(S&=
MQ P2,TG,(C&;Q!P2<TG,(S&?Q (2"TDL(K&8Q!(22TDL([&<Q H2*TFL(K&:
MQ!H2$P+5J#E])W]<?LL?E_#JA-3KFT!(3",QG<0,$C-)S"(QF\2<RY=+!)/S
MO>OT+CFN1V(^B04D%I)81&(QB24DEI)81F(YB14D5I)816(UB34D)N1S=N]\
M 6D[^4(9?@L8CS4YDH21/6Z#].ZFL\&O V-Z=?/Y9O'W0'MH!\[#K'V\AGHR
MF,X>RS7^:&]_;^=/7]F7.^3#] T>J*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J
M :J%J!:A6HQJ":JEJ):A6HYJ!:J5J%:A6HUJ#:J)CA30.[-0W&YHV>H$4]!E
MF15'A1-2TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M
M1[4"U4I4JU"M1K4&U81@.6RVWPTGZB:<J-)/5+Y=:_KCX.YA<;^8SJYO9A]?
M7;"1:[VS":EIJ*:OM)T+8H:CO=>FH .;J&:AFHUJ#JJYJ.:AFH]J :J%J!:A
M6HQJ":JEJ):A6HYJ!:J5J%:A6HUJ#:J)CIF\?_" N-W@L:GX5*0-7N_W-Z+O
MS1QHO2>J::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6
MHUJ!:B6J5:A6HUJ#:J)CGN\?2TY1_*ELFC\?;[A#+M:,T7!":AJJZ:AFH)J)
M:A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%J):A6JU:C6H)H0
M+(?-]KOA9-,+JG05@YZDEUP^:N\,@S:(HIJ.:@:JF:AFH9J-:@ZJN:CFH9J_
MTCHZRM$Q0U2+4"U&M0354E3+4"U'M0+52E2K4*U&M0;51,=DWS^;G**85-DT
MDRKR:M*D_?(P7Z:/^_9Z,/WX<=Y^G"[:QY@RN[KY,OT\F-[>/<SV[RDA.]]^
M0S4-U714,U#-1#4+U6Q4<U#-55[6CU[N[[#UT(']PP<.T(%#5(M0+4:U!-52
M5,M0+4>U M5*5*M0K4:U!M5$QXS=/V"<HDU5V=2I*O(^U;YW19%SO6,%VJ^*
M:CJJ&:AFHIJ%:C:J.:CFKK2=!O+)WL82#QW81[4 U4)4BU M1K4$U5)4RU M
M1[4"U4I4JU"M1K4&U43'5-X_>9RB5579U*HJTM:T(WK-Y&#O[(%VJZ*:CFH&
MJIFH9JVT0TK$;'1D!]7<?>]C=+;W[B8>.K*/:@&JA:@6H5J,:@FJI:B6H5J.
M:@6JE:A6H5J-:@VJB8ZYNG^T.$5AJK)I3%7DE:G[KX(9_/>@^^XQ<KEWQD#;
M4U%-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4
MJU"M1K4&U43'Q-\_IYRB>%7=%*^J7SO2J,MB5+1@%=4T5--1S4 U$]4L5+-1
MS4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"U$M4J5*M1K4$U(5@.F^UW
MP\FF8%65=J1]Q]93.=P[IJ!5JZBFHYJ!:B:J62MM=^?$Y7CO.@TZLM-C9!<=
MV4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:5!,=<W;_B'&*FE15
MW40,>4WJJ^LTD[>3X?\<O/+7CW>F\:?+:/)X(YK1W@""]JFBFH9J.JH9J&:B
MFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:B6H5J-:HUJ"8Z
M4D'_$'.*RE5U4[FJCMA%'+1X%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U
M$-4B5(M1+4&U%-4R5,M1K4"U$M4J5*M1K4$U(5@.F^UWP\FF>'7Y4/H)RV*Z
M:*\'-[-%N^07@_GRCWM#B93I'4I(34,U'=4,5#-1S4(U&]4<5'-1S4,U']4"
M5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:5!,=LWS_4/*5>[R#[[<U]>';
MX63R;3E]-VYLJE15>96JZ+=/!&U(134-U714,U#-1#4+U6Q4<U#-134/U7Q4
M"U M1+4(U6)42U M1;4,U7)4*U"M1+4*U6I4:U!-=,SU_4/'5VZ[(4$9#I\W
M/>P&CTU/JMK9D]JKQDS.]8X>:#LJJNFH9J":B6H6JMGJRR)0=;3W3L4..K"+
M:MZ>MZ'LKR7QT8$#5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:5!,=\W3_
MT'"*=E1UTXZJRMM1)1M41^>3;SM4]^Q+'>Y-'6AY*JIIJ*:CFH%J)JI9J&:C
MFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEJ):C6H%J):I5J%:C6H-JHB,,],\N
MI^A753?]JNK7DC5L7RK:KHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ
M$:K%J):@6HIJ&:KEJ%:@6HEJ%:K5J-:@FA LA\WVN^%DT]"J=C2T'KHO%:UC
M134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)4*U"M
M1+4*U6I4:U::HFRM!S_N_!R=3W97@X4X_*G8++T3)D:;&M61M FMYZY3.=8W
M4J":AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHYJA6H
M5J):A6HUJC4K;6>CW,M]G:M0@0XML+E\-WAL*E)'\HI4R?:0BZWM(?L+S/Y^
MM;Y,/FKOA(+VIZ*:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H)JJ6H
MEJ%:CFH%JI6H5J%:C6H-JHF.4- _PYRB@W6D;C*,BFX3&:'=JJBFH9J.:@:J
MF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:@FJI:B6H5J.:@6JE:A6H5J-:@VJ
M"<%RV&R_&TXVW:HC:3W:P=M$Y$SO4()VJJ*:CFH&JIFH9J&:C6H.JKFHYJ&:
MCVH!JH6H%J%:C&H)JJ6HEJ%:CFH%JI6H5J%:C6K-2GNQ]^/BY3:1PY^*S=*[
M86+3A;I\"&X3D6*](P6I::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6
MHUJ":BFJ9:B6HUJ!:B6J5:A6HUJSTK:WB8S4R6O;1,BA!3:7[P:/32OJ2-Z*
M^NHVD;'L-G?MP_SN7]?M[.[V9O;T*<ACEUGWWA&T4Q75-%334<U -1/5+%2S
M4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U M1+5*E2K4:U!-=&1%/H'
M&XC;#3:;UM71&;MW!&U=134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(
MU6)42U M1;4,U7)4*U"M1+4*U6I4:U!-");#9OO=<++I;AW)NUN3]LO#_.K3
M]+Z]'DQ?7?H9_/?@/_YQ,3H;[WL/O\J'Z!U8T,)65--1S4 U$]4L5+-1S4$U
M%]4\5/-1+4"U$-4B5(M7FJ)N?8ZN3/9?;IF@0Z>HEJ%:CFH%JI6H5J%:C6H-
MJHF.";Y_'CE%'^MHT\<ZDE:J';Z7%>UA134-U714,U#-1#4+U6Q4<U#-134/
MU7Q4"U M1+4(U6)42U M1;4,U7)4*U"M1+4*U6I4:U;:\YO=CE_N9#WPB=@,
MO1LD-MVI(WEWZNO[6#L^S$"[5%%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4
M"U$M0K48U1)42U$M0[4<U0I4*U&M0K4:U1I4$^M9_Z!/]@0VF>]DD/&F<G4L
MKUQ]=4OKV5M%?;WY[/JA'8AE:OG\N']ULB^DR,?M&U)034,U'=4,5#-1S4(U
M&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:5!,=L:#W
MD@S%[::837_K^&NW&K5_=8P6LZ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H
M%J):A&HQJB6HEJ):AFHYJA6H5J):A6HUJC6H)@3+8;/];CA1-^%$VJUV\'X1
M.=,[E*"%K*BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6
MHUJ!:B6J5:A6HUJSTIX7FITIZHL=(X<_%9NE=\/$IDAU+"]2[==])L=Z1PJT
M3A75=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$
MM0K5:E1K5MIAW6?HT *;RW>#QZ9T=?GPJ(TBDATBKW6;R8?J'4M(34,U'=4,
M5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:
M5!,=2:!_<(&XW>"R*6T=3]B](6CQ*JIIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C
M6H!J(:I%J!:C6H)J*:IEJ):C6H%J):I5J%:C6H-J0K <-MOOAI--\>I8VIUV
M8+?9WIB"5K"BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE*VW[
MHW9%'>_]J#U%1\Y0+4>U M5*5*M0K4:U!M5$QZS>/X2<HF!UO"E8'7<6K$[_
M?OQLY'YP]V'P^6[V\5^+=G[[=)^:O=$#+5-%-0W5=%0S4,U$-0O5;%1S4,U%
M-0_5?%0+4"U<:=L3LCJ\V#<?1^C ,:HEJ):B6H9J.:H5J%:B6H5J-:HUJ"8Z
MIO+^R>,45:KC397JN*-*];#VD:]?U;H[1]#&55334$U'-0/53%2S4,U&-0?5
M7%3S4,U'M0#50E2+4"U&M0354E3+4"U'M0+52E2K4*U&M0;51$<8Z)]=3M'>
M.MZTMXXOV7TE:&LKJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:
M@FHIJF6HEJ-:@6HEJE6H5J-:@VI"L!PVV^^$D\FFUG724>MZ8.>(G.D;2E!-
M0S4=U0Q4,U'-0C4;U1Q4<U=:]V7['CJN?_"X 3INB&H1JL6HEJ!:BFH9JN6H
M5J!:B6H5JM6HUJ":Z)B=>X<)BML-$YMVU8FT(.U]TEZWMU\6-W>SQYVI5^W@
M2SN_:F>+Z<=V\,/T?C!=?^&?>R.&\O*7I?)VJ Q59?>7Y6_RE]$[/J ]JJAF
MH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%J):A6JU:C6
MH)KHF-?[QY!3]*A.U$T,D?>H]MVF*N=Z?[:!]JFBFHYJ!JJ9J&:AFHUJ#JJY
MJ.:AFH]JP4K;WEAZMO]N62$Z<(1J,:HEJ):B6H9J.:H5J%:B6H5J-:HUJ"8Z
MIO+^R>,4I:N33>GJ1%ZZ^NHVU<NWP^&K]\A[W*^JM5?M[>_M_-4MJ_*1>X<4
MM*$5U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)4*U"M
M1+4*U6I4:U!-= 2#_CGF%!VNDTV'Z_+AHT]M65UQ5#@A-0W5=%0S4,U$-0O5
M;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$M0K5:E1K4$T(EL-F
M^]UPLNEIG4BKUKZC"DT.]XXI:&,KJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:
MB&K12MNYL\?YWD6H&!TX0;44U3)4RU&M0+42U2I4JU&M0371,:GWSR"GJ&.=
M;.I8)_(ZUH,OFT'+5U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M6FD7
M6XEC^'9X^3QLH*6JJ):B6H9J.:H5J%:B6G70OZ,:';-!-=$Q*_</$:>H4YUL
MZE0G\CK5IU66J[L_VMETMOAQ,-]</3.=70^N;^ZO/DWG']OE4V;7-X]?_W'U
MV<:/@YL/@ZN;^=7#[?UB.KMJ[P>W[?Y//- &5E334$U'-0/53%2S4,U&-0?5
M7%3S4,U'M0#50E2+)B_[7-<?>+S\R .M8$6U%-4R5,M1K4"U$M4J5*M1K4$U
MT3']]T\KIZA@G6PJ6"?R"E;1;ZD%;5A%-0W5=%0S4,U$-0O5;%1S4,U%-0_5
M?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$M6JE[=Q):+(_Z-;HR VJB8Z9O'_P
M.$5_ZF33GSJ15J!1%]4L#]#_NOHTG7UL!^&'#^U\;VQ!NU=134,U'=4,5#-1
MS4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:5!,=
M2:%_L#E%]^K9IGOU[&L=&W65S1G:P8IJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKY
MJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6HEJ%:K5J-:@FA LA\WVN^%DT^5ZUM7E
M>NQ5-G*X=TQ!NUY134<U ]5,5+-6VMG61Z.3L;+ODU$;'=@Y?& 7'=A#-1_5
M E0+42U"M1C5$E1+42U#M1S5"E0K4:U"M1K5&E03'3-V_X!QBI;6,W43,.0M
MK9)EG:T[^NY;UOEV;]^SO?$#;7-%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+
M4"U$M0C58E1+4"U%M0S5<E0K4*U$M0K5:E1K4$UTI(+^(>84A:]GF\+7LQ&[
MA(.VN**:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQJB6HEJ):AFHY
MJA6H5J):A6HUJC6H)@3+8;/];CC9M+@N'YYH"4<*]XXII*:AFHYJ!JJ9J&:A
MFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5*^V0ZVTJ=.0:U1I4
M$QVS>O\0 G&[(633UGHF;VL]M"E-SO2.'&@W*ZKIJ&:@FHEJ%JK9J.:@FHMJ
M'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6KG2E.%6YG@L07N\Y]INWD";65&M
M0371,8'WSQNG:&8]VS2SGLF;6?O5E,BQWJD#[6=%-1W5#%0S4<U"-1O5'%1S
M4<U#-1_5 E0+42U"M1C5$E1+42U#M1S5"E0K5]IA'W20(]>HUJ":Z)C)^P>/
M4[2YGFW:7,_D;:[$?M:#.DKDKZ-W9D$[75%-1S4#U4Q4LU#-1C4'U5Q4\U#-
M1[4 U4)4BU M1K4$U5)4RU M1[4"U4I4JU"M1K4&U41'3.B?:D[1^GJV:7T]
M^UKNAFUP17M?44U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+42U"M1C5$E1+
M42U#M1S5"E0K4:U"M1K5&E03@N6PV7XWG&R:8<_DS;#?L<$5[7E%-0W5=%0S
M4,U$-6NE;5>%G$_4_1TE:(GKX0.[Z, >JOFH%J!:B&H1JL6HEJ!:BFH9JN6H
M5J!:B6H5JM6HUJ":Z)BQ^P>,4S2TGF\:6L^E)6NOK^E<O)W(J^>=Z>QA.O_[
M<57G?%\ D0_<-X"@FH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE
MJ):B6H9J.:H5J%:B6H5J-:HUJ"8Z<D'O&$-QNS%FT^5ZKJ"+..=H@RNJ::BF
MHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFJ9:B6HUJ!:B6J5:A6
MHUJ#:D*P'#;;[X83=1-..GI@#[Q 6,[T#B5HKRNJZ:AFH)J):A:JV:CFH)J+
M:AZJ^:@6H%J(:A&JQ:B6H%JZTIY?Z'KQ[;*3I_\HN\N3V5%'Y4<=5:#OMT2U
M"M5J5&M0373,SOW#Q"GZ6,\W?:SGTDJUGE?_RK'>D0)M8T4U'=4,5#-1S4(U
M&]4<5'-1S4,U']4"5 M1+4*U&-425$M7VLY5K-]F]^=! NU:1;5BS_LXG^Q]
M&R4Z<(5J-:HUJ"8ZING^J>(41:KGFR+5Y</3;P,YZ.)>^2OI'4E(34,U'=4,
M5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U&M4:
M5!,=0:%_KH&XW5RSZ68]G[#[0M".5E334$U'-0/53%2S4,U&-0?57%3S4,U'
MM0#50E2+4"U&M0354E3+4"U'M0+52E2K4*U&M0;5A& Y;+;?#2>;(M=S>9'K
M\1?WRN'>,04M=44U'=4,5#-1S5IIV]?8*L/+R[U7]Z(C.SU&=M&1/53S42U
MM1#5(E2+42U!M135,E3+4:U M1+5*E2K4:U!-=$Q9_>/&*>H;#W?5+:>'UG9
M>OYV*%_748?JQ=[H@7:SHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$
M:C&J):B6HEJ&:CFJ%:A6HEJ%:C6J-:@F.O) __ARBF[6\TTWZSG;S7J.=K.B
MFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:B
M6H5J-:HUJ"8$RV&S_6XXV72SGLN[60^^K!=M8D4U#=5T5#-0S5QI%UN+',.W
MP_.A[ H^"WT)-JHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:B6H5J
M-:HUJ"8Z)O/^V>,4M:T7F]K6"WEM:])>M[=?%C=WL\?](E?MX$L[OVIGB^G'
M=O##]'XP77_AG_L2B1SOFTA034,U'=4,5#-7VG8B>9X_T %M5'-0S44U#]5\
M5 M0+42U"-5B5$M0+46U#-5R5"M0K42U"M5J5&M0371,Z+WS!\7MYH]-W^J%
MM#*M9PN)'.N=-]"V55334<U -7.E'= *8*$#VZCFH)J+:AZJ^:@6H%J(:A&J
MQ:B6H%J*:AFJY:A6H%J):A6JU:C6H)KHF,C[YXY35*E>J)O<T5&E^EW[60_J
M)Y&_@MYA!6UA134=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M
M0[4<U0I4*U&M0K4:U1I4$QT!H7^>.46;Z\6FS?7B:Z\;M<'U NUS134-U714
M,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M1;4,U7)4*U"M1+4*U6I4
M:U!-");#9OO=<+(IA5T^E&\R.;:?1 [WCBFDIJ&:CFH&JIFH9JVT[9:0R7CO
M\I&-#NP</K"+#NRAFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5J%:A6HUJ#:J)
MCAF[?\" N-V L6EGO9 6K,E6<]1)UVK.Y=[@@?:WHIJ&:CJJ&:AFHIJ%:C:J
M.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ%:A6HEJ%:C6J-:@F.O) __AR
MBO[6BTU_Z\49NWB#MK:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J
M,:HEJ):B6H9J.:H5J%:B6H5J-:HUJ"8$RV&S_6XXV32_7G0TOQ[83B)G>H<2
MM,\5U714,U#-7&G/;S!^KDZ>7YF#5K6BFH-J+JIYJ.:C6H!J(:I%J!:C6H)J
M*:IEJ):C6H%J):I5J%:C6H-JHF,"[Y\W3E'5>K&I:KV0MJU];R,)6MR*:AJJ
MZ:AFH)JYTJ2-)&@;*ZHYJ.:BFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:B
M6H5J-:HUJ"8Z)O3^^>,4;:P7FS;6"WD;:\]&$K23%=4T5--1S4 U<Z4=U$B"
M-K&BFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEJ):C6H%J):I5J%:C6H-JHF,B
M[Y\[3M'$>KEI8KV4-[%^WQ[6@QI)Y*^@;UA!-0W5=%0S4,U$-0O5;%1S4,U%
M-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*U$M0K5:E1K4$UT!(3>>8;B=O/,
MIMGU\FN#&[6I]1+M=D4U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B
M5$M0+46U#-5R5"M0K42U"M5J5&M030B6PV;[W7"B;L*)O/[U^$82.=P[IJ"M
MKJBFHYJ!:B:J62MMNQAD=#[:VTB"#NP</K"+#NRAFH]J :J%J!:A6HQJ":JE
MJ):A6HYJ!:J5J%:A6HUJ#:J)CAF[?\ X11_KY::/]5):J?;Z:LZDJU_>F<X>
MIO._GWKF]P80M+D5U314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M
M0;44U3)4RU&M0+42U2I4JU&M0371D0OZQYA3-+=>;II;EP_119PQ&DY(34,U
M'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"M1K4*U
M&M4:5!."Y;#9?C><;%I?+SM:7P]L)I$SO4,)VN6*:CJJ&2MM^RK>X=OALR(1
M$QW30C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[4<U0I4*U&M0K4:U1I4
M$QVS=_^P<8J.ULM-1^NEM&;M.VM)Y'CO"((VMJ*:CFK&2I,4B9CH@!:JV:CF
MH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%J):A6JU:C6H)KHF-#[YX]3
MU+!>;FI8+^4UK/UJ2>18[[R!EK&BFHYJQDK;+A)1U/U-(B8ZLH5J-JHYJ.:B
MFH=J/JH%J!:B6H1J,:HEJ):B6H9J.:H5J%:B6H5J-:HUJ"8Z9O+^P>,4?:R7
MFS[62WD?*[.3];!^$K2\%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B
M5(M1+4&U%-4R5,M1K4"U$M4J5*M1K4$UT1$4^N>:4_2\7FYZ7B^_]KEA6UO1
MIE=4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"
MU4I4JU"M1K4&U81@.6RVWPDGRG#3!OOX6+[?Y-B&D@ZY;U)A.8WE=)8S6,YD
M.6O-;?>%G"M[5Z=L=FBGQ] N.[3'<C[+!2P7LES$<C'+)2R7LES&<CG+%2Q7
MLES%<C7+-2PGNN;RWN$#\YZE#V4K?4C[UV2+/AUE])M%G]%P?SI!>UY93F,Y
MG>4,EC-9SF(YF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.YG.4*EBM9KF*Y
MFN4:EA-=B>&(C'.*!EAEJ&YE'!5= %I[6')!NU]93F<Y@^5,EK-8SF8YA^5<
MEO-8SF>Y@.5"EHM8+F:YA.52ELM8+F>Y@N5*EJM8KF:YAN6$@#TN!SQ++J.M
MY-)1+GM@\4F'TS^QH&6Q+*>SG+'FE.'6BL=C_8GZO "%'=AB.9OE')9S6<YC
M.9_E I8+62YBN9CE$I9+62YCN9SE"I8K6:YBN9KE&I8375/[$6'D% 6QRG"\
M%4;&'1M5OJ<8I4/O'U%(3F,YG>6,-2=K1V&'M%C.9CF'Y5R6\UC.9[F Y4*6
MBU@N9KF$Y5*6RU@N9[F"Y4J6JUBN9KF&Y4375']$.(&\9^%DLA5.Y!6Q_5I3
M.K3^802MBF4YG>6,-7=0=0H[ML5R-LLY+.>RG,=R/LL%+!>R7,1R,<LE+)>R
M7,9R.<L5+%>R7,5R-<LU+">ZYO@C4LDIFF25X=E6*I%WR3*[:P^J5.EX*?TC
M#5H]RW(ZRQDL9[*<Q7(VRSDLY[*<QW(^RP4L%[)<Q'(QRR4LE[)<QG(YRQ4L
M5[)<Q7(URS4L)[HBQ!&AYQ3UM<KP?"OT?.VIX[;;HAVV+*>QG,YR!LN9+&>Q
MG,UR#LNY+.>QG,]R <N%+!>Q7,QR"<NE+)>Q7,YR!<N5+%>Q7,UR#<L) 7M<
M#GB67"ZVDHN\ ?=[JEC01EN6TUA.9SF#Y4R6L];<=A_*:*2^4L6"MM;V&-IE
MA_98SF>Y@.5"EHM8+F:YA.52ELM8+F>Y@N5*EJM8KF:YAN5$UUQ^1/HX14NM
M,KS<2A_2JKG7%XO.MA>+-DM$1OO[?%V[?[D_E*!-MBRGL9S.<@;+F2QGL9S-
M<@[+N2SGL9S/<@'+A2P7L5S,<@G+I2R7L5S.<@7+E2Q7L5S-<@W+B:Z@<$2T
M.4G'K;+5<:L,V24AA6VV13F-Y726,UC.9#F+Y6R6<UC.93F/Y7R6"U@N9+F(
MY6*62U@N9;F,Y7*6*UBN9+F*Y6J6:UA."-CC<L"SY++5CZMT].,>VL B=_HG
M%K;M%N7T-?>\,N7L>66*P0YLLIS%<C;+.2SG'GS2/'9@_^"! W;@D.4BEHM9
M+F&YE.4RELM9KF"YDN4JEJM9KF$YT34A'Q$A3E(_JZA;$4):$]?WTF2YUC](
ML.6S**>ON9UKB=>7$@]?9 FV6A;E+):S6<YA.9?E/);S62Y@N9#E(I:+62YA
MN93E,I;+6:Y@N9+E*I:K6:YA.=$UQQ^12DY2+:ML5<LJ'=6RW[/;Y+ KDN6O
MH'^284MI44YG.8/E3):S6,YF.8?E7);S6,YGN8#E0I:+6"YFN83E4I;+6"YG
MN8+E2I:K6*YFN8;E1%=R."+KG*2Y5MEJKET^9K>?C-GD0G(:R^DL9["<R7(6
MR]DLY["<RW(>R_DL%[!<R'(1R\4LE[!<RG(9R^4L5[!<R7(5R]4LU["<$+#'
MY8!GR66KUE:1U]I^QQ7)<KE_AF$K;E%.9SF#Y4R6L];<]J+99+QWS<QFAW9Z
M#.VR0WLLY[-<P'(ART4L%[-<PG(IRV4LE[-<P7(ERU4L5[-<PW*B:RX_(GV<
MI+Y6V:JO53KJ:P_>_,IVSZ*<QG(ZRQDL9[*<M>8Z]V[:[,#.P0.[[, >R_DL
M%[!<R'(1R\4LE[!<RG(9R^4L5[!<R7(5R]4LU["<Z)JUC\@9)VF,5;8:8Q5I
ML]MW[T5YMK[SXV!SJ\(?!U$[O[F['H2S5Z(+6SZ+<AK+Z2QGL)S)<A;+V2SG
ML)S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+Y2Q7L%S)<A7+U2S7L)SHBA1'A*"3
ME,\J6^6SR@6\286MG$4YC>5TEC-8SF0YB^5LEG-8SF4YC^5\E@M8+F2YB.5B
MEDM8+F6YC.5REBM8KF2YBN5JEFM83@C8XW+ L^2R55RKR(MK-Y^V/.Y,N6H'
M7]KYU3+"3#^V@Q^F]X/I^@O_W)]CV)9:E--83E]S%UNK&LJ+ZYS9ZEF4LUC.
M9CF'Y5R6\UC.9[F Y4*6BU@N9KF$Y5*6RU@N9[F"Y4J6JUBN9KF&Y4375']$
M.#E)]:RZ53VK2BOB_J^L+65_WNU--O*7UCO9H)S&<CK+&2QGLIS%<C;+.2SG
MLIS'<C[+!2P7LES$<C'+)2R7LES&<CG+%2Q7LES%<C7+-2PGNB)%_Q!$><]"
MT%:+K:JP:TLJVV:+<AK+Z2QGL)S)<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7
ML%S*<AG+Y2Q7L%S)<A7+U2S7L)P0L,?E@&?)1=U*+O+R7'_ZU\WMP^WVDM+=
MA\'B4RNY''KYU]/%X';Z]^#W=C!OK]OVMKT>_'FS^/1TX*Q=+ ^YNVK;Z_M'
M[*J=+Z8WLT'[7P\WB[^77_G0+L&/]_N#$=O.BW(:R^EK;GNQ:OAV_'RY"AW4
M9#F+Y6R6<UC.93F/Y7R6"U@N9+F(Y6*62U@N9;F,Y7*6*UBN9+F*Y6J6:UA.
M=*6'(_+.26IYU:U:7O7(6M[)V^'PJ)M RP?LGUC8%EZ4TUG.8#F3Y2R6LUG.
M83F7Y3R6\UDN8+F0Y2*6BUDN8;F4Y3*6RUFN8+F2Y2J6JUFN83G1%12.B#8G
M:>%5MUIXEX_91:@QFUQ(3F,YG>4,EC-9SF(YF^4<EG-9SF,YG^4"E@M9+F*Y
MF.42EDM9+F.YG.4*EBM9KF*YFN4:EA,"]K@<\"RY;+7PJO(6WH-[\.1._\3"
M=NZNN-WEG.&S/C6='=5@.9/E+):S6<YA.?>P?P >.ZI_V*@!.VK(<A'+Q8=]
M3Q)VU)3E,I;+6:Y@N9+E*I:K6:YA.=$UOQZ1"$[2C*MN->.J\F;<[[SD6:[W
MSPEL7^Z*DURCK+-#&BQGLIS%<C;+.2SGLIS'<C[+!2P7LES$<C'+)2R7LES&
M<CG+%2Q7LES%<C7+-2PGNJ;Z(\+)2>ITU:TZ755>IROZW2A(KO4/(VP#[HK;
MON.,,ASNO>6,SHYML)S)<A;+V2SGL)S+<A[+^2P7L%S(<A'+Q2R7L%S*<AG+
MY2Q7L%S)<A7+U2S7L)SHFN./2"4GZ;=5M_IM56D/W?][5_*P];DHIZTYZ:4W
M.CNHP7(FRUDL9[.<PW(NRWDLY[-<P'(ART4L%[-<PG(IRV4LE[-<P7(ERU4L
M5[-<PW*B*ST<D7=.THJK;K7BJO)6W.^ZDF?Y-/VOJT_3V3(EA8\Q9G^$89MS
M44YC.9WE#)8S6<YB.9OE')9S6<YC.9_E I8+62YBN9CE$I9+62YCN9SE"I8K
M6:YBN9KE&I837<GAB*QSDI+=T5;)[NAK@QUV:<^(;<9%.8WE=)8S6,YD.8OE
M;)9S6,YE.8_E?)8+6"YDN8CE8I9+6"YEN8SE<I8K6*YDN8KE:I9K6$X(V.-R
MP+/DLM6,.Y(VV+U/VB\/\ZM/T_OV6K(.M3_#L!VY**>QG,YR!LN9+&>MN>T]
M1Z-S9=^6(YL=VNDQM,L.[;&<SW(!RX4L%[%<S'()RZ4LE[%<SG(%RY4L5[%<
MS7(-RXFNN?R(]'&2=MN1NI4^Y.VV!U]8+'?Z9PVV=A;E=)8S6,YD.6O-R:\$
MM=E1G<-&==E1/9;S62Y@N9#E(I:+62YAN93E,I;+6:Y@N9+E*I:K6:YA.=$U
M7Q^1,$[2)SO:ZI,='=TGVW7[PY&R/XJP?;(HI[&<SG(&RYDL9[&<S7(.R[DL
MY[&<SW(!RX4L%[%<S'()RZ4LE[%<SG(%RY4L5[%<S7(-RXFNH'!$M#E)G^QH
MJT]V^9C==#)FDPO):2RGLYS!<B;+62QGLYS#<B[+>2SGLUS <B'+12P7LUS"
M<BG+92R7LUS!<B7+52Q7LUS#<D+ 'I<#GB67K3[9$=0G*W?Z)Q:V3W;%*<-G
MJPCJBTI9=&"#Y4R6LUC.9CF'Y=R#_PUX[,#^P0,'[, ART4L%Q_\;4G8@5.6
MRU@N9[F"Y4J6JUBN9KF&Y4377'M$.CA)M^QHJUMV=-)N6;G>/S.PW;*C [IE
MT2$-EC-9SF(YF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.YG.4*EBM9KF*Y
MFN4:EA-=4_T1X>0DW;*CK6[9$=HM*]?ZAQ&V6W;4IUL6'=M@.9/E+):S6<YA
M.9?E/);S62Y@N9#E(I:+62YAN93E,I;+6:Y@N9+E*I:K6:YA.=$UQQ^12D[2
M+3O:ZI8=_?_5+2M_N?UC#]LM.SJH6Q8=U& YD^4LEK-9SF$YE^4\EO-9+F"Y
MD.4BEHM9+F&YE.4RELM9KF"YDN4JEJM9KF$YT94>CL@[)^F6'6UURXZ.[I;M
MOJKGL&Y9^2OH'V'8;EF4TUG.8#F3Y2R6LUG.83F7Y3R6\UDN8+F0Y2*6BUDN
M8;F4Y3*6RUFN8+F2Y2J6JUFN83G1E1R.R#HGZ98=;W7+CN%NV3';+8MR&LOI
M+&>PG,ER%LO9+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR&<OE+%>P7,ER%<O5
M+->PG!"PQ^6 9\EEJUMV?+)N6;G</\.PW;(HI[.<P7(FRUEK;J?@=72VOUL6
M'=KI,;3+#NVQG,]R <N%+!>Q7,QR"<NE+)>Q7,YR!<N5+%>Q7,UR#<N)KKG\
MB/1QDF[9L;J5/J!N6;G3/VNPW;(HI[.<P7(FRUEKKO-B4)L=V#EX8)<=V&,Y
MG^4"E@M9+F*YF.42EDM9+F.YG.4*EBM9KF*YFN4:EA-=L_81.>,D#;/CK8;9
M\=$-LY-]]SGVI_.K3X\W.1[M3R-LO2S*:2RGLYS!<B;+62QGLYS#<B[+>2SG
MLUS <B'+12P7LUS"<BG+92R7LUS!<B7+52Q7LUS#<J(K)1R1:TY2+SO>JI==
M/F;WG8S9Y$)R&LOI+&>PG,ER%LO9+.>PG,MR'LOY+!>P7,AR$<O%+)>P7,IR
M&<OE+%>P7,ER%<O5+->PG!"PQ^6 9\EEJUYV+*^7_9Y])VSA+,II:VY[ X,Z
M&NVO:T&'-EC.9#F+Y6R6<UC.93F/Y7R6"U@N9+F(Y6*62U@N9;F,Y7*6*UBN
M9+F*Y6J6:UA.=$WW1P24DS3<CK<:;L?RAEOO[OY^<#<;M'\M;F8?'V[N/SU]
MPG+W87#=_OY*,&%;;5%.6W/;P>3\E5C"=MNBG,ER%LO9+.>PG,MR'LOY+!>P
M7,AR$<O%+)>P7,IR&<OE+%>P7,ER%<O5+->PG.B:Y(^()2?IMAUO==N.Y=VV
MJZTJZ;-]+ >4I<CA_NF$K;E%.9WE#)8S6<YB.9OE')9S6<YC.9_E I8+62YB
MN9CE$I9+62YCN9SE"I8K6:YBN9KE&I8378'@B ASDB+<\581[O@"WK3"-M6B
MG,9R.LL9+&>RG,5R-LLY+.>RG,=R/LL%+!>R7,1R,<LE+)>R7,9R.<L5+%>R
M7,5R-<LU+"<$['$YX%ERV:JT'<LK;7O>6$BN]<\M;#TMRNDL9["<R7+6FMMI
M*5'4R2L-*6SY;(^Q779LC^5\E@M8+F2YB.5BEDM8+F6YC.5REBM8KF2YBN5J
MEFM83G3-X$=DCI-4RTZVJF4GT@JXUQ9\SCHN7%;W)A+Y6+T3"<II+*>SG,%R
M)LM9+&>SG,-R+LMY+.>S7,!R(<M%+!>S7,)R*<ME+)>S7,%R)<M5+%>S7,-R
MHBLC]$\UE/<LU6S5SDX4=@UHPI;-HIS&<CK+&2QGLIS%<C;+.2SGLIS'<C[+
M!2P7LES$<C'+)2R7LES&<CG+%2Q7LES%<C7+-2PG!.QQ.>!9<E&WDHN\LO8[
M+ER6R_TS#%MBBW+ZFMM>IOBV2O%LF<)@QS99SF(YF^4<EG-9SF,YG^4"E@M9
M+F*YF.42EDM9+F.YG.4*EBM9KF*YFN4:EA-=\_T1">4D9;>3K;+;24?9[:&E
M^G*G?QYA:VQ13F<Y@^5,EK-8SF8YA^5<EO-8SF>Y@.5"EHM8+F:YA.52ELM8
M+F>Y@N5*EJM8KEYSSV\-<O;LSB -.Z[HFMF/R"(G*:B=;!74+A_+LDC/';-R
MK7\B(3F-Y726,UC.9#F+Y6R6<UC.93F/Y7R6"U@N9+F(Y6*62U@N9;F,Y7*6
M*UBN9+F*Y>HU=\BGZ0T[MNB:XX]()9#W-96\N__4M@MMNIB^__FVG7]L?VL_
M?[X?7#V&C,=!MKXZF+<?'D/+3T)]\^[%URWE)UO9\W5?^2G<]_5FZ8BGOWBW
M&??]SU^F'UM_.O]X,[L??&X_+%_#\.WY\L3-;SY^^O:'Q=V799!Z,_C];K&X
MNWUZ^*F=7K?SQR<L__[#W=UB_8?' ?Z\F__[Z7V^_S]02P,$%     @ J817
M5@)1\)DV @  ( 4  !D   !X;"]W;W)K<VAE971S+W-H965T.3$N>&ULK51-
MC]L@$/TKB$I5*[7!'_G2UK;D37:W.6P4)6WW4/5 ['&,%AL72++]]P7L6%DI
MJ?;0"S P[S%OAB$Z"OFL2@"-7BI>JQB76C<WA*BLA(JJ@6B@-B>%D!75QI0[
MHAH)-'>@BI/ \\:DHJS&2>3V5C*)Q%YS5L-*(K6O*BK_W (7QQC[^+2Q9KM2
MVPV21 W=P0;T]V8EC45ZEIQ54"LF:B2AB''JW\Q"Z^\<?C XJK,ULDJV0CQ;
M8Y''V+,! 8=,6P9JI@/,@'-+9,+XW7'B_DH+/%^?V.^==J-E2Q7,!']BN2YC
M/,4HAX+NN5Z+XU?H](PL7R:X<B,ZMKZ3,4;97FE1=6 30<7J=J8O71[. /[P
M"B#H ,%; 6$'<)DC;61.UIQJFD12')&TWH;-+EQN'-JH8;6MXD9+<\H,3B?W
MBV6ZG"V6#RA=K]/EP]WCW?+;!GU&3RX!D*/T -+4$VTTM>;:C$@4:%%KD* T
M^C '31E7'R.B34"6EF3=Y;?MY<&5R^>0#5#H?T*!%P07X+.WP_W7<&+2T.<B
MZ',1.+[P*M]6HSE3&1=J+P']3+=*2_/0?EV2UG(-+W/9YKM1#<T@QJ:[%,@#
MX.3].W_L?;DD]#^1O9(=]K+#?[$G?:5I5VEV*JTTM;XDO>7S/4=H_XE#X@V\
MR608D<.YJLM^H^FT]VL#)F?OU_X=CU3N6*T0A\( O<%DA)%L^[$UM&C<D]X*
M;1K$+4OSA8&T#N:\$$*?#-LE_:>8_ 502P,$%     @ J8175O(U97E6!
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M3X@H3(!^/^=</0_,&20_<W:_ E!+ P04    " "IA%=64$BUWTH%  #['
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MZ9_5K@-_;/I@R77CRON<?5WEWN?\1_.+57'YS?OW^T;,>U?GZ^H_;3D(D3E
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M"/**7#+C15 8@ZH12DU-A("Q"&C&BUI\=OH\T.+7TZ>!4?[61_IC'YYZT-.
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M3ID4$RS#0>4()J=E0V*X!&E23$S_83@W)H:6(YB-]08^K,$5EW IX7&IP\P
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M81 F0.\O.%>[B3F@;>OI/U!+ P04    " "IA%=6>$(_'8H"  !!!P  &@
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M'I@*D,]7E(JWA1H9B[\(WC]02P,$%     @ J8175G#% ;9-(@  QH8" !H
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M0S5/:?7LEOVI4;@_]:<Z[AQ>U\YA1ZM9J"903:*:0C7=\OH;[DX-Z \/GAJ
MKI!%-8=JGM+J&X.RMC5JJ6T=<6I F.B<4;2GA6H"U22J*5336ZVZ0QXT/PE&
M1[2HYE#-4UH]A&7[:A2^ M03/_T)JYUSB1:Q4$V@FD0UA6IZJU4__1F,SQ]_
M^(..:E'-H9JGM'HVRXK5*%RQ>L*'/VAQ"M5B5!.H)E%-H9K>:M4/?\Y?-L\U
M0(>TJ.90S5-:/9-E<VH4;J[\E/R6S6YGQ;O/]5N)[2YR_<YS>9M\FJ;1[<WZ
MA[OK*+;M0]'>$ZK%J"903:*:0C6]U:K[T%[O=+AG)XK6FU#-H9JGM'I@RWK3
M*%QO>O_VXYOHFSZQ18M.J!:CFD UB6H*U32J&52SJ.90S5-:+<OCL@TU/L4^
ML1VC/2A4BU%-H)I$-85J&M4,JEE4<ZCF*:T>V[(O-0[WI;J_CPV#G<.+MJ10
M3:":1#6%:GJKA=_'HD-:5'.HYBFMGLFR_#1NN2[3A_??-"L.\YT3BA:B4$V@
MFD0UA6H:U0RJ651SJ.8IK1[ELA U'G"S8K3@A&HQJ@E4DZBF4$VCFD$UBVH.
MU3REU6-;=J'&X2[*$S]Y#:N=$XRVEE!-H)I$-85J>JN%;C:)#FA1S:&:I[1Z
M+,M6TCC<2OIY,7\A?DLO;E?9ES02T^QS5GRP\SZ]R&ZR=+XJ+B_U]J;8ORZC
M9'[\%:?"PW;.+=ID0C6!:A+5%*II5#.H9E'-H9JGM'K$R\[3F+OBU!@M.J%:
MC&H"U22J*533J&90S:*:0S5/:?78EG6H<;@.9>;%O2J+O?)R<VSJ9IK,GT>?
MBVGT,EI/FK?G"[3-G]&*%*K%J":V6G56.9KLN9J#1(=5J*91S:":136':I[2
MZEDM:U+C<$WJ39JODG40Q>QFNOB:IL44^=C#S4?-IM'N%*K%J"903:*:0C6-
M:@;5+*HY5/.45H]Z6; :<W?:&Z-=*E2+44V@FD0UA6H:U0RJ651SJ.8IK1;;
M2=FEFOQQ=]H+#]TUYJ@6HYI -8EJ"M7TY/&=]IKE#71 BVH.U3REU;-;%JHF
M_T$WV@NO:^>PHUTM5!.H)E%-H9IN>?WUC[C#'KI"%M4<JGE*JV\,RB;7)-SD
MZI_VAM&[:;)WPAU>MG,XT9H6J@E4DZBF4$VCFD$UBVH.U3REU7-:UK0F7$UK
M@M:T4"U&-8%J$M44JFE4,ZAF4<VAFJ>T>FS+FM8D7-/:G?"[/=,WN5U=+_+-
MS+GE@Z:PVSG#:%$+U02J2513J*91S:":136':GZKU4Z+/CNM?Q99SV?9UYJ$
M^UIO:B?B)U^2;+HY$_]JD=^?EC]?OP=NBRK:S4*U&-4$JDE44ZBF4<V@FD4U
MAVI^JU6CVC\-1K7L74W"UYKZ^7;V*<VCQ5647%YFQ=PWF7YC<-%V%JK%D\>7
M4^KU1GOZ%P(=5^X;=[!O7(6.JU'-H)I%-8=JGM+JH2Q;59-PJZH,Y=XD7MVN
M;O/TOF75FD:T6H5J,:H)5).HIE!-3QZ7R'IG_?[X\15MT'$MJCE4\Y163VS9
MK9J$NU4/!WR?1^_355&)7,]_WW_X)=J<413]*WHH7SV<QO#VZBJ[2//[,Q;>
MKJ[7@?\I+7*_+(+OT^1R_>5U=K->N#B?86^XT<85JL6H)E!-HII"-8UJ!M4L
MJCE4\Y16WP"4C:L)U[B:H(TK5(M13:":1#6%:AK5#*I95'.HYBFM%MNSLG%U
M%FY<_7U[6<C[0L:^L+8 @\U=4_?MG=^$E^P:3%03J"913:&:1C6#:A;5'*IY
M2JL'LZQ3G;7467[W"?7Z/[OTO[NO8[V=[[W?07A-N^ZN42U&-8%J$M44JFE4
M,ZAF4<VAFJ>T^E:A[%6=<;<'/$-K5J@6HYI -8EJ"M4TJAE4LZCF4,U36CVV
M9<WJ+'Q[P/7^M3A-N&A%K_?$NTNQYT5A>N]QK2W7.ZT<X3Q].5C_4S^^^28\
M;N=4HBTJ5).HIE!-HYI!-8MJ#M4\I=536;:HSL(MJC]BBOWQ;K$W\&@O"]5B
M5!.H)E%-H9I&-8-J%M4<JGE*JV\5RN[6V8B;8J,=+52+44V@FD0UA6H:U0RJ
M651SJ.8IK1[;LL=U%NYQ=9YBCX^=8J,%+%03J"913:&:1C6#:A;5'*IY2JNG
MLBQRG86+7'_(%/LZ3_<?QT:K8*@6HYI -8EJ"M4TJAE4LZCF4,U36GV[4-;%
MSLZX239:\D*U&-4$JDE44ZBF4<V@FD4UAVJ>TNJQ+4M>9^'[%G:>9)\?.\E&
M.URH)E!-HII"-8UJ!M4LJCE4\Y162^5YV>$Z#U>PS+NWD5S<SHN)\?W$>EE.
MCFM7K3RZ\A$>L>L^%]5B5!.H)E%-H9I&-8-J%M4<JGE*JZ>[+(*=]["I\CG:
MU$*U&-4$JDE44ZBF4<V@FD4UAVJ>TNJQ+9M:Y^$K8'6=*H>YSM%%VUJH)K;:
M6>T]P:AQ^7=T2(5J&M4,JEE4<ZCF*:V>R+*$=1XN87W+-/E ;2,\8N?0HF4N
M5!.H)E%-H9I&-8-J%M4<JGE*JZ>[+'.=#[EI,MJV0K48U02J2513J*91S:":
M136':I[2ZK$MVU;GX2ME=9XFHXTK5(M136RUEFDR6J1"-8UJ!M4LJCE4\Y16
M3V19I#H/%ZGV3Y,?]3.>KW]T,;V]+.+Z\3J-WEQGZ=7CASWQQJ3A=>P<<[3"
MA6H"U22J*533J&90S:*:0S5/:?7M05GA.I]P$VNT885J,:H)5).HIE!-HYI!
M-8MJ#M4\I=5C6S:LSL,7Y&J_L$<8Z!Q6M%>%:J+EJ3I\"1.)KH="-8UJ!M4L
MJCE4\Y16#V;9H3H/=ZC,_,MB>KM^RYM_C59I/LOFF]WI\^@F7WS.DUETD6?K
MGV?)\RB[BBZR_.)VMEP5%YY=1K-T]7P]CYZO)]CYL@ "Z4:OL85J,:H)5).H
MIEI>"[W-EF=ON-$J%JI95'.HYBFM%N[>:=G%*KX&WCX?\R:X9:BN&6:YF.4$
MRTF64RRG6<ZPG&4YQW(>XQH1[U4BSC6R=A:68;23Q7*"Y23+*9;3+&=8SK*<
M8SF/<8T,]RL9#M>S-GOF]/)YM)BG+U;9++V_<W#;U>1;V.YQ1GM:+"=V7/4Z
MZX/S/3=MD.S BN4TRQF6LRSG6,YC7".I@TI2GU+;VC>A_K!:7/P:+;8?-QTU
MP4;[6RP7LYQ@.<ERBN4TRQF6LRSG6,YC7"/RPTKDN2[7SL(RC+:Y6$ZPG&0Y
MQ7*:Y0S+699S+.<QKI'A427#X6*7F1>]KF('O=SLEF\V%P&YGV2OOMZDSXMC
MU\5#]H<:K7FQ7,QR8L>%FU[LH(KE-,L9EK,LYUC.8UPCJ^-*5I'*UX&S)?8'
M&"UPL5S,<H+E),LIEM,L9UC.LIQC.8]QC:1/*DGGREP["\LP6N=B.<%RDN44
MRVF6,RQG6<ZQG,>X1H;/*AD.UY6^<6:-MKY8+F8YL>/:9M9HR8OE-,L9EK,L
MYUC.8UPCJ^>5K+:4O?;.K ^?*_&$0]AHSXOE8I83+"=93K&<9CG#<I;E',MY
MC*L'OU>I@?5.N8EVC^UYH5S,<H+E),LIEM,L9UC.LIQC.8]QC0Q7>EZ]\"T8
MVT^A:!&Z)Y=M=Z&<:'NZ J=1L&NB6$ZSG&$YRW*.Y3S&-5)::7+UPDVN?]/Y
M%"VKT3WJ;/,+Y03+2993;:^(_L$-D6;7Q+"<93G'<A[C&E&O5,%Z+56P;XUZ
M^EN:7V3+Y-,TW48]NEI,IXN[8C>_NDZ/WA:PO;&67_OPZSEFUT2PG&0Y]?3G
M2;-K8EC.LIQC.8]QC=Q7^F"]8%OE4.Z/COW\MKA_3'&!H?MJ]SKJR2JZRZ;3
M*$]GQ>UGTFGV.2NV"JO%YB)$K3WP\!IWWP*PK3.4$RPG64ZQG&8YPW*6Y=R.
MJS;\>_WAV?!\7/^0Q&,#-S8"E4)9KZ50UO%0^M%5E?"XW:/,=LU03K"<9#G%
M<IKE#,M9EG,LYS&ND?=**:TW!H^@LW4SE(M93K"<9#G%<IKE#,M9EG,LYS&N
MD>%*W:P7OOWC,4?0V9(9RL4L)]J>KN 1=+90AG*:Y0S+699S+.<QKI'22J&L
MUU8H^S<=06>K9RV_5?"H&5LS0SG)<HKE-,L9EK,LYUC.8UPCZI4^6N])%Q\C
MCJ0==]B,;:NA7,QR@N4DRRF6TRQG6,ZRG-MQM0MC]$:C\_ZCHV:_2P^M7^FA
M]9]R.;*?%_,7Y3$SL3OX_3Z]R&ZR]/XQ3[EL=\O:=,XWRL4L)UA.LIQB.<UR
MAN4LRSF6\QC7V I4FFQ]\(IE?;;3AG(QRPF6DRRG6$ZSG&$YRW*.Y3S&-3)<
MZ;GUVWIN^T[[^GR_2U]/N[=]EK89>'B4[NEF:VPH)W9<=9XV'.R]@!DZL&(Y
MS7*&Y2S+.9;S&-<(;J6UUG_*!<R.F8)W/QLLO"K=T\U>T SE!,M)EE,LIUG.
ML)QE.<=R'N,:FX!*@:T_!.??;+4,Y6*6$RPG64ZQG&8YPW*6Y1S+>8QK9+C2
M/^N'^V='?)8=%KHGEVV2H9QH>[I"GV6C:Z)83K.<83G+<H[E/,8U4EIIC?6?
M<BFS8R;;Q]T(_NT\W1]]MH"&<C'+"9:3+*=83K.<83G+<H[E/,8U-@>5 EH?
MO-Y9GZVBH5S,<H+E),LIEM,L9UC.LIQC.8]QC0Q7ZFG]<)&KZRWB6[SN.68O
M<89R8L>U7.(,'52QG&8YPW*6Y1S+>8QKQ+-2*>L_Y1)GW(S[X]UB?\K9*AG*
MQ2PG6$ZRG&(YS7*&Y2S+.9;S&%??' PJA;,!>.&S 5L70[F8Y03+2993+*=9
MSK"<93G'<A[C&AFNU,4&X2MY=9YQA[WN.68K8R@G=ES+C!L=5+&<9CG#<I;E
M',MYC&O$L]($&[1<W^JTWX_>SN;9I]ME5-;"WDV3^5$ED3#?/:UL!0SE!,M)
MEE,LIUG.L)QE.<=R'N,:L:[TQ 8#<.;,%KU0+F8YP7*2Y13+:98S+&=9SK&<
MQ[A&ABM%KT&PAO+ZI^2W;'8[VYT=F=RNKA=Y]L^TO9<=AKL'FFU]H9S8<=5>
M=O_L=&\Q&QU9L9QF.<-REN4<RWF,:X2UTN@:A"M*X7ET]_)U>+CN$6;K7R@G
M6$ZRG&(YS7*&Y2S+.9;S&->(>:42-@ O)#9@>UPH%[.<8#G)<HKE-,L9EK,L
MYUC.8UPCPY4>U^";+R06%KHGEVUOH9QH>[I"Y6MT313+:98S+&=9SK&<Q[A&
M2BM-K<%3[DQ97&=H?V+9GA;*Q2PGVIZZWFDHLFQ["^4TRQF6LRSG6,YC7".R
ME?;6(-S>^H;WP,>?'!%>A^Y!9ZM:*"=83K*<8CG-<H;E+,LYEO,85\_^L%+5
M&H)5K2%;U4*YF.4$RTF64RRG6<ZPG&4YQW(>XQH9KE2UAG!5*^QUSS%;U4(Y
ML>/J5:W!H/D9$SJJ8CG-<H;E+,LYEO,8U\AGI:LU_):N5L?Y]:%3(<+KT#W3
M;*$+Y03+2993+*=9SK"<93G'<A[C&MFO%+J&8*%KR!:Z4"YF.<%RDN44RVF6
M,RQG6<ZQG,>X1H8KA:YAN-#5?7[-]KA0+F8YL>-:Y]=LAPOE-,L9EK,LYUC.
M8UPCGY4.U_!WZW#MF5]?Y^G^(]CAM>B>:K;:A7*"Y23+*9;3+&=8SK*<8SF/
M<8WT5ZI=0[#:-62K72@7LYQ@.<ERBN4TRQF6LRSG6,YC7"/#E6K7,-Q5ZC[#
M9HM>*!>SG-AQK3-LMM2%<IKE#,M9EG,LYS&ND<]*J6O8<A_%X S[Z#M#A4?I
MGEJV[(5R@N4DRRF6TRQG6,ZRG&,YCW&-=%?Z7\-S< ;-]KA0+F8YP7*2Y13+
M:98S+&=9SK&<Q[AZAD>5'M<H?(_'(TZ." N=DXMR,<N)MJ<K='($NB:*Y33+
M&9:S+.=8SF-<(Z65IM8HW-3J/H\^OF ='KI[O-E2%\H)EI,LIUA.LYQA.<MR
MCN4\QC4B7RE_C?K<Y'K$EKA0+F8YP7*2Y13+:98S+&=9SK&<Q[A&ABLEKE'X
M[HV=#T^'O>XY9HM<*"=V7-OA:714Q7*:Y0S+699S+.<QKI'/2D%K%"YH$=/J
M0[WJ\-#=H\QVN5!.L)QD.<5RFN4,RUF6<RSG,:X1^4KG:S0"I]5L<POE8I83
M+"=93K&<9CG#<I;E',MYC&MDN-+<&H7OT]A]6LVVMU N9CFQXUJGU6PK"^4T
MRQF6LRSG6,YC7".?E5;6*-S*0J;5!^O4X<&[AYFM<*&<8#G)<HKE-,L9EK,L
MYUC.8UPC])6JU^@,G%BSA2Z4BUE.L)QD.<5RFN4,RUF6<RSG,:Z1X4JA:Q2^
MH%?WB35;ZD*YF.7$CFN=6+-E+933+&=8SK*<8SF/<?5\CBMEK7&X?1286#^/
MWJ>KXOO%/'J7+S[GR6P]J2[OHOKVZBJ[2//HA_EE]";-5TDVC]ZNKM<_$;.;
MZ>)KFBZ?KQ]^,;V]+#+_\3J-WEQGZ=4>HD-Q._S[=-X^H%S,<H+E),LIEM,L
M9UC.LIQC.8]QC>U(I4XV[G%S]3';#T.YF.4$RTF64RRG6<ZPG&4YQW(>XQH9
MKO3#QN&+@QU1W X+W9/+ML)03K"<9#G5]L<\7"O7[)H8EK,LYUC.8UPCI94&
MV#C< %-Y,E^EE\^CQ3Q]L<IF:93<)7G['=W";/?HLD4PE!,L)UE.[;CJ_>;.
M1H_O-J?9<0W+699S+.<QKA'42A5L_.0JV!_^UOKX<SG"OV3WS09;.D,YP7*2
MY13+:98S+&=9SK&<Q[C&QJ52.AN#I;,Q6SI#N9CE!,M)EE,LIUG.L)QE.<=R
M'N,:&:Z4SL9PZ2SL=<\Q6SI#.<%RDN74CNN=-CZZ:WYXI]F!#<M9EG,LYS&N
M$=%*[VS\Y-[9GW .?^C$D? OV7V[P?;;4$ZPG&0YQ7*:Y0S+699S+.<QKK%Q
MJ?3;QF"_;<SVVU N9CG!<I+E%,MIEC,L9UG.L9S'N$:&*_VV,=QO"WO=<\SV
MVU!.L)QD.;7CCIG#LQ4WE+,LYUC.8UP]HI-*Q6WRGUMQZW*62OC7[+SE0+F8
MY03+2993+*=9SK"<93G'<A[C&IN72O-M C;?)FSS#>5BEA,L)UE.L9QF.<-R
MEN4<RWF,:V2XTGR;A,M2G6?Q8:][CMD>',H)EI,LIW;<$;-X=&##<I;E',MY
MC+N/Z,GR.DU7<;)*7K^:I?GG]$TZG2[7N\_;^9HO<OOPTRA/KXH$?_=#_]G)
MHY_KWG>V5_S\I&1>O[I9!_FG)/^<S9?1-+U:DZ<O)Z-G]X'>?;-:W*Q?-<^B
M3XO5:C';?'F=)I=I7CQ@_?^O%HO5[IMB@+M%_NMFM5__/U!+ P04    " "I
MA%=6^\"!T?H#  #O%0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL
MQ5AM;^(X$/XK5FYUVI6VS0LO+3U  L)I]T-W*[+=^^PF UA-XIQMH/OOSW9"
M(-1DBV3UOD#LS#SV/./'##/<4?;,UP "O61ISD?.6HCBSG5YO(8,\VM:0"[?
M+"G+L)!#MG)YP0 GVBE+W<#S^FZ&2>Z,AWKN@8V'="-2DL,#0WR399C]FD)*
M=R/'=_83"[):"S7ACH<%7D$$XK%X8'+DUB@)R2#GA.:(P7+D3/R[T+]1#MKB
M)X$=/WI&*I0G2I_5X&LR<CRU(T@A%@H"RZ\MS"!-%9+<Q[\5J%.OJ1R/G_?H
M?^O@93!/F,.,IO^01*Q'SJV#$ECB32H6=/<%JH!Z"B^F*=>?:%?9>@Z*-US0
MK'*6.\A(7G[CEXJ((P>_?\8AJ!R"4X?N&8=.Y=!YJT.W<NAJ9LI0- \A%G@\
M9'2'F+*6:.I!DZF]9?@D5WF/!)-OB?03X^C+9#&_FDZB>8AFW^\?YM^BR8^O
MW[^A*Q251P'1)8K6F,&5XC=!,YK)0\>Q3MO\13T#^AB"P"3EGZ3?8Q2BCQ\^
MH0^(Y.B>I*DTY$-7R-VJ-=VXVMFTW%EP9F=^@.YI+M8<S?,$DB: *\.L8PWV
ML4Z#5L00XFO4\3^CP L"PX9F;W?W#>[AV]V]EF@Z=>8Z&J]S!D_E@>:0"XYP
MGJ XQ9R3)8G+Q,BD\:.DQ<=)@S)III242W;-2ZH[Z(X7.(:1(R\9#FP+SOC/
M/_R^]Y>)3IM@H26P!M7=FNIN&_HX.L.DB<$2J:>1U*6[E0>Y/W2WQ\28;&Z;
M-J'!QNO5-HTP>G48O=8P%I(8S.*U/B\);.6E7\@K7.P/A%&DK9"7G@B;8*$E
ML :5_9K*_ON+KV^3:IM@H26P!M4W-=4WUL17(O4;PCK1GL'$.Y&>P<0W*^^V
MCN&V/099UY!\]1FM( >&4WUH<")_SPD7#*O2IU6$K>B7G@R;8*$EL :K@YK5
MP?N+<&"3:IM@H26P!M6^=Z@3/6LRK*":"NJ>"-%H=/HK:# :=,U:](]*7K\]
M%$'C9T0+<;8P;?6_]!!810MMH36Y"P[<!>^ON6I-6WS;1 MMH37Y/A3Y?FMA
M>YGL.J\5U3M5W>]MPG:;9B"'$MIOKZ$7T:-9:ZUN%^?>)EIH"ZU)V:%<]WO_
M@]:L%O16T4);:$V^#S6]WUK'7J:U_NO_9T=58L6.R:ASJK;71@/OC-H.-;/?
M7C3_!"YDP8D*8(0FQ@#: 3KHE_RO:%+LK-WSXIQ;0BN)<H\Z81FPE>XH<IG-
M32[*1E$]6W<M)[I7=S(_5=U,W6$[P)2MT'O,5B3G*(6EA/2N;V3F6-E=+ >"
M%KK?]D2%H)E^7 -.@"D#^7Y)J=@/U )UCW?\'U!+ P04    " "IA%=6@33,
M0,X+  !$:   &@   'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&ULS5UK;]LX
M%OTKA'<P:+&-;;V=;A(@L3H[!2:3(&D[V(^*1=M"9<E#R4F[F!^_U".F*=%7
MHGNUF )-;(4\) \I\ASQ2KIX2=G7;$UI3KYMXB2['*WS?/M^,LD6:[H)LG&Z
MI0G_RS)EFR#G7]EJDFT9#<(RTR:>F-.I.]D$43*ZNBB/W;.KBW27QU%"[QG)
M=IM-P+[?T#A]N1P9H]<##]%JG1<')E<7VV!%'VG^>7O/^+?)'B6,-C3)HC0A
MC"XO1]?&>W]F%QG*%%\B^I(=?"9%4Y[2]&OQY6-X.9H6-:(Q7>0%1,!_/=,Y
MC>,"B=?CSQITM"^SR'CX^17]E[+QO#%/04;G:?Q'%.;KR]%L1$*Z#'9Q_I"^
M_$KK!CD%WB*-L_(G>:G33D=DL<OR=%-GYC781$GU._A6$W&0P72/9##K#&8C
M@V$?R6#5&:R^&>PZ0TGUI&I*R8,?Y,'5!4M?""M2<[3B0TEFF9LW/TJ*?G_,
M&?]KQ//E5X^_7C]\.+NY?OS@D_G=[?V'WQ^O/WV\^YV<D<<\77PE=]NB?S+R
MQJ=Y$,796_Z7SX\^>?/36_(3F9!L'3":D2@AGY,HS][Q@_SS;13'1;:+2<XK
M610U6=05NJDJ9!ZID&&2VS3)UQGYD(0TE $FO'7[)IJO3;PQ042?+L;$,MX1
M<VJ:B@K-^V<W%-G]_MFG0&NL?8=9)9Y]K,/*7DFK7E'1"V8OII'WV398T,L1
MGR<RRI[IZ.KG?QCN]%\J:C#!?"0PB39[3YM=HEM':+NE^3H-29#P_QF?Y.I1
MS6>>YR#>!>4<E"Y)UL6NC<DN)IB/!":QZ^S9=<!!^>';EL_C-)3X(W&TI.3-
M=QJP[*V*2QC3(F5.%6^G9O1/R"CQX>[Y</OQ\9S&?&S%4?Y=14 %8DQ+E&*%
M?KZ:CBUO=C%Y/FRN,IDS->5DOAIMYNV324WQ]DWQP*8\1-G7LR6CE$_K.>5#
M)R<LR*FJ.9ZJ E.CV1QULJG=:,X1-%/=G-F^.;-^/1-&SU%(^73P/:)QJ&I.
M!30[++_1DLX4/I1"JO_YOO[GX#QV=WQJ.L><FC#!?"0PB3!C*A3.%.SR&[J*
MDB1*5L4$GZ\IV5(6\;7@#=<IE7I1SDXUJGO0=[/S:?&O,0K@XG6YPD*3R3J0
M@P9(UK]9D!2G1Q<Y1HL<TU62 Q:G30X2FDR.*<@Q.R8/RA91UH,>LT7/F:&D
M!RQ0FQXD-)D>H4P-6)KRN35BG)R4$6Y(ES3J,Y"L-E/J@80J1;'09*:$&#5
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M*9N^2ME$A)TFI:XWLH*JXE'1 BPTG5\EY&U8R4/KW#J+8V&BY:VJSYF[7%7
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M 6Q[.K9M"+K,CW]F5 B:YI<+P#$P%2"?SRD5#PUUHE2>4?;_ %!+ P04
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M.D"]7S$F=QM]0?TO(O@'4$L#!!0    ( *F$5U8I#?4T9 ,  )L*   :
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M13-]=!M-9^[V,#1=BW X>FH3=VT&IC*W/4*&C9#A22%7R8\-DY#BQW=>2I&
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M(;V+,3*2U2A4+;0H[7#P(#2.&O8QP^D1I#' ]RLA]'YA#FCFT>@74$L#!!0
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M%\ZY[[A:P4A\8["6&\]$N_+ ^7<]N I'5DOO""((E(:@^+>""4211L)]_"A
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M970Q,3DN>&ULK9AM<]HX$,>_BL;7N6EGFF#9@"$'S*0AG<M,TV1">W=OA;V
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MV':UW%TK5?W@30:PSK&I;6#OW]=.LED()J*G2/T"L3WS9)YG[(EG?!#RF]H
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M9-%L%0,MMGG[\2RT:6;RQXUI4$%: [.^$D*_#NP+JI9W^B]02P,$%     @
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MPU(B O'/AE_Q.)8DL1__::"#74S9</_U$YW5!R\.YBXH^%46_RU:E/=G@]F
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M;Q_!MGU39NOZ"6!W65EF2?WRG@<+GLL-Q/?++"N?WL@ NP?AG?\/4$L#!!0
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MT@3VVP?V'ZUVT++&BBP$^YWFNIAY$P_E9(-KIM_$_H6T>B+#EPFF["_:M]C
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M\'9!S+VSC"'$-\AWKY#G>-X1AQXNA[M'X.'E<.=,-'Z3$M_P!2?X(LGB9_3
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MH\(\T;:.=2P4ET*RK 8K!1G)JS=^KO.P!W![)P!>#?". ?X)0*<&=-X+\&N
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M5J!:B6KB:<;OKM$=_[1&QU9^LQPVQ-LIJ*G\/NFN_.Y=HZMGV\M+?2^>0WO
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MEC-9SF(YF^4<EG-9SF,YG^4"E@M9+F*YF.42EDM9+F.YG.4*EBM93@C8@W.
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MX&+5L5SKY<$MFT?:/+"#=DKG, 9]GXXD]NP29<IB2!03"9$PZUCG[MF%ZYN
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M8IT,G6N'Q+"D1:KG8OL9JGBL@Y%(E?TEV\K6<TA4*"VR"HP>9(R7_W17Z7
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MO(_W:?DM>_J7;%?(JWG++"V:?]E3&VM-V')?E-FF'5PMP2;9'OZ/G]L-<3+
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M*"U"T;I9HHQ$O@!7 JBQ"*4%4)J TD(H+4+1NA>Q*&/1,?>1O5P)S(#1%ZY
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MT$I/6B96Q2S8)F%W$-]^D/)'YCS?\(6X&!2_(KG(GL1@]NLO./!^MQ$("<:
MP QR_89<WX7>D&MC;)<YJC++7]&G68B)/QT^[3-A"?)I*XA9@CPR;H*,RD=-
MY2-GY?=G\[/JE+C=BDQ)=!<MI&T43I1CYQT2C &!&>P%#7M!'Z(*(,F%!&-
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M(E+!EG4"GW1_#Z.?A><KM;#A2_HA=S&/2-E9U'($NPHD5\/(=N,Y'  NKDX
MDA&0_ M8G #,1\ \&!TJ"[:^,F1Y:G1/C,]V;'X2SB;(.#=<^5O<H'&[W.$P
M?V %B)2BH_(+M!QAMP,L/@%;"7!7B4> R\_U7ICHX&\8=25/=2=3W4G@N3C!
M<U.6NE/(54TVR%3%3&7)<ULQ!/*ZVJ'OLT( 6:E.@F&^9=Z.V?Q<I;-G-6/M
MCP^U26S0^E!ZX/;H<?R_C6067Y[%<_+Z"+( \W;LU.C!S?M7]\A,S94E K9.
M;W;^Q761&3IY"%"WX58+C:ZUPK1QCQ^,3W#[6ZUQ'_C^FGXG^1]02P,$%
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M,([="&!N!V&((? TX@CF #Q@2!B:]^#>^RC8O*>"YG^8HS]02P,$%     @
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M_%F@8%D RZ+%\F9!-)OX0W?!A^S>G;B!QUGTP/DB4@ [ +#3&"#[,(\5R"Z
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M!T(-ZJT*US;JGIJL!@K/AAK4FQ6N@U:II@8*3X<:U-L5 &B9K5107'V NOP
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M2_]D*>IN?@)02P$"% ,4    " "IA%=6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *F$5U;>\4,O
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( *F$5U:97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ J8175J%HFR'I!P  SC
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M965T-2YX;6Q02P$"% ,4    " "IA%=6?<'^294$  !0$0  &
M    @(&9(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MJ8175BW^-B':"@  -FT  !@              ("!9"@  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *F$5U8UHG-T? H  - R   8
M          " @70S  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "IA%=6NP5@)74$  !<"@  &               @($F/@  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ J8175HZ ?1ZL*@  >X8
M !D              ("!T4(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "IA%=6*+7I *<)  #N%@  &0              @(&T;0
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *F$5U9=*J.#
M[ 4  /P/   9              " @9)W  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ J8175ABE2?CG#0  I"H  !D
M ("!M7T  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "I
MA%=6M<95 W "  !2!0  &0              @('3BP  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *F$5U9)\N"/'0,  ,<&   9
M          " @7J.  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#
M%     @ J8175B"3:CLR(   HX<  !D              ("!SI$  'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "IA%=6/*2ES> "   V
M!@  &0              @($WL@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+ 0(4 Q0    ( *F$5U:^O^(3Z"   &>(   9              " @4ZU
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ J8175A$6
M:=)#$P  ]#T  !D              ("!;=8  'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6Q02P$"% ,4    " "IA%=6GD^D=UL$  #2"@  &0
M    @('GZ0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M *F$5U8E<RT98Q@  /%E   9              " @7GN  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ J8175B6J'K"X P  C@@  !D
M             ("!$P<! 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "IA%=6.<8%S\D"  "'!@  &0              @($""P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *F$5U;,D9N\"@0
M $T)   9              " @0(. 0!X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ J8175N/?^$-G%0  =4(  !D              ("!
M0Q(! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "IA%=6
M+K_UDR$$  !,"@  &0              @('A)P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( *F$5U;))>Y9B0(  +8%   9
M      " @3DL 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ J8175B@CMXIS)@  L8<  !D              ("!^2X! 'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "IA%=696Q( P4(   V%0
M&0              @(&C50$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( *F$5U8=7$&Z8 L  *<=   9              " @=]= 0!X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ J8175E#\$TG
M-@  Z;T  !D              ("!=FD! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "IA%=6E]QO@<P%   3#@  &0
M@(%MH $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( *F$
M5U9 0J):^P4  #\4   9              " @7"F 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ J8175KC-^W^* @  ;04  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( *F$5U9=\3BJU D   LC   9
M  " @8[" 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MJ8175BS+4V9^!   /0P  !D              ("!F<P! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "IA%=6S1SY[44&   [%0  &0
M            @(%.T0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( *F$5U9LPH28L0(  -<%   9              " @<K7 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ J8175G:C-">* @
MMP4  !D              ("!LMH! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "IA%=6-Y6@8]\"   ?!@  &0              @(%S
MW0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *F$5U;U
M.!O5C0<  (H5   9              " @8G@ 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ J8175KI?7[?9 @  :08  !D
M     ("!3>@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F$5U:B4T^22@0  #D0   9              "
M@0#_ 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ J817
M5H;MBP 6!   ]@T  !D              ("!@0," 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " "IA%=6:90LX\L#  "F%0  &0
M        @('.!P( >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( *F$5U81<J^_L 0  )$A   9              " @= + @!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ J8175CJMHP>N!0  H1\
M !D              ("!MQ " 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " "IA%=6>F(E<D(%  #6'@  &0              @(&<%@(
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( *F$5U9&.TI3
M70(  +('   9              " @14< @!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ J8175N+JN"V+ @  H@8  !D
M ("!J1X" 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "I
MA%=62[KLN74"  "^!0  &0              @(%K(0( >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( *F$5U;WU,\CF (  *8%   9
M          " @1<D @!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#
M%     @ J8175L]SMDID @  Z 0  !D              ("!YB8" 'AL+W=O
M<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "IA%=6 E":C+P#  !U
M%0  &0              @(&!*0( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM
M;%!+ 0(4 Q0    ( *F$5U;(<(B5)P<  )P[   9              " @70M
M @!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ J8175H7B
M!C,I!   AA(  !D              ("!TC0" 'AL+W=O<FMS:&5E=',O<VAE
M970V-"YX;6Q02P$"% ,4    " "IA%=6'?P)B!8'  #0-@  &0
M    @($R.0( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M *F$5U9]TN14! 4  * <   9              " @7]  @!X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ J8175GC*E$$F!0  DRD  !D
M             ("!ND4" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    " "IA%=65PW/0E #  "."P  &0              @($72P( >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( *F$5U8OQ@1+, ,
M "P)   9              " @9Y. @!X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ J8175KBK#"B! @  9 4  !D              ("!
M!5(" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " "IA%=6
M@G^I-#$#  "="P  &0              @(&]5 ( >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( *F$5U8R.$I'$@,  %P'   9
M      " @258 @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ J8175OG1NVL5 P  >@H  !D              ("!;EL" 'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " "IA%=6S_$(TXX$  !*$@
M&0              @(&Z7@( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( *F$5U8 \3).B0(  &,&   9              " @7]C @!X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ J8175A6AWSB0
M @  V@8  !D              ("!/V8" 'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    " "IA%=6<F%K^"\$  #K%@  &0
M@($&:0( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( *F$
M5U;$.H!VC@(  *(&   9              " @6QM @!X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ J8175IR83DPX!@  '24  !D
M         ("!,7 " 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M    " "IA%=64,INZNPB  "MO ( &0              @(&@=@( >&PO=V]R
M:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( *F$5U8GJL(6S@(  '\)
M   9              " @<.9 @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL
M4$L! A0#%     @ J8175A#5E&AI"P  ;H@  !D              ("!R)P"
M 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " "IA%=6^AL3
MWS(#  !X"0  &0              @(%HJ ( >&PO=V]R:W-H965T<R]S:&5E
M=#@S+GAM;%!+ 0(4 Q0    ( *F$5U9_Q-+Q7A4  "YA 0 9
M  " @=&K @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @
MJ8175G ]!*TI!   G!<  !D              ("!9L$" 'AL+W=O<FMS:&5E
M=',O<VAE970X-2YX;6Q02P$"% ,4    " "IA%=6Q<HMBPL0  #^! $ &0
M            @('&Q0( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4
M Q0    ( *F$5U;Q(?41F0D  *5X   9              " @0C6 @!X;"]W
M;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ J8175NJ&C!*7'0
MK<X! !D              ("!V-\" 'AL+W=O<FMS:&5E=',O<VAE970X."YX
M;6Q02P$"% ,4    " "IA%=6,DE  &(6  !7L $ &0              @(&F
M_0( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( *F$5U;Q
MH82@2S@  (4J!0 9              " @3\4 P!X;"]W;W)K<VAE971S+W-H
M965T.3 N>&UL4$L! A0#%     @ J8175@)1\)DV @  ( 4  !D
M     ("!P4P# 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *F$5U902+7?2@4  /L<   9              "
M@0=C P!X;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ J817
M5HGISC'/"0  '$\  !D              ("!B&@# 'AL+W=O<FMS:&5E=',O
M<VAE970Y-RYX;6Q02P$"% ,4    " "IA%=6A[9S7A\#  #*"P  &0
M        @(&.<@, >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0
M   ( *F$5U:H@1(NM@,  ,D/   9              " @>1U P!X;"]W;W)K
M<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @ J8175N[P:.=<!0  >"$
M !H              ("!T7D# 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL
M4$L! A0#%     @ J8175NKL[Z J!   !1D  !H              ("!97\#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ J8175IKB
MC0T!$0  _?   !H              ("!QX,# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#(N>&UL4$L! A0#%     @ J8175HSDIR$Y P  YPL  !H
M     ("! )4# 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%
M  @ J8175O-3VO:; @  X@<  !H              ("!<9@# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @ J8175GA"/QV* @  00<
M !H              ("!1)L# 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL
M4$L! A0#%     @ J8175J*V1SU1 P  XPD  !H              ("!!IX#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ J8175FQ\
M&D I P  +@P  !H              ("!CZ$# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#<N>&UL4$L! A0#%     @ J8175G#% ;9-(@  QH8" !H
M     ("!\*0# 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%
M  @ J8175OO @='Z P  [Q4  !H              ("!=<<# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#DN>&UL4$L! A0#%     @ J8175H$TS$#."P  1&@
M !H              ("!I\L# 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL
M4$L! A0#%     @ J8175@[JO@2H"0  -4X  !H              ("!K=<#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%     @ J8175LR!
MOB7" P  KQ0  !H              ("!C>$# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,3(N>&UL4$L! A0#%     @ J8175J8(:-_) @  [ @  !H
M     ("!A^4# 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%
M  @ J8175CLJBH'8 @  40@  !H              ("!B.@# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,30N>&UL4$L! A0#%     @ J8175BD-]31D P  FPH
M !H              ("!F.L# 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL
M4$L! A0#%     @ J8175K#SDI T!   YA,  !H              ("!-.\#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,38N>&UL4$L! A0#%     @ J8175N60
M]HK2 P  R0\  !H              ("!H/,# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,3<N>&UL4$L! A0#%     @ J8175G!7_Q#?!   61(  !H
M     ("!JO<# 'AL+W=O<FMS:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%
M  @ J8175EVC8E&2!   5!$  !H              ("!P?P# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3DN>&UL4$L! A0#%     @ J8175EF!$B_  P  _@X
M !H              ("!BP$$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL
M4$L! A0#%     @ J8175AOBU (,"P  %&\  !H              ("!@P4$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,C$N>&UL4$L! A0#%     @ J8175I9F
M$9A)!   G1P  !H              ("!QQ $ 'AL+W=O<FMS:&5E=',O<VAE
M970Q,C(N>&UL4$L! A0#%     @ J8175C3>BAZ- P  / L  !H
M     ("!2!4$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C,N>&UL4$L! A0#%
M  @ J8175A=2@#QK P  ] H  !H              ("!#1D$ 'AL+W=O<FMS
M:&5E=',O<VAE970Q,C0N>&UL4$L! A0#%     @ J8175D\'-3:7 P  0Q
M !H              ("!L!P$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C4N>&UL
M4$L! A0#%     @ J8175M6&RA&Y @  ;@<  !H              ("!?R $
M 'AL+W=O<FMS:&5E=',O<VAE970Q,C8N>&UL4$L! A0#%     @ J8175DX$
MJ]H6,P  IX($ !H              ("!<",$ 'AL+W=O<FMS:&5E=',O<VAE
M970Q,C<N>&UL4$L! A0#%     @ J8175@0Z4F)" P  $PT  !H
M     ("!OE8$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C@N>&UL4$L! A0#%
M  @ J8175@\-Y+C% @  AP@  !H              ("!.%H$ 'AL+W=O<FMS
M:&5E=',O<VAE970Q,CDN>&UL4$L! A0#%     @ J8175K$C9EV;"@  )6\
M !H              ("!-5T$ 'AL+W=O<FMS:&5E=',O<VAE970Q,S N>&UL
M4$L! A0#%     @ J8175E9+:;%^!   \1T  !H              ("!"&@$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,S$N>&UL4$L! A0#%     @ J8175@&\
M ;E&#   %H$  !H              ("!OFP$ 'AL+W=O<FMS:&5E=',O<VAE
M970Q,S(N>&UL4$L! A0#%     @ J8175H)42K9>!@  -#4  !H
M     ("!/'D$ 'AL+W=O<FMS:&5E=',O<VAE970Q,S,N>&UL4$L! A0#%
M  @ J8175N,H^]/-!   S2$  !H              ("!TG\$ 'AL+W=O<FMS
M:&5E=',O<VAE970Q,S0N>&UL4$L! A0#%     @ J8175NVCE)T[ P  K@X
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M;',O+G)E;'-02P$"% ,4    " "IA%=6:A)-528)  ":60  #P
M    @ '4C@0 >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ J8175H/U682N
M P  NT\  !H              ( !)Y@$ 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ J8175F ;QJK, @  *TP  !,
M ( !#9P$ %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     )  D #,)P  "I\$
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1048</ContextCount>
  <ElementCount>637</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>287</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>24</UnitCount>
  <MyReports>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - AUDIT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/AUDITINFORMATION</Role>
      <ShortName>AUDIT INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LEASES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INCOMETAXES</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LOSSPERSHARE</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails</Role>
      <ShortName>INVENTORIES - Summary of Inventories, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Exchange Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails</Role>
      <ShortName>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>0000105 - Disclosure - LEASES - Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails</Role>
      <ShortName>LEASES - Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>0000106 - Disclosure - LEASES - Lease Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails</Role>
      <ShortName>LEASES - Lease Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>0000107 - Disclosure - LEASES - Lease Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails</Role>
      <ShortName>LEASES - Lease Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>0000108 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>0000109 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>0000110 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>0000111 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>0000112 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>0000113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>0000114 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>0000115 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>0000116 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>0000117 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Benefit from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>0000118 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>0000119 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>0000120 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>0000121 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>0000122 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails</Role>
      <ShortName>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>0000123 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>0000124 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>0000125 - Disclosure - LOSS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>0000126 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>0000127 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>0000128 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>0000129 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>0000130 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>0000131 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails</Role>
      <ShortName>SEGMENT INFORMATION - Capital Expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>0000132 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenues by Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>0000133 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographic Information, Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>0000134 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>0000135 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="bhc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - bhc-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - bhc-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: bhc:RevenuePerformanceObligationPaymentTerms, us-gaap:DebtInstrumentBasisSpreadOnVariableRate1, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod -  bhc-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="bhc-20221231.htm">bhc-20221231.htm</File>
    <File>bhc-20221231.xsd</File>
    <File>bhc-20221231_cal.xml</File>
    <File>bhc-20221231_def.xml</File>
    <File>bhc-20221231_lab.xml</File>
    <File>bhc-20221231_pre.xml</File>
    <File>exhibit2112022ye.htm</File>
    <File>exhibit2312022ye.htm</File>
    <File>exhibit3112022ye.htm</File>
    <File>exhibit3122022ye.htm</File>
    <File>exhibit3212022ye.htm</File>
    <File>exhibit3222022ye.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bhc-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2458">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>157
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 54,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 2458,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 1048,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 1170,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 20,
    "http://www.bauschhealth.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 25
   },
   "keyCustom": 141,
   "keyStandard": 496,
   "memberCustom": 168,
   "memberStandard": 110,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i1ae85f66dff14f5ab462f41c6f9548d4_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7def2285ac5140d38d1f9ffcf8a7126e_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7def2285ac5140d38d1f9ffcf8a7126e_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i02ae9ff0984e482c8f536551e5df3d8f_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7ec9432798a24a7081587f93c9df9218_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails",
     "shortName": "LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - LEASES - Narrative (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.bauschhealth.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000105 - Disclosure - LEASES - Lease Expenses (Details)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails",
     "shortName": "LEASES - Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000106 - Disclosure - LEASES - Lease Additional Information (Details)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails",
     "shortName": "LEASES - Lease Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000107 - Disclosure - LEASES - Lease Future Payments (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
     "shortName": "LEASES - Lease Future Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i2a6f01dc7e7849e1afb697e1681e7989_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000108 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i2f724b3f1785466b94b544893b47c1bb_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000109 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "if00b7cd8fe45432a9a85664c569eeb15_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000110 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id9b4ed96b070474b85b3598fd9c8445a_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i4af86b76b9ca457884f8cb258191be0c_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000111 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
     "shortName": "SHARE-BASED COMPENSATION - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ifbec3c0a1bba48549a90598d57c50657_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000112 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0e2ee13540d244e58ee59a9ca76630cb_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibdc8cd56812542429247ba8cba9a093a_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000114 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000115 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE, NET - Schedule of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000116 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
     "shortName": "OTHER EXPENSE, NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ib3c97c4ec64941ccb13c8842880f03f3_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000117 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000118 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000119 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000120 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id8dabfb23996479799c6a595815ba441_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000121 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id57f6448d77d4f498fcb2c7411041826_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000122 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
     "shortName": "INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id57f6448d77d4f498fcb2c7411041826_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000123 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000124 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000125 - Disclosure - LOSS PER SHARE - Narrative (Details)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
     "shortName": "LOSS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia4c4201e54a54c6f98adb0ed00e5bb30_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000126 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LegalSettlementsAndRelatedFees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000127 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
     "shortName": "LEGAL PROCEEDINGS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i20c9837df7684cbbb933fd9a731877c7_D20230201-20230223",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000128 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a7459d4547245ad9a36ea070c5f5ec3_D20220701-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000129 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000130 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "menuCat": "Details",
     "order": "130",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibbe5ab36687744168cda9b1f6f33e3fb_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000131 - Disclosure - SEGMENT INFORMATION - Capital Expenditures (Details)",
     "menuCat": "Details",
     "order": "131",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
     "shortName": "SEGMENT INFORMATION - Capital Expenditures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000132 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "menuCat": "Details",
     "order": "132",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
     "shortName": "SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000133 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "menuCat": "Details",
     "order": "133",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ie5509eedbfcd4499ab1122c8107d4239_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000134 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "menuCat": "Details",
     "order": "134",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
     "shortName": "SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia6353361e06042eabedeb74c21af8174_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000135 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "menuCat": "Details",
     "order": "135",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia6353361e06042eabedeb74c21af8174_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - FINANCING ARRANGEMENTS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - AUDIT INFORMATION",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.bauschhealth.com/role/AUDITINFORMATION",
     "shortName": "AUDIT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.bauschhealth.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - RESEARCH AND DEVELOPMENT",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - OTHER EXPENSE, NET",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARE",
     "shortName": "LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - LEGAL PROCEEDINGS",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "31",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.bauschhealth.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables",
     "shortName": "LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibb85da3e8b8943f38dca2d158d722362_I20220601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "if2d6a84c806e4b3f9c86f2c09ce06dd3_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id400ed351375491ab5e78bb9bcc861dc_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id1f1ef720adb45eb9d4ae7e6ff2c2e04_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "iba264d87eb1844f383743044281eca57_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "bhc:CashDiscountsAndAllowancesSettlementPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i3d9a436ca4734f6f94506b064f541daf_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i3d9a436ca4734f6f94506b064f541daf_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7f28cdba1c984df9bb56e87ea0c43627_D20210331-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "iab2851d6501645e39f0bde92ff897991_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ide1f360554f7411582424cb25e12139f_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "if6a4d57c84474ffbaacd60d50549e40e_D20211101-20211130",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i681759bbcf4146c19403440ab8bc7434_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i681759bbcf4146c19403440ab8bc7434_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id964973a928249758deda08b15dea7a2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "id964973a928249758deda08b15dea7a2_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i352ec3a38f244bdbafd755de208aa067_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i352ec3a38f244bdbafd755de208aa067_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "iab2851d6501645e39f0bde92ff897991_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "iab2851d6501645e39f0bde92ff897991_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "iab2851d6501645e39f0bde92ff897991_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ife4532439f68449aa15050571c32b49c_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i06acf7af14454dbf98480ff0d59fda6a_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i6298df68baef4a31a4dfad39a62b592c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i6298df68baef4a31a4dfad39a62b592c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia08ca18a2f12467bae0a8b8c719d3561_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i301added27ee4e56a32e9279750f97a2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i301added27ee4e56a32e9279750f97a2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails",
     "shortName": "INVENTORIES - Summary of Inventories, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "bhc:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0a1a172f25a841aeaa5ee92611763bda_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ia072a195239645fa87f61a77ca261bca_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LegalSettlementsAndRelatedFees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:AccruedProductRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ifb29815fc9674a7c99be25fdb001b3a9_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i4538c7b5b4ca4fdeab03c2bf4233e8d9_D20220601-20220601",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i8438d9428d694b1b806321debd8fbf57_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "icc4a098d6f0545d9a3df6e94e3949b54_D20220510-20220510",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
     "shortName": "FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i8e844fc59da8465586a93905777c04be_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:ExtinguishmentOfDebtThirdPartyFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ifdadcd473052481b9f108756b569bcf5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i8bb07bff0ebd439fb019a10f099085be_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i3cb3d1e5412446dc811ba962259a01d4_I20180601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i71bde11f22654ef58395cb62e46066e8_I20170331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "if254b82a71434782ad56911693096e5f_D20200526-20200526",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:PaymentForDebtAmortizationPrepaymentCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ica54d07af4a0484896e86ce0129c4df1_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i44dfd00931ad42be812dd2a8053ffa52_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7ce272f013fa44ac973752d5610d84eb_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i7ce272f013fa44ac973752d5610d84eb_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "icd7fe17c8c254fd4932b34fd4fa8868a_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "ibe44ed9726cb4d82a254bf78be905577_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i1915c72a7a63442e8bdd8f3e9c6725a2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20221231.htm",
      "contextRef": "i0c2bc4540e1f4f9d8a2273b518f2239a_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - bhc-20221231.htm",
     "menuCat": "Cover",
     "order": "136",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - bhc-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 287,
   "tag": {
    "bhc_A1261229BCLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1261229 B.C. Ltd.",
        "label": "1261229 B.C. Ltd. [Member]",
        "terseLabel": "1261229 B.C. Ltd."
       }
      }
     },
     "localname": "A1261229BCLtdMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A1375209BCLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1375209 B.C. Ltd.",
        "label": "1375209 B.C. Ltd. [Member]",
        "terseLabel": "Intermediate Holdco"
       }
      }
     },
     "localname": "A1375209BCLtdMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2022OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Omnibus Incentive Plan",
        "label": "2022 Omnibus Incentive Plan [Member]",
        "terseLabel": "2022 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "A2022OmnibusIncentivePlanMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2022OmnibusIncentivePlanRetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Omnibus Incentive Plan, Retention Program",
        "label": "2022 Omnibus Incentive Plan, Retention Program [Member]",
        "terseLabel": "2022 Omnibus Incentive Plan, Retention Program"
       }
      }
     },
     "localname": "A2022OmnibusIncentivePlanRetentionProgramMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.00SeniorNotesDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "5.00% Senior Notes Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Unsecured Notes Due January 2028"
       }
      }
     },
     "localname": "A5.00SeniorNotesDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.25SeniorNotesDueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "5.25% Senior Notes Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Unsecured Notes Due January 2030"
       }
      }
     },
     "localname": "A5.25SeniorNotesDueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.375SeniorNotesdueMarch2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.375% Senior Notes due March 2020 [Member]",
        "label": "5.375% Senior Notes due March 2020 [Member]",
        "terseLabel": "5.375% Senior Notes Due March 2020"
       }
      }
     },
     "localname": "A5.375SeniorNotesdueMarch2020Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.50SeniorNotesdueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "5.50% Senior Notes due March 2023 [Member]",
        "terseLabel": "5.50% Senior Unsecured Notes Due March 2023"
       }
      }
     },
     "localname": "A5.50SeniorNotesdueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.875SeniorNotesdueMay2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023 [Member]",
        "label": "5.875% Senior Notes due May 2023 [Member]",
        "terseLabel": "5.875% Senior Unsecured Notes Due May 2023"
       }
      }
     },
     "localname": "A5.875SeniorNotesdueMay2023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A6.125SeniorNotesdueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "6.125% Senior Notes due April 2025 [Member]",
        "terseLabel": "6.125% Senior Unsecured Notes due April 2025"
       }
      }
     },
     "localname": "A6.125SeniorNotesdueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.00SeniorUnsecuredNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "label": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "terseLabel": "7.00% Senior Unsecured Notes Due 2028"
       }
      }
     },
     "localname": "A7.00SeniorUnsecuredNotesDue2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.25SeniorUnsecuredNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "label": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "terseLabel": "7.25% Senior Unsecured Notes Due 2029"
       }
      }
     },
     "localname": "A7.25SeniorUnsecuredNotesDue2029Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A8.50SeniorNotesDueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "8.50% Senior Notes Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Unsecured Notes Due January 2027"
       }
      }
     },
     "localname": "A8.50SeniorNotesDueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Unsecured Notes Due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.25SeniorNotesDueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "9.25% Senior Notes Due April 2026 [Member]",
        "terseLabel": "9.25% Senior Unsecured Notes Due April 2026"
       }
      }
     },
     "localname": "A9.25SeniorNotesDueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ACertainInternationalBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Certain International Business [Member]",
        "label": "A Certain International Business [Member]",
        "terseLabel": "A Certain International Business"
       }
      }
     },
     "localname": "ACertainInternationalBusinessMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "label": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "terseLabel": "Retrospective effect of application of new accounting standard"
       }
      }
     },
     "localname": "AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccumulatedLossesAvailableForFederalPurposes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to accumulated losses available for federal and provincial purposes.",
        "label": "Accumulated Losses Available for Federal Purposes",
        "terseLabel": "Accumulated losses available for federal and provincial purposes"
       }
      }
     },
     "localname": "AccumulatedLossesAvailableForFederalPurposes",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquiredInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.",
        "label": "Acquired in Process Research and Development [Member]",
        "verboseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "label": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "terseLabel": "Summary of other operating lease information"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseInformationLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivables and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine And Venezuela",
        "label": "Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine And Venezuela [Member]",
        "terseLabel": "Argentina, Belarus, Brazil, Greece, Russia, Serbia, South Africa, Turkey, Ukraine and Venezuela"
       }
      }
     },
     "localname": "ArgentinaBelarusBrazilGreeceRussiaSerbiaSouthAfricaTurkeyUkraineAndVenezuelaMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetAcquisitionAndBusinessCombinationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition And Business Combination",
        "label": "Asset Acquisition And Business Combination [Axis]",
        "terseLabel": "Asset Acquisition And Business Combination [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAndBusinessCombinationAxis",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AssetAcquisitionAndBusinessCombinationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition And Business Combination [Domain]",
        "label": "Asset Acquisition And Business Combination [Domain]",
        "terseLabel": "Asset Acquisition And Business Combination [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionAndBusinessCombinationDomain",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetAcquisitionAndBusinessCombinationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition And Business Combination",
        "label": "Asset Acquisition And Business Combination [Line Items]",
        "terseLabel": "Asset Acquisition And Business Combination [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionAndBusinessCombinationLineItems",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AssetAcquisitionAndBusinessCombinationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition And Business Combination",
        "label": "Asset Acquisition And Business Combination [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionAndBusinessCombinationTable",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Licensing Agreements, And Divestiture Disclosure",
        "label": "Asset Acquisition, Licensing Agreements, And Divestiture Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AssetAcquisitionLicensingAgreementsAndDivestitureDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AssetImpairmentChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges",
        "label": "Asset Impairment Charges [Member]",
        "terseLabel": "Asset Impairments"
       }
      }
     },
     "localname": "AssetImpairmentChargesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Summary of right-of-use assets and right-of-use liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Lessee [Abstract]",
        "label": "Assets, Lessee [Abstract]",
        "terseLabel": "Right-of-use assets included in:"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "bhc_AurobindoPharmaLimitedLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurobindo Pharma Limited Litigation",
        "label": "Aurobindo Pharma Limited Litigation [Member]",
        "terseLabel": "Aurobindo Pharma Limited Litigation"
       }
      }
     },
     "localname": "AurobindoPharmaLimitedLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Base Rate Factor, SOFR"
       }
      }
     },
     "localname": "BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CaliforniaProposition65RelatedMatterLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Proposition 65 Related Matter Litigation",
        "label": "California Proposition 65 Related Matter Litigation [Member]",
        "terseLabel": "California Proposition 65 Related Matter Litigation"
       }
      }
     },
     "localname": "CaliforniaProposition65RelatedMatterLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capital expenditures, depreciation and amortization by segment.",
        "label": "Capital Expenditure and Depreciation and Amortization [Abstract]",
        "terseLabel": "Capital expenditures:"
       }
      }
     },
     "localname": "CapitalExpenditureAndDepreciationAndAmortizationAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CashDiscountsAndAllowancesSettlementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Discounts And Allowances, Settlement Period",
        "label": "Cash Discounts And Allowances, Settlement Period",
        "terseLabel": "Settlement period for cash discounts and allowances"
       }
      }
     },
     "localname": "CashDiscountsAndAllowancesSettlementPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_CertainEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Employees",
        "label": "Certain Employees [Member]",
        "terseLabel": "Certain Employees"
       }
      }
     },
     "localname": "CertainEmployeesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Executive Officers And Other Members Of Leadership",
        "label": "Certain Executive Officers And Other Members Of Leadership [Member]",
        "terseLabel": "Certain Executive Officers and Other Members of Leadership"
       }
      }
     },
     "localname": "CertainExecutiveOfficersAndOtherMembersOfLeadershipMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CollaborativeAgreementMilestonePaymentsAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.",
        "label": "Collaborative Agreement Milestone Payments, Aggregate",
        "terseLabel": "Milestone payments in terms of collaboration and license agreements, aggregate"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePaymentsAggregate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_ConcentrationRiskPercentageofNetTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Percentage of Net Trade Receivables",
        "label": "Concentration Risk, Percentage of Net Trade Receivables",
        "terseLabel": "Percentage of net trade receivables accounted for by largest wholesale customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentageofNetTradeReceivables",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_CrossCurrencyFinalSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross Currency, Final Settlement",
        "label": "Cross Currency, Final Settlement [Member]",
        "terseLabel": "Cross-currency swaps, final settlement"
       }
      }
     },
     "localname": "CrossCurrencyFinalSettlementMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "label": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "terseLabel": "Variable rate, if rate not ascertainable (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "label": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "terseLabel": "Credit spread adjustment (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "label": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "terseLabel": "Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings"
       }
      }
     },
     "localname": "DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Remaining mandatory quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "terseLabel": "Remaining quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage due to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "label": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "terseLabel": "Reduction of outstanding principal"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefaultJudgementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Default Judgement",
        "label": "Default Judgement [Member]",
        "terseLabel": "Default Judgement"
       }
      }
     },
     "localname": "DefaultJudgementMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Debt Discounts And Deferred Financing Costs",
        "label": "Deferred Tax Assets, Debt Discounts And Deferred Financing Costs",
        "terseLabel": "Debt discounts and deferred financing costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsDebtDiscountsAndDeferredFinancingCosts",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Prepaid Expenses",
        "label": "Deferred Tax Assets, Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsPrepaidExpenses",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on scientific research and experimental development pool, of the entity.",
        "label": "Deferred Tax Assets, Scientific Research and Experimental Development Pool",
        "terseLabel": "Scientific Research and Experimental Development pool"
       }
      }
     },
     "localname": "DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxLossCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on tax loss carryforwards available to the entity.",
        "label": "Deferred Tax Assets, Tax Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxLossCarryforwards",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.",
        "label": "Deferred Tax Liabilities, Basis Difference of Convertible Notes",
        "verboseLabel": "Plant, equipment and technology"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "terseLabel": "Threshold percentage for amortization of net actuarial gains and losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "label": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "terseLabel": "Benefit accrual, interest percentage earned on cash balance"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanEmployerContributionMaximumAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "label": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "terseLabel": "Employer contribution maximum age"
       }
      }
     },
     "localname": "DefinedBenefitPlanEmployerContributionMaximumAge",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "label": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "terseLabel": "Future benefit payments period"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "terseLabel": "Number of defined benefit plans amended"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "terseLabel": "Number of defined benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberofDefinedBenefitPlans",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanPercentageAllocationofFund": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Percentage Allocation of Fund",
        "label": "Defined Benefit Plan, Percentage Allocation of Fund",
        "terseLabel": "Percentage allocation of fund"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageAllocationofFund",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products",
        "verboseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DivestituresOfNoncoreProductsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures of Non-core Products [Policy Text Block]",
        "label": "Divestitures Of Non-core Products [Policy Text Block]",
        "terseLabel": "Divestitures of Products"
       }
      }
     },
     "localname": "DivestituresOfNoncoreProductsPolicyTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "negatedTerseLabel": "Adjustments to tax attributes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.",
        "label": "Emerging Markets [Member]",
        "verboseLabel": "Emerging markets"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "verboseLabel": "Stock options, Time-based RSUs, Performance-based RSUs"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EquipmentOnOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment On Operating Lease",
        "label": "Equipment On Operating Lease [Member]",
        "terseLabel": "Equipment on operating lease"
       }
      }
     },
     "localname": "EquipmentOnOperatingLeaseMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EuropeInterbankOfferedRateEURIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe Interbank Offered Rate (EURIBOR)",
        "label": "Europe Interbank Offered Rate (EURIBOR) [Member]",
        "terseLabel": "EURIBOR"
       }
      }
     },
     "localname": "EuropeInterbankOfferedRateEURIBORMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExchangeOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer",
        "label": "Exchange Offer [Member]",
        "terseLabel": "Exchange Offer"
       }
      }
     },
     "localname": "ExchangeOfferMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer",
        "label": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer [Member]",
        "terseLabel": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officer, Excluding The Chief Executive Officer",
        "label": "Executive Officer, Excluding The Chief Executive Officer [Member]",
        "terseLabel": "Executive Officer, Excluding The Chief Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExtinguishmentOfDebtThirdPartyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment Of Debt, Third Party Fees",
        "label": "Extinguishment Of Debt, Third Party Fees",
        "terseLabel": "Third party fees"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtThirdPartyFees",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EyenoviaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eyenovia, Inc.",
        "label": "Eyenovia, Inc. [Member]",
        "terseLabel": "Eyenovia, Inc."
       }
      }
     },
     "localname": "EyenoviaIncMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments",
        "label": "Fair Value Adjustments [Member]",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "FairValueAdjustmentsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag",
        "label": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag",
        "terseLabel": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ForeignCountryStateAndLocalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.",
        "label": "Foreign Country State and Local [Member]",
        "terseLabel": "Canadian Federal and Provincial"
       }
      }
     },
     "localname": "ForeignCountryStateAndLocalMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ForeignCurrencyTransactionAndOtherGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Transaction And Other Gain (Loss), Before Tax",
        "label": "Foreign Currency Transaction And Other Gain (Loss), Before Tax",
        "negatedLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionAndOtherGainLossBeforeTax",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GainContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Defendants",
        "label": "Gain Contingency, Number Of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberOfDefendants",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyNumberOfProceedings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Proceedings",
        "label": "Gain Contingency, Number Of Proceedings",
        "terseLabel": "Number of proceedings"
       }
      }
     },
     "localname": "GainContingencyNumberOfProceedings",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Stay Of Approval, Period",
        "label": "Gain Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "GainContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related To Litigation Settlement, Gross",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedTerseLabel": "Additions to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedTerseLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Transfers Related To Sale of Business Unit",
        "label": "Goodwill, Transfers Related To Sale of Business Unit",
        "terseLabel": "Assets held for sale reclassified to goodwill"
       }
      }
     },
     "localname": "GoodwillTransfersRelatedToSaleOfBusinessUnit",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_IPOAndOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO And Over-Allotment Option",
        "label": "IPO And Over-Allotment Option [Member]",
        "terseLabel": "IPO and Over-Allotment Option"
       }
      }
     },
     "localname": "IPOAndOverAllotmentOptionMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_IPOFoundersGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Founders Grants",
        "label": "IPO Founders Grants [Member]",
        "terseLabel": "IPO Founders Grants"
       }
      }
     },
     "localname": "IPOFoundersGrantsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag",
        "label": "Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag",
        "terseLabel": "Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "label": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "terseLabel": "Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)"
       }
      }
     },
     "localname": "IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.",
        "label": "Income Tax Reconciliation Change in Operating Losses Valuation Allowance",
        "negatedTerseLabel": "Change in valuation allowance related to foreign tax credits and NOLs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationDeferredIntercompanyProfit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.",
        "label": "Income Tax Reconciliation Deferred Intercompany Profit",
        "negatedTerseLabel": "Tax benefit on intra-entity transfers"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDeferredIntercompanyProfit",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.",
        "label": "Income Tax Reconciliation, Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationUncertainTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information relating to income taxes.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Liabilities, Current",
        "label": "Increase (Decrease) In Accrued Liabilities, Current",
        "negatedTerseLabel": "Decrease in accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesCurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current",
        "label": "Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current",
        "negatedTerseLabel": "Decrease in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investigation By The U.S. Attorney\u2019s Office For The District of Massachusetts-OraPharma Litigation",
        "label": "Investigation By The U.S. Attorney\u2019s Office For The District of Massachusetts-OraPharma Litigation [Member]",
        "terseLabel": "Investigation by the U.S. Attorney\u2019s Office for the District of Massachusetts-OraPharma Litigation"
       }
      }
     },
     "localname": "InvestigationByTheUSAttorneysOfficeForTheDistrictOfMassachusettsOraPharmaLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InvestmentGradeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Grade [Member]",
        "label": "Investment Grade [Member]",
        "terseLabel": "Investment grade"
       }
      }
     },
     "localname": "InvestmentGradeMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LegalSettlementsAndRelatedFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Settlements And Related Fees",
        "label": "Legal Settlements And Related Fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "LegalSettlementsAndRelatedFees",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee [Abstract]",
        "label": "Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease liabilities included in:"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Incremental credit facility borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationSettlementNumberOfObjectorsAppeals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number of Objectors' Appeals",
        "label": "Litigation Settlement, Number of Objectors' Appeals",
        "terseLabel": "Settlement, escrow fund included in restricted cash, number of objectors' appeals"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfObjectorsAppeals",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of additional suits filed, but not served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "terseLabel": "Stay of approval, motion to extend, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period One",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period One",
        "terseLabel": "Stay of approval, motion to extend, period one"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriodOne",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period Two",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period Two",
        "terseLabel": "Stay of approval, motion to extend, period two"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriodTwo",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of the approval period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsLupinANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsSlaybackANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.",
        "label": "Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents",
        "terseLabel": "Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)"
       }
      }
     },
     "localname": "MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.",
        "label": "Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities",
        "terseLabel": "Minimum period to classify uncertain tax position liabilities as long term liabilities"
       }
      }
     },
     "localname": "MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe Pharma Corporation"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NeurologyAndOtherReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurology And Other Reporting Unit",
        "label": "Neurology And Other Reporting Unit [Member]",
        "terseLabel": "Neurology and Other Reporting Unit"
       }
      }
     },
     "localname": "NeurologyAndOtherReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonExecutiveEligibleRecipientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Executive Eligible Recipients",
        "label": "Non-Executive Eligible Recipients [Member]",
        "terseLabel": "Non-Executive Eligible Recipients"
       }
      }
     },
     "localname": "NonExecutiveEligibleRecipientsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.DevelopedMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Developed Markets [Member]",
        "label": "Non-U.S. Developed Markets [Member]",
        "terseLabel": "Worldwide developed markets"
       }
      }
     },
     "localname": "NonU.S.DevelopedMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.OtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Other Assets [Member]",
        "label": "Non-U.S. Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "NonU.S.OtherAssetsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NoncashCumulativeForeignCurrencyTranslationLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Cumulative Foreign Currency Translation Loss",
        "label": "Noncash Cumulative Foreign Currency Translation Loss",
        "terseLabel": "Noncash cumulative foreign currency translation loss"
       }
      }
     },
     "localname": "NoncashCumulativeForeignCurrencyTranslationLoss",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_NorwichPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwich Pharmaceuticals Inc. Litigation",
        "label": "Norwich Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Norwich Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "NorwichPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NovaliqGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novaliq GmbH [Member]",
        "label": "Novaliq GmbH [Member]",
        "terseLabel": "Novaliq GmbH"
       }
      }
     },
     "localname": "NovaliqGmbHMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NumberOfLargestWholesaleCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of largest wholesale customers.",
        "label": "Number of Largest Wholesale Customers",
        "terseLabel": "Number of largest wholesale customers"
       }
      }
     },
     "localname": "NumberOfLargestWholesaleCustomers",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014, Retention RSU Grant",
        "label": "Omnibus Incentive Plan 2014, Retention RSU Grant [Member]",
        "terseLabel": "2014 Plan, Retention RSU Grant"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014RetentionRSUGrantMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "terseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherAssetsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Fixed Income Securities [Member]",
        "label": "Other Assets, Fixed Income Securities [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "terseLabel": "Foreign currency impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "negatedTerseLabel": "Amortization or settlement recognition of net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherEquipmentAndLeaseholdImprovementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other equipment and leasehold improvements.",
        "label": "Other Equipment and Leasehold Improvement [Member]",
        "terseLabel": "Other equipment and leasehold improvements"
       }
      }
     },
     "localname": "OtherEquipmentAndLeaseholdImprovementMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense), Net",
        "label": "Other Income (Expense), Net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNet",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other",
        "verboseLabel": "Out-licensed technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paragon Bio Teck Inc. Asset Acquisition And Total Titanium Inc. Business Combination",
        "label": "Paragon Bio Teck Inc. Asset Acquisition And Total Titanium Inc. Business Combination [Member]",
        "terseLabel": "Paragon Bio Teck Inc. Asset Acquisition and Total Titanium Inc. Business Combination"
       }
      }
     },
     "localname": "ParagonBioTeckIncAssetAcquisitionAndTotalTitaniumIncBusinessCombinationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships",
        "verboseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PastDuePeriodForAccountsReceivableToBeNegligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the past due period for which accounts receivables are negligible.",
        "label": "Past Due Period for Accounts Receivable to be Negligible",
        "terseLabel": "Past due period for receivables to be negligible (less than)"
       }
      }
     },
     "localname": "PastDuePeriodForAccountsReceivableToBeNegligible",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "negatedTerseLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentForDebtAmortizationPrepaymentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Debt Amortization Prepayment Cost",
        "label": "Payment For Debt Amortization Prepayment Cost",
        "terseLabel": "Repayment, outstanding debt"
       }
      }
     },
     "localname": "PaymentForDebtAmortizationPrepaymentCost",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities",
        "label": "Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities",
        "negatedLabel": "Third party fees paid in connection with the Exchange Offer"
       }
      }
     },
     "localname": "PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted",
        "label": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]",
        "terseLabel": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted"
       }
      }
     },
     "localname": "PendingLitigationAgreedStipulationsOfDismissalSubmittedMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "label": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "label": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PeriodReceivableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time the accounts receivable has been outstanding.",
        "label": "Period Receivable Outstanding",
        "terseLabel": "Period net trade receivable balance outstanding (more than)"
       }
      }
     },
     "localname": "PeriodReceivableOutstanding",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals, Ltd. Litigation",
        "label": "Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals, Ltd. Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to pooled scientific research and experimental development.",
        "label": "Pooled Scientific Research and Experimental Development Expenditures [Member]",
        "terseLabel": "Pooled Scientific Research and Experimental Development"
       }
      }
     },
     "localname": "PooledScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PreserVisionAREDSPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PreserVision\u00ae AREDS Patent Litigation",
        "label": "PreserVision\u00ae AREDS Patent Litigation [Member]",
        "terseLabel": "PreserVision\u00ae AREDS Patent Litigation"
       }
      }
     },
     "localname": "PreserVisionAREDSPatentLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Initial Public Offering, Net Of Costs, Related Party",
        "label": "Proceeds From Issuance Initial Public Offering, Net Of Costs, Related Party",
        "terseLabel": "Proceeds from B+L initial public offering, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands",
        "verboseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions Litigation",
        "label": "RICO Class Actions Litigation [Member]",
        "terseLabel": "RICO Class Actions Litigation"
       }
      }
     },
     "localname": "RICOClassActionsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, change in discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rates"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure",
        "label": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedTerseLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag",
        "label": "Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag",
        "terseLabel": "Restructuring Incurred Cost, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due February 2027",
        "label": "Revolving Credit Facility Due February 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due February 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "2023 Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due May 2027",
        "label": "Revolving Credit Facility Due May 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due May 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "terseLabel": "Charged to Benefit from income taxes"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SOFRCDORAndEURIBORRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR and EURIBOR Rates",
        "label": "SOFR, CDOR and EURIBOR Rates [Member]",
        "terseLabel": "SOFR, CDOR and EURIBOR Rates"
       }
      }
     },
     "localname": "SOFRCDORAndEURIBORRatesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDOREURIBORAndSONIARatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR, EURIBOR and SONIA Rates",
        "label": "SOFR, CDOR, EURIBOR and SONIA Rates [Member]",
        "terseLabel": "SOFR, CDOR, EURIBOR and SONIA Rates"
       }
      }
     },
     "localname": "SOFRCDOREURIBORAndSONIARatesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "label": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfAdditionalSharesAvailableForIssuance",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SaleOfStockOverAllotmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Over-Allotment, Term",
        "label": "Sale of Stock, Over-Allotment, Term",
        "terseLabel": "Underwriters option to purchase additional shares, term"
       }
      }
     },
     "localname": "SaleOfStockOverAllotmentTerm",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_SalixReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Reporting Unit",
        "label": "Salix Reporting Unit [Member]",
        "terseLabel": "Salix Reporting Unit"
       }
      }
     },
     "localname": "SalixReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix",
        "verboseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Schedule of Commitments [Line Items]",
        "terseLabel": "Other commitments"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsLineItems",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to commitments of the entity during the reporting period.",
        "label": "Schedule of Commitments [Table]",
        "terseLabel": "Schedule of Commitments [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsTable",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.",
        "label": "Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.",
        "label": "Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to calculate the fair values of performance-based RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "label": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "terseLabel": "Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition"
       }
      }
     },
     "localname": "ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SellingGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The allocation (or location) of expense to (in) selling, general and administrative expense.",
        "label": "Selling General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes4.502023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, 2023 [Member]",
        "label": "Senior Notes, 4.50%, 2023 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes euro-denominated debt Due May 2023"
       }
      }
     },
     "localname": "SeniorNotes4.502023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.00% Senior Notes due 2029",
        "verboseLabel": "5.00% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Notes due 2028",
        "verboseLabel": "5.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.25% Senior Notes due 2031",
        "verboseLabel": "5.25% Senior Notes Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Notes due 2030",
        "verboseLabel": "5.25% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes550DueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "Senior Notes, 5.50%, Due March 2023 [Member]",
        "verboseLabel": "5.50% Senior Notes Due March 2023"
       }
      }
     },
     "localname": "SeniorNotes550DueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.25% Senior Notes due 2029",
        "verboseLabel": "6.25% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.00% Senior Notes due 2028",
        "verboseLabel": "7.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "7.00% Senior Notes Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.25% Senior Notes due 2029",
        "verboseLabel": "7.25% Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Notes due 2027",
        "verboseLabel": "8.50% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes due 2025",
        "verboseLabel": "9.00% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "terseLabel": "9.25% Senior Notes due 2026",
        "verboseLabel": "9.250% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 11.00% Notes, First Lien, Due September 2028",
        "label": "Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]",
        "terseLabel": "11.00% First Lien Senior Notes Due September 2028"
       }
      }
     },
     "localname": "SeniorSecured1100NotesFirstLienDueSeptember2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 14.00% Notes, Second Lien, Due October 2030",
        "label": "Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]",
        "terseLabel": "14.00% Second Lien Senior Notes2 Due October 2030"
       }
      }
     },
     "localname": "SeniorSecured1400NotesSecondLienDueOctober2030Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.500% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.750% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "Senior Secured 6.125% Notes Due February 2027",
        "verboseLabel": "6.125% Senior Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028",
        "label": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]",
        "terseLabel": "9.00% Intermediate Holdco Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "label": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "terseLabel": "6.50% Senior Notes Due March 2022"
       }
      }
     },
     "localname": "SeniorSecuredNotes6.50PercentDueMarch2022Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "label": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "terseLabel": "7.000 % Senior Notes Due March 2024"
       }
      }
     },
     "localname": "SeniorSecuredNotes7.00PercentDueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorUnsecuredNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2023 [Member]",
        "label": "Senior Unsecured Notes Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Notes due 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2023Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Equity Instruments Other Than Options, Number Of Shares Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Equity Instruments Other Than Options, Number Of Shares Vesting",
        "terseLabel": "Involuntary termination program criteria, if circumstances met, number of shares that will vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetEquityInstrumentsOtherThanOptionsNumberOfSharesVesting",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Options, Number Of Shares Eligible To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Options, Number Of Shares Eligible To Vest",
        "terseLabel": "Involuntary termination program criteria, if circumstances met, number of shares that will remain eligible to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetOptionsNumberOfSharesEligibleToVest",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued",
        "terseLabel": "Maximum common shares issuable upon vesting (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "terseLabel": "Incentive stock plan, award type, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "terseLabel": "Incentive stock plan, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of stock options vested during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options Vested in Period, Total Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of stock options that will vest in the future period.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage",
        "terseLabel": "Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant",
        "verboseLabel": "Percentage of stock options that will vest on the anniversaries from the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs",
        "label": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower To Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower To Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "label": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "terseLabel": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc."
       }
      }
     },
     "localname": "SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SurgicalReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Reporting Unit",
        "label": "Surgical Reporting Unit [Member]",
        "terseLabel": "Surgical Reporting Unit"
       }
      }
     },
     "localname": "SurgicalReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaroPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taro Pharmaceuticals Inc. Litigation",
        "label": "Taro Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Taro Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "TaroPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxBenefitRecognitionMeasurementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefit Recognition, Measurement Percentage",
        "label": "Tax Benefit Recognition, Measurement Percentage",
        "terseLabel": "Tax benefit recognition, measurement percentage (greater than)"
       }
      }
     },
     "localname": "TaxBenefitRecognitionMeasurementPercentage",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_TaxYear2005ThroughTaxYear2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2005 Through Tax Year 2009",
        "label": "Tax Year 2005 Through Tax Year 2009 [Member]",
        "terseLabel": "Tax Year 2005 through Tax Year 2009"
       }
      }
     },
     "localname": "TaxYear2005ThroughTaxYear2009Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxYear2018And2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2018 And 2019",
        "label": "Tax Year 2018 And 2019 [Member]",
        "terseLabel": "Tax Year 2018 and 2019"
       }
      }
     },
     "localname": "TaxYear2018And2019Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Facility Due May 2027",
        "label": "Term Facility Due May 2027 [Member]",
        "terseLabel": "Term Facility Due May 2027"
       }
      }
     },
     "localname": "TermFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due February 2027",
        "label": "Term Loan B Facility Due February 2027 [Member]",
        "terseLabel": "Term Loan B Facility Due February 2027"
       }
      }
     },
     "localname": "TermLoanBFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025AndNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 And November 2025",
        "label": "Term Loan B Facility Due June 2025 And November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025 and November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025AndNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ThreeLargestUSWholesalerCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the three largest U.S. wholesaler customers.",
        "label": "Three Largest US Wholesaler Customers [Member]",
        "terseLabel": "Three largest U.S. wholesaler customers"
       }
      }
     },
     "localname": "ThreeLargestUSWholesalerCustomersMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-Based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TradeReceivableNetPortionPastDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Receivable, Net, Portion Past Due",
        "label": "Trade Receivable, Net, Portion Past Due",
        "terseLabel": "Portion of net trade receivables that is past due"
       }
      }
     },
     "localname": "TradeReceivableNetPortionPastDue",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type",
        "label": "Troubled Debt Restructuring, Debtor, Type [Axis]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Axis]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeAxis",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "label": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Domain]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeDomain",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_U.S.BroadMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Broad Market [Member]",
        "label": "U.S. Broad Market [Member]",
        "terseLabel": "U.S. broad market"
       }
      }
     },
     "localname": "U.S.BroadMarketMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate",
        "label": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]",
        "terseLabel": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate"
       }
      }
     },
     "localname": "USDollarBaseRateAndCanadianDollarPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unclaimed tax credits and research and development credits.",
        "label": "Unclaimed Tax Credits and Research and Development Credits",
        "terseLabel": "Unclaimed investment tax credits and research and development credits"
       }
      }
     },
     "localname": "UnclaimedTaxCreditsAndResearchAndDevelopmentCredits",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net decrease for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnutilizedITInfrastructureImprovementProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unutilized IT Infrastructure Improvement Project",
        "label": "Unutilized IT Infrastructure Improvement Project [Member]",
        "terseLabel": "Unutilized IT Infrastructure Improvement Project"
       }
      }
     },
     "localname": "UnutilizedITInfrastructureImprovementProjectMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "Valeant US Securities Litigation",
        "verboseLabel": "Valeant US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision Care, Surgical And Ophthalmic Reporting Units",
        "label": "Vision Care, Surgical And Ophthalmic Reporting Units [Member]",
        "terseLabel": "Vision Care, Surgical And Ophthalmic Reporting Units"
       }
      }
     },
     "localname": "VisionCareSurgicalAndOphthalmicReportingUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_XifaxanBrandedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xifaxan Branded Products",
        "label": "Xifaxan Branded Products [Member]",
        "terseLabel": "Xifaxan Branded Products"
       }
      }
     },
     "localname": "XifaxanBrandedProductsMember",
     "nsuri": "http://www.bauschhealth.com/20221231",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada",
        "verboseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China",
        "verboseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany",
        "verboseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France",
        "verboseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SERBIA",
        "terseLabel": "Serbia"
       }
      }
     },
     "localname": "RS",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/AUDITINFORMATION"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r920"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r342",
      "r391",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r419",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r979",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r342",
      "r391",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r419",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r979",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r503",
      "r531",
      "r869",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r281",
      "r352",
      "r359",
      "r365",
      "r436",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r731",
      "r734",
      "r736",
      "r737",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r281",
      "r352",
      "r359",
      "r365",
      "r436",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r731",
      "r734",
      "r736",
      "r737",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r281",
      "r352",
      "r359",
      "r365",
      "r436",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r731",
      "r734",
      "r736",
      "r737",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r425",
      "r887",
      "r984",
      "r1053"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r623",
      "r808",
      "r835",
      "r865",
      "r866",
      "r884",
      "r898",
      "r910",
      "r981",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r623",
      "r808",
      "r835",
      "r865",
      "r866",
      "r884",
      "r898",
      "r910",
      "r981",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r425",
      "r887",
      "r984",
      "r1053"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r421",
      "r813",
      "r885",
      "r908",
      "r975",
      "r976",
      "r984",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r421",
      "r813",
      "r885",
      "r908",
      "r975",
      "r976",
      "r984",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r569",
      "r623",
      "r656",
      "r657",
      "r658",
      "r807",
      "r808",
      "r835",
      "r865",
      "r866",
      "r884",
      "r898",
      "r910",
      "r970",
      "r981",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r569",
      "r623",
      "r656",
      "r657",
      "r658",
      "r807",
      "r808",
      "r835",
      "r865",
      "r866",
      "r884",
      "r898",
      "r910",
      "r970",
      "r981",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r503",
      "r531",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r624",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r365",
      "r624",
      "r921",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r422",
      "r423",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r886",
      "r909",
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r422",
      "r423",
      "r849",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r886",
      "r909",
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r365",
      "r624",
      "r921",
      "r922",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r954",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "British Columbia"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "Quebec"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r353",
      "r354",
      "r355",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r712",
      "r713",
      "r714",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r775",
      "r776",
      "r779",
      "r780",
      "r781",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Net trade receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r251",
      "r266"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r36",
      "r42",
      "r205",
      "r928",
      "r929",
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension adjustment, net of tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r121",
      "r292"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r298",
      "r828",
      "r843",
      "r847"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r38",
      "r42",
      "r205",
      "r802",
      "r838",
      "r839",
      "r928",
      "r929",
      "r930",
      "r945",
      "r946",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r34",
      "r42",
      "r205",
      "r316",
      "r317",
      "r767",
      "r768",
      "r769",
      "r770",
      "r772",
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r945",
      "r946",
      "r947",
      "r1034"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r173",
      "r174",
      "r628"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r299",
      "r429",
      "r439",
      "r440",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries of amounts previously written off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs charged against the allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r522",
      "r777",
      "r882",
      "r883",
      "r935"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt discounts and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r70",
      "r117"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r249",
      "r265",
      "r296",
      "r334",
      "r399",
      "r411",
      "r417",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r716",
      "r720",
      "r752",
      "r907",
      "r979",
      "r980",
      "r1044"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r287",
      "r302",
      "r334",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r716",
      "r720",
      "r752",
      "r907",
      "r979",
      "r980",
      "r1044"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australia",
        "verboseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements",
        "verboseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions and Acquisition-Related Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Canada.",
        "label": "Canada Revenue Agency [Member]",
        "terseLabel": "Canada Revenue Agency"
       }
      }
     },
     "localname": "CanadaRevenueAgencyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r72",
      "r290",
      "r867"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r240"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Components of the change in projected benefit obligations, change in plan assets and funded status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r257",
      "r274"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes\u00a020 and 21)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r479",
      "r480",
      "r851",
      "r978"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r945",
      "r946",
      "r1034"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748\u00a0issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r311",
      "r313",
      "r321",
      "r823",
      "r832"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r201",
      "r202",
      "r209",
      "r311",
      "r313",
      "r320",
      "r822",
      "r831"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r200",
      "r209",
      "r311",
      "r313",
      "r319",
      "r821",
      "r830"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r56",
      "r318",
      "r820",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r237",
      "r238",
      "r425",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r237",
      "r238",
      "r425",
      "r848",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r237",
      "r238",
      "r425",
      "r850",
      "r1055"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r262",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r84",
      "r85",
      "r237",
      "r238",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r81",
      "r84",
      "r85",
      "r86",
      "r237",
      "r239",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r237",
      "r238",
      "r425",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r206",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents",
        "verboseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r95",
      "r410",
      "r411",
      "r412",
      "r413",
      "r419",
      "r953"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r51",
      "r813"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit concentration"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r938",
      "r1023",
      "r1025"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r938",
      "r1023"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r191",
      "r694",
      "r704",
      "r938"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r82",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r333",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r516",
      "r523",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r250",
      "r254",
      "r264",
      "r342",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r778",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r254",
      "r264",
      "r527"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations",
        "verboseLabel": "Principal amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r244",
      "r246",
      "r500",
      "r778",
      "r880",
      "r881"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r514",
      "r751",
      "r880",
      "r881"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r22",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r342",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r778",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "netLabel": "Aggregate principal amount of debt exchanged",
        "terseLabel": "Total",
        "verboseLabel": "Repurchased aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r140",
      "r141",
      "r142",
      "r143",
      "r243",
      "r244",
      "r246",
      "r261",
      "r342",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r778",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r245",
      "r512",
      "r528",
      "r880",
      "r881"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r243",
      "r246",
      "r982"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt instrument, premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Possible decrease in unrecognized tax benefits realized in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r938",
      "r1024",
      "r1025"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r191",
      "r938",
      "r1024"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r674",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r191",
      "r695",
      "r703",
      "r704",
      "r938"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r4",
      "r5",
      "r252",
      "r263",
      "r688"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r674",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r689"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r1021"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1021"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r187",
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r690"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r188",
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r1022"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Outside basis differences"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "auth_ref": [
      "r42",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "terseLabel": "Unrecognized actuarial (losses) gains"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": {
     "auth_ref": [
      "r42",
      "r590"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax",
        "negatedLabel": "Unrecognized prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r560",
      "r890"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r546",
      "r585",
      "r611",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r546",
      "r586",
      "r612",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r594",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Percentage of expected return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation, end of year",
        "periodStartLabel": "Projected benefit obligation, beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r555",
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r597",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r562",
      "r572",
      "r615",
      "r888",
      "r889",
      "r890",
      "r891"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r888",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity securities:"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2028-2032"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r580",
      "r891"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Estimated company contributions in next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r546",
      "r584",
      "r610",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r559",
      "r570",
      "r572",
      "r573",
      "r888",
      "r889",
      "r890"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets, end of year",
        "periodStartLabel": "Fair value of plan assets, beginning of year",
        "terseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r544",
      "r568",
      "r890"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status, end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r546",
      "r551",
      "r583",
      "r609",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r581",
      "r607",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r604",
      "r605",
      "r890"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r604",
      "r605",
      "r890"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Underfunded pension benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r987"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r564",
      "r988"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r569",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Defined benefit plan, percentage of actual plan asset allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r547",
      "r588",
      "r614"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlement loss recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r549",
      "r582",
      "r608",
      "r890",
      "r891"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "For Determining Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "For Determining Net Periodic (Benefit) Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r620"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r70",
      "r119"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r30",
      "r32",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r304",
      "r305",
      "r751",
      "r871"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r31",
      "r218",
      "r247",
      "r303",
      "r871"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r751"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Derivative, Fair Value, Net",
        "terseLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r217",
      "r219",
      "r224",
      "r226",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r214",
      "r217",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r214",
      "r217",
      "r224",
      "r226",
      "r229",
      "r231",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r223",
      "r1032"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r223",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r304",
      "r305",
      "r751",
      "r871"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "totalLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1030",
      "r1031"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r211",
      "r212",
      "r214",
      "r215",
      "r228",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r630",
      "r660",
      "r661",
      "r663",
      "r668",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r118",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r115",
      "r123",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held For Sale"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r892",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "United States - Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r322",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r366",
      "r368",
      "r370",
      "r371",
      "r372",
      "r376",
      "r737",
      "r738",
      "r824",
      "r833",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r322",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r368",
      "r370",
      "r371",
      "r372",
      "r376",
      "r737",
      "r738",
      "r824",
      "r833",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share Attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r765"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r337",
      "r677",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Canadian statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "verboseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r139",
      "r281",
      "r315",
      "r316",
      "r317",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r364",
      "r379",
      "r436",
      "r532",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r736",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r772",
      "r802",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Extinguishment of Debt [Line Items]",
        "terseLabel": "Extinguishment of Debt [Line Items]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r740",
      "r741",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r514",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r741",
      "r804",
      "r805",
      "r806",
      "r880",
      "r881",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r740",
      "r741",
      "r743",
      "r744",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r514",
      "r572",
      "r577",
      "r741",
      "r804",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r514",
      "r572",
      "r577",
      "r741",
      "r805",
      "r880",
      "r881",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "netLabel": "Level 2",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r514",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r741",
      "r806",
      "r880",
      "r881",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration adjustments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r746"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments / Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r514",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r804",
      "r805",
      "r806",
      "r880",
      "r881",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r740",
      "r741",
      "r743",
      "r744",
      "r747",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Non-recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r748",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Effective Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r784",
      "r795"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "netLabel": "Finite lived intangible assets, useful life",
        "terseLabel": "Weighted- Average Remaining Useful Lives (Years)",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r294",
      "r465"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "netLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r462",
      "r464",
      "r465",
      "r467",
      "r814",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated aggregate amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r109",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r105",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r109",
      "r814"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r890",
      "r986"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed income securities",
        "verboseLabel": "Fixed income securities:"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r761",
      "r762",
      "r763",
      "r764"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r871",
      "r888",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r335"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "negatedTerseLabel": "Expected benefit from income taxes at Canadian statutory rate"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Patents allegedly infringed upon, number"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r935"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net gain on sale of assets",
        "negatedTerseLabel": "Net gain on sale of assets",
        "verboseLabel": "Milestone achievement, included in net (loss) gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r972"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r70",
      "r133",
      "r134"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r293",
      "r448",
      "r819",
      "r878",
      "r907",
      "r958",
      "r965"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r451",
      "r878"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r460",
      "r461",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r450",
      "r457",
      "r878"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges to date"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r70",
      "r449",
      "r454",
      "r460",
      "r878"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r453",
      "r878"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill reclassified to assets held for sale (Note 3)"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r214",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "B+L IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r935",
      "r969"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r935",
      "r969"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r70",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment write-down",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r336",
      "r705"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r248",
      "r258",
      "r276",
      "r399",
      "r410",
      "r416",
      "r419",
      "r825",
      "r877"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r336",
      "r705"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of loss before benefit of income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r892",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r468",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r678",
      "r686",
      "r693",
      "r701",
      "r707",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.",
        "label": "Income Tax Examination, Increase (Decrease) in Liability from Prior Year",
        "negatedLabel": "Reduction in NOLs"
       }
      }
     },
     "localname": "IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r338",
      "r363",
      "r364",
      "r397",
      "r676",
      "r702",
      "r708",
      "r834"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "(Provision for) benefit from income taxes",
        "negatedTotalLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r672",
      "r673",
      "r686",
      "r687",
      "r692",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r1018"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Change in valuation allowance on Canadian deferred tax assets and tax rate changes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1018"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "negatedTerseLabel": "Foreign tax rate differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r1018"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "negatedTerseLabel": "Non-deductible portion of Goodwill impairments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r1018"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "negatedTerseLabel": "Non-deductible amount of share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1018"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r66",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r106",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r108",
      "r810",
      "r811",
      "r812",
      "r814",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r293"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Capitalized interest"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r54",
      "r520",
      "r530",
      "r882",
      "r883"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.",
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpensePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r326",
      "r329",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r924"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r301",
      "r868",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r289",
      "r300",
      "r378",
      "r445",
      "r446",
      "r447",
      "r809",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r926"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r925"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r53",
      "r392"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land improvements"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r1041"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of lease expenses"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r1042"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of operating lease future payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r795"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r1040"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r1040"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r334",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r717",
      "r720",
      "r721",
      "r752",
      "r876",
      "r979",
      "r1044",
      "r1045"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r256",
      "r271",
      "r907",
      "r937",
      "r956",
      "r1037"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r288",
      "r334",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r717",
      "r720",
      "r721",
      "r752",
      "r907",
      "r979",
      "r1044",
      "r1045"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Facility fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee, unutilized commitments, percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "verboseLabel": "Litigation, amount paid"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of long-lived assets by geographic region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r254",
      "r268",
      "r513",
      "r529",
      "r880",
      "r881"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt and other",
        "verboseLabel": "Amount drawn under credit facility"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r131",
      "r342",
      "r983"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r131",
      "r342",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r131",
      "r342",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r131",
      "r342",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r131",
      "r342",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r131",
      "r342",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r481",
      "r482",
      "r483",
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Legal proceedings and other matters"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r481",
      "r482",
      "r483",
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of cases dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r972",
      "r973",
      "r974"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r128",
      "r129",
      "r481",
      "r482",
      "r483",
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Recent suits filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r973",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of cases"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LuxembourgInlandRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Luxembourg.",
        "label": "Luxembourg Inland Revenue [Member]",
        "terseLabel": "Luxembourg"
       }
      }
     },
     "localname": "LuxembourgInlandRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r1035"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r29",
      "r255",
      "r270",
      "r334",
      "r432",
      "r487",
      "r490",
      "r491",
      "r492",
      "r498",
      "r499",
      "r752"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r380",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r48",
      "r71",
      "r259",
      "r275",
      "r286",
      "r309",
      "r312",
      "r317",
      "r334",
      "r353",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r369",
      "r399",
      "r410",
      "r416",
      "r419",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r738",
      "r752",
      "r877",
      "r979"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r203",
      "r208",
      "r309",
      "r312",
      "r363",
      "r364",
      "r930"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r78",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r365",
      "r376",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r664",
      "r665",
      "r666",
      "r697",
      "r698",
      "r699",
      "r700",
      "r712",
      "r713",
      "r714",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r775",
      "r776",
      "r779",
      "r780",
      "r781",
      "r782",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r815",
      "r816",
      "r817",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r198",
      "r532",
      "r945",
      "r946",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "verboseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Years"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r399",
      "r410",
      "r416",
      "r419",
      "r877"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r788",
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of remaining lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Current portion",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r786",
      "r792"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid from operating cash flows for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r783"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r794",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r793",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]",
        "terseLabel": "Pension and postretirement benefit plan adjustments:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r35",
      "r39",
      "r589"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net actuarial gain (loss) arising during the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r200",
      "r201",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Release of foreign currency translation losses upon disposal of assets held for sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": {
     "auth_ref": [
      "r39",
      "r43",
      "r308",
      "r589"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r306",
      "r307",
      "r722",
      "r725",
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r139",
      "r310",
      "r313",
      "r318",
      "r766",
      "r771",
      "r772",
      "r820",
      "r829",
      "r928",
      "r929"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r37",
      "r39"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net pension and postretirement benefit plan adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r37",
      "r40",
      "r200"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r955",
      "r957",
      "r986",
      "r1036"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Other equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other (Income) Expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r147",
      "r544",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r594",
      "r595",
      "r597",
      "r600",
      "r603",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan",
        "verboseLabel": "U.S. Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Net proceeds, settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r471",
      "r934"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible assets and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r324",
      "r1026",
      "r1027",
      "r1028"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Total capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r569",
      "r571",
      "r577",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r617",
      "r618",
      "r620",
      "r626",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r253",
      "r267",
      "r545",
      "r568"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Liability, Defined Benefit Plan",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r153",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r146",
      "r544",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r594",
      "r595",
      "r597",
      "r600",
      "r603",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r625",
      "r890",
      "r891",
      "r895",
      "r896",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r597",
      "r888",
      "r889",
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r927"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r330",
      "r931"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Net proceeds, cross-currency swaps"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r932",
      "r933"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r286",
      "r309",
      "r312",
      "r327",
      "r334",
      "r353",
      "r363",
      "r364",
      "r399",
      "r410",
      "r416",
      "r419",
      "r432",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r498",
      "r499",
      "r715",
      "r718",
      "r719",
      "r738",
      "r752",
      "r825",
      "r877",
      "r903",
      "r904",
      "r930",
      "r979"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r120",
      "r291"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r122",
      "r273",
      "r827",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r323",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r272",
      "r277",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of capital expenditures, depreciation and amortization by segment"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r459",
      "r460",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r459",
      "r460",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r470",
      "r473",
      "r476",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r70",
      "r474",
      "r476",
      "r971"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r471",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Remaining restructuring liabilities"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r144",
      "r269",
      "r842",
      "r847",
      "r907"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r281",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r364",
      "r436",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r736",
      "r838",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r600",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r600",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r989",
      "r990",
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r544",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r594",
      "r595",
      "r597",
      "r600",
      "r603",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r625",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r544",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r594",
      "r595",
      "r597",
      "r600",
      "r603",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r622",
      "r625",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueCommissionersIrelandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Ireland.",
        "label": "Revenue Commissioners, Ireland [Member]",
        "terseLabel": "Revenue Commissioners, Ireland"
       }
      }
     },
     "localname": "RevenueCommissionersIrelandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r390",
      "r391",
      "r409",
      "r414",
      "r415",
      "r421",
      "r422",
      "r425",
      "r541",
      "r542",
      "r813"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember": {
     "auth_ref": [
      "r952"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment for satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Segment Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Segment Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerSegmentBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues and long-lived assets by geographic region"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares sold, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r42",
      "r1038",
      "r1039"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Actual asset allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r890",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of underfunded plans"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of (provision for) benefit from income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r227",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r950"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of (provision for) benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to income (loss) before income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and by product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Future benefit payments for the pension benefit plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExtinguishmentOfDebtTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to debt extinguished, including the amount of gain (loss) on the debt extinguished, the income tax effect on the gain (loss), and the amount of gain (loss), net of the related income tax.",
        "label": "Schedule of Extinguishment of Debt [Table]",
        "terseLabel": "Schedule of Extinguishment of Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfExtinguishmentOfDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r105",
      "r108",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r105",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r878",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r13",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of aggregate maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested performance-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested time-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of external customers that accounted for 10% or more of total revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r50",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenues by geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r46",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r93",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r90",
      "r91",
      "r93",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r627",
      "r629",
      "r631",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r162",
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r902",
      "r1020"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the beginning and ending amounts of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r425",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r473",
      "r478",
      "r878",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r399",
      "r402",
      "r413",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Granted, one-time award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant-Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Method and assumptions on valuation of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Company share volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised in the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Expired or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r631",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Vesting Period Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r634",
      "r653",
      "r654",
      "r655",
      "r656",
      "r659",
      "r667",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Incentive stock plan, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term (years)",
        "verboseLabel": "Expected stock option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r789",
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r284",
      "r387",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r425",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r473",
      "r478",
      "r878",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONCapitalExpendituresDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r139",
      "r281",
      "r315",
      "r316",
      "r317",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r364",
      "r379",
      "r436",
      "r532",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r736",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r772",
      "r802",
      "r838",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r379",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r951"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "verboseLabel": "Stock Compensation Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r139",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r139",
      "r144",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r139",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from B+L initial public offering, net of costs (Note 2)",
        "verboseLabel": "Issuance of common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r7",
      "r144",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r101",
      "r907",
      "r937",
      "r956",
      "r1037"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r198",
      "r199",
      "r207",
      "r281",
      "r282",
      "r316",
      "r349",
      "r350",
      "r351",
      "r354",
      "r362",
      "r436",
      "r532",
      "r664",
      "r665",
      "r666",
      "r699",
      "r700",
      "r736",
      "r766",
      "r767",
      "r772",
      "r802",
      "r839",
      "r840",
      "r937",
      "r956",
      "r1037"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Increase to accumulated deficit (less than)",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Total equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r791",
      "r906"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sub-lease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r773",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r773",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r773",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r179",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of open tax years by jurisdiction"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of troubled debt restructuring which results when the debtor restructures the terms of its debt with a creditor due to the debtor's financial difficulties and the creditor grants certain concessions to obtain payment it might not otherwise receive. Includes a description of the principal changes in terms, the major features of settlement for each restructuring, the aggregate gain on restructuring and the related income tax effect, the per share amount of the total gain on restructuring, net of related income tax effect, and the total gain (loss) on transfers of assets recognized during the period. After the troubled debt restructuring has occurred debtors discuss the extent and amount to which amounts contingently payable are included in the carrying amount of restructured payables, and the conditions under which those amounts would become payable or would be forgiven when there is at least a reasonable possibility that a liability for contingent payments will be incurred.",
        "label": "Summary of Troubled Debt Restructuring Note, Debtor [Table Text Block]",
        "terseLabel": "Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted"
       }
      }
     },
     "localname": "SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Other payments"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2012Member": {
     "auth_ref": [
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2012.",
        "label": "Tax Year 2012 [Member]",
        "terseLabel": "Tax Year 2012"
       }
      }
     },
     "localname": "TaxYear2012Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2013Member": {
     "auth_ref": [
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2013.",
        "label": "Tax Year 2013 [Member]",
        "terseLabel": "Tax Year 2013"
       }
      }
     },
     "localname": "TaxYear2013Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2015Member": {
     "auth_ref": [
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2015.",
        "label": "Tax Year 2015 [Member]",
        "terseLabel": "Tax Year 2015"
       }
      }
     },
     "localname": "TaxYear2015Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2016Member": {
     "auth_ref": [
      "r1019"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2016.",
        "label": "Tax Year 2016 [Member]",
        "terseLabel": "Tax Year 2016"
       }
      }
     },
     "localname": "TaxYear2016Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "B&amp;L Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r1029"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r826",
      "r888",
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government bond funds"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r671",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Net increase (decrease) recognized in interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r682"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "netLabel": "Existing Unsecured Senior Notes",
        "terseLabel": "Senior Unsecured Notes"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r381",
      "r382",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r691"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r939",
      "r940",
      "r941",
      "r942",
      "r943"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r944"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "negatedTerseLabel": "Reduction in variable consideration provision, adjustment"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r343",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "netLabel": "Sales return provisions",
        "terseLabel": "Charged to other accounts",
        "verboseLabel": "Current period provision"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r790",
      "r906"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r367",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r366",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares (in shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 24
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2599-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15765-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3581-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r911": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r912": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r913": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r914": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r915": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r916": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r917": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r918": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r919": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>158
<FILENAME>0000885590-23-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-23-000009-xbrl.zip
M4$L#!!0    ( *F$5U:X%R/@UI8( ++$6  0    8FAC+3(P,C(Q,C,Q+FAT
M;>Q]:W=31]+N]_=7Y.1\/9KTI?J6-9.S#"89YV [ 9,,?,FJ[JJV963)(\F
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MHS6<3$C!J9K:+J4O@DDNK3?*YQ.WO<EXVC/N1AZU0AL]. 3VD-&!Q.R.@QQ
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M7 MH5C-+L$3]*5Q*%J"T*J!=1HJABOZXJ()A6@_]N>]9@N7!@U5YDCO&;!Q
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ME@E7#5./"J3.[0H6%'+ K<)B+8NLC<-6;G'X_.W+MQ>7#]-V]3U0T!)" JX
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MQ&>??W-I#[Q"LM8@%%'R)-JM*T)-/'ZF0 U;ZJ"%]Y07'+0.X/",[3V7 M#
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M6AL:=$:LR'NC]9:MMA[7(CN67JOU'J$7%JBI0]3:J0 :[%:]/:E$[O#*T#E
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M<K9N27*(()DP4:W>JN90:Q.>S)Y:=KJ9/^-FML)LPRQ62NJ"">(B8P-$"<'
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MH"D[-LGFK1!(+(, *F/M($(,2Q?5IH&ASI[F4W9, OT!@5K/H8-A-W"HRVB
MYI H>T[*V>8 UXG9S6$6#:AS0HE#'E,'S(6#IT00-2Q2^8OE[<+X]]D1@%?/
MWIY>GO_\MZ^_W#!:_P(TAOG/+[_@2[\&1UC^>_<Z[QY[9S;[Y=(/<'3[R%_
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M_(C/3VUI6?/@(32.$(IW#*'O7WH?32JEBR'6BA6B 4E'CC&G('T8^JJF)[:
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MWES ?__\+;UY,N1+ [>#$E:A4X\HYO]^KR_F6YX.![VNGURJYH7641K J?'
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M(2!6:L\/0S-'N6HBQ:RQ_'U8F.$0;)!T:4+ $&/(*;M^W2LF?;.;=%H?:)/
MM1STB@&@_QS3S.S!,;#AM BE8(C-]3$X,*4U\-C._I=>.,NU)[]@7KQ9/TAG
M=$LB4M.#7]/$9[.LJ\EM#Y!]CC5CMSRILI^G\&Z3;@)NSE7 /H_8C'UW5(]K
MO;C/KDH[+I8;Z6V#<F.VYL][YF@55<1/E9_A]T0):ITQ / H=!ASJ&,=HAT3
M!4^GWS$6XO=/>FV**,>T]V%2<P5,^HW6'W,EZ3-@3?)PK8*81X29).8>>E5A
MU.!R56MN=U35QE=?J\NI8B]76<$E-RC+,.VAFO166:8"JT$2M$_=P7C8.YO(
MV55O72]NA[M+";))0>;5&X!^K19@MBX32LZM= :B:<U%0F(WR$4D +B]LV%W
M6/>C3?'D3Z%C35*Y22F'_K!"Z%0! A_EHK[IV^=I-T7L,&W8-<@-N\KA?"E)
M"0;"IT3JZ1!J,V">W<Y5_TV9#6UU,/#;>O$6EKDF8MI#O0H$O2K+/3P.O=[$
M#"M^N;QSI+@VB7O%(MU_T" -]RK?XVGL?@D>5K4W;&9W@1]6*>!)_ F>R5NZ
MM_4G>!T[]#T2VDO'<$?1U$S>.=O1@I".(2A(DKJ@.KTRZN40N-(<'0%?)\9/
M_!Y&Q:?4[6#"LZYJB##,#1$*8*",+[E:(R;LA^]=I2;,]&(OU=3:.E)5>/,M
M8#H9##/L ,B!BL@N1TBN"JC 03\IBWP,]_^.\Q%1N4KM/VJA>9Z+Q&"@XWZW
M$IGQT#\Y+T,B.J&LIT([SSA"%E-C3*"(&N&HHN]WL@P)BIZ '+ON"8C#_WN"
M+LO1JVQ+/N\-S/F33)_VQR<=/QAUZF\_*=)X0W[&8Q(J<.O?H/>,T> 8,1W%
MG0,[S?H. )7H2.&UTB((;>B3/\@:1W(-$[(&+# 1IPDU_WB0TK&K-VT^3!/'
MJ\6RTNZ#_DR *B\DB0(P%-A1H+4GG\,KZ]U EW>>IWO^/>[7%444K56_)#Z_
MOHJH,9TY$WI5;3@3I@S&HQQMR&&'"JZN1YH)K.75JL#J>; E(,M977TE\UG8
M-*/,M2!3O><"SD@17%12&.,U(TQ8PC%GUG A0K >9YRA" 8RCS,[>\^OV!>0
MAYEI6K6DV9]-LH6>JZ!G_W"7O'<\;1; MA,UTJ###1C,T8L.H]1%'XC!%%Q$
M*L@:H@ ^&E\"GN]*Q[=.&[Q34= W0JNM_<TWN]M[AP?%SM[F_NM7^Z\W#K>W
MBF=OB]?;S[=?;^]M;O_ C!8JW0]P+OEP=B9;\,_.X-G@5X./=0@O>M8#H7M<
MPI/B*^0]H3H@SG0'UA5UF%"T8ZDT':DYH1%SZ91]4@3 E]-4<EJ.PY,_7H%%
M5N'FSL[.W+$IP S@7HY,.MRS7\%5PD^P(,O)6N<SI*^#Z=-R\.5L%AJ8;M3*
MR+S1[X_!'-P-(<?S ,(S1AX/>AY<VO7B(&U7N/B$SUWPV*;[W_H#4*^C[-V9
M%"R9V_I5F#BJW3[72T[\]<JDMDO/@BF+*H:^!39LTDNUWL59EY!+9[?>4"0?
MO(@7([2.T ]5\6JUKM&M:A<O=!N\05O0>BKDVFXN*&4;GUR?QKFTWO6[*:Y*
M' =5_N-I&=*6FT]AMBS_>;ZXJQX)FGW%6!C2>'3Y*W=]I#.Z$8@6\-^%8J\+
M*Y !CLMH R5"2HZ84TI%S !1%;%:@_#']_+)Y#O'4X*=FB/0JV4P'SM95IZ:
MWF<0G">_G6=EX+UZ2(SD:K=K5_,\IZKSAJ?ZEFKZ(Q<#7371<\2:B$U:^IC_
MFW0'RK<\S=PTN31AV-3G=LI9]10*IO,)O\6%OY\\;&N72TQPM7%PN/'LY7:Q
M_[S8W-\[3$;"K9O17+6^2SC1%]M[VZ\W7H(-]'S_]>[&X<[^WJW&_,!;)?2Z
MXO1'0%:N(ZU_J.K\6Y^1=1#Z.Z]E5VA=LA\KD7_XP;)U+.D""N_OIZO8]Z4&
MS3;)W4?)4N.GU=+J01K;W7A6WVL%V*A9OS)7->^[B"F8+U7)X WY]-7&Z\-B
MY_NS>YA:P;LRJ?/4=L"3K&.$ZPNN@;S3>2W%?HD[G=&D/GJ5YG2_5/HQFS[&
M>YMP-6P?7'T([]-<');N@N&8I1E+<5RFN.0_ON](8_WD#_S/W\Q5&]!6$"$W
M6HA<ZAF][@X_%L^-&PW*%B9;F%P:F%0$8%(^'IQ\UN+D4L_H3;\,X&JF\LJ#
MD8FQ2)GYE$%<I4FVH-EPT.1/_N#LT8 F:3%SJ6?TJAR<IK&$%B1;D%P>D%2/
M"B1I"Y)+/:.7X<CT"H!*%W+_UA8K6ZQ<&JS4^%%A)6NQ<JEGM M7B@,3P^BL
MV.H.4UGFN&RMRQ8QEP@QV6T1L\GY_55/\/-6(2SUC':K#:MI5\#KRV7Y]5G>
MV_\[[H[.UN".7NXPF'=359L$BMW4XJ0<YFXGU6EZQ:MQZ8[-L-H]5GUWKKG"
M*JU>JVN:K6O@0:!L^",PSPMQ&R ^M_NCX;-_'>"+GX)?@NFW GWO DTI"+1Z
M! )=J1[9FE=+/:/=R\W>DML]'@Z[=8>XC;GF1,^GK9PV!WU?-1!,]P"$C7M5
M+ZG]TU")1VM'M;"[1+ K ';UXX'=MBASN6?T9^JRUAWEK<<)0JL9PM7>Y.)<
M]+/8L(/QJ*A=X53/N4I+T6)KL[&54/[D#XP>3R6G:K%UJ6<TLU(/9LTWDYEZ
M,#X][>6_37F6CVM=I6FW.-IT'%6/"T=UBZ-+/:/-W%\PM77/Z D&J3DJ0XVG
M^8B C:K5NLE]I/N3/U.GIO2%&0[/;-E56I\6<!L.N P_,L!MHP++/:/-03XW
MH[)6<\&H;ZN?6M!<+M!DCPPTVWV;RSVC_7QVP\ZL]^@J3:Z%RZ;#I4QP^1@2
M_H7>7(82GJM;[*J[/W+FADLS\WU3 :,I<_/ZYX,2[DF-^\ONT'?K$X/R 4&O
MRO I=3'>Z0]/ZZ.$;GV4=UL?U%B\X.C6>-'H\O)5KR_'J#4?EWI&6]UT8MN@
M'*X5V]-#T_8GAZ8E1WQSTNF^>)$.2TM!S3:.V>J,)=(9(NF,QU/=A-NNG,L]
MHQF0;LX=7[E*,VPQL^F8J1\99K:ME)9[1O4&Q+-B_W,?+,_C[FDJI]^LCU9Z
M%OH!3-*43*\^SY;IK'J_+L._=OOC*JU4B[T-QUY!'AGVMAV:EGM&$Y3- )HB
MKH"^PW.0>EC"XZN#(X=K=3E4%3<H=D $3M.9<&U8H(79I8)9_LA@MFWNM-PS
M>E5V^ZY["C;L7*7H\Q#JZOQ0?NJZMMJIQ=!EPE!U:PQM<CKNKU7/QK7MGI9[
M1MM?CKNV6^W7JF9WQ6ZNXL =!S_NM;JBU15+I"MDJHS%Z/'8V[=JV;3T$UL]
M,'T^*$\*C#K_71R,3TY,>;9<Y7DM#BT-#NGF,??!SHN]C<,WK[</5DED6R.@
MX<*G4OWF]XXUFTQL\G:6H?;. 'FY;LUS_FUD;"],UR+_G./&>B$869<<2'4Z
M&.;F8D_+')#_%'ZOSW7/,C+_Q?J8:#3[BK'#06\\NOXKM^#\^Q)UDL;4O< ?
M%U:FZ__?DYLT"'TR^=)Q.2/#4>C8,IB/'1-A@D]-[[,Y&S[Y[7QU?+??N;#N
MURU974A?+W8Z^OI\:?T\^GP8#T?=>%8OZA__M.5O%R7A(O7K([_KA8_YO]_K
MB_F6I_D(\,FE:I1H':5UGK!</86"Z76.TK_G_[ZK^3Q@6"8SR3-3M]Y[589A
M:EQRKI#JXD(NX[RN8OYOP?Z+T ^EZ=WE'*M+W92B&STE+#/&@H1^^XL+P)6?
MCT,9BM%Q !3MI]$5@[2+[7-W&(HR_.^X"]1>*TRO!W]%N+7OJCX,HV/@AHU^
M?VQZQ>MP.BA'J>]"LO,GU>9@[/^26CD2]/OYR_DB_OW78C2H+J:WUW>F*CW3
M/ZMO69M<_APN7AD/+UX9C,OZ4C$  .K"FIFR^ R2.DP73H_+W&C;I.D.BF=F
M/'3'Q;^"Z8V.B^JUW3"L!K33=^LY$Y#B/\.Q'79]UY3=M!(C\S' [ ='(2W3
M>K%3+\7Y*:[-K]9DFO4X_V-NE/6E-P=;DXOU\-[TNZ-0QYURM&E8^$$/)C2\
M\.C)(^ ?*MCO%QZS/2X'=9;XRF]M;EQ\\:;I&YAL?_*Z=1A*+PR'<VP![ OV
M' QO+?/-,$'!,)MX^45Q&B;S9F0R6QG@/C_EF@M,DEY\6F$*W&0RQFP%%TYL
M* N*UPJ"R%S)V"HBS6%I?(!A?QQ>.\UEQ1+, 4L.)V2M?/R:Y,!HTWFM5;\7
M?7-2)]F&59*MR!]7&\Y,C42GU5E^9XD3TM\U**PEYO@< (H,/"_UX>_.MMH"
MNYV.2["]PN1=E]^[=IL79WX'&3T"7/A:U6*L%P>#7NB=Y7?#)#\%@ R0J+7"
MU64;MWAQEL<2.!Z$;B(9906DYO0T).CJCHY3M\4TL@E?W"EUQ3J_ 7FOL(&3
M:'5H_O8%[\X"QE8\#1(NV>_W,NX;<F76#$R1WZND[FXQ/#NQX"JL%3:OZB"K
MN"DJ)B;H#T9 C%&JH:D)4T%=Q2:?0\+L1 Z@4 \^ $>B&*0BR,R:68G"_('
M9X4%KOC<!5Y-CS1#F,)H+3TQW13'/8#440'RFW((&0CF']DSG]<*4&?UV[IE
M4:9I9> >CD%KW9S-KL#-&YKS]$E#P/9J<Q70Z+,I?>?E8/ Q)??G&O"MJ$&W
M:<:Y#78YW=L;ZS7HU6LP!Y<5IYQO2EC;!.G,J\Z_3 D^SL0VF+NQ8M;$Q6_6
M#]8K-?ZJ['Y*0C([N:1X"?\<56]Z'=);BPT'%F*L];[6/+]RCNFGAL=P]A00
MA.'3I56)E4/8'<$0W WH<YV2O$BEN<5.&B#K!I#F 'H(/@7-=%!MQBZ(W)AH
MR+F5K]:YP)K2C$H # G-UNK*EOJK>/N*KX)+D!NMS3V#77[&M[CJZ@'?@,K%
M+T"87AK=)U"P4YO^^K69.!%Y?#X,7=FUE8UY,@ @]P$6MS?'K<?!9)F8>237
MP,.$Y^%)N9> S#ZO ;6\LU.MV3P9UV^IX#9*,(Q_3L[OQQ;X8;;>\%7[?3#
MSN&+K4V78;B(,]./0$6-0EJ0(IJ\\34I/-"5XY/3J@U!92*?9<HGO?<-4:ET
M+MP!WZG)GLF'-]8G-$_MJHOGU9OFJ'R>H)7;UY^W.Z?G$50F8>SVTM&I5=_!
M"1#.BU%ZPE24TKE0W>H,@U_F_-R#[<VI&YSNSZ^;R,:\-/N3;C^?-9779_X1
MFP<;DT>L%W\?AX3\U5K!NY+U\(W5 D/B!!Q9$!/7'>:ESK,!+RQU>IC8*5.[
MNPNF[C /((TU+P/XQ6"<]CQ8/&!#@4%SEA -'.5:W@R\/;\,G@YR.2'P]/M
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M&J2&;.-<PF1#KQL^U07X=7E0^E8&UG-"D"O:P(=(M7+A**7"4G:LXI3)%^=
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M4\=?(<UI\GIELN[66J+7ZDJPGEWT):V95-@B*)+C\CBT3D\X^.245Y<8P4^
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M!HI"BH1[03!*FC0OZBGL2@[$(+_)M49A*I8M6EI/\L&LG-F)1.H\;=*,7%V
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M ['4CBHV-<D7AX-=UA=B>V8\A,5Z]P$"Y!#ETIFW/&7=1AMM+6F)_';A;F^
M1)LJB/I%VFZ$,V*0QYX>!0BW'2=>;ZRMKR=-4>Q8\0JQ_4O0]\$S.R76HZUR
ML3:&B%CU9C%7&:% 6!7:KZ^*__3Q+#7BU'E:UA/3I:0J$^T084,8I=6>B3?W
M?ZC53 RTI]7;RS+%,Y9MW11I*TBMNPZJ&\"79T59_&?'E5^9*XDAG[BQS55R
M^FJ/_FX,AM43PTS*.OM VG%15W56:K*T*[@'8[W_X1+<M..AZP5IHRUM4'FW
MXZ,K\-&]B?GH;,PL7;8]\!C /,@.(48:14AM2-1/)V#=(R7> &@C934IS0+A
MU8+Q7AFL@ &9M2XLZ[NT,DA(O]_+3$F*<;58DD^7CE 0?OS^^-5HK7:,NXQ0
M/:;]12B,Q4\=\J0?0[3CQNL=!M*LR';969I?6Z?]7)\;AOL@Y?;4*3?BB7/C
M,#6VV):C;>[@%B/STE;E3@'>")8[TCC %,"7<QZ:+.V?BJC2)D<EG66UB\1<
M;9((&Q<U\>#^>/_1=_='6WGT3=;5ZRRJ?M]Z7/./#=1XMF6>QDCGJ95DO^Y,
MH"M"V4<V3MU8EZ"H49_B3LY9.^+7SY'-S4?)LF_WID6)#NAE@7F);2@P\2L5
MF'RXT9"4P^V'VHJ%0_]]!_K;.]J=[57.]I@^S&EO;VVF]]K' [RI2/W6.]%R
ME?W[P90\*:/X:/(HQ'<P/OP.!=U$FXM5!IDPK]OEW,;X'HR?//H.TV1^KU<\
MUDVJP(.6&:M%8-/MY2EFGL2=A#5=S,&->X+!/2W3Q8*!]^]K&MY_\@<DT]W,
MO+]P\'T[4_9Z,X;<EW!;9<WU)MP79*5F*T%[9#0I[B+A(CBIS^DG@#PNSI&"
M)WHD)]'D>[8LSAL\XV1W#%^IR3N5+*UT@K E2*NVL)I-77<\6 4?V/+MLW=O
M;?TV?/+,Y  7T2KL7"!RN6T$0>P.. G=? ,T%Y([T!M%34I 2J9VI_H%IXH&
MGZ"W!R-R6#7Z/6;L-*Z:9S1^.KM9@QD[ U><YS6RAS%?S0HD\=A]>_=V%T2Y
M5LWSL^F[)CU+;ZV?<'.$'F15,,*4>[UYW/N]^8K>D)9_GDHMRT<R;%LBZB(5
MFW3P*V83-*^UJ04M!@23 AT#5(%A^^6.9+NU)D.LYHLPQ'>\].6\].;L['0W
M'^[*LU_8@(,+1\S1HISZ SN/94F.6(6I:3J0[]QX,.UH>"F9<1EPQV'0\4A@
M\!9]N$>VA)T2C/FZ,BV<<3R!XXT!3=6,'SWK"^38)K7J)[(?VMX$SY89X&J=
MW':?<#-D__.T;TES_U?RBOSV.PK5#VCVZ#V':.PMCZV;R:#7^$JS(C=#1D7;
ML76"]7[9J^-G_%J@*R8Y3C''\*QO9F[ [IOEG,B[7!39&F2Z1^^W9E:2SF9$
MIAQ(R7CZH&HDCN)^+!;T3;E*'C[^;I2@CA(/>'CX'=<6TRH4KW\X7+:]Y&C:
M'6+)&HD]VB&6? 7$DELF1<+)W&DR[66@3&=F#5N(FX2!0DHOZZ:;TM[5/):B
M1;->T2+75G+5B4#(=BEYTZ6I>)Q'@91VG?5EVNAG 5"N'=2=F_,BP]6ME2SM
MJNVX3@5VI_WVG+3#0J?5 (*HX5#)<EDR;!==@ <DF93%6-$3)8_HU?:"AN9@
M*78>># A)-XT("-AN^;T^JU+/*5T 0('=7G.I==^ZVRIS4@%*;Z>\. >]O-G
M'!:8K]HB*V3<#A=OC]R<7\84Z6%_TZ(06U"KW!;J! CA_BWH'EW!P@I&1U/W
M,SI#^BH:Y\-[6LR@:MUXYW8X/C;-S]E3]F]T9P>E7W8([">4Y!V:!/O5X2L.
M'QQ,#_]L)^<M<;UIQ&KY)FN[7E_G&^\I^3I'[TY>G"6'HB)()IG*J@8KA16;
M8E#6Q(SR$1J@PK@61:'C"QM#?L]"VKTGDJ'_.569=$(W/JV(V+M>:YR6IB;!
M'I?Y!H(I1^)KCW>5_DU6)VN8/'2![EUOCQ 'C*_S#(]>O[CV'3BXUAVX3Y14
MEO6%C,,S"0:L PG443?2,6)O='V^^A(-=]/$^&T4VF^RGH3+IY _=_+ZD[$I
MN36/W8/P5=D:F,B1L.:D(DH7@)ZO4KT-C>O0/K;2O$7=@YG":F5XHL J"BU=
M.+]JJ?]NTH_TA#G]>2]\8B:%[7618U2&O[\+'P.7P IV:W>MN V2*]>+DES1
M!"$'\F"22=EC( ?MR$WAXF]^YC>4BY\7==?T.RZ^$E)A7W;%WK)OZ V,Z\1G
MFF_=O&2+ZM5A6/423 2^Y4X.HLFTD_&O/# &]VZ3F8&#!V85-EI%7GIR0?<A
M;W=W;%_[V)Q1/%^E9=_4%:(&69$G]]HZ+_J%^YQLV/M(+?23AEZ1CIA/D0?]
M3NM>4"=)SK:V;'GY8S))R9C)KM.^DY+;1=IA?I+2%4C2)QRNY2QNAO#_JYIP
M<<SLG:GZG4"YBO=MG=R7ZCMOD3##GJ2HMU;;C]IZ*M'$MB@Q+TG+S]! &*D!
M=U,VP!8<[E10QV[>&&X1+"H,#TPK':[<70 &JB#G"?7S,V[PVS'@M3+@JU]>
MG[[\OSNFNP+3W2/MNP N(4.DI4W'(:?:YS<MAS#,R^&C[^P@LC?OC]D-(JY:
M(EMARGKIR@LU]]&8G /&/'>)=N$3?');V."2H_:^Y<%M';47ZZ'3GU_^<G9R
M74SQ#<?N?>.]!5.XZ1_/CWXY._X16_KF]?/DEU?OWWVJZ6FWH]MV],W/)\F+
MH_\+=7V<5FF>CI*C'K#-99&R5OVQ)O?M)_J?^^A.6=?:TD]"VACE>H(K'ZCQ
MW+3TRG8V%1D!)"B2("J.$@N>]TFZG MF^;JW3?V</0J3O#?9O + X>JZBL2N
M?KSO7U_KT5J4+HO&985_VS?3E+9V7B],W78,\H.3#B&]PA%\\8%*V>4P'[V3
M:5<^IHV=_%6!1-)91^S!&=^C?D9<R65$?%8[\?=UQ=_P$-9DX2@6A@.8!3T5
M^O"D)[.+C"\)>Z$*[(84&/]E \"1G+I63KG-_LAFY3_%Z 5$@1NS+$FG<#EH
MI"\VH&2MZB79%HC_KM"MBC_8R>];+>\$ODA3F YU^J_5H3\SGVRWV)W;-C^R
M<P:4+7Q-D826VHCHJ'@D.QL*SQY])[ $-IB".LODX#&9#+WT^2)*/TK*8E%P
M]5AH&DB_FFD1(Z*OW$C>&Q**^<O*P5U&Y<H\1%9"GJX^[>J82\HZQX4-<')S
M(ZV!BNP9N$/MLFA\:9*F8-"9 5:V74^(\W!JS:3,J&=JVA_)++%+.4\W]-BO
MS7GR0"^VSBPW4'CBL$[2AE13,T[>HX*'*WQM7NW)T^_(CNR R+*H<;I6?))V
M0_'!2HL7. 0>25Z.7@,5+UT8N05_SX6W5E WE1&'W+IS+3G3:4,$B8IVGF=$
M5.>>R1.)EY#I5FS?% &\R5D_ M'?2;'[:]$UIF98*&)?]*J89O65#@+5_Y<Y
MB@?CZRMG_E__S[,G^X<WYEB>C9\]9C#=SI0EXV:=E+LBKZMIQ7/IPC+5')$Z
M-OVE46(D"3_!L,%X-?Y4-&*6DED/P0=1=AXQ1Y8N;<>AZ#-;*/F\V'M>0E7R
M]1FQQBJA9^;+PF3#R<]?A9DNPSE_@AUY,SF'C'P28D25GYK0MN.:K:6154MV
MN-0_:K\&>4N]&)22&*]F)<-'V%XC&<+*]F+SP=@FQ5[FICL>NM:>?JGL9.5V
M0^)=?]64^[$5L&IK,/&\(@YHDC-I8]M9']<M0^$[["R0;VB!P'V:%K.^45GI
MK(X )JF08"-:=MHH)[F<IUEM%GW9%E,+H>=OH"V*H]T!?IT^ 3\%9=.^V^U.
M:DF,B09D+/?IE$3:49XN.=3QLNR+_-,VR0V%$KGN0(>$H]18)UL#@:?450QC
M'BD;[LL&G<J\UYRKE^Q]E<Z$[]"P"TQ)S$D5X/T6EW+?L-P&F+>NH]I4YT53
M5POMR),I4=R?YSB-(R.-6=3G:2E@$3N.^Y8B\U)Y:%_2"9B(2ALFN6.?H:R_
M6I#I*U@7-\!#^U,AE:QU\>OI\?M?SKZ1('SXY(O8X^'3+^*/;X^J-/TV8N62
MCU]TM4S&)4Z$Q1[9+B)+$0<N22Y.FU2DL;I=5I#GM)= :-(B;>Y63O !G8/$
M5K;=,["- .-@'5&K@A'R)M&KG\KZG'HV%?S75A932S+18D;)I)@:V&W S:"%
M,VR0(DBD3=9#;0#G **)KK +"CYB)^;H[/2G9%K2[:Z31&Z(?_M7S6.^JDE9
MI1]WRO\*PNWL=7*/&-' EJO(L#-=.I$Y+D%=.>HZ]L</GG['!9\5/9K+/%%-
MKM@)%E=VXZVL'((Y$5=_2@/(63]Y760-$!'.7M\/RA,&=N"2'#([?X:$R0>S
MLO6+ C!'EFK'$S,N!B;'#DF+UO1XAZ3U%9"TOHI OR;QO63,F7/!?KSW_.BG
M^^11@0'OD9S:.]@7%-44W9M9B38NE OWBU0Z>1DH*@1I71ORM 0:Z]*"2[H)
M 18!:IDR*(O%N_"EQQPBWN E%/G__EOQZ,ET8AX</G[RY-'^P^SITZ?3@X>'
M>?[T</+LV>3!D^G_]^#AWVXZ=.0G@2+?T:&0Q3/G/7HAS3G8T3L*9@6O_=W_
M2A?+[U\D=3-+J^)W.Y(BDW(_\3-SOQ-,6QZJ5%##'#)*AT*!=IPXE"Q2-T9&
M_L6@C0</]]V3Z?-_&X7.XOK"8LDZ>9P<<3';"Y-)(>^#@Y$"-PYN-GJPOT^+
MM QA;XQ#_$^?"FXJ*:5&0,H6R[)>&768'[FKIVD&"YR,8%IS YXYK\MS<;;K
M8*-(!];-E_4NWAJB,!^7OG9J(V8F;]7?'QT^2V@I);L,?W_X^)']BZ_\^\-'
MA_[K"&5S_4EI*U#LT,^I0-@J<J<\*S[Z)]]):./P$#]DJ-Q&>LWCZQ[;Z_S:
MQ\EO2IJ-D09Y^B'3G\,MI-M,3(=Z'SXLL9,X*EV35J'/%PSZ+QE YIF$XW*T
M3 OZ9A1)5:#\%(_5O37YB263/FX*P*NBL^&ZO('@%JXDJZ^I+X#,IPRGX9UR
MR)DP!SV:(>UC@8B<141MN4EQMN(WG_:-E#LYP!>P.BD:I6^4MBG&'T>06F,^
ML*KH.RV4JAEUI:^89P#'"+F)0]BC)2QX5!I@%@LZ21X?FLX:H\@RG$B5U3#,
MP7_Z0DPXVJTS8Y)3<B+(('^\__V3<:+H6*]=---!NKXH6MKSUM+9$>W("NTR
M]+XO"X#WHU;OF/SUPBF^=USYRI>\66I*H>5''!Q^+X]\0S[">4$[&7WZTA[O
M,8[WN3M>1:Z2DC]Z-IJPY1<'^WL_;?!&+ZE)G]QN3?J^27.#= "1P%NNU*-_
MG'S,2MJX<PMD_3:H)/^IJB_V?JPO[JA4_0UB!G!+E2N]<8X:1^#3K.LERG/N
M RW5M,#:"]%A2Q)*6:$%!T$X2 PZ[/&(L3MYW_'SY:K!$J2 $5\(KGZV2LKT
M0H) 0(3)9.AO6->?LHQNK>0(W$ &((] HGE9*TX6U<EY,:M)1K7TJGKO46(J
MDBB947S6J:E$SO+:^$<U"TBD#XS;!6).I9)P7?(;GJG' IZ^H!?W0B,Y.'("
MXUW1?DA>TK[6S48N3<"@ BB=.[S3 FM50UFMGX;N [W4UEG!]H53 W]DS9>-
M2QWL7PM@Y^>X^.ZRY42:[*7)Q;&/I5[0@33N%PNH.P#NV)$Q#M,8VLT.[F7^
M:*3)(JMG%1,6:URT1A.QB4)$(J[JV:QE"V=6M*323>Y7T'JVY041O9<.BS@8
M5SK2;CC;XG:>-@5&<ENHXKX"6)HSUJ&_\=.+NBGSL0P\G9J<\9%E&58ILE_I
M5],8E#8G N:920GSP;[.EI/*9QZL0X:_N0#\YSG*6_P5W*2"V! LK9&=<)"[
MO#&VF<BC+.DFV%#N-RXJ-HM@#HX31XV#A;J&0+X]K#C>Z(F90E7_=U^9Y. )
M+->#9YO?XM'VMY"WW,/W"0R^-EIYVK$HTM/(4D% B?:TV[SHT;=X;]GC2[SP
M5SFV/^?EWPS(6"I!8)&R[=X6)!7H;"9$UI@<PT6I#&$F+$@O!=EL-2>+;O5
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M[BN0+\ZQJCN-K!H-5:]G>9@$U)\D\MUCW]Z&2;E%=4_BH@7=GO]VZ5S</N?
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MJ_*&639H=K^C1/5F?1;- )$]\ -3P6=(&HLOZ.#5AF-QS=J&UEG6+ZW#._<
MPC(.=BM2A&MW\8FVK8GSY)Y7(I+5O1^'O"&DXK9ZB'Y23/(V6N3-S4^V=28M
M@/?&C@6_76JG29(\RF5>;0?'0Z +=72M-:<X=<?0$>GO:9,SS*=_!BZZ@.^#
M*!O^ZQ_#Z17Y4 VHTI#)LY04 .TI(U](EGL)O,6H%B+>?,NF#J5/X\)!'^'
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M>IDLET2@I'L7*3T4A21HE%Q;<=K=*K5'FS(FC^Y: 5 EHUKKIBIE<V[\HRW
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M1= JAB_BF!SM_<P)"ZGUE/V?E$ZLT)]J+$1WV.F./X<!VS4.M%CKRDEMWT)
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ML'9WMNQ:2&,[MYEUU5NEV$[&NTF<LCV;W[\0"4H8@P '("5S/OU[^NG+Z7,
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MKQ1Y!+VOH6+K:6N75WEQ08X=A616%!@S-N+M9MB4[ /1\IR'Q[ 5[[;7[:G
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MX08.L9HQB[&.8^8:;G'$!A3Y!WIC;)'",=&ALSZ)/V3\;-E;4K>F0"-X"4
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MU,2^X$*Q,\54(HZ^@NVO72^8F]'WVX,K#-/QUUOFHS02?JFD"1.9MVB.TY1
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MG3V3MR8KJ,3?Q$F&,JWD4X2V1).M^^ZR/J^EC) Z4[C$7J2/Q,OC$E-G9L7
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MY"#3$-_J&RDK'R2U=KI03<$U8/)M)M2\YL@:UMA%9+5M*9K/D2,0#NRV*CY
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M4Z.)R &7E> K:!P2AD YZ5L$OWR+2@-<^='$MJBXT>==,-K_(1 P<RA%R&,
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M_(&!J>E@T^GL!7@[6U).J'.5, S=JF2X@UY:;6+&M<^;LEX55*  G#T=0=)
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M7J@-57YL9M(IAFMB\SOS&/VDNVIS/WXB['?IEA;8T,.E@-S<9$+4N!1-F>L
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M\5P_QDVW(9_19TS"H4%F 8A?]'/!T*BA4BXWE.$IDP7(>"6%,B2<;%P;Z!8
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M(_N61TP489KBD5%I[<[L%?.)EH@FL65,SPF;UUW[QG#(1X\-6: XR..XPPL
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M6B)C;0TVU=])OX4<KJ5+&M%0JDODGXU@7GJ3V=;X,M(;+'\:OQ2Q#3;Y.&_
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ME\?& =5U<_)).(NG5("WT'Q:B(K.'^QO3B-@ATDCF&=JZF=ML0#BGW)['7.
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M0@&JN1=[D]"\'<VV1UCN)(65@V),T!R##>,5R*G$O2SXM8(>M70[<C5.7=G
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M4%SQE@_H'?]RHX]^$@/RJF^(V^]// (O+ZM\@<Q"W> _WX-=[4\\(J?AN,6
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ME/TMX'!WRYY_&@"ZPYC]<<C=80P/(+T_Y$W\*^O/5UF5)B^KCOI?]A>G=V=
M=S%=%J$A[DJ694^0=7_ >AZ@=9,C^MEG>XZL^Q1,]>N:M/X409?\G[IY<X<]
MA#LU=,.D][N&51R2-X?DS8W&[,M;P2H.U<&W'NA?"&J\=$=/FKP@:.^A0'CC
M8^;]F,A#,?!0#+P9@.+!H1CX84QD72^:?KE,A9?D:=8XW[PZU 1O.'[/WED(
M_Z=T'P_]"[<8M,>/'A[\QP\"RR7!Y90U/^ZPOW.GQNS0LW#P'#^J<3SY PW
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M1;2TKVFR<>0G?AC!=U[H&8&((XJ@'Y/4BZ-)5 ADG(5&C?TKJOPE4O@,),A
MCMG(3Z*_-#A*F 8EBS$1J-1I!)]$.8[]*#("543(+WS+)<K2*IXFOM7@KZCK
M0 &?$38EODZOP!.1B??#G1%(3BR.B!"F'Q3>&_[WVR<>ZXTC\]X M31F,YU2
MC6,U(+@3.(,SA="02A_K!#^(>&V7L*X#[L7Q)4JBO&#4MI,D@4M\!I\'A-3(
M@,Z,:S,S=*"QZ,-2O\%\&7&2X#@/X-M\RN O<G, \\S2V$$1=)@#Q^3K.Q-G
MFRY&[5U% ;60Y1;@<S<MXPN52_TYOA"&(*;Q]'I;"%?B")<5O"CW5$2J%',U
MJ9%O_,K.^&:O7&0P7)\.!,V@B-NE0:BP$P]HEA%BVP[^*1"?0-PQP8E.TXP0
M,]-!+'B@O(<2NXT(/33/.RCZ0 F.AA%^]M9/I GB4C5^@I1A C+#)XDNS?-A
M?-H*<8BX&=!F DN/WP/)+\/%-A(T ]1&12"8/CA34#^#+!I0^R"+VTE(7T9"
M1(2OEFBI0IH^J+,JFV!;CJNQ$M!1M6"\^((X^J%BPK\=T-RP=<] )6H8$5EX
M \#$_!\"AYIJP%1&$\YS(#;ME:'&))ZJ *AN&Q\UBW!>MYEW!<<2F"E\$/)G
M!"@9!2;!XQ(J\PCTZ$0+R48:/ZHT6J$]>K&0ALCR8#MI8&F@I@.[U;!3DZ8M
M#1H 4O:*-!2]^\?2Q(I(+P0..X18/-#'%^/(LV>/U K-<1&O'=P8)?\$M2,M
M22$Q\&ZBC,S0 ":U*'''#4QIF#@4QKSY/1V8U"!"SL7Q 5'&T0#&@""_M),S
MV/U#^E//@?1PXB3^, +ND16/4+]"@TW051'&ES:\?BD)R4SN% 3J$/N"N2.(
M,#E7>3@' H1V()]%97/1T3)Z1FL&]3')$GOP=C).J]LDA><FV#2,-D6=+AIE
M^V4>TZBCJ(*7Y.4>T&=^5O!1>O+?NJ?::FGH"];A>51R5Q^N:""U41K=6/:=
M%J%X\&Y,5#926GO0AW04X_8#6<2'N(/=CVT:HCR'NUAK=S_5- YSLQE$E!A
M<]3 ! L\B.ETQ9]D1(4]NV7 :+PI!Y/<J@W%&/Z--F .^HN(,!1+H?L6>5X:
M"=A'.JYJI%_.AB)^6RLZ\_0A->=6(NF&"CE8P24(.NRE&.GN!U$:\FO4]10E
M(C8B8&$:)>324WX&&@O\# ]=PM^B$U2^,%!H#'-O16>Z?'[Q@B  :@P'3?A2
M]89^' OC()X]N3=C5.&=DQK^9T9>"6>YFR1.;?=TZL_08I8#6,^$FT'P9_GT
MRAU'Q[D2S1_??]A;\'[2N&WGB\[\^J)^$8P1>Q][SOB517;6WGWO!78%P..1
M-9TZ:\#6N62O2N8AF53"-D1%1Y:;[#T=PM'5GS DH&8BI&YQ P)6W.=F@!K6
MQ/^AZA:!W3/SH[\/';T)$P(UGH2AA+G_!S=Q8*&"JAZI>=71V^W1@&Q[1^=N
M;\V[<)JF1D>L$KY4[Z28%*ST>_DLQWX3P%)*SU]4XISXV#HRC2UA;FP*^(!-
MC:#*OO$P<.L4W$3 D EILE5O@[36",0+A3H_V#'P;@P4%48_ON=P?&JM(A$>
M5)SA@-)M=AP,<9!98/P2F#CW_@#AF<[\F)RGMI>'A+'RN=$YK1:J#8>6[[K1
M6_-6HA?^]9T:JZW&5.YKAVBN^ZA":O1SPNV-GV+2*R0SJBT L*=.24<;'I@^
MG"43F,Q,GTO3+$JP"W1L]^A0J"7-H O_FA'H0Y5):$0:)Z%?SC1=I49-LL6:
M6YA<C5-03PKJ#)"I6%UB1Z,"9]XA3]NTS% -SO70[&KQ8>J&%XRB:F_"=HP$
M?8XC? /$CE&F7"J,P3L^>#--][U&WP\58ME3+[");NJX@:I,,287(#>.BM@%
M V(+=&O3)KM3C=ZPKR[@,SN]PO9?()/FNKIHF8M& *CS\&"8*GY_F9..3>$B
MY[,A1O9)?7=O(#NA^G:T5/PLFY&K!54>XRN&*]I_:+XVU[VI\BX*:(N749,2
M5CJZ9*QY6+\KS)/P==Z!#EOXZ#,:1HEU.KH+("HK]F:_)W.X2IE6L9I6UC *
MSW?C^^:Y9#,XG -*!"J/9!9V#P^V.M0DBS,J&BQ6^XZ+3/G%S/&68[:".0OI
MNWAS1Y:NT[R, ]6I/":'OMRK0,Q$E !"]A8Y@-WH9'TT=0^_O<XMEO1H-[US
M] =CBX RMLTF^,0NM-RPZR:"HT/Z,9*?>[,U';'2TSYG_R'V\Y*?D!TITIF8
M2W3.SS,FS5[%N6*;(*V\4V;FE\4XS4 RACK Z@W\Y,?=6,]PR$LU,B^:>$/2
M?W(GTNV1829L1:S I-8:&F^W@>E]:3P:H$I1U[=Q2DS3Q/C\;10FL1]-R ^.
MK<]@C]^!D3>]CYP)A+92AT<,:PD25P9C^[+HUJ:?/Q_E1I:;GH[(SG"*P;,H
M;VU3D1RE2EZ2I$GE-#16L0@55UY0(Y080S8J*='T"$E#!8FQYTH,G>1E3\E_
ME< DPQG>LYA*35)NGB3?%Y*KPVW]^.USS^,JT?D_4;KS&+>H%$L5**<%#FG1
M5Q&V/+ROZ$'18*<]4'AL1$7,8HYYH.$U;0[7? [7_N(<KC8;:ZVSL9H7O$%2
MNYYGUL6-"4R=5$$(XPF7D:NU&&=I.:(0M=G0FR"J6!XT")1\G)9Q2)H]=@*%
MBU&&:BKI^WX(8I!37:M*(=_&<H&%\!U% _7TY3YAZ.Z4=^4R6#IV7NY!3 D-
M;';!/P<^:E7E5)PPDAQ\X]DC/%'191LU7;1 :!'07\BME8>5K_CAA)(4,M;;
M*6-9NT\X9:#2;K6B6_OFZ.N#D,=$9_0&Y6-6L#!=@)^-.$"*SV&JKX<:7#I$
MEY!#B,+_02:*D[: >H'D* 02%$%K#.^8*)GZ/6G"_BIJ;,:-E"DH@;V)4>D9
M^_%0S]#-[N+49&6MS3O.R=A2]@C%:59GB0H0G(IH=,-[G";&L7]%%^^W0AT3
M,H")_;,,R>*DJ (:PRDJ[+4WDHM\%.72)BP$@N<2/=?9,@E&TG$RF&LR-P/B
MU(2_4V#'-VS3S6Y#K8>C$#$?X7=7?0C:W$"-(8R&0QC_,$LG0& ,T%OC ^D<
M/6Z<_%E$PP+W6TTTD+-5MZ5.?$S9E_PG:S=R[8"U''&M1)A'%.%#0A=9:>\P
MS;>U:,=ND$9+8\9&U=SI:,YVW*8G77F]AYP6>)O;+#W*@G*2DX/W<67^RC@>
M/]'1C-WUHESKGA)_GNA,ZY<:L3A)-&^A05)W/G#M#.<O5<*4P$96>6B6Y10E
M9F<9ZSZ^M *7@S2L$IO,F[%Q>: GK^;3*A.*NNK6]8Y;+C/N0A@8>3=M!$3\
M=$Z)2_5<DHF2N!;C4[^+3JP->$,!TX;]67O7^DNY!>'NW(NQQ[R_B-:4*QGC
M\1NRH](X&'.8$3E8\R(-?ICPD1#,-$@U]57&OT'-8/_G_ .MP\7Y?W<:/FUE
MH.%*DIU1 2:BMW#E64K7%[PC[/3.>^._Y0N2^8=>3"\L,QW?VMO:@$& I)24
MBFFF0"_15QTN[C1R5L=X7MB+Z%-Z1]5E[3DN:]X(<_R9UO5T^;U(1ZQ.T+.D
MDN'S\LT.2G-8CM[NW_ -%,46!2K*<SQSA+:4V3[C3!F\$UG'JI-Z'_.J.B%R
M?(8:]0[>.B'RW:V_Z9N&?I1)Z-Z[]./2?+X6:_"-:=0!DF+E'A]UF*S'?W58
MX:!1II-!E&AG,C4J%KM$\<$9P;LOB1L,$\ 2E<29CB\=.QE7<XHT[\"80#4/
MU)SX>./G8H]1GH_*)IQF>;O?\JUT1ZY\$'AM0/G>C_\YI /V6>9?4LXWJIJI
MG)8AP5F\UA&=$ []RR@F#9=J8O@:DIZ9BT<949"(N8]SQ+53CDFNKKD+<K9
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MMNBSUB!9N1:WQ3?I>V[AC:KW':,!9RX95Q7^+,<9E\S=/ 47W0J,*VZC'J=
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M!\ABN0)U0"Q:15%:[1$8U75LD*Y%F0T('6D31]$' R4VN$>>N@9ZA(HQMGA
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MCT#L!H7VNE5R&3B3;IV30I?#OOP[NQ_,HN5HJ%"1]QFO!;#J<^X4C2_LLKU
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M:,57Z/#Y5N@UV,3B6G\*H_A.G-E LC7AS/LR9C-S/*?6W"Y0NT#/N4 'S[=
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MV$G3 F/MFM#FI981H'A/RX(*.C5CH-J4 :40Z,QG"&J"VA7@V)XH;[PE+&,
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MH-WMCF-S<QXV[)#O"8?1Z1Z2'3EHRD#M":,WZ@XG[!C-=,^2U([567\]ZWX
M%)'^4]4G^>O5SZ$:[/9( W4[F'\KF_HA=C)%GRW8_#+/;>F0H[59Q</"5J?
M.)198"A#C=:B'",+:._A/;!)$@TN#5L+U19+M&T6:B*H:"V0DZV\!8-5Q3)
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MR$(>G@C !G"E!I%"AW7LPYD^7BQ-$<=(2U/?0(2Y']<9,)]//YCD%*Z&1@"
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M(=V:UK!('BUKFU,O&0\7%((X'7:S<4PG+,0O"YHS/?@J$["?4*2<X=COD/P
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MJB6M$?2Z"#);;8VA6F/HS*S0CEHCY[618^X%.4\-X>Z$I7Q*[^/'88>!0NK
MN)N%6N5@<)_NTDECM]/6V#U>[+:LOL;ND6+WK&VV*D>I-%YKC]=.JZX\>U3A
MHO(TF&M9_NO%TV!J!8MR0GPD:[M."1P:FAJ:=86FSH"J(?U<K=1G-<ZH/NLX
M4\VL0G'6G0X6MCV.JYV)8C7:[<-/.SIZ'/5,C:.:X\AJ'7XRU7'CZ,SJ'G(N
MR'$CQ^P.=?;$*YA)_@EG45@ZBZ+>"&KK,_IZ(ZA3-:"I$?3*-DX%$T?CYC02
M7$X@"'3'7?ARVC"FW.,!<T6AU/'<\9PP"JB^WJG%=7I65_NCM<?1X5^'.78<
MM7L['N)J'+U6Z$#CI];XL;I[Y* 3".U\6U.-_[2".UVK:@!1^S^O'#SH5;5(
M-89>&4-=?8VIWACJ5748-()>V1C=8PC[! (]C_9&/*TPC]FP3!WFJ3N.VGV-
MH[KCJ-?1.*HWCLX .SI_I[;8L?K[P<X)!'C*NNF=5G!G4/F@1/L]KQW<T>&W
M>F,(V^N:UH7&4JVQU.[J(&F],;1727<*(9Y=^Q*?6.A'^ZOU1I"U:ST6C:'7
M8B%38ZC>&#JSS*&.^=05.Z;5THD]+YO8$P6Q'<4!Y38[7L2G 1U]-8R0+UB0
M7FN_^7H+4 A/+2[4TQ>&ZHV@;E4)H1'TRE:JSOBI-X+VF5"B$53S6\4G$ X2
M9?^YJ.;6,#R^6U[SP1K9;1WGJ3F"^E4EM,;0:QNANC1/O3%TUFX/=)RGMM@Q
MK?U$X9X:XWF*(7IDM8C[C5Y_1U^\-I6F-78W=%8<[)@AI;%[ -AM=ZM><M;8
M/13LGK5WJ NC\5I[O/9VK696O^K_=8X:E5?_OUUP/!WSII@[Y,^?E!MT9'39
MZ>H^0<>+VQU/Y#5N:X_;7G_'0NT:M[7'K9;(QXK9,\NJWH&^?A;@X25/W7@1
M#W@8/<4 /-@SZ<J)K3IIX)5#.AH_M<:/SKJI.8(T ]4;/V<5K!Z=$+6382-S
MHDXK'>K,;'1Z%>+E.E?@]?&S@\>C\?-Z^.FV-?_4%S\Z$:J^R#%;57.]:Y0,
M=0"FS2?F>,89WO%_AY?\8:&P\-@)9U@' ,L]COGHQ,I:#RK7#M2>SFM[.I;N
MN51;Y'0K9*YJY+PN<H9M'<6I-X;.VCJ*\S*0_>@'\"?:./:,>5-.M_BI.>N)
MQ7.TNU-;W.C&5_7&SUE;%T2N+W),W6V^MLBI;'CJ.$Z5[.O/6*5QQ"=@X\CT
M&R-B/Y[6;O[8\L(JW:G4MSX.!Z^-EJ7O\QPC9H=5SLTT7@\%KX/ACA%VC=O:
MX_9L6,%#TM?OG@_N7P/_W@FQ.B48@>_ %O3XQ(F,2>#/GVX1'JS;<3:H$$_5
M/N%KG[3J<%>M$:3;Z-4=0V?FGIJ :>QL=15ML)_#EA.(>'WA$?4FT1&N;.W^
MZHDQVJ>J/UZ'[;[&ZQ'BM;M#KI3&:^WQVK=T?.M8<7O6[E<PZ72 Z]D C_:>
MC&.Q* J<41RQD<N-R#<\'[[WHL!W75%_2ES7.[%(EZDC735&CJF14U_D:-S4
M%C<5'%J-F]?FF_V$'D\HN+5BZOR5Q:$],_[&F1O-C"M_#FMS8-H;SV[N:)6*
M?;YO S;&?HSSJ.T]S72OFP'Y=H_PJ3<?6U:%Q-EG!\Z>?5G-)9I+M@O"=G9V
M_#67:"XY$2[I]G;._])<HKGD-+BD;SVM48'F%,TII\$I9^TJ&32UX1(*4?Q,
M7CO\.W;N?_DS_$<M?,Z"J>/1].T\7?XG#B-GLA1?.=Z8>]%[J]/L=XEYGA7^
M9NLQ!%B(@$MCS"/FN'QLC)W0CD-*,?8G1C3CQI*SX-P'2)SC)T/<JP_5KR(Z
ML?S3?PTLLW\1&E;+,HV A[$;A2!$X,< 1GUPHAD\SJC:$#S2,FS8Y8@;$\2L
M ?_G@8%C6*V+7YG'IAQ+$R6#?D@7A??Y+SWF+D.'UO#1\9AG.\R%E7AC)U+/
M?)-+@$=DTQ+?"\4ZOO$H\,,%MR/GGAMW?$IED*[R^Z)]?/2#N6&VSO^'EF9>
M&(YG7/^8.2,G,H;#IHD/^W$@GAN<_X\Q(1C"$GYE2WBQ@<-8:<R&:&2%4B0J
M.A:1P,7"#VD;[P/N,ESBQ8,SCF:25[(O2MIOI:^P$9!Y'*U_)4.&-L<CM#U1
M7+]3!I04-,[X+V^<;G\RXFVKU^]W6QU[,!A,S(XU'@^LT7 X:O<G_V>U!F_4
M6[- [6$!Y',^"CC[[9Q-8(OOF?O EN&;G_/\"<Q9@/PZH$E6EN >P),9YAZ4
M,K<$ZR]_'@4P[6;\2T&5CZ'*+^F1]R2[U%=BE:UF"R&MY)C<@M$9-KLM_#?_
M]W/MY^7(9"5$2F2"["-$3")%D#'S #W(G7WC]]R+,S<UGF$K-=(HWTM40R"W
M;  RC47@P'Y@8F/*/93/@%^ZQK((_'%L@[YF+@\;^!R(]P5SX4F0OBB:L9H+
M6_ 8-#,.Q4AF?[II@!(+YBR"'4Z7I /XDALS"J(WA/*Q00<X(2JA]\:9\\X8
M!? 83+R8,7C3IB&9"[.>.? K+0SG@*'4D^J[LC?@E=OO5VH#(;UWYMR_,^9\
MC$_!^NX=&_9_AHD,#/;H8J%A>-GQHH#Y=NR"?E7?^8L9K-F=PV1A#(C' ?CO
ML;,@;85C,QX"*! *A0G>-0W1WCV!.,#0C<?< # ZH"Y%61Q +3ZNGA+@1P"[
M\"T RIO28[9_#EN:^Y&T"7+[HY0,W$IQL!2_$FL)IHI8 GJFQ8M-X"Q-U.7E
MPX+2A_=!*8XS,]#"DY4 [<83^! 'N(.)'\#T3@#/,[#EN%@V#./Y^"BH![ =
MFF %<..+'X'>MQK*$+F[_O3K]9?OQLV7C[???KW\?G/[1=D!D4]ZG\5@<<!2
M8+DDHHF*4XOD+H(O$%VA7 9'\XI-IP&?,@7.!$</,\>>P>X &O#"S'^@%SP&
M&^$-@\W!4HJ CIVY0DP,B S ;/.B968@@186SHR)ZS\(9F.3"5@[L+;1D@;E
M "P?*0OAY >$%LY@=H _G_H!C0<6%T@>H"(%V;!YI,+J-LZPR@,'@+T=-$RK
M8\!<KC(HX:M.._T*$4K:"7]#G=1 JU<:E>X2$ :HM)'F.0+S;=MLJ7>!MP.C
M\U/30"&9//0 W#&.\?Q/R";$4^Q-V+T?T+F@ \+4)OMY(FM<V7$0<* T8;2^
MM7KIZG+<=QT'_D+0Q67H,"G=</QT3, E2!,':4UP"/H! #C'BZ7IC%.8_4&Z
MB72.XODELD9F0'SU$LD7#>._Q_""U6L( UN(2%Q.!ERPY'NP8N=R7X-!^;9P
ME@\P2Q Z$X>/&\8=T-</&O+.=R,&LF,JF(\XGS2(/YF$/$(V "H#H;@RH1Q7
MGL#^M_'9GX]H2"H/[Q$L@+/5T(3#,,6B))\M)O3@6_C#!3(E468C5Q,:K589
MC.7":(^-[==WI!R+G*,<40D9N>6,E4$J3GP).FOB1*1I41$BK%/Z)S*[NOW?
MFP_GYA!P!QM$V4CN%R 'E 2 %MY%22K=8_@:IIW$ :E9X3PK19>* 5#<HQ!T
M-JX@Q*^ A*5NH7]-ZP*<T84?",Y1GNBW[ Z^BI5+Q?.L^'PYW FOQ8E@.GL+
M6_@*M17Z^*CBQ+8O75!>:*D W,$S#Z8< T'B-WA2R!N$YT=^M#;T98AVBE##
M+$@,J;SI"=^.X8D -,XTP&22G/U,- M4^!^@/I3,S+@'<<*%P0#V;&P+X0Y#
MLP#,*C(M(A).N7&:(I*=7#]/#!J2?<DP.%L QL74([$&"D3HJ @$F P!)0\H
M^Z=DU4JJ+M+IE %+ALTX1RHL0RIV@53&65*9<'Q$F%GD@C!GC*H8A+(PXP!
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M4.:6CITQ@MU@DPGF7](FQ2@ 3I#NR2;H5&-)L(G"3.JJ)\2,Z\P=N2UFH/!
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M_/+IYJ^?KXW+N[OK[W?&Y9</QJ?;VP__O/G\>>=J$XCU#74F<+"7S5^HC;K
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M*D*5Y*&RLAO0^SP(E:FPH$14H@%Q599(Q>9D+, S&#HK6P02(6 53ZF IL$
M B=4K$?M39PRB#"9[0#'HHV>O_*;76NH8E]%<A!V%DN*.F(4BX5@F@%I8=26
MNPWIN\01)GG 2)^)^-HP@#_"1!,1B/,6\?$F\GQ:E1;*F1UD@J_2F1UN:\ <
MJ;$@%C)&EB43\'WL(2%3>CA"XW WO59_EY/-+1@QOO&!XYD?'O4Y]K$Z>!_2
MTG8AX%V$.(-(I/*(@G:Y,GJDADD]J4M:#9$EY:(/!D[=CP@VU5#Q"I"@XFR
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M']_-KYN.8F%><2L=AJ,QT5*@\HOBWC%.@G(H6C;+7(G4/%BMG;FN<B8XPY3
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M-#INY!PB2:*",$7T(E->%2DQU6!OAU:_T#E*"&[L[R*;CC2$+%LL O\'5?T
M(@9OM% ##,7?-&51K#] 864^SA30D5P +,\#VPG39AL@8 %WKB^L=W^1;1VK
MZNA(7Y (CWQ.["5"1Q- FA3!H+87\E=1[6T^=T@;)#5NI3YB]T#*Y'RD$;.
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MQ,_2=B?+!3C2EO41,7BIH@A.,#Y'(PB^=41CEDRQVM0OH:%44?^)!$UR+I7
M2#6./I22Z(\<%].I^'?V@Z^OV%EK&I8[B' '5-U0AJ9EPR)A:2**%>Z7QIQ'
M,Q\LR0\<S!.*]+ ?V58\.2H)<K:;"G&#>ET "8,1N2X(4Q+)5N=8<KU@[X3"
M3BV?6Y04I79]21:#\E0]L6AI,U/L!AY\8,$X+-^7Z/HGFA6.J(]C=N%8D-F[
MYRJK#5WN> 3/.BQ00/ ]<L\32#B30@PJ.=O$6M+B$74P@T$K3OPNXOA-XVO@
MB][$HK=1%H<B.M?.'N\D$F7$/?#'(^';E+S5+[QE/BIPTD#%ID.W3&,K-+_^
M _9K.!9M0+&YO/,#!^,L\+"@,9U_*_=R]8A#E%$F*8IGU71BIUJ(X,EGY@AR
M\]%->MHVPIZ)  ?Z58(%EGH%SL"8):%4_F/A!&F9<: -24VJ,:CG) VPCM;D
MOJ5"O!FK60EZ\O$4-4>BURMUKPP3USKR,;!"?(?UJ_T@H4<B. ([$H$HDYX
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M*[+I934#8K]L>X.2EHQSLKK#E$#.?<"Y4G$;I/&4?*>?)3GX'JC+# F,6.@
M%%+B#4,?C#ND.V3KJM:6D/W*&"2MC<8<S@M4FLPR"?PY$".8]0GCR@'1W  %
MYC\@#TJJ!<J;R4T#?U_:-D $OG>7C95]9UVE_,:%5<G5U$5VRX(@B@)G%$?*
M.>',SL&!;-SH@;OWDO_ 8(M'(?\]QN'@!1P]STTK/"61W+%$TH$0<+[W/N N
M2;>+!V<<S618(/NBY,)6^@H;A6"11NM?R; G&M \V).1,K#*@"+^.TM:0RU
MC)V/ LY^.V<36.Q[YCZP9?CFY[Q, O%3@.&Z[>\@OB2 ?OGS*(!I-V-2!@CS
MB37R2R&8*&:HOA*K;#5;"#,5HI);,#K#9K>%_^;_?J[]O#;"QVR)*CC#.@VI
M5@,5N:@@$J0D&2=Z>(T>6_'N-GL[*W(A.QBLUW4?D0P9F5@4B6@U9#1O7F:(
M>:2XD*#*C@4_YH=Z(>#EY6 S$X K[#:K"F@ ET=B1*ME6<8#+LQ%7Q&<.L]X
M:QI 4B[*2PD"?.J K8Q''3#A[Q"R)562N@9 8NC"]VS'=4A+(J:S+ACY:P6Z
M#(NN5S+:BJK_DGL.L;OD+##0/!"?-GEMZ<NHU0B1. I\,#'^(1W[1]&&2.JN
MDSTR1E"4ERY;A/R]^G !Q+YPV?*]XQ%XZ:6+/%7@#(5X/4TH?DXU $A7T@(R
M,U#.+']NTD^%4P3QFV4VN[WU/[>:YMK?-@W;;W:M[DZC;OZMVWZ)M?;ZNZ[G
MM=<Z: XZA[+60Z(!TVRVK=Z!+/:0B*#7[ \[![+63G/8ZF\U:GEO5]/:T-RU
M<#:[GXR+04&SEW=G+$_?2?9D=K?9E/"[ZK2M?Z-A<.VA2?B!VWP^ F.A;3;(
M M@BC^?1-(2#A@LOA8OY'' 9OC$"_Z&8JG%0(+I2OA2YQX5S^XQ%N44#:+.[
MA9#8U NR!)95,G;J#6@)4@(S"^F?;S(HO(D4=X7)R<(Y<SAQK<+FE&JBH?R,
M4-Y24#P.DI.'I)8+KP/G#\73C@^%TPX-[8.1#X?JI/2;W>K'G")E%H_D100V
MW C"HZ.DR[D?>]%S;7F;5N1' [JO=B;6^XPWK/?#/,.MLJY+>Z5O>7&@]M=*
MM@/!KK=*ZGMI9+M]6XW6L/6D"WBUOQBB"?D4"'FW+JF:E#4IUXZ4M4S6A'PL
MA%RY:*4F9$W(M2-D;5QH4CX24M8R61/R41"RV3MN*JY2S^)I%%T_U-8/LWN
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M.5,W61D !] .PC . @XVKS2A>Z4^#HC&ZSCP%YQ&OF(>&[,\:$(#A&RIO2[
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M*AMC'C''Y6,#MF['8>CX'AZN13-N+#D+SGVPM<_Q4WIS5OQZY<]AP<L__=?
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M =$><* ":"*E'@!146#^!Q.H<3-A+DMS_BQ;TKBJV"VF'CE:2B8)+E^2,2Q
MW%!>XV-L,TS6$$\9M0$W/X''+9V!Q<O%0QG&6?DW2>X.?M^G\X?<)(R8.,<
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M1&^0W2]95_6ED!+;FMOJ#C,_#VUN+AQ^9%$:FMB9<"#K!)QF L[1.@'GATK
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M1E@L#\*NJ]?"Z)>=Z ^A5MSGU*[C3#P_9 6J=>^&9=K/3WSTQAG0&OUY^<#
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M, ;YJUPH0TW+,$$H,<Q:L<)-%W'F+P8_3"P&?!5OU:IRV-_]708[#QT,BC5
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M/5AZ[[CI-N(F8A G-K>]Q7^8_N<?(_3T#TNW9?G7;O''G23'-H(L$Z/-L/6
MEQH@ICU3D;-7DS/U?E7_3.P6_J'<J*BV45P(%36)"/Y \Q&;(L[B2TKM<$HA
M<5"F4Y2" #=_E)<38]L@!&^P&R.&3\JN\MO%1"AVS4F5GW%4SD0KCAQN:\PX
M>67I0Q\38*BOE*-I(P7%(KQ><,,? AB'$\U">@<V])X+&WHSN; ZR]-*YN#V
MGF)W(SZ8.+M1=LB0/%...V/)RW6NJR0?DZ-,HTIR%HS' 4&E[E1-5ZBK"90)
MLF%GG-=TNV2VW>M.$B1BFQOV7SD%TRE"3W=)[CF+[\Z2["5XWC]+6/IS80E_
M)DML5RYG-E\[R:NR%:ZVMD/F6R),&^L7OQ8)(]615ECV3'GG,!W6"LCO0%;6
MLR&KV0K/-D_FR2M^/<9RD(B)NG42R"-MPNX5Z8[*/)&*]I7ZBRO5.S]3GCAK
ML*JK=-5695.SE)TP&91;UF2/;W<2&BN[US0<,?6(Y:I@!UX^.I'6M3'Q68MU
M/*/\-&A37YH9SZK4R'*<7Q&Y+<CT-4%E,BZDX F74DP2F435[=>4]T[4[4C\
M5H7A3GFF"YK@N\7<3Y'PH/NF-98X\1J_4,K+ZN)B[L@;88/OT)#V BI,6U/G
M\V*VE(\$(\C"5BWV@@625]WDV==/;3Q/Y<*$CNXHHF+2P[QU-J]FB6/XA2Z@
M\DRYT<TRS.KMJM'AE%5Q\>$L/0>^'90V1)6T4L3*A;*3432UA8$MAESQ ?"C
M@,W<J0YZ['03]"6$K(*MQ5\AS_''?-0#K@:^BD3."MY>]%@3CV1MW<&02-(H
M+]*C*^WK='>[FL"%=*B($;.]O#9H0TQQJUX;&\J'X:@WXDT\68%,VNN-,-M[
M2$5F=9E<CB0YX.5TK =MBJ9_^JLH=:G<61D])QF?AUOL:W6.:_6//A*Z-YB(
M[7X?W4<G[.B0V?;XD.QN@?C*$28[5GS"KX1->I'0SUDA'Z!["?D30UXTQ^%R
M2=XIE,>BXI[]7M7<BWT5>, 3A^O#W<2^*HO@.7Y3:1\"H^,W,UB7^42GWF?Y
MM2"G%1P/J\(B&\Y?<[&J8B11Y)U4[0J:7[EHPYF5T^S&+ZT99VS+K\4+#$89
M)AIQ13]$B&(+8/*9%<BR_O^\WQ,B1:7E QK K<$\;O+Q/0M*_DA9+YEB%&72
M[_#Q\"Q/N6KEOBPIH$.6N8E9'U0^X85B(J722_+J?+:4=C=/6T4%3!&P1RE$
MQY3+<74&2$JX>0MA@>F.()<N:K&%JJ%.*51Y:(45E\.:"V8+JE>O)1_59Y^S
M4+60J!%%VY"G&Y19XI6*AQE*29E>5HAO?#"^/XY5@D<^5R+Z5L)*/AI@)GSI
M39RM ]<UY?&T[WM2VL9T,';,HY K!A,TUZA&<^98 9UGZH(X1Z1064$V9* )
M_TJS2P3.$)/A&:#?<]B8YT(!@P/5+N6KGA#W*M, SKGSZ5/Q"H\[SM70=/,-
MR*)\-*;: HP-.=^>HD!.67?WH^R<]$71<FDEG8&8BGX!Q[)O,8_X//NB)N_1
M#)NP!NJT5HAZ&M54^?40TY;,;6S(;71E;N-#Y#9NM$PZ6]89LB941PP(L)LH
MFV'#(>@X \'S"U-$.BEH&MLI%EWDRO[^,1JNK.<1UJ#SXN;S)!^R6/2 %RO5
MU- XR7K,:\(TJ,(P3C*QMJ(5$DYJA-OS8,!S,$5K#OHI$93.L#C7ZF#=+'K.
MRM+1H2"U\6J/NU'W:R(L2.9)P:)U'E!>DY'Y1HGX9!56A4)R="SEF.8)RGB&
M:2VL' H8B8E/]IZUB:D\R0/=29A@E=5,RALP52XIK_R8^D*SWVWI/;E#G,-]
M-G&.CS/C'$<LYZJ6R/ T(&=%Y7<'O0U#49B[DV2T3/3;%@7BPL#(WRN[71I6
M<1%QZ7NE/1BD0'1%4M'T]Y!":3\7M8'UULT-ES]3@#OJ*Y]HD/&QQERJFIQ_
MSTBWZ PSME%CVCU>^#$E631Q3&-"?RS<4'Z]G''.6\;1J 15X5((ZT^%.YYU
MX'5SY>L6GFR2KA1K:%7V'Q$M3;@YS')?V#A<?-&#3-R\O!^H#HS1,*Q?..S$
MZX/]C'A(F[Y&N.\6'XH%$[B[\%;_UEN&IK7@1&LF2;7]-M]^MA+,0^!#7(M[
MA23O*$':QV%[ X3*45^T M4-^__@V^!WZD]D;9WZ85EDBI^S!["[/%>WR!X<
ML4@L;DV8HZ2;I]PSU&/BE0F]F8='SL_16XIQ"7X0&'E@?171T$JN)BFT=BBL
M2#)@8_)P;.F_=1T/G1W\Y*&(AXE[$\S0S$7,"!-?407 ,V,E^8([9ZZX?I-R
M#>> :Y7ZRB(X?-AD2=A\I*F"2\<!;I5CCX3 35=E6F;M*RIG)S9K$B<]E>Z[
M-_7&#.(J'/D#.CD;ZC9,PTO^)&0G]&'S+K4B9S;G&< L/,4W'6U_!C6+WKHZ
M%KZ)[]E=1 XNOTN]E!%8M\O"8V QE+<6KLB^D">%'PT;>S<_A.\R-R@*YU(7
MNR+Q"<ACV\>64XT#J!_ >4I$%!*)*8])6'>+U;Y4;.STQF\UJ.!+JDVV-D=M
MVF0E:7NFDE1+CS@I(QY%7XJOH!+GK"\J^J$841P+S_E>GV7,XP?/%![GYA1)
M3Q;S9'FS/5FKL)7Y2OJ_[M7_]4!DTHQ#Q^V3,V5O;^_VL.L\%VM5U^8 L; )
M6M-*>2Z,"Y%0JWQF+4]0(#Y3[-UKR@\J'#>U5.CF+&.E3##F'1+'TFZ*,(C0
M\IB:?YREUS=5XO-S5?C/FFU0= V3*.7)!: H14R+I+#183YAD?*/MGEPLK1+
MRQ8L2=6_F_8&W?2&\E'$8^'367;GW+BHR'1 8Z/R.Z?%%<)1UL6?60$DJ)JB
MWQG-6>U761AY1<>SYC%RC@Z4NNY96.-E.RU0>N$9@YOJ@K&- (NS7]5&BB+$
M7S0 >0XZZ?#=_'"IX<;Q WJ,.#U&F K'..(=KP&%JUY]^/7KUU9 1GG8X?V:
MML &>\RH*:OV0W=HG^7K<)7_IBP$K24H"I#@3JDJ=:?L5I6S:6@X2(;@M&4^
M-:;%/-0L"VBL*</D\?(3Y3 MCO7VKE?;?S;"3)\IS"KVKGO$GBFL+B6LZC5T
MM-R=,;_(0\JS)8G5,9X-L1HSB?6TZ'QX] L;9G:20=VM_9'V*6_+*#[G_L]:
M:BZK..19O*?HM>FD73S[ S(</E]W^,I$GU=9]Z(K-?J4,!$2<V*8).9?%PZD
M,=;@O5F($ /%>:7U\RK:X0;5>:75>8UGOVX<FSV;.FO=G%UV) Z(\0J*6SBX
M?(Q[SC)8 _?HB=3Y0DE5]LI<A)=M\]0YJJ#X;&I#A[6-+!I<\"TNVO-6;4*B
M8HN3VA9O)),\FRIHW9K)),>EG5,KYOQ$Q8F=<J>VE"F" Y@9AYL3\[SFF+*T
M2,RU%SL%E_=Y"PTQM:J>U,12H=B0ES[/[< ]AA_T!R-_Z49F;F1_+6YD5Y=N
MY&?O1O[SUO+#?3:UW;H]Q_!>MJ?#FOK<Z4M(E<?L<_>:O-F4'G?.EJ_C/NRD
MX4B4@;%>.(35IY5]-8H2UW<OI!/A:WV#3LBT<!_..KS[%B(MD_^-17P3A<MQ
MT=@(CW"J)'6R54I&6?,PGFF%0DKYI.H*;ZE_A_C#C)/?A&,V-NZ8"["\7RA\
MK)Z172#6 NP9O:4LN2LJ"PN!3F_8!_VQ3(=RX$M)WQ-EZY-Z;B-SP#W@MFLN
M3'U\R>O,;F!5-,!43EE'@9MG:J0=IOV&Z,<*&NZ+-'%T;3TFCBM-G-5-'#BU
M4(4EXVBF=[S?Q\W[)V/W[!WN[/ZEG!TINW]]V?NX=W:Z"%CP!>P9+S#DR9&3
M!]$E@YR^*WYX'R7YH$MNWB5]MASVI8D-PP=<42R:)EWQ$/8\_K$@+=_?<C47
MJ6N8P?^CXL&"\+88X;T=1@V?P7E;YLR/M2W]EI_9YNWN.F^QGKNE&=92MWW+
M-H)O!FPW'N1_7YFO*E;FY&T,KA5]_ A1Q9C:\73P\$3)X$*H3HS=#T=8;UA2
MI=B".6^G*<P.6N;2)3>"4]WC[H6RPRKD!V.1[B7.7' A<BV\J<*P3RE6O8$$
M,27AV":86_H2%+#4NRY!'NO?LV:E8:'>>=?4G3E[.B]1YS^D4;913HGO'WV!
M2B>C,:AZP^'@W=NWF%8$R]PZ3Z_>MK.P TI>_I9&YR1[BP5%;SW/MGWM+:Q6
MUWU3-VS=-$W=<_VWD>V9CFM$]-K4MSI#X'",(O+AVT6*SC#I%ST/N+'>'IW#
ML8G,=ZP4TDVT:1*07JSVLO2Z%(P+M#O1^?T_;\D+WF-1-_*R-R%7ML6XKG$G
MCN*!B<=)"(LA&:TI2&&<SGBM^V3\:"QP5!; DTE-^6EJ"+,$@O&H*H&$]2?!
M;0;GML,4A^8BHK?Q%,60\C])E^)0A>,.R7HDI"-VP'G1;8&/1&G!K^'6./@K
M2^*^(7&_=@@O&_<-B?OKP7U3XK[$_47<9G)N6P_:>\NAO2G1OK;U+QOM38GV
MZT%[2Z*]1'O&;9IO:[H&G*9IGFT"MPU\T_"MO^FU9FKZ/#W_(ZLY4[ZPHC.!
MSIBES*&>][7[.@)0UQW&@=XR_APQ9>YEP/TR>_\" '^9;5@.\B?(30)^"?BV
M!'P)^(NYS9A6\)>'>7,YF#<DS$_O^$N'^97\.!+FFV'>6BJ<*V'^)<&\JVF&
M8SO ;:YEF!IPFU7H5'LL,W&4T<(QP\'\@,"-1;=,W6TA(['"PU[:/U_-W8/X
M?CXBV*$/"[8P6Y[U@<@H]G5@C4U(_Q*?B;OX P<6'-!N%X/"L)1A!B1#:3F2
M@66F*BS=:8CC511RSI)6)VY[SMKL%(U+G"T;]E<YI?TDS?@0,7C10W:K:$2K
M"C*\V-W2%EULS95N7*Q9S99,U<2S$>+$K-4ZSDV>A 2Z$NADF%("W;B[T#5U
MW;.TMY&AF[KI1P!T\W'N*!RF9<M]9*]G '?V8KBS'Q+!Q!XKU?9*#"LQ3(;<
M)(9-8IAK: Z&/'33U)W%&%;,#5%T[W[QB]US20B;!"5_3*UZ/#!JV"R)1B4:
MR9"01"-A.O(?T5$#QJ/VEOB:JSN^IU\9ZA4'E&M>U;:,'5FZ:6X#3"OC5\K&
MA]P/BAGV M7*F>_ZM*8REA=@F-)D#;K2[36%73*Z(;%K7)/RX+^^88,FI3FN
M9R_6I+Z.^E31[P.KDH?'*F^Q&>C>*U:-[Z9$JA*I'(E4$JG&D,H'@\_0O;>1
M"^:?K2]&*JX'<!/&GX"J^<':"0.O3WIL2A!CO;D.*N4,<:9 @I9RN-7>&L>?
M.WJMW$6JU?W"U<262KPJ\<K=C KALEF%Q*4'PR7=MAT--"C7<G3#7 :7;A3#
M7#,L+=*"%B/3.-2XLWU17BT.6#?UQB[R[QF'8 LM"4-3,.1)M4G"TS@\F8:C
M&>;;R+-US;16<)6;VH9CE+T,1MDS,0K?[QXQJF$?)5"50.5+H)) 50<JX!!;
M=PP-@,HW--]=4H]B7G-#VUB,<AY512IW1R)/E?JI2>B1T#,./:;F.SJ:<*9G
M+>%9JD3[ Z//G70B?QF=2'\@G4@"TS0PR:1T"4SCP*3KGFV9QMM(]QQMZ>@<
M\\]B-O3&H)*UY;GV#$OM_N-KY7ZL!VS>LHZA&]$!N+'WZ^:T!=8GMK#V3]G@
M=]49)K+QK6Q\^P!*B"P8D4K(N!("5H%E6_[;R/!-0UO",?.)!AFH$C>*SCR?
MAO$PP?=I->2N)7'P]H\9;6_81VDN54@ERT(D4DT@E6&[M@=(9?JN:RT1BC^E
M@V$]2',WJ+I=(=L=<X)T4&$6Y 3=KXE5E*Y9*V-4':(> T,FQU4^,WR4A2H2
M'Q?BH_'L\=%:A(^+\P F&RD_$#Z^ !U.%J1(C%J(4>;=,$HW7=O0?.7CUO:6
MLC^,ME:$GD47-\-24W'O'=6TR0Z_$H;6!4.RVD3"T,+F:V4_*,9<;#Q/#P!&
M.>W@F-&)T3WS%:/%YIAL_#>QZ2^[\9^U0G_77PE0'%(.DS+)$,D.Y=CN==@A
M_7-&4;TDSW'@K6P2.$\L/&Y1CQ0+&\2:_$>#4YWS5KR0I1N8V7U#.7/69B1R
MS;3DOQ-ZCO/04><['F7Y".N?09F#*]C%NH'73_!LR:_M<(@?@X(,REL[5]H]
M"B\4+10C,\W6QOGM?+QS+,9CQTD.E*C<4)(I[&FUW"V]R&=OB%3X,K%K&D=D
M58[$D7$<84#BZ 6.Z)J5CP:#+ALO#R<#S^&(<II<@QW:!X%^6OM<66@*Z]82
M[CK D0SH).>]%DHWVW*&,6(0MVW)4 F!XDC2K]8UI\&-PA.A\*L<G3Y^:3]K
MK6[%(W\)BNZ*6Y)/-!5:I9F0KFU9*_I-0!#^4<FVP_2JGK,L UP;(U9E#9D4
MJPL Q7M\L?H:X<;0WH.88S_I[]_<GZBM]Q-J$K0E](UW/EHFJ0F U'XL('W^
M-H(AJ](DF"T ,Z<9S#ZEH^S^T&S<=7V?1D+5%64*N2;Q9EYWDIGHY4CTNC?T
MDJ5K$KT6H)?[G-%KJMG'0@B;U[QD)H2Y$L+N#<)DX8N$L 409L^ L"2^%8(9
MW@8AV(KZUZI=30"\/ E>]P->L+=2_Y+@-0Y>NL:2*BOPTC$N6T2JYV+,)]#(
ML..VB#,SS#FA^9#Q%^"#I1SU^DDP8I<#X\)BE.,N ?"A<8P1;?B=@TI[D"7=
M N<TY35R_ZM5;_OJS4(/_V0!RTL(GLP_X!<419J_$>O)=@#BG4YVX!U(5VLL
MP5S UOOG+Y&D.BTE4L.8',NM17M[^8B<9Y0IS..IM0=D"+<$!10%1):$R$ZG
MPS2\5+[U ?+;Q;>4U^65^$'^1F'K94R]NOBZ;1SY#X"#(>S23;,**T#F'WZ5
M !@6J1'> J\"E_;H'/L+WF)XS8M!%EGW+9%E'%E\I@&X;XFN_?./CA:L6H*,
M.0XL\*$CD.2()VI^QO+$&J+<(X#,+."Y#8#PK*HB&7.\\:>S>L?A%P,?LBQ:
MPD>#8L+AXQ+'7=; XSI'J$C',60N?+P^3/L(%:-A"B9"_=(<[-C' )>U9'N[
M3?:/)[64F3 C*YLES"P+,\YUE&0TG+"!=MC?@$/K-A"K-62FCM+^1;*HCCR"
MT1DBW3/8S,REV"BP499 &]G-<]ENGL;$%LINGK*;I^SFN=E:B&QL(+60<2W$
M95J(_38R+=/7C(A>Z_#'IV#@Z#.SG^ZD=/!."T+S<"9G70J%1)HX#> BR^,E
MN"QKXNCZ-;!B+YWRQGHUFV8::XYIAE\CR%Y_ H@ ?;P9_VNS<73/2#2S8>9&
MF3\O!HAD?;T$HH;43<.NY828#'[B+!^=(\B0<2 Z.?TV"3Z+46#5?FSC"8T8
MI[E-8V_E)>3T+'M^ N)>#-+)DF>)=$NK7,9,E6M!5LW]*D_WVY9(*D^KIHX_
M;N4Q]T5R6)'8\=A2UN)2-F7^'!"TX]C1[!%:S/%W:\!R:T7II2D'<H"DY/#E
MM0-SMD-F,]V_,L%EL]!F0S+\'QQ2=&/#(67^ M=2;F-JE=)@8,JMH4\"B:$_
M0<_N3-ODKAFZL!MC"LWM2X>4%P M&Y+B+Z'E$:#%KMLC*K='D%5RQ( 50>;L
M]$1Y;$B9&2NZ#:1,#3NIP4I9(6_(LL39T"+3_Z6-)"8.F1;<V=+A'[J&\VUI
M3'1+N#S^)%V*8'(,,-$C(1VQ4T3F!V;LLR60;HOGCF#1//\)<$*?@1.\^%WT
M@L3K^#>:+RX:1<ZHJ.=?Y44^.FOY001J 0RP1B*#009HP'@='\NPLY-V8<MR
MH8'P>^CE39I0# PK>LTO;+^TF21SJ>,%5-?/??\<**A/SKF4/<[2ZQME.\G"
M41?,:Z0__J=3%)[L$IR2$W9H-.I207=6NU;S6M$T;^HU0=2"B*OF.J)Q347%
MO(SV)76!D.2Y1O*L6V;C%"5UJ"8=2M8V21UJ8FJC;CJ>X[Z-#-\!GHR '04W
M_FMXS?_VM^D]6-\AUES!T(N8T3P+[>,L\PQ>(0'K$&\Z8'B1EWCQ^A/<!>RM
M+05V0-4MWW;>C+MW#!FN6@PCLCA!PHB $<UR+<?7#0V;.3AO"1A)KJV[O^FU
M"LAAK%">4'ERYAAC<R&AT "8,_AEV3Q+'<-+T"Z7VH@9D<>"?E:O/M%GQR!7
M$B4O1X1L2 F*E!./W?+/JO?\*P7%(.FG<:Q\3/L@ L#J.\](3]FG0W2H5R*#
M>Q,FW.?:ZFE-SQD1E]SY%R ;EMP)V7?RD42"+ :2TF)<BX/;NYK%M3A;\PRA
MQ3FWB_24?5GR>NAYT@^Q9(1ETN28[*ORG(%TN>-Y 1)EN8V8G3!0&AQ_3 J6
MZ9:CPM[0)NT-T7?4DV[OV9)%%E])R3(>?7+P1QO'P:ODO"?Z=^WV!MWTAED6
MM1J)^JP-T1;?YBTG6DI A[\H[2O+B:)J$,C7-*>#CK*]I1R3 5E.PN@OSJDU
M[ZQ>@G29]_ZS2G XA7AHJHQ%Z17#+8A62HCIGO=RB*>4$(O;+1GF8D'Q=00@
M[MU50&QWL@13ZXG2#B\I)L$ND0)_/W4VLLW2K5%%EO5)5&DHW-7K-3CX7[WP
M/38F4,Q#F]*UJ%<CZ03D+)Q&=]:!C0)P& R2=#&X:,CSJX++M ?T%D/@EFD&
M^TP 8T,J\R1@; I@S)V082S61H1WR"C*89<&!V&A?MI2/J=9E#YB 9X<D;$"
M@&Q(_9T$D$T!$*YQF'YMG'? >'_ +9$XI<LZOX["8<K"[%H1Q133;Y?7.-(>
M6$(1N:3#SCV-RA: Y]]K&J=L/;]LZWES8@MEZWG9>EZVGM]P)4)6VDHE8H$2
MX=65B/.0]I95(JHTJ=LJ$:>4](FR3;)\EE5RYY'U#Z)$/!.PD"5E$BP:\BNM
M>G[E/T;59V@Q1+ :,+V$AZ5Q@?24W6Y$\SP=7=X\;'>/VDQ@8SHWQY19G[/Q
M0]:22?P8*TG5/=.T#<M]&]F^[1D^'W0CZ@.2#/@)6#YCN$&ZO.1T&D.JFH!R
M(+=@]T\I%JLVEZIN9S0"=,"_?0;^)OWA31VDA*9">FG_?"X>M9:-]X9 C20!
MVAH%>1(E),,[P/+G@UVNG//5I5G>4BB!*^$[/(K;)_TP@7U)^D"\PQ%K[ZCT
M20_>;LBQ!;_?Q9?/<O8Z29Z/< Q[0/J7_"\?21:"E9C##_U+Y7A_FS5U:$=@
M@2?Y,&,^#-B711UDYV<N+=#(&O)8&LYT:4!E[\6OGD-#V'X%?LQY$XN^(EB*
M[]PPA3\#Y QN<+?S$=[J]K14ZY(!A(FDN_4"P'Y#JKXDV&\*V!N&;CF6;F+_
M <\WO#K8G\+S@'LJ[FQ&\/\AO<'[I?FN+B3&^U,O ^OCG\(*,B"OO"4^+= \
M9<T0)C&]AGWX_/+CFZ>!YG-UYAE6]1A\W[8;^ N 15GY)&%Q,2R*<+\ N-4Q
M[?\I^VDO -[E[):@^VR6 OH(8-52MI-A@C^VE,.M]A:#J1-ZE7:O\)I/)$RZ
M"8)Y W)QN$^[$9RH<@JK$FCW[;3-;G-& 8WFWN'V^0WWB'W/.KM],:6_!.B7
MI4D2^ALROC2GEB)JH[$[-T64=5B\F>J,4&9L\((E3\B#4SC@ZTG71&N1YP*S
M%^"9^TDO@7O/OG!_= UF.NCHYTJ^]3__8IW/LZTN=]*VNS')D_,>44ZW!@SD
M%\&N?:_#([RF'%5M]0RSYX]4IBR1>=E(!3?SL0RMYJDU+-LW3)#=EF8XML-D
MMV_/P:G])*3]G$X!E0B4\-1.8S(DC*"A?"=YS@MA!'2(H,\<*%L +3Z#EJ8[
M*+PQ]!K;O<-+3?LQ;]$@Z@7@C"R:D3BS!,[ 91QHBJY0I9N00TK%@?:#H@JL
M2\+*!L**+*UYV;"RC*'E31E:#%"P7W#I_EE)KWD.!MC,5#II@#TL@LG:GI>-
M8,L:8!['K[.,1+1'LLL&='K-E)]"37ES*ROLRZA_CMSZO_%P#;:8)Y6F#80<
M60GPLB&G(3D/_NL;]MO(UAS7L^OY&D(;6I3:*]+"BA0NKA&MT!_ESLEU*_5B
M>2*Y=LJ+;!"VF"9?0INPQ;NP7)"ZRKM?;7#V"Y"#LLA%RL$%S@/36!BE;8/N
M#&)G! \@#<Z"KZ3/S%]+=+U8/2%QRD5P>M.GV?E-@Z@KBF;$!>WH"N?L1K=4
MW\W)[)CG#+A+DL +$#U+[L2&N8I>7(VF*6NLI/@:K]'4ICA60S8J./9TF Q&
M7?90-HZ%#H=C UQ+UM1M(:P2WASNV];I%EP>CK)DB%)J'_YU+G)-%\D0[5X=
MS7X#>NA^,3%&HL=L])!%.U-[HQL;CA[S%[B6"F_->\M,3/4?ZQJ9B"-',6-#
M.4Q["7>F\+C38) F_>&"+I;&9%>(973@;9)UL97Z7D@Z_&&(" .*#2*XDP4'
M"#(XZB;YL/+.W&^]RYVF_KP\E)$U,%)'F:P,,&S7,]Y&AF?ZMA[1:]\7#JUV
MEI'^^82K>>5.,C/K8DH0X95\ Y(Q]"C+@!M&0I3M=^=!BN_?#5(FG[4ZGOQ+
MMK5;1UL[2[:UDVWMQCZ3;>TV7L.0I592PYC0,#0?'1]O(]/T/-.I:Q@'),<,
MDE,*PI_K!/>@9TR6[K*FU]I#:!*3SUJY,]5<1>)Y (8E*YXD8"PV28S)=&%@
MRT= CQ7MD#N5L]_>#GD!J"'KER1J+%8SC#))M\]M8@"+["H)X74V3=&X8^>+
M6RH:2WDLG@EDR-HD"1F+(4,,'SPCU\!56/.X>5 Q<P*AA(HU084L I)0L=@F
M,1MLD@?%C16MD3OAAK1&YN"%K."1>+%8M;#JO?DIW5C]PI+ZQ3WCA:QTD'BQ
M&"]$CR>LF.MV:3C$],SC+!W :=YL+'C,["0GP6--X"'SS"5X+ 8/IR@7!M#8
M9:51&PL9CH2,>X8,F5PN(6,Q9+@%9)R+HGA@KQ-<S.9!QJKCB]<$&2\!*V2*
M^,O&"MUS--<RIL "N\?KKE<V/2@:0Z;D ?(NBJIM?1E\8/TA$2!FWKR$BS&L
M.RT;JQ2P<:KJ:_" UD'C,;AZZYDCEDPYE8BU#&*)EFWM/(>SX95Q\/.H-ZCJ
MY\I03@W1EH"RUH(JEZ]I3@<=Y9@,2".LF<O"FK=!L/;RRN=LF:LJD689I/$?
M#6EP/G-[JS:B^6YXXTN\>4R\D5FN$F^6P)NB+< CX,UV)P/.!PA1#K:4=G@I
MVM;>!72,V]AN8[@C0><NH"/S9"7H+ ,Z^F.;4Y^VE,]I%J5WA!M=ZCB/!3=
M0_K_E7#S/.%&K,?0=62"LNG91)_H>3CPW*G?E-3_[*G?'*/^[;2?,ZD1*\=9
M$M)?( BR3CK*Z7:*B5TY;RV^OW_\W(G?E-#_[(G?'(?^;=S_&$Z@Z'C) OB=
MA,:@C]%PQ+KP'\5P!;:#&F7YB/"BBE,:<E4,></4C.*[IR0+2)_FZM%UE]Z
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M2*KO_U7P/Y]8,B&F!?Y*AIVM%_+N9?HCNF&G_WE ^D1,I$)60/91T@Q^[@T
M3\DPS6X4T%+[^$=2C:]:=O><)[Y[_T+".4XS%"<Y]V GN2+<[TJ' -($F'R;
M]A*&, $-R0@$SK!#;V"_X--TV%%>)V^4?CI4>IB<A&YX1)[7"?SU5SKJ1DHW
MN:3=&X5_E6T]#OZ#>^-4ZUHR;;.O/HF5P2CH)B'< FR*L)OF-'IQY#V7RH\
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MG'L56T@#%S0LJ0A)L% W^%&-*Q; ._$("5<X1#F?Y:/@HF975UJ.6&W.5A4
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M1)QNKGPL)1/+XR\YKY(!<X.]7!9.!][KT:H:!0@?QF1P0=+ O=) HXI;I,&
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MF)E0LT^KLI;*4F6W+5TWL^Q6281W(\*BD]VZ.O,T9@ 525)+ HT\UP<!E^6
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MV.4H=OT ZQ#!P+I[=$@Z2S:7<=>EA4C&O1_&G=(T8C=R X^$JHL= :S0\=1
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M Y$!")[5"*%O;=-7 '<7P$NP!BJ [P? +3M 9M6):9U/W"PS E0(XK@1! 2
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M;=QFT',%=Y?!O72G507W@X&[Y<'"H&)"FDB4" 2,,67TDRB3VH(R6CE.56?
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M^A*>HHF 5XF@+YF[3#.7C."1R[4--6?8<>6C.ZO!7>$QS+,TF-F<Y4FOW^3
M9$K)RWYN]K+_9EI/[WB =6[)4E.RYV8ZV6SV*&ZI4$I DLE&K11-)BC!/8^S
MO$YVEM?)_CGEJ:'Q69K3ULFXD'<SDWZ6_E0G,RV#LS_/28<"X4T*#(D$7<)Y
MUA 3N2#1<6&"<9Y&L[8!ZVT5LJ9IKRJ@YYB&MT3S?*6LC>;_X. D5C O"<SM
M;"'%,FBU)\JC(I E1DRB,A^3(6\)#LX;L;9A*Y97#LL+Q;BE=0@Z2,<8\*R0
M8S(0O7;2!V=$N@:8KPI;553?+:I;&3<"2QU5\3)3R$>T5)'82+.1%6RP43)D
MJLR5,-THP*B KNTBJIRJG+JK[)K@$G.<&T81(&KCG30E)Q4H2PEX57:[>"RV
M@[$6)0L)&1%9K2$ .I^+B47"J'/4:8G)E_KB6F"\<F"NI+L:<EJ =+VD$&/2
MAC$$J[P#H$D$KB0P4()5TNTDZ;9"/,H(81T@<=I3 EF6!#/KDB"IEI13M%1W
MC'0?64GX?"B^N20>\M %X:M(:W7H1)53E=/#V&:W]UV>5Q,VPX>3R?0H#J>3
M@]%F7KMR!3AXA?VP,WR!Q_TI#AKN=!?5A=?QOR?]27\:W\3Q7WT?9_K%Z^A'
M[X?-IS2J1E4J%E,JOLQQ<#*GA:,R&W)0= K0.A]D4I*@)8N!<>]U&63 VQ[.
M"OV.0[]2=)53E=/C<'/6H[1S1^D<IZ@)D3/,5KG/)RC0Y D*"R3CNE2R4:8\
MK6?I2F*_<O1JR.DAO:*5H[O'T2T?*A61BA03X=X* C(E8IC41%%K:. @4K!=
MX^B:C+Y]=#P8?8ZQ][$_/2SU)OFV>E/\E+]B' <XC:$W'9W+2\>/. XU%[T&
M *N<JIR>4OKHI3K)ZQE1'HP.\-/O7VGTY6A<0[;+4#?H'.]J5$77\)K(*#R!
M1(%@%BY)()V'E%!$MK8AVQ';FC[:74!7XJURJG)ZH /R#AVK]8"\\P.R[3-5
MD5'C6#;%E<HG9+2:..".1!,=MQQ+Y50](5<,T95Y5T-.BS#O7;I+*_/>/?.V
M/*'6V6@,0#/[B0 R3A"U)CHDB%0S"RQTAWF7E$BZPC[0#)*8@= ;I=)Z-#\S
M[/F3\3@._>?>=)P_>3!KPC$832;Y:T^.\^^A/SD>37!0WH3YX>FD=Q@'H7Q
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MB^\[PO'[_O#,WVZ.IS^</E(<[.9\S-#'$M996W(\@=&S<$+SB<_[T_QM_NH
M R\!AH/#V$-?6FGC\'-_^+XW'$WS]^$X/SSL]?.UOA_CH'>,XVEOE'K3PSB)
M>;&'3<@ IS'T4G^(0]_/+YI,\P-'^?XFZ^>7JK5@IY< ?%V7.,CQ:-(OL9;G
MXSC :?^O^,/'?I@>G@7NOGGCZ1+3KV]!ER_E9'KY6^YQ[:]<Z9?$SEN5KVO3
MQ/:D3BX*KK26%+PQ)C'@(1CNK'5"IS\$U6MG[SH<G]W$,;Z/Q(TC_DDPY7M\
MCH./^'FR]J_S^S1OR0M+?]FJ+;*E_QDKK0UP&H#RY]H'G3XXV\'-!CM[:':5
M=)V6I3Z+3YW>0@_LNJ3EY_F_'WH7M*+0S2[X<?.W-R]^[OV\O?G+P<^]%_N[
MKS;W=K;?W$F0T5[KBF8AQIV]%^N7\MN=+][UKO3%_MZ;_5]VMC8/MK=Z;P[R
MC]WMO8,WO?V7O1>;;W[NO?QE__<W7;^)[_K#7O[401D#_?T_G2@%;/*2\Z,Y
MQ-IX&N#Q)#X_^^6'LT.P/VPNI7G3#^?!7;[@0C"W^;[9TZ<,8>VZD:*0Q*E"
M>/K%I_RQWO#'V6%\[CDMUC53ESY-U]D-GY."W^B=5UVL7-?FIM=SU3=J*I[\
MM<*U/O4?C(Y.M'G3UTHXFI^[<<4]7=JWC<GKW/^,&>XIZ>I:*_ VXGC2VQZ&
MK":>=;J;K8I@S\XM3)7Z52]=)%VGVSOBNBT.KW/#3VWA6%VXFRT<781J.MY@
M]%KW_ (GA[V7@]''2>_E>'34VS^.XVQ79^M^TV?S.AO.<7*GC4:O\1DWW6$/
MM]:+9&C6U:RKV<G57.WY@->ZZ[TX[95A@'<Q!'"197KHDI%K+=;U"T;FW>%#
ME7RL4)_[3HYC]6=U')]W#UX/\N/TW>__.=S_Z3>Z?_ ;>_OA[<?]4J.1/^_=
MA[W^WM;KP[W/9W4<(_KV:)N_^_#ZS[V#7[_L?7A/=P]^_'/_8"]__R;;^VG[
MT]NCW8][!V_IV\\7ZC@^O.Z_/7AWM/?3KVQO:Y?O;_WZ:?>G7^4NS_>Z]1M]
M>_"R__9+_HP/KS_\WY?=Z6Z_Z?@SW3UX*_<^;,(?#JUAP"V1MLR$ D6)08N$
M2RV\3R"D8[>=Q=J]>125<QXGYWA)(:L;VC"&8)4O_2F3"%Q)8* $:SB'G7$.
MJYQS'YRS]^("YT@7+(0R!R<F)""L)!9DWJ'..2^9=RF+9<,*73FG<D[G.0>I
MYLBLY,(JD F-3HJAUAZY8NYT'A<]XQQ:.>=>..>BGN.Y1AZE)())1\#HTHR
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MZ_&R+^LL"<ETL-P0JQVH(H5T1*G B#*22<DLBS+BY(;M\)"TP+UWAD0+W(T
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MMV/N8@OH>V*0M(#^08!>L4JTS#.KE2;*4DJX=)I8Q10!_<851<Q9SOG.GMI
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MV^IV757;=BK_=6N.@6M 8+OEAC.">RI-Y(9RQ94N@BJ PV2Y=MS'2D?\CD:
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M'\4 4@*H]N-DU"T! 8E<@#Z?FK[QIC,>I&^ER=]]E^3&K\ >NR7*VAZ<=M>
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M#N2'&G/9><0^EBMW=:^R3^9B12^FL:*WTU@1*&6@?2:M;#@*0X,ZGKU84%;
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MS ![[*3+RRG$1DA.PW3!G&Y7+AJ<==.M/GRW+#' D'#R&2CW&_L0X/,)8AV
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M$]QJM!S@JE\;0Q'.V(<81HD=P7>K;?]E?DT(LA&L@%1*BKOHE.=FN/(=6$5
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M]=SNOV[O_>??>X2/W*H7WV)GPSTW*-__^:_RK^/AZ?OC3_ROW]Y]@?MEK\[
M8GC6^_3^^) ='?O>7Q]//[TZ ^OA[(^SH^::?__KU)[YWM'9"[CWZ:>_CE_
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MSU%W',@@QC+5:)Y@+Y%U!9>/+#)Q'>UAXPK_]\57T\D=P<&UK.E:K.GW51M
M,L^I+BQ1/)?8Z"<28XI  HZFX(I1X\3.WFJGS._7(UH'XQ8#>&/AA1; /PC
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M#0\GAQ\.G[^L,/9]^.8@/7C_[#WLVXB^WSLT!Y^?GL@TX5*;&(23 :LIBY-
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MW AC\CSECQX76T=T*]A^:<'&PT+RJ. QF (LRP77(2]$(?.H5 FXI'<LV*A
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MT%;N\7J*M T?GLWJN74I\<YRJ2'^LD"P9X?O"6\RT?/13-EM;)#!@/%!0))
MKDF$G5= 3$T%"H#7R"GX*=P5MD<Z26-F:.@30>H&R$XX.3SA[^%.S6Q1H^"[
M_-1:JW'YL%I&XW6-_-FU[:&;T\)!59V"\=H=%G[=R8\>F?I+8,_P)"_.].4K
M6C%2[X^^M393-8?'R1MHX">\&0WVJL99\[AWG<]V7_?@^C=6W1O72 5&HVY$
MJ@<>FX#I>,8['<';#:$K/H+#, %E!#0] CD)'/"BLP>(<5:>L'P+?*"G1/AB
M;N4<O"$2(XI!IY=01%C318'X)*[WY5ZD14G/=MY7XWY&DF%G<,"GW/)+CS-(
MA]YFK=8> /[TL@!E,(GJ 0B B9,,;>AI2$(>3*P+D"3X.HOI&:]0(GV<5=(M
ML6?F^$WN5,S.X&F[-5<O#12O[MT+9);0&JU"#4:2BZ'!+\:H,CM;9^C#9;@5
M8Y!H^*#I@OQCC)LUS0).GW8'%ST& 6\%>"L=Y05>N-E6\X()#3^G 4B1>*V%
M1W^JIR!B<+V-GL_'\'C<0Y!__[WD!]]!8:$-R8B1_ -)ON7QW:GJ./P5K0$/
MX06IB:68#'"8_ -,BW.@Q$9/?[U 3 KW^WRBE"ESIG1@3&0"5O R$.":!4)$
M+ ./411Y].CQ;*K1;9F/5@,:2"Y@7X$V=@:BC<Z/*V?;_2J:YJ4&PW#Z0'5*
M:SM9B0B>&JP'C+HS"LIA<6(7GU^6 B32K'U2TPZA%>_L/"<9^ "C=)5!,\:-
M-T+'!U6&T,"O5O!0M,>Z:Y_.*F=78?P-;*-/Z$,A^3U=U+,S#1LD%@V\1=-H
M;VQV*U(S<CA)46"D;T"9&WRD7:"U^.S?FTZ?H%'<Z;7%'(C[,SZR)RJMYK!Z
MBEZU)K6$GI'53?;EG#=CU]7M&TG\M=6 >.8?\/(*_$T?ENS<^25GGQ39Y$S/
M*_)[O=-I772GX;PG:-^R_VO[2BNFY'SS5EBGM?EC\%OU>W\'_!&CX?[)/JGU
M*G^KX%J@:' 3X4HX.6Z)R05I\;%K;K6SFT%+SL'H7M Z\;93/:8;7GM'T)=H
MKY]9:M$3<N&L&41[@W?Y^#O\8@+>#6YS,])C ZKSH[7GNSVTA@P2W)(A\QO\
MNB,+OU6M]'/N$]P&_2"X0EP,+L"G:>_1FB KIL5X-E\ZG9Y#Z>R4M6U?C3P_
M$.&SCP>'YI@]H'[XBX[2O?P0G+'6)MP4$9*Z1A=VR0BJ]2FOE;\MW!3_ZJ(N
MP'#V\%U<"$->2RRU'+*QOVIZ;(>1 WY&X0(72VK MP0;<'_:ANN&&Y>U2L4V
M3C'W!OL9GR/-XR.5EKAC^.N9K(A"Z,<D[LC,<O( *:SN^>,^$M5_+%Z %+>P
MI+:@/*Q;.G$7;K?WDSL.H@#'BIEHPU(;Q=1E3^X'2#%"TQ###*WT<N$KOQ=+
MSO#JC2B8"7X%'M@UL= 'R3#'EW (Q<4PSDK!12N+>,\[0+-^AEX."%KG2X&@
MK\Z N.U73@BUQW ;<;TS>(-!IAZ/ML=Q;GW4I4!=Y>)1JX\8@@701C(H<.7B
MG[K[K7O-N9Z<S6H,/<'*B1X#\%G@!/WG0(CM)?['] [GHQDH<I#.]?HK4L0<
M[8=SBME0L,HJ1;<IG9;L;?W.X&C# F[\U.%@!$84F!%#_W*T5S9<CH^F$*N-
M3'9!-'OHDJ)L IW)4[M5\%O0&T#,UD #KL-#GCM>&_J<*,9/^W&G54J:ZC8Z
M:&-[6NT,GED:LBMJ%J? M/.;;RX2PM+NH)5AC0R,!%#H#JC7>G2H-D'$3*=@
M$4D;UI>Z]RQR_YUP[:M[N%E/E _&''X^0FU?HQ##F+;J[:V]C_Z$T4"0ADL*
MP!H@G=9H0R;(6>U[=B;>#J:-X10;2D>;K]ZJ342]O&M6/9!=8Z,:&-[MQ3TV
MF$=NBZ[4?K C&Q2,M\C<.]CMPC/I*R$*7*_^&+?!;BA84RNR_O7.JQWK4AYR
ME^#:JQ>GL)5@@ Y^PUAJ#-_M/:&_1?_\O6^VP8YWB0^\&URW9-9)%[!NDP4]
M#\0QC*?Y?DC?_YQT+=YW!G>!>Q/S="ONC/O._3A#2P8,_"GEG^R*X+.6'I'<
M0+@!5QK/WB[O),D/<$X3/+3JDT5S 0PXV00^6 $;;.$'E\ /BBW\X$[A!]?"
M"59@ 2PN,Q,EPI1IP9(R+/*H2+.L8"E3J1'99<^Y%DZP"G,(PQ@6$[-8:69B
M@QC^C!<FY++081H^'/C!D0\\C"D%B08$2$]T/U?R@E[K*(JOM+G:"?\$NHVB
M' ZC2>)7&Y!,:.I7NHLMX/Y:F8V^%N\"^1367S-+ADY/X;W1W$2+RL>KYS.K
MO!Q*@C*_%%.!&Q RU&?-ULTDI[I@T^<+TM<87Z_.<&NL@4!*"2B^7;M361,R
MV_#F+DX"?V\=%?<R-B3/K>.G;=H2@Y_M;ZV.=3&0SB$:]A '/24B:FMK4/;<
M*<1.;[WJWVLEJ;&$<AN<:S %;H."#"53F=%":Q8SI7.1ZR)54J4J2G@N!$7;
M(Q]M_VHXY*\XGN?+@_('\$R9G!1IJ4MI6,"ET@&+$QZ4A2KA0.!<N#9,1^5]
MG'^\/?0K#EWD+.4\-(&.>!$PD9B@3#(6)"8,3:;"2.7EYN'&EY1(>*0LV(N$
M";"VK0VI>.!1+^U:32_#+U#@YQ*)M!'J\G4H_3L@U@;4+_SM=E3;@\9M2?52
M4OW\-#W)8J5DEK) LC /P$ K@Y*E61 +*62>1:!9(ASS=W?8_3O06EN:^'8T
ML1^?E*K4413)($QEC%U:).@L4P8RX[&)59SFJ+/B];Z!GB:6 ?OW-IMQZ\2Q
M:$/95FUB"=O#3"2_<%Z U1$4J%^ $5SWX*.(@H2=L(%B%4A.,4UGN=>STYI/
MVF@.1EHH$N80,-;?H.UT$9@^*O",US[427=HYA@@[YX<N&<.#A!C@\ >_SP*
MZYSK\1C_]#%%F^+XSP+VU5S@ZHQ6Y&#A\E?OW2W]''ZEQ85?Y\"^'^6BG0[U
MJ\1[]NZ (:%YA9G;=GW]>W01)H3=PKU8.E#\@GRP. _M=M '-I..^P>+KRFK
M/G79:!? IC.J$)D%[#AM.EQSMS-^E=/YSF"W'S!>NLPN$+^C5L8^;XSAZS9#
M 9;";#%'\#AY@W+,JXF+NF(-IW?V7  3@Z4S2>!/93,5>&6W^A;PC+<!;ZUQ
MZ'(]]?OB .6(W+*64'\QIH.:NX70$Y=P\H26[7S/*Y(>N(<-A@;GHWJV.!W1
M^8[A>;WM<YEXT!T2\VXNW'K5+H(^F_GT9N/(L ?XI;P);WJ1>Y=K!H:K/@UQ
M#3Z?JMW&.>#"1D9J4YT6Y44WPR=X/AO\;8D(0]I7GGW3I@EZ26^;RG9;C4>R
M,]CK$&P*#I,V&(\.B&.XA"+N4N&]W[O" SFK,1Y.S_>&*FTKG[<K(J/6!46L
M9?Q ,^@'3JX]L;5O]E@MHU"2N@=^Y*>UUNWV-BCR^OEL+R%)*L_J4SZM/O.N
M..(,U->$2\Q03;6IYN[ZFN 3_<<XVH!=QZ@O=P'Z%C+2@Z$Z;K59:"O$;!;]
M09Y43_]_V0'U] 7L*H7HA@,LAS_SV2F*YJV=G)4BF/8B+&X/S;5\<)30<4(1
M:0#!72ZG:"&GS;R[IE?\1._5]#):C4L(6\S$-2OT"=Q-"_1)M]XV.&';>]B@
MQ:K:<*3+%KHP:"_/YA?:7SQ2HY7PA*-&B(/0\W-M5]][W0LK@98J+CQ.Q%Z$
MJL2KJ@NO&I8A(S:5O?J:#Y/<]UO-ZZR[?I2SKW]DQQ=+.)\."0#<HC]RJC[B
M\P45M:R :)9,S#6+LH^1VX@"7S%(R6!S:<NKJ?<*L'JG4L^6#..>%FXQ17:9
MK>;LH;\L<,^:#C80OI;VI(\)L=Z[MI\']3P#^_*1C++:UUIY48YVRTU>U]I*
MKJIG^24O.=$62MXOZ)O!PT^[N-+%TB[VH4*+,^7WL]%M4KW=)\Q;]\\5=3Y1
M")INSH@B<>IMP0L*$U#R=3KOU\TM9="[&D=;J>?@G4Z;+6WM!I-J5KO\<+<)
M#Y/!CY?.OV^'##M#L=,_EQ$(FO$6+C28(!ZX?T(]M H%'1%4(*II2^)*:TRO
M=X46?0")#XPZBYOR9, *6OLLF5SFHTOJ.M&P]D%5ETAKWZ[/<:XX@V FC5M?
M3V.;A76!G,+I\;WS9CL6:%>P O3:O']W#?QJQ<F-O*"'2=HOG0G;*].N>W!>
M+XB\-^900F0/D%)!$4$BU09 O(P:6N"[!9E00:P[U&%+;$YW#9U$LH9R,^PQ
MVLV<4[+8^P @*]N6*\0[)\N;0<09FW*0Z&@C*=8(A[VD$-H5<%FTE2OM?)CT
M\0)8'IGZR2QX >RWVV %!959=U$EK*O ,II!/P;XU^R"C^<76'7G3).>U^9+
M^2@[/[UH*\0OK3>_?!E+]S]SEWDQV5D<_HF.DC "3E7R8 ,@+?%:T6&>S2H7
M'$#(6RMMA]9XLD:O>XAOJM)!LCOA#$]ST*8ERN3SE;B8\S3)O<$20C!1IE:P
MX2)=/8GLL0R]#9 VQAQDW:/GOG5E2SPXF![-",-+&J-[G=^[6?"Z(_#O,/3.
M+97GN;,$<8KANX_D EA.I"P;<A?M& :!>&<>4@7V!E-O(\JZ-7V=S+$!)?^:
M_;B+L_)F(.9)[?GXWVH\9N4Q/25HG]@JC I1N[],I'ZO+T6?Z0=:0-P/F6-\
MH9,F/1P+$&[/O?899?!H)YKP-ZX3R Q,*K!"NL 0D!)\W6K%)_]^13]]P\=P
MX_ER%3]:?4M;_DK7'\F-WNV"(!X NO=JMVD1H+:@WX7V[ HVP'';51S(_PN*
M%A[PQ$4-*1>UB_6-MK3_3PVW6/GZ"16.P/W_#S6C& [VIW*'7J:]W2L40\C_
M.X/7I.113N!"5\,.C0WK.*U/96F->]=A&T+HTA@7C:_9)9,!6!=NNJSCW<\'
M1CLDM)5T_JY]!+"5D,Z*0.7O&\E@1-<">#&3CZ]BS0?7F*]+.E#5B0OFK&'*
MT#S?@E*_%)1:;D&I=PI*O19DN@(6S;.XB!)CXJB,65D6G,>")R:6PB2Q,/)2
M\.MU(-.5Y\@H3461Y;E,(@:K$XDVDJ<)XW&JX?.' TIU J>UHWK!5R[_LZ@L
MD\+V@"ONA?N;W0[=O^PN^18-SI!<BB];F4M"OKU\N!IGHJSJV/7Y<9*-:A3H
M=WT1[?V??F\F,-E@;;W^0OW$H.M08_M,C2BZ-%\5_#N#5[2^GDP%$[C1&+Y'
M3>G:9\PP9GFY@+=AYYDUZE86;G7J);BNU;+!*\0]E53ZMHF^EVL-A."@._:G
M2X$O#&_;9*G-)ONLHR\;@BN%-8,IG; 4UD%'L887Z JN*.N+Q9.NM>QZZ\;E
MED"K\>0UZ^VRCK17; (\Y#:8)2.+ CC1Q#%G3.M"%&G),JUD&*4B5N+6H,N7
MUGU^!@3ZQ)'T&SBW)\ZD>>H+X7==]>0Q_[0%+5T"6DH/CG?3$\6+B*<L#H2.
M9<!P,(HH)0\2F>' Q2R62?SH\88FU%\,9"ORLHQ")97BBND(U$F:E'F1IV4B
M0&3J6\.OMT1QIT3Q-#Z)A88C$28H1 A$H501\,SH(,MBD8I,92+#$;CK8QQ;
MHK@B6/;046[Y92U$;/\)I$)7/]E^]I=KEU ]7)>ZMKIEVF7S4?GJN=5-Y-=Y
MK06.VI2*:=O]&7?[XSLUV=2&T8B#\E%5:]RX>?%X@0V[5<U::';S\^[KWM^2
M%&UI#=B DZJQYL%]??$KB<Z^INR]YDIG'A>(="E6"X :-*-9/6_+Q*=6@OD8
M1.W:\=2V;28A QT:SB+R?-W2ZE.KWCP C"E1^L(MQ>9=%;;W  /-]G]U=[^_
MJ8%;DN2S:@H\BX%M=$U@VZ?SZV(F]V<OKJ32S>[S]>[P:J!0.\\$)1T*. IY
M;ZABZ6KW;(W*DM-AVF.0_ABZP):3EWWH#_D_QO76H]:*%;+$Z6Q&O0F\C^9R
M85VWSVDO7M9^2G$]NT3PAE;OX1&H+4O"=]C\;V>=-/I!U-;-/AV#K]6U)+0Y
MR!7<L'NS)3K )GE!]2D854KIZ1^_E"UX=+R?G!C#M$@BG)R8P?_IL P*!K:@
M*8$\L\A$>1D^>CP?5?7\PO$L'OA5[0Z3,,N$3%G(5,;*6/"8ER(TB8YU%L+C
MKFEWZ.S]%[HF(QYT_9$%R\#AO[#G>XS'NVUVN'*:!Y]/F.8ZY3(/,ISBQK*0
M@V6?YH&1>5H8%B<B!'=O"F)J?D'P^=5VA_=6(UVI?_ZB2/T-7RT*?Y:7N3Z!
M-;8I"!\?-%PZ.WHX^*C!.O8-^Q (=N8*-1SV!;%E%$&<+,;S*K!V4)=XZN3F
MR+8JY_9A)%I1(6S%*#'>W^<'>S(]R;DL1<I48")3!HPG,B@YSP,EBS37(E+*
MV"ZC-Y6AJN0LR21G><),9DJ6AID(,V92%BEN^H.<EL,E?V$01!_9A@;34R)]
ME)='QOM;6\&Y<GZGT8DR)HZ9,D%8:AVP4L@ QV<%"NTS*644R@+4X#GPANUP
MN"8YAS8[W+FE?O(!!84=7L^W<4-PPUG;0X)ZWRD'/6MYC,+T6R[SIW0L/Y\D
M&4MXHJ+ Y"H/,&$5<"/+($VBW C&C.'EC^.RER RS_D8F6W+8JN'EY[$F8IB
MGNL@YEJAB,3N#UD9"&.R6&2%S' &CT'_>".#49D$MK"B/LU@=@3T%\SU5ZL3
M4WPA7LMDOJ #\U@SG/-PT2I-FZS1GW0M*S=M!L%8+6BVY<CE9]@><:>S>45E
M+#TNEV.^<"W.VNYS/H7308W6YZ\@/+55NT,':=@H/AP:L5WSSN")>QF[VIX>
MIVHZ+XO:-)GSDWH;H_09R""T$#"\WQ#*NZ:7_(AMUU;VW$-+VN$JV,?WDS,V
ML-<L"#2*TF&>$P[G$/VZ2\!\:TM&%N6T0RZB5VOP<A&XA3-0P*5;<&Q-J"W,
MLG_5'.B$ BQR]A$7L#:M[$$8?2O=7]TX$M=:.9B98&';C^JY*_NH,2(_L^!K
MN]MM ]\>"- BHRE:ZC9ZB0-:DG%97HR!(82.K$K?-Y@RM'3]SN 9!GZIIAA7
M DR!^1ELC+34[]95HRX_8SF-W8]_8.SC]!3[VL[]C]I81J\XM%VLA8TC;+&C
MSVXB$%&G30V#H E6[]?>;HVBAWZD#X%)>U#+=I,:BKU,3\=KRZ0&N;X9U-)H
MJ6$7-NDW=NV&S"S5ME(Y,($I)V?8\<DU^+-/JWI]8(<W/MKE++9MD+OQ,20V
MW#GOF[M:,<JTE55[&K "U0Z4LA4M0+0"*-N.K:&[;B+,_GOZ$8FU=GO1="LB
M5#FL4S?=Z(>5L3\4!"9M08^UN@CX'TL'0&13;W'21;8C.F];"9/NN.=^]6:I
MM OL[5S0"<8CA;9\;IO=(]M6!*C%6+LWE=QQ8R%Z-75SN8B.J$S<_=IUAERF
MQQ;4Y]OB-@N!G.,D/G;T'+M:&N0B%[RLN_+^,1EM&Y]DRU3<C)6N_[1=JPO7
MDZ0]G5:VR_,SBE!:]WOIG5?>%(49X5N6[]5VS??^=,>."-OI"V4LF['@:RSL
M]+R*Q38T60NE/^UCVZW3:=1NZ!*LMOJDU<H22(_0&WUN1Q.X82Q$VYBN()5"
M+;A[I-U?=B?Q^VV77.M\X/.%Q=,XUNK-6?.-2*>])7=]Y3>*(1O8KJC3@KLA
M,:\;@76&0]FH11Z?S.IYKPZ0V'Q=.[;1:#]D:_=FOUM_"]@9W^' $L$5!;7+
MV^H/P\-@U[;LD@U:6_N_O6UWU2&W^@5.#>>?]65D6U4P1T0Q09I\?H$*BBV8
M:460?9NI-QWTHP%/0(YVIVH/:[)F%,-Z:E_M!?8YO/CEO*G7X<'QZ?F)B0N6
M)K$)E, APV7( R'S)"ABG0I3PHX*OH;"#%7)>!Y%19@S$ZDB#&7)I#195J9E
M7CX:Z$;R,X0(UXM[.:=T<_C7DQ$Q68^0!HZ2'B8JXPD9M[WV=212IM93ZO9#
M]?:C*]WJVI=:&WD526G;EW2_Q RA=#[)_HN7_\4G9__<&RZGTD$L8MJO<?XF
M#B&I=3\+Z&JU;.('O5H+<?6.^J7+7AHOZ)97U:Z+S^J02%<LNC8_8]TEMLQS
MZGSB#5*SE9B]Q? Q J!.41,@2-;U]R";M,9J"810@5@'3P KY_W?NZ=WHVI[
M;] ."NKUF:42LV;I6=B0\",N ",)71ND]HE7HE17#ZM3Y@1K>'G9YNL5'OH1
M#+[S?1Z^F<]N?HKV2#:<F-/2>*+*DAX_(W#%9W<2SJ!!;O$&6&]84Z/-8DQC
M9;TNMS>V:AOI93NT_<L*5.)P6Z!RIP4JUQ:<K)@L*@3K).0\D4PR,"%Y(0P<
MNE*BS..L+.^CD7(KI-!U)MOC73>=$OU!-S9Y2>:@9*DF8E$WK=Y:TIWH4+70
M2Y05*%&^0._:Z'KK::R7+URK039@?;ZGL_&7/N5C,IJL9W$,-_]S/),??DD7
MX^_/)V6J1%QR$>C2@(N1:!844O,@YT:G29B*@B</U64@8AA8$_I!>@?V!:F\
MJBNUEZLN X))3KLI+?:J,?V4^G=H1</+5TWXOLGOL;/6CED!R[ZZ#5BVE^3"
M!6QV3'I%=NO8W-WNRZ#MI&EO@XF2&]Q>H=&-XQ=J]"OLE4T[A;>_EWY$YV72
M=G5M?VW:Z@F%(FF##_5\<$J-66VO)C?P6#N7![Z@7O1MX.<W[!(YT;\/<?:\
MG7J%1N%9C6^S,_BK]Y+=<9$,=X/H<60]!O@^G?FB.)\V03'_$3LH8#VU:T5*
M<WU6K[C8%'X".ZGM&.2'I%T275JU4^\=[VT6+M]8D>TJV/IYA6'3K3JSZFSO
M[_A$1FDIA=:!RB*.XP>BH,AB'80\E7'(C"H2LSZT1Z5A4L"AI!P.1O"<17 \
MA52&I;F(5]5?;^NM\EAWM1Z@+KFL%OV:O5O:+2N),$E:5UVW2Y!TV,Z,ND-A
M YX)*!Q.K:(F,S>NQ^?_72=?;!9CYQ/RWMV][FDEG0OHF*INYNA MXZS^Y%-
MFVP G^]_H?:BQ_.U%[YEQ>T728>KBBM[1^""H=O:R4M03.$AO-.)*O,L,6D9
MY%DD A9'+.!AI@*6R3)B>9:I(GWT.(VN&@-PFQ.7:<BT-GD119R5F12,A291
M<9:RB&5)=.MRVNV)W^;$WWXZD8B:%\H$FJ5PXBK+@Y)+':0LB[0&S<%2@R>>
MWET--0_SF$=E&B=E!G?G16Y 9^6YY#%0G>1TZ*$_]'![Z'=\Z.P$;(4H%0),
M! ,<SK(T#LK,B"!,TC+C@L6A$8\>L_3R"3##=I;9T#81= 72X0,ID/Z1%NXK
M;)'^)\)!,*L#Y$S*^8C@D;M3M>_;T;W #I2_;IYX3T8GLLB*,#$R*%)>HI;2
M 8]+&:@HEK*(1"*CM3QQH:4HBJ24B0#Q@\5<+.,*.")ALM!<KEJ]=!P!G<>@
M?R"#7]CZO78/ER"=K8_<$&221@ $%N_4Y25G PW&\.Q"ZZ4$[2F"8<F2]%_#
M#H"?MU1MX,&Q<$.Z.6F?KKW<RU>OV_9RPT&O4Z,:&%[5%C2XC'_V*2F+=>FN
MHL1H[_D8NX#;M\N\%EE$F=FFFK?MW'HSBWWW^(\6#WSI<SS4KZMB(D2572M%
M<+#)ID/.O.K?!3<+;P/"VV@;Y[&>0[LA#AQ(?6RQP3&-2;=[_!'!V-0VLD5
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M&AZP7$:!B"(3<(DI),%+%K)'C[/L[F*N=QYHWY[\%YQ\>A)JEI8A*X,8-&O
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MLU$#:[W81G[]'TQF2H\[$&\+EW161,TIYD$AD#9X9+_SLR7F(_!._9(0NC_
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M 4>N:<H?@]^JWP=F@9!)]T34[K]5\&D[S%=<+ T/;H'#<!5<1A/7[%4T C3
M'.\%=DF>V0EROU4??\?GFLH6G^$.*VSV[2 MU"]Y!*<-:VA;"-BWDFUM0!N6
M:ULT-4O']I';J=>^ &0@@6"!\.#3/MBE[38 V_:T&Y'40SAWC^PU+@ J,@L7
ML%F:JT>CGVQ;=QM863KZ%AK3#H[:,*ZT110"HURXI@HX5'7E2@(V8N[? 9$W
M]:.N=8N>=9>#D=5=V"*:W3QQ>R/W<]?QR8*A;7SB<ECS?14RMY2O/=/BWLK5
M2U]YLZ1]P6M^"G3Z9S4[UO+#\.KF 3^QRCB:#@Y!,MDPL^O/.O15K__OX*_9
M1-C>YRB[-KZU3<M>Z$ B8YD92!1,.M:+TR49(*W6&6*PT.9(;2OY"\Q>C&PP
MTZHO*]X1?=<.)YYAQ)C$(05H7%:AU\H=KNDM#G[YH<_&_=YU+EV,)G'_#O:6
M?DD.5.3#K5T<;.@_4!H!2<VP:XJ.LSL6 NM[L3(7L?6@.EP8>;V?_&E-U7L.
MO.0VF!916YDVG;5X) Z2J9-/ZRV,*"C;6^3EA'BKF,55!/S3,.+Q#(MBCN'Z
M:;68W%?I<QV+=GFU^!H67=Z/ED.1LC\"Q0!9CO18#69G(["6QA/P-.&_&GV]
M4VKCUN$ZK/I$'3C5=F Y@ORG"X/ T-IVVB:6=CW>.OJCM -^.=8N_HO-B1K*
M9:C:5K77(!K 8T(^.)^/^@!5!V/ BU8>Q\^X].4M5X]HN(KYN]&_L$3A+)Z=
MP6Y7S]"KF6B-!C26J<?7!6E^:C%6:]J=T\$'?>&9M3,CG/7@(3)M LVR,P7L
M/:"\UE3/?Q7G_L3TN;L<S+?673]W,.S5G'5Q^,M'?9#\.T89NQRC=R./;P5=
MD;DVN4E8;K _<5CF1L6YEKDH,RFS$J$K-^D3_K);QZ&>/Z'RZ'L#0/G>H9.G
MYT?''Z*#XZ?QX?L/":SQI @54U%<(J0Q"1@KPX"781KD><&5+.*$I>FU6!04
M9B TP+NJ?C U^'5< "ULB>!&1/#YPPE/2L6-C@,3"1VP4,2!2 4/-,^E27F9
MIV5Y R*XLC'XCZ((ORBL09CO3M53OZ MA=R00HZ.GYX44<Q2*4V019D(6)2'
M@2C#,HB2,&51F64<LS/Q]6("K)_3ZH<KC6X=%(%'S?'TDXLV/7>HC2UQW( X
MV,'>P4E8:I6D,@HR*:1M[R!DR /L%J6S(A8%SQX]9LEUU.%W_D=1Q?;D;W7R
MQV]/9)JS*$GS0"1I'+"<%T&!\P:R,&%AG!4<"R(>KP]X7CIXTA-[E\#&?JB8
M\(MJ)TST.O1NU<=-Z>3]Z0E+65I*G@8(;0Y8' +%Y+D,0B4,9SI*C!9@8%P+
M>7ZU.#NS-5.V7X<]@*4^"#U_SGNR9(?XHC,_7-KFZ#'KOS8F@&.SI8GU^_!.
M/?_9EFE>7(JOPQJ+R_%UL]Y(P)=(6[C*P]E<4X#/U7X\.3HXV#_NLHM/C@Z/
M]P^?/SU\LO_TE2L*L9#'14U9$:7GO!ICAH/7E"[IFM"MN;ZMU]S;IC.<OSI;
M-..+%@"QA"^C4MTV47&7H?.?)D[>R[#?]R8(ET:J+&C&(6.BY80C-K' S)5J
MV\OTNW[-C!WO:0S(/@+-CKA: <M82'NUG(P<V.3EV =<J0"(JDK::644RMW%
MGAJ#%R,.3"SU8D[Q+K^V5SN[.T]WVM(HNK:MC?K_V?O2IC:29MV_HB#.C9@W
M+N6W]L5SKB.PP3Y,6&)LX_&!+T2M(*R%5Q+&\.MO5K<DM&$08!#0,V$0DKJ[
MEJRG,K,RGRR6;.%8*]VVT]4^<Q)J/@/\69SZ@'POLXFH1#/QI27>:!Z2<4[(
MJ%6TV',FJ1K6M6*LK&N57UQKB>2\[/[[7K<](7 [Z>W0[35#^U[M*.,=Y1.8
MJ5L'R05..=:(J%PSDDB"-'<)!9HTTTE*FNS:&\6O*7%5^^/R9'E0EA"$!3J2
MU^*,^126BAU6:AD,TW]'$?!#WVJMU85WBB+6H[/CR_64\[RRG/YK?9*[:K2>
M)GCQ:G_DRR9%N_8%YG@DWZ5#]?+]6D$=4^3L_74*\DSE,"R\MM$O',$CC^OE
M)>MEG'99K'K8U/+3"9[384C_N*IBCBN* :#N9UG(%^XZ$X@^CKG++2K.Z.UE
MZ,$X63PM'LZI41E2(8Q*'8Z:518?&9)'EPV^=#IGO;!,.Q\6FQR=QN<<"IB2
MO)L7/6[Z(F#PZ+1M2SW3=O)2JAV5K+%300_#IXR=T+E'DV-:9+=U1H$/GW\"
MM!T64O/'Q XZ+I0VX4_-:QKVZ:ES@7]/WVUXJW^-TQ9[<;K$17$V4+#(%DR-
M"\LWXD(,)CV^[1@'HSGVO6:AI!1WF;[=Z%&3R2%%D:5\[90G?WJ(ULL,RQ%_
M%4SF9(KG=-7G5NG7SX@_W!76QRDDHV4S&5<PE:]:LALM9P3( !J^EI8$!_A-
MC:-""6:M%TE(+UF!WYC@,C0/W\!I,&[/3LHE.SX"AH?2?[#;?9M#\T[RXMQ)
M%8HO1O&O+-N,*5$9P$)#,LI,D.L9,B0QE'R N0@,4Q;6WICY"I73(#Z!7@!%
M,2?E=09'1=9;#/-+8[CXI]C3[B9?H/ $L"4MR);BVC,K!4W<&B%!%U"2+E_W
MLI*O.\H7KV]^.C!@:\+"QT@H)Q'7(%J:8XH(4\;#PI?*@*VI]<WDJ]259U&]
MF)4) 9HB12J%J3,*(9B&VN7JQF]WLLQUAN$695WZ\O1V)/N3&_W54#I+";>D
MJ O*@XPN.9,X]\$ZE71D3&OIG"/25*+^X#'09W50B#VA@5%+$>QT"O&D%+(D
MQ5RKBR<B9" !%&)Z0RA=+.HE4?4?93[HOT;$6*5;;CEA+F(1"EOM-C)H G?:
MV&""A\ZYI(TFA 7. V/8R;+,,*YD\ %E\&<CGPP9*9.G'D7*..+<!F28X"AJ
M;K0'>"!8@@PN(**:%L(Q[WF94USD^V49@2M08<%<TG'\F@Q]1''^2.*5TSHR
M*P8T^=VXQ>_+!K\;MG?WLKF9":T2L"L$[+Q^X0^TMU9RSI$UR2&.O466$0 Y
MHX/W%+9S*];>L.NL_A$U2^'V'8/<C(EW$Z.GC$PN*V&.D_C'6+* =;?*'5V4
M.\JNSAU=(OV-TK4JX_3!,DY7(#V0OZ3TP,\QAWP.HRPW.N%S>6BSD=/8R]JA
MG;"=G>ZV]?>I:S7]3B;4@.^^RWZ6%<P5/-X>,2Z=[1V__;Y__,]1??.O5H-N
MX[UO7^G.[MOC?+_Z!6PAL+TT+C;$7G.6<>EML_[A<[OQ;>NLWO[*]HX_PS:T
M)^H?X!GM[8LZ_71>IUNLOMEJ_N_%]L7.YO:!=-%@!AL'*"L&<<<< @#!B$8F
M! G&+JC[A0W&6C!#C3*<*J55H,39&).5@$!T-E?P\]:7W<]?W^U^_;S=^+!>
MVP;=Z,/GC9PZN%[[LO7W1OFZ.-';_GNG]F[GR^Z76V0+7MNL)WADM7BE3PG_
M,#-J$ ^'1SN%)_%9'M5-$C/'DF XJ[,GN1+9:5F%HO"TMHODML+C.CQ7+H*W
M2[:68KC:P[/RTN]:ZQ?I'462%(QBN_3#YOR]=F[$Y(U&I[XC+J)A#=I>#*>=
MD"/[BE(9A9I=TIN4>6CY4/O:.2NY.,:9:W,)$_&RW1/<-K$@S%_4B<F4N:MN
M6R0)7O;!Y\8=11M\6=,A)PN6GTZ2+^4J2MF7G<\_ABV?*U!=)-2 _E?D]*'3
M0;.LNY2LGRP$4J89CKM5!NA/,&*7LCF:T7&$_ZA*4C^SN^1CBM),RG!?\)^4
M%O5EO8_9YO5N,AD+#Q)HX==?QGR*+E$=#&?<2!Y(<*"B.T=5<$YJL*%N'LT]
MT6;X(_9^W) )^M'-HP??V_;(SL8!IE&S1#'BB6@$(^V1=<&#.B$P<]9Y$LC:
M&S(?F5D;!=4\>Q =,Y@N(]"46I4"4\Y[DP/D+5@A(E-L$LT=I=?1H5\CV9>Z
M7-;4MH<-S*\K8;]"V'G][  KH8@4%"E," @[QLA& \+.+!-.YU!3OO:&7>L)
M6$80',/<<AR%CHE'[ S#PFK)C))<)QF7]GU7@G!'06B<'< >DV+".>14)?CA
M [*:<N288H)&&3#/"0O7G?'D/7$96>!)!BX]3LE@SJFU.?I5&:&$"]*Q..TD
MO,&1<B4+=Y,%T=@XH# %T@:'F% *0($'Y(BC2%!)0F1,)<NOCRW-:M!#6?*3
M4SL^+ME)993Q3F]!A=VMGX/\IVO%K4YN7:'"-;J#H8D?P_N6/7QQT[]%&YO?
M<]MP8_,KO)=)@;#TH/: >1\XXCG8V*1@$.%,&)TH50:TH5\JQN,Z%D,+<]I"
M'Z;>AHE(VB4/&NY=L?A[V)#WW=Z4E%6@L5AJ/&U\.HB1*IW9HWA,L(N !HV<
MD0E^!&6Y"@SGQ 5^;<K;HVH2U<PO._,[GPY@J#$6#L8XX0C3+R*R0EJ$92(T
MYJW<*=@NS*JK#M7D+SGYK'%XP&3BPN* HLMKWS#0%;QVB#JIO&<<E$JW4&^L
MS<=*T&$@;):$DH82]I5A.8G6;$7J)V=6+_;)?HDG=M)_M%Z[?&=ZXUPOO=RE
MDPE&"/X:?^'=B_#='DU08Y6AKD5N8_'6^A4>13L^V1ER/^<HKS(F_>W__3@Q
MV$5H6.&I&XK?;$)')D\?.SZ6?MB7;FM@\YR-3\UMKL(,XEU$5S;'U6TH'?'%
M3;>O:-;X+I./&OIJ2]ZV_O""83#;#'/*^!;U6%3%'1_!9S;Y4:AZ+[9MLZ!4
M&Y[6OQO1&?U1DKM-A<OE5A8-RKQAO?ST,<U[KD,V[N%$T\<.W)+)I/2.=V+V
M?^=X^'SM=+L+5NV"/;](&0BQN&?VFA=G=*WSDJ4H#(/A7\T.6W[JI:N\(%T9
M9KR5[X9F#U"F=3[+_;]@!G[5J>%$K,.H#H:\1IECL-TL;UE.4%$9&Z3W- QS
M@FSXT>QG%KT4APQZ,#"PI72F.)M&[1^/W6()S-YU&)+^44D[E>G_75$'*=<1
M*'J9&?CR749=+3\N*>X&<5A58&KX\\H8!G> F$YMC>N3>O[Z6/CFACU-<08O
M#BB^7'C%V%TYA4M:!XRJH)7#U&')<8I.@LVI+&,QD6 (NYO;\=U1IF!\*O%&
M#V]/LOKNUP/BE4O!>D1LU&!#4HU )13(8QS!N R49@6179/-OK2":&W"7$JM
ML0-#,&HMN&<RAZ19$FA@=_,S5C-_W<P?;Q\$:Z.@*>43% DS;QTR47N4</#6
M"LRTR3-_+<O%<](#;Z;G3*D;Z^-#85\F^XP"*XICZ_RE\?GDR3 ';'[[FH3G
ML>(XJTB6$%MJ*(OW2MA^[[Y;CD/[?[U7;N_F1/2>'2V[,O&\WTV#,UO4'!W1
M]PX5Y&+O[,4B7VW\]K5[YO!LN>A/UX\;GXE])TGJI[?!+[&HS[8^3 -L#;?R
M=K.3$^?&0;6WV_&NF9['W@&'??]0]GRC$S:F^CTDT:V0\8H JO/ZQ=Y!B"QR
M%2SB,0(R1A*1T4(CJXW4V<,>35Q[8_BJ[XF5+-Q-%AJ;]8-$$Y%)*H2Q-X@+
MV""=5 %)1T 6HL629L:X:ILLM\F8CVZ&1-LYN*C@V1[R<OA2*QL9'/U1H)'/
M? R#J\BK:YE+O2"6;;:'3-?=TU8N)CCF(;DV"GV9$&OQS"J,B)<20CQ"O?>V
MV?LG)S1<1@3W5R<D^.LHJ^2H<;SQL_YM_WN=?KW8;\/]-S]_WSL^^E[?/(3[
MO/_>N&BU][[]U=R;RRK9HO7-K9_[[4\7^[N-]M[NI[/&A\_-G0^?SG8VH<W?
M/K&=;_M'>^V_CHHLT8OM ^6E 7G'H.%SV-&"E\@&H9#VE*I(C;<QSH8$:QFI
M3@JT$AHYC<YJ8I56(NK K4QF-B3X_<;VY]H_&Q^_;M7J6QM?OGXN:X;<(NKW
M^B=/MS08%B5-2DIA.'/*,6NUMT[$:).4["E&"5^127))-ERFY,2)BF]CQ!Q7
MNB[C:?.X#J(_*BI1C$)(3TX+Y!W$PVYO6-J@W+!2-U>P[K^^IRV*R87C]PCP
MN'A$"^X1^>?#8.2B)LR(&R\Q\F-FK"\GA)2_"EHM^F?YQZ?3;I[H$UA0PX*E
M9:V_$4M(D:65Q[9P) ]3L^&]":JY/ZL)7I$)I@LF>,?E8.""XGNX5KN71>HG
MA6,H ^LE@XSMU_XS)1I%)CXH8KEJP4(Q6+^LPCQ\4,&)E0&E>]F&HEQN45_$
M=WN];E&(IR37F?A2*7R90J=D79FN0E!0PYRV6D5]ES%5^D+)++N6<:J2T161
M4;9 1K]VNG-2.A:>_FF1PE$*"<SKH)2B3G<D)L-#LO.A+VIXV65-WLL" -GG
MU05KH=CWRKTN%^7(58+@]J>%DZFHZEKRZX\+]4Y4?"X$/2^)@LV_&V*K%/S1
MTKC<'M>G2P!<MB%+]&49Q%$#QDD;$V4 AF71^[5,M%6XJ, B.CX-)7U2MS=,
MOBBWZV<;D[Y=KO"A7!2I(X/N2&LIT6 \UZ/R(R )4S6T,Y'>D)BAW2VN@GYD
M8L=6EDR8A+[O-5U67ESW1QPQ.0UUFJ%"V;]4ATJNKS,8^>$-BL:-"P5/3M?0
M;9H6ZEM#]"KG\5)&JF3H&R9#\ZJ0[FW3FA?:2]?:/S/VDA=24Q&9UHYSY[D&
MVS Y%2A.(@?M/45[Z8J*8)? ,D%F7*N7:[GP+14FU3\E 4(N<?\YYG.=O$^\
MS<6@YLS5W^BY^.*/8CAMQ9TT]F&4'=CHA(GFCUJ_TQFWM6CJ;MZ(7[2GX[A^
M8#(EF4X)*6\)XICDZ&B=$&8I.!ZCB2#?,YZ+!=*^4K)]M;NU--:+H)[+G>JH
M&7N9_19T[D(U&]8%ZX_J9)[ #MH9KHII+L29H*(QD_.U.W5[8D%-%D3J%/R,
MHP7EBNIJ11+FZVM5^R5GH.SJ'!:W[$D_OAZ]^!/4Q).6/7_=[!3C65STYS3
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M?7O44LD5(/T.0)J+NO(2E%N&"6)@9(.&I 2R(E*$/364*>6C64D-J8BZ^O?
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MXMX ;C7HB,W]F_I*H1RI/_N ;3 L1]U6B+W^J[%25.@FST07V5@(G?#S\PV
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MM:+JYSN[AZ1^\4G4-S^1QF;]0$;B!9<.19P<XCH77\58H,2,%RG*9!5;>[.
M!ST+Q%(E1"VUV'L6 \-<>6P#C]Y:D1D%?+1N:56O(H2])Y&H'^\=<$.2A^E
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M=,\[79#8#PG@WY[H^KP"^-B99"/G/!&6G1$&*#1X&Y7SED<32@!_ UC.A_D
MOI.!X]SM@M@8<_-.B;3'&"4@3WC!!<Z-6%83P'^AAVJO7)9;DXRFB2LB,+<\
M:"T#UE1';[)<9ZL+>1>!O1QZ9CVRRJ40L#((]DL!>GBV(K!!'A,=J9:4*1#7
MVLR;$$]WK'9!ZXJ]!(\ UVN]! 7 2P%X+LX; ],:)P8V# 5]6Q*= 1R1U<0$
MCP5A2H/X6^"TO+L/H&#W-4O:RFHN,%T.IK-REL+.1)XB4LH%@*FP2&,=D4X>
MK&42J$IN:Y>)^=[&1<Z^%*R:((2,@$KC!"<X62\,C])YEB0C4JPN4EC0NA1:
MYX*!5@7,B)%(N*P5)P):<8P4*>9QM#8J:M/6KL$/C@06M&ZN5OP(<"U:\8K,
MVOGPF#/"F& $DLIZQ(FGR 2I$0/1FRR7FB70B_D"+W31BS<5O9L%WJ(7WP>H
M<P$C'B3#48-2S&4"62L-,HIJ%"TEC&+OC3( 5+I)'JC76>U9+4SO7^<@KN[8
M=N;%5WUJ;FFP5$9C&(].:Q:T%])C$@7! 9>@T0:PG4_S02/L:6#!6!2PK+0#
MCJP.&(%6@ ,!;J0H!:;S&%6?=Q+9&WA,^,I%=B L*)^2(-%S)KF5."5CO-):
M:!I%J9/<2&C->KJL]CIHG9 53"-.>4!6JHBD#C*8Y#D758X_XP_V=6U>;MK+
M!O,RUO,CH+EDGCX"ON<"3E+!7I)$4'3$(8Y#1,8:@W)U-(\1U"!<X9L*\J+2
M3E\VM#<+V<6TO@=09P6QC,IPYPCBAH-A+9)"ACB''$W5^8HLA+"UNZ#ZMTCA
M%P/5&+UA"LP;8;C@#(S5I$C2BF6@!E-JTS81R?.U:2XW(U(662\5J-0L(FL)
M*-?!&2X%CU*82J6F\R*W@'FCP;R42KU^-!>5^C%,YOEH%19*R2 %PM9E64U!
M3'-&4+""6$R3YM9FA!,U7QA?E.I-!?=F8;LHU?>!ZER\RI$H#8N 3<T]XI%P
MI)5QB,7$C#;)2 O"F&R4=^MUE3?]8;O]=NPVZ@/;.^W>:?.\U#AE+D.H-CY2
MY:7A7%CNX'T^K#B?ZNJE*TU*-X'K?)X/5U'"L1*.(FI4/M;7"60YV -*!!R9
M!"9$U-8N+C5.CYEYK9G2Q$?'5>#8!D.\HTIXV"BF4Y2EQNFIT#/K",,^4"4Y
M $?1 /\0B8S'$CD7HXHF)45EEMB;E&%2T+KJ&J?UP[5D<ZX&P',AI^"H)(%S
MA#&SB&OFD)$B(.V8 :)EPL>T&, EEW-3L;M9T)WK#)*:WV- /V*W4^"[+'SG
M:HQ#PM9R@K"*"7$JLL4,9K-+RFA*0[34YD,U-.SA3T4&OU@<<Z^(5M*0$!Q/
MS-DDF"7"D:@TQH*7^J<G0NQ<P$D200WW!@40O"!PL4$6"X.P9Y2QQ"G(81"X
M0A>T/B^T+J,Q/P)<B\:\(I-W07M 4(XMY1$QPEG.<!;($"Z0"":"X&66J[@8
MPD5GWE3T;A9XB\Z\2@#/Q9F"IH!@&1&6('EY,!H9ER**!E.I8?-TE)NH-;^N
MVJBCZ$_;\*B3R^I8[D[_-'9+951NI\>((B$* >3+<TLI[H!LI=*"$L9XJ8S:
M!,;CYT--BOC@)!9()@UZ@Y(8:4DDTEIGEL.P8V%K5Y?*J$<4YH @D-J!@4[G
MN0K&&8ISXQA&M./P_Q)J>BKTS.5<&V&($1DS/A\2QRQRBA*D!7-*!V>L%/D4
M@9*G^<S0NHSA_ AP+8;S:@ \7]VD-0<S22#/J0/Q9VR&LD/1R\"<UM[DMB$O
M[<RTEXW=S8)N2<.\!TQGY6P4.%+O-2(8P,E)-HZ],LB%8(U@05CB)YH^%RG[
MXI :@Y9,<("C4%P+XRQLNZ:"*(9CHJ69WE-A=2Z8Y 63G"2.? )IRKT%8]+:
MB+B(F&MO\YD062?>I(3I@M85Z\2/ ->B$Z_(J%W03$_EH!'6(%^I1CQI@FQ.
MJ(0]M,K:D"Q3&<)%*WX^Z-TL\!:M^#Y G2].DBPH9B@"F9H0Q\0C"UL#RC&A
M(CH&!JT#\W6#).TJ2Y,(W:&;'B_J]&VKD2H@H%9&0J,YAD+#5EA8:]G&(P77
M7:<;8A?U.^=O\N[T.JUF:(Q6]T4S2V\%#UC9Q"VHMUP;&;7T$1-J/ ^)E#9F
MF\=+3^8]^4+I8*11R+GD<QLS@2Q+!F4_4' \<&<,J#QBF[,'=U!9%C//*,GF
MA?&!94R>1V $I5W#(["&N1B!"QYSE=T8,5> L\@1< J#J*42.QQD= 18 ]EF
M["'=&@I7>"Y<8;.80CGE=M4,8%8W,$80)YQ!PEJ.N#$<.6P#(CI&ZKC"C/E\
MQBU9V0$AA0F\)": +;%$T42%U9S8:*V(T5!)B)+,!5O:LFTB&Y@+; 0J*,UZ
M ,/P#P\TU[7EDV<QYE@Z'%/NRE"9"+CP@=?"!Y8Q$1Z!$103X3&\!_,A$ZJ#
MEBHHE+@'(P$KBAQ3$BG'I70L"B5\#IEL$SW/'(J1\/+XPF:QA6(DK)P%S 5C
M8F F2&J1Y]@@+L!"T$E')*)B#KX$%2%M[8IM*IZ->G!+M"8T>^<M>YEG$F_F
M'.67Y9<KKAC;Y+#?S__7GIW_]'OCJ&M#/+/=KZ^F1NS@;2D-6J>JH&1T5!G0
M-!WG1EHAM(H:<RL8UN+.AS'LM4-,UZL+[[_[UB"OXF^=3KAHMEI%>5B=\O#^
MXO=YY8$18FTN(I+:!,2U ^5!8XFL"41ZYH4*N<WLMC0/;L)1,J\>%][#FNVR
M2QN]2X4)OSHF[&>9L">6>AT8BMIKQ&WPR!*LD!&PVY1+JO(Y\(4)OVQX>ZT
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MS@6'B.0:<2(P<A'XATTB6D5@LRS8K.2ZB/:0=629T[ G)UD/Z<?M1@ -!+1
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MG%V7KG#W/BHED7)C%1N2 E9"!4E-CD(*;8C'UL!]&#>4^3O NJ#YB= \EY)
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M.+>9SS1A,?J]:7*%/0/Y!%LW0QV]A>,>5+1J&Z'9\YD<8'S>]DX;"< !A!<
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M#V!6^9(\]=']1\.!5:TH'UY8D&7V)(*.!5P GC1<ANTA00#%MV ?ZLL[^;=
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M;)@-OVVNWN]$,=JM<H3MSKW@VMW!1\;6QK24T]OWJA:NXTUBR,H_ZNOD5%.
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MTKG*^^ L8K6$O#VU6L;?$:%?B5HM8>\P8Z_D9LT[K.DKN5="WQ'Z6C2+7]W
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M-7).>V0"QCQW%!6. #:9*MA\L]B,@D)8QVR(V'*>9SU8X@*)03.63.D&O81
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M=)LUU[_RYK<_3II'#0Z?/=VE&S!.!V+O%/[^M(UW:1ZO[4J@S6CMK302<28
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MCWJT'M4O>0OI59 ^[G) ,M,JD9*U)!(\.="/PA/#:8XE%288Z$>Y%M(-:F_
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M&3+W7DE":2U0KQD)2@L@1I07^%LP5/[PXXJZN?\SU?0HZVW0$FQ!5=A(?<;
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M^KU\FF3K[3Y$QM7#2.K6[-Z+A%XVNV!7G;5>$VNR(C)R28)VC @E? Z.4A/
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M'[3G/$FI##@L0).-*SS1"- QZ+ T$")S+,U=E&4&N=L')88;,$=Y='I0-^+
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M[P&N<JWG,1L]1MRW :*K8HI=NJSTTOI4B 6R3V0*CKC /:'&4E,254KHM6W
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M.ZNX*W<(:#P??LP#/YB@XS!N]WU_:<?]!H<]$PSZMY>+#UWD$8R50I1VGLC
M.;&T6,*!:WN@)\8)CAFD*Z+J_\":/3N(TBOX.1\L(Z@YUXXQ\"&"\MYAE$P
M&ZR4R-Y*&JRU/%@-EMJP&%6A7P(C'/$2?MKBX5L8M3 ZV'O;!37*E>.*E*@H
MPLB3H!,G64F;-,4F=?2''_5:&-6]Z\'\]$\<KD+(7<OM/$!9Y"D\7K4C?CY<
M1$AOL$7((D*.7G0Q?U(RRPC7AH$5]H4XP10)(BO/ GA#'OL6K(J<5H1\G_E4
M&S3\J&&[MAGE_W9^&9Z&MB05@&W2@Q_J)HR?%CE&4(YZ$7C*M+'RK*G*Q2+I
MF-;&F65073^<V.(>Z$@XGW32$$:&HMEF:5T:(-R_;=V2<[WY,,"D^R9;[)8-
M<6[5%67!-9Q&/.LF[1B6&/=BEH?E:W6(=J+.!]=.U2U'V6R?#3M8-!JNOVZ"
M9U.(OXUR\X!98^6ZS' CL#A-EQ;@D_Z\7QL6M+&!&O(=-2T08.SXQ[K;5R.W
MTW>>>C#U\6NL;A.KC,,[;(77A[=E^+[ <#.7#7;I%<$IZ:2U(2OEI-8I)>_<
ME]5&6&O!MXIYIIAC5]#$2E"1,"<=D0)\).N$(<SD&"B&6QG[X4?S3*\UW37K
M=C1L0A1-UFV[^7!-H?6* T#?N('^N*J$!KS-/D3KLC0-.YIJY[_E,]]TWOH^
MK<'A8*'8O5M5C'VFT5*'<<TX=YV?GCU_UOEEDIXU5\(THY]7U4BSX=.OF8&]
MP>RWNJ>/6SZC(3!9N!E\MF$MFRQ3,8XS&KP4T;M(K?0Q2\&=3J(]FL\8=V3Z
MPZ+8\LO'%S"9Y+#\-AG&#XNY)X>?!GDT/NF=U;8#1V!'QLWP_LZQC7EU=Y!D
MA;UX%$N^:)F)5D+B 7U.P 4*Q-,@"C4I.Y%^^-&Z]=E[:^I[ [\8-6><ENSG
M3FM %RWGHLF\U/8$L^UC'(Y2S66M9R.NV,3+!=%J*F :QJK(09N\&B  ![D!
M9[6;>*.=YAA"<X^EIG%8</BJ@,SSN2\1 GCQRWWG=FI9J'J68C#\M.9EVT==
MZO+23%!KFYO[K*4&<S8P9QK++<>7YV)G9M6S'PUJ( <_J!>M7*A+=GU66NW*
M;>=O.VDG:OXMD+9XWF]8Q9HE:S6[Q[9,Z,?55ARSUWNT"OM;-(A$6W?KOI!_
M;7NVW/9Q6>HNM7*<GJ:9-UE<Z-FR:DI:MCZ7B.5@9R\O,NRE#C +=YLOP*PJ
M8</%ZZF/6I!\WF!QP_VB:*T+R82019"%*L\=,"MNI(W:!I%NW<-NVS;QBUCN
M^_TNS+TNA44B8S)8]@N[8CA.J$Z.!95SH.)V;1.;WIK7-H_SCF-N5HZ\4"#4
MV;.<M6/ C*@%,*SV:JY;<8QEK^SX]@G,ZC@/_N8+#._2A65D#B.0X,9P3 X/
MQ)GL23'6^B(Y-X7^\&/I?<SD BSGE>9O5<CK$;.VO]ME[5,3D5;V4[X>##HR
M2X$6.^H8#$N&:$H&MS<'5G@VJW/WMF"X.QB./G2!"#L3N"8IY( ES#3Q+%FB
MA:#>QN*",=>!X=ZZF*: Y4U1X3,E 09>68];C25D'DM1VRZFWPHG%#LDL4@Y
M"U$05@PH#7"7B%<RD9Q5XBYX;1.]39+995UQ4Q/3]G (4*'5'>JNMG9;[A&]
MDK\T96Q;>AEJD!<]N38VO. HU5,!5]VZF1>$(8$1?&NG\^ED"-\EPT_H0$RK
M@NS4^B$[G;WS"6:*PI=>C7KCDTO.T_BZD\+-6\QY50_=E,'PM->$-JYT),2'
MK#P0OEY0VT,)M</A_!S[E3O7^M@[G;-AK5P]GE2V?KQ<!:6]^(9,UZL=MA<\
MZ65NOV1*.I_ 2=LHES4E(7B@7B0N8^8^* %V1%BK$_?%;UOK?345<O2V*V1R
MH"P* 09IB30,B&66CF@>@Z8F<U%J/VYI[3TWU[LO'&R;ZVV\[I]?=(4.SLM
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MWRPJBUEYUM71H>9D'.[ 7CH=U];T?]II*AIUGOSY=%W4M,GKGA]YQW(0C<M
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M.X=!@&+A@:C,0&^*$I*+1=( EM(8QN[0W'S;?O#+P?KY73=F1P/7G 1E+)'
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M NZS"5Q&ESEHTQM+^*Y.]>J0^>9>/?SY<NH[/E8AN2D>/M_+I(L]";X@*/Y
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MKN^RHMNY4U:2\5*Z*$/!\G=,,ILS\]XXPST#]R4_F&[;9B7=B"Y,KM5&6F<
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M2<=<N)P=9'./1",\I1QA;0UX(IH@31U!2MED@W#P?SD=$^NG,W\?DZ?-T?#
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M/F)^.^<:Y.)?5Q>Q140EB[<"1L2KM<V?S+L8G>M1NRUUD_I>!FVW-]IO_E'
MW0YIME^_@GE5+?@4\YH?!W'GKD'C4Q,;<K^^J@O7 .!WWUTU0?TS?KT<1)EN
M>PK.8MN \ZPT458)3C@&U0IXQ\9Z%SBW7)%!1VDS8^^/<E P[V@R<;"SU_9
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MF.WM?&S3&(AF'"C<FIA;[E!P"YA$(<^PCA)KK0C8>>K)]F)]V+&^[W7<6XG
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MWK> WA4DH13T+@R]S7Y8D7J7C$62*X/ U7'(,F]0R!UC(I$F.#?IH*R ]RV
M=P7I* 6\BW-[F\DI)#'L,."5Z@2FL\,"695;=3(<0?'"?T%/*K4H\'T+\%U!
M8DJ![P+AV^QME$ADB0<DO'"(*Y^0EIBCI(,$K4P,P;[ ]S7!=[TR5!Y#;RGI
M7A"J&WDL8$EY@B68TYZ;C&J'#.$$64(#3@Q86Y!%EW07@*\AP)>?S5( O@*
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M=T/Q%5'<+XME"*]1()-*510[8,%ZRU2,2N=@L,2:IJH=]-A< -^"NZ@!>%4
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M9+#21<3"TZ-MM48(?AC^/]WR$FVHZ; _06R\=27>6I)>R&AA//><Z20E P7
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MK5Z/B4@F=1FFA54^RLQ#)9F:(;613".9FR 9XA')>4P&8P HW.=$TL[IP+5
M)UU',OR49'@CF74GF8N:#'$+I,R1"6XM VX]BTD(%I)2 @V6(-6C;;7U_?F?
M&LDTDEE.,A$!,'LK38J0G0Q2 VG3+J+G6EO;S*7[13(O+FHR=3HQA\C(.$H,
M$JDSGEO#I =:X0"TOGW59/2:I(EH)+.!)*,QA!*"()6:5F A*UUI8PO/T:@
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M.0C;*<@;UL?J9JH0VI/R)4!F&01X$*$8+E(,\(64^XU-[X1-=_KZF#7&"*.
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M **++"5E1#0<P',1HM/1J5CHEXQ"-S%\M\CM.<ZS+@8E%\QI#0Q,K,=A:D4
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MJ!&,YCP=&''!*3*.<)2T49B29!07108_9I;UEE-L3%#>">Z <QU60EO/I6'
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M;7 NL"9"822YEHA+II 5.B!"0S3,2IJ<V-HAY9CEX^7:H,%8% )66E-.LAL
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M5G?27PTL,_XF=S!_''<)94![3O0TRIV.!L-6.O_U^9)H9MT7=G#2B/\=M;X
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MC,@)RE$RQ K-J5*!Y.*3!78*[#P0V%F[-5E@Y[:P,V=,LJ1Y,LP@D;(Q&7A
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M6+WAGF3DBVH^WP_!6GIASW(:E5KHO1OCZ.M>_W6EK+P!),T3563@8AGH.<C
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M#^3(&Q>EC3FGE\TGC8- 6C"?4WSEG)D!"X7'91]17O99K?,J.BRD :^!Y;$
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M$"Y@ D!)K>/86VN(8HQ$%Y9HX-.+'.O^6+ X8ZP[L9$)XRQ*>>03IRDADT1
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M4%F"C'4>N:"TCRHP'.G*&GE#,)_I"TU,!?=YZ3.D-8O%;Q1]!;/^5[[!S):
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M>N184RDYY790.0"PD_]4AZ!^#3_WIT-04EKC#.4(DP@$+4B.K&<4&0[L7(@
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MJ$ES]6;M?UWWGVNS;GKLE105*C,[O!1?>5NT&![\J;Q+O(KQE0X/'J'!S:K
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M111M#-AS3*//TR'DJEJFYNB/%*Y\.L)7MAQYZHADS?>6A^^5$G'%]^K@XP(
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M@E#J?4[.2L6PR5^>OKU8]:NCD'44\D&9Y[V0<$ES%6NZ>5^Z6<87G>31)9G
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M+8.CBB 7K$#<1-#_,!=(,D6(EM$XH=<V.<'/ /V>@XOOGIPY.#U:A"^'SER
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M0?MHB2  !PZ0@#N?D)8A(,RDE3Q0D5)<V]2/!PD+<@$]%_/I_GF-*]A*_7F
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MA5#/!:&6YVJJ$&KY"#759"3!)EH=D=:Y):"B'FF) Y*)ZAB"TEZ;W.]^WIZ
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MJ*)!,$,%#X$G#N"YJ )(%8)6"%HAZ!,6FZL0]($(.F7"FQ"Q5$J@X%6N TL
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M$EL>%ND GO5'L^V_O3K,V[G<W]XAQXIQ%2W6H%;BA+CV','_#"()"TXM :8
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M6]'$T]#$X<4Q%H()HQ/"*N;F6\JB'&J)M,', 5%X'4&_,#]UWMS>OR/[(T_
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MDSS@_.)F:=A'L+0#KA&"DI>YK,,&!V.K.-$8H9%%X$D9FM#O@6 HT'6ZW\9
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MK$5&I82(-)0(0Q@8J+\D3Q^-$"IYNB!2L";JH%) 673F@#>,#%$4D6B2XC'
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M[X5R/<5WGZB[@QHI#!)%5X2KL(5PWQ+"[6TAW(\*X;X1DCV <"=9Y/(X9$G
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M2#=4<[R@RZF.WOW)!F)NW7STGA1^G-K $MWW4Y^C<1XT1/U0EA,9^=\W->S
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M"Z6$_=G1*GJO$D:4W<+";K8@<\MZI;!RX,6\@A]$]1_L$WED"K=!G.3H.VB
MP]PR.NA)I-&4AB)/>\)KG&@H4=6V*X,^[^.J.!/ 8TW;M2URO4WJV(Z#;9'K
MHQ:YWEBT.BAR+9RL<'R_<-+4#0(O3[,R9FZ9NW[B%FF1/GLJ@1'740 J$^&D
MK-=W_ SVZ3[/J36H612ARM[, (0TR32GB3P!MCK^P3K^N39B7DCC11DSVJ]I
M.&IW"<]LJO83SODYAS.9(,XY7YRS:0V_GE]UM2ZOS'@68=7@"* XA41>J4B$
M.J^O6V?CI!?EOMN%?_#""U@B9S3);U\>V_LJD"3.U?&-BOC%"UHB, >NM9*E
M,)&QC'PV4Y,V,.W7,0MZ/0D%WO!@Z2B3F'004?IB)ZJ:$J-J<O3BN^/?C13(
M\W4]G=:7@UYM>MAB*!,]"G*K!1A(TO7-R/ AI_T5 5O-."S&H/AGL)NH&!S?
M7<JW!M$:4.=>T$"\$T*2N/CVK"ZZ(*]J:[QQ;A:\F<GJ8EP9P5F(-AI^5#5B
M+!DO,52P>2'JA2B/%\97K<FCV"4CC!CQ_;:2;L# ;>OJS?[K]&\N6I:C$3\O
MJT*RQ5)%"\CA_&QYO@U>/'Q;*T_I1GBKJ#$<@?/]*"F]+1IFF]*[@?7='TOG
MW2L_]YXW#6Q!ZVW;,#X=;PEJ/4?"V/>L8&>@?7O4C_+#D<R=NKR?N>L182U4
M/!,)NXE FKY9W26?M]TL#S"QT3S.^)*!CTE:%@G-)%WRDGUA:.O.^0MK6DL#
M]^],[1F2A64R*K.GQM)/XZ$-L9Z5D[<P6>-E\<Q@YXRD5Y3X/B ?HFYQ;3YD
M*[__1#ZDY"PI/"=GG">![Z1IF19.F+J!X_FQQP.9#TF\Q%8_;/,ACY(/"0Y.
M=D_+/(C*+,KM/,U\;.$;VID+OY:Q'[ B#1P6WB<?@K^K38<J85#@;!R:1H$<
M:_O5<[IB3EZ@2(.&P!GUH*X/A.S2TW%'#%283L\H7?:RN0(-O-W[CWAVJ</*
M]*89 C$XMPMV)>L=P:XP7$V/NM_H_JNN65XY\(('T7SM="+?"KO VIM2@C?,
M@"'?KO0#X1C;4_+ACO=8C-,TDD[6Q;W?%UA2UHV4F_M/UC6_B3."ZK#-:NL'
MN%HG8%!?CX/$*T9<*?KBUH_Z9G?8-^='3<B+@F.M+)%L5'I5E-RN9HNZ6>K8
MK9*X'GKR+CX6WH#L+!&8<"<CNV7$O2*1?H!O1=_?.E9?U[$2 GQ;G\J+DX*5
M+,U]EP=NZ2<\]<LL]]R2.V69.>13>4[LN;;ZX3%\*K#J?GB/*D>/*N596=B\
MC"([B,"M2I.XM&'VP](KRSR_%\(,?Z>M)MRI[_*4OU<F:*M=MIF@KY^\V+J-
MVTS0QDR0PAL^7BI(>()_?PYG*^9?+0XVL9P=Q_W_OHG4S08OZ;X9G0,P6=QO
M+)NSE>0'FP7WJ6XIO;B(@SB,LR*(W)PQ[L8\#L(XS3(>ES*;$SJNK7[8>AZ/
MXGE\_.,T#!VOY)EK)WY>VD$*/V5>FMM!R5->A&D4\\?(Y9!ZN%:#_,W9'LG2
M>OMLS]9E^+LB;-ODSW>S\-ODSS;Y\ZTXD%NRHW_6'?_&I>FF5**@MNZHQI5Y
M04[5'%NR&G2ERG$Y.#ZTWH&IT;!E3;P [V4O/('+5"VFCP][/;</KD!01U.-
MD^X[>$WW+>7VR%XH0^]'/D%4(J@GZ$\D@ZDPVQ2FW[1]OO+6">('[9T@^<<W
MSPWFSV+*<X9=T LP<ORN% H5=]4*7_><%::W7&H3B()!"]GKYO;A(!7001'4
M2VX$AV"IK^BA=.%7)>C9:M['8.CQB?^&>.9OB '5JVGQT""0T 0-;Q>B67'7
M)KV3Y?[8A!72TR4MMT271!D+(//[NE! %+(T8DX)(I\$GA]D3I$G)6=^$L?P
M6$%TX3J!" 6XR'FR!78^2C @/-S_[;1DW(\C-[=]'F9VD'G,9E[BV2D+4C\,
MO13^>,]@0$\-T0DCJNM&Q.F:1.6W;2(8O1'\.Q@)NZNFSL#A5.@BQ135L5>M
M.ES1C4>]NGA[LO^C)_O7&99WNV']DW/R]2P:E&S#@,'\P'56R\!HV?)TW&+Q
M7MMQN.7I>%2>CAMY-P8\'2QA/"W [$G2+ B8EY:>5SAQF<=NG"1%^61X.KXQ
M+^%[/XK^(3^A9V[<["/\P,=BWS=2A^1M/2,GX5D6E&E4NGF0^"ES\[A(TZ ,
M,Y84.2?/R'=<X1G!#_ZC)$E_>,_HRROXSJO3W/>#*&>.G7 _M0,OX#8K<F;G
M69:'/&)>F=S7,\(=U!GF8_[0=QE2O1=N<QM)^JK 3<+7\!Y%'EZ\Q7.*&7S?
M<+C7[Y0VWDK@HV21=C^\VC^VUGKF/56!VHK/UU1@0E@(S[.=RL>82H^ I<A]
M*TW^%<8>+'[%X518,F0@1IL0SEQ%A5:#]4^@JUF-C&A+#AL/+*$+1L%-C JH
M+H<%)V]@P,-_L&_TG$6,V'8A'[:0%/"2BR0Z90I=RC\OJ 6ER6SK3JQLM01'
M0UZC68]G'%:V(!CLJE6X)_.FRD 3 I&CNPB6 ]PRVE'=#OZ+S18_6>_J68:9
M:MGDV0ABOZ0+WE$:N]>*040'QZ+99M-/%2R7/M+K1B+^5O-*>$B%:LW\K.\X
M)8R[(;BG05CF@><6*<L=5H(!G^1AP".54O)52LE'QPG!83,V;?__9V\/7U_C
M1X&9G_'FJ.SZ0C^S6I 4N-KYD;VFD]R':TZ=($ASIW#MP$TB.^!N9F<I^$].
M7$:9%[H.#])G/[NI\IK4JOY,,ZX,3YQ6E+R-2]_)R3^Q]@;V9;OX:O%/#DYS
M)PI*'N1V'J>%'11I8+,89IJ%1>(%L1L640*+'ZTOOK'O)P*AOX;HU_EEPZFA
MW("J;LF1J7.&#>1SWDYT[]W5O&150\2O?%EI'LH2UAL\\X(T/6G '+2:Z(0K
M1K5S=\WC>B$+F>^Z09X%95(F3I1EO@\RGS'?#P)942M#-I[K/53S#.,W\]7L
MLFZ*EL^W@JD%\X_3B+EQ5GJA'7D,5!,<17;JY:GMIW'BQ5'A%$[T[.>32SZ]
MX.O"V4F><3I=BB;'68LTJ_,EN-(M7R[A7/OI'@=6'K XS\H@]'-0GWX:.8X7
M9VX4!:"ARFPK-O^ V'P\.W73P$\R'MIE&0=VX&>QG01A8#MA4/@Y=T)6A,]^
M7E[6ZS(#1NYJ*G.1R'5;,OAUQ]K5A4=8S:#CPB),+ MIR$*_LPQY8>EX:9&[
M+ J"S$]95A1N%GN@>/(P]DL9+?8\WU8_;&7H*\L0/ \,HI!Q7A9VC,7^H'IB
M.W,82!,+W-3WD]S-V089JN=G-55$T._M?UO/W1?CMO>._/W]:PM6K<5(M.Q%
MEJ,PN4@!:EWL6']R)APO_&!B[6'[0&PH%?VW;"D5!:%G[_UR;#W_S\[^SN'.
M'SLO?J+C\KGWP$<?O_RW]>]Z*I1G_^GRV6X0^?;ONWOP_)?6\_T=['RU\T)[
M&_]'//*V@>.^H6"9OH@9"E69V$UA4;R/B(NVV\"H&=D:QN^TN[8GS;&C?'51
MR8H?T^?_/CDICA3SE#>1?K?>:Q/: LHIUA]KCUBQN:.%"I;O7+2!&_..U10/
MVM+)F=X&4^Y9KK2-2#TTS:2Z-DE5_(JUH##GO3:&!U7;UJNF,MH8!O_MN:*1
M8>RG]H?_'+^0O%2XC]*U?62!=3(ON%"^W699*J8UV$)@A]1S'5G:;I?M=OD6
M)U%M%Y+VP_I"%K)&ZQ(OCP80?3CX\%W!TKCYF#!W!+@7S4T;8KN@CZ7_1G2;
MZX-%K76;",SW:I9SAE$G"B>8A>[FY4[O>JKU/&O "^-%WSC6J"S92P4$@6 H
M;#KMQ2X67-0Z5Y3[6;!F"2/ MLK\LF,&U(-<$T?C]OC="FZ/O7;+I;3#L7"[
MQH?6E];F":&OBT%-9&N;KE,,EOV#<5_QHM_XI:C:Q0I'2S,AF#QN9*4RP T_
MBGG^;C6#X6PW\Z,@%GZHNM>C89\KT ,]Y_E>3%7'4W:5L?R3KG<Q/"+UMQ$>
M7?VUK\QGM=TN]Z^'R9IJ5L\KD&>$+S9+S %;5/P K_/"*IIZT?;Z-HK)5I2E
MW:K_K8Q7IM#U@,PTWMMQ6ZE[[/0V")[2</Z<G9.?PDJ,[>*4],-8;W&=X6R2
MA5^3\;[U^$+]Z1+;Z=45E\UQ*TQUF;NI]Z<.>=%CVI$&Q6!G3ZX?(IVSO;N/
M\7;I'?L XBY]CVN9N_KS<@\2JL!)8QY%4<G+*$@+GL$S?>[[+O.X&P293!6G
MKF.K'[;XZD<*C)_DIPESO<C-'3MP66H' ??L+'$*.P_#)$E3G_$XOB>^6@L0
MD>!^K\=T5WNJ+/6'G]/O5@LX+GM4%?31R-DL+MT>S-N#^5$/9BUNO5/YVG<Q
M3VL\<^FXIL22&\5N-')RTT/H4-342-[8)GJ4(U%LE#N<AQO*O,5]ONZ9R'TW
M3<*(Y7GB!J&;,L\I2S?+"B_P?(_%$HD _V>K'[9GXB.=B1]_.W6+)"JSS+6C
M($CL($]].TE#QTZS*"L2-^8!\^]Y)@KI^7X/Q,'9=\OJHNWY<N_S1>'K;I-E
MWS+%CY"'8.SUO8B]?J#8JQE;LDQV YELQQD^:5@!PMU\LH[ L^S*XI[:;-U$
MK*(2'A,M7QJZ/E9)GH'=B*G!18]!K0O,ST Q@E&2G^,A2U8)'LG&=-=DWH 1
M.Y<!]AXBM9J#<[XI9*XMY;?O/W2<+>O+)W RPP44\>W>4!949@$F5@&/*BIL
M"83?1V1KP9I"Q@ *E5P=&2\U6L<ZCQ*>+#)&7)'GPHN[B44'!MD-:*-4RY5
MO,(K=)/4BC[U9#IE%-+HC)K'6)7OM#U)1V6[FS>KS];^_K&>$9Q?!4.>;-C@
M:"&#S<3AGY<UK'?7NOED]V7/$4-"=<]QXXE>1%Z,2BC:QS 1AG=E2Q]L6!?R
MRRJ;5FQ[(-['X3*7$MV/>.*YP21THIZ71;(0_80?BVO5DKX0B/8UA-26N&83
M<4VT):YY5.*:&XEH!L0U?IP%S E*)RF2("N]+';S(O)#E_M>SH+LCO/V#>MT
MPB11/LQ-)AVO^&53+?&$+>!T;4"$Y%R*( E#-]AJ5_FYU+([UNX<_3*NO#*B
MIY><Y)>Z+J[6&;A8/-"$ OC]_AEX\B,E"]VTU40[KSF6:DZM/2R)J99X#/!&
M$$.;S\3S!ETE.J3Q>Y(!@&*G,DZ!AP[=MX1GH8UD&!J$9V<2ZRZXO401!(8L
MP JQ/M:(4^G@ FJ6"%G;+Z<P7[_#Q(BHC*,UHXIY)A.#EY>&J  1!HI F%9K
M^E:&1>"=J!N \!0[NNU!7$N651*V350_;H_(>Q^1E308112NK3XOT;;<:):
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MHY(M5U/L]UOPV;Q#IM?95$X#O?*HFK;@I"Q4SLKL ]TKPI'0F"D_@Q?K#U>
MES/T)"J:NM''[%@G0O67V"#M3KJ?L;Q@!5(2)G'@ER7+P?U,61C&3LQ=K]CJ
M_L??PTC Q#T'M'OBX/;-[2#)73L+HM1VTX1E09#"(>R![@_'=;\06FVI:00Y
M=HN^J IR(*D:ORK+5D"X>=>;B+#MY=:B>PR+CN@91<C)F'$TS/@%G]8+J[X
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M!4+"YF"9(:Y7&R6;;<[)NN8;:QG5Z3<,+$FXKHCNJP(&"1CX/@N'WPB\@\R
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MMY0/J23]"59I&G?O"=(MGRJZP\K[BZURS.4?7>=Y1E3$H'V?,U4$9[WZ#+X
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M8QS3 >Z/0@, ]>JO8$Q30Z7$$@?05S2QNN7X-#=X%+9*B4D'I 2Q16#%;:J
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M.5I1:S3.(H.6YE<CCWFKN2-QC.)!6/OAEHX:615FTYS':N^4T4L]J0%XUPS
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M;A4]E1M;SE2'Q .&LE9.VP T2@@R>>&%X1#+#H@H?/I8'1+W#N>SF@2J?\D
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MLN;$169(,@)Y%B E,!M;]@GCJS(>+5.NYBYMR)4/*Q_.\"$%%@,+24J19 P
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M!OT*YV7A/*L(>).SMRCYER /(C7SQ#.'/P1(9R S+F4)_[;(OK]44#]<4.>
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M*0!ES&ULG:;C.4GYVR]T1LL_O$:W\D$Z&:1AD0/CU0?"<;.R,[LINH@;),K
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M-HH@WB?O^(O4I =<HX[YPRZ?"BK+C-NPY%U)4!(L%1[)B*EHO1VU1:[FN_M
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M6.HIY;*>V/<(XG-V<!=<$I:[TL$-?R3&45N@CA@:2J=.P"UNZXG]"&!N)*>
M8IM@ALE ,S FI&<1?+8@TBT)YA7.R\%Y]L2F@3(/5) 8E2#2,4^\RIRDY'0H
M6:V,BHTM4X'\<($LP'M!@_*&2FE9<MG1DJ@9\"^?1;7!WSN4S]G@ V<F!.=+
MDP:.)W?,Q*H">F>2B]9!E$4N?R+5.C72KDA?M63.G=1*9YU9L=\;_,NR8$1
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MLD2)=HY)GFW.ML:IKBTVP6A&DTTA>"%]J7$K4735-E.KDXVU)L]:8G#V;!1
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M06D6D:LHD[$V\F0=ZFS*,,UOJVUT9<$5LN"<VX1G9:-E1%EFBE$U$DBHP)D
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M=9N,7_WNUZ[Z]?>4U2L?*^.;7'_?%-S^8._5Q+)-+=3]&2REWW?9NQDLN]Z
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MD5.!6R]H7%@Q@E/6)9^\"\5FTU<:29\S%>"2P'0U602#!0<+_DDV?BU.E!A
M)<PM<@W1V 8M)K"FZ,&"UXX%YYH$@D[9:U:FFM9WZB456] JLT6JVA>7H;,@
MQ//JM\&"@P5O! OZEJAEDW2,@%@U<_*&8@#Q ZU0X]"V"TAT\S6#C)BP6H+2
MX,3=8PM"=*6IA,VYW'NA(GQ%[?Q!<X/F;@;-(<NI8+(I9D9$SSI$GUK,'G4O
MH#:<O6O'@7-),@2IDBDJ!!,5BD%3;%M6)8II,P!8<>;LF3 D[V#!6\F"-826
M29NFDT'D%G5AB(DP4(TAML&"UXT%Y]8K70F1>G$(Y[ JC*XH0@!5J$$ 'QS-
MUBOO(IPW[_?VL."@P!O*?^+U&09RQI)'USB&YH%#R&P\I/P=BN,,_KM@R.^4
M35;:4]4QJ236KO=9;8J2N(5RWQ-B,1F:O[,<[VISWJ*;EX"E"RT#_WV/Y7#R
MLTQ^6YZ=>Y_=D^U]GIW\:<_,WBD/Q]=PA!PT]X(3=+W;V9WT=]Z?UDWYR&_U
MA_>3LK=^C*P_?/#HJO6GCW"2:]S?._LC?[C"7 6%TZLG"-//Z1\JXN^W]'#H
M_O"X/OUD3-Y4E::5WRIN<KKW>?,]?]R]\_?/KFIKLJU.C.)9 [#%TS?R[J.A
MB_+.HV?Z)(F?6Y0-H8Q)^W@T1,O_DZ9RV%-.^K-;,IMQ1\/89O^.I^'L+?=G
MD_#XJ<.SU/=T'[7C.7ET"4M(]YSN/X_^]F'V]R&[_G%.'=*2"&D')6N,F- ;
MX4]Q(DMMS;?JY,]#WI7/U/*@,QT6C:6!SK9Y#)A2*C[YD*+-SCKMSS%N]M/9
MJVZ&[\.?CN2WFVSAU,GVN.Z\F?*[]4E>>K)]R/0R:I_?R4/26=W?ZC7K3L0I
M9)B*[CM_N:!)591K*6961+0U=F9FH<RQA3*'%NISF_1S7J]E?[,^;4?6:;>;
MIT<?9$9O\^:Q:=I]L%W^M;/]YE\"^M+-T][NCQ\_G3QO/A @[+[HA/-"SN['
MS9W\]IK:I%>_KNN\]9]M_H7VGVZ]/'CU,!^L/%RSKQX_.WCUXOG6JQ>;ZZ\>
M/Y+/O#QXVNV5>;[Y],4S^^O!BEY]N/:ZF5[DR;&2&5\45C$HO5^.T@X=>9+[
MTV3"5['<[SKK3??KJ=/Y&/0+,7E/9\KC";/$T[K$>WO321*"+TM[.TN\].;3
MS)[6-YT*$HM+LR2_[*W7)9D@AP2QTV9_YZ.)UMV=V1,?*T]WE_JLO=L?85:^
ML;M92^]K/]SNH?%M.YN;.^]W[W\.F=.'$\Y!!C/;.4^=F_QNM]X__N6',ME]
MM\D?[T^V9Z,S^] /G_-19_P3MGIVP,.7CXP!T3U/OMN#H]RMHP,?F8I[,U-Q
MPK\X?,W'>][Y,U_6]^#,U_[T:^^1PTO_5KA'EF[]N<8O^M;K4("5CFGBT'^8
M[,G!\A=HL/^:;"_)<38%_[O_?>:V^B^ZV$-7\3LIS#F;/KNZSEGGN*@S$ZFO
M\?7#+;]^_=GUWX92&2_O_7QO9J+_O2]GM;/T?))WSIL ?5O6&2Y^_3<FQ%:=
MTU1K22V7WM&6$X Q.8(.(F@LG2I@1HCM_"$V>>\SE-?PU2]/4,Y/KVVM?%A[
M\9^WKWYYYE9_>>+6#AXX^2[[="[$)M+GX1N1.NN;:QMO[.K!\\G:P3_65W]Y
MOOGJX5M8V]C<6'GX5J11=K\>/#JE"'7O0@7>*%VSZ4L,3K$G5@4314);JL<[
MRW@WVG.VL[TXCK[SEJG!AX,/3];CCTRAI-""[@58HH#",6G6,:3DCA)/X)@/
M8?#AXO/AR<23ZI-&3$D9'X0/B_.*HCPDEW(T3#X6,^/#>%E=O@8?#CY<I L_
M3WT+WXK%5HLQ#8VQ$:KAY+SQX)JUWZ';^.##B_'A7#)R@AHK6J.:[CV*(2<E
M=STIN;O)1A\:]EYH>#?09>V:_^9\>&[!?[0:=YT$_T_KDVW^JI*8IUSLS2L"
MT,1]<R6;9/NT+I51&VZ)/6:G.9R^,C<V2GQ/;GHRKUT-M>; 1D7H>P5>RRI&
MRBJU6=^VFA"<<!-<N 3 Z03P39VQ$X?\JGH>MP+*D,'I[.5"JT=RT'<">"A-
M9Q.]<U>DR0:4SP?ED[(+8]4%M/@5H;%"VXR@N FR*43=3,[8DD"9+MR$<4!Y
M<:'<MWF B;'T<'-Q+7JBU*!YCLF4<D49G0/*YX+R_/;%:#'HE%4.OBA,-?26
M:@+E)F*!LP^5ZYUEBQ?6"Y<(Y=NP!O@3;W/Y.DUP*PJ#:<BLJ1AQ' "#TY1R
M2M9R\]J:&G!H@H5CGY5Y3< I>N/)JYI\5%@J*FZ!%&5H-3GO"O3JVF[4^+O!
M4&9C6<LTT#(','LOCH0MOH*!GN!\U#=Y:((%@_))3=!TR;JB4UYX62&;HE+*
MJ *$".! AU"Z([%(%?X&E"\[!26**K!(@#5C1$--P.TX%E&$MI@KVN4ZH'PN
M*,]I H%K=4;TO#?9*JRD%>=2% 'K"-HB5Q(H+U3EW=NP3/#OG4W>+F.=X,S6
M62G*S PEB:+%7 .7ZCF0<6R=B]4/3;!P[/-L7A- 2EJ$0!(1T/HZ06-%!4DU
MTUM)4_&!W)UE$RY<P7\$%Q<7RC%BTC8$#UDC420# 9T\6 _-']5&&YI@P:!\
M4A.4:#G[:A2'UM.S*JEHK54<(8O<RZV$#N4XU@EN,)0I.D !L07,J%UA%,ML
M0W..4\AIE#E<1"C/:0*YBZV66I2E)%#V+JE8K$B$EE/.@-&P$2C;1;+*MV&=
M8*5^.&5WT(A(_%YDE6SS%+(V*:"8G62UN)2&?$*=K4Y#$RP<^[R<UP36L^LE
MPU4.4!12)I5,<,J+ Z%=#"U'ZIK@LG:]C.#B D*Y^>!#<3Y7UEA=9+#.D^=6
MN;9,=FB"183R24U@LBFMM*9""E9A2EX1]-\"I%S19%VYUTL>4+[!4-;L6P0,
MC%B1B<B(J(_(3>2^B\T-3;" 4)[3!!:<]D!%02NLL!:!<N&@4@T4BF5-!@7*
M9I':W-^&=8+_93GH6"8XLSLH$H?LB!T#6JPLU@A+2A7D'\<Z),'"D<_:O"0H
MB<E7$#_"<%78"O;8(JG* 2#+727JY*-';/$&0[GH%'*-CH,.Z)I-V@7,V1?R
M!A*U(0D6$<ISJ4/82P)7I[*GODS@222!*2I"\28C:A'X/;8XH'R#H>RU\2%8
MB+J)50Z%Q 13K@5%+XI9QB$)%A#*<Y*@9<U69\%NTTZ@W+.&;&-EP6:MDZ6$
M,TEP874_E@G.!409YNU<QS+!V8N4)M3 +3;1!!Y]9"A%UTRMQ5Y@>6B"A6.?
M4UKO1M30BD%E*V>%J7?@$-]!020=#19Q%6O7!",'^09#.6;Q]*LE=*D@E=BW
M"=F4!:RY1QK#T 2+".7YRDY:V^BB0M):80Y&];KW2D/25#-#:[9#^<+Y!@/*
MBPME@:[3)!0NT@!#=,GX8DVV1?ZB8,+0! L(Y3E-(#PL"E\G%6K/ @S&JJAC
M543.>AV=@Q3O+$.@!8+R;5@F>+Z_NSL998?.KA_I,W&L,=K HF1QUCG%E5!2
M25PJ#$VP<.SSYI34H>QK)&*%NCB%B$%QHZ@T@N-4H7)-PC[G;D,_@HO7",K&
MUV()O(F6T; AH%*\"PUR"^B')EA(*)_4!*R3A6;$<RB ?6>043%04CX7;[2O
M*6N1]P+: >6;"^7F$MA2 V1*O<-@XBIRH&HVIHDUCD,3+""4YS1!*<Z$ODY
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MW(I"7YTB<%JY8GJ%N^):L,(^BQ2>&)'&R_8D1 (8IS/KK#&1.)&&=:LEF=;
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MWX>B?C5D*;F+-M8J<B=(C S+F;;)_B0^Y.%\3OFAR%H*5$K18IQU%453Q[=
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MW*?K&YC?(]G %+^HK*UZE 8+2^^+08AS&LXG@(?9C'"X#N^90RNB8>J>YI8
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MH3EC#9Q"PK@P_8*8EUJ+DZH2?C%Z/5D?7%#51H*#XCBTW-GB7*!5(WVXK,V
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M+6[^!\*I: 0'^(9 I$@&B(U&J*-4KUT=P-'5]MC:GCQ4#_ T<6:I&>S5QFK
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M"'/IQQI<!MLF9+5"B/5C-%C4!(1M7C2.O\=6O/BK.XI>=*&-)+/'7TM>[OV
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M*.\)-JZ,E5:,]' QZ0.$7>!'(!M^@I;-]#<]UZ:O6%Y07CSYH"@TV#(1M-U
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M7?Y^:]9TH;W1\!YN$YMR_X$3J>6]\O,?NI2_?8"5P M'5^3O?_G_4$L#!!0
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M6I.UX^7'+H*DF))@$22<IOK6*"U4$$%"T9*!HAV D)%\"::\4E)ZPUJ[YX_
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MK4$.2L6U(TN_PFJ7=UO9[@KC:MD)20'7P^]DNXHFE8"B4X3 I$2A@DZQ>9G
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MYY Z)S\#ZWH19Y,LS&4!S]=X_G3Z8CY;+"Z+]L]_#Y\6(\:CTS&2?YABG6E
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M>C1*SAJX+"1HGQ2&&#1O7M^U.;I!]37JD4,]R:M)0-8M^\92ZQ"45$?P^,*
M2U&SM"J"\\%2\&!4+%8'=GO@WKV!U[T?OF6._)N3>IM=[3U8.GGSXO37XW='
M_SR^T7)U?<FG[M2U&;6[1TP[/:95V+3_&AO%3E>/6;-AC6!D>0J%O IP/-1!
M1_1'K/,H. 9.W NQQ-:7 1Z LJ]-6M^Z>&BAWK.@'#/@?9WH%&,B$XE$?<6L
MM2A*RJV=W<<1#2D^:L&.VS:GH3Q:7OO$^?S:\.M;H Q3+#FN:V%J5YT:(6KR
MP%W@.63!,N>MQ^L\ 6E(R< ^6-)2(@>C2:CS!;CA4%AUE'*=.^""!"PL%3+*
M.33O!K(5379?\2LD1M49"_<OO&2FNNDQ28D"*AF2N=89A.*2WN=8DNRAG< &
MR(:D3%NRYZ'7I:&<FK\UKV9SVN;I0]AXC,K7YE12>48>K22=[RV'+*.T=6L*
M:WT==S-D0U*U!^%0.SDUX] 33@-G2G)>/#">!2@L!@*W-5:UM3$/JB1:I_BW
M<>)V7N_Z=;Z[X*S(#:H!F])UO@G##"XF#W6XC6)D!+5JK7"?@#0D3=N0+0]X
MKTT$T_KM6+^X=T$YEB,I  :.V8JL-J+FCD$R/NM89.(R],26!R -2:<>@"TM
M!-.,+:N%UM3Q*]J+%[/I<CR]&$_?K\O69M/%SU@(\;4,Q/$?RWD@L8RG8?[E
MA':SZR])_Y(V>M+EIE8S&T9"*HZ923(]@GSSP#W1'R,83G8B:NV-;ZV(>US.
M,^ST2_IBL1RGD44GE.6U:R>O;7%J5P$?!6 B\ZZ*8SZUOI6S!]PA:?^A\/NV
M,C@4&YY34:PUW2AG*XTM%GBJQ=2:,X@)$Q!21:XI+T6U=N9W1SLD8_0=D7<7
M+ASR<.%KK=)Q*9B6X\]?T=<&]],TGHR[AS8Y9-C^<3T<-NRYYIX/'0+Y6<99
M!Z*;VTF!+.D[9@"#3BYYZ9C^1@X='H^A[WM]1@:]S=HID'5(FA+.0[3!@!5<
M%^U5D:&UP=\>Y?#L_'XLNJWF>I9;8]-\YZ4EQ4]OYP6]UW%R>;Y[_B',\>>P
MJ ?Y'^M/NM_L*G%-TH)GQ2$)%FL2/:\TLX].EZ@1>>S'6]\3^/ ,=EL6'EZZ
M32HV[C$I88DWUW"4_^MBL>SN0;V;T6\<+9?S<;Q8XF6CH"),$@(U%%MJG4G1
M$%14D+G*& 7R(N0&!1XML RID*PES9Y%5DT8]L"+L6K!?3+]>O&N&\!6^\"N
M%C*9S'Y?W0K(.J88+$1I$R@K:J^^$ %Y"(K\5,;+)NS:%\>0+GZW9M9!9=2W
M0;U$?7DV4M^"KL#R/MR%HJL4..@H<TW]&O!6<W J1:U2T,A:9UGW1SVD>^$'
M-*5]R;5/+?<;@9E34%;SR&?K>E]R/SF]+MI(L,@M* (+@4</F=Q1-(X[O#TY
M;QN-=N\SAW2M^T#::_^][UM3W8Y<JCE_.28K7P\@QF$RHEC$H"@18DE$8R,<
M&6OGP"!Z(XI#5*V;5.P(=1-^V6^07X>4X'-$FB<?/X7QO/J+ZP&X+(O$.;T:
M4:0"*A0&GJ<(,M?B+4T^HFY=#[4'W$UHY[X_VC679)\V\&O]RQ+G]!N?PO3+
MV7Q6MT8*;A4* 5ZGVD6#E+&K#B2+J%4T5IF8=C>$#S]X$]KX;Y V_4NA;QVU
M&H?X-8@=:9VMDR5 $?4 GXE$]EIG* R]+RHG$PYD F]#VRBORKY!%O4IHD,>
M%M7=Z%(FL_)K^*_9O#MGJVLAV>2PN!-'A&EN,L2E.80>#I5ZV)MVL]!N/KI>
M=HHQI!)% =.I**LXQ"RK_\Y2,38:+EO?^+@/1ZNRVJO/_&4^JU>$I;!.D +6
MJLXA+(I!$)AIB0JY8:;PTE<9[4TD0SHJVIL'#]7*[K'YS>NK'\MA2+*\M%P%
M-DA?FYHAD+:.D$6404J,I;<++'LFGPXY/K=GCNPIE_X(LR*ORRHJP2QH7:^4
M&E4@2D_6/I!IM]H('5L?0&^B.;:+&^Y\(GU18Y@783[_4F;SW\,\+T;1%9;K
ML.&$M9PJHJ)M-QY2$DJZ'%BX75QW;ZRPT<,&K0>WE_SU\*#]9O?'<?KB\F=K
MM[8VVYA_QL71-'?3JL-D,;+9>451"X14&VP(S2$8:X#Q$H/D0F/SC,5N2(=T
M!-Z050<47Y,TQ1V<+S$N7ZY'X"RZ-B[K2S7C*2G\\?3]JIL"TU8I39Z!M;44
MS]5&=]P'<$E)KXI&7C9)5NSX^"$=;/>MDGH02#_,H2]>T/?CY0WM>7]'H&Y<
M3K!1 ]I<"&X4$$I,H%DN(1;#C=BD_^!>((9TB'T P]:/</KATGD:US.#,D[7
M(%:].1]7A&%R#>[9;#:IW1*E31RA)%<A2P>N%NH6GM#SHBA\V4D?;0MD2,?1
M?7.J5R'UZDC=\RJ0E\<T1FWJY03:EN(T>)L<Q-HW705D*;>N)=P0VI".JP_D
M*NTKH/[8<_,"\TB%X"@ D$!+K/&OE1"D2Q"RUY&GY#5O7?']!*0A'3X?@BU[
M"*0?VW4VQT]A?.GE+T887'+22XA))B)O0 C11<C)ZH1.Z\+-+J;IUG.&=/K;
MM^799XL/&:%?+VDFV[@^AUH\4O-<&$-E+ .9' >%DD)!5T=3IE@DUX%;T;H9
M91_K&-*9\O-$]_V*OC\2=P>:(YG)Q2^((%6]U\UYIF@R1/!"^N!,C*EY!]W[
MD0SJ7/D03-I^__OK#G7MD'/$DE/,D"'5=7"N<M6NHF-@C9,JZB1SZHL1]^%I
MR/MKG_K+;)9_'T\F],*>4  S?5]+BE9RN?W]*%@9+=*&&,4C*$_ALM?TK6*\
M9.0J,=3]O2*[@1YB*G]OMCWR2AU M*U]R&N0R4R,%Y<%E E/RXO9]#/.NSJW
M-[,E;1,WI!42UEOUB>(B9!0-1?J6B8"HT9 UV3+KL<WCAYC";\:F0XFE#TM^
M#6PWSWY]Z^FR,=9QF$_'T_=DN+A3MN1(L5+EN4Z9W&;KP)5DZX$_D;['X'5#
ME$/,]1](9S437G_NXC6TM=R %6^4RN0%Q>SJ42F#J"@D\R5H89+1P?<>OMR$
MU'S%7;MIC;6]= %N,HF:"P_.**07/(LB=<FNSQ?G@0JL89CS%LQXTDG>5@:'
M<9$#RR7&0AH_U7M_R81:.AS ^B1]\MP[UU<&^6D7>6C%23W08V^A;%B/N_YY
M_2-2)/_7?_N_4$L#!!0    ( *F$5U8ELU1 &$(! &54#@ 4    8FAC+3(P
M,C(Q,C,Q7V1E9BYX;6SLO5ES&TF2+OH^OZ)NG=<;7;$O;=-SC-JJ>4PE:D15
M][E/M%@\2$Q#@ 8 5=+\^NN!A:1(@,P$(A,@5#UC*I*BD%_XYQGA[N'+O__O
MKY^&/WV!R70P'OWM9_87^O-/,(KC-!A=_NWGWS^^(?;G__T?__9O__[_$/)_
M7WQX^].K<;S^!*/93R\GX&>0?OIC,+OZZ9\)IO_Z*4_&GW[ZYWCRK\$73\A_
MS/_1R_'G;Y/!Y=7L)TZYN/^WD[\RGV+.,9+H.2-2!D4L!$Y,R"H ,RQS^O]>
M_C4Z1RU^2YA.CDAJ.0E,>J*E<YYYHQA/\P\=#D;_^FOY(_@I_(2+&TWGW_[M
MYZO9[/-??_GECS_^^,O7,!G^93RY_(53*GY9_?;/RU__^N#W_Q#SWV;.N5_F
M?WOSJ]/!NE_$CV6__-_?WI['*_CDR6 TG?E1O'T /C[-;O[A733JE\5?XJ].
M!W^=SO_]VW'TLSD]3R[AIXV_4;XCJU\CY4>$<2+87[Y.T\__\6\__;20G)_$
MR7@('R#_M/SR]P^G#Y$.1K-?TN#3+\O?^<4/AXAX_@FS;Y_A;S]/!Y\^#V'U
MLZL)Y(WH5TLNH%2!\[_*I_VR,Z8K!#*)UP$(_A1&1<$K8ESWZ;MCOODLDB#[
MZ^&L(N*'GUT5[_B3']04\(./KH!V_D'D$WP*,*D)];O/O8-S!?(^PO*1P5_C
MZWT%?CB[^DL<?_IE#O'EV;OSL[>GKTX^OGYU_A'__.WUNX_G9V_.WK_^</+Q
M%/_V:=SA*B(VSAE?O-[_J\&'W@&-VC$8#<J&\Q:_77YR =<!?/@Z@U&"]/-/
M@_2WGP>V;//4!ZFDE]*D $Y%GW*4WEAM^$6#SR\+62UE.([?/6Y8=M+Q#?5#
M'V X_^G%]91<>O_YXGR&AUHYWW#M<(I?3B]BY,Y #L3;!$0:[XCU"8\>#CHJ
M*RT/^J'B3%>*F/TTS%5G^8A?"C6_P' V7?UD3M:<J,TH%@1MOZX/\ 5&US ]
M"=/9Q,?9A?7::\,$$98+/%"E)4Y:2QC-QN+_DC.^\JKN8_A^3;=J=S)9K6[Y
MXF[Y9A=SI"J[LW%%H2Z8PP7\_--XDF#RMY]I)9+?X+I?CD=S2/]$Z^SE]70V
M_@23UU_C\+H8=B?3*>#_IX_^ZX4*P1E+'0DV6K2_1"!6*4>49)Q;G@VC:[;%
M&GK0!F;_JK(;M^L5I3-B'NH2VU677HZGL^G)*+W^^AF/X3MR2"$&L(83%[TA
MTD9-+&[:A-H83196>)HK*\PF+,]^ ZDBY([(/\N_CL>IH#N'R9=!A.GY>)@N
MG'2@(:.7%J1$9#(1KRR08$ S;H#YR#J@?SV:_A6@#F-KU*""N#M0A',8XE]=
M_@HCF/@A@CM)GU#&9<VSP1=82N%",.$EM[A:%1*^ ^B8!TB&:&J=#N7_P-8V
MD1HA.Q(%Z8"&A\K"=S<_IH ?>(7X7N&!-QQ_+COE$MSM&1?_^WHP@70Z>C\9
MHYI/B\0N @"%(!+JN<+3SE--0I:*,.VXTMX8H+6-[!W@'HE:]4780UT3V^H:
M^K87)Y_&D]G@?^8QL;-\.IKYT>4@#*%83[/I+>X[OW8RG'\D6E;CE6%WN^G.
M-UJO@%,/FI@ BDB1) D".+Y*6H&R$;^)3[C976%[YMIV$)0]5$&YBPH6#'\,
MAL/33Y_]8#(W",?3Z;OQ['14EE)>EOG2;O_^Y96?7,+T(F6;\ 6Q!+?H8BX*
M3JRQB1@08)1WSB3>0,^V!G $RM2/\!]JC-KU@-R RODHF3&">"D157*<>*<C
M4:C!47*NE*>5S[ZCU(V*8GY(OMYEN\"#=C:YCK/K"6YR2SRXZM,B7C]\?QV&
M@WB6,\S_NHCD0D7%M! ,(09/I N:>,_QC$U:.8@JH2HWV"9:/_B9JT#WPGZH
M&6;7;>%L=@63L\]0C/G1)6YBXT\KD_X=S"X8SX:F+ C5TA$).A.7%1#KN=$Y
MY( ^8N7MX7%$SUQ'.A#[0Z6PM>-O%\SH@(]&;RXQ7&J(G 2N$8^%["-3.LO:
M@=K[&(Z$^)U$^Y!JM_/[_[T.%F/F0@4KC-:,:(=_R, 2NE<NH3*B;T^#M*)Z
M1&4-C&<?8-U5M!U$24Y'7_" *DM<8$)G"";XDPLFD@++.=%,4R)C0.7VR1$
M*UUB' E3E2G?A.79\UY%R!7#%K>X%CB66\\K"+.+($T4TN/",B D$1FQ@0FB
M$) 'F@+HVA'U-3".@/+=1%LQ0K""]"N*85KV')B>C5Y_+?O0]6!Z5=9\EN<
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MO3D$[)-$JR$&)Q0X-"5J6VP-H1V[HE0BI;(Q]1W$NZ!NK-:SO#!CSR;EU)_
M53%^O\#J/FY6O@U#>#VZ_K0T.I8!JWF!UYNAO[R@B1NF!)#$ 19=2EUDG% 7
MD\]4.A6;%'#V@?6(M/ @Z>V@*\Y[_VW>+O?->/+=<B\R S1/,B74E->J3+IR
M+"0B+)J[@B5O0_7^!1NP')%:515[!YE]WR]\D5)RP:/$=;I -"N^#P^>N"PM
MB=$:ZCRUBMM.#;\%CB-4@YW%W<%=^SG,QQ3]"B/<LH;S4,LGE#0"7;1/7R21
M7+A$9=#,D$0Y*JIGD7B@E&@9(3L'U-G'2H&W:D'>"-D1JDD'E'00R3^/5Y"N
MAW"6'S'=IHM[D4!#5-8:PH-!@]]807SDD0C!8HZ)*F%JIW^U@-?7L*CN%:<C
M2O;=FZ"! .?!W11\:045B1/SUMV4%^,JD:"S<49GJE5M(^8)2/N:E-"9)CQZ
MHNW&2 =W-1_Q]^Z)8%6=W !81_>)&T'MY\:P*H7C+N7?JX)(F0Q$+8GAJ8R]
M%YH$R2DQE.L<G92.U6XEW;-B/'$AMQ^]:"/V+L,[N-@RN?-RX<;/=\M5.P*)
MUI5)GBC.RAB9*$@(V9.L+7?"\1SNI[(_':#9^+3^K=M*U&R*J]21:^4V#^?P
MV2\ S>&AA/WP_748#N)9SK#2_Q70P$,4B^H*-+ZEHX(X(QW1P>)IF=!=NY__
MMU8!6CWT&/2@.RGW-SG]S<GIAW^<O/W]]6^O3\Y__[ <Y3#O&>A'Z4[;TM_
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M.HWU\D@FQ*3)RD<-7)I 03DGS\(37D,W0])&H@NM29<?S72VY*N.P7+ZJ.-
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MQV=WT3_4O]I;_TN"WPXP^G@L72RA_8>_W0?90_CWU;>'Y!J>]/?A>*ZX2JF
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M)@O:&6%T"(RKTOY%;164T[:'%O)O7&_Q(4SG8YQ^Q,M!5K.OH^_7J&+ I(4
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M=0Y8+XUUFP&UB[@/-P<L8N8&502M8QUZ15%-)%N'(HJFK\ S$X<^!HYM#M@
M-M!'R@>9 Q:,KX=<AB(] 5)!@@_*DGLD@O?U2?T^A=P)SP'KI9VM<\#ZB+;A
M9;^J=C@+[IQW=2=,5[]#@<NN@/3>^8 Z&;]?I?01=S#L<IGO*\,A.QBZX#C!
M#H9>XE]7_KZ+[(;L8(@QEU1OF$HI2L&IX;4,,D&@2" 4(93FFYYGCD&'/3H8
MFJBPC\@:A][/.*TFA'_^XNT\+R,Z,A9AR2E0VM'I0DX"A.0IBJ3#7R:OM,0N
M30PK?O0C]C'TDO&DG8 :WH*SZ?SLIGZG6I^E"SQHJ\"69&M/A8(HBP6GE,)8
MBG38J0:"?O(M+X=^=_/%/5CTJ=^#^TFQX0B$.T"NK+0+E#[A:U?%/L:-N*<B
M5JES#RDV/%=70:(8*PE#T18: D)'1J:X2]%O0TDN6^73_:;IXU7HFNMQ.'WV
M$=[0'7Z:12XBUCD*:C%(N[[!*@:TH5#0^\)8E[ESC]?AM[> -S7Y]9'.(S?Y
MO?HK?0WC6A-;<-JXOV_ESQZRM6_[9NYU]<6B; JD7A.4<EY'A5I['E*QZ,F#
M7=W5MW*9_=(WK_Z:C\9?+D:SK_5:?U_J-?_VNO:592&*+1)$$AP4PUR+DLG;
M)IB)_EP)UKK#;2.@MJ^<'_'[Q90D.L/\.B2\[!@Z\UH5D8L"4S2OHQ@=1(X%
M"O?5O\Q(#NN@#YXK81T^H=7.,C:_@>ZOA0&>M>Y"O(4K*"U25 D\KW/90R[@
MZ2Z%+$S,@D6OF1_4.GX%D]A1WH-VZ*TTTY>8IDA_]/YB/IN'<2;I?)B.QFGT
M/9R?26&$0^,KW1^"<H6#TTH ,TD%'ZR7G:AP]X1Q"E9R:&T,7G"UL9$9;;%"
M6CKKI*A5!$X"6;D&)FWB3AGF[@]D.^FV\D,=.LUT,L!K^^^C\60ZFO]<8KP.
M(&X@/O_Y(4SIEV<<K<@V+\I 2"+2U()TQ^OP\&(8<A%L:6P^/>"=DOT,I94!
MVOM^(TG-WDYF,YR]'Z^2R)G$'+#$ (K7?R02A#>H( ?C+"M)*]NZSF\KJ%,R
MEK8::)@'K9?K*CR?OXZFF:QW_O,U8GUIL=EJ;0%S3J#02G"QIM\)I\Z!HEG9
M93SD]I5.0>D#R/2AQG<>Y;#Z_OMC'+Y-IO/1_]#%-\5OHXMO9SE;AYD\)9U2
MJ=4J"KP@D-JBSR6AB\(-ZHD\Q'0*UC&(_!_:Q\[#'Z[K3])7S!>UCWVE+2^>
M@*1DS":3(-8G/84,P?'$@9M:ZJ11H&R=+>D ZU ]X\/91FO9'TLG^<JJN.PL
MFMI899BR=5(V!?G26."A<-H0XY*W]CV.J5ZXN:Z[U _WD?GA2D:[H/I5ZX=[
M::Q;[>@NXCY@_3 W1F-1D'2-F;0-$!=S+@W37OG$T,<G; 2[U \/8 -]I#R
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MP9\R!G*.6@G.0V)=^KC[KWQJAM%<VBN,8Z^&_HUP/V(5X6C\937NF(UA7"A
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M&%_^Q8<I.8*W+-3SPI1@$9RRJ4Y<SQ"B(]%(P9UURBC9A6"P[[I/V@X&%?(
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MJ N!Z=]GTWPA\?NTG*WDE>Q27O1<6(I4N:X#EB5FJ+>F]:U<),5]=K=;E#N
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MNI%>ONU"-]+'QN,Q3'21ZKG2C?3R6#>JB4W,/1X81)):I& !@Y.@E&($=RY
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M1;NT9XE!\M(&9U3B;%AM]WR*1!\T;#)%HH_]!TB9[V4!5H)KF[B#( 4'%;,
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M3]@&G5'81F05J2N/!5[XQ2Q^>C/Y'-;G@F94.FHE^O6V1"-!$R=L),;BUF)
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M>+3UB&0 Q#/-2582W2FK1,JUTR-[F]P%+9(>M+3_!76 BIU3392]$_VQ.,Q
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M'8OC^6N-L002+SL6>!*4= 2B"N"%8$)"Y2-D!YR+U(K:8NXBL_6A3?SX9!N
MX9)9P0CW$573.4-\3N4?X14X)G7U%E4-8%VT1M06^V/-D,>=&%.(D]OQ\'^7
M$-=7A-^?#&R:^^&F]@[&Z 8,\81C27A4UE3ZO^%>%GU<=:YP)@*/^"6+N=&1
MT7[LB]2%7@3]6#'4L5O&$Y@_?O+S_Y@L1JD49XKSZYPA%D\-_^0]FD@#9TU.
MV5%BLL:-CJ-?;R.ZVCPXY73I;9)J[R*'(;U(9>J1G,<JI3O8:]["'$4S!3\#
M-*$6J/GCVY*C\'*!^^9XOJKOCW__;ETU;C8PBFDMJ"*>)Q26LQ2MJNQQ@60K
MF7**RR9%!&KAN4@U.ADACY7*=*-4KV#+'-XA]NF6&2BO8HP )!HFT"CW0((Q
MB3@4+2H-1_OLB".M)9IGJ%"=D?%8G6R/>]13,Z!&.8ZJ3Q0OO2EBL>A*- "T
M="IQZUU6]7>HGT>=.B/CL3JYCJRH.SG=F7MH^MU9@3%.%U#>]0-5$?5?T,1*
MET&+/J/R)#I--0_!<%/[,O((N!>I:'W3M"7D=W2:^"'8UT]Z!]IEEJ7 S9;I
M(K,HB064&34F)LM0GJQV1=LCX/YT*G8(35M4[*BP\AW MXLBJYO\81%FPS3T
M4\3ZRW $ZQ#XW=^]A_EBBCMOIC8XSA.Q7/N2&,")9>C),J8HB\Y*Y_==9QXS
M_D4J2V\"WZ(E1X>9[P!=_^D_#\?+.-?U;#[\C*[G3<8C>38,HV5/I4%@*OOD
M'.%,NY(S6=IW@<,M-$J3+$TBU'[+VAS=16I.QR1LT9>C@]+;H&YLNXW+\'K\
M9NC#<#2<?[NS\OX+_'009:(B0B(Z6@3O(_J?1@EBE/0^&L>"KVT<'8/WV>E4
M)T1MT;*# ]S?8_ ;@$^=P+/W^/O)V(?1M\WZ&&AIF2@M=G$AH+@0*K%62L(D
M9$-YL!1J&T8' ;UHO>J>FBT*=7!@_ <!K-*O.0I<F R$FVA*62-'7-:" 'J6
MGN5(HVK20^?'3^VC,GL7YDI[D9S+.X6[*5PMYI\F4]S"EIFM% QBMC@59=&Q
M"[B'66<H":X4.DK<YES[*F,[DE,4@SJ&UJ>.C\/%VT7;ET>HUOFH37!U])C@
M*4RGK*MY'&][5>$(H?>I%)!,,LX)DFPH>5VENQY%I!RM&"<#XT'QBU:&1J4J
M^]&%-K*NG$/WRV0*P]OQRY*S,_VVK,QY-4YO\'\SVA3O]S%J"I88R3*12G+B
M\$MTMZ5SW"J@430X\O<.U'^R?AT^)ET)LXNRD#A?=(WC&N$:%+@@M(N,E":.
M1&JT@9S4&1T6U/3D(-I0W?3?!N3"-:">D#O8YW]4S4V14B<SY/*(*9<HJS<>
M;>%2(M]JZL$[+VAM>V\;CF?"^]$B[B 1]LWB3\0Q64QO7X]'OF3M?H7Q8M-!
MUT6CC0!)E"F'F;>"^$0UH3$;[I+)D=?F?R>@9Z((]83>2SF(%]\>9FTN+9W
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M)\$D-955YR"@_<<AZO(]Z9NL?DR?N[(":)SBT@J9*"M+B[@HB44X)&E@^$G
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M$G2')7$E 3B#ICRGD)RK79UL-Z)GI"\=4-!!,?G7XZ^HTT4"*V2OR\-;_,G
MT\"4"YP8G06"8[B]@=&$.A^\9UQ;6_LQS5-8GJ%25!%[Q6K#WW&M<*P5]!6$
M^2!DG5A6",GKDHP(.,\D+.'HO MO(AA?^\7K%AC/4@F.$_9C_NVQ_/^*@ID5
M4QAF-^/K/\NT%\/9IR*'F[P$Z'%FBOE(<K >)^P""0(GS(42$L"Q&&M?1>T%
M]0QUHRX1CS7%':LIOTRF,+P=OUQ,IZ5]^\>I'\]\+ (HT OR%X R@1( U"R4
M5ZRHSY(509A ;-"",*&3,D*$2&N;&2W@/4/MZ8J<+=&YH\.SWP.%FZ#R<+Q
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MG;UHSI/TG45E^^&\C5P[2!Z\BSAN*C[<53 4VF3<SJC3%F&91&RB@A@GJ#.
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M00'I4J,BHB"@TENB(DT$5 0$A*@(2(U("Q"(4J7&!B@(D2XB1'I/I"M%I$-
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M'#-$"J;\+5.^9P+1SRAO9OA26QR/\5_]?<;>S;6#=I0 N>@XQV*]T6 A4LE
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M;<&PGW/9L*2D^[[WB=K>HF/J/Y@ ^Z'&IW&=Q>+^.3]NG\.H< ^>>WAR9=G
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M;W3L=C?;J6N_.;S[[O],%$VH>L@!6.4-81U)?W-6HGCKN;+[G# N<&$%(6M
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M5^+T3-$UOMHYVN?3[ABT7A/L^0ZP12^JOR7MN&(VD.N21;1BLG,-[2K]#4.
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M0' "85M35DLUTT>;4L\_(=$G#'=18R+LG1SE10P)M]']46@\$Q20LVS<H);
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MZ<:K[X=CD-M^!O634WH^![U:SI@<C9:0C@M5."=R\/CP\>D\3"\&D$,1K4L
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M1U-\T-^&/?&4(4OZE*F44#2^\O4&_*1I8USK[<_XP^;1R:%K;I_^F5[Y^F<
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M^W+MW"::MTDFE-P7'J-#]Y*>*BGQ'W//34L7IH3\>=D0\:-/!68X"HG1 N<
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M\G?HJ>[QCTZ6")X;''JJW''U/QN/G^GG[)2I7&3:S>$G!W<,)QV!1-'"J'N
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M3JR 8*&^17,X=U*$^D$_WY7B>_TG;A^.>1? 9Z9[&!13J6K#DG)LJ4.D,:(
MB"[^YCDO-$*[>;)VXJS6.9XY/1_,8YE0N\O]O5]Z7X.P8__V[!M)7Y.7&&)
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ML+SP$^ZZN]TSBQ<1UNZ]7]U6+_=J,/UEX>_KIT1]?@1(J(B8+2&XBJ,*?5.
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MO(A]_^$YP;<DC5MFT?3^UW:GJ!+K>Y=!_"[.:^1?=+:JJJ$E%39DPF)L[Y8
M[?;H$\4W]8X0\.J5)]%^+\M-N@M;LME5(_FM4WJ(:N!O^PL=>!9DMMG$DT^N
M'2)<Y45>MAB"8(,MP>VT46! M 2J9.#.CXZ2^<]OY7]%.%V2ZHE_GGO'Y%C)
M9^:Q< ./PQ0<7@1E<?B>?M;EF[>$"OUSW>L]L&>18V%+#:;&S;.M@#?,^SF
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M_[ DZ5/Y>57O;'P7AZ&@(?0=ET/D,@PQ#^2^WXF8$WB!A_7V_?I=SHT=&ZE
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M0DI9B(TFL;D(<YOJ:\' NS0#92WX_I3BML:!!H&'$QQ"W^<((A\+B+TH@$Z
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M7;)\X1,6"X%@0F,,4<(IQ')"0\$B5TYYU^=Z@;4#^IZ;-;86']3R@[4"H-8
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M=6CFQW*_C ,*0^X'L>>'#$>:"<>/=V8R?Z9),1[]Y 7_#-JK_[780 H-I-1
MB:T?'G0,Y2!D(J$<$E]0B)##8!RY ?0)I@$6?N)[6DY5NQA/L1#L0)A+A*VB
M>YCE[6(VMCW: ^H"U.!=O/HD!R3%.8*>?JR:/10G"DY[]=DI,-4-#Z;<(6:0
M&@6FZ:%T(!+M2 .3A9[I*=*/-=-\8Y@-KAS.G^5@MR$)3A(G3AP0&&&>0$03
M'U(7!S!PG9 &'F(,&5TJ?]W\W&BT/C%1X@V,['@#GIY=/!R2D5G2  UC^W:W
MTI:LV#>-3VJK[E;LK46ZYRESN[/V2C77#-I@T\^B6H2)3QWLJ/M)2%6Y%1[$
M) R@YS(J* Y]7V_6[NUA;A.W%O("9&+_":<F=,>MG),!&?O(HG94MK>(WK4B
M_G@!/I\.CKX1<S)($]DN0\ RLE,. G' /-G]WF16R4&Q^\;(X0?-"(V+='&5
M52I4GG,YRF5]%G);W!7YM[2^\,$B@@ARH(M$J(IY"[F-ICXD#J,QYJY(D*_#
M:\<ZFAN]-;*"5MCVP%%""CJ!]2;V47P/DY]-U$;FP.& :4]N731VV#2E8#\]
MY-]^EDTTYHS\86/%'&UX$A+05:_C NWG!\>==NZZ[L T%>5O&4_+JDCIJA+\
M4UZ(]"&[(H6*I"P7+&8QB@(*.4XP1()CB)TPA '!?A@X)/!]HT,"<Q'F1B.W
MJZI,N6@RPP.>)E(A(<?&/-K.="ST=D+C(CPRY;PZ%.B)?P%>*0!:#4"G@M60
MO('PV8O.,Q5@ZD"]@0#MB-D;VM+ 8(U'4H@Z(XXJPB/-K.8\HRCD)UB?R[Y_
MV3S25NJZ_(,4_+:^%52JJ5^13%7 _8L4ZU$*>/E-%.1!?!%J"RI_K^ZHJT/<
M%5G>B^+)6W@"150X!.)0[2(]!T/*L*K!Y80."JGC"FH4^#&]#G-DX%8%0*HZ
M@5$;:KXI5FT86G*&#T./S6<^W&,?,2C5X/LZAU5??] #0)TE]Y]K00 U"JH$
M8XV#_&&#Q 7HL  M&&"-!NC! 10>%B-ISC>6MJ)RSJ#!M!$^YQNBK6BA,XIB
M[D*]SKZ)LE(R_%(0WB6!19@SE&"J@MM]B)@K?Z(DAIY+'2Y0X)-8:_';V\/<
MEJ:-D.!!2:GO*]P-X'%'ZLFPC$SA/41J 0<<"N^&1M^->C)$$[E1S:$R<J(>
MA.& $W7W>Y,Y40^*W7>B'GYP:)+PNR*7>_MR=VJ2NWR9LI=%XG$DB,>A"(6
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MGM;(P*14*CQ1\%+5 O^8JECI5)VIW2;O5Z7LHBQ%N4A(Z 3"D\:SB)G*5!5
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M1SC0.H$VZ'-N"TLK=AVIDM=[==8FS5IN1-<G-UWDCR\H(^ Y]BEU"^7ENEY
MEW^L)_6 W#_:7[/V"C$"MA,M"5H8VR%^0Y .,+UN2Y-1NZ%J?2XW?=5NY=BO
M2_)""?O;SJ*8$?,</Y <'F+'@8@0!V)"N:1TGX2,A(D;6RD>>TB(N='[T;*9
MG3+CE) ].%['UX I1F'D16'P %BN)7MP).R4D[4U(G.I*&L\-:P5E=5!<F!=
MV8--SZ*TK([RNM5EM=JRX=;ZO%)-YLGV7\J%$SM^+#P7^I3Z$#E1 #'&+HQX
M@@AC$7)B@YN$!CW/;3%J1%6'SKS=V:_]64K<4UPHA_ ?XKRRA.I9?%8;F'?]
M?3283W%068+[K'ZIH;"?Z(W2@,[("76HO3/ZGC34/.QRTFE@V'GI+R3-FL31
M#R)C<B6JE!/K<KD4#X(O7ZZSI%!_XK\]YZT4BRCF@1LX'/I^[$'D"5<N"8D/
M ^(AQ&G$$8Y,PI+-19C;VM"*#$@G,T@[H<%*2GT!LEINLZ/6 4.C=_HZ+N C
M+QM*>-"3_@)TZ*\5 -=OT/]\&'WC4]KA %HZN!T@P*1GN<,!>GN\>T)+5F.3
M593+?4$R]BANLW7*2<)=X0<.]!,62./8HS .B,JZ0>0_F$>X;Y2AR*#ON5'@
MGT6IQJ@]O0)23BNAESMAUV.YD< <F=YV!BAN K#JLKY*=H7P& DCS4$;-Q)P
M9\]S"-@[!(EF7-W!)DY-&-34AOOZ7 C"+_E?5V6E?GN;_9D4J:K(JW)++D+!
M RX"N9V/:0A1K"KD(LH@]K"+B,#405J5C89U/S<.:ZL<EK70@*RE!N^(M.U4
MN J3_]*,*1\X(CK[_3%Q'GW3_R;33(MYHP#8: #R#'0Z&"0N'HCZT,0_MM$_
M5[Z?TT?AA#0_)B!J9_?1:O1,27U,%-Z?R\>HE:'!U$7Z37Z+WT0OM%M9Y#=Y
M6;Y_^0_!'U3^8K%LDB\\IL_O7YHXS*_R$ZX-EAOU(<@_OG_9U=B7M/S;O1)V
M$3$:\$!P*&*Y_B <19"HX!8J<.*&B1.Y-#$QI:<3?6ZKV$;8_EV6"U!OG-\I
M]7\$O]>2&UZ,GO!KT+/PYSG&HZ^@IP_O@+#TJ9&V%N$^F> 3!\M//2#;<?>3
M2V"^)>KRL=[GS_<BNRMROF)5%W+FQMR/B4JJP1P.44A\&"<$0]=)PH1'L>"Q
M=J#^H8[FMD!TLEX *2V0XH).7GT;^R"PQ_<PMN :F6OW(S4@P.4@9/H;$%O0
M3;35&/"Q&6TE=. XL&DX^/IDVP,=)?H; :WG!V8^6R[S/XB4^%->?,Q7M$I6
MRTO&\I5D]R^""4G3DI+_4J25N$V2<N$'OH^C.(2.YV))HDR2*/($='R,:.(P
MGP?Q^CZE03HT,S&T/OPW]RLG8-I:/IA+ 0%[)(4ZD"(/<HDLJSIS >F4-$RB
M9CA$>L;T&(A/%KI>2PDV8EZ M3HJJVGGWU"FR06H=9"#8C'AVC#L;*5?,^Q]
MVF1LPZ#92LTVL)FA?@]:[<A-B")!D>=3&$8BA$@D 8P]06$2.TGD,)<0W]!'
ML:N;N9F+M;/0+&.A":BZ6_U3H9K"L3UR7L?#(%C;,>_L9.+=[2%%MW>B!Y\>
M1@%[MJJ7W]-R05V/,]_GT.$T@ B'#&(>1A!Y,</4BW$2^B8\<*"ON9%!FP5A
M+2OHA)4?O!37D!(.@:S'"Y:@&YD<!J-F3!$:>%CBB4,]34H6&BJ_90R=5P8X
MFTCYJ'BH-DHN,[ZV6<JOHJJ6=5?M?7@_$$GDLQ@*/U:6A.="['@<)CSP"/:Y
M$WE:@4-FW<Z-3#;R=4G<E*W.I#Z =PK5=WO7&R43#Y7^:&CXJT;!>&SOE0)R
M+75]ZW0C]P7HH6^:!<( 6P/'UB@83^7FLH6UF?/+&+)#KC#]QJ9SC!DK^,I-
M9O[VP/*Z;>X'N3EM[V^5JBJ<.@,1UW7BLS1[N&15^JV^9;SP8I^Q("*0^AZ!
MR$\\2'G,841=(0(4HH 8E2HW[']NZ\!G(1> 5NX+4&[F2IX ^:F4)6S2.K 7
M4/Y!GDV+\1H.CI[A.2+D(R\+G>3U8ONN$[ZN9_DCJ.6_ &L-P$8%BR5[AV%G
MJWRO8>_3EO(=!LU66=^!S8P5,G\OQZZ+W@XH"@*,,62>)W?/5#(@$2Z#''.2
M$!:[Q#?:/1OU/C?J>Q,V7TMJ.W"^#[X>N8T&Z<C4IAT\7XM_EO#Y'<!-%D#?
M[WMF(?0[8#$/HM_5R. LLF_N6:H[2$5*5W4PR_N7JZ?G9?XB)U2<N(0$ 8%>
M@!%$A+DPQD$$)8TYS(TB!V-A=B:@V?/<F$P-"LE> .N+:YQ;5A-UW4.#$; <
M_1QAU_5L]=]UP9572JBDYIT:5M/0FB%G+R&M9K]3IZ8U@V-'DEK#!@9&;S0)
MKGH9K=H<5POAQR06G,'$]:75%<G-)TX<!P;,Q['O(^3&Q*A>W;Z>YL9+%G,$
M'D<Y"!$.8R8@%8FJ2,MC&,=";O&QE_B1W-B[L;1M]=.*VT%Y@DSBDZ*LQ_Y6
ML!N9[3O8>D)>=$D!+8:G'$/"5B#*WGZF#3DYINY6<,G1%X:Q\6]9*>0T$%R=
M4+<;,.$S[ 61 WGD2H8@40RQ'X4PH6&8\-!)*-:Z<7F@C[DQ\%>1I7D!UI*"
MSWEE2@:[H(R(\!'&/B2!&THHY>*&0QQ!GV#?\S!S8LX7F= LW#44R'54X=CU
MLZZ^IXVO8 -DBZPE//5H]<0/;F1"W6!3!^38W^$?4-\2B^[J85+^/*#B6^8\
M].@PSKS)LX=[43RI!KOU/G+<2#""8!Q2N<>.Y&RG,9+$&0DG(@GV.:,FG+FC
MC[EQ9I<8^#DOZCB1/ %+*364?3\!+N4VF^Z[4*4AX\)C#HPQ<:2%*FU53%5"
M)\PBSE @O,!??!,%S2?"M=_7>,C>B++\$SB*[\:2/1UI/6(]$;V1B55)!Y5X
M-;&NC53P*ZE6A>7SH0-(6.+873U,RK$'5'S+L8<>'<:QGT6ECL;OBOQ;R@5_
M__);J>KG?$HSDK'7AZ'22$TDR2+( X=!Y,>*)!P$*?883:*844Y,-K3Z7<]M
MAZL.J>O0I)4Z74@SD'0R W+\C/34<="CD''0'9E9%+!U^$PGMG)IOONM0?E'
ML!9^E*-H<\0L,9!!QY,2DSD@;_EJ0 N#G9TJLD<V>9<O4R8;7%\J(%' &!,1
M=%6!9Q2I^$H7RUUVF'@QB5"2A$:G,ON[FIOAN)$4=*(.OK%Q &!M%YP%V,;W
MP0U!;(@7[@@8]MQP^SJ:V@]W1.$=CKAC;YB'95]]EUM4E5K@-DE2)HJK[VRY
M4@G6[Q_%A\=4)&\?:-TA)/$])_$XC B1ID\H'(A9*&#DJT2W5)"(:U?D&"C#
MW,AE+25HQ;P :TV 5 74NH"MQ_0CBX<.UF$^FF@(1B:JH>@/R%4P=!CTH[TG
M&(Z)0K^M3PJC$/ 3<3P0#SZTY<F"PT]4O1\I?FI3 U:E)!&L27C3UJU5^=J^
M"*5WNDR;V*9U5K?R/I=/7%9-R(!<%I_4.BG-W)AZ7L2@ZSL"HD3^1(1<HDCD
M4!^'3D <89!\P99<9N<FDV5CZ(D-JAQ4Y#L@:\D-N-'&R&FL5U,-Q$2+5Z=.
MOY"VT@B\5ND"](?I/J^?V^@E_UQK-O%P&:QK$P_;5(O<1,-GMO99Q/K00FBC
MF^E618N@O%HB;;8[]$Z^W.2(LFHKO"N'^,)S0C?D/((X%G()C*FO;A-X,!"8
M!(B'44A8MP3J^7IV]#)@01MY+>N$!**1TO3>_3:0#@N3F#H)=$640(0XEV8$
M0Y"+Q$5^&+N$\ &)G.R@.85Y8!]2/2?94(2F2EW0HM**=U&?_]E,6+!7>VN)
M"K9[F#A!P5X5MQ,3['_4?(\A&?B_!"D\QXTO,R[_A]MM>D)]-_0C2954I2TA
MV(7$H1@F+'$YB8)0+G^ZKJU]G<S-=Z4,$24H4)+6I_M*5GT[<B^8QTUY&Q"-
M/,U?HW/9HC/ <[07)GT3V@9<$YG%NV&S8]T>@^& Q;KWU<FLT&/"]RW+H\\.
MLQ:[//@W@I3B0U[*71QV'!9P!%GLN!"%*(1Q*# ,2<RD@F[DZ'GT]_8P-\Y;
MEV[(GT5!ZB.NI9(5,"FL8;#"-IQZYLU)((W,>FM\:N'4S:K2HFFS5W-+ALUV
M^Y.:-7O5>VO4['_0UN7,.VDL29ZOZV'^):T>+YED_]52[1S:IV[ILJV?7%YG
M5]^9*,O;1#W?7*J[?'@HZIW&)Y(6?R;+E>C_=<$3(D@01*H:!8((.QZDL=P@
M89]$/, >=9/8+%1R<AU,9MTT@9B_97+(DU6F(GZ>&^6'E%0^XU?A)Y@Z401#
MY#&(F"._#^XCZ,LU#,>)[PFS1 :S_B:F6*Z4D.";DE+%XZIO )!:T+E_"7HK
MX:S'=^25]L"UYC^DXJ"G^?J9C>XJW+)17GT8KRY#]_XQYO7GB49JM&O48\M_
MYNO8$PW/\6O=4PDR,%%/E;._/>9+^49Y]?=56KVL _K<V(F]*$@@]; G]T81
MAR1V&.2A2U$D]TVQQXRR\NSM:FZK3B,=>*<&DZ6ZY1TU(-5;%>P -3)]]X7\
M%] BUIWNU#NH*@=WI+X1,D;LY'&0;"71V=_1M!ESCBJ\E1[G^!L#DQL6XIFD
MO'5)7V;\5MV*:OBHN^'DQ:[<($4(AI$OV<,A+HQ][D#A!UX@:$ #)S1*:'B\
MS[G12"MR=WI4[DB%,,28U4%?CV@L8SHRXW1PMN+6:-8";]+@V$Z38 "0K52$
M&CU.FWY0'X*ME(,&KYH145E4BP^-%95^$TT<0I,O[S:YY/FSLJ4^YD\DS1:<
MQ4B02$#"54 <)QCBP&4P\CEFU,4QPEI9;O2[G!L-;:0&C=@776Y!N7/J1 >_
M-\)KGNL8#,!A*AH'UI&9R!*BVG1D#M(A-I*M]9A(_FO#0@8=34)"YHIW'#3@
M3?/3].N,%<J#_5$T_[_.#N2!2E 0,RJ@*Q"%" <48IK@.DZ7^0[S&$D, W,-
MNI]I@$TGN?+F$'OYHDS'YOAYO6VH)RLRTL#[KI/[1W"=@4$IIDX"6/^D?R2@
M)SK\MPFX463  -@.! N8M#99_,  %?LA!4->-S=*?R5_S8NN%F=95RUR0\)]
MY(:0<\PA2AB",4'2"HV8'X94H!AK9?;?W?S<C,U:0K 6T:@&U!X CQN0I\$R
MNK'8R&6ML--AC4^P_'8T.IF5MU^AOD5WX"E;@0-=O&4=SY)PY,C9ZT*'A %4
M2>HA=4@"1>([) I\SIE158[#W<UM+J\#?=FA()@AN X]'1V*UEF.,M?PV8TA
MTD-EM&/#5YV=^8QOE^+'#^1VOC6,/FJ'UF<I?F,X]$R)KK*%%V-"XA#Z6'G!
M$XH@556QA1.Y44("%H=:5=UT.YP;A33^V2S/X,G)?X]BK4<J-A$<F58:\#:R
M]O</(^2QU$7&$K4<[6Y2<M%5_BV]:+\W\'B>/0J^6HK;9%/KHBUC4I>YJ(_X
M;FMO5JE" YH[=V6Y>FI^=Z].8N_%]^J]5/9O"Q3'<8)) !GC#*(8^7(O$JM(
M-=\7A+@N]8S29MH5;V[DU6FGO+I_B/3AL1(<DF^B( ]"G=RU6L@?U1/R0P!<
M77^5/S\41$[75:G"J]7OWR\)^QN0[4G1Y</U:_"Y2.LD9D\Y%TO#$ .[GX4>
M<YYOL$?FV?XX[ZP7I+2[ +5^H%7P JQ5!#T=P>^UED"I"6H];88\C#( ML(D
M[ HW;6C%*,!NA6.,TXOYL<5E\)/C-(G"ZSSA'U?B?Y%L18H7.:IQ:TVA,'29
MX[B0!R&'R&41I"3Q(0KE2I&$W$5<Z]Q4M\.YD;\2^9_![D3U0"H 6@V 4D'?
M:ZZ%_?'S"-N(CLRPK\#<#>& BX5:6.H?/=C&=*(S!RO8&ATVF !UX)1!JYG)
MCA=,E.J?*QB]-^"(^>Y6!<Y(HU.5*JX3:31+1/MY>Y&/(\H<&,2<2').7!A'
M?@PC%+ D#J(D<K$N31_I:VX,+<5M8L"DP' M<6N@&9QC'D%8XW#8'FYC'PA+
MR"[W03: @8]A9W#N:P_#J<YZ#V%IZ517#Y1#)[E'6ICN]%9/E5<GMIJOF)/J
M39I)*_R#M.?2ZA-1N8JJESLAOPOYT3S(OWP65;]&\G7KW6'R3RK_AC3:E2E^
M6?XJZ4<-WTL=Z=C45UZ0,*&8Q"[T_4A Y/C2<*:AI.4P$%'LQ )YL2XCCRGH
MW.A\HU==Y%VE?W_N5R('Z5H[]8!^Q9/11_SX"C&7<1QY>5%JJK%I% 6=IG5T
M9&]L57K_5T7FP?6KH:WK-+4Z*^?:6FOYEH"=WC,9?/TE;BX?P43KXQ?Q+)MK
M4FL^"O#\ZA/(NM(9KZ>X>G![FH/GS;?PM/X6GC?:_V1GN9UB@ ZLU:-V/]E"
M/P6(?2MADOY..!U61; +\:@N@7:)$F_RLI1B76??1),:\3\$?Q"_D#13?WDO
MDKQ06127I"S3)&6-'S#C]^3[PN6,.3ST81(Z%"*6)#!6%H83^90&7BP"8G0G
MT[Z(<S,KE,S@W5)*_2,H!,L?LO2_FVH]S?$JZRL/U',#CJ7M#K+!0?;9AFZ2
MH^]7VG5I9M\I-7Z\J*V(C9*@UO("-,/=/D)K9<%;;6NO@=37\M'Y*&-A\[#=
MKH#3'\^/ O#. _UQ>CHU!$!)E6=J8;I-UBEWV]MU;7S3FX/=P'$BU\,Q9*Y*
M;Y;X&&(W]B'E* Z=*'(<9%1:^ 19YK8N;!109N:[9U6;JDXX) ?RQW76H6[C
MJ8BG(M]-8Y9.&3O30_E11V3"$_C7 ]/++=[=^WW7:O/C1(?M@X&U?K)N+LF9
MCM$'0[;_S'QXDZ?2[D=1I-](D^>\K(IZ[UQ>9U_E!EK43LFD+61'EG=YF2KB
M7V=JV4SG*,"8$8Z@AZ(8(AR%,!9N#'TG<ER&21PAHU!RR_+-C9[[C- D2:BM
MME[TJ/IU+I52^:'JA%%\C4-YH3A[N>*-H:^\"A_RK,R7*6_221'9%Q/@ZZ,P
MSKY@^[LPI?G)1WM"ZM_H!GK*J2%<JZ<>6RL(.@TO0)THKE9RHE7!ZCA87RGL
M2'>FU<,JM/M7%+O=#%MEKIZ>E_F+$%]%\2UE8A,8II8[N;35VXC/>;WI$+P.
M$ROO56GC_M_518;/>?5?HOJR=G T=]T_Y47[*_6<NW 23_A8+D(H80E$,18J
M&0:"<B%"L8<]A[#(9!&:5ORYK5%_>1L37 B54$#%]!;B[RNYG:@$*!MHE/^[
M3A A'P5_/*;L$:RRGC^*]0"I[UN!M*P3!S&U8%6YW)$ \J1*T\NGS5:LB;\Q
MO05MOE_.V.O=K@#CHI"/U*1S =9*=W''2DL5V 5>1 4VBJYSCL@-*^@I:V^Q
M.\\865H+)Q9^TJ7R/ /S=B4]DQ2G;N?DHBYY^48N^_PZJ^2\2^OS'[7%>..!
MX5X8$L<-H!,R7V[9Y$\4HQAZ?L*1QSU.D#=LRZ8MP]R6O+ZUSEXY:I):);A4
M.DF+O5-J4(:[(8-ENH\:90@FW"LU\L-: ;#1H,V%-]$FR!A$ZQL=?0G.M)DQ
MAFC_AL6\J:%)$;J-T8<\J_.%WLN&VG1NL4>(\((8)NIR"*)1 &,OPM!S"4=1
ME$0Q$F8I$?9W-C?VZ_DG.F$-\^9I0:Q'9;: &YFS!F$V("G"<3"LI40XT-7$
M"1&.*[V=#D'CG6&T<;E2R867*<GNR??:N&LJ8[>QX")@/(R3!&)U/P&%7@1I
MC#V88(>BB#/*'6%6,>5PAR9S8)KR)AMY02=P6_G=C#R. !U)I -'(AMP+,U6
M%TNSE7 ,'5^$'G*YYYG%"-F#>0J.7DMK%5,]2K:'U,BDO/]+'"&OA!XJEMCY
M2&>3\K.>XF\96O,M,X[F(EU<955:O7P1#ZGJ(*L^RP]D$<6A<).0P "KNI^8
M$TA=X4*.8Y<P%D=QH$46^SJ8&STT,H*-D$!)J<<5>T$\S XVH!F9#PQ1T::
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MW6S90U:64C1^-S\AE(6$*+5&_T=X$21A%$(E<I14"=/(\XUDR\64S$W^-,R
M/3?JXE3Q [H,5:4K6Y; CB?SB_IERW?>=#/9HHPLK2Y;CP&^[,L6QMP4,MD"
M3633&.G#L3)$.,&TQZ)PV?B3F0:<P-"]X[L9<*!N_+-44V^SXEYO8C6-9.67
M;"T_E_*A6(:^3Q@A%!(BU,V<\0#BF!+(14!CQ+%2DX65CMPWV]S.JN?$UBU5
M60G^T 2#BF++&,U^K W57U<(CJT&7P">O4)L HHKQ;AWKFD59!.V#Q1EHY>&
M"9/O\H=<;V7Q29&JYM&5H5?OMT6Y>:@C=KYLM)3[(45]V=_O?2FI'P51 @-?
M2(@2K"0.9PQR%B /1R05/K>1,T,)F9L(:OFH CM7BFBXTE0#6I&MFR7>R<U=
M3A_OU:T^EW?JJ+ 328-7S$Q:3;$.(PNRW1+H[P^T3( =%]72:#Y@Q4ACA!Q)
MT%V*IR,9.)B,2<7CI6"]E)P7CS>WAM5_EX52(]LND[?:V[&K_[<45$8A\R3T
M?2%TF6T.*98)Y,A+&>9*7$LKU>]UV)B;0*^H ZDN\OFCMQKGG+:"F:R?_P+/
M(9[%27_C&I!]?^,%V)>-_2OT.C99T-EW/NYEXG]('V23A9JN*[(1-4-,_7F>
MW6T^%SF5JV^*M ?U?6_+C--5\:44>[-,8X2,0I$R1'W(XS!0)V,LU&4EY3!!
M/@\C*GW$C)/2+.>>VW'6D ]J^L$+!A9 L?"V8[*T,1/;K8F)Q7XTI$>WT5N!
M/,@H;X>VC1E^--0G,[R[V>*6EO9!L/7:UNU&G-":/HC5Y_;S84,,NX]]E7\V
MA>BR]=VW?+-6/_*ZE.=U_OY>GW*[4G75$U6;LY6\U>$52Q)QYG,4Z&L5AX@D
M#.(TQ3#V0Q;[ B.?)C;7JHNHF=MQHI@!>UK!<W;4(H&:H4X9R/JQAB?P1\65
MI57^LO4TNQM-MDHC'T4=U&]*NA9*:RO [X]"MYZL:L!<MC[65Q0GN#JZ:5Q&
MRZ07!B>PO=3[W0PZM$5$_KC15>6^;M8W\DY/VJ@J6!V# 4X%3$B$(0K3"!*/
M)S#QTI2'6A3'5IZ%DS/-39;N"+7M W$*23-)YP2?D:78CL8%4%3"ALP1ZE6=
M!<-9_X=3\TS<_.$,NX>='\Z]<&E3^_>;'W)-UZ5N3UO<Z!XU4GR1=<&^[UHG
M7"8L2# /)&1Q4#6(32$5D8#,\SW!?<PD,U+(!LP]-Y'1T A6#9&@:LDQM"_X
M>>C/7]I'!'1D&7/0H[LEOFK1K>Z-+=@M ^#[N& /;:GN%/37:I!^(?@7-#DW
MAL^X9?GY$5^I ;DQJZ?;B9L/87\P7#^L,[8M=NGENKYAX/GHNRSU+S;K[S>_
M_YK3G;Y#,?$%0QP2C@A$:91"DD@?(H\@&1"$+.J[6,X]MX-!D]J4^]Q1#!3)
MH*+97&;9+L'Y V)$8$<^(!K*P;[<@:8=:.*/HCS K&L+M_D1,2+L$QT1MO"[
M.1L&XM9S-MB..-G9,)#5[MDP=(AA-H0OFZ)XOZEL$W+-GS[0!W7H%#>;[=U]
M6<=!Q&GJ4<8H)*F^*J2(0H9U2'3@XSCP$QD)*]OMV1GG=@XT%(*B(M'.L' >
M7C,#@U/01I;Q7ZK<[CVQ"] B6-.[<!VR80R.(\/#^?DF-4 8L__2$&'^XM"2
M"$+7ULY*604(OLQZ?O?T&_VO3?Y^18OBZF=6+(D44>Q+"5/LIQ#I)N>4^1@R
M)6-"GS") J,0@X'SSTWN[,EOXI\/DO[!'YIN2\^/[:J8":@1L1Y97'5@_C(,
MY@%E% :!Y:R>@MWL$Q=6& 3-886%8</8";HB+Y?7?Z[K JQ-]?D@1%PB'$"A
MM":($BJ5IA0K[4G01"0X\3PN3838D;'G)J!VY%E6[S\&6[^4N1",L2^UYC@8
MBXH>COO$@'JM(P+4W_:?_[$1)_FT>UAI/]N^1X8V$\JS'U3?GSJAE;^J<;72
M\V67T./%+!22IC"6D5(Y?,YT%VP&=344QE+BI\BW:U9F,NW</N0]U=T@[ 70
MA(,WFO1?+D@ -5P*,SW#/<"CNT0<83N@;Y -5,[Z!1E-.G&?(!L@#OL#6;UM
M)ZZ$S)8?U0U,1X"K+YUR/<\'6M+WVSQ7$RU3A#V$1 HYT5;XA"%(<,2@A\.
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M"WBMQ+D=4CVBW'"@R<2X'6-=$6[YYH [Q#U5)P27VS+C=/6R5#(.DC 4ZJY
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M&%?"L)MZ;I*FIA?0#L$@5Q0O=/6!AF;SFZ'E,IR_?X\'[NC"B&F?:DOY C1
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M'#=@^J#BN,D[PX1W6X%MB;#2:&-$((Z%$M1)PB%F2FQ(G\@D4O]#,K61&.W
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M)*&0$HJJ,J,Q]82ZD5LFVQ^?:&Z7;$TGV!.Z )K4@55&3H)K9I9S =G(!^Q
MM 8DO/=#X2R3_<0T$Z>H]S-[F'M^YOEAHN'S6GUO2NXTW4&^;589?]IWP0E%
M*D(4<)C&20I1F@I(11@JC3B(4."G/(ZIC8#HGVYN8J*EMNU[8R<8SD!K)A[<
M 3:RD'B)E;I!5;2"/YH_G38+LH/'D> X,]FDXL.,\9="Q/"M8:)$&TXJM7Z7
M(:G+#>EF1/D/6;R_I_F=%+>;JK94FQ^U9)Z@(6(>]'2E'T2B$-)(_14Q'X4D
MP%Y$(SN'Y! RYF>>>+_-<VU[?*R* ^O"C#\J[[&="!JT)'[@QR&A 0P5^DH5
M9!A2&0@8B##%:KT\)OAR+<M77HY=SZ5R;$L174G='[K<YNO]0E@&^@];"9D$
M42P$)&&:0,03"0G'@?HKP5X:BDAPHS+-4WT:DU03K*D$Y::I3DH;0B=8#[,C
M>VR41S[(;SZ^!VU[^@7P ^B1VB??E,[?,5592EJV%N!*B*RQLM0\ZB6J"PDV
M7+H[]B^!V)$R,(B$256$2T!ZJ3A<--8%357J-))L?5?7TV_TEJ^R7(J8$AER
M BF2,41AQ"#Q>01C$A-*N!?YA+8= V\MVZ.<G-7N8'HQ]WB?;/V5R5;Q7IO6
MQ3*$FA J44(E9$F@CB&<1A"' 8:14+#[B?10:!DTY@#E2;6QD0$V.U?<@3;R
M"5*CM:,4U*2"-PVQORS UQX A[58.8N+RRXIIR>;OM')6<:/]BHY_]: ?#T=
M"U$9LG4G%#5>?6#L RG8T_Z1ID;BE2Z0TYC+_R&SNWLE,:_4-TWO%$TRYYFZ
MI.89K\KI-"63EE&4$A8E*8S#0%T4>:0$4YR$,&1)%!+.XS0QLDE-2//<E.B6
M; @:PD%+.:A(UPXP4#%ND9LUT?*?]WS/<%''UMDU.Z#V5'9Y7CRKZLV>0/?!
MAG-0L=ZZ2$'+_*F=,:1ZW)3;PR(#<'[;9"+O.(3@ZV8MWZK_@F=3*A4G*\JB
MJEE7WF<%D*L*B;< 0D<YA=."WI>:.!$ETV4X3@OMLT3)B:<>G@V3E6T=_&>M
M0EXZ9R**<"!]#A/?9Q#%00Q9*"(H$X'#**2A'QAEN]M//3=5X1FM]HDJAGB;
MW8#&07'DL[E#=&4Q>T;V-%XR>]P<)L483CQYNHP=(,<2:2Q'<-5/HVEK6W63
M_$=6WG>:QS=/7;-5=E>)X.+S^N-/+HOB.M7/7Q6%5 3?W>65<:KOS27F<:SK
MRT-)M A,> RI[TF( D("SX]\'*++&G%,P\C<!&J'UET;XLV.VDM[>TRT.<SD
M]5]AR4>6_L>[B>C_@C\5_Z"[&]IG]HSH:E@U!CJ3I7JKAF%QYL4QNY!,NX:C
MM2^9B(U7[GLR[6*=;Y@R,3U#S]P\^U$U/-M'W!5?-^4'661W:SWC5?$W*>XJ
M^^GN 5W'<1G$E H_1!#'B$,D$8,4>Q0&.(X"3"+J,SS +36<HIFZK*IBI6U^
M:[D!:FG+VM9@><FX8*U,#[%1H9_J&&J9Z 3R%KJ(%-CSH7,I&TZZ3RVJO@4N
M3Y1+ 75V)@PF9&*I?BE@AW+YXA$'^(?H*OMY(^_T6$T&4RI0C&B4PH"HZP52
M-PZHI">'0E"?XS1./&Z4?W!\^+EI_A6%%A;S0[PPBV2(*8=>2#R(B/ 57C*
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M ZNV2Z<FFMNWOJ>S/M\UI0.;HI[$UNQS=H'8R)_V,+"L/_1S2#CZZ$].,ZD
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M0L$E#2B'/"%Z%HR#%&*>,!B%0M $<<61T[F\_2:F1OF[,JAS8R+@VD;'X?4
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M1HU;)K1"*\? :NN9^=YHJ][]TDMXT5<7V]'<.W3<P(S8[K/:)W#WJL].AM/
M[Z5WP+@'2O\\TJAGQ'TILGBR:EPY%;]0[FFA>'[\F4O*Q=N,F.)37G!-,)N5
MW.X[8BDE#I2"J31%+"4F)O270(8E(WHZJ;\>IT(G3JU/C;X;XTN%D[<98 78
M.>"\]]NO<QP7K+XA'VD%ZP7M_JM:%]1\+W.MVGZ?=:\++$<7PDX/.6,SNWKV
M5^UBI;L]RU28,AHQ*!0NS[X&>K[*4QC*.!8R3BFBL?-VZMM6ID9?U3QEL5S
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M7WI\I[O#CCE' GE@[CRAWK<MU]EVZ0*4'0*,.\#X,X:PGS6H@^O]G;9D(C*
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M"<4T(C*)D%7"D65[4Z/CRF3PRN8+4%JM80:UY<"8;D<IMKAW,_, : [,S#Z
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M'.@9LPP32+',8!)A$M!(,ZL=DWH ;TPM<A_06>T?G /(\'L")1:5>3TB-8=
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M-GV\?'+VNT0C=]K[;"L)N:;YO##G3O4/"Q/@6R_!4]7#Q:Z'5^T>ENT>%CL
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MN7J<15C1*,,1Y")6>AU'(H@#0:%(%14QC4DDPS,4>'034UN]E0<V\M:!#2/
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M]^/R6>H6U_?+-9V; A,K^B#O3(N_TA_YX^;1B&<E(>9F=T4BB&B80A*$&+*
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MA=@E3B$22D(<97IUC4*"8H&R$#EE)ENV.S4:/E!8NK'\ E2V VW\.<I%Q_O
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M(O2\CC&"51S@Q&G+R;']J=%(::<;7;@B;L<B ^(X,+DTEE>RMS\UQIO)[I]
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M%S,B(T;"1$*BB(0HI2$DF#,8,)IE%+,0Q4X' ?>;F!J7OXF@@M^-D8X1G0-
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M_5JH..:?O'SXQ$G]H@F%EY(@XB*$:2+D48<$!*8<^3 -$L9"07B<&E69&BK
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MU?5)%PO,,X[BD 20T"B&"(L$$A[&D! 6()HRZB56*2HG9YR;3:H%!A\:2?\
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M\K(U;W :1B+6]_L)@@BGJND4"2".:" M=N(A;'1->'B*N;'T5DK0BFF>)7T
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M;_)'153Z+K@78X$R+XR)#WV/!A Q/X0D4L&\?I1X7A(2ZAMEYCN4:6Z,T[^
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M=-'_S.O[RTU5%P\JQNU.5Y3F:WK_@,M_MG>FOI?QC"$.XQ AB#QU_\QB 8.
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MQA;RGUDL"*%93"++?I?#!)D;,<G',+)MA3EP"<SX: I@Q_<^*15 *ZKVP2]
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MA?.Z-$^*XS2)20*Y:EN!:")@1@,.?9;&A/LX$\0J)\YDTKDQ_(^K2] %,2V
M'T O6X"M(F"GB4XC[709V-G":%7,"-HUUF/'?HP$LS6QVN#FB#&-IIR4"FU
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MMTXX!C[D:\"*U0J7E?)Z@$KI_(?C $FWCX*A/3?;!1[;)#0(FZQ.Q$VV$"S
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M.5[]XO@MQBQVH:7,J]H6>M<,*,:+E_Q*U-4-K^2^=[Y<%K77[E;NP1:(>I)
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M"Z,8I@'S?/FK1U-MSM89<&J,K;JY;84&G=1@)[8^LVCA?9JJ;:/HF*A/ CB
MH[60U&=HVXB.Q,_#'TTC:C9!YP@Q:]UF-%HV4:I/RD;7#>P$DE>/1867?Y3%
MYO%BB:LJ%SG=57/(4.8E1)(QC<(4(B]@,,N"&%+AAQP%'">I;]3@X_AX4R/D
M3EQ0RPM>"FQ414,7<#W'KT48'3/R60B:M]+0P\56AXP3HXW;^$)/];U^%IJ7
M#:.7[US59U<'4[6'X,<J7U??;WZTBV;"Y0Z=) GT?5^UDQ32W).D CV11*EJ
MWQ42K=A:K=&F1BU2,,.XO.-@ZA&'-8@<T\9.SL9-"&I)P0>%VF\.3I.T<+%$
M&\?'&I4TM-1^31EZ%PTCC*OU/2__Q/0^7_'R61UL__<F?U3V;?N84QS2,,DX
M3#B7G('#&)(049C@F&+Y(9$FB0EGG!IP:K11RPMX)Z09@YQ$5X]$;&+FF$<:
MN+:R-K%'G;0.>$07&DM4<G*X4=E$5_G7A*)]W1FAK1]/!]E\- NRN=JLJ[5\
MGO+577/RL8@8#5,2^3"D?@01(@RF(?=A0!(O"9(P\)G19FDLP:?&<2_"4G=Q
M@D_RSP=C4\U/ST=_//3(=8J3[IBD1XLQ[8'0G3M;#A\=<>)L!H>.(?;XH9\C
M3L:;@9UCCC]L:;S U;T<1/VCUMPGO%2>Q2\X+_^&EQO^*:_HLJ@V)5]$F*=Q
ME@@8,.)!%/O2[@[B&,94+GJ8QE&@5^O >.2I+4Y*XMK^;D4V6VST ==;+9S
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MMU9:Y?2LQ:W3Q LEL$$L\Z").6VPN\-Y'"KKY <[!69@JT+=8*.#O],"2#7
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M@$*IU^1O LU#G,S[>_<9L:O4OT9+$B<3::U[B1OIAMD"JI%LOKIK'6<(1UZ
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M<,Q50Q/5DS6B$-,DC1AGA)'SJ,BXDL@8S&-0G>4$?@-996IE;MXD$4M%4_1
M<$40(Y9)T5/TY.MOH^#)#58-3.KHB:X%=-/X^;*J-IQ=KFY+O*HPK;>@/E>M
M0E (LY!D$&4D4N5.,I@FGD]82-*0:IGZ0P:?&C.TK=JK8MF< ]9G?Y7IX9\)
M^II'=(XP=7V0AIO^1K7@,]"(7O^AP;F17K60ZLEO\8!K &JVCJ%,AA[WL&@
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MFQI-->+71V"L6"YQ68%'7C;'86.=AEE_>AP?G[WG,S']\[8&'="#IXWA6DN
M0(O0#+0/GLK&K5&:@0XGT +5',T!!17851F<P%&=J_E_[[,]ZWK]:QP&NII.
M:Z>'S@2TYO]^G1ASS)6J$JI3CW$8L<2'B/)$E=Y((1,XBF@4Q$EJMK2?)<[4
MUN.W/>"/O?0P!XYPD^D;[ EW-"GOX@K?3]=[7U_X &S=.<--A'EO;_@ X#3<
MX4/N.K31&%GO%H;OG/&'>DFX+G/*I1A4N?'N>*_FX_RAV#3?E&L.6Y X]C+F
M93 B/(#(#^5&"Z49I"%),QX+FIG%%YXKT-3XN.O"\K@573'!8R<\P+7TRK9=
M RKM6\)!V:IBVMSLS)G4(^8QY\<Q-2M5>MN,&=AI VIU9N#ZQ:QM50*-3N#[
MJ9D:T%_-#KS6.K&=*<[(/=OL@+??W<W2?8=FBJCZ.5?B0A)#WE7DBI*(D(@(
M&/$@@0B+&)(L""&.$^QG$8H8,DP3V1]D:ES:R*C>Q$9*T]20-V#4([USP7%,
M9*]Q<9#??0P!:\D@;PPQ<B;(827WTT".?'?8>W[U6+<Z6=W5*29=*X)G:16J
M_@.JW)4?D80S7\#$BSR($I; -, "BE@P*A*/)XEOUJGKY)@FC_DX/;D:9Z#:
MW+8B@N6N:X,9)9Q&W,L(BU7.?!A@#I$@'*:^A#VA)$XY0J&?&)FW5O$>)0^F
MAW-=?=6TU/!IC/4XV"IRC@EY*RMH\_6VXL[ 3F![[*R-C26J/CW>J+RMK?YK
M$M>_<$@'W[[1>%$\\15>K1O#L)_ L0M]:UVVU0+QV/.$ET"1AB%$&6.2=*B
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M9I (E$*4X4@5LPIAX-,0)QB'":4F9QZF DQM-_JMWE*4Y7/]IM9KIQF'&L^
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M[V.":FW//XK0(WL*QIR(??_"J*.;>R6N<;E>\?*[.I%1M[O/'[M:ZW&<1'%
M":2JISI"G,HE(Y'6+F<,Q5DF/)3H.B(.#S,UBF\E!65?5/U]\1$\PRA!&0X%
M#)#JP!"F"4QC/Y(K<AH'L4A#XF.]C8,]1,?93+C#]+3;Q@Y.SH_E&H!>2#G
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MSMO-=)6+I1K$SDS50T[%9H.H]WO-S%5/OIJXO_DY+O(_(@=.BSQV-MIAD7^
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M<IWG%B"((Y)!DF:(H(13GEAY9<<ZFII5-+)VDF(< E(.XFEQ+.8)I8'MTVN
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M"6&:" F10 DD:1K#()<(DUQD-'1B7G?L?VJ+0D?\.NX)L!?%"W452K<5P'5
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MP>S4BR@7):QU;]C0W SE<!^"G6V=Q/ .;8X/YT::,E_-$#:DAUHA4WOB6:S
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MB#%$,4DAP5D.<Y('F8RPH*&31=O;T]2L5B,HZ$H*_JAEM3RM.XZNG<GR@MG
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M0(B,!S"@NE@%PAG$ZA=J#E.49GD<L,SI%OY]U9F:Z:BU,:=F8JL!("NP^BZ
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M.8P3H<L[H1#F 4>0LCA$24P0(]GLAUC2A7V!)V<I7.945Y8AIY11PKFJD_L
M"!2%693E4,815FMQKHDHA8"I0"FG&0\RZ51D8F#XQUB7[Q<KY?$N1QL"NVO
M@8$=_#C52 ^T:0.M_.!/I0!H-="I&HT.H%5"DS'X+-[5&T)OM;W<)1BY]%=O
MB-Y6!NO?5%]F*UF4@C>\$+?J [P3RQ\%$Z9LIF!9'"=I!'D0ZA!?GD*:\!"2
MD-( 49($0>Y&:'6@MZG9M$8T4RO0E:[J$*AVMLL;5 -;J49.T @*M*1GH,7.
M3Z51)TR\D4T=ZFMDCBD+M=]22]F\U*=R])(\+,H/Q>)>L']>E\PP5YTSY2U7
MA;FG+[GQ!NZ+%2F+]:-ZY,.Z4K)4U<7BD19E]^0P)CG- YVVA VQMPA@3J(8
M)C@2.8IBEB&K' +ODDW-&#7* :4=T.HUA>"UAJ"CHMD]ULY8JV7]9*LHZ&CJ
M4F?9YZ ?/T1YMZ$<V%C:CN*YPRCV.)'Q.YPNM;7?:5A'*\#M?WA]U>D> /F#
MQ;Q]]C=BQ>\!8'I9%GR(#OJY_OJZO8ZLF\\7?Q(%SHU47H-8+LW&PDA6-7,\
M#PGG:93 0.0,HDP0F--(PB#C7'"!DSBVJJ#5H^^IK<1WEQ?@CGT7?*W9$71Z
M0GX&-OJ C4)GH%6HKEA3'2)@/7F [#85 \$^\*IY"N(>KUM/ -'3GL2EYU%W
M*#T@>;U?Z=-$_YSF17FW6K!_7I G96?G)IJX:OC0^-5B>;76Q4ZNJVJM!9EE
M09[2/-9EA(,4(A9CF/,LA%(BG"<Q3V00N68Z.TDP-1M8*U GBE2 _"#%W) 5
MR<42%(W,)JVD?J)'[K/; -E9OT%A']@&-H@;X<] (WZ=S5&!5@&#?ZT":'7P
MFT/="SZ/F=5N_8^>;]T+GEU9V/T:ZFD/=X9JM@<T. ["#(<PED1 %*8(4LXD
MY(2D"::A3 ,KRD:;SB9GY=H< Y-L(+;B.IJS0_A:6BY/J UMI%K WH2&^_?"
M;"#Q97@.=36NC;%0^HTYL7G'_1QXXZ955[I4K+Z0NBG/F>&Z5*:*"=63<@E4
MS]?E#]7C8JFI2R*)TC1&%.I2Z\J<4$U=Q3#, IKBA*0ILS,GO268FHW9*F$6
M[[E1 ZB5?K4D7(#E1HV:'J78:F)_W-=OJ(Z?T@X^  .;JU?8?]I@W^H MDH8
M]*_'0]_^4'7P41CI\/3\44O<IJ:W)8.:%'71%)=@RA-ZT+R5#Z0H*_7TM@+H
M+^&O9AA-8OMZ^;2H3(U0M7U<,QT?T9U*JX4:3T#J'E??R0J0IZ?EXF?QJ'F;
M=1/%$I1BI5XB\^)?Y@/X83*7]&?P2_1K+:,11C>FKXAU9P^+!:] I0/W3*O+
M;9B??L'(TH:,FQ;(<OFLA2,;Y=L9_GP&'D2IJS?,GP%9K98%7:^,(*J_!55]
MB(H)O<]2.C^2Y3^5M&H5X>84T5>HX$G?UH'CX7[MCG8,?)+:W>/>TQIRIUJZ
M6/P0RPUMH<A3EB5,P)#( "(1"$B%R&%&(Z+YEZ(XLF*'?-/RU!91(YP-5^$1
MP XO>2?!,/CQ@"4"3A1*.[7MQ9WTLJ712)-V*M!E2]K]@*]0JG.U07^L.0F^
M:38#,F=KG3M2/GP1JUNSLA6L>5Z'9;QB*[@NU>01U:HNQJ#>^JI6IQFAF&C2
M&QCK2@J("0EQA *(488B(6F21N*TF*PAQ)Z:R6B%!*R5$BA'PC+3?.01MSLC
MF-XX#FSS=D>>=90&WPP;SE9M7241M(IOWM.J;WEN8,MSL_E"-OJ#KX>^$ _1
M;$,.V&!A<8,(_<[Q=4,.Q/% O4%[[[>V;=I4W57-J73Q+\%G$8I0G.(8IB13
MJU&:1! G.(4R0YBD@> L3%U6HWT=36W]Z(BFMFRUS&Z+QUY([<R]#Z &-M!;
M"ZIE!!TA_1G18S!X,GM[NQG54!U3]K5I.?J\^['OW7KYH*MK?Q5/NC98^: K
M7C5W&8%R0+E@$8Q#*B"B:JN9QYC"G)!4!'&(D\B:/.- /U,S!:VH8",KT,(Z
M%+L_@.GQ4UA/2 UL"_: U"-X]1!:]J>FGE ;Z6S4]1-S.N2S@.+ 4=ZAMT<[
ML+-0H7LL9_.X^^';9;DJ5L]_7\S7ZGM8/E\5<V5\9E&"4*2IC&5$$$0\Q)!F
M.%,.$HMQ)E*49E9&<6\/4S.'M9!@(R6HQ;0_D]N-X_&SN9/1&=@$N@+C=%1W
M4/E>1W:[6QSMZ.Z@0MTCO,,/]MON_+Y8\#^+^?SZ\8D42VW@]>']+ M$E+)(
M.3B4:J+.*(<41PB&89JH?X4,Y4Y';[N[F=J$;J747!2-F(X1,'O@3#D)0BPD
M##-E%5'&$,Q9$,(@YCD5*24IBF:E>""Z^-8HJ.8UJF_Z''"/M!'2"Z1V>\?3
MO[N!364KX!G8BFCNY_UM' ]CX&G;N*>343>-AQ5]O64\\G3?FY&GI6 %:1)<
MSA^UU_6OVDEG<9R+7(00237UD2X@A4.*8"QSB2.>ATPXQ58?Z&MJAK4KJ@DL
M(!UAZUB E7J^,.$G)O[=]7IB/^RV=PI>P!S\(F KI<X!>9J+#:1=D<_ ET7Y
MM%PT01@^3_*/PN3M^'U_3R.?F1]5^>U!]_%7>A:H:9*#;N3E3[V=6Q?5=VVZ
M= 8)7=WK$(L9)9D(I+(S09@&$)$@@CD*U4^<1CS+ BX"IX-JBSZG9F]:D;5I
M>2FT_HT6&_QA!+<\C7&!W\[>> 9UZ#.MT_%TKY)ACY"O"A<6/8Y;G<(>@C>5
M)1Q>[6F*Q(-N<'.RM(DM(ED8YW&204RDVNS0)(9Y2K"^-Z,X"]4?D1-IV+Z.
M)F=T:CD[)Y>N<5I'H;6T+1X &]J@],'*W80< <*7W=C7S;C&XHBR;RS$L>=[
MQX:]S&1M?W%=LL6CF$F,>);D*21)%NIRF/ID"64PHYD0-,J3* T=@[H.]3<U
M([')VVX8!)W#L Z":[O7\0;9X/N=UUGN52?UO1;7:YB2#2[^XHL.]C9V8)"-
MZCLB>JQ>\Q5F>F$*?5Z7S:]NZ+QX,-NJKXOY_&JQU*6Q9E(*+(,8PT@@#E'"
M$T@S)J':%\54H"3-8G):V*B-&%,S/+7,H##$_?\0IL!-&Q>X5>#4J%"K ;*V
M4@/#/KSQVA&UN1V'M^B#/[0FH%'%HR-T&I:#!51:"?'. 9(N0!T/>'1JK:_5
MI*OK4OERZ]J]XZ*.L*S#*>__7#01)$G$$(I% N-$*D<L1BG$24PA)QGFJ;*8
M*;.ZKG?L=VIVT1Q>;.4^ UO)SYH(:J"$=S6,=F-@:PF](SNXZ;,"=8!D>4>L
MO)DVNUY'MF5.4+PU7FZO]Z4HJLF?UV2^-88SS&*:99J&0U($D<X!HBQ.(0IR
MD0F*)<Z=V)AW]C(U2]12W9@,8%YHWA-7_HV=8-H9F9,A&MBD=.2S\5=[</X<
MT-\;K\^N/D;F[CF@YEM^GD,/NTWX:KF:W3%1$F4]E*,C&*DV%9]HEN8XD#"0
MFG)12 2QP!@&F,J,93B)4JN+\?U=3&VJMU*>@59.NXE^ ,3#L]P/- -/\58P
MCV[!<;T/36WU=F=:JW]MI_2!AD>9S\<5:R>SQ9,]RH+K/*R%_%8)<^YS0U=$
M[W2*\O(G,UL<N5C>U(P5Y8.I*?2I(+28%ZOG;6D'PP3Q5;#%0ZES-;X]+<IS
MOC!.QBP(98BR $&)=7G2, X@34@ !<[B(,Z#,+'+_1U#V*E9%Z,O7$BXKMIP
M&K!HE-8'#Z)1VY"(E.+/EEND?*C+<8%YH[X3^\O@G\1A"S>U@1[85F[&6"G;
M\+_>=(;XLCO$&Y7K0G=@H_2+HCHU+\M6<: U!ZWJ$_H.'&J53^A[&*O<WE2^
M"[>JYB,-U*%"YT.+,%[M\Y' ?%$.?:P^>\:J:%K1#T2GF"\>-;]6'9JW7&K1
M]*S\\+Q]Y)8\FV*(^BQV4ZR]DZG^M:C^>;44F^QSPUS!8BDIQAD4&280I2&%
MF%(&J7)6&*,BQMPI86)PB:?GM%3_A%()N4DR[T%3,OPXVQVF3&KT!O9$C"+0
M: *ZVH*.NH ^@^YSC<K Z*PVP4IK0W,ONJ0F9T!K#K3J6XH2O\0DHXV3KTBC
MP>4=-V1I+/C?Q#Z-UK&OR(</SPU?BEA=J/8?#'_>^<^BFD5([8XC)& 0!CE$
M*& PISR"69#*A$01SZ(3*Q?N[7MJ:\CN&W?]WTWP4*/ ,_A#*^ 8E^DR+'V#
M'+R _2Z1#;UP]A#*<!2QP>(7]O?\SD$+1R$Y'JEPO GW4\,Z*NR>_-1.?LF4
M^V_L[C>EY5)O&-1?;A=U=:AJ)C,B<HYB*.(H@,JL1<JC9AG,4I%%3/TEQ8%#
MSJQK_U;3;?PLVFWXT+J5&JS(3_#4RFU_4.,T&L</W[R#.Q9UDQ;;!)B^%/P,
M;$0W?[T=&&'[8ZVAD![IB.I>TU;KF/,M.S0OI%2^D^9XIF+UIQ#JHS95 XMZ
M=/07WA)C+Y;JF7K=(97FG59-U8=;NJ5F..^4$O7.8T.474>=Z$Q)_4_=&JO?
M.]2#^MO36C^F-C#DZ6EN**R-Q.JE:E4P( 77U-6@4CVN-9MUM\5E3;*] /]_
M=]_6&[>.I?L^OX(O@[,;*.ZC"W4[#P,XCM,3(#L.;*<;@_U0X-56=UGR2%5)
M/+_^D+I4R7:5BI0H63UHH+=C2^1:'\7%Q75]*KCZ=_.GJL^Y7+IMFNW4@)W:
MWJ_K7Y_8Y9:J7@_YDGIL:$;#S68/&\)DU[8UZ'WSHCH?F]U7JOD*^56K(^7#
M\PUO=L8=_[7]('GZY]J)"4FP'T+!0@91%/@P1MB!A/E^$OCR>&1: <Y&LRY.
MUV\)!UW*U3[=TZY?B$<?^_YS<#)$IU;HSX,)_E2$@XIR2T6WC9$:5-U'?Y;9
M*OX8,]ZM F3^\O1%OM^$,W],RZKT?V4SC1,<$R^)H4-8(.65QV <QP&D"2(Q
M$C["KE;K<^N4+4ZF-;1-7*"[?[6&&BYF6(-W,6OTEME^F\.Q OM5?+\BVEJ(
MOT.=['ZZ%EL*6PO.,=6N]2:P)L<[]4BNQ5]5?Z&Z8\O:=SSD.M2!$4LX1#@(
M5)HNA<1U_2"A"%,4#JA39D#"0LTN%Z_J%:F.29N^*EVCEV*P&!Z%[+L*VE<8
M*]K!;XKXTUUU;4C1<X!-)R=/SOS>DO <)!JR[NP0PZ19XXPK;_BFVONYO'W_
M/=T^/.0;%4/R*2^.^_;6W"-)X@L7)IR$2@D-8<P<"AWFQQ'%+/:2O6C3DVI#
M21D@XB:6;JT[7FXZ_OBTR9\Y!S\/G"C3$U>FMHI/996JFEU#4OGRL?*+&@K"
MP:NH)Q4G79EY1&3#PJHR/7=H7QV/HSAXKNV)RK$H6I*;@\F858B.!>NU1!T]
MWC#Q^N40^7V1L:HSMYI1:EBJH^[V>4UH3+C#0AB&"$/D<0(QQJI%5QP%@GM!
MY/-U9;O7$Z+G)C2ZHN^GG=!Y4;DE.@'RE4>!5[2"WY@\_FBZ/:VO# -=3^K9
MA')BZ?;E%7XU@?9$ERX4ED34V>EF%46ZS+\6.=KO#8S!W3T^XN+Y6MP5^8YL
M.%,)QC=<)1C3[:Y0/9_R+5>_S(N#O9VY)" X""'C%$%$F8!)0CFD28)#QB(6
MQ5J=/4=1L30[8;<<([Z_+RHE$3Q)ZFGZ),53W6.W5']F*A/_!]ZD;/,,MCR3
MZ\5K+VBY(Z646_*046UWJ?JR>MH565Q2/6DV^4)-+.(:^M4:M!S4A3)?\  4
M$RM0L]'4T 16'2U6\+05OCJ(AGE#4L? ]";,=-1@YO%5ZH9]6845W/.,/M]N
ML9S[0O7[EA+@CUSIAW?YU2\E!NHJ#M<97SLA3?P >9#$L:-J+0@H;\,"AG[(
ML</C*'*U,RV'$+ XX2J)K@1K0_8*/%:$JWLOKTA?M<$D>:;II1F\./VR<@[(
MI]8$)?F@0_\*5/A?"W"QQ[_F MSEX*K!ORDA<STY_OI!65.OPTS!69.MAU%<
MTA@P>^*3!@T[6YS2&*:[\4JCQAEH-LBS>RF;'ZO:TG*(*@(>.Q'R"8JAJZ)X
M$>8^C 5AT&&(4$SBP,6.B>I^;)*E'1Z*1JB(K%2Z%5!T#DHU.(JHIAU@)$Z3
M2WP)T9T91.8&@!X,;%WZCTTQ[T6_A\DWE_N^9P<T1WW(?_+B+J__^ZWN-+)/
MZ?V2;AL_]L5FP^^E(+K$NY*SZQ^X2'%VB57HY!_RF]H^\$V:/^+KXD/!<;EM
M_U)5M,$Q<40<(T@XYQ"Y@0OC4##(D!=2A"-*D=;5?R9ZER:*:E;5*=W\U'!]
M2/,'![Y!RSBH.0<-ZZ#F$'29!]<%J-EO_FK0T72&S^:\RKRPCV%J0\1LW\&0
M%K<S?! &K7*7]6',U7+W_06%61??^5:IKQOP#%3,UU5X/DA?=">><5I+W2S^
M6JCFDVZ$/"H< MT@(1#Y#H()K^+D,$<X(23@U,0+>GR:9?H^6=M^024D#6O6
M=Q13O<O->*0F/FZ/MJRHB)RP4<4+$*;J3U%/\KYM*5XP>K8;Q<NG!]QR>);F
MA;+1EXGC?-SQCYQ64D6"%;1EU)E(G)!$T*6^@ @E"8R%X\FK"@V)[U&.7+[^
MP0N2:]U3SL]H\JUWYYWNDT]^=YQ_!S7IE4.K!))RT)(.%.T&*J$.Z!&-A!?'
M\E:(N/)9^!!3'*KJD $181)SO5;S$T ^Q]7N".!, FX?9XV[E%WTIKX+=2!;
M@0K&U=MO=<@]1@-,@WN(75!GND><^"H-H36["N@#U:?*:XPRGRJNS](+5=K@
MM6&J\-<\8[Q,[S,5C]A\TF$84E=X/DRP5(91Z&*(8X="[B>8$:DA)V:UAX[,
ML339*R&6GW1+HRI!\)^<51?B0[,$,WWX&+!ZRO!(N"86MCI(3= !I <42YKQ
ML1EF58M[6'RM$_<].K8%=5T8X8.J[<GW11(^-H4Q+C*FJHW+F:N@ID/XEXO]
MF'L(0\Y=!A$E4F8X*(%4T)@+%TF98>06'$G/TN2+"N;.,]Z$[ZD<,T JCCIU
M14S[@HQ=,CUI-.-"3*TF=N(KFX(RS1H<J@5)O;$M :.B*1N6I@WALP.P]6[9
MPZAYIT[:HZ [W65[W+##)/%5DZMURXL?*>4GBEINJ@^K2L,[U%:N S\N\W);
M?DDS_GG+'U7 !D4)]8C4X4)YM7;<"&(A?"@23P0Q]\,X,:IA;)F^!4MJ)0'H
M!I=E*E*Z3V#M9LG1;F7<IM"4F1"WO=IZ0OT=UW!ROVAO'IVJ@5^M4ATMWS3G
M4GRMVIKX?RJV0,6712D_$>*6I+YMZF8]!2:"]O6I,-4TPTZ)[UFQ'UZ>24V.
M=KD_I+[Q#&^:I)^VA/$%I<6.L[7C(.*B4%[M'94T'= 0XL@ET,&8>X1P7W"C
M$V$$+4N3_@U9AVKU2DH\M?1WDZ5W':8KIUE37-!0B1^SCGJR?J;5F5BN=[FH
MG' M'ZN.]@[VO%3KMB\OW[!C3YI;P-22Y!Y#R:Q2V@)DKR6RC2'-W8<7X>^N
M%W0LLVS'+YZ*=--Q"H2!PTB, ^C'G$&$,(8D3D+Y3\IC*6,#CVO51M.<;VE2
MM*)X[S3X+M4MNE/.\X/[H&+ T+6E _QYUY9E."<6>R^1/(;? +>6#I#Z;BW+
M@,[DUK(!K)%3RP"F'J>6SBBS.;4,6.HZM4Q>&YBXPLN2\Q.=J;YGK"G#QMG5
M+RH?K2]^:^$QYKH)@CPAL:HEY$+,0[D((?5IX 0AUFM8.XJ*I8ERQ<3_ Y^;
M>MFM6FR8]3)H.?2TV\E!GEC U_2O7G?M6W7;]G79 #4?C;'"8FK-&!QMY=X,
MHF'>Y)PQ,+W)WADUV##1^#=ENL[NJ\0SBF,/B]"#'I&Z*?)='R9^1*%@44Q\
MX@KF&0F\SMA+$V,-:8.2]KJ0Z0FE@4!,+&HT,3 6'4>XM200NB//NLV/L/1Z
M\QY[9*##!Q>9'*G\QNOJ7Q_3C3ILUSYG#@E" 448!A"QP(,QBS#THB .8H\F
M(=<*ASPSS]*V:D-6[227LK%VN+QIH?$![TKZ /Z3RRO^0]6B$&?*\"-O_[^#
MW](,L'RSP45G",/Z7:>61=/#,A[LB<5!2Z%*\Z_+#ZHBUQ65%MT>_3#8<E^<
MF&5>-T0_JV_<"6<>'QC&@Y7;NJKR]56NO:I1@[,2TZKZ=/Z(TVR-'$<0'B,I
M45P7(H$<2%2DCN,PGWG4=Q-&C2)USDZY- FC*%:>W(IF\&=-I*%2H &TGJ"P
M"]_4WE4SY,QC8;3!L!7N<G[">2-:M %X$[2B_Z:YS?MKGGW__?;WC_P'W^1/
MG/V!BW_R;=G8"CWLR[L#85#^-X:(D  F+'0A"V+*"&&^%Q-=:W?O3$L3)'_/
MBPW[F3(.6$LO>*P)UK?&]F-[WJ!M#;&)98>D$RI"P9Y2T) ZP(3=#YJ^\=H:
M>#.9K<> :&2NU@*FQU#=__YL)FHM-KK&:;T7!BIG0_M35__77#CK6!)WS5#L
M.H&?0!&XRGCCN#!Q@@A2$A$JY/^P,&J_9).XI<GIUO)1%_@S5/1L+IJF2OA.
M2S&U\M@)S>LRUHW/4\WICH;P*<Y6]7] NYS?^I?37/N< '=;>JI-TN;5:"<
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M@0[SO<!W8A)PHRSP$;0L;<NV=)GI\&,60T][GPGBB<5$TS?E-\7'7X#:+^#
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MMBO$"G33NT!JO)0QLD/B"ORUR$N[]<#.XF'/QW%ZJKE]&V>9/N+3./_.T&)
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M9K*D:WN4OG.NMG7(SZ=XVY]RH%'Y=!SWQ6->;-/_J725)NSSOS@N/LEGUZ%
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M2Y,FBG+0H1'4= _2$@P60$_D3 /KQ.)G(*+&HL<<'$MBR&#B6462.2"OQ=.
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MI?2^,#"%5%Y;*R%S+6ZW.?WG0[Z1+Y=U LK^T'20Y\6^"CQE@0.1[\:08.%
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MU/HZC5Y8I]$+-3>7G8-?SUQF$=3)3?,GFN1(#;NA=NI>.&]@F;0/SF&V!?3
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MT7@\5 IV8@)R(A NYB"1(OB6(I=(-+ ;.Q6V-1;>S='Y.5TU>,A% %5<"14
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MMD73*S(JWE:>ZN-1,?I3[0QQY"1 O(LBH6 3!&A"!VU15-I8CZ,4BNRY>^Q
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MCX(J<+,V],82WH6F-#+&)G;-"5C,.5*$21X]YJ)XX_NG5%123%7P:&,W 5<
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M#%QH5CK7U)ZZ*IW47K%91I%U@O2CG?TC-GWW+J._F:W.:(EG406,A,X=E4,
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MCD\_[%9(].@1!4N*MA%7KBKR>K2X[1UV-[G5/ZC6OZ]5"UQ%+3AB(L?+R3A
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MB6J'L;=V%E!6%SV"*X^V7!OS.S]+I^#"3F<15E&X\4_C(=C.51**H1@"\!5
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M?G%V/KBX^OOY2:Z,.#T:_.>GX_.<J-S9#OWLB<6LTHM(+V2CGCUYO)_=*J(
MM%$4;+Y>;L$=<QYSI*0"1\S&@'EI+^2G1'76\'9]Q*/!)-& +"PO!)X L)T;
M-U :O#),2*%*9Y=^3E6_-JHL5EJWNMU-)S7;J..\O#\<OSL9'%Q>#IIIX!_.
MSH[^>GQRLH>W]+-G%O2>7D1^(4NUI>'9ACV3)0@3/2 1>Y,[[2D"\:-6\(<R
M@41N+'_%AG1=>ESM3^>UX]02D$GTS.9I109IJ2"X8(XRZ:)4ICOGJVQY16<V
MKCN4;3D+ZD2#%61%UIW/$%-K-JTAELO<?40PDL>W!:25,2A0SE*R%J?B>^^.
MI/9[@M,'6+O39$6 G6Y;D^]O<J_K@^M<*/_?C:Y770$>%ZH(H:2T"07- N+"
M>V0<(0@\%4RX-4&YTO<%2]+?[R',ZT/[U75>$=[/TJV\[UDA0H244D!)6 JL
M,(\<-QYI0STQV HB2V>HMI#3[U%)'X9V/XW4'/X<'!Y>?!H<0=AP=O7[X.+P
MT\7%X/3JY/C@W?')\=4^*>.V3RX6"NW$2JG4C?W1/!Q >>#][,:.[P\V(/*V
M08J !,WG"$J HRAPQHMGDBKL4O'FH%O(*7H79W83UVNE'AG@@(WRPG"PN-3G
M9G81&<T=PM9$AD,TLK--]^?4]9R^*827K5=MRFFG9@OV_OCTX/3P^/3#P<7%
MP>F'?6MWMSRM7.UN6Y(+6:>CZ!8;]D;/K==.*N2 ?]@;24!&Q8"<"XH:1J+S
MI;/)FRDI6;7BGARF!!>"E1:%I'S3!0S9X B*,FKGK>"*EQY>M8V>?NU. 21L
MJS#92_@U^."WMR"N9M,;8"1DEBYB+I?Q$'2,)I_SS<7\P^GLGDDPHM9PI1"3
MT8'T'+B!."HDI%,Q<FP8+8ZP70CM-T'2!?0Z5U<-F+Q;7Q]M9BIOY<OA-E=Q
M=KUAS4D0IPPZY>76]'G5R.%\#F2,PY;RW(*@,X/7CL9^\QF=&L$.E%2S]W4^
M.+T\/@-WYNC\[/+J8G!UO+R*-/AX?G+V]\'@W>!T\/[X*A^C[^Z4[?"2<H4
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M1KDNH&'WTV2T>(Y93GVPEFD40@"!:P([FH65;9G"3@NFI>^N.FD'@OL--ZL
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MR_6HR UO5\Q^R,M8L?(EO]S*X90$RRQZ"]X$!RIF!U[RNJ(O92\X\M+\%7(
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MC&(!%"H)H7!%]R\:4SSWC+?NQ!ZO//07Z5:A;KL2*"B*FOQ5,N^5QR@@.%$
MHX_)2D7&OG6AY_V4=%NR.00%]_1M'"KT#N[2.UR\_/DRS^/7;[C<U'4Y39Z
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M'>W.:B/AB7'R_N+\[2SF^:I.DXA?YXNSQ9>?6S:*<TDJ;2!'I<@!S((<P,1
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M9 4&I8ATB>M4W##;<?L3TZ9YCF4W#A)L-_B@&_-\.0L756!O\A76@X\&@Z$
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MG=H!=4V)ZAV6^V!FT8,".WA3W72\767CWM;_X/*D%\ZS13KIGKGMJ$5G!4+
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M.MW.NKBRUYP'KV7U+Q@H39SX5'>-VB*U,S(DU3J]?2\A70)H'T7?@="A4N\
M.H]:_[=7I44V*.04'X-:A]X\&$"1(\DI6YV4-5(<=>WJVS[V%3R3NW,$)7<
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MI5>X^OKF;/&O8Q?ZM29[VJK 495PC!+":&Q1Q0L069(7P4J 8'0"AURJ4J)
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M7TWP>_.O 0?H'+Z7?G+3K[_CY;?N1J(3$L")8:E4(8,DJ 0IL2FHS%V(IAL
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M$M;8%"N_T+VTITY8<J_T2AI$,$T";4/-^C2ZR"GX7/I#N5"*'S*Q+..Y3*!
M^&P-K=UX\*4]C?OT5Q<!+\+K '$T *]S^ '3:_B 7$325LU _SE9?GM[O5C.
MK@#M@*^K,L,-D9L<'B=9U% R]4J_'YT<<0S)%4BO4<8G*VOGYN^UT=: > A6
MGN0K#"VX!M"YY2A_P7^Z.L5,2.\H.*)SEB7_CY*03"2F)'T+!U;KVFV0=VRG
M&]+H7^]RW4L>+4*K$+(^EX)%PT PPD BBX+"\V*%) (]'HJF>TQ0N__7CNVT
MIL3V%/E+4-J3_PU :>W)/*%HD\U!)>-:9&*2RR6; UUG@5I><6VTS<%S4=M
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M$&,M.=\/(57DZL@/GBN6W#[0G4- (F[\0^0..&[+@&$+&8TOD]"$Y\;AO2I
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MX\*]%[&R;9UN0'D]\>JJ?&T))5;1!S?I;0Q>JJ0$M42YTJ13*W0/6"AIETR
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M2PDJ^ZOYPWC9"@@VX>68(M=H%8/&#2-^$]K'$K_U.=IDI(N/"_T.@\&8"O]
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M,R&RCT'7X<^6UQ(D!MYF#>AE],&)(HJ=&I65T.G;B:8&Y6!UG20F9]_P#(U
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MXXR-&*+C#J*3Q[N=5$8E"T=BPR")U-%Q)C87F<7PI*4HNG62V*99L:^RC<.
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M>J.5R$< E^@B Y@47/MHI%-PR:ML6800<K007* HV(L(43@$(9AAB1)IAL<
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M<EO1"@H[7(D=HI=.H;9Z7]\_EK5&;%O5$8HS@K(C2EHB**5KXW>N*3*FG'E
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ML*U%UXSXB<?*'@^SM]J])E%_!\%0'9+[)GRY7!?I@\Y944*@57VY2IIH5T&
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M)S E@2ASU%'CSJGT&YPT]S]W. GO+IFN$IL:B-(KU XK+2W7>-(J(=$@2AG
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M39=N;S#]:ZC:RCB-6"I62&MPZ,^"H"F!HXJ5ZRX,-XWD,9/CT[(5<4>:QCX
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M?2C-P5+/,42,66HTG][6[HG<!N6O/F/^"DQ ;TA^U?J_12PE&='E]0\H#)U
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M'H2CUM=.Z6R\N6%3,[UBKJ)4=H;;]S3SW>$ 5[S8G]>6U'(=8Q"0=3'G7%)
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M='^Z7;"1(*1*#FQW3K8@_IN)M@A;GW."3(0L-Z8";6 VP(1D64BN\V9F8Q,
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M;TN3=DN^YQXY;0%M!$=E50G/S&S !8O!<AFJEFO7!&^XM8'3O[6Q\R!5T8.
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M")YZJZ7+,6U2P_ST"L,^Z^D/ [],5*W#WQ9[;W'.HN:$@R^OYP4/'IPMAW=
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M]Z_1'QY$ILEZU$ZZ;TT+0C_[U>O+#WE]PXM]_NFWO+S(K_+E)@X**M7+(<E
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M__CTK&3)- 68('FFG:GV=G6%)[#:Z<)0A<3W92*.P_S'I\,N:]CC 7VD"3L
M_?G/9S9:+J*C7<E+"B]5+C71VY/;B3ID.IB2VW>3.P[TYS\/ _T17-$=:,(.
M0/_'V[,Z)D8.)DBA(ZC:AL35 H>R2(O!!.%LNPC]'\.\./Z(KN)&FK #T%^\
M.W,N)AV5!993H0 SY-KXTD(P/*HL8XYJGXYV'.@OW@T#_1'=Q8TT80^I7YMD
MQ_7B2P83;4O&9*8!-\GU1%7PFO[)*JX2FFAP4!6KNWY[&-R/X!JNB?'ZD?<-
M?>Y^^46%YC/W2E@$KFI[*N8U.!,T1!Z8XC*4</.IKI7&;_18>ZE>?3)IP4G!
M[8?$HU2-@4MGA%*02TW3E+SVB@P)-&W:CKN@M&E=VWHJC>IDJIC3\*>!1'4,
MF(]7HAK.OVT4^+WMIQ&K#OGB262KHZ<^M8 U!>4Y%@$EU8*%&!V@L!31%^>L
MD=YEV;R95I\"UB)2L%578HHEAP=5A"#)X4'OR/GQ411=6EOBCRA@'<.HQ@+6
M,1#.+3:\5UB7C"C!D'LD),L4=?G:2%)S.G.<$,6$2';\2\#:@@&#!*QCX)B;
M4_=&AI9QB55+XY+6H'(6- GZPUB?++*8M1H4Y/R1!*RC@!TD8!UCY<X%K"Q&
MQR-YNL+7IWJE6&T"R< XBM;0%&$&I? ^0@'K*!!'"%C'6+2'&]3G9])JQ@7M
MH"RQ0'MIXK2-UK?<6%/A#1KCVHF<7@Q[%#WQK?DA9#C0@AU@7N67WBB; X),
MM!^J& 5X58BT2D5D ;V2[6[-^Q2P'H/Y2 MV@'E]NK<V>*,+F$#;DY*^D,/.
M(G!KM,^H>,%]@<\DXH<3WYP?@_E("S:\MCE*MFQ39((9#AQKG1,1/3C-+6AE
M;41I:-CMI&T#9<LGEK >@_I("W:PTG_Z]<P7'XSW'#QRFK *B?8F9T!+GUQ1
M*5JSKRC>)++E$TM8C\%\I 4[P+P*,*W@TF, P5FJ^<2&QNX"6(,E&V2IQ'8G
M>I\2UF,P'VG!+G;W9Z_.@K+:"::@V"K!% R!B(M@42)7!EUT^^H23))\=F(1
MZU%^W#@+=H'ZVY_/HD^%21T@\L)HS$5"$*K4Y@(2:7\J6>^[.API71ZF;CNQ
MC/48U$=:L(/]_<6[LZJHSC0T,,D)BC>$HQ/)*^!)FZ1M=$[OZT8[C<[IQ#+6
MH\+T<2;L4N=D4I:"7!%.P2>H0.&'+YI#MDKQ[$/D8EJ=TR.YHCO:>/U(1,9+
M&9 I2U,5P"*SH%*MZ![=9L;2H \VR'WQWE\ZIPE?H$X*;@<D?K5:QJMU!>-Z
M(F?>!:>9EV!8W8%%*N"0(Z2J0,04(FM>Z_'F&!ZI0FD4\JN&,#2CT4G$1]_7
M+6\I,KK[ER<4$PV8RM2B(4][&1VUCKSD:*_[8OMD*$ N)7%T2:B]"15]BH:^
M%K+<+L:GG[\W]=//7[Z^ZQ)^O>5;LH<2(4!&5_.:,X=0<H*<O?,,;2"S3*8<
M.GC8G<J'QG#K?OG0:<#LX"B]5:+WZ>=W]'^];E^?62I6<9"QT(E@F >4D0-S
M#ETTUBC>FI=[AM.+KNA$U'BHE/*!./5(N3J1;6@6M Y!&P-&%3)1E!*\U BH
M3$P44:'@K:N [AG.O)1K!OE#5#K0_CU0:;OF;DUI&YR[>LNJ38%:#AJ4LN3=
MBN!!%L5"R@ZU;5U>]X$A=4:I0Z&_2:F&./1 J]LK[VE>Q@\?P_I?F^47Z:,Q
M: ^YF*K]XQY\\:PV2Z"EJ'W4V)Q7#XRIETN/;H['PQ'KDH&[V6Q7:[T'"HGV
M?H95)B2# \]-!(,T*Y,4QM Z[^*A,76VM1W%@ ?I=00<,S\![*Z*7N7+7:?&
M8OFF$T=RD8'*A0$:)+?"6Q<Q2*[+C>HU=][_W_KAW@AQ#&:K5@;LK]6E*HDA
MHY6 %"'3X>P28*X=JXJV63KE6=A7R&;B5I>3-1Z9Z\AJ@$*WC2UC3I&Y9,%'
M2Y,(T4*(KD 2NB2,*ED_* ?N#]'8<A2B@QI;CC'OS*?,$QKUXF)UM8[Y:5Z_
MS\MGJS4MH0T6NUVSMH!VVH$K1M*!3*&'PY(A&TR.:9>3&M)U^^$O]=CD<A24
MJ\GL.C-+?HK_R!<7JSLF43@*H44MX5RS0+4S@)QB1UZXR#K'[.40<MS[@?FR
M1=ISHHT5YVX+&=9IL0SG_[5YP'JQC-LIQ!B1B9B >R_(2Z,-%*77X+$H%;7.
M"@<U@[S[Y^=+(&E/@Q86["#TO>6-?6>CKR_72LL@;5+ -/VAT->28CF ,:H8
MBNPB3_N$:\<UNMT[M'DR5.;V:Z?$;U:![*!NE@&5UXHI"*PV!U0NDMMG S 7
M0DC6:#FLQ<\INXV>H+5M0PJ,Z2TZ!HWIA2C;OZA_8+C(__EO_P]02P,$%
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MOG FA+KE"A*T[F@D8-DD'1@7_#84JEB@"@*VTFG]T&SN@7'&*^(&K*U[@%]
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MUT,WSPF,$R;AH<%P999U8/QRNC!QV:4^'0S4F0*=!ZZUR074^ "=P:AEFH#
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M/7I>7@KK?1U"%K@9%^KXD,>/V(\>P1T]="^O]J\"\Z?%V7\!4$L! A0#%
M  @ J8175K@7(^#6E@@ LL18 !               ( !     &)H8RTR,#(R
M,3(S,2YH=&U02P$"% ,4    " "IA%=6?BO2#/(U  #)70( $
M    @ $$EP@ 8FAC+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( *F$5U83[$AU
MXC8  'PG @ 4              "  23-" !B:&,M,C R,C$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( *F$5U8ELU1 &$(! &54#@ 4              "  3@$
M"0!B:&,M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( *F$5U9!;)DF#;D
M $GE   3              "  8)&"@!B:&,M,C R,C$R,S%?9S$N:G!G4$L!
M A0#%     @ J8175FAIG)!79 ( 28,8 !0              ( !P/\* &)H
M8RTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ J8175EX,X!?[I0$ B 83
M !0              ( !260- &)H8RTR,#(R,3(S,5]P<F4N>&UL4$L! A0#
M%     @ J8175KW!BS?X%P  7SP" !0              ( !=@H/ &5X:&EB
M:70R,3$R,#(R>64N:'1M4$L! A0#%     @ J8175E$"7K1- P  YP@  !0
M             ( !H"(/ &5X:&EB:70R,S$R,#(R>64N:'1M4$L! A0#%
M  @ J8175G_Z8/2/"   -R8  !0              ( !'R8/ &5X:&EB:70S
M,3$R,#(R>64N:'1M4$L! A0#%     @ J8175G@)X#JA"   #28  !0
M         ( !X"X/ &5X:&EB:70S,3(R,#(R>64N:'1M4$L! A0#%     @
MJ8175LMAR!%(!@  JQ@  !0              ( !LS</ &5X:&EB:70S,C$R
M,#(R>64N:'1M4$L! A0#%     @ JH175JVX%&MQ!@  #QD  !0
M     ( !+3X/ &5X:&EB:70S,C(R,#(R>64N:'1M4$L%!@     -  T 40,
' -!$#P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
